<SEC-DOCUMENT>0001140361-23-014868.txt : 20230330
<SEC-HEADER>0001140361-23-014868.hdr.sgml : 20230330
<ACCEPTANCE-DATETIME>20230330170718
ACCESSION NUMBER:		0001140361-23-014868
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		106
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230330
DATE AS OF CHANGE:		20230330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ocuphire Pharma, Inc.
		CENTRAL INDEX KEY:			0001228627
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				113516358
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34079
		FILM NUMBER:		23781623

	BUSINESS ADDRESS:	
		STREET 1:		37000 GRAND RIVER AVE.
		STREET 2:		SUITE 120
		CITY:			FARMINGTON HILLS
		STATE:			MI
		ZIP:			48335
		BUSINESS PHONE:		248-681-9815

	MAIL ADDRESS:	
		STREET 1:		37000 GRAND RIVER AVE.
		STREET 2:		SUITE 120
		CITY:			FARMINGTON HILLS
		STATE:			MI
		ZIP:			48335

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REXAHN PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20050516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORPORATE ROAD SHOW DOT COM INC
		DATE OF NAME CHANGE:	20030423
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>brhc10050364_10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:ocup="http://ocuphire.com/20221231" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_f0958ed82ea846c79f495e7ace8652ef" contextRef="c20220101to20221231" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_b2a27dc4162d4322a9f788f303820c61" contextRef="c20220101to20221231" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_0f0156860f914e65a8107b058f82f9ec" contextRef="c20220101to20221231">2022</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_a929f8da061b4636a4ff53642fcbc402" contextRef="c20220101to20221231">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_8c4f7a4db80a46fe936861567f87584a" contextRef="c20220101to20221231">0001228627</ix:nonNumeric><ix:nonNumeric name="dei:AuditorFirmId" id="Fact_3ee0ed147ce34c3f88fb4e30185e37c7" contextRef="c20220101to20221231">42</ix:nonNumeric><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_43d8906c354b4cf393d97ed8bb0df71f" contextRef="c20221231" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_d61305f9bf5e4fdabd17d17016b342ca" contextRef="c20211231" unitRef="U001" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="ocup-20221231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20220101to20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221101to20221130_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ocup:WarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ocup:WarrantLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ocup:WarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_ZhejiangHaiChangBiotechnologyCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:ZhejiangHaiChangBiotechnologyCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_BioSenseGlobalLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:BioSenseGlobalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200629to20200629_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200629to20200629_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-29</xbrli:startDate><xbrli:endDate>2020-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201119_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_TypeOfArrangementAxis_WaiverAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:WaiverAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_BusinessAcquisitionAxis_RexahnStockholdersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210506to20210506_RelatedPartyTransactionsByRelatedPartyAxis_AccreditedInvestorMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ocup:AccreditedInvestorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210506to20210506_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RelatedPartyTransactionsByRelatedPartyAxis_AccreditedInvestorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ocup:AccreditedInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-06</xbrli:startDate><xbrli:endDate>2021-05-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_DebtInstrumentAxis_ShortTermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocup:ShortTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_PreMergerFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RelatedPartyTransactionAxis_PreMergerFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_RelatedPartyTransactionAxis_PreMergerFinancingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220408to20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220408to20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201130_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210222_PlanNameAxis_InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201130_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_PlanNameAxis_InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20201231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20201111to20201111_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-11</xbrli:startDate><xbrli:endDate>2020-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_BusinessAcquisitionAxis_RexahnStockholdersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentAndRegulatoryMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ocup:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:ApexianSublicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:ApexianSublicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ocup:SalesMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210311to20210311_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:AtTheMarketProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-11</xbrli:startDate><xbrli:endDate>2021-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210212to20210212_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ShelfRegistrationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:ShelfRegistrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210608to20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210608_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210608to20210608_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221106to20221106_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ocup:LicenseTransferFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-06</xbrli:startDate><xbrli:endDate>2022-11-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221106to20221106_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ocup:ResearchDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-06</xbrli:startDate><xbrli:endDate>2022-11-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221106to20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-06</xbrli:startDate><xbrli:endDate>2022-11-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ocup:ResearchDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ocup:LicenseTransferFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200310to20200310_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-10</xbrli:startDate><xbrli:endDate>2020-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210701to20210731_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:ProcessaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200310to20200310_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-10</xbrli:startDate><xbrli:endDate>2020-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:ProcessaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:ProcessaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:FormerRexahnOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:SeriesASeriesBAndRDOWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:FormerRexahnWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:FormerRexahnOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:FormerRexahnWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:SeriesASeriesBAndRDOWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ocup:RetirementPlan401KMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_RetirementPlanNameAxis_RetirementPlan401KMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ocup:RetirementPlan401KMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231_RetirementPlanNameAxis_RetirementPlan401KMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ocup:RetirementPlan401KMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EvergreenProvisionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EvergreenProvisionPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230101_PlanNameAxis_EvergreenProvisionPlan2020Member_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001228627</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EvergreenProvisionPlan2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>ocup:Product</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>ocup:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>ocup:Right</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>ocup:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="U009"><xbrli:measure>ocup:Director</xbrli:measure></xbrli:unit><xbrli:unit id="U010"><xbrli:measure>ocup:Investor</xbrli:measure></xbrli:unit><xbrli:unit id="U011"><xbrli:measure>ocup:Intallment</xbrli:measure></xbrli:unit><xbrli:unit id="U012"><xbrli:measure>ocup:Member</xbrli:measure></xbrli:unit><xbrli:unit id="U013"><xbrli:measure>ocup:Performanceobligation</xbrli:measure></xbrli:unit><xbrli:unit id="U014"><xbrli:measure>ocup:Country</xbrli:measure></xbrli:unit><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_37c7f8e7261c4c0ea247d23587c35f7a" toRefs="Foot_b060c1ad19c34ed89e1bcfe2db363855" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_3cfe8fa586b34f52a55e354dc7fa3bb7" toRefs="Foot_b060c1ad19c34ed89e1bcfe2db363855" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_46b97527dae540aca27bf64658108ec9" toRefs="Foot_b060c1ad19c34ed89e1bcfe2db363855" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_2e21a6a36c364fdba0d8dc06ccade1de" toRefs="Foot_b060c1ad19c34ed89e1bcfe2db363855" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_4ced063294be4461a959db5d39a759cf" toRefs="Foot_b060c1ad19c34ed89e1bcfe2db363855" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship></ix:resources></ix:header></div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman'; text-indent: -9pt; margin-left: 9pt;">UNITED STATES</div>

      <div style="text-align: center; font-size: 14pt; font-weight: bold; font-family: 'Times New Roman'; text-indent: -9pt; margin-left: 9pt;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-size: 12pt; font-weight: bold; font-family: 'Times New Roman';">Washington, D.C. 20549</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div>
          <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 12%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      </div>

      <div style="text-align: center; font-size: 18pt; font-weight: bold; font-family: 'Times New Roman';">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_9083dfc048294d64a80b99f3ac928412" contextRef="c20220101to20221231">10-K</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div>
          <div>
            <div>
              <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 12%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

          </div>

        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:DocumentAnnualReport" id="Fact_bc08c28ba02f4d30bb6f9f5695ce23c0" contextRef="c20220101to20221231" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">For the Fiscal Year Ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_7f559871c8c947b8aec0f102e4a164b9" contextRef="c20220101to20221231" format="ixt:date-monthname-day-year-en">December 31, 2022</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">or <br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 24.5pt; vertical-align: top; font-family: 'Times New Roman'; font-weight: bold;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_df2d3fc9cc7342c580367a2dde018fe1" contextRef="c20220101to20221231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-weight: bold;">Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">For the transition period from _____ to _____</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Commission File No. <ix:nonNumeric name="dei:EntityFileNumber" id="Fact_646e7277083c4cc1a4ddbbb96b1c3e9a" contextRef="c20220101to20221231">001-34079</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div>
          <div>
            <div>
              <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 12%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

          </div>

        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

      <div style="text-align: center; font-size: 24pt; font-weight: bold; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_ac4ff62998744f1282a45dcedb0974ed" contextRef="c20220101to20221231">Ocuphire Pharma, Inc.</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(Exact name of registrant as specified in its charter)</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <div>
          <div>
            <div>
              <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 12%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

          </div>

        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_8e6a949680794fcab0b7adaadb4a46cc" contextRef="c20220101to20221231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_8312ded7be3d4f148b5759399c97de62" contextRef="c20220101to20221231">11-3516358</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td colspan="1" style="width: 49.01%; vertical-align: top;">
              <div style="text-align: center;">&#160; (State or other jurisdiction of incorporation or organization)</div>
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_59a8140eeb0e426f9563fa01d57644df" contextRef="c20220101to20221231">37000 Grand River Avenue, Suite 120</ix:nonNumeric><br />
              </div>
              <div style="text-align: center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_1e0d9b8ea5554cfd92579607d0cbdf9d" contextRef="c20220101to20221231">Farmington Hills</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_ccbc074ab6204a15b539e4912cc5a19b" contextRef="c20220101to20221231">MI</ix:nonNumeric><br />
                </span>(Address of principal executive offices)<br />
              </div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top;">&#160;&#160;</td>

    <td colspan="1" style="width: 49%; vertical-align: top; text-align: center;" rowspan="2">(I.R.S. Employer Identification No.)&#160;
              <div style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_5170267e5bd14734a51d8e58411cef75" contextRef="c20220101to20221231">48335</ix:nonNumeric><br />
              </div>
              <div>(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_3acbe4f27bdd4794b674737509972021" contextRef="c20220101to20221231">248</ix:nonNumeric>)
        <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_906861cd1d5e430ab914dadd5ce34fdd" contextRef="c20220101to20221231">681-9815</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; margin-right: 0.8pt; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 21.08%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: center; margin-right: 0.8pt; font-weight: bold;">Trading Symbol</div>
            </td>

    <td style="width: 39.43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; margin-right: 0.8pt; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.43%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; margin-right: 0.8pt; font-weight: bold;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_47841d80476043309a66cf5418c8ed15" contextRef="c20220101to20221231">Common Stock, $0.0001 par value per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 21.08%; vertical-align: top;">
              <div style="text-align: center; margin-right: 0.8pt; font-weight: bold;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_72e3372373d5414c9cefdce3bca22b8e" contextRef="c20220101to20221231">OCUP</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 39.43%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; margin-right: 0.8pt; font-weight: bold;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_5d36d6c2fe3144d89e19fec8e413a561" contextRef="c20220101to20221231" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(g) of the Act: None</div>

      <div>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

        <div>
          <div>
            <div>
              <div>
                <div>
                  <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 12%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;" /></div>

              </div>

            </div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: 'Times New Roman';">&#9744;</span> &#160;&#160; <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" id="Fact_dc6b26e62aa74cefb88f00b9ae884f91" contextRef="c20220101to20221231">No</ix:nonNumeric> <span style="font-family: 'Times New Roman';">&#9746;</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes <span style="font-family: 'Times New Roman';">&#9744;</span> &#160;&#160; <ix:nonNumeric name="dei:EntityVoluntaryFilers" id="Fact_9ce0290664694702806fd18bff446716" contextRef="c20220101to20221231">No</ix:nonNumeric> <span style="font-family: 'Times New Roman';">&#9746;</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
        of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_14193fb1f41f42eb9aa044a2b62dce51" contextRef="c20220101to20221231">Yes</ix:nonNumeric> <span style="font-family: 'Times New Roman';">&#9746;</span> &#160;&#160; No <span style="font-family: 'Times New Roman';">&#9744;</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
        405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_01751b8c995045c89faf0e5528dcd597" contextRef="c20220101to20221231">Yes</ix:nonNumeric> <span style="font-family: 'Times New Roman';">&#9746;</span> &#160;&#160; No <span style="font-family: 'Times New Roman';">&#9744;</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
        company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 24%; vertical-align: top;">
              <div>Large accelerated filer&#160;&#160; <span style="font-family: 'Times New Roman';">&#9744;</span></div>
            </td>

    <td style="width: 0.97%; vertical-align: top;"><br />
            </td>

    <td style="width: 50.19%; vertical-align: top;">&#160;</td>

    <td colspan="1" style="width: 1%; vertical-align: top;"><br />
            </td>

    <td style="width: 24%; vertical-align: top;">
              <div>Accelerated filer&#160;&#160; <span style="font-family: 'Times New Roman';">&#9744;</span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 24%; vertical-align: top;">&#160;</td>

    <td style="width: 0.97%; vertical-align: top;"><br />
            </td>

    <td style="width: 50.19%; vertical-align: top;">&#160;</td>

    <td colspan="1" style="width: 1%; vertical-align: top;"><br />
            </td>

    <td style="width: 24%; vertical-align: top;"><br />
            </td>

  </tr>

  <tr>

    <td style="width: 24%; vertical-align: top;">
              <div><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_f03396a4da524442ba6383cf90b5a5d4" contextRef="c20220101to20221231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160;&#160; <span style="font-family: 'Times New Roman';">&#9746;</span></div>
            </td>

    <td style="width: 0.97%; vertical-align: top;"><br />
            </td>

    <td style="width: 50.19%; vertical-align: top;">&#160;</td>

    <td colspan="1" style="width: 1%; vertical-align: top;"><br />
            </td>

    <td style="width: 24%; vertical-align: top;">
              <div>Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_fc7960c237b4416a939f2321969bf792" contextRef="c20220101to20221231" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" colspan="4" style="vertical-align: bottom;">&#160;&#160;</td>

    <td style="width: 24%; vertical-align: bottom;">
              <div>Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_3213949ebded4c09ba40ceed502a7fc6" contextRef="c20220101to20221231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>
            </td>

  </tr>


</table>
      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
        any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: 'Times New Roman';">&#9744;</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its
        internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" id="Fact_3fc683e5535242ff87c9c88148b681b9" contextRef="c20220101to20221231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">If





          securities are registered pursuant to&#160;Section 12(b)&#160;of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family: 'Times New Roman';">&#9744;</span></div>

        <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </div>

        <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Indicate

















          by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to&#160;&#167;
          240.10D-1(b). <span style="font-family: 'Times New Roman';">&#9744;</span></div>

        <div><br /></div>

      </div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_e881d4858fbf4d3a9f40fe057318618c" contextRef="c20220101to20221231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;&#160;&#160; No <span style="font-family: 'Times New Roman';">&#9746;</span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; text-indent: 24.5pt; font-family: 'Times New Roman'; font-size: 10pt;">The aggregate market value of the common equity held by non-affiliates of the registrant on June 30, 2022, based on the closing price on that date
        of $1.92, was approximately $<ix:nonFraction name="dei:EntityPublicFloat" id="Fact_ed3dd85ab16a49c88f4c1000b59003cd" contextRef="c20220630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">37,236,094</ix:nonFraction>. As of March 27, 2023, there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_a2ce4c74d2ce4555b22b2fc27b002f1a" contextRef="c20230327" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,947,830</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: center; text-indent: 24.5pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Documents Incorporated by Reference</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Portions of the registrant&#8217;s Definitive Proxy Statement to be filed with the Commission pursuant to Regulation 14A in connection with the registrant&#8217;s 2023 Annual
        Meeting of Stockholders, to be filed subsequent to the date hereof, are incorporated by reference into Part III of this report.&#160; Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days after
        the conclusion of the registrant&#8217;s fiscal year ended December 31, 2022.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div>
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after:always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div>
        <div style="text-align: center; font-weight: bold;">
          <div style="color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

          <div style="color: #000000; font-weight: bold;">Form 10-K</div>

        </div>

        <div style="text-align: center; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-weight: bold;"><a id="TABLEOFCONTENTS"><!--Anchor--></a>TABLE OF CONTENTS</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td colspan="3" style="vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>PART I</div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: right;">6<br />
                </div>
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: top;"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 1.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM1.">BUSINESS</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">6<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 1A.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM1A.">RISK FACTORS</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">61<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 1B.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM1B.">UNRESOLVED STAFF COMMENTS</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">103<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 2.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM2.">PROPERTIES</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">103<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 3.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM3.">LEGAL PROCEEDINGS</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">103<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 4.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM4.">MINE SAFETY DISCLOSURES</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">103<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top;">
                <div>PART II</div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">104<br />
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 5.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM5.">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">104<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 6.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM6.">[RESERVED]</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">104<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 7.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM7.">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">105<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 7A.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM7A.">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">119<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 8.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM8.">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">119<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 9.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM9.">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">119<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 9A.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM9A.">CONTROLS AND PROCEDURES</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">119<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 9B.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM9B.">OTHER INFORMATION</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">120<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 9C.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM9C.">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">120<br />
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top;">
                <div>PART III</div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">121<br />
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 10.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM10.">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">121<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 11.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM11.">EXECUTIVE COMPENSATION</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">121<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 12.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM12.">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">121<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 13.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM13.">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">121<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 14.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM14.">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">121<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top;">
                <div>PART IV</div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">122<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div>ITEM 15.</div>
              </td>

    <td style="width: 79%; vertical-align: top;">
                <div><a href="#ITEM15.">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; text-align: right;">122<br />
              </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>ITEM 16.</div>
              </td>

    <td style="width: 79%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="#ITEM16.">FORM 10-K SUMMARY</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);"><br />
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top;">&#160;</td>

    <td style="width: 10%; vertical-align: top; text-align: right;">125<br />
              </td>

  </tr>

  <tr>

    <td colspan="3" style="vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: justify;"><a href="#SIGNATURES">SIGNATURES</a></div>
              </td>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">154<br />
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%3%%%-->
        <div style="text-align: justify; text-indent: 36pt;">In this Annual Report on Form 10-K, unless otherwise specified, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Ocuphire&#8221; or &#8220;the Company&#8221; mean Ocuphire Pharma, Inc. Our financial statements are prepared in
          accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</div>

        <div>&#160;</div>

        <div style="text-align: center; text-indent: -72pt; margin-left: 72pt; font-weight: bold;">FORWARD-LOOKING STATEMENTS</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of
          the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements relate to us, our business prospects and our results of operations and are subject to certain risks and uncertainties posed by many factors and
          events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not
          limited to, those described under the heading &#8220;Risk Factors&#8221; included in this Annual Report on Form 10-K. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. In
          some cases, you can identify forward-looking statements by the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221;
          or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that
          might subsequently arise. Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) that advise interested
          parties of the risks and factors that may affect our business.</div>

        <div><br />
        </div>

        <div style="text-align: center; font-weight: bold;">SUMMARY RISK FACTORS</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our business is subject to a number of risks, as fully described <span style="color: rgb(0, 0, 0);">in &#8220;Item 1A. Risk Factors&#8221;</span> in this Annual Report. The principal factors and
          uncertainties include, among others:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We currently depend entirely on the success of Nyxol and APX3330, our only product candidates. We may never complete clinical development of, receive marketing approval for, or successfully commercialize,
                  Nyxol alone or as adjunctive therapy with low dose pilocarpine (LDP), APX3330, or other product candidates we may pursue in the future for any indication.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Viatris has exclusive global rights to commercialize our Nyxol products in key global markets. Viatris&#8217; failure to timely develop or commercialize these products would have a material adverse effect on our
                  business and operating results.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory
                  authorities.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may result in changes to clinical trial protocols or additional clinical trial requirements, which
                  could result in increased costs to us or delays in its development timeline.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Adverse global economic conditions could have a negative effect on our business results of operations and financial condition and liquidity.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Adverse developments affecting the financial services industry could negatively affect our current and projected business operations, financial condition and results of operations.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Even if we receive marketing approval for our product candidates in the United States, we may never receive regulatory approval to market such product candidates outside of the United States.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Our employees or our representatives may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could
                  significantly harm our business.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We lack experience in commercializing products, which may have an adverse effect on our business.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-size: 10pt;">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell, market, and distribute APX3330, if
                    approved, we may not be successful in commercializing APX3330 if and when it is approved.</div>
                </div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Product liability lawsuits against us, or our suppliers and manufacturers, could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We are unable to control all aspects of our clinical trials due to our reliance on clinical research organizations (&#8220;CROs&#8221;), contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and other third
                  parties that assist us in conducting clinical trials.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>We are unable to control the supply, manufacture and testing of bulk drug substances and the formulation, testing and packaging of preclinical and clinical drug supplies of our product candidates, and will be unable to control these
                  elements at the commercial stage, due to our reliance on third party manufacturers and analytical facilities.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">If we are not able to establish new collaborations for APX3330 on commercially reasonable terms, we may have to alter our development, manufacturing, and commercialization plans.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">If we are unable to obtain and maintain sufficient patent protection for our product candidates, our competitors could develop and commercialize products or technology similar or identical to those of us,
                  which would adversely affect our ability to successfully commercialize any product candidates we may develop, our business, results of operations, financial condition and prospects.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidate, our business may be
                  materially harmed.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We may not be able to protect or practice our intellectual property rights throughout the world.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental agencies, and our patent
                  protection could be reduced or eliminated for noncompliance with these requirements.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We depend on intellectual property sublicensed from Apexian Pharmaceuticals, Inc. (&#8220;Apexian&#8221;) for our APX3330 product candidate under development and our additional pipeline candidates, and the termination
                  of, or reduction or loss of rights under, this sublicense would harm our business.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We will need to develop and expand our company and may encounter difficulties in managing this development and expansion, which could disrupt our operations.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Our insurance policies are expensive and protect only from some business risk, which leaves us exposed to significant uninsured liabilities.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Environmental, social, and governance matter and any related reporting obligations may impact our business.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">If we fail to comply with the continued listing standards of the Nasdaq Capital Market, our common stock could be delisted. If it is delisted, our common stock and the liquidity of our common stock would be
                  impacted.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The market price of our common stock may fluctuate significantly.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">We may be subject to securities litigation, which is expensive and could divert management attention.</div>
              </td>

  </tr>


</table>
        <div style="text-align: center; text-indent: -72pt; margin-left: 72pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; text-indent: -72pt; margin-left: 72pt; font-weight: bold;">INDUSTRY AND MARKET DATA</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In this Annual Report, we reference information, statistics and estimates regarding the medical devices and healthcare industries. We have obtained this information from various third-party
          sources, <span style="color: rgb(0, 0, 0);">including</span> industry and general publications, reports by market research firms and other sources. This information involves a number of assumptions and limitations, and we have not independently
          verified the accuracy or completeness of this information. Some data and other information are also based on the good faith estimates of management, which are derived from our research, review of internal surveys, general information discussed in
          the industry, and third-party sources. We believe that these external sources and estimates are reliable but have not independently verified them. The industries in which we operate are subject to a high degree of uncertainty, change, and risk
          due to a variety of factors, including those described in &#8220;Item 1A. Risk Factors.&#8221; These and other factors could cause results to differ materially from those expressed in this Annual Report and other publications.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: center; font-weight: bold;">PART I</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM1."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; font-weight: bold;">ITEM 1.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -72pt; margin-left: 72pt; font-weight: bold;">BUSINESS</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; font-weight: bold;">Overview</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire is a late clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire&#8217;s
          pipeline currently includes two small molecule product candidates targeting several of such indications.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Nyxol</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In November 2022, Ocuphire signed a license and collaboration agreement (the &#8220;Nyxol License Agreement&#8221;) with FamyGen Life Sciences, Inc.
              (acquired by Viatris, Inc. (&#8220;Viatris&#8221;) in January 2023) pursuant to which Ocuphire has granted to Viatris an exclusive license to develop, manufacture, import, export and commercialize Ocuphire&#8217;s product candidate phentolamine ophthalmic
              solution 0.75% (Nyxol<sup>&#174;</sup> Eye Drops or &#8220;Nyxol&#8221;) in all three indications (RM, presbyopia and DLD) in key territories. <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Under the terms of the Nyxol License
                Agreement, Ocuphire is conducting development of Nyxol in the United States with its partner Viatris, and Viatris is responsible for developing Nyxol in countries and jurisdictions outside of the United States. Viatris will reimburse
                Ocuphire for budgeted costs related to the development of Nyxol through U.S. Food and Drug Administration (&#8220;</span><span style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; color: #000000;">FDA</span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">&#8221;) approval as long as Ocuphire continues to conduct such development activities. Viatris or its affiliates will commercialize Nyxol in the Territory for each
                indication that receives regulatory approval.</span></div>

            <div>&#160;</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Pursuant to the Nyxol License Agreement, Ocuphire received an
              upfront cash payment of $35 million. In addition Ocuphire is eligible to receive potential additional payments of up to $130 million, in the aggregate, upon achieving certain specified regulatory or net sales milestones, with the first
              potential payment of $10 million to be made following approval by the FDA of Nyxol for the reversal of pharmacologically-induced mydriasis (&#8220;RM&#8221;) </span><span style="font-size: 10pt; font-family: 'Times New Roman';">(dilation of the pupil)</span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">. Ocuphire will also receive tiered royalties, starting at low double-digit royalties up to low twenty percent royalties, based on the aggregate annual net sales of
              Nyxol in the United States, and will receive low double-digit royalties based on all annual net sales outside of the United States. </span>Nyxol is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter
            and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of RM, presbyopia (age-related blurry near vision) and dim light or night vision disturbances (&#8220;DLD&#8221;) (halos, glares and starbursts).
            Ocuphire&#8217;s management believes these multiple indications potentially represent a significant market opportunity. Nyxol has been studied in a total of 12 clinical trials (3 Phase 1, 5 Phase 2 and 4 Phase 3) in a total of over 650 patients (with
            over 400 Nyxol-treated) and has demonstrated promising clinical data across the three targeted refractive indications.</div>

          <div>&#160;</div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire reported positive top-line data from Phase 3 trials in RM: MIRA-2 in March 2021, MIRA-3 in March 2022 and MIRA-4 in April 2022.
            Ocuphire also reported positive top-line data from a Phase 2 trial of Nyxol for treatment of presbyopia, both alone and with low-dose pilocarpine (<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">pilocarpine
              hydrochloride ophthalmic solution 0.4%,</span> &#8220;LDP&#8221;) as adjunctive therapy (VEGA-1). Ocuphire reported top-line data from a Phase 3 trial in DLD in May 2022 (LYNX-1). Ocuphire submitted a new drug application (&#8220;NDA&#8221;) to the U.S. Food and
            Drug Administration (&#8220;FDA&#8221;) in November 2022 under the 505(b)(2) pathway for Nyxol for RM with a Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2023.&#160; The first phase 3 registration trial of Nyxol for the treatment of
            presbyopia (VEGA-2), both alone and with LDP as adjunctive therapy, was started in late December 2022, and topline results from this trial are expected in late 2023. Future trials are planned to start in 2023 including the second Phase 3
            registration trials for presbyopia (VEGA-3) and DLD (LYNX-2), and supportive long-term safety trial for both chronic indications (LYRA-1).</div>

          <div>&#160;</div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">APX3330</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire&#8217;s product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as
          diabetic retinopathy (&#8220;DR&#8221;) and diabetic macular edema (&#8220;DME&#8221;) which, if left untreated, can result in permanent visual acuity loss and eventual blindness. DR is a disease resulting from diabetes in which chronically elevated blood sugar levels
          cause progressive damage to blood vessels in the retina. DME is a severe form of DR which involves leakage of protein and fluid into the macula, the central portion of the retina, causing swelling and vascular damage. Prior to Ocuphire&#8217;s
          in-licensing this product candidate, APX3330 had been studied by other sponsors in a total of 11 clinical trials (6 Phase 1 and 5 Phase 2) in a total of over 420 healthy volunteers or patients (with over 340 APX3330-treated) for inflammatory
          (hepatic) and oncology indications, and had demonstrated evidence of target engagement, pharmacokinetics, durability, and favorable safety and tolerability. Ocuphire has also in-licensed APX2009 and APX2014, which are second-generation product
          candidates and analogs of APX3330. In January 2023, Ocuphire reported top-line efficacy and safety results from the ZETA-1 Phase 2 trial conducted in 103 subjects (51 treated with 600 mg daily dose of APX3330) in DR, including moderately severe
          non-proliferative DR (&#8220;NPDR&#8221;) and mild proliferative DR (&#8220;PDR&#8221;), as well as patients with DME without loss of central vision. Although the ZETA-1 clinical trial did not meet the primary endpoint of % of patients with a &#8805; 2-step improvement in
          Early Treatment of Diabetic Retinopathy Study (ETDRS) diabetic retinopathy severity scale (DRSS) at week 24 in the study eye,&#160; statistical significance was achieved on a key pre-specified secondary endpoint of preventing clinically meaningful
          progression of diabetic retinopathy (defined by binocular 3 or more steps worsening on the DRSS scale, calculated as the sum of changes in each eye) after 24 weeks of treatment. Given the oral systemic delivery of APX3330, an endpoint that
          evaluates the effects on both eyes is the planned Phase 3 primary endpoint for future registration trials; this will be confirmed at an End-of-Phase 2 (EOP2) meeting with the FDA in second half of 2023. APX3330 demonstrated favorable safety and
          tolerability in the ZETA-1 trial, consistent with the safety data from the prior 11 clinical trials. Treatment-related adverse events were uncommon, and most were mild in severity. There were no treatment-related serious adverse events. No
          changes were observed in liver, kidney, or heart function as well as complete blood count and comprehensive metabolic panel.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and seek strategic partners for late-stage development, regulatory preparation,
          and commercialization of drugs in key global markets.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-weight: bold;">Corporate History</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In February 2018, Ocuphire Pharma, Inc. (&#8220;Private Ocuphire&#8221;) was founded and subsequently merged in April 2018 with Ocularis Pharma, LLC, (the
            original innovator of phentolamine mesylate ophthalmic solution to treat DLD), and in January 2020 obtained from Apexian Pharmaceuticals, Inc. certain rights to its Ref-1inhibitor program, including APX3330 (see &#8220;Apexian Sublicense Agreement&#8221;).
            Many of Ocuphire&#8217;s employees, directors, advisors and consultants have been involved in the development of Nyxol and other ophthalmic drugs including approved products such as LUMIFY<sup>&#174;</sup><span style="font-size: 8pt; font-family: 'Times New Roman';">, </span>Zirgan<sup>&#174;</sup>, Durezol<sup>&#174;</sup>, Upneeq<sup>&#174;</sup>,<span style="font-size: 8pt; font-family: 'Times New Roman';">&#160;</span>Rhopressa<sup>&#174;</sup>, Roclatan<sup>&#174;</sup>, Vyzulta<sup>&#174;</sup>, Xiidra<sup>&#174;</sup>,
            Cequa<sup>&#174;</sup>, and Dextenza<sup>&#174;</sup>. The management team, led by CEO and founder Mina Sooch, collectively has significant experience in operating pharmaceutical companies and discovering, developing, and commercializing treatments in
            multiple therapeutic areas. Ocuphire also has a world-class medical advisory board of over 20 key opinion leaders including retina specialists, refractive surgeons, and optometrists.</div>

          <div>&#160;</div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">In November 2020, Private Ocuphire completed a reverse merger (the "Merger&#8221;) into Rexahn Pharmaceuticals, Inc. (&#8220;Rexahn&#8221;), a publicly-traded company that had ceased its business of drug
          development activities, and simultaneously raised $20 million through an offering of common shares and warrants to purchase common shares.&#160; In connection with the Merger, Rexahn changed its name to Ocuphire Pharma, Inc. and has since conducted as
          a public company the business previously conducted by Private Ocuphire.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In November 2022, Ocuphire entered into the Nyxol License Agreement, licensing its product Nyxol to Viatris.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-weight: bold;">Strategy</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire&#8217;s goal is to build a leading ophthalmic biopharmaceutical company that discovers, develops, commercializes and/or out-licenses
            best-in-class therapies for patients and provides attractive solutions for physicians and payers. The key elements of Ocuphire&#8217;s strategy to achieve its goal are the following:</div>

          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="font-weight: bold; color: rgb(0, 0, 0);">Advance the clinical development of Nyxol and APX3330</span><span style="color: rgb(0, 0, 0);">. </span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Ocuphire entered into the Nyxol License Agreement in November 2022, pursuant to which Viatris has exclusive rights to develop and commercialize Nyxol. Pursuant to the Nyxol License Agreement, Ocuphire continues to conduct
                    development activities in the United States in partnership with Viatris, and is reimbursed by Viatris for such budgeted development activities. Ocuphire submitted a United States NDA for Nyxol for RM </span>with a PDUFA goal date of
                  September 28, 2023, and <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">is advancing Phase 3 trials for presbyopia and DLD. Viatris has exclusive rights to pursue development and undertake commercialization
                    efforts for Nyxol outside of the United States. Ocuphire plans an EOP2 meeting with the FDA to advance Phase 3 trials for APX3330 in DR.</span></div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Target Nyxol and APX3330 for large ophthalmic indications</span>. Ocuphire believes Nyxol has therapeutic potential to improve vision performance in RM, presbyopia and DLD.
                  Ocuphire also believes AXP3330 has potential to prevent or delay the progression of disease in patients with DR, DME, and other retinal diseases, while potentially reducing the burden of intravitreal injections.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Maintain and expand its intellectual property portfolio</span>.
                    Ocuphire has out-licensed the global patent rights to Nyxol with respect to its formulation, combinations, and use in multiple indications to <span style="font-size: 10pt; font-family: 'Times New Roman';">Viatris</span>. Ocuphire owns
                    an exclusive worldwide sublicense for the Ref-1 Inhibitor program, including its product candidate APX3330, for all its ophthalmic and diabetic indications, and compositions and methods of use for Ref-1 pipeline candidates, including
                    APX2009 and APX2014. Ocuphire continues to explore additional opportunities to expand and extend this intellectual property protection, both in the U.S. and in other jurisdictions.</div>
                </div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="font-weight: bold; color: rgb(0, 0, 0);">Maximize the global commercial value of Nyxol and APX3330.</span><span style="color: rgb(0, 0, 0);"> If cleared to market by the FDA, Nyxol will be commercialized by the Viatris Eye
                    Care Division in the U.S. and major non-U.S. markets pursuant to the Nyxol License Agreement. Ocuphire plans to seek one or more partners to commercialize APX3330 both in and outside of the United States.</span></div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Evaluate in-licensing and acquisition opportunities</span>. Ocuphire&#8217;s team is well qualified to identify and in-license or acquire clinical-stage ophthalmological assets
                  and continually evaluates opportunities to expand and diversify its pipeline.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire is developing Nyxol with its partner Viatris for multiple indications, and Ocuphire is continuing to develop APX3330 for multiple indications with the goal to eventually seek a
          commercial partner for APX3330. Ocuphire believes the two programs present similar potential advantages: (1) promising clinical data to date; (2) both small-molecule clinical candidates; (3) convenient dosing route and schedule; (4) potential for
          first-line or adjunctive therapy; and (5) significant commercial potential. <span style="font-weight: bold;"><span style="text-decoration: underline;">TABLE 1</span></span> below summarizes Ocuphire&#8217;s current development pipeline of product candidates and their target indications and
          anticipated milestones:</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: center;">TABLE 1: Ocuphire Pipeline: Product Candidates and Indications Pipeline </div>

        <div style="text-align: center;">
          <div><br />
          </div>

          <div><img height="318" width="696" src="image0.jpg" alt="graphic" /></div>

          <div><br />
          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Note: 0.75% POS (Phentolamine Ophthalmic Solution) is the same as 1% PMOS (Phentolamine Mesylate Ophthalmic Solution). References to Nyxol with both designations appear throughout this document,
          there is no difference in formulation between the two designations.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire submitted its first NDA to the FDA for Nyxol for RM in November 2022 utilizing the 505(b)(2) pathway of the U.S. Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;). The FDA notified Ocuphire
          in February 2023 that it accepted the application for filing and that it has set a PDUFA goal date of September 28, 2023 for approval. Ocuphire anticipates submitting supplemental NDAs for Nyxol for presbyopia and DLD and is advancing APX3330
          towards an NDA in the future.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Overview of Eye Disease Market</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Anterior (Front of the Eye) Segment Disease Market</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">There are approximately 100 million eye dilations in the United States and this number is expected to go up with the increasing aging and
            diabetic population that requires more frequent eye exams and procedures. Millions of Americans also suffer from various refractive errors. Presbyopia, one such refractive error, is common in patients over the age of 40 years which results in
            decreased ability to see objects at a near distance. This condition affects over 120 million Americans and usually requires reading glasses and/or contact lenses for focusing on near objects. Further according to GlobalData, approximately 38
            million patients in the U.S suffer from dim light or night vision disturbances caused by LASIK, night myopia, keratoconus, eye surgery, or the natural aging process. There is also a global trend in vision disturbances in younger individuals due
            to the overuse of smartphone screens. Nyxol, which was out-licensed in 2022, is currently in late-stage clinical development for reversal of mydriasis (eye dilation), presbyopia and night vision disturbances, and has the potential to address an
            unmet need for millions of patients in the U.S.</div>

          <div>&#160;</div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">Retinal (Back of the Eye) Disease Market</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Retinal damage is one of the leading causes of blindness and continues to grow with aging and larger diabetic populations around the world. Diabetes is the leading cause of blindness among adults
          aged 20 &#8211; 74. According to the National Eye Institute, in the United States alone, over 7 million patients suffer from diabetic retinopathy (DR), a complication of diabetes in which chronically elevated blood sugar levels cause damage to blood
          vessels in the retina. An additional 750,000 patients suffer from diabetic macular edema (DME), one of the most common complications of diabetic retinopathy where the macula swells from fluid leaked from damaged blood vessels. The disease
          progression of both DR and DME involves abnormal vessel proliferation via VEGF signaling and inflammation. Ocuphire&#8217;s APX3330 oral tablet recently completed a Phase 2 clinical trial for DR and has the potential to address this large DR and DME
          market with a novel, dual mechanism of action of inhibiting VEGF and inflammation. In addition, over 1 million patients in the United States suffer from wAMD. These retinal and choroidal vascular diseases, which cause damage to the macula, are
          leading causes of severe, permanent vision loss. Currently, there are several drugs on the market indicated for anti-VEGF therapy, including Lucentis&#174; (ranibizumab), a monoclonal antibody marketed by Genentech, and EYLEA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (aflibercept), a recombinant fusion protein marketed by Regeneron Pharmaceuticals, Inc., that have become the standard of care for treating severe forms of DME and
          wAMD amongst other retinal conditions. Avastin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (bevacizumab), a monoclonal antibody marketed by Genentech, is also used off-label to treat these same indications as
          it is more cost-effective than the other branded drugs. These three injectable drugs are biologics with treatment administered in an ophthalmologist&#8217;s office. Annual worldwide sales of Lucentis and EYLEA for all indications totaled over $13
          billion in 2020 ($3.5 billion for Lucentis and over $10 billion for EYLEA).</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Summary of Nyxol and APX3330</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Nyxol (phentolamine 0.75% ophthalmic solution)</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Nyxol, out-licensed to <span style="font-size: 10pt; font-family: 'Times New Roman';">Viatris</span> in 2022, is a once-daily, sterile,
            preservative-free eye drop formulation containing phentolamine mesylate, a reversible, non-selective alpha-1 and alpha-2 adrenergic antagonist that acts on the adrenergic nervous system and inhibits contraction of smooth muscle. Ocuphire
            submitted an NDA to the FDA in November 2022 under the 505(b)(2) pathway for Nyxol for RM. The submission was accepted for filing by FDA with a PDUFA goal date of September 28, 2023. Phentolamine mesylate, the drug substance and active
            component of Nyxol, is the active pharmaceutical ingredient (API) in two FDA-approved drugs, Regitine<sup>&#174;</sup> and OraVerse<sup>&#174;</sup>. Regitine, an injectable approved in 1952, is used mainly to treat pre- or intra-operative hypertensive
            episodes in patients with pheochromocytoma. OraVerse, approved in 2007, is an intraoral submucosal injection used to reverse anesthesia after oral surgery. The FDA has stated that it would be acceptable for the Nyxol application to reference
            the FDA&#8217;s previous review of safety and efficacy for Regitine<sup>&#174;</sup> (Phentolamine Mesylate Injection, NDA 008278) and Oraverse<sup>&#174;</sup> (Phentolamine Mesylate Injection, NDA 22159), pursuant to section 505(b)(2) of the U.S. Federal
            Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;). In multiple clinical trials, Nyxol has been shown to reduce pupil size, improve near and distance visual acuity in light and dark conditions, and improve low contrast visual acuity. Ocuphire and <span style="font-size: 10pt; font-family: 'Times New Roman';">Viatris </span>are pursuing multiple indications for Nyxol, including RM, presbyopia, and DLD. For treatment of presbyopia, Ocuphire is evaluating the efficacy of Nyxol both as a
            single-agent eye drop and as adjunctive therapy with LDP.</div>

        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Key attributes of&#160; Nyxol include the following:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Reduction in pupil diameter with durable effects</span>. In multiple Phase 2 and Phase 3 trials Nyxol reduced pupil diameter by approximately 1 &#8211; 1.5 mm in both mesopic
                  (dim) and photopic (bright) conditions, with such reductions sustained over 24 hours.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Improvement in distance corrected near visual acuity</span>. When studied in patients with presbyopia in Phase 2 trials, Nyxol alone and in combination with LDP showed
                  statistically significant improvement in distance-corrected near visual acuity with &#8805;3 lines gain from baseline. Nyxol provides an optimal pupil size of 2 mm &#8211; 3 mm.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Improvement in low contrast visual acuity</span>. When studied in patients with DLD in multiple Phase 2 trials, Nyxol showed statistically significant improvement in low
                  contrast mesopic best-corrected distance visual acuity at &#8805;1 and &#8805;2 lines, with a trend at &#8805;3 lines on a standard visual chart.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Favorable tolerability profile</span>. To date, Nyxol has been observed to be well-tolerated, with unchanged or decreased intraocular pressure in the 12 completed Phase 1,
                  Phase 2 and Phase 3 clinical trials conducted. Nyxol produces a transient, mild hyperemia effect that disappears within several hours or immediately upon application of anti-redness eye drops. Nyxol is also observed to have no systemic
                  effects such as changes in blood pressure or heart rate.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Designed to be a convenient, once-daily eye drop or tunable combination option</span>. Nyxol is being evaluated for chronic use as a once-daily administration before
                  bedtime. Nyxol has been shown in multiple Phase 2 trials and Phase 3 trials to have a durable effect of over 24 hours, which could encourage patient compliance. Use of LDP eye drops as an adjunct to Nyxol may offer the benefit of
                  tunability to presbyopia patients based on their vision and lifestyle needs.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Stable, cost-effective ophthalmic formulation</span>. Nyxol is a single-use, preservative-free, proprietary eye drop formulation with stability suitable to support potential
                  commercialization. Its active pharmaceutical ingredient, phentolamine mesylate USP grade, is a small molecule with advantages of standardized, scalable, and lower-cost manufacturing processes.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify;">
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire and Viatris are initially pursuing Nyxol for the following three indications under the Nyxol License Agreement as a first-line therapy (in the case of
              presbyopia, both as a single agent and with low-dose pilocarpine as an adjunctive drop):</div>

            <div>&#160;</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">RM</span>, the reversal of pharmacologically induced dilation of the pupils, where dilation leads to increased sensitivity to light and an inability to focus, making it
                  difficult to read, work, and drive. RM is a single-use indication for which no approved therapy is commercially available at present.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Presbyopia</span>, a condition in which the eye&#8217;s lens loses elasticity, affecting its ability to focus on near objects. Presbyopia typically occurs after age 40 and most
                  patients use reading glasses in order to read or see objects close to them. Vuity<sup>TM</sup>, approved in October 2021, is the only eye drop currently marketed for the treatment of presbyopia.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">DLD</span>, a condition in which peripheral imperfections (aberrations) of the cornea scatter light when the pupil opens wide in dim light. Patients with DLD experience
                  glare, halos, starbursts, and decreased contrast sensitivity. DLD is a new indication with no approved therapies.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">APX3330</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">APX3330 (E3330), originally developed by Eisai Co., Ltd. and Apexian Pharmaceuticals, Inc., is a small molecule that specifically targets Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1
          (APE-1/Ref-1, referred to as Ref-1), a dual function protein involved in the regulation of transcription factors critical to cell signaling. Ref-1 regulates inflammation, angiogenesis (blood vessel formation), and reduction-oxidation (redox)
          signaling, as well as DNA repair that is critical to normal function of neurons. By inhibiting redox activity and not DNA repair, APX3330 has been shown in preclinical studies to reduce angiogenesis and inflammation via modulation of several
          important proangiogenic and proinflammatory transcription factors such as NF-&#954;B and HIF-1a and its downstream target, VEGF (Vascular Endothelial Growth Factor). These transcription factors are implicated in multiple pathways relevant to the
          pathophysiology of retinal and choroidal vascular diseases, including diabetic retinopathy (DR), diabetic macular edema (DME), wet age-related macular degeneration (wAMD) and geographic atrophy (GA). Moreover, data from these preclinical studies
          suggest that APX3330 is a promising candidate for clinical evaluation of the efficacy and safety of an oral systemic therapy to treat these important diseases.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Key attributes of Ocuphire&#8217;s product candidate APX3330 include the following:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Potential to be the first oral therapy.</span> Compared to frequent intravitreal anti-VEGF injections, associated with ocular complications, once or twice a day oral
                  administration of APX3330 could be a convenient, new preventative therapeutic option or adjunctive treatment option for large number of patients with retinal diseases, if approved.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Upstream target implicated in two validated pathways. </span>APX3330 is designed to lead to inhibition of two validated cell signaling pathways (angiogenesis and
                  inflammation) known to cause various retinal diseases. Moreover, the APX3330 mechanism of action is distinct in working upstream of the current anti-VEGF therapies, suggesting that it could complement anti-VEGF therapies and potentially
                  reduce frequency of doctor visits and intravitreal injections.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">Favorable tolerability profile.</span> In 12 completed Phase 1 and Phase 2 clinical trials, APX3330 was well-tolerated. The AEs were mostly infrequent and mild with
                  transient pruritis being the most common. No systemic effects such as changes in blood pressure or heart rate were seen, and no toxicities related to neurological, cardiovascular, renal, pulmonary, or gastrointestinal organs were
                  observed.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;"> <span style="font-weight: bold;">Potential benefit of systemic administration.</span>&#160; As a systemic agent, APX3330 can be expected to treat bilateral binocular (both
                  eyes) retinal vascular disease. </td>

  </tr>


</table>
        </div>

        <div> <br />
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
                  </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;"> <span style="font-weight: bold;">Stable, cost-effective oral tablet. </span>APX3330 is formulated as an oral tablet with
                    favorable stability characteristics, and its active pharmaceutical ingredient is a small molecule with the advantages of standardized, scalable, and lower-cost manufacturing processes.</td>

  </tr>


</table>
          </div>

        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire is initially pursuing APX3330 for the DR indication as first-line therapy and may explore opportunities for clinical benefit as adjunctive therapy for other retinal indications such as
          DME, wAMD, and GA:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">DR</span>, the leading cause of vision loss in adults aged 20&#8211;74 years, which results from chronic elevations of glucose in the blood that leads to cell damage in the
                  retina. Retinal key opinion leaders&#8217; feedback suggests that slowing of DR progression with an oral agent would be a useful treatment in patients with background DR and good visual function.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">DME</span>, one of the most common complications of DR, in which vascular leakage causes swelling of the retinal macula and a loss of visual acuity.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">wAMD</span>, a chronic eye disorder that causes visual distortions in the central part of one&#8217;s vision, in which abnormal blood vessels leak fluid or blood into the macula,
                  the part of the eye that is critical for central and color vision.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-weight: bold;">GA, </span>an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-weight: bold;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Nyxol&#8217;s Target Indications</div>

        </div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">RM (Nyxol)</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Mydriasis Overview</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Every year in the U.S., over 100 million eye exams or procedures are performed that require dilation of the pupil (mydriasis) to examine the back of the eye either for routine check-ups, disease
          monitoring or surgical procedures. The mydriasis is achieved either by stimulating the iris dilator muscle with the use of alpha agonists (e.g., phenylephrine), or by blocking the iris sphincter muscle with the use of muscarinic antagonists
          (e.g., tropicamide) or a combination of both mydriatic agents. Typically, pharmacologically induced mydriasis dilates the pupil to 7 mm to 8 mm, a size suitable for ophthalmic examination of the retina and other structures of the interior of the
          eye. Such pharmacologically induced mydriasis can last from a few hours (typically 6 hours) up to 24 hours, depending on the pigmentation of the iris, one&#8217;s age, and other factors. Side effects of mydriasis include sensitivity to light and
          blurred vision, which make it difficult to read, work, or drive. Many dilating drops also cause cycloplegia, the temporary paralysis of the muscle which allows the eye to focus on near objects. For this reason, many patients may request to avoid
          dilation, thus limiting the eye care provider&#8217;s ability to conduct a comprehensive annual eye exam.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">Limitations of Existing Treatments for Reversal of Mydriasis</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; font-size: 8pt;"><span style="font-size: 10pt;">There is no approved product presently on the market for reversal of mydriasis and Ocuphire is not aware of any others in development. In 1990, the
            FDA approved the selective alpha-1 antagonist dapiprazole, marketed as Rev-Eyes<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, to reverse mydriasis induced by adrenergic or anticholinergic agents. Rev-Eyes
            was eventually withdrawn from the market for reasons unrelated to safety or efficacy, according to the FDA.</span></div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Nyxol Opportunity in RM</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Nyxol has been shown in clinical studies to expedite the reversal of mydriasis compared to the eye&#8217;s natural process. According to GlobalData market research, over 65% of patients report a
          moderate to severe negative impact of a dilated exam, underscoring the potential value of Nyxol&#8217;s role in improving comfort and daily function after pupil dilation. Additionally, an estimated 45% of patients responded that they would be very
          likely to request a dilation reversal drop, and more than 40% of eye care providers would be likely to use a reversal drop if such a treatment were commercially available. Ocuphire believes that many people who undergo pupil dilation would
          benefit from a reversal treatment that has the potential to get patients back to their normal routines faster and avoid the subjective discomfort of dilation. Ocuphire also believes that if providers can offer a reversal drop there could
          potentially be more compliance with annual dilated eye exams.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Presbyopia (Nyxol)</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Presbyopia Overview</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Presbyopia is an age-related condition with onset most common in people over 40 years old. As the eye ages, the lens becomes stiffer, which limits the eye&#8217;s ability to adjust its focus for
          reading or for other tasks that require clear vision at near distances. Presbyopia patients experience blurred near vision, difficulty seeing in dim light, and eye strain. In young healthy eyes, lenses are able to focus light from objects at
          different distances by a process called accommodation. During accommodation, muscles surrounding the lens contract, causing the lens to change shape and increasing the focusing power of the eye. This allows dynamic, clear vision at both near and
          far distances. With increasing age, the lens becomes stiffer as the structural crystallin proteins become misfolded. This increased lens stiffness limits the eye&#8217;s ability to adjust its focus for reading or for other tasks that require clear
          vision at near distances. Because of the ubiquity of the condition, presbyopia represents a large market both in the United States and abroad totaling over 2 billion presbyopia patients. It is estimated that 120 million Americans have presbyopia,
          and this number is expected to grow as the population above the age of 45 increases.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Existing Treatments for Presbyopia</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The U.S FDA approved Vuity<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> (1.25% pilocarpine) eye drop for the treatment of presbyopia in October 2021. Vuity
          was launched in December 2021 and is marketed by Allergan, an AbbVie company. Additional available treatments for presbyopia include reading glasses, bifocals, gradients, bifocal contact lenses, and multifocal intraocular lenses. Reading glasses
          can be inconvenient and must be taken off and put on frequently throughout the day to see objects at far and near distances, respectively. Many patients express frustration with losing or forgetting their glasses. Additionally, some patients find
          glasses unflattering. Contact lenses for presbyopia also have drawbacks. They can only be used monocularly, where one eye is fitted with a presbyopic lens while the other is used for distance vision, which often leads to eye strain. Cholinergic
          agonist (pilocarpine, carbachol, aceclidine) eyedrops have potential negative side effects such as headache, brow ache and retinal detachment.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">A small portion of patients elect surgical intervention, including laser treatment to achieve monovision and insertion of KAMRA Inlays, a plastic implant into the cornea of the non-dominant eye
          to increase its depth of field. The risks of such interventions are those associated with all ocular surgeries, such as a potential decrease in contrast sensitivity and the creation or worsening of dim light or night vision disturbances.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">Nyxol Opportunity in Presbyopia</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Pupil diameter management is a promising strategy for the pharmacological treatment of presbyopia. Recent research suggests that an optimal pupil size of 2 mm to 3 mm diameter will lead to
          significant improvement in presbyopia symptoms by increasing depth of focus without compromising distance vision in photopic or mesopic lighting conditions. Ocuphire has been evaluating Nyxol as both a single-agent eye drop and with LDP as an
          adjunctive eye drop to achieve optimal pupil size and improve near vision. Nyxol has shown in several Phase 2 trials the ability to reduce pupil diameter size by 1-1.5 mm alone and by 2-2.5 mm when Nyxol is used with LDP. Nyxol alone provides
          durable near vision efficacy gain of up to 18 hours, and the Nyxol + LDP combination allows additional efficacy gains of up to least 6 hours.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">With respect to the treatment of presbyopia, Ocuphire believes that tolerability, convenience, and preservation of distance vision quality are of the utmost importance. Presbyopia is considered a
          &#8220;benign&#8221; condition, in that there is no risk of death or complete vision loss. Thus, any therapies without robust tolerability will not be suitable alternatives to reading glasses or contact lenses. Nyxol is being developed to be applied once
          daily before bed, with potential resolution of any mild transient hyperemia by morning. Nyxol&#8217;s unique mechanism of action on the iris dilator muscle has no to low risk of retinal detachment. According to GlobalData market research, 69% of
          patients would consider an eye drop alternative. Ocuphire believes that many presbyopes who are unsatisfied with their reading glasses or monocular contact lenses, and who would prefer a less invasive alternative than surgical intervention, would
          find Nyxol single-agent eye drop or the Nyxol + LDP drops a promising option, if approved.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">DLD (Nyxol)</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">DLD Overview</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Vision at night or in dim light conditions is different from daytime vision in several important ways. Most notably, at night, the pupils dilate to allow more light into the eye. Diminished night
          vision is a natural part of aging as well as a common side effect of several conditions and procedures. DLD is caused by peripheral imperfections (aberrations) of the cornea which scatter light when the pupil dilates in dim light conditions.
          These imperfections can be naturally occurring, especially with age, or surgically induced from refractive procedures such as LASIK. As the pupil dilates in response to mesopic conditions, light passes through the periphery of the cornea and
          lens, unlike during photopic conditions. Any imperfections or aberrations present on the periphery cause light to reach the retina in a non-focused and scattered way, creating glare, halos, starbursts, ghosting, and a loss of contrast sensitivity
          (&#8220;CS&#8221;). These visual disturbances can be debilitating to a variety of everyday activities, especially driving. The light emitted by traffic lights and other cars scatters and obscures most of the visual field, making driving in dim light
          conditions hazardous. Glare, in particular, can be dangerous while driving. In one study of 297 drivers given vision tests that correlate with accidents, 45% of the drivers who reported difficulty driving at night were unable to perform any of
          the tests with glare.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The effects of DLD can be reduced or eliminated by reducing the pupil size to a smaller diameter that prevents the scattering effect without impeding the ability to see at night. DLD can occur
          naturally (night myopia) and is commonly caused by ocular surgery (&#8220;LASIK&#8221;). One significant cause of night myopia is keratoconus, an orphan disease that starts at a young age with progressive thinning of the cornea usually due to genetic and
          environmental causes. Ocuphire estimates there are about 38 million individuals in the U.S. that suffer from DLD, with an estimated 16 million having moderate-to-severe DLD that may be directly addressable with a pupil management approach. Market
          research conducted by GlobalData of patients who self-report DLD showed 25% completely avoid driving at night. Furthermore, 67% who report moderate or severe DLD would be willing to try an eye drop treatment option. These patients can be
          segmented by the origins of their vision disturbance. Approximately 44% of DLD are the result of night myopia, followed by approximately 30% from cortical cataracts, 15% from post-intraocular lens (&#8220;IOL&#8221;) implants, and 10% following LASIK
          surgery. These conditions span an age range of late teenagers to those 80 years and older.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Limitations of Existing Treatments for DLD</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The biggest challenge for the treatment of DLD is the lack of safe, tolerable, convenient, and effective treatments. Despite a large number of addressable patients with moderate-to-severe DLD,
          there is no FDA-approved treatment on the market for DLD. Some commonly used tools such as tinted glasses are not effective, and in fact, may worsen patients&#8217; vision at night. Off-label use of approved miotic agents, such as regular-strength
          pilocarpine, are unsuitable for the treatment of DLD because they reduce pupil size to a degree that may impede safe night vision and may cause loss of accommodation.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">Nyxol Opportunity in DLD</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire believes it may have a new DLD treatment option that could improve patients&#8217; ability to see in dim lighting and significantly improve their quality of life. Nyxol is currently the only
          product candidate in development for DLD and could become the first pharmacological treatment option if approved. In addition to a potential first-mover advantage, Nyxol is being developed to be administered via convenient, once-daily dosing
          before bedtime and has been shown in multiple Phase 2 clinical trials to improve low contrast visual acuity in mesopic (dim) conditions on the standard visual chart. Nyxol has also been shown to be well-tolerated in these trials<span style="color: rgb(0, 0, 0);">.</span></div>

        <div style="text-align: justify;"><br />
        </div>

        <div>
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">APX3330&#8217;s Target Indications</div>

          <div>&#160;</div>

        </div>

        <div style="font-style: italic; font-weight: bold;"> Diabetic Retinopathy (APX3330)</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Diabetic Retinopathy Overview</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Diabetic Retinopathy (&#8220;DR&#8221;) is an eye disease resulting from diabetes, affecting over 7 million patients in the U.S., in which chronically elevated blood sugar levels cause damage to blood
          vessels in the retina. It is the leading cause of vision loss in adults aged 20&#8211;74 years. There are two major types of DR:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Non-proliferative DR, or NPDR</span>. NPDR is an earlier, more typical stage of DR and can progress into more severe forms of DR over time if untreated and if exposure to
                  elevated blood sugar levels persists.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);"><span style="font-style: italic;">Proliferative DR, or PDR</span>. PDR is a more advanced stage of DR than NPDR. It is characterized by retinal neovascularization and, if left untreated, leads to permanent
                  damage and blindness.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Therapies for NPDR and PDR are distinct. For NPDR, treatment is usually directed at observation, lifestyle changes, and control of elevated blood sugars that led to progression of NPDR in the
          first place. Additionally, the current treatment paradigm is for physicians to wait and monitor early-stage DR patients, with anti-VEGF or steroid injectable therapy or laser treatment reserved for patients who advance to proliferative DR or DME.
          In the Protocol S trial by the Diabetic Retinopathy Clinical Research Network, Lucentis was found to be noninferior to laser therapy in patients with PDR. Moreover, in 2018, from Regeneron&#8217;s PANORAMA trial, EYLEA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> reversed disease progression in patients with moderately severe to severe NPDR.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Diabetic Macular Edema (APX3330)</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Diabetic Macular Edema Overview</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Diabetic Macular Edema (&#8220;DME&#8221;) is a common complication of DR where the macula swells with fluid leaked from damaged blood vessels as a result of worsening diabetic retinopathy. It is one of the
          most common reasons for blindness in diabetics, affecting approximately 750,000 patients. DME may cause blurriness in the center of vision, the appearance of straight lines as wavy, colors that look dull or washed out, or blind spots. The
          pathogenesis of DME involves vascular leakage, retinal ischemia, and release of vaso-proliferative growth factors and inflammatory mediators.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In DME, corticosteroids and anti-VEGF agents are used to treat vascular leakage, inflammation and hypoxia/angiogenesis. In patients whose disease has progressed to DR with DME, anti-VEGF agents
          are first line therapy followed by corticosteroids. Lucentis was approved for treatment of DME with a dosing regimen of a 0.3 mg injection approximately every four weeks. Similarly, EYLEA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> was approved with a dosing regimen of a 2.0 mg injection approximately every four weeks.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">Limitations of Existing Treatments for DR and DME</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In DR (especially NPDR), despite the approvals of anti-VEGF therapeutics in recent years, the use of injectables is not adopted in practice as preferred treatment as the disease is asymptomatic
          and patients are reluctant to undergo injections or laser therapy.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In DME and late-stage DR, intravitreal VEGF inhibitors are approved globally, however these therapies rarely provide a complete solution to the underlying vascular problem associated with DR and
          DME. Although these therapeutic agents have been successful for some patients, significant proportions of patients are resistant and refractory. Moreover, serious side effects including hemorrhage and intraocular infections are possible with
          intravitreal injections. Both Lucentis and EYLEA are also associated with increased risks of blood clots in the arteries. In addition, intravitreal injections require frequent visits to the ophthalmologist, usually on the order of every 4 weeks
          with a few anti-VEGF therapies in development that are working on increasing the time between injections (8 &#8211; 12 weeks).</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Furthermore, retinal diseases are initially or over time bilateral, and thus treatments that only treat one eye, leave the other eye to remain untreated.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">APX3330 Opportunity in DR and DME</div>

        <div>&#160;</div>

        <div>
<div><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;&#160;&#160; </span><br /></div>

          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">In addition to being characterized by abnormal increases in VEGF levels, recent scientific literature reports indicate that diabetic
            eye disease has an inflammatory component, unrelated to VEGF. Because inflammation and hypoxic signaling (VEGF production) play crucial roles in both vascular leakage and neovascularization of DR and DME, treatments that impinge upon both
            pro-inflammatory and hypoxic signaling offer a promising therapeutic strategy. APX3330&#8217;s target of Ref-1 (a protein associated with inflammation and immune response) may leverage this dual mechanism of action (MOA) to reduce the production and
            hence the quantity of VEGF while also preventing inflammatory damage. The MOA of APX3330 is differentiated from traditional anti-VEGF treatments in that it does not neutralize&#160;the&#160;elevated levels of&#160;VEGF,&#160;but rather brings VEGF levels to normal
            homeostatic levels, thereby making it an ideal treatment option to prevent progression or worsening in earlier stages of diabetic eye disease.</div>

        </div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">This potentially allows for improved response to DR treatment and may extend the duration between invasive treatments for late-stage retinal diseases (DME, wAMD). Moreover, as a potential
          first-in-class, orally administered product candidate twice a day, it has the potential to be a more convenient option at an earlier stage of disease especially for DR than intravitreal anti-VEGF injections, which are burdensome to patients and
          have a significant side effect profile including cataract formation, increased intraocular pressure, intraocular infections, and retinal detachments. Furthermore, as a systemic therapy, APX3330 offers the potential to treat both eyes while
          maintaining a favorable safety profile.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Other Indications: </div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">wAMD </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Age-Related Macular Degeneration (&#8220;AMD&#8221;) is a common eye condition affecting 11 million individuals in the U.S. and 196 million globally, mostly over the age of 55 years. It is a progressive
          disease affecting the central portion of the retina, known as the macula, which is the region of the eye responsible for sharpness, central vision and color perception. wAMD is an advanced form of AMD characterized by neovascularization and fluid
          leakage under the retina. It is the leading cause of severe vision loss in patients over the age of 50 in the United States and EU. While wAMD represents only 10% of the number of cases of AMD overall, it is responsible for 90% of AMD-related
          severe vision loss. Untreated or undertreated wAMD results in further blood vessel leakage, fluid in the macula, and ultimately scar tissue formation, which can lead to permanent vision loss or even blindness as a result of the scarring and
          retinal deformation that occur during periods of non-<span style="color: rgb(0, 0, 0);">treatment or undertreatment. Similar to severe DR and DME, current therapy for wAMD consists of intravitreal injections, mainly of Lucentis and EYLEA. The
            limitations of these therapies are described in the section above titled, &#8220;Limitations of Existing Treatment for DR and DME&#8221;. Based on APX3330 targeting Ref-1 with a MOA of reducing overexpression of VEGF and inflammation, it has potential use
            in wAMD. Further, to enter the wAMD injectable market, Ocuphire is considering the utility of an intravitreal or sustained delivery formulation of APX3330 and its second-generation analogs, APX2009 and APX2014. APX2009 and APX2014 data suggest
            improved efficacy against the Ref-1 target compared to APX3330 (as published in the Journal of Pharmacology and Experimental Therapeutics).</span></div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">GA</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and irreversible vision loss. AMD is the leading cause of permanent vision loss in people over the age
          of 65 in developed countries, and the risk of developing AMD increases with age. Based on published studies, approximately 1 million people have GA in the United States, and 5 million people have GA globally. In people with GA, photoreceptors,
          which are light sensitive cells, deteriorate in the macula, a central portion of the retina responsible for central vision and color perception. This damage starts as small spots that grow into larger patches. As the cells in the macula die, the
          person starts to lose vision. A person with early AMD may notice problems with reading or night vision. Eventually, if the disease progresses to advanced stages, permanent blind spots (scotomas) in the center of the visual field will develop. The
          cause of GA is thought to be multifactorial including inflammation, with numerous environmental and genetic risk factors. The dysregulation of the complement cascade, an important part of the body&#8217;s immune system, plays a pivotal role. Excessive
          activation of the complement cascade results in destruction of healthy cells, which can lead to the onset or progression of many diseases including GA. SYFOVRE&#174; is the only FDA approved treatment for GA and requires monthly or every other month
          intravitreal injections. Based on APX3330 targeting Ref-1 with a MOA of anti-VEGF and anti-inflammatory MOA, it has potential use in GA.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Product Candidates-Nyxol </div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Nyxol Mechanism of Action</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Nyxol is a once-daily sterile eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. The
            active pharmaceutical ingredient of Nyxol, phentolamine mesylate, is a non-selective alpha-1 and alpha-2 adrenergic antagonist that inhibits activation of the smooth muscle of the iris, reducing pupil diameter. Unlike phentolamine, cholinergic
            agonists (such as pilocarpine, carbachol and aceclidine) work on the iris sphincter muscle to reduce the pupil diameter, and are associated with side effects given the engagement of the cilliary muscle such as headaches, brow aches and retinal
            detachments and have limited use in patients with high myopia. Nyxol shares many of the attributes of existing ophthalmic eye drops, including a convenient route of administration and cost-effective manufacturing process, with the potential
            advantage of once-daily dosing (<span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">FIGURE 1</span></span>).</div>

          <div>&#160;</div>

        </div>

        <div style="font-weight: bold;">FIGURE 1: Nyxol Product Candidate Profile</div>

        <div><br />
        </div>

        <div style="text-align: center;"><img height="304" width="622" src="image1.jpg" alt="graphic" /></div>

        <div style="text-align: center;"><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Phentolamine is a nonselective alpha-1 &amp; alpha-2 adrenergic antagonist. Dilation of the pupil is controlled by the radial iris dilator muscles surrounding the pupil which are activated by the
          alpha-1 receptors of the adrenergic nervous system. Alpha-1 antagonists bind to the receptors to inhibit the pupillary response and reduce dilation (<span style="font-weight: bold;"><span style="text-decoration: underline;">FIGURE 2</span></span>). Phentolamine mesylate is the active
          ingredient in two injectable FDA-approved drugs, Regitine and OraVerse, as described previously.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">For the RM indication, pharmacologically induced mydriasis is achieved either by stimulating the iris dilator muscle with the use of alpha agonists (e.g., phenylephrine), or by blocking the iris
          sphincter muscle with the use of muscarinic antagonists (e.g., tropicamide). Nyxol, either by directly antagonizing the alpha-1 agonist or by indirectly antagonizing the pupil dilation effect of muscarinic blocking, may expedite the reversal of
          mydriasis prior to natural reversal.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">For presbyopic patients, to overcome the lens&#8217; inability to change shape (accommodation) and focus light from near objects, pupil diameter reduction to a small size will allow light to come in
          the eye only in a near straight direction and increase the depth of focus (the &#8220;pinhole effect&#8221;). Ocuphire believes that it is possible to reach a target 2 mm to 3 mm optimal pupil diameter by relaxing the dilator iris muscle with Nyxol and
          contracting the iris sphincter muscle with a muscarinic agonist such as a low dose pilocarpine. This could result in an optimal depth of focus and near vision clarity without the assistance of lenticular accommodation.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Lastly, for the DLD indication, it is proposed that a moderate miotic effect by application of Nyxol might mitigate night vision difficulties, a large portion of which are caused by imperfections
          or aberrations present on the periphery of the cornea. Therefore, the effects of these imperfections can be reduced or eliminated by reducing the pupil size to a smaller diameter, knowing that a smaller pupil blocks what would be unfocused,
          aberrant rays of light on the retina.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-weight: bold;">FIGURE 2: Nyxol&#8217;s Mechanism of Action</div>

        <div>&#160;</div>

        <div style="text-align: center;">
<div><img height="256" width="624" src="image2.jpg" alt="graphic" /></div>

          <div><br />
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: center;"><img height="236" width="620" src="image3.jpg" alt="graphic" /><br />
          <br />
        </div>

        <div style="font-style: italic; font-weight: bold;">Nyxol Clinical Experience Summary</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Nyxol has been assessed in twelve investigator-initiated and company-sponsored Phase 1, Phase 2 and Phase 3 clinical trials. Across all trials,
            over 400 adult patients have been exposed to at least one dose of phentolamine ophthalmic solution. Phase 2 and Phase 3 trials have been accepted for poster or oral presentation at the annual American Academy of Ophthalmology (AAO), Association
            for Research in Vision and Ophthalmology (ARVO), or American Society of Cataract and Refractive Surgery (ASCRS) meetings.</div>

          <div>&#160;</div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire believes that results from Nyxol&#8217;s Phase 1, Phase 2 and Phase 3 trials support its current development plan focused on RM, presbyopia and DLD patients. Specifically, patients treated
          with Nyxol were observed to have statistically significant decreases in pupil diameter and improved visual acuity. Nyxol has shown consistent ability to decrease pupil diameter at the selected dose of 0.75% Phentolamine Ophthalmic Solution (POS)
          by approximately 20-25% (~1 &#8211; 1.5 mm) in both mesopic and photopic conditions.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">A summary of Ocuphire&#8217;s completed clinical trials is shown below (<span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">TABLE 2</span>).</span> Note that Nyxol in its current proprietary formulation of phentolamine mesylate ophthalmic solution was first introduced in the NYX-01a2 trial, and prior to that, a formulation of phentolamine mesylate in
            artificial tears solution was used. In subsequent sections, completed Phase 3 trials for RM (MIRA-2, MIRA-3, and MIRA-4), a Phase 2 trial for Presbyopia (VEGA-1) and a Phase 3 trial for DLD (LYNX-1) will be highlighted. Additionally, an ongoing
            Phase 3 trial for Presbyopia (VEGA-2) and preclinical animal studies will also be presented.</div>

          <div>&#160;</div>

        </div>

        <div style="font-weight: bold;">TABLE 2: Summary of Completed Clinical Trials with Nyxol</div>

        <div style="font-weight: bold;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trial</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(IND</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Number)</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Patient /</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Indication</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Phase</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td style="width: 18%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trial Objectives</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Doses</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Number of</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Patients&#94;</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Dosing</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Key</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Endpoints</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">NYX-001</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(67-288)</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Healthy Volunteers</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">1</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 18%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, single dose, 3-arm controlled, parallel trial to determine the efficacy and safety of phentolamine mesylate</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">0.2%</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PMOS</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nyxol*=15, Visine=15,</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Visine + Nyxol*=15</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total = 45</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Single-dose</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (PD)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">NYX-002&#94;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(67-288)</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Healthy Volunteers</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">1</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 18%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, placebo-controlled, single-dose, incomplete block, 3-period crossover, dose escalation trial evaluating the tolerability and efficacy of
                  phentolamine mesylate</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">0.2%, 0.4%, 0.8%</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PMOS</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nyxol*=16 Placebo=12</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total = 16</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="vertical-align: top; width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Single-dose</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (PD, VA)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">19</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OP-NYX-004&#94;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(73-987)</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Night Vision Disturbances Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">1 / 2</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 18%; vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, placebo-controlled, single-dose, incomplete block 3-period crossover, dose escalation trial to determine the efficacy and safety of
                  phentolamine mesylate</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">0.2%, 0.4%, 0.8%</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PMOS</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nyxol*=16 Placebo=12</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total = 16</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td rowspan="1" style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Single-dose</div>
                <div style="text-align: center; font-weight: bold;">&#8203;</div>
              </td>

    <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OP-NYX-SNV</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-736)</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Severe Night Vision Disturbances Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, placebo-controlled, single-dose trial to assess the efficacy and safety of phentolamine mesylate ophthalmic solution</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">1.0%</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PMOS</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nyxol*=16, Placebo=8</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total = 24</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Single-dose</div>
                <div style="text-align: center; font-weight: bold;">&#8203;</div>
              </td>

    <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (PD, LCVA, CS, WA)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OP-NYX-01a2</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-499)</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Severe Night Vision Disturbances Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, placebo-controlled, single-dose, 3-arm trial to assess the efficacy and safety of Nyxol</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">0.5%, 1.0%</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PMOS</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nyxol=40 Placebo=20</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total = 60</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Multiple doses (15-28 days)</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (PD, LCVA, CS)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OPI-NYXG-201</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(ORION-1)</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-499)</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Glaucoma and Ocular Hypertension, Elderly Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2b</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, placebo-controlled, multiple-dose, multi-center trial to assess the efficacy and safety of Nyxol</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div>&#160;</div>
                <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-weight: bold;">1.0%</div>
                <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-weight: bold;">PMOS</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nyxol=19 Placebo=20</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total = 39</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Multiple doses (14 days)</div>
                <div style="text-align: center;">&#8203;</div>
              </td>

    <td colspan="1" rowspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (IOP, PD, near VA, VA)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OPI-</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">NYXRM-201</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(MIRA-1)</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-499)</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Healthy Patients/ Reversal of Mydriasis</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2b</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, placebo-controlled, crossover, single-dose, multi-center trial to assess the efficacy and safety of Nyxol in reducing pharmacologically
                  induced mydriasis</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>&#160;</div>
                <div style="text-align: center; margin-left: 18pt; color: rgb(0, 0, 0); font-weight: bold;">1.0%</div>
                <div style="text-align: center; margin-left: 18pt; color: rgb(0, 0, 0); font-weight: bold;">PMOS</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nyxol=31 Placebo=32</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total = 32</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Single-dose</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (PD, Accommodation, VA)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OPI-</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">NYXRM-301</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(MIRA-2)</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-499)</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Healthy Patients/ Reversal of Mydriasis (including 12&#8211;17 years-old)</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">3</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, placebo-controlled, single-dose, multi-center trial to assess the efficacy and safety of Nyxol in reducing pharmacologically induced
                  mydriasis</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">0.75%</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">POS</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nyxol=94</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Placebo=91</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total = 185</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Single-dose</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (PD, Accommodation, VA)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">20</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OPI-NYXRM-302 (MIRA-3)</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-499)</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-weight: bold;">Healthy Patients/ Reversal of Mydriasis (including 12-17-years old)</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-weight: bold;">Double-masked, randomized, placebo-controlled, single-dose, multi-center trial to assess the efficacy and safety of Nyxol in reducing pharmacologically induced mydriasis</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">0.75%</div>
                <div style="text-align: center; font-weight: bold;">POS</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">POS=214</div>
                <div style="text-align: center; font-weight: bold;">Placebo=124</div>
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">Total = 368</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-weight: bold;">Single-dose</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-weight: bold;">Safety and Efficacy (PD, Accommodation, VA)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OPI-NYXRMP-303&#160; (MIRA-4)</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-499)</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Healthy Patients/ Reversal of Mydriasis (between ages of 3-and 11)</div>
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top;">
                <div style="text-align: center; font-weight: bold;">Randomized, Parallel-Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically Induced
                  Mydriasis in Healthy Pediatric Subjects</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">0.75%</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">POS</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="vertical-align: top; width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">POS=11</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Placebo-12</div>
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total=23</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Single-dose</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="vertical-align: top; width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (PD, VA)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OPI-NYXP-201</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(VEGA-1)</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-499)</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-weight: bold;">Presbyopia patients (ages of 40 and 64)</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-weight: bold;">2</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-weight: bold;">Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) with Low-Dose (0.4%) Pilocarpine Eye Drops in Subjects with
                  Presbyopia</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">0.75%</div>
                <div style="text-align: center; font-weight: bold;">POS</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 12%;">
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">Nyxol +LDP</div>
                <div style="text-align: center; font-weight: bold;">= 44</div>
                <div style="text-align: center; font-weight: bold;">Placebo alone = 45</div>
                <div style="text-align: center; font-weight: bold;">Nyxol&#160; alone</div>
                <div style="text-align: center; font-weight: bold;">&#160;= 30</div>
                <div style="text-align: center; font-weight: bold;">Placebo +LDP = 31</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-weight: bold;">Multiple doses (4-5 days), Single dose of LDP</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 12%;">
                <div style="text-align: center; font-weight: bold;">Safety and Efficacy (DCNVA, VA, PD)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 11%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OPI-NYXDLD-301</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(LYNX-1)</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(70-499)</div>
              </td>

    <td colspan="1" style="width: 1%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td style="width: 11%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Night Vision Disturbances in adults</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 18%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects with Dim Light Vision Disturbances</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">0.75%</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">&#160;POS</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 12%;">
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">&#160;POS=72</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Placebo=73</div>
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Total =145</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
                <div style="text-align: center; font-weight: bold;">Multiple doses</div>
                <div style="text-align: center; font-weight: bold;">(14 days)</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Safety and Efficacy (mLCVA, VA, PD)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; margin-right: 1pt; font-style: italic;">
          <div style="text-align: justify; margin-right: 1pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Note: Nyxol = phentolamine mesylate in proprietary formulation, Nyxol* = phentolamine mesylate in commercial artificial
            tears solution. &#94; Total patient numbers will not equal to the sum of the subgroups in crossover studies (NYX-002, NYX-004, and NYXRM-201). <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">0.75% POS (Phentolamine
              Ophthalmic Solution) is the same as 1% PMOS (Phentolamine Mesylate Ophthalmic Solution). References to Nyxol with both designations appear throughout this document, and there is no difference in formulation between the two designations.</span></div>

        </div>

        <div>CS, contrast sensitivity; DCNVA, distance-corrected near visual acuity; DLD, dim light vision disturbances; IND, Investigational New Drug application; IOP, intraocular pressure; LCVA, low-contrast visual acuity; LDP, low-dose pilocarpine; OHT,
          ocular hypertension; PD, pupil diameter; POS, Phentolamine Ophthalmic Solution or Nyxol; PMOS, Phentolamine Mesylate Ophthalmic Solution or Nyxol; * represents phentolamine mesylate in commercial artificial tears solution; RM, reversal of
          mydriasis; VA, visual acuity; WA, wavefront aberrometry.</div>

        <div>Total subject numbers will not equal the sum of the subgroups in crossover studies (NYX-002, NYX-004, and NYXRM-201).</div>

        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">MIRA PROGRAM &#8211; Reversal of Mydriasis Indication for Nyxol</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Nyxol RM: MIRA-3 and MIRA-2 Phase 3 Registration Trials (Completed)</div>

        <div>&#160;</div>

        <div style="text-indent: 9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MIRA-2 and MIRA-3 were double-masked, randomized, placebo-controlled, multi-center trials of Nyxol compared with vehicle (placebo) in normal healthy subjects. In MIRA-2, a total of 185 subjects (including 14
          pediatric subjects aged 12&#8211;17 years) were randomized 1:1 to receive Nyxol or placebo treatment 1 hour following dilation with 1 of 3 mydriatic agents (2.5% phenylephrine, 1% tropicamide, or Paremyd 3:1:1, respectively). Stratification by light or
          dark irides was 1:1. Measurements were taken at 0 minutes, 30 minutes, 1 hour, 90 minutes, 2 hours, 3 hours, 4 hours, and 6 hours following administration of study medication. In MIRA-3, treatment randomization was 2:1 (Nyxol or vehicle
          [placebo], respectively) and stratification by light or dark irides was 1:1. As in MIRA-2, the mydriatic agent randomization was 3:1:1 (2.5% phenylephrine, 1% tropicamide, or Paremyd), respectively, and the randomized subjects received 1 drop of
          mydriatic agent 1 hour before treatment. In MIRA-3, a total of 368 subjects (including 31 pediatric subjects aged 12&#8211;17 years) were randomized to treatment.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">In MIRA-2 and MIRA-3, treatment (Nyxol or placebo) was administered OU, with the study eye defined as the right eye (OD) and the fellow eye defined as the left eye (OS). Subjects had 2 drops of treatment administered
          5 minutes apart in the study eye (OD) and 1 drop of treatment administered in the fellow eye (OS) 1 hour after mydriatic drug administration. Pediatric subjects (aged 12&#8211;17 years) in MIRA-2 received only 1 drop of treatment OU.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">
          <div>In both of the 2 Phase 3 registration studies, Nyxol met the primary endpoint <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(<span style="text-decoration: underline;">FIGURE 3A</span>)</span>. In the mITT Population, a statistically significant
            and clinically meaningful greater percent of subjects treated with Nyxol had study eyes that showed reversal of mydriasis 90 minutes post-dose, using a PD threshold of &#8804;&#160;0.2&#160;mm from baseline compared with the placebo treatment (49% vs 7%,
            respectively, in MIRA-2 and 58% vs 6%, respectively, in MIRA-3; all p&lt;0.0001). Importantly, similar statistically significant results were observed 60 minutes post-dose (28% vs 2%, respectively, in MIRA-2; p&lt;0.0001 and 42% vs 2%,
            respectively, in MIRA-3; p&lt;0.0001). The statistically significant benefit was also seen at all other time points and persisted through 24 hours. In the 2 studies 80% and 79% of Nyxol-treated subjects had their pupils return to pre-dilation
            pupil size within 3 hours compared with only 18% and 14% of subjects treated with placebo for the MIRA-2 and MIRA-3 studies, respectively. <br />
          </div>

        </div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">In each of the studies, Nyxol effect on mean PD further supported the results of the primary endpoint analysis. A statistically significant reduction in mean PD from maximum PD (0 minutes) with Nyxol versus placebo
          treatment was observed as early as 60 minutes post-dose, increasing in magnitude through 90 minutes. The significant reduction in PD compared to placebo persisted through 24 hours. Results were consistent between the 2 trials <span style="font-weight: bold;">(<span style="text-decoration: underline;">FIGURE 3B</span>)</span>. In both studies, the mean PD of Nyxol-treated study eyes returned from maximum PD to predilation baseline values (&gt; 1.8 mm decrease) at 90 minutes post-dose. In contrast, in study eyes
          treated with placebo, the mean PD decreased by &lt; 0.5 mm at 90 minutes post-treatment and the mean PD remained greater than baseline through 6 hours (7 hours after dosing of the mydriatic) in both studies. Overall, Nyxol reduced PD from
          baseline by 20 to 30% (1 to 1.5 mm)</div>

        <div>&#160;</div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">22</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">FIGURE 3: Study OPI-NYXRM-302 (MIRA-3) and OPI-NYXRM-301 (MIRA-2): Percent of patients returning to &#8804;0.2 mm of baseline pupil diameter in MIRA-3 (left panel) and MIRA-2 (right panel)</div>

        <div>&#160;</div>

        <div>1.</div>

        <div>&#160;</div>

        <div style="text-align: center;"><img height="235" width="616" src="image4.jpg" alt="graphic" /></div>

        <div>&#160;</div>

        <div>B.</div>

        <div>&#160;</div>

        <div style="text-align: center;"><img height="212" width="616" src="image5.jpg" alt="graphic" /></div>

        <div style="text-align: center;"> <br />
        </div>

        <div>Note: POS = Nyxol</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Similar efficacy results were observed regardless of whether eyes were treated with 1 drop or 2 drops. Efficacy was demonstrated across all 3 mydriatic agents and in light and dark irides.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Treatment with Nyxol was generally safe and well tolerated. The most common adverse reactions (&gt;&#8239;5.0%) that have been reported are conjunctival hyperemia, instillation site discomfort, and dysgeusia; all were
          transient and primarily mild. Most TEAEs were ocular, as expected, and the vast majority were mild in intensity and resolved within hours of study medication instillation. There were no deaths, serious AEs or other significant AEs. Results from
          MIRA-2 and MIRA-3 studies were presented at several medical conferences in 2022.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Nyxol RM: MIRA-4 Pediatric Trial (Completed)</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">MIRA-4 was a 1-day, double-masked, randomized, placebo-controlled, single-dose, multi&#8209;center study with 23 pediatric subjects </span>aged 3 to 11 years<span style="color: rgb(0, 0, 0);">, healthy or with ocular conditions. A total of 23&#8239;randomized pediatric subjects were evaluated for the safety and efficacy of Nyxol in reversal of pharmacologically induced mydriasis. Each subject was randomized to
            unmasked mydriatic agent and masked treatment. Treatment randomization was 1:1 (Nyxol or placebo [vehicle], respectively) and stratification by subject age group was 1:1, 3 to 5 years of age or 6 to 11 years of age. The mydriatic agent
            randomization was 3:1:1 (2.5% phenylephrine, 1% tropicamide, or Paremyd, respectively).</span></div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">23</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">In MIRA-4,</span> study treated with Nyxol, 64% had PD returned to &#8804; 0.2 mm from baseline PD at 90 minutes compared to 25% of study eyes treated with placebo eyes in the mITT
          Population. This effect is similar to those seen in the adult registration studies (study eye: 49% vs 7%, respectively, in MIRA-2; p&lt;0.0001 and 58% vs 6%, respectively, in MIRA-3; p&lt;0.0001; fellow eye: 49% vs 6%, respectively, in MIRA-2;
          p&lt;0.0001 and 52% vs 6%, respectively, in MIRA-3; p&lt;0.0001). Among subjects aged 3 to 5 years (n=11), Nyxol showed numerically greater reversal of mydriasis in the study eye compared with placebo at 90 minutes (60% vs 17%, respectively), 3
          hours (80% vs 50%, respectively), and 24 hours (100% vs 50%, respectively). Among subjects aged 6 to 11 years (n=12), Nyxol showed numerically greater reversal of mydriasis in the study eye compared with placebo at 90 minutes (67% vs 33%,
          respectively), 3 hours (83% vs 17%, respectively), and 24 hours (83% vs 50%, respectively).</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt; color: rgb(0, 0, 0);">The efficacy of Nyxol in pediatric subjects showed a similar magnitude of reversal of mydriasis to the efficacy of Nyxol in adults overall and across mydriatic agents. In a pooled analysis of 45
          pediatric subjects (aged 12-17 years) in MIRA-2 and MIRA-3, 44% of Nyxol-treated study eyes (vs 6% placebo; p=0.0286) at 60 minutes and 63% (vs 0% placebo; p=0.0067) at 90 minutes returned to baseline PD. Results with the individual agents were
          also similar to those observed in adults.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">No overall differences in safety have been observed between pediatric subjects aged 3 to 17 years or the elderly when compared to adult subjects. Results from MIRA-4 study were presented at the annual American
          Academy of Optometry 2022 meeting in San Diego.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">VEGA PROGRAM &#8211; Presbyopia Indication for Nyxol and Nyxol+LDP</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Nyxol Presbyopia: Phase 2 VEGA-1 Trial (Completed)</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">VEGA-1 (NYXP-201) was a double-masked, randomized, placebo-controlled, multi-center trial of Nyxol and LDP compared with vehicle (placebo) ophthalmic solution in presbyopic patients. A total of 150 patients were
          randomized 3:2:2:3 to receive Nyxol + LDP, Nyxol alone, LDP alone, or placebo, respectively. Nyxol or placebo was dosed for 3 or 4 consecutive evenings prior to binocular and monocular testing under photopic and mesopic lighting conditions.
          Measurements were made between 0 and 6 hours following administration of Treatment 2 (LDP or No Treatment). The primary efficacy endpoint for this study was the percent of patients who improved by &#8805; 15 letters in DCNVA at 90 minutes
          post-treatment.<span style="color: rgb(164, 38, 44);"><span style="text-decoration: underline;">&#160;</span></span>The data from this study was presented at several medical conferences in 2021 and 2022.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Nyxol as a Single Agent</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt;">Following 3 to 4 days of treatment with Nyxol or placebo, 29% of Nyxol-treated subjects had &#8805; 15 letters improvement in photopic binocular DCNVA compared with 12% of placebo-treated subjects 12 hours after the last
          dose (p=0.02). This benefit was durable and remained stable over the next 6 hours (or 18 hours), with a mean of 37% of Nyxol-treated subjects improving by &#8805; 15 letters DCNVA 18 hours post-dose. Using a clinically meaningful criterion of a
          10-letter improvement in DCNVA, 53% of subjects responded to Nyxol at the 12-hour time point compared to 28% of placebo-treated subjects (p=0.0046) <span style="font-weight: bold;">(<span style="text-decoration: underline;">FIGURE 4</span>)</span>.</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Nyxol + LDP as Adjunctive Therapy</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt;">A statistically significant greater number of subjects in the PP Population treated with Nyxol + LDP had &#8805; 15 letters improvement in photopic binocular DCNVA at 1-hour post-LDP treatment (primary endpoint) compared
          with placebo alone (61% vs 14%, respectively; p&lt;0.0001). In addition, the Nyxol + LDP arm had significantly more subjects with &#8805; 15 letters improvement in photopic binocular DCNVA compared with placebo alone at all time points from 30 minutes
          through 4 hours post-LDP treatment (p&#8804;0.0166). This benefit was retained for all time points between 30 minutes and 4 hours when requiring that subjects with &#8805; 15 letters improvement in photopic binocular DCNVA also had to have &lt; 5 letters
          loss in photopic binocular BCDVA, the accepted registration endpoint. The percentage of Nyxol + LDP responders was also significantly better than placebo at 30 minutes (77% vs 51%, respectively; p=0.0146) and all subsequent timepoints through 3
          hours (p&#8804;0.0312) when using a clinically meaningful criterion of a 10-letter improvement in DCNVA <span style="font-weight: bold;">(<span style="text-decoration: underline;">FIGURE 4</span>)</span>.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">24</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">FIGURE 4: Study OPI-NYXP-201 (VEGA-1): Percent of Patients Gaining &#8805; 15 Letters in Binocular Photopic DCNVA by Treatment Arm and Timepoints</div>

        <div>&#160;</div>

        <div style="text-align: center;">&#160;<img height="262" width="614" src="image6.jpg" alt="graphic" /></div>

        <div><br />
        </div>

        <div style="text-indent: 36pt;">Nyxol and Nyxol+LDP provided durable optimal pupil diameter of ~ 2 mm to 3 mm, offering improvement in near vision without the loss of distance vision (<span style="font-weight: bold;"><span style="text-decoration: underline;">FIGURE 5</span></span>). Nyxol
          and Nyxol+LDP maintained a dynamic pupillary response when transitioning between photopic and mesopic lighting conditions.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">25</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">FIGURE 5: Study OPI-NYXP-201 (VEGA-1): Mean pupil diameter</div>

        <div><br />
        </div>

        <div style="text-align: center;"><img height="345" width="625" src="image7.jpg" alt="graphic" /></div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Nyxol alone as well as Nyxol +LDP were both well-tolerated with a favorable safety profile. Instillation site discomfort and conjunctival hyperemia were the only adverse events (AEs) that occurred in &#707;5% patients,
          and 95% of the AEs were mild and none were severe. Visual acuity was not adversely affected. There were no deaths, no systemic AEs, no serious AEs or withdrawals due to AEs in patients receiving Nyxol only. No headaches, brow aches or blurry
          vision AEs were observed.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-weight: bold;"><span style="font-style: italic;">Nyxol Presbyopia: Phase 3 VEGA-2 Trial (Ongoing)</span></div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">VEGA-2 (NYXP-301) is a double-masked, randomized, placebo-controlled multi-center trial of Nyxol as a single agent compared to placebo and with adjunctive LDP compared with vehicle (placebo) in presbyopic patients.&#160;
          Approximately 320 subjects are randomized to one of 4 treatment groups in 2 stages.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">The first stage consists of 2 treatment groups (Nyxol or Placebo [i.e., Nyxol vehicle]), with approximately 160 subjects in each group.&#160; Stage 2 consists of 4 treatment groups (Nyxol + LDP, Nyxol + LDP vehicle,
          placebo + LDP, and placebo + LDP vehicle), with approximately 80 subjects per treatment group. Randomization will be stratified by light/dark irides. The first subject was enrolled into the study in late December 2022. Patients are treated with
          Nyxol or Placebo for 7 days followed by a washout period of 7 to 14 days. During the washout period, patients will return on Day 10 to assess the resolution of drug treatments effects on PD.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">In the second stage, Nyxol + LDP will be evaluated following 1 day and 7 days of dosing with both treatment regimes. For both stages of the trial, Nyxol or Placebo is dosed once daily in each eye in the evening and
          for stage 2, LDP or LDP vehicle is dosed once daily in each eye in the morning.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">The primary efficacy endpoint is the percent of subjects with &#8805; 15 letters of improvement in photopic binocular DCNVA and with &lt; 5 letters of loss in photopic binocular BCDVA from Baseline comparing Nyxol-treated
          subjects to placebo-treated subjects at 12 hours post-dose at Day 8 during stage 1. The key secondary endpoint to evaluate LDP adjunctive to Nyxol in stage 2 is the percent of subjects with &#8805; 15 letters of improvement in photopic binocular DCNVA
          and with &lt; 5 letters of loss in photopic binocular BCDVA at 30 minutes post-LDP/vehicle comparing LDP as adjunctive therapy to Nyxol to placebo, Nyxol alone, and LDP alone following 8 days of dosing. This trial is ongoing with topline results
          expected in late 2023.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">26</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">LYNX PROGRAM &#8211; Dim Light Vision Disturbances Indication for Nyxol</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Nyxol DLD: Phase 3 LYNX-1 Trial (Completed)</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">LYNX-1 (NYXDLD-301) was a Phase 3 double-masked, randomized, placebo-controlled, multi-center study of POS compared with placebo ophthalmic
          solution in patients with dim light vision disturbances (DLD) at multiple sites in the U.S. In this trial, 145 patients who experienced vision impairment under dim light conditions were randomized to receive either Nyxol or placebo. Each subject
          was randomized 1:1 to treatment with Nyxol or placebo ophthalmic solution and<span style="font-size: 12pt; font-family: 'Times New Roman';">&#160;</span>stratified by iris color (light/dark irides). Treatment was self-administered in each eye QD at or
          near bedtime for 14 days.<span style="font-size: 12pt; font-family: 'Times New Roman';">&#160;</span>Efficacy was measured by assessment of mLCVA, photopic LCVA (pLCVA), best-corrected distance visual acuity (BCDVA), mesopic high-contrast BCDVA
          (mHCVA), distance-corrected near visual acuity (DCNVA), mesopic high-contrast DCNVA, mesopic PD, photopic PD, subject questionnaire, and wavefront aberrometry. Safety assessments included conjunctival hyperemia, slit lamp biomicroscopy,
          ophthalmoscopy, IOP, physical exams, HR, and BP. Data from LYNX-1 may support the Nyxol-single agent differentiation in presbyopia.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">At Day 8 (primary endpoint), a statistically significantly greater percent of subjects treated with Nyxol in the mITT Population had study eyes
          with &#8805; 15 letters improvement from baseline in mLCVA compared with placebo treatment (13% vs 3%, respectively; p=0.0459). A significantly greater percentage of subjects treated with Nyxol also had study eyes with &#8805; 15 letters improvement from
          baseline in mLCVA compared with placebo treatment at Day 15 (21% vs 3%, respectively; p=0.0042) <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(<span style="text-decoration: underline;">FIGURE 6</span>)</span>.</div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">FIGURE 6: Percent of Subjects With &#8805; 15 Letters Improvement in Mesopic Low-Contrast Best-Corrected Distance Visual Acuity in the Study Eye by Visit (mITT Population)</div>

        <div>&#160;</div>

        <div style="text-align: center; text-indent: 36pt;"><img height="284" width="375" src="image8.jpg" alt="graphic" /></div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Nyxol was safe and well tolerated in this study. Adverse events occurring in &#8805; 5% of subjects were instillation site erythema, instillation site
            pain, conjunctival hyperemia, and dysgeusia. No subjects in the Nyxol group experienced AEs of vitreous floaters, retinal tears, or retinal detachment. No subjects had any serious TEAEs or any TEAEs leading to withdrawal from the study, and no
            subjects died during the study. One subject in each treatment group had TEAEs leading to study medication discontinuation (instillation site erythema and instillation site pain in the Nyxol group and instillation site irritation and lacrimation
            increased in the placebo group. A total of 66 TEAEs were reported in 23 subjects (32%) treated with Nyxol and 22 TEAEs were reported in 12 subjects (16%) treated with placebo. All TEAEs were mild or moderate in intensity, except for 1 TEAE
            experienced by a subject in the Nyxol group, which was severe in intensity (instillation site pain), which was considered definitely related per the Investigator).</div>

        </div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">27</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Nyxol Nonclinical Toxicology Studies</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div>As part of a comprehensive nonclinical toxicity program, Ocuphire conducted 3 exploratory and 2 GLP single- and repeated-dose toxicity studies of phentolamine mesylate drug substance in rabbits and beagle dogs. There were no Nyxol-related
            histopathologic ocular pathology findings. <br />
          </div>

          <div> <br />
          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Nonclinical information (pharmacological properties, general and reproductive toxicology) for phentolamine mesylate is described in the literature in connection with other approved phentolamine
          drug products and formulations, and was reviewed by the FDA in the approval process of the market applications for Oraverse and Regitine.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">For chronic administration of Nyxol, a 6-month repeated-dose toxicity study with Phentolamine Ophthalmic Solution 0.75% in Dutch-belted rabbits showed that topical administration of the drug
          product is safe and well tolerated. The study was reported to the FDA and no adverse comments were received. This 6-month toxicology study supports the long-term safety exposure trial which will be the basis of the marketing authorization for
          long-term treatment and chronic indications of presbyopia and DLD for Nyxol.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In support of administration of Pilocarpine Hydrochloride Ophthalmic Solution 0.4% (LDP) as adjuctive therapy to Nyxol for long term treatment, Ocuphire has performed a 99-day nonclinical
          toxicology study with Nyxol and LDP doses in Dutch belted rabbits. The study showed that the combination was well tolerated, with findings similar across all nonclinical studies performed with Nyxol by Ocuphire. The findings of this study support
          any future chronic indication for such combination.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Product Candidates-APX3330</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">APX3330 (E3330) is an oral formulation administered twice a day and is designed to target multiple pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR)
          and diabetic macular edema (DME), which, if left untreated, may progress to permanent visual acuity loss and eventual blindness. Mechanistic studies and prior clinical experience suggest that APX3330 is a promising candidate for clinical
          evaluation of its efficacy and safety in the treatment of these diseases, beginning with DR and DME. Ocuphire believes APX3330 shares desirable attributes for back of the eye therapies, including broad therapeutic applications, a convenient route
          of administration and cost-effective manufacturing process, without the need for uncomfortable intravitreal injections (<span style="font-weight: bold;"><span style="text-decoration: underline;">FIGURE 7</span></span>).</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In preclinical pharmacology studies in animal models or in vitro, APX3330 has demonstrated the ability to decrease angiogenesis and inflammation in the retina whether delivered orally,
          systemically, or directly into the eye via intravitreal injections. In humans, APX3330 was shown to be clinically well-tolerated in multiple Phase 1 and 2 trials with fewer than 10% of the patients experiencing mild, self-limiting side effects,
          such as nausea or diarrhea. In addition, it was shown that significant amounts of oral APX3330 reach the bloodstream concentrations in humans and higher than the levels in mice which showed effects in the retina.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire is initially pursuing a moderate-to-severe non-proliferative retinopathy (NPDR) or mild proliferative retinopathy (PDR) indication, as well as patients with DME without loss of central
          vision. Additionally, Ocuphire may explore opportunities for clinical benefit as adjunctive therapy for other retinal indications such as DME, wAMD, and GA. Second-generation candidate, APX2009, may also be considered for intravitreal or
          sustained injections.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">28</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-weight: bold;">FIGURE 7: APX3330 Product Candidate Profile</div>

        <div>&#160;</div>

        <div style="text-align: center;">
<div><img height="233" width="615" src="image9.jpg" alt="graphic" /></div>

          <div><br />
          </div>

        </div>

        <div>*1 subject had vision blur thought to be related by investigator in ZETA-1 trial</div>

        <div><br />
        </div>

        <div style="text-align: justify; font-style: italic; font-weight: bold;">APX3330 Mechanism of Action</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">APX3330 is a highly selective small molecule that acts on the dual-functioning Apurinic/Apyrimidinic Endonuclease 1/Redox Effector Factor-1 (APE1/Ref-1) protein, referred to as Ref-1. This
          protein is implicated in both redox signaling and DNA repair. Because APX3330 selectively inhibits the redox function without affecting <span style="color: rgb(0, 0, 0);">the molecule&#8217;s ability to carry out DNA repair, normal cell function is
            left intact. Moreover, interference of Ref-1 activity with APX3330 blocks angiogenesis and inflammation by simultaneously decreasing the activity of several important transcription factors such as HIF-1&#945; and NF-&#954;B (</span><span style="font-weight: bold; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">FIGURE 8</span></span><span style="color: rgb(0, 0, 0);">). HIF-1&#945; regulates the expression of VEGF, a protein that is paramount for angiogenesis, and NF-&#954;B is an upstream regulator of proteins
            involved in inflammatory processes such as TNF&#945; and chemokines.</span></div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The development of DR/DME involves leakage from retinal vessels, lack of blood flow to the retina, and release of angiogenic growth factors and inflammatory mediators. The downstream targets of
          HIF-1&#945; and NF-&#954;B serve as key mediators of these disease features and are targets of current therapy for diabetic eye disease and wAMD. Rather than inhibiting the action of VEGF protein, APX3330 has been shown in preclinical models to inhibit its
          formation; this is a key potential distinction of APX3330 from the drugs currently approved or under development for DR/DME such as Lucentis and EYLEA. APX3330&#8217;s potential ability to inhibit the activity of these two transcription factors may
          mitigate the need for frequent intravitreal anti-VEGF or steroid injections.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">APX3330 has a dual mechanism that decreases both abnormal angiogenesis and inflammation. APX3330 blocks pathways downstream of Ref-1. Blocking HIF-1&#945; reduces VEGF signaling, and blocking NF-kB
          modulates VEGF, TNF-&#945; and other inflammatory cytokine production. In contrast, anti-VEGF agents solely inhibit the actions of VEGF <span style="font-weight: bold;">(</span><span style="font-weight: bold; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">FIGURE</span></span><span style="font-weight: bold;"><span style="text-decoration: underline;"> 8</span>)</span>.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">29</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-weight: bold;">FIGURE 8: APX3330 Dual Mechanism of Action in Validated Disease Pathways</div>

        <div>&#160;</div>

        <div style="text-align: center;"><img height="285" width="286" src="image10.jpg" alt="graphic" /></div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0);">&#8201;Note: Eylea<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is registered trademark of Regeneron and Lucentis<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> is registered trademark of Roche/Genentech</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">APX3330 Clinical Experience Summary</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">APX3330 has been studied in over 375 (of over 470 total) healthy volunteers or patients with hepatitis or cancer or diabetic retinopathy patients, over 270 of whom were given the product
          candidate for an average of 75 days or more. In these 12 Phase 1 and 2 non-ocular and ocular clinical trials, clinical data on safety and efficacy, effect upon the Ref-1 molecular target, and pharmacodynamic characteristics were collected.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">A summary of the 12 completed trials including the Phase 2 ZETA-1 trial can be found below (<span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">TABLE 3</span>)</span>. <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">In subsequent sections, a Phase 2b trial for DR/DME (ZETA-1), a Phase 1 trial for oncology (APX CLN 0011),
              Phase 1 and 2 trials for chronic hepatitis disease (APX CLN 0001-0010), and nonclinical studies will be highlighted.</span></div>

          <div>&#160;</div>

        </div>

        <div style="text-align: justify; font-weight: bold;">TABLE 3: Summary of APX3330 Completed Clinical Trials</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trial Number /</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Name</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 8.14%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Patient /</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Indication</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Phase</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 14%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Trial Objectives</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 8%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Doses</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 11.24%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Number</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">of</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Patients&#94;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">APX3330 Total Exposure Days</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Dosing</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td style="width: 11%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Key Endpoints</div>
              </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0001</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Healthy Volunteers</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">1</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Single-dose placebo-controlled trial of APX3330 to investigate safety and pharmacokinetics</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">10 mg 30 mg 60 mg 120 mg 180 mg 240 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 12 Placebo = 6</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center;">36<span style="font-weight: bold; color: rgb(0, 0, 0);"> <span style="font-weight: normal;">days</span></span></div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Single dose</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Plasma Concentration of total quinone forms, safety</div>
              </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0002</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Healthy Volunteers</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">1</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 14%; vertical-align: top;">&#160;
                <div style="text-align: center; color: rgb(0, 0, 0);">Repeat-dose placebo-controlled trial to investigate safety and pharmacokinetics</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">120 mg QD 120 mg BID</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 12 Placebo = 6</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center;">96 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">8 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Plasma Concentration of APX3330, safety</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">30</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0003</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Healthy Volunteers</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">1</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Repeat-dose trial to determine effects of food on pharmacokinetics</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">240 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 6</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center;">84 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">1 week</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Plasma Concentration of APX3330, safety</div>
              </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0004</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Healthy Volunteers</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">1</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Single-dose trial to determine the effects of meals on pharmacokinetics</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">120 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 6</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center;">6 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Single dose</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Plasma Concentration of APX3330, Safety</div>
              </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0005</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Chronic Hepatitis B Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">2</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Dose-escalation trial to investigate safety, efficacy and tolerability</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">20 mg 60 mg 120 mg 240 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 40</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center;">3360 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">12 weeks</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Safety</div>
              </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0006</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Chronic Hepatitis C Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">2</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Dose-escalation trial to investigate safety, efficacy and tolerability</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">20 mg 60 mg 120 mg 240 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 51</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center;">4284 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">12 weeks</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Safety</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">31</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0007</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Chronic Hepatitis C Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 5%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">2</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 14%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Double-masked, placebo-controlled trial to investigate safety, efficacy and tolerability</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">120 mg 240 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 128</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">&#8195;</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Placebo = 68</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center;">10,752 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 11%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Placebo = 82 days</div>
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 120 mg = 79 days</div>
                <div>&#160;</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">240 mg = 78 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Rate of change in GPT level, improvement in liver function, general performance</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0008&#94;</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Healthy Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="vertical-align: top; width: 5%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">1</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="vertical-align: top; width: 14%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Single-blind, single-dose, 3-step trial to investigate safety and pharmacokinetics of higher doses</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">300 mg 420 mg 600 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 18</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center;">54 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="vertical-align: top; width: 11%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Single dose</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Plasma Concentration of APX3330, safety</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0009</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Advanced Liver Cirrhosis Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 5%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">2</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 14%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Repeated-dose trial to investigate safety, efficacy and tolerability</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">120 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 30</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center;">420 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 11%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">2 weeks</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Liver function, patient functional status, tolerability</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX_CLN_0010</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Eisai)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Advanced Liver Cirrhosis Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="vertical-align: top; width: 5%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">2</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="vertical-align: top; width: 14%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Repeated-dose trial to investigate safety, efficacy and tolerability</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">120 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">APX3330 = 18</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top;">
                <div style="text-align: center;">504 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="vertical-align: top; width: 11%;">
                <div style="text-align: center; color: rgb(0, 0, 0);">4 weeks</div>
              </td>

    <td colspan="1" style="vertical-align: top; width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">Liver function, patient functional status, tolerability</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 12%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">APX_CLN_0011</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">(Apexian)</div>
                <div style="text-align: center; color: rgb(0, 0, 0);">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8.14%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Advanced Solid Tumor Patients</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 5%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">1</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 14%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Multicenter, open-label, dose-escalation to investigate safety, efficacy, pharmacokinetics, and recommended Phase 2 dose</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">240 mg 360 mg 480 mg 600 mg 720 mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">APX3330 = 19</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; font-weight: bold;">2354 days</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="vertical-align: top; background-color: rgb(204, 237, 255); width: 11%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">21-day cycles until disease progression or study withdrawal</div>
              </td>

    <td colspan="1" style="vertical-align: top; background-color: rgb(204, 237, 255); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; background-color: rgb(204, 237, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Tumor response, safety, PK, target engagement</div>
              </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">ZETA-1</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Ocuphire)</div>
                <div style="font-weight: bold; text-align: center;">Completed</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 8.14%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Diabetic Retinopathy and DME</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 5%;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2</div>
                &#160;</td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 14%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Double-masked, randomized, placebo-controlled, multi-center trial</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">600mg</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 11.24%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">APX3330 = 51</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Placebo =52</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">&gt;7,900</div>
                <div>&#160;</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">600mg daily for 24 weeks</div>
              </td>

    <td colspan="1" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>

    <td style="width: 11%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">&#8805; 2 step improvement</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">on the DRSS score at week 24, binocular &#8805;3 step worsening or improvement and safety</div>
              </td>

  </tr>


</table>
        <div style="font-style: italic;"> <br />
        </div>

        <div style="font-style: italic;">&#94; Total patient numbers will not equal to the sum of the subgroups in crossover studies</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">APX3330 Phase 2b Trial in DR/DME Patients (ZETA-1) (Completed)</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">32</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In August 2022 Ocuphire completed ZETA-1, a Phase 2b double-masked, randomized, placebo-controlled, multi-center trial in patients with DR and
            DME, which started in April 2021. 103 DR subjects were enrolled with 90% having NPDR (baseline DRSS of 47 or 53); mean baseline CST was 270 &#181;m. This study evaluated the effect of 600 mg daily dose of APX3330 in treating patients with DR,
            including moderately severe NPDR to mild PDR, as well as patients with DME without loss of central vision. The primary endpoint was percent of patients with a &#8805;2 step improvement in Early Treatment of Diabetic Retinopathy Study (ETDRS) diabetic
            retinopathy severity scale (DRSS) at week 24 in the study eye. Key secondary endpoints at multiple time points included change in monocular and binocular DRSS, CST, and BCVA. Patient safety was assessed by AE monitoring, clinical laboratory
            evaluations, IOP, and vital sign assessments.</div>

        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The ZETA-1 trial did not meet the primary endpoint in the study eye, however, the trial achieved statistical significance on a key pre-specified
            secondary endpoint of preventing clinically meaningful progression of diabetic retinopathy when evaluating both eyes. In contrast to intravitreal injections which treat a single eye, systemic drugs treat both eyes, and thus the response of both
            eyes needs to be considered. Furthermore, APX3330 inhibits Ref-1 which reduces VEGF and inflammatory cytokines to normal physiological levels supporting the prevention of worsening. In ZETA-1, binocular 3 or more steps worsening on the DRSS
            scale, calculated as the sum of changes in each eye, after 24 weeks of treatment showed no (0%) APX3330-treated patients had a binocular &#8805; 3-step worsening of DRSS from baseline compared with 16% for placebo-treated patients (p=0.04) (Figure
            11). This is the planned primary endpoint for Phase 3 registration trials that will be confirmed at the EOP2 meeting with the FDA in the second half of 2023. Additional efficacy endpoints were directionally favorable to support the effect of
            APX3330 in slowing the progression of DR and preserving vision. Visual acuity was stable with APX3330 and a trend was seen with fewer APX3330 treated patients losing 5 or more letters of distance vision compared to placebo patients (5% vs 19%,
            p=0.07) <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(<span style="text-decoration: underline;">FIGURE 9</span>)</span>.</div>

          <div>&#160;</div>

        </div>

        <div style="font-weight: bold;">FIGURE 9: Percentage of Subjects with Binocular &#8805;3-Step Worsening in DRSS and &#8805;5 Letters of BCVA</div>

        <div>&#160;</div>

        <div style="text-align: center;"><img src="image00015.jpg" alt="graphic" /></div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">APX3330 showed a favorable safety profile. 14 treatment-emergent serious AEs were considered unrelated to study medication, 11 in the placebo group and 3 in the APX3330 group. Two subjects in each group withdrew due
          to an AE, where one placebo subject had OU DME worsening considered treatment related. Overall, there were 211 AEs (91 APX3330, 120 placebo) in 64 subjects (29 APX3330, 35 placebo). Only 31 of these AEs were considered drug-related (14 APX3330,
          17 placebo). All treatment related AEs were mild or moderate in severity. There were no adverse treatment effects on any other characteristics of the ophthalmic examination or on any assessments of systemic safety <span style="font-weight: bold;">(<span style="text-decoration: underline;">FIGURE 10</span>)</span>.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">33</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">FIGURE 10: ZETA-1 Safety Overview</div>

        <div>&#160;</div>

        <div style="text-align: center;"><img height="303" width="621" src="image12.jpg" alt="graphic" /></div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">APX3330 Phase 1 Oncology Trial - Apexian (APX CLN 0011)</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Clinical development of APX3330 by Eisai Co., Ltd. in Japan was suspended with the in-licensing of anti-viral and biological agents for hepatitis C and rheumatoid arthritis. Later, while doing
          research on the Ref-1 protein, Dr. Mark Kelley from Indiana University and others identified that the molecular target of APX3330 was the Ref-1 protein. The elucidation of the mechanism of action with which APX3330 modulated the Ref-1 protein,
          and the concurrent advancement in understanding the role played by Ref-1 as a critical &#8220;gate-keeper&#8221; for controlling a variety of pro-inflammatory transcription factors, led to the establishment of Apexian in order to determine the utility of
          using APX3330 as a modulator of the Ref-1 protein in the treatment of inflammatory diseases. The clinical trial, APX_CLN_0011 under IND 125360 with the FDA Division of Oncology, was initiated by Apexian in order to identify the highest dose of
          APX3330 that could be safely administered in a chronic manner and to confirm molecular engagement of APX3330 with the Ref-1 protein by obtaining tumor biopsy samples and circulating tumor cell samples.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="font-weight: bold; color: rgb(0, 0, 0);">APX_CLN_0011</span><span style="color: rgb(0, 0, 0);"> was a multi-center, open-label, dose-escalation Phase 1 oncology trial in patients
            with advanced solid tumors. Patients received daily oral doses of APX3330 each day of repeated 21-day cycles until disease progression or trial withdrawal. Nineteen patients received APX3330 in escalating doses from 240 mg/d dose to 720 mg/day
            in increments of 120mg/day. The highest dose tested (720 mg/day) produced a self-limiting, diffuse macular rash and was confirmed as the dose-limiting toxicity. The dose of 600 mg/day was then confirmed as a dose tolerable for chronic
            administration and for further clinical development as a modulator of Ref-1 activity in inflammatory diseases. Biopsy analyses of patients participating in the trial confirmed that APX3330 directly targets the Ref-1 protein and that the
            targeting produces subsequent regulation of transcription factors such as NF-&#954;B and HIF-1&#945;, regulators of VEGF and other inflammatory molecules. This mechanism of action provides significant rationale for testing APX3330 in diseases in which
            inflammation and neo-vascular development play a critical pathogenic role.&#160; </span>APX3330 was also well-tolerated in cancer patients who were treated daily for up to 400 days (4% diarrhea/soft stool and 4% rash).</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Overall, APX3330 demonstrated a favorable safety profile and was well tolerated. No effects of APX3330 on vital signs on laboratory measures have been observed. Across 11 Phase 1 and Phase 2
          trials, the rate of adverse events was similar in APX3330 treated patients (N=346) and placebo treated patients, including a &lt;3% difference between APX3330 and placebo in rates of diarrhea/soft stool and rash/pruritis. Among healthy patients
          and hepatitis patients (N=327), any adverse event occurred in 14% of patients receiving APX3330 and 14% of patients receiving placebo.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">34</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">APX3330 &#8211; Ten Phase 1 and 2 Trials - Eisai (APX CLN 0001-0010)</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Under the sponsorship of Eisai Co., Ltd., 10 clinical trials were conducted involving healthy volunteers as well as patients with chronic hepatitis diseases (i.e., Type C, B, alcohol-induced) in
          Japan with the intent of developing a TNF-&#945; blocking agent. At the time of their clinical trials, the molecular target of APX3330 had not been confirmed and was not known to be the Ref-1 protein.</div>

        <div>&#160;</div>

        <div style="text-align: justify;">Across these 10 trials, it was found that APX3330 exhibits predictable pharmacokinetics that were consistent with the pharmacokinetic data obtained in non-clinical studies. In addition, there was a lack of
          significant acute toxicity at doses up to 600 mg/day. APX3330 has been demonstrated to be well-tolerated. Moreover, in two studies it was found that meals have no impact on the product candidate&#8217;s pharmacokinetics. Safety tolerability measures
          showed no changes in vital signs and no changes in clinical laboratory values. Only adverse events included diarrhea and rash, which each occurred in &lt;5% of patients and were mild. Liver function tests were used primarily to evaluate efficacy
          in Phase 2 studies of hepatitis patients and the overall assessment of liver function over time suggests that APX3330 had a minor positive, and no negative, effect. Additionally, there was a lack of acute neurologic, cardiovascular, hepatic, or
          pulmonary toxicity. Only a single ocular adverse event has been reported in APX3330 clinical trials; mild orbital region discomfort at 60 mg/day in CLN_0006. No mild, no moderate, and no severe rashes were observed in healthy patients dosed with
          APX3330.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">APX3330 Nonclinical Studies</div>

        <div>&#160;</div>

        <div style="font-style: italic;">Preclinical Studies with APX3330 and Next Generation APX Small Molecules</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In animal studies, APX3330 delivered orally, intraperitoneally or intravitreally (directly into the eye), and APX2009 and APX2014 delivered by intraperitoneal injection reduced neovascularization
          in mouse models that recapitulate features of retinal neovascularization (seen in PDR and wAMD) called the L-CNV model. Although in humans intravitreal injection is the habitual delivery route of the standard-of-care anti-VEGF biologics, to
          ensure the delivery of the drug to the affected area, such administration is labor-intensive, causes patient discomfort, and incurs a risk of potentially vision-threatening intraocular infections. As a result, systemic administration
          (intraperitoneal injections) of Ref-1 inhibitors were explored for similar effects as those seen with anti-VEGF biologics in mouse models. Treatment with APX3330 (10 mg/kg) via oral gavage in rats with type 1 diabetes and induced stroke
          (conditions that promote neovascularization) shows a significant decrease (~55%) of VEGF signaling (or lesion volume) (<span style="font-weight: bold;"><span style="text-decoration: underline;">FIGURE 11</span>)</span>. As seen in the first panel in <span style="font-weight: bold;"><span style="text-decoration: underline;">FIGURE








              11</span></span>, expression of VEGF was lower in APX3330-treated cells compared to control cells in a stroke model. As seen in the second panel, APX3330 also demonstrated anti-inflammatory effects by reducing cytokines in lipopolysaccharide
          (LPS)- stimulated macrophages. The third panel demonstrates APX3330 increased DNA oxidative repair and neuronal protection by enhancing endonuclease activity.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">35</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-weight: bold;">FIGURE 11: APX3330 Reduces VEGF Levels and Inflammatory Cytokines and Provides Neuronal Protection (in-vitro)</div>

        <div>&#160;</div>

        <div style="text-align: center;"><img height="252" width="613" src="image13.jpg" alt="graphic" /></div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">While numerous published studies using APX3330 through intravitreal or systemic intraperitoneal administration have shown successful neovascularization reduction in vitro or animal models,
          additional studies with oral administration of 2 doses of APX3330 (25 mg/kg and 50 mg/kg per day) resulted in a more robust correction of the lesion volume in the L-CNV mouse model. Animals treated with APX3330 displayed a significant reduction
          (~55%) in the volume of the neovascular lesion (red staining) <span style="font-weight: bold;">(<span style="text-decoration: underline;">FIGURE 12</span>)</span>.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-weight: bold;">FIGURE 12: Lesion Size and Corresponding Fluorescent Stains in L-CNV Models Treated with APX3330</div>

        <div>&#160;</div>

        <div style="text-align: center;"><img height="315" width="626" src="image14.jpg" alt="graphic" /></div>

        <div><br />
        </div>

        <div style="text-align: justify; font-style: italic;">L-CNV mice treated with APX3330 at either 25 mg/kg or 50 mg/kg resulted in a decreased volume of neovascularization (lesion volume).</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">36</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">Pharmacokinetics/Metabolism</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Pharmacokinetic (PK) studies were conducted in rats and dogs to understand the absorption, distribution, and elimination of APX3330. APX3330 is well absorbed orally with a bioavailability of &#8805;
          60%. In a protein binding study in rats, it was shown that&#160; &#8805; 90% of the product candidate is bound to protein. Half-life after intravenous administration of APX3330 was 8 hours in rats, 7.8 to 8.7 hours in dogs, and 25.5 hours in monkeys.
          Excretion occurred mainly in bile, as a monoglucuronide or other conjugates. In rats and beagles, a part of the administered APX3330 is excreted in stool as the unchanged compound.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Toxicology</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">APX3330 has been studied extensively in over 20 in vitro and animal studies and demonstrated a favorable safety profile in each.&#160; APX3330 was not genotoxic and had no toxicologically significant effects in
          developmental studies performed to date. Over 15 single- and repeat- dose toxicology studies in rats and dogs up to 3 months duration have been conducted.&#160; Also, PK, ADME and safety pharmacology studies along with over 5 developmental,
          genotoxicity, and antigenicity studies have been completed. The FDA did not request any further toxicology studies to support the initiation of the 24-week ZETA-1 clinical trial.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Ocuphire Clinical Development Plan</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire is developing Nyxol in partnership with Viatris. For Nyxol, the investigational new drug (IND) application was submitted to the FDA
          Division of Ophthalmology in July 2011 and is in effect (IND 70499). In November 2022, Ocuphire submitted an NDA for Nyxol for RM and in February 2023 received notification of FDA acceptance to file and a PDUFA goal date of September 28, 2023.
          Nyxol has completed 12 trials (3 Phase 1 trials, 5 Phase 2 trials and 4 Phase 3 trials), mostly in young and older healthy volunteers and in presbyopia, DLD and glaucoma patients. In May 2020, Ocuphire completed an EOP2 meeting with the FDA,
          which included a discussion and agreement around the design and scope of future registration trials for Nyxol across its indications. In June 2021, Ocuphire completed a Type C meeting with the FDA on CMC for Nyxol. In February 2022, Ocuphire
          completed a Type C meeting with the FDA which included discussion and guidance around the design of VEGA Phase 3 trials and registration package for Presbyopia for Nyxol alone and Nyxol with LDP as adjunctive therapy. In June 2022, Ocuphire
          completed a Type B (Pre-NDA) meeting with the FDA to obtain FDA scientific and regulatory input to guide the NDA submission for RM. Ocuphire plans a Type C meeting in the first half of 2023 to obtain further guidance on the presbyopia and DLD
          registration programs. Ocuphire anticipates engaging in similar discussions with other foreign regulatory authorities in the future.</div>

        <div>&#160;</div>

        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">For APX3330, the IND application for APX3330 to pursue retinal choroidal vascular diseases was submitted to the FDA Division of Ophthalmology in
          December 2018 and is in effect (IND 142152). APX3330 also has an IND with the FDA Division of Oncology for the treatment of pancreatic cancer (IND 125360). APX3330 has completed 12 trials (6 Phase 1 and 6 Phase 2 trials), mostly related to
          patients with liver disease, patients with solid tumors and diabetic retinopathy. Ocuphire plans an EOP2 meeting in the second half of 2023 to obtain guidance on the registration program including confirmation of the primary endpoint for
          registration of a systemic agent for DR.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-weight: bold;">Current and Planned Nyxol Trials:</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Nyxol Presbyopia: Phase 3 Trials</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The VEGA-2 (NYXP-301) a double-masked, randomized, placebo-controlled, multicenter trial in approximately 320 patients with presbyopia was initiated in December 2022. This registration trial is
          to evaluate efficacy and safety to achieve both labels - single agent Nyxol and LDP as adjunctive therapy to Nyxol. Key endpoints such as distance corrected near visual acuity, pupil diameter, and best corrected distance acuity will be measured
          at multiple timepoints after the first dose and multiple doses to assess the onset and duration of efficacy. The primary endpoint to establish the efficacy will be the percentage of patients who gain 15 or more letters of DCNVA without loss of 5
          or more letters of BCDVA. Key secondary endpoints such as distance corrected near visual acuity, pupil diameter, and best corrected distance acuity will be measured at multiple timepoints after the first dose and multiple doses to assess the
          onset and duration of efficacy. A hierarchical analysis will be used to allow both single agent (compared to placebo) and combination (compared to individual components) endpoints to be evaluated with appropriate statistical significance.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">37</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The VEGA-3 (NYXP-302) trial is planned as a double-masked, randomized, placebo-controlled, multicenter trial in approximately 400 patients with
            presbyopia. <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">This second registration trial will evaluate efficacy and safety and be similarly designed to VEGA-2 and include similar primary and key secondary
              endpoints and analysis. If the VEGA Phase 3 program is successful, Ocuphire expects to file a sNDA for Nyxol to treat presbyopia in 2024 and to follow later with a NDA for Nyxol + LDP.</span></div>

        </div>

        <div>&#160;</div>

        <div>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Nyxol DLD: LYNX-2 2<sup>nd</sup> Phase 3 Trial</div>

          <div>&#160;</div>

          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Based on the positive results of the first Phase 3 trial, LYNX-1, Ocuphire and its partner, Viatris, are planning a similar second registration
            trial for Nyxol in up to 200 subjects for the treatment of DLD. <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">If the LYNX Phase 3 program is successful, Ocuphire expects to file a sNDA for Nyxol to treat DLD in
              2024.</span></div>

          <div>&#160;</div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Nyxol Chronic Safety Trial for Nyxol as a single agent and with adjunctive low dose pilocarpine (&#8220;LDP&#8221;): LYRA-1 Phase 3 Trial</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">For an NDA for Nyxol chronic indications (Presbyopia and DLD), Ocuphire and its partner, Viatris, plan to conduct a chronic safety trial
              LYRA-1 with approximately 425 subjects, which is expected to initiate after the FDA review of the 6-month repeated-dose toxicity study. The planned LYRA-1 Phase 3 trial evaluating chronic safety exposure is targeting 300 patients for 6
              months, followed by 100 of the patients continuing for an additional 6 months in a double-masked, placebo-controlled design. Long-term endothelial cell count (ECC) clinical data will also be collected.</div>

            <div>&#160;</div>

          </div>

        </div>

        <div style="font-weight: bold;">Potential Clinical Plans for APX3330:</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Based on the Phase 2 safety, tolerability and efficacy results of APX3330 in patients with DR/DME reported in January 2023, Ocuphire expects to request an EOP2
            meeting with the FDA in the second half of 2023 to confirm registration endpoints to finalize the design of the Phase 3 registration trials for APX3330 as first-line therapy in DR/DME in addition to defining the chronic safety exposure trial
            and any further animal toxicology studies necessary prior to an NDA submission. Ocuphire may explore opportunities for clinical benefit as adjunctive therapy for other retinal indications such as DME, wAMD, and GA.</div>

        </div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Future In-Licensing and Acquisition Opportunities</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire continually evaluates product candidates based on scientific merit, patent protection, regulatory pathways, and commercial opportunity. Its focus is on product candidates in the
          ophthalmology space.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Sales and Marketing</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div>Ocuphire has entered into a licensing agreement with <span style="font-size: 10pt; font-family: 'Times New Roman';">Viatris</span> for the development and commercialization of all Nyxol indications in the U.S. and ex-U.S. markets (excluding
            certain countries in Asia). The company maintains discussions with a range of ophthalmic drug companies regarding development and commercialization of APX3330, including co-development, distribution, license, or mergers and acquisitions. As
            part of the pre-commercialization planning, Ocuphire has started market development activities which include engaging with Key Opinion Leaders as well as increased visibility and presence at retina, ophthalmology and optometry medical and
            industry conferences. There are several global pharmaceuticals with major ophthalmic drug businesses as well as numerous other smaller global or regional companies that could provide significant reach in specific markets such as Europe or Asia.
            <br />
          </div>

        </div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Manufacturing</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div>For Nyxol, APX3330, and for other product candidates that will be developed in the future, Ocuphire&#8217;s contract manufacturers are currently producing, and will produce, its bulk drug substances and drug products for use in Ocuphire&#8217;s
            preclinical studies and clinical trials, utilizing reliable and reproducible synthetic processes and common manufacturing techniques. Pursuant to the Nyxol License Agreement, Ocuphire intends to transfer commercial manufacturing
            responsibilities for Nyxol to <span style="font-size: 10pt; font-family: 'Times New Roman';">Viatris</span>. Ocuphire does not have any long-term agreements but Ocuphire or its development partners intend to secure such arrangements for drug
            substances or drug products as appropriate, and currently uses purchase orders with multiple manufacturers. Ocuphire is qualifying its selected manufacturers to provide bulk drug substances and drug products in conjunction with the NDA
            regulatory submission to the FDA. Ocuphire plans to continue to rely upon contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of its drug substances and drug products, if approved for marketing
            by the applicable regulatory authorities. Ocuphire does not own or operate, and currently has no plans to establish, any manufacturing facilities. <br />
          </div>

        </div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">38</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Nyxol</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div>
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The proprietary formulation of Nyxol is a sterile, preservative-free, isotonic, buffered aqueous solution containing phentolamine mesylate,
              mannitol, and sodium acetate. The drug substance phentolamine mesylate USP is a small molecule that can be manufactured by reliable and reproducible synthetic processes from readily available starting materials. Ocuphire currently obtains the
              active pharmaceutical ingredient for Nyxol from a single supplier in Italy and is presently taking steps to develop a second source, but is working with Viatris to determine the long-term commercial manufacturing strategy. All lots of drug
              substance phentolamine mesylate and Nyxol drug product used in clinical trials are manufactured under current good manufacturing practices (cGMP), a quality-system regulating manufacturing, with processes registered by the supplier with FDA
              in an active Drug Master File (DMF). Nyxol was previously packaged in a single-use bottle with cap served as the container closure system for Phase 1 and 2 clinical trials. Ocuphire transitioned the container closure system to an industry
              standard, single-use preservative-free blow-fill-seal (&#8220;BFS&#8221;) container for Nyxol, which is being formulated and filled by a leading U.S. manufacturer. Nyxol eye drops in the BFS container are classified by FDA as a drug-device combination
              product. The current manufacturing process has been scaled to a commercial capacity. Nyxol has demonstrated stability at 5&#176;C refrigerated for a minimum of two years. Ocuphire is performing additional stability studies on lots of both the drug
              substance phentolamine mesylate and the drug product of Nyxol in order to establish expiry dating and to support regulatory submissions and commercial manufacturing. To supply eventual global markets and to avoid reliance on a single
              facility, Ocuphire and its partner Viatris are evaluating the establishment of second-source manufacturing facilities for drug substance and drug product.</div>

            <div>&#160;</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Pilocarpine</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Pilocarpine Hydrochloride Ophthalmic Solution 0.4% or Low Dose Pilocarpine (LDP) is a proprietary formulation of pilocarpine hydrochloride. It is a preserved, aqueous sterile solution comprised
          of the active ingredient pilocarpine hydrochloride, benzalkonium chloride, boric acid, Hypromellose 2910, sodium citrate, and sodium chloride, in sterile water for injection. Similarly to Nyxol, the drug substance for LDP, pilocarpine
          hydrochloride&#160; USP is a small molecule that can be manufactured by reliable and reproducible processes as a plant extract. Ocuphire obtains the active pharmaceutical ingredient for LDP from a single supplier in Brazil, and intends to secure a
          long-term supply contract.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">APX3330</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">APX3330 is an oral formulation of a small molecule drug substance that is synthesized from readily available raw materials and using conventional chemical processes. The APX3330 drug substance is
          currently obtained from a single supplier in India, although alternative manufacturing sources are available. The APX3330 drug product is manufactured in the U.S.. Process and analytical development of APX3330 drug product have been completed,
          and its production has been scaled-up under cGMP regulatory requirements. Previously, the APX3330 drug product manufacturer has performed pharmaceutical development to support the cGMP manufacturing campaign for tablets of 60 mg and 120 mg dose
          strengths, the latter being used in ongoing clinical trials. Under this tablet size, long-term ICH-stability studies of various strengths (60 and 120 mg tablet) have been conducted and have demonstrated a 3-year shelf life when stored at 25&#176;C/60%
          relative humidity. Ocuphire is evaluating 300 mg tablets for convenient twice a day dosing. Ocuphire is also planning additional stability studies for future lots of both the drug substance and drug product of APX3330 in order to establish expiry
          and to support regulatory approval and commercial stage.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">39</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">Apexian Sublicense Agreement</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">&#160;On January 21, 2020, Ocuphire entered into a sublicense agreement with Apexian pursuant to which it in-licensed patents and other intellectual property relating to the APX3330 product candidate
          and second-generation product candidates owned by Apexian, and intellectual property that Apexian in-licensed from Eisai, including certain study reports, manufacturing and analytical records, data, know-how, technical and other proprietary
          information relating to APX3330. This intellectual property constitutes a Ref-1 Inhibitor program focused on developing therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions. The lead compound in the
          Ref-1 Inhibitor program is APX3330, which Ocuphire intends to develop as an oral tablet therapeutic to treat DR and DME, and potentially wAMD. See &#8220;<span style="font-style: italic;">Ocuphire Management&#8217;s Discussion and Analysis of Financial
            Condition and Results of Operations&#8212;Contractual Obligations and Commitments&#8212;Apexian Sublicense Agreement</span>&#8221; for more details regarding the Apexian Sublicense Agreement.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Intellectual Property</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Nyxol</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire&#8217;s patent estate includes patents and patent applications to forms of phentolamine mesylate, formulations containing phentolamine mesylate, methods of using phentolamine mesylate, and
          methods of manufacturing phentolamine mesylate. Ocuphire primarily protects its intellectual property through a combination of patents and patent applications on inventions, trademark protection on Ocuphire&#8217;s product name, and trade secret
          protection as Ocuphire deems appropriate. Ocuphire owns all of the worldwide rights to Nyxol for all indications, but has out-licensed certain rights to Nyxol pursuant to the Nyxol License Agreement.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As of February 10, 2023, Ocuphire&#8217;s patent estate relating to Nyxol contains ten U.S. patents, eight pending U.S. non-provisional patent applications, as well as issued patents in Australia,
          Canada, Europe, Japan, and Mexico and pending patent applications in Australia, Canada, Europe, Japan, China, and other foreign countries.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire&#8217;s U.S. Patents 9,795,560; 10,278,918; 10,772,829 and 11,090,261 and counterpart Australian Canadian, European, and Japanese patents each contain composition of matter claims to aqueous
          phentolamine mesylate formulations and are scheduled to expire in year 2034. In the same patent family, Ocuphire also has 1 pending U.S. patent application with additional claims to aqueous phentolamine mesylate formulations, whereby a patent, if
          granted, would expire in year 2034. The patents and patent applications cover the current clinical formulation for the Nyxol product.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire&#8217;s U.S. Patent Nos. 9,089,560; 9,789,088 and 11,000,509 contain claims directed to methods of improving visual performance using, for example, phentolamine mesylate and are scheduled to
          expire in year 2034. Counterpart patents have issued in Australia, Canada, Europe, and Japan, which are scheduled to expire in year 2034. In the same patent family, Ocuphire also has 1 pending U.S. patent application with additional claims to
          methods of improving visual performance using, for example, phentolamine mesylate, whereby a patent, if granted, based on this pending application would expire in year 2034. The patents and patent applications cover uses of the current clinical
          formulation for the Nyxol product.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire has patent applications pending in the U.S., Australia, Canada, China, Europe, and Japan directed to treating glaucoma and other medical disorders using phentolamine mesylate. Patents,
          if granted, based on these pending applications would expire in year 2039.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire&#8217;s U.S. Patent 10,993,932 contains claims directed to methods of treating presbyopia using phentolamine mesylate with adjunctive pilocarpine and is scheduled to expire in year 2039.&#160;
          Ocuphire&#8217;s U.S. Patent 11,400,077 contains claims directed to methods of treating mydriasis using phentolamine mesylate and is scheduled to expire in year 2039.&#160; In the same patent family as U.S. Patent Nos. 10,993,932 and 11,400,077, Ocuphire
          has four pending U.S. patent applications, two of which have claims to treating presbyopia and the other two U.S. applications have claims to treating mydriasis. Counterpart patent applications are pending in Australia, Canada, China, Europe,
          Japan, and other foreign countries, whereby a patent, if granted, based on these pending U.S. and foreign patent applications would expire in year 2039.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">40</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire&#8217;s U.S. Patent 11,566,005 contains claims directed to phentolamine mesylate composition of matter (the active pharmaceutical component in Nyxol), process to make phentolamine mesylate
          from phentolamine and methods for inhibiting pupil dilation, improving visual contrast sensitivity or visual acuity, and for treating dim light or night vision disturbance, reversal of mydriasis and presbyopia, with the above-claimed phentolamine
          mesylate.&#160; In the same patent family, there is a pending U.S. patent application, and a pending international patent application directed to methods of making high-purity phentolamine mesylate and compositions resulting from such methods.&#160; This
          U.S. patent and other patents, if granted, based on the foregoing patent applications are scheduled to expire in year 2042.&#160; Ocuphire also has one pending patent application in China directed to methods of making high-purity phentolamine mesylate
          and compositions resulting from such methods, whereby any patents, if granted, based on this patent application in China would expire in year 2041. Ocuphire also has a pending international patent application directed to additional methods for
          treating mydriasis and glaucoma, whereby any U.S. or foreign patents, if granted, from on a patent application filed based on this international patent application would expire in year 2042.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire also owns an issued patent in Mexico that is scheduled to expire in year 2025 and has claims to ophthalmic formulations.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire has registered trademark protection in the United States for the NYXOL<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174; </sup>.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">APX3330</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">As of February 10, 2023, the patent estate that Ocuphire has in-licensed for APX3330 and related compounds contains seven U.S. patents and two pending U.S. non-provisional patent applications, as well as issued
          patents in Europe, Japan, Canada, and Australia, and pending patent applications in Europe, Japan, Canada, China, South Korea and Australia. The license is for the use and commercialization of APX3330 and related composition of matter compounds
          covered by the subject patents and patent applications in the field of human health uses for ophthalmic and diabetes mellitus indications.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In-licensed U.S. patent 9,040,505 has claims to methods of treating diabetic retinopathy and other diseases using, for example, APX3330 and is scheduled to expire in year 2030. Counterpart
          patents have issued in Europe, Japan, Australia, and Canada, which are scheduled to expire in year 2028, and there is a related pending U.S. patent application with method of treatment claims that, if issued as a patent, would expire in year
          2028. Pending U.S. application 16,968,009 and pending applications in Europe, Japan, Canada, China, South Korea and Australia have claims to methods of treating wAMD and other diseases using, for example, APX3330, along with other formulations
          such as APX2009 and APX2014. These patents, if granted, would expire in year 2039. The U.S. and certain foreign countries permit extension of patent term for up to five years to compensate for patent term lost during the government regulatory
          review process for a new medicine. If U.S. patent 9,040,505 qualifies for the full five years of patent term extension, the expiration of U.S. patent 9,040,505 would be in year 2035. Whether U.S. patent 9,040,505 qualifies for the full five years
          of patent term extension depends in part on the date of FDA approval for the new medicine.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In-licensed patent applications directed to a combination therapy composition comprising an APE1/REF-1 inhibitor, such as APX3330, and a second therapeutic agent, and methods of using such
          combination therapy to treat retinal diseases and/or treat other indications are pending in the U.S. and Canada. Patents, if granted, would expire in year 2038. In-licensed patent applications directed to use of an APE1/REF-1 inhibitor, such as
          APX3330, in monotherapy or combination therapy to reduce neuronal sensitivity and/or treat other indications are pending in Europe, Japan, and Canada, whereby patents, if granted based on these applications, would expire in year 2038.&#160; This same
          patent family includes one in-licensed U.S. patent directed to methods using APX3330 to treat inflammation and pain as part of a combination therapy.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">U.S. patents that Ocuphire has in-licensed to derivatives of APX3330 include U.S. patents 9,089,605; 9,193,700; 9,877,936; 10,154,973; and 11,160,770.&#160; These U.S. patents are schedule to expire
          from 2029 to 2032.&#160; Foreign patents that Ocuphire has in-licensed to derivatives of APX3330 include patents in Europe, Japan, China, and Canada that are scheduled to expire between the years 2028 to 2032.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">41</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-indent: 36pt;">In addition to patents and patent applications that Ocuphire has in-licensed, as of February 10, 2023, Ocuphire owns one pending international patent application directed to methods of treating diabetic retinal
          diseases using APX3330.&#160; Patents, if granted, from an application filed based on this pending international patent application would expire in year 2042.&#160; Additionally, Ocuphire owns one pending U.S. provisional patent application directed to
          certain salt forms of APX3330 and methods of use, whereby any patents, if granted, from on an application filed based on this provisional patent application would expire in year 2043, and Ocuphire owns one pending U.S. provisional patent
          application directed to additional therapeutic methods using APX3330 in patients with diabetic retinal disease, whereby any patents, if granted, from on an application filed based on this provisional patent application would expire in year 2044.</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">Additional Background</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As background, the patent term is typically 20 years from the date of filing a non-provisional application. In the United States, a patent&#8217;s term may be lengthened several ways. First, patent
          term adjustment (PTA) compensates a patentee for administrative delays by the USPTO in granting a patent. Second, in certain instances, a patent term extension (PTE) can be granted to recapture a portion of the term effectively lost as a result
          of the FDA regulatory review period, as provided under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. This restoration period cannot be longer than 5 years for approval of a drug compound,
          and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. Only patent(s) applicable to an approved drug is eligible for the PTE and the application for the extension must be submitted prior to
          the expiration of the patent and within 60 days from market approval. Independent of patent protection, in the United States, the Hatch-Waxman Act provides a 5-year period of non-patent data exclusivity within the United States to the first
          applicant to gain approval of an NDA for a new chemical entity (NCE). Under this provision, APX3330 may be eligible for up to 5 years of data and market exclusivity under the Hatch-Waxman Act, because it is considered an NCE as the FDA has not
          previously approved any other drug containing the active ingredient of APX3330.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In Europe, under the Data Exclusivity Directive, pharmaceutical companies may receive up to 11 years to market their product without risk of competition. In Japan, under the Pharmaceuticals Act
          of Japan, the market authorization holder, based on the length of a required study period reexamination, may have up to 10 years before a generic can enter the market. Further, the expiration date of certain patents may be extended for up to a
          maximum of 5 additional years to accommodate for time spent seeking government approval to market a new medicine, in those countries that permit extension of patent term to accommodate for time spent seeking government approval to market a new
          medicine.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire also protects its proprietary information through written agreements. Ocuphire&#8217;s employees, consultants, contractors, partners and other advisors are required to execute nondisclosure
          and assignment of invention agreements upon commencement of employment or engagement. In addition, Ocuphire protects its proprietary information through written confidentiality agreements with outside parties who may come into possession of
          Ocuphire&#8217;s confidential information.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Competition</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There is intense competition within the pharmaceutical industry. While Ocuphire believes that its product candidates, APX3330 and Nyxol, are well positioned for development in each indication,
          Ocuphire or its development partners will face competition from both branded and generic pharmaceutical companies as well as products that are currently in development. Many of these companies have significantly greater financial and human
          resources and experience in drug development, R&amp;D, and commercialization. These competitors compete with Ocuphire in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient
          enrollment for clinical trials as well as acquiring products, product candidates or other technologies complementary to Ocuphire program. Smaller and other early-stage companies may also prove to be significant competitors if they choose to
          partner with large, established companies.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">APX3330</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The key competitive factors affecting the success of APX3330, assuming APX3330 is approved, are likely to be its oral dosage form, tolerability, durability, price, and the availability of
          coverage and reimbursement from government and other third-party payors.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">42</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">Competition in Diabetic Retinopathy / Diabetic Macular Edema / wAMD</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire believes that APX3330, if approved, could have a competitive advantage in the DR/DME/wAMD markets because it is an oral tablet with a dual mechanism and potential to address multiple
          indications. However, Ocuphire may face potential competition from both existing therapies and those in development. Current therapies for these retinal diseases rely on suppressing the activity of vascular endothelial growth factors (VEGF) via
          intravitreal injection or by mitigating the inflammation via intravitreal corticosteroid-releasing implants including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Lucentis<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (ranibizumab) and Avastin&#174; (bevacizumab), which are anti-VEGF monoclonal antibody intravitreal injections,
                  developed by Genentech, Inc and Roche AG.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="color: rgb(0, 0, 0);">EYLEA</span><sup style="color: #000000; vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup><span style="color: rgb(0, 0, 0);"> (aflibercept), a VEGF inhibitor intravitreal
                    injection, developed by Regeneron Pharmaceuticals.</span></div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Vabysmo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (Faricimab), a bispecific monoclonal antibody targeting VEGF-A and Ang-Tie2 pathway developed by Genentech, Inc and
                  Roche AG.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Beovu<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (Brolucizumab), an anti-VEGF monoclonal antibody intravitreal injection, developed by Novartis AG.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">MACUGEN<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (pegaptanib sodium injection), a selective inhibitor of VEGF-165, developed by Bausch + Lomb.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Ozurdex<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (dexamethasone), a corticosteroid IVT implant, developed by Allergan plc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Iluvien (fluocinolone acetonide), a corticosteroid IVT implant, developed by Alimera Sciences, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify;">There are also several pharmacological therapies in development, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Abicipar, an anti-VEGF intravitreal injection with a long duration of action, developed by Allergan plc and Molecular Partners.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">KSI-301, an anti-VEGF antibody intravitreal injection coupled with a biopolymer that is intended to increase the time between injections, developed by Kodiak Sciences.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">OPT-302, an intravitreal injection which binds to multiple types of VEGF receptors that could be used with other anti-VEGF agents, developed by Opthea Limited.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">ALG-1001, an integrin peptide therapy intravitreal injection that is being evaluated as a sequential or in-combination therapy with bevacizumab in patients with DME, developed by Allegro Ophthalmics, LLC.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">RG-7774, an orally administered selective CB2 (Cannabinoid 2) receptor agonist that is being evaluated in patients with moderately severe to severe non-proliferative diabetic retinopathy, developed by
                  Hoffmann-LA Roche, AG.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">RZ402, an oral small molecule selective and potent plasma kallikrein inhibitor (PKI) for the chronic treatment of diabetic macular edema (DME), developed by Rezolute, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">Xiflam&#8482;, an oral small molecule drug for the treatment of dry form of Age-Related Macular Degeneration (AMD), Geographic Atrophy (GA), Diabetic Retinopathy (DR) manifesting Diabetic Macular Edema (DME),
                  developed by InflammX.</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">43</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">AKST4290, an oral small molecule CCR3 Eotaxin inhibitor for the treatment of diabetic retinopathy (terminated in 2022) and wet AMD by Alkahest.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">BAY1101042, an oral guanylate cycles activator for the treatment of diabetic retinopathy developed by Bayer.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">OPL-0401, an oral ROCK 1/2 inhibitor for the treatment of diabetic retinopathy, developed by Valo Health.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">BI 1467335, an oral AOC3 inhibitor for the treatment of diabetic retinopathy, developed by Boehringer Ingelheim.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="color: rgb(0, 0, 0);">LY333531, an oral Protein Kinase C inhibitor for the treatment of diabetic retinopathy was terminated by Eli Lilly in 2006.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-weight: bold;">Nyxol will be commercialized by Viatris pursuant to the Nyxol License Agreement, and Viatris may face competition as well. </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The key competitive factors affecting the success of Nyxol, assuming Nyxol is approved, are likely to be the combination of efficacy, durability, tolerability, convenience, price (private pay),
          and stable, preservative-free formulation that will potentially allow it to compete effectively in these markets.</div>

        <div>&#160;</div>

        <div style="font-style: italic;">Competition in RM</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There are currently no approved and commercially available drug treatments for RM, and Ocuphire is not aware of any in development. Rev-Eyes<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (dapiprazole), an alpha-1 antagonist, was approved by the FDA in 1990 to reverse mydriasis induced by adrenergic or anticholinergic agents. Rev-Eyes was withdrawn in the past from the market for reasons unrelated to
          safety or efficacy, according to the FDA.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Competition in Presbyopia</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The FDA approved Vuity<sup>TM</sup> eye drop for the treatment of presbyopia in October 2021. Vuity was launched in December 2021 and is
            marketed by Allergan, an AbbVie company. The competition also includes reading glasses, multifocal contact lenses, and monovision contact lenses (e.g., where one eye wears a near vision lens and the other eye wears a distance vision lens).
            Nyxol will also compete against several pharmacological therapies in development for the temporary treatment of presbyopia, many of which are cholinergic agonist-based pupil management therapies, including:</div>

          <div>&#160;</div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>CSF-1, with low dose pilocarpine and a secondary agent (lubricant), developed by Orasis Pharmaceuticals Ltd. (PDUFA date is October 22, 2023)</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>LNZ100 and LNZ101, with aceclidine (another miotic agent) and brimonidine, developed by Lenz Therapeutics.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>MicroLine<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, which is a micro-dose delivery of pilocarpine using proprietary device developed by Eyenovia, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>KT-101, which uses pilocarpine in the AcuStream delivery system, developed by Kedalion Therapeutics, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Brimochol<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>, with brimonidine and carbachol (both are miotic agents), developed by Visus Therapeutics, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">44</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>UNR844, which uses a mechanism that involves softening the lens to increase near visual acuity, developed by Novartis AG (originally Encore Vision, Inc.). This development program has been terminated.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There are a few approved devices for presbyopia. One of these is the KAMRA Inlay, developed by AcuFocus, Inc. and marketed by SightLife Surgical, Inc. Another is the eyelike NoanPinhole,
          developed by Koryo Eyetech, the first commercially available pinhole soft contact lens. Nyxol would not directly compete against these devices, but rather would be a non-invasive alternative for presbyopes who are averse to surgical intervention.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Competition in DLD</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">DLD is a new indication in which Nyxol could be the first approved drug. There are currently no FDA-approved therapies for DLD nor is Ocuphire aware of any in development. Existing miotic agents
          are rarely used off-label given their limitations of tachyphylaxis (brimonidine, a generic drug, marketed by various pharmaceutical companies) and warning in the label of difficulties while driving at night or performing hazardous activities in
          poor illuminations (attributable to pilocarpine, a generic molecule marketed by various pharmaceutical companies at common doses of 1%, 2%, and 3%).</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Government Regulation and Product Approvals</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union (EU), extensively regulate, among other
          things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of
          pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities,
          require the expenditure of substantial time and financial resources.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The EMA is a decentralized agency governed by an independent management board responsible for the evaluation, supervision, and safety monitoring of medicines in the EU.&#160; The Medicines and
          Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices, and blood components in the United Kingdom (UK) and serves as a similar function to the EMA in the EU, following the exit of the UK from the EU in Brexit. The
          Japanese Pharmaceuticals and Medical Devices Agency serves a similar function to the FDA in the United States and is an independent administrative institution. The National Medical Products Administration (NMPA) is the Chinese agency for
          regulating drugs and medical devices (formerly the China Food and Drug Administration or CFDA).</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Review and Approval of Drugs in the United States</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The failure to comply with applicable requirements
          under the FDCA and other applicable laws at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the
          FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution,
          injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>completion of preclinical laboratory tests, animal studies and formulation studies in compliance, as applicable, with the Animal Welfare Act and FDA&#8217;s good laboratory practice, or GLP, regulations;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">45</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>submission to the FDA of an IND, which must take effect before human clinical trials may begin;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, and other applicable regulations to establish the safety and efficacy of the proposed drug product for each proposed
                  indication;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>manufacturing, packaging, labelling, and distribution of drug substances and drug products consistent with the FDA&#8217;s Good Manufacturing Practice (GMP) regulations which are utilized in the GLP non-clinical and GCP clinical studies to
                  investigate the drug candidate;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>development of product label, package inserts, and prescriber information that is intended to be used and included with the commercial product;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>preparation and submission to the FDA of an NDA;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>review of the product by an FDA advisory committee, where appropriate or if applicable;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices, or cGMP,
                  requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>payment of user fees and securing FDA approval of the NDA; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval studies required by the FDA.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Preclinical Studies</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient and the formulated drug or drug product, as
          well as<span style="font-style: italic;"> in vitro</span> and <span style="font-style: italic;">in vivo</span> animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for
          therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available
          clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as 6-month toxicology studies, may continue after the IND is submitted.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Companies usually must complete some long-term preclinical testing, such as 6-month or longer toxicology studies, and must also develop additional information about the chemistry and physical
          characteristics of the investigational product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches
          of the candidate product and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability
          studies must be conducted to demonstrate that the candidate product does not undergo unacceptable deterioration over its shelf life.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">46</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">The IND and IRB Processes</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial. In support of a request for an IND,
          applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of preclinical tests, together with manufacturing information, analytical
          data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. An IND goes into effect 30-days after its filing, unless during this 30-day period the FDA raises
          concerns or questions and imposes a clinical hold.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of
          only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial
          clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the
          investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed. The FDA may also place a
          clinical hold or partial clinical hold on a trial after a clinical trial has begun.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless
          waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain FDA regulatory requirements in order to use the trial as support for an IND or application for marketing approval,
          including that such trials must be conducted in accordance with GCP, including review and approval by an independent ethics committee, or IEC, and obtaining informed consent from patients. The GCP requirements in the final rule encompass both
          ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human patients enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting
          data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB
          must exercise continuing supervision over the trial. The IRB must review and approve, among other things, the trial protocol and informed consent information to be provided to trial patients. An IRB must operate in compliance with FDA
          regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has
          been associated with unexpected serious harm to patients.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides
          authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the trial. Suspension or termination of development during any phase of clinical trials can
          occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by Ocuphire based on evolving business objectives and/or competitive climate.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on its ClinicalTrials.gov website.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Human Clinical Trials in Support of an NDA</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Clinical trials involve the administration of the investigational product to human patients under the supervision of qualified investigators in accordance with GCP requirements, which include,
          among other things, the requirement that all research patients provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things,
          the inclusion and exclusion criteria, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">47</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Human clinical trials are typically conducted in 3 sequential phases, but the phases may overlap.</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="font-style: italic;">Phase 1</span>. The drug is initially introduced into healthy human patients or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage
                  tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="font-style: italic;">Phase 2</span>. The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific
                  targeted diseases and to determine dosage tolerance and optimal dosage.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><span style="font-style: italic;">Phase 3</span>. The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to
                  statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Reports detailing activities under, and the status of, an IND must be submitted at least annually to the FDA. In addition, IND safety reports must be submitted to the FDA for any of the
          following: serious and unexpected suspected adverse reactions; findings from other studies or animal or<span style="font-style: italic;"> in vitro</span> testing that suggest a significant risk in humans exposed to the drug; and any clinically
          important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at
          all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or
          terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to
          patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as
          well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other
          things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug
          candidate does not undergo unacceptable deterioration over its shelf life.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Submission of an NDA to the FDA</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating to the
          product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most
          NDAs is subject to an application user fee (up to a maximum to 5), which for federal fiscal year 2022 is $3,117,281 for an application requiring clinical data. The sponsor of an approved NDA is also subject to an annual prescription drug program
          fee, which for fiscal year 2022 is $369,413. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for drugs with orphan designation and a waiver for certain small businesses.&#160; The FDA
          conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> day after the FDA&#8217;s receipt of the submission to determine
          whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing, and the sponsor receives a Refuse to File Notice. In this event, the application must
          be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has
          agreed to certain performance goals in the review process of NDAs. The goal for review of most standard applications is within 10 months from the date of filing, and for &#8220;priority review&#8221; products the review goal is within 6 months of filing. The
          review process may be extended by the FDA for 3 additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">48</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections (PAIs) may cover all facilities
          associated with an NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it
          determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications at the commercial scale. Additionally, before approving
          an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, as a condition of approval, the FDA may require an applicant to develop a Risk Evaluation and Mitigation Strategies (REMS). REMS uses risk minimization strategies to ensure that the
          benefits of the product outweigh the potential risks. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special
          training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS at the time of approval or post-approval if it becomes aware
          of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The FDA may refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including
          clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but
          it considers such recommendations carefully when making decisions.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Fast Track, Breakthrough Therapy, and Priority Review Designations</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or
          condition. These programs are referred to as fast-track designation, breakthrough therapy designation, and priority review designation.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or
          life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review
          of sections of a Fast Track product&#8217;s application before the application is complete. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user
          fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that
          the designation is no longer supported by data emerging in the clinical trial process.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or
          condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in
          clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development
          and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">49</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Third, the FDA may designate a product for Priority Review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness.
          The FDA determines, on a case- by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the
          treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a
          new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from 10 months to 6 months.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">The FDA&#8217;s Decision on an NDA</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter, or a
          complete response letter (CRL). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and
          may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA may issue an approval
          letter. The FDA has committed to reviewing such resubmissions in 2 or 6 months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy
          the regulatory criteria for approval.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require
          that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions,
          including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the
          results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing
          requirements and FDA review and approval.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Post-Approval Requirements</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping,
          periodic reporting (such as annual reports and quarterly safety reports for the first 3 years), product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to
          the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements for any marketed products, as well as new application fees for
          supplemental applications with clinical data.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and
          are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented.
          FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly,
          manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">50</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the
          market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to
          the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include,
          among other things:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>fines, warning letters or holds on post-approval clinical trials;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>product seizure or detention, or refusal to permit the import or export of products; or</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>injunctions or the imposition of civil or criminal penalties.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with
          the provisions of the approved label. All promotional materials must be submitted to FDA prior to the time of their first use.&#160; The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and
          a company that is found to have improperly promoted off-label uses may be subject to significant liability.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drug samples at the federal
          level and sets minimum standards for the registration and regulation of drug sample distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure
          accountability in distribution.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Section 505(b)(2) NDAs</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">NDAs for most new drug products are based on 2 adequate and well-controlled clinical trials which must contain substantial evidence of the safety and efficacy of the proposed new product. These
          applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This type of application allows the applicant to rely, in part, on the
          FDA&#8217;s previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section 505(b)(2) applies to an NDA for a drug for which the investigations to show whether the drug is safe and effective and relied
          upon by the applicant for approval of the application &#8220;were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&#8221;</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Thus, Section 505(b)(2) authorizes the FDA to approve an NDA based in part on safety and effectiveness data that were not developed by the applicant. Section 505(b)(2) may provide an alternate
          and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the Section 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous approval is scientifically
          appropriate, the applicant may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the
          approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">51</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Abbreviated New Drug Applications for Generic Drugs</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA
          provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and
          clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Specifically, in order for an ANDA to be approved, the FDA generally must find that the generic version is identical to the RLD with respect to the active ingredients, the route of
          administration, the dosage form, and the strength of the drug. The FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if &#8220;the rate and extent of
          absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221;</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication Approved Drug Products with Therapeutic Equivalence
          Evaluations, also referred to as the Orange Book. Clinicians and pharmacists often consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance
          programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing clinicians or patient.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of
          non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other
          NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of
          five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies,
          that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period applies to the condition(s) of use for which the new clinical investigation was conducted, and often protects
          changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided
          the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the
          date of approval of the original drug product.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Hatch-Waxman Patent Certification and the 30-Month Stay</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the
          product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference
          product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. To the extent that the Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the
          applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Specifically, the applicant must certify with respect to each patent that: (1) the required patent information has not been filed, (2) the listed patent has expired, (3) the listed patent has not
          expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patent is invalid, unenforceable or will not be infringed by the new product.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">52</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If
          the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) application will not be approved until all the listed patents claiming the referenced product have
          expired (other than method of use patents involving indications for which the applicant is not seeking approval).</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has
          been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the
          receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is
          favorable to the ANDA applicant.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">To the extent that the Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed
          for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a Section 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any
          non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement
          suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">505(b)(2) and NCE Data Exclusivity in U.S.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">In the United States, the Hatch-Waxman Act provides a 3-year period of non-patent data exclusivity within the United States to the first applicant to gain approval through a 505(b)(2) application
          seeking regulatory approval of, for example, a new indication, dosage, or strength of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigation and does not prohibit the FDA
          from approving an ANDA for drugs containing the original active agent. Under this provision, Nyxol for use in treating presbyopia, mydriasis, or DLD may be eligible for 3 years of data exclusivity under the Hatch-Waxman Act.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">In the United States, the Hatch-Waxman Act provides period of 5-years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new
          chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug
          substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit
          its application four years following the original product approval.</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">Pediatric Studies and Exclusivity</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed
          indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation
          Act or FDASIA, in 2012, sponsors must also submit pediatric trial plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric trial or studies the applicant plans to conduct, including trial objectives and
          design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final
          plan. The FDA or the applicant may request an amendment to the plan at any time.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">53</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full
          or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric
          data requirements do not apply to products with orphan designation.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional 6 months to the term of any patent or
          regulatory exclusivity, including orphan exclusivity. This 6-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product
          to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by
          the FDA within the statutory time limits, the latest statutory or regulatory period of exclusivity or patent covering the product is extended by 6 months. This is not a patent term extension, but it effectively extends the regulatory period
          during which the FDA cannot approve another application.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Orphan Drug Designation and Exclusivity</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the
          United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the
          product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any
          advantage in or shorten the duration of the regulatory review and approval process.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or
          condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve any other applications for the same product for the same indication for 7 years, except
          in certain limited circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or
          drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Patent Term Restoration and Extension</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to 5 years for patent term lost
          during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA
          and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the
          extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals.
          The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA. Ocuphire cannot provide any assurance that any patent term extension with respect to any U.S.
          patent will be obtained and, if obtained, the duration of such extension, in connection with any of its product candidates.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">54</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-weight: bold;">Review and Approval of Drug Products in the European Union</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality,
          safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, Ocuphire would need to obtain the necessary
          approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can
          involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory
          approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Procedures Governing Approval of Drug Products in the European Union</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Pursuant to the European Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states.
          Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial after a
          competent ethics committee has issued a favorable opinion. Clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and
          corresponding national laws of the member states and further detailed in applicable guidance documents.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">To obtain marketing approval of a product under European Union regulatory systems, an applicant must submit a marketing authorization application, or MAA, either under a centralized or
          decentralized procedure. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. The centralized procedure is compulsory for specific
          products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain
          diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency, or EMA, is responsible for conducting the initial
          assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the
          European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated
          evaluation might be granted by the CHMP in exceptional cases when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA
          ensures that the opinion of the CHMP is given within 150 days.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The decentralized procedure is available to applicants who wish to market a product in various European Union member states where such product has not received marketing approval in any European
          Union member states before. The decentralized procedure provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one-member state designated by the applicant, known as the reference
          member state. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference member state
          and concerned member states. The reference member state prepares a draft assessment report and drafts of the related materials within 210 days after receipt of a valid application. Within 90 days of receiving the reference member state&#8217;s
          assessment report and related materials, each concerned member state must decide whether to approve the assessment report and related materials.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution
          mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">55</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Within this framework, manufacturers may seek approval of hybrid medicinal products under Article 10(3) of Directive 2001/83/EC. Hybrid applications rely, in part, on information and data from a
          reference product and new data from appropriate pre-clinical tests and clinical trials. Such applications are necessary when the proposed product does not meet the strict definition of a generic medicinal product, or bioavailability studies
          cannot be used to demonstrate bioequivalence, or there are changes in the active substance(s), therapeutic indications, strength, pharmaceutical form or route of administration of the generic product compared to the reference medicinal product.
          In such cases the results of tests and trials must be consistent with the data content standards required in the Annex to the Directive 2001/83/EC, as amended by Directive 2003/63/EC.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Hybrid medicinal product applications have automatic access to the centralized procedure when the reference product was authorized for marketing via that procedure. Where the reference product
          was authorized via the decentralized procedure, a hybrid application may be accepted for consideration under the centralized procedure if the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or
          technical innovation, or the granting of a community authorization for the medicinal product is in the interest of patients at the community level.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Clinical Trial Approval in the European Union</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Requirements for the conduct of clinical trials in the European Union including Good Clinical Practice, or GCP, are set forth in the Clinical Trials Directive 2001/20/EC and the GCP Directive
          2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the E.U. member states. Under this system,
          approval must be obtained from the competent national authority of each E.U. member state in which a trial is planned to be conducted. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier, or
          IMPD, and further supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started after a competent ethics committee has issued a
          favorable opinion on the clinical trial application in that country.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In April 2014, the E.U. passed the new Clinical Trials Regulation (EU) No 536/2014. The new Clinical Trials Regulation, which will replace the Clinical Trials Directive, introduces a complete
          overhaul of the existing regulation of clinical trials for medicinal products in the E.U., including a new coordinated procedure for authorization of clinical trials that is reminiscent of the mutual recognition procedure for marketing
          authorization of medicinal products, and increased obligations on sponsors to publish clinical trial results. The entry into application of the Clinical Trials Regulation has been delayed. The Clinical Trials Directive may be replaced with the
          new Clinical Trials Regulation in late 2022. The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application
          procedure via a single entry point, the E.U. portal; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures that will spare sponsors from submitting broadly identical information
          separately to various bodies and different member states; a harmonized procedure for the assessment of applications for clinical trials, which is divided into two parts (Part I is assessed jointly by all member states concerned, and Part II is
          assessed separately by each member state concerned); strictly defined deadlines for the assessment of clinical trial applications; and the involvement of the ethics committees in the assessment procedure in accordance with the national law of the
          member state concerned but within the overall timelines defined by the Clinical Trials Regulation.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Periods of Authorization and Renewals</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA
          or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy,
          including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the
          European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the
          European Union market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">56</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Data and Market Exclusivity in the European Union</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In the European Union, new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if
          granted, prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted, and the innovator&#8217;s
          data may be referenced, but not approved for two years. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for
          one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new
          chemical entity and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company can complete a full MAA with a complete database of
          pharmaceutical test, preclinical tests and clinical trials and obtain marketing approval of its product.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Orphan Drug Designation and Exclusivity</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Regulation 141/2000 provides that a drug shall be designated as an orphan drug if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of a
          life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Community when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a
          life-threatening, seriously debilitating or serious and chronic condition in the European Community and that without incentives it is unlikely that the marketing of the drug in the European Community would generate sufficient return to justify
          the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European
          Community or, if such method exists, the drug will be of significant benefit to those affected by that condition.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Regulation 847/2000 sets out criteria and procedures governing designation of orphan drugs in the European Union. Specifically, an application for designation as an orphan product can be made any
          time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. This period may, however, be reduced to six years if, at the end of the
          fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very
          selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#8220;clinically relevant superiority&#8221; by a similar medicinal product, or, after a review by the
          Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs pursuant to
          Regulation 141/2000 shall be eligible for incentives made available by the European Community and by the member states to support research into, and the development and availability of, orphan drugs.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Regulatory Requirements after Marketing Authorization</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As in the United States, both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent authorities of
          the individual EU Member States both before and after grant of the manufacturing and marketing authorizations. The holder of an EU marketing authorization for a medicinal product must, for example, comply with EU pharmacovigilance legislation and
          its related regulations and guidelines which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. The manufacturing process for medicinal products in the European Union
          is also highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with
          various requirements set out in the applicable EU laws, including compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">57</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">In the European Union, the advertising and promotion of approved products are subject to EU Member States&#8217; laws governing promotion of medicinal products, interactions with clinicians, misleading
          and comparative advertising and unfair commercial practices. In addition, other legislation adopted by individual EU Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional materials and
          advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. Promotion of a medicinal product that does not comply with the SmPC is considered to
          constitute off-label promotion, which is prohibited in the European Union.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Healthcare Reform</div>

        <div><span style="font-weight: bold;"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The healthcare industry in the United States, including the research-based pharmaceutical sector, is highly regulated and subject to frequent substantial changes. Any significant efforts from the
          federal or state governments to change how healthcare is provided or funded within the United States could have a material impact on Ocuphire&#8217;s business. Currently, the United States Patient Protection and Affordable Care Act of 2010, as amended
          by the Health Care and Education Reconciliation Act (the &#8220;ACA&#8221;) is the seminal legislation that has had, and continues to have, the most substantial impact on the healthcare industry. <span style="color: rgb(0, 0, 0);">The ACA is intended to
            expand coverage for uninsured individuals and contain the overall cost of healthcare services. Some provisions of the ACA have yet to be fully implemented, while certain other provisions have been subject to reform through legislation,
            Executive Orders of the President, and to judicial challenges. With regard to the research-based pharmaceutical sector and pharmaceutical products, provisions in the ACA impacting </span>Ocuphire&#8217;s potential drug candidates<span style="color: rgb(0, 0, 0);"> include:</span></div>

        <div style="text-align: justify;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>A special, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare
                  programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications;</div>
              </td>

  </tr>


</table>
        <div style="text-align: justify;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing
                  a manufacturer&#8217;s Medicaid rebate liability;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#8220;average manufacturer price,&#8221; or AMP, for calculating
                  and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for individuals enrolled in Medicare Advantage plans; addressed a new methodology by which rebates owed by
                  manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Expanded the types of entities eligible for the 340B drug discount program;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 50% point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap
                  period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>A new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">58</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There may be additional legislative changes, including potential repeal and replacement of certain provisions of the ACA. While the timing and scope of any potential future legislation to repeal
          and replace ACA provisions is highly uncertain in many respects, it is also possible that some of the ACA provisions that generally are not favorable for the research-based pharmaceutical sector could also be repealed along with ACA coverage
          expansion provisions.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="font-weight: bold;">Healthcare Laws and Regulations</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">There are other healthcare-related laws and regulations that extensively govern how pharmaceutical companies, like Ocuphire, are operated and regulate activities related to pharmaceutical
          products. These laws and regulations may require administrative guidance to implement. Failure to comply could subject the company to legal and/or administrative actions, which may include substantial fines and/or penalties; orders to stop
          non-compliant activities; criminal charges; warning letters; product recalls or seizures; delays in product approvals; exclusion from participation in government reimbursement programs or contracts as well as limitations on conducting business in
          applicable jurisdictions.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Applicable federal and state healthcare laws and regulations include:</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce
                  or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be
                  presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</div>
              </td>

  </tr>


</table>
        <div style="text-align: justify;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The federal Physician Payments Sunshine Act (part of the ACA), commonly known as the Sunshine Act or Open Payments, requires certain manufacturers of drugs, devices, biologics and medical supplies to disclose certain payments and
                  financial relationships with healthcare providers directly to the Centers for Medicare &amp; Medicaid Services (CMS). Failure to comply with these laws can result in significant civil monetary penalties;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (collectively, "HIPAA"). HIPAA mandates, among other things, the
                  adoption of uniform standards for the electronic exchange of information in common health care transactions as well as standards relating to the privacy and security of individually identifiable health information. These standards require
                  the adoption of administrative, physical and technical safeguards to protect such information. In addition, many states have enacted comparable laws addressing the privacy and security of health information, some of which are more
                  stringent than HIPAA. Failure to comply with these laws can result in the imposition of significant civil and criminal penalties;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">59</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Other analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare related items or services that are reimbursed by non-governmental third-party payors, including
                  private insurers.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify;">&#160;<span style="font-weight: bold;">Healthcare Reimbursement</span></div>

        <div><span style="font-weight: bold;"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Healthcare providers and third-party payors play a primary role in recommending and prescribing pharmaceutical products that are granted regulatory approval. If our potential drug candidates
          receive regulatory approval, successful commercialization of the products may depend, in part, on obtaining and maintaining adequate reimbursement levels with third-party payors, including commercial health insurers, managed care organizations,
          and government health programs in the United States such as Medicare and Medicaid. However, a growing trend in the United States healthcare industry and elsewhere is cost containment.</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Recently, there has been greater scrutiny from governmental bodies over how pharmaceutical manufacturers and distributors set prices for their products. This has resulted in congressional
          inquiries as well as other proposed and enacted legislation designed to (i) bring more transparency to product pricing, (ii) limit coverage and reimbursement for drugs and other medical products, and (iii) reform government health program
          reimbursement within the healthcare system as a whole. While proposed reform measures will require the U.S. Congress to pass legislation to become effective, President Biden&#8216;s administration and the U.S. Congress have each indicated that they
          will continue to seek new legislative and/or administrative measures to control drug costs.</div>

        <div> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">For example, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap for single source and innovator
          multiple source drugs, beginning January 1, 2024. Further, on July 9, 2021, President Biden signed an executive order to promote competition in the U.S. economy that included several initiatives addressing prescription drugs. Among other
          provisions, the executive order directed the Secretary of HHS to issue a report to the White House that includes a plan to, among other things, reduce prices for prescription drugs, including prices paid by the federal government for such drugs.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">The report, issued on September 9, 2021 entitled a Comprehensive Plan for Addressing High Drug Prices: A Report in Response to the Executive Order on Competition in the American Economy,
          identified potential legislative policies and administrative tools that Congress and the agency can pursue in order to (i) make drug prices more affordable and equitable, (ii) improve and promote competition throughout the prescription drug
          industry, and (iii) foster scientific innovation. In addition, individual states in the United States have also become increasingly active in passing laws and implementing regulations designed to control pharmaceutical product pricing, including
          reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Furthermore, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) into law. The IRA includes several provisions that may potentially impact our business,
          including provisions that (i) create a $2,000 cap on out-of-pocket expenses for Medicare Part D beneficiaries, (ii) impose new manufacturer financial liability on all drugs in Medicare Part D, (iii) allow the U.S. government to negotiate Medicare
          Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, (iv) require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and (v) delay the rebate rule
          that would require pass-through of pharmacy benefit manager rebates to beneficiaries. The effect of IRA on our business and the healthcare industry in general is not yet known.</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Human Capital Resources</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As of December 31, 2022, Ocuphire had nine full-time employees, with the following assignments: two engaged in clinical research and development activities, one of whom holds a Ph.D. degree, four
          engaged in research and development activities and also business development and finance, and three engaged in finance, human resources, and administrative support. Ocuphire plans to continue to utilize expert consultants and contract
          organizations to support execution of the day-to-day operations. None of Ocuphire&#8217;s employees are represented by labor unions or covered by collective bargaining agreements. Ocuphire believes that it maintains good relations with its employees.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">60</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <a id="ITEM1A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; font-weight: bold;">ITEM 1A.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">RISK FACTORS</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">An investment in our securities has a high degree of risk. Before you invest you should carefully consider the risks and uncertainties described below and the other
          information in this Annual Report. Any of the risks and uncertainties set forth herein could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the
          trading price or value of our securities. Additional risks not currently known to us or which we consider immaterial based on information currently available to us may also materially adversely affect us. As a result, you could lose all or part
          of your investment.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Risks Related to Development of Our Product Candidates</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic; font-weight: bold;">Viatris has exclusive global rights to commercialize our Nyxol products in key global markets. Viatris&#8217; failure to timely develop or commercialize these products would have a
          material adverse effect on our business and operating results.</div>

        <div style="text-align: justify;"> <br />
        </div>

        <div style="text-align: justify;"><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;&#160;&#160;&#160;</span>We granted Viatris an exclusive right to commercialize our Nyxol products in key global markets. Additionally, we
          granted Viatris the exclusive right and license to develop Nyxol outside of the United States. The collaboration with Viatris may not be successful due to several factors, including the following:</div>

        <div style="text-align: justify;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Viatris may not be able to obtain from us or manufacture our products in a timely or cost-effective manner;</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Viatris may not timely perform its obligations under the Nyxol License Agreement;</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Viatris may fail to effectively commercialize our products;<br />
                </div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div>
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Viatris</span> may not be able to sublicense Nyxol to one or more suitable parties outside
                      the United States; or</div>
                  </div>
                </td>

  </tr>


</table>
          <div><br /></div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>
                  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Contractual disputes or other disagreements between us and <span style="font-size: 10pt; font-family: 'Times New Roman';">Viatris</span>, including those
                    regarding the development, manufacture, sub licensure and commercialization of our products, interpretation of the Nyxol License Agreement, and ownership of proprietary rights. Viatris may select a new development partner for Nyxol in
                    the U.S. upon 90 days&#8217; notice to Ocuphire.</div>
                </div>
              </td>

  </tr>


</table>
        <div style="text-align: justify;"> <br />
        </div>

        <div style="text-align: justify;"><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;&#160;&#160;&#160;</span>Any of the foregoing could adversely impact the likelihood and timing of any payments we are eligible to receive
          under the Nyxol License Agreement. The Company will be reliant on Viatris to drive the commercialization and sales of our products. If Viatris does not perform its obligations under the Nyxol License Agreement, this could result in a material
          adverse effect on our business, results of operations and prospects and would likely cause our stock price to decline.</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">We currently depend entirely on the success of Nyxol and APX3330, our only product candidates. </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We currently have only two product candidates, Nyxol and APX3330, in clinical development, and our business depends on their successful clinical development, regulatory approval and
          commercialization (by us our by our strategic partner). The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of a drug product are subject to extensive regulation by the FDA and other regulatory authorities
          in the United States and other countries, where regulations may differ. We are not permitted to market our product candidates in the United States until we receive approval of an NDA from the FDA or in any foreign countries until we receive the
          requisite approval from such countries. We have submitted an NDA to the FDA for Nyxol for the treatment of RM.&#160; The application was accepted for filing by the FDA with a PDUFA date of September 28, 2023. For other indications, and for APX3330,
          before obtaining regulatory approval for the commercial sale of our product candidates for a particular indication, we must demonstrate through preclinical testing and clinical trials that the applicable product candidate is safe and effective
          for use in that target indication. This process can take many years and may be followed by post-marketing studies and surveillance together which will require the expenditure of substantial resources beyond the proceeds raised <span style="color: rgb(0, 0, 0);">in our equity and debt financings to date</span>. Of the large number of drugs in development in the United States, only a small percentage of drugs successfully complete the FDA regulatory approval process and are
          commercialized. Accordingly, even if we are able to complete development of our product candidates, we cannot assure you that our product candidates will be approved or commercialized.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">61</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Obtaining approval of an NDA is an extensive, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of our product candidates for many reasons, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the data collected from preclinical studies and clinical trials of our product candidates may not be sufficient to support the submission or acceptance of an NDA for one or more indications;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we may not be able to demonstrate to the satisfaction of the FDA that our product candidates are safe and effective for any indication;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the results of clinical trials may not meet the level of statistical significance or clinical significance required by the FDA for approval;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the FDA may disagree with the number, design, size, conduct, or implementation of our clinical trials;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the FDA may not find the data from preclinical studies and clinical trials sufficient to demonstrate that our product candidates&#8217; clinical and other benefits outweigh the safety risks;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the FDA may not accept data generated at our clinical trial sites;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval,
                  additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the FDA may require development of a Risk Evaluation and Mitigation Strategy (REMS) as a condition of approval;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the FDA may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we entered or enter into agreements for clinical and commercial supplies; or</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the FDA may change its approval policies or adopt new regulations.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S.
          regulatory authorities.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The results from the prior preclinical studies and clinical trials for Nyxol and APX3330 discussed elsewhere in this Annual Report may not necessarily be predictive of the results of future
          preclinical studies or clinical trials. Even if we are able to complete our planned clinical trials of our product candidates according to our current development timeline, the results from our prior clinical trials of our product candidates may
          not be replicated in these future trials. Many companies in the pharmaceutical and biotechnology industries (including those with greater resources and experience than us) have suffered significant setbacks in late-stage clinical trials after
          achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or
          safety or efficacy observations made in clinical trials, including previously unreported adverse events (&#8220;AEs&#8221;). Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that
          believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless have failed to obtain FDA approval. If we fail to produce positive results in our clinical trials of any of our product candidates,
          the development timelines, regulatory approvals, and commercialization prospects for our product candidates, as well as Ocuphire&#8217;s business and financial prospects, would be adversely affected. Further, Ocuphire&#8217;s product candidates may not be
          approved even if they achieve their respective primary endpoints in additional Phase 3 registration trials. The FDA or non-U.S. regulatory authorities may disagree with our trial designs or our interpretation of data from preclinical studies and
          clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a clinical registration trial that has the
          potential to result in approval by the FDA or another regulatory authority. Furthermore, any of these regulatory authorities may also approve our product candidates for fewer or more limited indications than we request or may grant approval
          contingent on the performance of costly post-marketing clinical trials.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">62</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">&#160;Before obtaining regulatory approvals for the commercial sale of any product candidate for any target indication, we must demonstrate with substantial evidence gathered in preclinical studies
          and adequate and well-controlled clinical studies, and, with respect to approval in the United States, to the satisfaction of the FDA, that the product candidate is safe and effective for use for that target indication. We cannot assure you that
          the FDA or non-U.S. regulatory authorities would consider our planned clinical trials to be sufficient to serve as the basis for approval of our product candidates for any indication. The FDA and non-U.S. regulatory authorities retain broad
          discretion in evaluating the results of our clinical trials and in determining whether the results demonstrate that our product candidates are safe and effective. If we are required to conduct clinical trials of our product candidates in addition
          to those we have planned prior to approval, we may need substantial additional funds, and cannot assure you that the results of any such outcomes trial or other clinical trials will be sufficient for approval.</div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Additional data and/or time may be required to obtain U.S. regulatory approval for any of our product candidates that are deemed to be a drug/device combination product
          candidate.</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Our eye drop product candidates are now considered combination products with both drug and device components. The FDA requires both the drug and device components of combination product
          candidates to be reviewed as part of an NDA submission. The FDA&#8217;s application of the regulations is evolving for drug/device combination products including single-use and multi-dose eye droppers. We may experience requests for additional data
          and/or delays in the development and commercialization of our drug-led combination product candidates, due to regulatory uncertainties in the product development and approval process.</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">If clinical trials of APX3330 fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or
          experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Before obtaining marketing approval from regulatory authorities for the sale of APX3330, we need to conduct further animal toxicology studies and additional clinical trials before obtaining
          marketing approval from regulatory authorities. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of
          development.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may&#160; experience delays in manufacturing and our clinical trials, and we, or our future collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that
          could result in increased development costs and delay, and could limit or prevent our, or our future collaborators&#8217;, ability to receive marketing approval or commercialize our product candidates, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>regulators or IRBs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site including due to the ongoing COVID-19 pandemic or other public health emergency;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">63</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>government or regulatory delays and changes in regulatory requirements, policy and guidelines may require us to perform additional clinical trials or use substantial additional resources to obtain regulatory approval;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require it, to conduct additional clinical trials or abandon product development programs;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the number of patients required for clinical trials may be larger, enrollment in these clinical trials may be slower or participants may drop out of these clinical trials at a higher rate than we anticipate;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our patients or medical investigators may be unwilling to follow our clinical trial protocols;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we might have to suspend or terminate clinical trials for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the cost of clinical trials may be greater than we anticipate;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the supply or quality of any product candidate or other materials necessary to conduct clinical trials may be insufficient or inadequate;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the product candidate may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate the trials;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>clinical trials may be delayed or terminated ; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>federal agencies may, due to reduced manpower or diverted resources, require more time to review clinical trial protocols and INDs.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our ability to conduct and complete those clinical trials, and our ability to seek and receive necessary
          regulatory approvals, could be delayed or prevented.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We or our future collaborators may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to
          participate in these trials as required by the FDA or analogous regulatory authorities outside the United States. Patient enrollment can be affected by many factors, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>severity of the disease under investigation;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>availability and efficacy of medications already approved for the disease under investigation;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>eligibility criteria and visit schedule for the trial in question;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>competition for eligible patients with other companies conducting clinical trials for product candidates seeking to treat the same indication or patient population;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">64</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our payments for conducting clinical trials;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>perceived risks and benefits of the product candidate under study;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>efforts to facilitate timely enrollment in clinical trials;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>patient referral practices of physicians;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the ability to monitor patients adequately during and after treatment;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>proximity and availability of clinical trial sites for prospective patients; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">the ability of patients to safely participate in clinical trials during any public health emergencies such as the COVID-19 pandemic. Our inability to enroll a sufficient number of patients for
          our clinical trials or retain sufficient enrollment through the completion of our trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result
          in increased development costs for our product candidates and cause our stock price to decline.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">We or others could discover that our product candidates lack sufficient efficacy, or sufficient efficacy compared to competitor
            products or that they cause undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or commercialization.</div>

        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Because both Nyxol and APX3330 have been tested in relatively small patient populations, at a limited range of daily doses up to 0.75% Phentolamine Ophthalmic Solution (which is the same as 1.0%
          Phentolamine Mesylate Ophthalmic Solution) and up to 720 mg respectively, and for limited durations to date, it is possible that our clinical trials have or will indicate an apparent positive effect of Nyxol or APX3330 that is greater than the
          actual positive effect, if any, or that additional and unforeseen side effects may be observed as its development progresses. The discovery that either Nyxol (alone or&#160;&#160; with adjunctive LDP) or APX3330 lacks sufficient efficacy, or that they
          cause undesirable side effects (including side effects not previously identified in our completed clinical trials), could cause us or regulatory authorities to interrupt, delay, or discontinue clinical trials, and could result in the denial of
          regulatory approval by the FDA or other non-U.S. regulatory authorities for any or all targeted indications.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The discovery that our product candidates lack sufficient efficacy or that they cause undesirable side effects that were not previously identified could prevent us from commercializing such
          product candidates and generating revenues from sales. In addition, if we receive marketing approval for our product candidates and we or others later discover that they are less effective, or identify undesirable side effects caused by our
          product candidates:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>regulatory authorities may withdraw their approval of the product;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we may be required to recall the product, change the way this product is administered, conduct additional clinical trials, or change the labeling or distribution of the product (including REMS);</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the product;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we may be subject to fines, injunctions, or the imposition of civil or criminal penalties;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we could be sued and held liable for harm caused to patients;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the product may be rendered less competitive and sales may decrease; or</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our reputation may suffer generally among both clinicians and patients.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">65</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Any one or a combination of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate or could substantially increase the costs and expenses
          of commercializing the product candidate, which in turn could delay or prevent us from generating significant, or any, revenues from the sale of the product candidate.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">
          <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may result in changes
            to clinical trial protocols or additional clinical trial requirements, which could result in increased costs to us or delays in development timelines.</div>

        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may require us to amend clinical trial protocols or the FDA may impose additional clinical
          trial requirements. Amendments to our clinical trial protocols would require resubmission to the FDA and IRBs for review and approval, and may adversely impact the cost, timing or successful completion of a clinical trial. If we experience delays
          completing, or if we terminate, any Phase 2 or Phase 3 trials, or if we are required to conduct additional clinical trials, the commercial prospects for our product candidates may be harmed and our ability to generate product revenues will be
          delayed.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we fail to receive regulatory approval for any of our planned indications for our product candidates or fail to develop additional product candidates, our commercial opportunity will be
          limited.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We are initially focused on the development of our product candidates for our target indications, the reversal of pharmacologically-induced mydriasis, treatment of presbyopia, DLD, DR and DME.
          However, we cannot assure you that we will be able to obtain regulatory approval of our product candidates for any indication, or successfully commercialize our product candidates, if approved. If we do not receive regulatory approval for, or
          successfully commercialize, our product candidates for one or more of our targeted or other indications, our commercial opportunity will be limited.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may pursue clinical development of additional acquired or in-licensing product candidates. Developing, obtaining regulatory approval for and commercializing additional product candidates will
          require substantial additional funding beyond the net proceeds of <span style="color: rgb(0, 0, 0);">our completed equity and debt financings</span>, and are prone to the risks of failure inherent in drug product development. We cannot assure
          you that we will be able to successfully advance any additional product candidates through the development process.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Even if we obtain FDA approval to market additional product candidates, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the
          marketplace, or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We have limited drug research and discovery capabilities and may need to acquire or license product candidates from third parties to expand our product candidate pipeline.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We currently have limited drug research and discovery capabilities. Accordingly, if we are to expand our product candidate pipeline beyond Nyxol and APX3330 and our pipeline candidates, we may
          need to acquire or license product candidates from third parties. We would face significant competition in seeking to acquire or license promising product candidates. Many of our competitors for such promising product candidates may have
          significantly greater financial resources and more extensive experience in preclinical testing and clinical trials, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products, and thus, may be a more attractive option
          to a potential licensor than us. If we are unable to acquire or license additional promising product candidates, we may not be able to expand our product candidate pipeline.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">If we are able to acquire or license other product candidates, such license agreements will likely impose various obligations upon us, and our licensors may have the right to terminate the
          license thereunder in the event of a material breach or, in some cases, at will. A termination of a future license could result in our loss of the right to use the licensed intellectual property, which could adversely affect our ability to
          develop and commercialize a future product candidate, if approved, as well as harm our competitive business position and our business prospects.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">66</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Because we have limited financial and managerial resources, we are currently focusing only on development programs that we identify for specific indications for our product candidates. As a
          result, we may forego or delay pursuit of opportunities for other indications, or with other potential product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize
          on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications or future product candidates may not yield any commercially viable product. If we do
          not accurately evaluate the commercial potential or target market for our product candidates, we may not gain approval or achieve market acceptance of that candidate, and our business and financial results will be harmed.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Risks Related to Our Financial Position and Need for Additional Capital</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">As of December 31, 2022, we had an accumulated deficit of $71.5 million. We have funded our operations primarily through issuance of promissory notes and convertible notes in private placements,
          and then common stock and warrants after becoming a publicly-traded company, and more recently, through fees received under the Nyxol License Agreement. We have devoted substantially all of our financial resources and efforts to the clinical
          development of our product candidates. Even assuming we obtain regulatory approval for one or more of our product candidates, we expect it to be at least a year before we potentially receive any royalty payments under the Nyxol License Agreement,
          and several years before APX3330 is potentially ready for commercialization.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">To become and remain profitable from our product candidates, we must develop and eventually commercialize a product with market potential. This will require us to be successful in a range of
          challenging activities, including completing preclinical testing and clinical trials, obtaining regulatory approval for a product candidate, manufacturing, marketing, and selling any drug for which it may obtain regulatory approval and satisfying
          any post-marketing requirements. We are in the early stages of most of these activities. We may never succeed in these activities and, even if we does, we may never generate revenues that are significant or large enough to achieve profitability.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">If we do achieve profitability from our product candidates, we may not be able to sustain or increase profitability on an annual basis. Our failure to become or remain profitable from our product
          candidates may decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations.</div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">&#160;We have not generated any revenue from sales of any products and may never be profitable.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">We have no products approved for commercial sale, and do not anticipate generating any product revenue, unless and until APX3330 or another product candidate
            receives the regulatory approvals necessary for commercialization in one or more jurisdictions. </span>Our ability to generate revenue from APX3330 depends on a number of factors, including our ability to:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>obtain favorable results from and complete the clinical development of&#160; APX3330 for their planned indications, including successful completion of additional clinical trials for these indications;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>submit applications to regulatory authorities for both product candidates and receive timely marketing approvals in the United States and foreign countries;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>establish and maintain commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market
                  demand for product candidates that we develop, if approved;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">67</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>establish sales and marketing capabilities to effectively market and sell our product candidates in the United States or other markets, either alone or with a pharmaceutical partner;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>address any competing products and technological and market developments;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>obtain coverage and adequate reimbursement for customers and patients from government and third-party payors for product candidates that we develop; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>achieve market acceptance of our product candidates.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Even if APX3330 is approved for commercial sale in one or all of the initial indications that we are pursuing, it may not gain market acceptance or achieve commercial success. In addition, we
          anticipate incurring significant costs associated with commercializing our product candidates. We may not achieve profitability soon after generating product revenue, if ever, and may be unable to continue operations without continued funding.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Our relatively short operating history may make it difficult for investors to evaluate the success of our business to date and to assess our future viability.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We are a clinical-stage company, and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, and developing our product candidates. We
          have not yet demonstrated our ability to successfully obtain regulatory approval, manufacture a product at commercial scale, or conduct sales and marketing activities necessary for successful product commercialization.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Additionally, there is no operating history on which investors may evaluate our business and our prospects. Investment in a start-up company such as ours is inherently subject to many risks.
          These risks and difficulties include challenges in accurate financial planning as a result of: (a) accumulated losses; (b) uncertainties resulting from a relatively limited time period in which to develop and evaluate business strategies as
          compared to companies with longer operating histories; (c) compliance with regulations required to commence sales on future products; (d) reliance on third parties for clinical, manufacturing, analytical laboratory work, preclinical, regulatory,
          commercialization or other activities; (e) financing the business; and (f) meeting the challenges of the other risk factors described herein. We have no operating history upon which investors may base an evaluation of our performance; therefore,
          we are subject to all risks incident to the creation and development of a new business. There can be no assurance that we can realize our plans on our projected timetable in order to reach sustainable or profitable operations.</div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Adverse developments affecting the financial services industry could negatively affect our current and projected business operations and our financial condition and results of
          operations.</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our
          current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These
          factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the
          financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry
          companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">68</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-indent: 36pt; color: rgb(0, 0, 0);">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our
          financial condition and results of operations. These could include, but may not be limited to, the following:</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Loss of access to revolving existing credit facilities or other working capital sources and/or the inability to refund, roll over or extend the maturity of, or enter into new credit facilities or other
                  working capital resources;</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Potential or actual breach of contractual obligations that require us to maintain letters or credit or other credit support arrangements; or</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0);"><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;">&#160;&#160;&#160;&#160;</span>In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable
          commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on
          acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other
          obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related
          or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt; color: rgb(0, 0, 0);">In addition, any further deterioration in the macroeconomic economy or financial services industry could lead to losses or defaults by parties with whom we conduct business, which in turn, could
          have a material adverse effect on our current and/or projected business operations and results of operations and financial condition. For example, a party with whom we conduct business may fail to make payments when due, default under their
          agreements with us, become insolvent or declare bankruptcy. Any bankruptcy or insolvency, or the failure to make payments when due, of any counterparty of ours, or the loss of any significant relationships, could result in material losses to us
          and may material adverse impacts on our business.</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We will need to raise additional capital to continue to fund the further development of our product candidates and operations. Our future capital requirements may be substantial and will depend
          on many factors including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the scope, size, rate of progress, results, and costs of researching and developing our product candidates, and initiating and completing our preclinical studies and clinical trials;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the cost, timing and outcome of our efforts to obtain marketing approval for our product candidates in the United States and other countries, including to fund the preparation and filing of NDAs with the FDA for our product candidates
                  and to satisfy related FDA requirements and regulatory requirements in other countries;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the number and characteristics of any additional product candidates we develop or acquire, if any;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our ability to establish and maintain collaborations on favorable terms, if at all;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">69</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the amount of revenue, if any, from commercial sales, should our product candidates receive marketing approval;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the costs associated with commercializing our product candidates, if we receive marketing approval, including the cost and timing of developing sales and marketing capabilities or entering into strategic collaborations to market and
                  sell our product candidates;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the cost of manufacturing our product candidates or products we successfully commercialize; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the costs associated with general corporate activities, such as the cost of filing, prosecuting and enforcing patent claims and making regulatory filings.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Changing circumstances may cause us to consume capital significantly faster than we currently anticipate. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably
          estimate the actual amounts necessary to successfully complete the development, regulatory approval and commercialization of our product candidates. Additional financing may not be available when we need it, or may not be available on terms that
          are favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If adequate funds are
          unavailable to us on a timely basis, or at all, we may not be able to continue the development of our product candidates, or commercialize our product candidates, if approved, unless we find a strategic partner.</div>

        <div>&#160;</div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Worldwide economic and social instability could adversely affect our revenue, financial condition, or results of operations.</div>

        <div><span style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The health of the global economy, and the equity and credit markets in particular, as well as the stability of the social fabric of our society, affects our business and
          operating results. For example, the equity and credit markets may be adversely affected by the current conflict between Russia and Ukraine and measures taken in response thereto. If the equity and credit markets are not favorable, we may be
          unable to raise additional financing when needed or on favorable terms. Our vendors and development partners may experience financial difficulties or be unable to borrow money to fund their operations, which may adversely impact their ability to
          purchase our products or to pay for our products on a timely basis, if at all. In addition, adverse economic conditions, such as recent supply chain disruptions and labor shortages and persistent inflation, have affected, and may continue to
          adversely affect our suppliers&#8217; ability to provide our manufacturers with materials and components, which may negatively impact our business. These economic conditions make it more difficult for us to accurately forecast and plan our future
          business activities.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Adverse global economic conditions could have a negative effect on our business, results of operations and financial condition and Adverse global economic conditions could have a negative effect
          on our business, results of operations and financial condition and liquidity.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">A general slowdown in the global economy, including a recession, or in a particular region or industry, an increase in trade tensions with U.S. trading partners, inflation or a tightening of the
          credit markets could negatively impact our business, financial condition and liquidity. Adverse global economic conditions have from time to time caused or exacerbated significant slowdowns in the industries and markets in which we operate, which
          have adversely affected our business and results of operations. Macroeconomic weakness and uncertainty also make it more difficult for us to accurately forecast revenue, gross margin and expenses, and may make it more difficult to raise or
          refinance debt.</div>

        <div><br />
        </div>

        <div style="font-style: italic; font-weight: bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and debt financings as well as potential strategic
          collaborations and licensing arrangements. We do not have any committed external source of funds. Debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to
          take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">70</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">If we raise funds through strategic collaborations or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
          revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product
          development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. This may reduce the value of our common stock.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Risks Related to Government Regulation</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">The FDA requires the completion of a toxicology study of similar duration before trials longer than six months can be conducted such as Phase 3 safety exposure trials for chronic indications or
          efficacy trials with such six-month endpoints. This may lead to a significant delay in the commencement of long-term clinical trials by us or the failure of our product candidates to obtain marketing approval.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">At this time, we can run long-term trials for chronic indications using Nyxol&#160;&#160; based on our completed 6-month toxicology study using phentolamine mesylate in a ocular-relevant rodent species
          (rabbit). This 6-month study validates the duration of the registration studies and their safety extensions: a planned 1-year Phase 3 safety exposure trial to support chronic indications of presbyopia and DLD.&#160; For APX3330, the drug has already
          been dosed for more than a year in humans and completed over 15 single- and repeat-dose toxicology studies in rats and dogs (including 2 studies up to 3 months in duration); with this data we initiated our 24-week clinical trial for APX3330
          without further toxicology studies being requested by the FDA. We expect to complete further toxicology studies in support of future clinical trials, per FDA&#8217;s guidelines, prior to any marketing approval from regulatory authorities for the sale
          of APX3330. Clinical trials may be delayed due to these regulatory restrictions and additional oversight by the FDA. In addition, the findings in the toxicology studies could affect the outcome of NDA reviews, and, if approved, labels and uses of
          our product candidates.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Even if we receive marketing approval for our product candidates in the United States, we may never receive regulatory approval to market such product candidates outside of the United States.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition to the United States, we intend to seek regulatory approval to market our product candidates in Europe, Japan, Canada, and Australia, and potentially other markets. If we pursue
          additional product candidates in the future, we may seek regulatory approval of such product candidates outside the United States. In order to market any product outside of the United States, however, we must establish and comply with the
          numerous and varying safety, efficacy and other regulatory requirements of these other countries. Approval procedures vary among countries and can involve additional product candidate testing and additional administrative review periods. The time
          required to obtain approvals in other countries might differ from that required to obtain FDA approval. The marketing approval processes in other countries may include all of the risks detailed above regarding FDA approval in the United States as
          well as other risks. In particular, in many countries outside of the United States, products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can result in substantial delays in
          bringing products to market in such countries. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the regulatory
          process in others. Failure to obtain marketing approval in other countries or any delay or other setback in obtaining such approval would impair our ability to market our product candidates in such foreign markets. Any such impairment would
          reduce the size of our potential market, which could have an adverse impact on our business, results of operations and prospects.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">71</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify;">
          <div style="font-style: italic; font-weight: bold;">Even if we obtain marketing approval for our product candidates, such product candidates could be subject to post-marketing, obligations, restrictions or withdrawal from the market, and we may
            be subject to substantial penalties if we fail to comply with regulatory requirements or experience unanticipated problems with a product following approval.</div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Any product candidate for which we, or our future collaborators, obtain marketing approval in the future, as well as the manufacturing processes, post-approval studies and measures, labeling,
          advertising, and promotional activities for such drug, among other things, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other
          post-marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the
          distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of
          approval, including the requirement to implement a REMS, which could include requirements for a restricted distribution system.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product candidate. The FDA and other agencies,
          including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the
          provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we, or any future collaborator, does not market a product candidate for which it receives marketing
          approval for only its approved indications, we, or the collaborator, may be subject to warnings or enforcement action for off-label promotion. Violation of the Federal Food, Drug, and Cosmetic Act (&#8220;FDC Act&#8221;) and other statutes, including the
          False Claims Act, relating to the promotion and advertising of prescription drugs, may lead to investigations or allegations of violations of federal or state healthcare fraud and abuse laws and state consumer protection laws.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, later discovery of previously unknown AEs or other problems with our product candidates or our manufacturers or manufacturing processes, or failure to comply with regulatory
          requirements, may yield various results, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>litigation involving patients taking our drugs;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>restrictions on such drugs, manufacturers, or manufacturing processes;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>restrictions on the labeling or marketing of a drug;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>restrictions on drug distribution or use;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>requirements to conduct post-marketing studies or clinical trials;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>warning letters or untitled letters;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>withdrawal of the drugs from the market;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>refusal to approve pending applications or supplements to approved applications that we submit;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>product recall or public notification or medical product safety alerts to healthcare professionals;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>fines, restitution, or disgorgement of profits or revenues;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>suspension or withdrawal of marketing approvals;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>damage to relationships with any potential collaborators;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>unfavorable press coverage and damage to our reputation;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">72</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>refusal to permit the import or export of drugs;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>product seizure; or</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>injunctions or the imposition of civil or criminal penalties.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We may seek to avail ourselves of mechanisms to expedite the development or approval for product candidates we may pursue in the future, such as fast track or breakthrough designation, but such
          mechanisms may not actually lead to a faster development or regulatory review or approval process.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may seek fast track designation, breakthrough designation, orphan drug designation, priority review, or accelerated approval for product candidates we may pursue in the future. For example, if
          a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. However, the FDA
          has broad discretion with regard to these mechanisms, and even if we believe a particular product candidate is eligible for any such mechanism, we cannot guarantee that the FDA would decide to grant it. Even if we obtain fast track or priority
          review designation or pursue an accelerated approval pathway, we may not experience a faster development process, review, or approval compared to conventional FDA procedures. The FDA may withdraw a particular designation if it believes that the
          designation is no longer supported by data from our clinical development program.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary
          clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly,
          even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. We cannot be sure that our evaluation of a product candidate as
          qualifying for breakthrough therapy designation will meet the FDA&#8217;s requirements. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review, or approval compared
          to conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more product candidates qualifies as a breakthrough therapy, the FDA may later decide that the product candidate no longer meets the
          conditions for qualification or may decide that the time period for FDA review or approval will not be shortened.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Recently enacted and future legislation may increase the difficulty and cost for us and our future collaborators to obtain marketing approval of our product candidates and affect their pricing.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or
          delay marketing approval of a product candidate, restrict or regulate post-approval activities and affect our ability, or the ability of our future collaborators, to profitably sell any drug for which we, or they, obtain marketing approval. We
          expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and cause downward pressure on the price that we, or our future collaborators, may charge for
          any approved drug.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">For example, in March 2010, the United States Congress enacted the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;), and the Health Care and Education Reconciliation Act, or the Healthcare
          Reform Act, which expanded health care coverage through Medicaid expansion and the implementation of the individual mandate for health insurance coverage and which included changes to the coverage and reimbursement of drug products under
          government healthcare programs.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There have also been efforts by federal and state government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on
          drug importation. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing and proposals to address the perceived high cost of pharmaceuticals. There have also been recent state legislative efforts to address
          drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">73</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">General legislative cost control measures may also affect reimbursement for our product candidates. The Budget Control Act, as amended, resulted in the imposition of 2% reductions in Medicare
          (but not Medicaid) payments to providers in 2013 and will remain in effect through 2027 unless additional Congressional action is taken. Any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized
          health programs that may be implemented and/or any significant taxes or fees that may be imposed on us could have an adverse impact on results of operations.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Adoption of new legislation at the federal or state level could affect demand for, or pricing of, our current or future products if approved for sale. We cannot, however, predict the ultimate
          content, timing or effect of any changes to the Healthcare Reform Act or other federal and state reform efforts. There is no assurance that federal or state health care reform will not adversely affect our future business and financial results.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There have been judicial and congressional challenges and amendments to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future, as
          well as efforts to repeal and replace it. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These new laws have resulted in additional reductions in Medicare and other healthcare funding and
          otherwise may affect the prices we may obtain for any product candidate for which marketing approval is obtained. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from
          private payors. Moreover, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. The implementation of cost containment measures or other healthcare reforms may
          prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.&#160; Further, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug
          rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024. In addition, Congress is considering additional health reform measures, such as capping the costs for prescription drugs covered by Medicare Part D and
          by setting the annual out-of-pocket limit at $2,000 beginning in 2024, as part of other health reform initiatives.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether
          additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of a product candidate, if any, may be. In addition,
          increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval or subject us or our future collaborators to more stringent drug labeling and post-marketing testing and other
          requirements.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenue from the sales of a drug, if any.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In some countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental
          authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we, or our future collaborators, may be required to conduct a clinical trial that compares
          the cost-effectiveness of our products to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Our relationships with healthcare providers and third-party payors will be subject to applicable fraud and abuse and other healthcare laws and regulations, which could expose us to criminal
          sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings, among other penalties and consequences.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">74</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidate for which we obtain marketing approval. Our current and future
          arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market,
          sell, and distribute product candidates for which we obtain marketing approval. Restrictions and obligations under applicable federal and state healthcare laws and regulations include the following:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or
                  reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the federal false claims and civil monetary penalties laws, including the civil False Claims Act, impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly
                  presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>HIPAA imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain people and entities with respect
                  to safeguarding the privacy, security, and transmission of individually identifiable health information;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the federal Physician Payments Sunshine Act under the Affordable Care Act requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s
                  Health Insurance Program, with specific exceptions, to report specially to the Centers for Medicare &amp; Medicaid Services within the U.S. Department of Health and Human Services information related to physician payments and other
                  transfers of value and physician ownership and investment interests; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
                  third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the
                  federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. Certain state and foreign laws also govern the privacy and
                  security of health information in ways that differ from each other and often are not preempted by HIPAA, thus complicating compliance efforts.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible
          that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are
          found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government funded healthcare
          programs, such as Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or
          other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, and administrative sanctions, including exclusions from government funded healthcare
          programs. Defending against any such actions can be costly, time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us,
          our business may be impaired.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">75</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal
          standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations which could harm our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations
          administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT
          Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other
          partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United
          States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees
          of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not
          explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges,
          debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Our employees or representatives may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which
          could significantly harm our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>comply with the regulations of the FDA and applicable non-U.S. regulators;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>provide accurate information to the FDA and applicable non-U.S. regulators;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>comply with healthcare fraud and abuse laws and regulations in the United States and abroad;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>report financial information or data accurately; or</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>disclose unauthorized activities to us.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing,
          and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could
          also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee
          misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
          failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
          the imposition of significant civil, criminal, and administrative penalties, damages, fines, exclusion from government funded healthcare programs such as Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages,
          reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">76</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If found to have improperly promoted off-label uses, we may become
          subject to significant liability.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not
          approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for our product candidates for a certain indication, physicians may nevertheless prescribe such products to
          their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines
          against companies for improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional
          conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would adversely affect our business and financial condition.</div>

        <div>&#160;</div>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Changes to U.S. tax laws may adversely affect our financial condition or results of operations and create the risk that we may need to adjust our
          accounting for these changes.</div>

        <div style="text-align: justify;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The accounting treatment of these tax law changes is complex, and some of the changes may affect both current and future periods. Consistent with guidance from the SEC, our
          consolidated financial statements reflect our estimates of the tax effects of the current tax laws and regulation.</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Risks Related to Commercialization of Our Product Candidates</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The development and commercialization of new drug products is highly competitive. We expect to face competition with respect to our product candidates, if approved, and will face competition with
          respect to any future product candidates that we may seek to develop or commercialize from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities and other research institutions, and government
          agencies worldwide. The ophthalmic therapies market is highly competitive and dynamic. Our success will depend, in part, on our ability to obtain a share of the market for our planned indications.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;"><span style="text-decoration: underline;">APX3330</span></div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We are developing APX3330 for use in two different indications initially: the treatment of DR and DME, and potentially later the treatment of wAMD. In addition to currently approved therapies,
          any product that is developed for either of the three indications could directly compete with APX3330. Such a product could reduce the overall market opportunity for APX3330. Other pharmaceutical companies may develop therapies for the same
          indications that would compete with APX3330, if approved, and that would not infringe the claims of our in-licensed patents, pending patent applications, or other proprietary rights, which could adversely affect our business and results of
          operations.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">77</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">Competition in Diabetic Retinopathy / Diabetic Macular Edema / wAMD</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may face potential competition from both existing therapies and those in development. Current therapies for these retinal diseases rely on suppressing VEGF activity via intravitreal injection
          or by mitigating the inflammation via intravitreal corticosteroid-releasing implants including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div> Lucentis<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (ranibizumab) and Avastin&#174; (bevacizumab), which are anti-VEGF monoclonal antibody intravitreal injections, developed by Genentech, Inc and
                  Roche AG.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>EYLEA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (aflibercept), a VEGF inhibitor intravitreal injection, developed by Regeneron Pharmaceuticals.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Vabysmo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (Faricimab), a bispecific monoclonal antibody targeting VEGF-A and Ang-Tie2 pathway developed by Genentech, Inc and Roche AG.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Beovu<sup>&#174;</sup> (Brolucizumab), an anti-VEGF monoclonal antibody intravitreal injection, developed by Novartis AG.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>MACUGEN<sup>&#174;</sup> (pegaptanib sodium injection), a selective inhibitor of VEGF-165, developed by Bausch + Lomb.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Ozurdex<sup>&#174;</sup> (dexamethasone), a corticosteroid IVT implant, developed by Allergan plc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Iluvien (fluocinolone acetonide), a corticosteroid IVT implant, developed by Alimera Sciences, Inc</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There are also several pharmacological therapies in development, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Abicipar, an anti-VEGF intravitreal injection with a long duration of action, developed by Allergan plc and Molecular Partners.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>KSI-301, an anti-VEGF antibody intravitreal injection coupled with a biopolymer that is intended to increase the time between injections, developed by Kodiak Sciences.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>OPT-302, an intravitreal injection which binds to multiple types of VEGF receptors that could be used with other anti-VEGF agents, developed by Opthea Limited.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>ALG-1001, an integrin peptide therapy intravitreal injection that is being evaluated as a sequential or in-combination therapy with bevacizumab in patients with DME, developed by Allegro Ophthalmics, LLC.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>RG-7774, an orally administered selective CB2 (Cannabinoid 2) receptor agonist that is being evaluated in patients with moderately severe to severe non-proliferative diabetic retinopathy, developed by Hoffmann-LA Roche, AG.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>RZ402, a small molecule selective and potent plasma kallikrein inhibitor (PKI) for the chronic treatment of diabetic macular edema (DME), developed by Rezolute, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Xiflam&#8482;, an oral small molecule drug for the treatment of dry form of Age-Related Macular Degeneration (AMD), Geographic Atrophy (GA), Diabetic Retinopathy (DR) manifesting Diabetic Macular Edema (DME), developed by InflammX.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>AKST4290, an oral small molecule CCR3 Eotaxin inhibitor for the treatment of diabetic retinopathy and wet AMD.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">78</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>BAY1101042, an oral guanylate cycles activator for the treatment of diabetic retinopathy.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;"><span style="text-decoration: underline;">Nyxol</span></div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Ocuphire is developing Nyxol, with our partner Viatris, for use in three different indications: the reversal of pharmacologically induced mydriasis (&#8220;RM&#8221;), the treatment of presbyopia and the
          treatment of NVD. In addition to currently approved therapies, any product that is developed for any of the three indications could compete with Nyxol. Such a product could reduce the overall market opportunity for Nyxol. Other pharmaceutical
          companies may develop therapies for the same indications that would compete with Nyxol, if approved, and that would not infringe the claims of Ocuphire&#8217;s patents, pending patent applications, or other proprietary rights, which could adversely
          affect its business and results of operations.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">RM</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Currently, there are no available and approved pharmacological therapies for NVD or RM and Ocuphire is not aware of any in development. Rev-Eyes<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (dapiprazole), an alpha-1 antagonist, was approved by the FDA in 1990 to reverse mydriasis induced by adrenergic or anticholinergic agents. Rev-Eyes was withdrawn in the past from the market for reasons unrelated
          to safety or efficacy, according to the FDA.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Presbyopia</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The FDA approved VuityTM eye drop for the treatment of presbyopia in October 2021. Vuity was launched in December 2021 and is marketed by Allergan, an AbbVie company. The competition also
          includes reading glasses, multifocal contact lenses, and monovision contact lenses (e.g., where one eye wears a near vision lens and the other eye wears a distance vision lens). Ocuphire will also compete against several pharmacological therapies
          in development for the temporary treatment of presbyopia, many of which are cholinergic agonist-based pupil management therapies, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 72pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>CSF-1, with low dose pilocarpine and a secondary agent (lubricant), developed by Orasis Pharmaceuticals Ltd.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 72pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>LNZ100 and LNZ101, with aceclidine (another miotic agent), developed by Lenz Therapeutics.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 72pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>MicroLine<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, which is a micro-dose delivery of pilocarpine using proprietary device developed by Eyenovia, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 72pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>KT-101, which uses pilocarpine in the AcuStream delivery system, developed by Kedalion Therapeutics, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 72pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Brimochol<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>, with brimonidine and carbachol (both are miotic agents), developed by Visus Therapeutics, Inc.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 72pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>UNR844, which uses a mechanism that involves softening the lens to increase near visual acuity, developed by Novartis AG (originally Encore Vision, Inc.).</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There are approved devices for presbyopia. One of these is the KAMRA Inlay, developed by AcuFocus, Inc. and marketed by SightLife Surgical, Inc. Another is the eyelike NoanPinhole, developed by
          Koryo Eyetech, the first commercially available pinhole soft contact lens. Nyxol would not directly compete against these devices, but rather would be a non-invasive alternative for presbyopes who are averse to surgical intervention.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">79</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Our competitors may develop products that are more effective, safer, more convenient, or less costly than any that we are developing, or that would render our product candidates obsolete or
          non-competitive. Our competitors may also render our technologies obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process.
          Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products more rapidly than we obtain approval for our products, which could result in our competitors establishing a strong market position
          before we are able to enter the market.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Many of our competitors have significantly greater name recognition, financial resources, and expertise in research and development, manufacturing, preclinical testing, conducting clinical
          trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our
          competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies compete with us in recruiting, hiring, and
          retaining qualified scientific and management personnel, engaging contract service providers, manufacturers and consultants, establishing clinical trial sites, recruiting patients for clinical trials, and entering into strategic transactions, as
          well as in acquiring technologies complementary to, or necessary for, our programs.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We lack experience in commercializing products, which may have an adverse effect on our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">If APX3330 receives marketing approval, we will need to transition from a company with a development focus to a company capable of supporting commercial activities, and we may not be successful
          in making that transition. We&#160; have not yet demonstrated the ability to obtain marketing approval for, or to commercialize, any product candidate. As a result, our clinical development and regulatory approval activities, and our ability to
          successfully commercialize any approved products, may involve more inherent risk, take longer, and cost more than would be the case if we were a company with experience obtaining marketing approval for and commercializing a product candidate.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell, market, and distribute APX3330, if approved, we may not be successful in
          commercializing APX3330 if and when it is approved.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We do not have any sales or marketing infrastructure and have no capabilities in place at the present time for the sale, marketing, or distribution of pharmaceutical products. To achieve
          commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource part or all of these functions to other third parties.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There are risks involved with us both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting
          and training a sales force is expensive and time-consuming, which could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur
          for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the inability to recruit and retain adequate numbers of effective sales and marketing personnel or enter into distribution agreements with third parties;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our product candidate;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">80</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>If we enter into arrangements with third parties to perform sales, marketing, and distribution services, our product revenues or the profitability of these product revenues to us are likely to be lower than if we were to market and
                  sell a product that we developed ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market any product candidate or may be unable to do so on terms that are favorable to us. We
                  likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market a drug effectively. If we do not establish sales and marketing capabilities successfully,
                  either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Our future commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, third-party payors, and others in the medical
          community.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Even if our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors, or others in the medical
          community. If such product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and may not become profitable. The degree of market acceptance of a product candidate, if approved for
          commercial sale, will depend on a number of factors, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>efficacy and potential advantages compared to alternative treatments;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the ability to offer our product for sale at competitive prices;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any restrictions on the use of our product together with other medications;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>interactions of our product with other medicines patients are taking;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>inability of certain types of patients to take our product;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>demonstrated ability to treat patients and, if required by any applicable regulatory authority in connection with the approval for target indications as compared with other available therapies;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the relative convenience and ease of administration as compared with other treatments available for approved indications;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the prevalence and severity of any adverse side effects;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>limitations or warnings contained in the labeling approved by the FDA;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>availability of alternative treatments already approved or expected to be commercially launched in the near future;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the effectiveness of our sales and marketing strategies;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our ability to increase awareness through marketing efforts;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">81</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>guidelines and recommendations of organizations involved in research, treatment and prevention of various diseases that may advocate for alternative therapies;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our ability to obtain sufficient third-party coverage and adequate reimbursement;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the willingness of patients to pay out-of-pocket in the absence of third-party coverage; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>physicians or patients may be reluctant to switch from existing therapies even if potentially more effective, safe or convenient.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We have not yet sold any of our products. We cannot assure investors that there is a sufficient market demand for our products. Achieving market acceptance for our products will require
          substantial marketing efforts and expenditure of funds to create awareness and demand by participants in the industry. We have not conducted any independent market research to determine the extent of any demand that exists for the products to be
          provided by us and there is no guarantee that a sufficient interest in the market will exist for the products and services being produced by, or for, us. Any lack of sufficient demand for the products contemplated to be provided by us will have a
          material adverse effect on us.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If the FDA or a comparable foreign regulatory authority approves generic versions of our product candidates that receive marketing approval, or if such authorities do not grant our product
          candidates appropriate periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Once an NDA is approved, the product covered thereby becomes a &#8220;reference listed drug&#8221; in the FDA&#8217;s publication, &#8220;<span style="font-style: italic;">Approved Drug Products with Therapeutic
            Equivalence Evaluations</span>.&#8221; Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications (&#8220;ANDAs&#8221;) in the United States. In support of an ANDA, a generic manufacturer
          need not conduct clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration, and conditions of use or labeling as the reference listed drug
          (&#8220;RLD&#8221;) and that the generic version is bioequivalent to the RLD, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the RLD, and companies that
          produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or RLD may be lost to the generic product.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference listed drug has expired. The FDC Act provides a period of five years
          of non-patent exclusivity for a new drug containing a new chemical entity (&#8220;NCE&#8221;). Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is
          accompanied by a Paragraph IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years after approval of
          the RLD. It is unclear whether the FDA will treat the active ingredients in its product candidates as NCEs and, therefore, afford them five years of NCE exclusivity if they are approved. If any product we develop does not receive five years of
          NCE exclusivity, we may nonetheless be eligible for three years of exclusivity, which means that the FDA may approve generic versions of such product three years after its date of approval. Manufacturers may seek to launch these generic products
          following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Competition that our product candidates would face from generic versions could materially and adversely impact our future revenue, profitability, and cash flows and substantially limit our
          ability to obtain a return on the investments we have made in any such product candidate.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">82</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify;">
          <div style="font-style: italic; font-weight: bold;">Even if we are able to commercialize APX3330, our profitability will likely depend in significant part on third-party reimbursement practices, which, if unfavorable, would harm our business.</div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Our ability to commercialize APX3330 successfully will depend in part on the extent to which coverage and adequate reimbursement will be available from government health administration
          authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish
          reimbursement levels. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. Increasingly, third-party payors are requiring that drug companies
          provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is
          available, whether the level of reimbursement will be adequate. Assuming we obtain coverage for our product candidates, if approved, by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments
          that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or some of the costs associated with
          their prescription drugs. Patients are unlikely to use a product candidate, if approved, unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of its products. Therefore, coverage and adequate
          reimbursement are critical to new product acceptance. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.&#160;&#160;
          Furthermore, drug pricing and access policies in the United States and internationally may change and negatively impact our product candidates&#8217; commercial viability. Proposed policy changes, including the potential for Medicare to negotiate with
          drug manufacturers, may limit our ability to competitively price our product candidates, if approved.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which a product candidate is approved by the FDA or
          similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
          sale, and distribution. Interim reimbursement levels for a new product, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical
          setting in which it is used, may be based on reimbursement levels already set for lower cost medicines, and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates
          required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Third-party payors
          often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, there is no uniform policy requirement for coverage and reimbursement for drug products among third-party payors in the United
          States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often time-consuming and costly, and it will require us to provide scientific and
          clinical support for the use of our products to each payor separately. There is no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Any inability to promptly obtain coverage and profitable payment rates from government-funded or private payors for any approved products that we develop could have an adverse effect on our
          operating results, our ability to raise capital needed to commercialize products, and our overall financial condition.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Product liability lawsuits against us, or our suppliers and manufacturers, could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may
          develop.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any
          products that we may develop. Product liability claims might be brought against us by patients, healthcare providers, or others selling or otherwise coming into contact with our product candidates during product testing, manufacturing, marketing,
          or sale. For example, we may be sued under allegations that a product candidate caused injury or that the product was otherwise unsuitable. Any such product liability claims may include allegations of manufacturing or design defects, failure to
          warn of dangers inherent in the product, such as interactions with alcohol or other drugs, negligence, or breach of warranty. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against
          claims that our product candidate caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">83</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>decreased demand for any product candidate that we are developing;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>injury to our reputation and significant negative media attention;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>withdrawal of clinical trial participants;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>increased FDA warnings on product labels;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>significant costs to defend the related litigation;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>substantial monetary awards to trial participants or patients;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>distraction of management&#8217;s attention from our primary business;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>loss of revenue; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the inability to commercialize any product candidate that we may develop.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our product liability and/or clinical trial insurance coverage may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand clinical
          trials and if we successfully commercialize our product candidates. Insurance coverage is increasingly expensive, and we may not be able to obtain product liability insurance on commercially reasonable terms or for a sufficient amount to satisfy
          liabilities that may arise.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Similarly, we may be a party to, or may be otherwise responsible for, pending or threatened lawsuits or other claims related to products purchased from our manufacturers and suppliers. Although
          we intend to require our providers to have product liability insurance, the ability to obtain such coverage and the sufficiency thereof is uncertain. Such cases and claims may raise difficult and complex factual and legal issues and may be
          subject to many uncertainties and complexities, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. Such litigation could
          result in additional expense and exposure in excess of&#160; our anticipated reserves, especially if such matters are not covered by insurance. Upon resolution of any pending legal matters or other claims, we may incur charges in excess of established
          reserves. Product liability lawsuits and claims, safety alerts or product recalls in the future, regardless of their ultimate outcome, could have a material adverse effect on the business and reputation and on our ability to attract and retain
          customers and strategic partners. The business, profitability and growth prospects could suffer if we face such negative publicity.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we or our third-party manufacturers fail to comply with environmental or health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an
          adverse effect on the success of our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by ourselves and our third-party
          manufacturers. Our manufacturers are subject to federal, state, and local laws and regulations in the United States and abroad governing laboratory procedures and the use, manufacture, storage, handling, and disposal of medical and hazardous
          materials. Although we believe that our manufacturers&#8217; procedures for using, handling, storing, and disposing of these materials comply with legally prescribed standards, we cannot eliminate the risk of contamination or injury resulting from
          medical or hazardous materials. As a result of any such contamination or injury, we may incur liability, or federal, state, city, or local authorities may curtail our use of these materials and interrupt our business operations. In the event of
          an accident, we could be held liable for damages or fined, and such liability or fines could exceed our resources. We do not have insurance for liabilities arising from medical or hazardous materials. Although we maintain workers&#8217; compensation
          insurance for costs and expenses that we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. Compliance with applicable
          environmental and health and safety laws and regulations is expensive, and current or future environmental regulations may impair our research, development, and production efforts, which could harm our business, prospects, financial condition, or
          results of operations.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">84</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Federal legislation and actions by state and local governments could permit reimportation of drugs from foreign countries into the United States, which could adversely affect our operating results
          when the drugs are sold at lower prices in foreign countries than in the United States.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may face competition for our product candidates, if approved, from other therapies sourced from foreign countries that have price controls on pharmaceutical products. The Medicare
          Modernization Act contains provisions that may change U.S. reimportation laws and expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of approved drugs or competing products from Canada, where there are government price
          controls. These changes to U.S. importation laws would not take effect unless and until the Secretary of Health and Human Services certifies that the changes would pose no additional risk to the public&#8217;s health and safety and would result in a
          significant reduction in the cost of products to consumers. The Secretary of Health and Human Services has so far declined to approve a reimportation plan. Proponents of drug reimportation may attempt to pass legislation that would directly allow
          reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any product we may develop and adversely affect our future revenues and prospects for
          profitability.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Risks Related to Our Reliance on Third Parties</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We will be unable to control all aspects of our non-clinical studies and our clinical trials due to our reliance on CROs and other third parties that assist us in conducting non-clinical studies
          and clinical trials.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We rely on third-party CROs and other third parties to assist in managing, monitoring, and otherwise carrying out our non-clinical studies and clinical trials. We expect to continue to rely on
          third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct our non-clinical studies and clinical trials in the future, including our Phase 3 development program for Nyxol. We
          compete with many other companies for the resources of these third parties.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As a result, we will have limited control over the conduct, timing, and completion of these non-clinical studies and clinical trials and the management of data developed through the non-clinical
          studies and clinical trials. We have experienced in the past, and may experience in the future, schedule disruptions due to events affecting the performance of third parties on which we rely. Communicating with outside parties can also be
          challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Additionally, other unexpected natural events and disruptions in the supply chain and operations may affect the ability of third parties to fulfill
          their obligations to us. Outside parties may:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>have staffing difficulties;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>fail to comply with contractual obligations;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>experience regulatory compliance issues;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>undergo changes in ownership or management;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>undergo changes in priorities or become financially distressed; or</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>form relationships with other entities, some of which may be our competitors.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">85</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">These factors may adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">While our reliance on these third parties for research and development activities will reduce our control over these activities, it will not relieve us of our responsibilities and requirements.
          For example, the FDA requires us to comply with standards, commonly referred to as good clinical practices (&#8220;GCP&#8221;), for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and
          accurate and that the rights, integrity, and confidentiality of clinical trial participants are protected.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Problems with the timeliness or quality of the work of any CRO may lead us to seek to terminate our relationship with any such CRO and use an alternative service provider. Making this change may
          be costly or delay our clinical trials, and contractual restrictions may make such a change difficult or impossible. If we must replace any CRO that is conducting our clinical trials, our clinical trials may have to be suspended until we find
          another CRO that offers comparable services. The time that it would take us to find alternative organizations may cause a delay in the commercialization of our product candidates, or it may cause us to incur significant expenses to replicate any
          lost data. Although we do not believe that any CRO on which we would rely would offer services that are not available elsewhere, we may be difficult to find a replacement organization that can conduct our clinical trials in an acceptable manner
          and at an acceptable cost. Any delay in or inability to complete our clinical trials could significantly compromise our ability to secure regulatory approval for our product candidates and preclude our ability to commercialize our product
          candidates, thereby limiting or preventing our ability to generate sales revenue.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We rely completely on third parties<span style="color: rgb(255, 0, 0);">&#160;</span>to supply and manufacture bulk drug substances and to formulate and package preclinical and clinical drug supplies
          of our product candidates as well as to conduct analytical testing of drug substances and products in the manufacturing processes and intend to rely on third parties to produce and test commercial supplies of our current and any future product
          candidates. </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We do not currently have, nor do we plan to acquire, the infrastructure or capability to internally manufacture our clinical drug supply of product candidates for use in the conduct of our
          preclinical studies and clinical trials. We lack the internal resources and the capability to manufacture any product candidates on a clinical or commercial scale. The process of manufacturing drug products is complex, highly regulated, and
          subject to several risks. For example, the facilities used by our contract manufacturers to manufacture and conduct analytical testing of the active pharmaceutical ingredient (or drug substance) and final drug product for product candidates must
          be inspected by the FDA and other comparable foreign regulatory agencies in connection with our submission of an NDA or relevant foreign regulatory submission to the applicable regulatory agency. In addition, the manufacturing of drug substance
          or product is susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, or vendor or operator error. Moreover, the manufacturing facilities in which product candidates are made could be
          adversely affected by equipment failures, labor shortages, natural disasters, power failures, or other factors.&#160; Manufacturing timelines may be negatively affected by material shortages, construction delays and supply chain challenges due to,
          among other factors, global supply chain shortages .</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We do not control the manufacturing and testing processes of our contract manufacturers and analytical labs, and are completely dependent on them to comply with current good manufacturing
          practices (&#8220;cGMP&#8221;) for manufacture and good lab practices (&#8220;GLP&#8221;) of both active drug substances and finished drug products. If our contract manufacturers and analytical labs cannot successfully manufacture and test materials that conform to our
          specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies, we will not be able to secure and/or maintain regulatory approval for our products. In addition, we have no control over our contract
          manufacturers&#8217; and analytical labs&#8217; ability to maintain adequate quality control, quality assurance, and qualified personnel. Failure to satisfy the regulatory requirements for the production and testing of those materials and products may affect
          the regulatory clearance of our contract manufacturers&#8217; and analytical labs&#8217; facilities generally. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the manufacture and testing of product candidates, or if
          it withdraws its approval in the future, we may need to find alternative manufacturing and testing facilities, which would adversely impact our ability to develop, obtain regulatory approval for, or market product candidates. Furthermore, all of
          our contract manufacturers and analytical labs are engaged with other companies to supply and/or manufacture and/or test materials or products for such companies, which exposes our manufacturers to regulatory and sourcing risks for the production
          of such materials and products. To the extent practicable, our attempts to identify more than one supplier. However, some raw materials are available only from a single source or only one supplier has been identified, even in instances where
          multiple sources exist.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">86</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">We have relied and will rely upon third-party manufacturers and testing labs in the United States and overseas for the manufacture and testing of Nyxol and APX3330 for preclinical and clinical
          testing purposes and intend to continue to do so in the future for Nyxol, APX3330, Nyxol with adjunctive low-dose pilocarpine, and any other product candidates, including for commercial purposes. If our third-party manufacturers and analytical
          labs are unable to supply or test drug substance and/or drug product on a commercial basis, we may not be able to successfully produce and market product candidates, if approved, or we could be delayed in doing so. For instance, we presently rely
          on one supplier in Italy for the drug substance for Nyxol, and one manufacturer in India for APX3330 drug substance. If there is any delay or problem with the manufacture of these drug substances or if there is a delay in producing finished drug
          product from these drug substances, the development and possible approval of our product candidates and potential commercial launch may be delayed or otherwise adversely affected.&#160; We will rely on comparison of product specifications (identity,
          strength, quality, and potency) to demonstrate equivalence of the current drug substance and/or drug product to the drug substance and/or drug product used in previously completed preclinical and clinical testing. If we are unable to demonstrate
          such equivalence, we may be required to conduct additional preclinical and/or clinical testing of our product candidates. The formulation of the low-dose pilocarpine as adjunctive product candidate with Nyxol is still in development. We have
          already experienced a few interruptions in our manufacturing, supply chain, research and development operations, regulatory and financial position, including, for example, the shipment of active pharmaceutical ingredient supply from overseas.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Due to these and other potential problems, we are exploring the possibility of establishing additional sources of supply, with U.S. manufacturers, for the active pharmaceutical ingredients of
          both Nyxol and APX3330. Establishing these additional sources, including qualifying their manufacturing processes and demonstrating the equivalence of their products, may be costly, time-consuming, and difficult to effectuate, and may delay our
          research and development activities. If we must replace any manufacturer, our research and development activities may have to be suspended until we find another manufacturer that offers comparable services. The time that it takes us to find
          alternative organizations may cause a delay in the development and commercialization of product candidates.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We have entered into the Nyxol License Agreement and may form or seek additional strategic alliances or enter into licensing arrangements in the future, and may not realize benefits from such
          alliances or licensing arrangements.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We have entered into the Nyxol License Agreement, and may form or seek additional strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with
          third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates. Any of these relationships may require us to incur non-recurring and other charges, increase our near- and
          long-term expenditures, or issue securities that dilute our existing stockholders, which may disrupt our management and business. Our likely collaborators include large, mid-size, regional, or national pharmaceutical companies and biotechnology
          companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of product candidates.
          Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a strategic transaction or
          license, we will achieve the revenue or specific net income that justifies such transaction. Collaborations involving product candidates pose the following risks to us:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators may not perform their obligations as expected;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators may not pursue development and commercialization or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available
                  funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">87</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product
                  candidate for clinical testing;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidate if the collaborators believe that competitive products are more likely to be successfully
                  developed or can be commercialized under terms that are more attractive than ours;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>a collaborator with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing or distribution of any such product candidate;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose
                  us to litigation;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>disputes may arise between us and collaborators that result in the delay or termination of research, development, or commercialization of our product candidates, or in litigation or arbitration that diverts management attention and
                  resources;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborations may be terminated and such terminations may create a need for additional capital to pursue further development or commercialization of the applicable product candidates;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators may learn about our discoveries and use this knowledge to compete with us in the future;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the results of collaborators&#8217; preclinical or clinical studies could harm or impair other development programs;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>there may be conflicts between different collaborators that could negatively affect those collaborations and potentially others;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the number and nature of our collaborations could adversely affect our attractiveness to potential future collaborators or acquirers;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaboration agreements may not lead to development or commercialization of our product candidate in the most efficient manner or at all. If a present or future collaborator of us were to be involved in a business combination, the
                  continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished, or terminated; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>collaborators may be unable to obtain the necessary marketing approvals.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">88</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">If future collaboration partners fail to develop or effectively commercialize product candidates for any of these reasons, such product candidates may not be approved for sale and our sales of
          such product candidates, if approved, may be limited, which would have an adverse effect on our operating results and financial condition.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we are not able to establish new collaborations for APX3330 on commercially reasonable terms, we may have to alter our development, manufacturing, and commercialization plans.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We face significant competition in attracting collaborators for development, manufacturing or commercialization plans. Whether we reach a definitive agreement for collaboration for APX3330 will
          depend, among other things, upon our assessment of the proposed collaborator&#8217;s resources, expertise, and evaluation of a number of factors related to the associated product candidate, as well as the terms and conditions of the proposed
          collaboration. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the product candidate, the costs and
          complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which may exist if there is a challenge to such
          ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for
          collaborations and whether such a collaboration could be more attractive than one with us. We may not be able to enter into these agreements on commercially reasonable terms, or at all.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Much of the potential revenue from future commercial collaborations may consist of contingent payments, such as payments for achieving regulatory milestones or royalties payable on sales of our
          product candidate, if approved. The milestone and royalty revenue that we may receive under these collaborations would depend upon our collaborators&#8217; ability to successfully develop, introduce, market and sell our product candidate, if approved.
          In addition, collaborators may decide to enter into arrangements with third parties to commercialize products developed under collaborations related to our product candidates, which could reduce the milestone and royalty revenue received, if any.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming
          to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may not be able to negotiate collaborations on a timely basis and on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for
          which we are seeking to collaborate, reduce or delay our development program or that of one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, or increase our
          expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which
          may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidate or bring us to market and generate product revenue.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we engage in acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities
          and subject us to other risks.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may engage in various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any
          acquisition or strategic partnership may entail numerous risks, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>increased operating expenses and cash requirements;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the assumption of indebtedness or contingent liabilities;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">89</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the issuance of our equity securities which would result in dilution to our stockholders;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the diversion of management&#8217;s attention from our existing product candidates and initiatives in pursuing such an acquisition or strategic partnership;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, if we undertake such a transaction, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Risks Related to Our Intellectual Property</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we are unable to obtain and maintain sufficient patent protection for our product candidates, our competitors could develop and commercialize products or technology similar or identical to
          those of us, which would adversely affect our ability to successfully commercialize any product candidates we may develop, our business, results of operations, financial condition and prospects.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We primarily protect our intellectual property through a combination of patents and patent applications on inventions, trademark protection on our product name, and trade secret protection as we
          deem appropriate.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As of February 10, 2023, our patent estate relating to the Nyxol contains ten U.S. patents, eight pending U.S. non-provisional patent applications, as well as issued patents in Australia, Canada,
          Europe, Japan, and Mexico and pending patent applications in Australia, Canada, Europe, Japan, China, and other foreign countries, all of which are owned by us.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our U.S. Patents 9,795,560; 10,278,918; 10,772,829, 11,090,261, 11,566,005 and counterpart Australian, Canadian, European, and Japanese patents each contain composition of matter claims to
          aqueous phentolamine mesylate formulations and are scheduled to expire in year 2034. In the same patent family, we also have 1 pending U.S. patent application with additional claims to aqueous phentolamine mesylate formulations, whereby a patent,
          if granted, based on this patent application would expire in year 2034. The patents and patent applications cover the current clinical formulation for the Nyxol product.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Our U.S. Patent Nos. 9,089,560; 9,789,088; and 11,000,509 contain claims directed to methods of improving visual performance using, for example, phentolamine mesylate and are scheduled to expire
          in year 2034. Counterpart patents have issued in Australia, Canada, Europe and Japan, which are scheduled to expire in year 2034.&#160; In the same patent family, we also have 1 pending U.S. patent application with additional claims to methods of
          improving visual performance using, for example, phentolamine mesylate, whereby a patent, if granted from this pending patent application, would expire in year 2034. The patents and patent applications cover uses of the current clinical
          formulation for the Nyxol product.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We have patent applications pending in the U.S., Australia, Canada, China, Europe, and Japan directed to treating glaucoma and other medical disorders using phentolamine mesylate. Patents, if
          granted, based on these pending applications would expire in year 2039.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">90</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Our U.S. Patent 10,993,932 contains claims directed to methods of treating presbyopia using phentolamine mesylate in combination with pilocarpine and is scheduled to expire in year 2039.&#160; Our
          U.S. Patent 11,400,077 contains claims directed to methods of treating mydriasis using phentolamine mesylate and is scheduled to expire in year 2039.&#160;&#160; In the same patent family as U.S. Patent Nos. 10,993,932 and 11,400,077 , we have four pending
          U.S. patent applications, two of which have claims to treating presbyopia and the other two U.S. application have claims to treating mydriasis. Counterpart patent applications are pending in Australia, Canada, China, Europe, Japan, and other
          foreign countries, whereby a patent, if granted, based on these pending U.S. and foreign patent applications would expire in year 2039.</div>

        <div style="text-align: justify;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We have one U.S. Patent 11,566,005, a pending U.S. patent application, and a pending international patent application directed to phentolamine mesylate composition of matter and methods of making
          high-purity phentolamine mesylate, and compositions with claimed phentolamine mesylate for the treatment of presbyopia, dim light or night vision disturbances and others.&#160; Our U.S. patent 11,566,005 claims include phentolamine mesylate
          composition of matter, topical ophthalmic composition containing 1% of the claimed phentolamine mesylate composition of matter and methods of use for the claimed composition in presbyopia, dim light and night vision disturbances and treatment of
          pharmacologically induced mydriasis. This patent and other patents based on the foregoing patent applications in its class if granted, are scheduled to expire in year 2042.&#160; We also have one pending patent application in China directed to methods
          of making high-purity phentolamine mesylate and compositions resulting from such methods, whereby any patents, if granted, based on this patent application in China would expire in year 2041. We also have a pending international patent
          application directed to additional methods for treating mydriasis and glaucoma, whereby any U.S. or foreign patents, if granted, from on a patent application filed based on this international patent application would expire in year 2042</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">We also own an issued patent in Mexico that is scheduled to expire in year 2025 and has claims to ophthalmic formulations.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We have in-licensed a patent estate directed to APX3330 and related compounds that, as of February 10, 2023, contains seven U.S. patents, two pending U.S. non-provisional patent applications, as
          well as issued patents in Europe, Japan, Canada, and Australia, and pending patent applications in Europe, Japan, Canada, China, South Korea and Australia. Our in-licensed U.S. patent 9,040,505 has claims to methods of treating diabetic
          retinopathy and other diseases using, for example, APX3330 and is scheduled to expire in year 2030. Counterpart patents have issued in Europe, Japan, Australia, and Canada, which are scheduled to expire in year 2028, and there is a related
          pending U.S. patent application with method of treatment claims that, if issued as a patent, would expire in year 2028. Our in-licensed pending U.S. patent application 16,968,009 and pending applications in Europe, Japan, Canada, South Korea and
          Australia have claims to methods of treating wAMD and other diseases using, for example, APX3330, whereby patents, if granted based on these pending patent applications, would expire in year 2039. Our in-licensed patent applications directed to a
          combination therapy composition comprising an APE1/REF-1 inhibitor, such as APX3330, and a second therapeutic agent, and are pending in the U.S. and Canada, whereby patents, if granted based on these pending patent applications, would expire in
          year 2038. In-licensed patent applications directed to use of an APE1/REF-1 inhibitor, such as APX3330, in monotherapy or combination therapy to reduce neuronal sensitivity and/or treat other indications are pending in Europe, Japan, and Canada,
          whereby patents, if granted based on these applications, would expire in year 2038. This same patent family includes one in-licensed U.S. patent directed to methods using APX3330 to treat inflammation and pain as part of a combination therapy.&#160;
          Patents to derivatives of APX3330 have been issued in the U.S., Europe, and other countries that are scheduled to expire from year 2028 to 2032.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">In addition to patents and patent applications that we have in-licensed,&#160; as of <span style="text-decoration: underline;">February 10, 2023</span>, we own o<span style="color: rgb(73, 130, 5);"><span style="text-decoration: underline;">n</span></span>e pending international patent application
          directed to methods of treating diabetic retinal diseases using APX3330.&#160; Patents, if granted, from an application filed based on this pending international patent applications would expire in year 2042.&#160; Additionally, we own one pending U.S.
          provisional patent application directed to certain salt forms of APX3330 and methods of use, whereby any patents, if granted, from an application filed based on this provisional patent application would expire in year 2043, and we own one pending
          U.S. provisional patent application directed to additional therapeutic methods using APX3330 in patients with diabetic retinal disease, whereby any patents, if granted, from an application filed based on this provisional patent application would
          expire in year 2044.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">91</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">The patent prosecution process is expensive and time-consuming, and we and our future licensors, licensees, or collaboration partners may not be able to prepare, file, and prosecute all necessary
          or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or any future licensors, licensees, or collaboration partners may fail to identify patentable aspects of inventions made in the course of
          development and commercialization activities before it is too late to obtain patent protection on them. We and our licensors&#8217; patent applications cannot be enforced against third parties practicing the technology claimed in such applications
          unless and until a patent is issued from such applications, and then only to the extent the issued claims cover the technology.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We cannot assure you that any of our patents have matured, or that any of our pending patent applications will mature, into issued patents that will include, claims with a scope sufficient to
          protect our product candidates. Others have developed technologies that may be related or competitive to our approach, and may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with
          our patent applications, for example by claiming the same compounds, methods or formulations or by claiming subject matter that could dominate the patents that we owns or in-licenses. The patent positions of biotechnology and pharmaceutical
          companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity, and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if
          issued, may be challenged, deemed unenforceable, invalidated, or circumvented. U.S. patents and patent applications may also be subject to interference proceedings,<span style="font-style: italic;"> ex parte</span> reexamination, or<span style="font-style: italic;"> inter partes</span> review proceedings, supplemental examination and challenges in district court. Patents may be subjected to opposition, post-grant review, or comparable proceedings in various national and
          regional patent offices. These proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such
          interference, re-examination, opposition, post-grant review,<span style="font-style: italic;"> inter partes</span> review, supplemental examination, or revocation proceedings may be costly or time-consuming. Thus, any patents that we may own or
          exclusively license may not provide any protection against competitors. Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to
          develop, market or otherwise commercialize our product candidates.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Furthermore, the issuance of a patent, while presumed valid, is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or
          competitive advantages against competitors with similar products. Competitors may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs, or methods. We may not
          be able to prevent the unauthorized disclosure or use of any technical knowledge or trade secrets by consultants, vendors, former employees, or current employees. The laws of some foreign countries do not protect proprietary rights to the same
          extent as do the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. If these developments were to occur, they could have a material adverse effect on our sales.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise the components that are used in their products.
          Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. Any litigation to enforce or defend our patent rights, if any, even if we were to prevail, could be costly and
          time-consuming and would divert the attention of management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be
          commercially meaningful.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. Such proceedings could also provoke
          third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If, in any proceeding, a court invalidated or found unenforceable our patents covering our
          product candidates, our financial position and results of operations would be adversely impacted. In addition, if a court found that valid, enforceable patents held by third parties covered our product candidates, our financial position and
          results of operations would also be adversely impacted.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">92</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our product candidates;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any of our pending patent applications will result in issued patents;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we will be able to successfully commercialize our product candidates, if approved, before our relevant patents expire;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we were the first to make the inventions covered by each of our patents and pending patent applications;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we were the first to file patent applications for these inventions;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>others will not develop similar or alternative technologies that do not infringe our patents;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any of our patents will be valid and enforceable;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>we will develop additional proprietary technologies or product candidates that are separately patentable; or</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our commercial activities or products will not infringe upon the patents of others.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Patents have a limited lifespan. The natural expiration of a patent is generally 20 years after its effective filing date. Various extensions may be available; however, the life of a patent, and
          the protection it affords, is limited. Given the extensive period of time between patent filing and regulatory approval for a product candidate, the time during which we can market a product candidate under patent protection is limited, and our
          patent may expire before we obtain such approval. Without patent protection for our product candidates, we may be vulnerable to competition from generic versions of our product candidates, which may affect the profitability of our product
          candidates.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidate, our business may
          be materially harmed.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Depending upon the timing, duration of regulatory review, and date of FDA marketing approval of our APX3330 or other product candidates, if any, one of such U.S. patents may be eligible for
          patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act provides for a patent restoration term, or patent term extension, of up to five years as
          compensation for the time the product is under FDA regulatory review. The duration of patent term extension is calculated based on the time spent in the regulatory review process. In the future, we may plan to seek patent term extension for one
          or more of our patents related to our APX3330 or other product candidates. However, we may not be granted an extension because of, for example, failing to apply within the applicable deadline, expiration of relevant patents prior to obtaining
          approval, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be shorter or less than what we request. If we are unable to obtain patent term extension or
          the term of any such extension is less than we request, our revenue could be reduced, possibly materially.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">93</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify;">
          <div style="font-style: italic; font-weight: bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">In 2011, the United States enacted wide-ranging patent reform legislation with the America Invents Act (&#8220;AIA&#8221;).</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or
          more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before we could therefore be awarded a patent covering an invention of ours even
          if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent
          applications on our inventions.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any
          issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to
          invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a
          district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The
          AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Additionally, the U.S. Supreme Court&#8217;s holdings in several patent cases in recent years, such as Association for Molecular Pathology v. Myriad Genetics, Inc. (Myriad I), Mayo Collaborative
          Services v. Prometheus Laboratories, Inc., and Alice Corporation Pty. Ltd. v. CLS Bank International, have narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations.
          In addition to increasing uncertainty about our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the
          federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken&#160; our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We may not be able to protect or practice our intellectual property rights throughout the world.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In jurisdictions where we have not obtained patent protection, competitors may use our intellectual property to develop their own products and further, may export otherwise infringing products to
          territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the United States. Competitor products may compete with our product candidates in jurisdictions where we do not have issued or granted
          patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing
          countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to pharmaceuticals. This could make it difficult for us to prevent the infringement
          of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts
          and attention from other aspects of our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in
          protecting and defending such rights in such jurisdictions. If we, or any future licensor, encounters difficulties in protecting, or is otherwise precluded from effectively protecting, the intellectual property rights important for our business
          in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant
          licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the
          value of such patent. If we, or any licensor, is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results
          of operations may be adversely affected.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">94</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Competitors may infringe on our patents, the patents of our licensing partners, or other intellectual property rights. To counter infringement or unauthorized use, we may be required to file
          infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that our patent is invalid or unenforceable, or may refuse to stop the other party from using the technology on the
          grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial
          amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Moreover, there can be no assurance
          that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Litigation proceedings may fail and, even if successful, may be costly and a distraction to our management and other employees. We may not be able to prevent, alone or with our collaborators,
          misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be
          negative, we could have a substantial adverse effect on the price of our common stock.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have an adverse effect on the
          success of our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without
          infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. We may in the future
          become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our medicines and technology, including interference or derivation proceedings, post-grant reviews, <span style="font-style: italic;">inter partes</span> reviews, or other procedures before the USPTO or other similar procedures in foreign jurisdictions. Third parties may assert infringement claims against us based on existing patents or patents
          that may be granted in the future. If we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our medicines and technology.
          However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, we could be non-exclusive, thereby giving our competitors and other third parties access to the same
          technologies licensed to us. We could be forced, including by court order, to cease developing and commercializing the infringing technology or medicine. In addition, we could be held liable for substantial monetary damages, potentially including
          treble damages and attorneys&#8217; fees, if found to have willfully infringed. A finding of infringement could prevent us from commercializing a product candidate or force us to cease some of our business operations, which could harm our business.
          Alternatively, we may need to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could
          have a similar negative impact on our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The cost to us of any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial and may result in substantial costs and
          distraction to our management and other employees. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from
          the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">95</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our employees and consultants have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we are not aware of
          any claims currently pending against us, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information or intellectual property of the former employers of
          our employees. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such
          claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could detract from our ability to develop or commercialize our product candidates.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of any product we may pursue could be significantly diminished.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may rely upon trade secrets, know-how, and continuing technological innovation to develop and maintain our competitive position. However, trade secrets are difficult to protect. We rely in
          part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers, vendors, and other advisors to protect our trade secrets and other proprietary information. These
          agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, we cannot guarantee that we have executed these
          agreements with each party that may have or has had access to trade secrets.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">If a party breaches an agreement and discloses our proprietary information, including our trade secrets, we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a
          party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome is unpredictable. In addition, some courts in and outside of the United States are less willing or unwilling to protect trade
          secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they disclose such trade secrets, from using that technology or information to
          compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be harmed.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Obtaining and maintaining our trademark protection depends on approval from the USPTO and other foreign government agencies, and third parties may challenge, infringe, or otherwise weaken our
          trademark rights.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We have obtained registration of the &#8220;Nyxol&#8221; trademark in the United States. We have not yet registered trademarks for any other product candidates in any jurisdiction. If we do not secure and
          maintain registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would, which could affect our business. When we file trademark applications for a product candidate, those
          applications may not be allowed for registration, and registered trademarks may not be obtained, maintained, or enforced. During trademark registration proceedings in the United States and foreign jurisdictions, we may receive rejections. We are
          given an opportunity to respond to those rejections, but may not be able to overcome such rejections. In addition, the USPTO and comparable agencies in many foreign jurisdictions allow third parties opportunities to oppose pending trademark
          applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks and our trademarks may not survive such proceedings.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, any proprietary name we propose to use with a future product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to
          register it, as a trademark. The FDA typically conducts a review of proposed drug names, including an evaluation of potential for confusion with other drug names. If the FDA objects to any proposed proprietary drug name for any product candidate,
          we may be required to expend significant additional resources in an effort to identify a suitable substitute proprietary drug name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be
          acceptable to the FDA.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">96</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">If we register any of our trademarks, our trademarks or trade names may be challenged, infringed, circumvented, declared generic, or determined to infringe on other marks. We may not be able to
          protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition
          based on our trademarks and trade names, we may not be able to compete effectively, and our business may be adversely affected.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental agencies, and our
          patent protection could be reduced or eliminated for noncompliance with these requirements.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment or other provisions during the patent application process. In
          addition, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. While an inadvertent lapse can in many cases be cured by payment
          of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in
          the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which would have an adverse effect on our business.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We depend on intellectual property sublicensed from Apexian Pharmaceuticals, Inc. (&#8220;Apexian&#8221;) for our APX3330 product candidate under development and our additional pipeline candidates, and the
          termination of, or reduction or loss of rights under, this sublicense would harm our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We entered into a sublicense agreement with Apexian (as amended, the &#8220;Apexian Sublicense Agreement&#8221;) to in-license patents and other intellectual property relating to the APX3330 product
          candidate and second-generation product candidates owned by Apexian, and intellectual property that Apexian in-licensed from Eisai Co., Ltd. (&#8220;Eisai&#8221;) including certain study reports, manufacturing and analytical records, data, know-how,
          technical and other proprietary information relating to APX3330. The rights granted under the Apexian Sublicense Agreement are subject to various milestone payment, royalty, insurance or other obligations on us, and may be revocable under certain
          circumstances including if we cease to do business, fail to make the payments due thereunder, commit a material breach of the agreement that is not cured within a certain time period after receiving written notice or fail to meet certain
          specified development and commercial timelines. Termination of the Apexian Sublicense Agreement may result in us having to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all, which may
          mean we are unable to develop or commercialize APX3330 and second-generation assets.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We do not have total control over the preparation, filing, prosecution and maintenance of patents and patent applications covering the technology that we license under the Apexian Sublicense
          Agreement. Under the Sublicense Agreement, Indiana University Research and Technology Corp. (&#8220;IURTC&#8221;), the owner of the patents licensed to Apexian and sublicensed to us, maintains the right to control all prosecution and maintenance of such
          patents. Therefore, we cannot always be certain that these patents and patent applications will be prepared, filed, prosecuted and maintained in a manner consistent with the best interests of our business. Although we have a right to have our
          comments considered in connection with, and have agreed to bear the costs of, the prosecution and maintenance of the licensed patents, if IURTC fails to prosecute and maintain such patents, or loses rights to those patents or patent applications
          as a result of its control of the prosecution activities, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be
          adversely affected.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">97</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Further, if Apexian breaches its license agreement with IURTC and fails to cure such breach within a 60-day cure period, IURTC may terminate such license agreement with Apexian, in which case,
          our license shall also terminate and we will lose all rights under the license agreement with Apexian. While the Apexian Sublicense Agreement provides that Apexian must cooperate with us to remedy and cure Apexian&#8217;s breach of the license
          agreement with IURTC in order to prevent the termination of such license agreement, we cannot guarantee that such efforts will be successful in preventing the termination of the license agreement between Apexian and IURTC. Similarly, if Apexian
          breaches its license agreement with Eisai and fails to cure such breach within a 60-day cure period, Eisai may terminate such license agreement with Apexian, in which case, our sublicense rights under such license shall also terminate. While we
          do not have any material obligations under the license agreement between Eisai and Apexian, Apexian has certain confidentiality and payment obligations that, if not met, could result in breach of the Eisai license agreement.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Under Apexian&#8217;s license agreement with IURTC, any act or omission by us that would be a breach of the license agreement with IURTC if imputed to Apexian is deemed to be a breach by Apexian of
          such license agreement and cause for termination, including, in particular, any breach by us of our payment, reporting, audit, and indemnification obligations.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">The Apexian Sublicense Agreement obligates us to make certain milestone payments.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We are obligated to pay certain milestone payments to Apexian pursuant to the Apexian Sublicense Agreement. These milestone payments include (i) payments for specified developmental and
          regulatory milestones totaling up to $11 million in the aggregate and (ii) payments for specified sales milestones of up to $20 million in the aggregate.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Because certain milestone payments payable by us are due upon certain events related to the development and regulatory approval of our product candidates, we may be required to make such payments
          prior to the time at which we are able to generate revenue, if any, from sales any of our product candidates, if approved. There can be no assurance that we will have the funds necessary to make such payments, or be able to raise such funds when
          needed, on terms acceptable to us, or at all. Furthermore, if we are forced to raise additional funds, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop
          and market product candidates that we would otherwise develop and market themselves. If we are unable to raise additional funds or maintain sufficient liquidity to make our payment obligations if and when they become due, we may be in material
          breach of our license and acquisition agreements and our counterparties may seek legal action or remedies against us, which would harm our business, financial condition, results of operations and prospects.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We may enter into collaborations, in-licensing arrangements, joint ventures, strategic alliances or partnerships with third parties that may not result in the development of commercially viable
          products or the generation of significant future revenues.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We may enter into certain license or other collaboration agreements in the future. Such agreements may impose various diligence, milestone payment, royalty, insurance or other obligations on us.
          If we fail to comply with such obligations,&#160; our licensor or collaboration partners may have the right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licensed
          intellectual property. Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the scope of rights granted under the license agreement and other interpretation-related issues;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the sublicensing of patent and other rights under our collaborative development relationships;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">98</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the priority of invention of patented technology.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, the agreements under which intellectual property or technology is licensed from third parties are complex, and certain provisions in such agreements may be susceptible to multiple
          interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our
          financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we
          have licensed prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse
          effect on our business, financial conditions, results of operations, and prospects.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, we cannot be certain that the preparation, filing, prosecution and maintenance activities by any future licensors have been or will be conducted in compliance with applicable laws
          and regulations or will result in valid and enforceable patents and other intellectual property rights.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Risks Related to Our Employee Matters and Managing Growth</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We are highly dependent on our management, scientific, and medical personnel, including Mina Sooch, our President, Chief Executive Officer and Board Vice Chair. We have entered into employment
          agreements with our executive officers, but any employee may terminate his or her employment with us. The loss of the services of any of our executive officers, other key employees or consultants, or other scientific and medical advisors in the
          foreseeable future might impede the achievement of our research, development, and commercialization objectives. If we fail to retain key personnel and are unable to hire highly qualified replacements, we may not be able to meet key objectives,
          such as meeting financial goals, and maintaining or expanding our business. We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our
          consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Recruiting and retaining qualified scientific
          personnel and business and commercial personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for
          similar personnel. We also experience competition for the hiring of scientific personnel from universities and research institutions. Failure to succeed in clinical trials may also make it more challenging to recruit and retain qualified
          scientific personnel.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We will need to develop and expand our company and may encounter difficulties in managing this development and expansion, which could disrupt our operations.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As of March 1, 2023, we had ten full-time employees, and we expect to increase our number of employees and the scope of our operations as we further the clinical development of our product
          candidates. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified
          personnel. Also, our management may need to divert a disproportionate amount of our attention away from our day-to-day activities and devote a substantial amount of time to managing these development activities. Due to our limited resources, we
          may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, and give rise to operational mistakes, loss of business opportunities,
          loss of employees, or reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of product candidates. If
          our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business
          strategy. Our future financial performance and our ability to commercialize product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage our future development and expansion.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">99</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">A variety of risks associated with operating internationally for us and our collaborators could adversely affect our business.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition to our U.S. operations, we may pursue international operations in the future and would face risks associated with such global operations, including possible unfavorable regulatory,
          pricing and reimbursement, legal, political, tax, and labor conditions, which could harm our business. We plan to conduct clinical trials outside of the United States. We are subject to numerous risks associated with international business
          activities, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>compliance with differing or unexpected regulatory requirements for our product candidates;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>different medical practices and customs affecting acceptance of our product candidates, if approved, or any other approved product in the marketplace;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>language barriers;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the interpretation of contractual provisions governed by foreign law in the event of a contract dispute;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>difficulties in staffing and managing foreign operations, and an inability to control commercial or other activities where it is relying on third parties;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>workforce uncertainty in countries where labor unrest is more common than in the United States;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>potential liability under the Foreign Corrupt Practice Act of 1977 or comparable foreign regulations;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>production shortages resulting from any events affecting raw material supply or manufacturing capability abroad;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>foreign government taxes, regulations, and permit requirements;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>U.S. and foreign government tariffs, trade restrictions, price and exchange controls, and other regulatory requirements;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>economic weakness, including inflation, natural disasters, war, events of terrorism, or political instability in particular foreign countries;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>fluctuations in currency exchange rates, which could result in increased operating expenses and reduced revenues;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>compliance with tax, employment, immigration, and labor laws, regulations, and restrictions for employees living or traveling abroad;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>changes in diplomatic and trade relationships; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">100</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 74pt;"><br />
              </td>

    <td style="width: 16pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>challenges in enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Our business and operations would suffer in the event of system failures or unplanned events.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Despite the implementation of security measures, our internal computer systems and those of our current and future contractors and consultants are vulnerable to damage from computer viruses,
          unauthorized access, natural disasters, terrorism, war, and telecommunications and electrical failures. In March 2021, we were the victim of a business email compromise. This fraud did not cause any losses to us. If another such event were to
          occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result
          in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or
          inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. We may be required to expend significant resources,
          fundamentally change our business activities and practices, or modify our operations, including our clinical trial activities, or information technology in an effort to protect against security breaches and to mitigate, detect and remediate
          actual or potential vulnerabilities.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Furthermore, any unplanned event, such as flood, fire, explosion, tornadoes, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunications failure, other natural or
          manmade accidents or incidents, or pandemics, that result in us being unable to fully utilize the facilities, may have an adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative
          consequences on its financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates, or interruption of our business operations.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Our insurance policies are expensive and protect only from some business risk, which leaves us exposed to significant uninsured liabilities.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We do not carry insurance for all categories of risks that our business may encounter, and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain
          existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse the company for any expenses or losses we may suffer. If we obtain marketing approval for any
          product candidates that we may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. Required coverage
          limits for such insurances are difficult to predict and may not be sufficient. If potential losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held
          liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business,
          including by preventing or limiting the development and commercialization of any product candidates that the company or our collaborators may develop.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">In addition, as a public company, it may be more difficult or more costly for us to obtain certain types of insurance, including directors&#8217; and officers&#8217; liability insurance, and we may be forced
          to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our
          board of directors, our board committees or as executive officers.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">101</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Environmental, social and governance matters and any related reporting obligations may impact our businesses.</div>

        <div><span style="font-style: italic;"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">U.S. and international regulators, investors and other stakeholders are increasingly focused on environmental, social, and governance (ESG) matters. For
            example, new domestic and international laws and regulations relating to ESG matters, including human capital, diversity, sustainability, climate change and cybersecurity, are under consideration or being adopted, which may include specific,
            target-driven disclosure requirements or obligations. Our response will require additional investments and implementation of new practices and reporting processes, all entailing additional compliance risk.</span>&#160;<span style="color: rgb(0, 0, 0);">Our aspirations and disclosures related to environmental, social, and governance (&#8220;ESG&#8221;) matters expose us to risks that could adversely affect our reputation and performance.</span></div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Risks Related to Ownership of Our Common Stock</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We do not anticipate paying any cash dividends in the foreseeable future.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will
          be investors&#8217; sole source of gain, if any, for the foreseeable future.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we fail to comply with the continued listing standards of the Nasdaq Capital Market, our common stock could be delisted. If it is delisted, the liquidity of our common stock would be impacted.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The continued listing of our common stock on Nasdaq is contingent on our continued compliance with a number of listing standards. There is no assurance that we will remain in compliance with
          these standards. Delisting from Nasdaq would adversely affect our ability to raise additional financing through the public or private sale of equity securities, significantly affect the ability of investors to trade our securities and negatively
          affect the value and liquidity of our common stock. Delisting also could limit our strategic alternatives and attractiveness to potential counterparties and have other negative results, including the potential loss of employee confidence, the
          loss of institutional investors or interest in business development opportunities.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">In addition, if our common stock is delisted from the Nasdaq Capital Market and the trading price remains below $5.00 per share, trading in our common stock might also become
          subject to the requirements of certain rules promulgated under the Exchange Act, which require additional disclosure by broker-dealers in connection with any trade involving a stock defined as a &#8220;penny stock&#8221; (generally, any equity security not
          listed on a national securities exchange or quoted on Nasdaq that has a market price of less than $5.00 per share, subject to certain exceptions).</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">The market price of our common stock may fluctuate significantly.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The market price of our common stock may fluctuate significantly in response to factors, some of which are beyond our control, such as:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the announcement of new products or product enhancements by us or our competitors;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>changes in our relationships with our licensors or other strategic partners;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>developments concerning intellectual property rights and regulatory approvals;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>variations in ours and our competitors&#8217; results of operations;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>substantial sales of shares of our common stock due to the release of lock-up agreements;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the announcement of clinical trial results;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the announcement of potentially dilutive financings;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>changes in earnings estimates or recommendations by securities analysts;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">102</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>changes in the structure of healthcare payment systems; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 56pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>developments and market conditions in the pharmaceutical and biotechnology industries, including due to the COVID-19 pandemic.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Further, the stock market, in general, and the market for biotechnology companies, in particular, have experienced extreme price and volume fluctuations. Continued market fluctuations could
          result in extreme volatility in the price of our common stock, which may be unrelated or disproportionate to our operating performance and which could cause a decline in the value of our common stock.</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">We may be subject to securities litigation, which is expensive and could divert management attention.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The market price of our common stock may be volatile, and in the past companies that have experienced volatility in the market price of their stock have been subject to securities class action
          litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and direct our management&#8217;s attention from other business concerns, which could seriously harm our
          business.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM1B."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 1B.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">UNRESOLVED STAFF COMMENTS</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Not applicable.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM2."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 2.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">PROPERTIES</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our headquarters is currently located in Farmington Hills, Michigan, and consists of approximately 1,600 square feet of leased office space under a lease that expires on December 31, 2023. We may
          extend our current space or require additional space and facilities as our business expands, and we believe that suitable additional and alternative spaces will be available in the future on commercially reasonable terms.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM3."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 3.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">LEGAL PROCEEDINGS</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">From time to time, we are subject to litigation and claims arising in the ordinary course of business. Although the results of litigation and claims cannot be predicted with certainty, as of the
          date of this filing, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business
          or financial condition. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM4."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 4.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">MINE SAFETY DISCLOSURES</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Not applicable.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">103</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: center; font-weight: bold;">PART II</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM5."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; font-weight: bold;">ITEM 5.</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; font-weight: bold;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Market Information</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Our shares of common stock trade on the Nasdaq Capital Market under the symbol &#8220;OCUP&#8221;.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Holders</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As of March 27, 2023, there were approximately 83 holders of record of our common stock. The number of holders of record is based on the actual number of holders registered on the books of our
          transfer agent and does not reflect holders of shares in &#8220;street name&#8221; or persons, partnerships, associations, corporations, or other entities identified in security position listings maintained by depository trust companies.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Dividend Policy</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We have not paid any cash dividends on our common stock since our inception and do not anticipate paying any cash dividends in the foreseeable future. We plan to retain our earnings, if any, to
          provide funds for the expansion of our business.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Recent Sales of Unregistered Securities</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">None.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM6."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 6.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">[RESERVED]</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">104</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <a id="ITEM7."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 7.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; font-style: italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes
          included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related
          financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Annual Report, our actual results could differ materially
          from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Overview </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We are a late clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Our pipeline
          currently includes two small molecule product candidates targeting several of such indications.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">Nyxol</div>

        <div>&#160;</div>

        <div>
          <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">In November 2022, we entered into a license and collaboration agreement (the &#8220;Nyxol License Agreement&#8221;) with FamyGen Life Sciences, Inc. </span>(acquired by
            Viatris, Inc. (&#8220;Viatris&#8221;) in January 2023)<span style="color: rgb(0, 0, 0);"> pursuant to which we granted Viatris an exclusive license to develop, manufacture, import, export and commercialize our </span>product candidate phentolamine
            ophthalmic solution 0.75% (Nyxol<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> Eye Drops or &#8220;Nyxol&#8221;)<span style="color: rgb(0, 0, 0);">.</span></div>

          <div>&#160;</div>

          <div><br />
          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt;">Nyxol is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as
          treatment of pharmacologically-induced mydriasis (&#8220;RM&#8221;) (dilation of the pupil), presbyopia (age-related blurry near vision) and dim light or night vision disturbances (&#8220;DLD&#8221;) (halos, glares and starbursts). Our management believes these multiple
          indications potentially represent a significant market opportunity. Nyxol has been studied in a total of 12 clinical trials (3 Phase 1, 5 Phase 2 and 4 Phase 3) in a total of over 650 patients (with over 400 Nyxol-treated) and has demonstrated
          promising clinical data across the three targeted refractive indications.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We reported positive top-line data from Phase 3 trials in RM: MIRA-2 in March 2021, MIRA-3 in March 2022 and MIRA-4 in April 2022. We also reported positive top-line data from a Phase 2 trial of
          Nyxol for treatment of presbyopia, both alone and with low-dose pilocarpine (<span style="color: rgb(0, 0, 0);">pilocarpine hydrochloride ophthalmic solution 0.4%,</span> &#8220;LDP&#8221;) as adjunctive therapy (VEGA-1). We reported top-line data from a
          Phase 3 trial in DLD in May 2022 (LYNX-1). We submitted a new drug application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in November 2022 under the 505(b)(2) pathway for Nyxol for RM with a Prescription Drug User Fee Act (PDUFA)
          goal date of September 28, 2023. The first phase 3 registration trial of Nyxol for the treatment of presbyopia (VEGA-2), both alone and with LDP as adjunctive therapy, was started in late December 2022, and topline results from this trial are
          expected in late 2023. Future trials are planned to start in 2023 including the second registration trials for presbyopia (VEGA-3) and DLD (LYNX-2), and supportive long-term safety trial for both chronic indications (LYRA-1).</div>

        <div>&#160;</div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">105</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">APX3330</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Our product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as diabetic
          retinopathy (&#8220;DR&#8221;) and diabetic macular edema (&#8220;DME&#8221;) which, if left untreated, can result in permanent visual acuity loss and eventual blindness. DR is a disease resulting from diabetes in which chronically elevated blood sugar levels cause
          progressive damage to blood vessels in the retina. DME is a severe form of DR which involves leakage of protein and fluid into the macula, the central portion of the retina, causing swelling and vascular damage. Prior to our in-licensing this
          product candidate, APX3330 had been studied by other sponsors in a total of 11 clinical trials (6 Phase 1 and 5 Phase 2) in a total of over 420 healthy volunteers or patients (with over 340 APX3330-treated) for inflammatory (hepatic) and oncology
          indications, and had demonstrated evidence of target engagement, pharmacokinetics, durability, and favorable safety and tolerability. We also in-licensed APX2009 and APX2014, which are second-generation product candidates and analogs of APX3330.
          In January 2023, we reported top-line efficacy and safety results from the ZETA-1 Phase 2 trial conducted in 103 subjects (51 treated with 600 mg daily dose of APX3330) in DR, including moderately severe non-proliferative DR (&#8220;NPDR&#8221;) and mild
          proliferative DR (&#8220;PDR&#8221;), as well as patients with DME without loss of central vision. Although the ZETA-1 clinical trial did not meet the primary endpoint of % of patients with a &#8805; 2-step improvement in Early Treatment of Diabetic Retinopathy
          Study (ETDRS) diabetic retinopathy severity scale (DRSS) at week 24 in the study eye,&#160; statistical significance was achieved on a key pre-specified secondary endpoint of preventing clinically meaningful progression of diabetic retinopathy
          (defined by binocular 3 or more steps worsening on the DRSS scale, calculated as the sum of changes in each eye) after 24 weeks of treatment. Given the oral systemic delivery of APX3330, an endpoint that evaluates the effects on both eyes is the
          planned Phase 3 primary endpoint for future registration trials; this will be confirmed at an End-of-Phase 2 (EOP2) meeting with the FDA in second half of 2023. APX3330 demonstrated favorable safety and tolerability in the ZETA-1 trial,
          consistent with the safety data from the prior 11 clinical trials. Treatment-related adverse events were uncommon, and most were mild in severity. There were no treatment-related serious adverse events. No changes were observed in liver, kidney,
          or heart function as well as complete blood count and comprehensive metabolic panel.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As part of its our strategy, we will continue to explore opportunities to acquire additional ophthalmic assets and seek strategic partners for late-stage development, regulatory preparation, and
          commercialization of drugs in key global markets.</div>

        <div>&#160;</div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Strategic Outlook</div>

          <div>&#160;</div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">In November 2022, we entered into the Nyxol License Agreement.&#160; As part of our strategy, we will continue to explore opportunities to acquire additional ophthalmic assets
            and to seek strategic partners for late-stage development, regulatory preparation and commercialization of APX3330 in key global markets. To date, our primary activities have been conducting research and development activities, planning
            clinical trials, performing business and financial planning, recruiting personnel and raising capital. We do not have any products approved for sale, and we do not expect to consistently generate significant revenues, other than license and
            collaborations revenue, until, and unless, the FDA or other regulatory authorities approve Nyxol or APX3330 and we successfully commercialize our product candidates. Until such time, if ever, as we can consistently generate substantial product
            revenue, we expect to finance our cash needs through a combination of equity and debt financings as well as through collaborations, strategic alliances and licensing arrangements.</div>

          <div>&#160;</div>

          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Through December 31, 2022, we have funded our operations primarily through equity financings that totaled $54.1 million in gross proceeds, of which $21.15 million was
            received in connection with the merger (&#8220;Merger&#8221;) with Rexahn Pharmaceuticals, Inc. (&#8220;Rexahn&#8221;) and through the issuance of convertible notes in private placements that totaled $8.5 million in gross proceeds net cash. In addition, we recently
            received a one-time non-refundable licensee fee payment in connection with the Nyxol License Agreement of $35.0 million.</div>

          <div>&#160;</div>

          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Our net income was $17.9 million for the year ended December 31, 2022 as compared to a net loss of $56.7 million for the year ended December 31, 2021. As of December 31,
            2022, we had an accumulated deficit of $71.5 million.&#160; As noted above, our net income for the year ended December 31, 2022 was primarily due to a one-time non-refundable payment made to us pursuant to the Nyxol License Agreement. Furthermore,
            we anticipate that our expenses will increase as we:</div>

        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">continue clinical trials for Nyxol, APX3330 and for any other product candidate in our future pipeline;</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">continue preclinical studies for Nyxol, APX3330 and for any other product candidate in our future pipeline;</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">develop additional product candidates that we identify, in-license or acquire;</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">seek regulatory approvals for any product candidates that successfully complete clinical trials;</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">106</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">contract to manufacture our product candidates;</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">maintain, expand and protect our intellectual property portfolio;</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">hire additional staff, including clinical, scientific, operational and financial personnel, to execute our business plan;</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">add operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts;</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">continue to operate as a public company; and</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 54pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#8226;</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify; color: rgb(0, 0, 0);">establish on our own or with partners, a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval;</div>
                </td>

  </tr>


</table>
        </div>

        <div style="text-align: justify;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Our net income (loss) will likely continue to fluctuate significantly from quarter to quarter and year to year, depending on the timing of our preclinical studies, clinical
            trials, expenditures on other research and development activities (and reimbursement thereof), and from potential milestone payments received from and revenue earned under the Nyxol License Agreement or any other license and collaboration
            agreements that we enter into, and potential payments we that may become payable from time to time under the Apexian Sublicense Agreement.</div>

          <div><br /></div>

          <div style="color: rgb(0, 0, 0); font-weight: bold;">Recent Developments</div>

          <div>&#160;</div>

          <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">License and Collaboration Agreement with Viatris</div>

          <div><br /></div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">
            <div>
              <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">In November 2022, we entered into a license and collaboration
                  agreement (the &#8220;Nyxol License Agreement&#8221;) with FamyGen Life Sciences, Inc. </span>(acquired by Viatris, Inc. (&#8220;Viatris&#8221;) in January 2023)<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"><span style="text-decoration: underline;">&#160;</span>pursuant to
                  which we granted Viatris an exclusive license to develop, manufacture, import, export and commercialize our </span>product candidate phentolamine ophthalmic solution 0.75% (Nyxol<sup>&#174;</sup> Eye Drops or &#8220;Nyxol&#8221;)<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">.</span></div>

            </div>

          </div>

          <div>
<div>&#160;
            </div>
<div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Clinical Milestones</div>

            <div>&#160;</div>

            <div style="color: rgb(0, 0, 0); font-style: italic;">APX3330</div>

            <div>
<div>&#160;
              </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">
                <div>
                  <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In January 2023, we announced topline efficacy and safety results from ZETA-1, a Phase 2b trial of APX3330 in diabetic
                    retinopathy patients. Although the primary endpoint (a precedented endpoint for local administration of anti-VEGF intravitreal injections) was not met, the ZETA-1 results on a key pre-specified endpoint demonstrated statistical
                    significance on a potential binocular DR worsening registration endpoint with a favorable systemic and ocular safety profile that support our plans to move forward to an End-of-Phase 2 meeting with the FDA.&#160;</div>

                  <div>&#160;</div>

                </div>

              </div>

              <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Nyxol</div>

              <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;"> <br />
              </div>

              <div>
                <div style="text-indent: 36pt; color: rgb(0, 0, 0);">
                  <div>
                    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">In January 2023, we announced the initiation of the VEGA-2
                        Phase 3 pivotal trial with the first patient enrolled in late December 2022. This is the first of two Phase 3 registration trials intended to support a presbyopia indication for Nyxol alone and Nyxol with LDP. In addition, the
                        VEGA-3 trial (the second Phase 3), the LYNX-2 trial (the second Phase 3), and LYRA-1 trial (1-year safety) are planned to begin in 2023. If successful, we plan to file a supplemental NDA for Nyxol as a single-agent for presbyopia
                        and DLD and a new NDA for </span>Nyxol + LDP<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;"> thereafter.</span></div>

                    <div>&#160;</div>

                  </div>

                </div>

                <div>
                  <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Non-clinical Update</div>

                  <div>&#160;</div>

                  <div>
                    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">In support of conducting clinical trials using Nyxol for chronic indications such as presbyopia and DLD, we have successfully completed a 6-month rabbit ocular toxicology study. The
                      findings from the 6-month study provide support for the conduct of the planned 1-year Phase 3 safety trial LYRA-1. The submission of the final was completed November 2022 to the FDA.</div>

                    <div>&#160;</div>

                  </div>

                </div>

              </div>

            </div>

          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">107</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <div style="text-indent: 36pt; color: rgb(0, 0, 0);">In support of the combination of Nyxol and LDP treatment in presbyopia, a 99-day nonclinical ocular toxicology study with Nyxol and LDP in Dutch-belted rabbits has been completed. The final
            report is being finalized with a subsequent submission to the FDA in 2Q 2023.</div>

          <div>
<div>&#160;
            </div>
<div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Regulatory Update</div>

            <div>&#160;</div>

            <div>
              <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">In November 2022, we announced the submission of an NDA to the FDA for Nyxol for the reversal of pharmacologically-induced mydriasis produced by adrenergic agonist
                (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents, or a combination thereof.</div>

              <div>
<div>&#160;
                </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">In January 2023, we announced that the FDA has accepted the NDA for Nyxol for the treatment of pharmacologically-induced mydriasis. The FDA assigned a Prescription
                  Drug User Fee Act (PDUFA) date of September 28, 2023.</div>

                <div>
                  <div>&#160;</div>

                  <div style="text-align: justify; color: rgb(0, 0, 0);">&#160;<span style="font-weight: bold; font-style: italic;">Presentations, Publications and Conferences</span></div>

                  <div>
<div>&#160;
                    </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">
                      <div>
                        <div style="text-align: justify; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Our management team and medical advisors have participated by invitation at over 35 medical, scientific, industry
                          and investment conferences in 2022, at which over 20 papers, posters and panel talks were presented. We have been engaging with many key opinion leaders to expand awareness of the Nyxol and APX3330 development programs.</div>

                        <div>&#160;</div>

                      </div>

                    </div>

                    <div>
                      <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Global Economic Conditions</div>

                      <div>
<div>&#160;
                        </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Generally, worldwide economic conditions remain uncertain, particularly due to the effects of the recent instability in the financial services industry, the
                          COVID-19 pandemic and increased inflation. The general economic and capital market conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected our access to capital and increased
                          the cost of capital. The capital and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, our future cost of equity or debt capital and access to the
                          capital markets could be adversely affected.</div>

                        <div>
<div>&#160;
                          </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The COVID-19 pandemic that began in late 2019 introduced significant volatility to the global economy, disrupted supply chains and had a widespread adverse
                            effect on the financial markets. As a result of the COVID-19 pandemic, we have experienced, and may continue to experience, delays and disruptions in our clinical trials, as well as interruptions in our manufacturing, supply
                            chain, shipping and research and development operations.&#160; Testing and clinical trials, manufacturing, component supply, shipping and research and development operations may be further impacted by the continuing effects of
                            COVID-19.</div>

                          <div>
<div>&#160;
                            </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">&#160;Additionally, our operating results could be materially impacted by changes in the overall macroeconomic environment and other economic factors. Changes
                              in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflict in Ukraine, and steps taken by governments and central banks, particularly in response to the COVID-19 pandemic as well as
                              other stimulus and spending programs, have led to higher inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy, including increased interest rates.</div>

                            <div>&#160;</div>

                          </div>

                        </div>

                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">108</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <div style="font-weight: bold;">Financial Operations Overview</div>

          <div>&#160;</div>

          <div style="font-style: italic; font-weight: bold;">License and Collaborations Revenue</div>

          <div>&#160;</div>

          <div>
            <div style="text-align: justify; text-indent: 36pt;">License and collaborations revenue to date was derived <span style="color: rgb(0, 0, 0);">from a one-time non-refundable payment and reimbursement of expenses earned under the Nyxol License
                Agreement, and to a much lesser degree, from license agreements with BioSense Global LLC (&#8220;BioSense&#8221;) and Processa Pharmaceuticals, Inc. (&#8220;Processa&#8221;) in connection with the Rexahn RX-3117 drug compound. We anticipate that we will recognize
                revenue as we earn reimbursement for research and development services in connection with the Nyxol License Agreement and we may earn additional revenues from potential milestone and royalty payments from the agreements with Viatris,
                BioSense, Processa, or from other license agreements entered into the future; however, the attainment of milestones or level of sales required to earn royalty payments is highly uncertain for the reasons explained below.</span></div>

            <div>
<div>&#160;
              </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">To date, outside of the license and collaborations revenue referenced above, we do not expect to generate significant revenue unless or until regulatory approval is
                obtained and commercialization begins for Nyxol or APX3330. If we fail to complete the development of Nyxol, APX3330, or any other product candidate we may pursue in the future, in a timely manner, or fail to obtain regulatory approval, our
                ability to generate significant revenue would be compromised.</div>

              <div>
<div>&#160;
                </div>
<div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">General and Administrative Expenses</div>

                <div>&#160;</div>

                <div>
                  <div style="text-indent: 36pt; color: rgb(0, 0, 0);">General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation costs, for personnel in functions not
                    directly associated with research and administrative activities. Other significant costs include insurance coverage for directors and officers and other property and liability exposures, legal fees relating to intellectual property and
                    corporate matters, professional fees for accounting and tax services, other services provided by business consultants and legal settlements.</div>

                  <div>
                    <div>&#160;</div>

                    <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Research and Development Expenses</div>

                    <div>&#160;</div>

                    <div>
                      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">To date, our research and development expenses have related primarily to the clinical stage development of Nyxol and APX3330. Research and development expenses
                        consist of costs incurred in performing research and development activities, including compensation and benefits for research and development employees and costs for consultants, costs associated with preclinical studies and
                        clinical trials, regulatory activities, manufacturing activities to support clinical activities, license fees, nonlegal patent costs, fees paid to external service providers that conduct certain research and development, and an
                        allocation of overhead expenses.</div>

                      <div>&#160;</div>

                      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Pursuant to the Nyxol License Agreement, our budgeted research and development expenses related to the development of Nyxol are fully reimbursed by Viatris.&#160;
                        However, all research and development costs, including those related to Nyxol, are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the
                        services are being provided by monitoring the status of the study or project, and the invoices are received from our external service providers. We adjust our accrual as actual costs become known. Research and development activities
                        are central to our business model.</div>

                      <div>&#160;</div>

                      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">We expect that Nyxol and APX3330 will have higher development costs during the later stages of clinical development, as compared to costs incurred during their
                        earlier stages of development, primarily due to the increased size and duration of the later-stage clinical trials. We expect our research and development expenses to increase over the next several years. However, it is difficult
                        for us to determine with certainty the duration, costs and timing to complete our current or future preclinical programs and clinical trials of Nyxol, APX3330, and other product candidates. The duration, costs and timing of clinical
                        trials and development of Nyxol, APX3330 and other product candidates will depend on a variety of factors that include, but are not limited to, the following:</div>

                      <div>&#160; <br />
                      </div>

                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div style="color: rgb(0, 0, 0);">per patient trial costs;</div>
                            </td>

  </tr>


</table>
                      <div>&#160;</div>

                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div style="color: rgb(0, 0, 0);">the number of patients that participate in the trials;</div>
                            </td>

  </tr>


</table>
                      <div>&#160;</div>

                      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                            </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div style="color: rgb(0, 0, 0);">the number of sites included in the trials;</div>
                            </td>

  </tr>


</table>
                      <div> <br />
                      </div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">109</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">the countries in which the trials are conducted;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">the length of time required to enroll eligible patients;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">the number of doses that patients receive;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">the drop-out or discontinuation rates of patients;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">potential additional safety monitoring or other studies requested by regulatory agencies;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">the duration of patient follow-up;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">the phase of development of the product candidate;</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">arrangements with contract research organizations and other service providers; and</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt;"><br />
                </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="color: rgb(0, 0, 0);">the efficacy and safety profile of the product candidates.</div>
                </td>

  </tr>


</table>
          <div>&#160;</div>

          <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Interest Expense</div>

          <div>&#160;</div>

          <div>
            <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Interest expense consists of interest costs on principal related to a short-term loan (related to financing an insurance policy) during the period it was outstanding.&#160;
              The short-term loan had an annual interest rate of 5.5%. The short-term loan was fully repaid in May 2022.</div>

            <div>
              <div>&#160;</div>

              <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Fair Value Change in Warrant Liabilities</div>

              <div>
<div>&#160;
                </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The fair value change in warrant liabilities consists of the change in the fair value of the warrant liabilities during the period they are outstanding.&#160; The
                  applicable warrants were reclassified to equity in the first quarter of 2021, and as a result, are no longer subject to fair value remeasurement.</div>

                <div>
                  <div>&#160;</div>

                  <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Other Expense, net</div>

                  <div>
<div>&#160;
                    </div>
<div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Other expense, net reflected in this line item includes payments made by us in connection with the Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;) with
                      former Rexahn shareholders. In addition, other expense, net includes interest earned from cash and cash equivalent investments, realized and unrealized gains (losses) from equity investments and reimbursements in connection with
                      grants and other sources when they occur.</div>

                    <div>&#160;</div>

                  </div>

                </div>

              </div>

            </div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Provision for Income Taxes</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Provision for income taxes consists of federal and state income taxes in the United States, as well as deferred income taxes and changes in related valuation allowance
          reflecting the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Currently, a full valuation allowance has been provided
          on the net deferred tax assets as of December 31, 2022 and 2021 given the uncertainty of future taxable income and other related factors impacting the realizability or our remaining net deferred tax assets.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">110</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Results of Operations</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The following table summarizes our operating results for the periods indicated (in thousands):</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the Year Ended</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Change</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">License and collaborations revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">39,850</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">589</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">39,261</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Operating expenses:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">General and administrative</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">7,269</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">8,121</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(852</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">14,355</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">15,173</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(818</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Total operating expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">21,624</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">23,294</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(1,670</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Income (loss) from operations</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">18,226</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(22,705</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">40,931</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(9</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(2</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(7</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Fair value change in&#160; warrant liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">&#8212;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(33,829</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">33,829</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other expense, net</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(14</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(157</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">143</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Income (loss) before income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">18,203</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(56,693</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">74,896</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Provision for income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(315</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">&#8212;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(315</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net income (loss)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">17,888</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(56,693</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">74,581</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Comparison of Years Ended December 31, 2022 and 2021</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">License and Collaborations Revenue</div>

          <div><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">License and collaborations revenue was $39.8 million for the year ended December 31, 2022 compared to $0.6 million for the year ended December 31, 2021. Revenue during 2022
            was derived from the Nyxol License Agreement in the fourth quarter associated largely with the transfer of a perpetual, sub-licensable license to develop, manufacture, import, export and commercialize the Nyxol Products, and to a lesser extent,
            from the reimbursement of research and development services. Revenue during the year ended December 31, 2021 was derived from the collaboration and license agreements with Processa and BioSense related to certain technology transfers in
            connection with the Rexahn RX-3117 drug compound, a legacy asset not under development by Ocuphire.</div>

        </div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">General and Administrative</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">General and administrative expenses for the year ended December 31, 2022 were $7.3 million compared to $8.1 million for the year ended December 31, 2021. The $0.9 million
          decrease was primarily attributable to a non-cash settlement cost of $1.6 million in the prior year period. Other expense decreases from the prior year were attributed to stock-based compensation of $0.1 million and other operating expenses of
          $0.2 million. Partially offsetting the expense decreases from the prior year were increases in administrative employee headcount costs in the amount of $0.4 million, legal fees of $0.4 million and professional service costs in the amount of $0.2
          million. General and administrative expenses included $1,060,000 and $1,116,000 in stock-based compensation expense during the years ended December 31, 2022, and 2021, respectively.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Research and Development</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Research and development expenses for the year ended December 31, 2022 were $14.4 million compared to $15.2 million for the year ended December 31, 2021. The $0.8 million
          decrease was primarily attributable to a decrease in contract research organization expense of $1.5 million as a result of the completion of clinical trials along with an associated decrease in manufacturing activities to support clinical
          advancement of $0.9 million, offset in part by cost increases attributable to staff headcount in the amount of $0.5 million, consulting services of $0.8 million as well as increases attributable to regulatory and other research and development
          efforts of $0.3 million on a net basis. Research and development expenses also included $0.7 million and $0.8 million in stock-based compensation expense during the years ended December 31, 2022 and 2021, respectively.</div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Interest Expense</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Interest expense for the years ended December 31, 2022 and 2021 was $9,000 and $2,000, respectively, and was attributable to a short-term loan (related to financing an
          insurance policy).</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">111</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Fair Value Change in Warrant Liabilities</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">The fair value change in warrant liabilities was a non-cash
              expense of $33.8 million for the year ended December 31, 2021 and was due primarily to the issuance of the Series A warrants in connection with the Pre-Merger Financing and to the fluctuations in Ocuphire&#8217;s common stock fair value and the
              number of potential shares of common stock issuable upon conversion of the underlying Ocuphire warrant liabilities that were outstanding during that period. Upon the execution of the Waiver Agreements in the first quarter of 2021 described in
              Note 3 &#8212; Pre-Merger Financing included in &#8220;Part II, Item 8 &#8211; Financial Statements</span><span style="font-size: 12pt; font-family: 'Times New Roman';">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">and</span><span style="font-size: 12pt; font-family: 'Times New Roman';">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Supplementary Data&#8221; of this Annual Report, the Series A Warrants were reclassified to equity, and
              as a result, were no longer subject to fair value remeasurement.</span></div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The fair value change in warrant liabilities during the year ended December 31, 2022 was de minimis in connection with the Rexahn warrants.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="color: rgb(0, 0, 0);">&#160;<span style="font-weight: bold; font-style: italic;">Other Expense, net</span></div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 20pt; color: rgb(0, 0, 0);">During the year ended December 31, 2022, we had other expense, net of $14,000 stemming from net unrealized losses attributed to our short-term investments of $170,000 and
            realized currency losses of approximately $3,000, offset largely by interest income of $159,000 related to cash and cash equivalents.</div>

          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 20pt; color: rgb(0, 0, 0);">During the year ended December 31, 2021, we had other expense, net of $91,000 stemming from payments due in connection with the CVR Agreement and $70,000 stemming
            principally from net unrealized losses from our short-term investments, offset in part by interest earnings of $4,000 on our cash and cash equivalent investments.</div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Provision for Income Taxes</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Provision for income taxes consisted of federal and state income taxes in the United States in the amount of $315,000 for the year ended December 31, 2022 resulting from our
          net taxable income after the application of net operating loss carryforwards and research credits.&#160; There was no tax provision during the prior year period.</div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Liquidity and Capital Resources</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Capital Resources</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">As of December 31, 2022, our principal sources of liquidity
                consisted of cash and cash equivalents of $42.6 million. We believe that our cash on hand at the end of 2022 will be sufficient to fund our operations</span> for at least twelve months beyond the date of this filing<span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">. As of December 31, 2022, our cash and cash equivalents were invested primarily in cash deposits and cash equivalent investments at two large financial institutions.</span></div>

          </div>

        </div>

        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Historical Capital Resources</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Our primary source of cash to fund our operations has been various equity offerings in the amount of $54.1 million and the issuance of convertible notes in the amount of $8.5 million, inclusive
          of the promissory notes exchanged for Ocuphire convertible notes. In addition, during the fourth quarter of 2022,we received a one-time non-refundable cash payment of $35.0 million in connection with the Nyxol License Agreement.</div>

        <div>&#160;</div>

        <div style="text-align: justify; font-style: italic;">At-The-Market Program</div>

        <div>&#160;</div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">On February 4, 2021, we filed a Form S-3 shelf registration under the Securities Act which was declared effective by the SEC on February 12, 2021 (the &#8220;2021 Shelf&#8221;) under
            which the Company may offer and sell, from time to time in our sole discretion, securities having an aggregate offering price of up to $125 million. In connection with the 2021 Shelf, on March 11, 2021, we entered into a sales agreement with
            JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) under which we may offer and sell, from time to time at our sole discretion, to or through JonesTrading, acting as agent and/or principal, shares of our common stock having an aggregate
            offering price of up to $40 million (the &#8220;ATM&#8221;). A total of 4,627,870 shares of common stock were sold under the ATM for net proceeds through September 2022 in the amount of $17.3 million.&#160; No shares of common stock were sold under the ATM
            during the fourth quarter of 2022.</div>

          <div><br />
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">112</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; font-style: italic;">Registered Direct Offering</div>

        <div>&#160;</div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">On June 4, 2021, we entered into a placement agency agreement with A.G.P./Alliance Global Partners (&#8220;AGP&#8221;). Pursuant to the terms of the placement agency agreement, AGP on
            June 8, 2021, sold an aggregate of 3,076,923 shares of our common stock and warrants to purchase 1,538,461 shares of our common stock (the &#8220;RDO Warrants&#8221;) at an offering price of $4.875 per share and 0.50 RDO Warrants, for gross proceeds of
            $15.0 million, before deducting AGP&#8217;s fees and related offering expenses in the amount of $1.1 million. The purchase agreement contains customary representations, warranties and agreements by the Ocuphire, customary conditions to closing,
            indemnification obligations of Ocuphire, other obligations of the parties and termination provisions.</div>

          <div><br />
          </div>

          <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">The RDO Warrants have an exercise price of $6.09 per share, are exercisable upon the initial issuance date of June 8, 2021, and will expire five years
              following the initial exercise date.</span>&#160;<span style="color: rgb(0, 0, 0);">Subject to limited exceptions, a holder of a RDO Warrant will not have the right to exercise any portion of its RDO Warrants if the holder, together with its
              affiliates, would beneficially own in excess of 4.99% (or, at the election of a holder prior to the date of issuance, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise; provided,
              however, that upon prior notice to us, the holder may increase or decrease the beneficial ownership limitation, provided further that in no event shall the beneficial ownership limitation exceed 9.99%.</span> As of December 31, 2022,
            1,538,461 RDO Warrants were still outstanding. <span style="color: rgb(0, 0, 0);">The offering of the securities was made pursuant to our effective shelf registration statement on Form S-3.</span></div>

        </div>

        <div><br />
        </div>

        <div style="text-align: justify; font-style: italic;">Pre-Merger Financing</div>

        <div>&#160;</div>

        <div style="text-align: justify;"><span style="text-decoration: underline;">Securities Purchase Agreement</span></div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">On June 17, 2020, Ocuphire, Rexahn and certain investors entered into a Securities Purchase Agreement, which was amended and restated in its entirety on June 29, 2020 (as amended and restated,
          the &#8220;Securities Purchase Agreement&#8221;).&#160; Pursuant to the Securities Purchase Agreement, the investors invested a total of $21.15 million in cash, including $300,000 invested by directors of Ocuphire Pharma, Inc. prior to the Merger, and one
          director of Rexahn, upon closing of the Merger (the &#8220;Pre-Merger Financing&#8221;). Pursuant to the Pre-Merger Financing, (i) Ocuphire issued and sold to the investors shares of common stock of Ocuphire Pharma, Inc. prior to the Merger (the &#8220;Initial
          Shares&#8221;) which converted pursuant to the exchange ratio in the Merger into an aggregate of 1,249,996 shares (the &#8220;Converted Initial Shares&#8221;) of common stock, (ii) Ocuphire deposited into escrow, for the benefit of the Investors, additional shares
          of common stock of Ocuphire Pharma, Inc. prior to the Merger (the &#8220;Additional Shares&#8221;) which converted pursuant to the exchange ratio in the Merger into an aggregate of 3,749,992 shares of common stock (the &#8220;Converted Additional Shares&#8221;), which
          Converted Additional Shares were delivered (or became deliverable) to the investors on November 19, 2020, and (iii) we agreed to issue to each investor on the tenth trading day following the consummation of the Merger (x) Series A Warrants
          representing the right to acquire shares of common stock equal to the sum of (A) the Converted Initial Shares purchased by the investor, (B) the Converted Additional Shares delivered or deliverable to the investor, without giving effect to any
          limitation on delivery contained in the Securities Purchase Agreement and (C) the initial number of shares of common stock, if any, underlying the Series B Warrants issued to the Investor and (y) additional warrants to purchase shares of common
          stock.</div>

        <div>&#160;</div>

        <div style="text-align: justify;"><span style="text-decoration: underline;">Waiver Agreements</span></div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Effective February 3, 2021, each investor that invested in the Pre-Merger Financing (each, a &#8220;Holder&#8221;) entered into a Waiver Agreement with the Company (collectively, the &#8220;Waiver Agreements&#8221;).
          Pursuant to the Waiver Agreements, the Holders and Ocuphire agreed to waive certain rights, finalize the exercise price and number of Series A Warrants and Series B Warrants, eliminate certain financing restrictions, extend the term of certain
          leak-out agreements, and, in the case of certain Holders, grant certain registration rights for the shares underlying the warrants.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">113</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt;">The Waiver Agreements provide for the permanent waiver of the full ratchet anti-dilution provisions, contained in the Series A Warrants (as certain of the anti-dilution provisions had
            previously caused liability accounting treatment for the Series A Warrants). Upon the effective date of the Waiver Agreement, the Series A Warrants were reclassified to equity.</div>

          <div>&#160;</div>

          <div style="text-align: justify; text-indent: 36pt;">Pursuant to the Waiver Agreements, the number of shares underlying all of the Series B Warrants was fixed to 1,708,335 in the aggregate with respect to all Holders.</div>

          <div>&#160;</div>

        </div>

        <div style="text-align: justify;"><span style="text-decoration: underline;">Series A Warrants</span></div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The Series A Warrants were issued on November 19, 2020 at an initial exercise price of $4.4795 per share, were immediately exercisable upon issuance and have a term of five years from the date of
          issuance. The Series A Warrants are exercisable for 5,665,838 shares of common stock in the aggregate (without giving effect to any limitation on exercise contained therein). As of December 31, 2022, 5,665,838 Series A Warrants were still
          outstanding.</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">At issuance, the Series A Warrants contained certain provisions that could have resulted in a downward adjustment of the initial exercise price and an upward adjustment in the number of shares
          underlying the warrants if Ocuphire were to have issued or sold, or made an agreement to issue or sell, any shares of common stock for a price lower than the exercise price then in effect.&#160; Pursuant to the terms of the Waiver Agreements, these
          provisions are no longer in effect.</div>

        <div>&#160;</div>

        <div style="text-align: justify;"><span style="text-decoration: underline;">Series B Warrants</span></div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The Series B Warrants have an exercise price of $0.0001, were exercisable upon issuance and will expire on the day following the later to occur of (i) the Reservation Date (as defined therein),
          and (ii) the date on which the investor&#8217;s Series B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein) and no shares remain issuable thereunder. The Series B Warrants were initially
          exercisable for 665,836 shares of common stock in the aggregate (without giving effect to any limitation on exercise contained therein) and ultimately became exercisable for 1,708,335 shares of common stock upon execution of the Waiver
          Agreements. As of December 31, 2022, 17,869 Series B Warrants were still outstanding.</div>

        <div><br />
        </div>

        <div style="text-indent: 36pt;">At issuance, the Series B Warrants contained certain provisions that could have resulted in the issuance of additional Series B Warrants depending on the dollar volume-weighted average prices of a share of Common
          Stock during a 45-trading day Reset Period.&#160; Pursuant to the terms of the Waiver Agreements, those provisions are no longer in effect.</div>

        <div><br />
        </div>

        <div style="text-align: justify; font-style: italic;">Ocuphire Convertible Notes</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">From May 2018 through March 2020, we issued convertible notes (the &#8220;Ocuphire convertible notes&#8221;) for aggregate gross proceeds of $8.5 million, inclusive of the promissory notes exchanged for
          Ocuphire convertible notes. The final closing of the Ocuphire convertible notes occurred on March 10, 2020. The Ocuphire convertible notes had an interest rate of 8% per annum. On November 4, 2020,<span style="color: rgb(0, 0, 0);"> all of
            Ocuphire&#8217;s outstanding notes were converted into 977,128 shares of Ocuphire common stock in connection with the completion of the Merger.</span></div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">114</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Cash Flows</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The following table summarizes our cash flows for the periods indicated (in thousands):</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the Year Ended</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net cash provided by (used in) operating activities</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">14,314</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(19,370</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net cash used in investing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">&#8212;</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(100</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net cash provided by financing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">3,786</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">27,605</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net increase in cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">18,100</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">8,135</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Cash Flow from Operating Activities</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">For the year ended December 31, 2022, cash provided by operating activities of $14.3 million was attributable to net income of $17.9 million, coupled with $2.0 million in
          non-cash operating expenses and offset by a net cash use of approximately $5.6 million resulting from the change in Ocuphire&#8217;s operating assets and liabilities. The non-cash expenses consisted largely of stock-based compensation of $1.8 million
          and a net unrealized loss in our short-term investments of $0.2 million. The change in operating assets and liabilities was primarily attributable to our increase in our accounts receivable and contract asset associated with the Nyxol License
          Agreement of $8.3 million and to a lesser extent from the decrease in our accounts payable and accrued expenses and increases in our prepaid expenses associated with the fluctuations of Ocuphire&#8217;s operating expenses.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">For the year ended December 31, 2021, cash used in operating activities of $19.4 million was attributable to a net loss of $56.7 million, partially offset by $37.1 million in
          non-cash operating expenses and a net change of $0.2 million in Ocuphire&#8217;s net operating assets and liabilities. The non-cash expenses consisted largely of stock-based compensation of $1.9 million, fair value change in warrant liabilities in the
          amount of $33.8 million, a share settlement with certain investors in the amount of $1.6 million and non-cash impact from the receipt of common stock stemming from the fulfillment of revenue milestones ($0.2) million. The change in operating
          assets and liabilities was primarily attributable to an overall net increase in our accounts payable offset in part by both an increase in prepaid expenses and a decrease in accrued expenses associated with the fluctuations of our operating
          expenses.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="color: rgb(0, 0, 0);">&#160;<span style="font-weight: bold; font-style: italic;">Cash Flow from Investing Activities</span></div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">During the year ended December 31, 2021, net cash used in investing activities was $0.1 million and were attributed to the payment of the remaining transaction costs
          associated with the Merger. There were no investing activities during the current year period.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="color: rgb(0, 0, 0);">&#160;<span style="font-weight: bold; font-style: italic;">Cash Flow from Financing Activities</span></div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Net cash provided by financing activities during the year ended December 31, 2022 was $3.8 million that consisted principally of proceeds received from the ATM, net of
          issuance costs, in the amount of $4.3 million, offset in part by payments made on the short-term loan of $0.5 million.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">Net cash provided by financing activities during the year ended December 31, 2021 was $27.6 million&#160; relating principally to </span>proceeds received in
          connection with both the Registered Direct Offering and ATM, net of issuance costs, in the amount of $27.0 million. Proceeds, net of payments, received in connection with a short-term loan in the amount of $0.5 million and the exercise of stock
          options in the amount of $0.1 million comprised the balance of financing activities during the period.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">115</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="color: rgb(0, 0, 0);">&#160;<span style="font-weight: bold; font-style: italic;">Liquidity and Capital Resource Requirements</span></div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">As of December 31, 2022, we had cash and cash equivalents of
              $42.6 million. </span>License and collaborations revenue to date was derived <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">from a one-time non-refundable payment of $35 million and expected reimbursement of
              expenses earned under the Nyxol License Agreement, and to a much lesser degree, from license agreements with BioSense Global LLC (&#8220;BioSense&#8221;) and Processa Pharmaceuticals, Inc. (&#8220;Processa&#8221;) in connection with the Rexahn RX-3117 drug compound.
              We anticipate that we will recognize revenue as we earn reimbursement for research and development services in connection with the Nyxol License Agreement and we may earn additional revenues from future potential milestone and royalty
              payments from the agreements with Viatris, BioSense, Processa, or from other license agreements entered into the future; however, the attainment of milestones or level of sales required to earn royalty payments is highly uncertain for the
              reasons explained below.</span></div>

        </div>

        <div style="text-align: justify;"><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">To date, outside of the license and collaborations revenue referenced above, we do not expect to generate significant revenue unless or until regulatory approval is obtained
          and commercialization begins for Nyxol or APX3330. If we fail to complete the development of Nyxol, APX3330, or any other product candidate we may pursue in the future, in a timely manner, or fail to obtain regulatory approval, our ability to
          generate significant revenue would be compromised.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the
          terms of these securities may include liquidation, warrants, or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our
          ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through future collaborations, strategic alliances or licensing arrangements with pharmaceutical
          partners, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or through
          collaborations, strategic alliances or licensing arrangements when needed, we may be required to delay, limit, reduce or terminate our product development, future commercialization efforts, or grant rights to develop and market our product
          candidates that we would otherwise prefer to develop and market ourselves.</div>

        <div><br />
        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Future Capital Requirements</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">The development of APX3330 is subject to numerous uncertainties, and we have based these estimates on assumptions that may prove to be substantially different than what we
            currently anticipate and could result in cash resources being used sooner than what we currently expect. Additionally, the process of advancing early-stage product candidates and testing product candidates in clinical trials is costly, and the
            timing of progress in these clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving a level of product sales adequate to support our cost structure. We cannot give any assurance
            that we will ever be profitable or generate positive cash flow from operating activities.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

          <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Contractual Obligations and Commitments</div>

          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

          <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Facility Lease</div>

          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">We lease a facility under a non-cancellable operating lease that expires on December 31, 2023, as amended, for a base rent in the amount of $3,000 per month.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">&#160;<span style="font-weight: bold; font-style: italic;">Apexian Sublicense Agreement</span></div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">On January 21, 2020, we entered into the Apexian Sublicense Agreement, pursuant to which we obtained exclusive worldwide patent and other intellectual property rights that
            constitute a Ref-1 Inhibitor program relating to therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions. The lead compound in the Ref-1 Inhibitor program is APX3330, which we intend to develop as an
            oral tablet therapeutic to treat DR and DME, and potentially wAMD.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">In connection with the Apexian Sublicense Agreement, we issued 843,751 shares of our common stock to Apexian and certain of Apexian&#8217;s affiliates.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">116</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">We agreed to make one-time milestone payments under the Apexian Sublicense Agreement for each of the first ophthalmic indication and the first diabetes mellitus indication.
            These milestone payments include (i) payments for specified developmental and regulatory milestones (including completion of the first Phase 2 trial (if such trial meets a primary endpoint) and the first Phase 3 pivotal trial in the United
            States, and filing and achieving regulatory approval from the FDA for the first New Drug Application for a compound) totaling up to $11 million in the aggregate and (ii) payments for specified sales milestones of up to $20 million in the
            aggregate, each of which net sales milestone payments is payable once, upon the first achievement of such milestone.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">Lastly, we also agreed to make royalty payments equal to a single-digit percentage of our net sales of products covered by the patents under the Apexian Sublicense
            Agreement. None of the milestone or royalty payments were triggered as of the date of this Annual Report.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">&#160;<span style="font-weight: bold; font-style: italic;">Other Commitments</span></div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0); text-indent: 36pt;">In the course of normal operations, we entered into cancellable purchase commitments with our suppliers for various key research, clinical and manufacturing services. The
            purchase commitments covered by these arrangements are subject to change based on our research and development efforts.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; color: rgb(0, 0, 0);">&#160;<span style="font-weight: bold; font-style: italic;">Other Funding Requirements</span></div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">As noted above, certain of our cash requirements relate to the funding of our ongoing research and development of APX3330, inclusive of any potential milestone and royalty
            obligations under our intellectual property licenses. See &#8220;Part I, Item 1&#8212; Business&#8212;APX3330 Clinical Experience Summary &#8212;Ocuphire Clinical Development Plan &#8212;Potential Clinical Plans for APX3330&#8212;Future In-Licensing and Acquisition
            Opportunities&#8212;Manufacturing&#8212;Apexian Sublicense Agreement&#8212; Review and Approval of Drugs in the United States&#8221; in this Annual Report for a discussion of design, development, pre-clinical and clinical activities that we may conduct in the future,
            including expected cash expenditures required for some of those activities, to the extent we are able to estimate such costs.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Our other cash requirements within the next twelve months include accounts payable, accrued expenses, purchase commitments and other current liabilities. Our other cash
            requirements greater than twelve months from various contractual obligations and commitments may include operating leases and contractual agreements with third-party service providers for clinical research, product development, manufacturing,
            commercialization, supplies, payroll, equipment maintenance, and audits for periods into calendar year 2024. Refer to Note 4 &#8211; Commitments and Contingencies included in &#8220;Part II, Item 8 &#8211; Financial Statements and Supplementary Data&#8221; of this
            Annual Report for further detail of our lease obligation and license agreements with regard to the timing of expected future payments.</div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">&#160;We expect to satisfy our short-term and long-term obligations through cash on hand, from future equity and debt financings, and from reimbursement payments, potential
            milestone and royalty payments under the Nyxol License Agreement and any future collaborations and license agreements, until we generate an adequate level of revenue from commercial sales to cover expenses, if ever.</div>

          <div>&#160;</div>

        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Critical Accounting Policies and Estimates</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Our financial statements are prepared in accordance with U.S. GAAP. These accounting principles require us to make estimates and judgments that can affect the reported
          amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which we rely are reasonably based
          upon information available to us at the time that we make these estimates and judgments. To the extent that there are material differences between these estimates and actual results, our financial results will be affected. The accounting policies
          that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described below.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">117</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">Our significant accounting policies are discussed in Note 1 &#8212; Company Description and Summary of Significant Accounting Policies, included in &#8220;Part II, Item 8 &#8211; Financial
              Statements</span> and <span style="color: rgb(0, 0, 0);">Supplementary Data&#8221; of this Annual Report. We believe that the following accounting policies and estimates are the most critical to aid in fully understanding and evaluating our
              reported financial results. These estimates require our most difficult, subjective, or complex judgments because they relate to matters that are inherently uncertain. We have reviewed these critical accounting policies and estimates and
              related disclosures with the Audit Committee of our Board of Directors. We have not made any material changes to date, nor do we believe there is a reasonable likelihood of a material future change to the accounting methodologies for the
              areas described below.</span></div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

          <div style="color: rgb(0, 0, 0); font-style: italic;">License and Collaborations Revenue</div>

          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">We account for license and collaborations revenue in accordance with the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards
              Codification (&#8220;ASC&#8221;) 606, </span><span style="font-style: italic; color: rgb(0, 0, 0);">Revenue from Contracts with Customers</span><span style="color: rgb(0, 0, 0);">. The guidance provides a unified model to determine how revenue is
              recognized. We have entered into license and collaboration agreements which have revenue recognition implications. We recognize license and collaborations revenue by first allocating the transaction price of a contract to each performance
              obligation under the contract based on its stand-alone price. The stand-alone price of each performance obligation is based on its fair value utilizing a discounted cash flow approach, taking into consideration assumptions, including
              projected worldwide net profit for each of the respective programs based on probability assessments, projections based on internal forecasts, industry data, and information from other guideline companies within the same industry and other
              relevant factors. To date, we have not had, nor do we expect to have in the future, significant variable consideration adjustments related to our existing license and collaborations revenue recognized. For discussion about the determination
              of license and collaborations revenue, see Note 10 &#8212; License and Collaboration Agreements included in &#8220;Part II, Item 8 &#8211; Financial Statements</span>&#160;<span style="color: rgb(0, 0, 0);">and Supplementary Data&#8221; of this Annual Report.</span></div>

        </div>

        <div>
          <div><span style="color: rgb(0, 0, 0);"> </span><br />
          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Warrant Liabilities</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">Following the Merger, we issued the Series A Warrants in connection with the Pre-Merger Financing, and assumed Rexahn warrants issued prior to the Merger. We
              account for these warrants as a liability at fair value as long as certain provisions precluding equity accounting treatment are present.&#160; Upon the execution of the Waiver Agreements described in Note 9 &#8212; Stockholders&#8217; Equity included in
              &#8220;Part II, Item 8 &#8211; Financial Statements</span>&#160;<span style="color: rgb(0, 0, 0);">and</span>&#160;<span style="color: rgb(0, 0, 0);">Supplementary Data&#8221; of this Annual Report, the Series A Warrants were no longer subject to cash settlement or
              indexation provisions precluding equity classification, and as a result, not subject to fair value remeasurement. We will continue to adjust the Rexahn warrant liability for changes in fair value until the earlier of the exercise, expiration,
              or until such time that cash settlement or indexation provisions are no longer in effect for the Rexahn warrants.&#160; We do not expect that the fluctuations in fair value attributed to the Rexahn warrant liability will be significant.</span></div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-style: italic;">Stock-based Compensation</div>

        <div><br />
        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">We account for stock-based compensation in accordance with the provisions of ASC 718, Compensation &#8212; Stock Compensation. Accordingly, compensation costs related to equity
            instruments granted are recognized at the grant date fair value based on a Black-Scholes model which is not subject to remeasurement. We record equity instrument forfeitures when they occur. For discussions about the application of grant date
            fair value associated with our stock-based compensation, see Note 7 &#8212; Stock-based Compensation included in &#8220;Part II, Item 8 &#8211; Financial Statements and Supplementary Data&#8221; of this Annual Report.</div>

        </div>

        <div>
          <div><br />
          </div>

          <div style="color: rgb(0, 0, 0); font-style: italic;">Income Tax Assets and Liabilities</div>

          <div><br />
          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">A full valuation allowance has been provided on our net deferred tax assets given the uncertainty of future taxable income and other related factors impacting the
          realizability of our remaining net deferred tax assets. For additional information, see Note 12 &#8212; Income Taxes included in &#8220;Part II, Item 8 &#8211; Financial Statements and Supplementary Data&#8221; of this Annual Report.</div>

        <div>
          <div><br />
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">118</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div>
          <div style="color: rgb(0, 0, 0); font-style: italic;">Contingencies</div>

          <div><br />
          </div>

        </div>

        <div>
          <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">We are subject to numerous contingencies arising in the ordinary course of business, including obligations related to certain license agreements. For
              additional information, see Note 4 &#8212; Commitments and Contingencies included in &#8220;Part II, Item 8 &#8211; Financial Statements</span>&#160;<span style="color: rgb(0, 0, 0);">and Supplementary Data&#8221; of this Annual Report.</span></div>

        </div>

        <div>
          <div><br />
          </div>

        </div>

        <div style="color: rgb(0, 0, 0); font-weight: bold;">Recent Accounting Pronouncements</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="color: rgb(0, 0, 0);">From time to time the FASB, or other standard-setting bodies, issue new accounting pronouncements. Where applicable, we adopt these new standards according to
            the specified effective dates. Unless otherwise disclosed in the notes to the financial statements appearing in this Annual Report, we believe that the impact of any recently issued standard(s) that are not yet effective will not have a
            material impact on our financial position or results of operations upon adoption. See Note 1, &#8220;Company Description and Summary of Significant Accounting Policies,&#8221; included in &#8220;Part II, Item 8 &#8211; Financial Statements</span>&#160;and&#160;<span style="color: rgb(0, 0, 0);">Supplementary Data&#8221; of this Annual Report for a more in-depth discussion of recently issued accounting standard(s).</span></div>

        <div><br />
        </div>

        <div>
          <a id="ITEM7A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 7A.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Not applicable.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM8."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 8.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The information required by this item is included in this Annual Report beginning on page F-1 and is incorporated herein by reference.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM9."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 9.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">None.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM9A."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 9A.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">CONTROLS AND PROCEDURES</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Evaluation of Disclosure Controls and Procedures </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, under the direction of the Chief Executive Officer and the principal financial officer, we
          have evaluated our disclosure controls and procedures as defined in Rule 13a-15(e) or 15d-15(e) as of the end of the period covered by this Annual Report.&#160; Based on this evaluation, our Chief Executive Officer and principal financial officer have
          concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.</div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of
          our financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that: (i)
          pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation
          of financial statements in accordance with U.S. generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and Board; and (iii) provide reasonable
          assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">119</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Our management, including our Chief Executive Officer and principal financial officer, recognizes that our internal control over financial reporting cannot prevent or detect
          all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that
          there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that
          misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events,
          and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</div>

        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Management, with the participation of the Chief Executive Officer and principal financial officer, assessed our internal control over financial reporting as of December 31,
          2022, the end of our fiscal year. Management based its assessment on criteria established in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation,
          management has concluded that the Company&#8217;s internal control over financial reporting was effective as of December 31, 2022.</div>

        <div><br />
        </div>

        <div style="font-weight: bold;">Changes in Internal Control over Financial Reporting</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d&#8209;15(f) under the Exchange Act) that occurred during the quarter ended December 31,
          2022 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM9B."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 9B.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">OTHER INFORMATION</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">None.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM9C."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 9C.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">Not applicable.</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">120</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PART III</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">We will file a definitive Proxy Statement for our 2023 Annual Meeting of Stockholders (the &#8220;2023 Proxy Statement&#8221;) with the SEC, pursuant to Regulation 14A, not later than 120 days after the end
          of our fiscal year. Accordingly, certain information required by Part III has been omitted under General Instruction G(3) to Form 10-K. Only those sections of the 2023 Proxy Statement that specifically address the items set forth herein are
          incorporated by reference.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM10."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 10.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The information required by Item 10 is hereby incorporated by reference to the sections of the 2023 Proxy Statement under the captions &#8220;Board and Committee Information&#8221;, &#8220;Delinquent Section 16(a)
          Reports&#8221;, and &#8220;Proposal No. 1 &#8211; Election of Directors,&#8221; &#8220;Executive Officers&#8221;.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM11."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 11.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">EXECUTIVE COMPENSATION</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The information required by Item 11 is hereby incorporated by reference to the sections of the 2023 Proxy Statement under the captions &#8220;Executive Compensation&#8221; and &#8220;Proposal No. 1 &#8211; Election of
          Directors &#8211; Non-Employee Director Compensation.&#8221;</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM12."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 12.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The information required by Item 12 is hereby incorporated by reference to the sections of the 2023 Proxy Statement under the captions &#8220;Security Ownership of Certain Beneficial Owners and
          Management&#8221; and &#8220;Executive Compensation &#8211; Securities Authorized for Issuance under Equity Compensation Plans.&#8221;</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM13."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 13.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The information required by Item 13 is hereby incorporated by reference to the sections of the 2023 Proxy Statement under the captions &#8220;Certain Relationships and Related-Party Transactions&#8221; and
          &#8220;Board and Committee Information.&#8221;</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM14."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 14.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The information required by Item 14 is hereby incorporated by reference to the sections of the 2023 Proxy Statement under the caption &#8220;Proposal No. 2 &#8211; Ratification of Independent Registered
          Public Accounting Firm.&#8221;</div>

        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">121</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <div style="text-align: center; font-weight: bold;">PART IV</div>

        <div>&#160;</div>

        <a id="ITEM15."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">ITEM 15.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div>The following documents are filed as a part of this Annual Report on Form 10-K:</div>

        <div> <br />
        </div>

        <div>
          <div>
            <div>
              <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                      <div style="text-align: left;">(a)</div>
                    </td>

    <td style="vertical-align: top; width: auto;">
                      <div style="text-align: left;">Financial Statements: The financial statements filed as part of this report are listed in Part II, Item 8.</div>
                    </td>

  </tr>


</table>
            </div>

          </div>

        </div>

        <div> <br />
        </div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: left;">(b)</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: left;">Financial Statement Schedules: The schedules are either not applicable or the required information is presented in the consolidated financial statements or notes thereto.</div>
                </td>

  </tr>


</table>
        </div>

        <div><br />
        </div>

        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="vertical-align: top; width: 18pt;">
                  <div style="text-align: left;">(c)</div>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <div style="text-align: left;">Exhibits: The following exhibits are incorporated by reference or filed as part of this Annual Report on Form 10-K:</div>
                </td>

  </tr>


</table>
        </div>

        <div style="text-indent: -40.5pt; margin-left: 76.5pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">EXHIBIT</div>
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">NUMBER</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">DESCRIPTION OF DOCUMENT</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: bottom;">&#160;</td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120014267/ex2_1.htm">2.1+</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Agreement and Plan of Merger, dated as of June 17, 2020, by and among the Registrant, Razor Merger Sub, Inc. and Ocuphire Pharma, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Current
                  Report on Form 8-K, filed on June 19, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015244/nt10013045x2_ex2-1.htm">2.2</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">First Amendment to Agreement and Plan of Merger and Reorganization, dated as of June 29, 2020, by and among Rexahn, Merger Sub and Ocuphire (incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s
                  Current Report on Form 8-K , filed on July 1, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000089383805000094/corpdefm14a.txt">3.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Appendix G to the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A, filed on April 29, 2005).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036117018620/ex3_1.htm">3.2</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on May 5,
                  2017).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036118037339/ex3_1.htm">3.3</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on August 30,
                  2018).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036119006977/ex3_1.htm">3.4</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 12,
                  2019).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120024749/brhc10016678_ex3-1.htm">3.5</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on November 6, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120024749/brhc10016678_ex3-2.htm">3.6</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on November 6, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120024749/brhc10016678_ex3-3.htm">3.7</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant&#8217;s Current Report on Form 8-K, filed on November 6, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036122022593/brhc10038658_ex3-1.htm">3.8</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Amendment to Second Amended and Restated Bylaws of Ocuphire Pharma, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on June 10, 2022).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036122023457/brhc10038830_ex3-1.htm">3.9</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Second Amendment to Second Amended and Restated Bylaws of Ocuphire Pharma, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on June 17, 2022).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036105008759/ex4_3.htm">4.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Specimen Certificate for the Registrant&#8217;s Common Stock, par value $.0001 per share (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-129294),
                  filed on October 28, 2005).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036117038582/ex4_1.htm">4.2</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on October 13, 2017).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036118040906/ex4_1.htm">4.3</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on October 19, 2018).</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">122</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center;"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036119001600/ex4_1.htm">4.4</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on January 25, 2019).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center;"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015244/nt10013045x2_ex4-1.htm">4.5</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Form of Series A/B Warrants (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on July 1, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center;"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/brhc10021462_ex4-11.htm">4.6</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Description of Securities (incorporated by reference to Exhibit 4.11 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 11, 2021).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center;"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121020067/nt10025479x3_ex4-1.htm">4.7</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Form of Warrant to purchase shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K/A, filed on June 7, 2021).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-27.htm">10.1*++</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Amended and Restated Employment Agreement by and among the Company and Mina Sooch, effective as of November 5, 2020 (incorporated by reference to Exhibit 10.27 to the Registrant&#8217;s Registration Statement on
                  Form S-4 (File No. 333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center;"><a href="brhc10050364_ex10-1-1.htm">10.1.1*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">First Amendment to the Amended and Restated Employment Agreement by and among the Company and Mina Sooch, effective as of March 26, 2023.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-29.htm">10.2*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Amended and Restated Employment Agreement by and among the Company and Bernhard Hoffmann, effective as of November 5, 2020 (incorporated by reference to Exhibit 10.29 to the Registrant&#8217;s Registration
                  Statement on Form S-4 (File No. 333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center;"><a href="brhc10050364_ex10-2-1.htm">10.2.1*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">First Amendment to the Amended and Restated Employment Agreement by and among the Company and Bernhard Hoffmann, effective as of March 26,
                    2023.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-30.htm">10.3*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.30 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-31.htm">10.4++</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Sublicense Agreement, dated as of January 21, 2020, by and between Ocuphire Pharma, Inc. and Apexian Pharmaceuticals, Inc (incorporated by reference to Exhibit 10.31 to the Registrant&#8217;s Registration
                  Statement on Form S-4 (File No. 333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-32.htm">10.4.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">First Amendment to Sublicense Agreement, dated as of June 4, 2020, by and between Apexian Pharmaceuticals, Inc. and Ocuphire Pharma, Inc (incorporated by reference to Exhibit 10.32 to the Registrant&#8217;s
                  Registration Statement on Form S-4 (File No. 333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-33.htm">10.5</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Lease Agreement, dated as of May 19, 2019, by and between Ocuphire Pharma, Inc. and Duke &amp; Duke, LP (incorporated by reference to Exhibit 10.33 to the Registrant&#8217;s Registration Statement on Form S-4
                  (File No. 333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-34.htm">10.5.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">First Amendment to Lease Agreement, dated as of October 29, 2019, by and between Ocuphire Pharma, Inc. and Duke &amp; Duke, LP (incorporated by reference to Exhibit 10.34 to the Registrant&#8217;s Registration
                  Statement on Form S-4 (File No. 333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/brhc10021462_ex10-43.htm">10.5.2</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Second Lease Amendment, dated as of November 17, 2020, by and between the Company and Duke &amp; Duke (incorporated by reference to Exhibit 10.43 to the Registrant&#8217;s Annual Report on Form 10-K, filed on
                  March 11, 2021).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121037545/brhc10030460_ex10-1.htm">10.5.3</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Third Lease Amendment, dated as of September 9, 2021, by and between the Company and Duke &amp; Duke (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on
                  November 12, 2021).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036122040029/brhc10043598_ex10-1.htm">10.5.4</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Fourth Lease Amendment, dated as of October 17, 2022, by and between the Company and Duke &amp; Duke (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on
                  November 4, 2022).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-35.htm">10.6*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Ocuphire Pharma, Inc. 2018 Equity Incentive Plan, dated as of April 9, 2018 (incorporated by reference to Exhibit 10.35 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-239702), filed on
                  September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-36.htm">10.6.1*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">First Amendment to 2018 Equity Incentive Plan, dated as of December 23, 2019 (incorporated by reference to Exhibit 10.36 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-239702), filed
                  on September 30, 2020).</div>
              </td>

  </tr>


</table>
        <div> <br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">123</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_ex10-37.htm">10.6.2*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Form of Option Agreement issuable under the Ocuphire Pharma, Inc. 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.37 to the Registrant&#8217;s Registration Statement on Form S-4 (File No.
                  333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/nt10013045x1_s4.htm#tANND">10.7*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.38 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-239702), filed on September 30, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10050364_ex10-7-1.htm">10.7.1*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Form of Restricted Stock Unit Grant Notice issued under the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10050364_ex10-7-2.htm">10.7.2*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Form of Stock Option Grant Notice issued under the Ocuphire Pharma, Inc. 2020 Equity Incentive Plan.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036120024749/brhc10016678_ex10-4.htm">10.8++</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Contingent Value Rights Agreement, dated as of November 5, 2020, by and among the Company, Shareholder Representative Services LLC and the Olde Monmouth Stock Transfer Co., Inc. (incorporated by reference
                  to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K, filed on November 6, 2020).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/brhc10021462_ex10-41.htm">10.9*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Ocuphire Pharma, Inc. 2021 Inducement Plan (incorporated by reference to Exhibit 10.41 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 11, 2021)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10050364_ex10-9-1.htm">10.9.1*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Form of Stock Option Grant Notice issued under the Ocuphire Pharma, Inc. 2021 Inducement Plan</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/brhc10021462_ex10-42.htm">10.10*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Employment Agreement dated November 11, 2020, by and between the Company and Amy Rabourn (incorporated by reference to Exhibit 10.42 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 11, 2021)</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10050364_ex10-10-1.htm">10.10.1*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">First Amendment to the Employment Agreement by and among the Company and Amy Rabourn, effective as of March 26, 2023.</div>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121008130/nt10021594x2_ex1-1.htm">10.11</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Capital on Demand&#8482; Sales Agreement, dated March 11, 2021 between the Company and JonesTrading Institutional Services LLC (incorporated by reference to Exhibit 1.1 to the Registrant&#8217;s Current Report on Form
                  8-K, filed on March 11, 2021).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121020067/nt10025479x3_ex10-1.htm">10.12</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Form of Securities Purchase Agreement, dated as of June 4, 2021, by and among Ocuphire Pharma, Inc. and the purchasers identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 to
                  the Registrant&#8217;s Current Report on Form 8-K/A, filed on June 7, 2021).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121022033/brhc10026111_ex10-1.htm">10.13++</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Processa License Agreement dated June 16, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on June 23, 2021).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036122040303/brhc10043812_ex10-1.htm">10.14++</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Famy License and Collaboration Agreement dated November 6, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on November 7, 2022).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036122019002/brhc10037352_ex10-1.htm">10.15*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Consulting Agreement dated April 8, 2022, by and between the Company and Jay Pepose (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May 13, 2022).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10050364_ex10-15-1.htm">10.15.1*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">First Amendment to the Consulting Agreement dated September 19, 2022, by and between the Company and Jay Pepose.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10050364_ex10-15-2.htm">10.15.2*</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Second Amendment to the Consulting Agreement dated December 1, 2022, by and between the Company and Jay Pepose.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036122029461/brhc10040525_ex10-1.htm">10.16</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Amended and Restated Non-Employee Director Compensation Policy dated July 1, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on August 12, 2022).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="brhc10050364_ex21-1.htm">21.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Subsidiaries of the Registrant.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="brhc10050364_ex23-1.htm">23.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Consent of Ernst &amp; Young, LLP.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">124</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-size: 8pt; font-style: italic; font-weight: normal;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; color: #000000; font-weight: bold;">Form 10-K</div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="brhc10050364_ex31-1.htm">31.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
                  2002.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="brhc10050364_ex31-2.htm">31.2</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as adopted pursuant to section 302 of the Sarbanes-Oxley Act of
                  2002.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 238);"><a href="brhc10050364_ex32-1.htm">32.1</a></div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">&#8203;</div>
              </td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rules 13a-14(b) and 15d-14(b) promulgated under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, as
                  adopted pursuant to section 906 of The Sarbanes-Oxley Act of 2002.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">101.INS</div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">101.SCH</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Schema Document</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">101.CAL</div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">101.DEF</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">101.LAB</div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Label Linkbase Document</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: rgb(0, 0, 0);">101.PRE</div>
              </td>

    <td style="width: 1%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 89%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</div>
              </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">104</div>
              </td>

    <td style="width: 1%; vertical-align: bottom;">&#160;</td>

    <td style="width: 89%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 9pt; vertical-align: top; color: rgb(0, 0, 0);">*</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Indicates management contract or compensatory plan.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 9pt; vertical-align: top; color: rgb(0, 0, 0);">+</td>

    <td style="width: auto; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0);">++ Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.</div>

        <div>&#160;</div>

        <div>
          <a id="ITEM16."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 54pt;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">ITEM 16.</div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt; font-weight: bold;">FORM 10-K SUMMARY</div>
                </td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">None</div>

        <div>&#160;</div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">125</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

          </div>

        </div>

      </div>

    </div>

    <div style="width: 100%;" class="BRPFPageFooter"></div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div>
          <!--Anchor-->
          <div style="font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">OCUPHIRE PHARMA, INC.</div>

          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 72pt; vertical-align: top; align: right; font-weight: bold;">ITEM 8.</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold;">CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</div>
                  </td>

  </tr>


</table>
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>

          <div style="text-align: justify; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor-->INDEX TO FINANCIAL STATEMENTS</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;" class="cfttable">


  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 95.82%;">
                  <div style="margin-left: 18pt;"><a href="#ReportofIndependentRegist">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID: <span style="-sec-ix-hidden:Fact_3ee0ed147ce34c3f88fb4e30185e37c7">42</span>)<br />
                  </div>
                </td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right; width: 4.18%;">127<br />
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 95.82%;">
                  <div style="margin-left: 18pt;"><a href="#BalanceSheets">Balance Sheets</a></div>
                </td>

    <td style="vertical-align: top; text-align: right; width: 4.18%;">129 </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 95.82%;">
                  <div style="margin-left: 18pt;"><a href="#ComprehensiveIncome">Consolidated Statements of Comprehensive Income (Loss)</a></div>
                </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 4.18%;">
                  <div style="text-align: right;">130 </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 95.82%;">
                  <div style="margin-left: 18pt;"><a href="#StockholdersEquity">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</a></div>
                </td>

    <td style="vertical-align: top; text-align: right; width: 4.18%;"> 131 </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 95.82%;">
                  <div style="margin-left: 18pt;"><a href="#CashFlows">Consolidated Statements of Cash Flows</a></div>
                </td>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255); text-align: right; width: 4.18%;"> 132 </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 95.82%;">
                  <div style="margin-left: 18pt;"><a href="#Notes">Notes to Consolidated Financial Statements</a></div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 4.18%;">133<br />
                </td>

  </tr>


</table>
          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">126</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span> </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div>
          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor--><!--Anchor--><a id="ReportofIndependentRegist"><!--Anchor--></a>Report of Independent Registered Public Accounting Firm</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">To the Board of Directors and Stockholders</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire Pharma, Inc.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Opinion on the Financial Statements</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">We have audited the accompanying balance sheets of Ocuphire Pharma, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of
              comprehensive income (loss), changes in stockholders&#8217; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial
              statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each
              of the two years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</div>

          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Basis for Opinion</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We
            are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
            applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
            financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are
            required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such
            opinion.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
            respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
            estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Critical Audit Matter</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the
            audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not
            alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or
            disclosures to which it relates.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">127</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span> </div>

            </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td style="vertical-align: top; padding-left: 9pt;" colspan="1"><br />
                </td>

    <td style="vertical-align: top;">
                  <div style="font-weight: bold;"><span style="font-style: italic;">Measurement of License and Collaboration revenue</span><br />
                  </div>
                  <div>&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-left: 9pt; white-space: nowrap;" colspan="1">
                  <div style="font-style: italic; text-indent: -9pt; margin-left: 9pt; text-align: justify;">Description of the Matter&#160; </div>
                  <span style="font-style: italic;"> </span> </td>

    <td style="vertical-align: top;">
                  <div>As discussed in Notes 1 and 10 to the consolidated financial statements, the Company entered into a license and collaboration agreement on November 6, 2022. The agreement was assessed under the recognition and measurement rules of
                    Accounting Standards Codification 606, Revenue from Contracts with Customers. The Company identified two performance obligations within the arrangement: (i) a license to intellectual property and (ii) research and development services.
                    The license and collaboration agreement transaction price was allocated between the performance obligations based on their relative standalone selling prices, which were estimated using a discounted royalty cash flow approach and an
                    expected cost plus margin approach.&#160; For the year ended December 31, 2022, the Company recognized $39.8 million of revenue related to this agreement.<br />
                  </div>
                  <div> <br />
                  </div>
                  <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Auditing the Company&#8217;s accounting for the license and collaboration agreement was complex due to the judgment used by management to determine the license of
                      intellectual property&#8217;s relative standalone selling price valuation assumptions. These assumptions include, but were not limited to discount rates, future royalty cash flows and development milestones. These assumptions are
                      forward-looking and could be affected by future economic and market conditions.</span> </div>
                  <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <br />
                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: top; padding-left: 9pt;" colspan="1">
                  <div style="font-style: italic;">How we Addressed the<br />
                  </div>
                  <span style="font-style: italic;"> </span> <span style="font-style: italic;"> </span>
                  <div style="font-style: italic;">Matter in Our Audit<br />
                  </div>
                  <span style="font-style: italic;"> </span> </td>

    <td style="vertical-align: top;">
                  <div>To test the measurement of license and collaboration revenue, our audit procedures included, among others, inspecting the license and collaboration agreement, assessing the completeness and accuracy of the Company&#8217;s technical
                    accounting analyses, evaluating the selection of relative standalone selling price valuation methodology and assumptions, and testing the underlying data. For example, we compared the assumption of anticipated future royalty cash flows
                    to current industry, market and economic trends. Our audit procedures also included the involvement of valuation specialist resources to assist in evaluating management&#8217;s valuation methodology and relative standalone selling price
                    calculation.</div>
                </td>

  </tr>


</table>
          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">/s/ <ix:nonNumeric name="dei:AuditorName" id="Fact_696a130351a94d0c8fc587e007153641" contextRef="c20220101to20221231">Ernst &amp; Young LLP</ix:nonNumeric></div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">We have served as the Company&#8217;s auditor since 2018.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:AuditorLocation" id="Fact_e9edf4bd46904db6a113e4c80b4cc25f" contextRef="c20220101to20221231">Detroit, Michigan</ix:nonNumeric><br />
          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">March 30, 2023</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">128</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span> </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div>
          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire Pharma, Inc.</div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor-->
            <!--Anchor--><a id="BalanceSheets"><!--Anchor--></a>Balance Sheets</div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(in thousands, except share amounts and par value)</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; font-weight: bold;">As of December 31,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">2022<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">2021<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Assets</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current assets:</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_4c3cf5caf77f4e5da037fafa8bae1953" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,634</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_40541f5983434d01a3b2f52cdc14f86f" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,534</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;" rowspan="1">
                  <div style="margin: 0px 0px 0px 16.2pt; text-indent: -7.2pt;">Accounts receivable (Note 10)<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_57a15117328a4c2dacdc53aab37087d0" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_0716a84377b3474981c11557857a13fb" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">
                  <div style="margin: 0px 0px 0px 16.2pt; text-indent: -7.2pt;">Contract asset (Note 10) <br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:ContractAssetCurrent" id="Fact_b0ef46df5a694ee582135a7fbdad491b" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,552</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:ContractAssetCurrent" id="Fact_694b873b10be4f5f82e10b6e4424c338" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Prepaids and other current assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_5e7905a52b3b4832ae31148a683a964a" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,453</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_d2af3956605443cab2678029fdf4bbf3" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,314</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Short-term investments</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ShortTermInvestments" id="Fact_4cf2da1d4c7e4d7da5171911bbd8bc1d" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:ShortTermInvestments" id="Fact_225258f3f0d74d729666ccec140c7a71" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total current assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_ee81b576bc25413cb7a62fbc8196321b" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,986</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_184843c3bd824037aa3cec844a19d775" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,067</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Property and equipment, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_cc7a924d5667424f8c959babee79b86e" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_a35d03b264ec4ae9a60ae4f61e0ce03f" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:Assets" id="Fact_597af46d25eb4b8b81eaa8fd6ecd9e53" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,992</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:Assets" id="Fact_70294fb5f79346cdb77d26980a6796e7" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,077</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Liabilities and stockholders&#8217; equity<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current liabilities:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accounts payable</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_d2274ba9bdab4d918c0e31c84c37c9f3" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,069</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_1e3929fc952f4919983d6a68e4de32c2" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,584</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accrued expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_94b6a818ac9d4d15bdbf9a8f7b119fa9" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,684</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_22d5050fa5e14d6b928622028c26edc4" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,733</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Short-term loan</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ShortTermBorrowings" id="Fact_5f805b7af1ae4f3b8fa793fd0bbdaded" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:ShortTermBorrowings" id="Fact_8ccb6c3046ca468f99884ee0d62f86ec" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total current liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_e0b02fb09bd445b28b22c745614224ac" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,753</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_52cf5ce5c64a44358cce16c3e67adcaf" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,855</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrant liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" id="Fact_7468ad245b9749ffbc584a4b9950df1c" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" id="Fact_eb12305b81514f35b6eadb5a5f914bc0" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_de1f3d838d69414180d715025f04a384" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,753</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_57db8be508bc42668c45494a0b9e1284" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,855</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Commitments and contingencies (Note 4 and Note 8)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><span style="-sec-ix-hidden:Fact_43d8906c354b4cf393d97ed8bb0df71f"> </span></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><span style="-sec-ix-hidden:Fact_d61305f9bf5e4fdabd17d17016b342ca"> </span></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Stockholders&#8217; equity<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Preferred stock, par value $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_1d2ec47d13ea44a7a91d3308f3e68ac9" contextRef="c20211231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_a100338abbcc49ac9808b1194f17d508" contextRef="c20221231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span>; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_d12c026eccc34727b9f0a437d54276e4" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_1c2637b74e574bfd8ef7edf8c42dfaa0" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized as of December 31, <span style="text-indent: 0pt;">2022</span> and <span style="text-indent: 0pt;">2021</span>; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_5d43c7f01ac540afb459ef7b0ad68cdb" contextRef="c20211231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_8ced08c698294d6fad90561f1a139828" contextRef="c20221231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_4bc14a08c386400daa81551883f893ed" contextRef="c20211231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_de589a2ecd3c4af58e633ab46624fe88" contextRef="c20221231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at December 31, <span style="text-indent: 0pt;">2022</span>
                      and <span style="text-indent: 0pt;">2021</span>.</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div><span style="color: #000000;"><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_3cfbaa8b6f164362b585c55da7df6050" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div><span style="color: #000000;"><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_968a6b746aeb454c95126e21c8fd8515" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Common stock, par value $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_c797ebe90f1e45a891ead8b192975f2c" contextRef="c20211231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_15c53a0e26bc4275be133d4f38030590" contextRef="c20221231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span>; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_228f30a44e464efab17634dfad95a427" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_f6c07a433dde43c1ae0d8d0e0510c2bd" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized as of December 31, <span style="text-indent: 0pt;">2022</span> and <span style="text-indent: 0pt;">2021</span>; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_1dfc57c6a4fb4846b8c8a70f5769a4f7" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_c49b62bd1ca443c7bc4e72696b36eefd" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,861,315</ix:nonFraction></ix:nonFraction></span> and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_4688bdf4210049f5856926ea9fcf0659" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_8f001feee6364c33be001a9ee96c18dd" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,845,828</ix:nonFraction></ix:nonFraction></span> shares issued
                      and outstanding at December 31, <span style="text-indent: 0pt;">2022</span> and <span style="text-indent: 0pt;">2021</span>, respectively.</div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_3c46c99f58b5447b98d4e12a86cd3bb9" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_d956aa6ee79548e5850f4387da0a4eba" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Additional paid-in capital</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_a573c28abd63414ca51efe97c97c61d5" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,717</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_a8c93ba164a64090803a6d8bc9227a8d" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,588</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accumulated deficit</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_e4072fa9f7d54735b863fae870d041e6" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">71,480</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_8544106db22c4914916307b23dff6050" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,368</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total stockholders&#8217; equity<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_580765c1d14e4dd392c24cca20c380d8" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,239</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_a868d43f52c74a139afc0bb697b2f287" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,222</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Total liabilities and stockholders&#8217; equity<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_972c4be22c8a4d06808d773f2ccd3e80" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,992</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_4cfc4847382a4598bc498bd01c8a0e34" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,077</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

          <div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">See accompanying notes.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">129</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span> </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div>
          <div style="text-align: center; font-style: normal; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire Pharma, Inc.</div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Consolidated
            <!--Anchor-->Statements of
            <!--Anchor--><a id="ComprehensiveIncome"><!--Anchor--></a>Comprehensive Income (Loss)</div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(in thousands, except share and per share amounts)</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

          <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">For the Year Ended</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: #000000; font-weight: bold;">2022<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: #000000; font-weight: bold;">2021<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">License and collaborations revenue<br />
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_aa762ff8a9b94b4cb4f4d9f8b3e6a3d1" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,850</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6f1f052f8b514084b7e854648ad3edec" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">589</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">Operating expenses:</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">General and administrative</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_88875b60153745a5893dda65eac02f2e" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,269</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_2d49c03a9ff440ceac62af29ab2f5fe7" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,121</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Research and development</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_6f8f72ee9c4647d882108f6dccba6192" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,355</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" id="Fact_0b8dd95974684155bc00f9b932cbb901" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,173</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Total operating expenses</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_ad16dfae06a249479c28bb296d71280d" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,624</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_0cd2f16d9e0d4f828159bab89a683278" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,294</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income (loss) from operations</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_a37ee4b0c17f448a9004f7860da879bd" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,226</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_477c33f635ab4a779d30f9655f62787f" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,705</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_ba1eb086ff7b45c98fb86b0903f9b6c0" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_448dd48e63c84a0c9eb589aa5cf678cc" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Fair value change in warrant liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" id="Fact_e5c4220debd34d6db0813184c57261bb" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" id="Fact_c2c391e5f8404371992593b5799d043b" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,829</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other expense, net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_3c0bc2209b35484d972256497df8d235" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">14</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_09cda20bf42c4c6ea9e98918270eb3de" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">157</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income (loss) before income taxes</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_d5b8c87f95d94024b35aeb100b4a7054" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,203</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_eaacc63d939e479b83e6833c660f85df" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56,693</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Provision for income taxes</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_dd84e31c91dd4905810b121100d48b61" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">315</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_905d3b66a0b34365b578d84e34d33161" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ee9ef358b0fe49caa8404ce4fad109a1" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,888</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a3f5f1fa75a140f29cafca5feba95350" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56,693</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other comprehensive income (loss), net of tax</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_0703789e551d4fa9940696d89287b672" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_770020a0fabb4a1180a78c1e4d4fe6b4" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Comprehensive income (loss)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_6625dc0ab4b74dd9aeec15f79a9b66d7" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,888</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_d0578a3fc98c49b8bcc2c049b14b08fe" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56,693</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss) per share (Note 11):</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Basic<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_efe3520d9153418e90a4c01c101ad29b" contextRef="c20220101to20221231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.90</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_30e06911d217456b9c43e0ce6fd9a0c5" contextRef="c20210101to20211231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">3.82</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">Diluted<br />
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_becb3dd27c8b466385a7a728e96360a3" contextRef="c20220101to20221231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.87</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_156ec40b25fe421f833677213b2c60a5" contextRef="c20210101to20211231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">3.82</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Number of shares used in per share calculations:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Basic</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_ee1f2f9338da4da7946981e980d92baa" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,931,080</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_d1751ebb777a4ff1b269979ea50d6eff" contextRef="c20210101to20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,852,745</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">Diluted <br />
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_428950934e0d4f8b886974bf22e627c8" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,597,212</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_56156f5badc240a18d0ae32ca2ccf080" contextRef="c20210101to20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,852,745</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">See accompanying notes.</div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">130</span></div>

            <div class="BRPFPageBreak" style="page-break-after:always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span> </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div>
          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire Pharma, Inc.</div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated Statements of
              <!--Anchor-->Changes in <a id="StockholdersEquity"><!--Anchor--></a>Stockholders&#8217; Equity (Deficit)</div>

          </div>

          <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(in thousands, except share amounts)</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                  <div style="text-align: center; font-weight: bold;">Common Stock</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Additional</div>
                  <div style="text-align: center; font-weight: bold;">Paid&#8211;In</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Accumulated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Total</div>
                  <div style="text-align: center; font-weight: bold;">Stockholders&#8217;</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Amount</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Capital</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Deficit</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Equity</div>
                  <div style="text-align: center; font-weight: bold;">(Deficit)</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Balance at December 31, <span style="text-indent: 0pt;">2020</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_a957f37183ae4fb2937b44963997d1db" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,882,495</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">$ <br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_659d8efc7709442e90b10de0faffbb85" contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">$ <br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_dd2fafd698fc4ad899e23710386697ff" contextRef="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,207</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">$ <br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0c523b2030024fceb1cf82a1bf7147b8" contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32,675</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">$ <br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8781ed68629042f58942debfd4af43bc" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,467</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">Reclassification of Series A warrant liability to equity<br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" id="Fact_0c2eb6bb5af54cce8dc19945c3983ef2" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" id="Fact_9712668b20964321872219e8ca3b0ada" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,793</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" id="Fact_c2ab2761c8084e6ba4a40ca92140bd5f" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" id="Fact_b8673f7d797f41f69b95c789b4699a6d" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,793</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of common stock and warrants in connection with registered direct offering<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" id="Fact_1f533885deec4acb9eb6add4ebfda68c" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,076,923</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" id="Fact_b904ac6c76d541dcb07173c2066718fa" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" id="Fact_7c4f035f382840d0a210b09b5e95c8be" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,999</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" id="Fact_d85cdaebe012448d9b9412373d9629f6" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" id="Fact_8c6a3bcc031d4878bb47795d4f3b0009" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of common stock in connection with the at-the-market program<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodSharesAtTheMarketProgram" id="Fact_69e0d3ab2fba489b95e8c25cd615ee7c" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,778,890</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueAtTheMarketProgram" id="Fact_56df9cb157a340b0886968b5e1442a42" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueAtTheMarketProgram" id="Fact_9a857e87370e4b8b8d2c996c1c2b6b8d" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,491</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueAtTheMarketProgram" id="Fact_613b7797b3e9420797f5bcbff3331138" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueAtTheMarketProgram" id="Fact_d553dca2d7fa45e7bb2be821e46ea6db" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,491</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of common stock in connection with settlement with investors<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodSharesInSettlementWithInvestors" id="Fact_5ae3f8aa7b49432f95a1ec7ef61eef01" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">350,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors" id="Fact_d2bb7d75171c46619a335c5db0c94c0d" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors" id="Fact_c0676eef05a243738e1de3c57e756f18" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,614</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors" id="Fact_4a09e49eb3394b11baac1e76fdbb5143" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors" id="Fact_677c7236f1cf4fa89211090766ed838f" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,614</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">Issuance costs<br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="Fact_fef84335ab9b4120b4977a996076d04f" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="Fact_35d3548289734c339420ccaee2963311" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,517</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="Fact_e3df0db3ab0549929a073f5c5e1f120b" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="Fact_598dd949c65643eca823e2a4b3c04377" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,517</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);" rowspan="1">Exercise of Series B warrants<br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodSharesExerciseOfWarrants" id="Fact_4133f520a760474183cf9cf92291217c" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,629,634</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="Fact_d9a94f7cf164428c99a895d45ff56dfa" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="Fact_1ecae6997aae4f4dbdbbfa5df55609fc" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="Fact_5182726086e543dcbeb5efe666cd7da3" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="Fact_1df0253c1a2a4020b66051c22768a646" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">Stock-based compensation<br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_fae42f7588d1410b92e659fdc54065f1" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">54,444</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_fee17e26df0c48288eff3130e43cb09e" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_066ba84bc0ad4fab99974c4f801dc7fc" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,914</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_291d02c779464b0ebccf6defe3d78db1" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_cb12aac59b4c40538113ddc97231b885" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,914</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);" rowspan="1">Exercise of stock options<br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_e0b7b8e60aad4fb29007dea33274dbef" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">73,442</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_a59f043a3b314be69e2ab19c47e95251" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_80179f40af8c42f696b3a4de99e19e16" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_b67ce146dfc24c55a9f1f76b7658fc63" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_828c6e17576f47ee9e664cbbb2001903" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;" rowspan="1">Net and comprehensive loss<br />
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a0d133d2e6374c82b891a9e089e0de66" contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_382c78240c474e79a10419f590ae6f5a" contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_479fd01b11e4404fbd59186ed9716c53" contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56,693</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_471baea161fa40ffb6c951469f25f9e6" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56,693</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);" rowspan="1">Balance at December 31, 2021</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_3368e74a578e4737a1a8f61ca862e789" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,845,828</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_74896f5a7790468fbf4023ec55176e73" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c766083c36c34ceb852f08fe1779522c" contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,588</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_705d2c3bc292482f9b6839003bf818ea" contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,368</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><br />
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c04b49edbcb241dab212d41b15bbbd1e" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,222</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Issuance of common stock in connection with the at-the-market program <br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodSharesAtTheMarketProgram" id="Fact_8ab18d98ae4341fa8b0d85c87f470761" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,848,980</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueAtTheMarketProgram" id="Fact_8535c33354e74ec3baaaa5e828612697" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueAtTheMarketProgram" id="Fact_6811a09f89ed4db486d0af5d83497640" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,428</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueAtTheMarketProgram" id="Fact_51df469e64bb4a67b4e79a78cd53077f" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueAtTheMarketProgram" id="Fact_481666e696ca40a9b1f1ae49db30c2ac" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,428</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Issuance costs <br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="Fact_c9cbb17d7b0d4d3990d67fdc3650ede9" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="Fact_e49ea9cd80c4498d97f2d57a3a26b1f5" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">133</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="Fact_566b38c47f0f434abb5b3172ebc07f48" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="Fact_bc1df6eb5ff243579028deecc37115fe" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">133</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Exercise of Series B warrants <br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodSharesExerciseOfWarrants" id="Fact_120e2a58b45b4334b4bf61b3247f857c" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,832</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="Fact_8df28b1279ee451a9fdc5473f208eccb" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="Fact_7679066f8cea4c3aad281ec09b31b4de" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="Fact_d34b45ccda3d458293ea3d817957f80b" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="Fact_d91ad72c7ca845288eb1a7a9d692a353" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Stock-based compensation <br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_2d2215d9ba224da9949403c1c3931c09" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">81,366</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_52e6a89e42c24a97ba829fa9c62bedf8" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_727bba064a304576a5d1f33822e600de" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,807</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_5bb97720b27c4067afeac13ddae19ec5" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_e96e7b715500478f88ff5d9670dbe07c" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,807</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Exercise of stock options <br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_43a7e156e7f146f79fa12bae756ec681" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,309</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_d083c10acb2f49c1b4b9bca338589782" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_43089e12c9b2444c9e519cc1953879ce" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_548f552b407745d08260e91044da32f1" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_0adcd247b9d74f23a744adfb553e1739" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Net and comprehensive income<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#8212;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f1944e245d934e6b91b1041030b92f60" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e14d8f45b324488fa33f2188bfb10a39" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_aef221e09dbb436e9f04c226a24ee3bd" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,888</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_af7fde185b14426aa6b25bc7e96787a0" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,888</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Balance at December 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_45d847830db24a21a10fe9cd1491cc17" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,861,315</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c5105cef0fab421c98500c1a5bd07eff" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b35edda9be8a440a81908b78cb0b13ff" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,717</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_cf8ffff7302d4a8885f8edfbd75ddcdd" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">71,480</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_ac8e7843f1e64ed3a3c8f6bc2050bb5a" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,239</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">See accompanying notes.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">131</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span> </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div>
          <div>
            <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire Pharma, Inc.</div>

            <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Consolidated
              <!--Anchor-->Statements of
              <!--Anchor--><a id="CashFlows"><!--Anchor--></a>Cash Flows</div>

            <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">(in thousands)</div>

          </div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
          </div>

          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
                    <div style="color: rgb(0, 0, 0); font-weight: bold;">For the Year Ended</div>
                    <div>December 31,</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Operating activities</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_3b79b566744c43fe82297a3134031f10" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,888</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_742bf4f5096f480ea1311fe7783d9968" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56,693</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_5d9368a01ffb48fe9d177a7ea3974f49" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,807</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_9730e9f4fd8047bdb07ada47ccc2e60e" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,914</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Depreciation</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_f1824d084b814e80ada01bc0890fa34b" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_f8f93eaa7385408aacd4d93d8e1344a6" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Fair value change in warrant liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" id="Fact_0aa17d4f0ae74292ac51273f267fc3d2" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" id="Fact_05c54a465d404d13b73bf16af55b95b2" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,829</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">
                  <div style="margin-left: 9pt;">Non-cash share settlement with investors</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="ocup:ShareSettlementWithInvestors" id="Fact_b9967463e6274ea2a3571d02902d1764" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="ocup:ShareSettlementWithInvestors" id="Fact_eab57389ba0e49ba8636793407f762e3" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,614</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="margin-left: 9pt;">Receipt of investments related to license agreement<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="ocup:IncomeLossFromInvestmentsRelatedToLicenseAgreement" id="Fact_f4ad1cd66c6b40fb89b9c862eb83c59d" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="ocup:IncomeLossFromInvestmentsRelatedToLicenseAgreement" id="Fact_ed85664d9e8a42e4ba112e38b81943f0" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">289</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">
                  <div style="margin-left: 9pt;">Unrealized loss from short-term investments<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_f3aa0250ee324b9c96e4bfe4c8953ca7" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">170</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_d08ce584a7574152a2b7e6423db9d793" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">70</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0);">Change in assets and liabilities:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">
                  <div style="margin: 0px 0px 0px 16.2pt; text-indent: -7.2pt;">Accounts receivable <br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_e2ae4a783e004109b41e913f574aa12f" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_e5bce0d9edf9465fb05db5c6ea5f1d87" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="margin: 0px 0px 0px 16.2pt; text-indent: -7.2pt;">Contract asset <br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="ocup:IncreaseDecreaseInContractAssetCurrent" id="Fact_ff299707451942c98bb865bf1e9a1348" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,552</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="ocup:IncreaseDecreaseInContractAssetCurrent" id="Fact_81cbaf51cb3340aa949c15f7806db84c" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="margin: 0px 0px 0px 16.2pt; color: #000000; text-indent: -7.2pt;">Prepaid expenses and other assets</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_3c01a1ee899148c8be138f9996f61e82" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">139</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_08d54f2a6b9d462a85a877dd26f6acd3" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                  <div style="margin: 0px 0px 0px 16.2pt; color: #000000; font-size: 10pt; text-indent: -7.2pt;">Accounts payable</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_53463c5f5b8b4f40bddc90b32f13cbcc" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">515</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_594e47798b61457e8bd32880954838e6" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">381</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                    <div style="margin: 0px 0px 0px 16.2pt; text-align: left; text-indent: -7.2pt;">Accrued expenses</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_11076cee8b2f4ff68fad244babb9cd9f" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">51</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_676802fb30a14660bfea1fbd54e4dd73" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">155</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net cash provided by (used in) operating activities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_2f8601085ccb4b28942f37ac60a053c9" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,314</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_6a55622e63c940f2aec8b68b7e2d7310" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,370</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Investing activities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Transaction costs in connection with asset acquisition</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:OtherPaymentsToAcquireBusinesses" id="Fact_9abfa638e1bc4abf859e4f7747947f5b" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:OtherPaymentsToAcquireBusinesses" id="Fact_82fcfa3dd255434f821ec24a42dd4e77" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">100</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
                    <div style="text-align: left;">Net cash used in investing activities</div>
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_e4db1d225f824fba944b6f450c52d03b" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_7356182db3504d18b927caf603625e03" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Financing activities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">Proceeds from issuance of common stock<br />
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_fe490e89baef4154ba477e2f54e71324" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,428</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_f50fa4afdad844faaaa438b592a17d32" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,491</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Issuance costs attributed to common stock<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_4ebb6cbaf999487fbd288f878eb69b74" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">131</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_eef91258db4843f9955c85ffada390a7" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,511</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">Proceeds from short-term loan<br />
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" id="Fact_b41441e399ff4813a9c8269dc3335d7b" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" id="Fact_aefead4f7c8e48d9ad9dfc96590a8f23" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">646</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">Payments made on short-term loan principal<br />
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" id="Fact_5e7ae98f346b4b09bd2afc35238fc0df" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" id="Fact_d21492fe5be34fea831466056a114700" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">108</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Exercise of stock options and Series B warrants<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_086d8f3875a14160a7c1c0a1a5a83cb3" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_94cafed9cace4acd9fb55e48ff4511ce" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net cash provided by financing activities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_e8775b72d8624bea83f1eae4e5a17c1c" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,786</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_bf013c471c9f4f6d9559b77f1a1e5a29" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,605</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net increase in cash and cash equivalents</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_a356e64535234f8eb1c79a3ea727a6a2" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,100</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_a18fcae02d064c4dab4975bb7fbd8cdd" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,135</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cash and cash equivalents at beginning of period</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_adde8b87fee74852b253ac4699402925" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,534</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_9948fb31d65740d899c6bf9928176183" contextRef="c20201231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,399</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cash and cash equivalents at end of period</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_a292aad77a4e4979b5cd5efea22c70f8" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,634</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_c46937c7dc164b3a8c8a77ead0b9a133" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,534</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-style: italic;">Supplemental disclosure of cash flow information:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cash paid for income taxes</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_f7fd891789a14091ae226c54ee8d8a6b" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_8c4f8f25ea234a8b87625f23aeeae385" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cash paid for interest</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_bc380c3dcaa44a17bbe00eba8cbbed4c" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_ff7c209c80a74190bc4d70356da77db5" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-style: italic;">Supplemental non-cash financing transactions:</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">Non-cash reclassification of Series A warrant liability to equity<br />
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="ocup:NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" id="Fact_0f125608860f469a9d3745310fc16f9d" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="ocup:NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" id="Fact_febc298c265a48fe94f4af95ff90380c" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,793</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Unpaid issuance costs</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" id="Fact_feab414b85614da59a32ce49b5c0fc38" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: #000000;"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" id="Fact_88581b1e5084408da256da35f8adfb9e" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
          <div style="text-align: justify; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>

          <div style="text-align: justify; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">See accompanying notes.</div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">132</span></div>

            <div class="BRPFPageBreak" style="page-break-after:always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span> </div>

            </div>

          </div>

        </div>

      </div>

    </div>

    <div>
      <!--PROfilePageNumberReset%Num%141%%%--> </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

        <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor--><!--Anchor--><a id="Notes"><!--Anchor--></a>Notes to Consolidated Financial Statements</div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>


        <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Text_f1dbbe8dce714ee3a93360c4ebafcce6" contextRef="c20220101to20221231" escape="true" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b1">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">1.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Company Description and Summary of Significant Accounting Policies</div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b1" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b2" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b3"><ix:nonNumeric name="ocup:NatureOfBusinessPolicyTextBlock" id="Text_6d1ba289d8b34393abc8b1d726be1ad8" contextRef="c20220101to20221231" escape="true" continuedAt="Text_137032662d66403b940da414c9e437f31">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Nature of Business</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b3" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b4"><ix:continuation id="Text_137032662d66403b940da414c9e437f31" continuedAt="Text_137032662d66403b940da414c9e437f32">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b4" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b5"><ix:continuation id="Text_137032662d66403b940da414c9e437f32" continuedAt="Text_137032662d66403b940da414c9e437f33">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Ocuphire Pharma, Inc. (the &#8220;Company&#8221; or &#8220;Ocuphire&#8221;) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and
            retinal eye disorders. Ocuphire&#8217;s pipeline currently includes <ix:nonFraction name="ocup:NumberOfSmallMoleculeProductCandidates" id="Fact_862459d95c0d48e8965af036cdd7e08f" contextRef="c20220101to20221231" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> small molecule product candidates targeting several of such
            indications.</span><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b5" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b6"><ix:continuation id="Text_137032662d66403b940da414c9e437f33" continuedAt="Text_137032662d66403b940da414c9e437f34">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b6" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b7"><ix:continuation id="Text_137032662d66403b940da414c9e437f34" continuedAt="Text_137032662d66403b940da414c9e437f35">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2022, the Company entered into a license and collaboration agreement (the &#8220;Nyxol License Agreement&#8221;) with FamyGen Life Sciences, Inc. (acquired by Viatris, Inc. (&#8220;Viatris&#8221;) in January
            2023) pursuant to which it granted Viatris an exclusive license to develop, manufacture, import, export and commercialize its product candidate phentolamine ophthalmic solution 0.75% (Nyxol&#174; Eye Drops or &#8220;Nyxol&#8221;). Nyxol is a once-daily eye drop
            formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically-induced mydriasis (&#8220;RM&#8221;) (dilation of the pupil),
            presbyopia (age-related blurry near vision) and dim light or night vision disturbances (&#8220;DLD&#8221;) (halos, glares and starbursts).</span><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b7" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b8"><ix:continuation id="Text_137032662d66403b940da414c9e437f35" continuedAt="Text_137032662d66403b940da414c9e437f36">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b8" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b9"><ix:continuation id="Text_137032662d66403b940da414c9e437f36" continuedAt="Text_137032662d66403b940da414c9e437f37">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company&#8217;s second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as
            diabetic retinopathy (&#8220;DR&#8221;) and diabetic macular edema (&#8220;DME&#8221;) which, if left untreated, can result in permanent visual acuity loss and eventual blindness. The Company has also in-licensed APX2009 and APX2014, which are second-generation
            product candidates and analogs of APX3330.</span><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b9" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b10"><ix:continuation id="Text_137032662d66403b940da414c9e437f37" continuedAt="Text_137032662d66403b940da414c9e437f38">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b10" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b11"><ix:continuation id="Text_137032662d66403b940da414c9e437f38">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">License and collaborations revenue to date was derived from a one-time non-refundable payment and reimbursement of expenses earned under the Nyxol License Agreement, and to a much lesser degree, from
            license agreements with BioSense Global LLC (&#8220;BioSense&#8221;) and Processa Pharmaceuticals, Inc. (&#8220;Processa&#8221;) in connection with the Rexahn RX-3117 drug compound. The Company anticipates that it will recognize revenue as it earns reimbursement for
            research and development services in connection with the Nyxol License Agreement and it may earn additional revenues from future potential milestone and royalty payments from the agreements with Viatris, BioSense, Processa, or from other
            license agreements entered into the future; however, the attainment of milestones or level of sales required to earn royalty payments is highly uncertain. Outside of the license and collaborations revenue, the Company does not expect to
            generate significant revenue unless or until regulatory approval is obtained and commercialization begins for Nyxol or APX3330. Management plans to continue financing the Company&#8217;s operations primarily through additional issuances of the
            Company&#8217;s equity and debt securities or through collaborations or partnerships with other companies. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and
            development programs.</span><br />
        </div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b11" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b12">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br />
        </div>
</ix:continuation>
        <div style="text-align: justify;">
          <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
            <div style="text-align: justify;">
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b12" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b13"><ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" id="Text_c197bba8ef4e40fa84dd0c66435a6e6e" contextRef="c20220101to20221231" escape="true" continuedAt="Text_385a9abe68a642758c41fa975a14d71c1">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: italic; font-weight: bold;">Reverse Merger with Rexahn</div>
</ix:nonNumeric></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b13" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b14"><ix:continuation id="Text_385a9abe68a642758c41fa975a14d71c1" continuedAt="Text_385a9abe68a642758c41fa975a14d71c2">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-style: normal;"><br class="Apple-interchange-newline" />
                </span></span></div>
</ix:continuation></ix:continuation></div>

            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b14" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b15"><ix:continuation id="Text_385a9abe68a642758c41fa975a14d71c2" continuedAt="Text_385a9abe68a642758c41fa975a14d71c3">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-style: normal;"> </span> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b15" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b16"><ix:continuation id="Text_385a9abe68a642758c41fa975a14d71c3" continuedAt="Text_385a9abe68a642758c41fa975a14d71c4">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;">&#160;On June 17, 2020, Ocuphire, Rexahn
                Pharmaceuticals, Inc. (&#8220;Rexahn&#8221;), Razor Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rexahn (&#8220;Merger Sub&#8221;), entered into an Agreement and Plan of Merger and Reorganization, as amended on June 29, 2020 (as amended,
                the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub would merge with and into Ocuphire, with Ocuphire continuing as a
                wholly-owned subsidiary of Rexahn and the surviving corporation of the merger (the &#8220;Merger&#8221;). The Merger closed on November 5, 2020. Upon completion of the Merger, Rexahn changed its name to Ocuphire Pharma, Inc. and changed its ticker
                symbol on the Nasdaq Capital Market to &#8220;OCUP&#8221;.</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b16" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b17"><ix:continuation id="Text_385a9abe68a642758c41fa975a14d71c4" continuedAt="Text_385a9abe68a642758c41fa975a14d71c5">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b17" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b18"><ix:continuation id="Text_385a9abe68a642758c41fa975a14d71c5" continuedAt="Text_385a9abe68a642758c41fa975a14d71c6">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b18" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b19"><ix:continuation id="Text_385a9abe68a642758c41fa975a14d71c6" continuedAt="Text_385a9abe68a642758c41fa975a14d71c7">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b19" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b20"><ix:continuation id="Text_385a9abe68a642758c41fa975a14d71c7" continuedAt="Text_385a9abe68a642758c41fa975a14d71c8">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b20" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b21"><ix:continuation id="Text_385a9abe68a642758c41fa975a14d71c8">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">The Company&#8217;s headquarters is located in Farmington Hills, Michigan.</div>
</ix:continuation></ix:continuation>

            </div>

          </div>

        </div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b21" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b22">
<div>&#160;
          </div>
</ix:continuation>
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">133</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of
                    Contents</a></span></div>

              <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

              </div>

            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">
          <div>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b22" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b23">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Global Economic Conditions</div>
</ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b23" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b24">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b24" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b25">
<div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Generally, worldwide economic conditions remain uncertain, particularly due to the effects of th<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">e COVID&#8209;</span></span><span style="background-color: rgb(255, 255, 255); font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">19</span><span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> pande</span>mic and increased
              inflation. The general economic and capital market conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company&#8217;s access to capital and increased the cost of capital. The capital
              and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, the Company&#8217;s future cost of equity or debt capital and access to the capital markets could be adversely
              affected.</span></div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b25" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b26">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b26" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b27">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The COVID-19 pandemic that began in late 2019 introduced significant volatility to the global
                economy, disrupted supply chains and had a widespread adverse effect on the financial markets.&#160;As a result of the COVID-19 pandemic, the Company has experienced, and may continue to experience, delays and disruptions in our clinical trials,
                as well as interruptions in our manufacturing, supply chain, shipping and research and development operations.&#160; Testing and clinical trials, manufacturing, component supply, shipping and research and development operations may be further
                impacted by the continuing effects of COVID-19.</span></div>
</ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b27" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b28">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b28" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b29">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Additionally, the Company&#8217;s operating results could be materially impacted by changes in the
                overall macroeconomic environment and other economic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflict in Ukraine, and steps taken by governments and central banks,
                particularly in response to the COVID-</span>19<span style="font-size: 10pt; font-family: 'Times New Roman';"> pandemic as well as other stimulus and spending programs, have led to higher inflation, which has led to an increase in costs and
                has caused changes in fiscal and monetary policy, including increased interest rates.</span></div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b29" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b30">
<div><br /></div>
</ix:continuation>
        </div>


        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b30" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b31"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_c7feab1b45df4f7c99239758858b20cb" contextRef="c20220101to20221231" escape="true" continuedAt="Text_6c5e5290f68f4b26a9cd325f9e1cec701">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Basis of Presentation</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b31" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b32"><ix:continuation id="Text_6c5e5290f68f4b26a9cd325f9e1cec701" continuedAt="Text_6c5e5290f68f4b26a9cd325f9e1cec702">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b32" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b33"><ix:continuation id="Text_6c5e5290f68f4b26a9cd325f9e1cec702" continuedAt="Text_6c5e5290f68f4b26a9cd325f9e1cec703">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America (&#8220;GAAP&#8221;). <br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b33" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b34"><ix:continuation id="Text_6c5e5290f68f4b26a9cd325f9e1cec703" continuedAt="Text_6c5e5290f68f4b26a9cd325f9e1cec704">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b34" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b35"><ix:continuation id="Text_6c5e5290f68f4b26a9cd325f9e1cec704">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';">On December 31, 2021, the Company merged its wholly owned subsidiary, OcuSub Inc, with and into the Company, with
            the Company remaining as the surviving entity. The merger of the Company&#8217;s wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of this merger, the Company did not have any remaining entities that
            required consolidation for financial statement reporting purposes.</div>
</ix:continuation></ix:continuation>
        </div>


        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b35" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b36">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b36" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b37"><ix:nonNumeric name="ocup:LiquidityPolicyTextBlock" id="Text_0863595062114c5a8383dcd4cd55e0bf" contextRef="c20220101to20221231" escape="true" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b01">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Liquidity</div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b37" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b38"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b01" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b02">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></div>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b38" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b39"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b02" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b03">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b39" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b40"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b03" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b04">
<div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b40" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b41"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b04" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b05">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b41" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b42"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b05" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b06">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b42" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b43"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b06" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b07">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;">The accompanying consolidated financial statements have
            been prepared on the basis that the Company will continue as a going concern. From its inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting clinical trials.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b43" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b44"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b07" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b08">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation></ix:continuation>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;">
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b44" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b45"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b08" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b09">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"><span style="font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company entered into the Nyxol License Agreement, and the</span> Company received a $<ix:nonFraction name="ocup:NonRefundableUpfrontPaymentReceived" id="Fact_c2b4b20e75494bb0a9977fd77aaa76c5" contextRef="c20221101to20221130_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction> million <span style="font-size: 10pt; font-weight: normal; font-style: normal;">one-time </span> non-refundable payment in November 2022, and commitment from
                Viatris to reimburse budgeted development costs for Nyxol. See Note 10 &#8211; License and Collaboration Agreements for additional information related to the Nyxol License Agreement. Management believes that the Company, as a result of this cash
                payment receipt, has adequate liquidity to meet obligations as they come due without raising additional funds for at least twelve months from the date of issuance of these financial statements. As of December 31, 2022, the Company had $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_f990d52bc044431b92b62a8844c5244c" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">42.6</ix:nonFraction> million in cash and cash equivalents.</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b45" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b46"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b09" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b010">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b46" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b47"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b010" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b011">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"> <br />
              </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b47" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b48"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b011" continuedAt="Text_fbfe87a6e83846f88590fa8c56b1d9b012">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b48" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b49"><ix:continuation id="Text_fbfe87a6e83846f88590fa8c56b1d9b012">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"> <span style="font-weight: normal; font-size: 10pt; font-style: normal;">In the future, the Company may need to raise additional funds until it is able to generate sufficient revenues to fund its development activities. The Company&#8217;s future
                  operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to
                  predict the ultimate outcome of these actions to generate the liquidity ultimately required.</span></span></div>
</ix:continuation></ix:continuation>
          </div>
<ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b49" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b50">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span>
          </div>
</ix:continuation> </div>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b50" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b51">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b51" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b52"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_d631c76888554c638da934f5c3017694" contextRef="c20220101to20221231" escape="true" continuedAt="Text_63857001a48a4fa293407cb37c51c85f1">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Use of Estimates</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b52" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b53"><ix:continuation id="Text_63857001a48a4fa293407cb37c51c85f1" continuedAt="Text_63857001a48a4fa293407cb37c51c85f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b53" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b54"><ix:continuation id="Text_63857001a48a4fa293407cb37c51c85f2">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported
          in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div>
</ix:continuation></ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b54" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b55">
<div>&#160;
          </div>
</ix:continuation>
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">134</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of
                    Contents</a></span></div>

              <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

              </div>

            </div>

          </div>

        </div>


        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b55" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b56"><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Text_fc20d4026e33408c9d950b2383011b29" contextRef="c20220101to20221231" escape="true" continuedAt="Text_d5d407c57766444eb523fd4bc2932c771">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Segment Information</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b56" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b57"><ix:continuation id="Text_d5d407c57766444eb523fd4bc2932c771" continuedAt="Text_d5d407c57766444eb523fd4bc2932c772">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b57" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b58"><ix:continuation id="Text_d5d407c57766444eb523fd4bc2932c772">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating
          decision maker in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its
          business in <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_9cc1957144d84e2cbb5feb374cf4c7b8" contextRef="c20220101to20221231" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment, which is the business of development and commercialization of products related to vision
          performance and health. Accordingly, the Company has a single reporting segment.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b58" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b59">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b59" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b60"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_fffa5701510144218e097a4d10b4df8b" contextRef="c20220101to20221231" escape="true" continuedAt="Text_0a78d4ffaac84f808538e587e73c12f31">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Cash and Cash Equivalents</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b60" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b61"><ix:continuation id="Text_0a78d4ffaac84f808538e587e73c12f31" continuedAt="Text_0a78d4ffaac84f808538e587e73c12f32">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b61" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b62"><ix:continuation id="Text_0a78d4ffaac84f808538e587e73c12f32">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of deposit to be cash equivalents.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b62" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b63">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b63" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b64"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="Text_5caaf684a68345f99084758bbe2b7437" contextRef="c20220101to20221231" escape="true" continuedAt="Text_9e108b32250f47e297244791752016311">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Concentration of Credit Risk</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b64" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b65"><ix:continuation id="Text_9e108b32250f47e297244791752016311" continuedAt="Text_9e108b32250f47e297244791752016312">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b65" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b66"><ix:continuation id="Text_9e108b32250f47e297244791752016312" continuedAt="Text_9e108b32250f47e297244791752016313">
<div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b66" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b67"><ix:continuation id="Text_9e108b32250f47e297244791752016313" continuedAt="Text_9e108b32250f47e297244791752016314">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
        <div style="text-align: justify;"><ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b67" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b68"><ix:continuation id="Text_9e108b32250f47e297244791752016314" continuedAt="Text_9e108b32250f47e297244791752016315">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <div><ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b68" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b69"><ix:continuation id="Text_9e108b32250f47e297244791752016315" continuedAt="Text_9e108b32250f47e297244791752016316">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b69" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b70"><ix:continuation id="Text_9e108b32250f47e297244791752016316" continuedAt="Text_9e108b32250f47e297244791752016317">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b70" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b71"><ix:continuation id="Text_9e108b32250f47e297244791752016317">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Financial instruments that potentially subject the
                Company to a concentration of credit risk consist of cash and cash equivalents. As of December 31, 2022, the Company&#8217;s cash was held by two large financial institutions in the United States. Amounts on deposit may at times exceed federally
                insured limits. As of December 31, 2022, the Company had deposits that exceeded federally insured amounts by approximately $<ix:nonFraction name="us-gaap:CashUninsuredAmount" id="Fact_00e55f2329be47c29c2f6675985657cc" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">42.1</ix:nonFraction>
                million.</div>
</ix:continuation></ix:continuation>
            </div>


            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b71" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b72">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b72" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b73"><ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" id="Text_617e973009fd4c2ebcc2315c407db08d" contextRef="c20220101to20221231" escape="true" continuedAt="Text_3862483395a14ab6b89486b253d2f3541">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Short-term Investments<br />
              </div>
</ix:nonNumeric></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b73" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b74"><ix:continuation id="Text_3862483395a14ab6b89486b253d2f3541" continuedAt="Text_3862483395a14ab6b89486b253d2f3542">
<div style="font-family: 'Times New Roman';"><br />
              </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b74" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b75"><ix:continuation id="Text_3862483395a14ab6b89486b253d2f3542">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and are recorded on a settlement
                date basis. The Company&#8217;s investments are comprised of equity securities, which in accordance with the fair value hierarchy described below are recorded at fair value using Level l inputs on the balance sheets.&#160; Subsequent changes in fair
                values are recorded in other expense, net on the&#160; consolidated statements of comprehensive income (loss). The Company classifies investments available to fund current operations as current assets on its balance sheets. The Company did <ix:nonFraction name="us-gaap:ImpairmentOfInvestments" id="Fact_6126547c55914aae8de3ed7102a999e6" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize any impairments on its investments to date through December 31, 2022.</div>
</ix:continuation></ix:continuation>

            </div>

            <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b75" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b76">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br />
              </span></div>
</ix:continuation>
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b76" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b77"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Text_38ef849f5ae24df4afc422e341c81547" contextRef="c20220101to20221231" escape="true" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799521">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue Recognition</div>
</ix:nonNumeric></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b77" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b78"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799521" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799522">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b78" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b79"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799522" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799523">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company follows the provisions of&#160;Accounting Standards Codification (&#8220;ASC&#8221;) 606,&#160;</span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Revenue from Contracts with Customers</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">. The guidance provides a five-step model to determine
                  how revenue is recognized. The Company has entered into license agreements which have revenue recognition implications (See Note 10 &#8211; License and Collaboration Agreements).</span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b79" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b80"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799523" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799524">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b80" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b81"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799524" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799525">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the contracts with a
                customer; (ii) determination of the performance obligations in the contract; (iii) measurement of the transaction price, including potential constraints on variable consideration; (iv) allocation of the transaction price to the performance
                obligations based on estimated stand-alone selling prices; and (v) recognition of revenue when (or as) the Company satisfies a performance obligation.</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b81" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b82"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799525" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799526">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b82" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b83"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799526" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799527">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to
                  the customer and is the unit of account in ASC 606. Performance obligations may include license rights, development and other services. Significant management judgment is required to determine the level of effort required under an
                  arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become
                  inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b83" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b84"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799527" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799528">
<div style="font-family: 'Times New Roman';"><br />
              </div>
</ix:continuation></ix:continuation>
              <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                <div style="width: 100%;" class="BRPFPageFooter"></div>

                <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">135</span></div>

                <div class="BRPFPageBreak" style="page-break-after: always;">
                  <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);" /></div>

                <div style="width: 100%;" class="BRPFPageHeader">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of
                        Contents</a></span></div>

                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

                  </div>

                </div>

              </div>

              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b84" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b85"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799528" continuedAt="Text_b4b6a8beff6d492c9ce0e02da44799529">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each
                performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount
                rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the relative standalone selling prices of the promised goods or service underlying each
                performance obligation.</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b85" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b86"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da44799529" continuedAt="Text_b4b6a8beff6d492c9ce0e02da447995210">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b86" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b87"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da447995210" continuedAt="Text_b4b6a8beff6d492c9ce0e02da447995211">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Licenses of intellectual property and research and development services:</span> If the license to the Company&#8217;s intellectual
                property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the
                customer, and the customer can use and benefit from the license. For licenses that are bundled with other obligations, such as research and development services, the Company utilizes judgment to assess the nature of the combined performance
                obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable,
                up-front fees. For research and development services that are distinct from a license transfer obligation, the Company determines whether the services are satisfied over time or at a point in time and, if over time, the appropriate method
                of measuring progress for purposes of recognizing revenue from such services. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b87" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b88"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da447995211" continuedAt="Text_b4b6a8beff6d492c9ce0e02da447995212">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b88" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b89"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da447995212" continuedAt="Text_b4b6a8beff6d492c9ce0e02da447995213">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Milestone payments: </span>At the inception of each arrangement that includes milestone payments, the Company evaluates
                whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur,
                the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable
                of being achieved until such contingency occurs (such as receipt of those approvals).</div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b89" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b90"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da447995213" continuedAt="Text_b4b6a8beff6d492c9ce0e02da447995214">
<div style="font-family: 'Times New Roman';"><br />
              </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b90" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b91"><ix:continuation id="Text_b4b6a8beff6d492c9ce0e02da447995214">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Royalties:</span> For arrangements that include sales-based royalties, including milestone payments based on the level of
                sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the
                royalty has been allocated has been satisfied (or partially satisfied).</div>
</ix:continuation></ix:continuation>

              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b91" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b92">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
              </div>
</ix:continuation>

              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b92" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b93"><ix:nonNumeric name="ocup:ContractAssetPolicyTextBlock" id="Text_e1d6039b61954b0a8c6a2d6203cd9301" contextRef="c20220101to20221231" escape="true" continuedAt="Text_6b1105b1d0384c16b93d1fecac0b256b1">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Contract Asset</span><br />
              </div>
</ix:nonNumeric></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b93" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b94"><ix:continuation id="Text_6b1105b1d0384c16b93d1fecac0b256b1" continuedAt="Text_6b1105b1d0384c16b93d1fecac0b256b2">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
                </span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b94" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b95"><ix:continuation id="Text_6b1105b1d0384c16b93d1fecac0b256b2">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> The Company recognizes a contract asset when goods or services are transferred to the customer before the customer pays or before payment is due, excluding any amounts presented as an
                  accounts receivable. The Company recorded a contract asset in connection with a license and collaboration agreement in the amount of $<ix:nonFraction name="ocup:ContractAssetCurrent" id="Fact_c10f695b87174ebe94821ca01b5bca68" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction>
                  million as of December 31, 2022.&#160; See Note 10 - License and Collaboration Agreements.</span><br />
              </div>
</ix:continuation></ix:continuation>

              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b95" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b96">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
                </span></div>
</ix:continuation>

              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b96" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b97"><ix:nonNumeric name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="Text_7f0ca4a3de0b41c98cfcb6f58fbae1b2" contextRef="c20220101to20221231" escape="true" continuedAt="Text_7ceca6d537b14bff8adef21a77353ada1">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;">Accounts Receivable and Allowances for Doubtful Accounts</div>
</ix:nonNumeric></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b97" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b98"><ix:continuation id="Text_7ceca6d537b14bff8adef21a77353ada1" continuedAt="Text_7ceca6d537b14bff8adef21a77353ada2">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"> <br />
                      </span></span></span></span></div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b98" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b99"><ix:continuation id="Text_7ceca6d537b14bff8adef21a77353ada2">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;">The Company records a provision for doubtful accounts, when appropriate, based on historical experience
                        and a detailed assessment of the collectability of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of the accounts receivable, its historical
                        write-offs, the credit worthiness of each customer, and general economic conditions. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered.
                        Actual write-offs may be in excess of the Company&#8217;s estimated allowance.&#160; The Company has <ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" id="Fact_683b23f476dd41969ecba877b38fcbda" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" id="Fact_610d969f35854a448447b8f591590e69" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t incurred any bad debt
                        expense during the years ended December 31, 2022 or 2021 and <ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact_51b1e411006349f69f2546adb695ec5f" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact_0d33cde2828b4e1eb80bf8e82e7df320" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts has been recorded
                        during the periods presented.</span></span></span></span></div>
</ix:continuation></ix:continuation>

              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b99" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b100">
<div><br /></div>
</ix:continuation>
                <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div style="width: 100%;" class="BRPFPageFooter"></div>

                  <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">136</span></div>

                  <div class="BRPFPageBreak" style="page-break-after: always;">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of
                          Contents</a></span></div>

                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

                      <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

        </div>


        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b100" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b101"><ix:nonNumeric name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="Text_7227cbf2796646bd9e90ef1c4ec58b0d" contextRef="c20220101to20221231" escape="true" continuedAt="Text_dd581d14b62b4876a80f26a5494472e81">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">General and Administrative Expenses</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b101" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b102"><ix:continuation id="Text_dd581d14b62b4876a80f26a5494472e81" continuedAt="Text_dd581d14b62b4876a80f26a5494472e82">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b102" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b103"><ix:continuation id="Text_dd581d14b62b4876a80f26a5494472e82">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">General and administrative expenses (&#8220;G&amp;A&#8221;) consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in
          functions not directly associated with research and development activities. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and tax services, settlement costs
          with third parties and other services provided by business consultants.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b103" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b104">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b104" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b105"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_7fae9398664d405ea0bf0b685ba5fa79" contextRef="c20220101to20221231" escape="true" continuedAt="Text_7a1a99822c0041c3b4930fafbb9793d21">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Research and Development</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b105" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b106"><ix:continuation id="Text_7a1a99822c0041c3b4930fafbb9793d21" continuedAt="Text_7a1a99822c0041c3b4930fafbb9793d22">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <div style="text-align: justify;">
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b106" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b107"><ix:continuation id="Text_7a1a99822c0041c3b4930fafbb9793d22">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Research and development expenses (&#8220;R&amp;D&#8221;) consist of costs incurred in performing research and development activities, including compensation for research and
            development employees and consultants, costs associated with preclinical studies and clinical trials, regulatory activities, manufacturing activities to support clinical activities, license fees, fees paid to external service providers that
            conduct certain research and development, and an allocation of R&amp;D related overhead expenses. R&amp;D costs include costs that are reimbursed under the Nyxol License Agreement.</div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b107" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b108">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        </div>


        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b108" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b109"><ix:nonNumeric name="ocup:OtherIncomeExpenseNetPolicyTextBlock" id="Text_e1df800b48924c1e8bb1915674ef31b4" contextRef="c20220101to20221231" escape="true" continuedAt="Text_2f55bff944b04295903dc493bc0a408d1">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Other Expense, net</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b109" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b110"><ix:continuation id="Text_2f55bff944b04295903dc493bc0a408d1" continuedAt="Text_2f55bff944b04295903dc493bc0a408d2">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b110" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b111"><ix:continuation id="Text_2f55bff944b04295903dc493bc0a408d2">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Other expense, net reflected in this line item includes payments made by the Company in connection with the Contingent Value Rights Agreement discussed further below
          with former Rexahn shareholders. In addition, other expense, net includes interest earned from cash and cash equivalent investments, realized and unrealized gains (losses) from equity investments and reimbursements in connection with grants and
          other sources when they occur.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b111" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b112">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b112" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b113"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_33c799f4f8954cea87024db2d024952c" contextRef="c20220101to20221231" escape="true" continuedAt="Text_8f63372aa80c466fa9bcf41052a96f7a1">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based Compensation</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b113" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b114"><ix:continuation id="Text_8f63372aa80c466fa9bcf41052a96f7a1" continuedAt="Text_8f63372aa80c466fa9bcf41052a96f7a2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <div style="text-align: justify;">
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b114" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b115"><ix:continuation id="Text_8f63372aa80c466fa9bcf41052a96f7a2">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The Company accounts for stock-based compensation in accordance with the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718, <span style="font-style: italic;">Compensation &#8212; Stock Compensation</span>. Accordingly, compensation costs related to equity instruments granted are recognized at the grant date fair value. The Company records forfeitures when they occur.
            Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718.</div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b115" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b116">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        </div>


        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b116" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b117"><ix:nonNumeric name="ocup:WarrantLiabilitiesPolicyTextBlock" id="Text_e00369ee1c82481782513fc41fb90a65" contextRef="c20220101to20221231" escape="true" continuedAt="Text_8842a58337c24a6797ad6c1c6fcf871f1">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Warrant Liabilities</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b117" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b118"><ix:continuation id="Text_8842a58337c24a6797ad6c1c6fcf871f1" continuedAt="Text_8842a58337c24a6797ad6c1c6fcf871f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b118" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b119"><ix:continuation id="Text_8842a58337c24a6797ad6c1c6fcf871f2">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company issued Series A Warrants in connection with the Pre-Merger Financing (see Note 3 &#8211; Pre-Merger Financing) and assumed Rexahn warrants issued prior to
            the Merger. The Company accounts for these warrants as a liability while outstanding at fair value during periods when certain provisions preclude equity accounting treatment for these instruments. Additionally, issuance costs associated with
            the warrants classified as liabilities were expensed as incurred and reflected as interest expense in the accompanying consolidated statements of comprehensive income (loss). The change in fair value of the warrant liabilities while outstanding
            were recognized as a component of the fair value change in warrant liabilities line item in the consolidated statements of comprehensive income (loss).</div>
</ix:continuation></ix:continuation>
        </div>


        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b119" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b120">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b120" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b121"><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Text_989964be4b2e41b297a0769123677eb5" contextRef="c20220101to20221231" escape="true" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5851">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Measurements</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b121" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b122"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5851" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5852">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b122" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b123"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5852" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5853">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as
          &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three-level hierarchy:</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b123" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b124"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5853" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5854">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b124" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b125"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5854" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5855">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 1 inputs: Unadjusted quoted prices for identical assets or liabilities in active markets;</div>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b125" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b126"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5855" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5856">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b126" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b127"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5856" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5857">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 2 inputs: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the
                  asset or liability; and</div>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b127" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b128"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5857" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5858">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b128" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b129"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5858" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f5859">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br />
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 3 inputs: Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or
                  liability at the measurement date.</div>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b129" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b130"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f5859" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58510">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">137</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%140%%%-->
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b130" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b131"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58510" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58511">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">As of December </span>31,<span style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</span>2022<span style="font-size: 10pt; font-family: 'Times New Roman';"> and </span>2021,<span style="font-size: 10pt; font-family: 'Times New Roman';"> the fair values of cash and cash equivalents, accounts receivable, contract asset, prepaid and other
              assets, accounts payable, accrued expenses and short-term loan, while outstanding,&#160; approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the short-term investments was based on
              observable Level </span>1<span style="font-size: 10pt; font-family: 'Times New Roman';"> inputs in the form of quoted market prices from a major stock exchange. The fair value of the warrant liabilities, while outstanding, was based on cash
              flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and were based on Level </span>3<span style="font-size: 10pt; font-family: 'Times New Roman';"> inputs.</span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b131" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b132"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58511" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58512">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b132" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b133"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58512" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58513">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">There were <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" id="Fact_4be0e52b2b0f4a92be25224efa3ce87e" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" id="Fact_1426a5f9696f425d807a111479cf2938" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" id="Fact_df0f3cdb7a154efa943876ac9ef3349b" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" id="Fact_8c9417764310400db99d3897ed7998c7" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> transfers between fair value
            hierarchy levels during the years ended December 31, 2022 and 2021.</div>
</ix:continuation></ix:continuation>
        </div>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b133" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b134"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58513" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58514">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b134" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b135"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58514" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58515"><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Text_7650f1381721419d9c52d6c18d2a805e" contextRef="c20220101to20221231" escape="true" continuedAt="Text_fb62439d273b45d8a6b1a51cb1f82b341">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of financial instruments measured on a recurring basis is as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b135" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b136"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58515" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58516"><ix:continuation id="Text_fb62439d273b45d8a6b1a51cb1f82b341" continuedAt="Text_fb62439d273b45d8a6b1a51cb1f82b342">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b136" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b137"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58516" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58517"><ix:continuation id="Text_fb62439d273b45d8a6b1a51cb1f82b342" continuedAt="Text_fb62439d273b45d8a6b1a51cb1f82b343">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">As of December 31, 2022</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;">
                <div>Description</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Total</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Level 1</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Level 2</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Level 3</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52.02%;">
                <div>Assets:<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);"> Short-term investments<br />
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_9f6ebe5145a046828ee51077058f0d94" contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_28a1aae7be4648b28bc2ca5e119f7635" contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_182efa6ab2184ae9bd0cca877e3bf0f7" contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_3e5a523338924e3fb0d9fc529fa1f572" contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;">
                <div>Total assets at fair value</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_f903bd52f9504bad90481cd9ca85cf51" contextRef="c20221231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_7e317467126b4fb6b66791fa3ff1d4bd" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_138a70b1b1cd40ba8f2161f97c3c9218" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_ae97dadd3e4e421ba5c9e8c0b819518f" contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b137" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b138"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58517" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58518"><ix:continuation id="Text_fb62439d273b45d8a6b1a51cb1f82b343" continuedAt="Text_fb62439d273b45d8a6b1a51cb1f82b344">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b138" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b139"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58518" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58519"><ix:continuation id="Text_fb62439d273b45d8a6b1a51cb1f82b344">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; font-weight: bold;">As of December 31, 2021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;">
                <div>Description</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Total</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Level 1</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Level 2</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Level 3</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52.02%;">
                <div>Assets:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="3" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                <div>Short-term investments</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_154f208cf8a741ae83e44a9772a54084" contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_ef64c83f9c5747a1ac6fa1e305f94946" contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_904b8fd04d2d4b1eac51515466296060" contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_36448ddc3d954bd48d477e34b20f6307" contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;">
                <div>Total assets at fair value</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_8811a118ff6b478380404d950661e0bb" contextRef="c20211231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_16e8814191014792afe83371cc638547" contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_9abc59797b2e4bc0bbe7258043469473" contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);">
                <div><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_a1231afc250b4cf199342e126f3107a4" contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b139" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b140"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58519" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58520">
<div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b140" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b141"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58520" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58521"><ix:nonNumeric name="ocup:ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" id="Text_27ac5e463e434d38a3fcdba4a75099c2" contextRef="c20220101to20221231" escape="true" continuedAt="Text_8aa80a5c758e41889842199c6d7a5eb01">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides a roll-forward of investments measured at fair value on a recurring basis using observable level 1 inputs for the year ended December
            31, 2022 and 2021 (in thousands):</div>
</ix:nonNumeric></ix:continuation></ix:continuation>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b141" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b142"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58521" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58522"><ix:continuation id="Text_8aa80a5c758e41889842199c6d7a5eb01" continuedAt="Text_8aa80a5c758e41889842199c6d7a5eb02">
<div><br />
          </div>
</ix:continuation></ix:continuation></ix:continuation>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b142" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b143"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58522" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58523"><ix:continuation id="Text_8aa80a5c758e41889842199c6d7a5eb02">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021<br />
                  </div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Short-term investments</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of beginning of period</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_bcae4e4996e64d6791f38a43cd52bb4f" contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_45da091e1065482190698f0ec8e890f3" contextRef="c20201231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Receipt of investments related to license agreement</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="ocup:ReceiptOfInvestmentsRelatedToLicenseAgreement" id="Fact_7ff5b784bfab4dfca7e18f3c397916a0" contextRef="c20220101to20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="ocup:ReceiptOfInvestmentsRelatedToLicenseAgreement" id="Fact_fa88759b101d4433baa6689466bd392e" contextRef="c20210101to20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">289</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Unrealized loss</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_6fb1ac02b63b4d429560e5438f270981" contextRef="c20220101to20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">170</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" id="Fact_5b5a507ee19848b9b7ec8084debde3ca" contextRef="c20210101to20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">70</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of end of period</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_418221681d64424caed85815d6e6aa84" contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" id="Fact_1d74a3c08942429597d67ff0c3cd35f9" contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation>
           </div>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b143" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b144"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58523" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58524">
<div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b144" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b145"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58524" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58525"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="Text_90c51b56b1114195b18eff2231cd1758" contextRef="c20220101to20221231" escape="true" continuedAt="Text_1e4573c058df4001a6a6a3dfedd117f21">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides a roll-forward of the warrant liabilities measured at fair value on a recurring basis using unobservable level 3 inputs for the year
          ended December 31,&#160; 2021 (in thousands):</div>
</ix:nonNumeric></ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b145" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b146"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58525" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58526"><ix:continuation id="Text_1e4573c058df4001a6a6a3dfedd117f21" continuedAt="Text_1e4573c058df4001a6a6a3dfedd117f22">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation></ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b146" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b147"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58526" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58527"><ix:continuation id="Text_1e4573c058df4001a6a6a3dfedd117f22">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;"><span style="font-weight: bold;">2021<br />
                  </span></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrant liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of beginning of period</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_2b637e2a2be84981bc649e49d3916e43" contextRef="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,964</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_8f8d443c08dc4913a337403f4d96cd57" contextRef="c20210101to20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,829</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Reclassification of warrants from liability to equity</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" id="Fact_58ca351961a745b0b6193bcba82efa3f" contextRef="c20210101to20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">61,793</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of end of period</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" id="Fact_53519d353f5148389e4f15b2dc54f86f" contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        </div>
</ix:continuation></ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b147" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b148"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58527" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58528">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b148" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b149"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58528" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58529">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The fair value of the warrant liabilities associated with the Rexahn warrants was de minimis during the years ended December 31, 2022 and 2021. See Note 2 - Merger.<br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b149" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b150"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58529" continuedAt="Text_4d76f316b94042dc8f9e8883ce93f58530">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b150" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b151"><ix:continuation id="Text_4d76f316b94042dc8f9e8883ce93f58530">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">There were <ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_5c98959abc134018b463ec9ace830591" contextRef="c20211231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Fact_e3c4cd300cf64f70a8c56607c05a9d5c" contextRef="c20221231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> financial instruments measured on a
          non-recurring basis for any of the periods presented.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b151" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b152">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">138</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>


        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b152" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b153"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_4e7a10ea0fa44b2f9329cd52a6b4f1a0" contextRef="c20220101to20221231" escape="true" continuedAt="Text_3825fe15fcad426cb00989d39dbc41691">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Income Taxes</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b153" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b154"><ix:continuation id="Text_3825fe15fcad426cb00989d39dbc41691" continuedAt="Text_3825fe15fcad426cb00989d39dbc41692">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b154" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b155"><ix:continuation id="Text_3825fe15fcad426cb00989d39dbc41692">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company utilizes the liability method of accounting for income taxes as required by ASC 740, <span style="font-style: italic;">Income Taxes</span>. Under this
          method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences
          are expected to reverse. The Company currently has a provision for income taxes, but the Company has historically incurred operating losses for all prior year periods.&#160; As such, a full valuation allowance has been provided on the net deferred tax
          assets given the uncertainty of future taxable income and other related factors impacting the realizability or the Company&#8217;s remaining net deferred tax assets.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b155" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b156">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b156" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b157"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Text_f841712e64e646a1be6b8756a78ca59b" contextRef="c20220101to20221231" escape="true" continuedAt="Text_4bb1ba7861184f49815e2743f218beea1">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Property and Equipment, net<br />
        </div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b157" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b158"><ix:continuation id="Text_4bb1ba7861184f49815e2743f218beea1" continuedAt="Text_4bb1ba7861184f49815e2743f218beea2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b158" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b159"><ix:continuation id="Text_4bb1ba7861184f49815e2743f218beea2">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment, net is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the
          assets using the straight-line method. Equipment and furniture are depreciated over a <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_c5616a9cc6aa4fb5976f6dfc698d3a83" contextRef="c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" format="ixt-sec:durwordsen"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_f725755bb90948cba0fdf7a0fa10c3d0" contextRef="c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric></ix:nonNumeric> estimated useful life. Tangible
          assets acquired for research and development activities which have alternative use are capitalized and depreciated over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are
          made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged
          directly to expense as incurred.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b159" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b160">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b160" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b161"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_9287d18005894536848f6118ff6bf899" contextRef="c20220101to20221231" escape="true" continuedAt="Text_f5ce4085c387432688ed419263ac5a961">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Recent Accounting Pronouncements</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b161" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b162"><ix:continuation id="Text_f5ce4085c387432688ed419263ac5a961" continuedAt="Text_f5ce4085c387432688ed419263ac5a962">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b162" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b163"><ix:continuation id="Text_f5ce4085c387432688ed419263ac5a962" continuedAt="Text_f5ce4085c387432688ed419263ac5a963">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, &#8220;<span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Financial












































            Instruments &#8211; Credit Losses&#8221;</span>. The ASU sets forth a current expected credit loss (&#8220;CECL&#8221;) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical
          experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some
          off-balance sheet credit exposures. The Company does not expect that the adoption of this ASU on January 1, 2023 will have a significant impact on its consolidated financial statements.</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b163" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b164"><ix:continuation id="Text_f5ce4085c387432688ed419263ac5a963" continuedAt="Text_f5ce4085c387432688ed419263ac5a964">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b164" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b165"><ix:continuation id="Text_f5ce4085c387432688ed419263ac5a964" continuedAt="Text_f5ce4085c387432688ed419263ac5a965">
<div style="text-align: justify;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In August 2020, FASB issued ASU 2020-06,</span>
          <span style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
            and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span>, <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">which, among other things, provides guidance on how to account for contracts on an entity&#8217;s own equity. This &#8203;ASU eliminates the beneficial conversion and cash
            conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this
            ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for public business entities that meet the definition
            of a Securities and Exchange Commission (&#8220;SEC&#8221;) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
            For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. </span><span style="font-size: 10pt; font-family: 'Times New Roman';">The Company
            does not expect that the adoption of this ASU on January 1,&#160;2023 on its consolidated financial statements will be material</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span> </div>
</ix:continuation></ix:continuation>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b165" continuedAt="Text_e05b52d9ad6545e79b7dcab6d730015b166"><ix:continuation id="Text_f5ce4085c387432688ed419263ac5a965" continuedAt="Text_f5ce4085c387432688ed419263ac5a966">
<div><br /></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_e05b52d9ad6545e79b7dcab6d730015b166"><ix:continuation id="Text_f5ce4085c387432688ed419263ac5a966">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In November 2021, <span style="font-size: 10pt; font-family: 'Times New Roman';">the FASB issued ASU 2021-10,&#160;Government Assistance (Topic
              832) - Disclosures by Business Entities about Government Assistance,&#160;to increase the transparency of government assistance including the disclosure of the types of assistance, an entity&#8217;s accounting for the assistance, and the effect of the
              assistance on an entity&#8217;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15,&#160;2021. The Company adopted this
              guidance on January 1,&#160;2022 and it did not have a material impact to the consolidated financial statements.</span></div>
</ix:continuation></ix:continuation>

          <div>
<div>&#160;&#160;
            </div>
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">139</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of
                      Contents</a></span></div>

                <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

                </div>

              </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" id="Text_0f80218aa1404bf1bcf82c50f1661e71" contextRef="c20220101to20221231" escape="true" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc91">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Merger</div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc91" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc92">
<div>&#160;&#160;
          </div>
</ix:continuation><ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc92" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc93">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On November 5, 2020, the Company completed the Merger transaction with Rexahn. In connection with the Merger, the Company, Shareholder Representatives Services
            LLC, as representative of the Rexahn stockholders prior to the Merger, and Olde Monmouth Stock Transfer Co., Inc., as the rights agent, entered into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;).</div>
</ix:continuation>
          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc93" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc94">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc94" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc95">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the terms of the Merger and the CVR Agreement, Rexahn stockholders of record as of immediately prior to the effective time of the Merger received <ix:nonFraction name="ocup:ContingentValueRightEntitledPerEachShareOfCommonStockHeld" id="Fact_b9db115b4690424da01874434e075d2f" contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> contingent value right (&#8220;CVR&#8221;) for each share of Rexahn common stock held.</div>
</ix:continuation>
          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc95" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc96">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc96" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc97">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Each CVR entitles such holders to receive, for each calendar quarter (each, a &#8220;CVR Payment Period&#8221;) during the <ix:nonNumeric name="ocup:ContingentValueRightsPaymentPeriod" id="Fact_605183b9dc3b4888b9ed4b01ca774c81" contextRef="c20220101to20221231" format="ixt-sec:duryear">15</ix:nonNumeric>-year period after the Closing (the &#8220;CVR Term&#8221;), an amount equal to the following:</div>
</ix:continuation>
          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc97" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc98">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
          <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
            <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc98" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc99">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br />
                  </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="color: rgb(0, 0, 0); text-align: justify;"><ix:nonFraction name="ocup:ContingentValueRightsPercentage" id="Fact_4b84d85f39c447f5a272b39ce2240d11" contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_BioSenseGlobalLLCMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">90</ix:nonFraction>% of all payments received by Rexahn or its affiliates during such
                      CVR Payment Period from or on behalf of BioSense Global LLC (&#8220;BioSense&#8221;) pursuant to that certain License and Assignment Agreement, dated as of February 25, 2019, by and between BioSense and Rexahn, as amended by Amendment No. 1,
                      dated August 24, 2019, and as further amended by Amendment No. 2, dated March 10, 2020, minus certain permitted deductions;</div>
                  </td>

  </tr>


</table>
</ix:continuation>
            <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc99" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc910">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc910" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc911">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br />
                  </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="color: rgb(0, 0, 0); text-align: justify;"><ix:nonFraction name="ocup:ContingentValueRightsPercentage" id="Fact_bc61ce2073f14429a0f48586b7e12025" contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_ZhejiangHaiChangBiotechnologyCoLtdMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">90</ix:nonFraction>% of all payments received by Rexahn or its affiliates during such
                      CVR Payment Period from or on behalf of Zhejiang HaiChang Biotechnology Co., Ltd. (&#8220;HaiChang&#8221;) pursuant to that certain Exclusive License Agreement, dated as of February 8, 2020, by and between HaiChang and Rexahn, minus certain
                      permitted deductions; and</div>
                  </td>

  </tr>


</table>
</ix:continuation>
            <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc911" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc912">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc912" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc913">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br />
                  </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="color: rgb(0, 0, 0); text-align: justify;"><ix:nonFraction name="ocup:PercentageOfCashConsiderationPayment" id="Fact_a33ff8bd138e4dfaa124ed8b4ca76b22" contextRef="c20201105" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>% of the sum of (i) all cash consideration paid by a third party to
                      Rexahn or its affiliates during the applicable CVR Payment Period in connection with the grant, sale or transfer of rights to Rexahn&#8217;s pre-closing intellectual property (other than a grant, sale or transfer of rights involving a sale
                      or disposition of the post-Merger combined company) that is entered into during the <ix:nonNumeric name="ocup:ContingentValueRightsIPTerm" id="Fact_76720dc150cb41768e858f6d96f140a9" contextRef="c20220101to20221231" format="ixt-sec:duryear">10</ix:nonNumeric>-year period after the Closing
                      (&#8220;Parent IP Deal&#8221;), plus (ii) with respect to any non-cash consideration received by Rexahn or its affiliates from a third party during the applicable CVR Payment Period in connection with any Parent IP Deal, all amounts received by
                      Rexahn and its affiliates for such non-cash consideration at the time such non-cash consideration is monetized by Rexahn or its affiliates, minus (iii) certain permitted deductions.</div>
                  </td>

  </tr>


</table>
</ix:continuation>
            <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc913" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc914">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
                </span></span></div>
</ix:continuation>
            <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc914" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc915">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument, will not accrue interest and will not be registered with the SEC or listed for trading on any exchange.
                The CVR Agreement will continue in effect until the later of the end of the CVR Term and the payment of all amounts payable thereunder. </span>As of December 31, 2022, <ix:nonFraction name="ocup:NumberOfMilestonesAccrued" id="Fact_daead475874a458084fd8b9081cfc933" contextRef="c20201105" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="ocup:NumberOfMilestonesAccrued" id="Fact_0e6673e5a00e4deb9b9fa88221812ba1" contextRef="c20221231" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> milestones had been accrued as there were <ix:nonFraction name="ocup:NumberOfPotentialMilestones" id="Fact_81a95aab41eb49379671b583faf93c12" contextRef="c20221231" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="ocup:NumberOfPotentialMilestones" id="Fact_02fe62fe32b24971932e215068be8c3f" contextRef="c20201105" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>
              additional potential milestones yet considered probable beyond those previously reported in the second and third quarters of calendar year 2021.</div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc915" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc916">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc916" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc917">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Former Rexahn Warrants</div>
</ix:continuation>
          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc917" continuedAt="Text_81b17cc7a9fd464484cddf71b8a48bc918">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">&#160;</div>
</ix:continuation>
          <ix:continuation id="Text_81b17cc7a9fd464484cddf71b8a48bc918">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Following the closing of the Merger, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_d5c437b30f4c4747bd1e517c885a9658" contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">231,433</ix:nonFraction>
            outstanding, unexercised Rexahn warrants to purchase common stock remained outstanding, the majority of which were subsequently repurchased according to the terms of the original warrant agreements.&#160; As of December 31 2022, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_cf1f001dcc7c4dff969a87cca0b30feb" contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,713</ix:nonFraction> of the Rexahn warrants remained outstanding with exercise prices ranging from $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_0cc45dfb61144090b5ec56aa77af36b7" contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RangeAxis_MinimumMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">38.40</ix:nonFraction> to $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_968b2bad1d984b7dae0875827184516b" contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RangeAxis_MaximumMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">136.80</ix:nonFraction> per share with an average remaining contractual life of <ix:nonNumeric name="ocup:WeightedAverageRemainingContractualTermsWarrants" id="Fact_6cc1d79995f141dc9d044a4605d3fd54" contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember" format="ixt-sec:duryear">1.0</ix:nonNumeric> years.</div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <ix:nonNumeric name="ocup:PreMergerFinancingTextBlock" id="Text_72d6e04543794ec0b779c576fffd483a" contextRef="c20220101to20221231" escape="true" continuedAt="Text_6982b3594ff347bf998a16f6596597a81">
<div>
        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">3.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Pre-Merger Financing</div>
              </td>

  </tr>


</table>
      </div>
</ix:nonNumeric>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a81" continuedAt="Text_6982b3594ff347bf998a16f6596597a82">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a82" continuedAt="Text_6982b3594ff347bf998a16f6596597a83">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On June 17, 2020, Ocuphire, Rexahn and certain investors entered into a Securities Purchase Agreement, which was amended and restated in
        its entirety on June 29, 2020 (as amended and restated, the &#8220;Securities Purchase Agreement&#8221;).&#160; Pursuant to the Securities Purchase Agreement, the investors invested a total of $<ix:nonFraction name="ocup:ProceedsFromPreMergerFinancing" id="Fact_d396c6dd022d42ea8d5a736008f312fd" contextRef="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember" unitRef="U001" decimals="-4" scale="6" format="ixt:num-dot-decimal">21.15</ix:nonFraction> million in cash, including $<ix:nonFraction name="ocup:ProceedsFromPreMergerFinancing" id="Fact_e84c8255687049789976ee4e945c842f" contextRef="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction>,000 invested by <ix:nonFraction name="ocup:NumberOfDirectors" id="Fact_bc80ebcff77940c0be7bc02ebb25589e" contextRef="c20200629to20200629_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> directors of Ocuphire Pharma, Inc., prior to the Merger and <ix:nonFraction name="ocup:NumberOfDirectors" id="Fact_827d4cf19e604093a31c93ae35e97042" contextRef="c20200629to20200629_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> director of Rexahn upon closing of the Merger (the &#8220;Pre-Merger Financing&#8221;).&#160; The Pre-Merger Financing also included the issuance of Series A Warrants and Series B Warrants discussed
        further below.</div>
</ix:continuation>
      <div><ix:continuation id="Text_6982b3594ff347bf998a16f6596597a83" continuedAt="Text_6982b3594ff347bf998a16f6596597a84">
<div><br /></div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">140</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a84" continuedAt="Text_6982b3594ff347bf998a16f6596597a85">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Waiver Agreements</div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a85" continuedAt="Text_6982b3594ff347bf998a16f6596597a86">
<div><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a86" continuedAt="Text_6982b3594ff347bf998a16f6596597a87">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective February 3, 2021, each investor that invested in the Pre-Merger Financing entered into a Waiver Agreement with the Company
        (collectively, the &#8220;Waiver Agreements&#8221;). Pursuant to the Waiver Agreements, the investors and the Company agreed to waive certain rights, finalize the exercise price and number of Series A Warrants and Series B Warrants, eliminate certain financing
        restrictions, extend the term of certain leak-out agreements, and, in the case of certain investors, grant certain registration rights for the shares underlying the warrants.</div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a87" continuedAt="Text_6982b3594ff347bf998a16f6596597a88">
<div><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a88" continuedAt="Text_6982b3594ff347bf998a16f6596597a89">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Waiver Agreements provide for the elimination of the full ratchet anti-dilution provisions contained in the Series A Warrants (as
        certain of the anti-dilution provisions had previously caused liability accounting treatment for the Series A Warrants). Upon the effective date of the Waiver Agreements, the Series A Warrants were reclassified to equity.</div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a89" continuedAt="Text_6982b3594ff347bf998a16f6596597a810">
<div><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a810" continuedAt="Text_6982b3594ff347bf998a16f6596597a811">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Waiver Agreements, the number of shares underlying all of the Series B Warrants was fixed in the aggregate with respect
        to all investors, eliminating any future resets.</div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a811" continuedAt="Text_6982b3594ff347bf998a16f6596597a812">
<div><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a812" continuedAt="Text_6982b3594ff347bf998a16f6596597a813">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Series A Warrants</div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a813" continuedAt="Text_6982b3594ff347bf998a16f6596597a814">
<div><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a814" continuedAt="Text_6982b3594ff347bf998a16f6596597a815">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Series A Warrants were issued on November 19, 2020 at an initial exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_49611750bce142348129a093a1f8fc6f" contextRef="c20201119_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">4.4795</ix:nonFraction> per share, were immediately exercisable upon issuance and have a term of <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_a401a326856446ca847c25f307ed9f1a" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> from the date of issuance. The Series A Warrants are exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_ea496e52b36048f8a0d971b1cae3ac4c" contextRef="c20201119_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,665,838</ix:nonFraction> shares of common stock in the
        aggregate (without giving effect to any limitation on exercise contained therein) and were outstanding as of December 31, 2022. Prior to the execution of the Waiver Agreements, the Series A Warrants were accounted for and classified as liabilities
        on the accompanying balance sheets given certain price reset provisions not used for a fair valuation under a fixed for fixed settlement scenario as required for equity balance sheet classification. Upon the February 3, 2021 effective date of the
        Waiver Agreements, the Series A Warrants were reclassified to equity. A final fair valuation of the Series A Warrants was performed utilizing a Black Scholes model to estimate the aggregate fair value of the Series A Warrants prior to being
        re-classified as equity. Input assumptions used were as follows: risk-free interest rate <ix:nonFraction name="us-gaap:DerivativeAssetMeasurementInput" id="Fact_584c1d12d5914102a994857512fa800c" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.4</ix:nonFraction>%; expected volatility of <ix:nonFraction name="us-gaap:DerivativeAssetMeasurementInput" id="Fact_2f19a5f82eb64ffebf42caeb360a58ae" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">86.6</ix:nonFraction>%; expected life of <ix:nonNumeric name="ocup:FairValueAssumptionsExpectedLife" id="Fact_d8fefc8e5148412f90e120e06d26cd0d" contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember" format="ixt-sec:duryear">4.8</ix:nonNumeric> years; and
        expected dividend yield <ix:nonFraction name="us-gaap:DerivativeAssetMeasurementInput" id="Fact_122c4bb2f6264cf6a732a1caf3b9ddf1" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> percent. The underlying stock price used was the market price as quoted on Nasdaq as of&#160; February 3, 2021,
        the effective date of the Waiver Agreement.&#160; The fair value change of the Series A Warrants was $<ix:nonFraction name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" id="Fact_27521bed342943b58f5df6c5d0c5e289" contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_TypeOfArrangementAxis_WaiverAgreementsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">33.8</ix:nonFraction> million and was recorded to the
        fair value change in warrant liabilities line item on the accompanying&#160; consolidated statements of comprehensive income (loss) for year ended December 31, 2021. As a result of the reclassification to equity, the Series A Warrants are no longer
        subject to remeasurement.</div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a815" continuedAt="Text_6982b3594ff347bf998a16f6596597a816">
<div><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a816" continuedAt="Text_6982b3594ff347bf998a16f6596597a817">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Series B Warrants</div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a817" continuedAt="Text_6982b3594ff347bf998a16f6596597a818">
<div><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6982b3594ff347bf998a16f6596597a818">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Series B Warrants have an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_009a84abecde461cbbc384763f8618ab" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>, were exercisable upon issuance and will expire on the day following the later to occur of (i) the Reservation Date (as defined therein), and (ii) the date on which the investor&#8217;s
        Series B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein) and <ix:nonFraction name="ocup:RemainingIssuableShares" id="Fact_154d3faab63947d0affebc4c2fc05d8e" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares
        remain issuable thereunder. The Series B Warrants outstanding as of December 31, 2022 were exercisable for <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_e054d6e0cc1f4efb9750775778e051cb" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">17,869</ix:nonFraction> shares of common
        stock. The Series B Warrants were accounted for and classified as equity on the accompanying balance sheets.</div>
</ix:continuation>

      <div><br />
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_f4324b533615435389f491f72b1e967e" contextRef="c20220101to20221231" escape="true" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3301">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">4.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Commitments and Contingencies</div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3301" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3302">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3302" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3303">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Apexian Sublicense Agreement</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3303" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3304">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3304" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3305">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On January 21, 2020, the Company entered into a sublicense agreement with Apexian Pharmaceuticals, Inc., pursuant to which it obtained exclusive worldwide patent and
          other intellectual property rights. In exchange for the patent and other intellectual rights, the Company agreed to certain milestone payments and royalty payments on future sales (See Note 8 &#8212; Apexian Sublicense Agreement). As of December 31,
          2022, there was sufficient uncertainty with regard to any future cash milestone payments under the sublicense agreement, and as such, no liabilities were recorded related to the sublicense agreement.</div>
</ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3305" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3306">
<div>&#160;
          </div>
</ix:continuation>
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">141</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of
                    Contents</a></span></div>

              <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

              </div>

            </div>

          </div>

          <!--PROfilePageNumberReset%Num%144%%%--> </div>

        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3306" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3307">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Facility Leases</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3307" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3308">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3308" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b3309">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company has a short-term non-cancellable facility lease (the &#8220;HQ Lease&#8221;) for its operations and headquarters. Additionally, Ocuphire leased office space in
          Rockville, Maryland through June 30, 2021 previously occupied by Rexahn (the &#8220;Rexahn Lease&#8221;). The HQ Lease and the Rexahn Lease qualified for the short-term lease exception under ASC 842, Leases. The monthly base rent, as amended, for the HQ
          Lease is approximately $<ix:nonFraction name="ocup:OperatingLeasesMonthlyBaseRent" id="Fact_46a73dbc50aa4370a05a0fe51a291e35" contextRef="c20220101to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000</ix:nonFraction>. The monthly base rent for the Rexahn Lease was $<ix:nonFraction name="ocup:OperatingLeasesMonthlyBaseRent" id="Fact_2909c23e759e41cc944cd38069c5eb2a" contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">13,000</ix:nonFraction>. The rent expense associated with the HQ Lease and Rexahn Lease amounted to $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_acd4391f619947c89b1754ba44563897" contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_5844fb5f0d184c40a5ce1dac3d8b052b" contextRef="c20220101to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">39,000</ix:nonFraction></ix:nonFraction>
          and $<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_feb1801141004d87b3efcd1a9b8d3d98" contextRef="c20210101to20211231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_a82916da2d47498d9980e1194b8e9a8d" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">116,000</ix:nonFraction></ix:nonFraction> during the years ended December 31, 2022 and 2021, respectively. The total remaining expected rental payments under
          the HQ Lease amount to $<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" id="Fact_1316947663e44f7391a28e1586ac24e6" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">36,000</ix:nonFraction> through its current expiration date of December 31, 2023.</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b3309" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b33010">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b33010" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b33011">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Issuance of Settlement Shares</span></div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b33011" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b33012">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b33012" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b33013">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> On May 6, 2021, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_15bdc3ecc4fa488f853767be39ceb1ab" contextRef="c20210506to20210506_RelatedPartyTransactionsByRelatedPartyAxis_AccreditedInvestorMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">350,000</ix:nonFraction> shares of common stock of the Company to <ix:nonFraction name="ocup:NumberOfAccreditedInvestors" id="Fact_dc3a73151a2f432990b2b32d3c61b006" contextRef="c20210506" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> accredited investors pursuant to a settlement agreement, dated May 6, 2021, in exchange for a release of potential claims. The fair value of
            the share settlement of $<ix:nonFraction name="ocup:FairValueShareSettlementAmount" id="Fact_313f9bf0c0854b8a9b69b069716d0f88" contextRef="c20210506to20210506_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RelatedPartyTransactionsByRelatedPartyAxis_AccreditedInvestorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,614,000</ix:nonFraction> was based on the closing Ocuphire stock price for that day. The fair value of the share settlement
            was recorded in general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss).</span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b33013" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b33014">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b33014" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b33015">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Other</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b33015" continuedAt="Text_e503ec8aa7224465b2ccb1c6c230b33016">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_e503ec8aa7224465b2ccb1c6c230b33016">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In the ordinary course of business, from time to time, the Company may be subject to a broad range of claims and legal proceedings that relate to contractual
          allegations, patent infringement and other claims. In addition, the Company from time to time may be potentially committed to reimburse third parties for costs incurred associated with business development related transactions upon the
          achievement of certain milestones. The Company establishes accruals when applicable for matters and commitments which it believes losses are probable and can be reasonably estimated. To date, no loss contingency for such matters and potential
          commitments have been recorded. Although it is not possible to predict with certainty the outcome of these matters or potential commitments, the Company is of the opinion that the ultimate resolution of these matters and potential commitments
          will not have a material adverse effect on its results of operations or financial position.</div>
</ix:continuation>
        </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Text_c445b60d482d4dc0b9318692297addbf" contextRef="c20220101to20221231" escape="true" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b01">
<div> <br />
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b01" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b02">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">5.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Supplemental Balance Sheet Information</div>
              </td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b02" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b03">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b03" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b04">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Prepaid and Other Assets</div>
</ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b04" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b05">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b05" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b06"><ix:nonNumeric name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Text_6da40a05a283487d9fa0af81d68d5025" contextRef="c20220101to20221231" escape="true" continuedAt="Text_a39592da6a1d4b91ba2decd7ccce68791">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Prepaid and other assets consist of the following (in thousands):</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b06" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b07"><ix:continuation id="Text_a39592da6a1d4b91ba2decd7ccce68791" continuedAt="Text_a39592da6a1d4b91ba2decd7ccce68792">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b07" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b08"><ix:continuation id="Text_a39592da6a1d4b91ba2decd7ccce68792">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Prepaids</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" id="Fact_e7dc0a3d4fdb4d6398f06fab011c03eb" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,373</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" id="Fact_f6ec9f0dd0fe44dcb70ff469295e57da" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,243</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div>Other</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                <div><ix:nonFraction name="us-gaap:OtherAssetsCurrent" id="Fact_5ff281c9fa0348848d82df85b7ae8dfd" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">80</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                <div><ix:nonFraction name="us-gaap:OtherAssetsCurrent" id="Fact_fde24924796045d89bbfa5ab3f5970b3" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Total prepaids and other assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_3343b59c4f2740d7977c95e320d895b9" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,453</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_c51e28e90b2f4be0a7ae8af26f2021a9" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,314</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b08" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b09">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b09" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b010">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Property and Equipment, net</div>
</ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b010" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b011">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b011" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b012"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_40d20a7209fe4f6c97e60e04992cba96" contextRef="c20220101to20221231" escape="true" continuedAt="Text_4f8ea5108c9e4bb38666da936c4836fe1">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment held for use by category are presented in the following table (in thousands):</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b012" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b013"><ix:continuation id="Text_4f8ea5108c9e4bb38666da936c4836fe1" continuedAt="Text_4f8ea5108c9e4bb38666da936c4836fe2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b013" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b014"><ix:continuation id="Text_4f8ea5108c9e4bb38666da936c4836fe2">
<table cellspacing="0" cellpadding="0" border="0" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="6">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Equipment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_cf9a385737ac4fc4a898f5834f69b236" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_127bf8cb31454abbb5d9a5ca187f7452" contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div>Furniture</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_d622f9340ab04b418a207467af0ec1f6" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_c7f26d35f6f140e19a1e34cfe9bcf46f" contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Total property and equipment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_06da0c0eac7a40b2aae3e0925cca4430" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_74d1ab19ad6545ceacc349506c654908" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div>Less accumulated depreciation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_28200a2975b54ac98bee880e049dfa65" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_ac57ff1e94604dc6bb865dfe574c5e4e" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Property and equipment, net</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_8731bb59e67749fdbcb3a533d808e250" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_b79d4619d45c4991befb7f1187e7382e" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b014" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b015">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b015" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b016">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Depreciation expense was $<ix:nonFraction name="us-gaap:Depreciation" id="Fact_8087a9de95334730858fa497827ed648" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_d301e02165304b92815539f7145c56e8" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></ix:nonFraction>,000 during each of the
          years ended December 31, 2022 and 2021.</div>
</ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b016" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b017">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">142</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b017" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b018">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Accrued Expenses</div>
</ix:continuation>
        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b018" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b019">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_94cbc1daf51a44dc9149b8fdf8dc4c21" contextRef="c20220101to20221231" escape="true"><ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b019" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b020">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div>Accrued expenses consist of the following (in thousands):</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div>
                  <div>
                    <div>Income taxes</div>
                  </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" id="Fact_3fd79259409241c497ce2fc0417cc137" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">315</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" id="Fact_52cc192e8e314eb3818a37705a83addb" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div>Payroll</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_5890481403094ff1a7c480ec0ea32810" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">782</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_ceb39b8bb1f8405f8a796a2e046added" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">488</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div>Professional services</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_705faaa93edc42e4bc37781f185123ce" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">208</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_e454e388033a4429a3e9146ac31cc93f" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">84</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div>R&amp;D services and supplies</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="ocup:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" id="Fact_8af833c7ea8a46ef9c91c3033ca8dc8f" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">212</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="ocup:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" id="Fact_017ff32a08d747808ba3443021a878e8" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,081</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>Other</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_cc11575681d9456cb5f70b1baad7925b" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">167</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_4316811ea0b545deb9f2c054f15ea794" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">80</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                <div>Total</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_3adfaff6ad2444b8963b9016a710947d" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,684</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_02dda446576d474d94d2815c4d6a8dc0" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,733</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:nonNumeric>

        <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b020" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b021">
<div><br />
        </div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b021" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b022">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Short-Term Loan</div>
</ix:continuation>
          <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b022" continuedAt="Text_dbc575ca9b0f4eb9b48991cdec9677b023">
<div><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_dbc575ca9b0f4eb9b48991cdec9677b023">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company entered into an unsecured short-term loan (the &#8220;Loan&#8221;) agreement in the amount of $<ix:nonFraction name="us-gaap:ShortTermBorrowings" id="Fact_233ec4e5a2964773b697f3557c2c2a9c" contextRef="c20211130" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million in November 2021 related to financing an insurance policy.&#160; The Loan was payable in <ix:nonFraction name="ocup:DebtInstrumentNumberOfInstallments" id="Fact_17542d96b95c480895d198fa4c23d644" contextRef="c20220101to20221231" unitRef="U011" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction> monthly installments of $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" id="Fact_e0bc5faa70834530b5bd2d2cc7d994b3" contextRef="c20210101to20211231_DebtInstrumentAxis_ShortTermLoanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">108,000</ix:nonFraction> beginning in December 2021.&#160; The Loan
            had an annual interest rate of <ix:nonFraction name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" id="Fact_9326f12e65ec4f6290ac9ede48df269e" contextRef="c20221231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.5</ix:nonFraction>% per annum.&#160; Interest expense in the amount of $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_809f1e6702ec4a8fa9491c2282f51333" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction>,000 and $<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_d03d1edff1be45059769ae38dc793d48" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction>,000 was recognized in connection with the Loan
            during the years ended December 31, 2022 and 2021, respectively. The final payment on the Loan was made in May 2022.<br />
          </div>
</ix:continuation>
           </div>

        <div><br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Text_44f1238d532f43e0b9bdbb44d3eb273c" contextRef="c20220101to20221231" escape="true" continuedAt="Text_eb75479289494b3daed231a5ea3ce9b21">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">6.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Related Party Transactions</div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_eb75479289494b3daed231a5ea3ce9b21" continuedAt="Text_eb75479289494b3daed231a5ea3ce9b22">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_eb75479289494b3daed231a5ea3ce9b22" continuedAt="Text_eb75479289494b3daed231a5ea3ce9b23">
<div style="text-align: justify; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Pre-Merger Financing and Waiver Agreements</div>
</ix:continuation>
        <ix:continuation id="Text_eb75479289494b3daed231a5ea3ce9b23" continuedAt="Text_eb75479289494b3daed231a5ea3ce9b24">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_eb75479289494b3daed231a5ea3ce9b24" continuedAt="Text_eb75479289494b3daed231a5ea3ce9b25">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="ocup:NumberOfDirectors" id="Fact_a706f4c55dfb473f9d7f9f526287ca39" contextRef="c20220101to20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">Five</ix:nonFraction> directors of Ocuphire Pharma, Inc., prior to the
          Merger, and <ix:nonFraction name="ocup:NumberOfDirectors" id="Fact_45fc4f3d616f45acae1282676cbc827b" contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_PreMergerFinancingMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> director of Rexahn participated in the Pre-Merger Financing, investing an aggregate of $<ix:nonFraction name="ocup:AmountInvestedInPreMergerFinancing" id="Fact_f899f8a7462049709790fc6ae64fdf60" contextRef="c20220101to20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction>.&#160; Following the closing of the Merger, these directors received <ix:nonFraction name="ocup:NumberOfConvertedInitialSharesReceivedByDirectors" id="Fact_99018ed311e0466fa9e326b1e553a9bf" contextRef="c20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">17,729</ix:nonFraction> converted initial shares of common stock, <ix:nonFraction name="ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors" id="Fact_766c92a3ddae4a5e94a89ab2ea5d9e5d" contextRef="c20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">53,189</ix:nonFraction>
          converted shares of additional common stock, <ix:nonFraction name="ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors" id="Fact_0a8367f74dca456fb01448716b5c3531" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_RelatedPartyTransactionAxis_PreMergerFinancingMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">80,366</ix:nonFraction> Series A Warrants and <ix:nonFraction name="ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors" id="Fact_1cac354f7de64a9387c733a6723b3a28" contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RelatedPartyTransactionAxis_PreMergerFinancingMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,444</ix:nonFraction> Series B Warrants. In connection with the Pre-Merger Financing, <ix:nonFraction name="ocup:NumberOfDirectorsSignedWaiverAgreements" id="Fact_881e475e5f574135b03e2d116c42c09b" contextRef="c20220101to20221231" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction>
          directors of the Company signed Waiver Agreements, waiving certain reset provisions and financing restrictions. These directors did not receive any of the additional Series B Warrants that were issued in connection with the Waiver Agreements. See
          Note 3 &#8211; Pre-Merger Financing.</div>
</ix:continuation>
        <ix:continuation id="Text_eb75479289494b3daed231a5ea3ce9b25" continuedAt="Text_eb75479289494b3daed231a5ea3ce9b26">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_eb75479289494b3daed231a5ea3ce9b26" continuedAt="Text_eb75479289494b3daed231a5ea3ce9b27">
<div style="text-align: justify; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Other</div>
</ix:continuation>
        <ix:continuation id="Text_eb75479289494b3daed231a5ea3ce9b27" continuedAt="Text_eb75479289494b3daed231a5ea3ce9b28">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_eb75479289494b3daed231a5ea3ce9b28">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On April 8, 2022, Ocuphire entered into a consulting agreement with a director of the Company. The consulting agreement provided for $<ix:nonFraction name="ocup:ConsultingFeePayable" id="Fact_b0beb34095d9464db10c9dd6b51d2922" contextRef="c20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> a month in cash payments, effective as of April 1, 2022. Additionally, on April 8, 2022, in connection with the consulting arrangement, the
          director received a stock option grant for <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_ce7869d0541d425da4740cf3c05ec67a" contextRef="c20220408to20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction> options, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact_3fb60a4c5a524b3aa43667a57d06e696" contextRef="c20220408to20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of which will vest on March 31, 2023, with the remainder vesting in equal monthly installments over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_019ea7690f904aa8b4080c76ad1e45b2" contextRef="c20220101to20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember" format="ixt-sec:durwordsen">36 months</ix:nonNumeric>. The consulting agreement was amended on September 19, 2022 to provide for vesting acceleration for stock-based awards in the event of a change in control. The
          consulting agreement was also amended effective December 1, 2022 to increase the cash payment to $<ix:nonFraction name="ocup:ConsultingFeePayable" id="Fact_3b26b3e88fa8471199a2ba48901e2768" contextRef="c20221201" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> per month. The Company
          incurred related consulting expenses of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Fact_eb3c7497c1714179bcdbe77dc8aa9f7d" contextRef="c20220101to20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">105,000</ix:nonFraction> during the year ended December 31, 2022. There were <ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Fact_62f4bf6f16da42dc9d120bcad5660aba" contextRef="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> related consulting expenses incurred during the year ended December 31, 2021. As of December 31, 2022, $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" id="Fact_e762d2abeb2149b0ad6369bea7ddc4e1" contextRef="c20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> of the related consulting expenses were unpaid.</div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_e19d84f56a1547d1939fe9ec7bb5720d" contextRef="c20220101to20221231" escape="true" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a21">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">7.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Stock-based Compensation</div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a21" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a22">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a22" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a23"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_ce369da47f764472a9af8d3eda0756be" contextRef="c20220101to20221231" escape="true" continuedAt="Text_0f19e523028d4039a634ef6544c896281">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of
          comprehensive income (loss) for the periods indicated below (in thousands):</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a23" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a24"><ix:continuation id="Text_0f19e523028d4039a634ef6544c896281" continuedAt="Text_0f19e523028d4039a634ef6544c896282">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a24" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a25"><ix:continuation id="Text_0f19e523028d4039a634ef6544c896282">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;"> 2022<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2021<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>General and administrative</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_8b943d13dfa940868cb908f32877b9e6" contextRef="c20220101to20221231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,060</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_137d8bf287744ab48ab5bd0b1ff6f7a8" contextRef="c20210101to20211231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div>Research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_1e6c431043334c8eb5820a884c4aaf06" contextRef="c20220101to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">747</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f3d8e5be876d471c9df99ca1b4a4afd7" contextRef="c20210101to20211231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">798</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Total stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_c3922fd56ae64e09a033fc113173345a" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,807</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_371536f81dea451b8e09885eec615e28" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,914</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a25" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a26">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">143</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a26" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a27">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire Stock Options</div>
</ix:continuation>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a27" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a28">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
          <div style="font-family: 'Times New Roman'; font-size: 10pt;">
            <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a28" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a29">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); font-variant: normal; text-transform: none;">Inducement Plan</div>
</ix:continuation>
            <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a29" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a210">
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
            <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a210" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a211">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On February 22,
              2021, the Company adopted the Ocuphire Pharma, Inc. 2021 Inducement Plan (the &#8220;Inducement Plan&#8221;), pursuant to which the Company reserved <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_e2caa4dd44204418a61e1dd8ef9b081c" contextRef="c20210222_PlanNameAxis_InducementPlanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">325,258</ix:nonFraction>
              shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&#8217;s entry into employment with the Company within
              the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.</div>
</ix:continuation>
            <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a211" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a212">
<div><br />
            </div>
</ix:continuation>
          </div>

        </div>

        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a212" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a213">
<div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2020 Equity Incentive Plan</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a213" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a214">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a214" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a215">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In November 2020, the stockholders of the Company approved the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) for stock-based awards. Under the 2020 Plan, (i) <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_0177a438720640cc996bb5dd8e48b2de" contextRef="c20201130_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction> new shares of common stock were reserved for issuance and (ii) up to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_e2d0eb0082dc494dab58645dc35f50d5" contextRef="c20201130_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">70,325</ix:nonFraction> additional shares of common stock may be issued, consisting of (A) shares that remain available for the issuance of awards under prior equity plans and (B) shares of
          common stock subject to outstanding stock options or other awards covered by prior equity plans that have been cancelled or expire on or after the date that the 2020 Plan became effective. Under the 2020 Plan, the shares reserved automatically
          increase on January 1 of each year, for a period of not more than <ix:nonNumeric name="ocup:MaximumPeriodOfSharesReservedUnderPlan" id="Fact_e78c4edaf47748c2aead983c3cf3a479" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date the 2020 Plan is approved by the
          stockholders of the Company, commencing on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" id="Fact_61cf147c1ab24b0b8af40b0e50430abc" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of
          the shares of common stock outstanding as of December 31st of the preceding calendar year. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The 2020 Plan permits the grant of incentive and nonstatutory stock options, appreciation rights, restricted stock, restricted stock units, performance stock and cash awards, and other
            stock-based awards</span>.</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a215" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a216">
<div><br /></div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a216" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a217">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2018 Equity Incentive Plan</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a217" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a218">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a218" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a219">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Prior to the 2020 Plan, the Company had adopted a 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) in April 2018 under which <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_6511eebb48854fbaa5d7c0a2615dc988" contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,175,000</ix:nonFraction> shares of the Company&#8217;s common stock were reserved for issuance to employees, directors and consultants. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Upon the effective date of the 2020 Plan,&#160;<ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_3b126692b99347929e7e73aa2cb486f6" contextRef="c20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> additional shares were available for issuance under the 2018 Plan</span>.</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a219" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a220">
<div style="font-style: italic;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a220" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a221">
<div style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">General</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a221" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a222">
<div><br /></div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a222" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a223">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">During the years ended December 31, 2022 and 2021, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_f235835d35c34424abe11fdcc9219914" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">893,305</ix:nonFraction>
            and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_0d0112bb2a5f4436b55d15ab592b9f90" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">420,300</ix:nonFraction> stock options were granted to officers, directors, employees and consultants, respectively, generally vesting over a
            five (<ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_79effd737e7d4eef9a7e7c2b2264c471" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MinimumMember" format="ixt-sec:durmonth">5</ix:nonNumeric>) to forty-eight (<ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_ca3379e32e974777a3752763d24b401b" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MaximumMember" format="ixt-sec:durmonth">48</ix:nonNumeric>)
            month period. The Company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f09d06155d484070b4e5c10553f73bcb" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_9e487174aa5d4959af17a1be7fd64e65" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction> million in stock-based compensation expense related to stock options during the years ended December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_c83979174d334614b845657778200395" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,309</ix:nonFraction> and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_addc35c7d4ba4cb986325820398fa7a9" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">73,442</ix:nonFraction> stock options were
            exercised, respectively, with an intrinsic value of $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_85f244f3c97d4a05a6289e5cf5df707a" contextRef="c20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">59,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_4a58fc8f7dcc490aa2be4d0626bfe6c7" contextRef="c20211231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">345,000</ix:nonFraction>, respectively. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_28c984ccdc3e482885c0eb9898e76a28" contextRef="c20220101to20221231" escape="true" continuedAt="Text_84b511328f3b430696deff6a627bd1f71"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table summarizes the Company&#8217;s stock option plan activity:</span></ix:nonNumeric></div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_84b511328f3b430696deff6a627bd1f71" continuedAt="Text_84b511328f3b430696deff6a627bd1f72"><ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a223" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a224">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_84b511328f3b430696deff6a627bd1f72" continuedAt="Text_84b511328f3b430696deff6a627bd1f73"><ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a224" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a225">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1"> </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Options</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                <div style="text-align: center; font-weight: bold;">Weighted Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Term (years)</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="2">
                <div style="text-align: center; font-weight: bold;">Aggregate</div>
                <div style="text-align: center; font-weight: bold;">Intrinsic</div>
                <div style="text-align: center; font-weight: bold;">Value<sup>(1)</sup></div>
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Outstanding at December 31, 2020</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_c30c6dd73c134f9994b04485ef6537ca" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,784,198</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_0aa796396746408984faac57074c5b53" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.17</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_4756c611fd67476e95db364b85cf9118" contextRef="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" format="ixt-sec:duryear">8.87</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_46b97527dae540aca27bf64658108ec9" contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,744</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                <div>Granted</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_8bd0c8e2fe6f4b1597b5dbe0afa12abc" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">420,300</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_26c8c403726b4957b667e2d61db5ac43" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.72</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                <div>Exercised</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_f17a79f80ac44063b1b7bc8525d3cff3" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">73,442</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_51e765073d0a4bc68b2d3b82c48b94ea" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
                <div>Forfeited/Cancelled</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" id="Fact_4b543b09362349e092a6f1064a38188f" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">34,220</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" id="Fact_5c4d73b060ee47b38856658a3ff51580" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>&#8212;</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Outstanding at December 31, 2021</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_fd4990cf3ffd4772962701b198f88822" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,096,836</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_3428813e05454c1bae3d055ef6421683" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.97</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_213a3daea95546e0923248e62dc502ab" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" format="ixt-sec:duryear">8.20</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_3cfe8fa586b34f52a55e354dc7fa3bb7" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,795</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;">
                <div>Granted</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_1ae669ee470d4b7197d985e7828f539d" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">893,305</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_a7bc92342f62424486235cb4a1598ddc" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.64</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                <div>Exercised</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_a8d96e33bf0b48b49c07e07f47501d17" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,309</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_cbc5203c9cd54ca6ad629659db5ecfe1" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.09</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px;">
                <div>Forfeited/Cancelled</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" id="Fact_a4dfb84f1a014332a4f191b2392ac384" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">29,788</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" id="Fact_bfb9b8dcf9f840d883264db0dbb9f1d0" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.21</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1"></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1"></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Outstanding at December 31, 2022</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_d7acd6cdacfd46f29f47044cb4ed156d" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,936,044</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_1bfe52cfc35e4e34a5e74c3b4bcb01eb" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.87</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_288bae3959fa4e9ab975217b37b74fd9" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" format="ixt-sec:duryear">7.82</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_37c7f8e7261c4c0ea247d23587c35f7a" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,314</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" rowspan="1">Vested and expected to vest at December 31, 2022</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1" rowspan="1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_5e8c37a9a5894c428a8c698f7b0bcfa8" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,936,044</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1"><ix:nonFraction name="ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" id="Fact_9f8a65c280ed4874b376de2e6036e583" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.87</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1"><ix:nonNumeric name="ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" id="Fact_8df741c91b5c4665b228503aaaffb3c7" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" format="ixt-sec:duryear">7.82</ix:nonNumeric></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1" rowspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1" rowspan="1"><ix:nonFraction name="ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" id="Fact_4ced063294be4461a959db5d39a759cf" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,314</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <div>Vested and exercisable at December 31, 2022</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" id="Fact_f952b6aa6fe94d10a38cb0363e59b400" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,723,792</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" id="Fact_c4e2e8004813494cad4a03b664c0d31d" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.56</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Fact_33c9f80574b9448eb3947ece1b0b9514" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" format="ixt-sec:duryear">7.07</ix:nonNumeric></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" id="Fact_2e21a6a36c364fdba0d8dc06ccade1de" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,680</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_84b511328f3b430696deff6a627bd1f73" continuedAt="Text_84b511328f3b430696deff6a627bd1f74"><ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a225" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a226">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_84b511328f3b430696deff6a627bd1f74"><ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a226" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a227">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></td>

    <td style="width: auto; vertical-align: top;">
                <div><ix:footnote id="Foot_b060c1ad19c34ed89e1bcfe2db363855" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and
                  the fair value of our common stock as of December 31, 2022 and 2021 of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" id="Fact_155f4d69648a48edb7d4b1e426b649e3" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.53</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" id="Fact_b8e48a7bee99487b9af8787da75af04d" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.73</ix:nonFraction> per share, respectively.</ix:footnote></div>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a227" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a228">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">144</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a228" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a229">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The weighted average
          fair value per share of options granted during the years ended December 31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" id="Fact_7fee624f3917421783cc39ac611086d9" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.06</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" id="Fact_bda0a7e2611746a8a1a3b2766ae87dc2" contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.36</ix:nonFraction>, respectively. The Company measures the fair value of stock options with service-based vesting criteria to employees, directors, consultants and
          directors on the date of grant using the Black-Scholes option pricing model. The Company does not have adequate history to support an internal calculation of volatility and expected term. As such, the Company has used a weighted average
          volatility considering the volatilities of several guideline companies.</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a229" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a230">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a230" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a231">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">For purposes of
            identifying similar entities (guideline companies), the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The average expected life of the options was based on the contractual term for
            agreements that allow for exercise of vested options through the end of the contractual term upon termination of continuous service, and for all other agreements, was based on the mid&#8209;point between the vesting date and the end of the
            contractual term according to the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin 110. The risk&#8209;free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to
            the expected life assumed at the date of grant. The Company records forfeitures when they occur. The assumed dividend yield was based on the Company&#8217;s expectation of not paying dividends in the foreseeable future.</div>
</ix:continuation>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a231" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a232">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
          </div>
</ix:continuation>
        </div>


        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a232" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a233"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_416d0ff8b902480f84750f2d3ed8b433" contextRef="c20220101to20221231" escape="true" continuedAt="Text_aa74b1a608924b7dba674185a3bea43f1">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The weighted average assumptions used in the Black-Scholes option pricing model are as follows during the years ended December 31, 2022 and 2021:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a233" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a234"><ix:continuation id="Text_aa74b1a608924b7dba674185a3bea43f1" continuedAt="Text_aa74b1a608924b7dba674185a3bea43f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a234" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a235"><ix:continuation id="Text_aa74b1a608924b7dba674185a3bea43f2">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: middle; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2022<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2021<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: #CCEEFF;">
                <div>Expected stock price volatility</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_7019c0240be447d085c3f6fd0d8efd10" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">97.4</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_ba110d49eecd4072936192ab9f681898" contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">98.1</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%;">
                <div>Expected life of options (years)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_3507cf65de6142f5b3780a940797b9a9" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member" format="ixt-sec:duryear">5.8</ix:nonNumeric></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_a2e7e64447da4fc1b4ad08a953fd1fac" contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member" format="ixt-sec:duryear">5.8</ix:nonNumeric></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%; background-color: #CCEEFF;">
                <div>Expected dividend yield</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_10652bd0686446048a83e644a49bfcd9" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_59d78bbed1614928b52ff313154a1567" contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%;">
                <div>Risk free interest rate</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_d476bce210a841e08e0ea7774a3aeb9e" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.3</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_098be008da944828879e2fc262c4372a" contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.9</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>%</div>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a235" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a236">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a236" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a237">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">During the years ended December 31, 2022 and 2021, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" id="Fact_5d7a4bb747fb4e42aebe1813998c363e" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">488,621</ix:nonFraction>
          and <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" id="Fact_967e39bffe874c37a8e3e5e3449c59af" contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">468,301</ix:nonFraction> stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended
          December 31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" id="Fact_1239b7e2414449a49ae3d4754413a2de" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.29</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" id="Fact_8060c494397a4f929e159c789afc6acf" contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.49</ix:nonFraction>,
          respectively. During the years ended December 31, 2022 and 2021, <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" id="Fact_1e89e3f0312144c399a0ff4de2897486" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">29,788</ix:nonFraction> and <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" id="Fact_dcaec75bd422438388d811e183f2288b" contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">34,220</ix:nonFraction> stock options were forfeited, respectively. As of December 31, 2022, <ix:nonFraction name="ocup:CommonStockCapitalSharesAvailableForFutureIssuance" id="Fact_5b1cc856134c4f8cbc904172a6ad20b7" contextRef="c20221231_PlanNameAxis_InducementPlanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="ocup:CommonStockCapitalSharesAvailableForFutureIssuance" id="Fact_0fd6d528b1054bc58606c0af0c66c2dc" contextRef="c20221231_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">894,920</ix:nonFraction></ix:nonFraction>
          shares in the aggregate were available for future issuance under the 2020 Plan and Inducement Plan.</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a237" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a238">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a238" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a239">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Unrecognized stock-based compensation cost was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" id="Fact_6e2d4625b8874670bcda4fb37d53bfe2" contextRef="c20221231_PlanNameAxis_EquityIncentivePlan2018Member" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction>
          million as of December 31, 2022. The unrecognized stock-based expense is expected to be recognized over a weighted average period of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_8b487cba5cfa48a2accfc0a5f786607b" contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member" format="ixt-sec:duryear">1.2</ix:nonNumeric>
          years.</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a239" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a240">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div style="font-style: italic; font-weight: bold;">
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a240" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a241">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Restricted Stock Awards</div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a241" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a242">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a242" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a243">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On November 11, 2020, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_150dd139817f49cc8b7bcbd0666fbdd9" contextRef="c20201111to20201111_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,000</ix:nonFraction>
          restricted stock awards (&#8220;RSAs&#8221;) that vested on January 8, 2021. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_e29efb79e92446dc93016fd12288eb40" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_a1c565d0dd9643c58cb6f2ccd68a6ed3" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> RSAs granted during the years ended December 31,
          2022 or 2021.</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a243" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a244">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160; <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a244" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a245">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The stock-based compensation expense attributed to the RSAs during each of the years ended December 31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_4a14ec592bb94e838795f7973d6349bf" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_7ea84af383b14814964e99aeec87742b" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">22,000</ix:nonFraction>, respectively.</div>
</ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a245" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a246">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">145</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>


        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a246" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a247"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Text_ace1c54d93bf432388e0694dd9356ffd" contextRef="c20220101to20221231" escape="true" continuedAt="Text_3636b4de7d7544b787ca420e4f9a27911">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A summary of RSA activity is as follows for the year ended December 31, 2021:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a247" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a248"><ix:continuation id="Text_3636b4de7d7544b787ca420e4f9a27911" continuedAt="Text_3636b4de7d7544b787ca420e4f9a27912">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a248" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a249"><ix:continuation id="Text_3636b4de7d7544b787ca420e4f9a27912">
<table cellspacing="0" cellpadding="0" border="0" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>Non-vested at December 31, 2020</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_522c8cf81a4e48478638d9112d022ec0" contextRef="c20201231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
                <div>Granted</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_2b7ff9a033fc4182a65424fcbcb035e9" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>Vested</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_794af1b256ce40b98309235a1dd9fe78" contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;">
                <div>Non-vested at December 31, 2021</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_b21fbb1eaf56464594bfb76fe64a9d51" contextRef="c20211231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a249" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a250">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a250" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a251">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Common Stock Issued
            for Services <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a251" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a252">
<div><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a252" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a253">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The Company granted
            common stock for services in the amount of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_0dc0850aa5624d119613a7fadb7ade81" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">74,396</ix:nonFraction> and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" id="Fact_095696f1357e4a438e4a7d736586c2f5" contextRef="c20210101to20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">21,414</ix:nonFraction> shares of common stock during the years ended December 31, 2022 and 2021, respectively, to <ix:nonFraction name="ocup:NumberOfBoardMembersGrantedStockForServices" id="Fact_7fc25f2f627c4bffa598e8c97318dbb4" contextRef="c20220101to20221231" unitRef="U012" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> and <ix:nonFraction name="ocup:NumberOfBoardMembersGrantedStockForServices" id="Fact_a202e25fa9584acb8bce03347b8bc297" contextRef="c20210101to20211231" unitRef="U012" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> board members during those periods, respectively, who elected
            to receive their board retainers in the form of stock for services. The stock-based compensation related to these services amounted to $<ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" id="Fact_7429844d5d9448c5be772fab97526d73" contextRef="c20220101to20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">154,000</ix:nonFraction>
            and $<ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" id="Fact_6c2c307dc6d3416ea8ac39ad630cdc9c" contextRef="c20210101to20211231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">108,000</ix:nonFraction> during the years ended December 31, 2022 and 2021, respectively.</div>
</ix:continuation>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a253" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a254">
<div><br />
          </div>
</ix:continuation>
        </div>

        <div>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a254" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a255">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Former Rexahn Options</div>
</ix:continuation>
          <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a255" continuedAt="Text_a0609cfaedc347b2931f357b9e9f29a256">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
          <div>
            <ix:continuation id="Text_a0609cfaedc347b2931f357b9e9f29a256">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Following the closing of the Merger, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_9cf644ff0ce848aa8f5aad98380a1332" contextRef="c20211231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">123</ix:nonFraction>
              unexercised and vested options to purchase common stock granted under the Rexahn Pharmaceuticals Stock Option Plan, as amended (the&#160;&#8220;Rexahn 2003 Plan&#8221;, and together with the Rexahn 2013 Plan, the&#160;&#8220;Prior Plans&#8221;) were outstanding. As of
              December 31, 2022, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_a3cd9498ad7e4d0596bbe2438844954b" contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction> of the former Rexahn options remained outstanding under the Prior Plans. During the year ended December
              31, 2022, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" id="Fact_d6a6ea9d3cf8465580021657d821a242" contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">82</ix:nonFraction> of the former Rexahn options expired.</div>
</ix:continuation>
             </div>

        </div>

        <div><br /></div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div><ix:nonNumeric name="ocup:ApexianSublicenseAgreementTextBlock" id="Text_2074a37595f94f3fb91cf9d3e70aaa8f" contextRef="c20220101to20221231" escape="true" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b1">
<div>  <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b1" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Apexian Sublicense Agreement</div>
              </td>

  </tr>


</table>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b2" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b3">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b3" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b4">
<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b4" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b5">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b5" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b6">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On January 21, 2020, as amended on June 4,
          2020, the Company entered into a sublicense agreement (the &#8220;Sublicense Agreement&#8221;) with Apexian, pursuant to which it obtained exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to
          therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions. The lead compound in the Ref-1 Inhibitor program is APX3330, which the Company intends to develop as an oral pill therapeutic to treat diabetic
          retinopathy and diabetic macular edema initially, and potentially later to treat wet age-related macular degeneration.</div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b6" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b7">
<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b7" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b8">
<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b8" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b9">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company agreed to
          make one-time milestone payments under the Sublicense Agreement for each of the first ophthalmic indication and the first diabetes mellitus indication for the Development and Regulatory milestones, and once for each of the Sales milestones. These
          milestone payments include (i) payments for specified developmental and regulatory milestones (including completion of the first Phase 2 trial that meets a primary endpoint and the first Phase 3 pivotal trial in the United States, and filing and
          achieving regulatory approval from the FDA for the first New Drug Application for a compound) totaling up to $<ix:nonFraction name="ocup:FutureMilestoneMethodRevenueNotRecognized" id="Fact_7a4ebca61ea84e7baa3c62d6362728f4" contextRef="c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentAndRegulatoryMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">11</ix:nonFraction> million in the
          aggregate and (ii) payments for specified sales milestones of up to $<ix:nonFraction name="ocup:FutureMilestoneMethodRevenueNotRecognized" id="Fact_4c62d27f43cf4789ba2e8e05f9962bac" contextRef="c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">20</ix:nonFraction> million in the aggregate, which net sales milestone payments
          are payable once, upon the first achievement of such milestone. Lastly, the Company also agreed to make a royalty payment equal to a single-digit percentage of its net sales of products associated with the covered patents under the Sublicense
          Agreement. If it is not terminated pursuant to its terms, the Sublicense Agreement shall remain in effect until expiration of the last to expire of the covered patents.</div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b9" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b10">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b10" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b11">
<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b11" continuedAt="Text_c5467589cff44f93807e7b1e8b99776b12">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_c5467589cff44f93807e7b1e8b99776b12">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">None of the milestone
          or royalty payments, were triggered or deemed probable as of December 31, 2022.</div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_60b313f530e24d9eb46ede39723c428e" contextRef="c20220101to20221231" escape="true" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">9.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Stockholder Equity<br />
                </div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b1" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <div>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b2" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b3">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: italic; font-variant: normal; text-transform: none;">At-The-Market
              Program</div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b3" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b4">
<div><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b4" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b5">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On February 4, 2021, Ocuphire filed a Form S-3 shelf registration under the Securities Act of 1933 which was declared effective by the SEC on February 12,&#160;2021 (the &#8220;2021 Shelf&#8221;) under which the
                Company may offer and sell, from time to time in its sole discretion, securities having an aggregate offering price of up to $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_87dc7453a26242e89235234264c82100" contextRef="c20210212to20210212_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ShelfRegistrationMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">125</ix:nonFraction>
                million. In connection with the 2021 Shelf, on March 11,&#160;2021, Ocuphire entered into a sales agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) under which the Company may offer and sell, from time to time at its sole
                discretion, to or through JonesTrading, acting as agent and/or principal, shares of its common stock having an aggregate offering price of up to $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_355a0d916e4c4fc78f6f1d315ab8a8ae" contextRef="c20210311to20210311_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">40</ix:nonFraction>
                million (the &#8220;ATM&#8221;). During the years ended December 31,&#160;2022 and 2021, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_959a628e896b4c5799b2b75a806e3be8" contextRef="c20220101to20221231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,848,980</ix:nonFraction> and </span><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_d604b8ea295c487dbd6d373ef5c9cb59" contextRef="c20210101to20211231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,778,890</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> shares of common stock were sold under the ATM for aggregate gross proceeds in the amount of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_f4be0caa3cba4114b7ebb87fc0fd126e" contextRef="c20220101to20221231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_7f2cae5c954f426a8ba218356cc553e8" contextRef="c20210101to20211231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.5</ix:nonFraction> million, respectively, before
                deducting issuance expenses, including the placement agent&#8217;s fees, legal and accounting expenses, in the amount of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_1a6c6ec10bfa43c4a6c03d39fbfeee8d" contextRef="c20220101to20221231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">133,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_8f4ef4defb394fae9d92cb398d80d2fc" contextRef="c20210101to20211231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million, respectively.</span></div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b5" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b6">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br />
              </span></div>
</ix:continuation>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">146</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of
                      Contents</a></span></div>

                <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

                </div>

              </div>

            </div>

            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b6" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b7">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;">Registered Direct Offering</div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b7" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b8">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b8" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b9">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On June 4,&#160;2021, the Company entered into a placement agency agreement for a registered direct offering (&#8220;RDO&#8221;) with A.G.P./Alliance Global Partners (&#8220;AGP&#8221;). Pursuant to the terms of the
                placement agency agreement, AGP on June 8,&#160;2021 sold an aggregate of </span><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_aa2856fbac4a4a4da7e9cc59b02ef4da" contextRef="c20210608to20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,076,923</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> shares of the Company&#8217;s common stock and warrants to purchase </span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_120f2bcc68e24f65b7f757e4043924e3" contextRef="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,538,461</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> shares of the Company&#8217;s common stock (the &#8220;RDO Warrants&#8221;) at an offering price of $<ix:nonFraction name="ocup:StockSoldPricePerShare" id="Fact_879be5e604aa45079fddc709ba342521" contextRef="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U003" decimals="3" scale="0" format="ixt:num-dot-decimal">4.875</ix:nonFraction> per one share and </span><ix:nonFraction name="ocup:StockSoldPricePerShare" id="Fact_a0aefcbdc9664962b957bc66c762cb84" contextRef="c20210608_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.50</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> RDO Warrants, for gross proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_0ddcd0ec321e4b9a9d7114943e95df71" contextRef="c20210608to20210608_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million, before AGP&#8217;s fees and related offering expenses in the amount of approximately $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_e5b811d7ecf2475b8048055af73e3e47" contextRef="c20210608to20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction> million. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The proceeds were allocated between the relative fair values of common stock and warrants at the sale date. The purchase agreement contains customary representations, warranties and agreements by the
                Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions. The RDO&#160; was made pursuant to the Company&#8217;s 2021 shelf registration.</span></div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b9" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b10">
<div><br /></div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b10" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b11">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The RDO Warrants have an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_0b81eb6ab0c244dabba28e6ca7c78323" contextRef="c20210608_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.09</ix:nonFraction> per share, are exercisable from the
                initial issuance date of June 8,&#160;2021, and will expire </span><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Fact_f7547903f1cb43ba8caecc1b0341b740" contextRef="c20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> following the initial issuance date. As of December 31,&#160;2022, </span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_ffa20a9e3b0e4879b04d8fa734966760" contextRef="c20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,538,461</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> RDO Warrants were outstanding.</span></div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b11" continuedAt="Text_69241a6b8d3e45128d84c0667a3f827b12">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br />
              </span></div>
</ix:continuation>
            <ix:continuation id="Text_69241a6b8d3e45128d84c0667a3f827b12">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman';">Subject to limited
                exceptions, a holder of a RDO Warrant will not have the right to exercise any portion of its RDO Warrants if the holder, together with its affiliates, would beneficially own in excess of <ix:nonFraction name="ocup:MinimumPercentageOfBeneficialOwnership" id="Fact_f16bb2dd0c17425e842ed74782a70913" contextRef="c20220101to20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.99</ix:nonFraction>% (or, at the election of a holder prior to the date of issuance, <ix:nonFraction name="ocup:MaximumPercentageOfBeneficialOwnershipLimitation" id="Fact_a3be6244d18a473884b0bd7246fbc110" contextRef="c20220101to20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.99</ix:nonFraction>%)
                of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise; provided, however, that upon prior notice to the Company, the holder may increase or decrease the beneficial ownership
                limitation, provided further that in no event shall the beneficial ownership limitation exceed <ix:nonFraction name="ocup:MaximumPercentageOfBeneficialOwnershipLimitation" id="Fact_2927aab3dd724f2d86dcab1a67297d05" contextRef="c20220101to20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.99</ix:nonFraction>%.</span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          </div>

        </div>


        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt;"> </span> </span></div>

    <div>
      <ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Text_b2bdb8e0cda94547911aa84e669ba94b" contextRef="c20220101to20221231" escape="true" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b1">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">10. License and Collaboration Agreements</div>
</ix:nonNumeric>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b1" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b2">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman';"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b2" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b3">
<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Nyxol&#160; License Agreement</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b3" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b4">
<div><br />
      </div>
</ix:continuation>
      <div>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b4" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b5">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On November 6, 2022, the Company entered into the Nyxol License Agreement, pursuant to which it granted Famy an exclusive, perpetual, sub-licensable
          license to develop, manufacture, import, export and commercialize (i) Nyxol for treating (a) reversal of mydriasis, (b) night vision disturbances or dim light vision, and (c) presbyopia, and (ii) Nyxol and low dose pilocarpine for treating
          presbyopia (together, the &#8220;Nyxol Products&#8221;) worldwide except for certain countries and jurisdictions in Asia (the &#8220;Viatris Territory&#8221;). The Company retains the exclusive right to develop, manufacture, have manufactured, import, export and
          commercialize the Product outside of the Viatris Territory.&#160; In 2023, Famy was acquired by Viatris Inc., and Viatris has assumed all of Famy&#8217;s obligations under the Nyxol License Agreement.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b5" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b6">
<div><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
          <div>
            <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b6" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b7">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Nyxol License Agreement, the Company will develop the Nyxol Products in the United States in partnership with Viatris, and
              Viatris will be responsible for developing the Nyxol Products in countries and jurisdictions in the Viatris Territory outside of the United States.&#160;Viatris will reimburse the Company for budgeted costs related to the development of the Nyxol
              Products through FDA approval. The parties established a joint steering committee, which oversees and makes decisions regarding the development of the Nyxol Products. The committee is composed of an equal number of representatives of Viatris
              and Ocuphire. Viatris will commercialize the Nyxol Products in the Viatris Territory for each indication that receives regulatory approval.</div>
</ix:continuation>
          </div>

        </div>

      </div>

      <div>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b7" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b8">
<div><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b8" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b9">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Nyxol License Agreement, the Company received a one-time non-refundable cash payment of $<ix:nonFraction name="ocup:NonRefundableCashPaymentReceived" id="Fact_f2fe4157faa54671a004bb09a9301149" contextRef="c20221101to20221130_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">35</ix:nonFraction> million in November 2022 for the exclusive, perpetual, sub-licensable license to develop, manufacture, import, export and commercialize the Nyxol Products in the Viatris
          Territory. In addition, with respect to each Nyxol Product, the Company will be eligible to receive potential additional payments of up to $<ix:nonFraction name="ocup:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" id="Fact_c2d489545a0c484bb36bd28ee8fd182b" contextRef="c20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">130</ix:nonFraction>
          million in the aggregate upon achieving certain specified regulatory or net sales milestones, with the first potential payment of $<ix:nonFraction name="ocup:FirstPotentialMilestonePaymentToBeReceived" id="Fact_e101ef46208d43c4b599b5214d76728a" contextRef="c20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>
          million to be made following approval by the FDA of Nyxol for reversal of mydriasis. The Company will also receive tiered royalties, starting at low double-digit royalties up to low <ix:nonFraction name="ocup:MaximumPercentageOfTieredRoyaltiesReceivable" id="Fact_ce8b2bae2de04f4bb96cba7cccdc3d8f" contextRef="c20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">twenty </ix:nonFraction>percent royalties, based on the aggregate annual net sales of all Nyxol Products in the United States, and will receive low double-digit royalties based on all annual net sales in
          the Viatris Territory outside of the United States. The royalty payments will continue on a country-by-country basis from the date of the first commercial sale of the first Nyxol Product in a country of the Viatris Territory until December 31,
          2040.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b9" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b10">
<div><br />
        </div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">147</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>

      </div>

      <div>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b10" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b11">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Either party may terminate the Nyxol License Agreement upon written notice in the case of the other party&#8217;s material breach (subject to applicable
          cure periods) or if the other party becomes subject to an insolvency event. In addition, the Company may terminate the agreement in its entirety if Famy, Viatris or their affiliates commence an action challenging the validity, enforceability or
          scope of any of Ocuphire&#8217;s patents that are exclusively licensed under the Nyxol License Agreement. Additionally, if Viatris determines not to pursue development or commercialization of a Product in a country or jurisdiction in the Viatris
          Territory, Viatris may terminate the license with respect to such Product in such country or jurisdiction.</div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b11" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b12">
<div><br />
        </div>
</ix:continuation>
      </div>

      <div>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b12" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b13">
<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Both Ocuphire and Viatris have agreed to indemnify the other party against certain losses and expenses relating to any breach of the indemnifying
          party&#8217;s obligations, representations, warranties or covenants under the Nyxol License Agreement.</div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b13" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b14">
<div><br />
        </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b14" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b15">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Nyxol License Agreement was accounted for under the provisions of ASC 606. In accordance with the p<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">rovisions under ASC 606, the Company identified <ix:nonFraction name="ocup:NumberOfPerformanceObligations" id="Fact_f3423a0dd685426ab3e59658a228f028" contextRef="c20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U013" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> distinct performance obligations: <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(1) the license to its intellectual property (&#8220;license transfer&#8221;) and (2) research and development services.</span></span><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b15" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b16">
<div><br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b16" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b17">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The aggregate transaction price associated with the Nyxol License Agreement was $<ix:nonFraction name="ocup:RevenueFromContractWithCustomerToBeRecognized" id="Fact_4f63833d1f504fcd83d6d902d73e5757" contextRef="c20221106to20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.2</ix:nonFraction> million which comprised the Initial License Transfer fee of $<ix:nonFraction name="ocup:RevenueFromContractWithCustomerToBeRecognized" id="Fact_9593d4f1e028421bb36aa8566684a8a0" contextRef="c20221106to20221106_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction> million and the estimated $<ix:nonFraction name="ocup:RevenueFromContractWithCustomerToBeRecognized" id="Fact_99c6f8ceba8b48cfab8bc166f07da126" contextRef="c20221106to20221106_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.2</ix:nonFraction> million payment anticipated under the research and development services that were not subject to cancellation. The transaction price was allocated
        between performance obligations based on their relative standalone selling price (&#8220;SSP&#8221;).</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b17" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b18">
<div>&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b18" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b19">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The SSP for the license transfer and for the research and development services was determined to be $ <ix:nonFraction name="ocup:EstimatedStandaloneSellingPriceForLicenseAgreement" id="Fact_56ca38346ba34327be746215c43937e7" contextRef="c20221106to20221106_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">287.8</ix:nonFraction> million and $<ix:nonFraction name="ocup:EstimatedStandaloneSellingPriceForLicenseAgreement" id="Fact_42eb03da25874b98ac14bfbb541a14b8" contextRef="c20221106to20221106_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.2</ix:nonFraction> million, respectively. The SSP for the
        license tran<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">sfer was determined based on
          a <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">discounted royalty cash flow approach, taking into consideration assumptions, including</span></span> projected worldwide net profit for each of the respective programs based on probability
        assessments, projections based on internal forecasts, industry data, and information from other guideline companies within the same industry and other relevant factors. The SSP for the research and development services was determined using a cost
        plus margin approach, based on anticipated expenditure outlays within the first <ix:nonNumeric name="ocup:PeriodOfNonCancellationWindowAgreement" id="Fact_50806cbd423f42aa97cf34c5de4c109f" contextRef="c20221106to20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember" format="ixt-sec:durwordsen">120-day</ix:nonNumeric> non-cancellation window. On a relative SSP
        basis, $<ix:nonFraction name="ocup:TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" id="Fact_74a78f933ebe4d3d887078ee72212f62" contextRef="c20221106to20221106_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">39.5</ix:nonFraction> million and $<ix:nonFraction name="ocup:TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" id="Fact_f42aebd72a204d6c8aec2d29422623e1" contextRef="c20221106to20221106_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>
        million of the transaction price was allocated to the license transfer and to the research and development services obligations, respectively. <br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b19" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b20">
<div>&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b20" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b21">
<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Recognition of Revenue</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b21" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b22">
<div>&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b22" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b23">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> determined that the licenses transferred represented functional intellectual property. As such, the revenue related to the licenses
            was recognized at the point in time in which the license/know-how was delivered to Famy which occurred during the fourth quarter of 2022. The Company determined that revenue related to the research and development services was to be recognized
            over time as the services are rendered based on an estimated percentage of completion input model.</span> </span>Revenue recognized under the Nyxol License Agreement during the year ended December 31, 2022 was $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_72aa2e3183ad4c2f8e0d598c2ec185b9" contextRef="c20220101to20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">39.8</ix:nonFraction> million.</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b23" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b24">
<div>&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b24" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b25">
<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Regulatory Milestones under the Nyxol License Agreement</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b25" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b26">
<div>&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b26" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b27">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has evaluated the regulatory milestones that may be received in connection with the Nyxol License Agreement. There is uncertainty that
        the events to obtain the regulatory milestones will be achieved given the nature of clinical development and the stage of the development of the Products. The remaining regulatory milestones will be constrained until it is probable that a
        significant revenue reversal will not occur.</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b27" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b28">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br />
      </div>
</ix:continuation>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter"></div>

        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">148</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

            <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

          </div>

        </div>

      </div>

      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b28" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b29">
<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Sales Milestone and Royalty Payments</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b29" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b30">
<div style="text-align: justify;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b30" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b31">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Sales milestones and royalties relate predominantly to a license of intellectual property granted to Famy and are determined by sales or
        usage-based thresholds. The sales milestones and royalties are accounted for under the royalty recognition constraint and will be accounted for as constrained variable consideration. The Company applies the royalty recognition constraint for each
        commercial milestone and will not recognize revenue for each until the subsequent sale of a licensed product (achievement of each) occurs.</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b31" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b32">
<div>&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b32" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b33">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">With the exception of the license transfer and the research and development services obligations, each of the remaining regulatory and sales
        milestone performance obligations and royalty payments were fully constrained as of December 31, 2022.</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b33" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b34">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b34" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b35"><ix:nonNumeric name="ocup:ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" id="Text_b9374f1b7035421a99606737d320be5d" contextRef="c20220101to20221231" escape="true" continuedAt="Text_4644ebec23f7469292e53876640065261">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of the closing balance of the contract asset associated with the Nyxol License Agreement is as follows as of December 31, 2022 (in thousands):&#160;</div>
</ix:nonNumeric></ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b35" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b36"><ix:continuation id="Text_4644ebec23f7469292e53876640065261" continuedAt="Text_4644ebec23f7469292e53876640065262">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b36" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b37"><ix:continuation id="Text_4644ebec23f7469292e53876640065262">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contract Asset</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of&#160;&#160;December 31, 2021</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="ocup:ContractAssetCurrent" id="Fact_7a288b845321488a86dd3e54c2babd75" contextRef="c20211231_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
            </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;" rowspan="1">Revenue recognized &#8211; license transfer <br />
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a33b0cac03c0432487c129207073ca99" contextRef="c20220101to20221231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,519</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Execution of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Nyxol License Agreement and&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">one-time non-refundable&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">payment</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="ocup:NonRefundableCashPaymentReceived" id="Fact_d3e940e90b204c01b5bb67e622d7cc03" contextRef="c20220101to20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Revenue recognized &#8211; research and development services</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_7b41045a7dd54c9ba70c38b4afb81c7d" contextRef="c20220101to20221231_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">331</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reclassification to accounts receivable related to&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">costs billed under the Nyxol License Agreement</span></div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="ocup:ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" id="Fact_72506667dd5c4b21ba39356fac637d7b" contextRef="c20220101to20221231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of December 31, 2022</div>
            </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1"><ix:nonFraction name="ocup:ContractAssetCurrent" id="Fact_6102c46148c546adb9e37f113dec7c70" contextRef="c20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,552</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b37" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b38">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b38" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b39">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The remaining amounts in the contract asset as of December 31, 2022 attributed to the research and development services are expected to be settled during the first
        half of 2023.</div>
</ix:continuation>
    </div>

    <div><ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b39" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b40">
<div><span style="font-family: 'Times New Roman';"><br />
      </span></div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b40" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b41">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;">BioSense License and Assignment Agreement</div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b41" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b42">
<div style="font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b42" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b43">
<div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">On March 10, 2020, pre-Merger, Rexahn entered into an amendment to its collaboration and license agreement, (as amended, the &#8220;BioSense License
          and Assignment Agreement&#8221;) with BioSense to advance the development and commercialization of RX-3117 for all human uses in the Republic of Singapore, China, Hong Kong, Macau, and Taiwan (the &#8220;BioSense Territory&#8221;). Under the terms of the BioSense
          License and Assignment Agreement, the Company (i) granted BioSense an exclusive license to develop and commercialize pharmaceutical products containing RX-3117 as a single agent for all human uses in the BioSense Territory and (ii) assigned and
          transferred all of the former Rexahn patents and patent applications related to RX-3117 in the BioSense Territory. The upfront payment consisted of an aggregate of $<ix:nonFraction name="ocup:NonRefundableCashPaymentReceived" id="Fact_40b278db80aa40fc8825ddfdc9ae4466" contextRef="c20200310to20200310_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,650,000</ix:nonFraction>, of which $<ix:nonFraction name="ocup:NonRefundableCashPaymentReceived" id="Fact_12efd9b0b1504d2194e77fc2c8071ea1" contextRef="c20200310to20200310_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,550,000</ix:nonFraction> was paid to Rexahn prior to the Merger.During
          the year ended December 31, 2021, the Company satisfied a performance obligation for the $<ix:nonFraction name="ocup:MilestonePaymentAchievedForPerformanceObligation" id="Fact_5b95e7947e634f488a9678a5beddd88d" contextRef="c20210101to20211231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> payment that was remaining and
          recorded this amount as license and collaborations revenue.</div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b43" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b44">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> <br />
      </div>
</ix:continuation>
      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b44" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b45">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b45" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b46">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b46" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b47">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Under the BioSense
          License and Assignment Agreement, the Company is eligible to receive additional milestone payments in an aggregate of up to $<ix:nonFraction name="ocup:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" id="Fact_0679eb3753f140dc9969657a25205319" contextRef="c20221231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">84,500,000</ix:nonFraction>
          upon the achievement of development, regulatory and commercial goals and will also be eligible to receive tiered royalties at low double-digit rates on annual net sales in the BioSense Territory. The Company determined that none of the milestone
          payments under the BioSense License and Assignment Agreement were probable of payment as of December 31, 2022, and as a result, <ix:nonFraction name="ocup:MilestonePaymentsAmountReceived" id="Fact_535f8cdc98d14622857eca6215206063" contextRef="c20220101to20221231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>
          revenue related to the milestones was recognized as the achievement of events entitling the Company to any milestone payments were highly susceptible to factors outside of the Company&#8217;s control. Future sales-based royalties related to the
          exclusive license to develop RX-3117 will be recognized in the period the underlying sales transaction occurs.</div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b47" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b48">
<div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b48" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b49">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b49" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b50">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b50" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b51">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b51" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b52">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Payments received
          under the BioSense License and Assignment Agreement are subject to the CVR Agreement described in Note 2 &#8211; Merger.</div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b52" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b53">
<div style="font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">149</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b53" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b54">
<div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-size: 10pt; text-align: justify; font-family: 'Times New Roman';">Processa License Agreement</div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b54" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b55">
<div style="font-size: 10pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b55" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b56">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b56" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b57">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b57" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b58">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b58" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b59">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On June 16, 2021, the
          Company entered into a license agreement (the &#8220;Processa License Agreement&#8221;) with Processa Pharmaceuticals, Inc. (&#8220;Processa&#8221;), pursuant to which the Company has agreed to grant Processa an exclusive license to develop, manufacture and
          commercialize RX-3117 globally, excluding the BioSense Territory.</div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b59" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b60">
<div><span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b60" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b61">
<div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">As consideration for the Processa License Agreement, the Company received an upfront payment in July 2021 consisting of <ix:nonFraction name="ocup:UpfrontPaymentReceivedInCommonStockShares" id="Fact_6f21a529b6734f5f98396f87ca903d5c" contextRef="c20210701to20210731_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">44,689</ix:nonFraction> shares of Processa common stock with a fair value of $<ix:nonFraction name="ocup:UpfrontPaymentReceivedInCommonStockFairValue" id="Fact_e4c0bb9f47df45b5900c4c30491c5deb" contextRef="c20210701to20210731_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">289,000</ix:nonFraction> (at the contract date) and a $<ix:nonFraction name="ocup:NonRefundableCashPaymentReceived" id="Fact_6e115dfc17e14cb194b658c755cb0227" contextRef="c20210701to20210731_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000</ix:nonFraction> cash payment.The Company was
          restricted from selling the Processa common stock for a period of <ix:nonNumeric name="ocup:PeriodOfRestrictionFromSellingStock" id="Fact_7f284c287be1484998101d34534bc057" contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric> ending June 16, 2022. As additional consideration, Processa
          will make payments to the Company upon the achievement of certain development and regulatory milestones, which primarily consist of dosing a patient in pivotal trials or having a drug indication approved by a regulatory authority in the United
          States or another country. In addition, Processa will pay the Company mid-single-digit royalties based on annual sales under the license and will make <ix:nonFraction name="ocup:NumberOfTimesPaymentsForSalesMilestone" id="Fact_6fa6fb88aa924f7885fbe4329ee40295" contextRef="c20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>-time
















          sales milestone payments based on the achievement during a calendar year of certain thresholds for annual sales. Processa is also required to give the Company <ix:nonFraction name="ocup:PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" id="Fact_89496d34f3804659a6023119c2957c42" contextRef="c20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">32</ix:nonFraction>% of any milestone payments received based on any sub-license agreement Processa may enter into with respect to the Processa License Agreement.The Company determined that none of the
          milestone payments under the Processa License Agreement were probable of payment as of December 31, 2022, and as a result, <ix:nonFraction name="ocup:MilestonePaymentsAmountReceived" id="Fact_dc195ed47fdc494ebfe9739b2c404f33" contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> revenue
          related to the milestones was recognized, as the achievement of events entitling the Company to any milestone payments were highly susceptible to factors outside of the Company&#8217;s control.</div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b61" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b62">
<div style="font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b62" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b63">
<div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">Processa is required to use commercially reasonable efforts, at its sole cost and expense, to conduct development activities in <ix:nonFraction name="ocup:MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" id="Fact_794b2fa53ddc44bf821fd7641fe3976c" contextRef="c20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" unitRef="U014" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> or more countries, including meeting specific diligence milestones that consist of: (i) first patient administered drug in a clinical trial of a
          licensed product prior to the three (<ix:nonNumeric name="ocup:MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" id="Fact_7996e550867c4a988a3aa951ef2b2a63" contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" format="ixt-sec:duryear">3</ix:nonNumeric>) year anniversary of the effective date; and (ii) first patient administered drug in a pivotal
          clinical trial of a licensed product or first patient administered drug in a clinical trial for a second indication of a licensed product prior to the five (<ix:nonNumeric name="ocup:MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" id="Fact_a6e1981d043d433fb2462fa288a3388e" contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" format="ixt-sec:duryear">5</ix:nonNumeric>) year anniversary of the effective date. Either party may terminate the agreement in the event of a material breach of the agreement that has not been cured following written notice and
          a <ix:nonNumeric name="ocup:PeriodOfOpportunityToCureBreachOfAgreement" id="Fact_d62c01492b8940b2b14732a134aad90a" contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" format="ixt-sec:durday">120</ix:nonNumeric>-day opportunity to cure such breach, and Processa may terminate the agreement for any reason upon <ix:nonNumeric name="ocup:PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" id="Fact_27437d2b26eb42d69a92a98b2e4c5bdc" contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember" format="ixt-sec:durwordsen">120 days</ix:nonNumeric> prior written notice to Ocuphire.</div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b63" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b64">
<div><span style="font-family: 'Times New Roman';"><br />
          </span> </div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b64" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b65">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December 31,
          2021, the Company had fulfilled its performance obligations with respect to the upfront payment under the Processa License Agreement and had recognized the associated licensing revenue in connection with the payment.</div>
</ix:continuation>
      </div>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b65" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b66">
<div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </span> </div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b66" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b67">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b67" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b68">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b68" continuedAt="Text_6678ab917ba04f3690cb59d35f436c4b69">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_6678ab917ba04f3690cb59d35f436c4b69">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Payments received
          under the Processa License Agreement will be subject to the CVR Agreement described in Note 2 &#8211; Merger.</div>
</ix:continuation>

        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
        </div>

      </div>

    </div>

    <div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" id="Text_b389e89bb99a44f2b22914b55ad571ce" contextRef="c20220101to20221231" escape="true" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc721">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">11.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Net income (loss) per share</div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc721" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc722">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div>
          <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc722" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc723">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Basic income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during
            the period.&#160; Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any
            common stock equivalents, if dilutive. The Company&#8217;s warrants, stock options and restricted stock awards, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method
            for the warrants, stock options and restricted stock. Incremental common stock equivalents that were antidilutive were excluded in calculating diluted income per share.&#160; For the year ended December 31, 2021, no common stock equivalents were
            included in the diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the prior year period.</div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc723" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc724">
<div><br /></div>
</ix:continuation>
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc724" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc725"><ix:nonNumeric name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="Text_41a540260c584531a085cecea1cd0c27" contextRef="c20220101to20221231" escape="true" continuedAt="Text_2266a425c21a4eb5a10fe0bb23135a1d1">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';">The following table presents the computation of weighted average common shares considered in the computation of
            diluted net income (loss) per share:</div>
</ix:nonNumeric></ix:continuation>
          <div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"><ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc725" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc726"><ix:continuation id="Text_2266a425c21a4eb5a10fe0bb23135a1d1" continuedAt="Text_2266a425c21a4eb5a10fe0bb23135a1d2">
<div><br /></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc726" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc727"><ix:continuation id="Text_2266a425c21a4eb5a10fe0bb23135a1d2">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" rowspan="1">&#160;2022 </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" rowspan="1">2021 <br />
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman';">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Denominator (weighted average shares)</div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;">&#160;<br />
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;">&#160;<br />
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Basic common shares outstanding</div>
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><br />
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_8fb0e766be404c1f87447d0d4880c691" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,931,080</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><br />
                    </div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_03f0373541424e8b94365e50f7479703" contextRef="c20210101to20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,852,745</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Dilutive stock options</div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="ocup:IncrementalCommonSharesAttributableToOptions" id="Fact_fbbb129270c0422db3292d8ae6e102d5" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">589,165</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="ocup:IncrementalCommonSharesAttributableToOptions" id="Fact_a1bc913e75b24c3a9eec83fe9a5fd7f5" contextRef="c20210101to20211231" unitRef="U002" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Dilutive warrants</div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="ocup:IncrementalCommonSharesAttributableToWarrants" id="Fact_be00286fdb7f4ef4811765daa12d114e" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">76,967</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="ocup:IncrementalCommonSharesAttributableToWarrants" id="Fact_368d137a301a4011a08d203800e7615e" contextRef="c20210101to20211231" unitRef="U002" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px;">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Diluted common shares outstanding</div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_f5e2200b590449a5b7eb457579632d60" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,597,212</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_e2af5fd2efa048729f71b43915fb94bb" contextRef="c20210101to20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,852,745</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
            </div>

          <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc727" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc728">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">150</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of
                    Contents</a></span></div>

              <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

                <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

              </div>

            </div>

          </div>

        </div>


        <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc728" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc729"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_1e7d9862e0914a08aa475a8026f53290" contextRef="c20220101to20221231" escape="true" continuedAt="Text_49c5b8afa90544f2bb58e802e68e4f5f1">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The following potential common shares were not
            considered in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive for the year end periods presented below:</span> <br />
        </div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc729" continuedAt="Text_a17e8553a1d44f28ab04b39d97f3bc7210"><ix:continuation id="Text_49c5b8afa90544f2bb58e802e68e4f5f1" continuedAt="Text_49c5b8afa90544f2bb58e802e68e4f5f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_a17e8553a1d44f28ab04b39d97f3bc7210"><ix:continuation id="Text_49c5b8afa90544f2bb58e802e68e4f5f2">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2022<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2021<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Series A, Series B and RDO warrants</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_a52d93040d754faa9eac39bbcabe42a5" contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,145,201</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_db61516ca985443780773ed3c60fb077" contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,282,999</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>Stock options</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2029e214b9054ee09ce7011c42bd4c92" contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,346,879</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_9f682611a2c942b4a117d23f95eba74d" contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,096,836</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Restricted stock awards including pending issuances of stock for services <br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_b2d6bd2824e64df6aad870fd1d5e8eb0" contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_cb5203c15eb549d39c2d41d145b00281" contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,970</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%;">
                <div>Former Rexahn warrants</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_0ad51c329f8b409eb304759a256cede3" contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,713</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_5e3977beac1c4c61885c3886462269de" contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">66,538</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>Former Rexahn options</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_f53eaeb20ccb489dbcd4b25c78d8c2e4" contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnOptionsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_ab0a6853353e453fb0946bd6ec3f3187" contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnOptionsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">82</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_50148989e6f34ac8a68fb7d33b1f8246" contextRef="c20220101to20221231" escape="true" continuedAt="Text_d6f55cc5924744959855b48272d83a111">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">12.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Income Taxes<br />
                </div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a111" continuedAt="Text_d6f55cc5924744959855b48272d83a112">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a112" continuedAt="Text_d6f55cc5924744959855b48272d83a113">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The effective tax rate for the years ended December 31, 2022 and 2021 was <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_4719cc6b5cb44740985b6b7d978abceb" contextRef="c20220101to20221231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.7</ix:nonFraction> percent and <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_05c46e94de9c477fa89a2f9a4d1443f7" contextRef="c20210101to20211231" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction> percent, respectively.</div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a113" continuedAt="Text_d6f55cc5924744959855b48272d83a114">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>

        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a114" continuedAt="Text_d6f55cc5924744959855b48272d83a115"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Text_2df74980b6b743c0aede47789fbe3fd4" contextRef="c20220101to20221231" escape="true" continuedAt="Text_44edbdc2c10147a28e6b70e66dc1bc2f1">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements
          of comprehensive income (loss) is as follows for the years ended December 31, 2022 and 2021:</div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a115" continuedAt="Text_d6f55cc5924744959855b48272d83a116"><ix:continuation id="Text_44edbdc2c10147a28e6b70e66dc1bc2f1" continuedAt="Text_44edbdc2c10147a28e6b70e66dc1bc2f2">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a116" continuedAt="Text_d6f55cc5924744959855b48272d83a117"><ix:continuation id="Text_44edbdc2c10147a28e6b70e66dc1bc2f2">
<table cellspacing="0" cellpadding="0" border="0" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: middle; border-bottom: #000000 solid 2px;" colspan="2">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" rowspan="1">Income tax (benefit) provision at federal statutory rate</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="ocup:EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" id="Fact_1bf4612edbaa487db4f1f090d24d0ab6" contextRef="c20220101to20221231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">%<br />
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="ocup:EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" id="Fact_dc76014ab7264f95a9718b7cee8f8e1c" contextRef="c20210101to20211231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)%<br />
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="color: rgb(0, 0, 0);">Valuation allowance</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_3e2860fae86f4ab9bdb34a11cd295fff" contextRef="c20220101to20221231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">21.4</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)<br />
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_5ffdcfbf84c941a8a6db5c4dea845493" contextRef="c20210101to20211231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">11.9</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div>State income tax, net of federal benefit</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_91bab5305d644891a2332e56ae8444e8" contextRef="c20220101to20221231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.9</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_19154e229e644f73a7ee2628034dfe7e" contextRef="c20210101to20211231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">4.8</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)<br />
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="color: rgb(0, 0, 0);">Warrants</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="ocup:EffectiveIncomeTaxRateReconciliationWarrantsPercent" id="Fact_da67d441ccfc483fb35b80d3f315556d" contextRef="c20220101to20221231" unitRef="U007" decimals="3" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1"><ix:nonFraction name="ocup:EffectiveIncomeTaxRateReconciliationWarrantsPercent" id="Fact_d0af7e51399f46899cf1e02599d38605" contextRef="c20210101to20211231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">15.3</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0);">Stock options</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_a6b6e8196aa941338a51d9f22d605a4c" contextRef="c20220101to20221231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.4</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_c61f0406ec094f6989fdecceda087ca9" contextRef="c20210101to20211231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.1</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)<br />
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="color: rgb(0, 0, 0);">Research and development</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" id="Fact_1d53e59a08fb49a0a5fdc59dc837e49b" contextRef="c20220101to20221231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.1</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)<br />
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" id="Fact_86f57de1d8524390ba7b847ad52cc20a" contextRef="c20210101to20211231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.1</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)<br />
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="color: rgb(0, 0, 0);">Other</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" id="Fact_3abaacf0a8d241e88b07cd147f4a1872" contextRef="c20220101to20221231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.1</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)<br />
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" id="Fact_6121ad0752374aa298edf6aa5a845060" contextRef="c20210101to20211231" unitRef="U007" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.2</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)<br />
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                <div style="color: rgb(0, 0, 0);">Effective tax rate</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_5714fbd188b34893aa42fb13bce6af48" contextRef="c20220101to20221231" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.7</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">%<br />
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_d12189c5b3fa4bb797aaadc01ec42a59" contextRef="c20210101to20211231" unitRef="U007" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction><br />
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">%</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a117" continuedAt="Text_d6f55cc5924744959855b48272d83a118">
<div> <span style="font-family: 'Times New Roman';"><br />
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a118" continuedAt="Text_d6f55cc5924744959855b48272d83a119">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></div>
</ix:continuation>
        <ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Text_65ef6dfbb2374b06bdb00faf4c7c3175" contextRef="c20220101to20221231" escape="true" continuedAt="Text_af72e7a24603445bb57ad3bed93463231"><ix:continuation id="Text_d6f55cc5924744959855b48272d83a119" continuedAt="Text_d6f55cc5924744959855b48272d83a1110">
<div> <br /></div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_af72e7a24603445bb57ad3bed93463231" continuedAt="Text_af72e7a24603445bb57ad3bed93463232"><ix:continuation id="Text_d6f55cc5924744959855b48272d83a1110" continuedAt="Text_d6f55cc5924744959855b48272d83a1111">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The components of income tax provision (benefit) consisted of the following for the years ended December 31, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2022 and 2021 (in thousands):</span></div>
</ix:continuation></ix:continuation>
      </div>

      <div><ix:continuation id="Text_af72e7a24603445bb57ad3bed93463232" continuedAt="Text_af72e7a24603445bb57ad3bed93463233"><ix:continuation id="Text_d6f55cc5924744959855b48272d83a1111" continuedAt="Text_d6f55cc5924744959855b48272d83a1112">
<div><span style="font-family: 'Times New Roman';"><br />
        </span></div>
</ix:continuation></ix:continuation>
        <div><ix:continuation id="Text_af72e7a24603445bb57ad3bed93463233" continuedAt="Text_af72e7a24603445bb57ad3bed93463234"><ix:continuation id="Text_d6f55cc5924744959855b48272d83a1112" continuedAt="Text_d6f55cc5924744959855b48272d83a1113">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_af72e7a24603445bb57ad3bed93463234"><ix:continuation id="Text_d6f55cc5924744959855b48272d83a1113" continuedAt="Text_d6f55cc5924744959855b48272d83a1114">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" rowspan="1" colspan="2"><span style="font-weight: bold; font-family: 'Times New Roman';"> 2022 </span><span style="font-family: 'Times New Roman';"><br />
                  </span></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" rowspan="1" colspan="2"><span style="font-weight: bold; font-family: 'Times New Roman';">2021 </span><span style="font-family: 'Times New Roman';"><br />
                  </span></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Income (loss) before income taxes:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_f79df070aa504b639261ad99e216116d" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,203</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_543142ee2e0d429d96a433f95808a4a8" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56,693</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Current:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" colspan="1">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Federal</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_51cc5f04d77b4137b1e016d4e392ccfa" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">279</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_5bd0e1f7144741e0aaee20de73dfdbdf" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">State</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_2888c737d1f44ba4a867cdbf79d0591d" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_fb074044e70646e98a15fb4b1643a30f" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" colspan="1">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Total current tax provision (benefit)</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_e06e02e0a3cb4349ac64529363f09cd2" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">315</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_f78e1e361d0047279dab46090cf36909" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" colspan="1">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Deferred:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" colspan="1">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Federal</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_8a518f5a5dcc44f2bc70f5965a644804" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_b1d29ce2cfcc457b9d5066e773ae67f8" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">State</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_0751244d2edf41e29a92b09182ef163e" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_53030fd15823411daa498fbb9bf9ba5d" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: middle; width: 76%; padding-bottom: 4px;" colspan="1">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Total tax provision (benefit</span><span style="font-family: 'Times New Roman';">)</span></div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_a0f7c6e7246944d9af70ea11d1377122" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">315</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">$</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_d74097b046f44b6b8b3699bdb1393b54" contextRef="c20210101to20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
           </div>

        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1114" continuedAt="Text_d6f55cc5924744959855b48272d83a1115">
<div> <br />
        </div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">151</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>


        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1115" continuedAt="Text_d6f55cc5924744959855b48272d83a1116"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Text_7c7b46a6693c4bb28d230a8db5fa8696" contextRef="c20220101to20221231" escape="true" continuedAt="Text_5a6c553208af46c4b7e2e2dc5000a8a01">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities are summarized in the tables below as of December 31, 2022 and 2021 (in thousands):<br />
        </div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1116" continuedAt="Text_d6f55cc5924744959855b48272d83a1117"><ix:continuation id="Text_5a6c553208af46c4b7e2e2dc5000a8a01" continuedAt="Text_5a6c553208af46c4b7e2e2dc5000a8a02">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1117" continuedAt="Text_d6f55cc5924744959855b48272d83a1118"><ix:continuation id="Text_5a6c553208af46c4b7e2e2dc5000a8a02">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2022<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2021<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom;">
                <div style="font-weight: bold;">Deferred tax assets:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">Federal and state operating loss carryforwards</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_f0a36a13d4c04d4fa6f9692ad85dfb91" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,087</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_76d90d17394144ea8f90607da5ee0c70" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,244</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>Acquired intangibles</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" id="Fact_fe795f59bd984e8a8535f3de1381703b" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">547</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" id="Fact_4568cadaa3bb433cbd9a38767481b391" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">547</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">Deferral of research and development costs <br />
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" id="Fact_ce6125cf7cb3459c8aea7b86f9a2f9fc" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,820</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" id="Fact_932b9ea99c1243b3aa2057c852ca30a1" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>Organizational costs</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" id="Fact_961bdd56e7df4f04bf9c4b48cee9d464" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" id="Fact_909521014bc14f729a03a46f47688483" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">Other</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" id="Fact_b3ad390323eb4d7389ba2f9566bd21cf" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">62</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" id="Fact_8d22e90740f44908909ee885b43bc586" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_94fd58cd138e4633b6b3aff7fdb9c2fb" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,152</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_3465b989e8ac4df69e3ad1494274f8b5" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">811</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Research and development credit carryforward<br />
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="ocup:DeferredTaxAssetsResearchAndDevelopment" id="Fact_b5a33cef17434ebe977d8fbba6867938" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">731</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                <div><ix:nonFraction name="ocup:DeferredTaxAssetsResearchAndDevelopment" id="Fact_470abd24691543398bc3de6c7f75be92" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,035</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div>Subtotal</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_8196e3008ccd4323baa67a1cfa5bf8ae" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,406</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_d878e6a75389414aaf35fef7ba7f61f7" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,662</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Valuation allowance</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_35449218ccd04cfd9e9ac9cf82e907f2" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,770</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                <div>(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_8ff6e79ac99347a3a2f05f38a9b141ce" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,662</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
                <div>Total deferred tax assets, net of valuation allowance</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_322313bec1724c2caa59a3bbc8dc4e4c" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">636</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_80d74139865e4bea953365ad19e8292e" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="font-weight: bold;">Deferred tax liabilities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">Deferred revenue <br />
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:DeferredRevenue" id="Fact_a6f01c808eab411c8b4b5adb82f76eca" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">636</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:DeferredRevenue" id="Fact_a878704f4da0490bb2cc61e7612b56fe" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Total deferred tax liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" id="Fact_e5a4d027826b40b5a26f08c6081a3f96" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">636</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">
                <div><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" id="Fact_b7494cb692164ce290c9f2f0bff61886" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px;">
                <div style="font-weight: bold;">Net deferred tax assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_99b5a44b05b540a6b55b87789004940f" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                <div><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_921cfad713244ccb9558d248f1eb348c" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1118" continuedAt="Text_d6f55cc5924744959855b48272d83a1119">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1119" continuedAt="Text_d6f55cc5924744959855b48272d83a1120">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2022 and 2021, the Company had gross deferred tax assets of approximately $<ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_a3ad7526232245a49def00138527d47f" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_c0636b763bea440b80911e26021fe19a" contextRef="c20211231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction> million, respectively. Realization of the deferred tax
          assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has cumulative pre&#8209;tax losses <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">and faces significant challenges
            to becoming profitable in the future. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance</span> of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_e554b7f243d14fc9a9189721efcec161" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.8</ix:nonFraction>
          million and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_5fc6641b754b4c34b9d8853717257910" contextRef="c20211231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction> million as of December 31, 2022 and 2021, respectively. U.S. net deferred tax assets will continue to require a
          valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1120" continuedAt="Text_d6f55cc5924744959855b48272d83a1121">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1121" continuedAt="Text_d6f55cc5924744959855b48272d83a1122">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2022 and 2021, the tax effect of the Company&#8217;s federal net operating loss carryforwards was approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_7a21961b7aa94811aef8952f1956472b" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_ced72ccc59244c7eb82cbab4bdbe9c6a" contextRef="c20211231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.7</ix:nonFraction> million,
          respectively. The Company had federal research credit carryforwards as of December 31, 2022 and 2021 of approximately $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" id="Fact_951880c5fa2c4928b2f00b9a4afb75eb" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million and
          $<ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" id="Fact_523837b4cb9a4f1383429f78305eaa09" contextRef="c20211231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million, respectively. The federal net operating loss carryforwards will not expire and the tax credit carryforwards will begin to
          expire in 2041 if not utilized.&#160; As of December 31, 2022 and 2021, the Company had state net operating loss carryforwards with a tax effect of approximately $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" id="Fact_13b07bf6cff14ff2b1c30a16089f850e" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.2</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" id="Fact_60f37ec6ce7b4466a59ec7da82eb4b8f" contextRef="c20211231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction> million, respectively. The Company did <ix:nonFraction name="ocup:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" id="Fact_73d3dd5280874765bf035e4ee71be654" contextRef="c20211231" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="ocup:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" id="Fact_180626b903a54b7a9ddc720c4985f9b0" contextRef="c20221231" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any state research credit carryforwards as of December 31, 2022 and 2021. The state net operating loss carryforwards will begin to expire in 2028.</div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1122" continuedAt="Text_d6f55cc5924744959855b48272d83a1123">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1123" continuedAt="Text_d6f55cc5924744959855b48272d83a1124">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company
            utilized federal and state net operating tax carryforwards with a tax effect in the amount of $<ix:nonFraction name="ocup:FederalOperatingLossCarryforwardsTaxEffect" id="Fact_79041aa4b9fe4f668d483572f9993b02" contextRef="c20220101to20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction> million and $<ix:nonFraction name="ocup:StateAndLocalOperatingLossCarryforwardsTaxEffect" id="Fact_561759a5a89344629d7e81adb0fa3b95" contextRef="c20220101to20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction> million, respectively, to offset taxable income for the year ended December 31, 2022. In addition, the Company also utilized its federal
            research credit carryforwards in the amount of $<ix:nonFraction name="ocup:UtilizedFederalResearchCreditCarryforwards" id="Fact_99896d65a98648a4bf168014b8644fae" contextRef="c20220101to20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million to partially offset its tax liability for the year ended December 31,
            2022.</span></div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1124" continuedAt="Text_d6f55cc5924744959855b48272d83a1125">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1125" continuedAt="Text_d6f55cc5924744959855b48272d83a1126">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by
          Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#8220;5-percent shareholders&#8221; increase their
          ownership, in the aggregate, by more than 50 percentage points over a 3 year testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and
          credits before utilization. As a result of the Merger, the Company recorded deferred tax assets of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_97855a0ea19b4fd9bd08d88e4232f666" contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.3</ix:nonFraction> million relating to net
          operating loss carryforwards which were fully offset by a valuation allowance. The $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_805f6156266a47489ab32b1b84b3c0e0" contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.3</ix:nonFraction> million net deferred tax assets recorded in
          relation to the Merger did not include federal and state net operating loss carryforwards that were estimated to expire under Internal Revenue Code Sections 382 as a result of the Merger. The Company has not yet evaluated the impact of Section
          382 and Section 383 on its remaining tax attributes that were generated by Ocuphire since the formation of the Company in 2018.</div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1126" continuedAt="Text_d6f55cc5924744959855b48272d83a1127">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">152</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Ocuphire Pharma, Inc.</span></div>

              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Notes to Consolidated Financial Statements</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1127" continuedAt="Text_d6f55cc5924744959855b48272d83a1128">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_a8f50486263042799e8426b47287c126" contextRef="c20211231" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_0b3905ab6a7c48b78303a94b533c5b32" contextRef="c20221231" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> uncertain tax positions as of December 31, 2022 and 2021, and as such, <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" id="Fact_dfa602b2a530471c91ffda4e330d41c9" contextRef="c20220101to20221231" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" id="Fact_a11f0d76f3314601853715526fa7ec68" contextRef="c20210101to20211231" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> interest or penalties were recorded to income tax expense.</div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1128" continuedAt="Text_d6f55cc5924744959855b48272d83a1129">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
</ix:continuation>
        <ix:continuation id="Text_d6f55cc5924744959855b48272d83a1129">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s corporate returns are subject to examination beginning with the 2019 tax year for federal income tax purposes and 2018 for state income tax purposes.</div>
</ix:continuation>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">
        <ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Text_36390a6c84034e2598bd59693969b64d" contextRef="c20220101to20221231" escape="true" continuedAt="Text_2b950df5f2e34618bd648e8bca837fef1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman';">13.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; font-family: 'Times New Roman';">Deferred Compensation Plan </div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_2b950df5f2e34618bd648e8bca837fef1" continuedAt="Text_2b950df5f2e34618bd648e8bca837fef2">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_2b950df5f2e34618bd648e8bca837fef2" continuedAt="Text_2b950df5f2e34618bd648e8bca837fef3">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_2b950df5f2e34618bd648e8bca837fef3" continuedAt="Text_2b950df5f2e34618bd648e8bca837fef4">
<div><span style="font-family: 'Times New Roman';"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_2b950df5f2e34618bd648e8bca837fef4" continuedAt="Text_2b950df5f2e34618bd648e8bca837fef5">
<div><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_2b950df5f2e34618bd648e8bca837fef5">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Effective October 1, 2021, the Company began offering a 401(k) plan (&#8220;401K Plan&#8221;) to its
          employees. All employees are eligible to participate in the 401K Plan. The Company makes matching contributions equal to <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" id="Fact_2ddacee8eabc47d5a388b9cce2902596" contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% on the
          first <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" id="Fact_d5a6517693a34059bf91fed1995f2c26" contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% of compensation that is deferred as an elective deferral and an additional <ix:nonFraction name="ocup:DefinedContributionPlanAdditionalEmployerMatchingContribution" id="Fact_2354f68b3b2f4577857d7ab950eaf771" contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% on the next <ix:nonFraction name="ocup:DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" id="Fact_eaa9068dadd940d7b706943beb9c98a4" contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>% of compensation. The Company&#8217;s matching
          contributions are made on a monthly basis. During the years ended December 31, 2022 and 2021, the Company contributed $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_f28bfeb2dbed48aa85be00840285119f" contextRef="c20220101to20221231_RetirementPlanNameAxis_RetirementPlan401KMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">76,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_a1271597ed034037a89678a5090b3bda" contextRef="c20210101to20211231_RetirementPlanNameAxis_RetirementPlan401KMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">15,000</ix:nonFraction> to the 401K Plan, respectively.</span></div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman';"> </span>
      <span style="font-family: 'Times New Roman';"><br />
      </span></div>
</div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_6c4226b9648741c3a703c84d6d351ba9" contextRef="c20220101to20221231" escape="true" continuedAt="Text_8b09bd4824614d018f6ed7a2dc35d5681">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">14.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Subsequent Events</div>
              </td>

  </tr>


</table>
</ix:nonNumeric>
        <ix:continuation id="Text_8b09bd4824614d018f6ed7a2dc35d5681" continuedAt="Text_8b09bd4824614d018f6ed7a2dc35d5682">
<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160; <br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_8b09bd4824614d018f6ed7a2dc35d5682" continuedAt="Text_8b09bd4824614d018f6ed7a2dc35d5683">
<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2020 Plan Evergreen Provision</div>
</ix:continuation>
        <ix:continuation id="Text_8b09bd4824614d018f6ed7a2dc35d5683" continuedAt="Text_8b09bd4824614d018f6ed7a2dc35d5684">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);"> </span><br />
        </div>
</ix:continuation>
        <ix:continuation id="Text_8b09bd4824614d018f6ed7a2dc35d5684">
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the 2020 Plan, the shares reserved automatically increase on January 1 of each year, for a period of not more than <ix:nonNumeric name="ocup:MaximumPeriodOfSharesReservedUnderPlan" id="Fact_aeefe2d1f86a455b88f424bd9a9c68ce" contextRef="c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date the 2020 Plan is approved by the stockholders of the Company, commencing on January 1, 2021 and ending on (and including)
          January 1, 2030, by an amount equal to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" id="Fact_3bca7085f1ab4a6aad5b32ab8726eb6a" contextRef="c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the shares of common stock outstanding as of December 31 of the preceding calendar year.
          Notwithstanding the foregoing, the Board of&#160; Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase in the share reserve for such year or that the increase in the share reserve for such year will
          be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, <ix:nonFraction name="ocup:AggregateNumberOfCommonStockReservedForFutureIssuance" id="Fact_7bdcf4199547494891c37a33665c69bb" contextRef="c20230101to20230101_PlanNameAxis_EvergreenProvisionPlan2020Member_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,043,066</ix:nonFraction>
          shares were added to the 2020 Plan as a result of the evergreen provision.</div>
</ix:continuation>
        <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">  </div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">153</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" /></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><span style="font-size: 8pt; font-style: italic;"><a href="#TABLEOFCONTENTS">Table of Contents</a></span></div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div>
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
          undersigned, thereunto duly authorized.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 49.96%; vertical-align: bottom;">&#160;</td>

    <td style="width: 50.04%; vertical-align: bottom;" colspan="2">
                <div style="color: rgb(0, 0, 0);">OCUPHIRE PHARMA, INC.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.09%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46.96%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Dated: March 30, 2023</div>
              </td>

    <td style="width: 3.09%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">By:</div>
              </td>

    <td style="width: 46.96%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ Mina Sooch</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.09%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46.96%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0);">Mina Sooch</div>
              </td>

  </tr>

  <tr>

    <td style="width: 49.96%; vertical-align: bottom;">&#160;</td>

    <td style="width: 3.09%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46.96%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">President, Chief Executive Officer and Director</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the
          capacities and on the dates indicated.</div>

        <div><span style="color: rgb(0, 0, 0);"> </span><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 2.99%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By</div>
              </td>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ Mina Sooch</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">&#160;Date: March 30, 2023</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: middle;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Mina Sooch</div>
              </td>

    <td style="width: 1%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">President, Chief Executive Officer and Director</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: middle;">&#160;</td>

    <td style="width: 46%; vertical-align: middle;">&#160;</td>

    <td style="width: 1%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By</div>
              </td>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ Amy Rabourn</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">&#160;Date: March 30, 2023</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Amy Rabourn</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">Senior Vice President of Finance</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: middle;">&#160;</td>

    <td style="width: 46%; vertical-align: middle;">&#160;</td>

    <td style="width: 1%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By</div>
              </td>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ Sean Ainsworth</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">&#160;Date: March 30, 2023</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Sean Ainsworth</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">Director</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: middle;">&#160;</td>

    <td style="width: 46%; vertical-align: middle;">&#160;</td>

    <td style="width: 1%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By</div>
              </td>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ James S. Manuso</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">&#160;Date: March 30, 2023</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">James S. Manuso</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">Director</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: middle;">&#160;</td>

    <td style="width: 46%; vertical-align: middle;">&#160;</td>

    <td style="width: 1%; vertical-align: middle;">&#160;</td>

    <td style="width: 50%; vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By</div>
              </td>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ Cam Gallagher</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">&#160;Date: March 30, 2023</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Cam Gallagher</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">Director</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By</div>
              </td>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ Jay Pepose</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">&#160;Date: March 30, 2023</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Jay Pepose</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">Director</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By</div>
              </td>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ Richard J. Rodgers</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">&#160;Date: March 30, 2023</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Richard J. Rodgers</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">Director</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">&#160;</td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">By</div>
              </td>

    <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="color: rgb(0, 0, 0);">/s/ Susan K. Benton</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">&#160;Date: March 30, 2023</div>
              </td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Susan K. Benton</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 2.99%; vertical-align: top;">&#160;</td>

    <td style="width: 46%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0); font-style: italic;">Director</div>
              </td>

    <td style="width: 1%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div><br />
        </div>

        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

    </div>

    <div style="width: 100%;" class="BRPFPageFooter"></div>

  </div>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1-1
<SEQUENCE>2
<FILENAME>brhc10050364_ex10-1-1.htm
<DESCRIPTION>EXHIBIT 10.1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <div>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; margin-left: 36pt; font-weight: bold;">Exhibit 10.1.1</div>
        <div><br>
        </div>
        <div style="text-align: center; font-weight: bold;"><u>FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT </u></div>
        <div style="text-align: center; font-weight: bold;"><u>AGREEMENT</u></div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 36pt;">THIS FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this <font style="font-weight: bold; font-style: italic;">&#8220;Amendment&#8221;</font>) between <font style="font-weight: bold; font-variant: small-caps;">Ocuphire Pharma, Inc.</font>, a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>), and Mina Sooch <font style="font-variant: small-caps;">(</font><font style="font-weight: bold; font-style: italic;">&#8220;Executive&#8221;</font>) is entered into and made effective as of the 26th day of March, 2023 (the <font style="font-weight: bold; font-style: italic;">&#8220;Effective Date&#8221;</font>).</div>
        <div><br>
        </div>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Recitals</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Whereas</font><font style="font-size: 10pt;">, on November 5, 2020, the Company and Executive entered
            into an Amended and Restated Employment Agreement (the <font style="font-weight: bold; font-style: italic;">&#8220;Employment Agreement&#8221;</font>); and</font></div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Whereas</font><font style="font-size: 10pt;">, the Company and Executive now wish to amend the
            Employment Agreement as provided herein.</font></div>
        <div><br>
        </div>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Agreement</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Now</font><font style="font-size: 10pt; font-variant: small-caps;">,</font><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;"> Therefore</font><font style="font-size: 10pt;">, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:</font></div>
        <div><br>
        </div>
        <div style="text-indent: 36pt;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Amendment to Section 5</font><font style="font-weight: bold;">.</font>&#160; As of the Effective Date, Section
          5(a) is amended to add Section 5(a)(iv):</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-style: italic;">(iv) COBRA. </font><font style="font-size: 10pt;">Provided that the Executive timely elects continued health insurance
            coverage under the federal COBRA law and under the Company&#8217;s group health plans following the Termination Date, then the Company shall pay 100% of the COBRA premiums necessary to continue the Executive&#8217;s and the Executive&#8217;s covered dependents&#8217;
            health insurance coverage in effect for the Executive (and the Executive&#8217;s covered dependents) on the Termination Date until the earliest of: (A) eighteen (18) months following the Termination Date; (B) the date when the Executive becomes
            eligible for substantially equivalent health insurance coverage in connection with new employment; or (C) the date the Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from
            the Termination Date through the earlier of (A)-(C) (the <font style="font-weight: bold; font-style: italic;">&#8220;COBRA Payment Period&#8221;</font>).&#160; Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA
            premiums on the Executive&#8217;s behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), or not
            available for other reasons, then in lieu of paying COBRA premiums pursuant to this <u>Section 5(a)(iv)</u>, the Company shall pay the Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment
            equal to the premium for such month, subject to applicable tax withholding, for the remainder of the COBRA Payment Period.&#160; Nothing in this Agreement shall deprive the Executive of the Executive&#8217;s rights under COBRA or ERISA for benefits under
            plans and policies arising under the Executive&#8217;s employment by the Company.</font></div>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div style="text-indent: 36pt;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Construction.</font>&#160; Unless otherwise defined herein, capitalized terms shall have the meanings set
          forth in the Employment Agreement.&#160; The terms of this Amendment amend and modify the Employment Agreement as if fully set forth in the Employment Agreement.&#160; If there is any conflict between the terms, conditions and obligations of this Amendment
          and the Employment Agreement, this Amendment&#8217;s terms, conditions and obligations shall control.&#160; All other provisions of the Employment Agreement not specifically modified by this Amendment are preserved.&#160; This Amendment may be executed in
          counterparts (including via facsimile or .pdf), each of which shall be deemed an original, and all of which together shall constitute one and the same document.</div>
        <div><br>
        </div>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Signatures on the Following Page</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div style="text-align: justify; font-size: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">In Witness Whereof</font><font style="font-size: 10pt; font-variant: small-caps;">,</font><font style="font-size: 10pt;"> the parties have executed this Amendment as of the date first written above.</font></div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" id="zf5240a65ba2b4a9095703b33611cb293" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify; font-weight: bold;">EXECUTIVE:</div>
              </td>
              <td style="width: 50%; vertical-align: top;" rowspan="1">
                <div style="text-align: justify; font-weight: bold;">THE COMPANY:</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;" rowspan="1"><br>
              </td>
              <td style="vertical-align: top; width: 50%;" rowspan="1"><br>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;"><br>
              </td>
              <td style="vertical-align: top; width: 50%;">
                <div style="text-align: justify; font-variant: small-caps; font-weight: bold;">Ocuphire Pharma, Inc.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;"><br>
              </td>
              <td style="width: 50%; vertical-align: top;" rowspan="1"><br>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" id="z1c1a1c1953954496a16d91df5a6fa8c5" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;"><br>
              </td>
              <td style="width: 3%; vertical-align: top;">
                <div style="text-align: justify;">By:</div>
              </td>
              <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
                <div style="text-align: justify;">/s/ Cam Gallagher</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" id="zf92a1641bf484e09a9dd5b434af3d401" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 28%; vertical-align: top; border-bottom: 2px solid black;">
                <div style="text-align: center;">/s/ Mina Sooch</div>
              </td>
              <td style="width: 22%; vertical-align: top; padding-bottom: 2px;"><br>
              </td>
              <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" rowspan="1">
                <div style="text-align: justify;">Name: Cam Gallagher</div>
              </td>
            </tr>
            <tr>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: justify; font-variant: small-caps; font-weight: bold;">Mina Sooch</div>
              </td>
              <td style="width: 50%; vertical-align: top;" rowspan="1">
                <div style="text-align: justify;">Title: Chair of the Compensation Committee</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div style="text-align: center; font-variant: small-caps;">Signature Page to</div>
        <div style="text-align: center; font-variant: small-caps;">First Amendment to Amended and Restated Employment Agreement</div>
        <div><br>
        </div>
        <div><br>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2-1
<SEQUENCE>3
<FILENAME>brhc10050364_ex10-2-1.htm
<DESCRIPTION>EXHIBIT 10.2.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 10.2.1</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT </u></div>
      <div style="text-align: center; font-weight: bold;"><u>AGREEMENT</u></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">THIS FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this <font style="font-weight: bold; font-style: italic;">&#8220;Amendment&#8221;</font>) between <font style="font-weight: bold; font-variant: small-caps;">Ocuphire Pharma, Inc.</font>, a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>), and Bernhard Hoffmann (<font style="font-weight: bold; font-style: italic;">&#8220;Executive&#8221;</font>)
        is entered into and made effective as of the 26th day of March, 2023 (the <font style="font-weight: bold; font-style: italic;">&#8220;Effective Date&#8221;</font>).</div>
      <div><br>
      </div>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Recitals</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Whereas</font><font style="font-size: 10pt;">, on November 5, 2020, the Company and Executive entered
          into an Amended and Restated Employment Agreement (the <font style="font-weight: bold; font-style: italic;">&#8220;Employment Agreement&#8221;</font>); and</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Whereas</font><font style="font-size: 10pt;">, the Company and Executive now wish to amend the
          Employment Agreement as provided herein.</font></div>
      <div><br>
      </div>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Agreement</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Now</font><font style="font-size: 10pt; font-variant: small-caps;">,</font><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;"> Therefore</font><font style="font-size: 10pt;">, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Amendment to Section 5</font><font style="font-weight: bold;">.</font>&#160; As of the
        Effective Date, Section 5(a) is amended to add Section 5(a)(iv):</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-style: italic;">(iv) COBRA. </font><font style="font-size: 10pt;">Provided that the Executive timely elects continued health insurance coverage
          under the federal COBRA law and under the Company&#8217;s group health plans following the Termination Date, then the Company shall pay 100% of the COBRA premiums necessary to continue the Executive&#8217;s and the Executive&#8217;s covered dependents&#8217; health
          insurance coverage in effect for the Executive (and the Executive&#8217;s covered dependents) on the Termination Date until the earliest of: (A) nine (9) months following the Termination Date; (B) the date when the Executive becomes eligible for
          substantially equivalent health insurance coverage in connection with new employment; or (C) the date the Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the Termination
          Date through the earlier of (A)-(C) (the <font style="font-weight: bold; font-style: italic;">&#8220;COBRA Payment Period&#8221;</font>).&#160; Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on the
          Executive&#8217;s behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), or not available for other
          reasons, then in lieu of paying COBRA premiums pursuant to this <u>Section 5(a)(iv)</u>, the Company shall pay the Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the premium
          for such month, subject to applicable tax withholding, for the remainder of the COBRA Payment Period.&#160; Nothing in this Agreement shall deprive the Executive of the Executive&#8217;s rights under COBRA or ERISA for benefits under plans and policies
          arising under the Executive&#8217;s employment by the Company.</font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Construction.</font>&#160; Unless otherwise defined herein, capitalized terms shall have
        the meanings set forth in the Employment Agreement.&#160; The terms of this Amendment amend and modify the Employment Agreement as if fully set forth in the Employment Agreement.&#160; If there is any conflict between the terms, conditions and obligations of
        this Amendment and the Employment Agreement, this Amendment&#8217;s terms, conditions and obligations shall control.&#160; All other provisions of the Employment Agreement not specifically modified by this Amendment are preserved.&#160; This Amendment may be
        executed in counterparts (including via facsimile or .pdf), each of which shall be deemed an original, and all of which together shall constitute one and the same document.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Signatures on the Following Page</div>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">In Witness Whereof</font><font style="font-size: 10pt; font-variant: small-caps;">,</font><font style="font-size: 10pt;"> the parties have executed this Amendment as of the date first written above.</font></div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z7620a406845e4772853992574936e2f7">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: bold;">EXECUTIVE:</div>
            </td>
            <td rowspan="1" style="width: 50%; vertical-align: top; font-weight: bold;">THE COMPANY:</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-weight: bold;">Ocuphire Pharma, Inc</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top;"><br>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z6966b09f31954524af73335a6d3dad0d">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-indent: 9pt;">/s/ Mina Sooch</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za18027bbde994fe8a0bd2f578f4df4a8">

          <tr>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: center;">/s/ Bernhard Hoffman</div>
            </td>
            <td style="width: 25%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div>Name: Mina Sooch</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="width: 50%; vertical-align: top;">
              <div style="font-variant: small-caps; font-weight: bold;">Bernhard Hoffmann</div>
            </td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">
              <div>Title: Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-variant: small-caps;">Signature Page to</div>
      <div style="text-align: center; font-variant: small-caps;">First Amendment to Amended and Restated Employment Agreement</div>
      <div><br>
      </div>
      <br>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7-1
<SEQUENCE>4
<FILENAME>brhc10050364_ex10-7-1.htm
<DESCRIPTION>EXHIBIT 10.7.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

  <div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 10.7.1</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">OCUPHIRE PHARMA, INC.</div>
      <div style="text-align: center; font-weight: bold;">RSU AWARD GRANT NOTICE</div>
      <div style="text-align: center; font-weight: bold;">(2020 EQUITY INCENTIVE PLAN)</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Ocuphire Pharma, Inc., a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>) has awarded to you (the <font style="font-weight: bold; font-style: italic;">&#8220;Participant&#8221;</font>) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the <font style="font-weight: bold; font-style: italic;">&#8220;RSU Award&#8221;</font>).&#160; Your RSU Award is
        subject to all of the terms and conditions as set forth herein and in the Company&#8217;s 2020 Equity Incentive Plan (the <font style="font-weight: bold; font-style: italic;">&#8220;Plan&#8221;</font>) and the Award Agreement (the <font style="font-weight: bold; font-style: italic;">&#8220;Agreement&#8221;</font>), which are incorporated herein in their entirety.&#160; Capitalized terms not explicitly defined herein but defined in the Plan or the Agreement shall have the meanings set forth in the Plan or the Agreement.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd9396296d6324fc28f7289f43c5a0c63">

          <tr>
            <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">
              <div>Participant:</div>
            </td>
            <td style="width: 37.6%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 22%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">
              <div>Date of Grant:</div>
            </td>
            <td style="width: 37.6%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 22%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">
              <div>Vesting Commencement Date:</div>
            </td>
            <td style="width: 37.6%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 22%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">
              <div>Number of Restricted Stock Units:</div>
            </td>
            <td style="width: 37.6%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 22%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Vesting Schedule</font>:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing, vesting shall terminate upon the Participant&#8217;s termination of Continuous Service.</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Issuance Schedule</font>:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;One share of Common Stock will be issued for each restricted stock unit which vests at the time set forth in <u>Section 5</u> of the Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">Participant Acknowledgements</font><font style="font-size: 10pt;">: By your signature below or by electronic acceptance or authentication in a form
          authorized by the Company, you understand and agree that:</font></div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0f98a50c7ea94a8f999e0ef6630f9616">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The RSU Award is governed by this RSU Award Grant Notice (the <font style="font-weight: bold; font-style: italic;">&#8220;Grant Notice&#8221;</font>), and the provisions of the Plan and the Agreement, all of which are made a part of this document.&#160;
                Unless otherwise provided in the Plan, this Grant Notice and the Agreement (together, the <font style="font-weight: bold; font-style: italic;">&#8220;RSU Award Agreement&#8221;</font>) may not be modified, amended or revised except in a writing signed
                by you and a duly authorized officer of the Company.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z557f3bb6e2a24e918eee73676efd7207">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div> You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus.&#160; In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan,
                the terms of the Plan shall control.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z695a2a07ff8b40bea133c62f48664cff">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with
                the exception of: (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in
                each case that specifies the terms that should govern this RSU Award.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0668b313a5ef4f8fb94b707919ca1e75">

          <tr>
            <td colspan="2" style="vertical-align: top;">
              <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">OCUPHIRE PHARMA, INC</font><font style="font-size: 10pt;">.</font></div>
            </td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">PARTICIPANT</font><font style="font-size: 10pt;">:</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 42%; vertical-align: top;">
              <div style="text-align: center;">Signature</div>
            </td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center;">Signature</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze0a108e069904d6c92b32c7e69e8baa7">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Title:</div>
            </td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td colspan="1" style="width: 3%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Date:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4491536311dc4bc1abe502382cefee79">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Date:</div>
            </td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
            <td colspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">OCUPHIRE PHARMA, INC.</div>
      <div style="text-align: center; font-weight: bold;">2020 EQUITY INCENTIVE PLAN</div>
      <div style="text-align: center; font-weight: bold;">AWARD AGREEMENT (RSU AWARD)</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">As reflected by your Restricted Stock Unit Grant Notice (the <font style="font-weight: bold; font-style: italic;">&#8220;Grant Notice&#8221;</font>), Ocuphire Pharma, Inc., a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>) has granted you a RSU Award under its 2020 Equity Incentive Plan (the <font style="font-weight: bold; font-style: italic;">&#8220;Plan&#8221;</font>) for the number of restricted stock units
        as indicated in your Grant Notice (the <font style="font-weight: bold; font-style: italic;">&#8220;RSU Award&#8221;</font>).&#160; The terms of your RSU Award as specified in this Award Agreement for your RSU Award (this <font style="font-weight: bold; font-style: italic;">&#8220;Agreement&#8221;</font>) and the Grant Notice constitute your <font style="font-weight: bold; font-style: italic;">&#8220;RSU Award Agreement&#8221;</font>.&#160; Defined terms not explicitly defined in this Agreement but defined in the Grant
        Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The general terms applicable to your RSU Award are as follows:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Governing Plan Document.</font><font style="font-weight: bold;">&#160; </font>Your RSU
        Award is subject to all the provisions of the Plan.&#160; Your RSU Award is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.&#160; In the event of any
        conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall control.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Grant of the RSU Award.</font>&#160; This RSU Award represents your right to be issued
        on a future date the number of shares of the Company&#8217;s Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice subject to your satisfaction of the vesting conditions set forth therein (the <font style="font-weight: bold; font-style: italic;">&#8220;Restricted Stock Units&#8221;</font>).&#160; Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the Plan and the provisions of <u>Section


          3</u> below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered by your
        RSU Award.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Dividends</font><font style="font-weight: bold;">.&#160; </font>You may become entitled
        to receive payments equal to any cash dividends and other distributions paid with respect to a corresponding number of shares of the Common Stock to be issued in respect of the Restricted Stock Units covered by your RSU Award.&#160; Any such dividends
        or distributions shall be subject to the same forfeiture restrictions as apply to the Restricted Stock Units and shall be paid at the same time that the corresponding shares are issued in respect of your vested Restricted Stock Units, provided,
        however that to the extent any such dividends or distributions are paid in shares of the Common Stock, then you will automatically be granted a corresponding number of additional Restricted Stock Units subject to the RSU Award (the <font style="font-weight: bold; font-style: italic;">&#8220;Dividend Units&#8221;</font>), and further provided that such Dividend Units shall be subject to the same forfeiture restrictions and restrictions on transferability, and same timing requirements for
        issuance of shares, as apply to the Restricted Stock Units subject to the RSU Award with respect to which the Dividend Units relate.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Withholding Obligations.</font><font style="font-weight: bold;">&#160; </font>As
        further provided in <u>Section 8</u> of the Plan, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local and
        foreign tax withholding obligations, if any, which arise in connection with your RSU Award (the <font style="font-weight: bold; font-style: italic;">&#8220;Withholding Taxes&#8221;</font>) in accordance with the withholding procedures established by the
        Company.&#160; Unless the Withholding Taxes are satisfied, the Company shall have no obligation to deliver to you any Common Stock in respect of the RSU Award.&#160; In the event the Withholding Obligation of the Company arises prior to the delivery to you
        of Common Stock or it is determined after the delivery of Common Stock to you that the amount of the Withholding Obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless from any failure
        by the Company to withhold the proper amount.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold;"><font style="font-variant: small-caps;">Date of Issuance</font>.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">&#160;(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent your RSU Award is exempt from application of Section 409A of the Code and any state law of similar effect (collectively <font style="font-weight: bold;">&#8220;</font><font style="font-weight: bold; font-style: italic;">Section 409A</font><font style="font-weight: bold;">&#8221;</font>), the Company will deliver to you a number of shares of the Company&#8217;s Common Stock equal to the
        number of vested Restricted Stock Units subject to your RSU Award, including any additional Restricted Stock Units received pursuant to <u>Section 3</u> above that relate to those vested Restricted Stock Units on the applicable vesting date(s), or
        if such date is not a business day, such delivery date shall instead fall on the next following business day (the <font style="font-weight: bold; font-style: italic;">&#8220;Original Distribution Date&#8221;</font>).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">&#160;(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing, in the event that you are prohibited from selling shares of the Company&#8217;s Common Stock in the public market on
        the scheduled delivery date by the Trading Policy or otherwise, and the Company elects not to satisfy its tax withholding obligations by withholding shares from your distribution, then such shares shall not be delivered on such Original
        Distribution Date and shall instead be delivered on the first business day when you are not prohibited from selling shares of the Company&#8217;s Common Stock in the open market, but in no event later than the fifteenth (15th) day of the third calendar
        month of the calendar year following the calendar year in which the shares covered by the RSU Award vest.&#160; Delivery of the shares pursuant to the provisions of <u>Section 5</u> is intended to comply with the requirements for the short-term
        deferral exemption available under Treasury Regulations Section 1.409A-1(b)(4) and shall be construed and administered in such manner.&#160; However, if and to the extent the RSU Award is a Non-Exempt Award, the provisions of the Plan with respect to
        Non-Exempt Awards shall apply in lieu of the provisions in this <u>Section 5</u>.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Transferability</font><font style="font-weight: bold;">.&#160; </font>Except as
        otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and distribution.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Corporate Transaction.</font>&#160; Your RSU Award is subject to the terms of any
        agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and
        any contingent consideration.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">No Liability for Taxes.</font>&#160; As a condition to accepting the RSU Award, you
        hereby (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company compensation and (b) acknowledge that you were advised to
        consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.</div>
      <br>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Severability.</font>&#160; If any part of this Agreement or the Plan is declared by any
        court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.&#160; Any Section of this Agreement (or part of such a
        Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">10.</font>&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Other Documents.</font>&#160; You hereby acknowledge receipt of or the right to receive a
        document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.&#160; In addition, you acknowledge receipt of the Company&#8217;s Trading Policy.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">11.</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Questions</font><font style="font-weight: bold;">.&#160; </font>If you have questions
        regarding these or any other terms and conditions applicable to your RSU Award, including a summary of the applicable federal income tax consequences please see the Prospectus.</div>
      <div>&#160;</div>
      <div>47480502.1</div>
      <div style="text-align: center;">
        <div><br>
        </div>
        <br>
        <font style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7-2
<SEQUENCE>5
<FILENAME>brhc10050364_ex10-7-2.htm
<DESCRIPTION>EXHIBIT 10.7.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">



  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 10.7.2</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">OCUPHIRE PHARMA, INC.</div>
      <div style="text-align: center; font-weight: bold;">STOCK OPTION GRANT NOTICE</div>
      <div style="text-align: center; font-weight: bold;">(2020 EQUITY INCENTIVE PLAN)</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Ocuphire Pharma, Inc., a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>), pursuant to its 2020 Equity Incentive Plan (the <font style="font-weight: bold; font-style: italic;">&#8220;Plan&#8221;</font>), has granted to you (<font style="font-weight: bold; font-style: italic;">&#8220;Optionholder&#8221;</font>) an option to purchase the number of shares of the Common Stock set forth below (the <font style="font-weight: bold; font-style: italic;">&#8220;Option&#8221;</font>).&#160; Your Option is subject to all of the terms and conditions as set forth herein and in the Plan, and the Stock Option Agreement and the Notice of Exercise, all of which are attached
        hereto and incorporated herein in their entirety.&#160; Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9397d2938a7a428d9eefc255dfd165d7" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-weight: bold;">Optionholder:</div>
            </td>
            <td style="width: 38.5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 16.5%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-weight: bold;">Date of Grant:</div>
            </td>
            <td style="width: 38.5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 16.5%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-weight: bold;">Vesting Commencement Date:</div>
            </td>
            <td style="width: 38.5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 16.5%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-weight: bold;">Number of Shares of the Common Stock<br>
                Subject to Option:<br>
              </div>
            </td>
            <td style="width: 38.5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 16.5%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-weight: bold;">Exercise Price (Per Share):</div>
            </td>
            <td style="width: 38.5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 16.5%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-weight: bold;">Total Exercise Price:</div>
            </td>
            <td style="width: 38.5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 16.5%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 45%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-weight: bold;">Expiration Date:</div>
            </td>
            <td style="width: 38.5%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 16.5%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Type of Grant:</font> [Incentive Stock Option] OR [Nonstatutory Stock Option]</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Exercise and Vesting Schedule:</font> Subject to the Optionholder&#8217;s Continuous Service through each applicable vesting date, the Option will vest as follows:</div>
      <div>&#160;</div>
      <div style="text-align: justify;"><font style="font-weight: bold;">Optionholder Acknowledgements:</font> By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf3b572a0dc644bf6a7b6519723314cd5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Option is governed by this Stock Option Grant Notice, and the provisions of the Plan and the Stock Option Agreement and the Notice of Exercise, all of which are made a part of this document.&#160; Unless otherwise provided in the Plan,
                this Grant Notice and the Stock Option Agreement (together, the <font style="font-weight: bold; font-style: italic;">&#8220;Option Agreement&#8221;</font>) may not be modified, amended or revised except in a writing signed by you and a duly authorized
                officer of the Company.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z2c1028fea5ac4b3d93a780484bd87872" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>If the Option is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options granted to you) cannot be first <font style="font-style: italic;">exercisable</font> for more than $100,000 in value (measured by exercise
                price) in any calendar year.&#160; Any excess over $100,000 is a Nonstatutory Stock Option.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z33c6a9423e5f47cd8d7cd58d93d52dda" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>You consent to receive this Grant Notice, the Stock Option Agreement, the Plan, the Prospectus and any other Plan-related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established
                and maintained by the Company or another third party designated by the Company.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <table cellspacing="0" cellpadding="0" id="z5234b4d1fc314bfcb49f9c0aa61b3fd2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>You have read and are familiar with the provisions of the Plan, the Stock Option Agreement, the Notice of Exercise and the Prospectus.&#160; In the event of any conflict between the provisions in this Grant Notice, the Option Agreement, the
                Notice of Exercise, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z53c72302477e44cdac6a427c4b7e07f8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the
                exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that
                specifies the terms that should govern this Option.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0b73473a8e574faa8f496bc202d6c446" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
                method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div><br>
      </div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z73e83257910842dd986d53f29ef4e6ec" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">OCUPHIRE PHARMA, INC</font><font style="font-size: 10pt;">.</font></div>
            </td>
            <td style="width: 3%; vertical-align: top;"><br>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">OPTIONHOLDER</font><font style="font-size: 10pt;">:</font></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top;" rowspan="1" colspan="2"><br>
            </td>
            <td style="width: 3%; vertical-align: top;"><br>
            </td>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>By:</div>
            </td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top;" rowspan="1" colspan="2">
              <div style="text-align: center;">Signature</div>
            </td>
            <td style="width: 3%; vertical-align: top;"><br>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: center;">Signature</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zbf139a157bd04f1ebb49540849ba3016" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Title:</div>
            </td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div>Date:</div>
            </td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z0a6ad23afa894324b0fdd9f37fdd4c7d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div>Date:</div>
            </td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">OCUPHIRE PHARMA, INC.</div>
      <div style="text-align: center; font-weight: bold;">2020 EQUITY INCENTIVE PLAN</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">STOCK OPTION AGREEMENT</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">As reflected by your Stock Option Grant Notice (the <font style="font-weight: bold; font-style: italic;">&#8220;Grant Notice&#8221;</font>) Ocuphire Pharma, Inc., a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>) has granted you an option under its 2020 Equity Incentive Plan (the <font style="font-weight: bold; font-style: italic;">&#8220;Plan&#8221;</font>) to purchase a number of shares of the Common
        Stock at the exercise price indicated in your Grant Notice (the <font style="font-weight: bold; font-style: italic;">&#8220;Option&#8221;</font>).&#160; Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall
        have the meanings set forth in the Grant Notice or Plan, as applicable.&#160; The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">The general terms and conditions applicable to your Option are as follows:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Governing Plan Document.</font><font style="font-variant: small-caps;">&#160; </font>Your

        Option is subject to all the provisions of the Plan.&#160; Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.&#160; In the event of any
        conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-weight: bold;"><font style="font-variant: small-caps;">Exercise</font>.</font></div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; You may generally exercise the vested portion of your Option for whole shares of the Common Stock at any time during its term by delivery of
        payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic submission.&#160;
        Please review the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; To the extent permitted by Applicable Law, you may pay your Option exercise price as follows:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;cash, check, bank draft or money order;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(ii)</font>&#160;&#160;&#160;&#160; &#160; &#160; subject to Company and/or Committee consent at the time of exercise, pursuant to a &#8220;cashless exercise&#8221; program as further described in the Plan
        if at the time of exercise the Common Stock is publicly traded;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; subject to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of the Common Stock as further
        described in the Plan; or</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; subject to Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221;
        arrangement as further described in the Plan.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Term</font><font style="font-weight: bold;">.&#160; </font>You may not exercise your
        Option before the commencement of its term or after its term expires.&#160; The term of your option commences on the Date of Grant and expires upon the earliest of the following:</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; immediately upon the termination of your Continuous Service for Cause;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 3 months after the termination of your Continuous Service for any reason other than Cause, Disability or death;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 12 months after the termination of your Continuous Service due to your Disability;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 18 months after your death if you die during your Continuous Service;</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction,</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; the Expiration Date indicated in your Grant Notice; or</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; the day before the 10th anniversary of the Date of Grant.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">Notwithstanding the foregoing, if you die during the period provided in <u>Section 3(b)</u> or 3(c) above, the term of your Option shall not expire until the earlier of (i) eighteen months after
        your death, (ii) upon any termination of the Option in connection with a Corporate Transaction, (iii) the Expiration Date indicated in your Grant Notice, or (iv) the day before the tenth anniversary of the Date of Grant.&#160; Additionally, the
        Post-Termination Exercise Period of your Option may be extended as provided in the Plan.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;">To obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your Option and ending on the day three
        months before the date of your Option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability.&#160; If the Company provides for the extended exercisability of your Option under certain
        circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more than three months after the date your employment terminates.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Withholding Obligations.&#160; </font>As further provided in the Plan: (a) you may not
        exercise your Option unless the applicable tax withholding obligations are satisfied, and (b) at the time you exercise your Option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from
        payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the
        extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with the exercise of your Option in accordance with the withholding procedures
        established by the Company.&#160; Accordingly, you may not be able to exercise your Option even though the Option is vested, and the Company shall have no obligation to issue shares of the Common Stock subject to your Option, unless and until such
        obligations are satisfied.&#160; In the event that the amount of the Company&#8217;s withholding obligation in connection with your Option was greater than the amount actually withheld by the Company, you agree to indemnify and hold the Company harmless from
        any failure by the Company to withhold the proper amount.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Incentive Stock Option Disposition Requirement.&#160; </font>If your option is an
        Incentive Stock Option, you must notify the Company in writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two years after the date of your option
        grant or within one year after such shares of the Common Stock are transferred upon exercise of your option.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Transferability</font><font style="font-weight: bold;">.&#160; </font>Except as
        otherwise provided in the Plan, your Option is not transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Corporate Transaction</font><font style="font-weight: bold;">.&#160; </font>Your Option
        is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect
        to any escrow, indemnities and any contingent consideration.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">No Liability for Taxes</font>.&#160; As a condition to accepting the Option, you hereby
        (a) agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the Option or other Company compensation and (b) acknowledge that you were advised to consult
        with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so.&#160; Additionally, you acknowledge that the Option is exempt from
        Section 409A only if the exercise price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with
        the Option.&#160; Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such
        exercise is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Obligations; Recoupment</font><font style="font-weight: bold;">.&#160; </font>You hereby
        acknowledge that the grant of your Option is additional consideration for any obligations (whether during or after employment) that you have to the Company not to compete, not to solicit its customers, clients or employees, not to disclose or
        misuse confidential information or similar obligations.&#160; Accordingly, if the Company reasonably determines that you breached such obligations, in addition to any other available remedy, the Company may, to the extent permitted by Applicable Law,
        recoup any income realized by you with respect to the exercise of your Option within two years of such breach.&#160; In addition, to the extent permitted by Applicable Law, this right to recoupment by the Company applies in the event that your
        employment is terminated for Cause or if the Company reasonably determines that circumstances existed that it could have terminated your employment for Cause.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">10.</font>&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Severability</font>.&#160; If any part of this Option Agreement or the Plan is declared by
        any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.&#160; Any Section of this Option Agreement (or
        part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">11.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Indebtedness to the Company</font>.&#160; In the event that you have any loans, draws,
        advances or any other indebtedness owing to the Company at the time of exercise of all or a portion of the Option, the Company may deduct and not deliver that number of shares of the Common Stock with a Fair Market Value subject to the Option equal
        to such indebtedness to satisfy all or a portion of such indebtedness, to the extent permitted by law and in a manner consistent with Section 409A of the Code, if applicable.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">12.</font>&#160;&#160; &#160; &#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Other Documents</font><font style="font-weight: bold;">.&#160; </font>You hereby
        acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated under the Securities Act, which includes the Prospectus.&#160; In addition, you acknowledge receipt of the Company&#8217;s Trading
        Policy.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">13.</font>&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-weight: bold; font-variant: small-caps;">Questions</font><font style="font-weight: bold;">.&#160; </font>If you have questions
        regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable federal income tax consequences please see the Prospectus.</div>
      <div>&#160;</div>
      <div style="text-align: center;">*&#160; *&#160; *&#160; *</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font> </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9-1
<SEQUENCE>6
<FILENAME>brhc10050364_ex10-9-1.htm
<DESCRIPTION>EXHIBIT 10.9.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%--><font style="font-size: 10pt; font-family: 'Times New Roman';">
  </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Exhibit 10.9.1</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Ocuphire Pharma, Inc.</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Stock Option Grant Notice</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">(2021 Inducement Plan)</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: small-caps;">Ocuphire Pharma, Inc</font><font style="font-size: 10pt; font-family: 'Times New Roman';">., a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>), pursuant to its 2021 Inducement Plan<font style="font-weight: bold;">&#160;</font>(the
          <font style="font-weight: bold; font-style: italic;">&#8220;Plan&#8221;</font>), hereby grants to Optionholder an option to purchase the number of shares of the Company&#8217;s Common Stock set forth below.&#160; This option is subject to all of the terms and
          conditions as set forth in this Stock Option Grant Notice, in the Option Agreement, the Plan and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety.&#160; Capitalized terms not explicitly defined herein
          but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is any conflict between the terms in this Stock Option Grant Notice and the Plan, the terms of the Plan will control.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" id="z675360500c7541909b844f94d9cec71e" style="border-collapse: collapse; width: 60%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">

          <tr>
            <td style="width: 30%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Optionholder:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Date of Grant:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Vesting Commencement Date:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Number of Shares Subject to Option:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Exercise Price (Per Share):</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Total Exercise Price:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Expiration Date:</div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z2e76d53cb86a490893fc1fd219255292" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Type of Grant:</div>
            </td>
            <td style="width: 82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Nonstatutory Stock Option</div>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Exercise Schedule</font><font style="font-size: 10pt; font-family: 'Times New Roman';">:</font></div>
            </td>
            <td style="width: 82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Same as Vesting Schedule</div>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Vesting Schedule</font><font style="font-size: 10pt; font-family: 'Times New Roman';">:</font></div>
            </td>
            <td style="width: 82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">______________, subject to Optionholder&#8217;s Continuous Service as of each such date</div>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0); font-weight: bold;">Payment:</div>
            </td>
            <td style="width: 82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">By one or a combination of the following items (described in the Option Agreement):</div>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 82%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;">&#9746;<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160; &#160; By cash, check, bank draft or money order payable to the Company</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 82%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;">&#9746;<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160; &#160; Pursuant to a Regulation T Program if the shares are publicly traded</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 82%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;">&#9746;<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160; &#160; By delivery of already-owned shares if the shares are publicly
                  traded</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 18%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 82%; vertical-align: top;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 12pt;">&#9746;<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160; &#160; Subject to the Company&#8217;s consent at the time of exercise, by a &#8220;net
                  exercise&#8221; arrangement</font></div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Additional Terms/Acknowledgements:</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160; Optionholder acknowledges receipt of, and understands and agrees to, this Stock Option Grant Notice, the Option Agreement and the Plan.&#160; Optionholder acknowledges and agrees that this Stock Option
          Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan.<font style="font-weight: bold; color: rgb(0, 112, 192);">&#160;</font> Optionholder further acknowledges that as of the Date of Grant, this
          Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and written agreements, promises and/or representations
          on that subject with the exception of, if applicable, (i) equity awards previously granted and delivered to Optionholder, (ii) any compensation recovery policy that is adopted by the Company or is otherwise required by applicable law and (iii)
          any written employment or severance arrangement or other written agreement entered into between the Company and Optionholder specifying the terms that should govern this option upon the terms and conditions set forth therein.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">By accepting this option, Optionholder acknowledges having received and read the Stock Option Grant Notice, the Option Agreement and the Plan and agrees to
        all of the terms and conditions set forth in these documents, Optionholder consents to receive Plan and related documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by
        the Company or another third party designated by the Company.</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5aa31e358da34d22a12293849e9e4598" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0); font-variant: small-caps; font-weight: bold;">Ocuphire Pharma, Inc.</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0); font-variant: small-caps; font-weight: bold;">Optionholder:</div>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z9051c3c2a9ca4a418954722ec7704904" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3.71%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 41.82%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 4.82%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 44.83%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">&#160;</td>
            <td style="width: 4.83%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Signature</div>
            </td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="2">
              <div style="text-align: left; color: rgb(0, 0, 0);">Signature</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 5.56%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 39.72%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 4.72%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 5.56%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Date:</div>
            </td>
            <td style="width: 39.72%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 4.72%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 5.56%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';">
              <div style="text-align: left; color: rgb(0, 0, 0);">Date:</div>
            </td>
            <td style="width: 39.72%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 4.72%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
            <td style="width: 45.28%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';" colspan="2"><br>
            </td>
            <td style="width: 4.72%; vertical-align: top; font-size: 10pt; font-family: 'Times New Roman';"><br>
            </td>
          </tr>

      </table>
      <div style="font-size: 10pt; font-family: 'Times New Roman';"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Attachments</font><font style="font-size: 10pt; font-family: 'Times New Roman';">:&#160; Option Agreement, 2021 Inducement Plan<font style="font-weight: bold; color: rgb(0, 112, 192);">&#160;</font>and Notice of Exercise (<font style="font-variant: small-caps;"><u>Attachment I</u></font>);
          Ocuphire Pharma, Inc. 2021 Inducement Plan (<font style="font-variant: small-caps;"><u>Attachment II</u></font>); and Notice of Exercise (<font style="font-variant: small-caps;"><u>Attachment III</u></font>).</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Attachment I</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-variant: small-caps; font-weight: bold;"> <font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
        </font></div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Ocuphire Pharma, Inc.</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Option Agreement</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">(2021 Inducement Plan)</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">(Nonstatutory Stock Option)</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to your Stock Option Grant Notice (the <font style="font-weight: bold; font-style: italic;">&#8220;Grant Notice&#8221;</font>) and this
        Option Agreement (this <font style="font-weight: bold; font-style: italic;">&#8220;Agreement&#8221;</font>), Ocuphire Pharma, Inc., a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>) has granted you an option
        under the Ocuphire Pharma, Inc. 2021 Inducement Plan (the <font style="font-weight: bold; font-style: italic;">&#8220;Plan&#8221;</font>) to purchase the number of shares of the Company&#8217;s Common Stock indicated in your Grant Notice at the exercise price
        indicated in your Grant Notice.&#160; The option is granted to you effective as of the date of grant set forth in the Grant Notice (the <font style="font-weight: bold; font-style: italic;">&#8220;Date of Grant&#8221;</font>).&#160; The option is granted in compliance
        with Nasdaq Listing Rule 5635(c)(4) as a material inducement to you entering into employment with the Company.&#160; If there is any conflict between the terms in this Agreement and the Plan, the terms of the Plan will control. Capitalized terms not
        explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan.</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows:</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Vesting.</font>&#160; Subject to the provisions contained herein, your option will vest as provided in your Grant Notice.&#160; Vesting will cease upon the
          termination of your Continuous Service.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Number of Shares and Exercise Price.</font>&#160; The number of shares of Common Stock subject to your option and your exercise price per share in your
          Grant Notice will be adjusted for Capitalization Adjustments.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Exercise Restriction for Non-Exempt Employees.</font>&#160; If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act
          of 1938, as amended (that is, a <font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">&#8220;Non-Exempt Employee&#8221;</font>), and except as otherwise provided in the Plan, you may not exercise your option until
          you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions of the Worker Economic Opportunity Act, you
          may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change in
          Control or (iv) your termination of Continuous Service on your &#8220;retirement&#8221; (as defined in the Company&#8217;s benefit plans).</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Method of Payment.</font>&#160; You must pay the full amount of the exercise price for the shares you wish to exercise.&#160; You may pay the exercise price in
          cash or by check, bank draft or money order payable to the Company or in any other manner permitted by the Grant Notice, which may include one or more of the following:</font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Provided
          that at the time of exercise the Common Stock is publicly traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash
          (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds.&#160; This manner of payment is also known as a &#8220;broker-assisted exercise&#8221;, &#8220;same day sale&#8221;, or &#8220;sell to
          cover&#8221;.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Provided
          that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or
          security interests, and that are valued at Fair Market Value on the date of exercise.&#160; &#8220;Delivery&#8221; for these purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your
          attestation of ownership of such shares of Common Stock in a form approved by the Company.&#160; You may not exercise your option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement
          restricting the redemption of the Company&#8217;s stock.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to
          the consent of the Company at the time of exercise, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a
          Fair Market Value that does not exceed the aggregate exercise price.&#160; You must pay any remaining balance of the aggregate exercise price not satisfied by the &#8220;net exercise&#8221; in cash or other permitted form of payment.&#160; Shares of Common Stock will
          no longer be outstanding under your option and will not be exercisable thereafter if those shares (i) are used to pay the exercise price pursuant to the &#8220;net exercise,&#8221; (ii) are delivered to you as a result of such exercise, and (iii) are
          withheld to satisfy your tax withholding obligations.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Whole Shares.</font>&#160; You may exercise your option only for whole shares of Common Stock.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Securities Law Compliance.</font>&#160; In no event may you exercise your option unless the shares of Common Stock issuable upon exercise are then
          registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration requirements of the Securities Act.&#160; The exercise of your option also
          must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in material compliance with such laws and regulations (including any
          restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable).</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">7.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Term.</font>&#160; You may not exercise your option before the Date of Grant or after the expiration of the option&#8217;s term.&#160; The term of your option
          expires, subject to the provisions of Section 5(h) of the Plan, upon the earliest of the following:</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160; &#160;&#160; &#160; &#160;
          immediately upon the termination of your Continuous Service for Cause;</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160; &#160;&#160; &#160;&#160; three (3)
          months after the termination of your Continuous Service for any reason other than Cause,<font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>your Disability or your death (except as otherwise provided in Section 7(d)
          below); <font style="font-family: 'Times New Roman'; font-style: italic;">provided, however, </font>that if during any part of such three (3) month period your option is not exercisable solely because of the condition set forth in the
          section above regarding &#8220;Securities Law Compliance,&#8221; your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous
          Service; <font style="font-family: 'Times New Roman'; font-style: italic;">provided further,</font> if during any part of such three (3) month period, the sale of any Common Stock received upon exercise of your option would violate the
          Company&#8217;s insider trading policy, then your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months after the termination of your Continuous Service during which
          the sale of the Common Stock received upon exercise of your option would not be in violation of the Company&#8217;s insider trading policy.&#160; Notwithstanding the foregoing, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates
          within six (6) months after the Date of Grant, and (iii) you have vested in a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is
          seven (7) months after the Date of Grant, and (B) the date that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date;</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160; &#160; &#160;&#160; twelve (12)
          months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 7(d)) below;</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(d)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; &#160; eighteen (18)
          months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than Cause;</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(e)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; the
          Expiration Date indicated in the Grant Notice; or</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(f)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; the day
          before the tenth (10<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) anniversary of the Date of Grant.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">8.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Exercise</font><font style="font-family: 'Times New Roman'; font-variant: small-caps;">.</font></font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; You may
          exercise the vested portion of your option (and the unvested portion of your option if your Grant Notice so permits) during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents
          and/or procedures designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company&#8217;s Secretary, stock plan administrator, or such other person as the Company may designate, together
          with such additional documents as the Company may then require.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By
          exercising the Grant Notice you agree that, as a condition to any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company
          arising by reason of (i) the exercise of your option, (ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon
          such exercise.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">9.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Transferability.</font>&#160; Except as otherwise provided in this Section 9, your option is not transferable, except by will or by the laws of descent
          and distribution, and is exercisable during your life only by you.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold;">Certain Trusts.</font>&#160; Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option to a trust if you are considered to be
          the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust.&#160; You and the trustee must enter into transfer and other agreements required by the Company.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold;">Domestic Relations Orders.</font>&#160; Upon receiving written permission from the Board or its duly authorized designee, and provided that you and the designated transferee enter
          into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury
          Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer.&#160; You are encouraged to discuss the proposed terms of any division of this option with the Company prior to finalizing the domestic
          relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; font-weight: bold;">Beneficiary Designation.</font>&#160; Upon receiving written permission from the Board or its duly authorized designee, you may, by delivering written notice to the Company, in a
          form&#160;approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and receive the Common Stock or other consideration
          resulting from such exercise.&#160; In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the Common Stock or other consideration resulting
          from such exercise.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">10.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Option not a Service Contract.</font>&#160; Your option is not an employment or service contract, and nothing in your option will be deemed to create in
          any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment.&#160; In addition, nothing in your option will obligate the Company or an
          Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">11.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; font-variant: small-caps;">Withholding Obligations.</font></font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the time
          you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for
          (including by means of a &#8220;same day sale&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign
          tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your option.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; &#160; Upon your
          request and subject to approval by the Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a
          number of whole shares of Common Stock having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the maximum amount of tax permitted to be withheld by law (or such lower amount as may be necessary to avoid
          classification of your option as a liability for financial accounting purposes).</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You may not
          exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.&#160; Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no
          obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any escrow provided for herein, if applicable, unless such obligations are satisfied.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">12.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Tax Consequences</font>. You hereby agree that the Company does not have a duty to design or administer the Plan or its other compensation programs
          in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from your option or your other compensation. In
          particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant Notice is at least equal to the &#8220;fair market value&#8221; per share of the Common Stock on the Date of
          Grant and there is no other impermissible deferral of compensation associated with the option.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">13.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Notices.</font> Any notices provided for in your option or the Plan will be given in writing (including electronically) and will be deemed
          effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.&#160; The
          Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means.&#160; By accepting this option,
          you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">14.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Governing Plan Document.</font>&#160; Your option is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your
          option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan.&#160; If there is any conflict between the provisions of your option and those of
          the Plan, the provisions of the Plan will control.&#160; In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with The Dodd&#8211;Frank Wall Street Reform and Consumer Protection Act
          and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">15.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Other Documents.&#160; </font>You hereby acknowledge receipt of and the right to receive a document providing the information required by Rule 428(b)(1)
          promulgated under the Securities Act, which includes the Plan prospectus.&#160; In addition, you acknowledge receipt of the Company&#8217;s policy permitting certain individuals to sell shares only during certain &#8220;window&#8221; periods and the Company&#8217;s insider
          trading policy, in effect from time to time.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">16.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Effect on Other Employee Benefit Plans.</font>&#160; The value of this option will not be included as compensation, earnings, salaries, or other similar
          terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of
          the Company&#8217;s or any Affiliate&#8217;s employee benefit plans.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">17.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Voting Rights.</font>&#160; You will not have voting or any other rights as a stockholder of the Company with respect to the shares to be issued pursuant
          to this option until such shares are issued to you.&#160;&#160; Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company.&#160; Nothing contained in this option, and no action taken pursuant to its provisions, will create
          or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">18.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Severability.</font>&#160; If all or any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or
          invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid.&#160; Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or
          invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">19.</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Miscellaneous</font>.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(a)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160; The rights and
          obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company&#8217;s successors and assigns.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(b)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; You agree
          upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(c)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;You
          acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully understand all provisions of your option.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(d)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Option
          Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">(e)</font><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; All
          obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of
          all or substantially all of the business and/or assets of the Company.</font></div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">*&#160; &#160; &#160; &#160; &#160; *&#160; &#160; &#160; &#160; &#160; *</div>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This Option Agreement will be deemed to be signed by you upon the signing by you of the Stock Option Grant Notice to which it is attached.</div>
      <div style="text-align: center;"><br>
      </div>
      <br>
      <div style="font-size: 10pt; font-family: 'Times New Roman';">
        <div style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-size: 10pt; font-family: 'Times New Roman';">
  </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10-1
<SEQUENCE>7
<FILENAME>brhc10050364_ex10-10-1.htm
<DESCRIPTION>EXHIBIT 10.10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <!--PROfilePageNumberReset%Num%1%%%-->
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 10.10.1</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>FIRST AMENDMENT TO EMPLOYMENT AGREEMENT</u></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this <font style="font-weight: bold; font-style: italic;">&#8220;Amendment&#8221;</font>) between <font style="font-weight: bold; font-variant: small-caps;">Ocuphire
          Pharma, Inc.</font>, a Delaware corporation (the <font style="font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>), and Amy Zaremba Rabourn (<font style="font-weight: bold; font-style: italic;">&#8220;Executive&#8221;</font>) is entered into and made
        effective as of the 26th day of March, 2023 (the <font style="font-weight: bold; font-style: italic;">&#8220;Effective Date&#8221;</font>).</div>
      <div><br>
      </div>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Recitals</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Whereas</font><font style="font-size: 10pt;">, on November 11, 2020 the Company and Executive entered
          into an Employment Agreement (the <font style="font-weight: bold; font-style: italic;">&#8220;Employment Agreement&#8221;</font>); and</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Whereas</font><font style="font-size: 10pt;">, the Company and Executive now wish to amend the
          Employment Agreement as provided herein.</font></div>
      <div><br>
      </div>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Agreement</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">Now</font><font style="font-size: 10pt; font-variant: small-caps;">,</font><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;"> Therefore</font><font style="font-size: 10pt;">, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Amendment to Section 5</font><font style="font-weight: bold;">.</font>&#160; As of the
        Effective Date, Section 5(a) is amended to add Section 5(a)(iv):</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-style: italic;">(iv) COBRA. </font><font style="font-size: 10pt;">Provided that the Executive timely elects continued health insurance coverage
          under the federal COBRA law and under the Company&#8217;s group health plans following the Termination Date, then the Company shall pay 100% of the COBRA premiums necessary to continue the Executive&#8217;s and the Executive&#8217;s covered dependents&#8217; health
          insurance coverage in effect for the Executive (and the Executive&#8217;s covered dependents) on the Termination Date until the earliest of: (A) nine (9) months following the Termination Date; (B) the date when the Executive becomes eligible for
          substantially equivalent health insurance coverage in connection with new employment; or (C) the date the Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination (such period from the Termination
          Date through the earlier of (A)-(C) (the <font style="font-weight: bold; font-style: italic;">&#8220;COBRA Payment Period&#8221;</font>).&#160; Notwithstanding the foregoing, if at any time the Company determines that its payment of COBRA premiums on the
          Executive&#8217;s behalf would result in a violation of applicable law (including, but not limited to, the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), or not available for other
          reasons, then in lieu of paying COBRA premiums pursuant to this <u>Section 5(a)(iv)</u>, the Company shall pay the Executive on the last day of each remaining month of the COBRA Payment Period, a fully taxable cash payment equal to the premium
          for such month, subject to applicable tax withholding, for the remainder of the COBRA Payment Period.&#160; Nothing in this Agreement shall deprive the Executive of the Executive&#8217;s rights under COBRA or ERISA for benefits under plans and policies
          arising under the Executive&#8217;s employment by the Company.</font></div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold; font-variant: small-caps;">Construction.</font>&#160; Unless otherwise defined herein, capitalized terms shall have
        the meanings set forth in the Employment Agreement.&#160; The terms of this Amendment amend and modify the Employment Agreement as if fully set forth in the Employment Agreement.&#160; If there is any conflict between the terms, conditions and obligations of
        this Amendment and the Employment Agreement, this Amendment&#8217;s terms, conditions and obligations shall control.&#160; All other provisions of the Employment Agreement not specifically modified by this Amendment are preserved.&#160; This Amendment may be
        executed in counterparts (including via facsimile or .pdf), each of which shall be deemed an original, and all of which together shall constitute one and the same document.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold;">Signatures on the Following Page</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; font-size: 12pt; text-indent: 36pt;"><font style="font-size: 10pt; font-weight: bold; font-variant: small-caps;">In Witness Whereof</font><font style="font-size: 10pt; font-variant: small-caps;">,</font><font style="font-size: 10pt;"> the parties have executed this Amendment as of the date first written above.</font></div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf21f2c80b71d4276ad4fdb0b148136ab">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: bold;">EXECUTIVE:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: bold;">THE COMPANY:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-variant: small-caps; font-weight: bold;">Ocuphire Pharma, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" id="z2cc13f33ac3e40d786a2faa860c4327f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-indent: 9pt;">/s/ Mina Sooch</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" id="z0b39e5d7e42745c390d19dea839df752" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 25%; vertical-align: top; border-bottom: 2px solid black;">
              <div style="text-align: center;">/s/ Amy Rabourn</div>
            </td>
            <td style="width: 25%; vertical-align: top; padding-bottom: 2px;"><br>
            </td>
            <td rowspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div>Name: Mina Sooch</div>
            </td>
          </tr>
          <tr>
            <td colspan="2" style="width: 50%; vertical-align: top;">
              <div style="font-variant: small-caps; font-weight: bold;">Amy Zaremba Rabourn</div>
            </td>
            <td rowspan="1" style="width: 50%; vertical-align: top;">
              <div>Title: Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: center; font-variant: small-caps;">Signature Page to</div>
      <div style="text-align: center; font-variant: small-caps;">First Amendment to Employment Agreement</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15-1
<SEQUENCE>8
<FILENAME>brhc10050364_ex10-15-1.htm
<DESCRIPTION>EXHIBIT 10.15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%--><font style="font-size: 10pt;">
  </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Exhibit 10.15.1</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>FIRST AMENDMENT TO CONSULTING AGREEMENT</u></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS FIRST AMENDMENT TO CONSULTING AGREEMENT (this <font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">&#8220;Amendment&#8221;</font>) between <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Ocuphire Pharma, Inc.</font>, a Delaware corporation (the <font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">&#8220;Company&#8221;</font>), and <font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Jay S. Pepose, M.D.,</font> (<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">&#8220;Consultant&#8221;</font>) is entered into and made effective as of the 19th day of September, 2022 (the <font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">&#8220;Effective Date&#8221;</font>).</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Recitals</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Whereas</font><font style="font-size: 10pt;">, on April 8, 2022, the Company and Consultant entered into a Consulting Agreement (the <font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">&#8220;Consulting Agreement&#8221;</font>); and</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Whereas</font><font style="font-size: 10pt;">, the Company and Consultant now wish to amend the Consulting Agreement as provided herein.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Agreement</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Now</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: small-caps;">,</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;"> Therefore</font><font style="font-size: 10pt;">, in consideration of the foregoing and the terms and conditions set forth below, the parties agree as follows:</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Amendment to Section 4</font><font style="font-family: 'Times New Roman'; font-weight: bold;">.</font>&#160; As of the Effective Date, Section
            4 of the Consulting Agreement is hereby amended to add a new Section 4(d):</font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;If within twelve (12) months following or three (3) months prior to the effective date of a Change in Control (as defined in the Ocuphire
        Pharma, Inc. 2020 Equity Incentive Plan (the <font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">&#8220;2020 Plan</font>&#8221;)): (i) Consultant effects a termination for Good Reason (as defined below) or (ii) the
        Company terminates the Consulting Agreement other than due to Consultant&#8217;s death, a termination due to a Disability (as defined in the 2020 Plan) or a termination for Cause (as defined in the 2020 Plan), all of the Consultant&#8217;s remaining stock
        options, restricted stock or other equity awards that were issued by the Company and assumed, continued or substituted by the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) in a
        transaction that constitutes a Change in Control and remain subject to time vesting conditions shall fully vest and become immediately exercisable in accordance with the terms of the applicable award agreements. Notwithstanding the foregoing, a
        Change in Control will not be deemed to occur (i) in connection with the issuance of securities of the Company as part of a joint venture or strategic partnership to which the Company is party or (ii) in connection with the license of Nyxol to any
        strategic partner.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Good Reason</font>&#8221; means the occurrence
        of either of the following events: (i) a reduction of Consultant&#8217;s cash compensation rate or (ii) a material reduction in Consultant&#8217;s duties and responsibilities.&#8221;</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">Construction.</font>&#160; Unless otherwise defined herein, capitalized terms shall have the meanings set forth in the Consulting Agreement.&#160; The terms
            of this Amendment amend and modify the Consulting Agreement as if fully set forth in the Consulting Agreement.&#160; If there is any conflict between the terms, conditions and obligations of this Amendment and the Consulting Agreement, this
            Amendment&#8217;s terms, conditions and obligations shall control.&#160; All other provisions of the Consulting Agreement not specifically modified by this Amendment are preserved.&#160; This Amendment may be executed in counterparts (including via facsimile
            or .pdf), each of which shall be deemed an original, and all of which together shall constitute one and the same document.</font></font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps; font-weight: bold;">Signatures on the Following Page</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; font-variant: small-caps;">In Witness Whereof</font><font style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: small-caps;">,</font><font style="font-size: 10pt;"> the parties have executed this Amendment as of the date first written above.</font></div>
      <div style="font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z74d1a8554eba4b9f91f0fcf9c18b9739" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">CONSULTANT:</div>
            </td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">THE COMPANY:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">Ocuphire Pharma, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
            <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
            </td>
            <td style="width: 44%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman'; text-indent: 9pt;">/s/ Bernhard Hoffmann</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">/s/ Jay S. Pepose</div>
            </td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;"><br>
            </td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman';">Name:<br>
              </div>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">Bernhard Hoffmann</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt; padding-bottom: 2px;" colspan="2">
              <div style="text-align: left; font-family: 'Times New Roman'; font-variant: small-caps; font-weight: bold;">Jay S. Pepose, M.D.</div>
            </td>
            <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" rowspan="1">
              <div style="text-align: left; font-family: 'Times New Roman';">Title:<br>
              </div>
            </td>
            <td style="width: 42%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">VP &#8211; Corp. Ev. &amp; Operations</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" rowspan="1">&#160;</td>
          </tr>

      </table>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps;">Signature Page to</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-variant: small-caps;">First Amendment to Consulting Agreement</div>
      <div style="font-size: 10pt;"><br>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
    </div>
  </div>

  <div style="text-align: center;" class="BRPFPageNumberArea">
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15-2
<SEQUENCE>9
<FILENAME>brhc10050364_ex10-15-2.htm
<DESCRIPTION>EXHIBIT 10.15.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 10.15.2</div>
      <div style="text-align: right; font-size: 12pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: right; font-size: 12pt; font-weight: bold;">
        <div style="text-align: center; font-size: 10pt; font-weight: bold;">AMENDMENT NO. 2 TO CONSULTING AGREEMENT</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">This <font style="font-weight: bold;">AMENDMENT NO. 2 </font><font style="font-weight: normal;">(&#8220;Amendment No. 2&#8221;) to the <font style="font-weight: bold;">CONSULTING
              AGREEMENT</font> dated April 8, 2022, as amended on September 19, 2022 (the <font style="font-style: italic;">&#8220;<font style="font-weight: bold;">Agreement</font>&#8221;</font>) between <font style="font-weight: bold;">OCUPHIRE PHARMA, INC.</font>,
            a Delaware corporation having its principal place of business at 37000 Grand River Avenue, Suite 120, Farmington Hills, Michigan 48335 (the <font style="font-style: italic;">&#8220;Company&#8221;</font>), and <font style="font-weight: bold;">JAY S.
              PEPOSE,</font> whose address is [*] (<font style="font-style: italic;">&#8220;<font style="font-weight: bold;">Consultant</font>&#8221;</font>) is made as of December 1, 2022 (the <font style="font-style: italic;">&#8220;<font style="font-weight: bold;">Effective

                Date</font>&#8221;</font>).</font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zb9b26176987049ee8a166451598e87c6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top;">I.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The following statement is added at the end of Paragraph 2 <font style="font-weight: bold;">SERVICES.</font>:</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; margin-left: 36pt; font-size: 10pt; font-weight: normal;">Consultant shall track both total hours of Services performed and the number of hours of Services performed on activities related to the Nxyol program, using
          the tracking application supplied by the Company.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5f7f3dc435c5432aaac72e5ef02e41f5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top;">II.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Paragraph 4. (a) will be replaced in its entirety as follows:</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; margin-left: 36pt; font-size: 10pt; font-weight: normal;">4. (a) <font style="font-weight: bold;">COMPENSATION</font>. In consideration of Consultant&#8217;s performance of the Services, the Company shall pay Consultant
          at a rate of $25,000 per month for the Services rendered by Consultant.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2b0544189eb84ed9976e9af46c5dcca1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top;">III.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>All other terms of the Agreement remain in effect without change.</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; margin-left: 36pt; font-size: 10pt; font-weight: normal;">Having understood and agreed to the foregoing, the Company and Consultant have signed this Amendment No. 2 and the same shall be effective as of the
          Effective Date.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" id="z68311b3a4ae343528d0d64afa6882951" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="font-weight: bold;">CONSULTANT:</div>
              </td>
              <td style="width: 3%; vertical-align: top;">&#160;</td>
              <td style="width: 47%; vertical-align: top;">
                <div style="font-weight: bold;">THE COMPANY:</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 3%; vertical-align: top;">&#160;</td>
              <td style="width: 47%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 3%; vertical-align: top;">&#160;</td>
              <td style="width: 47%; vertical-align: top;">
                <div style="font-weight: bold;">OCUPHIRE PHARMA, INC.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 3%; vertical-align: top;">&#160;</td>
              <td style="width: 47%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; border-bottom: 2px solid black;">
                <div>/s/ Jay S. Pepose, M.D.</div>
              </td>
              <td style="width: 3%; vertical-align: top;">&#160;</td>
              <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
                <div>/s/ Bernhard Hoffmann</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>Jay S. Pepose, M.D.</div>
              </td>
              <td style="width: 3%; vertical-align: top;">&#160;</td>
              <td style="width: 47%; vertical-align: top;">
                <div>Bernhard Hoffman</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 3%; vertical-align: top;">&#160;</td>
              <td style="width: 47%; vertical-align: top;">
                <div>VP &#8211; Corporate Development &amp; Operations</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt; text-align: left;"><br>
        </div>
        <div style="font-size: 10pt; text-align: left;"><br>
        </div>
        <div style="font-size: 10pt; text-align: left;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>10
<FILENAME>brhc10050364_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Exhibit 21.1</div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">LIST OF SUBSIDIARIES</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Subsidiaries of Ocuphire Pharma, Inc.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Subsidiaries</div>
            </td>
            <td style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Jurisdiction of Incorporation</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">None</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>brhc10050364_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(34, 34, 34); font-weight: bold;">Exhibit 23.1</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(34, 34, 34); font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
      <div><font style="color: rgb(34, 34, 34);">&#160;</font><br>
      </div>
      <div>We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-252715) and Form S-8 (No. 333-264139, 333-254923, 333-249978, 333-217627, 333-189240, and 333-129294) of Ocuphire Pharma, Inc., of our report dated
        March 30, 2023, relating to the consolidated financial statements of Ocuphire Pharma, Inc., included in this Annual Report (Form 10-K) of Ocuphire Pharma, Inc. for the year ended December 31, 2022.</div>
      <div><br>
      </div>
      <div>/s/ Ernst &amp; Young LLP</div>
      <div>&#160;<br>
      </div>
      <div>Detroit, MI</div>
      <div>March 30, 2023</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>12
<FILENAME>brhc10050364_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Exhibit 31.1</div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a)</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">I, Mina Sooch, certify that:</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">1. I have reviewed this Annual Report on Form 10-K of Ocuphire Pharma, Inc. (the &#8220;Company&#8221;);</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
        circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
        and cash flows of the registrant as of, and for, the periods presented in this report;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
        15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
        registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
        regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
        procedures, as of the end of the period covered by this report based on such evaluation; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth
        fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit
        committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s
        ability to record, process, summarize and report financial information; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Date: March 30, 2023</div>
            </td>
            <td colspan="2" rowspan="1" style="vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);"><u>/s/ Mina Sooch</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Mina Sooch</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Chief Executive Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>13
<FILENAME>brhc10050364_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Exhibit 31.2</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a), AS ADOPTED</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">I, Amy Rabourn, certify that:</div>
      <div><font style="color: rgb(0, 0, 0);">&#160;</font><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">1. I have reviewed this Annual Report on Form 10-K of Ocuphire Pharma, Inc. (the &#8220;Company&#8221;);</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
        circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
        and cash flows of the registrant as of, and for, the periods presented in this report;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and
        15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the
        registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
        regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
        procedures, as of the end of the period covered by this report based on such evaluation; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth
        fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit
        committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s
        ability to record, process, summarize and report financial information; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0);">(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Date: March 30, 2023</div>
            </td>
            <td colspan="2" style="width: 5.13%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; color: rgb(0, 0, 0);"><u>/s/ Amy Rabourn</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5.13%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Amy Rabourn</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5.13%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Senior Vice President of Finance</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5.13%; vertical-align: top;">&#160;</td>
            <td style="width: 45%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">(Principal Financial Officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>14
<FILENAME>brhc10050364_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solution Inc.
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; color: rgb(0, 0, 0); font-weight: bold;">Exhibit 32.1</div>
      <div><font style="color: rgb(0, 0, 0);">&#160;</font><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">In connection with the Annual Report on Form 10-K for the year ended December 31, 2022 (the &#8220;Report&#8221;) of Ocuphire Pharma, Inc., a Delaware corporation (the &#8220;Company&#8221;) as filed
        with the Securities and Exchange Commission (the &#8220;Report&#8221;), Mina Sooch, as Chief Executive Officer of the Company, and Amy Rabourn, as Senior Vice President of Finance of the Company, each hereby certifies, pursuant to Section 906 of the
        Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to the best of her knowledge and belief:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Date: March 30, 2023</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);"><u>/s/ Mina Sooch</u></div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Mina Sooch</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Chief Executive Officer</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">(<font style="font-style: italic;">Principal Executive Officer</font>)</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);"><u>/s/ Amy Rabourn</u></div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Amy Rabourn</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: rgb(0, 0, 0);">Senior Vice President of Finance</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; color: #000000;">(<font style="font-style: italic;">Principal Financial Officer and Principal Accounting Officer</font>)</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: right;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>ocup-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<xs:schema targetNamespace="http://ocuphire.com/20221231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ocup="http://ocuphire.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ocup-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ocup-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ocup-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ocup-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://ocuphire.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>010000 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <!--Parent Role: Balance Sheets-->
        <link:definition>010100 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" id="ConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>020000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" id="ConsolidatedStatementsOfChangesInStockholdersEquityDeficit">
        <link:definition>030000 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies" id="CompanyDescriptionAndSummaryOfSignificantAccountingPolicies">
        <link:definition>060100 - Disclosure - Company Description and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/Merger" id="Merger">
        <link:definition>060200 - Disclosure - Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/PremergerFinancing" id="PremergerFinancing">
        <link:definition>060300 - Disclosure - Pre-Merger Financing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>060400 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformation" id="SupplementalBalanceSheetInformation">
        <link:definition>060500 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>060600 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockbasedCompensation" id="StockbasedCompensation">
        <link:definition>060700 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/ApexianSublicenseAgreement" id="ApexianSublicenseAgreement">
        <link:definition>060800 - Disclosure - Apexian Sublicense Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockholderEquity" id="StockholderEquity">
        <link:definition>060900 - Disclosure - Stockholder Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreements" id="LicenseAndCollaborationAgreements">
        <link:definition>061000 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/NetIncomeLossPerShare" id="NetIncomeLossPerShare">
        <link:definition>061100 - Disclosure - Net income (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>061200 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/DeferredCompensationPlan" id="DeferredCompensationPlan">
        <link:definition>061300 - Disclosure - Deferred Compensation Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>061400 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>070100 - Disclosure - Company Description and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>080100 - Disclosure - Company Description and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationTables" id="SupplementalBalanceSheetInformationTables">
        <!--Parent Role: Supplemental Balance Sheet Information-->
        <link:definition>080500 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockbasedCompensationTables" id="StockbasedCompensationTables">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>080700 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsTables" id="LicenseAndCollaborationAgreementsTables">
        <!--Parent Role: License and Collaboration Agreements-->
        <link:definition>081000 - Disclosure - License and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/NetIncomeLossPerShareTables" id="NetIncomeLossPerShareTables">
        <!--Parent Role: Net income (loss) per share-->
        <link:definition>081100 - Disclosure - Net income (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <!--Parent Role: Income Taxes-->
        <link:definition>081200 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090100 - Disclosure - Company Description and Summary of Significant Accounting Policies, Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090106 - Disclosure - Company Description and Summary of Significant Accounting Policies, Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090108 - Disclosure - Company Description and Summary of Significant Accounting Policies, Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090110 - Disclosure - Company Description and Summary of Significant Accounting Policies, Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090112 - Disclosure - Company Description and Summary of Significant Accounting Policies, Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090114 - Disclosure - Company Description and Summary of Significant Accounting Policies, Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090116 - Disclosure - Company Description and Summary of Significant Accounting Policies, Fair Value of Financial Instruments Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090118 - Disclosure - Company Description and Summary of Significant Accounting Policies, Equity Investments Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090120 - Disclosure - Company Description and Summary of Significant Accounting Policies, Warrant Liabilities and Premium Conversion Derivatives Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" id="CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails">
        <!--Parent Role: Company Description and Summary of Significant Accounting Policies-->
        <link:definition>090122 - Disclosure - Company Description and Summary of Significant Accounting Policies, Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails" id="MergerContingentValueRightsAgreementDetails">
        <!--Parent Role: Merger-->
        <link:definition>090206 - Disclosure - Merger, Contingent Value Rights Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails" id="MergerFormerRexahnWarrantsDetails">
        <!--Parent Role: Merger-->
        <link:definition>090208 - Disclosure - Merger, Former Rexahn Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/PremergerFinancingDetails" id="PremergerFinancingDetails">
        <!--Parent Role: Pre-Merger Financing-->
        <link:definition>090300 - Disclosure - Pre-Merger Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: Commitments and Contingencies-->
        <link:definition>090400 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails" id="SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails">
        <!--Parent Role: Supplemental Balance Sheet Information-->
        <link:definition>090500 - Disclosure - Supplemental Balance Sheet Information, Prepaid and Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails" id="SupplementalBalanceSheetInformationPropertyAndEquipmentDetails">
        <!--Parent Role: Supplemental Balance Sheet Information-->
        <link:definition>090502 - Disclosure - Supplemental Balance Sheet Information, Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails" id="SupplementalBalanceSheetInformationAccruedExpensesDetails">
        <!--Parent Role: Supplemental Balance Sheet Information-->
        <link:definition>090504 - Disclosure - Supplemental Balance Sheet Information, Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails" id="SupplementalBalanceSheetInformationShorttermLoanDetails">
        <!--Parent Role: Supplemental Balance Sheet Information-->
        <link:definition>090506 - Disclosure - Supplemental Balance Sheet Information, Short-Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <!--Parent Role: Related Party Transactions-->
        <link:definition>090600 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" id="StockbasedCompensationStockbasedCompensationExpenseDetails">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>090700 - Disclosure - Stock-based Compensation, Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails" id="StockbasedCompensationStockOptionPlanActivityDetails">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>090702 - Disclosure - Stock-based Compensation, Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails" id="StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>090704 - Disclosure - Stock-based Compensation, Weighted Average Assumptions Used in Black-Scholes Option-pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails" id="StockbasedCompensationRestrictedStockAwardsActivityDetails">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>090706 - Disclosure - Stock-based Compensation, Restricted Stock Awards Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails" id="StockbasedCompensationCommonStockIssuedForServicesDetails">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>090708 - Disclosure - Stock-based Compensation, Common Stock Issued for Services (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails" id="StockbasedCompensationFormerRexahnOptionsDetails">
        <!--Parent Role: Stock-based Compensation-->
        <link:definition>090710 - Disclosure - Stock-based Compensation, Former Rexahn Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/ApexianSublicenseAgreementDetails" id="ApexianSublicenseAgreementDetails">
        <!--Parent Role: Apexian Sublicense Agreement-->
        <link:definition>090800 - Disclosure - Apexian Sublicense Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails" id="StockholdersEquityAtthemarketProgramDetails">
        <!--Parent Role: Stockholder Equity-->
        <link:definition>090900 - Disclosure - Stockholders' Equity, At-The-Market Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails" id="StockholdersEquityRegisteredDirectOfferingDetails">
        <!--Parent Role: Stockholder Equity-->
        <link:definition>090902 - Disclosure - Stockholders' Equity, Registered Direct Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails" id="LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails">
        <!--Parent Role: License and Collaboration Agreements-->
        <link:definition>091000 - Disclosure - License and Collaboration Agreements, Nyxol License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails" id="LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails">
        <!--Parent Role: License and Collaboration Agreements-->
        <link:definition>091002 - Disclosure - License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails" id="NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails">
        <!--Parent Role: Net income (loss) per share-->
        <link:definition>091100 - Disclosure - Net income (loss) per share, Computation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails" id="NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails">
        <!--Parent Role: Net income (loss) per share-->
        <link:definition>091102 - Disclosure - Net income (loss) per share, Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" id="IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091200 - Disclosure - Income Taxes, Reconciliation of Statutory to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" id="IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091204 - Disclosure - Income Taxes, Components of Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091206 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails" id="IncomeTaxesOperatingLossCarryforwardsDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>091208 - Disclosure - Income Taxes, Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/DeferredCompensationPlanDetails" id="DeferredCompensationPlanDetails">
        <!--Parent Role: Deferred Compensation Plan-->
        <link:definition>091300 - Disclosure - Deferred Compensation Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ocuphire.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
        <!--Parent Role: Subsequent Events-->
        <link:definition>091400 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" id="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodValueStockExerciseOfWarrants" id="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesExerciseOfWarrants" id="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueInSettlementWithInvestors" id="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesInSettlementWithInvestors" id="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueAtTheMarketProgram" id="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesAtTheMarketProgram" id="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" id="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" id="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" id="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ContractAssetCurrent" id="ocup_ContractAssetCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PreMergerFinancingAbstract" id="ocup_PreMergerFinancingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PreMergerFinancingTextBlock" id="ocup_PreMergerFinancingTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PreMergerFinancingOfWarrantsAbstract" id="ocup_PreMergerFinancingOfWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfDirectors" id="ocup_NumberOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RemainingIssuableShares" id="ocup_RemainingIssuableShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="RexahnStockholdersMember" id="ocup_RexahnStockholdersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FairValueAssumptionsExpectedLife" id="ocup_FairValueAssumptionsExpectedLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromPreMergerFinancing" id="ocup_ProceedsFromPreMergerFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="WaiverAgreementsMember" id="ocup_WaiverAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SecuritiesPurchaseAgreementMember" id="ocup_SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeriesBWarrantsMember" id="ocup_SeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeriesAWarrantsMember" id="ocup_SeriesAWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncreaseDecreaseInContractAssetCurrent" id="ocup_IncreaseDecreaseInContractAssetCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" id="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncomeLossFromInvestmentsRelatedToLicenseAgreement" id="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ShareSettlementWithInvestors" id="ocup_ShareSettlementWithInvestors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="OperatingLeasesMonthlyBaseRent" id="ocup_OperatingLeasesMonthlyBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AccreditedInvestorMember" id="ocup_AccreditedInvestorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IssuanceOfSettlementSharesAbstract" id="ocup_IssuanceOfSettlementSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FairValueShareSettlementAmount" id="ocup_FairValueShareSettlementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="NumberOfAccreditedInvestors" id="ocup_NumberOfAccreditedInvestors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationWarrantsPercent" id="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" id="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DeferredTaxAssetsResearchAndDevelopment" id="ocup_DeferredTaxAssetsResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="WarrantsAndStockOptionsAbstract" id="ocup_WarrantsAndStockOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WeightedAverageRemainingContractualTermsWarrants" id="ocup_WeightedAverageRemainingContractualTermsWarrants" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ContingentValueRightsAgreementAbstract" id="ocup_ContingentValueRightsAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContingentValueRightsIPTerm" id="ocup_ContingentValueRightsIPTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfCashConsiderationPayment" id="ocup_PercentageOfCashConsiderationPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfMilestonesAccrued" id="ocup_NumberOfMilestonesAccrued" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ContingentValueRightsPaymentPeriod" id="ocup_ContingentValueRightsPaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ContingentValueRightsPercentage" id="ocup_ContingentValueRightsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" id="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="BioSenseGlobalLLCMember" id="ocup_BioSenseGlobalLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ZhejiangHaiChangBiotechnologyCoLtdMember" id="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfPotentialMilestones" id="ocup_NumberOfPotentialMilestones" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AtTheMarketProgramAbstract" id="ocup_AtTheMarketProgramAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AtTheMarketProgramMember" id="ocup_AtTheMarketProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShelfRegistrationMember" id="ocup_ShelfRegistrationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RegisteredDirectOfferingMember" id="ocup_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RegisteredDirectOfferingsAbstract" id="ocup_RegisteredDirectOfferingsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockSoldPricePerShare" id="ocup_StockSoldPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="MinimumPercentageOfBeneficialOwnership" id="ocup_MinimumPercentageOfBeneficialOwnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MaximumPercentageOfBeneficialOwnershipLimitation" id="ocup_MaximumPercentageOfBeneficialOwnershipLimitation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" id="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LiquidityPolicyTextBlock" id="ocup_LiquidityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NatureOfBusinessPolicyTextBlock" id="ocup_NatureOfBusinessPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WarrantLiabilitiesPolicyTextBlock" id="ocup_WarrantLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OtherIncomeExpenseNetPolicyTextBlock" id="ocup_OtherIncomeExpenseNetPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ContractAssetPolicyTextBlock" id="ocup_ContractAssetPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NatureOfBusinessAbstract" id="ocup_NatureOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfSmallMoleculeProductCandidates" id="ocup_NumberOfSmallMoleculeProductCandidates" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DefinedContributionPlanAdditionalEmployerMatchingContribution" id="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RetirementPlan401KMember" id="ocup_RetirementPlan401KMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" id="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LicenseAndCollaborationAgreementsAbstract" id="ocup_LicenseAndCollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" id="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LicenseTransferFeeMember" id="ocup_LicenseTransferFeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" id="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ResearchDevelopmentServicesMember" id="ocup_ResearchDevelopmentServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NyxolLicenseAgreementMember" id="ocup_NyxolLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborationAndLicenseAgreementAbstract" id="ocup_CollaborationAndLicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FirstPotentialMilestonePaymentToBeReceived" id="ocup_FirstPotentialMilestonePaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="EstimatedStandaloneSellingPriceForLicenseAgreement" id="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NonRefundableCashPaymentReceived" id="ocup_NonRefundableCashPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NumberOfPerformanceObligations" id="ocup_NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="MaximumPercentageOfTieredRoyaltiesReceivable" id="ocup_MaximumPercentageOfTieredRoyaltiesReceivable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" id="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="RevenueFromContractWithCustomerToBeRecognized" id="ocup_RevenueFromContractWithCustomerToBeRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" id="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PeriodOfNonCancellationWindowAgreement" id="ocup_PeriodOfNonCancellationWindowAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProcessaLicenseAgreementMember" id="ocup_ProcessaLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfTimesPaymentsForSalesMilestone" id="ocup_NumberOfTimesPaymentsForSalesMilestone" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" id="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" id="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="MilestonePaymentAchievedForPerformanceObligation" id="ocup_MilestonePaymentAchievedForPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PeriodOfOpportunityToCureBreachOfAgreement" id="ocup_PeriodOfOpportunityToCureBreachOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MilestonePaymentsAmountReceived" id="ocup_MilestonePaymentsAmountReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="BioSenseLicenseAndAssignmentsAgreementMember" id="ocup_BioSenseLicenseAndAssignmentsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="UpfrontPaymentReceivedInCommonStockFairValue" id="ocup_UpfrontPaymentReceivedInCommonStockFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" id="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PeriodOfRestrictionFromSellingStock" id="ocup_PeriodOfRestrictionFromSellingStock" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" id="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" id="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="UpfrontPaymentReceivedInCommonStockShares" id="ocup_UpfrontPaymentReceivedInCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionsAbstract" id="ocup_StockOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumPeriodOfSharesReservedUnderPlan" id="ocup_MaximumPeriodOfSharesReservedUnderPlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InducementPlanMember" id="ocup_InducementPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2018Member" id="ocup_EquityIncentivePlan2018Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2020Member" id="ocup_EquityIncentivePlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ConcentrationOfCreditRiskAbstract" id="ocup_ConcentrationOfCreditRiskAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PremiumConversionDerivativesMember" id="ocup_PremiumConversionDerivativesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantLiabilitiesMember" id="ocup_WarrantLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SupplementalBalanceSheetInformationAbstract" id="ocup_SupplementalBalanceSheetInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonStockCapitalSharesAvailableForFutureIssuance" id="ocup_CommonStockCapitalSharesAvailableForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="RestrictedStockAwardsAbstract" id="ocup_RestrictedStockAwardsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ReceiptOfInvestmentsRelatedToLicenseAgreement" id="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" id="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="FormerOptionsAbstract" id="ocup_FormerOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonStockIssuedForServicesAbstract" id="ocup_CommonStockIssuedForServicesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfBoardMembersGrantedStockForServices" id="ocup_NumberOfBoardMembersGrantedStockForServices" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentNumberOfInstallments" id="ocup_DebtInstrumentNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShortTermLoanMember" id="ocup_ShortTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncrementalCommonSharesAttributableToOptions" id="ocup_IncrementalCommonSharesAttributableToOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IncrementalCommonSharesAttributableToWarrants" id="ocup_IncrementalCommonSharesAttributableToWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NonRefundableUpfrontPaymentReceived" id="ocup_NonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LiquidityAbstract" id="ocup_LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityInvestmentMember" id="ocup_EquityInvestmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PreMergerFinancingMember" id="ocup_PreMergerFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PreMergerFinancingAndWaiverAgreementsAbstract" id="ocup_PreMergerFinancingAndWaiverAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfConvertedAdditionalSharesReceivedByDirectors" id="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfDirectorsSignedWaiverAgreements" id="ocup_NumberOfDirectorsSignedWaiverAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AmountInvestedInPreMergerFinancing" id="ocup_AmountInvestedInPreMergerFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="ConsultingFeePayable" id="ocup_ConsultingFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfConvertedInitialSharesReceivedByDirectors" id="ocup_NumberOfConvertedInitialSharesReceivedByDirectors" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="SubsequentEventsAdditionalInformationAbstract" id="ocup_SubsequentEventsAdditionalInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AggregateNumberOfCommonStockReservedForFutureIssuance" id="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EvergreenProvisionPlan2020Member" id="ocup_EvergreenProvisionPlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ApexianSublicenseAgreementAbstract" id="ocup_ApexianSublicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ApexianSublicenseAgreementTextBlock" id="ocup_ApexianSublicenseAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DevelopmentAndRegulatoryMilestonesMember" id="ocup_DevelopmentAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SalesMilestonesMember" id="ocup_SalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ApexianSublicenseAgreementMember" id="ocup_ApexianSublicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SublicenseAgreementAbstract" id="ocup_SublicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FutureMilestoneMethodRevenueNotRecognized" id="ocup_FutureMilestoneMethodRevenueNotRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="SeriesASeriesBAndRDOWarrantsMember" id="ocup_SeriesASeriesBAndRDOWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FormerRexahnWarrantsMember" id="ocup_FormerRexahnWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FormerRexahnOptionsMember" id="ocup_FormerRexahnOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StateAndLocalOperatingLossCarryforwardsTaxEffect" id="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="FederalOperatingLossCarryforwardsTaxEffect" id="ocup_FederalOperatingLossCarryforwardsTaxEffect" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="UtilizedFederalResearchCreditCarryforwards" id="ocup_UtilizedFederalResearchCreditCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" id="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>ocup-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationAccruedExpensesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="ocup-20221231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ocup-20221231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://ocuphire.com/role/BalanceSheets" xlink:type="simple" xlink:href="ocup-20221231.xsd#BalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="WarrantsAndRightsOutstanding" xlink:title="calculation: Liabilities to WarrantsAndRightsOutstanding" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="ShortTermBorrowings" xlink:title="ShortTermBorrowings" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ShortTermBorrowings" xlink:title="calculation: LiabilitiesCurrent to ShortTermBorrowings" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="ShortTermInvestments" xlink:title="ShortTermInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="ShortTermInvestments" xlink:title="calculation: AssetsCurrent to ShortTermInvestments" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetCurrent" xlink:label="ContractAssetCurrent" xlink:title="ContractAssetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="ContractAssetCurrent" xlink:title="calculation: AssetsCurrent to ContractAssetCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AccountsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to AccountsReceivableNetCurrent" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="OtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTax to OtherComprehensiveIncomeLossNetOfTax" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OtherNonoperatingIncomeExpense" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="calculation: OperatingIncomeLoss to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to GeneralAndAdministrativeExpense" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="InterestExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to InterestExpense" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to GainLossOnDerivativeInstrumentsNetPretax" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="NetIncomeLoss" xlink:title="calculation: ComprehensiveIncomeNetOfTax to NetIncomeLoss" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="ProceedsFromShortTermDebt" xlink:title="ProceedsFromShortTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromShortTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromShortTermDebt" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="RepaymentsOfShortTermDebt" xlink:title="RepaymentsOfShortTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfShortTermDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfShortTermDebt" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfStockIssuanceCosts" order="4.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="18.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to Depreciation" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsReceivable" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncreaseDecreaseInContractAssetCurrent" xlink:label="IncreaseDecreaseInContractAssetCurrent" xlink:title="IncreaseDecreaseInContractAssetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInContractAssetCurrent" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInContractAssetCurrent" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:label="IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:title="IncomeLossFromInvestmentsRelatedToLicenseAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncomeLossFromInvestmentsRelatedToLicenseAgreement" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareSettlementWithInvestors" xlink:label="ShareSettlementWithInvestors" xlink:title="ShareSettlementWithInvestors" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareSettlementWithInvestors" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareSettlementWithInvestors" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="UnrealizedGainLossOnInvestments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to UnrealizedGainLossOnInvestments" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="19.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="17.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDerivativeInstrumentsNetPretax" order="16.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="OtherPaymentsToAcquireBusinesses" xlink:title="OtherPaymentsToAcquireBusinesses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="OtherPaymentsToAcquireBusinesses" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to OtherPaymentsToAcquireBusinesses" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="PrepaidExpenseCurrent" xlink:title="PrepaidExpenseCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="PrepaidExpenseCurrent" xlink:title="calculation: PrepaidExpenseAndOtherAssetsCurrent to PrepaidExpenseCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="OtherAssetsCurrent" xlink:title="calculation: PrepaidExpenseAndOtherAssetsCurrent to OtherAssetsCurrent" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to EmployeeRelatedLiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to OtherAccruedLiabilitiesCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:label="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:title="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedProfessionalFeesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="TaxesPayableCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to TaxesPayableCurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncrementalCommonSharesAttributableToOptions" xlink:label="IncrementalCommonSharesAttributableToOptions" xlink:title="IncrementalCommonSharesAttributableToOptions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="IncrementalCommonSharesAttributableToOptions" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to IncrementalCommonSharesAttributableToOptions" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncrementalCommonSharesAttributableToWarrants" xlink:label="IncrementalCommonSharesAttributableToWarrants" xlink:title="IncrementalCommonSharesAttributableToWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="IncrementalCommonSharesAttributableToWarrants" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to IncrementalCommonSharesAttributableToWarrants" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:label="EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:title="EffectiveIncomeTaxRateReconciliationWarrantsPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationWarrantsPercent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:label="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:title="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="4.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to DeferredFederalIncomeTaxExpenseBenefit" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentStateAndLocalTaxExpenseBenefit" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentFederalTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentFederalTaxExpenseBenefit" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to CurrentIncomeTaxExpenseBenefit" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsValuationAllowance" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOther" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOther" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsInProcessResearchAndDevelopment" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DeferredTaxAssetsResearchAndDevelopment" xlink:label="DeferredTaxAssetsResearchAndDevelopment" xlink:title="DeferredTaxAssetsResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsResearchAndDevelopment" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsResearchAndDevelopment" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="DeferredTaxAssetsTaxDeferredExpenseOther" xlink:title="DeferredTaxAssetsTaxDeferredExpenseOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseOther" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseOther" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="7.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsGross" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsGross" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredTaxAssetsNet" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredTaxAssetsNet" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="DeferredRevenue" xlink:title="DeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="DeferredRevenue" xlink:title="calculation: DeferredIncomeTaxLiabilities to DeferredRevenue" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredIncomeTaxLiabilities" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredIncomeTaxLiabilities" order="2.0" weight="-1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>ocup-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://ocuphire.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/DeferredCompensationPlanDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#DeferredCompensationPlanDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesOperatingLossCarryforwardsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockholdersEquityRegisteredDirectOfferingDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockholdersEquityAtthemarketProgramDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/ApexianSublicenseAgreementDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#ApexianSublicenseAgreementDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationFormerRexahnOptionsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationCommonStockIssuedForServicesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationRestrictedStockAwardsActivityDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationStockOptionPlanActivityDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationShorttermLoanDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationAccruedExpensesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/PremergerFinancingDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#PremergerFinancingDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#MergerFormerRexahnWarrantsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#MergerContingentValueRightsAgreementDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShareTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#LicenseAndCollaborationAgreementsTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://ocuphire.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ocup-20221231.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://ocuphire.com/role/DeferredCompensationPlan" xlink:type="simple" xlink:href="ocup-20221231.xsd#DeferredCompensationPlan" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShare" />
  <link:roleRef roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreements" xlink:type="simple" xlink:href="ocup-20221231.xsd#LicenseAndCollaborationAgreements" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockholderEquity" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockholderEquity" />
  <link:roleRef roleURI="http://ocuphire.com/role/ApexianSublicenseAgreement" xlink:type="simple" xlink:href="ocup-20221231.xsd#ApexianSublicenseAgreement" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://ocuphire.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ocup-20221231.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformation" />
  <link:roleRef roleURI="http://ocuphire.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="ocup-20221231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://ocuphire.com/role/PremergerFinancing" xlink:type="simple" xlink:href="ocup-20221231.xsd#PremergerFinancing" />
  <link:roleRef roleURI="http://ocuphire.com/role/Merger" xlink:type="simple" xlink:href="ocup-20221231.xsd#Merger" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="ocup-20221231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" xlink:href="ocup-20221231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" />
  <link:roleRef roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ocup-20221231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://ocuphire.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="ocup-20221231.xsd#BalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://ocuphire.com/role/BalanceSheets" xlink:type="simple" xlink:href="ocup-20221231.xsd#BalanceSheets" />
  <link:roleRef roleURI="http://ocuphire.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ocup-20221231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/BalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/BalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:label="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:title="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:label="StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:title="StockIssuedDuringPeriodValueAtTheMarketProgram" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueAtTheMarketProgram" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:label="StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:title="StockIssuedDuringPeriodSharesAtTheMarketProgram" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesAtTheMarketProgram" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:label="StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:title="StockIssuedDuringPeriodValueInSettlementWithInvestors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueInSettlementWithInvestors" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:label="StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:title="StockIssuedDuringPeriodSharesInSettlementWithInvestors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesInSettlementWithInvestors" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:label="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:title="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueStockExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockExerciseOfWarrants" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesExerciseOfWarrants" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesShareBasedCompensation" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="19.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/Merger" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/PremergerFinancing" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/RelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ApexianSublicenseAgreement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockholderEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/LicenseAndCollaborationAgreements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShare" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/DeferredCompensationPlan" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SubsequentEvents" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/LicenseAndCollaborationAgreementsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShareTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LiquidityAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LiquidityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CashAndCashEquivalentsAtCarryingValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NonRefundableUpfrontPaymentReceived" xlink:label="NonRefundableUpfrontPaymentReceived" xlink:title="NonRefundableUpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableUpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableUpfrontPaymentReceived" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NyxolLicenseAgreementMember" xlink:label="NyxolLicenseAgreementMember" xlink:title="NyxolLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="NyxolLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to NyxolLicenseAgreementMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:title="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByAssetClassAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByAssetClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="ShortTermInvestmentsMember" xlink:title="ShortTermInvestmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="ShortTermInvestmentsMember" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to ShortTermInvestmentsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:label="InvestmentsFairValueDisclosureAbstract" xlink:title="InvestmentsFairValueDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="InvestmentsFairValueDisclosureAbstract" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to InvestmentsFairValueDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="InvestmentsFairValueDisclosure" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to InvestmentsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:label="ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:title="ReceiptOfInvestmentsRelatedToLicenseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to ReceiptOfInvestmentsRelatedToLicenseAgreement" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="UnrealizedGainLossOnInvestments" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to UnrealizedGainLossOnInvestments" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByAssetClassAxis" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByAssetClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" xlink:title="definition: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="ShortTermInvestmentsMember" xlink:title="ShortTermInvestmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="ShortTermInvestmentsMember" xlink:title="definition: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to ShortTermInvestmentsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FinancialLiabilitiesFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueAdjustmentOfWarrants" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsNonrecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsNonrecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByLiabilityClassAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" xlink:title="definition: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WarrantLiabilitiesMember" xlink:label="WarrantLiabilitiesMember" xlink:title="WarrantLiabilitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="WarrantLiabilitiesMember" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to WarrantLiabilitiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PremiumConversionDerivativesMember" xlink:label="PremiumConversionDerivativesMember" xlink:title="PremiumConversionDerivativesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="PremiumConversionDerivativesMember" xlink:title="definition: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to PremiumConversionDerivativesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetByTypeAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsAgreementAbstract" xlink:label="ContingentValueRightsAgreementAbstract" xlink:title="ContingentValueRightsAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ContingentValueRightsAgreementAbstract" xlink:title="definition: BusinessAcquisitionLineItems to ContingentValueRightsAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:label="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:title="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:title="definition: BusinessAcquisitionLineItems to ContingentValueRightEntitledPerEachShareOfCommonStockHeld" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsPaymentPeriod" xlink:label="ContingentValueRightsPaymentPeriod" xlink:title="ContingentValueRightsPaymentPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ContingentValueRightsPaymentPeriod" xlink:title="definition: BusinessAcquisitionLineItems to ContingentValueRightsPaymentPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsPercentage" xlink:label="ContingentValueRightsPercentage" xlink:title="ContingentValueRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ContingentValueRightsPercentage" xlink:title="definition: BusinessAcquisitionLineItems to ContingentValueRightsPercentage" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PercentageOfCashConsiderationPayment" xlink:label="PercentageOfCashConsiderationPayment" xlink:title="PercentageOfCashConsiderationPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="PercentageOfCashConsiderationPayment" xlink:title="definition: BusinessAcquisitionLineItems to PercentageOfCashConsiderationPayment" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsIPTerm" xlink:label="ContingentValueRightsIPTerm" xlink:title="ContingentValueRightsIPTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ContingentValueRightsIPTerm" xlink:title="definition: BusinessAcquisitionLineItems to ContingentValueRightsIPTerm" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfMilestonesAccrued" xlink:label="NumberOfMilestonesAccrued" xlink:title="NumberOfMilestonesAccrued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="NumberOfMilestonesAccrued" xlink:title="definition: BusinessAcquisitionLineItems to NumberOfMilestonesAccrued" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfPotentialMilestones" xlink:label="NumberOfPotentialMilestones" xlink:title="NumberOfPotentialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="NumberOfPotentialMilestones" xlink:title="definition: BusinessAcquisitionLineItems to NumberOfPotentialMilestones" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RelatedPartyTransactionAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_BioSenseGlobalLLCMember" xlink:label="BioSenseGlobalLLCMember" xlink:title="BioSenseGlobalLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="BioSenseGlobalLLCMember" xlink:title="definition: RelatedPartyTransactionDomain to BioSenseGlobalLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:label="ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:title="ZhejiangHaiChangBiotechnologyCoLtdMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:title="definition: RelatedPartyTransactionDomain to ZhejiangHaiChangBiotechnologyCoLtdMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WarrantsAndStockOptionsAbstract" xlink:label="WarrantsAndStockOptionsAbstract" xlink:title="WarrantsAndStockOptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="WarrantsAndStockOptionsAbstract" xlink:title="definition: BusinessAcquisitionLineItems to WarrantsAndStockOptionsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: BusinessAcquisitionLineItems to ClassOfWarrantOrRightOutstanding" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: BusinessAcquisitionLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WeightedAverageRemainingContractualTermsWarrants" xlink:label="WeightedAverageRemainingContractualTermsWarrants" xlink:title="WeightedAverageRemainingContractualTermsWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="WeightedAverageRemainingContractualTermsWarrants" xlink:title="definition: BusinessAcquisitionLineItems to WeightedAverageRemainingContractualTermsWarrants" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/PremergerFinancingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingOfWarrantsAbstract" xlink:label="PreMergerFinancingOfWarrantsAbstract" xlink:title="PreMergerFinancingOfWarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="PreMergerFinancingOfWarrantsAbstract" xlink:title="definition: ClassOfWarrantOrRightLineItems to PreMergerFinancingOfWarrantsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ProceedsFromPreMergerFinancing" xlink:label="ProceedsFromPreMergerFinancing" xlink:title="ProceedsFromPreMergerFinancing" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ProceedsFromPreMergerFinancing" xlink:title="definition: ClassOfWarrantOrRightLineItems to ProceedsFromPreMergerFinancing" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="NumberOfDirectors" xlink:title="definition: ClassOfWarrantOrRightLineItems to NumberOfDirectors" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAndRightsOutstandingTerm" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="DerivativeAssetMeasurementInput" xlink:title="DerivativeAssetMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="DerivativeAssetMeasurementInput" xlink:title="definition: ClassOfWarrantOrRightLineItems to DerivativeAssetMeasurementInput" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FairValueAssumptionsExpectedLife" xlink:label="FairValueAssumptionsExpectedLife" xlink:title="FairValueAssumptionsExpectedLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="FairValueAssumptionsExpectedLife" xlink:title="definition: ClassOfWarrantOrRightLineItems to FairValueAssumptionsExpectedLife" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="definition: ClassOfWarrantOrRightLineItems to GainLossOnDerivativeInstrumentsNetPretax" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RemainingIssuableShares" xlink:label="RemainingIssuableShares" xlink:title="RemainingIssuableShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="RemainingIssuableShares" xlink:title="definition: ClassOfWarrantOrRightLineItems to RemainingIssuableShares" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightTable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesAWarrantsMember" xlink:label="SeriesAWarrantsMember" xlink:title="SeriesAWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesAWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SeriesAWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesBWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SeriesBWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ClassOfWarrantOrRightTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SecuritiesPurchaseAgreementMember" xlink:label="SecuritiesPurchaseAgreementMember" xlink:title="SecuritiesPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SecuritiesPurchaseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to SecuritiesPurchaseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WaiverAgreementsMember" xlink:label="WaiverAgreementsMember" xlink:title="WaiverAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="WaiverAgreementsMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to WaiverAgreementsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ClassOfWarrantOrRightTable to RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="InvestorMember" xlink:title="definition: RelatedPartyDomain to InvestorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="DirectorMember" xlink:title="definition: RelatedPartyDomain to DirectorMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ClassOfWarrantOrRightTable to BusinessAcquisitionAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="MeasurementInputTypeAxis" xlink:title="definition: ClassOfWarrantOrRightTable to MeasurementInputTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain_2" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain_2" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDescriptionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IssuanceOfSettlementSharesAbstract" xlink:label="IssuanceOfSettlementSharesAbstract" xlink:title="IssuanceOfSettlementSharesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="IssuanceOfSettlementSharesAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to IssuanceOfSettlementSharesAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: LesseeLeaseDescriptionLineItems to StockIssuedDuringPeriodSharesNewIssues" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfAccreditedInvestors" xlink:label="NumberOfAccreditedInvestors" xlink:title="NumberOfAccreditedInvestors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NumberOfAccreditedInvestors" xlink:title="definition: LesseeLeaseDescriptionLineItems to NumberOfAccreditedInvestors" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FairValueShareSettlementAmount" xlink:label="FairValueShareSettlementAmount" xlink:title="FairValueShareSettlementAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="FairValueShareSettlementAmount" xlink:title="definition: LesseeLeaseDescriptionLineItems to FairValueShareSettlementAmount" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_OperatingLeasesMonthlyBaseRent" xlink:label="OperatingLeasesMonthlyBaseRent" xlink:title="OperatingLeasesMonthlyBaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeasesMonthlyBaseRent" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeasesMonthlyBaseRent" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseCost" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseCost" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: LesseeLeaseDescriptionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: LesseeLeaseDescriptionTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: LesseeLeaseDescriptionTable to RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AccreditedInvestorMember" xlink:label="AccreditedInvestorMember" xlink:title="AccreditedInvestorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="AccreditedInvestorMember" xlink:title="definition: RelatedPartyDomain to AccreditedInvestorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: LesseeLeaseDescriptionTable to IncomeStatementLocationAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="Depreciation" xlink:title="definition: PropertyPlantAndEquipmentLineItems to Depreciation" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="ShortTermDebtLineItems" xlink:title="ShortTermDebtLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="ShortTermBorrowingsAbstract" xlink:title="ShortTermBorrowingsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShortTermDebtLineItems" xlink:to="ShortTermBorrowingsAbstract" xlink:title="definition: ShortTermDebtLineItems to ShortTermBorrowingsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="ShortTermBorrowings" xlink:title="ShortTermBorrowings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShortTermDebtLineItems" xlink:to="ShortTermBorrowings" xlink:title="definition: ShortTermDebtLineItems to ShortTermBorrowings" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DebtInstrumentNumberOfInstallments" xlink:label="DebtInstrumentNumberOfInstallments" xlink:title="DebtInstrumentNumberOfInstallments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShortTermDebtLineItems" xlink:to="DebtInstrumentNumberOfInstallments" xlink:title="definition: ShortTermDebtLineItems to DebtInstrumentNumberOfInstallments" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="DebtInstrumentPeriodicPayment" xlink:title="DebtInstrumentPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShortTermDebtLineItems" xlink:to="DebtInstrumentPeriodicPayment" xlink:title="definition: ShortTermDebtLineItems to DebtInstrumentPeriodicPayment" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="ShortTermDebtPercentageBearingFixedInterestRate" xlink:title="ShortTermDebtPercentageBearingFixedInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShortTermDebtLineItems" xlink:to="ShortTermDebtPercentageBearingFixedInterestRate" xlink:title="definition: ShortTermDebtLineItems to ShortTermDebtPercentageBearingFixedInterestRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShortTermDebtLineItems" xlink:to="InterestExpense" xlink:title="definition: ShortTermDebtLineItems to InterestExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="ScheduleOfShortTermDebtTable" xlink:title="ScheduleOfShortTermDebtTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShortTermDebtLineItems" xlink:to="ScheduleOfShortTermDebtTable" xlink:title="definition: ShortTermDebtLineItems to ScheduleOfShortTermDebtTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShortTermDebtTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: ScheduleOfShortTermDebtTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShortTermLoanMember" xlink:label="ShortTermLoanMember" xlink:title="ShortTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ShortTermLoanMember" xlink:title="definition: DebtInstrumentNameDomain to ShortTermLoanMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:label="DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:title="DueToRelatedPartiesCurrentAndNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to DueToRelatedPartiesCurrentAndNoncurrentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingAndWaiverAgreementsAbstract" xlink:label="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:title="PreMergerFinancingAndWaiverAgreementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to PreMergerFinancingAndWaiverAgreementsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfDirectors" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfDirectors" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AmountInvestedInPreMergerFinancing" xlink:label="AmountInvestedInPreMergerFinancing" xlink:title="AmountInvestedInPreMergerFinancing" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="AmountInvestedInPreMergerFinancing" xlink:title="definition: RelatedPartyTransactionLineItems to AmountInvestedInPreMergerFinancing" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfConvertedInitialSharesReceivedByDirectors" xlink:label="NumberOfConvertedInitialSharesReceivedByDirectors" xlink:title="NumberOfConvertedInitialSharesReceivedByDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfConvertedInitialSharesReceivedByDirectors" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfConvertedInitialSharesReceivedByDirectors" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:label="NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:title="NumberOfConvertedAdditionalSharesReceivedByDirectors" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfConvertedAdditionalSharesReceivedByDirectors" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfDirectorsSignedWaiverAgreements" xlink:label="NumberOfDirectorsSignedWaiverAgreements" xlink:title="NumberOfDirectorsSignedWaiverAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfDirectorsSignedWaiverAgreements" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfDirectorsSignedWaiverAgreements" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ConsultingFeePayable" xlink:label="ConsultingFeePayable" xlink:title="ConsultingFeePayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ConsultingFeePayable" xlink:title="definition: RelatedPartyTransactionLineItems to ConsultingFeePayable" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="definition: RelatedPartyTransactionLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="DueToRelatedPartiesCurrentAndNoncurrent" xlink:title="DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DueToRelatedPartiesCurrentAndNoncurrent" xlink:title="definition: RelatedPartyTransactionLineItems to DueToRelatedPartiesCurrentAndNoncurrent" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingMember" xlink:label="PreMergerFinancingMember" xlink:title="PreMergerFinancingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="PreMergerFinancingMember" xlink:title="definition: RelatedPartyTransactionDomain to PreMergerFinancingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain_2" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain_2" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityInvestmentMember" xlink:label="EquityInvestmentMember" xlink:title="EquityInvestmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="EquityInvestmentMember" xlink:title="definition: EquityMethodInvesteeNameDomain to EquityInvestmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to ClassOfWarrantOrRightAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesAWarrantsMember" xlink:label="SeriesAWarrantsMember" xlink:title="SeriesAWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesAWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SeriesAWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesBWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to SeriesBWarrantsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to BusinessAcquisitionAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="DirectorMember" xlink:title="definition: RelatedPartyDomain to DirectorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="VestingAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to VestingAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain_2" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain_2" xlink:title="definition: VestingAxis to VestingDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VestingDomain" xlink:to="ShareBasedCompensationAwardTrancheOneMember" xlink:title="definition: VestingDomain to ShareBasedCompensationAwardTrancheOneMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPeriodOfSharesReservedUnderPlan" xlink:label="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="MaximumPeriodOfSharesReservedUnderPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to MaximumPeriodOfSharesReservedUnderPlan" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_InducementPlanMember" xlink:label="InducementPlanMember" xlink:title="InducementPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="InducementPlanMember" xlink:title="definition: PlanNameDomain to InducementPlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2020Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2020Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2018Member" xlink:label="EquityIncentivePlan2018Member" xlink:title="EquityIncentivePlan2018Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2018Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2018Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="CommonStockCapitalSharesAvailableForFutureIssuance" xlink:title="CommonStockCapitalSharesAvailableForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesAvailableForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesAvailableForFutureIssuance" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2020Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2020Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2018Member" xlink:label="EquityIncentivePlan2018Member" xlink:title="EquityIncentivePlan2018Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2018Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2018Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_InducementPlanMember" xlink:label="InducementPlanMember" xlink:title="InducementPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="InducementPlanMember" xlink:title="definition: PlanNameDomain to InducementPlanMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RestrictedStockAwardsAbstract" xlink:label="RestrictedStockAwardsAbstract" xlink:title="RestrictedStockAwardsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockAwardsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockAwardsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerOptionsAbstract" xlink:label="FormerOptionsAbstract" xlink:title="FormerOptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="FormerOptionsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to FormerOptionsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ApexianSublicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SublicenseAgreementAbstract" xlink:label="SublicenseAgreementAbstract" xlink:title="SublicenseAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SublicenseAgreementAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to SublicenseAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FutureMilestoneMethodRevenueNotRecognized" xlink:label="FutureMilestoneMethodRevenueNotRecognized" xlink:title="FutureMilestoneMethodRevenueNotRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="FutureMilestoneMethodRevenueNotRecognized" xlink:title="definition: RelatedPartyTransactionLineItems to FutureMilestoneMethodRevenueNotRecognized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain_2" xlink:title="RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain_2" xlink:title="definition: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ApexianSublicenseAgreementMember" xlink:label="ApexianSublicenseAgreementMember" xlink:title="ApexianSublicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionDomain" xlink:to="ApexianSublicenseAgreementMember" xlink:title="definition: RelatedPartyTransactionDomain to ApexianSublicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="HealthCareOrganizationRevenueSourcesAxis" xlink:title="HealthCareOrganizationRevenueSourcesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="HealthCareOrganizationRevenueSourcesAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to HealthCareOrganizationRevenueSourcesAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="HealthCareOrganizationRevenueSourcesDomain" xlink:title="HealthCareOrganizationRevenueSourcesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="HealthCareOrganizationRevenueSourcesAxis" xlink:to="HealthCareOrganizationRevenueSourcesDomain" xlink:title="definition: HealthCareOrganizationRevenueSourcesAxis to HealthCareOrganizationRevenueSourcesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="HealthCareOrganizationRevenueSourcesDomain_2" xlink:title="HealthCareOrganizationRevenueSourcesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="HealthCareOrganizationRevenueSourcesAxis" xlink:to="HealthCareOrganizationRevenueSourcesDomain_2" xlink:title="definition: HealthCareOrganizationRevenueSourcesAxis to HealthCareOrganizationRevenueSourcesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DevelopmentAndRegulatoryMilestonesMember" xlink:label="DevelopmentAndRegulatoryMilestonesMember" xlink:title="DevelopmentAndRegulatoryMilestonesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="HealthCareOrganizationRevenueSourcesDomain" xlink:to="DevelopmentAndRegulatoryMilestonesMember" xlink:title="definition: HealthCareOrganizationRevenueSourcesDomain to DevelopmentAndRegulatoryMilestonesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SalesMilestonesMember" xlink:label="SalesMilestonesMember" xlink:title="SalesMilestonesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="HealthCareOrganizationRevenueSourcesDomain" xlink:to="SalesMilestonesMember" xlink:title="definition: HealthCareOrganizationRevenueSourcesDomain to SalesMilestonesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AtTheMarketProgramAbstract" xlink:label="AtTheMarketProgramAbstract" xlink:title="AtTheMarketProgramAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="AtTheMarketProgramAbstract" xlink:title="definition: SubsidiarySaleOfStockLineItems to AtTheMarketProgramAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: SubsidiarySaleOfStockLineItems to StockIssuedDuringPeriodValueNewIssues" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: SubsidiarySaleOfStockLineItems to StockIssuedDuringPeriodSharesNewIssues" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: SubsidiarySaleOfStockLineItems to ProceedsFromIssuanceOfCommonStock" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="definition: SubsidiarySaleOfStockLineItems to PaymentsOfStockIssuanceCosts" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="definition: SubsidiarySaleOfStockLineItems to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsidiarySaleOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShelfRegistrationMember" xlink:label="ShelfRegistrationMember" xlink:title="ShelfRegistrationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="ShelfRegistrationMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to ShelfRegistrationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AtTheMarketProgramMember" xlink:label="AtTheMarketProgramMember" xlink:title="AtTheMarketProgramMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AtTheMarketProgramMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to AtTheMarketProgramMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="RangeAxis" xlink:title="definition: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RegisteredDirectOfferingsAbstract" xlink:label="RegisteredDirectOfferingsAbstract" xlink:title="RegisteredDirectOfferingsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="RegisteredDirectOfferingsAbstract" xlink:title="definition: ClassOfWarrantOrRightLineItems to RegisteredDirectOfferingsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: ClassOfWarrantOrRightLineItems to StockIssuedDuringPeriodSharesNewIssues" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockSoldPricePerShare" xlink:label="StockSoldPricePerShare" xlink:title="StockSoldPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="StockSoldPricePerShare" xlink:title="definition: ClassOfWarrantOrRightLineItems to StockSoldPricePerShare" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: ClassOfWarrantOrRightLineItems to ProceedsFromIssuanceOfCommonStock" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="definition: ClassOfWarrantOrRightLineItems to PaymentsOfStockIssuanceCosts" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAndRightsOutstandingTerm" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MinimumPercentageOfBeneficialOwnership" xlink:label="MinimumPercentageOfBeneficialOwnership" xlink:title="MinimumPercentageOfBeneficialOwnership" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="MinimumPercentageOfBeneficialOwnership" xlink:title="definition: ClassOfWarrantOrRightLineItems to MinimumPercentageOfBeneficialOwnership" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPercentageOfBeneficialOwnershipLimitation" xlink:label="MaximumPercentageOfBeneficialOwnershipLimitation" xlink:title="MaximumPercentageOfBeneficialOwnershipLimitation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="MaximumPercentageOfBeneficialOwnershipLimitation" xlink:title="definition: ClassOfWarrantOrRightLineItems to MaximumPercentageOfBeneficialOwnershipLimitation" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightTable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: ClassOfWarrantOrRightTable to SubsidiarySaleOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RegisteredDirectOfferingMember" xlink:label="RegisteredDirectOfferingMember" xlink:title="RegisteredDirectOfferingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="RegisteredDirectOfferingMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to RegisteredDirectOfferingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="WarrantMember" xlink:title="definition: EquityComponentDomain to WarrantMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CollaborationAndLicenseAgreementAbstract" xlink:label="CollaborationAndLicenseAgreementAbstract" xlink:title="CollaborationAndLicenseAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAndLicenseAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAndLicenseAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:label="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:title="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetCurrent" xlink:label="ContractAssetCurrent" xlink:title="ContractAssetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractAssetCurrent" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractAssetCurrent" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NonRefundableCashPaymentReceived" xlink:label="NonRefundableCashPaymentReceived" xlink:title="NonRefundableCashPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableCashPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableCashPaymentReceived" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:label="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:title="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FirstPotentialMilestonePaymentToBeReceived" xlink:label="FirstPotentialMilestonePaymentToBeReceived" xlink:title="FirstPotentialMilestonePaymentToBeReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="FirstPotentialMilestonePaymentToBeReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to FirstPotentialMilestonePaymentToBeReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPercentageOfTieredRoyaltiesReceivable" xlink:label="MaximumPercentageOfTieredRoyaltiesReceivable" xlink:title="MaximumPercentageOfTieredRoyaltiesReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumPercentageOfTieredRoyaltiesReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumPercentageOfTieredRoyaltiesReceivable" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfPerformanceObligations" xlink:label="NumberOfPerformanceObligations" xlink:title="NumberOfPerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfPerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfPerformanceObligations" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RevenueFromContractWithCustomerToBeRecognized" xlink:label="RevenueFromContractWithCustomerToBeRecognized" xlink:title="RevenueFromContractWithCustomerToBeRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerToBeRecognized" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerToBeRecognized" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:label="EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:title="EstimatedStandaloneSellingPriceForLicenseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to EstimatedStandaloneSellingPriceForLicenseAgreement" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfNonCancellationWindowAgreement" xlink:label="PeriodOfNonCancellationWindowAgreement" xlink:title="PeriodOfNonCancellationWindowAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PeriodOfNonCancellationWindowAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PeriodOfNonCancellationWindowAgreement" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:label="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:title="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="15.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NyxolLicenseAgreementMember" xlink:label="NyxolLicenseAgreementMember" xlink:title="NyxolLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="NyxolLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to NyxolLicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LicenseTransferFeeMember" xlink:label="LicenseTransferFeeMember" xlink:title="LicenseTransferFeeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="LicenseTransferFeeMember" xlink:title="definition: ProductsAndServicesDomain to LicenseTransferFeeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ResearchDevelopmentServicesMember" xlink:label="ResearchDevelopmentServicesMember" xlink:title="ResearchDevelopmentServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchDevelopmentServicesMember" xlink:title="definition: ProductsAndServicesDomain to ResearchDevelopmentServicesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CollaborationAndLicenseAgreementAbstract" xlink:label="CollaborationAndLicenseAgreementAbstract" xlink:title="CollaborationAndLicenseAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAndLicenseAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAndLicenseAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NonRefundableCashPaymentReceived" xlink:label="NonRefundableCashPaymentReceived" xlink:title="NonRefundableCashPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableCashPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableCashPaymentReceived" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePaymentAchievedForPerformanceObligation" xlink:label="MilestonePaymentAchievedForPerformanceObligation" xlink:title="MilestonePaymentAchievedForPerformanceObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePaymentAchievedForPerformanceObligation" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MilestonePaymentAchievedForPerformanceObligation" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePaymentsAmountReceived" xlink:label="MilestonePaymentsAmountReceived" xlink:title="MilestonePaymentsAmountReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePaymentsAmountReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MilestonePaymentsAmountReceived" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_UpfrontPaymentReceivedInCommonStockShares" xlink:label="UpfrontPaymentReceivedInCommonStockShares" xlink:title="UpfrontPaymentReceivedInCommonStockShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceivedInCommonStockShares" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceivedInCommonStockShares" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_UpfrontPaymentReceivedInCommonStockFairValue" xlink:label="UpfrontPaymentReceivedInCommonStockFairValue" xlink:title="UpfrontPaymentReceivedInCommonStockFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceivedInCommonStockFairValue" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceivedInCommonStockFairValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfRestrictionFromSellingStock" xlink:label="PeriodOfRestrictionFromSellingStock" xlink:title="PeriodOfRestrictionFromSellingStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PeriodOfRestrictionFromSellingStock" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PeriodOfRestrictionFromSellingStock" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfTimesPaymentsForSalesMilestone" xlink:label="NumberOfTimesPaymentsForSalesMilestone" xlink:title="NumberOfTimesPaymentsForSalesMilestone" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfTimesPaymentsForSalesMilestone" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfTimesPaymentsForSalesMilestone" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:label="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:title="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:label="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:title="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:label="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:title="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:label="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:title="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfOpportunityToCureBreachOfAgreement" xlink:label="PeriodOfOpportunityToCureBreachOfAgreement" xlink:title="PeriodOfOpportunityToCureBreachOfAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PeriodOfOpportunityToCureBreachOfAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PeriodOfOpportunityToCureBreachOfAgreement" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:label="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:title="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_BioSenseLicenseAndAssignmentsAgreementMember" xlink:label="BioSenseLicenseAndAssignmentsAgreementMember" xlink:title="BioSenseLicenseAndAssignmentsAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BioSenseLicenseAndAssignmentsAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BioSenseLicenseAndAssignmentsAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ProcessaLicenseAgreementMember" xlink:label="ProcessaLicenseAgreementMember" xlink:title="ProcessaLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ProcessaLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to ProcessaLicenseAgreementMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to BusinessAcquisitionAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="EarningsPerShareBasicAbstract" xlink:title="EarningsPerShareBasicAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareBasicAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareBasicAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesASeriesBAndRDOWarrantsMember" xlink:label="SeriesASeriesBAndRDOWarrantsMember" xlink:title="SeriesASeriesBAndRDOWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="SeriesASeriesBAndRDOWarrantsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to SeriesASeriesBAndRDOWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerRexahnWarrantsMember" xlink:label="FormerRexahnWarrantsMember" xlink:title="FormerRexahnWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="FormerRexahnWarrantsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to FormerRexahnWarrantsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerRexahnOptionsMember" xlink:label="FormerRexahnOptionsMember" xlink:title="FormerRexahnOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="FormerRexahnOptionsMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to FormerRexahnOptionsMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="definition: BusinessAcquisitionLineItems to DeferredTaxAssetsNetOfValuationAllowanceAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionLineItems" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="definition: BusinessAcquisitionLineItems to DeferredTaxAssetsOperatingLossCarryforwards" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="BusinessAcquisitionLineItems" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="definition: BusinessAcquisitionLineItems to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="definition: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain_2" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain_2" xlink:title="definition: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="definition: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/DeferredCompensationPlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="DefinedBenefitPlanDisclosureLineItems" xlink:title="DefinedBenefitPlanDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="DeferredCompensationArrangementsAbstract" xlink:title="DeferredCompensationArrangementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="DeferredCompensationArrangementsAbstract" xlink:title="definition: DefinedBenefitPlanDisclosureLineItems to DeferredCompensationArrangementsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:title="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:title="definition: DefinedBenefitPlanDisclosureLineItems to DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="DefinedContributionPlanEmployerMatchingContributionPercent" xlink:title="DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="DefinedContributionPlanEmployerMatchingContributionPercent" xlink:title="definition: DefinedBenefitPlanDisclosureLineItems to DefinedContributionPlanEmployerMatchingContributionPercent" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:label="DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:title="DefinedContributionPlanAdditionalEmployerMatchingContribution" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:title="definition: DefinedBenefitPlanDisclosureLineItems to DefinedContributionPlanAdditionalEmployerMatchingContribution" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:label="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:title="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:title="definition: DefinedBenefitPlanDisclosureLineItems to DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="definition: DefinedBenefitPlanDisclosureLineItems to DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:title="ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:title="definition: DefinedBenefitPlanDisclosureLineItems to ScheduleOfDefinedBenefitPlansDisclosuresTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="RetirementPlanNameAxis" xlink:title="RetirementPlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="RetirementPlanNameAxis" xlink:title="definition: ScheduleOfDefinedBenefitPlansDisclosuresTable to RetirementPlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="RetirementPlanNameDomain" xlink:title="RetirementPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RetirementPlanNameAxis" xlink:to="RetirementPlanNameDomain" xlink:title="definition: RetirementPlanNameAxis to RetirementPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="RetirementPlanNameDomain_2" xlink:title="RetirementPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RetirementPlanNameAxis" xlink:to="RetirementPlanNameDomain_2" xlink:title="definition: RetirementPlanNameAxis to RetirementPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RetirementPlan401KMember" xlink:label="RetirementPlan401KMember" xlink:title="RetirementPlan401KMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RetirementPlanNameDomain" xlink:to="RetirementPlan401KMember" xlink:title="definition: RetirementPlanNameDomain to RetirementPlan401KMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SubsequentEventsAdditionalInformationAbstract" xlink:label="SubsequentEventsAdditionalInformationAbstract" xlink:title="SubsequentEventsAdditionalInformationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventsAdditionalInformationAbstract" xlink:title="definition: SubsequentEventLineItems to SubsequentEventsAdditionalInformationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPeriodOfSharesReservedUnderPlan" xlink:label="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="MaximumPeriodOfSharesReservedUnderPlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="definition: SubsequentEventLineItems to MaximumPeriodOfSharesReservedUnderPlan" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="definition: SubsequentEventLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:label="AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:title="AggregateNumberOfCommonStockReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:title="definition: SubsequentEventLineItems to AggregateNumberOfCommonStockReservedForFutureIssuance" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="PlanNameAxis" xlink:title="definition: SubsequentEventTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EvergreenProvisionPlan2020Member" xlink:label="EvergreenProvisionPlan2020Member" xlink:title="EvergreenProvisionPlan2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EvergreenProvisionPlan2020Member" xlink:title="definition: PlanNameDomain to EvergreenProvisionPlan2020Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="definition: SubsequentEventTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>ocup-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl1" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl">Accounts receivable (Note 10)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl">Professional services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl1">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl">Accrued Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:title="label: AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Less accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in-capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid-In Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Stock based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US" id="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl">Allowance for doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:title="label: AllowanceForDoubtfulAccountsReceivableCurrent to us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Antidilutive securities excluded from computation of net loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl">Assets at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAxis_lbl">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:title="label: BusinessAcquisitionAxis to us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionAcquireeDomain_lbl">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:title="label: BusinessAcquisitionAcquireeDomain to us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationsAbstract_lbl">Merger [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xlink:title="label: BusinessCombinationsAbstract to us-gaap_BusinessCombinationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" id="us-gaap_BusinessAcquisitionLineItems_lbl">Business Acquisition [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:title="label: BusinessAcquisitionLineItems to us-gaap_BusinessAcquisitionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="BusinessCombinationsPolicy" xlink:title="BusinessCombinationsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationsPolicy_lbl">Reverse Merger with Rexahn</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:title="label: BusinessCombinationsPolicy to us-gaap_BusinessCombinationsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationsPolicy_lbl1" xml:lang="en-US" id="us-gaap_BusinessCombinationsPolicy_lbl1">Business Combinations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl1" xlink:title="label: BusinessCombinationsPolicy to us-gaap_BusinessCombinationsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="BusinessCombinationDisclosureTextBlock" xlink:title="BusinessCombinationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_BusinessCombinationDisclosureTextBlock_lbl">Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:title="label: BusinessCombinationDisclosureTextBlock to us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="CashUninsuredAmount" xlink:title="CashUninsuredAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashUninsuredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US" id="us-gaap_CashUninsuredAmount_lbl">Deposits that exceeded federally insured amounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" xlink:title="label: CashUninsuredAmount to us-gaap_CashUninsuredAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashUninsuredAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashUninsuredAmount_lbl1" xml:lang="en-US" id="us-gaap_CashUninsuredAmount_lbl1">Cash, Uninsured Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl1" xlink:title="label: CashUninsuredAmount to us-gaap_CashUninsuredAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInContractWithCustomerAssetAbstract" xlink:label="ChangeInContractWithCustomerAssetAbstract" xlink:title="ChangeInContractWithCustomerAssetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ChangeInContractWithCustomerAssetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ChangeInContractWithCustomerAssetAbstract_lbl" xml:lang="en-US" id="us-gaap_ChangeInContractWithCustomerAssetAbstract_lbl">Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInContractWithCustomerAssetAbstract" xlink:to="us-gaap_ChangeInContractWithCustomerAssetAbstract_lbl" xlink:title="label: ChangeInContractWithCustomerAssetAbstract to us-gaap_ChangeInContractWithCustomerAssetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Warrants issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1">Warrant issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis_lbl">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightLineItems_lbl">Class of Warrant or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:title="label: ClassOfWarrantOrRightLineItems to us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightTable_lbl">Class of Warrant or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:title="label: ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain_lbl">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1">Number of warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl">License and Collaboration Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">Commitments and contingencies (Note 4 and Note 8)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl">Common stock reserved for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, par value $0.0001; 75,000,000 shares authorized as of December 31, 2022 and 2021; 20,861,315 and 18,845,828 shares issued and outstanding at December 31, 2022 and 2021, respectively.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, shares, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl">Deferred Compensation Plan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:title="label: CompensationAndRetirementDisclosureAbstract to us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl">Deferred Tax Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:title="label: ComponentsOfDeferredTaxAssetsAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl">Deferred Tax Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:title="label: ComponentsOfDeferredTaxLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:title="label: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl">Components of Income Tax Provision (Benefit) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:title="label: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl">Comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:label="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:title="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract_lbl">Reconciliation of Closing Balance of Contract Asset [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract_lbl" xlink:title="label: ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract to us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:title="label: CurrentStateAndLocalTaxExpenseBenefit to us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1">Current State and Local Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1" xlink:title="label: CurrentStateAndLocalTaxExpenseBenefit to us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentFederalTaxExpenseBenefit_lbl">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:title="label: CurrentFederalTaxExpenseBenefit to us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1">Current Federal Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xlink:title="label: CurrentFederalTaxExpenseBenefit to us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl">Total current tax provision (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1">Current Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl">Current:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:title="label: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:title="label: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="DebtInstrumentPeriodicPayment" xlink:title="DebtInstrumentPeriodicPayment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentPeriodicPayment_lbl">Payment on short term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:title="label: DebtInstrumentPeriodicPayment to us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentPeriodicPayment_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentPeriodicPayment_lbl1">Debt Instrument, Periodic Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl1" xlink:title="label: DebtInstrumentPeriodicPayment to us-gaap_DebtInstrumentPeriodicPayment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl">Acquired intangibles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:title="label: DeferredTaxAssetsGoodwillAndIntangibleAssets to us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xlink:title="label: DeferredTaxAssetsGoodwillAndIntangibleAssets to us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl">Deferred tax assets relating to net operating loss carryforwards [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xlink:title="label: DeferredTaxAssetsNetOfValuationAllowanceAbstract to us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl1">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl1" xlink:title="label: DeferredTaxAssetsNetOfValuationAllowanceAbstract to us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="DeferredCompensationArrangementsAbstract" xlink:title="DeferredCompensationArrangementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementsAbstract_lbl">Deferred Compensation Plan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementsAbstract" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xlink:title="label: DeferredCompensationArrangementsAbstract to us-gaap_DeferredCompensationArrangementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCompensationArrangementsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredCompensationArrangementsAbstract_lbl1">Deferred Compensation Arrangements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCompensationArrangementsAbstract" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract_lbl1" xlink:title="label: DeferredCompensationArrangementsAbstract to us-gaap_DeferredCompensationArrangementsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl">Prepaid and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:title="label: DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock to us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxLiabilities_lbl">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:title="label: DeferredIncomeTaxLiabilities to us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxLiabilities_lbl1">Deferred Tax Liabilities, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xlink:title="label: DeferredIncomeTaxLiabilities to us-gaap_DeferredIncomeTaxLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl">Deferred:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:title="label: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:title="label: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="DeferredRevenue" xlink:title="DeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenue_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:title="label: DeferredRevenue to us-gaap_DeferredRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenue_lbl1" xml:lang="en-US" id="us-gaap_DeferredRevenue_lbl1">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl1" xlink:title="label: DeferredRevenue to us-gaap_DeferredRevenue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1">Deferred Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl">State net operating loss carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl">Total deferred tax assets, net of valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl1">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl">Subtotal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl1">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl">Deferral of research and development costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:title="label: DeferredTaxAssetsInProcessResearchAndDevelopment to us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" xlink:title="label: DeferredTaxAssetsInProcessResearchAndDevelopment to us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl">Federal and state operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1">Deferred tax assets relating to net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOther_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:title="label: DeferredTaxAssetsOther to us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOther_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOther_lbl1">Deferred Tax Assets, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl1" xlink:title="label: DeferredTaxAssetsOther to us-gaap_DeferredTaxAssetsOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl">Federal research credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsResearch to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="DeferredTaxAssetsTaxDeferredExpenseOther" xlink:title="DeferredTaxAssetsTaxDeferredExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl">Organizational costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseOther to us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl1">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl1" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseOther to us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="DefinedContributionPlanEmployerMatchingContributionPercent" xlink:title="DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl">Deferred compensation matched by employer, first match</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:title="label: DefinedContributionPlanEmployerMatchingContributionPercent to us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl1" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl1">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl1" xlink:title="label: DefinedContributionPlanEmployerMatchingContributionPercent to us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:title="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl">Employer matching contribution, first match</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:title="label: DefinedContributionPlanEmployerMatchingContributionPercentOfMatch to us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl1" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl1">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl1" xlink:title="label: DefinedContributionPlanEmployerMatchingContributionPercentOfMatch to us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl">Employer contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="DefinedBenefitPlanDisclosureLineItems" xlink:title="DefinedBenefitPlanDisclosureLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US" id="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:title="label: DefinedBenefitPlanDisclosureLineItems to us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl" xml:lang="en-US" id="us-gaap_Depreciation_lbl">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="DerivativeAssetMeasurementInput" xlink:title="DerivativeAssetMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DerivativeAssetMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DerivativeAssetMeasurementInput_lbl" xml:lang="en-US" id="us-gaap_DerivativeAssetMeasurementInput_lbl">Percentage of measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeAssetMeasurementInput" xlink:to="us-gaap_DerivativeAssetMeasurementInput_lbl" xlink:title="label: DerivativeAssetMeasurementInput to us-gaap_DerivativeAssetMeasurementInput_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="DueToRelatedPartiesCurrentAndNoncurrent" xlink:title="DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl">Consulting expenses unpaid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:title="label: DueToRelatedPartiesCurrentAndNoncurrent to us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:label="DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:title="DueToRelatedPartiesCurrentAndNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract_lbl">Related Party Transaction [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract_lbl" xlink:title="label: DueToRelatedPartiesCurrentAndNoncurrentAbstract to us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">Basic (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Diluted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareTextBlock_lbl">Net income (loss) per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:title="label: EarningsPerShareTextBlock to us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="EarningsPerShareBasicAbstract" xlink:title="EarningsPerShareBasicAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAbstract_lbl">Net Loss Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:title="label: EarningsPerShareBasicAbstract to us-gaap_EarningsPerShareBasicAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAbstract_lbl1">Earnings Per Share, Basic [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl1" xlink:title="label: EarningsPerShareBasicAbstract to us-gaap_EarningsPerShareBasicAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl">Net income (loss) per share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl1">Net income (loss) per share (Note 11):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl1" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl">State income tax, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl">Stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl">Effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl">Effective Federal Income Tax Rate Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl">Unrecognized stock-based compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Ocuphire Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl1">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl">Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="EmployeeBenefitsAndShareBasedCompensation" xlink:title="EmployeeBenefitsAndShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl">Share based compensation for services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:title="label: EmployeeBenefitsAndShareBasedCompensation to us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl1">Employee Benefits and Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl1" xlink:title="label: EmployeeBenefitsAndShareBasedCompensation to us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl">Payroll</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="us-gaap_EquipmentMember_lbl">Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:title="label: EquipmentMember to us-gaap_EquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquipmentMember_lbl1" xml:lang="en-US" id="us-gaap_EquipmentMember_lbl1">Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl1" xlink:title="label: EquipmentMember to us-gaap_EquipmentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">Stockholder Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants_lbl">Change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants_lbl1">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl1" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByMeasurementFrequencyAxis_lbl">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:title="label: FairValueByMeasurementFrequencyAxis to us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByLiabilityClassAxis_lbl">Liability Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:title="label: FairValueByLiabilityClassAxis to us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl">Asset Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByAssetClassAxis_lbl">Asset Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" xlink:title="label: FairValueByAssetClassAxis to us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl">Transfers in into Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsNonrecurringMember_lbl">Nonrecurring Basis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:title="label: FairValueMeasurementsNonrecurringMember to us-gaap_FairValueMeasurementsNonrecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsNonrecurringMember_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementsNonrecurringMember_lbl1">Fair Value, Nonrecurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl1" xlink:title="label: FairValueMeasurementsNonrecurringMember to us-gaap_FairValueMeasurementsNonrecurringMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl">Transfers out of Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl">Recurring Basis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl1">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl">Balance as of beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1">Balance as of end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xml:lang="en-US" id="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" xlink:title="label: FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementFrequencyDomain_lbl">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:title="label: FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:title="FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl">Fair Value of Financial Instruments Measured on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisTextBlock to us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisTextBlock to us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl1">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl1">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl1" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl1">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl1" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl">Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl1" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl1" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl">Warrant Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl1" xlink:title="label: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl">Financial instruments liabilities at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1">Financial Liabilities Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xlink:title="label: FinancialLiabilitiesFairValueDisclosure to us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:title="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" id="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xlink:title="label: FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract to us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl1" xml:lang="en-US" id="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl1">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl1" xlink:title="label: FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract to us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember_lbl">Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember_lbl1">Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US" id="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl">Fair value change in warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xlink:title="label: GainLossOnDerivativeInstrumentsNetPretax to us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl1">Fair value change in warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl1" xlink:title="label: GainLossOnDerivativeInstrumentsNetPretax to us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl2" xml:lang="en-US" id="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl2">Fair value change of warrant liability and premium conversion derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl2" xlink:title="label: GainLossOnDerivativeInstrumentsNetPretax to us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl3" xml:lang="en-US" id="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl3">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl3" xlink:title="label: GainLossOnDerivativeInstrumentsNetPretax to us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl">General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="HealthCareOrganizationRevenueSourcesDomain" xlink:title="HealthCareOrganizationRevenueSourcesDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xml:lang="en-US" id="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xlink:title="label: HealthCareOrganizationRevenueSourcesDomain to us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="HealthCareOrganizationRevenueSourcesAxis" xlink:title="HealthCareOrganizationRevenueSourcesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xml:lang="en-US" id="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xlink:title="label: HealthCareOrganizationRevenueSourcesAxis to us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="ImpairmentOfInvestments" xlink:title="ImpairmentOfInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfInvestments_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOfInvestments_lbl">Impairments on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl" xlink:title="label: ImpairmentOfInvestments to us-gaap_ImpairmentOfInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfInvestments_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOfInvestments_lbl1">Other than Temporary Impairment Losses, Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfInvestments" xlink:to="us-gaap_ImpairmentOfInvestments_lbl1" xlink:title="label: ImpairmentOfInvestments to us-gaap_ImpairmentOfInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl">Income (loss) before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (loss) before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl1" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl1">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl1" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">Consolidated Statements of Comprehensive Income (Loss) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Total tax provision (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl2">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxesPaidNet_lbl">Cash paid for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:title="label: IncomeTaxesPaidNet to us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="IncomeTaxUncertaintiesAbstract" xlink:title="IncomeTaxUncertaintiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxUncertaintiesAbstract_lbl">Income Tax Uncertainties [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xlink:title="label: IncomeTaxUncertaintiesAbstract to us-gaap_IncomeTaxUncertaintiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Change in assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl2" xml:lang="en-US" id="us-gaap_InterestExpense_lbl2">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl2" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="InvestmentPolicyTextBlock" xlink:title="InvestmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InvestmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_InvestmentPolicyTextBlock_lbl">Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:title="label: InvestmentPolicyTextBlock to us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InvestmentPolicyTextBlock_lbl1">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl1" xlink:title="label: InvestmentPolicyTextBlock to us-gaap_InvestmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:label="InvestmentsFairValueDisclosureAbstract" xlink:title="InvestmentsFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl">Equity Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" xlink:title="label: InvestmentsFairValueDisclosureAbstract to us-gaap_InvestmentsFairValueDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_InvestmentsFairValueDisclosure_lbl">Balance as of beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:title="label: InvestmentsFairValueDisclosure to us-gaap_InvestmentsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_InvestmentsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_InvestmentsFairValueDisclosure_lbl1">Balance as of end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl1" xlink:title="label: InvestmentsFairValueDisclosure to us-gaap_InvestmentsFairValueDisclosure_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsFairValueDisclosure_lbl2" xml:lang="en-US" id="us-gaap_InvestmentsFairValueDisclosure_lbl2">Investments, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl2" xlink:title="label: InvestmentsFairValueDisclosure to us-gaap_InvestmentsFairValueDisclosure_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestorMember_lbl" xml:lang="en-US" id="us-gaap_InvestorMember_lbl">Investors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:title="label: InvestorMember to us-gaap_InvestorMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl">Expected rent payment for the year end 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl1">Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable_lbl">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems_lbl">Lessee, Lease, Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl">Facility Lease [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" xlink:title="label: LesseeOperatingLeaseDescriptionAbstract to us-gaap_LesseeOperatingLeaseDescriptionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">Liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeDomain_lbl">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xlink:title="label: MeasurementInputTypeDomain to us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl">Risk-Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:title="label: MeasurementInputRiskFreeInterestRateMember to us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedTermMember_lbl">Expected Term [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:title="label: MeasurementInputExpectedTermMember to us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeAxis_lbl">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:title="label: MeasurementInputTypeAxis to us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputPriceVolatilityMember_lbl">Expected Volatility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:title="label: MeasurementInputPriceVolatilityMember to us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputExpectedDividendRateMember_lbl">Expected Dividend Yield Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:title="label: MeasurementInputExpectedDividendRateMember to us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net and comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" xml:lang="en-US" id="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl">Unpaid issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" xlink:title="label: NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 to us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl1" xml:lang="en-US" id="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl1">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl1" xlink:title="label: NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 to us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl">Supplemental non-cash financing transactions:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:title="label: NoncashInvestingAndFinancingItemsAbstract to us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments_lbl1" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl1">Number of Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl1" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseCost_lbl">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseCost_lbl1">Operating Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl1" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Income (loss) from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl">Federal net operating loss carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">Company Description and Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl">Company Description and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl">Other comprehensive income (loss), net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeLossNetOfTax to us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract" xlink:label="OtherThanTemporaryImpairmentLossesInvestmentsAbstract" xlink:title="OtherThanTemporaryImpairmentLossesInvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract_lbl">Other than Temporary Impairment Losses, Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherThanTemporaryImpairmentLossesInvestmentsAbstract" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract_lbl" xlink:title="label: OtherThanTemporaryImpairmentLossesInvestmentsAbstract to us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsCurrent_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:title="label: OtherAssetsCurrent to us-gaap_OtherAssetsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="OtherPaymentsToAcquireBusinesses" xlink:title="OtherPaymentsToAcquireBusinesses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xml:lang="en-US" id="us-gaap_OtherPaymentsToAcquireBusinesses_lbl">Transaction costs in connection with asset acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:title="label: OtherPaymentsToAcquireBusinesses to us-gaap_OtherPaymentsToAcquireBusinesses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherPaymentsToAcquireBusinesses_lbl1" xml:lang="en-US" id="us-gaap_OtherPaymentsToAcquireBusinesses_lbl1">Other Payments to Acquire Businesses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl1" xlink:title="label: OtherPaymentsToAcquireBusinesses to us-gaap_OtherPaymentsToAcquireBusinesses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl">Issuance expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl1">Issuance costs attributed to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl2" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl2">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl2" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl">Deferred Compensation Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl1" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl1">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl1" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Preferred stock, par value $0.0001; 10,000,000 shares authorized as of December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred stock, shares, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="PrepaidExpenseCurrent" xlink:title="PrepaidExpenseCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseCurrent_lbl">Prepaids</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:title="label: PrepaidExpenseCurrent to us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl">Prepaid and Other Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrentAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaids and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1">Total prepaids and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Gross proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="ProceedsFromShortTermDebt" xlink:title="ProceedsFromShortTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromShortTermDebt_lbl">Proceeds from short-term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:title="label: ProceedsFromShortTermDebt to us-gaap_ProceedsFromShortTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromShortTermDebt_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromShortTermDebt_lbl1">Proceeds from Short-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl1" xlink:title="label: ProceedsFromShortTermDebt to us-gaap_ProceedsFromShortTermDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Exercise of stock options and Series B warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl1">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Total property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl">Property and Equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl">Property and Equipment, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl">Property and Equipment, net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetByTypeAbstract to us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1">Property, Plant and Equipment, Net, by Type [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentNetByTypeAbstract to us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="ProvisionForDoubtfulAccounts" xlink:title="ProvisionForDoubtfulAccounts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" id="us-gaap_ProvisionForDoubtfulAccounts_lbl">Bad debt expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:title="label: ProvisionForDoubtfulAccounts to us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:title="ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US" id="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl">Accounts Receivable and Allowances for Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:title="label: ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy to us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl1" xml:lang="en-US" id="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl1">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl1" xlink:title="label: ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy to us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract_lbl">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems_lbl">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl">Consulting expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:title="label: RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty to us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl">Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionDomain_lbl">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:title="label: RelatedPartyTransactionDomain to us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionAxis_lbl">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:title="label: RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="RepaymentsOfShortTermDebt" xlink:title="RepaymentsOfShortTermDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfShortTermDebt_lbl">Payments made on short-term loan principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:title="label: RepaymentsOfShortTermDebt to us-gaap_RepaymentsOfShortTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfShortTermDebt_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfShortTermDebt_lbl1">Repayments of Short-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl1" xlink:title="label: RepaymentsOfShortTermDebt to us-gaap_RepaymentsOfShortTermDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:title="label: ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost to us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost to us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockMember_lbl">Ocuphire Restricted Stock Awards [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockMember_lbl1">Restricted Stock Awards Including Pending Issuances of Stock for Services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl1" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="RetirementPlanNameAxis" xlink:title="RetirementPlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_RetirementPlanNameAxis_lbl">Retirement Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl" xlink:title="label: RetirementPlanNameAxis to us-gaap_RetirementPlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="RetirementPlanNameDomain" xlink:title="RetirementPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetirementPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_RetirementPlanNameDomain_lbl">Retirement Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl" xlink:title="label: RetirementPlanNameDomain to us-gaap_RetirementPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl">License and collaborations revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1">Revenue recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:title="label: RevenueFromContractWithCustomerPolicyTextBlock to us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl">Weighted average remaining contractual term, vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl">Stock options vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl">Vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl">Weighted average fair value per share of options granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl1">Weighted average fair value per share of options vesting (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected life of options (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl">Aggregate intrinsic value, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl">Stock options forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl">Weighted average remaining contractual term, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl">Weighted average period to recognized stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="us-gaap_SaleOfStockNameOfTransactionDomain_lbl">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:title="label: SaleOfStockNameOfTransactionDomain to us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl">Restricted Stock Awards Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:title="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl">Computation of Weighted Average Common Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:title="label: ScheduleOfWeightedAverageNumberOfSharesTableTextBlock to us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl1">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl1" xlink:title="label: ScheduleOfWeightedAverageNumberOfSharesTableTextBlock to us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Weighted-Average Assumptions Used in Black-Scholes Option-pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Stock Option Plan Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:title="label: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl">Components of Income Tax Provision (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:title="label: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock to us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl">Reconciliation of Statutory to Effective Income Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl">Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:title="ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:title="label: ScheduleOfDefinedBenefitPlansDisclosuresTable to us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:title="label: ScheduleOfBusinessAcquisitionsByAcquisitionTable to us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="ScheduleOfShortTermDebtTable" xlink:title="ScheduleOfShortTermDebtTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShortTermDebtTable_lbl">Schedule of Short-term Debt [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:title="label: ScheduleOfShortTermDebtTable to us-gaap_ScheduleOfShortTermDebtTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl">Segment Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xlink:title="label: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1" xlink:title="label: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl">General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpensesPolicyTextBlock to us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl">Vesting on March 31, 2023 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:title="label: ShareBasedCompensationAwardTrancheOneMember to us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Number of stock option granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl">Percentage of common stock shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl">Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl">Summary of RSA Activity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl">Non-vested at ending (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1">Non-vested at beginning (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl">Aggregate intrinsic value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Weighted-average Assumptions Used in Black-Scholes Option-pricing Model [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Expected stock price volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Risk free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl">Aggregate intrinsic value, vested and exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl">Vested and exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">Outstanding, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Number of shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1">Outstanding, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl">Number of options expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl">Forfeited/Cancelled (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl">Forfeited/Cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl">Number of Options [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl">Stock-based Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:title="label: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="ShortTermBorrowings" xlink:title="ShortTermBorrowings" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US" id="us-gaap_ShortTermBorrowings_lbl">Short-term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:title="label: ShortTermBorrowings to us-gaap_ShortTermBorrowings_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShortTermBorrowings_lbl1" xml:lang="en-US" id="us-gaap_ShortTermBorrowings_lbl1">Short-term loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl1" xlink:title="label: ShortTermBorrowings to us-gaap_ShortTermBorrowings_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="ShortTermDebtPercentageBearingFixedInterestRate" xlink:title="ShortTermDebtPercentageBearingFixedInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl">Annual interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xlink:title="label: ShortTermDebtPercentageBearingFixedInterestRate to us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="ShortTermBorrowingsAbstract" xlink:title="ShortTermBorrowingsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US" id="us-gaap_ShortTermBorrowingsAbstract_lbl">Short-Term Loan [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl" xlink:title="label: ShortTermBorrowingsAbstract to us-gaap_ShortTermBorrowingsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="ShortTermDebtLineItems" xlink:title="ShortTermDebtLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" id="us-gaap_ShortTermDebtLineItems_lbl">Short-term Debt [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:title="label: ShortTermDebtLineItems to us-gaap_ShortTermDebtLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="ShortTermInvestments" xlink:title="ShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US" id="us-gaap_ShortTermInvestments_lbl">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:title="label: ShortTermInvestments to us-gaap_ShortTermInvestments_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="ShortTermInvestmentsMember" xlink:title="ShortTermInvestmentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShortTermInvestmentsMember_lbl" xml:lang="en-US" id="us-gaap_ShortTermInvestmentsMember_lbl">Short- term investments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" xlink:title="label: ShortTermInvestmentsMember to us-gaap_ShortTermInvestmentsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShortTermInvestmentsMember_lbl1" xml:lang="en-US" id="us-gaap_ShortTermInvestmentsMember_lbl1">Short- term investments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl1" xlink:title="label: ShortTermInvestmentsMember to us-gaap_ShortTermInvestmentsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">Balance Sheets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">Consolidated Statements of Changes in Stockholders' Equity (Deficit) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl">Shares sold (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1">Common stock issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl">Granted stock for services performed (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:title="label: StockIssuedDuringPeriodSharesIssuedForServices to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl">Aggregate offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl">Stock-based compensation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Stockholder Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">Stockholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockAxis_lbl">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:title="label: SubsidiarySaleOfStockAxis to us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_lbl1" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockAxis_lbl1">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl1" xlink:title="label: SubsidiarySaleOfStockAxis to us-gaap_SubsidiarySaleOfStockAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockLineItems_lbl">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:title="label: SubsidiarySaleOfStockLineItems to us-gaap_SubsidiarySaleOfStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" id="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:title="label: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl">Supplemental Balance Sheet Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:title="label: SupplementalBalanceSheetDisclosuresTextBlock to us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1" xlink:title="label: SupplementalBalanceSheetDisclosuresTextBlock to us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_TaxesPayableCurrent_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xlink:title="label: TaxesPayableCurrent to us-gaap_TaxesPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnInvestments_lbl">Unrealized loss from short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:title="label: UnrealizedGainLossOnInvestments to us-gaap_UnrealizedGainLossOnInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UnrealizedGainLossOnInvestments_lbl1" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnInvestments_lbl1">Unrealized loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl1" xlink:title="label: UnrealizedGainLossOnInvestments to us-gaap_UnrealizedGainLossOnInvestments_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrealizedGainLossOnInvestments_lbl2" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnInvestments_lbl2">Unrealized Gain (Loss) on Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl2" xlink:title="label: UnrealizedGainLossOnInvestments to us-gaap_UnrealizedGainLossOnInvestments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl">Interest and penalty on income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense to us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="us-gaap_VestingAxis_lbl">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:title="label: VestingAxis to us-gaap_VestingAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="us-gaap_VestingDomain_lbl">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xlink:title="label: VestingDomain to us-gaap_VestingDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl1" xml:lang="en-US" id="us-gaap_WarrantMember_lbl1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstanding_lbl">Warrant liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:title="label: WarrantsAndRightsOutstanding to us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstanding_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstanding_lbl1">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl1" xlink:title="label: WarrantsAndRightsOutstanding to us-gaap_WarrantsAndRightsOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl">Expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1">Exercisable term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xlink:title="label: WarrantsAndRightsOutstandingTerm to us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Diluted common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1">Diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Basic common shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1">Basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl">Number of shares used in per share calculations:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl1">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl">Computation of weighted average common shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:title="label: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl1">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl1" xlink:title="label: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_DirectorMember_lbl" xml:lang="en-US" id="srt_DirectorMember_lbl">Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:title="label: DirectorMember to srt_DirectorMember_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="srt_DirectorMember_lbl1" xml:lang="en-US" id="srt_DirectorMember_lbl1">Director [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl1" xlink:title="label: DirectorMember to srt_DirectorMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" id="srt_EquityMethodInvesteeNameDomain_lbl">Investment, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xlink:title="label: EquityMethodInvesteeNameDomain to srt_EquityMethodInvesteeNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="srt_ProductsAndServicesDomain_lbl">Product and Service [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xlink:title="label: ProductsAndServicesDomain to srt_ProductsAndServicesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="srt_ProductOrServiceAxis_lbl">Product and Service [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:title="label: ProductOrServiceAxis to srt_ProductOrServiceAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" id="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl">Investment, Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:title="label: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentAnnualReport_lbl" xml:lang="en-US" id="dei_DocumentAnnualReport_lbl">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:title="label: DocumentAnnualReport to dei_DocumentAnnualReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:label xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" id="dei_IcfrAuditorAttestationFlag_lbl">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:title="label: IcfrAuditorAttestationFlag to dei_IcfrAuditorAttestationFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="dei_EntityPublicFloat_lbl">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorName_lbl" xml:lang="en-US" id="dei_AuditorName_lbl">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorName" xlink:to="dei_AuditorName_lbl" xlink:title="label: AuditorName to dei_AuditorName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorLocation_lbl" xml:lang="en-US" id="dei_AuditorLocation_lbl">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:title="label: AuditorLocation to dei_AuditorLocation_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorFirmId_lbl" xml:lang="en-US" id="dei_AuditorFirmId_lbl">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:title="label: AuditorFirmId to dei_AuditorFirmId_lbl" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:label="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:title="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" />
    <link:label xlink:type="resource" xlink:label="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl" xml:lang="en-US" id="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl">Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock and . Includes, but is not limited to, legal and accounting fees and direct costs associated with common stock; ATM and Registered Direct Financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:to="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing to ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl1" xml:lang="en-US" id="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl1">Adjustments to Additional Paid in Capital, Issuance Costs related to Common Stock, ATM and Registered Direct Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:to="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing to ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl2" xml:lang="en-US" id="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl2">Issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:to="ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing to ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueStockExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl">Value of stock issued as a result of the exercise of stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:to="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockExerciseOfWarrants to ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl1" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl1">Stock Issued During Period, Value, Stock, Exercise of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:to="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodValueStockExerciseOfWarrants to ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl2" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl2">Exercise of Series B warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:to="ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl2" xlink:title="label: StockIssuedDuringPeriodValueStockExerciseOfWarrants to ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl">Number of shares issued after exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfWarrants to ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl1" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl1">Stock Issued During Period Shares, Exercise of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfWarrants to ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl2" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl2">Exercise of Series B warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesExerciseOfWarrants to ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:label="StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:title="StockIssuedDuringPeriodValueInSettlementWithInvestors" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl">Equity impact of the value of new stock issued in settlement with investors during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:to="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl" xlink:title="label: StockIssuedDuringPeriodValueInSettlementWithInvestors to ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl1" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl1">Stock Issued During Period Value, In Settlement with Investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:to="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl1" xlink:title="label: StockIssuedDuringPeriodValueInSettlementWithInvestors to ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl2" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl2">Issuance of common stock in connection with settlement with investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:to="ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl2" xlink:title="label: StockIssuedDuringPeriodValueInSettlementWithInvestors to ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:label="StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:title="StockIssuedDuringPeriodSharesInSettlementWithInvestors" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl">Number of new stock issued in settlement with investors during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:to="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl" xlink:title="label: StockIssuedDuringPeriodSharesInSettlementWithInvestors to ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl1" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl1">Stock Issued During Period, Shares, In Settlement with Investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:to="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesInSettlementWithInvestors to ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl2" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl2">Issuance of common stock in connection with settlement with investors (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:to="ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesInSettlementWithInvestors to ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:label="StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:title="StockIssuedDuringPeriodValueAtTheMarketProgram" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl">Equity impact of the value of new stock issued in connection with the at-the-market program during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:to="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl" xlink:title="label: StockIssuedDuringPeriodValueAtTheMarketProgram to ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl1" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl1">Stock Issued During Period Value At-the-Market Program</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:to="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl1" xlink:title="label: StockIssuedDuringPeriodValueAtTheMarketProgram to ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl2" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl2">Issuance of common stock in connection with the at-the-market program</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:to="ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl2" xlink:title="label: StockIssuedDuringPeriodValueAtTheMarketProgram to ocup_StockIssuedDuringPeriodValueAtTheMarketProgram_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:label="StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:title="StockIssuedDuringPeriodSharesAtTheMarketProgram" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl">Number of new stock issued in connection with the at-the-market program during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:to="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl" xlink:title="label: StockIssuedDuringPeriodSharesAtTheMarketProgram to ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl1" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl1">Stock Issued During Period shares At-the-Market Program</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:to="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesAtTheMarketProgram to ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl2" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl2">Issuance of common stock in connection with the at-the-market program (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:to="ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesAtTheMarketProgram to ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:label="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:title="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl">Equity impact of the value of new stock issued in connection with registered direct offering during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:to="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering to ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl1" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl1">Stock Issued During Period, Value, in Connection with Registered Direct Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:to="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl1" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering to ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl2" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl2">Issuance of common stock and warrants in connection with registered direct offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:to="ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl2" xlink:title="label: StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering to ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl">Number of shares of stock issued equity impact of the value of new stock issued in connection with registered direct offering during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:to="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering to ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl1" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl1">Stock Issued During Period, Shares, in Connection with Registered Direct Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:to="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering to ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl2" xml:lang="en-US" id="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl2">Issuance of common stock and warrants in connection with registered direct offering (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:to="ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering to ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" />
    <link:label xlink:type="resource" xlink:label="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl" xml:lang="en-US" id="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl">Adjustment to additional paid in capital resulting from the warrants converting to equity issued originally in Pre-Merger financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:to="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity to ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl1" xml:lang="en-US" id="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl1">Adjustments to Additional Paid in Capital, Reclassification of Warrants to Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:to="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity to ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl2" xml:lang="en-US" id="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl2">Reclassification of warrants from liability to equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:to="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity to ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl3" xml:lang="en-US" id="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl3">Reclassification of Series A warrant liability to equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:to="ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl3" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity to ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetCurrent" xlink:label="ContractAssetCurrent" xlink:title="ContractAssetCurrent" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ContractAssetCurrent_lbl" xml:lang="en-US" id="ocup_ContractAssetCurrent_lbl">Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetCurrent" xlink:to="ocup_ContractAssetCurrent_lbl" xlink:title="label: ContractAssetCurrent to ocup_ContractAssetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ContractAssetCurrent_lbl1" xml:lang="en-US" id="ocup_ContractAssetCurrent_lbl1">Contract Asset, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetCurrent" xlink:to="ocup_ContractAssetCurrent_lbl1" xlink:title="label: ContractAssetCurrent to ocup_ContractAssetCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="ocup_ContractAssetCurrent_lbl2" xml:lang="en-US" id="ocup_ContractAssetCurrent_lbl2">Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetCurrent" xlink:to="ocup_ContractAssetCurrent_lbl2" xlink:title="label: ContractAssetCurrent to ocup_ContractAssetCurrent_lbl2" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetCurrent_lbl3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="ocup_ContractAssetCurrent_lbl3" xml:lang="en-US" id="ocup_ContractAssetCurrent_lbl3">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetCurrent" xlink:to="ocup_ContractAssetCurrent_lbl3" xlink:title="label: ContractAssetCurrent to ocup_ContractAssetCurrent_lbl3" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetCurrent_lbl4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ContractAssetCurrent_lbl4" xml:lang="en-US" id="ocup_ContractAssetCurrent_lbl4">Contract asset (Note 10)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetCurrent" xlink:to="ocup_ContractAssetCurrent_lbl4" xlink:title="label: ContractAssetCurrent to ocup_ContractAssetCurrent_lbl4" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingAbstract" xlink:label="PreMergerFinancingAbstract" xlink:title="PreMergerFinancingAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PreMergerFinancingAbstract_lbl1" xml:lang="en-US" id="ocup_PreMergerFinancingAbstract_lbl1">Pre-Merger Financing [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingAbstract" xlink:to="ocup_PreMergerFinancingAbstract_lbl1" xlink:title="label: PreMergerFinancingAbstract to ocup_PreMergerFinancingAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingTextBlock" xlink:label="PreMergerFinancingTextBlock" xlink:title="PreMergerFinancingTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PreMergerFinancingTextBlock_lbl" xml:lang="en-US" id="ocup_PreMergerFinancingTextBlock_lbl">The entire disclosure for information about pre-merger financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingTextBlock" xlink:to="ocup_PreMergerFinancingTextBlock_lbl" xlink:title="label: PreMergerFinancingTextBlock to ocup_PreMergerFinancingTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PreMergerFinancingTextBlock_lbl1" xml:lang="en-US" id="ocup_PreMergerFinancingTextBlock_lbl1">Pre-Merger Financing [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingTextBlock" xlink:to="ocup_PreMergerFinancingTextBlock_lbl1" xlink:title="label: PreMergerFinancingTextBlock to ocup_PreMergerFinancingTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PreMergerFinancingTextBlock_lbl2" xml:lang="en-US" id="ocup_PreMergerFinancingTextBlock_lbl2">Pre-Merger Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingTextBlock" xlink:to="ocup_PreMergerFinancingTextBlock_lbl2" xlink:title="label: PreMergerFinancingTextBlock to ocup_PreMergerFinancingTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingOfWarrantsAbstract" xlink:label="PreMergerFinancingOfWarrantsAbstract" xlink:title="PreMergerFinancingOfWarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingOfWarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PreMergerFinancingOfWarrantsAbstract_lbl1" xml:lang="en-US" id="ocup_PreMergerFinancingOfWarrantsAbstract_lbl1">Pre-Merger Financing of Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="ocup_PreMergerFinancingOfWarrantsAbstract_lbl1" xlink:title="label: PreMergerFinancingOfWarrantsAbstract to ocup_PreMergerFinancingOfWarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingOfWarrantsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PreMergerFinancingOfWarrantsAbstract_lbl2" xml:lang="en-US" id="ocup_PreMergerFinancingOfWarrantsAbstract_lbl2">Pre-Merger Financing [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="ocup_PreMergerFinancingOfWarrantsAbstract_lbl2" xlink:title="label: PreMergerFinancingOfWarrantsAbstract to ocup_PreMergerFinancingOfWarrantsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfDirectors_lbl" xml:lang="en-US" id="ocup_NumberOfDirectors_lbl">Number of directors of the company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="ocup_NumberOfDirectors_lbl" xlink:title="label: NumberOfDirectors to ocup_NumberOfDirectors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfDirectors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfDirectors_lbl1" xml:lang="en-US" id="ocup_NumberOfDirectors_lbl1">Number of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="ocup_NumberOfDirectors_lbl1" xlink:title="label: NumberOfDirectors to ocup_NumberOfDirectors_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfDirectors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfDirectors_lbl2" xml:lang="en-US" id="ocup_NumberOfDirectors_lbl2">Number of directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="ocup_NumberOfDirectors_lbl2" xlink:title="label: NumberOfDirectors to ocup_NumberOfDirectors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RemainingIssuableShares" xlink:label="RemainingIssuableShares" xlink:title="RemainingIssuableShares" />
    <link:label xlink:type="resource" xlink:label="ocup_RemainingIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_RemainingIssuableShares_lbl" xml:lang="en-US" id="ocup_RemainingIssuableShares_lbl">Number of shares of remaining issuable shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingIssuableShares" xlink:to="ocup_RemainingIssuableShares_lbl" xlink:title="label: RemainingIssuableShares to ocup_RemainingIssuableShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_RemainingIssuableShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_RemainingIssuableShares_lbl1" xml:lang="en-US" id="ocup_RemainingIssuableShares_lbl1">Remaining Issuable Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingIssuableShares" xlink:to="ocup_RemainingIssuableShares_lbl1" xlink:title="label: RemainingIssuableShares to ocup_RemainingIssuableShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_RemainingIssuableShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_RemainingIssuableShares_lbl2" xml:lang="en-US" id="ocup_RemainingIssuableShares_lbl2">Remaining issuable shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingIssuableShares" xlink:to="ocup_RemainingIssuableShares_lbl2" xlink:title="label: RemainingIssuableShares to ocup_RemainingIssuableShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:label xlink:type="resource" xlink:label="ocup_RexahnStockholdersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_RexahnStockholdersMember_lbl" xml:lang="en-US" id="ocup_RexahnStockholdersMember_lbl">Entity owned or controlled by another entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RexahnStockholdersMember" xlink:to="ocup_RexahnStockholdersMember_lbl" xlink:title="label: RexahnStockholdersMember to ocup_RexahnStockholdersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_RexahnStockholdersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_RexahnStockholdersMember_lbl1" xml:lang="en-US" id="ocup_RexahnStockholdersMember_lbl1">Rexahn stockholders [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RexahnStockholdersMember" xlink:to="ocup_RexahnStockholdersMember_lbl1" xlink:title="label: RexahnStockholdersMember to ocup_RexahnStockholdersMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_RexahnStockholdersMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_RexahnStockholdersMember_lbl2" xml:lang="en-US" id="ocup_RexahnStockholdersMember_lbl2">Rexahn [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RexahnStockholdersMember" xlink:to="ocup_RexahnStockholdersMember_lbl2" xlink:title="label: RexahnStockholdersMember to ocup_RexahnStockholdersMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FairValueAssumptionsExpectedLife" xlink:label="FairValueAssumptionsExpectedLife" xlink:title="FairValueAssumptionsExpectedLife" />
    <link:label xlink:type="resource" xlink:label="ocup_FairValueAssumptionsExpectedLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_FairValueAssumptionsExpectedLife_lbl" xml:lang="en-US" id="ocup_FairValueAssumptionsExpectedLife_lbl">Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedLife" xlink:to="ocup_FairValueAssumptionsExpectedLife_lbl" xlink:title="label: FairValueAssumptionsExpectedLife to ocup_FairValueAssumptionsExpectedLife_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_FairValueAssumptionsExpectedLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_FairValueAssumptionsExpectedLife_lbl1" xml:lang="en-US" id="ocup_FairValueAssumptionsExpectedLife_lbl1">Fair Value Assumptions, Expected Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedLife" xlink:to="ocup_FairValueAssumptionsExpectedLife_lbl1" xlink:title="label: FairValueAssumptionsExpectedLife to ocup_FairValueAssumptionsExpectedLife_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_FairValueAssumptionsExpectedLife_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_FairValueAssumptionsExpectedLife_lbl2" xml:lang="en-US" id="ocup_FairValueAssumptionsExpectedLife_lbl2">Expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssumptionsExpectedLife" xlink:to="ocup_FairValueAssumptionsExpectedLife_lbl2" xlink:title="label: FairValueAssumptionsExpectedLife to ocup_FairValueAssumptionsExpectedLife_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ProceedsFromPreMergerFinancing" xlink:label="ProceedsFromPreMergerFinancing" xlink:title="ProceedsFromPreMergerFinancing" />
    <link:label xlink:type="resource" xlink:label="ocup_ProceedsFromPreMergerFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ProceedsFromPreMergerFinancing_lbl" xml:lang="en-US" id="ocup_ProceedsFromPreMergerFinancing_lbl">This is a cash inflow, proceeds received from Pre-merger Financing,</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromPreMergerFinancing" xlink:to="ocup_ProceedsFromPreMergerFinancing_lbl" xlink:title="label: ProceedsFromPreMergerFinancing to ocup_ProceedsFromPreMergerFinancing_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ProceedsFromPreMergerFinancing_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ProceedsFromPreMergerFinancing_lbl1" xml:lang="en-US" id="ocup_ProceedsFromPreMergerFinancing_lbl1">Proceeds from Pre-Merger Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromPreMergerFinancing" xlink:to="ocup_ProceedsFromPreMergerFinancing_lbl1" xlink:title="label: ProceedsFromPreMergerFinancing to ocup_ProceedsFromPreMergerFinancing_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ProceedsFromPreMergerFinancing_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ProceedsFromPreMergerFinancing_lbl2" xml:lang="en-US" id="ocup_ProceedsFromPreMergerFinancing_lbl2">Total investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromPreMergerFinancing" xlink:to="ocup_ProceedsFromPreMergerFinancing_lbl2" xlink:title="label: ProceedsFromPreMergerFinancing to ocup_ProceedsFromPreMergerFinancing_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WaiverAgreementsMember" xlink:label="WaiverAgreementsMember" xlink:title="WaiverAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="ocup_WaiverAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_WaiverAgreementsMember_lbl" xml:lang="en-US" id="ocup_WaiverAgreementsMember_lbl">Information related to waiver agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WaiverAgreementsMember" xlink:to="ocup_WaiverAgreementsMember_lbl" xlink:title="label: WaiverAgreementsMember to ocup_WaiverAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_WaiverAgreementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_WaiverAgreementsMember_lbl1" xml:lang="en-US" id="ocup_WaiverAgreementsMember_lbl1">Waiver Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WaiverAgreementsMember" xlink:to="ocup_WaiverAgreementsMember_lbl1" xlink:title="label: WaiverAgreementsMember to ocup_WaiverAgreementsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_WaiverAgreementsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_WaiverAgreementsMember_lbl2" xml:lang="en-US" id="ocup_WaiverAgreementsMember_lbl2">Waiver Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WaiverAgreementsMember" xlink:to="ocup_WaiverAgreementsMember_lbl2" xlink:title="label: WaiverAgreementsMember to ocup_WaiverAgreementsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SecuritiesPurchaseAgreementMember" xlink:label="SecuritiesPurchaseAgreementMember" xlink:title="SecuritiesPurchaseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="ocup_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" id="ocup_SecuritiesPurchaseAgreementMember_lbl">Information by securities purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesPurchaseAgreementMember" xlink:to="ocup_SecuritiesPurchaseAgreementMember_lbl" xlink:title="label: SecuritiesPurchaseAgreementMember to ocup_SecuritiesPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_SecuritiesPurchaseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_SecuritiesPurchaseAgreementMember_lbl1" xml:lang="en-US" id="ocup_SecuritiesPurchaseAgreementMember_lbl1">Securities Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesPurchaseAgreementMember" xlink:to="ocup_SecuritiesPurchaseAgreementMember_lbl1" xlink:title="label: SecuritiesPurchaseAgreementMember to ocup_SecuritiesPurchaseAgreementMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocup_SeriesBWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_SeriesBWarrantsMember_lbl" xml:lang="en-US" id="ocup_SeriesBWarrantsMember_lbl">A classification of Information by type of warrant or right issued, for example Series B Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBWarrantsMember" xlink:to="ocup_SeriesBWarrantsMember_lbl" xlink:title="label: SeriesBWarrantsMember to ocup_SeriesBWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_SeriesBWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_SeriesBWarrantsMember_lbl1" xml:lang="en-US" id="ocup_SeriesBWarrantsMember_lbl1">Series B Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBWarrantsMember" xlink:to="ocup_SeriesBWarrantsMember_lbl1" xlink:title="label: SeriesBWarrantsMember to ocup_SeriesBWarrantsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesAWarrantsMember" xlink:label="SeriesAWarrantsMember" xlink:title="SeriesAWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocup_SeriesAWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_SeriesAWarrantsMember_lbl" xml:lang="en-US" id="ocup_SeriesAWarrantsMember_lbl">A classification of Information by type of warrant or right issued, for example Series A Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAWarrantsMember" xlink:to="ocup_SeriesAWarrantsMember_lbl" xlink:title="label: SeriesAWarrantsMember to ocup_SeriesAWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_SeriesAWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_SeriesAWarrantsMember_lbl1" xml:lang="en-US" id="ocup_SeriesAWarrantsMember_lbl1">Series A Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAWarrantsMember" xlink:to="ocup_SeriesAWarrantsMember_lbl1" xlink:title="label: SeriesAWarrantsMember to ocup_SeriesAWarrantsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncreaseDecreaseInContractAssetCurrent" xlink:label="IncreaseDecreaseInContractAssetCurrent" xlink:title="IncreaseDecreaseInContractAssetCurrent" />
    <link:label xlink:type="resource" xlink:label="ocup_IncreaseDecreaseInContractAssetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_IncreaseDecreaseInContractAssetCurrent_lbl" xml:lang="en-US" id="ocup_IncreaseDecreaseInContractAssetCurrent_lbl">Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractAssetCurrent" xlink:to="ocup_IncreaseDecreaseInContractAssetCurrent_lbl" xlink:title="label: IncreaseDecreaseInContractAssetCurrent to ocup_IncreaseDecreaseInContractAssetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_IncreaseDecreaseInContractAssetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_IncreaseDecreaseInContractAssetCurrent_lbl1" xml:lang="en-US" id="ocup_IncreaseDecreaseInContractAssetCurrent_lbl1">Increase (Decrease) in Contract Asset Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractAssetCurrent" xlink:to="ocup_IncreaseDecreaseInContractAssetCurrent_lbl1" xlink:title="label: IncreaseDecreaseInContractAssetCurrent to ocup_IncreaseDecreaseInContractAssetCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_IncreaseDecreaseInContractAssetCurrent_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ocup_IncreaseDecreaseInContractAssetCurrent_lbl2" xml:lang="en-US" id="ocup_IncreaseDecreaseInContractAssetCurrent_lbl2">Contract asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractAssetCurrent" xlink:to="ocup_IncreaseDecreaseInContractAssetCurrent_lbl2" xlink:title="label: IncreaseDecreaseInContractAssetCurrent to ocup_IncreaseDecreaseInContractAssetCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" xlink:label="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" xlink:title="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" />
    <link:label xlink:type="resource" xlink:label="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl" xml:lang="en-US" id="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl">The value of the Series A Warrants in connection with the Pre-Merger Financing which was composed of just common stock and warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" xlink:to="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl" xlink:title="label: NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount to ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl1" xml:lang="en-US" id="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl1">Noncash or Part Noncash Reclassification of Warrants to Equity, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" xlink:to="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl1" xlink:title="label: NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount to ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl2" xml:lang="en-US" id="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl2">Non-cash reclassification of Series A warrant liability to equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" xlink:to="ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl2" xlink:title="label: NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount to ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:label="IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:title="IncomeLossFromInvestmentsRelatedToLicenseAgreement" />
    <link:label xlink:type="resource" xlink:label="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl" xml:lang="en-US" id="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl">The is the portion of collaborations revenue from the license agreement paid in the form of non-cash equity investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:to="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl" xlink:title="label: IncomeLossFromInvestmentsRelatedToLicenseAgreement to ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl1" xml:lang="en-US" id="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl1">Income (Loss) from Investments Related to License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:to="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl1" xlink:title="label: IncomeLossFromInvestmentsRelatedToLicenseAgreement to ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl2" xml:lang="en-US" id="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl2">Receipt of investments related to license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:to="ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl2" xlink:title="label: IncomeLossFromInvestmentsRelatedToLicenseAgreement to ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareSettlementWithInvestors" xlink:label="ShareSettlementWithInvestors" xlink:title="ShareSettlementWithInvestors" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareSettlementWithInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ShareSettlementWithInvestors_lbl" xml:lang="en-US" id="ocup_ShareSettlementWithInvestors_lbl">The amount of non-cash share settlement with investors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareSettlementWithInvestors" xlink:to="ocup_ShareSettlementWithInvestors_lbl" xlink:title="label: ShareSettlementWithInvestors to ocup_ShareSettlementWithInvestors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareSettlementWithInvestors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ShareSettlementWithInvestors_lbl1" xml:lang="en-US" id="ocup_ShareSettlementWithInvestors_lbl1">Share Settlement with Investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareSettlementWithInvestors" xlink:to="ocup_ShareSettlementWithInvestors_lbl1" xlink:title="label: ShareSettlementWithInvestors to ocup_ShareSettlementWithInvestors_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareSettlementWithInvestors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ShareSettlementWithInvestors_lbl2" xml:lang="en-US" id="ocup_ShareSettlementWithInvestors_lbl2">Non-cash share settlement with investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareSettlementWithInvestors" xlink:to="ocup_ShareSettlementWithInvestors_lbl2" xlink:title="label: ShareSettlementWithInvestors to ocup_ShareSettlementWithInvestors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_OperatingLeasesMonthlyBaseRent" xlink:label="OperatingLeasesMonthlyBaseRent" xlink:title="OperatingLeasesMonthlyBaseRent" />
    <link:label xlink:type="resource" xlink:label="ocup_OperatingLeasesMonthlyBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_OperatingLeasesMonthlyBaseRent_lbl" xml:lang="en-US" id="ocup_OperatingLeasesMonthlyBaseRent_lbl">The amount of rental expense payable per month for operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesMonthlyBaseRent" xlink:to="ocup_OperatingLeasesMonthlyBaseRent_lbl" xlink:title="label: OperatingLeasesMonthlyBaseRent to ocup_OperatingLeasesMonthlyBaseRent_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_OperatingLeasesMonthlyBaseRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_OperatingLeasesMonthlyBaseRent_lbl1" xml:lang="en-US" id="ocup_OperatingLeasesMonthlyBaseRent_lbl1">Operating Leases Monthly Base Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesMonthlyBaseRent" xlink:to="ocup_OperatingLeasesMonthlyBaseRent_lbl1" xlink:title="label: OperatingLeasesMonthlyBaseRent to ocup_OperatingLeasesMonthlyBaseRent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_OperatingLeasesMonthlyBaseRent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_OperatingLeasesMonthlyBaseRent_lbl2" xml:lang="en-US" id="ocup_OperatingLeasesMonthlyBaseRent_lbl2">Monthly base rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesMonthlyBaseRent" xlink:to="ocup_OperatingLeasesMonthlyBaseRent_lbl2" xlink:title="label: OperatingLeasesMonthlyBaseRent to ocup_OperatingLeasesMonthlyBaseRent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AccreditedInvestorMember" xlink:label="AccreditedInvestorMember" xlink:title="AccreditedInvestorMember" />
    <link:label xlink:type="resource" xlink:label="ocup_AccreditedInvestorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_AccreditedInvestorMember_lbl" xml:lang="en-US" id="ocup_AccreditedInvestorMember_lbl">An accredited investor is an individual or a business entity that is allowed to trade securities that may not be registered with financial authorities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccreditedInvestorMember" xlink:to="ocup_AccreditedInvestorMember_lbl" xlink:title="label: AccreditedInvestorMember to ocup_AccreditedInvestorMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_AccreditedInvestorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_AccreditedInvestorMember_lbl1" xml:lang="en-US" id="ocup_AccreditedInvestorMember_lbl1">Accredited Investor [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccreditedInvestorMember" xlink:to="ocup_AccreditedInvestorMember_lbl1" xlink:title="label: AccreditedInvestorMember to ocup_AccreditedInvestorMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IssuanceOfSettlementSharesAbstract" xlink:label="IssuanceOfSettlementSharesAbstract" xlink:title="IssuanceOfSettlementSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_IssuanceOfSettlementSharesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_IssuanceOfSettlementSharesAbstract_lbl1" xml:lang="en-US" id="ocup_IssuanceOfSettlementSharesAbstract_lbl1">Issuance of Settlement Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfSettlementSharesAbstract" xlink:to="ocup_IssuanceOfSettlementSharesAbstract_lbl1" xlink:title="label: IssuanceOfSettlementSharesAbstract to ocup_IssuanceOfSettlementSharesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FairValueShareSettlementAmount" xlink:label="FairValueShareSettlementAmount" xlink:title="FairValueShareSettlementAmount" />
    <link:label xlink:type="resource" xlink:label="ocup_FairValueShareSettlementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_FairValueShareSettlementAmount_lbl" xml:lang="en-US" id="ocup_FairValueShareSettlementAmount_lbl">The amount of fair value shares settlement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueShareSettlementAmount" xlink:to="ocup_FairValueShareSettlementAmount_lbl" xlink:title="label: FairValueShareSettlementAmount to ocup_FairValueShareSettlementAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_FairValueShareSettlementAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_FairValueShareSettlementAmount_lbl1" xml:lang="en-US" id="ocup_FairValueShareSettlementAmount_lbl1">Fair value share settlement amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueShareSettlementAmount" xlink:to="ocup_FairValueShareSettlementAmount_lbl1" xlink:title="label: FairValueShareSettlementAmount to ocup_FairValueShareSettlementAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_FairValueShareSettlementAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_FairValueShareSettlementAmount_lbl2" xml:lang="en-US" id="ocup_FairValueShareSettlementAmount_lbl2">Fair value share settlement amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueShareSettlementAmount" xlink:to="ocup_FairValueShareSettlementAmount_lbl2" xlink:title="label: FairValueShareSettlementAmount to ocup_FairValueShareSettlementAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfAccreditedInvestors" xlink:label="NumberOfAccreditedInvestors" xlink:title="NumberOfAccreditedInvestors" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfAccreditedInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfAccreditedInvestors_lbl" xml:lang="en-US" id="ocup_NumberOfAccreditedInvestors_lbl">The number of accredited investors to whom shares are issued by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAccreditedInvestors" xlink:to="ocup_NumberOfAccreditedInvestors_lbl" xlink:title="label: NumberOfAccreditedInvestors to ocup_NumberOfAccreditedInvestors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfAccreditedInvestors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfAccreditedInvestors_lbl1" xml:lang="en-US" id="ocup_NumberOfAccreditedInvestors_lbl1">Number of Accredited Investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAccreditedInvestors" xlink:to="ocup_NumberOfAccreditedInvestors_lbl1" xlink:title="label: NumberOfAccreditedInvestors to ocup_NumberOfAccreditedInvestors_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfAccreditedInvestors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfAccreditedInvestors_lbl2" xml:lang="en-US" id="ocup_NumberOfAccreditedInvestors_lbl2">Number of accredited investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAccreditedInvestors" xlink:to="ocup_NumberOfAccreditedInvestors_lbl2" xlink:title="label: NumberOfAccreditedInvestors to ocup_NumberOfAccreditedInvestors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:label="EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:title="EffectiveIncomeTaxRateReconciliationWarrantsPercent" />
    <link:label xlink:type="resource" xlink:label="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl" xml:lang="en-US" id="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:to="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationWarrantsPercent to ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl1" xml:lang="en-US" id="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl1">Effective Income Tax Rate Reconciliation, Warrants, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:to="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationWarrantsPercent to ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl2" xml:lang="en-US" id="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl2">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:to="ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationWarrantsPercent to ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:label="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:title="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" />
    <link:label xlink:type="resource" xlink:label="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl" xml:lang="en-US" id="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl">Percentage of domestic federal statutory tax rate pf income tax (benefit) provision applicable to pretax income (loss).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:to="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl" xlink:title="label: EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent to ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl1" xml:lang="en-US" id="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl1">Effective Income Tax (Benefit) Provision Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:to="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl1" xlink:title="label: EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent to ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl2" xml:lang="en-US" id="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl2">Income tax (benefit) provision at federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:to="ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl2" xlink:title="label: EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent to ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DeferredTaxAssetsResearchAndDevelopment" xlink:label="DeferredTaxAssetsResearchAndDevelopment" xlink:title="DeferredTaxAssetsResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl" xml:lang="en-US" id="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsResearchAndDevelopment" xlink:to="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl" xlink:title="label: DeferredTaxAssetsResearchAndDevelopment to ocup_DeferredTaxAssetsResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl1" xml:lang="en-US" id="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl1">Deferred Tax Assets, Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsResearchAndDevelopment" xlink:to="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl1" xlink:title="label: DeferredTaxAssetsResearchAndDevelopment to ocup_DeferredTaxAssetsResearchAndDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl2" xml:lang="en-US" id="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl2">Research and development credit carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsResearchAndDevelopment" xlink:to="ocup_DeferredTaxAssetsResearchAndDevelopment_lbl2" xlink:title="label: DeferredTaxAssetsResearchAndDevelopment to ocup_DeferredTaxAssetsResearchAndDevelopment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WarrantsAndStockOptionsAbstract" xlink:label="WarrantsAndStockOptionsAbstract" xlink:title="WarrantsAndStockOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_WarrantsAndStockOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_WarrantsAndStockOptionsAbstract_lbl1" xml:lang="en-US" id="ocup_WarrantsAndStockOptionsAbstract_lbl1">Warrants and Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndStockOptionsAbstract" xlink:to="ocup_WarrantsAndStockOptionsAbstract_lbl1" xlink:title="label: WarrantsAndStockOptionsAbstract to ocup_WarrantsAndStockOptionsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_WarrantsAndStockOptionsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_WarrantsAndStockOptionsAbstract_lbl2" xml:lang="en-US" id="ocup_WarrantsAndStockOptionsAbstract_lbl2">Former Rexahn Warrants and Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndStockOptionsAbstract" xlink:to="ocup_WarrantsAndStockOptionsAbstract_lbl2" xlink:title="label: WarrantsAndStockOptionsAbstract to ocup_WarrantsAndStockOptionsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WeightedAverageRemainingContractualTermsWarrants" xlink:label="WeightedAverageRemainingContractualTermsWarrants" xlink:title="WeightedAverageRemainingContractualTermsWarrants" />
    <link:label xlink:type="resource" xlink:label="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl" xml:lang="en-US" id="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl">Weighted average remaining contractual term for warrants excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingContractualTermsWarrants" xlink:to="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl" xlink:title="label: WeightedAverageRemainingContractualTermsWarrants to ocup_WeightedAverageRemainingContractualTermsWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl1" xml:lang="en-US" id="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl1">Weighted Average Remaining Contractual Terms, Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingContractualTermsWarrants" xlink:to="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl1" xlink:title="label: WeightedAverageRemainingContractualTermsWarrants to ocup_WeightedAverageRemainingContractualTermsWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl2" xml:lang="en-US" id="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl2">Average remaining contractual life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageRemainingContractualTermsWarrants" xlink:to="ocup_WeightedAverageRemainingContractualTermsWarrants_lbl2" xlink:title="label: WeightedAverageRemainingContractualTermsWarrants to ocup_WeightedAverageRemainingContractualTermsWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsAgreementAbstract" xlink:label="ContingentValueRightsAgreementAbstract" xlink:title="ContingentValueRightsAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ContingentValueRightsAgreementAbstract_lbl1" xml:lang="en-US" id="ocup_ContingentValueRightsAgreementAbstract_lbl1">Contingent Value Rights Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsAgreementAbstract" xlink:to="ocup_ContingentValueRightsAgreementAbstract_lbl1" xlink:title="label: ContingentValueRightsAgreementAbstract to ocup_ContingentValueRightsAgreementAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsIPTerm" xlink:label="ContingentValueRightsIPTerm" xlink:title="ContingentValueRightsIPTerm" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsIPTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ContingentValueRightsIPTerm_lbl" xml:lang="en-US" id="ocup_ContingentValueRightsIPTerm_lbl">Period for parent IP deal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsIPTerm" xlink:to="ocup_ContingentValueRightsIPTerm_lbl" xlink:title="label: ContingentValueRightsIPTerm to ocup_ContingentValueRightsIPTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsIPTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ContingentValueRightsIPTerm_lbl1" xml:lang="en-US" id="ocup_ContingentValueRightsIPTerm_lbl1">Contingent Value Rights IP Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsIPTerm" xlink:to="ocup_ContingentValueRightsIPTerm_lbl1" xlink:title="label: ContingentValueRightsIPTerm to ocup_ContingentValueRightsIPTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsIPTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ContingentValueRightsIPTerm_lbl2" xml:lang="en-US" id="ocup_ContingentValueRightsIPTerm_lbl2">Parent IP deal period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsIPTerm" xlink:to="ocup_ContingentValueRightsIPTerm_lbl2" xlink:title="label: ContingentValueRightsIPTerm to ocup_ContingentValueRightsIPTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PercentageOfCashConsiderationPayment" xlink:label="PercentageOfCashConsiderationPayment" xlink:title="PercentageOfCashConsiderationPayment" />
    <link:label xlink:type="resource" xlink:label="ocup_PercentageOfCashConsiderationPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PercentageOfCashConsiderationPayment_lbl" xml:lang="en-US" id="ocup_PercentageOfCashConsiderationPayment_lbl">Cash consideration paid by a third party to Rexahn or its affiliates during the applicable CVR payment period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCashConsiderationPayment" xlink:to="ocup_PercentageOfCashConsiderationPayment_lbl" xlink:title="label: PercentageOfCashConsiderationPayment to ocup_PercentageOfCashConsiderationPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PercentageOfCashConsiderationPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PercentageOfCashConsiderationPayment_lbl1" xml:lang="en-US" id="ocup_PercentageOfCashConsiderationPayment_lbl1">Percentage of Cash Consideration Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCashConsiderationPayment" xlink:to="ocup_PercentageOfCashConsiderationPayment_lbl1" xlink:title="label: PercentageOfCashConsiderationPayment to ocup_PercentageOfCashConsiderationPayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PercentageOfCashConsiderationPayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PercentageOfCashConsiderationPayment_lbl2" xml:lang="en-US" id="ocup_PercentageOfCashConsiderationPayment_lbl2">Sum of cash consideration paid by a third party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCashConsiderationPayment" xlink:to="ocup_PercentageOfCashConsiderationPayment_lbl2" xlink:title="label: PercentageOfCashConsiderationPayment to ocup_PercentageOfCashConsiderationPayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfMilestonesAccrued" xlink:label="NumberOfMilestonesAccrued" xlink:title="NumberOfMilestonesAccrued" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfMilestonesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfMilestonesAccrued_lbl" xml:lang="en-US" id="ocup_NumberOfMilestonesAccrued_lbl">Number of milestones had been accrued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonesAccrued" xlink:to="ocup_NumberOfMilestonesAccrued_lbl" xlink:title="label: NumberOfMilestonesAccrued to ocup_NumberOfMilestonesAccrued_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfMilestonesAccrued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfMilestonesAccrued_lbl1" xml:lang="en-US" id="ocup_NumberOfMilestonesAccrued_lbl1">Number of Milestones Accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonesAccrued" xlink:to="ocup_NumberOfMilestonesAccrued_lbl1" xlink:title="label: NumberOfMilestonesAccrued to ocup_NumberOfMilestonesAccrued_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfMilestonesAccrued_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfMilestonesAccrued_lbl2" xml:lang="en-US" id="ocup_NumberOfMilestonesAccrued_lbl2">Number of milestones accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonesAccrued" xlink:to="ocup_NumberOfMilestonesAccrued_lbl2" xlink:title="label: NumberOfMilestonesAccrued to ocup_NumberOfMilestonesAccrued_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsPaymentPeriod" xlink:label="ContingentValueRightsPaymentPeriod" xlink:title="ContingentValueRightsPaymentPeriod" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsPaymentPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ContingentValueRightsPaymentPeriod_lbl" xml:lang="en-US" id="ocup_ContingentValueRightsPaymentPeriod_lbl">Payment period for contingent value rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsPaymentPeriod" xlink:to="ocup_ContingentValueRightsPaymentPeriod_lbl" xlink:title="label: ContingentValueRightsPaymentPeriod to ocup_ContingentValueRightsPaymentPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsPaymentPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ContingentValueRightsPaymentPeriod_lbl1" xml:lang="en-US" id="ocup_ContingentValueRightsPaymentPeriod_lbl1">Contingent Value Rights Payment Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsPaymentPeriod" xlink:to="ocup_ContingentValueRightsPaymentPeriod_lbl1" xlink:title="label: ContingentValueRightsPaymentPeriod to ocup_ContingentValueRightsPaymentPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsPaymentPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ContingentValueRightsPaymentPeriod_lbl2" xml:lang="en-US" id="ocup_ContingentValueRightsPaymentPeriod_lbl2">Contingent value rights payment period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsPaymentPeriod" xlink:to="ocup_ContingentValueRightsPaymentPeriod_lbl2" xlink:title="label: ContingentValueRightsPaymentPeriod to ocup_ContingentValueRightsPaymentPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsPercentage" xlink:label="ContingentValueRightsPercentage" xlink:title="ContingentValueRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ContingentValueRightsPercentage_lbl" xml:lang="en-US" id="ocup_ContingentValueRightsPercentage_lbl">Percentage of payments received by Rexahn or its affiliates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsPercentage" xlink:to="ocup_ContingentValueRightsPercentage_lbl" xlink:title="label: ContingentValueRightsPercentage to ocup_ContingentValueRightsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ContingentValueRightsPercentage_lbl1" xml:lang="en-US" id="ocup_ContingentValueRightsPercentage_lbl1">Contingent Value Rights Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsPercentage" xlink:to="ocup_ContingentValueRightsPercentage_lbl1" xlink:title="label: ContingentValueRightsPercentage to ocup_ContingentValueRightsPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightsPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ContingentValueRightsPercentage_lbl2" xml:lang="en-US" id="ocup_ContingentValueRightsPercentage_lbl2">Percentage of payments received by Rexahn or its affiliates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightsPercentage" xlink:to="ocup_ContingentValueRightsPercentage_lbl2" xlink:title="label: ContingentValueRightsPercentage to ocup_ContingentValueRightsPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:label="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:title="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl" xml:lang="en-US" id="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl">Contingent value right per each share of the Company's common stock held of record as of immediately prior to the closing of the merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:to="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl" xlink:title="label: ContingentValueRightEntitledPerEachShareOfCommonStockHeld to ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl1" xml:lang="en-US" id="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl1">Contingent Value Right Entitled Per Each Share Of Common Stock Held</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:to="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl1" xlink:title="label: ContingentValueRightEntitledPerEachShareOfCommonStockHeld to ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl2" xml:lang="en-US" id="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl2">Number of contingent value right received per common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:to="ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl2" xlink:title="label: ContingentValueRightEntitledPerEachShareOfCommonStockHeld to ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_BioSenseGlobalLLCMember" xlink:label="BioSenseGlobalLLCMember" xlink:title="BioSenseGlobalLLCMember" />
    <link:label xlink:type="resource" xlink:label="ocup_BioSenseGlobalLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_BioSenseGlobalLLCMember_lbl" xml:lang="en-US" id="ocup_BioSenseGlobalLLCMember_lbl">Entity entered into License and Assignment Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BioSenseGlobalLLCMember" xlink:to="ocup_BioSenseGlobalLLCMember_lbl" xlink:title="label: BioSenseGlobalLLCMember to ocup_BioSenseGlobalLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_BioSenseGlobalLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_BioSenseGlobalLLCMember_lbl1" xml:lang="en-US" id="ocup_BioSenseGlobalLLCMember_lbl1">BioSense Global LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BioSenseGlobalLLCMember" xlink:to="ocup_BioSenseGlobalLLCMember_lbl1" xlink:title="label: BioSenseGlobalLLCMember to ocup_BioSenseGlobalLLCMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:label="ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:title="ZhejiangHaiChangBiotechnologyCoLtdMember" />
    <link:label xlink:type="resource" xlink:label="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl" xml:lang="en-US" id="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl">Entity entered into Exclusive License Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:to="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl" xlink:title="label: ZhejiangHaiChangBiotechnologyCoLtdMember to ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl1" xml:lang="en-US" id="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl1">Zhejiang HaiChang Biotechnology Co., Ltd [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:to="ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl1" xlink:title="label: ZhejiangHaiChangBiotechnologyCoLtdMember to ocup_ZhejiangHaiChangBiotechnologyCoLtdMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfPotentialMilestones" xlink:label="NumberOfPotentialMilestones" xlink:title="NumberOfPotentialMilestones" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfPotentialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfPotentialMilestones_lbl" xml:lang="en-US" id="ocup_NumberOfPotentialMilestones_lbl">Number of potential milestones had been accrued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPotentialMilestones" xlink:to="ocup_NumberOfPotentialMilestones_lbl" xlink:title="label: NumberOfPotentialMilestones to ocup_NumberOfPotentialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfPotentialMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfPotentialMilestones_lbl1" xml:lang="en-US" id="ocup_NumberOfPotentialMilestones_lbl1">Number of Potential Milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPotentialMilestones" xlink:to="ocup_NumberOfPotentialMilestones_lbl1" xlink:title="label: NumberOfPotentialMilestones to ocup_NumberOfPotentialMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfPotentialMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfPotentialMilestones_lbl2" xml:lang="en-US" id="ocup_NumberOfPotentialMilestones_lbl2">Number of potential milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPotentialMilestones" xlink:to="ocup_NumberOfPotentialMilestones_lbl2" xlink:title="label: NumberOfPotentialMilestones to ocup_NumberOfPotentialMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AtTheMarketProgramAbstract" xlink:label="AtTheMarketProgramAbstract" xlink:title="AtTheMarketProgramAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_AtTheMarketProgramAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_AtTheMarketProgramAbstract_lbl1" xml:lang="en-US" id="ocup_AtTheMarketProgramAbstract_lbl1">At-The-Market Program [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketProgramAbstract" xlink:to="ocup_AtTheMarketProgramAbstract_lbl1" xlink:title="label: AtTheMarketProgramAbstract to ocup_AtTheMarketProgramAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_AtTheMarketProgramAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_AtTheMarketProgramAbstract_lbl2" xml:lang="en-US" id="ocup_AtTheMarketProgramAbstract_lbl2">At-The-Market Program [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketProgramAbstract" xlink:to="ocup_AtTheMarketProgramAbstract_lbl2" xlink:title="label: AtTheMarketProgramAbstract to ocup_AtTheMarketProgramAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AtTheMarketProgramMember" xlink:label="AtTheMarketProgramMember" xlink:title="AtTheMarketProgramMember" />
    <link:label xlink:type="resource" xlink:label="ocup_AtTheMarketProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_AtTheMarketProgramMember_lbl" xml:lang="en-US" id="ocup_AtTheMarketProgramMember_lbl">At-the-market is an instruction given to a broker to place a market order to buy or sell securities at the prevailing market bid or ask price during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketProgramMember" xlink:to="ocup_AtTheMarketProgramMember_lbl" xlink:title="label: AtTheMarketProgramMember to ocup_AtTheMarketProgramMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_AtTheMarketProgramMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_AtTheMarketProgramMember_lbl1" xml:lang="en-US" id="ocup_AtTheMarketProgramMember_lbl1">At-The-Market Program [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketProgramMember" xlink:to="ocup_AtTheMarketProgramMember_lbl1" xlink:title="label: AtTheMarketProgramMember to ocup_AtTheMarketProgramMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_AtTheMarketProgramMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_AtTheMarketProgramMember_lbl2" xml:lang="en-US" id="ocup_AtTheMarketProgramMember_lbl2">ATM [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarketProgramMember" xlink:to="ocup_AtTheMarketProgramMember_lbl2" xlink:title="label: AtTheMarketProgramMember to ocup_AtTheMarketProgramMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShelfRegistrationMember" xlink:label="ShelfRegistrationMember" xlink:title="ShelfRegistrationMember" />
    <link:label xlink:type="resource" xlink:label="ocup_ShelfRegistrationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ShelfRegistrationMember_lbl" xml:lang="en-US" id="ocup_ShelfRegistrationMember_lbl">Shelf registration, shelf offering, or shelf prospectus is a type of public offering where certain issuers are allowed to offer and sell securities to the public without a separate prospectus for each act of offering and without the issue of further prospectus.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationMember" xlink:to="ocup_ShelfRegistrationMember_lbl" xlink:title="label: ShelfRegistrationMember to ocup_ShelfRegistrationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ShelfRegistrationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ShelfRegistrationMember_lbl1" xml:lang="en-US" id="ocup_ShelfRegistrationMember_lbl1">Shelf Registration [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationMember" xlink:to="ocup_ShelfRegistrationMember_lbl1" xlink:title="label: ShelfRegistrationMember to ocup_ShelfRegistrationMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ShelfRegistrationMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ShelfRegistrationMember_lbl2" xml:lang="en-US" id="ocup_ShelfRegistrationMember_lbl2">2021 Shelf [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShelfRegistrationMember" xlink:to="ocup_ShelfRegistrationMember_lbl2" xlink:title="label: ShelfRegistrationMember to ocup_ShelfRegistrationMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RegisteredDirectOfferingMember" xlink:label="RegisteredDirectOfferingMember" xlink:title="RegisteredDirectOfferingMember" />
    <link:label xlink:type="resource" xlink:label="ocup_RegisteredDirectOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_RegisteredDirectOfferingMember_lbl" xml:lang="en-US" id="ocup_RegisteredDirectOfferingMember_lbl">A Registered Direct Offering is an offering of securities that has been registered with the Securities and Exchange Commission (SEC) to pre-identified investors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RegisteredDirectOfferingMember" xlink:to="ocup_RegisteredDirectOfferingMember_lbl" xlink:title="label: RegisteredDirectOfferingMember to ocup_RegisteredDirectOfferingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_RegisteredDirectOfferingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_RegisteredDirectOfferingMember_lbl1" xml:lang="en-US" id="ocup_RegisteredDirectOfferingMember_lbl1">Registered Direct Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RegisteredDirectOfferingMember" xlink:to="ocup_RegisteredDirectOfferingMember_lbl1" xlink:title="label: RegisteredDirectOfferingMember to ocup_RegisteredDirectOfferingMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_RegisteredDirectOfferingMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_RegisteredDirectOfferingMember_lbl2" xml:lang="en-US" id="ocup_RegisteredDirectOfferingMember_lbl2">Registered Direct Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RegisteredDirectOfferingMember" xlink:to="ocup_RegisteredDirectOfferingMember_lbl2" xlink:title="label: RegisteredDirectOfferingMember to ocup_RegisteredDirectOfferingMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RegisteredDirectOfferingsAbstract" xlink:label="RegisteredDirectOfferingsAbstract" xlink:title="RegisteredDirectOfferingsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_RegisteredDirectOfferingsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_RegisteredDirectOfferingsAbstract_lbl1" xml:lang="en-US" id="ocup_RegisteredDirectOfferingsAbstract_lbl1">Registered Direct Offerings [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="ocup_RegisteredDirectOfferingsAbstract_lbl1" xlink:title="label: RegisteredDirectOfferingsAbstract to ocup_RegisteredDirectOfferingsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_RegisteredDirectOfferingsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_RegisteredDirectOfferingsAbstract_lbl2" xml:lang="en-US" id="ocup_RegisteredDirectOfferingsAbstract_lbl2">Registered Direct Offerings [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="ocup_RegisteredDirectOfferingsAbstract_lbl2" xlink:title="label: RegisteredDirectOfferingsAbstract to ocup_RegisteredDirectOfferingsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockSoldPricePerShare" xlink:label="StockSoldPricePerShare" xlink:title="StockSoldPricePerShare" />
    <link:label xlink:type="resource" xlink:label="ocup_StockSoldPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StockSoldPricePerShare_lbl" xml:lang="en-US" id="ocup_StockSoldPricePerShare_lbl">Per share amount received for each share of common stock issued or sold in the stock transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockSoldPricePerShare" xlink:to="ocup_StockSoldPricePerShare_lbl" xlink:title="label: StockSoldPricePerShare to ocup_StockSoldPricePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StockSoldPricePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockSoldPricePerShare_lbl1" xml:lang="en-US" id="ocup_StockSoldPricePerShare_lbl1">Stock Sold, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockSoldPricePerShare" xlink:to="ocup_StockSoldPricePerShare_lbl1" xlink:title="label: StockSoldPricePerShare to ocup_StockSoldPricePerShare_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockSoldPricePerShare_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockSoldPricePerShare_lbl2" xml:lang="en-US" id="ocup_StockSoldPricePerShare_lbl2">Offering price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockSoldPricePerShare" xlink:to="ocup_StockSoldPricePerShare_lbl2" xlink:title="label: StockSoldPricePerShare to ocup_StockSoldPricePerShare_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MinimumPercentageOfBeneficialOwnership" xlink:label="MinimumPercentageOfBeneficialOwnership" xlink:title="MinimumPercentageOfBeneficialOwnership" />
    <link:label xlink:type="resource" xlink:label="ocup_MinimumPercentageOfBeneficialOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MinimumPercentageOfBeneficialOwnership_lbl" xml:lang="en-US" id="ocup_MinimumPercentageOfBeneficialOwnership_lbl">Minimum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfBeneficialOwnership" xlink:to="ocup_MinimumPercentageOfBeneficialOwnership_lbl" xlink:title="label: MinimumPercentageOfBeneficialOwnership to ocup_MinimumPercentageOfBeneficialOwnership_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MinimumPercentageOfBeneficialOwnership_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MinimumPercentageOfBeneficialOwnership_lbl1" xml:lang="en-US" id="ocup_MinimumPercentageOfBeneficialOwnership_lbl1">Minimum Percentage of Beneficial Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfBeneficialOwnership" xlink:to="ocup_MinimumPercentageOfBeneficialOwnership_lbl1" xlink:title="label: MinimumPercentageOfBeneficialOwnership to ocup_MinimumPercentageOfBeneficialOwnership_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MinimumPercentageOfBeneficialOwnership_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MinimumPercentageOfBeneficialOwnership_lbl2" xml:lang="en-US" id="ocup_MinimumPercentageOfBeneficialOwnership_lbl2">Minimum percentage of beneficial ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfBeneficialOwnership" xlink:to="ocup_MinimumPercentageOfBeneficialOwnership_lbl2" xlink:title="label: MinimumPercentageOfBeneficialOwnership to ocup_MinimumPercentageOfBeneficialOwnership_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPercentageOfBeneficialOwnershipLimitation" xlink:label="MaximumPercentageOfBeneficialOwnershipLimitation" xlink:title="MaximumPercentageOfBeneficialOwnershipLimitation" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl" xml:lang="en-US" id="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl">Maximum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentageOfBeneficialOwnershipLimitation" xlink:to="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl" xlink:title="label: MaximumPercentageOfBeneficialOwnershipLimitation to ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl1" xml:lang="en-US" id="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl1">Maximum Percentage of Beneficial Ownership Limitation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentageOfBeneficialOwnershipLimitation" xlink:to="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl1" xlink:title="label: MaximumPercentageOfBeneficialOwnershipLimitation to ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl2" xml:lang="en-US" id="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl2">Maximum percentage of beneficial ownership limitation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentageOfBeneficialOwnershipLimitation" xlink:to="ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl2" xlink:title="label: MaximumPercentageOfBeneficialOwnershipLimitation to ocup_MaximumPercentageOfBeneficialOwnershipLimitation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl">Tabular disclosure of investments, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" xlink:to="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:title="label: ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock to ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl1" xml:lang="en-US" id="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl1">Schedule of Fair Value, Investments Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" xlink:to="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl1" xlink:title="label: ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock to ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl2" xml:lang="en-US" id="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl2">Fair Value, Investments Measured on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" xlink:to="ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl2" xlink:title="label: ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock to ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LiquidityPolicyTextBlock" xlink:label="LiquidityPolicyTextBlock" xlink:title="LiquidityPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_LiquidityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_LiquidityPolicyTextBlock_lbl" xml:lang="en-US" id="ocup_LiquidityPolicyTextBlock_lbl">Disclosure of accounting policy for the liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityPolicyTextBlock" xlink:to="ocup_LiquidityPolicyTextBlock_lbl" xlink:title="label: LiquidityPolicyTextBlock to ocup_LiquidityPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_LiquidityPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_LiquidityPolicyTextBlock_lbl1" xml:lang="en-US" id="ocup_LiquidityPolicyTextBlock_lbl1">Liquidity [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityPolicyTextBlock" xlink:to="ocup_LiquidityPolicyTextBlock_lbl1" xlink:title="label: LiquidityPolicyTextBlock to ocup_LiquidityPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_LiquidityPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_LiquidityPolicyTextBlock_lbl2" xml:lang="en-US" id="ocup_LiquidityPolicyTextBlock_lbl2">Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityPolicyTextBlock" xlink:to="ocup_LiquidityPolicyTextBlock_lbl2" xlink:title="label: LiquidityPolicyTextBlock to ocup_LiquidityPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NatureOfBusinessPolicyTextBlock" xlink:label="NatureOfBusinessPolicyTextBlock" xlink:title="NatureOfBusinessPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_NatureOfBusinessPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NatureOfBusinessPolicyTextBlock_lbl" xml:lang="en-US" id="ocup_NatureOfBusinessPolicyTextBlock_lbl">Disclosure of accounting policy for nature of business.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfBusinessPolicyTextBlock" xlink:to="ocup_NatureOfBusinessPolicyTextBlock_lbl" xlink:title="label: NatureOfBusinessPolicyTextBlock to ocup_NatureOfBusinessPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NatureOfBusinessPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NatureOfBusinessPolicyTextBlock_lbl1" xml:lang="en-US" id="ocup_NatureOfBusinessPolicyTextBlock_lbl1">Nature of Business [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfBusinessPolicyTextBlock" xlink:to="ocup_NatureOfBusinessPolicyTextBlock_lbl1" xlink:title="label: NatureOfBusinessPolicyTextBlock to ocup_NatureOfBusinessPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NatureOfBusinessPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NatureOfBusinessPolicyTextBlock_lbl2" xml:lang="en-US" id="ocup_NatureOfBusinessPolicyTextBlock_lbl2">Nature of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfBusinessPolicyTextBlock" xlink:to="ocup_NatureOfBusinessPolicyTextBlock_lbl2" xlink:title="label: NatureOfBusinessPolicyTextBlock to ocup_NatureOfBusinessPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WarrantLiabilitiesPolicyTextBlock" xlink:label="WarrantLiabilitiesPolicyTextBlock" xlink:title="WarrantLiabilitiesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_WarrantLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_WarrantLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US" id="ocup_WarrantLiabilitiesPolicyTextBlock_lbl">Disclosure of accounting policy for warrant liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesPolicyTextBlock" xlink:to="ocup_WarrantLiabilitiesPolicyTextBlock_lbl" xlink:title="label: WarrantLiabilitiesPolicyTextBlock to ocup_WarrantLiabilitiesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_WarrantLiabilitiesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_WarrantLiabilitiesPolicyTextBlock_lbl1" xml:lang="en-US" id="ocup_WarrantLiabilitiesPolicyTextBlock_lbl1">Warrant Liabilities [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesPolicyTextBlock" xlink:to="ocup_WarrantLiabilitiesPolicyTextBlock_lbl1" xlink:title="label: WarrantLiabilitiesPolicyTextBlock to ocup_WarrantLiabilitiesPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_WarrantLiabilitiesPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_WarrantLiabilitiesPolicyTextBlock_lbl2" xml:lang="en-US" id="ocup_WarrantLiabilitiesPolicyTextBlock_lbl2">Warrant Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesPolicyTextBlock" xlink:to="ocup_WarrantLiabilitiesPolicyTextBlock_lbl2" xlink:title="label: WarrantLiabilitiesPolicyTextBlock to ocup_WarrantLiabilitiesPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_OtherIncomeExpenseNetPolicyTextBlock" xlink:label="OtherIncomeExpenseNetPolicyTextBlock" xlink:title="OtherIncomeExpenseNetPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl" xml:lang="en-US" id="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl">Disclosure of accounting policy for other income (expense), net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomeExpenseNetPolicyTextBlock" xlink:to="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl" xlink:title="label: OtherIncomeExpenseNetPolicyTextBlock to ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl1" xml:lang="en-US" id="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl1">Other Income (Expense), Net [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomeExpenseNetPolicyTextBlock" xlink:to="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl1" xlink:title="label: OtherIncomeExpenseNetPolicyTextBlock to ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl2" xml:lang="en-US" id="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl2">Other Expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomeExpenseNetPolicyTextBlock" xlink:to="ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl2" xlink:title="label: OtherIncomeExpenseNetPolicyTextBlock to ocup_OtherIncomeExpenseNetPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetPolicyTextBlock" xlink:label="ContractAssetPolicyTextBlock" xlink:title="ContractAssetPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ContractAssetPolicyTextBlock_lbl" xml:lang="en-US" id="ocup_ContractAssetPolicyTextBlock_lbl">Disclosure of accounting policy for contract assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetPolicyTextBlock" xlink:to="ocup_ContractAssetPolicyTextBlock_lbl" xlink:title="label: ContractAssetPolicyTextBlock to ocup_ContractAssetPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ContractAssetPolicyTextBlock_lbl1" xml:lang="en-US" id="ocup_ContractAssetPolicyTextBlock_lbl1">Contract Asset [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetPolicyTextBlock" xlink:to="ocup_ContractAssetPolicyTextBlock_lbl1" xlink:title="label: ContractAssetPolicyTextBlock to ocup_ContractAssetPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ContractAssetPolicyTextBlock_lbl2" xml:lang="en-US" id="ocup_ContractAssetPolicyTextBlock_lbl2">Contract Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetPolicyTextBlock" xlink:to="ocup_ContractAssetPolicyTextBlock_lbl2" xlink:title="label: ContractAssetPolicyTextBlock to ocup_ContractAssetPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NatureOfBusinessAbstract" xlink:label="NatureOfBusinessAbstract" xlink:title="NatureOfBusinessAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_NatureOfBusinessAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NatureOfBusinessAbstract_lbl1" xml:lang="en-US" id="ocup_NatureOfBusinessAbstract_lbl1">Nature of Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfBusinessAbstract" xlink:to="ocup_NatureOfBusinessAbstract_lbl1" xlink:title="label: NatureOfBusinessAbstract to ocup_NatureOfBusinessAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NatureOfBusinessAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NatureOfBusinessAbstract_lbl2" xml:lang="en-US" id="ocup_NatureOfBusinessAbstract_lbl2">Nature of Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfBusinessAbstract" xlink:to="ocup_NatureOfBusinessAbstract_lbl2" xlink:title="label: NatureOfBusinessAbstract to ocup_NatureOfBusinessAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfSmallMoleculeProductCandidates" xlink:label="NumberOfSmallMoleculeProductCandidates" xlink:title="NumberOfSmallMoleculeProductCandidates" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfSmallMoleculeProductCandidates_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfSmallMoleculeProductCandidates_lbl" xml:lang="en-US" id="ocup_NumberOfSmallMoleculeProductCandidates_lbl">The number of small molecule product candidates targeting front and back of the eye indications.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSmallMoleculeProductCandidates" xlink:to="ocup_NumberOfSmallMoleculeProductCandidates_lbl" xlink:title="label: NumberOfSmallMoleculeProductCandidates to ocup_NumberOfSmallMoleculeProductCandidates_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfSmallMoleculeProductCandidates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfSmallMoleculeProductCandidates_lbl1" xml:lang="en-US" id="ocup_NumberOfSmallMoleculeProductCandidates_lbl1">Number of Small Molecule Product Candidates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSmallMoleculeProductCandidates" xlink:to="ocup_NumberOfSmallMoleculeProductCandidates_lbl1" xlink:title="label: NumberOfSmallMoleculeProductCandidates to ocup_NumberOfSmallMoleculeProductCandidates_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfSmallMoleculeProductCandidates_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfSmallMoleculeProductCandidates_lbl2" xml:lang="en-US" id="ocup_NumberOfSmallMoleculeProductCandidates_lbl2">Number of small molecule product candidates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSmallMoleculeProductCandidates" xlink:to="ocup_NumberOfSmallMoleculeProductCandidates_lbl2" xlink:title="label: NumberOfSmallMoleculeProductCandidates to ocup_NumberOfSmallMoleculeProductCandidates_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:label="DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:title="DefinedContributionPlanAdditionalEmployerMatchingContribution" />
    <link:label xlink:type="resource" xlink:label="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl" xml:lang="en-US" id="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl">Additional percentage employer matches of the employee's percentage contribution matched.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:to="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl" xlink:title="label: DefinedContributionPlanAdditionalEmployerMatchingContribution to ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl1" xml:lang="en-US" id="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl1">Defined Contribution Plan, Additional Employer Matching Contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:to="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl1" xlink:title="label: DefinedContributionPlanAdditionalEmployerMatchingContribution to ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl2" xml:lang="en-US" id="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl2">Additional employer matching contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:to="ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl2" xlink:title="label: DefinedContributionPlanAdditionalEmployerMatchingContribution to ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RetirementPlan401KMember" xlink:label="RetirementPlan401KMember" xlink:title="RetirementPlan401KMember" />
    <link:label xlink:type="resource" xlink:label="ocup_RetirementPlan401KMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_RetirementPlan401KMember_lbl" xml:lang="en-US" id="ocup_RetirementPlan401KMember_lbl">A defined-contribution retirement account which allows employees to save a portion of their salary in a tax-advantaged manner. The money earned in a 401(k) Plan is not taxed until after the employee retires, at which time their income will typically be lower than during their working years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetirementPlan401KMember" xlink:to="ocup_RetirementPlan401KMember_lbl" xlink:title="label: RetirementPlan401KMember to ocup_RetirementPlan401KMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_RetirementPlan401KMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_RetirementPlan401KMember_lbl1" xml:lang="en-US" id="ocup_RetirementPlan401KMember_lbl1">Retirement Plan, 401K [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetirementPlan401KMember" xlink:to="ocup_RetirementPlan401KMember_lbl1" xlink:title="label: RetirementPlan401KMember to ocup_RetirementPlan401KMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_RetirementPlan401KMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_RetirementPlan401KMember_lbl2" xml:lang="en-US" id="ocup_RetirementPlan401KMember_lbl2">401K Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetirementPlan401KMember" xlink:to="ocup_RetirementPlan401KMember_lbl2" xlink:title="label: RetirementPlan401KMember to ocup_RetirementPlan401KMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:label="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:title="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" />
    <link:label xlink:type="resource" xlink:label="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl" xml:lang="en-US" id="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl">Additional percentage employer matches of the employee's deferred percentage contribution matched.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:to="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl" xlink:title="label: DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred to ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl1" xml:lang="en-US" id="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl1">Defined Contribution Plan, Additional Employer Matching Contribution Deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:to="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl1" xlink:title="label: DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred to ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl2" xml:lang="en-US" id="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl2">Additional deferred compensation matched by employer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:to="ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl2" xlink:title="label: DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred to ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LicenseAndCollaborationAgreementsAbstract" xlink:label="LicenseAndCollaborationAgreementsAbstract" xlink:title="LicenseAndCollaborationAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_LicenseAndCollaborationAgreementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_LicenseAndCollaborationAgreementsAbstract_lbl1" xml:lang="en-US" id="ocup_LicenseAndCollaborationAgreementsAbstract_lbl1">License and Collaboration Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseAndCollaborationAgreementsAbstract" xlink:to="ocup_LicenseAndCollaborationAgreementsAbstract_lbl1" xlink:title="label: LicenseAndCollaborationAgreementsAbstract to ocup_LicenseAndCollaborationAgreementsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" xlink:label="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" xlink:title="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl" xml:lang="en-US" id="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl">Tabular disclosure of the reconciliation using contract asset associated with agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" xlink:to="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl" xlink:title="label: ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock to ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl1" xml:lang="en-US" id="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl1">Schedule of Reconciliation of Contract Asset Associated [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" xlink:to="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl1" xlink:title="label: ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock to ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl2" xml:lang="en-US" id="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl2">Reconciliation of Contract Asset Associated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" xlink:to="ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl2" xlink:title="label: ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock to ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LicenseTransferFeeMember" xlink:label="LicenseTransferFeeMember" xlink:title="LicenseTransferFeeMember" />
    <link:label xlink:type="resource" xlink:label="ocup_LicenseTransferFeeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_LicenseTransferFeeMember_lbl" xml:lang="en-US" id="ocup_LicenseTransferFeeMember_lbl">License transfer fee related to terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseTransferFeeMember" xlink:to="ocup_LicenseTransferFeeMember_lbl" xlink:title="label: LicenseTransferFeeMember to ocup_LicenseTransferFeeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_LicenseTransferFeeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_LicenseTransferFeeMember_lbl1" xml:lang="en-US" id="ocup_LicenseTransferFeeMember_lbl1">License Transfer Fee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseTransferFeeMember" xlink:to="ocup_LicenseTransferFeeMember_lbl1" xlink:title="label: LicenseTransferFeeMember to ocup_LicenseTransferFeeMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_LicenseTransferFeeMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_LicenseTransferFeeMember_lbl2" xml:lang="en-US" id="ocup_LicenseTransferFeeMember_lbl2">License Transfer Fee [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseTransferFeeMember" xlink:to="ocup_LicenseTransferFeeMember_lbl2" xlink:title="label: LicenseTransferFeeMember to ocup_LicenseTransferFeeMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:label="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:title="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl" xml:lang="en-US" id="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl">This line item represents amounts invoiced that were previously reflected in the Contract Asset account.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:to="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl" xlink:title="label: ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement to ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl1" xml:lang="en-US" id="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl1">Contract Asset, Reclassification to Accounts Receivable Related to Costs Billed under License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:to="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl1" xlink:title="label: ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement to ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl2" xml:lang="en-US" id="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl2">Reclassification to accounts receivable related to costs billed under the Nyxol License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:to="ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl2" xlink:title="label: ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement to ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ResearchDevelopmentServicesMember" xlink:label="ResearchDevelopmentServicesMember" xlink:title="ResearchDevelopmentServicesMember" />
    <link:label xlink:type="resource" xlink:label="ocup_ResearchDevelopmentServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ResearchDevelopmentServicesMember_lbl" xml:lang="en-US" id="ocup_ResearchDevelopmentServicesMember_lbl">Information related to research and development services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentServicesMember" xlink:to="ocup_ResearchDevelopmentServicesMember_lbl" xlink:title="label: ResearchDevelopmentServicesMember to ocup_ResearchDevelopmentServicesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ResearchDevelopmentServicesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ResearchDevelopmentServicesMember_lbl1" xml:lang="en-US" id="ocup_ResearchDevelopmentServicesMember_lbl1">Research Development Services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentServicesMember" xlink:to="ocup_ResearchDevelopmentServicesMember_lbl1" xlink:title="label: ResearchDevelopmentServicesMember to ocup_ResearchDevelopmentServicesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ResearchDevelopmentServicesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ResearchDevelopmentServicesMember_lbl2" xml:lang="en-US" id="ocup_ResearchDevelopmentServicesMember_lbl2">Research and Development Services [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentServicesMember" xlink:to="ocup_ResearchDevelopmentServicesMember_lbl2" xlink:title="label: ResearchDevelopmentServicesMember to ocup_ResearchDevelopmentServicesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NyxolLicenseAgreementMember" xlink:label="NyxolLicenseAgreementMember" xlink:title="NyxolLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="ocup_NyxolLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NyxolLicenseAgreementMember_lbl" xml:lang="en-US" id="ocup_NyxolLicenseAgreementMember_lbl">Nyxol license and agreement entered by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NyxolLicenseAgreementMember" xlink:to="ocup_NyxolLicenseAgreementMember_lbl" xlink:title="label: NyxolLicenseAgreementMember to ocup_NyxolLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NyxolLicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NyxolLicenseAgreementMember_lbl1" xml:lang="en-US" id="ocup_NyxolLicenseAgreementMember_lbl1">Nyxol License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NyxolLicenseAgreementMember" xlink:to="ocup_NyxolLicenseAgreementMember_lbl1" xlink:title="label: NyxolLicenseAgreementMember to ocup_NyxolLicenseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NyxolLicenseAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NyxolLicenseAgreementMember_lbl2" xml:lang="en-US" id="ocup_NyxolLicenseAgreementMember_lbl2">Nyxol License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NyxolLicenseAgreementMember" xlink:to="ocup_NyxolLicenseAgreementMember_lbl2" xlink:title="label: NyxolLicenseAgreementMember to ocup_NyxolLicenseAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CollaborationAndLicenseAgreementAbstract" xlink:label="CollaborationAndLicenseAgreementAbstract" xlink:title="CollaborationAndLicenseAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_CollaborationAndLicenseAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_CollaborationAndLicenseAgreementAbstract_lbl1" xml:lang="en-US" id="ocup_CollaborationAndLicenseAgreementAbstract_lbl1">Collaboration and License Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="ocup_CollaborationAndLicenseAgreementAbstract_lbl1" xlink:title="label: CollaborationAndLicenseAgreementAbstract to ocup_CollaborationAndLicenseAgreementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_CollaborationAndLicenseAgreementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocup_CollaborationAndLicenseAgreementAbstract_lbl2" xml:lang="en-US" id="ocup_CollaborationAndLicenseAgreementAbstract_lbl2">Collaboration and License Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="ocup_CollaborationAndLicenseAgreementAbstract_lbl2" xlink:title="label: CollaborationAndLicenseAgreementAbstract to ocup_CollaborationAndLicenseAgreementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FirstPotentialMilestonePaymentToBeReceived" xlink:label="FirstPotentialMilestonePaymentToBeReceived" xlink:title="FirstPotentialMilestonePaymentToBeReceived" />
    <link:label xlink:type="resource" xlink:label="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl" xml:lang="en-US" id="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl">The amount of potential milestone payment received upon achieving performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstPotentialMilestonePaymentToBeReceived" xlink:to="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl" xlink:title="label: FirstPotentialMilestonePaymentToBeReceived to ocup_FirstPotentialMilestonePaymentToBeReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl1" xml:lang="en-US" id="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl1">First Potential Milestone Payment to be Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstPotentialMilestonePaymentToBeReceived" xlink:to="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl1" xlink:title="label: FirstPotentialMilestonePaymentToBeReceived to ocup_FirstPotentialMilestonePaymentToBeReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl2" xml:lang="en-US" id="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl2">First potential payments to be received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FirstPotentialMilestonePaymentToBeReceived" xlink:to="ocup_FirstPotentialMilestonePaymentToBeReceived_lbl2" xlink:title="label: FirstPotentialMilestonePaymentToBeReceived to ocup_FirstPotentialMilestonePaymentToBeReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:label="EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:title="EstimatedStandaloneSellingPriceForLicenseAgreement" />
    <link:label xlink:type="resource" xlink:label="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl" xml:lang="en-US" id="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl">Amount of estimated standalone selling price for license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:to="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl" xlink:title="label: EstimatedStandaloneSellingPriceForLicenseAgreement to ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl1" xml:lang="en-US" id="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl1">Estimated Standalone Selling Price for License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:to="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl1" xlink:title="label: EstimatedStandaloneSellingPriceForLicenseAgreement to ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl2" xml:lang="en-US" id="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl2">Estimated standalone selling price for license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:to="ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl2" xlink:title="label: EstimatedStandaloneSellingPriceForLicenseAgreement to ocup_EstimatedStandaloneSellingPriceForLicenseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NonRefundableCashPaymentReceived" xlink:label="NonRefundableCashPaymentReceived" xlink:title="NonRefundableCashPaymentReceived" />
    <link:label xlink:type="resource" xlink:label="ocup_NonRefundableCashPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NonRefundableCashPaymentReceived_lbl" xml:lang="en-US" id="ocup_NonRefundableCashPaymentReceived_lbl">The amount of non-refundable cash payments received during the period under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableCashPaymentReceived" xlink:to="ocup_NonRefundableCashPaymentReceived_lbl" xlink:title="label: NonRefundableCashPaymentReceived to ocup_NonRefundableCashPaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NonRefundableCashPaymentReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NonRefundableCashPaymentReceived_lbl1" xml:lang="en-US" id="ocup_NonRefundableCashPaymentReceived_lbl1">Non-refundable Cash Payment Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableCashPaymentReceived" xlink:to="ocup_NonRefundableCashPaymentReceived_lbl1" xlink:title="label: NonRefundableCashPaymentReceived to ocup_NonRefundableCashPaymentReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NonRefundableCashPaymentReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NonRefundableCashPaymentReceived_lbl2" xml:lang="en-US" id="ocup_NonRefundableCashPaymentReceived_lbl2">Non-refundable cash payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableCashPaymentReceived" xlink:to="ocup_NonRefundableCashPaymentReceived_lbl2" xlink:title="label: NonRefundableCashPaymentReceived to ocup_NonRefundableCashPaymentReceived_lbl2" />
    <link:label xlink:type="resource" xlink:label="ocup_NonRefundableCashPaymentReceived_lbl3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ocup_NonRefundableCashPaymentReceived_lbl3" xml:lang="en-US" id="ocup_NonRefundableCashPaymentReceived_lbl3">Execution of Nyxol License Agreement and one-time non-refundable payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableCashPaymentReceived" xlink:to="ocup_NonRefundableCashPaymentReceived_lbl3" xlink:title="label: NonRefundableCashPaymentReceived to ocup_NonRefundableCashPaymentReceived_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfPerformanceObligations" xlink:label="NumberOfPerformanceObligations" xlink:title="NumberOfPerformanceObligations" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfPerformanceObligations_lbl" xml:lang="en-US" id="ocup_NumberOfPerformanceObligations_lbl">The number of performance obligations in accordance with the provisions under ASC 606, the Company identified.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligations" xlink:to="ocup_NumberOfPerformanceObligations_lbl" xlink:title="label: NumberOfPerformanceObligations to ocup_NumberOfPerformanceObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfPerformanceObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfPerformanceObligations_lbl1" xml:lang="en-US" id="ocup_NumberOfPerformanceObligations_lbl1">Number of Performance Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligations" xlink:to="ocup_NumberOfPerformanceObligations_lbl1" xlink:title="label: NumberOfPerformanceObligations to ocup_NumberOfPerformanceObligations_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfPerformanceObligations_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfPerformanceObligations_lbl2" xml:lang="en-US" id="ocup_NumberOfPerformanceObligations_lbl2">Number of distinct performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligations" xlink:to="ocup_NumberOfPerformanceObligations_lbl2" xlink:title="label: NumberOfPerformanceObligations to ocup_NumberOfPerformanceObligations_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPercentageOfTieredRoyaltiesReceivable" xlink:label="MaximumPercentageOfTieredRoyaltiesReceivable" xlink:title="MaximumPercentageOfTieredRoyaltiesReceivable" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl" xml:lang="en-US" id="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl">The maximum percentage of tiered royalties receivable based on the aggregate annual net sales of all Nyxol Products in the United States.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentageOfTieredRoyaltiesReceivable" xlink:to="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl" xlink:title="label: MaximumPercentageOfTieredRoyaltiesReceivable to ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl1" xml:lang="en-US" id="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl1">Maximum Percentage of Tiered Royalties Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentageOfTieredRoyaltiesReceivable" xlink:to="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl1" xlink:title="label: MaximumPercentageOfTieredRoyaltiesReceivable to ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl2" xml:lang="en-US" id="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl2">Maximum percentage of tiered royalties receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPercentageOfTieredRoyaltiesReceivable" xlink:to="ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl2" xlink:title="label: MaximumPercentageOfTieredRoyaltiesReceivable to ocup_MaximumPercentageOfTieredRoyaltiesReceivable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:label="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:title="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" />
    <link:label xlink:type="resource" xlink:label="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl" xml:lang="en-US" id="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl">Amount of transaction price of license agreement allocated on estimated standalone selling price obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:to="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl" xlink:title="label: TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations to ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl1" xml:lang="en-US" id="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl1">Transaction Price Allocated on Estimated Standalone Selling Price Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:to="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl1" xlink:title="label: TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations to ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl2" xml:lang="en-US" id="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl2">Transaction price allocation of ESSP obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:to="ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl2" xlink:title="label: TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations to ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RevenueFromContractWithCustomerToBeRecognized" xlink:label="RevenueFromContractWithCustomerToBeRecognized" xlink:title="RevenueFromContractWithCustomerToBeRecognized" />
    <link:label xlink:type="resource" xlink:label="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl" xml:lang="en-US" id="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl">Amount to be recognized, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerToBeRecognized" xlink:to="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl" xlink:title="label: RevenueFromContractWithCustomerToBeRecognized to ocup_RevenueFromContractWithCustomerToBeRecognized_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl1" xml:lang="en-US" id="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl1">Revenue from Contract With Customer, to be Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerToBeRecognized" xlink:to="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl1" xlink:title="label: RevenueFromContractWithCustomerToBeRecognized to ocup_RevenueFromContractWithCustomerToBeRecognized_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl2" xml:lang="en-US" id="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl2">Aggregate transaction price to be recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerToBeRecognized" xlink:to="ocup_RevenueFromContractWithCustomerToBeRecognized_lbl2" xlink:title="label: RevenueFromContractWithCustomerToBeRecognized to ocup_RevenueFromContractWithCustomerToBeRecognized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" id="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl">Milestone payments receivable upon the achievement of development, regulatory and commercial goals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:to="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones to ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl1" xml:lang="en-US" id="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl1">Maximum Amount Of Payments Receivable for Development, Regulatory and Commercial Milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:to="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones to ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl2" xml:lang="en-US" id="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl2">Maximum amount of payments receivable for development, regulatory and commercial milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:to="ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones to ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfNonCancellationWindowAgreement" xlink:label="PeriodOfNonCancellationWindowAgreement" xlink:title="PeriodOfNonCancellationWindowAgreement" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfNonCancellationWindowAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PeriodOfNonCancellationWindowAgreement_lbl" xml:lang="en-US" id="ocup_PeriodOfNonCancellationWindowAgreement_lbl">Period of non-cancellation window agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfNonCancellationWindowAgreement" xlink:to="ocup_PeriodOfNonCancellationWindowAgreement_lbl" xlink:title="label: PeriodOfNonCancellationWindowAgreement to ocup_PeriodOfNonCancellationWindowAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfNonCancellationWindowAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PeriodOfNonCancellationWindowAgreement_lbl1" xml:lang="en-US" id="ocup_PeriodOfNonCancellationWindowAgreement_lbl1">Period of Non-Cancellation window Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfNonCancellationWindowAgreement" xlink:to="ocup_PeriodOfNonCancellationWindowAgreement_lbl1" xlink:title="label: PeriodOfNonCancellationWindowAgreement to ocup_PeriodOfNonCancellationWindowAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfNonCancellationWindowAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PeriodOfNonCancellationWindowAgreement_lbl2" xml:lang="en-US" id="ocup_PeriodOfNonCancellationWindowAgreement_lbl2">Period of non-cancellation window agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfNonCancellationWindowAgreement" xlink:to="ocup_PeriodOfNonCancellationWindowAgreement_lbl2" xlink:title="label: PeriodOfNonCancellationWindowAgreement to ocup_PeriodOfNonCancellationWindowAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ProcessaLicenseAgreementMember" xlink:label="ProcessaLicenseAgreementMember" xlink:title="ProcessaLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="ocup_ProcessaLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ProcessaLicenseAgreementMember_lbl" xml:lang="en-US" id="ocup_ProcessaLicenseAgreementMember_lbl">"On June 16, 2021, the Company entered into a license agreement (the "Processa License Agreement") with Processa Pharmaceuticals, Inc. ("Processa"), pursuant to which the Company has agreed to grant Processa an exclusive license to develop, manufacture and commercialize RX-3117 globally, excluding China."</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProcessaLicenseAgreementMember" xlink:to="ocup_ProcessaLicenseAgreementMember_lbl" xlink:title="label: ProcessaLicenseAgreementMember to ocup_ProcessaLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ProcessaLicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ProcessaLicenseAgreementMember_lbl1" xml:lang="en-US" id="ocup_ProcessaLicenseAgreementMember_lbl1">Processa License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProcessaLicenseAgreementMember" xlink:to="ocup_ProcessaLicenseAgreementMember_lbl1" xlink:title="label: ProcessaLicenseAgreementMember to ocup_ProcessaLicenseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ProcessaLicenseAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ProcessaLicenseAgreementMember_lbl2" xml:lang="en-US" id="ocup_ProcessaLicenseAgreementMember_lbl2">Processa License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProcessaLicenseAgreementMember" xlink:to="ocup_ProcessaLicenseAgreementMember_lbl2" xlink:title="label: ProcessaLicenseAgreementMember to ocup_ProcessaLicenseAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfTimesPaymentsForSalesMilestone" xlink:label="NumberOfTimesPaymentsForSalesMilestone" xlink:title="NumberOfTimesPaymentsForSalesMilestone" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl" xml:lang="en-US" id="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl">Number of time sales milestone payments eligible to receive based on the achievement of annual sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTimesPaymentsForSalesMilestone" xlink:to="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl" xlink:title="label: NumberOfTimesPaymentsForSalesMilestone to ocup_NumberOfTimesPaymentsForSalesMilestone_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl1" xml:lang="en-US" id="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl1">Number of Times Payments for Sales Milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTimesPaymentsForSalesMilestone" xlink:to="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl1" xlink:title="label: NumberOfTimesPaymentsForSalesMilestone to ocup_NumberOfTimesPaymentsForSalesMilestone_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl2" xml:lang="en-US" id="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl2">Number of times sales milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTimesPaymentsForSalesMilestone" xlink:to="ocup_NumberOfTimesPaymentsForSalesMilestone_lbl2" xlink:title="label: NumberOfTimesPaymentsForSalesMilestone to ocup_NumberOfTimesPaymentsForSalesMilestone_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:label="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:title="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" />
    <link:label xlink:type="resource" xlink:label="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl" xml:lang="en-US" id="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl">Percentage of milestone payments eligible to receive on sub-license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:to="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl" xlink:title="label: PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement to ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl1" xml:lang="en-US" id="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl1">Percentage of Milestone Payments Eligible to Receive on Sub-license Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:to="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl1" xlink:title="label: PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement to ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl2" xml:lang="en-US" id="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl2">Percentage of milestone payments eligible to receive on sub-license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:to="ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl2" xlink:title="label: PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement to ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:label="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:title="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" />
    <link:label xlink:type="resource" xlink:label="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl" xml:lang="en-US" id="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl">Minimum number of countries to conduct development activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:to="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl" xlink:title="label: MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted to ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl1" xml:lang="en-US" id="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl1">Minimum Number of Countries Development Activities to be Conducted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:to="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl1" xlink:title="label: MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted to ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl2" xml:lang="en-US" id="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl2">Number of countries</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:to="ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl2" xlink:title="label: MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted to ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePaymentAchievedForPerformanceObligation" xlink:label="MilestonePaymentAchievedForPerformanceObligation" xlink:title="MilestonePaymentAchievedForPerformanceObligation" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl" xml:lang="en-US" id="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl">Milestone payments achieved under the collaboration agreement during the period and recorded as collaboration revenue for the performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentAchievedForPerformanceObligation" xlink:to="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl" xlink:title="label: MilestonePaymentAchievedForPerformanceObligation to ocup_MilestonePaymentAchievedForPerformanceObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl1" xml:lang="en-US" id="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl1">Milestone Payment Achieved for Performance Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentAchievedForPerformanceObligation" xlink:to="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl1" xlink:title="label: MilestonePaymentAchievedForPerformanceObligation to ocup_MilestonePaymentAchievedForPerformanceObligation_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl2" xml:lang="en-US" id="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl2">Milestone payment achieved for performance obligation, recorded as collaboration revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentAchievedForPerformanceObligation" xlink:to="ocup_MilestonePaymentAchievedForPerformanceObligation_lbl2" xlink:title="label: MilestonePaymentAchievedForPerformanceObligation to ocup_MilestonePaymentAchievedForPerformanceObligation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfOpportunityToCureBreachOfAgreement" xlink:label="PeriodOfOpportunityToCureBreachOfAgreement" xlink:title="PeriodOfOpportunityToCureBreachOfAgreement" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl" xml:lang="en-US" id="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl">Period of opportunity to cure breach of agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfOpportunityToCureBreachOfAgreement" xlink:to="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl" xlink:title="label: PeriodOfOpportunityToCureBreachOfAgreement to ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl1" xml:lang="en-US" id="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl1">Period of Opportunity to Cure Breach Of Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfOpportunityToCureBreachOfAgreement" xlink:to="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl1" xlink:title="label: PeriodOfOpportunityToCureBreachOfAgreement to ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl2" xml:lang="en-US" id="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl2">Period of opportunity to cure breach of agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfOpportunityToCureBreachOfAgreement" xlink:to="ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl2" xlink:title="label: PeriodOfOpportunityToCureBreachOfAgreement to ocup_PeriodOfOpportunityToCureBreachOfAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePaymentsAmountReceived" xlink:label="MilestonePaymentsAmountReceived" xlink:title="MilestonePaymentsAmountReceived" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePaymentsAmountReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MilestonePaymentsAmountReceived_lbl" xml:lang="en-US" id="ocup_MilestonePaymentsAmountReceived_lbl">The amount of milestone payment received upon achieving performance obligation..</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAmountReceived" xlink:to="ocup_MilestonePaymentsAmountReceived_lbl" xlink:title="label: MilestonePaymentsAmountReceived to ocup_MilestonePaymentsAmountReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePaymentsAmountReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MilestonePaymentsAmountReceived_lbl1" xml:lang="en-US" id="ocup_MilestonePaymentsAmountReceived_lbl1">Milestone Payments Amount Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAmountReceived" xlink:to="ocup_MilestonePaymentsAmountReceived_lbl1" xlink:title="label: MilestonePaymentsAmountReceived to ocup_MilestonePaymentsAmountReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePaymentsAmountReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MilestonePaymentsAmountReceived_lbl2" xml:lang="en-US" id="ocup_MilestonePaymentsAmountReceived_lbl2">Milestone payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsAmountReceived" xlink:to="ocup_MilestonePaymentsAmountReceived_lbl2" xlink:title="label: MilestonePaymentsAmountReceived to ocup_MilestonePaymentsAmountReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_BioSenseLicenseAndAssignmentsAgreementMember" xlink:label="BioSenseLicenseAndAssignmentsAgreementMember" xlink:title="BioSenseLicenseAndAssignmentsAgreementMember" />
    <link:label xlink:type="resource" xlink:label="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl" xml:lang="en-US" id="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl">BioSense license and assignments agreement entered by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BioSenseLicenseAndAssignmentsAgreementMember" xlink:to="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl" xlink:title="label: BioSenseLicenseAndAssignmentsAgreementMember to ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl1" xml:lang="en-US" id="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl1">BioSense License and Assignments Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BioSenseLicenseAndAssignmentsAgreementMember" xlink:to="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl1" xlink:title="label: BioSenseLicenseAndAssignmentsAgreementMember to ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl2" xml:lang="en-US" id="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl2">BioSense License and Assignments Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BioSenseLicenseAndAssignmentsAgreementMember" xlink:to="ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl2" xlink:title="label: BioSenseLicenseAndAssignmentsAgreementMember to ocup_BioSenseLicenseAndAssignmentsAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_UpfrontPaymentReceivedInCommonStockFairValue" xlink:label="UpfrontPaymentReceivedInCommonStockFairValue" xlink:title="UpfrontPaymentReceivedInCommonStockFairValue" />
    <link:label xlink:type="resource" xlink:label="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl" xml:lang="en-US" id="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl">The fair value of common shares of an entity that have been received as an upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedInCommonStockFairValue" xlink:to="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl" xlink:title="label: UpfrontPaymentReceivedInCommonStockFairValue to ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl1" xml:lang="en-US" id="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl1">Upfront Payment Received in Common Stock, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedInCommonStockFairValue" xlink:to="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl1" xlink:title="label: UpfrontPaymentReceivedInCommonStockFairValue to ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl2" xml:lang="en-US" id="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl2">Upfront payment received in common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedInCommonStockFairValue" xlink:to="ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl2" xlink:title="label: UpfrontPaymentReceivedInCommonStockFairValue to ocup_UpfrontPaymentReceivedInCommonStockFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:label="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:title="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl" xml:lang="en-US" id="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl">Milestone period to administer drug clinical trail of licensed product on first patient after second indication in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:to="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl" xlink:title="label: MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication to ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl1" xml:lang="en-US" id="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl1">Milestone Period to Administer Drug Clinical Trial of Licensed Product on First Patient for Second Indication</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:to="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl1" xlink:title="label: MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication to ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl2" xml:lang="en-US" id="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl2">Milestone period to administer drug clinical trial of licensed product on first patient for second indication</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:to="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl2" xlink:title="label: MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication to ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfRestrictionFromSellingStock" xlink:label="PeriodOfRestrictionFromSellingStock" xlink:title="PeriodOfRestrictionFromSellingStock" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfRestrictionFromSellingStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PeriodOfRestrictionFromSellingStock_lbl" xml:lang="en-US" id="ocup_PeriodOfRestrictionFromSellingStock_lbl">Period, that entity is restricted from selling the common stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfRestrictionFromSellingStock" xlink:to="ocup_PeriodOfRestrictionFromSellingStock_lbl" xlink:title="label: PeriodOfRestrictionFromSellingStock to ocup_PeriodOfRestrictionFromSellingStock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfRestrictionFromSellingStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PeriodOfRestrictionFromSellingStock_lbl1" xml:lang="en-US" id="ocup_PeriodOfRestrictionFromSellingStock_lbl1">Period of Restriction from Selling Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfRestrictionFromSellingStock" xlink:to="ocup_PeriodOfRestrictionFromSellingStock_lbl1" xlink:title="label: PeriodOfRestrictionFromSellingStock to ocup_PeriodOfRestrictionFromSellingStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfRestrictionFromSellingStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PeriodOfRestrictionFromSellingStock_lbl2" xml:lang="en-US" id="ocup_PeriodOfRestrictionFromSellingStock_lbl2">Period of restriction from selling common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfRestrictionFromSellingStock" xlink:to="ocup_PeriodOfRestrictionFromSellingStock_lbl2" xlink:title="label: PeriodOfRestrictionFromSellingStock to ocup_PeriodOfRestrictionFromSellingStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:label="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:title="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl" xml:lang="en-US" id="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl">Milestone period to administer drug clinical trail of licensed product on first patient in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:to="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl" xlink:title="label: MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient to ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl1" xml:lang="en-US" id="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl1">Milestone Period to Administer Drug Clinical Trial of Licensed Product on First Patient</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:to="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl1" xlink:title="label: MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient to ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl2" xml:lang="en-US" id="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl2">Milestone period to administer drug clinical trial of licensed product on first patient</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:to="ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl2" xlink:title="label: MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient to ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:label="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:title="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl" xml:lang="en-US" id="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl">Period of prior written notice to be served for termination of agreements in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:to="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl" xlink:title="label: PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements to ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl1" xml:lang="en-US" id="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl1">Period of Prior Written Notice to be Served For Termination Of Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:to="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl1" xlink:title="label: PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements to ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl2" xml:lang="en-US" id="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl2">Period of prior written notice to be served for termination of agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:to="ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl2" xlink:title="label: PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements to ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_UpfrontPaymentReceivedInCommonStockShares" xlink:label="UpfrontPaymentReceivedInCommonStockShares" xlink:title="UpfrontPaymentReceivedInCommonStockShares" />
    <link:label xlink:type="resource" xlink:label="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl" xml:lang="en-US" id="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl">Total number of common shares of an entity that have been received as an upfront payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedInCommonStockShares" xlink:to="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl" xlink:title="label: UpfrontPaymentReceivedInCommonStockShares to ocup_UpfrontPaymentReceivedInCommonStockShares_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl1" xml:lang="en-US" id="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl1">Upfront Payment Received in Common Stock Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedInCommonStockShares" xlink:to="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl1" xlink:title="label: UpfrontPaymentReceivedInCommonStockShares to ocup_UpfrontPaymentReceivedInCommonStockShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl2" xml:lang="en-US" id="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl2">Upfront payment received in common shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedInCommonStockShares" xlink:to="ocup_UpfrontPaymentReceivedInCommonStockShares_lbl2" xlink:title="label: UpfrontPaymentReceivedInCommonStockShares to ocup_UpfrontPaymentReceivedInCommonStockShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_StockOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StockOptionsAbstract_lbl1" xml:lang="en-US" id="ocup_StockOptionsAbstract_lbl1">Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAbstract" xlink:to="ocup_StockOptionsAbstract_lbl1" xlink:title="label: StockOptionsAbstract to ocup_StockOptionsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StockOptionsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StockOptionsAbstract_lbl2" xml:lang="en-US" id="ocup_StockOptionsAbstract_lbl2">Ocuphire Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAbstract" xlink:to="ocup_StockOptionsAbstract_lbl2" xlink:title="label: StockOptionsAbstract to ocup_StockOptionsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPeriodOfSharesReservedUnderPlan" xlink:label="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="MaximumPeriodOfSharesReservedUnderPlan" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl" xml:lang="en-US" id="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl">The period of shares reserved under plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPeriodOfSharesReservedUnderPlan" xlink:to="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl" xlink:title="label: MaximumPeriodOfSharesReservedUnderPlan to ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl1" xml:lang="en-US" id="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl1">Period of Shares Reserved Under Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPeriodOfSharesReservedUnderPlan" xlink:to="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl1" xlink:title="label: MaximumPeriodOfSharesReservedUnderPlan to ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl2" xml:lang="en-US" id="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl2">Period of shares reserved under plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPeriodOfSharesReservedUnderPlan" xlink:to="ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl2" xlink:title="label: MaximumPeriodOfSharesReservedUnderPlan to ocup_MaximumPeriodOfSharesReservedUnderPlan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl">Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl1" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Service Time Condition, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl2" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl2">Vested and exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl2">Vested and expected to vest (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl">Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl1" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl2" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl2">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl">Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl2" xml:lang="en-US" id="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl2">Weighted average remaining contractual term, vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:to="ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm to ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_InducementPlanMember" xlink:label="InducementPlanMember" xlink:title="InducementPlanMember" />
    <link:label xlink:type="resource" xlink:label="ocup_InducementPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_InducementPlanMember_lbl" xml:lang="en-US" id="ocup_InducementPlanMember_lbl">Information related to inducement plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlanMember" xlink:to="ocup_InducementPlanMember_lbl" xlink:title="label: InducementPlanMember to ocup_InducementPlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_InducementPlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_InducementPlanMember_lbl1" xml:lang="en-US" id="ocup_InducementPlanMember_lbl1">Inducement Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlanMember" xlink:to="ocup_InducementPlanMember_lbl1" xlink:title="label: InducementPlanMember to ocup_InducementPlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_InducementPlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_InducementPlanMember_lbl2" xml:lang="en-US" id="ocup_InducementPlanMember_lbl2">Inducement Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InducementPlanMember" xlink:to="ocup_InducementPlanMember_lbl2" xlink:title="label: InducementPlanMember to ocup_InducementPlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2018Member" xlink:label="EquityIncentivePlan2018Member" xlink:title="EquityIncentivePlan2018Member" />
    <link:label xlink:type="resource" xlink:label="ocup_EquityIncentivePlan2018Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_EquityIncentivePlan2018Member_lbl" xml:lang="en-US" id="ocup_EquityIncentivePlan2018Member_lbl">Information related to 2018 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2018Member" xlink:to="ocup_EquityIncentivePlan2018Member_lbl" xlink:title="label: EquityIncentivePlan2018Member to ocup_EquityIncentivePlan2018Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_EquityIncentivePlan2018Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_EquityIncentivePlan2018Member_lbl1" xml:lang="en-US" id="ocup_EquityIncentivePlan2018Member_lbl1">Equity Incentive Plan 2018 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2018Member" xlink:to="ocup_EquityIncentivePlan2018Member_lbl1" xlink:title="label: EquityIncentivePlan2018Member to ocup_EquityIncentivePlan2018Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_EquityIncentivePlan2018Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_EquityIncentivePlan2018Member_lbl2" xml:lang="en-US" id="ocup_EquityIncentivePlan2018Member_lbl2">2018 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2018Member" xlink:to="ocup_EquityIncentivePlan2018Member_lbl2" xlink:title="label: EquityIncentivePlan2018Member to ocup_EquityIncentivePlan2018Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:label xlink:type="resource" xlink:label="ocup_EquityIncentivePlan2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" id="ocup_EquityIncentivePlan2020Member_lbl">Information related to 2020 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="ocup_EquityIncentivePlan2020Member_lbl" xlink:title="label: EquityIncentivePlan2020Member to ocup_EquityIncentivePlan2020Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_EquityIncentivePlan2020Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_EquityIncentivePlan2020Member_lbl1" xml:lang="en-US" id="ocup_EquityIncentivePlan2020Member_lbl1">Equity Incentive Plan 2020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="ocup_EquityIncentivePlan2020Member_lbl1" xlink:title="label: EquityIncentivePlan2020Member to ocup_EquityIncentivePlan2020Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_EquityIncentivePlan2020Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_EquityIncentivePlan2020Member_lbl2" xml:lang="en-US" id="ocup_EquityIncentivePlan2020Member_lbl2">2020 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="ocup_EquityIncentivePlan2020Member_lbl2" xlink:title="label: EquityIncentivePlan2020Member to ocup_EquityIncentivePlan2020Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ConcentrationOfCreditRiskAbstract" xlink:label="ConcentrationOfCreditRiskAbstract" xlink:title="ConcentrationOfCreditRiskAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_ConcentrationOfCreditRiskAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ConcentrationOfCreditRiskAbstract_lbl1" xml:lang="en-US" id="ocup_ConcentrationOfCreditRiskAbstract_lbl1">Concentration of Credit Risk [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationOfCreditRiskAbstract" xlink:to="ocup_ConcentrationOfCreditRiskAbstract_lbl1" xlink:title="label: ConcentrationOfCreditRiskAbstract to ocup_ConcentrationOfCreditRiskAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ConcentrationOfCreditRiskAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ConcentrationOfCreditRiskAbstract_lbl2" xml:lang="en-US" id="ocup_ConcentrationOfCreditRiskAbstract_lbl2">Concentration of Credit Risk [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationOfCreditRiskAbstract" xlink:to="ocup_ConcentrationOfCreditRiskAbstract_lbl2" xlink:title="label: ConcentrationOfCreditRiskAbstract to ocup_ConcentrationOfCreditRiskAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PremiumConversionDerivativesMember" xlink:label="PremiumConversionDerivativesMember" xlink:title="PremiumConversionDerivativesMember" />
    <link:label xlink:type="resource" xlink:label="ocup_PremiumConversionDerivativesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PremiumConversionDerivativesMember_lbl" xml:lang="en-US" id="ocup_PremiumConversionDerivativesMember_lbl">This item represents premium conversion derivatives obligations meeting the definition of a liability which are reported as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumConversionDerivativesMember" xlink:to="ocup_PremiumConversionDerivativesMember_lbl" xlink:title="label: PremiumConversionDerivativesMember to ocup_PremiumConversionDerivativesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PremiumConversionDerivativesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PremiumConversionDerivativesMember_lbl1" xml:lang="en-US" id="ocup_PremiumConversionDerivativesMember_lbl1">Premium Conversion Derivatives [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumConversionDerivativesMember" xlink:to="ocup_PremiumConversionDerivativesMember_lbl1" xlink:title="label: PremiumConversionDerivativesMember to ocup_PremiumConversionDerivativesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_PremiumConversionDerivativesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_PremiumConversionDerivativesMember_lbl2" xml:lang="en-US" id="ocup_PremiumConversionDerivativesMember_lbl2">Premium Conversion Derivatives [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumConversionDerivativesMember" xlink:to="ocup_PremiumConversionDerivativesMember_lbl2" xlink:title="label: PremiumConversionDerivativesMember to ocup_PremiumConversionDerivativesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WarrantLiabilitiesMember" xlink:label="WarrantLiabilitiesMember" xlink:title="WarrantLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="ocup_WarrantLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_WarrantLiabilitiesMember_lbl" xml:lang="en-US" id="ocup_WarrantLiabilitiesMember_lbl">This item represents warrants meeting the definition of a liability which are reported as of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesMember" xlink:to="ocup_WarrantLiabilitiesMember_lbl" xlink:title="label: WarrantLiabilitiesMember to ocup_WarrantLiabilitiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_WarrantLiabilitiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_WarrantLiabilitiesMember_lbl1" xml:lang="en-US" id="ocup_WarrantLiabilitiesMember_lbl1">Warrant Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesMember" xlink:to="ocup_WarrantLiabilitiesMember_lbl1" xlink:title="label: WarrantLiabilitiesMember to ocup_WarrantLiabilitiesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_WarrantLiabilitiesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_WarrantLiabilitiesMember_lbl2" xml:lang="en-US" id="ocup_WarrantLiabilitiesMember_lbl2">Warrant Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantLiabilitiesMember" xlink:to="ocup_WarrantLiabilitiesMember_lbl2" xlink:title="label: WarrantLiabilitiesMember to ocup_WarrantLiabilitiesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SupplementalBalanceSheetInformationAbstract" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:title="SupplementalBalanceSheetInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_SupplementalBalanceSheetInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_SupplementalBalanceSheetInformationAbstract_lbl1" xml:lang="en-US" id="ocup_SupplementalBalanceSheetInformationAbstract_lbl1">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="ocup_SupplementalBalanceSheetInformationAbstract_lbl1" xlink:title="label: SupplementalBalanceSheetInformationAbstract to ocup_SupplementalBalanceSheetInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="CommonStockCapitalSharesAvailableForFutureIssuance" xlink:title="CommonStockCapitalSharesAvailableForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl" xml:lang="en-US" id="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl">Aggregate number of common shares available for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesAvailableForFutureIssuance" xlink:to="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl" xlink:title="label: CommonStockCapitalSharesAvailableForFutureIssuance to ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl1" xml:lang="en-US" id="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl1">Common Stock, Capital Shares Available for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesAvailableForFutureIssuance" xlink:to="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl1" xlink:title="label: CommonStockCapitalSharesAvailableForFutureIssuance to ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl2" xml:lang="en-US" id="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl2">Common stock available for future issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesAvailableForFutureIssuance" xlink:to="ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl2" xlink:title="label: CommonStockCapitalSharesAvailableForFutureIssuance to ocup_CommonStockCapitalSharesAvailableForFutureIssuance_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RestrictedStockAwardsAbstract" xlink:label="RestrictedStockAwardsAbstract" xlink:title="RestrictedStockAwardsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_RestrictedStockAwardsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_RestrictedStockAwardsAbstract_lbl1" xml:lang="en-US" id="ocup_RestrictedStockAwardsAbstract_lbl1">Restricted Stock Awards [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockAwardsAbstract" xlink:to="ocup_RestrictedStockAwardsAbstract_lbl1" xlink:title="label: RestrictedStockAwardsAbstract to ocup_RestrictedStockAwardsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_RestrictedStockAwardsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_RestrictedStockAwardsAbstract_lbl2" xml:lang="en-US" id="ocup_RestrictedStockAwardsAbstract_lbl2">Ocuphire Restricted Stock Awards [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockAwardsAbstract" xlink:to="ocup_RestrictedStockAwardsAbstract_lbl2" xlink:title="label: RestrictedStockAwardsAbstract to ocup_RestrictedStockAwardsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:label="ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:title="ReceiptOfInvestmentsRelatedToLicenseAgreement" />
    <link:label xlink:type="resource" xlink:label="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl" xml:lang="en-US" id="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl">The is the portion of collaborations revenue from the license agreement stemming from the receipt of non-cash equity investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:to="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl" xlink:title="label: ReceiptOfInvestmentsRelatedToLicenseAgreement to ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl1" xml:lang="en-US" id="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl1">Receipt of Investments Related to License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:to="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl1" xlink:title="label: ReceiptOfInvestmentsRelatedToLicenseAgreement to ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl2" xml:lang="en-US" id="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl2">Receipt of investments related to license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:to="ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl2" xlink:title="label: ReceiptOfInvestmentsRelatedToLicenseAgreement to ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:label="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:title="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" />
    <link:label xlink:type="resource" xlink:label="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl" xml:lang="en-US" id="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development service and supplies. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:to="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl" xlink:title="label: AccruedResearchAndDevelopmentServicesAndSuppliesCurrent to ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl1" xml:lang="en-US" id="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl1">Accrued Research And Development Services and Supplies Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:to="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl1" xlink:title="label: AccruedResearchAndDevelopmentServicesAndSuppliesCurrent to ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl2" xml:lang="en-US" id="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl2">R&amp;D services and supplies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:to="ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl2" xlink:title="label: AccruedResearchAndDevelopmentServicesAndSuppliesCurrent to ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerOptionsAbstract" xlink:label="FormerOptionsAbstract" xlink:title="FormerOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_FormerOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_FormerOptionsAbstract_lbl1" xml:lang="en-US" id="ocup_FormerOptionsAbstract_lbl1">Former Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerOptionsAbstract" xlink:to="ocup_FormerOptionsAbstract_lbl1" xlink:title="label: FormerOptionsAbstract to ocup_FormerOptionsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_FormerOptionsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_FormerOptionsAbstract_lbl2" xml:lang="en-US" id="ocup_FormerOptionsAbstract_lbl2">Former Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerOptionsAbstract" xlink:to="ocup_FormerOptionsAbstract_lbl2" xlink:title="label: FormerOptionsAbstract to ocup_FormerOptionsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CommonStockIssuedForServicesAbstract" xlink:label="CommonStockIssuedForServicesAbstract" xlink:title="CommonStockIssuedForServicesAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_CommonStockIssuedForServicesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_CommonStockIssuedForServicesAbstract_lbl1" xml:lang="en-US" id="ocup_CommonStockIssuedForServicesAbstract_lbl1">Common Stock Issued for Services [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedForServicesAbstract" xlink:to="ocup_CommonStockIssuedForServicesAbstract_lbl1" xlink:title="label: CommonStockIssuedForServicesAbstract to ocup_CommonStockIssuedForServicesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_CommonStockIssuedForServicesAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_CommonStockIssuedForServicesAbstract_lbl2" xml:lang="en-US" id="ocup_CommonStockIssuedForServicesAbstract_lbl2">Common Stock Issued for Services [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockIssuedForServicesAbstract" xlink:to="ocup_CommonStockIssuedForServicesAbstract_lbl2" xlink:title="label: CommonStockIssuedForServicesAbstract to ocup_CommonStockIssuedForServicesAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfBoardMembersGrantedStockForServices" xlink:label="NumberOfBoardMembersGrantedStockForServices" xlink:title="NumberOfBoardMembersGrantedStockForServices" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfBoardMembersGrantedStockForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfBoardMembersGrantedStockForServices_lbl" xml:lang="en-US" id="ocup_NumberOfBoardMembersGrantedStockForServices_lbl">The number of board members for whom stock granted for services performed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardMembersGrantedStockForServices" xlink:to="ocup_NumberOfBoardMembersGrantedStockForServices_lbl" xlink:title="label: NumberOfBoardMembersGrantedStockForServices to ocup_NumberOfBoardMembersGrantedStockForServices_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfBoardMembersGrantedStockForServices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfBoardMembersGrantedStockForServices_lbl1" xml:lang="en-US" id="ocup_NumberOfBoardMembersGrantedStockForServices_lbl1">Number of Board Members Granted Stock for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardMembersGrantedStockForServices" xlink:to="ocup_NumberOfBoardMembersGrantedStockForServices_lbl1" xlink:title="label: NumberOfBoardMembersGrantedStockForServices to ocup_NumberOfBoardMembersGrantedStockForServices_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfBoardMembersGrantedStockForServices_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfBoardMembersGrantedStockForServices_lbl2" xml:lang="en-US" id="ocup_NumberOfBoardMembersGrantedStockForServices_lbl2">Number of board members, stock granted for services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBoardMembersGrantedStockForServices" xlink:to="ocup_NumberOfBoardMembersGrantedStockForServices_lbl2" xlink:title="label: NumberOfBoardMembersGrantedStockForServices to ocup_NumberOfBoardMembersGrantedStockForServices_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DebtInstrumentNumberOfInstallments" xlink:label="DebtInstrumentNumberOfInstallments" xlink:title="DebtInstrumentNumberOfInstallments" />
    <link:label xlink:type="resource" xlink:label="ocup_DebtInstrumentNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_DebtInstrumentNumberOfInstallments_lbl" xml:lang="en-US" id="ocup_DebtInstrumentNumberOfInstallments_lbl">Number of installments to paid monthly for the loan repayment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfInstallments" xlink:to="ocup_DebtInstrumentNumberOfInstallments_lbl" xlink:title="label: DebtInstrumentNumberOfInstallments to ocup_DebtInstrumentNumberOfInstallments_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_DebtInstrumentNumberOfInstallments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_DebtInstrumentNumberOfInstallments_lbl1" xml:lang="en-US" id="ocup_DebtInstrumentNumberOfInstallments_lbl1">Debt Instrument, Number of Installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfInstallments" xlink:to="ocup_DebtInstrumentNumberOfInstallments_lbl1" xlink:title="label: DebtInstrumentNumberOfInstallments to ocup_DebtInstrumentNumberOfInstallments_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_DebtInstrumentNumberOfInstallments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_DebtInstrumentNumberOfInstallments_lbl2" xml:lang="en-US" id="ocup_DebtInstrumentNumberOfInstallments_lbl2">Number of installments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNumberOfInstallments" xlink:to="ocup_DebtInstrumentNumberOfInstallments_lbl2" xlink:title="label: DebtInstrumentNumberOfInstallments to ocup_DebtInstrumentNumberOfInstallments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShortTermLoanMember" xlink:label="ShortTermLoanMember" xlink:title="ShortTermLoanMember" />
    <link:label xlink:type="resource" xlink:label="ocup_ShortTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ShortTermLoanMember_lbl" xml:lang="en-US" id="ocup_ShortTermLoanMember_lbl">Short term borrowing supported by a written promise to pay an obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLoanMember" xlink:to="ocup_ShortTermLoanMember_lbl" xlink:title="label: ShortTermLoanMember to ocup_ShortTermLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ShortTermLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ShortTermLoanMember_lbl1" xml:lang="en-US" id="ocup_ShortTermLoanMember_lbl1">Short-term Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLoanMember" xlink:to="ocup_ShortTermLoanMember_lbl1" xlink:title="label: ShortTermLoanMember to ocup_ShortTermLoanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ShortTermLoanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ShortTermLoanMember_lbl2" xml:lang="en-US" id="ocup_ShortTermLoanMember_lbl2">Short-term Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLoanMember" xlink:to="ocup_ShortTermLoanMember_lbl2" xlink:title="label: ShortTermLoanMember to ocup_ShortTermLoanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncrementalCommonSharesAttributableToOptions" xlink:label="IncrementalCommonSharesAttributableToOptions" xlink:title="IncrementalCommonSharesAttributableToOptions" />
    <link:label xlink:type="resource" xlink:label="ocup_IncrementalCommonSharesAttributableToOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_IncrementalCommonSharesAttributableToOptions_lbl" xml:lang="en-US" id="ocup_IncrementalCommonSharesAttributableToOptions_lbl">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of options using the treasury stock method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToOptions" xlink:to="ocup_IncrementalCommonSharesAttributableToOptions_lbl" xlink:title="label: IncrementalCommonSharesAttributableToOptions to ocup_IncrementalCommonSharesAttributableToOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_IncrementalCommonSharesAttributableToOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_IncrementalCommonSharesAttributableToOptions_lbl1" xml:lang="en-US" id="ocup_IncrementalCommonSharesAttributableToOptions_lbl1">Incremental Common Shares Attributable To Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToOptions" xlink:to="ocup_IncrementalCommonSharesAttributableToOptions_lbl1" xlink:title="label: IncrementalCommonSharesAttributableToOptions to ocup_IncrementalCommonSharesAttributableToOptions_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_IncrementalCommonSharesAttributableToOptions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_IncrementalCommonSharesAttributableToOptions_lbl2" xml:lang="en-US" id="ocup_IncrementalCommonSharesAttributableToOptions_lbl2">Dilutive stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToOptions" xlink:to="ocup_IncrementalCommonSharesAttributableToOptions_lbl2" xlink:title="label: IncrementalCommonSharesAttributableToOptions to ocup_IncrementalCommonSharesAttributableToOptions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncrementalCommonSharesAttributableToWarrants" xlink:label="IncrementalCommonSharesAttributableToWarrants" xlink:title="IncrementalCommonSharesAttributableToWarrants" />
    <link:label xlink:type="resource" xlink:label="ocup_IncrementalCommonSharesAttributableToWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_IncrementalCommonSharesAttributableToWarrants_lbl" xml:lang="en-US" id="ocup_IncrementalCommonSharesAttributableToWarrants_lbl">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of warrants using the treasury stock method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToWarrants" xlink:to="ocup_IncrementalCommonSharesAttributableToWarrants_lbl" xlink:title="label: IncrementalCommonSharesAttributableToWarrants to ocup_IncrementalCommonSharesAttributableToWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_IncrementalCommonSharesAttributableToWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_IncrementalCommonSharesAttributableToWarrants_lbl1" xml:lang="en-US" id="ocup_IncrementalCommonSharesAttributableToWarrants_lbl1">Incremental Common Shares Attributable To Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToWarrants" xlink:to="ocup_IncrementalCommonSharesAttributableToWarrants_lbl1" xlink:title="label: IncrementalCommonSharesAttributableToWarrants to ocup_IncrementalCommonSharesAttributableToWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_IncrementalCommonSharesAttributableToWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_IncrementalCommonSharesAttributableToWarrants_lbl2" xml:lang="en-US" id="ocup_IncrementalCommonSharesAttributableToWarrants_lbl2">Dilutive warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToWarrants" xlink:to="ocup_IncrementalCommonSharesAttributableToWarrants_lbl2" xlink:title="label: IncrementalCommonSharesAttributableToWarrants to ocup_IncrementalCommonSharesAttributableToWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NonRefundableUpfrontPaymentReceived" xlink:label="NonRefundableUpfrontPaymentReceived" xlink:title="NonRefundableUpfrontPaymentReceived" />
    <link:label xlink:type="resource" xlink:label="ocup_NonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NonRefundableUpfrontPaymentReceived_lbl" xml:lang="en-US" id="ocup_NonRefundableUpfrontPaymentReceived_lbl">The amount of non-refundable upfront payment received under the license and collaboration agreement with FamyGen Life Sciences, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableUpfrontPaymentReceived" xlink:to="ocup_NonRefundableUpfrontPaymentReceived_lbl" xlink:title="label: NonRefundableUpfrontPaymentReceived to ocup_NonRefundableUpfrontPaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NonRefundableUpfrontPaymentReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NonRefundableUpfrontPaymentReceived_lbl1" xml:lang="en-US" id="ocup_NonRefundableUpfrontPaymentReceived_lbl1">Non-Refundable Upfront Payment Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableUpfrontPaymentReceived" xlink:to="ocup_NonRefundableUpfrontPaymentReceived_lbl1" xlink:title="label: NonRefundableUpfrontPaymentReceived to ocup_NonRefundableUpfrontPaymentReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NonRefundableUpfrontPaymentReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NonRefundableUpfrontPaymentReceived_lbl2" xml:lang="en-US" id="ocup_NonRefundableUpfrontPaymentReceived_lbl2">Non-refundable upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableUpfrontPaymentReceived" xlink:to="ocup_NonRefundableUpfrontPaymentReceived_lbl2" xlink:title="label: NonRefundableUpfrontPaymentReceived to ocup_NonRefundableUpfrontPaymentReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_LiquidityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_LiquidityAbstract_lbl1" xml:lang="en-US" id="ocup_LiquidityAbstract_lbl1">Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAbstract" xlink:to="ocup_LiquidityAbstract_lbl1" xlink:title="label: LiquidityAbstract to ocup_LiquidityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_LiquidityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_LiquidityAbstract_lbl2" xml:lang="en-US" id="ocup_LiquidityAbstract_lbl2">Liquidity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiquidityAbstract" xlink:to="ocup_LiquidityAbstract_lbl2" xlink:title="label: LiquidityAbstract to ocup_LiquidityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityInvestmentMember" xlink:label="EquityInvestmentMember" xlink:title="EquityInvestmentMember" />
    <link:label xlink:type="resource" xlink:label="ocup_EquityInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_EquityInvestmentMember_lbl" xml:lang="en-US" id="ocup_EquityInvestmentMember_lbl">Equity investment means purchasing stake in a business and receiving partial ownership in it.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityInvestmentMember" xlink:to="ocup_EquityInvestmentMember_lbl" xlink:title="label: EquityInvestmentMember to ocup_EquityInvestmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_EquityInvestmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_EquityInvestmentMember_lbl1" xml:lang="en-US" id="ocup_EquityInvestmentMember_lbl1">Equity Investment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityInvestmentMember" xlink:to="ocup_EquityInvestmentMember_lbl1" xlink:title="label: EquityInvestmentMember to ocup_EquityInvestmentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingMember" xlink:label="PreMergerFinancingMember" xlink:title="PreMergerFinancingMember" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_PreMergerFinancingMember_lbl" xml:lang="en-US" id="ocup_PreMergerFinancingMember_lbl">Pre-Merger Financing with directors of Ocuphire and Rexahn.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingMember" xlink:to="ocup_PreMergerFinancingMember_lbl" xlink:title="label: PreMergerFinancingMember to ocup_PreMergerFinancingMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PreMergerFinancingMember_lbl1" xml:lang="en-US" id="ocup_PreMergerFinancingMember_lbl1">Pre-Merger Financing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingMember" xlink:to="ocup_PreMergerFinancingMember_lbl1" xlink:title="label: PreMergerFinancingMember to ocup_PreMergerFinancingMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingAndWaiverAgreementsAbstract" xlink:label="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:title="PreMergerFinancingAndWaiverAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_PreMergerFinancingAndWaiverAgreementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_PreMergerFinancingAndWaiverAgreementsAbstract_lbl1" xml:lang="en-US" id="ocup_PreMergerFinancingAndWaiverAgreementsAbstract_lbl1">Pre-Merger Financing and Waiver Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="ocup_PreMergerFinancingAndWaiverAgreementsAbstract_lbl1" xlink:title="label: PreMergerFinancingAndWaiverAgreementsAbstract to ocup_PreMergerFinancingAndWaiverAgreementsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:label="NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:title="NumberOfConvertedAdditionalSharesReceivedByDirectors" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl" xml:lang="en-US" id="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl">The number of converted additional shares received by directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:to="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl" xlink:title="label: NumberOfConvertedAdditionalSharesReceivedByDirectors to ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl1" xml:lang="en-US" id="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl1">Number of Converted Additional Shares Received by Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:to="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl1" xlink:title="label: NumberOfConvertedAdditionalSharesReceivedByDirectors to ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl2" xml:lang="en-US" id="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl2">Number of converted additional shares (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:to="ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl2" xlink:title="label: NumberOfConvertedAdditionalSharesReceivedByDirectors to ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfDirectorsSignedWaiverAgreements" xlink:label="NumberOfDirectorsSignedWaiverAgreements" xlink:title="NumberOfDirectorsSignedWaiverAgreements" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl" xml:lang="en-US" id="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl">This element represents number of directors signed waiver agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsSignedWaiverAgreements" xlink:to="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl" xlink:title="label: NumberOfDirectorsSignedWaiverAgreements to ocup_NumberOfDirectorsSignedWaiverAgreements_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl1" xml:lang="en-US" id="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl1">Number of Directors Signed Waiver Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsSignedWaiverAgreements" xlink:to="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl1" xlink:title="label: NumberOfDirectorsSignedWaiverAgreements to ocup_NumberOfDirectorsSignedWaiverAgreements_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl2" xml:lang="en-US" id="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl2">Number of directors signed waiver agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectorsSignedWaiverAgreements" xlink:to="ocup_NumberOfDirectorsSignedWaiverAgreements_lbl2" xlink:title="label: NumberOfDirectorsSignedWaiverAgreements to ocup_NumberOfDirectorsSignedWaiverAgreements_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AmountInvestedInPreMergerFinancing" xlink:label="AmountInvestedInPreMergerFinancing" xlink:title="AmountInvestedInPreMergerFinancing" />
    <link:label xlink:type="resource" xlink:label="ocup_AmountInvestedInPreMergerFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_AmountInvestedInPreMergerFinancing_lbl" xml:lang="en-US" id="ocup_AmountInvestedInPreMergerFinancing_lbl">Amount invested by directors in Pre-Merger Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountInvestedInPreMergerFinancing" xlink:to="ocup_AmountInvestedInPreMergerFinancing_lbl" xlink:title="label: AmountInvestedInPreMergerFinancing to ocup_AmountInvestedInPreMergerFinancing_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_AmountInvestedInPreMergerFinancing_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_AmountInvestedInPreMergerFinancing_lbl1" xml:lang="en-US" id="ocup_AmountInvestedInPreMergerFinancing_lbl1">Amount Invested in Pre-Merger Financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountInvestedInPreMergerFinancing" xlink:to="ocup_AmountInvestedInPreMergerFinancing_lbl1" xlink:title="label: AmountInvestedInPreMergerFinancing to ocup_AmountInvestedInPreMergerFinancing_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_AmountInvestedInPreMergerFinancing_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_AmountInvestedInPreMergerFinancing_lbl2" xml:lang="en-US" id="ocup_AmountInvestedInPreMergerFinancing_lbl2">Amount invested in pre-merger financing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmountInvestedInPreMergerFinancing" xlink:to="ocup_AmountInvestedInPreMergerFinancing_lbl2" xlink:title="label: AmountInvestedInPreMergerFinancing to ocup_AmountInvestedInPreMergerFinancing_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ConsultingFeePayable" xlink:label="ConsultingFeePayable" xlink:title="ConsultingFeePayable" />
    <link:label xlink:type="resource" xlink:label="ocup_ConsultingFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ConsultingFeePayable_lbl" xml:lang="en-US" id="ocup_ConsultingFeePayable_lbl">The amount of consultation fee payable in cash per month to the director.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsultingFeePayable" xlink:to="ocup_ConsultingFeePayable_lbl" xlink:title="label: ConsultingFeePayable to ocup_ConsultingFeePayable_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ConsultingFeePayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ConsultingFeePayable_lbl1" xml:lang="en-US" id="ocup_ConsultingFeePayable_lbl1">Consulting Fee Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsultingFeePayable" xlink:to="ocup_ConsultingFeePayable_lbl1" xlink:title="label: ConsultingFeePayable to ocup_ConsultingFeePayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ConsultingFeePayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ConsultingFeePayable_lbl2" xml:lang="en-US" id="ocup_ConsultingFeePayable_lbl2">Consulting fee payable in cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsultingFeePayable" xlink:to="ocup_ConsultingFeePayable_lbl2" xlink:title="label: ConsultingFeePayable to ocup_ConsultingFeePayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfConvertedInitialSharesReceivedByDirectors" xlink:label="NumberOfConvertedInitialSharesReceivedByDirectors" xlink:title="NumberOfConvertedInitialSharesReceivedByDirectors" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl" xml:lang="en-US" id="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl">The number of converted initial shares received by directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConvertedInitialSharesReceivedByDirectors" xlink:to="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl" xlink:title="label: NumberOfConvertedInitialSharesReceivedByDirectors to ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl1" xml:lang="en-US" id="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl1">Number of Converted Initial Shares Received by Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConvertedInitialSharesReceivedByDirectors" xlink:to="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl1" xlink:title="label: NumberOfConvertedInitialSharesReceivedByDirectors to ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl2" xml:lang="en-US" id="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl2">Number of converted initial shares received by directors (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfConvertedInitialSharesReceivedByDirectors" xlink:to="ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl2" xlink:title="label: NumberOfConvertedInitialSharesReceivedByDirectors to ocup_NumberOfConvertedInitialSharesReceivedByDirectors_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SubsequentEventsAdditionalInformationAbstract" xlink:label="SubsequentEventsAdditionalInformationAbstract" xlink:title="SubsequentEventsAdditionalInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_SubsequentEventsAdditionalInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_SubsequentEventsAdditionalInformationAbstract_lbl1" xml:lang="en-US" id="ocup_SubsequentEventsAdditionalInformationAbstract_lbl1">Subsequent Events, Additional Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAdditionalInformationAbstract" xlink:to="ocup_SubsequentEventsAdditionalInformationAbstract_lbl1" xlink:title="label: SubsequentEventsAdditionalInformationAbstract to ocup_SubsequentEventsAdditionalInformationAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_SubsequentEventsAdditionalInformationAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_SubsequentEventsAdditionalInformationAbstract_lbl2" xml:lang="en-US" id="ocup_SubsequentEventsAdditionalInformationAbstract_lbl2">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAdditionalInformationAbstract" xlink:to="ocup_SubsequentEventsAdditionalInformationAbstract_lbl2" xlink:title="label: SubsequentEventsAdditionalInformationAbstract to ocup_SubsequentEventsAdditionalInformationAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:label="AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:title="AggregateNumberOfCommonStockReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl" xml:lang="en-US" id="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl">Aggregate number of common shares reserved for future issuance" given the addition added to reserve due to Evergreen provision.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:to="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl" xlink:title="label: AggregateNumberOfCommonStockReservedForFutureIssuance to ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl1" xml:lang="en-US" id="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl1">Aggregate Number of Common Stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:to="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl1" xlink:title="label: AggregateNumberOfCommonStockReservedForFutureIssuance to ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl2" xml:lang="en-US" id="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl2">Number of shares added (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:to="ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl2" xlink:title="label: AggregateNumberOfCommonStockReservedForFutureIssuance to ocup_AggregateNumberOfCommonStockReservedForFutureIssuance_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EvergreenProvisionPlan2020Member" xlink:label="EvergreenProvisionPlan2020Member" xlink:title="EvergreenProvisionPlan2020Member" />
    <link:label xlink:type="resource" xlink:label="ocup_EvergreenProvisionPlan2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_EvergreenProvisionPlan2020Member_lbl" xml:lang="en-US" id="ocup_EvergreenProvisionPlan2020Member_lbl">Information related to 2020 Plan Evergreen Provision.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EvergreenProvisionPlan2020Member" xlink:to="ocup_EvergreenProvisionPlan2020Member_lbl" xlink:title="label: EvergreenProvisionPlan2020Member to ocup_EvergreenProvisionPlan2020Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_EvergreenProvisionPlan2020Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_EvergreenProvisionPlan2020Member_lbl1" xml:lang="en-US" id="ocup_EvergreenProvisionPlan2020Member_lbl1">Evergreen Provision Plan 2020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EvergreenProvisionPlan2020Member" xlink:to="ocup_EvergreenProvisionPlan2020Member_lbl1" xlink:title="label: EvergreenProvisionPlan2020Member to ocup_EvergreenProvisionPlan2020Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_EvergreenProvisionPlan2020Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_EvergreenProvisionPlan2020Member_lbl2" xml:lang="en-US" id="ocup_EvergreenProvisionPlan2020Member_lbl2">2020 Plan Evergreen Provision [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EvergreenProvisionPlan2020Member" xlink:to="ocup_EvergreenProvisionPlan2020Member_lbl2" xlink:title="label: EvergreenProvisionPlan2020Member to ocup_EvergreenProvisionPlan2020Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ApexianSublicenseAgreementAbstract" xlink:label="ApexianSublicenseAgreementAbstract" xlink:title="ApexianSublicenseAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_ApexianSublicenseAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ApexianSublicenseAgreementAbstract_lbl1" xml:lang="en-US" id="ocup_ApexianSublicenseAgreementAbstract_lbl1">Apexian Sublicense Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApexianSublicenseAgreementAbstract" xlink:to="ocup_ApexianSublicenseAgreementAbstract_lbl1" xlink:title="label: ApexianSublicenseAgreementAbstract to ocup_ApexianSublicenseAgreementAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ApexianSublicenseAgreementTextBlock" xlink:label="ApexianSublicenseAgreementTextBlock" xlink:title="ApexianSublicenseAgreementTextBlock" />
    <link:label xlink:type="resource" xlink:label="ocup_ApexianSublicenseAgreementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ApexianSublicenseAgreementTextBlock_lbl" xml:lang="en-US" id="ocup_ApexianSublicenseAgreementTextBlock_lbl">The entire disclosure for Apexian Sublicense Agreement related to exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApexianSublicenseAgreementTextBlock" xlink:to="ocup_ApexianSublicenseAgreementTextBlock_lbl" xlink:title="label: ApexianSublicenseAgreementTextBlock to ocup_ApexianSublicenseAgreementTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ApexianSublicenseAgreementTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ApexianSublicenseAgreementTextBlock_lbl1" xml:lang="en-US" id="ocup_ApexianSublicenseAgreementTextBlock_lbl1">Apexian Sublicense Agreement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApexianSublicenseAgreementTextBlock" xlink:to="ocup_ApexianSublicenseAgreementTextBlock_lbl1" xlink:title="label: ApexianSublicenseAgreementTextBlock to ocup_ApexianSublicenseAgreementTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ApexianSublicenseAgreementTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ApexianSublicenseAgreementTextBlock_lbl2" xml:lang="en-US" id="ocup_ApexianSublicenseAgreementTextBlock_lbl2">Apexian Sublicense Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApexianSublicenseAgreementTextBlock" xlink:to="ocup_ApexianSublicenseAgreementTextBlock_lbl2" xlink:title="label: ApexianSublicenseAgreementTextBlock to ocup_ApexianSublicenseAgreementTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DevelopmentAndRegulatoryMilestonesMember" xlink:label="DevelopmentAndRegulatoryMilestonesMember" xlink:title="DevelopmentAndRegulatoryMilestonesMember" />
    <link:label xlink:type="resource" xlink:label="ocup_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_DevelopmentAndRegulatoryMilestonesMember_lbl" xml:lang="en-US" id="ocup_DevelopmentAndRegulatoryMilestonesMember_lbl">Represents development and regulatory milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentAndRegulatoryMilestonesMember" xlink:to="ocup_DevelopmentAndRegulatoryMilestonesMember_lbl" xlink:title="label: DevelopmentAndRegulatoryMilestonesMember to ocup_DevelopmentAndRegulatoryMilestonesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_DevelopmentAndRegulatoryMilestonesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_DevelopmentAndRegulatoryMilestonesMember_lbl1" xml:lang="en-US" id="ocup_DevelopmentAndRegulatoryMilestonesMember_lbl1">Development and Regulatory Milestones [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DevelopmentAndRegulatoryMilestonesMember" xlink:to="ocup_DevelopmentAndRegulatoryMilestonesMember_lbl1" xlink:title="label: DevelopmentAndRegulatoryMilestonesMember to ocup_DevelopmentAndRegulatoryMilestonesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SalesMilestonesMember" xlink:label="SalesMilestonesMember" xlink:title="SalesMilestonesMember" />
    <link:label xlink:type="resource" xlink:label="ocup_SalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_SalesMilestonesMember_lbl" xml:lang="en-US" id="ocup_SalesMilestonesMember_lbl">Represents sales milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesMilestonesMember" xlink:to="ocup_SalesMilestonesMember_lbl" xlink:title="label: SalesMilestonesMember to ocup_SalesMilestonesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_SalesMilestonesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_SalesMilestonesMember_lbl1" xml:lang="en-US" id="ocup_SalesMilestonesMember_lbl1">Sales Milestones [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesMilestonesMember" xlink:to="ocup_SalesMilestonesMember_lbl1" xlink:title="label: SalesMilestonesMember to ocup_SalesMilestonesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ApexianSublicenseAgreementMember" xlink:label="ApexianSublicenseAgreementMember" xlink:title="ApexianSublicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="ocup_ApexianSublicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_ApexianSublicenseAgreementMember_lbl" xml:lang="en-US" id="ocup_ApexianSublicenseAgreementMember_lbl">Sublicense agreement with Apexian Pharmaceuticals, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApexianSublicenseAgreementMember" xlink:to="ocup_ApexianSublicenseAgreementMember_lbl" xlink:title="label: ApexianSublicenseAgreementMember to ocup_ApexianSublicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_ApexianSublicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_ApexianSublicenseAgreementMember_lbl1" xml:lang="en-US" id="ocup_ApexianSublicenseAgreementMember_lbl1">Apexian Sublicense Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApexianSublicenseAgreementMember" xlink:to="ocup_ApexianSublicenseAgreementMember_lbl1" xlink:title="label: ApexianSublicenseAgreementMember to ocup_ApexianSublicenseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_ApexianSublicenseAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_ApexianSublicenseAgreementMember_lbl2" xml:lang="en-US" id="ocup_ApexianSublicenseAgreementMember_lbl2">Apexian Sublicense Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ApexianSublicenseAgreementMember" xlink:to="ocup_ApexianSublicenseAgreementMember_lbl2" xlink:title="label: ApexianSublicenseAgreementMember to ocup_ApexianSublicenseAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SublicenseAgreementAbstract" xlink:label="SublicenseAgreementAbstract" xlink:title="SublicenseAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="ocup_SublicenseAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_SublicenseAgreementAbstract_lbl1" xml:lang="en-US" id="ocup_SublicenseAgreementAbstract_lbl1">Sublicense Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SublicenseAgreementAbstract" xlink:to="ocup_SublicenseAgreementAbstract_lbl1" xlink:title="label: SublicenseAgreementAbstract to ocup_SublicenseAgreementAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_SublicenseAgreementAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_SublicenseAgreementAbstract_lbl2" xml:lang="en-US" id="ocup_SublicenseAgreementAbstract_lbl2">Sublicense Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SublicenseAgreementAbstract" xlink:to="ocup_SublicenseAgreementAbstract_lbl2" xlink:title="label: SublicenseAgreementAbstract to ocup_SublicenseAgreementAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FutureMilestoneMethodRevenueNotRecognized" xlink:label="FutureMilestoneMethodRevenueNotRecognized" xlink:title="FutureMilestoneMethodRevenueNotRecognized" />
    <link:label xlink:type="resource" xlink:label="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl" xml:lang="en-US" id="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl">The amount of consideration not recognized during the period for the future milestone or milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureMilestoneMethodRevenueNotRecognized" xlink:to="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl" xlink:title="label: FutureMilestoneMethodRevenueNotRecognized to ocup_FutureMilestoneMethodRevenueNotRecognized_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl1" xml:lang="en-US" id="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl1">Future Milestone Method, Revenue not Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureMilestoneMethodRevenueNotRecognized" xlink:to="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl1" xlink:title="label: FutureMilestoneMethodRevenueNotRecognized to ocup_FutureMilestoneMethodRevenueNotRecognized_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl2" xml:lang="en-US" id="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl2">Milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FutureMilestoneMethodRevenueNotRecognized" xlink:to="ocup_FutureMilestoneMethodRevenueNotRecognized_lbl2" xlink:title="label: FutureMilestoneMethodRevenueNotRecognized to ocup_FutureMilestoneMethodRevenueNotRecognized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesASeriesBAndRDOWarrantsMember" xlink:label="SeriesASeriesBAndRDOWarrantsMember" xlink:title="SeriesASeriesBAndRDOWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl" xml:lang="en-US" id="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl">A classification of Information by type of warrant or right issued, for example Series A Warrants, Series B Warrants and RDO warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesASeriesBAndRDOWarrantsMember" xlink:to="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl" xlink:title="label: SeriesASeriesBAndRDOWarrantsMember to ocup_SeriesASeriesBAndRDOWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl1" xml:lang="en-US" id="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl1">Series A, Series B and RDO Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesASeriesBAndRDOWarrantsMember" xlink:to="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl1" xlink:title="label: SeriesASeriesBAndRDOWarrantsMember to ocup_SeriesASeriesBAndRDOWarrantsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl2" xml:lang="en-US" id="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl2">Series A, Series B and RDO Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesASeriesBAndRDOWarrantsMember" xlink:to="ocup_SeriesASeriesBAndRDOWarrantsMember_lbl2" xlink:title="label: SeriesASeriesBAndRDOWarrantsMember to ocup_SeriesASeriesBAndRDOWarrantsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerRexahnWarrantsMember" xlink:label="FormerRexahnWarrantsMember" xlink:title="FormerRexahnWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="ocup_FormerRexahnWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_FormerRexahnWarrantsMember_lbl" xml:lang="en-US" id="ocup_FormerRexahnWarrantsMember_lbl">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount that are formerly Rexahn Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerRexahnWarrantsMember" xlink:to="ocup_FormerRexahnWarrantsMember_lbl" xlink:title="label: FormerRexahnWarrantsMember to ocup_FormerRexahnWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_FormerRexahnWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_FormerRexahnWarrantsMember_lbl1" xml:lang="en-US" id="ocup_FormerRexahnWarrantsMember_lbl1">Former Rexahn Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerRexahnWarrantsMember" xlink:to="ocup_FormerRexahnWarrantsMember_lbl1" xlink:title="label: FormerRexahnWarrantsMember to ocup_FormerRexahnWarrantsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerRexahnOptionsMember" xlink:label="FormerRexahnOptionsMember" xlink:title="FormerRexahnOptionsMember" />
    <link:label xlink:type="resource" xlink:label="ocup_FormerRexahnOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_FormerRexahnOptionsMember_lbl" xml:lang="en-US" id="ocup_FormerRexahnOptionsMember_lbl">Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time that are formerly Rexahn options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerRexahnOptionsMember" xlink:to="ocup_FormerRexahnOptionsMember_lbl" xlink:title="label: FormerRexahnOptionsMember to ocup_FormerRexahnOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_FormerRexahnOptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_FormerRexahnOptionsMember_lbl1" xml:lang="en-US" id="ocup_FormerRexahnOptionsMember_lbl1">Former Rexahn Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FormerRexahnOptionsMember" xlink:to="ocup_FormerRexahnOptionsMember_lbl1" xlink:title="label: FormerRexahnOptionsMember to ocup_FormerRexahnOptionsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect" xlink:label="StateAndLocalOperatingLossCarryforwardsTaxEffect" xlink:title="StateAndLocalOperatingLossCarryforwardsTaxEffect" />
    <link:label xlink:type="resource" xlink:label="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl" xml:lang="en-US" id="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl">Amount of the related state and local income tax effect on operating loss carry forward.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalOperatingLossCarryforwardsTaxEffect" xlink:to="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl" xlink:title="label: StateAndLocalOperatingLossCarryforwardsTaxEffect to ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl1" xml:lang="en-US" id="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl1">State And Local Operating Loss Carryforwards Tax Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalOperatingLossCarryforwardsTaxEffect" xlink:to="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl1" xlink:title="label: StateAndLocalOperatingLossCarryforwardsTaxEffect to ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl2" xml:lang="en-US" id="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl2">State operating loss carryforwards, tax effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalOperatingLossCarryforwardsTaxEffect" xlink:to="ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl2" xlink:title="label: StateAndLocalOperatingLossCarryforwardsTaxEffect to ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FederalOperatingLossCarryforwardsTaxEffect" xlink:label="FederalOperatingLossCarryforwardsTaxEffect" xlink:title="FederalOperatingLossCarryforwardsTaxEffect" />
    <link:label xlink:type="resource" xlink:label="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl" xml:lang="en-US" id="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl">Amount of the related federal income tax effect on operating loss carry forward.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalOperatingLossCarryforwardsTaxEffect" xlink:to="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl" xlink:title="label: FederalOperatingLossCarryforwardsTaxEffect to ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl1" xml:lang="en-US" id="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl1">Federal Operating Loss Carryforwards, Tax effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalOperatingLossCarryforwardsTaxEffect" xlink:to="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl1" xlink:title="label: FederalOperatingLossCarryforwardsTaxEffect to ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl2" xml:lang="en-US" id="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl2">Federal operating loss carryforwards, tax effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalOperatingLossCarryforwardsTaxEffect" xlink:to="ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl2" xlink:title="label: FederalOperatingLossCarryforwardsTaxEffect to ocup_FederalOperatingLossCarryforwardsTaxEffect_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_UtilizedFederalResearchCreditCarryforwards" xlink:label="UtilizedFederalResearchCreditCarryforwards" xlink:title="UtilizedFederalResearchCreditCarryforwards" />
    <link:label xlink:type="resource" xlink:label="ocup_UtilizedFederalResearchCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_UtilizedFederalResearchCreditCarryforwards_lbl" xml:lang="en-US" id="ocup_UtilizedFederalResearchCreditCarryforwards_lbl">Amount of the federal research credit carryforwards Utilized during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UtilizedFederalResearchCreditCarryforwards" xlink:to="ocup_UtilizedFederalResearchCreditCarryforwards_lbl" xlink:title="label: UtilizedFederalResearchCreditCarryforwards to ocup_UtilizedFederalResearchCreditCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_UtilizedFederalResearchCreditCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_UtilizedFederalResearchCreditCarryforwards_lbl1" xml:lang="en-US" id="ocup_UtilizedFederalResearchCreditCarryforwards_lbl1">Utilized Federal Research Credit Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UtilizedFederalResearchCreditCarryforwards" xlink:to="ocup_UtilizedFederalResearchCreditCarryforwards_lbl1" xlink:title="label: UtilizedFederalResearchCreditCarryforwards to ocup_UtilizedFederalResearchCreditCarryforwards_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_UtilizedFederalResearchCreditCarryforwards_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_UtilizedFederalResearchCreditCarryforwards_lbl2" xml:lang="en-US" id="ocup_UtilizedFederalResearchCreditCarryforwards_lbl2">Utilized federal research credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UtilizedFederalResearchCreditCarryforwards" xlink:to="ocup_UtilizedFederalResearchCreditCarryforwards_lbl2" xlink:title="label: UtilizedFederalResearchCreditCarryforwards to ocup_UtilizedFederalResearchCreditCarryforwards_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" />
    <link:label xlink:type="resource" xlink:label="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl" xml:lang="en-US" id="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit state and local operating loss carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:to="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal to ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl" />
    <link:label xlink:type="resource" xlink:label="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl1" xml:lang="en-US" id="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl1">Deferred Tax Assets Tax Credit Carryforwards Research, State,and,Local</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:to="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl1" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal to ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl1" />
    <link:label xlink:type="resource" xlink:label="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl2" xml:lang="en-US" id="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl2">State research credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:to="ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl2" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal to ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>ocup-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.1.5138 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://ocuphire.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SubsequentEventsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/DeferredCompensationPlanDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#DeferredCompensationPlanDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesOperatingLossCarryforwardsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockholdersEquityRegisteredDirectOfferingDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockholdersEquityAtthemarketProgramDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/ApexianSublicenseAgreementDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#ApexianSublicenseAgreementDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationFormerRexahnOptionsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationCommonStockIssuedForServicesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationRestrictedStockAwardsActivityDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationStockOptionPlanActivityDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationShorttermLoanDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationAccruedExpensesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/PremergerFinancingDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#PremergerFinancingDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#MergerFormerRexahnWarrantsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#MergerContingentValueRightsAgreementDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShareTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShareTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreementsTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#LicenseAndCollaborationAgreementsTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensationTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformationTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://ocuphire.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ocup-20221231.xsd#SubsequentEvents" />
  <link:roleRef roleURI="http://ocuphire.com/role/DeferredCompensationPlan" xlink:type="simple" xlink:href="ocup-20221231.xsd#DeferredCompensationPlan" />
  <link:roleRef roleURI="http://ocuphire.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ocup-20221231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://ocuphire.com/role/NetIncomeLossPerShare" xlink:type="simple" xlink:href="ocup-20221231.xsd#NetIncomeLossPerShare" />
  <link:roleRef roleURI="http://ocuphire.com/role/LicenseAndCollaborationAgreements" xlink:type="simple" xlink:href="ocup-20221231.xsd#LicenseAndCollaborationAgreements" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockholderEquity" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockholderEquity" />
  <link:roleRef roleURI="http://ocuphire.com/role/ApexianSublicenseAgreement" xlink:type="simple" xlink:href="ocup-20221231.xsd#ApexianSublicenseAgreement" />
  <link:roleRef roleURI="http://ocuphire.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="ocup-20221231.xsd#StockbasedCompensation" />
  <link:roleRef roleURI="http://ocuphire.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ocup-20221231.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://ocuphire.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="ocup-20221231.xsd#SupplementalBalanceSheetInformation" />
  <link:roleRef roleURI="http://ocuphire.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="ocup-20221231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://ocuphire.com/role/PremergerFinancing" xlink:type="simple" xlink:href="ocup-20221231.xsd#PremergerFinancing" />
  <link:roleRef roleURI="http://ocuphire.com/role/Merger" xlink:type="simple" xlink:href="ocup-20221231.xsd#Merger" />
  <link:roleRef roleURI="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="ocup-20221231.xsd#CompanyDescriptionAndSummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="ocup-20221231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" xlink:type="simple" xlink:href="ocup-20221231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" />
  <link:roleRef roleURI="http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ocup-20221231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://ocuphire.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="ocup-20221231.xsd#BalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://ocuphire.com/role/BalanceSheets" xlink:type="simple" xlink:href="ocup-20221231.xsd#BalanceSheets" />
  <link:roleRef roleURI="http://ocuphire.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ocup-20221231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentAnnualReport" xlink:title="presentation: CoverAbstract to DocumentAnnualReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: CoverAbstract to EntityWellKnownSeasonedIssuer" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: CoverAbstract to EntityVoluntaryFilers" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="IcfrAuditorAttestationFlag" xlink:title="presentation: CoverAbstract to IcfrAuditorAttestationFlag" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: CoverAbstract to EntityPublicFloat" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorName" xlink:title="presentation: CoverAbstract to AuditorName" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorLocation" xlink:title="presentation: CoverAbstract to AuditorLocation" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AuditorFirmId" xlink:title="presentation: CoverAbstract to AuditorFirmId" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/BalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetCurrent" xlink:label="ContractAssetCurrent" xlink:title="ContractAssetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="ContractAssetCurrent" xlink:title="presentation: AssetsCurrentAbstract to ContractAssetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="ShortTermInvestments" xlink:title="ShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="ShortTermInvestments" xlink:title="presentation: AssetsCurrentAbstract to ShortTermInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="ShortTermBorrowings" xlink:title="ShortTermBorrowings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ShortTermBorrowings" xlink:title="presentation: LiabilitiesCurrentAbstract to ShortTermBorrowings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to WarrantsAndRightsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/BalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: IncomeStatementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: OperatingExpensesAbstract to OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="InterestExpense" xlink:title="presentation: OperatingExpensesAbstract to InterestExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="presentation: OperatingExpensesAbstract to GainLossOnDerivativeInstrumentsNetPretax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: OperatingExpensesAbstract to OtherNonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: OperatingExpensesAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: OperatingExpensesAbstract to IncomeTaxExpenseBenefit" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: OperatingExpensesAbstract to OtherComprehensiveIncomeLossNetOfTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: OperatingExpensesAbstract to ComprehensiveIncomeNetOfTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:label="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:title="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:label="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:title="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:label="StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:title="StockIssuedDuringPeriodValueAtTheMarketProgram" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueAtTheMarketProgram" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueAtTheMarketProgram" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:label="StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:title="StockIssuedDuringPeriodSharesAtTheMarketProgram" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesAtTheMarketProgram" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesAtTheMarketProgram" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:label="StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:title="StockIssuedDuringPeriodValueInSettlementWithInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueInSettlementWithInvestors" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueInSettlementWithInvestors" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:label="StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:title="StockIssuedDuringPeriodSharesInSettlementWithInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesInSettlementWithInvestors" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesInSettlementWithInvestors" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:label="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:title="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueStockExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockExerciseOfWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockExerciseOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesExerciseOfWarrants" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesShareBasedCompensation" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDerivativeInstrumentsNetPretax" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareSettlementWithInvestors" xlink:label="ShareSettlementWithInvestors" xlink:title="ShareSettlementWithInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareSettlementWithInvestors" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareSettlementWithInvestors" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:label="IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:title="IncomeLossFromInvestmentsRelatedToLicenseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncomeLossFromInvestmentsRelatedToLicenseAgreement" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncomeLossFromInvestmentsRelatedToLicenseAgreement" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="UnrealizedGainLossOnInvestments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to UnrealizedGainLossOnInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncreaseDecreaseInContractAssetCurrent" xlink:label="IncreaseDecreaseInContractAssetCurrent" xlink:title="IncreaseDecreaseInContractAssetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInContractAssetCurrent" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInContractAssetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="OtherPaymentsToAcquireBusinesses" xlink:title="OtherPaymentsToAcquireBusinesses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="OtherPaymentsToAcquireBusinesses" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to OtherPaymentsToAcquireBusinesses" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfStockIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="ProceedsFromShortTermDebt" xlink:title="ProceedsFromShortTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromShortTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromShortTermDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="RepaymentsOfShortTermDebt" xlink:title="RepaymentsOfShortTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfShortTermDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfShortTermDebt" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="IncomeTaxesPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to IncomeTaxesPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" xlink:label="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" xlink:title="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:label="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/Merger">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="BusinessCombinationDisclosureTextBlock" xlink:title="BusinessCombinationDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="BusinessCombinationDisclosureTextBlock" xlink:title="presentation: BusinessCombinationsAbstract to BusinessCombinationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/PremergerFinancing">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingAbstract" xlink:label="PreMergerFinancingAbstract" xlink:title="PreMergerFinancingAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingTextBlock" xlink:label="PreMergerFinancingTextBlock" xlink:title="PreMergerFinancingTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAbstract" xlink:to="PreMergerFinancingTextBlock" xlink:title="presentation: PreMergerFinancingAbstract to PreMergerFinancingTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformation">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SupplementalBalanceSheetInformationAbstract" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:title="SupplementalBalanceSheetInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="SupplementalBalanceSheetDisclosuresTextBlock" xlink:title="presentation: SupplementalBalanceSheetInformationAbstract to SupplementalBalanceSheetDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/RelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ApexianSublicenseAgreement">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ApexianSublicenseAgreementAbstract" xlink:label="ApexianSublicenseAgreementAbstract" xlink:title="ApexianSublicenseAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ApexianSublicenseAgreementTextBlock" xlink:label="ApexianSublicenseAgreementTextBlock" xlink:title="ApexianSublicenseAgreementTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApexianSublicenseAgreementAbstract" xlink:to="ApexianSublicenseAgreementTextBlock" xlink:title="presentation: ApexianSublicenseAgreementAbstract to ApexianSublicenseAgreementTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockholderEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/LicenseAndCollaborationAgreements">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LicenseAndCollaborationAgreementsAbstract" xlink:label="LicenseAndCollaborationAgreementsAbstract" xlink:title="LicenseAndCollaborationAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAndCollaborationAgreementsAbstract" xlink:to="CollaborativeArrangementDisclosureTextBlock" xlink:title="presentation: LicenseAndCollaborationAgreementsAbstract to CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShare">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="EarningsPerShareTextBlock" xlink:title="EarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/DeferredCompensationPlan">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SubsequentEvents">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NatureOfBusinessPolicyTextBlock" xlink:label="NatureOfBusinessPolicyTextBlock" xlink:title="NatureOfBusinessPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureOfBusinessPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NatureOfBusinessPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="BusinessCombinationsPolicy" xlink:title="BusinessCombinationsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="BusinessCombinationsPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to BusinessCombinationsPolicy" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LiquidityPolicyTextBlock" xlink:label="LiquidityPolicyTextBlock" xlink:title="LiquidityPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="LiquidityPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to LiquidityPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to UseOfEstimates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SegmentReportingPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SegmentReportingPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to CashAndCashEquivalentsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConcentrationRiskCreditRisk" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="InvestmentPolicyTextBlock" xlink:title="InvestmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="InvestmentPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to InvestmentPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to RevenueFromContractWithCustomerPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetPolicyTextBlock" xlink:label="ContractAssetPolicyTextBlock" xlink:title="ContractAssetPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ContractAssetPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ContractAssetPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:title="ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ResearchAndDevelopmentExpensePolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_OtherIncomeExpenseNetPolicyTextBlock" xlink:label="OtherIncomeExpenseNetPolicyTextBlock" xlink:title="OtherIncomeExpenseNetPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OtherIncomeExpenseNetPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OtherIncomeExpenseNetPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WarrantLiabilitiesPolicyTextBlock" xlink:label="WarrantLiabilitiesPolicyTextBlock" xlink:title="WarrantLiabilitiesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="WarrantLiabilitiesPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to WarrantLiabilitiesPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueMeasurementPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to IncomeTaxPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:title="FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" xlink:label="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" xlink:title="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationTables">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SupplementalBalanceSheetInformationAbstract" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:title="SupplementalBalanceSheetInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:title="presentation: SupplementalBalanceSheetInformationAbstract to DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: SupplementalBalanceSheetInformationAbstract to PropertyPlantAndEquipmentTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: SupplementalBalanceSheetInformationAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/LicenseAndCollaborationAgreementsTables">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LicenseAndCollaborationAgreementsAbstract" xlink:label="LicenseAndCollaborationAgreementsAbstract" xlink:title="LicenseAndCollaborationAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" xlink:label="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" xlink:title="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAndCollaborationAgreementsAbstract" xlink:to="ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" xlink:title="presentation: LicenseAndCollaborationAgreementsAbstract to ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShareTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:title="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NatureOfBusinessAbstract" xlink:label="NatureOfBusinessAbstract" xlink:title="NatureOfBusinessAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfSmallMoleculeProductCandidates" xlink:label="NumberOfSmallMoleculeProductCandidates" xlink:title="NumberOfSmallMoleculeProductCandidates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfBusinessAbstract" xlink:to="NumberOfSmallMoleculeProductCandidates" xlink:title="presentation: NatureOfBusinessAbstract to NumberOfSmallMoleculeProductCandidates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureOfBusinessAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NatureOfBusinessAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NyxolLicenseAgreementMember" xlink:label="NyxolLicenseAgreementMember" xlink:title="NyxolLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="NyxolLicenseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to NyxolLicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LiquidityAbstract" xlink:label="LiquidityAbstract" xlink:title="LiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: LiquidityAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NonRefundableUpfrontPaymentReceived" xlink:label="NonRefundableUpfrontPaymentReceived" xlink:title="NonRefundableUpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAbstract" xlink:to="NonRefundableUpfrontPaymentReceived" xlink:title="presentation: LiquidityAbstract to NonRefundableUpfrontPaymentReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LiquidityAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LiquidityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ConcentrationOfCreditRiskAbstract" xlink:label="ConcentrationOfCreditRiskAbstract" xlink:title="ConcentrationOfCreditRiskAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashUninsuredAmount" xlink:label="CashUninsuredAmount" xlink:title="CashUninsuredAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationOfCreditRiskAbstract" xlink:to="CashUninsuredAmount" xlink:title="presentation: ConcentrationOfCreditRiskAbstract to CashUninsuredAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConcentrationOfCreditRiskAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConcentrationOfCreditRiskAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract" xlink:label="OtherThanTemporaryImpairmentLossesInvestmentsAbstract" xlink:title="OtherThanTemporaryImpairmentLossesInvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="ImpairmentOfInvestments" xlink:title="ImpairmentOfInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherThanTemporaryImpairmentLossesInvestmentsAbstract" xlink:to="ImpairmentOfInvestments" xlink:title="presentation: OtherThanTemporaryImpairmentLossesInvestmentsAbstract to ImpairmentOfInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OtherThanTemporaryImpairmentLossesInvestmentsAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OtherThanTemporaryImpairmentLossesInvestmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInContractWithCustomerAssetAbstract" xlink:label="ChangeInContractWithCustomerAssetAbstract" xlink:title="ChangeInContractWithCustomerAssetAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetCurrent" xlink:label="ContractAssetCurrent" xlink:title="ContractAssetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInContractWithCustomerAssetAbstract" xlink:to="ContractAssetCurrent" xlink:title="presentation: ChangeInContractWithCustomerAssetAbstract to ContractAssetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="AllowanceForDoubtfulAccountsReceivableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInContractWithCustomerAssetAbstract" xlink:to="AllowanceForDoubtfulAccountsReceivableCurrent" xlink:title="presentation: ChangeInContractWithCustomerAssetAbstract to AllowanceForDoubtfulAccountsReceivableCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="ProvisionForDoubtfulAccounts" xlink:title="ProvisionForDoubtfulAccounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInContractWithCustomerAssetAbstract" xlink:to="ProvisionForDoubtfulAccounts" xlink:title="presentation: ChangeInContractWithCustomerAssetAbstract to ProvisionForDoubtfulAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ChangeInContractWithCustomerAssetAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ChangeInContractWithCustomerAssetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="ShortTermInvestmentsMember" xlink:title="ShortTermInvestmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="ShortTermInvestmentsMember" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to ShortTermInvestmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="presentation: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByAssetClassAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:title="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="AssetsFairValueDisclosure" xlink:title="presentation: FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract to AssetsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByMeasurementFrequencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="FairValueByAssetClassAxis" xlink:title="FairValueByAssetClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="ShortTermInvestmentsMember" xlink:title="ShortTermInvestmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="ShortTermInvestmentsMember" xlink:title="presentation: FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain to ShortTermInvestmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByAssetClassAxis" xlink:to="FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:title="presentation: FairValueByAssetClassAxis to FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByAssetClassAxis" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosureAbstract" xlink:label="InvestmentsFairValueDisclosureAbstract" xlink:title="InvestmentsFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure" xlink:title="InvestmentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsFairValueDisclosureAbstract" xlink:to="InvestmentsFairValueDisclosure" xlink:title="presentation: InvestmentsFairValueDisclosureAbstract to InvestmentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:label="ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:title="ReceiptOfInvestmentsRelatedToLicenseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsFairValueDisclosureAbstract" xlink:to="ReceiptOfInvestmentsRelatedToLicenseAgreement" xlink:title="presentation: InvestmentsFairValueDisclosureAbstract to ReceiptOfInvestmentsRelatedToLicenseAgreement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="UnrealizedGainLossOnInvestments" xlink:title="UnrealizedGainLossOnInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsFairValueDisclosureAbstract" xlink:to="UnrealizedGainLossOnInvestments" xlink:title="presentation: InvestmentsFairValueDisclosureAbstract to UnrealizedGainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="InvestmentsFairValueDisclosure_2" xlink:title="InvestmentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsFairValueDisclosureAbstract" xlink:to="InvestmentsFairValueDisclosure_2" xlink:title="presentation: InvestmentsFairValueDisclosureAbstract to InvestmentsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="InvestmentsFairValueDisclosureAbstract" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to InvestmentsFairValueDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsNonrecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsNonrecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByMeasurementFrequencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="FairValueByLiabilityClassAxis" xlink:title="FairValueByLiabilityClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WarrantLiabilitiesMember" xlink:label="WarrantLiabilitiesMember" xlink:title="WarrantLiabilitiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="WarrantLiabilitiesMember" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to WarrantLiabilitiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PremiumConversionDerivativesMember" xlink:label="PremiumConversionDerivativesMember" xlink:title="PremiumConversionDerivativesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="PremiumConversionDerivativesMember" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to PremiumConversionDerivativesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByLiabilityClassAxis" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="presentation: FairValueByLiabilityClassAxis to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueByLiabilityClassAxis" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueByLiabilityClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueAdjustmentOfWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:label="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward to FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="FinancialLiabilitiesFairValueDisclosure" xlink:title="FinancialLiabilitiesFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="FinancialLiabilitiesFairValueDisclosure" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to FinancialLiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="presentation: FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="PropertyPlantAndEquipmentNetByTypeAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentNetByTypeAbstract to PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetByTypeAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetByTypeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_BioSenseGlobalLLCMember" xlink:label="BioSenseGlobalLLCMember" xlink:title="BioSenseGlobalLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="BioSenseGlobalLLCMember" xlink:title="presentation: RelatedPartyTransactionDomain to BioSenseGlobalLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:label="ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:title="ZhejiangHaiChangBiotechnologyCoLtdMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="ZhejiangHaiChangBiotechnologyCoLtdMember" xlink:title="presentation: RelatedPartyTransactionDomain to ZhejiangHaiChangBiotechnologyCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="presentation: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsAgreementAbstract" xlink:label="ContingentValueRightsAgreementAbstract" xlink:title="ContingentValueRightsAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:label="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:title="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentValueRightsAgreementAbstract" xlink:to="ContingentValueRightEntitledPerEachShareOfCommonStockHeld" xlink:title="presentation: ContingentValueRightsAgreementAbstract to ContingentValueRightEntitledPerEachShareOfCommonStockHeld" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsPaymentPeriod" xlink:label="ContingentValueRightsPaymentPeriod" xlink:title="ContingentValueRightsPaymentPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentValueRightsAgreementAbstract" xlink:to="ContingentValueRightsPaymentPeriod" xlink:title="presentation: ContingentValueRightsAgreementAbstract to ContingentValueRightsPaymentPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsPercentage" xlink:label="ContingentValueRightsPercentage" xlink:title="ContingentValueRightsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentValueRightsAgreementAbstract" xlink:to="ContingentValueRightsPercentage" xlink:title="presentation: ContingentValueRightsAgreementAbstract to ContingentValueRightsPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PercentageOfCashConsiderationPayment" xlink:label="PercentageOfCashConsiderationPayment" xlink:title="PercentageOfCashConsiderationPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentValueRightsAgreementAbstract" xlink:to="PercentageOfCashConsiderationPayment" xlink:title="presentation: ContingentValueRightsAgreementAbstract to PercentageOfCashConsiderationPayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContingentValueRightsIPTerm" xlink:label="ContingentValueRightsIPTerm" xlink:title="ContingentValueRightsIPTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentValueRightsAgreementAbstract" xlink:to="ContingentValueRightsIPTerm" xlink:title="presentation: ContingentValueRightsAgreementAbstract to ContingentValueRightsIPTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfMilestonesAccrued" xlink:label="NumberOfMilestonesAccrued" xlink:title="NumberOfMilestonesAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentValueRightsAgreementAbstract" xlink:to="NumberOfMilestonesAccrued" xlink:title="presentation: ContingentValueRightsAgreementAbstract to NumberOfMilestonesAccrued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfPotentialMilestones" xlink:label="NumberOfPotentialMilestones" xlink:title="NumberOfPotentialMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentValueRightsAgreementAbstract" xlink:to="NumberOfPotentialMilestones" xlink:title="presentation: ContingentValueRightsAgreementAbstract to NumberOfPotentialMilestones" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="ContingentValueRightsAgreementAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to ContingentValueRightsAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="BusinessCombinationsAbstract" xlink:title="BusinessCombinationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WarrantsAndStockOptionsAbstract" xlink:label="WarrantsAndStockOptionsAbstract" xlink:title="WarrantsAndStockOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndStockOptionsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: WarrantsAndStockOptionsAbstract to ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndStockOptionsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: WarrantsAndStockOptionsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WeightedAverageRemainingContractualTermsWarrants" xlink:label="WeightedAverageRemainingContractualTermsWarrants" xlink:title="WeightedAverageRemainingContractualTermsWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndStockOptionsAbstract" xlink:to="WeightedAverageRemainingContractualTermsWarrants" xlink:title="presentation: WarrantsAndStockOptionsAbstract to WeightedAverageRemainingContractualTermsWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="WarrantsAndStockOptionsAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to WarrantsAndStockOptionsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationsAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: BusinessCombinationsAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/PremergerFinancingDetails">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingAbstract" xlink:label="PreMergerFinancingAbstract" xlink:title="PreMergerFinancingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesAWarrantsMember" xlink:label="SeriesAWarrantsMember" xlink:title="SeriesAWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesAWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SeriesAWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesBWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SeriesBWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SecuritiesPurchaseAgreementMember" xlink:label="SecuritiesPurchaseAgreementMember" xlink:title="SecuritiesPurchaseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="SecuritiesPurchaseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to SecuritiesPurchaseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_WaiverAgreementsMember" xlink:label="WaiverAgreementsMember" xlink:title="WaiverAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="WaiverAgreementsMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to WaiverAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember" xlink:label="InvestorMember" xlink:title="InvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="InvestorMember" xlink:title="presentation: RelatedPartyDomain to InvestorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="DirectorMember" xlink:title="presentation: RelatedPartyDomain to DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to BusinessAcquisitionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="MeasurementInputRiskFreeInterestRateMember" xlink:title="MeasurementInputRiskFreeInterestRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputRiskFreeInterestRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputRiskFreeInterestRateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="MeasurementInputPriceVolatilityMember" xlink:title="MeasurementInputPriceVolatilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputPriceVolatilityMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputPriceVolatilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="MeasurementInputExpectedTermMember" xlink:title="MeasurementInputExpectedTermMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedTermMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedTermMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="MeasurementInputExpectedDividendRateMember" xlink:title="MeasurementInputExpectedDividendRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputExpectedDividendRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputExpectedDividendRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="presentation: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="MeasurementInputTypeAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to MeasurementInputTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingOfWarrantsAbstract" xlink:label="PreMergerFinancingOfWarrantsAbstract" xlink:title="PreMergerFinancingOfWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ProceedsFromPreMergerFinancing" xlink:label="ProceedsFromPreMergerFinancing" xlink:title="ProceedsFromPreMergerFinancing" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="ProceedsFromPreMergerFinancing" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to ProceedsFromPreMergerFinancing" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="NumberOfDirectors" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to NumberOfDirectors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to WarrantsAndRightsOutstandingTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetMeasurementInput" xlink:label="DerivativeAssetMeasurementInput" xlink:title="DerivativeAssetMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="DerivativeAssetMeasurementInput" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to DerivativeAssetMeasurementInput" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FairValueAssumptionsExpectedLife" xlink:label="FairValueAssumptionsExpectedLife" xlink:title="FairValueAssumptionsExpectedLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="FairValueAssumptionsExpectedLife" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to FairValueAssumptionsExpectedLife" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="GainLossOnDerivativeInstrumentsNetPretax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="GainLossOnDerivativeInstrumentsNetPretax" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to GainLossOnDerivativeInstrumentsNetPretax" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RemainingIssuableShares" xlink:label="RemainingIssuableShares" xlink:title="RemainingIssuableShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="RemainingIssuableShares" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to RemainingIssuableShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingOfWarrantsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: PreMergerFinancingOfWarrantsAbstract to ClassOfWarrantOrRightOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="PreMergerFinancingOfWarrantsAbstract" xlink:title="presentation: ClassOfWarrantOrRightLineItems to PreMergerFinancingOfWarrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightLineItems" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAbstract" xlink:to="ClassOfWarrantOrRightTable" xlink:title="presentation: PreMergerFinancingAbstract to ClassOfWarrantOrRightTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AccreditedInvestorMember" xlink:label="AccreditedInvestorMember" xlink:title="AccreditedInvestorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="AccreditedInvestorMember" xlink:title="presentation: RelatedPartyDomain to AccreditedInvestorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to IncomeStatementLocationAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:label="LesseeOperatingLeaseDescriptionAbstract" xlink:title="LesseeOperatingLeaseDescriptionAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_OperatingLeasesMonthlyBaseRent" xlink:label="OperatingLeasesMonthlyBaseRent" xlink:title="OperatingLeasesMonthlyBaseRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeasesMonthlyBaseRent" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeasesMonthlyBaseRent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to OperatingLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseDescriptionAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:title="presentation: LesseeOperatingLeaseDescriptionAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseDescriptionAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseDescriptionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IssuanceOfSettlementSharesAbstract" xlink:label="IssuanceOfSettlementSharesAbstract" xlink:title="IssuanceOfSettlementSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfSettlementSharesAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: IssuanceOfSettlementSharesAbstract to StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfAccreditedInvestors" xlink:label="NumberOfAccreditedInvestors" xlink:title="NumberOfAccreditedInvestors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfSettlementSharesAbstract" xlink:to="NumberOfAccreditedInvestors" xlink:title="presentation: IssuanceOfSettlementSharesAbstract to NumberOfAccreditedInvestors" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FairValueShareSettlementAmount" xlink:label="FairValueShareSettlementAmount" xlink:title="FairValueShareSettlementAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfSettlementSharesAbstract" xlink:to="FairValueShareSettlementAmount" xlink:title="presentation: IssuanceOfSettlementSharesAbstract to FairValueShareSettlementAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="IssuanceOfSettlementSharesAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to IssuanceOfSettlementSharesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LesseeLeaseDescriptionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SupplementalBalanceSheetInformationAbstract" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:title="SupplementalBalanceSheetInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="PrepaidExpenseCurrent" xlink:title="PrepaidExpenseCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidExpenseCurrent" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="OtherAssetsCurrent" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to OtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: PrepaidExpenseAndOtherAssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:title="presentation: SupplementalBalanceSheetInformationAbstract to PrepaidExpenseAndOtherAssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SupplementalBalanceSheetInformationAbstract" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:title="SupplementalBalanceSheetInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="EquipmentMember" xlink:title="EquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="EquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to EquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="Depreciation" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: SupplementalBalanceSheetInformationAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SupplementalBalanceSheetInformationAbstract" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:title="SupplementalBalanceSheetInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="TaxesPayableCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to TaxesPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedProfessionalFeesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:label="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:title="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedResearchAndDevelopmentServicesAndSuppliesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="AccruedLiabilitiesCurrentAbstract" xlink:title="presentation: SupplementalBalanceSheetInformationAbstract to AccruedLiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SupplementalBalanceSheetInformationAbstract" xlink:label="SupplementalBalanceSheetInformationAbstract" xlink:title="SupplementalBalanceSheetInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="ScheduleOfShortTermDebtTable" xlink:title="ScheduleOfShortTermDebtTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShortTermLoanMember" xlink:label="ShortTermLoanMember" xlink:title="ShortTermLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ShortTermLoanMember" xlink:title="presentation: DebtInstrumentNameDomain to ShortTermLoanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermDebtTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: ScheduleOfShortTermDebtTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="ShortTermDebtLineItems" xlink:title="ShortTermDebtLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="ShortTermBorrowingsAbstract" xlink:title="ShortTermBorrowingsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="ShortTermBorrowings" xlink:title="ShortTermBorrowings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBorrowingsAbstract" xlink:to="ShortTermBorrowings" xlink:title="presentation: ShortTermBorrowingsAbstract to ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DebtInstrumentNumberOfInstallments" xlink:label="DebtInstrumentNumberOfInstallments" xlink:title="DebtInstrumentNumberOfInstallments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBorrowingsAbstract" xlink:to="DebtInstrumentNumberOfInstallments" xlink:title="presentation: ShortTermBorrowingsAbstract to DebtInstrumentNumberOfInstallments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="DebtInstrumentPeriodicPayment" xlink:title="DebtInstrumentPeriodicPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBorrowingsAbstract" xlink:to="DebtInstrumentPeriodicPayment" xlink:title="presentation: ShortTermBorrowingsAbstract to DebtInstrumentPeriodicPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:label="ShortTermDebtPercentageBearingFixedInterestRate" xlink:title="ShortTermDebtPercentageBearingFixedInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBorrowingsAbstract" xlink:to="ShortTermDebtPercentageBearingFixedInterestRate" xlink:title="presentation: ShortTermBorrowingsAbstract to ShortTermDebtPercentageBearingFixedInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermBorrowingsAbstract" xlink:to="InterestExpense" xlink:title="presentation: ShortTermBorrowingsAbstract to InterestExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermDebtLineItems" xlink:to="ShortTermBorrowingsAbstract" xlink:title="presentation: ShortTermDebtLineItems to ShortTermBorrowingsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermDebtTable" xlink:to="ShortTermDebtLineItems" xlink:title="presentation: ScheduleOfShortTermDebtTable to ShortTermDebtLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalBalanceSheetInformationAbstract" xlink:to="ScheduleOfShortTermDebtTable" xlink:title="presentation: SupplementalBalanceSheetInformationAbstract to ScheduleOfShortTermDebtTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingMember" xlink:label="PreMergerFinancingMember" xlink:title="PreMergerFinancingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="PreMergerFinancingMember" xlink:title="presentation: RelatedPartyTransactionDomain to PreMergerFinancingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="presentation: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityInvestmentMember" xlink:label="EquityInvestmentMember" xlink:title="EquityInvestmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvesteeNameDomain" xlink:to="EquityInvestmentMember" xlink:title="presentation: EquityMethodInvesteeNameDomain to EquityInvestmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="presentation: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesAWarrantsMember" xlink:label="SeriesAWarrantsMember" xlink:title="SeriesAWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesAWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SeriesAWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="SeriesBWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to SeriesBWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to BusinessAcquisitionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="DirectorMember" xlink:title="presentation: RelatedPartyDomain to DirectorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingDomain" xlink:to="ShareBasedCompensationAwardTrancheOneMember" xlink:title="presentation: VestingDomain to ShareBasedCompensationAwardTrancheOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="presentation: VestingAxis to VestingDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="VestingAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to VestingAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:label="DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:title="DueToRelatedPartiesCurrentAndNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PreMergerFinancingAndWaiverAgreementsAbstract" xlink:label="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:title="PreMergerFinancingAndWaiverAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="NumberOfDirectors" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to NumberOfDirectors" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AmountInvestedInPreMergerFinancing" xlink:label="AmountInvestedInPreMergerFinancing" xlink:title="AmountInvestedInPreMergerFinancing" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="AmountInvestedInPreMergerFinancing" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to AmountInvestedInPreMergerFinancing" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfConvertedInitialSharesReceivedByDirectors" xlink:label="NumberOfConvertedInitialSharesReceivedByDirectors" xlink:title="NumberOfConvertedInitialSharesReceivedByDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="NumberOfConvertedInitialSharesReceivedByDirectors" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to NumberOfConvertedInitialSharesReceivedByDirectors" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:label="NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:title="NumberOfConvertedAdditionalSharesReceivedByDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="NumberOfConvertedAdditionalSharesReceivedByDirectors" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to NumberOfConvertedAdditionalSharesReceivedByDirectors" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfDirectorsSignedWaiverAgreements" xlink:label="NumberOfDirectorsSignedWaiverAgreements" xlink:title="NumberOfDirectorsSignedWaiverAgreements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="NumberOfDirectorsSignedWaiverAgreements" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to NumberOfDirectorsSignedWaiverAgreements" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ConsultingFeePayable" xlink:label="ConsultingFeePayable" xlink:title="ConsultingFeePayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="ConsultingFeePayable" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to ConsultingFeePayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="DueToRelatedPartiesCurrentAndNoncurrent" xlink:title="DueToRelatedPartiesCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:to="DueToRelatedPartiesCurrentAndNoncurrent" xlink:title="presentation: PreMergerFinancingAndWaiverAgreementsAbstract to DueToRelatedPartiesCurrentAndNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:to="PreMergerFinancingAndWaiverAgreementsAbstract" xlink:title="presentation: DueToRelatedPartiesCurrentAndNoncurrentAbstract to PreMergerFinancingAndWaiverAgreementsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="DueToRelatedPartiesCurrentAndNoncurrentAbstract" xlink:title="presentation: RelatedPartyTransactionLineItems to DueToRelatedPartiesCurrentAndNoncurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_InducementPlanMember" xlink:label="InducementPlanMember" xlink:title="InducementPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="InducementPlanMember" xlink:title="presentation: PlanNameDomain to InducementPlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2020Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2020Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2018Member" xlink:label="EquityIncentivePlan2018Member" xlink:title="EquityIncentivePlan2018Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2018Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2018Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: StockOptionsAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPeriodOfSharesReservedUnderPlan" xlink:label="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="MaximumPeriodOfSharesReservedUnderPlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="presentation: StockOptionsAbstract to MaximumPeriodOfSharesReservedUnderPlan" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: StockOptionsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: StockOptionsAbstract to AllocatedShareBasedCompensationExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2020Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2020Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EquityIncentivePlan2018Member" xlink:label="EquityIncentivePlan2018Member" xlink:title="EquityIncentivePlan2018Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2018Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2018Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_InducementPlanMember" xlink:label="InducementPlanMember" xlink:title="InducementPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="InducementPlanMember" xlink:title="presentation: PlanNameDomain to InducementPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CommonStockCapitalSharesAvailableForFutureIssuance" xlink:label="CommonStockCapitalSharesAvailableForFutureIssuance" xlink:title="CommonStockCapitalSharesAvailableForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="CommonStockCapitalSharesAvailableForFutureIssuance" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to CommonStockCapitalSharesAvailableForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RestrictedStockAwardsAbstract" xlink:label="RestrictedStockAwardsAbstract" xlink:title="RestrictedStockAwardsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockAwardsAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: RestrictedStockAwardsAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockAwardsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: RestrictedStockAwardsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockAwardsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockAwardsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CommonStockIssuedForServicesAbstract" xlink:label="CommonStockIssuedForServicesAbstract" xlink:title="CommonStockIssuedForServicesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockIssuedForServicesAbstract" xlink:to="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="presentation: CommonStockIssuedForServicesAbstract to StockIssuedDuringPeriodSharesIssuedForServices" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfBoardMembersGrantedStockForServices" xlink:label="NumberOfBoardMembersGrantedStockForServices" xlink:title="NumberOfBoardMembersGrantedStockForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockIssuedForServicesAbstract" xlink:to="NumberOfBoardMembersGrantedStockForServices" xlink:title="presentation: CommonStockIssuedForServicesAbstract to NumberOfBoardMembersGrantedStockForServices" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="EmployeeBenefitsAndShareBasedCompensation" xlink:title="EmployeeBenefitsAndShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockIssuedForServicesAbstract" xlink:to="EmployeeBenefitsAndShareBasedCompensation" xlink:title="presentation: CommonStockIssuedForServicesAbstract to EmployeeBenefitsAndShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="CommonStockIssuedForServicesAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to CommonStockIssuedForServicesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerOptionsAbstract" xlink:label="FormerOptionsAbstract" xlink:title="FormerOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FormerOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: FormerOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FormerOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="presentation: FormerOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="FormerOptionsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to FormerOptionsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/ApexianSublicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ApexianSublicenseAgreementAbstract" xlink:label="ApexianSublicenseAgreementAbstract" xlink:title="ApexianSublicenseAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ApexianSublicenseAgreementMember" xlink:label="ApexianSublicenseAgreementMember" xlink:title="ApexianSublicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDomain" xlink:to="ApexianSublicenseAgreementMember" xlink:title="presentation: RelatedPartyTransactionDomain to ApexianSublicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAxis" xlink:to="RelatedPartyTransactionDomain" xlink:title="presentation: RelatedPartyTransactionAxis to RelatedPartyTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="HealthCareOrganizationRevenueSourcesAxis" xlink:title="HealthCareOrganizationRevenueSourcesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="HealthCareOrganizationRevenueSourcesDomain" xlink:title="HealthCareOrganizationRevenueSourcesDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DevelopmentAndRegulatoryMilestonesMember" xlink:label="DevelopmentAndRegulatoryMilestonesMember" xlink:title="DevelopmentAndRegulatoryMilestonesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HealthCareOrganizationRevenueSourcesDomain" xlink:to="DevelopmentAndRegulatoryMilestonesMember" xlink:title="presentation: HealthCareOrganizationRevenueSourcesDomain to DevelopmentAndRegulatoryMilestonesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SalesMilestonesMember" xlink:label="SalesMilestonesMember" xlink:title="SalesMilestonesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HealthCareOrganizationRevenueSourcesDomain" xlink:to="SalesMilestonesMember" xlink:title="presentation: HealthCareOrganizationRevenueSourcesDomain to SalesMilestonesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HealthCareOrganizationRevenueSourcesAxis" xlink:to="HealthCareOrganizationRevenueSourcesDomain" xlink:title="presentation: HealthCareOrganizationRevenueSourcesAxis to HealthCareOrganizationRevenueSourcesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="HealthCareOrganizationRevenueSourcesAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to HealthCareOrganizationRevenueSourcesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SublicenseAgreementAbstract" xlink:label="SublicenseAgreementAbstract" xlink:title="SublicenseAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FutureMilestoneMethodRevenueNotRecognized" xlink:label="FutureMilestoneMethodRevenueNotRecognized" xlink:title="FutureMilestoneMethodRevenueNotRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SublicenseAgreementAbstract" xlink:to="FutureMilestoneMethodRevenueNotRecognized" xlink:title="presentation: SublicenseAgreementAbstract to FutureMilestoneMethodRevenueNotRecognized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SublicenseAgreementAbstract" xlink:title="presentation: RelatedPartyTransactionLineItems to SublicenseAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ApexianSublicenseAgreementAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: ApexianSublicenseAgreementAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ShelfRegistrationMember" xlink:label="ShelfRegistrationMember" xlink:title="ShelfRegistrationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="ShelfRegistrationMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to ShelfRegistrationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AtTheMarketProgramMember" xlink:label="AtTheMarketProgramMember" xlink:title="AtTheMarketProgramMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AtTheMarketProgramMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to AtTheMarketProgramMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsidiarySaleOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="RangeAxis" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="SubsidiarySaleOfStockLineItems" xlink:title="SubsidiarySaleOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AtTheMarketProgramAbstract" xlink:label="AtTheMarketProgramAbstract" xlink:title="AtTheMarketProgramAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AtTheMarketProgramAbstract" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: AtTheMarketProgramAbstract to StockIssuedDuringPeriodValueNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AtTheMarketProgramAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: AtTheMarketProgramAbstract to StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AtTheMarketProgramAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: AtTheMarketProgramAbstract to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AtTheMarketProgramAbstract" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: AtTheMarketProgramAbstract to PaymentsOfStockIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockLineItems" xlink:to="AtTheMarketProgramAbstract" xlink:title="presentation: SubsidiarySaleOfStockLineItems to AtTheMarketProgramAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="SubsidiarySaleOfStockLineItems" xlink:title="presentation: SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable to SubsidiarySaleOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:title="presentation: EquityAbstract to SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RegisteredDirectOfferingMember" xlink:label="RegisteredDirectOfferingMember" xlink:title="RegisteredDirectOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="RegisteredDirectOfferingMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to RegisteredDirectOfferingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to SubsidiarySaleOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="WarrantMember" xlink:title="presentation: EquityComponentDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RegisteredDirectOfferingsAbstract" xlink:label="RegisteredDirectOfferingsAbstract" xlink:title="RegisteredDirectOfferingsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: RegisteredDirectOfferingsAbstract to StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: RegisteredDirectOfferingsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StockSoldPricePerShare" xlink:label="StockSoldPricePerShare" xlink:title="StockSoldPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="StockSoldPricePerShare" xlink:title="presentation: RegisteredDirectOfferingsAbstract to StockSoldPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: RegisteredDirectOfferingsAbstract to ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: RegisteredDirectOfferingsAbstract to PaymentsOfStockIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: RegisteredDirectOfferingsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="WarrantsAndRightsOutstandingTerm" xlink:title="presentation: RegisteredDirectOfferingsAbstract to WarrantsAndRightsOutstandingTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: RegisteredDirectOfferingsAbstract to ClassOfWarrantOrRightOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MinimumPercentageOfBeneficialOwnership" xlink:label="MinimumPercentageOfBeneficialOwnership" xlink:title="MinimumPercentageOfBeneficialOwnership" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="MinimumPercentageOfBeneficialOwnership" xlink:title="presentation: RegisteredDirectOfferingsAbstract to MinimumPercentageOfBeneficialOwnership" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPercentageOfBeneficialOwnershipLimitation" xlink:label="MaximumPercentageOfBeneficialOwnershipLimitation" xlink:title="MaximumPercentageOfBeneficialOwnershipLimitation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RegisteredDirectOfferingsAbstract" xlink:to="MaximumPercentageOfBeneficialOwnershipLimitation" xlink:title="presentation: RegisteredDirectOfferingsAbstract to MaximumPercentageOfBeneficialOwnershipLimitation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="RegisteredDirectOfferingsAbstract" xlink:title="presentation: ClassOfWarrantOrRightLineItems to RegisteredDirectOfferingsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightLineItems" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ClassOfWarrantOrRightTable" xlink:title="presentation: EquityAbstract to ClassOfWarrantOrRightTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LicenseAndCollaborationAgreementsAbstract" xlink:label="LicenseAndCollaborationAgreementsAbstract" xlink:title="LicenseAndCollaborationAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NyxolLicenseAgreementMember" xlink:label="NyxolLicenseAgreementMember" xlink:title="NyxolLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="NyxolLicenseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to NyxolLicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LicenseTransferFeeMember" xlink:label="LicenseTransferFeeMember" xlink:title="LicenseTransferFeeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="LicenseTransferFeeMember" xlink:title="presentation: ProductsAndServicesDomain to LicenseTransferFeeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ResearchDevelopmentServicesMember" xlink:label="ResearchDevelopmentServicesMember" xlink:title="ResearchDevelopmentServicesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchDevelopmentServicesMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchDevelopmentServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CollaborationAndLicenseAgreementAbstract" xlink:label="CollaborationAndLicenseAgreementAbstract" xlink:title="CollaborationAndLicenseAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NonRefundableCashPaymentReceived" xlink:label="NonRefundableCashPaymentReceived" xlink:title="NonRefundableCashPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="NonRefundableCashPaymentReceived" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to NonRefundableCashPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FirstPotentialMilestonePaymentToBeReceived" xlink:label="FirstPotentialMilestonePaymentToBeReceived" xlink:title="FirstPotentialMilestonePaymentToBeReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="FirstPotentialMilestonePaymentToBeReceived" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to FirstPotentialMilestonePaymentToBeReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPercentageOfTieredRoyaltiesReceivable" xlink:label="MaximumPercentageOfTieredRoyaltiesReceivable" xlink:title="MaximumPercentageOfTieredRoyaltiesReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="MaximumPercentageOfTieredRoyaltiesReceivable" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to MaximumPercentageOfTieredRoyaltiesReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfPerformanceObligations" xlink:label="NumberOfPerformanceObligations" xlink:title="NumberOfPerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="NumberOfPerformanceObligations" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to NumberOfPerformanceObligations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RevenueFromContractWithCustomerToBeRecognized" xlink:label="RevenueFromContractWithCustomerToBeRecognized" xlink:title="RevenueFromContractWithCustomerToBeRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="RevenueFromContractWithCustomerToBeRecognized" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to RevenueFromContractWithCustomerToBeRecognized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:label="EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:title="EstimatedStandaloneSellingPriceForLicenseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="EstimatedStandaloneSellingPriceForLicenseAgreement" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to EstimatedStandaloneSellingPriceForLicenseAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfNonCancellationWindowAgreement" xlink:label="PeriodOfNonCancellationWindowAgreement" xlink:title="PeriodOfNonCancellationWindowAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="PeriodOfNonCancellationWindowAgreement" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to PeriodOfNonCancellationWindowAgreement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:label="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:title="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAndLicenseAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAndLicenseAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:label="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:title="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetCurrent" xlink:label="ContractAssetCurrent" xlink:title="ContractAssetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:to="ContractAssetCurrent" xlink:title="presentation: ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract to ContractAssetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:to="NonRefundableCashPaymentReceived" xlink:title="presentation: ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract to NonRefundableCashPaymentReceived" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:label="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:title="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:to="ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" xlink:title="presentation: ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract to ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ContractAssetCurrent" xlink:label="ContractAssetCurrent_2" xlink:title="ContractAssetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:to="ContractAssetCurrent_2" xlink:title="presentation: ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract to ContractAssetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAndCollaborationAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: LicenseAndCollaborationAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails">
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_LicenseAndCollaborationAgreementsAbstract" xlink:label="LicenseAndCollaborationAgreementsAbstract" xlink:title="LicenseAndCollaborationAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_BioSenseLicenseAndAssignmentsAgreementMember" xlink:label="BioSenseLicenseAndAssignmentsAgreementMember" xlink:title="BioSenseLicenseAndAssignmentsAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BioSenseLicenseAndAssignmentsAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to BioSenseLicenseAndAssignmentsAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_ProcessaLicenseAgreementMember" xlink:label="ProcessaLicenseAgreementMember" xlink:title="ProcessaLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ProcessaLicenseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to ProcessaLicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAcquireeDomain" xlink:to="RexahnStockholdersMember" xlink:title="presentation: BusinessAcquisitionAcquireeDomain to RexahnStockholdersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to BusinessAcquisitionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_CollaborationAndLicenseAgreementAbstract" xlink:label="CollaborationAndLicenseAgreementAbstract" xlink:title="CollaborationAndLicenseAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NonRefundableCashPaymentReceived" xlink:label="NonRefundableCashPaymentReceived" xlink:title="NonRefundableCashPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="NonRefundableCashPaymentReceived" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to NonRefundableCashPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePaymentAchievedForPerformanceObligation" xlink:label="MilestonePaymentAchievedForPerformanceObligation" xlink:title="MilestonePaymentAchievedForPerformanceObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="MilestonePaymentAchievedForPerformanceObligation" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to MilestonePaymentAchievedForPerformanceObligation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePaymentsAmountReceived" xlink:label="MilestonePaymentsAmountReceived" xlink:title="MilestonePaymentsAmountReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="MilestonePaymentsAmountReceived" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to MilestonePaymentsAmountReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_UpfrontPaymentReceivedInCommonStockShares" xlink:label="UpfrontPaymentReceivedInCommonStockShares" xlink:title="UpfrontPaymentReceivedInCommonStockShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="UpfrontPaymentReceivedInCommonStockShares" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to UpfrontPaymentReceivedInCommonStockShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_UpfrontPaymentReceivedInCommonStockFairValue" xlink:label="UpfrontPaymentReceivedInCommonStockFairValue" xlink:title="UpfrontPaymentReceivedInCommonStockFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="UpfrontPaymentReceivedInCommonStockFairValue" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to UpfrontPaymentReceivedInCommonStockFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfRestrictionFromSellingStock" xlink:label="PeriodOfRestrictionFromSellingStock" xlink:title="PeriodOfRestrictionFromSellingStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="PeriodOfRestrictionFromSellingStock" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to PeriodOfRestrictionFromSellingStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_NumberOfTimesPaymentsForSalesMilestone" xlink:label="NumberOfTimesPaymentsForSalesMilestone" xlink:title="NumberOfTimesPaymentsForSalesMilestone" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="NumberOfTimesPaymentsForSalesMilestone" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to NumberOfTimesPaymentsForSalesMilestone" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:label="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:title="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:label="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:title="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:label="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:title="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:label="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:title="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfOpportunityToCureBreachOfAgreement" xlink:label="PeriodOfOpportunityToCureBreachOfAgreement" xlink:title="PeriodOfOpportunityToCureBreachOfAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="PeriodOfOpportunityToCureBreachOfAgreement" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to PeriodOfOpportunityToCureBreachOfAgreement" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:label="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:title="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborationAndLicenseAgreementAbstract" xlink:to="PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" xlink:title="presentation: CollaborationAndLicenseAgreementAbstract to PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAndLicenseAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAndLicenseAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAndCollaborationAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: LicenseAndCollaborationAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncrementalCommonSharesAttributableToOptions" xlink:label="IncrementalCommonSharesAttributableToOptions" xlink:title="IncrementalCommonSharesAttributableToOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="IncrementalCommonSharesAttributableToOptions" xlink:title="presentation: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to IncrementalCommonSharesAttributableToOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_IncrementalCommonSharesAttributableToWarrants" xlink:label="IncrementalCommonSharesAttributableToWarrants" xlink:title="IncrementalCommonSharesAttributableToWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="IncrementalCommonSharesAttributableToWarrants" xlink:title="presentation: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to IncrementalCommonSharesAttributableToWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SeriesASeriesBAndRDOWarrantsMember" xlink:label="SeriesASeriesBAndRDOWarrantsMember" xlink:title="SeriesASeriesBAndRDOWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="SeriesASeriesBAndRDOWarrantsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to SeriesASeriesBAndRDOWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerRexahnWarrantsMember" xlink:label="FormerRexahnWarrantsMember" xlink:title="FormerRexahnWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="FormerRexahnWarrantsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to FormerRexahnWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FormerRexahnOptionsMember" xlink:label="FormerRexahnOptionsMember" xlink:title="FormerRexahnOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="FormerRexahnOptionsMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to FormerRexahnOptionsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="EarningsPerShareBasicAbstract" xlink:title="EarningsPerShareBasicAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareBasicAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareBasicAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareBasicAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: EarningsPerShareAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:label="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:title="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:label="EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:title="EffectiveIncomeTaxRateReconciliationWarrantsPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationWarrantsPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationWarrantsPercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateContinuingOperations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentFederalTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsGoodwillAndIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsInProcessResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="DeferredTaxAssetsTaxDeferredExpenseOther" xlink:title="DeferredTaxAssetsTaxDeferredExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseOther" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsTaxDeferredExpenseOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsOther" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DeferredTaxAssetsResearchAndDevelopment" xlink:label="DeferredTaxAssetsResearchAndDevelopment" xlink:title="DeferredTaxAssetsResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsResearchAndDevelopment" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsResearchAndDevelopment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsGross" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsValuationAllowance" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsNet" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to ComponentsOfDeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="DeferredRevenue" xlink:title="DeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="DeferredRevenue" xlink:title="presentation: ComponentsOfDeferredTaxLiabilitiesAbstract to DeferredRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="DeferredIncomeTaxLiabilities" xlink:title="presentation: ComponentsOfDeferredTaxLiabilitiesAbstract to DeferredIncomeTaxLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to ComponentsOfDeferredTaxLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsLiabilitiesNet" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract to OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="presentation: DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract to DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:title="presentation: DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract to DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:title="presentation: DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract to DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_FederalOperatingLossCarryforwardsTaxEffect" xlink:label="FederalOperatingLossCarryforwardsTaxEffect" xlink:title="FederalOperatingLossCarryforwardsTaxEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="FederalOperatingLossCarryforwardsTaxEffect" xlink:title="presentation: DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract to FederalOperatingLossCarryforwardsTaxEffect" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect" xlink:label="StateAndLocalOperatingLossCarryforwardsTaxEffect" xlink:title="StateAndLocalOperatingLossCarryforwardsTaxEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="StateAndLocalOperatingLossCarryforwardsTaxEffect" xlink:title="presentation: DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract to StateAndLocalOperatingLossCarryforwardsTaxEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_UtilizedFederalResearchCreditCarryforwards" xlink:label="UtilizedFederalResearchCreditCarryforwards" xlink:title="UtilizedFederalResearchCreditCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="UtilizedFederalResearchCreditCarryforwards" xlink:title="presentation: DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract to UtilizedFederalResearchCreditCarryforwards" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="IncomeTaxUncertaintiesAbstract" xlink:title="IncomeTaxUncertaintiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxUncertaintiesAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: IncomeTaxUncertaintiesAbstract to UnrecognizedTaxBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxUncertaintiesAbstract" xlink:to="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:title="presentation: IncomeTaxUncertaintiesAbstract to UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxUncertaintiesAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxUncertaintiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="BusinessAcquisitionAxis" xlink:title="BusinessAcquisitionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="BusinessAcquisitionAcquireeDomain" xlink:title="BusinessAcquisitionAcquireeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="BusinessAcquisitionAcquireeDomain" xlink:title="presentation: BusinessAcquisitionAxis to BusinessAcquisitionAcquireeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RexahnStockholdersMember" xlink:label="RexahnStockholdersMember" xlink:title="RexahnStockholdersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionAxis" xlink:to="RexahnStockholdersMember" xlink:title="presentation: BusinessAcquisitionAxis to RexahnStockholdersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionAxis" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="BusinessAcquisitionLineItems" xlink:title="BusinessAcquisitionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="presentation: DeferredTaxAssetsNetOfValuationAllowanceAbstract to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessAcquisitionLineItems" xlink:to="DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:title="presentation: BusinessAcquisitionLineItems to DeferredTaxAssetsNetOfValuationAllowanceAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="BusinessAcquisitionLineItems" xlink:title="presentation: ScheduleOfBusinessAcquisitionsByAcquisitionTable to BusinessAcquisitionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/DeferredCompensationPlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:title="ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="RetirementPlanNameAxis" xlink:title="RetirementPlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="RetirementPlanNameDomain" xlink:title="RetirementPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_RetirementPlan401KMember" xlink:label="RetirementPlan401KMember" xlink:title="RetirementPlan401KMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RetirementPlanNameDomain" xlink:to="RetirementPlan401KMember" xlink:title="presentation: RetirementPlanNameDomain to RetirementPlan401KMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RetirementPlanNameAxis" xlink:to="RetirementPlanNameDomain" xlink:title="presentation: RetirementPlanNameAxis to RetirementPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="RetirementPlanNameAxis" xlink:title="presentation: ScheduleOfDefinedBenefitPlansDisclosuresTable to RetirementPlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="DefinedBenefitPlanDisclosureLineItems" xlink:title="DefinedBenefitPlanDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="DeferredCompensationArrangementsAbstract" xlink:title="DeferredCompensationArrangementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:title="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCompensationArrangementsAbstract" xlink:to="DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:title="presentation: DeferredCompensationArrangementsAbstract to DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="DefinedContributionPlanEmployerMatchingContributionPercent" xlink:title="DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCompensationArrangementsAbstract" xlink:to="DefinedContributionPlanEmployerMatchingContributionPercent" xlink:title="presentation: DeferredCompensationArrangementsAbstract to DefinedContributionPlanEmployerMatchingContributionPercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:label="DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:title="DefinedContributionPlanAdditionalEmployerMatchingContribution" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCompensationArrangementsAbstract" xlink:to="DefinedContributionPlanAdditionalEmployerMatchingContribution" xlink:title="presentation: DeferredCompensationArrangementsAbstract to DefinedContributionPlanAdditionalEmployerMatchingContribution" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:label="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:title="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCompensationArrangementsAbstract" xlink:to="DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" xlink:title="presentation: DeferredCompensationArrangementsAbstract to DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredCompensationArrangementsAbstract" xlink:to="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="presentation: DeferredCompensationArrangementsAbstract to DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DefinedBenefitPlanDisclosureLineItems" xlink:to="DeferredCompensationArrangementsAbstract" xlink:title="presentation: DefinedBenefitPlanDisclosureLineItems to DeferredCompensationArrangementsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="DefinedBenefitPlanDisclosureLineItems" xlink:title="presentation: ScheduleOfDefinedBenefitPlansDisclosuresTable to DefinedBenefitPlanDisclosureLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://ocuphire.com/role/SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_EvergreenProvisionPlan2020Member" xlink:label="EvergreenProvisionPlan2020Member" xlink:title="EvergreenProvisionPlan2020Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EvergreenProvisionPlan2020Member" xlink:title="presentation: PlanNameDomain to EvergreenProvisionPlan2020Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="PlanNameAxis" xlink:title="presentation: SubsequentEventTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="RangeAxis" xlink:title="presentation: SubsequentEventTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_SubsequentEventsAdditionalInformationAbstract" xlink:label="SubsequentEventsAdditionalInformationAbstract" xlink:title="SubsequentEventsAdditionalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_MaximumPeriodOfSharesReservedUnderPlan" xlink:label="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="MaximumPeriodOfSharesReservedUnderPlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAdditionalInformationAbstract" xlink:to="MaximumPeriodOfSharesReservedUnderPlan" xlink:title="presentation: SubsequentEventsAdditionalInformationAbstract to MaximumPeriodOfSharesReservedUnderPlan" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAdditionalInformationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:title="presentation: SubsequentEventsAdditionalInformationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ocup-20221231.xsd#ocup_AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:label="AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:title="AggregateNumberOfCommonStockReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAdditionalInformationAbstract" xlink:to="AggregateNumberOfCommonStockReservedForFutureIssuance" xlink:title="presentation: SubsequentEventsAdditionalInformationAbstract to AggregateNumberOfCommonStockReservedForFutureIssuance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventsAdditionalInformationAbstract" xlink:title="presentation: SubsequentEventLineItems to SubsequentEventsAdditionalInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '>!!4# 2(  A$! Q$!_\0
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M+@9.<]ATR<@ ]7N;JWLK62YNYXH+>)=TDLKA40>I)X I8)X;JWBN+>6.:"5
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M'WMHXW'DUUM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !117"?&;_DDNO?[D7_HY* .[
MHKYB:Q\/W=QH^D>#/"VMZ+XTD,4\-U>R-"NP EY 'E.Y2%8\+R <>A[CQO\
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MXC;2KU+Z 0LH#.AR V0<K],'WK:=0Z,AZ,,'%<5H&L>.XO%"Z1XFT33I;6:
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M7]E=Z'%:Z9>00V5W<13O%)&^>7\O<Q/'& />NXU_Q[X7\+ZC;V&LZQ#:75P
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MIW]G;MOVO[4GDYSC&_.,YXZT)XBT.2TNKM-9T]K:T;9<S"Z0I"W3#G.%/UH
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M$MQH=O%%<R0L$W_)N4,1C=QR.O6NG_X3:T_Z WB+_P $\_\ \31_PFUI_P!
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M_P#XFC_A-K3_ * WB+_P3S__ !- '345S#>.+-5+-H_B$ #))TB?_P")I?\
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MU&<#/TK(^$__ "2SP_\ ]>W_ +,U6_\ A.K'_H$^(/\ P43_ /Q-'_"=6/\
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M]K-]NL+[0+E8_P"R=+^P!^?FB@5L;RN" [')(Y/%>R?\+#TK_H':[_X*I_\
MXFC_ (6'I7_0.UW_ ,%4_P#\31=!='BO@22QL?&WAFSTA;76KB*5UG+:5)87
MNGJ1M?S"C;)  >2Y<]0,9K%ATEYKVZTC5-8N[?Q.VJL38P>'XY[QW+!Q,MR6
M1MI^]]X<<X(.:^A/^%AZ5_T#M=_\%4__ ,31_P +#TK_ *!VN_\ @JG_ /B:
M+H+HV==O[[2/#MW?66GOJEY;Q;UM8VV--C&0N W.,D  YZ5Y3X/U?3?$'Q;M
M=9\&P7"VMY8O)XB+J^R.1@2BY;C?O 'R\$ X_BKO?^%AZ5_T#M=_\%4__P 3
M1_PL/2O^@=KO_@JG_P#B:+H+HZVBN2_X6'I7_0.UW_P53_\ Q-'_  L/2O\
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MTR2,6CM(=HDNI"7D9@&.TL0 I]*]B^$/^O\ &W_8QW/\Q6Y_PL;2/^?#7/\
MP53?_$T?\+&TC_GPUS_P53?_ !-%T%T=?17(?\+&TC_GPUS_ ,%4W_Q-21?$
M#39FVQ:9KSL!G"Z3.?\ V6G<+HZNBN9_X3:T_P"@-XB_\$\__P 31_PFUI_T
M!O$7_@GG_P#B:!G345S/_";6G_0&\1?^">?_ .)H_P"$VM/^@-XB_P#!//\
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M1M0A%G-J)N3):NOD!C\N_(^7/;/6O6O^$VM/^@-XB_\ !//_ /$T?\)M:?\
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M!Z@@&KU4=)_M4V9;619+=-(Y$=GN*1IGY5W-@NV.K;5!/85>H **** (;O\
MX\I_^N;?RJ4=!45W_P >4_\ US;^52CH*?0746BBBD,**** "BBB@ HHHH *
M*** "BBB@ J"\_X]6_WE_P#0A4]4]5<QZ9.Z_>49'YT7MJ%KZ$M%<E_;U_\
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M]M7O]]?^^11_;5[_ 'U_[Y%']H4O,/J%7R.GHKF/[:O?[Z_]\BC^VKW^^O\
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M'+MW8^YJ[/"MS;RP.9 DB%&,<C(P!&.&4@J?<$$=J:OU'%/=DE%>;VMFTO\
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MN[:"Q(45!%X#M%DFFGUC6KFX:U>TM[B6[_>VD;-N/ER*H;=D+\SECA0,XR"
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M1F.44KN&=H88QD,*V=-LR=3\0>'I-4U1=/M#:W"RM>N90KH=Z><Q+A28\G#
MC<<$"@#HDT."+4-5OH;BXCN-2CC21E9?W>Q2JE,C@\YYSS5>?PMI\WA:W\/A
MIH[6V2%89$8>9&8BI1P2"-P*@YQS6#H%K/JN@:GB\UB71_MS2Z;Y=XRW%S;J
MBG:)F8/L:3>58NI*X^;8<5I>!;RXG\/S1WL\KW%I>3P.EPY>6!0Y*1R.?OLJ
M%,L"0>N3U(!T]9^AZ/;^']"LM(M'E>WLXA%&TI!<@>I  S^%<GIOB;4ETW0Y
M;:S&H7OB1Y;J,7%VT44";0ZK]U]H$8484<L"<?,34C?$$'2=/OLZ!9M=+)OA
MU36OLK*Z.48)^Z;>N5/S<=N* .HT32+?0='M],M7E>" $*TI!8Y)/. !W]*S
MX_"&GQI HFN<0ZK)JRY9>9G+DJ?E^Y^\; Z\#FL'Q;JFLW'A*QU?3M4L;:V-
MS:^?]@E-QYV^YC3:DWR_)ACD[<GIP,YJ^+]1O4U#Q)>Q7EY"= L;6YM8H)G1
M'=FD9]Z@XD#!%7# @#.,$YH W;'P%86%S9RKJ6J21V0F6U@:9%6%)00R@HJM
MW!#$EA@?-URK>!+&YBNAJ6HZCJ4L]LELL]R\8DA17WKM:-%^8.%;<VXY4>^:
M7B]+G2=1L=8BN]553?0>?.;D_9+6#<J,C0J1NW[CAMC$%LEE &-C2KJ6#Q3K
M.CRS22HJ0W\!D<L424NK("><!XF('8. .   "]I6E2:;Y[3:I?ZC-.P9I+QU
M^4 8 5$544=^%!)/)/%9NF>$WTK4KB\@\0:JXN;EKFXAD2V996/9F\G?M P
M-W   P!71T4 9&L>'XM7N;2[2]N["^M-ZQ75H4WA' #(0ZLI4X4\C@J",5BK
M\.=,BM8K:WU'5((5M)+*4)*A,\+NSE69D+=6/*E3SR378T4 <I<^ =.N8Y$:
M]OU62PM[)]K1_-Y#[XI.4^^"3_LG/*FM/1?#T6BW=_=B]O+NXOV1[B2Y9"69
M5V@@*J@<8& ,<< 5L44 <\W@[3VTN:R6>[0OJ$FI1SJZ^9#.TADW(=N, L0
M01C@YK)UCPCJ$USX?2VU/5+AH-2DNKF_DGC\Z(&"1054J$ R5&Q4QR20<L3V
M]% ',_\ "%6<<%J;74+^UOK=Y7_M")HVGD,IS+OWHR'<0#]T8VC;@#%6=.\)
M:9I5U;S6HE5;>P^P)$SY4QEMQ)R,EB>ISW-;M% ')0^ K:TLK*"QUK5K2:TL
MS8+=0O#YKV^<JC9C*_+_  L &'//)S-JW@>QU7[0HU#4K1+NS%E=K!.#]IB
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MU8HHH- HHHH **** (IOX:BJ6;^&HJ1+W"BBB@04444 %%%% !1110 4444
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M)'@8V[4B",I!/#JWKU (MZ+HMOH=G)!!)--)-,T\\\[!I)I&ZLV !G@#
M   %>:):0ZQXB\0RW_@G^WKR6ULSN,=M^Y=K<$KNE=67GNH.,5I:]X?MQX6L
M=,O((]4\9W&GI:VMPS%GAE1<&X5CS$J,=Q<8+$*.6*B@#H="\,_98M+CNUE1
M]!DFALF1EV30LNU"1R>$(7G!W*3R,9V=%TBWT+2X]/M7E>%'D<-*06R[LYZ
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M/E..8IO'.KGQ%=6]II[S6MG?QV4EM#IMS,\@.SS)!<*/*3;OSM89(0Y*[A@
M]!HKA/B##!<:WX1BN=(_M>%KZ?=8[(F\W_1I<<2LJ<'YN2.G'.*PKW2;_3DM
M'M--BT6"Z\1VK6-A+L9+?$15G*1-M&6!;8K<XZ@L2 #UBBN"/C'4TTMHIY["
M+4H]6FTXRQV-Q<"4(I?=';QDN3MQD;\##'/0&H/''B"Y\-:;J<5I#;K*ET+F
MY.G3W*++#(4"F.)M\:MM8[CN"XP<T >D45YUJWC_ %%=1N(]&M5NXK2T@N?+
MM["YO/MOF#?LCEB&V(;1P[@Y)S@ <]KJ>G6NM:7Y%W9K<Q-B3[-.Q5'8<A9
M,Y&<9!!'L<4 :%%<C\/\V^FZIIKHL,UCJ<T;VT1S#;A\2+'$>,H%D7'"]_E
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M*_VZ ;AG@XW<4S^WO$G_ $)ES_X,+?\ ^*H Z:BN9_M[Q)_T)ES_ .#"W_\
MBJ/[>\2?]"9<_P#@PM__ (J@#IJ\5\8,?["^),]T=LZZIIZ$L>D*M;E/H.6/
MXFO1/[>\2?\ 0F7/_@PM_P#XJJL=[K,.IW&HQ^![A;NXC2*5QJ,/SJA8KD;L
M9&YN<9[=A0!POQ OK/6IO$>HZ)<P7EC%X;>"\NK5Q)$TAF4QH67(+ ;SCJ ?
M>N5:UN3K>E:=.C_9O#&K6MK;%SU%S<^:N/I&B#_(KV[^WO$G_0F7/_@PM_\
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M/^A,N?\ P86__P 52&=-17,_V]XD_P"A,N?_  86_P#\51_;WB3_ *$RY_\
M!A;_ /Q5 '345S/]O>)/^A,N?_!A;_\ Q5']O>)/^A,N?_!A;_\ Q5 '345S
M/]O>)/\ H3+G_P &%O\ _%4?V]XD_P"A,N?_  86_P#\50!TU%<S_;WB3_H3
M+G_P86__ ,51_;WB3_H3+G_P86__ ,50!TU%<S_;WB3_ *$RY_\ !A;_ /Q5
M']O>)/\ H3+G_P &%O\ _%4 =-4%Y_QZM_O+_P"A"L#^WO$G_0F7/_@PM_\
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MUCHZ*YS^W/$/_0HW'_@=!_\ %4?VYXA_Z%&X_P# Z#_XJF*QT=9U_P#Z]?\
M=_J:S?[<\0_]"C<?^!T'_P 55&]UK7C,-WA2=?EZ?;8?_BJ3V)DM"UJ>F6^J
MV;6]PN0?NL.JGU%>7:OI%QH]X89QE3RCCHPKOO[8UW_H5I__  -A_P#BJIZE
M-JNJV;6]QX4G(/*L+R'*GU'-3:^C,90N>>UL:#H,^M7.!E+=#^\DQ^@]Z5/#
M&L>=M;3)FVX9HQ)&#@_[1;;V]377VE[JUC;);V_A.9(T& !>0_\ Q5)0MN1&
MF^IO6EI!8VR6]N@2-!P!W]S4]8']L:[_ -"M/_X&P_\ Q5']L:[_ -"M/_X&
MP_\ Q5,TL;]%8']L:[_T*T__ (&P_P#Q5']L:[_T*T__ (&P_P#Q5*P6-^BL
M#^V-=_Z%:?\ \#8?_BJ/[8UW_H5I_P#P-A_^*HL%C?HK _MC7?\ H5I__ V'
M_P"*H_MC7?\ H5I__ V'_P"*HL%C:F_AJ*L:76-<XSX7G'_;Y#_C4?\ :^N?
M]"Q/_P"!D/\ C1831NT5A?VOKG_0L3_^!D/^-']KZY_T+$__ (&0_P"-%A6-
MVBL+^U]<_P"A8G_\#(?\:9)KFL1*&D\-RJI(&3>PCD\#O18+,Z"BL+^U]<_Z
M%B?_ ,#(?\:/[7US_H6)_P#P,A_QHL%C=HK"_M?7/^A8G_\  R'_ !H_M?7/
M^A8G_P# R'_&BP6-VBL+^U]<_P"A8G_\#(?\:/[7US_H6)__  ,A_P :+!8W
M:U_#W_(0D_ZY'^8KB_[7US_H6)__  ,A_P :T]#UK7TO7*>%)Y#Y9X%[".X]
M6IQ6I<%[R.M\1^%=$\6V,=GKE@EW!&_F("[(5;&,AE((_.LG0_A?X.\-ZO#J
MNDZ/]FO80PCE^TS/C<"IX9R.A/:K/]O>)/\ H3+G_P &%O\ _%4?V]XD_P"A
M,N?_  86_P#\56QUG35#=VL-]9SVEPF^">-HI%R1N5A@C(YZ&N?_ +>\2?\
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M#Y>9'9V5<\[07(&><"H/[>\2?]"9<_\ @PM__BJ/[>\2?]"9<_\ @PM__BJ
M)9/ _AZ6"UADLYFCMH1;JINYOWD0.X1R?/\ O4!SA7W 9(Q@FM>\TZUOY+5[
MJ(R&UF$\/SD!7 (!(!P<9/7///4"L/\ M[Q)_P!"9<_^#"W_ /BJ/[>\2?\
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M(@&!!_=M(5[GMUYZU!_;WB3_ *$RY_\ !A;_ /Q5']O>)/\ H3+G_P &%O\
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M*** "BBB@ HHHH **** "BBB@ HHHH AN_\ CRG_ .N;?RJ4=!45W_QY3_\
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M]J1=&O&'=O\ 8]N_\NQ1$CC6.-55% "JHP !V%,M[>&TMH[>WC6.&)0J(HX
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MHRGNV\XR1]P\'M=TN_N#K^KZ1=R^:UOY=U Y4 ^1+N 4X !VO'(,^FW.3DD
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MV!.!0!Y&?%-S-X:L;.6_O[(/>WJKJ$NKR2V[-&JL!'-'MEF4[V$:F0<C!+E
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M>F.PXKDI?A9XJ;29+1;!?*71DDC@$\?_ !_F..%U^]C_ %:,=W3YNIKZ"HH
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MYM6,@R.3@!6)'MU-7K#PU;6&HVM_]KO;BYM[)K/S+F;S#(K.'9F)&=VY>V
M<  8Q%J_A?\ M76[75DUG4;*>UB:*%;=8'1-Q^9P)8GPQ'RY&.!CN<@'%:UJ
M&MI::M<WU]<PZCX>T*SO EO,T<4ETWF-*753M=28@N"" "V.M;WBR"2"YM;B
MPU+5/[=O;F(65JMTPC1%*^;F$$(8PNXLS@D%@-V2@K2U'P9::I/'-=:A?EF@
MCM[S:8P+Z-&W*LHV>I;[FSAB.G 63PFY\076LP>(-5MKBY"(ZHELZJB]$4O"
MS*N<G /4D]30!FZQ;26GBK2UTW4]3GU:ZO1//"UTS0QV8!#[HLB-4 PJMMW%
ML<D[C7:USEGX3>QUFZU*#Q#JH:[N!//$R6S+)CI&6,._8!\H ;@="#S71T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-W_ ,>4
M_P#US;^52CH*BN_^/*?_ *YM_*I1T%/H+J+1112&%%%% !1110 4444 %%%%
M !1110 5!>?\>K?[R_\ H0J>H+S_ (]6_P!Y?_0A36XGL%%%%22%%%% !111
M0 4444 %%%% !1110 56JS5:@ HHHI""BBB@ HHHH **** "BBB@ HHHH A;
M[Q^M)2M]X_6DI""BBBD 4444 %%%% !1110 4444 %9U_P#Z]?\ =_J:T:SK
M_P#UZ_[O]32>Q$]BK1114F84444 %%%% !1110 4444 %%%% $4W\-15+-_#
M45(E[A4-U:PWML\$Z!XW&"*FHH$>8:WHLVD76TY:!C^[D]?;ZUEUZW>V<%_:
MO;W";D;\P?4>]>:ZOI$^DW9BD&Z-N8W X8?XTFKZHSE'JC.KL_#'AO 2_O4Y
MZQ1D?J:B\,>'/-V7]ZG[OK%&P^][GV_G_/M::5BHQMJ%%%%!04444 %:_A[_
M )"$G_7(_P Q616OX>_Y"$G_ %R/\Q3CN73^)'2T445N=@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"JZ_^-UTU%,HYG_A/_#_ /SUU#_P577_ ,;H_P"$_P##_P#SUU#_ ,%5U_\
M&ZZ:B@#F?^$_\/\ _/74/_!5=?\ QNC_ (3_ ,/_ //74/\ P577_P ;KIJ*
M .9_X3_P_P#\]=0_\%5U_P#&Z/\ A/\ P_\ \]=0_P#!5=?_ !NNFHH YG_A
M/_#_ /SUU#_P577_ ,;H_P"$_P##_P#SUU#_ ,%5U_\ &ZZ:B@#F?^$_\/\
M_/74/_!5=?\ QNC_ (3_ ,/_ //74/\ P577_P ;KIJ* .9_X3_P_P#\]=0_
M\%5U_P#&Z/\ A/\ P_\ \]=0_P#!5=?_ !NNFHH YG_A/_#_ /SUU#_P577_
M ,;H_P"$_P##_P#SUU#_ ,%5U_\ &ZZ:B@#F?^$_\/\ _/74/_!5=?\ QNC_
M (3_ ,/_ //74/\ P577_P ;KIJ* .9_X3_P_P#\]=0_\%5U_P#&Z/\ A/\
MP_\ \]=0_P#!5=?_ !NNFHH YG_A/_#_ /SUU#_P577_ ,;H_P"$_P##_P#S
MUU#_ ,%5U_\ &ZZ:B@#F?^$_\/\ _/74/_!5=?\ QNC_ (3_ ,/_ //74/\
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M **** "BBB@ HHHH A;[Q^M)2M]X_6DI""BBBD 4444 %%%% !1110 4444
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M(<C9''"'"!>,]'.<D]!6:W@:R;4_M?\ :.HK&-0&I):J\?E+/W/W-Q!YR"Q
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MBBI)"BBB@ HHHH **** "BBB@ HHHH *K59JM0 4444A!1110 4444 %%%%
M!1110 4444 0M]X_6DI6^\?K24A!1112 **** "BBB@ HHHH **** "LZ_\
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M9I6LQ9BRWEAYFP)L#9QC=CG..M4['P;IEA?0WD3W#30Z:NF@NX(,8.=Y&/\
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MI*R:MHS(****!A1139)$AC:21PB*,LS'  H <2 ,DX KB/$GBW(>RTU^.CS
M]?9?\:I^)/%37^ZTLBR6W1GZ&3_ZU<K2;L9RGT1U7AOQ6UAMM+XE[;HK]3'_
M /6KT&.1)8UDC8.C#*LIR"*\4K?\/>)9M(<0S9DM&/*]U]Q_A0I7W%&?1GIU
M%0VUU#>6Z3V\@DC<9#"IJ9J13?PU%4LW\-14B7N%%%% @HHHH **** "BBB@
M HHHH *U_#W_ "$)/^N1_F*R*U_#W_(0D_ZY'^8IQW+I_$CI:***W.P****
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M!'X4_JU'^5?<+VM3N=9_PLGQ)_S\0?\ ?E:RM:\3ZGX@CC34)(W$9RNU O\
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M:^.=4O/$<D,%A)+8IJKZ<T,>F7+,JJQ1IS<C]U@."2F.%_BSQ73>)="MM;L
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M;1%)S&7>*>1(7'[MF&T^8&QGJBG P*ZZW6=8L7,D<DFYCNCC*#;D[1@L>0,
MG/)!.!G SM6TJ34I],A'E)86UPMS,N3N9H^8E QC&_#$Y_@ P<Y%S3[1[*T,
M+W$DY\V23?(S,<,[,%RQ)P =HYZ =.E %JBBB@ HHHH **** "BBB@ HHHH
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MWX'^-'_"F[7_ *#,W_?@?XUZ=11]=K_S?D'U>EV/,?\ A3=K_P!!F;_OP/\
M&HO^%06W_08F_P"_(_QKU.JU'UVO_-^0OJ]+L>:_\*@MO^@Q-_WY'^-'_"H+
M;_H,3?\ ?D?XUZ511]=Q'\WY!]7I=CS7_A4%M_T&)O\ OR/\:/\ A4%M_P!!
MB;_OR/\ &O2J*/KN(_F_(/J]+L>:_P#"H+;_ *#$W_?D?XT?\*@MO^@Q-_WY
M'^->E44?7<1_-^0?5Z78\U_X5!;?]!B;_OR/\:/^%06W_08F_P"_(_QKTJBC
MZ[B/YOR#ZO2['FO_  J"V_Z#$W_?D?XT?\*@MO\ H,3?]^1_C7I5%'UW$?S?
MD'U>EV/-?^%06W_08F_[\C_&C_A4%M_T&)O^_(_QKTJBCZ[B/YOR#ZO2['F1
M^$EL#C^UY?\ OR/\:3_A4EM_T%Y?^_(_QKTAOO'ZTE3]>Q'\WY"^KT^QYQ_P
MJ2V_Z"\O_?D?XT?\*DMO^@O+_P!^1_C7H]%'U[$?S?D'U>GV/./^%26W_07E
M_P"_(_QH_P"%26W_ $%Y?^_(_P :]'HH^O8C^;\@^KT^QYQ_PJ2V_P"@O+_W
MY'^-'_"I+;_H+R_]^1_C7H]%'U[$?S?D'U>GV/./^%26W_07E_[\C_&C_A4E
MM_T%Y?\ OR/\:]'HH^O8C^;\@^KT^QYQ_P *DMO^@O+_ -^1_C1_PJ2V_P"@
MO+_WY'^->CT4?7L1_-^0?5Z?8\X_X5);?]!>7_OR/\:YCQAX.B\,0V\D=X]Q
MYK;2&0+C]:]NK$UK3K6^O+:2YC$GD?.BGIGGDBKIYA5C).;NOD14H0Y?=1YO
MX5\%-=;+_5$*P=8X".7]V]![=Z]'5510J*%4#  & *6BN7$8B=>7-(4(*"L@
MHHHK L.HP:XKQ+X2!#WNFQ\]9(%'ZK_A7:T4":ON>)$$'!ZT5Z)XD\*I?A[N
MQ4)==60<"3_ UY[)&\4C1R*5=3@J1@@U#C;4QE%H;10 2< 9-=QX:\) !+W4
MH^>L<#?S;_"A1N*,6RGX:\*->[;R_4K;]4C/!D_P%=^B+&BHBA448"@8 %.H
MJ_0W22V(IOX:BJ6;^&HJ0GN%%%% @HHHH **** "BBB@ HHHH *U_#W_ "$)
M/^N1_F*R*U_#W_(0D_ZY'^8IQW+I_$CI:***W.P*HZSI<&MZ)?:7<_ZF\@>!
MSC) 8$9'N,YJ]10!YGH5Y+XJO_"EA>#,NC027>HIV%U$6MD![_?$S#_<%5_A
MOX?5] T._?PAX:(VB3^T3)FZR"</M\C[V?\ ;_&O0].T'2])OM0O;&S2"YU&
M42W<BDDRN!@'D\=3TQU)[UGV'@K1M,\A;)M4AC@8-'"NKW?E+@YQL\W;CVQC
MVH Y:UTRQUW2-6U;6-"EUG4VU&YM2(_*\^SCCD94$32NHCPH5OE()+;N2<U4
MUS6+7Q+I6A6=M+J[0C3AJ:SBREN)EFV[;8RB%6 .[S'/09C&*[G4?"&BZI<W
M$]S;SAKE0MRL%W-"EP,8_>I&P63CCY@>..G%7=/T73=)EGDL+2.W,X176/(4
M*B[555Z*H'90!R3U)H S-)\766JZ9I<Y@OUDU")3MCLIG6)\[65W52J%6!!W
M$8Q6/H^D:;'XXCD\.626]GI\,T&I7<1XNIV*XC9CS*Z$$L[$D$XSNW ==9:7
M9Z=!/!:1&&.>:2>15=OON<L1S\N22>,<FL_1_"6DZ"T/]G?VA%'"I6.%]2N9
M(E!_Z9O(5_2@# ^(&@:->3Z)=W.D6$]S-J]K#+-+;(SO&2058D9*^QXJ75-7
MO-&NKW2?#=II=I:Z-IHOY898"$E#,^(XPC*(_P#5N2V&&6''6NLOM-M-2%N+
MN+S/L\Z7$7S$;9%^Z>#SCT/%4M6\,Z3KDR3:A;/(ZQF)BD\D8DC)R4D",!(F
M?X6R.3QR: .3OO&NN8UG4+&+3UTW2;*WOWAGC<S3H\?F,@8,%0X#8;#<D<=Z
MRK*_6W\423+:Q22-KU^\;R[PT9%BK< ,!SC!R#P>,'FNK_X0BTN_%6J:IJ,2
MRVUP+800QSR("(P<K*BD*ZYP0K;AUX%:I\+:,;LW1L_WQGEN2WFO_K)(_+=L
M9QR@QCH.HYH X^T\>ZQ9Z=;:CK$5C/#=>'I-:CBLXGB:,H(SY99G8-D2=<#&
M.AK9\)>)-7U:_>UU&U9HS:I<+=)I=S9QJY.&B_???(X(8$9&>!CG9A\-:/ +
M-4L4*V=D=/@5V9U6W(4%""2&!"+R<GCW-)I'AG2="E:6P@E$C1+#OGN9)V6-
M<[44R,Q51G[HP/:@#EK#PWH6M^,_&DFK:397;K=VZ+--"K/&OV2+[KXROKD$
M8ZUGQ^,]7LO!FCO!>P3WS:;+<EIK&XO)+@(=J,PB*B-6&"9';&3TZD=C>>#-
M%OKZ\O)H[U9;T@W2PZC<11S80(-R(X4_*H'3D=:EU#PGHFJ/ UU9'$,!ME2&
M9XD:$X_=LJ, Z<#Y6!'M0!QR>)]437]6U9K^VBL/^$?L[R&UG24I$\ADQ]TD
MDY!SM3+#8HP1D]#X/\17VM76L6E^$9[&:,1S+8RV9D1XPW,,K,ZD-N&2>1@@
M8Y-R7P;H,\2Q26;E!8II^/M,HS ARBGYN2IY#'Y@22#S5O2O#^FZ)-<S6,,B
MS76WSY)9Y)7E*Y +,[$DX.,]<8'84 9'@K_6>)?^PY<?^@I65:>--3O/%%MI
ML,UE);7LMW;PR)IUP$A>(,5/G.RK./D.X(!@\;NA/1KX1TF/49;Z+^T(9II_
MM$BPZG<QQO)QDF-9 AS@9&,&FVO@S0;+4H=0@LY%N()I)H"US*RPM)NW^6A8
MJBMO.54 'CCY1@ X#0O&FO0>&?#]BL_VF^FTG[=)=2:;=7K29;:B$1,6!.#F
M1CCIA>>/10]MKWA..;6+22SMKJU66ZMKES&8E(#,DAXX'(8' (R",$BJK^!O
M#[V<%J+6XCCMU>.(Q7L\;JCG+1[U<-L.!\F=O XXK0O] TS4M"_L2XM<:;L2
M,00R-"%5<;5!0@@# X![4 >=2V4:Z9=2V%DMEX;UC6-/@AM%01))"759'\O
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M>F!Z8XJA%X'@_L%]#O=9U._TLVJVJ6UP(%$07;L96CB5MR[1@DGW!- &?/\
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M** "BBB@ HHHH *SK_\ UZ_[O]36C6=?_P"O7_=_J:3V(GL5:***DS"BBB@
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M "LZ_P#]>O\ N_U-:-9U_P#Z]?\ =_J:3V(GL5:***DS"BBB@ HHHH ****
M"BBB@ HHHH BF_AJ*I9OX:BI$O<****!!1110 4444 %%%% !1110 5K^'O^
M0A)_UR/\Q616OX>_Y"$G_7(_S%..Y=/XD1>+/^$=_M'2_P#A)_[+^P[9MO\
M:?E^5YGR8QYG&[&??K7(B;PK%\5_!Z>$)=&198K]+U=(:(!U\M&02>7U&5)
M/<<=*]-U'2]/U>V^S:G86M[;[@WE7,*R+D=#A@1GFJ=CX4\.:7=I=Z?H&E6E
MRF=DUO9QQNN1@X8 $<$BMSL->LCQ5_R)^M_]>$__ *+:M>F2Q1SPO#-&DD4B
ME71URK \$$'J* ,73].M=7\"V6G7T0EM;G3HXI4/=3& ?Q]ZY+1K:[N_#_B3
M4=7N_MM[80W>D6\Q3!$4606/^W(0"Q_V5';GL='T+PU8S/>:)I6DV\H+P/-9
M6\:-E6PR%E'9EP1ZCVK12QM(X9H4M8%BG9GE18P%D9OO%AW)[YZT >;6,VJ7
M:> ['5;*RL+)1#<6U]%=-,9I$@.V'!C7RV92S=2,*P!)Q4.HZK=#5KOQE'HU
M_+;65\$COD>'RA8Q;HIL@R>81N:9^$YVIVYKTB]M])CL(8+^&R2S22-(8YU0
M1JX($84'@'. H'?&*B$^@VLL7AP2Z;#(\)$>F!D4M%@Y B[K@-VQP: &&:76
M#=:?-IVIV=M_#>I<1H)@&'W&CD,BY'<A3CT-8OPRMH;/P;]EMXQ'!#J%['&@
MZ*HN9 !^5='!J6E+?G1K>]LA>6\8)LHY5\R-,#!V Y"X([8Y%6(+:VLH3';P
M101;FD*QH%7<Q+,<#N222>Y- '-> O\ D&ZQ_P!AW4/_ $H>N=L?$^N-::1J
M4FHF0ZQ;WKR630QA;)HD9EV$+N^4J$;>6R6'3I796_AOPM<W,>LVVBZ/+/*P
MNH[Z.UB9G8_,)!(!DDYSNS[U<BT328+NZNX=+LH[F[!6XF2W0/,#U#G&6_&@
M#SN+Q3XATK3$O9M0DU22Y\+2:P(IH(U6.9/+X7RU4[/WAR&)/R]170^'[W4H
M_&,VD7.O-JUNNE0W89XHE8.[L"<QJHP0 0,=#WZUT<VDVQMBEG'%9W"6S6MO
M<10(6@0X^5001M!53MQCY1Q6+X6\')X>O[J^=]/\Z:%(%CT[3Q9PHBEFSL#-
MEB6))SV' Q0 FL_\E&\*_P#7M?\ \HJY[4/%'B/_ (2;53:B=+;3=1M[00L]
MI':LCB,L96D<3;V\P[=GR\(,,=U>C/:V\ES%<R01//"&$4K("R!L;@#U&<#.
M.N!5:;1=*N=3BU.?3+*74(0!%=26ZM*@&< .1D=3T/<T <%+K7B![6XN4UR:
M-I/$O]E1H+>$I%#Y^S(RF2V#C))' XSDDM=8\06UW'+/KL]U%!XB_L@PR6\*
MB:)OXG*H#O&X8*[1A1E3R3Z!_9FG[-GV&VV^?]IQY*X\W.[S.GW\\[NN:7^S
M-/Y_T&VYG^TG]RO^M_YZ=/O?[76@#G_$ELUSXDT9M/U6VL];@AN7M8;RV:6&
MXC(0..&7# [#D-D G@@FL"+6Y8-*:RL[:?3=4GUN6UGBTGR[CSYA&99&A:XV
MQH#C)+#@AQC<=U=]J.E:=K%L+;4["UO8 P<17,*R*&&0#A@1GD\^]0S:!HUS
MID6F3Z382Z?$08[5[9&B3'3"$8'4]N] 'F6G:OJFKW7A/5I[^XEN(O[40QQK
M"1/Y+$+G:A&64 $K@?W<9J+^W?$>L>$KS[9<77V?4_#US=L9FLEVN$! MTC9
MG:,AF5O,!8?+R"37K$.E:=;R1R06%K$\;NZ,D*J59_OD$#@MW/?O45KH.CV4
MMU+::38V\EWG[2\5NB&;.<[R!\W4]?6@#AK76=6TV33O#@U&26ZU".QDL)I(
MH]RPX_TA<!0#M6)CDCCS5YK6\</=IKG@]K&"">Y&IR;(YYC$C?Z--G+!6(XS
M_":UX/#=O#KMI?(MK':Z?;/!86L%L(Q!YA7><@X.=@  "X!/7/&O+:V\\L,L
MT$4DD#%X7= 3&Q!!*D]#@D9'8F@#S;Q#HVJ1+_:%[);6=[JFOZ<52S<S+"$*
MH&W.J[GXSRH'"CG%3?\ "0ZM';76E/J6H7%['KKZ?!-:VUL;F>,0"?'S[85(
MR<L5Z+@#)R/0Y[6WNA&+B"*81R+*@D0-M=3E6&>A!Z'M52ZT'1[Z":"\TFQN
M(9IO/ECFMD=7DP%WL".6P ,GG H \[L_$GB75_#FDRVU],\S-?+<_86LS=N(
MI2D<@27$;H ,/LQRRD<'%)J?C/7+Z9Y-&FN1;V^BP:C%)'':PQ3M)O.^?[0X
M98AL Q&<C+9;[M>@W/AO0KRU%K=:+IT]N)6F$4MJC()&R6?!&-QR<GJ<U)>:
M%I&HO;/?:58W36O_ ![F>W1S#T^[D?+T'3T% "32VL^FVDNH_8XWE:)HA.5=
M%G."FW)PS;L8P<GM6#X',B2>);&65);F#57,]W;C;%)(\:.=B'.S:&"E26Y!
M)/.!U-W9VU_:R6MY;0W-O*,20S('1QZ$'@TVQL+/3+..SL+2"TM8\[(8(Q&B
MY))PHX&22?QH \N\(/JT$/A[28=;NXH+R[U>2=O)@+_NKG@#,>!D[B>#]]L8
M&W;"OB;4XO!FG+87=U;7*:9<WL@L+6TCC0+(55Y#+\HC!SE8T+'D^Q]2@T?2
M[6Y-S;Z;9PSM))*98X%5B[XWMD#.YMJY/4X&>E0R>'=#F%J)=&T]Q:$FV#6J
M'R<G)V<?+DC/% ',^#;R34?%VKWTH427.CZ5,X7H"PG)Q^==S5:UTZQL3FSL
MK>W/EI#F&)4^1 0B\#[J@G Z#)Q5F@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** (;O_CRG_P"N;?RJ4=!45W_QY3_]<V_E4HZ"GT%U%HHHI#.8
M^(__ "3;Q'_V#YO_ $$UR\6IWFL^!KJRTSQAHUWJ<&G)<6L&E9BG1X]K8<B=
MR5. AX'WOPKT^J]]9PZA92VDYE$4HVMY,SQ-CV9"&'X&@#QRY\0ZSJ7AR#Q,
MMW<V^EZQKBJXEOI+6."T1"B R*&,"O(N690,[@">:ZJTFO;CX+:M)?7J7K'3
M[T17"M(^^+:^S+R(C/A<#?M^; /.<GN;"QM=,T^WL;*%8;6WC$<4:]%4# %6
M* /&DU.TU/3_  ,-#O8;B_TW2Y6O)+24.;6+['M*R%3\I+[  ><CVIVG7,MO
MH'@:;6-<U*'2=3MWFU.^FU*9,S>4#$AEW9B4_/PI4,5&<GK['10!X;:Z[<RW
M&@)XGU_4K&QETF\<3&[DM6F"S 02.5V_,4VD$X+$@<[L&KJ?B#Q';6OA[4-2
MU6Z\[^S;9Y--ANY+.[DD,OWXE*^5<,PVAHV#'!(P,YKV]](L9-:AUAX,W\,#
M6\<N]N(V()&,XZ@<XS5V@! <@'&/8TM%% !4%Y_QZM_O+_Z$*GJ"\_X]6_WE
M_P#0A36XGL%%%%22%%%% !1110 4444 %%%% !1110 56JS5:@ HHHI""BBB
M@ HHHH **** "BBB@ HHHH A;[Q^M)2M]X_6DI""BBBD 4444 %%%% !1110
M 4444 %9U_\ Z]?]W^IK1K.O_P#7K_N_U-)[$3V*M%%%29A1110 4444 %%%
M% !1110 4444 13?PU%4LW\-14B7N%%%% @HHHH **** "BBB@ HHHH *U_#
MW_(0D_ZY'^8K(K7\/?\ (0D_ZY'^8IQW+I_$CI:***W.P*S/$=Y-IWA?5KZV
M!,]M9331@=V5"1^HK3ILD:31/%(H:-U*LI'!!ZB@#SZ<ZE:WFFZ%I6L3Z?9V
M_A][K=#%%(\CH44$M(K==Q)[GUJ2'4/$&KZ/H^IP#Q(/MFG6]Q)_98TT0[W0
M,V/M'SYR?ITQ75:3H<&G6-O;S"*ZDMX3:Q7#Q#S/L^?EC9B26X"@GHQ&<#I6
MC!!#:V\5O;Q1PP1($CCC4*J*!@  <  =J /*O'VIM)/IT5];ZPD>FWNGO'NL
M97$\K2QL[L\2&,LJY4*K<L[@#A:L7C.]_JY&/[0_X2W3_*# AA%Y=OCCJ!L\
MW/MN]Z],N+6WNXUCN8(ID5UD59$# ,IRK8/<$ @]B*@?2=-DU2/5'T^T;4(D
MV1W;0J947G@/C(')XSW- 'G=@7.H:1M(.H?\)=J'G8^]Y>RXSGVV>5U[;?:M
MK2-0\2R_$/6+6ZM+(6J6MFS1KJ4CK"I:?YT4P@%FQ\P^7[J\GMU2:3IL>J2:
MHFGVBZA*FR2[6%1*Z\<%\9(X'&>PJV<X..#VS0!SOA)BAUVS4'R+3594AR>B
MNJ2D#V#2, .V,5T=9^BZ6-(TX0-+YT\DCSW$VW;YDKL6=@,G R>!DX  R<5H
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 <W)8>,6E<Q^(='5"Q*J='D) [#/VCFF_V?XT_Z&31O_!-)_P#)%=-1
M0!S/]G^-/^ADT;_P32?_ "11_9_C3_H9-&_\$TG_ ,D5TU>6W$=Q?ZU\0KB3
M6-4MY-*\M[)HM0F2.W(M@^?+#!&&X9(8$'GUH ZS^S_&G_0R:-_X)I/_ )(H
M_L_QI_T,FC?^":3_ .2*X-/B#KD=TLL5O;"ZNH]&5A<-,R*URK;_ )-^U2#_
M '5'OGC&II_COQ$=7MHKY=+DM#K\NARB"WD1W959A*I,C!1]T;2&Z'YN> #J
M/[/\:?\ 0R:-_P"":3_Y(H_L_P :?]#)HW_@FD_^2*K:C>72?%?0[-+F9;63
M3+IW@$A",P:/!*]"1DX/O6-XL\97OA[Q7JD5K!'+)'I=L;<2RR[/-EN#$"R!
MMNT9!)"ACC&[I@ Z+^S_ !I_T,FC?^":3_Y(H_L_QI_T,FC?^":3_P"2*XCQ
M#XI\2R0ZIIKW=K!>:;KFGVT5Q9I)"LJR;6.]=Y.TYP5!Z<<]:EO?%OB6^ETN
MUCOK*UG@\4OI-T\-L^RX"IO4[3)E5QU7<<\?,!D$ [+^S_&G_0R:-_X)I/\
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M3_H9-&_\$TG_ ,D4?V?XT_Z&31O_  32?_)%=-10!S/]G^-/^ADT;_P32?\
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MBBX7,+[%XH_Z#>F?^"Q__CU:>AV/BUKUQ%KVE(WEGEM*=N,C_IN*M5K^'O\
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MYA<  +"_3RSW'6J5E\1M+FFL?M[0:7;W5@;KSKVY6,)()-ABYP"<AN0><=*
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MMCAI%0N3@X5=PYQU*CC- '*ZIX.U>?PUJDMC"L>M+?:A);(SKBXMYW;=&3G
MW*589QAE7..:MZEX6U7Q-#9V%WYFF6NDV\4MG,KJS/?!?EE^4GY(_0XW$GL
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M6GB.PD:YOWD$:EN(H_,<[5W$#"X&[ ZCCAW^'_B6+PYHB6^E7":M;Z6+-_\
M2;::U;]\6,=S!)\K)ALAD+$'G;E16[JWA3Q#//XF":89FN=2L=1MY(YHU281
M"/>@W-N#?*V-P X^]0!Z)<^(=$LUE:ZUC3X%BE\F0RW2*$DV[MAR>&V\XZXY
MK.TOQSX?U;4;BPAU"".XBN/L\2RS1@W)V*^Z(!B77##D5Q">$M?O=:CO[G1F
M@C?Q7'JACDGB9D@6#:&.UB,AL< GGID<TZ^\*>(+F^\064>C%8]3UVWO8=2\
M^+;%%&8R6(W;\_*P4 'J<X'4 ]'&OZ,VH3:>NK6!O8%+RVPN4\R-0,DLN<@
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M5UI5CN$ULT,3PJ8Y4,T@61U!^9B.>>_6N3^(EA:6'B9!9VT=O'-:QRM'$NU
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M/_\ %UTU% ',_P#"O_#7_/E/_P"!L_\ \71_PK_PU_SY3_\ @;/_ /%UTU%
M',_\*_\ #7_/E/\ ^!L__P 71_PK_P -?\^4_P#X&S__ !==-10!S/\ PK_P
MU_SY3_\ @;/_ /%T?\*_\-?\^4__ (&S_P#Q==-10!S/_"O_  U_SY3_ /@;
M/_\ %T?\*_\ #7_/E/\ ^!L__P 77344 <S_ ,*_\-?\^4__ (&S_P#Q='_"
MO_#7_/E/_P"!L_\ \77344 <S_PK_P -?\^4_P#X&S__ !='_"O_  U_SY3_
M /@;/_\ %UTU% '*7/@'PVMI,PLI\A&(_P!-G]/]^I!\/_#6/^/*?_P-G_\
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M3<YS_A!?#O\ SYS?^!DW_P 71_P@OAW_ )\YO_ R;_XNNCHH"YSG_""^'?\
MGSF_\#)O_BZ/^$%\._\ /G-_X&3?_%UT=% 7.<_X07P[_P ^<W_@9-_\71_P
M@OAW_GSF_P# R;_XNNCHH"YSG_""^'?^?.;_ ,#)O_BZ/^$%\._\^<W_ (&3
M?_%UT=% 7.<_X07P[_SYS?\ @9-_\71_P@OAW_GSF_\  R;_ .+KHZ* N<Y_
MP@OAW_GSF_\  R;_ .+JC>^"= 28!;2;[O\ S]S?_%UV-9U__KU_W?ZFDWH3
M)NQRW_"%Z#_SZ3?^!<W_ ,51_P (7H/_ #Z3?^!<W_Q5;]%1=F=V8'_"%Z#_
M ,^DW_@7-_\ %4?\(7H/_/I-_P"!<W_Q5;]%%V%V8'_"%Z#_ ,^DW_@7-_\
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M_P#\71_PK_PU_P ^4_\ X&S_ /Q==-10!S/_  K_ ,-?\^4__@;/_P#%T?\
M"O\ PU_SY3_^!L__ ,77344 <S_PK_PU_P ^4_\ X&S_ /Q='_"O_#7_ #Y3
M_P#@;/\ _%UTU% ',_\ "O\ PU_SY3_^!L__ ,71_P *_P##7_/E/_X&S_\
MQ==-10!S/_"O_#7_ #Y3_P#@;/\ _%T?\*_\-?\ /E/_ .!L_P#\77344 <S
M_P *_P##7_/E/_X&S_\ Q='_  K_ ,-?\^4__@;/_P#%UTU% ',_\*_\-?\
M/E/_ .!L_P#\71_PK_PU_P ^4_\ X&S_ /Q==-10!S/_  K_ ,-?\^4__@;/
M_P#%T?\ "O\ PU_SY3_^!L__ ,77344 <S_PK_PU_P ^4_\ X&S_ /Q='_"O
M_#7_ #Y3_P#@;/\ _%UTU% ',_\ "O\ PU_SY3_^!L__ ,71_P *_P##7_/E
M/_X&S_\ Q==-10!S/_"O_#7_ #Y3_P#@;/\ _%T?\*_\-?\ /E/_ .!L_P#\
M77344 <S_P *_P##7_/E/_X&S_\ Q='_  K_ ,-?\^4__@;/_P#%UTU% ',_
M\*_\-?\ /E/_ .!L_P#\71_PK_PU_P ^4_\ X&S_ /Q==-10!S/_  K_ ,-?
M\^4__@;/_P#%T?\ "O\ PU_SY3_^!L__ ,77344 5M/T^VTNQCLK-&2WCSM5
MG9R,DD\L23R3WHJS10 4444 %%%% !1145S(8;6:50"R(6&>G H EHKSG1/&
M?B!]'\,:UJITR:QUR>.V:&UMI(I+=Y =C;FD<.,K@C"GY@>QKF;?XRZW)X!U
M'4WL=/\ [:ANE6WB"/Y3PE7<L1OW9 AF[CE10![917F$'Q"O[G69+.ZUWPWH
M<::?9W2MJ$+$S/-'N<+F=.%/UZBO3(2Q@C+NDC%1ET&%8XZ@9.!^)H ?1110
M 4444 0W?_'E/_US;^52CH*BN_\ CRG_ .N;?RJ4=!3Z"ZBT45Y_XN\=ZCHR
M>*&TVWM770K.WD9IU9M\TK<+PP^4)SZY8>G*&>@5YOXE\&Z[XM\4ZO)(]I9Z
M8NF?V=:&ZA\_S?,^:210LJE&!" %@?N]/7;N?B%IMKK<^FO8:B1;WT-A-=*B
M>4DLH!C_ (]Q!W8R%.,<XXSE6?Q/.Z\^WZ#?H1KAT>SB@,3M)(%SAB9  <@Y
M/"C>O)PS  K6?AWQ3JFM^&]1U!KO2)[;19+6]GMI;>1Q-O7CY@X(8*6R!QQR
M.E0>)OAS>:KIVD^$M)C%GH6F1/="^N"DKS77.Q<')QN9G<[<'.!BNEF\?V%K
MXAL]%N].U"VNKMQ'%YWDKE]A; 7S-Q&1LWA2F[C=WJM<?$C3'T47EG'=B232
MKC4AOMU?[.D1VD2)YB_-NRNT,,E2,CK0!@^)K;QEXLMM%T[4_#E[#I#PB768
M+*ZMO,FE5CB(%I5PAVAL@YPP'4&G3>#-6FUN2S6Q9-/G\10:W]L\R,)'&D8S
M$5W;M^Y0!@%<'.>,5;'Q36TGUN;4M)NUTW2[6QE,\*QEW:X. =GF' .Y2 ,D
M!6R<E16Q=?$*PL))$O=+U.W^S)')?EEB86*2.50RE9#UQN^3<0.3CF@#C].\
M!:LUA9Z;J6CB6WT?2;RQ >Z1%U!Y'&S8REF0;5SE@""0,'DUT_@3P[J.G:IJ
MVKZD+Y)+V*V@2.^FADF B4C+&$;,9; QR0N3R35ZY\>Z=:^*8_#TUK=PW4[,
ML$LHC5)2JELA-_F;,JRA]FTD'!/6F>'_ !DMS\-;3Q9KABMU:V,T_D(VT?,1
MA1DGG@ 9/)H ZVBN-NOB1INGVEW)?Z9JMI=6LD"R6,D<9F*S'$;KM<J5)R#A
ML@J00.,]9:3R7-K'-+:S6LCC)@F*%T]CL9E_(F@":J.L?\@BY_W*O51UC_D$
M7/\ N5,_A94?B1PU%%%?,'T(4444 %%%% !1110 4444 3VEW-93"6%L'N.S
M#T-=;8:A#?Q;D^5Q]Y#U'_UJXNI(9I+>598F*NIX(KJPV*E1=MT<N(PT:JOU
M.\JM4>F7S7UKYC1E&!P3C@_2I*]R,E.*DMCQ9Q<)<K"BBBF0%%%% !1110 4
M444 %%%% !1110!"WWC]:2E;[Q^M)2$%%%%( HHHH **** "BBB@ HHHH *S
MK_\ UZ_[O]36C6=?_P"O7_=_J:3V(GL5:***DS"BBB@ HHHH **** "BBB@
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M6L*F%PQECW[U*D97'EOG<!T]QGF+#P5?076FW;I:02Q:N;^X07MQ<LR?9WA
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M3HUO?/&A/EPSAFCD$8).%;"G&>WJ22 =C5'6/^01<_[E7JI:LI;2KA5&6*X
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MXO#W_/GJ?_?J/_XNC_A<7A[_ )\]3_[]1_\ Q= 'H5%>>_\ "XO#W_/GJ?\
MWZC_ /BZ/^%Q>'O^?/4_^_4?_P 70!Z%17GO_"XO#W_/GJ?_ 'ZC_P#BZ/\
MA<7A[_GSU/\ []1__%T >A45Y[_PN+P]_P ^>I_]^H__ (NC_A<7A[_GSU/_
M +]1_P#Q= 'H5%>>_P#"XO#W_/GJ?_?J/_XNC_A<7A[_ )\]3_[]1_\ Q= '
MH5%>>_\ "XO#W_/GJ?\ WZC_ /BZ/^%Q>'O^?/4_^_4?_P 70!WEW_QY3_\
M7-OY5*.@KSJX^+_A^2VE06>IY9"!F*/T_P!^I/\ A</A['_'GJ?_ 'ZC_P#B
MZ?074]"K!E\':-)JUUJ:K?P7=VZO.]MJ5S"LA50JDJD@4X  Z5S?_"XO#W_/
MGJ?_ 'ZC_P#BZ/\ A<7A[_GSU/\ []1__%TAG3KX0T)=9.K"Q_THS_:<><_E
M>=MV^;Y6[8),#&_;GWJK_P (!X8+SEM+#K-'-&8GFD:.-9CF3RT+;8RW<H%-
M87_"XO#W_/GJ?_?J/_XNC_A<7A[_ )\]3_[]1_\ Q= &W#\/O#,"W 6PE8W$
MD$DS2WDTC.T))B)9G).W/'/3 Z#%:.L>&],UV>SGOXIS/9,[6\L%U+ \98;6
MPT;*>1Q7)_\ "XO#W_/GJ?\ WZC_ /BZ/^%Q>'O^?/4_^_4?_P 70!TA\&:
M=.BL19.D<5PUTDJ7$JSB9L[I/.#>86.3DELD<&HY/ GAJ6V2W;2T$*6+:>J+
M*ZCR&(9EX;J2 2WWL]^37/\ _"XO#W_/GJ?_ 'ZC_P#BZ/\ A<7A[_GSU/\
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MYZG_ -^H_P#XNHKCXO:!+"46SU/)(ZQ1^H_VZ:W$]CT"BN _X6]H'_/GJ?\
MWZC_ /BZ/^%O:!_SYZG_ -^H_P#XNI$=_17 ?\+>T#_GSU/_ +]1_P#Q='_"
MWM _Y\]3_P"_4?\ \70!W]%<!_PM[0/^?/4_^_4?_P 71_PM[0/^?/4_^_4?
M_P 70!W]%<!_PM[0/^?/4_\ OU'_ /%T?\+>T#_GSU/_ +]1_P#Q= '?UE6&
MCI!.US/AI2Q*CLO/\ZY7_A;V@?\ /GJ?_?J/_P"+H_X6]H'_ #YZG_WZC_\
MBZB5.,FG+H7&<HII=3OZ*X#_ (6]H'_/GJ?_ 'ZC_P#BZ/\ A;V@?\^>I_\
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M_P + TK_ )][W_OA?_BJ+,.5G5T5RG_"P-*_Y][W_OA?_BJ/^%@:5_S[WO\
MWPO_ ,519ARLZNBN4_X6!I7_ #[WO_?"_P#Q5'_"P-*_Y][W_OA?_BJ+,.5G
M5T5RG_"P-*_Y][W_ +X7_P"*H_X6!I7_ #[WO_?"_P#Q5%F'*SJZ*Y3_ (6!
MI7_/O>_]\+_\51_PL#2O^?>]_P"^%_\ BJ+,.5G5UK^'O^0A)_UR/\Q7GO\
MPL#2O^?>]_[X7_XJKVE?$W1;&Z:66UORI0K\L:9ZC_;]J<4[E0B^9'K-%>>_
M\+B\/?\ /GJ?_?J/_P"+H_X7%X>_Y\]3_P"_4?\ \76QUGH5%>>_\+B\/?\
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MYZG_ -^H_P#XNC_A<7A[_GSU/_OU'_\ %T >A45Y[_PN+P]_SYZG_P!^H_\
MXNC_ (7%X>_Y\]3_ ._4?_Q= 'H5%>>_\+B\/?\ /GJ?_?J/_P"+H_X7%X>_
MY\]3_P"_4?\ \70!Z%17GO\ PN+P]_SYZG_WZC_^+H_X7%X>_P"?/4_^_4?_
M ,70!Z%17GO_  N+P]_SYZG_ -^H_P#XNC_A<7A[_GSU/_OU'_\ %T >A45Y
M[_PN+P]_SYZG_P!^H_\ XNC_ (7%X>_Y\]3_ ._4?_Q= 'H5%>>_\+B\/?\
M/GJ?_?J/_P"+H_X7%X>_Y\]3_P"_4?\ \70!Z%17GO\ PN+P]_SYZG_WZC_^
M+H_X7%X>_P"?/4_^_4?_ ,70!Z%17GO_  N+P]_SYZG_ -^H_P#XNC_A<7A[
M_GSU/_OU'_\ %T >A45Y[_PN+P]_SYZG_P!^H_\ XNC_ (7%X>_Y\]3_ ._4
E?_Q= 'H5%9^AZQ;Z_H\&IVJ2I!/NVK* &&UBIS@D=0>]% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '; \T# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BDI: (+FX%NH)&<U7&I+GE<4NI<K&/<UG@
MYXII"-F&=)@2O;K4M4=-^[)^%7J0PHI*6@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYW=?:J_P^+:9XS\1Z/ [O:+#.HYX_=OM5C^!(_&IGAZ:YE!N\1QK3T<MF/\
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MQZM)XFT>+75T1[U1J+$ 0;&SR-PYQCI[T:GXFT?1[^"RO[U8;F< QH48[LG
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M]^HXTHQM;H4]6TR#6=)NM.N@?)N(RC$=1Z$>X.#^%>4GX9>+H+:72+;6K?\
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M_B!7E6_ Y]J]#HK.G5E3ES1*G",U:1Y!+\.O&FN/'#KFNQM:QMGYIGDQ[A<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** $%+2"EH Q[S_CZ>H\<5/=
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M4Q^M2^/;I_%7CO2?#UC,3"H4LR'N^&9O?" '\ZF.%YK-/1J]^UANO:Z:U1[
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MA-3BI(****S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $%+2"D9MHS0!
MF71_TEZCI975KIOFQGU%2^4NW_6**8A+3_C[7Z&M2L2*;;=8!SCN!Q6M$^Y:
M0(D-+333J!A1110 4444 %%%% !7EWQ@TK4=3?1_L&GW5WY8FW_9X6DVYV8S
M@<=#^5>HT5K1JNE-370BI#GCRL@LU*V-NK AA&H((Z<5PGQ;TZ^U+0;&.PLK
MBZ=;K<RP1,Y VGD@#I7H5%*G4<)J:"<.:/*9&C69?P=I]C=1NA;3XX94889?
MW8!!!Z&O'K32=3\$:G>0:AX3CUNWDXBE:#>O&<,K;6QG/*]>E>\45I3Q#A?2
MZ9,Z2E;75'F7@32]=GN[O4KO2=/TI#&XM<:>D4BNW3& &V@>O7WYKG+V;6OM
M5Y;^)_!IU:[D.(;F& QD'&.'C7YQT/7->X45:Q7O.3C_ %ZDNA[J5SR/PGX!
MU.7P/KEI?(UK-J(C,$4O!4QDL"P[9/'KBL'3_P"U/#^G3Z3=^!(KV]W-Y-U+
M9^85S_P$[P#R.:]ZHIK&2N^97OJ+ZNK*SV/,]*T/6(OAYKC7^F6T-]=V[+%!
M:6:1RD '&X(!DDG@=OQK1^$]A>Z=X4N(;ZTGM93>.P2>,HQ&Q.<'MP:[NBLY
MXARBXM;NY<:2BT^QROQ"T%M?\(W,,,9DNH")X%49)9>H'J2"1CUQ7(_"GPQ?
MV^J7FKZM:7,$D<8A@%S&RL<]2-W/  'XFO6**4<1*-)TUU"5).:F>*^(=)U+
M2/B3/J]UH$VLV,LA>- A=&RN #@$ J>Q':FZ=8Z])\3-/UN[\.W5G;S2HP2&
M!BD*%=@W$#"XQDYQZX%>V45K]<?+:W2Q'U=7O?K<\=\9VNKZ-\38O$%KI<]Y
M#A'38C%20FTJ2 <'BE\86FL:[XB\,ZG'HUZ-UO"TZI;N1"WF$LI..,>_:O8:
M*4<4URNVJ5ANA>^N^IQ?Q-\/2:[X6+VL+RWEHXEB1%+,P/#* /;G_@-8OPH\
M-WME)J&L:K;7$-U*?)C%PA5R/O,V&YY.WGV->G45FL1)4G2Z%.DG4YSQ;7_#
M>H^&_'%QK*:$NM:9<R/*8C%YB_/R01@[2">#C^M7/#-IK&N>*8KL>%].TK28
MW5R)-/0$8Y^5BH8L3W' KUVBM'BVXV:UM:Y"H).Z>@5Y/X-TC4[7XJZO>7&G
M7<-K(]R4FD@94;,F1AB,'(KUBBL:=5PC)=S6<%)I]@KROX?Z3J5E\1-<NKK3
M[N"WD28)++"RHV95(P2,'CFO5**(57",H]PE!2:?8\X^*GA*^UN*TU+3(3//
M;*4DA499D)R"!WP<\>]<K+<ZOJ_V:STOP#965RI FE?3D*L??>@"#O\ UKW&
MBM:>*<8J+5[;&<J"E)M.USROQYX&U&[T+2KBPMX9;NQA\N>"UB"*V><HH[!L
M\=\UA2W.KZO]FL]+\ V5E<J0)I7TY"K'WWH @[_UKW&BG#%M1LU>PI4$W=.Q
MYMXMUW7O!.D:/#I]K:&/RBMP\=J1"LG'"XP%R2V!WKTFL36O#%GK]_87%]+.
MT5FQ<6P?]W(W&"P[XY_.MNLJDXRC&RUUN:0BU)WV/(/B9INL2^.+#4-.TJ\N
MU@MXF#16[NNY9'."5'T_.K/_  GWCS_H3I?_  #GKU:BM%B5RJ,HIV(=%\S:
ME:YY'\3;'6==TSPW<Q:3=R7!MW>XB@MW;RG81DJ0 2.<CGTIK^+?B%=6/V&U
M\-36S&/RQ-]DE#*,8R"QP#7KU%$<2E%1<4[ Z+<FU+<X7X;^"Y_#%G/=ZAM^
MWW0 **V?+0<X)]2>OT%8OQ?TG4M3N-)-AI]W=B-)0Y@A:3;DKC.!Q7JE%3'$
MR57VKU93HQ=/D1P/Q+;5)/"=MIFFV%Y<R73*)O(A9]J+@X.!QDX_(U2T#X4:
M-+H-E+JT5S]NDC#S*)"NTGG;CL0"!^%>ET4+$3C#DCH#HQ<N:6IXM<>&M1\%
M?$2UO-&TV_NM-4JV8H6EPC#:ZD@=>I'X5[3114U:SJVYMT.G34+VZGD_@W2-
M3M?BKJ]Y<:==PVLCW)2:2!E1LR9&&(P<BO6***56JZDKL=."@K'E?P_TG4K+
MXB:Y=76GW<%O(DP266%E1LRJ1@D8/'-7?BIX2OM;BM-2TR$SSVRE)(5&69"<
M@@=\'/'O7H]%:?69>U51$>Q7)R,\.EN=7U?[-9Z7X!LK*Y4@32OIR%6/OO0!
M!W_K6[X\\#:C=Z%I5Q86\,MW8P^7/!:Q!%;/.44=@V>.^:]4HJOK;4DXJUB?
M8)IJ3W/#I;G5]7^S6>E^ ;*RN5($TKZ<A5C[[T 0=_ZUU'BW7=>\$Z1H\.GV
MMH8_**W#QVI$*R<<+C 7)+8'>O2:Q-:\,6>OW]A<7TL[16;%Q;!_W<C<8+#O
MCG\Z:Q$)27-'1?,/8R2=GJ;=>->-='U*R^(O]MRZ++J^G.481*A93A NTX!Q
MSSR.??FO9:*QHUG2E>U[Z&E2GSJQX:]GKUWX[TG7)?#%W96?GPLL,%NS"*-6
M .[ X/4\@5NZEI.I/\:[>_33[MK,/&3<"%C&,1@'YL8ZUZK16KQ;OMTL9J@N
M_6YY5\2M)U*_\8Z-/9Z?=W$,:('DAA9U7]X3R0..*C\<Z#K6D^-8?%FC6CW2
MDH[K&A8JRC:00.=I4=1[UZS12CBI145;96];CE03N[[GA'B^;Q9XS6TNW\-W
MD%K!E(XXX7=BQP68\9QP.<8KV[3U9--M4=2K+"@((P0<"K-%15K^TBHI62*A
M3Y6Y-WN>5>/?"^MVOBF'Q3H,+W#J59XXUW,CJ ,[>I!'7'O63K>L>,O'%E'I
M'_".26\9D#2/Y+J-P]6;A17M=%:1Q325XIM;,F5"[=G9,\R\3>$+ZU^%%EH]
MJC7=S92K-(L(+%LEBVT=3@O^0JCIDFN^(OAQJ'A\:5/:S6EO$L#LK+]HPV67
MD 9P!QGO7K=%2L2^6S5W>XW15[I]+'@VFPZPOA:ZT"U\%R_;Y WFW\D)5MO7
M'S+UQP!G\,ULZ+I>J)\(-<TV32[Z.\-P&2%[=PS@F/E1C)Z'IZ5[!15RQC?V
M>MR5ATNO2QXEX=U?QAX-T!K0>'+F:&X9I(&>%\Q,?E.X >V0#CU[UJ^"/">J
M6'AKQ!J-_;2)=WUI)'#"R_O"-K$Y'7))&!UXKUBBE/%MIVC:^X1H6:N[V/(?
M!WA/4+[P#KVDWEI/93W$JM#]IB:/+* 1U'3(QFL/3_[4\/Z=/I-WX$BO;W<W
MDW4MGYA7/_ 3O /(YKWJBG]<=W=:/4/JZLK/8XWX>:5J=CI<USJUC96EQ.1M
MC@M4A?:,_?V <G/3M^-=E117-4FYR<F;1CRJP4445!04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<5\4-3
MOM)\*1W&GW4MM,;I%+QM@X(;C]*\<_X3?Q/_ -!R]_[^FNRC@Y58\R9SU,0J
M<N5H^F**^9_^$W\3_P#0<O?^_IH_X3?Q/_T'+W_OZ:U_LV?=&?UR/8^F**^9
M_P#A-_$__0<O?^_IH_X3?Q/_ -!R]_[^FC^S9]T'UR/8^F**^9_^$W\3_P#0
M<O?^_IH_X3?Q/_T'+W_OZ:/[-GW0?7(]CZ8HKYG_ .$W\3_]!R]_[^FC_A-_
M$_\ T'+W_OZ:/[-GW0?7(]CZ7 Q05##FOFC_ (3?Q/\ ]!R]_P"_IH_X3?Q/
M_P!!R]_[^FC^S9]T'UR/8^D6M8VZBF_8HJ^</^$W\3_]!R]_[^FC_A-_$_\
MT'+W_OZ:/[-GW0?7(]CZ1%I&.U2J@7I7S3_PF_B?_H.7O_?TT?\ ";^)_P#H
M.7O_ ']-']FS[H/KD>Q]+D9I:^9_^$W\3_\ 0<O?^_IH_P"$W\3_ /0<O?\
MOZ:/[-GW0?7(]CZ8HKYG_P"$W\3_ /0<O?\ OZ:/^$W\3_\ 0<O?^_IH_LV?
M=!]<CV/IBBOF?_A-_$__ $'+W_OZ:/\ A-_$_P#T'+W_ +^FC^S9]T'UR/8^
MF**^9_\ A-_$_P#T'+W_ +^FC_A-_$__ $'+W_OZ:/[-GW0?7(]CZ8HKYG_X
M3?Q/_P!!R]_[^FC_ (3?Q/\ ]!R]_P"_IH_LV?=!]<CV/IBBOF?_ (3?Q/\
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MC_A-_$__ $'+W_OZ:/[-GW0?7(]CZ8HKYG_X3?Q/_P!!R]_[^FC_ (3?Q/\
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M?\)OXG_Z#E[_ -_31_9L^Z#ZY'L?3%%?,_\ PF_B?_H.7O\ W]-'_";^)_\
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M#[BA%W ''!/'Y5G]:E)QY%U:M\BO8**?,SR/PQH$GB;7(M,BG6!I%9M[+D#
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M\Z\RHI?5:5K6_%C]O4[A111708A1110 4444 %%%% !1110 5M_\R-_W$O\
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M1S&[(2,$J<4G0BE[FCM8?M9/XCTSXQ:^EWJ%KHUO*&2US+/M.1YAX ^H&?\
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MY>_^! _^)KM**/;U?YF'LH=CB_\ A5GAC^Y>_P#@0/\ XFC_ (59X8_N7O\
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MY>_^! _^)KM**/;U?YF'LH=CB_\ A5GAC^Y>_P#@0/\ XFC_ (59X8_N7O\
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MX4 -USZ=,UREU\/_ !/)\$+'PZFF9U6+4#,]O]HBX3+\[MVWN.])?76OZ?\
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MG[0&^PB(2%857'S9Y7(QR,GK6KX<B^)\)T'0I-/M=+TW3@L5U>>9'+]HB7
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M;WQ)=V=V[*=\;.W[M@<X R#G(KN](\07FK^--;T^%(?[*TM(X3+M.][AAN8
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M;!(SG&*]*HI6"YRGAOPI+H'B?6KU7B-A=6]G!;(&)=1#&4.[@#TQ@G\*Q!X
MU4?!^W\(_:+/^T(Y%8R;V\K N/-Z[<_=]NOYUZ-118+G.:3H%U8>-_$6M2R0
MFVU-+5855CO7RT96W#&!R>,$_A7.#P!JH^#]OX1^T6?]H1R*QDWMY6!<>;UV
MY^[[=?SKT:BBP7.&$+:W\7Q=Q'-IH-B87?M]HEYVCZ)@GTR*[FH;>TMK7S?L
MUO%#YLAED\M N]SU8XZD^M34T 4444 %%%% !3_^6/\ P*F4_P#Y8_\  J&
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MLT4450@HHHH **** "BBB@!Y_P!4OU/]*93S_JE^I_I3*$ 4444 >5Q^'?\
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M2L##(;B02O*PS@C"@Y[8'& .*LZ%\-K**TT>2_O]6N(+-8YX=,NIP8(90O\
M=QDX)X!/%%F!R6MWEU=^$O%0N;F:80^+EBB$CEO+0/%A5ST R>!7J'B\:HWA
M'4UT6=(-1,)$$C.$P?\ >/ .,X)[XJA/X TJXT_4K)[B]$>H:G_:<I#KE9<J
M<+\OW?E'!R?>MW5])L]=TBZTN_B\RUN4*2+G!QZCT(."#ZBFD(\N\+ZDUAK<
MFGW%UXETZ]ET^4FPUAC,D\BC)DBEW<$8/;!JI)<AOACX?U2YU779]<O+<6UE
M:VNHR1FYE+M@L ><9Y8]@!Z5W>G_  ^LK/44OKK5=5U*:"![>U-[.'%NCC#;
M<*.2.,G-9_\ PJ;2TETR6VUO7;673;;[-;/!<1@JN6)/^K/)W$$C'&*5F.YR
MVJ)K_AN#POX5N=1UW4)KWSKK4);&;=<R%5&(HW9@0@[\YQSWKHOA_/K4'B'4
M]-N+?6DT?R4FM?[8=7FB?.&3<&)*GJ,^GYZ\_P /[.[T^W@NM9UFXN[6X:XM
M=1DN5^TP$J 55@H&TXZ$&K_AWPG:>'I[N[^UW=_J%X5\^\O7#R,%Z*,  */0
M4).X7.3\::'#??%7P=OO-0B^U)>!O)NG39LB4C9@_+G/S8ZCK6=IEGJ7BKP?
MJ7B^?Q'JMIJ.ZYDM8K>Y,<-LL98*ACZ'.WG/7->CWV@6NH:_I.LRR3+<Z6)A
M J,-C>:H5MPQD\#C!'XUS]W\,]+N)KQ8=3U:ST^^D,MUIUM<!()6/WN-N0#W
M /-%@N<E!/JGCKQ1X=MY]7U'3[6[\.+>7D=E.8O,?S,9'4#)(.>N.*]<M+<6
M=E!;+)+*L,:QAY7W.V!C+'N3W-9=OX7TZU\0V^L6XDBEMM/_ +.B@0@1+$&#
M#C&<C '7&.U;5-(3"BBBF 5=M_\ 4+^-4JNV_P#J%_&IGL..Y+1116184444
M 0W/^J_&J=7+G_5?C5.M8;$2W"BBBJ$8OA2PN=,\/QVMW'Y<PGN'*[@>&F=E
MY'J&!K:HHH HKH]@NNOK0@QJ+VXM6FWMS$&W!=N<=><XS4+>'-(?Q&GB V2_
MVJD)A%P&8'9Z$9P?J1FM2B@#E8_AQX4BU1-0CTI5E27STC\U_*63.=PCW;0?
MPJ74_ /AK5]6DU.]T[S+F7;YVV9U2;;]W>@8*V/<5TM%*R"YA:;X.T'2);"2
MQL?*:P22.U_?2-Y:R'+@ L<Y/KT[8K=HHI@9EIX>TJQUR]UFVLTCU"^55N)@
MQRX48'&<#H.@&>]5)/!?AZ;2)M*DTU7LIKEKIHVD<GS6.2X;.5/T(K>HHL!S
M%O\ #[PQ;:?-9)II:*>5)IF>>1I)'0Y4ERVXX/;./:I]<\$^'_$5XMYJ5B7N
M53R_.BF>)F3^ZQ0C(]C704460&./"VB+;Z7 FGHD.ER"6S1&91$^",\'GJ>N
M<YJU_8]A_;O]M^1_Q,?LWV3SM[?ZK=OV[<X^]SG&:O44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !3_P#EC_P*F4__ )8_\"H8
M#**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *K\:IUK#8B6X52U:_DTW3)KJ*RN+V5 !';P+EY&)P![#/4G@#)J[15"..\
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M_P"6/_ J&!YC\8]3U70--T76]-O;F"*VOE6YCAD*K*AYPP'4?)CG^]7&^/\
MQWK5K\1S<Z5J%R-%TEK5;F.&0B.3<=YW <'(.W\*]2^)6BR:_P##W5[&"%IK
MCRO-A1%RS.A# *!U)QC'O7F?A/P+JEW\)?%8U.QNH]6U!M\<4\++*WD@,GRD
M9Y;<!4.]QHWO^$MD_P"%NZ[=7.KS0^'-$L%>2-9#Y3NP4#Y1P22YQ[@5NZ)\
M5]%UG5[33WL=4T\WW_'E->VX2.Y]-IR>O;\/6O-O#W@'Q!J7PK\3FXL[J'6;
MVYB9(+F,Q/*D.&QA@.NYL>ZBD\.^&;S5=>\/0R:/XQ5K"1'N)M3NQ'!;.FT_
MN@8SD?+TX/0>]%V.R-"W\2ZXW@+XA71U:]-Q9Z@$MI?.;="OF@84YX&..*]=
M\(7$UWX*T&YN)7EGFTZWDDD<Y9V,:DDGN2:\?M_#^M+X ^(EL=(OQ/=Z@'MX
MC;/NF7S0<H,988YR*Z=/AD_B'0?#]S<ZUJ^ESPZ1:V\EK"VP*RQC.0>0V3@_
M2A7$SFO'>E>)O"^K:)%#XYUF5=6O3 09&7R067I\W/WOTKIH_%EM\.KB;P_?
M:EK?BK57;[0RQ0^8\"%1P<MP,#=^/;-/^*NDZA?ZMX,:QL;J[2VU$/,T,+.(
MUW1_,Q X'!Y/I6??+K/@;XJ:SXA7P_?ZQIVJP*L;V2&1XV 7Y2,<#*_ECTQ1
MLP&?$3Q^FJ_"^WUSPMJ=U;,=02&0QL8Y4.QR4;!^AZXZ5U_B3XD:5X=UC^R%
MLM1U/45C$LMOI\'F-$G7+<C''/XCIFO(]2\%^)!\,+^>31[O[;J>MK=K801-
M(\,>V3DJ!D<M^6*U?%_AK4],^)FJ:Q+:>)I].U"-3#/H$F) ^%&Q^#QD?RZ]
M*+L+(]#N_BGX>MO!MOXH3[5<6,UP+8I$B^9&^"2&!(Q@#U/48S5:#XN:')H=
MYK$UCJ=O9P2QQ0F2$!KIGSCRQNYX!/..,5YSJW@O5K;X-+;6NAZJMW=:LMRU
MDSFYE4;&7<0D:E<X'!![<\XKT;XIGQ#:>$;6+PS%=A%G1+G[ I,Z0@'[F.?3
MD<].V:=V%D0)\7+&>RU=%T;5[;5=/M_/%C<VV)'4D*&"YZ#<I.<<9(S5#P!\
M31/X'OM6\3-=*UFY>2Z>$".;>S;4BQU(QC';]:Y?PSH.HM\0KJZ@T;Q#%87F
ME30PW.KHS2.Y3&9&Z*20< GT]15.RT/7=<^#MQX7CT34K?4=*NQ=%9X3&MP"
M7RJ9ZL <X^F*5V.R/4O#_P 4-'U[68=*>QU+3;FY0R6OV^ 1BX7KE3D]LG\.
MM<QXL^,&FW.A:U;:+#JV8T:"+58(L0++VPX.1GL<5@>'/"]SKGBO2W;2_&$2
M6:EI;K6+P*L#@<J@,>6'08!!/MBJEM%XET'X>ZUX#;P?J5Q>RRNZW<$)>%D^
M4E@<<GY>,=>._%%V%D>N^"9;S6/AGICSWLQN[JRPUT6+.&((W9]1UKS#6=&\
M3Z5\0]$\+KX\UJ2/4HFD:<R,"F-W &[G[OKWKU3X>6MQ9?#[1+:[@E@N([8*
M\4J%64Y/!!Y%<QXITO4;CXW>$]0@L+J6R@MV$MPD+&.,_O.&8# ZCKZTVM!(
MBA^(VF>#$D\/W%QK?B2ZTYF-]?Q0!_*!8G#DM_#T]./PK?U;XG^'M)\.Z7KS
M-<7&GZC+Y<<D" E#SG<"01C!! R>*X.U_M_P!JWBVP/A?4-7CUB9Y;.YM8S(
MK;MV!(0..&Y^A['-<]XF\.ZCX7^%7A6QO8=U\^JF<VQ.=I8'"'],^Y-*["QZ
MGI7Q1T?7KZ?2?LVIZ9>/;O-;_;(!&9D"D[DYZX!(^G6L_P )>.-,T;X8_P!O
M:IJ^I7T NGB66\C'GR-V0 .P/0]^@/2L"Z&N>/?B)INJKX;U'2K32K602O=Q
M%&=]K?(O'S<D# [$FL6+P9XAN?@SIT<6E70O]/U5KIK">)D>1.G"D9/;\,T7
M861Z=H?Q3T+5[NXL[FWO])NH(&N6BU"'RRT2C)88)[<_RS533OC#HE_JEA:M
MINKVMMJ$GE6E[<VX6*5\XP#D\9(&1TSSBL^/Q9XQ\176I3:/X0?3HX=/<1W&
MH0%+AIP#A4)P",G@8QP<]<5YO+I>OZD-!O9]'\77>H6UZCZA->Q.\:?-G$28
MSC Y...!W%%V%CU/PGJ^HW7Q?\7Z?<7UQ+9VR1F&!Y"4CSMSM'05A_%35[ZV
M^(.A::OB6[T/3KBU)GGAE*JIW-\Q (ST K:\(Z7J%M\8?&%]/8W,5I<)&(9Y
M(66.3[OW6(P?PK$^*6GWC?$?0-3_ .$9O=<TZVM2)X8+5IE;YF^4\$9Y!YHZ
M!U(6UP^&?"FN:II?C;4?%$QB6W3 WBS=PQ65LL<#Y3S]*Y*?QCKFF?#B.X@U
M+Q.VH:I<HDEW>$^5&$!8B%LY&[<N,==C=,5VDET-5\'>)M,TGX=:AH4LUB6S
M]@,?VA@P 0 *-S?,2!]:K>+-"U>Y^!WA73X-*OI;V"X@,MLEN[21@)("64#(
MQD=?6D,W-+\>Z;X5T+3M.=?$VLZI=*\XM;B+S;Q%W$?O!GY1P2!SQS6ZOQ2\
M,MX1D\2-/,EM'+Y#P-'B82_W-N>N.>N,9YX-<'\0/#6I6OQ,D\0-:^()]+N[
M94\W07Q/$RA5VG@_*<9]\]>,5C3?#S6I? <FH66CZE'=C5$NS87UR)I9D4,"
MQ4(N&RW0Y)&?Q=V*R/2M/^+.D7YNX#I6L6^H6\!N%L9K8"69!_<&>3@YQQWK
MGO 7Q7>?POK&J^)EO#]FE,QN(X (=I**L,?/WLGI[Y)ZUO\ AKQ1K_B?Q:7/
MA.32])CM]LMU?P,EP7Y^53QD9/3'8^N*X'PG::K;_#?7_"-YX.U"\N8YFG:.
M4-"D@W(/D?'+@KN '4#C-%V!Z;X;^(^G^(=7CTMM+U73KN:'SX%O;?8)8\9#
M*03U )].#S795X5\-M,U^Q\;V::7!XCM/#ZPM]NAUB/8BOM("IV;#;<$ 'KD
M8KW6J3NA,****8!1110 \_ZI?J?Z4RGG_5+]3_2F4( HHHH S=1\/:-J]Q%<
M:EI-E>31<1R3P*[*/0$CI6+X@\&0:G/H:V5O8V]G8WYNKB#R@JR@J0PV@8))
M/.>M=9118"AIFB:5HL;II>FVEDLARXMX5CW'WP.>M2:CI6G:O;BWU*QMKR$-
MN$=Q$LB@^N".M6Z* ,R^\.:'J<D,E_H]A=/" L;36Z.4 Z 9' ]JTD18T5$4
M*JC"J!@ >E+10!A'P3X3)R?#&BDG_IPB_P#B:V+>W@M+>.WMH8X8(E"QQ1J%
M5 .@ ' %2T4 06=E:Z?:I:V5M#;6Z9V10QA$7)R< <#DD_C4-UI&F7UY;WEW
MI]K/=6QS!-+"K/$<Y^4D9'//%7:* ,Q_#FAR:F-3?1[!K\'<+DVR&3/KNQG/
MO6G110!EIX;T*/5#J::-8+?EMQN1;(),^N[&<^]/U'0-&UB6*74]*LKR2+_5
MO<0*Y7V!(Z5HT4 -1%C1410J*,*JC  ]!4$6GV4"7"0V=O&MR[23A(E E9AA
MF; ^8D=2>M6:* ,^?0M(N=,339]+LI+",82V:!3&GT7&!U[5+;:7I]G8&PM;
M&VALR"IMXXE6,@]<J!CFK=% &39>%O#^G.CV6AZ=;NC^8C16J*5;!&00.#@D
M?C5ZUL;2QM!:6=K!;VPSB&&,(@R23P..22?QJQ10!FV/AW1=,NY+NPTBQM;F
M08>6"W1&(],@5I444 %%%% !1110 4444 %%%% !1110 4444 %7;?\ U"_C
M5*KMO_J%_&IGL..Y+1116184444 0W/^J_&J=7+G_5?C5.M8;$2W"BBBJ$4M
M*TR#1]/6RMVD:-9)) 9""<N[.>@'=C5VBB@ HJ"[O;33[=KB]NH;:!?O2S2!
M%'XGBHM/U?3=7B:73=0M+V-3AFMIED ^I4F@"Y1110 44C,JC+, ,@9)[G@4
MM !1110 44A90P4L 3T&>M+0 4444 %%%% !14,EW;0W$-O+<1)-.2(HV<!I
M,#)VCJ<#DXI+B]M;2)I+FYAAC5@A:20* QQ@9/<Y''O0!/114/VNV^V"S^T1
M?:C'YHAWC?LSC=MZXSQF@":BD5E895@1DC(/<<&EH **ANKJWL;62ZNYXH+>
M,;GEE<*JCU)/ J4$$ @Y!Y!% "T5"]W;1W4=J]Q$MQ*I:.(N [@=2!U(%34
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1O%+ Y_?F9 S#YON@?='4>IKKM ^'>H:*_A#-Y;2KH\MW+<@%@/WRD!8A@\
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MP SPD>;(2 "F,[E)/!]C6[7A/B&.;5]-U1[S4+]OLWC(VL*BZ<*D;&/@#/\
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M=>TQW6)I4C6[3,FW(P.>I((^M3^$?$MMXK\.VNJ0/!OD4>=#%*'\ER,[&/J
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M*Y>VNM9TZ"=#AHI;I%9>_()R* -.BF1317$2RPR))&XRKHP((]B*?0 4444
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M\5/'L_@X^*UT[11IMM<""<;9 \I) RHW< ;@,YZUTVI>/_$>K>*K;P_X/L;
MW'V&.^N);\L51656"_*1V=1G_:[=:KP?#+6HO@[<^$&NK#^T);D2K()'\K'F
M*W)V9S@'M6'XBM_^$2\<:;<V'B*RTG6O[*B@N1?Q.;:9%4+E7"G^YT('*BC5
M!H:VD?%K54T?Q=?:_IUK%-HDD4$=M;Y!:5F="K,2<@,HY';/6JVA_%S5_P"W
MM'@UEM!N+/5G5%739RTMHS8"B0%CW(S^//&*Q?A]X4;QGX?\=6]Q?-*NH7<9
MAU#RL"25&=]^/0EAD>C5TOA[X:>(+?5]+?55\,PV.G$9-CIR--=8Q@NSQ\'@
M<C!Z]^:-1Z&;J7COQ=XLT+Q1>:+ING'PY:1S6TGFEO/=-AW.I!QD*=V/0XYK
MM/@[_P DIT3Z3?\ HZ2N7?X:>,-+@UK0_#^KZ;'X?U61Y&^T*WFQAA@J,+CD
M87/H.U=[X!\/W?A;P3IVBWTD,ES;"3>T#$H=TC,,$@'HP[4U>XGL<(WQ'\9:
MU%K.L^&=)TUM"TJ1U8W18RS!1EB,,!P/FQ[CK1K'Q9UB6+PK)X;TVUF?7(W7
MR+G)*S!M@ 8,!@-Z]1Z4K_#?QCH\>LZ/X9UC3H]!U61V=;I6\V$,,,%PI'(^
M7/L.E:"?"^YT_5?!;Z?=6[66@A_M!F)625F;<2H"D=2>I%+4-#M?#TVMQ^'E
MG\4?9(]07>THM<[%4$XZD]AFO']:\;^,/%_@37M6M=+TZ/PU\]L59F^T!>/G
M'.#C(S^./6O=Y(UEC:-U#(X*L#W!KQD_"_QM9:#J7A72]:TS_A'[F1I4:=6\
M[U"'"X ) R1GOCTINX(AM_B%<>%_!'@[1=,6Q74+ZS#FXU"39!!'DC+$$=2#
M^7?-7M.^,TL.B:^=6@L+C4=+5#$^GRY@NMS!0022>"03[=@13]1^$^IRZ1X9
MFM9M+EU?1[?[/+#>1F6UG7).#E<]6/4=^V*GM?A1>7WAW6[76IM)M[S4 OD+
MIEC''';%2&'S!0S#( ()Z>_(7O!H:'ASQ%\09]2TMM9T&PETK4HQ+YUD6#6J
MD9&_<WN./KZ8K&T/Q[XY\2:]J%K86.D1Z?IE\8[NZE##;#O(X&_E@JL3CVZ=
M]/P_X4\?QZOI']M^(;:/2M*01K#8.X-T !CS 0 >@SGWXY)K5\">#+WPTWB(
M:E):S1ZG>-/&L+,<(<\-E1SSVS3U#0X&;XV:U-'=:Q91Z#'ID$VQ+"YG(O)D
MR/F !QW]/7KBNE\3_$#7(X=/NM$_L6PTZ\L5NUN]7N5!<D9\M$5MV1D#IC.>
MF,U@Q?!_Q#IJ7&EZ=+X;ETZ6?S$OKVQ$MW$N1\O*$'I_/IFM35?AEKD'C"+5
M]%DT2ZA^Q):!-3M^+<JH&^.-%V@\9&,#+$8Q2]X-""3XPZE_PJVW\1QZ=;#4
M'O\ [#(6#F",[=V_ .[&,<9Z]^U:&A?$K4ET/6M4UDZ/?6>G0"2.YTJX_P!:
MQ( 1HV.Y<E@,D#H>#572?AGXHTCP%<:!;ZMIJ3G4#<C='YL-Q$54;) R9'*Y
MXSZ5#HWP>NYI=<N-:;3;#^TK/[+':Z2K^5&=RMOP_N@./<]*-0T*.G?&768K
MS2[K5O[ ET[4)1&UO8SDW-J#T+@L?J?RXK1O?'?B[Q%>^)(_#6FZ<^CZ1OAG
M-RS>;/@,#L(.,_*2./3/7%1:-\*_$,-SIMKJ'_",1Z?8N-\]MIR27%RH[,9(
MR,]L_CS5NX^'GB[2]7UZ/PSJVG0:1KDC/.+E6,D&[.[9@8_B('/3'IFC4-"_
M\"_^29V__7S-_.O2:Y'X;^%K[P?X0BTC4);>6X29Y"UNS,N&/') /Z5UU4MA
M/<****8!1110 \_ZI?J?Z4RGG_5+]3_2F4( HHHH **** "BBB@ HHHH ***
M* /-_$B^9XENP>[(O_CJUZ0  , 8 Z5Y_P")D\OQ#.^.&"./^^0/Y@UWX(90
MPZ$9%;U7>,3EH*TYGD7QWD(L-$B!X:65B/H%Q_,UXI7MWQVA9M+T:<#Y4GD0
MGW901_Z":\1J8;'0]R6=(8_*\F?S=T89_D*[&[KSUQZU&%)4L!P.O-2PW+0V
M]Q"(XF$ZA2S("RX.?E/8U#5""COBMSP_X2U?Q)*!90;8 </<2_+&OX]S["O7
MO#GP^TC0-LSI]MO1R9IEX4_[*]!^IH(E-1/./#7PYU;75CGNRUC8'Y@T@^=_
M]U?ZG]:]<T+PQI7AR'9I]L!(1AIWYD;ZG^@J]<WR6US;12*W^D.4#]@<< _6
MK$SQVUI-=3.!'$A<XZ\5FYK7R,W&I*VF^Q(D4D@)520*E6SD(R=J_4U+97/G
MV4,QC,?F(&V'J,^M3-,B DGI6?M&]BO8QCI(I&UF'\.?H:L::2)V'J.:/ML>
M.5:I+%S-<,^T *.PJKRMJ2HQ4ERLT:I7WRW6G/W%P1^<;BKM4+[YK_3$R.9G
M;\HV_P :$=$MB_1112*"BBB@ HHHH **** "BBB@ J[;_P"H7\:I5=M_]0OX
MU,]AQW):***R+"BBB@"&Y_U7XU3JY<_ZK\:IUK#8B6X44450@HHHH *1E5U*
MLH96&"",@BEHH ^?OB3X!?P[>-J>G1EM+G;E1SY#'L?]D]C^'U\^KZ]N;:&\
MMI+:YB66&12KHXR&!KP/Q]\-[CP[+)J&F*\^E,<D=6@]CZK[_GZGTL/B.;W9
M;G#6HV]Z.QY]11178<H5ZG\(O&":?=-H%])M@N&W6SL>%D[K]#_/ZUY92@E6
M!!((.01VJ*D%./*RX3<)71]@T5X[X&^+*)%'IOB-R-H"Q7N,\>C_ /Q7Y^M>
MNV]S!>0+/;31S1.,J\; @_B*\BI2E3=I'HPJ1FKHRM8\)Z%KS;]1TV&67&/-
MQM?\QS69:_#/PG:2B1=*61@<@2NS#\B:ZVBDJDTK)C<(MW:&111P1+%#&D<:
M#"HBX 'L*?17*^*?'^B^&(7629;F]Q\MK"P+9_VC_"*48RD[(;DHJ[+7C'Q/
M;^%= FO)&4W# I;QGJ[]OP'4U\PSSR7-Q)/,Q>61B[L>I).2:T_$?B34/$^J
M-?:A)D](XU^[&OH!_G-9%>KAZ/LXZ[GGUJO._(****W,0J[I.E7FMZE#I]A"
M9;B5L*!T'J3Z >M2:+H>H>(-12QTZW:65NI_A0>I/85]$^#/!5EX0T_9'B:^
ME \^X(Y/L/1:PKUU37F;4J3F_(L^$/"MIX3T5+.##SOAKB;',C?X#L*WZ**\
MF4G)W9Z*22L@HHHI#"BBB@ HHHH **** "BBB@ I_P#RQ_X%3*?_ ,L?^!4,
M!E%%% !1110 4444 %%%% !1110 4444 %5+_2M.U6-8]1T^UO$4Y5;B%9 #
MZ@,#5NB@"*VMK>S@6"U@B@A3[L<2!5'T XJ6BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** 'G_5+]3_2F4\_ZI?J?Z4RA
M %%%% !1110 4444 %%%% !1110!R/BZW_TJWG_O(4/'H<_U-=%I,WGZ3:R=
M_+ /U'']*K>(;4W.ENRC+1'>![=ZJ>%K@&VEMB?F1MRCU!_^O_.M7K#T.9>[
M6?F9WQ1T=M9\!7RQKNFM<748_P!S[W_CI:OF:OLEE#*5(R",&O%/^%.K%X@N
MGO;G9I?FEK>*'[[H3T)_A Z=S4P?0VFTE=GEVFZ5?ZQ=BVT^UDN)3U"#@>Y/
M0#ZUZKX;^%=I9!+G7'%W<#D6Z?ZI?J?XC^0^M=UIVF6.D6BVNGVT=O"/X4'7
MW)[GZU;J[G-*JWL-CC2&-8HD5(T&%11@ >PJO>WWV%4<V\TL9.&:(9V>Y%6J
MCFGBMHS)-*D:#JS'%1+;1V)I_$KJ_D9FJ:EIZZ9#<3H9D=@\*8()8=_;%8[>
M*HKP-#>V"FV<C=L<DCG-,\5G[0;.[B;?;.A"L!QG-<Y7DXG$SC4:6WYGUV6Y
M9AZF'4YWOKU>G_!/1[G5H;>"%XUEG\X9B2%2=W^%6XG:2)'>-HV89*,<E?:L
M?1[B'3M&LHKV987E!*!^.,__ %ZV@0R@J00>A%>G2ES*[?R/F<535.3BEU>O
M<6M73(\0M(1]XX'T%9L4332!$ZFMY$6-%11A5&!5R[&5"-W<=5%OWFMH.HA@
M)QGH6. ?R4U=)"@EB !R2>U4-*)G2>]((^T2%H\]0@X7^6?QJ4=$MTC0HHHI
M%A1110 4444 %%%% !1110 5=M_]0OXU2J[;_P"H7\:F>PX[DM%%%9%A1110
M!#<_ZK\:IU<N?]5^-4ZUAL1+<****H04444 %%%% !2,JNI5E#*1@@C((I:*
M /*/&GPCBO&DO_#H2&8\O9DX1O\ </\ "?;I]*\<OK"[TVZ>UO;>2"=#\R2+
M@BOKJLK6_#FD^(K7R-3LXYP/NOT=/HPY%=E+%RCI+5'-4PZEK'0^4J*]6U_X
M+7D!:70[Q;B/J(9_E<>V>A_2O.M4T+5=%E\O4K">V.< NAVGZ'H?PKNA5A/X
M6<<J<H[HSJT=+U[5M%DWZ;J$]L>X1_E/U'0UG45HTGHR4VMCT&S^,GBBV4+,
M+*ZQ_%+"03_WR0/TJU+\;/$#)B.QTY#Z['/_ +-7FE%9>PI]C3VL^YU&J_$3
MQ1K"M'/JDD43<&.W C'Z<G\37,,Q9BS$DGJ3245I&*CHD0Y-[A13XXI)I%CB
M1G=CA549)_"NRT/X6^)-8*O+;"Q@/\=S\IQ_N]?SQ2E.,5>3",7+9'%5VOA+
MX:ZOXE9+B939:>3DSR+RP_V5[_7I7JGAKX6Z%H+)<7"?VA>+R))U^13_ +*]
M/Q.:[GH,"N*KC.D#JIX;K,R= \.:9X:T\6>FP!%ZO(W+R'U8]ZUJ**X6VW=G
M6DDK(****0PHHHH **** "BBB@ HHHH **** "G_ /+'_@5,I_\ RQ_X%0P.
M6\=^+T\$>'AJSV37@,ZP^6LFSJ#SG!]*SK7XDV5S\-)O&?V1DCA#![4R@D.'
MVA=V.^5/3O6-\>_^2<K_ -?T7\FKS2^M[JW\07OPTC1UM;[78;E".BPL,D?]
M\E#_ ,!-0VTQI'JVB?%&?7_!U]KNG^&KF>:UN5MQ913;W?(!+ A>V?3M7?6]
MP9K2&:5/)=XP[1L>4R,D'Z5\V!5C^#7BY$4*JZZH '0#*UT-SH%GXE^+VC:;
MJ'F-9OH4+31I(4\P!"0I(YQG!_"A286/8/$>M7.C:$^HZ?I<VK2JRA;>W;YF
M!.,@@'I]*T[:<S6L,LD9A>2,.T;'E"1D@_2OFB9&LOAMXYTB.1VL['6HXX$9
ML[1YC#]=HKJ?$6C6_B#XH>!]*O#)]EN-%43*CE2ZJDC%<CG!VX/UI\P6/<?.
MB\M9/,38W1MPP?QIS,J*69@J@9))P!7S/8^$=.N=&^(:3O<O#H$THTZ(SMLB
M(9\MC."2$4<_X5KWEW;Z_H'@31[JTU#6M3FLR\=@+T6\$B@L-TCXW$@(>A'W
M3Z\G,%CV#QGXKC\(>%Y=;-K]L1'11&DFW=N.,YP:UHM1B;1H]3F_=0FW$[YY
MVKMW'ZXKYEBDGA^&7C;2W8+!9ZI;B*%)3(D9,C@A6[CY1SWQFO>]4TRUU?X7
MO97D9>!M,1RH8CE$#KR/=10G<&C0\*^)K3Q=HJZK8QR);O*Z(),!B%8C)';.
M*VE=7SM8-M.#@]#7S/8K_87P'N-5TAWAU#4KM;:^ECD.1$&?''\.>G&,YK?N
M-*TGP3XV\$R>#]0DEDU*58[Q%N-XGB)0;V';(9CZ<<=*.8+'K?C/Q.O@_P ,
M7.M/:&Z6!D7R@^S.Y@O7!]?2LA_B38M\,Y/&=K:M/'$$$EKY@5D<NJ%2V#TW
M9Z<C'K53XU_\DMU+_KI#_P"C5KQ[Q58WW@70KG3(%>30O$EE;SQ9.1%,K1NP
M^O!'N&7TH;:8)'TKIFH)J.BV>I%1"ES;I/M9L[ RAL9]LU=!!&0<@UX+?0P^
M(?&'@OPWKUS)#H?]AP3)")?+6:0QGJ?7*@?AQUK>^%#_ -G^-?%?A[3;N2ZT
M&S=6MRTF\1,3@J#^8_X!0I!8[.3QI''\1$\)&R.YK3[4;HR\ <\;<>W7-=0K
M*ZAD8,IZ$'(->+^)= L?$OQ_@TW4ED>S;3 \D:2%/,QNP"1@XS@_A7&G4=1\
M.^ ?&6EZ9<SI:P:VMHI#G,<1\P-@]L[%!QZT<P6/II75\[6#8.#@]#Z4C21J
MZHSJ';[JD\GZ5\]>%-/U+0O'WAV33],@TB*Y4+<Q'6X9S>1MU?;NR3WP!VX'
M%8/B=+/6-.U[Q)I>GWDT<-^%_MF_U$"7>6'R1PJ ,<Y[X'IC%',%CZC9U09=
M@HSC).*YGPQXR3Q)KOB+2UL6MSHUR+<R&7=YN2XSC Q]SWZUY2D-OXW^)&FZ
M=XLNW;3XM"@N(8WG*++(T2,QSD<Y9SG_ &*S?"UWI6B^'_B2)+Z^?3Q<0V\4
M]I(HFF4O*JX8@CYAU..F:.8+'T<LD;LRHZLRG# '.#[TN]=X3<-Q&0N><5\V
M^'X+KPY\2?#4ECI']E_;;5F^S?;S<-<J4;#2=@6.#C &1T%2>&=(\-:]X-O/
M%/B?Q#<V>LC4</?+,QDC^[A0@]<GD#CZ T<P6/9I/&D<?Q$3PD;([FM/M1NC
M+P!SQMQ[=<UU"LKJ&1@RGH0<@UX=JNB:=XK^-NG65]+-=V$NC1RLV\QFX4*2
M"V,$9X)'%<L=1U'P[X!\9:7IES.EK!K:VBD.<QQ'S V#VSL4''K1S!8^FE=7
MSM8-@X.#T/I2;T,AC#KO R5SR!7SOX:L=1\/^-]!GL;"WT2&XCQ=!M;AG^U1
M'K)M+=OO8 [<#BL""V_X1Z2/6-7LGU&U74"1K^E:D?,=O0Y+ ],X*J??%',%
MCZIHI%8.H8=",C(I:H04444 %%%% !1110 4444 //\ JE^I_I3*>?\ 5+]3
M_2F4( HHHH **** "BBB@ HHHH **** $(!!!&0>"#7)312:'JZR1@F+.5_V
MD[C_ #[&NNJGJ5@M_;;,A9%Y1B._H?:JC*QE5@Y*ZW19CD2:)9(SE&&0:9<6
MZW$6UN&'W3Z&L32KXV,C65V"J@_*3_"?3Z>_^1T-)JS'"2G'4P'A=)3&5^84
M[[/)[?G6Q-;I.OS<,.C#J*H3QW%OEBH>,?Q#^OI3YGT,94E'<K&V?V_.JES9
M07#1FY@60H<IO&<&K9N6[ 8J-F+,230DWI(CF47>+U,[59K>*VCAFMQ.)Y%B
M6+US_A5*XT73-,@EO4LVG:(;@C2$C\C^=;#P122QR/&K/&248CE<^E/8!E*L
M 5(P0>]1*DI-M_(WIXJ5**C%M+KKN1;;>^M5+(DL,B@@,,@BI(8EC1(84"JO
MRJBC]*DM+(F-8K>(+$GRC PJBMBVLTMVWD[I.Q]*O;7J9*+F[+X1+.S^SC<^
M#(1S_L^U6J*KWEVEG!O(+.3M1%ZLQZ 5.YTI*"*VILUQLTZ)\-/_ *Q@>4C[
MG\>G^35^-%BC6-!A$ 51Z 53TZTEA$D]R0UU,<N1T4=E'TJ]38HI[L****18
M4444 %%%% !1110 4444 %7;?_4+^-4JNV_^H7\:F>PX[DM%%%9%A1110!#<
M_P"J_&J=7+G_ %7XU3K6&Q$MPHHHJA!1110 4444 %%%% !1110 4R6*.:-H
MY8UDC88*N,@_A3Z*!'*ZC\.?"NI%FDTF*%S_ !6Y,?Z#C]*YRZ^">B2$FVU"
M\A] VU_Z"O3:*UC6J1V9#I0>Z/'Y/@:,_NM;X_VH/_KU&OP-ES\VN)CVMS_C
M7LE%7]:J]R?84^QY1!\#[$$&XUBX;V2(#^>:W+'X1^%;0AIH;BZ8?\]I2!^2
MXKNZ*EXBH^HU1@NA0T[1-+TA-NG:?;6PQ@F*, GZGJ:OT45DVWN:)6V"BBBD
M,**** "BBB@ HHHH **** "BBB@ HHHH **** "G_P#+'_@5,I__ "Q_X%0P
M,C7_  [I7B?3O[/UBU^TVN\2>7YC)\PS@Y4@]S4+^$M#D\30^(WL%.K0IY<=
MQYC\#!7[N=I."1DC-;5% ',_\*^\+_V/>:3_ &7_ *#>7'VF>+[1+\\G'S9W
M9'0< @5=A\*:)!KD.M166W4(+<6L<WFN=L0& NW..G?&:V:*+(#F9/A[X6FL
M]2M)-+S!J<XN;M?M$O[R0$D-G=D<D\# JZ?"NBG6M/U@V7^GZ?!]GM9?-?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I__+'_ (%3*?\ \L?^!4,!E%%% !1110 4444
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MS(J*E^SR_P!W]:/L\O\ =_6BZ"S(J*E^SR_W?UH^SR_W?UHN@LR*BI?L\O\
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A!M9[B0R2NOS,0!FM2N*<7"3B^AVPDIQ4EU"BBBI*/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &R!"(# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^HSEF(!
MP/2GFFI]]OH/ZT -,+'^/]*3R#_ST_2IJ* (/(/_ #T_2CR#_P ]/TJ>B@"#
MR#_ST_2CR#_ST_2IZ* (/(/_ #T_2CR#_P ]/TJ>B@"#R#_ST_2CR#_ST_2I
MZ* (/(/_ #T_2CR#_P ]/TJ>B@"#R#_ST_2CR#_ST_2IZ* (/(/_ #T_2CR#
M_P ]/TJ>B@"#R#_ST_2CR#_ST_2IZ* (/(/_ #T_2CR#_P ]/TJ>B@"#R#_S
MT_2CR#_ST_2IZ* (/(/_ #T_2CR#_P ]/TJ>B@"#R#_ST_2CR#_ST_2IZ* (
M/(/_ #T_2CR#_P ]/TJ>B@"#R#_ST_2CR#_ST_2IZ* (/(/_ #T_2CR#_P ]
M/TJ>B@"#R#_ST_2CR#_ST_2IZ* (/(/_ #T_2CR#_P ]/TJ>B@"#R#_ST_2C
MR#_ST_2IZ* (/(/_ #T_2CR#_P ]/TJ>B@"#R#_ST_2@P''^L_2IZ:_W#0!"
M(#_ST_2E\@_\]/TJ133Z (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_
M2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(
M/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\
M/3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ*
M (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3
M]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*
M/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(
M/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GH
MH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_
M #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3
M]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\
M@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_
M2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(
M/_/3]*GHH @\@_\ /3]*/(/_ #T_2IZ* (/(/_/3]*/(/_/3]*GHH @\@_\
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M"*^?] O9;3QYX[$7@<^)=VK/E@J'R/GDX^93U]O2O?-*.[2+)OL0L=T"$V@
M'D94?)QQQTX]* +=%%% !1110 4444 %%%% !3)N(C3ZBN.(&_#^= !&>*EJ
MO$>*G% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_\ 5M]#
M2)TI7_U;?0TB=* 'T444 (:8GWV^@_K3S3$^^WT']: )**** "BBB@ HHHH
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M?1M/@2V6YC)7@D'&X_3M[#L,#M6G#XAT^9,K<)],T7068:3,T+/ILV!)!]S
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M_P#&C^W]9_Z"U_\ ^!+_ .-9U%%@-'^W]9_Z"U__ .!+_P"-']OZS_T%K_\
M\"7_ ,:SJ*+ :/\ ;^L_]!:__P# E_\ &C^W]9_Z"U__ .!+_P"-9U%%@-'^
MW]9_Z"U__P"!+_XT?V_K/_06O_\ P)?_ !K.HHL!H_V_K/\ T%K_ /\  E_\
M:/[?UG_H+7__ ($O_C6=118#1_M_6?\ H+7_ /X$O_C1_;^L_P#06O\ _P "
M7_QK.HHL!H_V_K/_ $%K_P#\"7_QH_M_6?\ H+7_ /X$O_C6=118#1_M_6?^
M@M?_ /@2_P#C1_;^L_\ 06O_ /P)?_&LZBBP&C_;^L_]!:__ / E_P#&C^W]
M9_Z"U_\ ^!+_ .-9U%%@-'^W]9_Z"U__ .!+_P"-']OZS_T%K_\ \"7_ ,:S
MJ*+ :/\ ;^L_]!:__P# E_\ &C^W]9_Z"U__ .!+_P"-9U%%@-'^W]9_Z"U_
M_P"!+_XT?V_K/_06O_\ P)?_ !K.HHL!H_V_K/\ T%K_ /\  E_\:/[?UG_H
M+7__ ($O_C6=118#1_M_6?\ H+7_ /X$O_C1_;^L_P#06O\ _P "7_QK.HHL
M!H_V_K/_ $%K_P#\"7_QH_M_6?\ H+7_ /X$O_C6=118#1_M_6?^@M?_ /@2
M_P#C1_;^L_\ 06O_ /P)?_&LZBBP&C_;^L_]!:__ / E_P#&C^W]9_Z"U_\
M^!+_ .-9U%%@-'^W]9_Z"U__ .!+_P"-']OZS_T%K_\ \"7_ ,:SJ*+ :/\
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M=>6_#;_D8KC_ *]&_P#0TKU*LI;FD=AK_P"K;Z&D3I2O_JV^AI$Z5(Q]%%%
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MPR]#TJ2QH7:V#]T]/K2\I(./:I]@=/8]O0U$HWHP/WEX/THN-JQ,5& W/O\
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M,I1:U0Z2$$;E'N<=ZA23:V#2(\D#8;[I[CI4CQI,-R$;OKUHVT8O0>^'3)Y
MZ^J__6J 90A6QCL?\]J:!+$,CD#]*D8++#N5<'NOO[4TA-W%B=8)L_\ +,_>
M']VGW,>[E?O=015=6W(!_$.Y[TJ2 *8V.!VSVILFXD<NR59,<'AA1<)MG.#P
MW(/O5.>X"[U'WAU']:-]Q?F&**)LC[S < 52B]S-S2T+9N5&Q\C=C]1_D4EQ
M?Q)=1N""I&[_ #^M*NC[FWLY8YQM4;L'^5(VC1I*<H0?]I\?H*I*)7[UK1%.
M:_22:1TY7(P<5WF@SI)X*TL[OE-[<\_A'_C7&O8*L?W4S_P*MB6_&E>#-
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MT$C>2TS_ #%,_*2/7%9LOAR[CR69 !Z#'\ZNR,^>QG)XDU"/[ZQM^%68_%K
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M*"1G6T5Q$=\T^Y6ZKC;C\ZM'5+-.5QD#!:L&^DEFO1)">.N%&1FM#3/#%]?
M32HR19S\W!:JE3C;FFRB-KR>ZF*PLS@]L<"G-#*I!<8-=K8:'%96_P"\5$XZ
M#^IK,U2*)&( Y/K4J5_A0-EWP?J#07: MT-?0.AW0GM4.>U?,VER&"\4CUKW
MGP;>^;:H">U=5&=]#.1W%4M6_P"0;+]5_P#0A5Q3D53U;_D&R_5?_0A7005K
M'[HJ?5_^0%?_ /7M)_Z":@L?NBI]6_Y =_\ ]>TG_H)H0'DF*,4_%)BMC(;B
MC%/Q28H ;BBG8HQ0 W%&*?BDQ0 W%%/Q1B@!F*,4[%&* &XHQ3L5%<3);VSW
M$C!(DZLW3Z#U-#:6XT*[A,#JQZ =34-Q>V>G+YU_.BMU6/.3^5<;JGB^;>R6
M*A,\&0\L?\*YI[J660O([/(>K$\U-P.VO_&DTQ*64?EK_?<9/X#H*PYM0DF;
MS+F:25O]MR?TZ5C*[]ADTX+<.>!31#9:FU%CPO'T%5OW\QR=P'TJY;6MR?F(
MQ_P$5H("HPT\*G_:D'^-)L5[&3':,>I!^HJ86H'WE4_C6H"/^?N#\&I2<CF:
M%OJ12L%S+^SIV1A]!FGI;[^ X^F<5;:$DY$7_ HSFD ;H9 ?:50:H5V1K9D?
M>B!^E3) RGY1,GZBI4A+=8+=_HY6IH[92?\ CQ<>\<^?Z4FQHB!N(^1,A]G0
MBI!?S#@[?^ R5:^Q,1\C7L3>^&%,^R/G$L\9_P"NT&,_C4.2*2&_:T8?O@R#
MUD7(_.M6QT[2M1BXEM-W8B78WY&HK?258?NMA)XQ"_7\#5T6'D2;;FT!C(QO
M^S\_FM1*>FA<8DBZ!J-K\UI<CRST#=/S%6[=IH2R7W![%*IBT2PD:=-0DM(1
MSG)"G\*J7GBBVA(2&5;J7J2H.2?8"LW6OHD:JEU-UQ:S@K,J2KC[PX9?QJ@U
MHZ\;S(A/R[QR![UFVD/BK7&_T;P[=&-OXI(3&#[Y;%:FI_#?Q0/#HO/MD4;J
MC/<6TLVWRP,\A\X(QZXJ/WC=T:<L=F5Y)MA$3D;1SQC^=4+K4+!&/F,%F48/
M/)KB3=-;X4W9/?[Q(JL]U; -(9@[9Y'.:$Y]2O8Q[GIVD>+=#TFU)E@F9^AP
M>/PJC)XULQ=275G%(68\1NN?Y9KG/!7C73?#>LO=ZCIK7D#0-'Y856.XD$'Y
MN.Q_.N\D^/VFPKBS\*R #INE11^@-"IW=VPO%*R5S.L_$NN^([G[%;:!,[R
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M-]45&=M&=QI:3SZ=$RKT&":V(;2<J!M)-+X3:2;2D"1J$7[SOT^GO6Q)%F7
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MA'Y5^YQWKCS*<]3^%>D_$"P*SN^.]>92A@W'6N1I7-KEU+A50$@Y]ZD%X\C
M)A?>LN."4G+9Q]:T(H%&-W _(5FU%%)7)Q'NE#+\[=V JT_EQQ!';GTS2^?L
MA(BPN1C<>*KPP(S?-OD;J<#BA-M:@TEL6;>**61<#\A756:Q01@B/! Y)Y/_
M -:L"&Y%F!LME4_WW-#ZG(9MAD:1C_ HP!6-2\MBEYG4B]5LD$A!UP<9I3K)
M*F,1JJCN:X_=>74Q!FPH_N]!^-:*2"-!L)9@.<\G_P"M6+IVW&K/1%N]MH]0
MD_?2-L(SC-8]YH<11FA7$:CJPK:L%5E5YR%YZ9R34MT5NRT,0' Z>E0JDHNR
M>A?*NIV7PIU&TUWP?>^$[X"3[.CQ%">9(),Y_(DC\J^=?%/A^Y\,>)+[1[H'
M?;2%5;'WTZJP^HP:](TB[NO!OB2WU>$DHIVW$?021G[P_J/<"NY^+7@N#QUX
M:MO$^@E;B\MX-Z^6,_:(.3CUW Y('N17LT*JG'0Y:L'%G@VA_P"E^&/$FG'J
MD,.H1^[12;"/^^)Y#_P&N=KH?!;HOBZQMYF"PWI>PD)Z!9T:$D_3?G\*P7BD
MAD:*52DB$JRGJ".HK8R&44ZDQ0 "G4@%+0 4444 %%%*!F@!41G8*H)8G  '
M)-?5_AW3T^&7PH7S55-0:/S90<9-PXX7WV\#Z*37F7P0^'[:MJJ>)]1B(L+*
M3_14=>)IA_%_NJ><_P!X#T(KHOB3XF;7-<33;-]^GV38+JW$DO<^X'('X^M9
M5I\D;FM&FYR.'M[/8["96PYR9.I)]ZGDLV5<(2R$\'.1_P#6K4MX_,BVNOMS
M4:H]K.=K!E[*W:N",I2.^4>Q1MTFMC\CD<\AAD&M%)KGR\F,-[H:<]Q%,-K(
M8SWXJ1()"H9'# ?Y^M.^NQ%M-2NMUY@(:/)[@\TJ26X?@M"WMTJ5HXV?,IVG
MUI9M+:6/<DF]3[YK126RT,I(=/%'.H!*G/&Y1@TD=C);C,4K*#U (*G\^:S8
M/MMO-)$8F=5Z9':K:WXY5MR'T89%3ZHS9:$DUONWSQG/;!&/R-8UW]JN/,>&
MY@E/90Q!'ZU8N;Z,(QD2-QZJ2/\ ZU8=W);R+OC#HPZ'.13LNQ.Q$QFW[9OO
M5WO@BV#3(<=Z\\CF:64!CGFO7/ EIPC8K2"U!['JFGIL@4>U)JW_ "#9?JO_
M *$*L6Z[8E'M5?5O^0;+]5_]"%=9D5K'[HJUJ) TF[)Z"!\_]\FJMC]T5=O%
M\S3KA#_%$P_0T,#SN.*2Y.%!5/YUJVUE';H"14P6.VCZ 5D7^L@,8X?F<<'T
M%<<I?:DSJITY3?)!&E<:A%;1EF8*!7)ZEXCDN/EM]RQMG:1]Z3Z>WO5"YEGO
M+IA<G*KSL)X(]3[>@[U3\_YW:(AG<9+MSM7U^GH._6L93;/5H8*,'>6K'R(S
M02,\GEDCYBO1!]>YHM#''!YI7;M&(H^^#T_$_P">]0R3++$L2@F)""P/61ST
M7^IJQ'"J3"6XE&V)=P [L>I_EC\*S/0;!H6R_G'"%=\\G9O1![?Y[TY5GEE!
M93&-N3_LCL/]X_I3O*E>>-Y>(Q\P3.<'L/ZGU./2K",TT;&)E.> S=.O)I,2
M[E=3MFF>(X;:%4MT'H![#J?4TD,+H\:CF)5)9CR?\G)-*\4B3HBC(+9=N.G_
M ->IK(,DL5N3OD(+.WIGG]2:"K*.Q< $;%L$L1C\*K73>5$,'+ KPW)P2!FI
MW#R>4PD!CSN&!U]*@:XC6ZFPVZ4( 4ST'.*0M7L5V\K=*KEMZ $_B<"F6ZIY
MKL9!D+CYCPO>F1M_K'F(\V1@Y Z#'0?04D1PC- FYC(5'& 6[DGT'K[8H-'>
MWO&DSV4B>8+KRHE. TT9 /T(SG\J:MC>RJ"L.] >3 XE 'OCD?B!5#6)_P"S
M[2>],A98DW8_SWS7!R>.=4E@FB@@MUN74JLRR$O&/4*<$'W%;PASZI'GUL1[
M#1ROY-?Y6,WQ8+*3Q)=06LT;1QM@*S;<'OC..]8DF(@!-&2O^WR#^(K:?QGK
M6Q(M9C@U2'&%_M*W6<X]I#AQ_P!]4^#4?#%V2&L+W3)&')L+GS(_^_4G)_[Z
M-=RC96/"G-RDVSGA$IXAF"*?X9#D?Y_"@BYMVV[71O\ ID^,CZ=ZZ4^&M.U$
M_P#$MUS39G[170-E)_X]^[_\>%4[WPSKFC[/MFFW26S'Y9-F^,CV894_@33L
M3<R2>T@7=_M+@T8##EO^^A_6K)VY/EM_P$ C].E1<,<@8I,:!(^>>?QJU&E,
M1*MQ1YQ639M%6-W2]51[)-*U>)[G3E),++_K;0GJ8R?X?5#P?8\U<N/#<UGY
M<Z2)=6,Q_<740^5_8CJK#NIYK-L;;<02*[GP\ES:HWRJ;*8 30RCY90/;U'9
MATH6HV[&';::HQD9-=1HEL^GWD=RZ*(P"LD;?\M$(PRX]Q5^6SL[:T>\TW+P
MH,RJW,L/U]5_VA^-<[=ZX!D1\^]59(B[D=/?)#ILWEQ'="RB2*1OXD/0_P!#
M[BLBXUB->"^<=JSXKZ76M%GM"Q^U60:X@QU>+_EHOX?>_P"^JYQIB>K4-C2[
MG1RZ[_<%49-6F?\ BQ6.TV*B:X-26DC3:\D;JY_.HC<^]9IG/K3?-)I%&@;G
MWIAN?>J.YC1G_:HL!<-R?6D^T&JF]?K1YHI@6_M!I?/-5/.%*)318+EOSC[T
MOFFJOF-Z4OF-Z46%<L^<?>D\\CO5?S3Z4GF^U%@+7GGUH^TGUJKYP]*:95]*
M+ 7/M1]:477O5'>II,CL:8C2%U[U*MV1T;]:R-Q[4>:PZT ;\>HRI]US5V'7
M)4^\<URHN"*E6Y]Z!-';V^OH3R2IK434(+I<2!)![]?SKSI;GWK8T2/[;>XD
ME,5K"AFN9!_!&.OXG@#W(IW)<4=J-,BM+)[VW?;=W*-';A_X%/#.#[\J/Q-<
M5?:.T)VRQ%">A['Z&KLWB>:ZOGG90D9PL<8Z(@X51]!6MIU]_:DBVD<7G22?
M\L\9S_\ 6]Z+)B5T<!=:<4R<59_L6UT>-+K7D<R, T.FHVV1QV,A_P"6:GT^
M\>V.M=_/96FF[I-,,4^H#I*_S1PG_IGGJW^T>!V]:X#5+:5KB5KC>9V8LYD.
M6)/<GO\ 6I<;%J5S$UC5+O5YT>Y95CB79!!$NV*!/[J*. /U/4DUD,O-:4\6
MTFJ;I4EE?;FA@,<*,^IYJ8)04S3"Q (F8?,05/UP/RXJ,P$ [Y-JCJ.!^@K7
ML-+OM2G\NPM+B]F[K#&SE?J1TK0E\*O:MG5]6TW3L?\ +'S!+*/^ 1AB#_O$
M5:,6TCERD)&V"W>0_P!]^GX#I^=#%P<W-PD9Z;<[FQZ8' ^E=$\GA>P!'_$Q
MU%_]IA:H?KC<Y'XBHQXJNK+_ ) VF6&E#M+#;@R_]_9=S?D15$G=>!?M4_AW
MRI-*NH(8FS'<SIY4<H/HS8!(K:2.WBN9&>]C=,?<B4L4/^\<#'YUXU/J.JW%
MVM_>:M,;K/$LD[/+^!)R!6]X8UJ1-=BBN[Z9DG^4M<,/O=NO3GCL.:YZE):R
M1Z.'Q<K*G)V]#T5KE6D"VZ.$Z^8\@.[V  X^N31$=K(#%M#2[#GZ'!'MG%4K
MR[L(+J&(7<,5PC']SY@R0>HQFM"WO%5>5WQLV%=.<#W'Z5RO4]:-DK)_J$9>
MYA@D#!71CYHZ= 1C^52I-&]I'(2 '"GVR:,P"5ID.UG^\,\$^N/6J,L[R*_F
MPCI@J#E6^G_UZ6@XQD2RJKF6)W^5E(..N?:JJ&,W&" 60[<-W##I[Y_I432&
M5C&A9"\88-R".?\ ]5.A F#K)&T4Q !D ]#D$'ZTC1^1=:,-&(Y2S8'#9^8>
MA^H]:@GC1%)D >*48EQQ@_WAZ>]3B:"YC#JPD9<D!3@@_3^AJ.*0N[(Z'RRO
M&Y<?4$4S.R:T*\[- ([A6,FQ=LAQ@L!ZCU!_K2JP28R$_NI,;R.BD]&^A_G5
MEHQ$R>6/E*[6#G.<#@_7''O4"&(1LBQ\Q*5:/KO0]0/?T_\ KTR;M$LD>QSL
M;RI@-QZ[7 [\=QZCD5HZ;XBN+48N@TD*G#/CYX_KC[P]Q663FW'F2;HE(\N9
M3RO]UOZ&HI6>#;')@ D[3'_"WM]>N/J*:;6QE4I1JJTD>C6]]%<Q*Z.KHW0@
M\&FW%BDZY6O/+&_DLBS0OL(;YTSE.>F/8]?QKL-*U^.X(C?Y)>ZGO]*VC43T
M9Y=?!3I+FCJC<\+PR0:O*C<KY!P?^!+77U@Z(R27C.N,^6?YBMZNRG\)YL]Q
MK_ZMOH:1.E*_^K;Z&D3I5DCZ*** $-,3[[?0?UIYIB??;Z#^M $E,E&Y"*?2
M'D4 >3_$'3RT+L%[5X;=(R3LI]:^G?%M@+BSDX[5\Z^(;0VUZXQWK"HK,TCL
M9283EGY]*GCE/\*9;MFJ0&3\QP*L!XPN%S^%8R1HBY:S)YH:9M[CMV'TJQ>3
MKY6Z*49!P47^M80N(E; )+YX45>L[">[^9FVH3R/6ER6=V'H#2W%QE-S,H/&
M#Q^=6[=RB8*8]@.O^?>KK)%I]N(0=\K'&!U%->,QVZ^:ODQLW&?O.:=[K03T
M)X6 CVIDRGJ%YQ]34Y8VX#S'@?P _P ZK)>QJX14"A1T']:?::?)K%V9&+"V
M3[S'I]!6+5MRXW-2WNSJ++#90_-TR!P*W;>T32X2+@KYF,TEFD&DVV(4"G^7
M_P!>I[6PGOY_M$Y(0\A6ZFN*HG)V6QT1<8J[.=UF&:]A8HNR,^O4FM+X;>-Y
M/"-__8FJ,3I$S968G/V=SW_W#W_/UJ]J852L9"A1P/3_ /57-W.FQWMR0@R@
M&2Q[^];T*SI;[&;7M3H?BG\)I+B63Q5X2CWRL?/GM8>2YZ^9'CJ>Y Z]1Z5X
M_P"-X0GC"_G5"B7I2^52,;1.BS;?PWX_"O8?"/CV^\+2+87JM=:.I 4 ?O(>
M?X?4>Q_#'-=3XL^'?AKXFVBZOI=XL-ZJ>4ES#RAP2=LB>OS>QY&>U>M3JQJ*
MZ.2=-P>I\JTN*Z[Q1\-O$_A,N^H:>SVJ_P#+U;YDB_$XR/Q KDRA%:&8VBEV
MFC:: $HJ18F;D"NB\)^"]3\6:JEG96\YC(<O.L6Y$(0L QR ,D #)')% ['-
MA<FO3?AM\*+SQ?*NH7_F6FC(PRY7YKCGE4]O]KM[\X[OP;\#+#2 NJ>+KF&X
M:+]Y]E5L0)CG,C'&['IP..=PK:\0_$NR%NVE^&F7RXQY+7$:[511QB+Z=,].
M.,\&HJ34%=E0BV[(G^('BM/#FE1^']!B2-O+\J4P# M8\8"J!T8C\A[D5Y78
MLA@5EP%!Y'>NCL[,-G<PPW)8]\]_\:K7VBC39#,H#1MS@=J\F5=U9ZH]"$%3
M6A$TT6T$$@@55FO(U3;C.>WI3)83< [20/0'I5$6\\#GS/G&>#BNB*LBE)6+
MJ73C!,8E'MPP%78I8R-T9*GN.A'X50ML,X*D'V-79%5QRI5QT-3;6Y%2I<U;
M:UCNQ\XS[BJ]_8R6KK) S!%/S#'6L^'4;FR.]5,B#N.HK5LM>AO583)CG!4]
M12=[Z&=TUJ48];!<(T8?'!&.0*+XVMU'NP"/4]16I/IMA=QGRR%?U'!K"NK.
M]L!\L8N4]^H_+_Z]5;0R;LS-DM4D<G(?'0YY%9=Y:-"#AB1[]?\ Z]; N--N
M<QRQF";UW 9_$<53GC5?D64NO;=51(=BCID#2W:#'>O>/!-CY=NC$=J\P\-:
M4)KE3M[U[IH-F+>U08[5T4T1)FVHPHJGJW_(-E^J_P#H0J[5+5O^0;+]5_\
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MZ06!9W7TI_VA\\#]343CBA>>:+("<73CUY]Z3[5+ZG\S4+$=.](SA1C.319
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MYI=P&.<'M3:N!J1,TTGEO\MY%]T_W_:K<-P'&>A'!![&LM91<H 3MF0?*?\
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MZ+KYV^ G_(\WO_8-D_\ 1L5?1-;T_A.#$?&-?_5M]#2)TI7_ -6WT-(G2M#
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MKJC"YFY'.>'/!<<(1Y(QGZ5Z'9V$=M&%50,58B@2)0 .E2UJE8S;N'2BBBF
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M&KD>OP-Q-;.A]8VR/R.*+H7*RS@^E(5'I2KJ>G2?\MBG^^A%2J]M)]RXA/\
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MJ7;1MHN*Q&!05J3&*=BBX[$.*3:<U*1@T<T7"Q#C%&,BI-I]*0IBG<5AFVD
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MIW_"'^)O^A=U;_P"D_\ B:=GV!27<Q,4  UMCP=XF_Z%W5__  "D_P#B:/\
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M+KN8>SF@J:WO^$0\38_Y%S5__ &3_P")H'A#Q-GGPYJ__@#)_P#$T:CYH]S
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M#+_\30?!WB@C_D6]7_\  &7_ .)I68<R[F!FG@5N#P9XGQ_R+FK_ /@#+_\
M$TH\&^)\_P#(N:O_ . ,O_Q-%F":[F%MHQBM_P#X0[Q/_P!"YJ__ ( R?_$T
MT^#?$Y_YES5__ &7_P")HLQ\T>YA!>].QS6W_P (;XG_ .A<U?\ \ 9?_B:7
M_A#_ !/GGPYJ_P#X R__ !-*S#FCW,0K25O_ /"'^)L?\BYJ_P#X!2?_ !-)
M_P (;XF/_,NZO_X!2?\ Q-%F.\>YA@ TX"MH>#O$W_0N:O\ ^ 4G_P 33_\
MA#O$W;P[JW_@%)_\32LQJ4>Y@E!FC;6\/!_B;OX=U;_P"D_^)I3X/\2G_F7=
M6_\  *3_ .)HLPO'N<^1@4*,BMX^#O$W_0NZO_X!2?\ Q-)_PA_B<?\ ,NZO
M_P" 4G_Q-%F+FCW,7':E5*VO^$0\3?\ 0NZO_P" 4G_Q-2#PAXEQ_P B[JW_
M (!2?_$TK,?-'N88':EV5N?\(CXE_P"A>U;_ , I/\*4>$?$O_0O:M_X!2?X
M4K/L/FCW,,#'%.(XXK:_X1'Q+_T+VK?^ 4G_ ,32_P#"(^)?^A>U;_P"D_\
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M8]<5[BNF6"-<LEC;*;O_ (^"(E'G=?O\?-U/7U-216EM;VHM8;>*.W5=HB1
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MBJWDT>30!9HJMY-'DT 6:*K>31Y- %FBJWDT>30!9HJMY-'DT 6:*K>31Y-
M%FBJWDT>30!9HJMY-'DT 6:*K>31Y- %FBJWDT>30!9HJMY-'DT 6:*K>31Y
M- %FBJWDT>30!9HJMY-*(10!,_\ JV^AH7I3!$OH/RJ6@ HHHH **** $HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
G HHHH **** "BBB@ HHHH **** "BBB@ HHHH 6BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image3.jpg
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %] ^D# 2(  A$! Q$!_\0
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M?_B:\&HKL_LZEW?]?(P^N3[(]Y_X63X8_P"@G_Y+R_\ Q-'_  LGPQ_T$_\
MR7E_^)KP:BC^SJ7=_P!?(/KD^R/>?^%D^&/^@G_Y+R__ !-'_"R?#'_03_\
M)>7_ .)KP:BC^SJ7=_U\@^N3[(]Y_P"%D^&/^@G_ .2\O_Q-'_"R?#'_ $$_
M_)>7_P")KP:BC^SJ7=_U\@^N3[(]Y_X63X8_Z"?_ )+R_P#Q-'_"R?#'_03_
M /)>7_XFO!\$=0:3D]*7]G4N[_KY!]<GV1[S_P +)\,?]!/_ ,EY?_B:/^%D
M^&/^@G_Y+R__ !->#44_[.I=W_7R#ZY/LCWG_A9/AC_H)_\ DO+_ /$T?\+)
M\,?]!/\ \EY?_B:\&HH_LZEW?]?(/KD^R/>?^%D^&/\ H)_^2\O_ ,31_P +
M)\,?]!/_ ,EY?_B:\&HH_LZEW?\ 7R#ZY/LCWG_A9/AC_H)_^2\O_P 31_PL
MGPQ_T$__ "7E_P#B:\&HP3VH_LZEW?\ 7R#ZY/LCWG_A9/AC_H)_^2\O_P 3
M1_PLGPQ_T$__ "7E_P#B:\&HH_LZEW?]?(/KD^R/>?\ A9/AC_H)_P#DO+_\
M31_PLGPQ_P!!/_R7E_\ B:\&HH_LZEW?]?(/KD^R/>?^%D^&/^@G_P"2\O\
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ME_\ B:/^%D^&/^@G_P"2\O\ \37@U%']G4N[_KY!]<GV1[S_ ,+)\,?]!/\
M\EY?_B:/^%D^&/\ H)_^2\O_ ,37@U%']G4N[_KY!]<GV1[S_P +)\,?]!/_
M ,EY?_B:/^%D^&/^@G_Y+R__ !->#44?V=2[O^OD'UR?9'O/_"R?#'_03_\
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M"NE70\#^(?"JNL&L12R*R[L;@RKM;_=8#&:;8Z;<^#_A-K%OKI1);CS1% 9
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M73NP3T7+]%&>V>@KRA=5U%+26S2_N4M96+20+*PC<GJ2H.#T'Y5F_OC+L#G
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M3D#IWKWKP_\ #OPK>^&]+N[C2M\\]I%+(WVB4;F9 2<!L=3712QF'BG**?\
M7S.6O0KRLI6^2M^2/$++4+W39_/L;N>VE(VEX9"A(],CM5F3Q#K4JS+)J]^R
MSC$H-R^)!C&&&>1CBO=_^%8^#_\ H#_^3,W_ ,71_P *Q\'_ /0'_P#)F;_X
MNM'CZ#=W%_<O\S#ZK4[GSS#-+;S)-!(\4L;!D=&*LI'0@CH:LOJVI27ZW[ZA
M=M>+]VX,S&0=N&SFO??^%8^#_P#H#_\ DS-_\71_PK'P?_T!_P#R9F_^+I_V
MA1?1_A_F+ZI4[H^?I;^\FO?MLMW/)=Y#>>\A+Y' .[KQ@5:O?$&LZC;^1>ZK
M>W$.<^7+.S*?P)KW?_A6/@__ * __DS-_P#%T?\ "L?!_P#T!_\ R9F_^+I?
M7Z/\K_#_ #']5J=SP :GJ T\Z>+ZY%D3DVWFMY9.<_=SCKS0^IW\E@M@]]<M
M9H<K;F5C&IZ\+G'<U[__ ,*Q\'_] ?\ \F9O_BZ/^%8^#_\ H#_^3,W_ ,71
M_:%'L_P_S#ZK4[GSM6C9:_K&G6_D66JWMO#U\N*=E4?@#7O'_"L?!_\ T!__
M "9F_P#BZ/\ A6/@_P#Z _\ Y,S?_%TWF%%[I_A_F)82HMF?/;W-Q)<FY>>5
MK@MO,I<EMWKGKFKMSXAUJ]M?LMUJU]- >L<EPS*?J">:]W_X5CX/_P"@/_Y,
MS?\ Q='_  K'P?\ ] ?_ ,F9O_BZ3Q]%]'^'^8_JM3N> 1ZG?PV,EC%?7*6D
MAR\"RL(V/NN<'H/RJ2PUG5-+#"PU&ZM58Y(AF90?J :][_X5CX/_ .@/_P"3
M,W_Q='_"L?!__0'_ /)F;_XNCZ_1?V7^'^8?5:G<^?+F[N;VX:XNKB6>9NLD
MKEF/XFKTOB37)[0VLNL7[VY7:8VN&*D>A&>E>Z_\*Q\'_P#0'_\ )F;_ .+H
M_P"%8^#_ /H#_P#DS-_\71]?HO[+_#_,/JM3N> V&J7^E2M)I][<6KN-K-#(
M5)'H<5*VO:PXN0VJWI%U_KQ]H;$O&/F&>>..>U>\_P#"L?!__0'_ /)F;_XN
MC_A6/@__ * __DS-_P#%T?7Z#=^5_<O\P^JU.Y\_V6H7NFS-+8WEQ:R,NTO!
M*R$CTR#TX%022/+*TLCL\CL69V.22>I)]:^A_P#A6/@__H#_ /DS-_\ %T?\
M*Q\'_P#0'_\ )F;_ .+I_P!H4;WL_P /\Q?5*G='A3>)-<:U-JVL7[0$8,9N
M'*D>F,]*RZ^B?^%8^#_^@/\ ^3,W_P 71_PK'P?_ - ?_P F9O\ XNDLPHK9
M/\/\P>$J/=G@EEK>JZ;$T5CJ5W;1M]Y89F0'\ :;+J^ISV?V.;4;N2USN\AY
MV*9SG.TG'7FO??\ A6/@_P#Z _\ Y,S?_%T?\*Q\'_\ 0'_\F9O_ (NCZ_0O
M?E?W+_,?U6IW/ ++4]0TUG:POKFU+C#F"5DW?7!YJK7T3_PK'P?_ - ?_P F
M9O\ XNC_ (5CX/\ ^@/_ .3,W_Q=/^T*.]G^'^8OJE3NCP*35M2FL5L9=0NW
MLTQMMVF8QC'3"YQ4-K>75C<+<6=S-;S+D"2%RC#/7D<U]!_\*Q\'_P#0'_\
M)F;_ .+H_P"%8^#_ /H#_P#DS-_\71_:%':S_#_,/JE3N>##7M8$EQ(-6O@]
MP )V^T/F4 8&XY^;CCFH8-3U"UM9;6WOKF&WFR)88Y65'R,'< <'CCFO?_\
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M/;<HH[S#C\:6>T'FSJ!TA)JZ(R^KQ0CMB0_]\FII8_\ 3;U<=+>BXFM#)TZ
M-I3R$=%)IF@VOFV#-CJY J]8+MT&Y/3"?TJUX8@_XD43$?>+']:;(BM5Z&=#
M (K&=B.(W?\ G5?1X,Z?)*?[Y8U=O6_T&:!/OS7+*/IGFELT\KPW/*!U=@OY
MXH!6OZ(KVD 33C,1][<_ZUFW$6Y$MU_WW_$\"NCU%%LM'MHVX+!1CZ#FJ$5J
M0\(=<R3RF1AZ =!33ZBDM>4ECLRL:\=!59(C-</(%RJ?*O'YUM78,< 51^\D
M.Q![U:M[!8(%C"]!S]:B[-N57L87V0D988K+^S?:]6" 9CA&3]:ZG4"EI:23
M-QM''UK.TJT^SV#W4P(:3,C?2FF*23:1ES6X>_5/X8AO8^E)%;95KN3A<?(/
M:I[5&OI&0 _O6W2GT7L/QK1E@$\Z6Z+\B?,^/T%.]B4KZF5#:$1[F&&;DT\V
MP"ECC%;)@]JH7JCB(#KRWTI)MFCBHHSH(S*S-CY>U2M;]JU(;/RX%4_>ZFE^
MSBCF$H::F/\ 9,]J@N+=(H6<C@"MD*ID**,XZ^U9FI.C2B(_ZN/YG]SV%5%W
M9$XI(Q9(L!!@[I.B^U6XM/95W,/F/Z5I66GL3]JG3]XWW ?X15X0$]J;D9PI
M]68)M.V*A>WVUT+P>HJ![= C,>,4*0W3, Q4FS%:LEKD\"H#%A]O4U5R>6Q6
M3(J9#GBAT]J$&#Q4L<2W&@Q5B.,&JL;]B*M1A6Z$@UFS>)*!SCK4\,*L<FHE
M3%3Q'::AMFBBF2>2,U((R,8%/3!Q5CRSCCFE<3CW*+Q;C5>6+ K3* =!5:9.
M*N+,9Q1B7"^U?37A7_D3]$_Z\(/_ $6M?-=RO)KZ4\*_\B?HG_7A!_Z+6NVA
M\#^7ZGFXE6DOG^AKT445H<X4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!F-_Q^2?[U3U W_'Y)_O5/0!R_CW_D
M4[WZQ_\ HQ:\MLOF(6O4O'O_ "*=[_VS_P#1BUY9: [@5KGK;G7AUH=!:J%
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MBGF7<OF(>#UI'3=A6_X":KX>"0J1U[>M:V.5RLR;?O7!_&H%)A;8W*'H:>,
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M?:[@9"GK["LC0+RWLHKO7+N8-/RJ*3R6-.VI/-96.AN)(I_%$DAQ]ETR')]
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M]:U/M$ 9%,T>Z3.P;AEL=<>M<YX,\0ZSX@@OWUC0GTEH)_+B5G)\U<?>Y H
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M6=O:P[BWEP1!%R>2< 8R:\N^'OQEG\<>+6T9M'BM8?)DE643EFPI&,C'O7K
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M@IE?^\Q ^8^YJS10 4444 9C?\?DG^]4]0-_Q^2?[U3T <K\0!GPA?#WC_\
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M6\M+QOLD?F?NT5.1\N/[Y9NO7'OGF_#=C?ZC\*?&5KIUY#;3/JB;A+.L(E0
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M]5C-N/+8_&J2,^9(LF=H<!F5E'0&HB"&\V1>O('I43- HW%V=QZ# J!KDL>
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MRBFDM0F^5'*:Q=-=73<\9JK;VV[DCZ4Y8FF?I]:W=.LA(@P,XZULCA;*,=L
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MT%8LM^ANBP]:M6FJ!;_SR< # JDQ&YJUHRK!!#DN1R?KUJ74;5+2SCMDZA
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M4 %%%% !1110 4444 %%%% !1110 445#=6T5[:RVTZEHI5*L 2#CV(Y!]Z
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MO"C22R.<*B@9))] !4M8'CK_ ))]XE_[!5U_Z*:@""'XB^#)Y5BC\3Z478X
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M>+_ >J:Y;:-X=CUS2]2O7OK5TNT@-O))]Y'#=5&!R/3WX]0IDDL<0!D=4!.
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MDW5G3(K,2%PWK4DET,?*0:A$Y/.!32%<JO(ZB2,9*GK4D'E.["99!CN%J47
MR2<?0"GIK$L$I"*<9I712)D\N--J,'7T>.LJ]A1I<L H]CBMB;6I3%N,0?\
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M:+F[DO;IKB?YF8_*@JS8V#7$GG3=!T%;15D<TI.<M".SLI+J83S#C^$5U=G
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M$1?H!P*IZMX<T37O+_M;2;*^,?W#<0*Y7Z$CB@#YV&M3ZO\  +Q(DVFV%O\
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MI+JNC6%[(G"O<6ZNP'IDC./:K%SH^FWFEG3+G3[66P*A?LSQ*8\#H-N,<=J
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MT.ZVEE@5VA.0<H2,J<@=/04R/0M(AGNYXM*L4FO05NI%MT#3@]0YQ\V<]\T
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MLH(:0CD^E>^^%?\ D3]$_P"O"#_T6M=U/X'\OU/&Q/QKY_H:]%%%,Q"BBB@
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MUVQ!6)9L<FJS0LK<-^M/FDC9PI3-./6G7AF(^HJW'KF0,%3]&KGF+ '*YIN
M1RN*I569RP4'L=2=8C=<.&'ZUB:M8:?J:'>$!/?96<0R\HY7Z&D,MPHR'##T
M(JE5,)8!]#E=7\,1VQ+07$;CT*E:YR6UDB)!"G'HU>CS3"1,2P[A[5E3Z79W
M!S]WZBM8U4<E3 U%LCB%C9F 9&QFM3*>4L2QL%_G6ZNB6R]'7\ZE&G!!\DN,
M= &J_:(YWAJBZ'/22PQ0%<.#4=H8S;,S;L$YK?ETIYSS*33QI,ZQ;%=MOI3Y
MT+V$^QRJF-IC]X@&II,*@*HW ]*Z!=,E0\J/J5%2'3II%VL3M] *7,@]C+L<
MY:HC0N2AQCBGV]M(SHXAX[9-=+'ICHNU$(IS6MR@^ZY_&CVB&L/+L9 BN/*$
M:0<$_P!TU.J7*P2H$"[B/X:N+;WA;_5C_@3BK*6%TW62%?S/]*GG1HL--[(R
MK&RNDWCS%5'Z@G%"6<"3OYDH;YCG!-;::5*QYG9O94Q_.H8M(7[0^5)^8]3[
MTO;(T6"GU*:K:QME(_R4?US5V&1,<69D'^VS8_3%:L.EJF#M5?H*M?9AG&W-
M92K'5# Q7Q,SHKV]3BW@A@'_ $S49J;=?2\RSM5_[, /F 4#DD\"B3[/'$&:
M8-GH(_F_E4<\GL:^SH0W*JQX&6=F-2H!T"\FH/MBB4K&@50,F2?*K_+FJT^H
MQKND338+L '=-$YQ_*ERR>XGB:<-(HO2>8K!0<9J6*#3@Q^V7\*$=5:0 URU
MSJ-Q\A2REB+\J([ECG\QBJ$KWL$WGM8GGEF=5)_3K^5+DUU)EBI->[H>@I?>
M'H4VK=6[/_UT%<[J&ODS210O''"#@,@5F/Z\5RS7EO=2YN;--YXPC! /PQ3W
ML0N&BMB!CH5#?J*;LC%3F]=S46\TZ1OWTKNQ_P">K''^%6TLK2<>:A'/381T
MKGH;6WN&V.L8<?P.FQJD&G)$28I)[4^H;BH<5W-E4E;5(Z*.WAA'RQJ#ZXR?
MSHDVR'#HN/I6&ESJ=F,,ZW,?KCYJGAUB*XX/R,.N:SE%]#:%2+T>@7>DP.Q:
M*-0QYQTS^/:J866!A@^?'G!!X9#]:V=RM$6#Y8] *I7-NSJ6C^5\8^M.,GU)
MG36Z)[5VF0E'W%>L3<./\:L),G8'Z=Q6:A>2)9X_EG0?Y!JR)?- EVX)'-*5
MK%POU))OW@P<$'UHCC\I<1G<@Z#_ .O463U!!I2TC,.?E]N*1II<>>7SFIX9
M0'_2F1@*=P(_&I3&LH.Q2IH41N0U^3][\JD"J$&1DU%&AW%2<$>M65 ZXR*.
M4',D3. VW ]:D.W\ZD2,?9L;@&ZX)J(<CJ*+$<PD@&T'KBJLP++D\59+; <X
M.>E5YI"01CBKB839FW"#9D'WKZ%\*_\ (GZ)_P!>$'_HM:^=[MB1@5]$>%?^
M1/T3_KP@_P#1:UZ.'^!_+]3R,7\:^?Z&O1116IS!1110 4444 %%%% !1110
M!SWCW_DG?B7_ +!=S_Z*:OFO3_%ITKX3#2Y_ \5Q#=>=#%K-POR;F+?=.S[R
M]OF[5]0>)M,FUKPKJ^EVS1I/>64UO&TA(4,Z%03@$XR?0UQV@_#:6#X0R>"]
M:DMI)G$N)8"S(CERR,,@'(.#T[4 >5>,?#MSX:_9\T&UNYXI99]66Z_=.'15
M>*0@!AP>,'(XY/UJJVO2>$OA]XT\#/(?M2:HMO;#^)HW)W8'IMB_\B5V]]\*
M/&.H_"NQ\)75_I#7%CJ G@E\Z7;Y.QQM)\O.0S\<8Q]*TO$OP@NM;^+-GXHC
MGLAI@D@ENX9&82.T> 0 %P00J]2.] &#\"-+;1/&_BS2W.9+1(X7/^TK,#^N
M:]ZKRB'P?K7A/4/B!XE.J:?:+J44DUI/N=C;G+,&D&P],CINKK/AK>ZOJ/P]
MTB]UV22749T>21Y$"EE,C;#@ ?P;>U 'D/CC5H=$_:%^W3Z1+JT:6:@VD48=
MGS$1G!!Z=?PJGI%IKR^(/%7CW3] F\,V,&F3-;Q/#L D\L ;5*@'D%SQC->I
M2>!-4;XU1>,Q/9_V<EMY1BWMYV?+*]-N,9/K75^+-)GUWPEJVDVKQI/>6LD,
M;2DA0S*0,D G'X4 >1^#M>\?7?AQ/'>M:_$^AV4,[O8K$J/=;%8#D)@9< 9]
MJY(_%SQ2VGG7_P#A,;%;L3<:"+$X,>[IOVX]_O9QWSQ7MWA3P5)IOPLB\'ZS
M)%(S6\\$[VS$KB1W.5+ '(##J.HKSNW^$GCK3[)=!L]5T%=*$Q=;TV_^DJN[
M..4/UQGVSB@!GCSXGZT;GPP;/4I-!T;5-/2[FO8;47#+(V=R#.,[2%!Q@_-G
MG@5+=:]JFO? SQ5+J>OZ9K7E^6L4]FK)(%\Q>)4*+M/ (X[GTKI_%G@7Q3-/
MIC^'M3L;JQM+=89=+U>,-!*P!&\J%P2<^@P1QZ5CZ3\'=5L/ _BJPDN].&K:
MZ8R(X=R6T 1RP ^7..3_  \8 H Y2ROOB)X8^%NE>++37+<:5;JD::;]G4@1
M%]H+$C))..^1NX(Z5UUAX_UF+XH:$M]>D^'?$>GQSVL#(F()'0?+N"@DAQCD
M]'%9K?"KXAW'AFS\'W/B'2O^$?1E>0HK&1>=Q0?+\P#$D9(Z#ITJ/XYQ:!I_
MA'1-'L[Y5UC2'BBM8%;,PBV8R<=/NH<^H]Z (!\5_$4>E^+/%2W(FTM;P:?H
M]N\2A [$MO) R2J*#@GDM4NI>)/B3X!T_1O$^NZS;:IIM_*@N;+R54Q[E+!0
M0HP=H/(XR.0:ZRS^%D%W\&+3PG<L;:\9!=/+MR4N3\W([@9V_05A-\+?''B-
M=*TCQ=K]A+H.FNI5+4'S90HP,Y4<X^7)/&3UH 77_$WC74OC'/X5\.:W%:6<
MUJDB/+ CK"IC5V<<9)/09_O=NH7P]XQ\36FH>,?!WB2\BOK[3-.FN+:\\I1N
M 0$ KC# AU;D>N<UC>(;+7;K]HVZ7PU>6]IJ<-FDD37"DQL!$H*M@'@@GM_C
M76>&/AEKEM-XFUOQ!J%I<:]K5G+:J(<^5&''<[0>H4<#@#OF@#GM"\5>)5^"
MUIJ=EJVCZ;<-?21S7=TD<05,\!(U3:S?AG /7LOPX^(6L7/Q+7PY/XE3Q%IE
MS$[)=&U\DJZH7. 0#C@CG(Z8J2X^"_B!OA[H^DI?Z<=2TR]EN1&S.UO,KX.#
ME<Y&WNN.36MHGP[\81?$K2_%^L7FB.(8FBEMK0/&L2%&0+&-N#C=GDCO0!W?
MCF_U33/"-[=Z/=:?:7: 8N+^39%$,\GD$$]@#W/X'QCPY\2=>M?B%HFG/XOA
M\16FHRI#=HEIY:PNYVX4E5S@D'(X/I7K'Q-\'77CCP?)I-G=I;7 F29#)G8Y
M7(VMCG'.>AY K@H_AAXXN];\,:I?W7A^-=%FCVV=J'C7RT923D(<NV.>@X%
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M8Y\QXI68'Z9V_A72:U\$[G5/BK_PD*7%D-$ENH[JXMV9_-9A@N -N"&8'O\
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M\9]:CN)MD+X/48_/BNR?X::X1\MS8 GK^\?_ .(J"3X6ZZVT"YL,9RV9'_\
MB*/92[!]8CW.0AE\JY@/3"D _E4MW=-<W$,;L2 =Y_#I^M=2WPLUYGC(NM/
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M>['J:BOYGDDB@1L;CN8^@KLE^%?B)?\ EZT[_OZ__P 13#\*/$1E9_M6F\C
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MD-8B'<Y6*7,F2=M2"7U.<5U'_"JO$ Z7>G_]_'_^(I1\+?$.,?:M._[^O_\
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M=5ZX..N>E>=?\+M_ZE[_ ,G?_M=;4\/4J*\%<SG6A!VDSU'R!Z4>0/2O+?\
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M_M='U*O_ "_B@^LTNYZEY ]*/('I7EO_  NW_J7O_)W_ .UT?\+M_P"I>_\
M)W_[71]2K_R_B@^LTNYZEY ]*/('I7EO_"[?^I>_\G?_ +71_P +M_ZE[_R=
M_P#M='U*O_+^*#ZS2[GJ7D#TH\@>E>6_\+M_ZE[_ ,G?_M='_"[?^I>_\G?_
M +71]2K_ ,OXH/K-+N>I>0/2CR!Z5Y;_ ,+M_P"I>_\ )W_[71_PNW_J7O\
MR=_^UT?4J_\ +^*#ZS2[GJ7D#TH\@>E>6_\ "[?^I>_\G?\ [71_PNW_ *E[
M_P G?_M='U*O_+^*#ZS2[GJ7D#TH\@>E>6_\+M_ZE[_R=_\ M='_  NW_J7O
M_)W_ .UT?4J_\OXH/K-+N>I>0/2CR!Z5Y;_PNW_J7O\ R=_^UT?\+M_ZE[_R
M=_\ M='U*O\ R_B@^LTNYZEY ]*/('I7EO\ PNW_ *E[_P G?_M='_"[?^I>
M_P#)W_[71]2K_P OXH/K-+N>I>0/2CR!Z5Y;_P +M_ZE[_R=_P#M='_"[?\
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M_M='_"[?^I>_\G?_ +71]2K_ ,OXH/K-+N>I>0/2CR!Z5Y;_ ,+M_P"I>_\
M)W_[71_PNW_J7O\ R=_^UT?4J_\ +^*#ZS2[GJ7D#TH\@>E>6_\ "[?^I>_\
MG?\ [71_PNW_ *E[_P G?_M='U*O_+^*#ZS2[GJ7D#TH\@>E>6_\+M_ZE[_R
M=_\ M='_  NW_J7O_)W_ .UT?4J_\OXH/K-+N>I>0/2CR!Z5Y;_PNW_J7O\
MR=_^UT?\+M_ZE[_R=_\ M='U*O\ R_B@^LTNYZEY ]*/('I7EO\ PNW_ *E[
M_P G?_M='_"[?^I>_P#)W_[71]2K_P OXH/K-+N>I>0/2CR!Z5Y;_P +M_ZE
M[_R=_P#M='_"[?\ J7O_ "=_^UT?4J_\OXH/K-+N>I>0/2CR!Z5Y;_PNW_J7
MO_)W_P"UT?\ "[?^I>_\G?\ [71]2K_R_B@^LTNYZEY ]*/('I7EO_"[?^I>
M_P#)W_[71_PNW_J7O_)W_P"UT?4J_P#+^*#ZS2[GJ7D#TH\@>E>6_P#"[?\
MJ7O_ "=_^UT?\+M_ZE[_ ,G?_M='U*O_ "_B@^LTNYZEY ]*/('I7EO_  NW
M_J7O_)W_ .UT?\+M_P"I>_\ )W_[71]2K_R_B@^LTNYZEY ]*<(@*\K_ .%V
M_P#4O?\ D[_]KI?^%V_]2]_Y._\ VNCZE7_E_%!]9I=SUA4Q3L55TJ]_M/1[
=+4/+\O[5;QS>7NSMW*#C/?&:N5S-6=F;IWU/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image4.jpg
<TEXT>
begin 644 image4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (7!7H# 2(  A$! Q$!_\0
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M)ZDUE?\ "7>(O^@O)_WXA_\ B*T5)M7,W52=CUZBO(?^$N\1?]!>3_OQ#_\
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MO$7_ $%Y/^_$/_Q%'_"7>(O^@O)_WXA_^(H]C(/;1/7J*\A_X2[Q%_T%Y/\
MOQ#_ /$4?\)=XB_Z"\G_ 'XA_P#B*/8R#VT3UZBO(?\ A+O$7_07D_[\0_\
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M?]^(?_B*/8R#VT3UZBO(?^$N\1?]!>3_ +\0_P#Q%'_"7>(O^@O)_P!^(?\
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M=%FBJW]HV/\ S^6__?U?\:/[1L?^?RW_ ._J_P"-%F%T>5>+O^1PU3_?C_\
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MRN=X4@$\XY_2LCXC?\?.G_[C_P Q0IW:!PLF<11116AF%%%% !1110 4444
M%%%% !1110 4444 %%%% !45S_QZS?[A_E4M17/_ !ZS?[A_E0![Y15;^T;'
M_G\M_P#OZO\ C1_:-C_S^6__ ']7_&N.S.VZ+-%5O[1L?^?RW_[^K_C1_:-C
M_P _EO\ ]_5_QHLPNBS15;^T;'_G\M_^_J_XT?VC8_\ /Y;_ /?U?\:+,+HL
MT56_M&Q_Y_+?_OZO^-']HV/_ #^6_P#W]7_&BS"Z+-%5O[1L?^?RW_[^K_C1
M_:-C_P _EO\ ]_5_QHLPNBS15;^T;'_G\M_^_J_XT?VC8_\ /Y;_ /?U?\:+
M,+HLT56_M&Q_Y_+?_OZO^-']HV/_ #^6_P#W]7_&BS"Z+-%5O[1L?^?RW_[^
MK_C1_:-C_P _EO\ ]_5_QHLPNBS15;^T;'_G\M_^_J_XT?VC8_\ /Y;_ /?U
M?\:+,+HLT56_M&Q_Y_+?_OZO^-']HV/_ #^6_P#W]7_&BS"Z+-%5O[1L?^?R
MW_[^K_C1_:-C_P _EO\ ]_5_QHLPNBS15;^T;'_G\M_^_J_XT?VC8_\ /Y;_
M /?U?\:+,+HLUY#XN_Y'#5/]^/\ ]%)7JO\ :-C_ ,_EO_W]7_&O*/%4B2^+
M=3>-U="\>&4Y!_=)6E+XC*K\)D4445T'.%%%% !1110 4444 %%%% !1110
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M03Q^5=#:ZKX=\,Z=<)I]V]U+)\P4_,2<<<X  J=M6?1O VGW<44<DNU%3>.
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M^6__ ']7_&C^T;'_ )_+?_OZO^-8V9O=%FBJW]HV/_/Y;_\ ?U?\:/[1L?\
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M^@AJ/_?47_Q%'_"N-,_Z"&H_]]1?_$5V-%'/+N')'L<=_P *XTS_ *"&H_\
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M[AR1[''?\*XTS_H(:C_WU%_\11_PKC3/^@AJ/_?47_Q%=C11SR[AR1[''?\
M"N-,_P"@AJ/_ 'U%_P#$4?\ "N-,_P"@AJ/_ 'U%_P#$5V-%'/+N')'L<=_P
MKC3/^@AJ/_?47_Q%'_"N-,_Z"&H_]]1?_$5V-%'/+N')'L<=_P *XTS_ *"&
MH_\ ?47_ ,11_P *XTS_ *"&H_\ ?47_ ,178T4<\NX<D>QQW_"N-,_Z"&H_
M]]1?_$4?\*XTS_H(:C_WU%_\178T4<\NX<D>QQW_  KC3/\ H(:C_P!]1?\
MQ%'_  KC3/\ H(:C_P!]1?\ Q%=C11SR[AR1[''?\*XTS_H(:C_WU%_\11_P
MKC3/^@AJ/_?47_Q%=C11SR[AR1[''?\ "N-,_P"@AJ/_ 'U%_P#$4?\ "N-,
M_P"@AJ/_ 'U%_P#$5V-%'/+N')'L<=_PKC3/^@AJ/_?47_Q%'_"N-,_Z"&H_
M]]1?_$5V-%'/+N')'L<=_P *XTS_ *"&H_\ ?47_ ,11_P *XTS_ *"&H_\
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M@OAW_GQD_P# J;_XNNCHHYI=PY8]CG/^$%\._P#/C)_X%3?_ !='_""^'?\
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M "BBB@ JMJ/_ "#+O_KB_P#Z":LU6U'_ )!EW_UQ?_T$TUN#+-%%%("MJ/\
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M$S)]X1R!B/KB@">BH(;ZTN)GAANH)94^\B2 LOU Z4->VJ7*VSW,*SM]V(R
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M Z6BJ&DZS9ZU;/-9NW[MS'+'(A1XV'564\@TFI:YIFD!1?7D<4C?<B'S2/\
M[JC)/X"@#0HK&L-7U#4KQ-FC3VUA@[I[M@CMQQMCY/7UQ4'B;4KVWDTW3=-E
M6"[U&X\L3L@;RD4;F8 \$XZ9H Z"BN:T.^U*#Q#?:%J=V+QHH4N8+GRA&S(2
M5(8#C(([5+J4/B&]UAXK2]73--BB#"X$22O,YZC#?= ^G_U@#H**P?"&KW.M
M: EU=%'E65XO-C7"S!6P' ]_\:AO?'&DV-W=VSQWLCV;8N3#;,ZQ#&=S$< ?
MX&@#I**P;+QAI.H:C#9P&X'V@L+>9X&6*<J"3L8C!Q@U23XB:"\<<Q-XEJ[;
M#=/;,(E?^Z6]: .KHK(TGQ)8ZQ=2VL*74%Q&@D,5S T;%#P& /45+J^N66BI
M";DR/+.VR&"&,O)*>X51R: -*BN*\0>-XT\,WEQI0N4OHY%A99+8[[9F(Y=2
M.."<9X)XKH=*\^/0E>6YNIY2C.'NXA'(/0%0!C% &I17E=OK^KCPE'K;^,H#
M>>67%A+!"=Y!("<8;)QVKMIO%$%G#91W-M=2:A<6ZSM9VL#2N@P,D@= "<<T
M ;U%<^_C'2OL5E<P?:;HWN[R8;>!GE.WAOE[8/6I6\6Z0-(BU(32-%-)Y,<:
MQ,96DSC8$Z[O:@#;HKC==\7+)X3U6YTN2>UU"S,8>*XAV21;G4<JPZ$$\U?F
M\06VF7VO37E]+);V/V?= ( !!O'9ARVXD$YZ4 ='16%IOBW3=3U)+&-+N&65
M#) ;BW:-9E'4H3U%0_\ ";Z-]H"[KG[,9?)%[Y#?9]^<8\SIU[]/>@#HZ*R_
M$EW/8>&=3N[9_+GAMG>-\ [6 .#@\5QVH7WB/0?#MIK[^(5O5=8G:QFM8U\S
M?C(5EYR,T >BT5P^G_\ "0ZYJ>M&#Q%)91VE\\$47V2.0   C.1GOZUL^&-7
MO+]+ZRU)8QJ&GSF"9HN%D&,JX';([4 ;]%%% !1110 4444 %%%% !1110 5
M6U'_ )!EW_UQ?_T$U9JMJ/\ R#+O_KB__H)IK<&6:***0%;4?^09=_\ 7%__
M $$U9JMJ/_(,N_\ KB__ *":LT^@!1112 **** "BBB@ HHHH **** "BBB@
M HHHH **** ./\>1332>'HK>X-O,VJ($F"!MAVMS@\&K4'A6YEU2TO\ 6=;G
MU)K-B\$9A2)%;^\0HY-=#-:V]PT33P12M$^^,N@8HWJ,]#[U+0!XM!;O<^'-
M4N;^71(;HW,GVBXN@YNXI W&W'([8 KJ;728=3\9W<FHP17ES!I5NR^:AP9"
M#\V#T.1W&1FNRDT;2YKX7LNFVCW0Z3-"I?\ /&:LK;0)<O<K!&)W4*\H0;F
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MC_R#+O\ ZXO_ .@FK-5M1_Y!EW_UQ?\ ]!--;@RS1112 K:C_P @R[_ZXO\
M^@FK-5M1_P"09=_]<7_]!-6:?0 HHHI %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!Q7C.QGFU?3[RZTRYU71H8V$MI;G++(>CE,C=QQ[5C12V$&A^))?#%Y);
M6A:33+@/&UL0#N=<G()'IQG'-=;K&EZS_;$6K:)=P"40^1+:W9;RI%SD$;>C
M9[XK./AC5=4EU2^U:>SBO+O3WL(8[4,4C5N<L3RQS0!/H6L7R3Z)I5W%!NGT
M\SF2-F. NT+U[D'GWI+GQ?+;KJ:BS66>#4$L+6,/CS7< C)[=3^50+H7B.%M
M'OX3IAO[&W:UEB9W\N2,XP0V,@\>E11^#M5DL;][J\M1J4FHIJ-O)&K&-)%
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MPDAN[W6]=Y\K4;D" G^**(;%;Z'G'M0!U%%%% !1110 4444 %%%% !1110
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M>&*&X:!?/4HS[0,G:>5Y)&#SQVZ5<U'_ )!EW_UQ?_T$TUN#+-%%%("MJ/\
MR#+O_KB__H)JS5;4?^09=_\ 7%__ $$U9I] "BBBD 4444 %%5;34K.^EN8K
M6=96MI/*FV]%;&<9Z'KVJK8^(M(U*\:TL[Z.68 D* 0& .#M)&&Q[9H U**R
M['Q%I&I7C6EG>QRS $A0" P!P=I(PV/;-26FN:=?7<]K;W.Z:'=O!1E'RG:Q
M!(PP!X)&<&@#0HJ"SO(-0LXKNV<O!*NY&*D;AZ\]JGH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH :Z)+&T<B*Z."K*PR"#U!%)%%'!$L4,:1QJ,*B+@#Z 4^B@ HHHH B@MH
M+966W@CB5F+,(T"Y)ZDX[U+110 4P0Q"9IA&@E90I?:-Q Z#/IR:?10 4444
M %%%% ",H92K %2,$$=:2.-(8EBB14C0!551@*!V IU% !1110 4444 %%%%
M !14<]Q#:P23SRI%%&I=W=L!5'4D^E06&I6>J0--9SB5%;8W!!4X!P0>1P0>
M>Q% %NBLZ+7M*FN+B".^A,ENK-+DX"A3ACD\$*>#CIWIL?B+2);"6^2^C^SQ
M,%=B"""<8&",\Y&..<C% &G15!M:TU-);5'O(EL5!)F8X P<$>N<C&.N>.M7
MZ "BBB@#G-7T[5;[Q/8SV,\=K'9VLI$TL/FHSR%5QMW*<A5)Z]ZFB\(Z4FFV
MEI)$SRVR;4NU8QS@DY+!UP1DDG ..:W:* .<_P"$68WQW7Y;3S=I>M;&/YWE
M4+C<^>5W*&QMZCKCBI+W0=0NG@N(]52&]%L]K/.MM]]&(.4&[Y&!'!R>O(-;
M]% '+)X-C@;[+!=^7I#2PS26GE99VB1%4;\_=/EH2,<XZ\U8L/##6E_;22WO
MFV=E)++:6XBV[&D)R7;)W$!F X'7G)KH:* *&F:;_9\E_(TWFO>737#';C&0
MJA>IZ*H&:OT44 %8U]XGTW3[^2SG:??$L;2ND+,D0<D*68# Y%;-<>/#FH:I
MJ.L27=R+>QO+Q/,MS#EY(H@H7:^[Y0Q4YX/!XQF@#83Q)93WK6UFD]WY;E9Y
MX4_<PXZ[G.!D>@R?:J>D>(;R_O;$W%M%'::E#)/:!2?,5%*X+YX^96!XZ<#G
MK5Z;PWI<MVUTD#6\TF1*UNYC$P(P0X'#?B":I:?X;O+)XIFU1);BVMDM+5OL
MV%CB#*6RN[EV"@%L@<#CL0!M_P")+J"\NVM[>%["PGAM[EW)WN\A7(3''RAU
M//4G''6JH\9R0PQ:E=V\2Z5<I/);["3+LC4L&(Z88#@#IE>N:NR^%VFU&1GO
M?^)=)>+?/:B+YFE &,OG[N5#8QG(ZXXJHG@GS+$6EYJ!FBM[,V5D$AV>2AQ\
MS<G>_P JC/ P.G)H L6^OZG%)<07^G*]TMK'=)#:/R [,NQB^ "-O+9 //''
M.GX?U&?5] LM1N(5ADNHA-Y:G(56Y49^F*I)X?N6MM6>XU%7U'48/(-PD.U(
M5"D*%3<3@%F;[W))K:M;=+2SAMHAB.&-8U^@&!0!+59/^0G/_P!<8_\ T)ZL
MU63_ )"<_P#UQC_]">F!9HHJ"[NX+"TDNKF01PQC+-@G'X#K2 GHK!A\4PW&
MD6=[!9W+R7LSP6]M@+(S*6!SD@* $).>E.'B:%[&"6.TN'NIKAK5;/Y0XE7.
MX$YP  I.<]* -RBN8E\:6Z1!Q8W!,:R-=(2H:W".$;//S')Z#J.:W+&_6_>Y
M,<9$4,QA60GB0K]['L#E?J#0!;HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI+
M6WFFCFE@B>6+_5NR LGT/:I:* "BBB@")K6W>Y2X>")IT&$E* LH] >HJ6BB
M@ IDD,4P42QH^Q@Z[E!PPZ$>XI]% !1110 4444 %,BAB@39#&D:9)VHH R3
MDGCWI]% !1110 4444 %%%% !1110 4444 %%%% !1110!D>)]3ET?P[=WL#
M1K.H5(C)]T.S!5S[985B/K/B2-M2M;."VU*:TGC1IXX]NP,FY@$+_.5XXW X
M8=ZZ/5=*@U>&WAN3F&*=)FCP")-O(4@]LX/X58L[*TT^W6WLK:&V@4Y$<*!%
M'X"@#BWNHK^XM(=5O[B;3X+:XO+HW,)MR[H54*4P#M0,3CGG:<GBI_.O)/!>
M@V4\\D<]Z]O!<N7(D2-AN()SD,5&W/7+>M=7=Z=97YB-Y9V]QY3;H_.B#[#Z
MC/0TDVF6%REPD]E;2K<D&</$I$I  &[CG  '/I0!PEHUO<ZHVGO+Y?AU;FZN
M%4N0CI"D2%0<\IYC2-CI\OI5%9WNM NYM2DGQ9:8C6$)D8.9)FD\INN2P C4
M'L<^]>CS:3IMQ;PV\^GVLL$)!BC>%2J8Z;1C _"GRZ=8SW<-W-9V\ES#Q%,\
M0+I]#C(_"@#G8[>[D\=V8N;^:46^GM,\/ C1V*HI  Y)Q+R2?;%=748@A6X:
MX$2"9U"-(%&YE&2 3UP,G\S4E !1110!QNIV6K:EXHU,V,5L(UT];$37)8;#
M(69G3"G=@;>,C) YK2'A*UMY([G3KFYL;Y8HX7N(F!\Y44*H=&RK<#K@'WKH
M** .27P]JL<RQ!K0VEM>3W\.9&WSRNSLBR?+\JJS\D;B<#BI-5T#4[VYOU@E
MMHX-5MXH+N0NV^)5W!@@VX;*L0,D8//-=310!RB>&;W[6+4R6Z:4NH&_W(S>
M;(V=RH1C "M@YR<A0,"GZ%X>O[.;31?/;>1I5J;:U6!B3(2 #(^0-IVKC:,]
M3S7444 9F@:=-I>DK!<LCW+RRS3,A)!=W9S@D#^]C\*M:C_R#+O_ *XO_P"@
MFK-5M1_Y!EW_ -<7_P#0336X,LT444@*VH_\@R[_ .N+_P#H)JS5;4?^09=_
M]<7_ /035FGT ****0!3)HDN()(9 2DBE& )!P1@\CD4^B@#C-)L4LD\766F
MP+$J/LACC'0_9UQ^.:S+EX[O0/"<.ELK70MG*"/DJ!;,K9QT^; ^M>A1P0Q2
M2R1PQH\K;I&50"YQC)/<X %06VEZ?9W$MQ:V-M!/+_K)(XE5G^I YH Y"SFM
MKB#P*EDZ-*B[B$.2J" A\^G. ?>DU314L+I+."[FD^T1S@1JH!M[5G$DV".2
M2<(I/3=[5V%MI>GV=Q+<6MC;03R_ZR2.)59_J0.:F%M +IKH1+Y[((S)CG:"
M2!],DT 8OAG6I-3C:"6SAMC';P3QK#(77RY 2HZ#! 7!%;]5;+3;'34=+&T@
MMED;<XBC"[C[XJU0!FV>J-?7VIVT4 'V"Y6W9GDQO)ACER..F)0/P-7=UQ_S
MRB_[^'_XFL3P]_R'/%G_ &%4_P#2*UKH* (MUQ_SRB_[^'_XFC=<?\\HO^_A
M_P#B:EHH BW7'_/*+_OX?_B:-UQ_SRB_[^'_ .)J6B@"+=<?\\HO^_A_^)HW
M7'_/*+_OX?\ XFI:* (MUQ_SRB_[^'_XFC=<?\\HO^_A_P#B:EHH BW7'_/*
M+_OX?_B:-UQ_SRB_[^'_ .)J6B@"+=<?\\HO^_A_^)HW7'_/*+_OX?\ XFI:
M* (MUQ_SRB_[^'_XFC=<?\\HO^_A_P#B:EHH BW7'_/*+_OX?_B:-UQ_SRB_
M[^'_ .)J6B@"+=<?\\HO^_A_^)HW7'_/*+_OX?\ XFI:* (MUQ_SRB_[^'_X
MFC=<?\\HO^_A_P#B:EHH BW7'_/*+_OX?_B:-UQ_SRB_[^'_ .)J6B@"+=<?
M\\HO^_A_^)HW7'_/*+_OX?\ XFI:* (MUQ_SRB_[^'_XFC=<?\\HO^_A_P#B
M:EHH BW7'_/*+_OX?_B:-UQ_SRB_[^'_ .)J6B@"+=<?\\HO^_A_^)HW7'_/
M*+_OX?\ XFI:* (MUQ_SRB_[^'_XFC=<?\\HO^_A_P#B:EHH BW7'_/*+_OX
M?_B:-UQ_SRB_[^'_ .)J6B@"+=<?\\HO^_A_^)HW7'_/*+_OX?\ XFI:* (M
MUQ_SRB_[^'_XFC=<?\\HO^_A_P#B:EHH BW7'_/*+_OX?_B:-UQ_SRB_[^'_
M .)J6B@"+=<?\\HO^_A_^)HW7'_/*+_OX?\ XFI:* (MUQ_SRB_[^'_XFC=<
M?\\HO^_A_P#B:EHH BW7'_/*+_OX?_B:-UQ_SRB_[^'_ .)J6B@"O+/+!"\L
MB1*B*68^8> .3_#7GOAE-4U$V-Q;#4;:XFM[B6\N;AI-@,G,80.-C8+!AM!
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M_$T;KC_GE%_W\/\ \34M5M0$YTRZ%K(L=P87\IVZ*^#@G\: )-UQ_P \HO\
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M0N\)C&W<PXSG'/M4EOXINYKRUF>QB72;N\>RAF$Q,N]2P#%<8VDH0.<]#WH
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M10 4444 <_X>_P"0YXL_["J?^D5K705S_A[_ )#GBS_L*I_Z16M=!0 4444
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MPHHHKB.D**** ,CQ1KG_  C?AVZU;[/]H\C9^ZW[-VYPO7!]<]*\Z_X7<?\
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MU_ZF#_R-1[;R#^U/^G;/:Z*\4_XK7_J8/_(U'_%:_P#4P?\ D:CVWD']J?\
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M?X4?:$_NR_\ ?IO\* ):*B^T)_=E_P"_3?X4?:$_NR_]^F_PH \H^-W70O\
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MK(Z@1J50,(ASD$)\QXQN+<\4 =97/^'O^0YXL_["J?\ I%:UT%<YH+LNN^+
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M,>GA?X85GZR+P6#2VFHPV'E9DEFFM_-&P YXW+CUS[5H5G:[I9UK1+K31<&
M7*;&D"[L+D;AC(ZC(_&N(Z3 TN\\3WWAZVNY;JR@%Q(\S74L&/)MMN4)3=C<
MW4Y. #WJD?%.O3Z5I5W;VRDW E.Z.U=EN&6550#G,:NA9\GT]!SN^)O#USKM
MM:6MM?Q6EK"^^6W>V,J3XQM5@'7Y1UQT/'I5F;3=1N/#\FG3:A$;B4>6]Q#
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M*** "BBB@ HHHH **** "BBB@ HHHH *\4\!?\CKI_\ VT_]%M7M=>*> O\
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M/_Z!'7+C_P"";X7^(>AT445X9Z84444 %8_BS_D3M:_Z\9O_ $ UL5C^+/\
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M+_\ D6KG_K\;_P! 2CXH?\BU;?\ 7XO_ * ]'PO_ .1:N?\ K\;_ - 2L/\
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MKV(S&&Q]T+75G3(SX_TMWEFFGM;"25V>0E5)V1KM7H,_O"3C)KK:* "BBB@
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M/?\ (<\6?]A5/_2*UKH*Y_P]_P ASQ9_V%4_](K6N@H **** "BBB@ HHHH
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MR4/2_P#MK_Z*>N1KKOAA_P E#TO_ +:_^BGKHK_PI>C,J7QKU/HFBBBOFSV
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M1M9:E=K!]B$('E([%4(?J6^[G/')Z5#8^)=6A%VUR9+B8Q[4@>$((KEI"J1
M@#((P23DX&>]7++PUJD4>G:9/+:_V7IUT)XI$9C+(%)**5(P,$C)R<X%:>J:
M1<ZKJ#EY!%;PVKK;$'GSG!4N1_LKP/\ >- &G8"1;"!9;H74JH%DF&/G8=3Q
MP.:LUSWA;1;C1X[DSPVUN)?+"P6S;D&Q I;H.6(ST].]=#0!S_A[_D.>+/\
ML*I_Z16M=!7.:##%)KOBPO$C'^U8QEE!_P"7*UK>^RV__/"+_O@4 2T5%]EM
M_P#GA%_WP*/LMO\ \\(O^^!0!+147V6W_P">$7_? H^RV_\ SPB_[X% $M%1
M?9;?_GA%_P!\"C[+;_\ /"+_ +X% $M%1?9;?_GA%_WP*/LMO_SPB_[X% $M
M%1?9;?\ YX1?]\"C[+;_ //"+_O@4 2T5@2Z]HL.K/ISPMYL<T<$D@MB8TD<
M HI?& 3N ^IJ,>(]&E6::UM7N;*".22:]B@'D($!)PYQO/&/ES0!T=%<SHVH
M7%WJ,=KJ.G6D+7%H+R)8@28UW ;'R/O<CD>_I55O$02X6[DLK1-&>\DLUD*G
MS245RTG3&W<C#'7 SGM0!V%%</\ \)1):6R75_I-L$N[-KNS@B'[P?/&B(^1
MC+&5.1TY'-6)=>N--M-5%]H\%U=Z>B2,+, (59&;)+_= VG)Y[8'.* .6^*'
M_(RVW_7FO_H;UZ/X>_Y%K2O^O.'_ - %>5^.GDFO]+GFACAFETV*26.,856)
M8D"O3_#]M WAO2R88R39Q$DH/[@K"'\21Y6$_P!\JFO147V6W_YX1?\ ? H^
MRV__ #PB_P"^!6YZI+28&W&!CIBH_LMO_P \(O\ O@5RUUX[\&V5Y/:7%[&D
M\$C1R+]DD.UE.",A,=151A*?PJY,I1CNSK&170HR@J1@J1Q2[5+!B!N'0XZ5
MQO\ PL7P/_T$(_\ P#E_^(H_X6+X'_Z"$?\ X!R__$5?L*O\K^X7M8=T=G15
M2T^PWMG!=V\<3P3QK+&WEXW*PR#@C/0U-]EM_P#GA%_WP*R+/&? 7_(ZZ?\
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M *8OWG)_@?U-'PRB5_#=P27'^F-]UR/X$]#6'_+T\K_F8_([FBHOLZ?WI?\
MOZW^-'V=/[TO_?UO\:W/5):YW5/#E[J<TT,FK'^R[B:.66U>'<XVE3L1]WRJ
M2H)&#WQC-;OV=/[TO_?UO\:Y:Z\>^$;*[FM;C5I4F@D:.1=DYPRG!&0,=151
MA*?PJY,I1CNRU)X5>?7!>W%W#) MR+E5%JHF)'*HTN>44X(&,\#FIM9\.G6I
M;MI[D*K6OV>V&S(B+'+L1GYLX48XX!'<UE?\+&\&?]!F7_OW<?\ Q-'_  L;
MP9_T&9?^_=Q_\35^PJ_RO[A>UAW1T.B:8VDZ>T#R))(\TDS^6FQ%+L6(5<G
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MBUYU\9O^11L_^O\ 3_T7)71A?XT3*O\ PV>&T445]">0>B_!G_D;[S_KP?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\4\!?\CKI_P#VT_\
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M3_\ HQJR:^FA\*/%E\3"O=/@U_R)US_U_/\ ^@1UX77NGP:_Y$ZY_P"OY_\
MT".N7'_P3?"_Q#T.BBBO#/3,S7/^/-/^N@_D:P*W]<_X\T_ZZ#^1K K2.QG+
M<*SO$'_(N:G_ ->DO_H)K1K.\0?\BYJ?_7I+_P"@FM(?$B);,\+HHHKZ$\H<
MGWU^M?6M?)2??7ZU]:UY69?9^?Z'=@_M!5;4?^09=_\ 7%__ $$U9JMJ/_(,
MN_\ KB__ *":\Q;G<RS1112 K:C_ ,@R[_ZXO_Z":LU6U'_D&7?_ %Q?_P!!
M-6:?0 KG=6U2RFO[G3;O3([NRL[?[5>RS!62$88J-I^\3M/TKHJYS6?"G]JW
ML\T>I36L-Y&D5["B*?/12<8)Y4X)&1VI 4?#-Y!'J%O&WANSTG^T;<SVLEOM
MRZ#!*OA1@X8''/Z5V-8\.BR#Q!_:=Q="2.&(PV=ND>U85.-Q)S\Q.T>F!6Q0
M 4444 %%%% !1110!S_A[_D.>+/^PJG_ *16M=!7/^'O^0YXL_["J?\ I%:U
MT% !1110 4444 %%%% !1110 4444 %%%<YXOUY=(M;:T6Y%K/?N8UN6'RP(
M!\[_ % / [DCMF@#HZ*\XTR[TZ[\ Z)=:AJ-Y-'"IB-K;RN)+N<_=7Y2&8CK
MC..<GI4USI6NVVCZ5?:C>[390;[B1[EMUOME#EN/]:WE@QG/4^Q- 'H-%<KX
M7U>*6[GM[KSEU.ZD>:4.IV*5"_N5/JBL@/ON/K754 >3?%#_ )&6V_Z\U_\
M0WKT?P]_R+6E?]></_H KSCXH?\ (RVW_7FO_H;UZ/X>_P"1:TK_ *\X?_0!
M6$/XDCRL)_OE4TJ***W/5"OE_P 5?\C?K?\ U_S_ /HQJ^H*^7_%7_(WZW_U
M_P __HQJ]++?CD<>,^%&11117KGGGU!X5_Y$_1/^O"#_ -%K6O61X5_Y$_1/
M^O"#_P!%K6O7S$_B9[4?A1XIX"_Y'73_ /MI_P"BVKVNO%/ 7_(ZZ?\ ]M/_
M $6U>UUS4/A/,R?^ _7]$%%%%;GJGSK\3?\ DH>J_P#;+_T4E<E76_$W_DH>
MJ_\ ;+_T4E<E7TE#^%'T1X]7XWZA7T5\,?\ DGFE?]M?_1KU\ZU]%?#'_DGF
ME?\ ;7_T:]<F8_PEZ_YF^#^-^AUM%%%>,>B%%%% !7AGQF_Y'"T_Z\$_]&25
M[G7AGQF_Y'"T_P"O!/\ T9)7;@/XQS8K^&>=T445[AYA[G\&?^1/N_\ K_?_
M -%QUZ)7G?P9_P"1/N_^O]__ $7'7HE?/8K^-(]>A_#04445SFH4444 >1_&
M[KH7_;?_ -IUY)7K?QNZZ%_VW_\ :=>25[^"_@1^?YGE8G^*PKUSX(]-=_[=
M_P#VI7D=>N?!'IKO_;O_ .U*,;_ E\OS##?Q4>MT445X!ZH4444 %>=?&;_D
M4;/_ *_T_P#1<E>BUYU\9O\ D4;/_K_3_P!%R5T87^-$RK_PV>&T445]">0>
MB_!G_D;[S_KP?_T9'7N5>&_!G_D;[S_KP?\ ]&1U[E7AX_\ C'IX7^&%4M5_
MY!LWX?S%7:I:K_R#9OP_F*XUN=#V.:HHHK4S.=\<_P#(G7W_ &S_ /1BUXY7
ML?CG_D3K[_MG_P"C%KQRO6P'\-^O^1PXGXPKKOAA_P E#TO_ +:_^BGKD:Z[
MX8?\E#TO_MK_ .BGKHK_ ,*7HS*E\:]3Z)HHHKYL]@*K)_R$Y_\ KC'_ .A/
M5FJR?\A.?_KC'_Z$],#D-7U'P]K\6H7&J:5/<6&CA@MTQ*I(^0&5,$9.0!3/
M""Z98ZND)\+G1;RZ@,MN[3>=YL8QD9_A/()6HV\+:Y) GAUTM?[#%Z;A[D2'
MS'BWE_+*^N3UK9AL-6U'QBFIW]O':V.G++%9HLF]IB^ 7..@P.G6D!TU%%%
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MJ]/\STL'\#]3B?BA_P BU;?]?B_^@/1\+_\ D6KG_K\;_P! 2CXH?\BU;?\
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M_!1&8:YB1DQY'W0.?]9ZBO)J]<^"/37?^W?_ -J48W^!+Y?F&&_BH]6\E_\
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M[&NCKG_#W_(<\6?]A5/_ $BM: -O=<?\\HO^_A_^)HW7'_/*+_OX?_B:EHH
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M $,UGU]##X4>5+=A7N'P=,H\'W.Q$8?;GY9R/X$]C7A]>Z?!K_D3KG_K^?\
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M $\^AP:]!KE[".]O_%4>J?V1+ID4=N\4[3,F^X)*[1A2>%P3D^M=10 4444
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MB?\ 7A!_Z+6M>LCPK_R)^B?]>$'_ *+6M>OF)_$SVH_"CQ3P%_R.NG_]M/\
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M^'\Q5VJ6J_\ (-F_#^8KC6YT/8YJBBBM3,YWQS_R)U]_VS_]&+7CE>Q^.?\
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M/D5I43:J]23NZ] />N<U.BHKE/%-UKUC/!_9>I6PDO)D@M;22SW$MC+$OO\
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M'>Z!+)-&UNXU*5=WE-@*(ASQNX/3M5_Q5;ZR-3TC4='M5N6M#*)HY)Q&A5E
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M=>*> O\ D==/_P"VG_HMJ\^K\43@S#^/0]?U1[71116YZH5Y%\;OO:'])_\
MVG7KM>1?&[[VA_2?_P!IUU8+^/'Y_D88G^$SR6BBBO?/*.O^&'_)0],^DO\
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M_P"09=_]<7_]!-6:K:C_ ,@R[_ZXO_Z":\Q;G<RS1112 K:C_P @R[_ZXO\
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MP_\ Q-&ZX_YY1?\ ?P__ !- $M%1;KC_ )Y1?]_#_P#$T;KC_GE%_P!_#_\
M$T 2T5%NN/\ GE%_W\/_ ,31NN/^>47_ '\/_P 30!+146ZX_P">47_?P_\
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M&<KE\Y]%QC'>EU+36U&YL0\@%K;S>?)%CF5E^X/H&^;ZJ*N;KC_GE%_W\/\
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M_P#0'H^%_P#R+5S_ -?C?^@)7D_\O3D_YF/R.VHHHK<]4*^7O%'_ "-NM?\
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MX?R%=-7,ZK_R$IOP_D*J&Y,MBG1116A!YY\4.NE?]M?_ &2O/:]"^*'72O\
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M<_X_4_ZYC^9K,K5;&;W"O+/B5_R,=O\ ]>B_^AO7J=>6?$K_ )&.W_Z]%_\
M0WKLP7\4Y\1\!QM%%%>P>>>Y_!G_ )$^[_Z_W_\ 1<=>B5YW\&?^1/N_^O\
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MO_Y*%IGTE_\ 13UR%=?\+_\ DH6F?27_ -%/6E?^%+T9-+XUZGT11117S9[
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MI:K_ ,@V;\/YBN-;G0]CFJ***U,SG?'/_(G7W_;/_P!&+7CE>Q^.?^1.OO\
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M_P#(PZG_ -?<O_H9K/KZ&'PH\J6["O=/@U_R)US_ -?S_P#H$=>%U[I\&O\
MD3KG_K^?_P! CKDQ_P#!-\+_ !#T.BBBO#/3,S7/^/-/^N@_D:P*W]<_X\T_
MZZ#^1K K2.QG+<*SO$'_ "+FI_\ 7I+_ .@FM&L[Q!_R+FI_]>DO_H)K2'Q(
MB6S/"Z***^A/*')]]?K7UK7R4GWU^M?6M>5F7V?G^AW8/[056U'_ )!EW_UQ
M?_T$U9JMJ/\ R#+O_KB__H)KS%N=S+-%%%("MJ/_ "#+O_KB_P#Z":LU6U'_
M )!EW_UQ?_T$U9I] "BBBD 4444 %1SRB"WEF(R(T+8^@S4E(RAU*L,J1@CU
MH X:PGU"VMO#NLRZE=3R:K.B7,#OF("5&8;%_AVD#I[YI6N]8TC5;N[F2\D!
M>= DLF89F9U%LL0SP<9S@>N>U:FG^%I[66PBGU(W&GZ<Y>T@\G:P."%WMGYM
MH) P![UJ7>F->ZM:7,T@-M:JS)"!R96XWD^RY _WC0!#X>N;6735MX=3CU"X
M@XN)5EWG>223[#.<=L# Z5KU@>'_  [+HTI>:[2?9;1VD(2+9B-"Q!;DY;YN
MO'3WK?H XRQ\1Z'HOB/Q3!JNLZ=832:E'(D=U=)$S)]CMAN 8@D9!&?4'TJ]
M=>.?"+6DRKXJT,DQL !J$7/'^]72T4 >9_\ "7^&?^ABTC_P-C_^*H_X2_PS
M_P!#%I'_ (&Q_P#Q5>F45?.3RGDNM^*_#DN@ZC''X@TIY'M9555O(R6)4X &
M>M>,_P!HV7_/Y;_]_5_QK[ HKHH8N5)-)&-3#J;NV?'_ /:-E_S^6_\ W]7_
M !K4\-:MIL'BK1YIM0M(XH[V%G=YE"J X)))/ KZLHK:68R:MRD+"13O<Y__
M (3OP?\ ]#7H?_@QA_\ BJ/^$[\'_P#0UZ'_ .#&'_XJN@HKSCK.?_X3OP?_
M -#7H?\ X,8?_BJY/_A+_#/_ $,6D?\ @;'_ /%5Z9133L)JYYG_ ,)?X9_Z
M&+2/_ V/_P"*H_X2_P ,_P#0Q:1_X&Q__%5Z915<XN4^/_[1LO\ G\M_^_J_
MXT?VC9?\_EO_ -_5_P :^P**[_[2G_*<OU./<^/_ .T;+_G\M_\ OZO^-?4'
M_"=^#_\ H:]#_P#!C#_\57045S8C$NO:ZM8VI453O9[GC7C[5M-UG78+C2]0
MM+Z!;94:2UF650VYC@E21G!''N*[?1?&GA6UT+3[>X\2Z-#/%;1I)')?Q*R,
M% ((+9!![5RGQ0_Y&6V_Z\U_]#>O1_#W_(M:5_UYP_\ H KSX?Q)'!A/]\JG
M%W7C'PPUW,R^(]((,C$$7T7//^]4/_"7^&?^ABTC_P #8_\ XJO3**ZN<]/E
M/,_^$O\ #/\ T,6D?^!L?_Q5>-:WJFGRZ]J,D=_:O&]U*RLLRD,"QP0<U]8T
M5M0Q+I-M(RJ4%-6;/C_^T;+_ )_+?_OZO^-']HV7_/Y;_P#?U?\ &OL"BNG^
MTI_RF7U./<XOPUXV\*0>%=(AF\3Z+'+'90JZ/?Q!E(0 @@MP:U/^$[\'_P#0
MUZ'_ .#&'_XJN@HKSF[NYUI65CPSPA?V>F>*;.\O[N"TM8]^^:>01HN48#+'
M@9) _&NRU+QEX6DU"5D\2:.RG&"+Z(CH/]JN5\!?\CKI_P#VT_\ 1;5[76&&
M=HGE90KT'Z_HCS/_ (2_PS_T,6D?^!L?_P 51_PE_AG_ *&+2/\ P-C_ /BJ
M],HKIYSU.4^7/&.L:7=>*[V:WU*SFB;9M>.=64_(HX(-87]HV7_/Y;_]_5_Q
MK[ HKMAF$HQ4;;'-+"1;O<^/_P"T;+_G\M_^_J_XU[Q\._&'ABR\":;;W?B/
M2+>=/-W12WT2,N97(R"V>A%>D45E7Q<JT>5JQ=+#JG*Z9S__  G?@_\ Z&O0
M_P#P8P__ !5'_"=^#_\ H:]#_P#!C#_\57045R'0<)K'C3PK+>*T?B;1G'E@
M96_B/<_[59W_  E_AG_H8M(_\#8__BJ],HJE*Q+B>9_\)?X9_P"ABTC_ ,#8
M_P#XJO-OB#KFD7NOP26NJ6,\8M54M%<(P!W-QD'WKZ5HK6C7=*7,D14I*:L?
M'_\ :-E_S^6__?U?\:/[1LO^?RW_ ._J_P"-?8%%=?\ :4_Y3#ZG'N>1_";Q
M7X<TWPK=0WVOZ5:RM>NP2>\C1B-B#.">G!_*N\_X3OP?_P!#7H?_ (,8?_BJ
MZ"BN"I-U)N3ZG5"/+%1.?_X3OP?_ -#7H?\ X,8?_BJR=:\:^%)?(\OQ/HKX
MW9VW\1QT_P!JNVHJ4[,;5SS/_A+_  S_ -#%I'_@;'_\51_PE_AG_H8M(_\
M V/_ .*KTRBJYQ<I\\_$;Q!HM]_9OV35["XV>;N\JY1]N=F,X/L:X7^T;+_G
M\M_^_J_XU]@45UTL=*G!12.>>%4Y<USX_P#[1LO^?RW_ ._J_P"->H?![Q-H
M&F#6?M^N:;:>9Y&S[1=QQ[L>9G&3SC(_.O<**5;&RJP<&MQT\,H2YKG/_P#"
M=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 57045Q'2<?K'C?PG+
M:(L?BC17/F X6_B/8_[58?\ PE_AG_H8M(_\#8__ (JO3**I2L2XW/,_^$O\
M,_\ 0Q:1_P"!L?\ \57)_$'Q)H5[H,$=KK6G3R"Z5BL5TC$#:W. ?>O>**TI
MUG"2E;8F5-25CX__ +1LO^?RW_[^K_C1_:-E_P _EO\ ]_5_QK[ HKL_M*?\
MIS_4X]SY\^$WB'1=-\4W4U]K&GVL363*'GN412=Z'&2>O!_*O8_^$[\'_P#0
MUZ'_ .#&'_XJN@HKCKUG5GS-'13IJG'E1S__  G?@_\ Z&O0_P#P8P__ !55
M-3\<>$I-/E5/%.B,QQ@#4(B>H_VJZNBL30\S_P"$O\,_]#%I'_@;'_\ %4?\
M)?X9_P"ABTC_ ,#8_P#XJO3**OG)Y3Q;QEXH\/W7A2]AM]=TR:5MFU([N-F/
MSJ>@->4?VC9?\_EO_P!_5_QK[ HKIHXR5*/*D8U,.IN[9\?_ -HV7_/Y;_\
M?U?\:ZGX=:WI-CX[TZXN]4LK>!/-W22W"(JYB<#))QU-?2]%:3S"4XN-MR(X
M11DG<Y__ (3OP?\ ]#7H?_@QA_\ BJUM/U*PU:U%UIM[;7EN25$MM*LB$CJ,
MJ2*M45YYUA59/^0G/_UQC_\ 0GJS59/^0G/_ -<8_P#T)Z8%FBBBD 56O;^T
MTVW\^]N8H(L[0TC8R?0>I]JLUSOB">&RUS0[V\D6*SB>97ED.$C=DPI)Z#^(
M9]Z -)]=TI#:AK^W_P!* ,)#@AP3@$'TR0/K5N&YAG>9(I YA?RY,?PM@''Y
M$5Y^FF+)H$FHQ2R(+JYDCMK<*,3HURSPKSRH).<C^$GZUJ>%M1NH]2;1Y6MY
M GVAI=BD2HZR ;Y#G!\S<6' _&@#L:Y_P]_R'/%G_853_P!(K6N@KF%M/$6F
M:SK$^GV&EW=MJ%TERK7&H20.F((HBI40N#S%G.>_3B@#IZYG^U;W_GM_XZ/\
M*F^V>,/^@%H?_@YF_P#D6L;^S?&'_0+T/_P:S?\ R-51MU)E?H:?]JWO_/;_
M ,='^%']JWO_ #V_\='^%9G]F^,/^@7H?_@UF_\ D:C^S?&'_0+T/_P:S?\
MR-57B*TCL-/E>>QCDD;<YSDX]S5FO)=3\'_$F\U"6XM=5LK*!\;;>+5[C:F
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M]J3';N!&<?9_>JARJ29,N9IH\)HKO/\ A3GC#_GKH?\ X&3?_&:/^%.>,/\
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M .BGKZ(KQOPO\.?&'AOQ#:ZMY>AW'D;_ -U]OF3=N4KU\@^OI7HGVSQA_P!
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MB*56S\KQA@#@8P<YXSWJQHFD?V1;3B2X-S<7,[7$\Q0+N<X' [   8]JTZ*
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M:.V"M''C=@,S?,=S$#'8>U;W_"0Z)_T&-/\ _ E/\:\X_P"%7ZW_ ,_6G_\
M?Q__ (BC_A5^M_\ /UI__?Q__B*.>I_*'UO&?\^CT?\ X2'1/^@QI_\ X$I_
MC1_PD.B?]!C3_P#P)3_&O./^%7ZW_P _6G_]_'_^(H_X5?K?_/UI_P#W\?\
M^(HYZG\H?6\9_P ^C8^(VJZ=?>'K>*TO[6XD%TK%8IE<@;'YP#TY%6_A?_R+
M5S_U^-_Z E<Y_P *OUO_ )^M/_[^/_\ $5W'@W0;KP]I$UI=R0O(\YE!B)(P
M54=P.>#1%2<^9HC#QKSQ?M:D+:'0T445N>P9NO:;<ZOH\]C:WQLGFPK3*FXA
M>X'(Z].M0:%I5_I,0MY[^VFM439%#!9^2$]\[CFMFB@ HHHH **** "BBB@
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5D_Y"<_\
MUQC_ /0GJS59/^0G/_UQC_\ 0GI@6:***0!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYA::28QW]RGF2'+-B0C)/K72U3TW38=+AFB@:1EEGDG;>03N=BQ P!QDU<H
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M0&NM&U>\CM$,UK<)%:Q;C^^61ML9_'GIZ5N>+=$N->T3[/93)#>Q2I-;RN2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F10Q0*RQ1I&&8L0B@9
M)Y)^II]% !1110 4444 %,6&))))$C19),%V"@%L# R>_%/HH **** "JVH_
M\@R[_P"N+_\ H)JS5;4?^09=_P#7%_\ T$TUN#+-%%%("MJ/_(,N_P#KB_\
MZ":LU7OU9].N552S-$P  R2<&D^W0_W+C_P'D_\ B:?019HJM]NA_N7'_@/)
M_P#$T?;H?[EQ_P" \G_Q-%F.Z+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XF
MBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_
M (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P#
M>3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_
M\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !
MY/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT
M/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\
M!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OM
MT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=
M#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5O
MMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B
M:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z
M+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC
M[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_X
MFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/
M_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\
MXFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX
M_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_
M (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\
M<N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N
M/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]
MRX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT
M/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5
MOMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_
M '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"
MZ+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/
MMT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS
M"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P#
M>3_XFC[=#_<N/_ >3_XFBS"Z+-5D_P"0G/\ ]<8__0GH^W0_W+C_ ,!Y/_B:
M@6Z07TLACN-C1(H/V>3J"V>WN*+,5S0HJM]NA_N7'_@/)_\ $T?;H?[EQ_X#
MR?\ Q-%F.Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT
M/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\
M!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OM
MT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=
M#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5O
MMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B
M:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z
M+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC
M[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_X
MFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/
M_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\
MXFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX
M_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_
M (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\
M<N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N
M/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]
MRX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT
M/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5
MOMT/]RX_\!Y/_B:/MT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_
M '+C_P !Y/\ XFBS"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"
MZ+-%5OMT/]RX_P# >3_XFC[=#_<N/_ >3_XFBS"Z+-%5OMT/]RX_\!Y/_B:/
MMT/]RX_\!Y/_ (FBS"Z+-%5OMT/]RX_\!Y/_ (FC[=#_ '+C_P !Y/\ XFBS
M"Z+-%5OMT/\ <N/_  'D_P#B:/MT/]RX_P# >3_XFBS"Z+-%5OMT/]RX_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image5.jpg
<TEXT>
begin 644 image5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'C!7H# 2(  A$! Q$!_\0
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MM._\"D_QH_X230O^@UIW_@4G^->.44>Q7</;/L>Q_P#"2:%_T&M._P# I/\
M&C_A)-"_Z#6G?^!2?XUXY11[%=P]L^Q['_PDFA?]!K3O_ I/\:/^$DT+_H-:
M=_X%)_C7CE%'L5W#VS['L?\ PDFA?]!K3O\ P*3_ !H_X230O^@UIW_@4G^-
M>.44>Q7</;/L>Q_\))H7_0:T[_P*3_&C_A)-"_Z#6G?^!2?XUXY11[%=P]L^
MQ['_ ,))H7_0:T[_ ,"D_P :/^$DT+_H-:=_X%)_C7CE%'L5W#VS['L?_"2:
M%_T&M._\"D_QH_X230O^@UIW_@4G^->.44>Q7</;/L>Q_P#"2:%_T&M._P#
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M['_PDFA?]!K3O_ I/\:/^$DT+_H-:=_X%)_C7CE%'L5W#VS['L?_  DFA?\
M0:T[_P "D_QH_P"$DT+_ *#6G?\ @4G^->.44>Q7</;/L>Q_\))H7_0:T[_P
M*3_&C_A)-"_Z#6G?^!2?XUXY11[%=P]L^Q['_P ))H7_ $&M._\  I/\:/\
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M:=_X%)_C7CE%'L5W#VS['L?_  DFA?\ 0:T[_P "D_QH_P"$DT+_ *#6G?\
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M39_Q+R-N<X^;IFI<FT-129Y4>M%!ZT5L8A1110 4444 %%%% !1110 4444
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M!9HJM]FF_P"?ZX_[YC_^)H^S3?\ /]<?]\Q__$T 6:*K?9IO^?ZX_P"^8_\
MXFC[--_S_7'_ 'S'_P#$T 6:*K?9IO\ G^N/^^8__B:/LTW_ #_7'_?,?_Q-
M %FBJWV:;_G^N/\ OF/_ .)H^S3?\_UQ_P!\Q_\ Q- %3Q)_R*VK_P#7E-_Z
M :\<KUOQ%;RKX8U8F]G8"SF)4JF#\A]%KR2MZ.QSUMT%%%%:F04444 %%%%
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M?1QM<22H\3L0X7@@KCH!ZFK=("M??\>Z_P#7:+_T8M6:K7W_ ![K_P!=HO\
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M7VF#_GM'_P!]BC[3!_SVC_[[% $M%1?:8/\ GM'_ -]BC[3!_P ]H_\ OL4
M2T5%]I@_Y[1_]]BC[3!_SVC_ .^Q0!+7;_#7_CZU?_<@_G)7!_:8/^>T?_?8
MKNOAFZ27.KE&5AL@&0<]Y*BI\++I_$CT*BBBN4Z@HHHH **** *UM_Q\7O\
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M4?:8/^>T?_?8HL%RU;7,UG<QW$#[)8VW*V <'\:V?^$SU_\ Y_\ _P @Q_\
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M]S;L/$NK:;;_ &>VNRL0Z*RAMOTR.*H7=Y<W]PUQ=3-+*W5FJG]I@_Y[1_\
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M@PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"L__(3@_P"N,G_H
M259JL_\ R$X/^N,G_H259IB*U]_Q[K_UVB_]&+5FJU]_Q[K_ -=HO_1BU9HZ
M#"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNGV$I@>:\=E:>0?>"8.!^/M6+>^)K+Q-\3?"DNF>;+90/,HN6B9%D<IE@NX
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M&::X@\%?$-[8D,=8=&*G!"F0!OT)'XT >C0?$#PI<Z@+&+6[=IRVT [@I/3
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M+9]:O/B)I6A:;K<^F0W-FTCM&@;YE+GH<>@'6M7X8,S_  YT@L23MD'/H)'
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M>UEM/M,,\HS)'ST8Y/H>N>W3- $W@[XBV6JZ;J$^K:A#'<0223&-8V CMP5
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MK@#%.HH *Y[2M!N-'\3:G<VK0C2M0 G>')#1W'1B!C&UAR>>HKH:* "BBB@
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M1!GT//YUW/B'PSIWB:UBAOED5X7\R&>%MDD3>JMV_P#K#TJ__:%C_P _EO\
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M9?\ /Y;_ /?U?\:/[1LO^?RW_P"_J_XT 4-9\.6>N7VEWES).DFFS_:(1&P
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M^-']HV7_ #^6_P#W]7_&@"S15;^T;+_G\M_^_J_XT?VC9?\ /Y;_ /?U?\:
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MGJ17I]5+?2]/M+J2ZM[&VAN)?ORQQ*K-]2!DU;H S[C4S#KEGI20[I+FVGN
MY? 41-$I'0\GS1^1JWNN/^>47_?P_P#Q-8EY_P E#T;_ +!5_P#^C;2N@H B
MW7'_ #RB_P"_A_\ B:-UQ_SRB_[^'_XFI:* (MUQ_P \HO\ OX?_ (FC=<?\
M\HO^_A_^)J6B@"+=<?\ /*+_ +^'_P")HW7'_/*+_OX?_B:EHH BW7'_ #RB
M_P"_A_\ B:-UQ_SRB_[^'_XFI:* (MUQ_P \HO\ OX?_ (FC=<?\\HO^_A_^
M)J6B@"+=<?\ /*+_ +^'_P")HW7'_/*+_OX?_B:EHH BW7'_ #RB_P"_A_\
MB:-UQ_SRB_[^'_XFI:* (MUQ_P \HO\ OX?_ (FC=<?\\HO^_A_^)J6B@"+=
M<?\ /*+_ +^'_P")HW7'_/*+_OX?_B:EHH BW7'_ #RB_P"_A_\ B:-UQ_SR
MB_[^'_XFI:* (MUQ_P \HO\ OX?_ (FC=<?\\HO^_A_^)J6B@"+=<?\ /*+_
M +^'_P")HW7'_/*+_OX?_B:EHH BW7'_ #RB_P"_A_\ B:-UQ_SRB_[^'_XF
MI:* (MUQ_P \HO\ OX?_ (FC=<?\\HO^_A_^)J6B@"+=<?\ /*+_ +^'_P")
MHW7'_/*+_OX?_B:EHH BW7'_ #RB_P"_A_\ B:-UQ_SRB_[^'_XFI:* (MUQ
M_P \HO\ OX?_ (FC=<?\\HO^_A_^)J6B@"+=<?\ /*+_ +^'_P")HW7'_/*+
M_OX?_B:EHH BW7'_ #RB_P"_A_\ B:-UQ_SRB_[^'_XFI:* (MUQ_P \HO\
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MQ_SRB_[^'_XFI:* (MUQ_P \HO\ OX?_ (FC=<?\\HO^_A_^)J6B@"+=<?\
M/*+_ +^'_P")HW7'_/*+_OX?_B:EHH BW7'_ #RB_P"_A_\ B:-UQ_SRB_[^
M'_XFI:* &H7*_.H!] <_TIU%% !1110!6MO^/B]_Z[#_ -%I5FJUM_Q\7O\
MUV'_ *+2K--@BM;?\?%[_P!=A_Z+2K-5K;_CXO?^NP_]%I5FA@@HHHI %%%%
M !1110!D>)K'5=1T*:#1-02QU#*M%+(@9&P<E'&#\K#(..>?PKGO#_A76#XH
MBU[7DTJV-I;/;V5CI@;RT+D&21BP'S' &,8Q[UW%% !7/^._^2>>)O\ L%77
M_HIJZ"N?\=_\D\\3?]@JZ_\ 134 =!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6?_D)P?\ 7&3_
M -"2K-5G_P"0G!_UQD_]"2K-,16OO^/=?^NT7_HQ:LU6OO\ CW7_ *[1?^C%
MJS1T&%%%%( HHHH **** "BBB@ HHHH Y^\_Y*'HW_8*O_\ T;:5T%<_>?\
M)0]&_P"P5?\ _HVTKH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BH;O[3]ED^Q^3]HQ\GG9V9]\<UC_P#%6?\ 4%_\BTTKB;L;
MI90P4L-QZ#/)I:\JU#2O$,OB&1WMYGNGEW++$&V#GC#'HHXZ]*[<?\): !G1
M3[_O:IPMU)4[]#0UG4/[)T6\U 1>;]FA:79NQNP,XSVKFG\7:[:Z6NJW?A@#
M3_+65Y(;Y794(SG;M&>M6M?_ +5_X0O7?[4^Q9^R/Y?V7=_=.<[OPK/LO"NJ
M:OX=L[>_\37#Z?-;QEK:*VCC.W:#MW@9QVJ"T=!I_B!-1UNXL(HAY4=K%<I-
MN^^),D<8X_.M"#4+*ZE:*WO+>:1>62.4,1]0#7 ZQ)::5JGBCS(96M(M*MHO
M*A?:Q4DJ #V'(R?2L^WC6S\6^%]L&B6K,[!8]-8M)L*8_>-T/]>>: /43=VR
MW(MFN(1.1D1%QN/X=:1KVT2Y6V>ZA6X;[L1D 8_AUKS?3$\.2>$[J[U[;_:O
MVUS<NI'VI91+\H3^+IMX'O6'!;O<^'-4N+^70XKHW,GVB>Z#F[BD#<;<<CM@
M 4 >H_\ "101^(;S3+GRK>.WACD$\DH4,7)XP?IZUK//#'!Y[RHL(&XR,P"X
M]<UY];6^E7'CN8:^;6:==*@*_:E 5FQ\YPW?ZC(R:R;+[/)'H<%ZV?#9U:\6
M'S3^[9 /W(.>HW;NM 'JT%S!=1"6WFCFC/1XV##\Q5#6M6.F+:Q0Q":\O)U@
M@B+8!/5F/L%!)K T..S@^(.I0Z,(ET_[#&UPD&/+6?><8 X!V^E6=5;_ (N-
MX?20?(+:Y,1_V\#/_CM '0RZC90'$UY;QG=LP\JCYO3D]>14KW$$;;7FC4^A
M8"N M=$TW4=1\97%[9Q3RK,R(TBAB@\O.5ST.>XYXJIINB76J:'I=T/#NE:A
MFSC7[1=7#*YP,8(P>G2@#T6XU"SM+*6\GN8TMH1F23=D+6/H'BRWUVVU*[6!
MX+6SE*AGSN= H;=C''TI_AS2C9Z7-;7.D6-B'EW>3;OYB-P/F.1UX_052\,2
MI#J?BJ65PD::@69F.  $7)- $$?C>\$%KJ-UH,EOH]U*L<=T;A6=0QPK-'C@
M'Z_TK1UWQ7;Z+JNEZ:(O/NKZX2,J&QY2,VW>>#W/ [X-<[_:UOXQOH[JXO+6
MWT>TE\RVM))U66[E7[K."?E7/0=^]8^H1Z_9BRNM2T%C?W.LV\SS_:XR)&!/
MEPJ 3M7' )]R: /1Y=7-OXC@TN>(+'=0L]M*#]YU^^A'K@@C\:U*Y+Q5*YN/
M"LAB\N[;4XLQY#%%*-O&1UQFNMH **** "BBB@ HHHH **** *UM_P ?%[_U
MV'_HM*LU6MO^/B]_Z[#_ -%I5FFP16MO^/B]_P"NP_\ 1:59JM;?\?%[_P!=
MA_Z+2K-#!!1112 **** "BBB@ HHHH *Y_QW_P D\\3?]@JZ_P#135T%<_X[
M_P"2>>)O^P5=?^BFH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J7VIZ?IB(]_?6UHKG"&XF
M6,,?;)YJW5+4-(TW55C74;"VNQ&24$\2OMSUQD<4XVOJ)WMH9]SXR\.6UK+/
M_;6GS>6I;RX;E'=\=E /)-4=%^(?A_5[>262\BT]D;;LO9DC+>XR>:T1X0\-
M Y&@:8"._P!E3_"D'@[PT!C^PM.;_?MU8_J*VO1MU,6JW.FFK#_^$L\.?]#!
MI7_@9'_C5#6-1N)=9TRWLM82TM+F"24S(L;JV,;<%@1W[5<_X0_PU_T+^F?^
M B?X5%>>'HKC6],;[%;-IUK;R1F(HNU<XV@+^%9RY/LW-8\W4RT\376FQ:R)
MKN+5([&.-H[A%"Y9^-C;>./;WJ[)9^)H;!K_ /MA6NU3S&M#;KY1[E,_>]LY
MK3U'0K2^T2XTR*..VCE''E( %;J#@?05ENWBN:P.GM9V:RLOEM?>?E<="VS&
M<U!1GW/B:6]FL6?46TBQN+42K,(0^^3.&3<00-N*Z/0)[R>RD-W<P7860B&Z
MA*XF3L2!P#U%9@TK5-%$4%A#%J6G"!8C:SR!"KC.6!((YSDU;\-Z3/IQOKB>
M*&W-W*'6U@.4B &.OJ>^/:@!;KQ1;6UW>6RV5]</9X,YAB!"@C.<DCM^-2OX
MA@$<,L-G?W,4T8E22WMRZX/OZ^U0PZ7<I>^()65=MZ%\D[NN(]O/IS4%CX81
MM)L8KV:ZBG@@6-E@N65>/IQ0 _5?$,L.@RWEM:SV\OFI"INX2@3<0-Y!Z@9_
M.H[;4KO3O$<>E7^H)>1SVYF64QK&T9'4';QMP":M7&C/;:'=6FGL)Y)3NVW[
MF56Z94Y[$#\ZQ;7PC]MN9)+NQCTNW$!A6*VFWNQ;[S%L=,< >] %O3=?O-3\
M5+&GR:7);NT *C,NU@-_J!G.*ZJN4@\*36GB&SN(K^^>T@@VY>?)R&&$QC[A
M Y%=70 4444 %%%% !1110!6?_D)P?\ 7&3_ -"2K-5G_P"0G!_UQD_]"2K-
M,16OO^/=?^NT7_HQ:LU6OO\ CW7_ *[1?^C%JS1T&%%%%( HHHH **** "BB
MB@ HHHH Y^\_Y*'HW_8*O_\ T;:5T%<_>?\ )0]&_P"P5?\ _HVTKH* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9
M-#%<0O#/$DL3C:Z.H96'H0>HI8XTBC6.-%1$ 5548  Z "G44 0-96CRRRM:
MP-),@25C&"74= Q[CV-58-!T>UV_9]*LHBL@E4I;J,..C#CJ,GFM&B@"B^BZ
M7+?K?R:=:-=J<B=H5+Y['.,YHDT72YKX7LNFVCW0_P"6S0J7_/&:O44 4;O1
M=*U!V>\TVTN';&6EA5B<=.2.V3^=32V%G/9_8Y;2"2UP%\EHP4P.@V]*L44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"L
M_P#R$X/^N,G_ *$E6:K/_P A.#_KC)_Z$E6:8BM??\>Z_P#7:+_T8M6:K7W_
M ![K_P!=HO\ T8M6:.@PHHHI %%%% !1110 4CNL:,[D*JC))["EI&571D8
MJPP0>XH \L\.?:(M5T&]GMYH$N)I4;5'E+?;]P;8I3JN>HSZ<5ZI7.V?@^TM
M+BT8WM]/;63[[6UFD!CA;G!'&3C)QDG%=%0!SM_(D?Q!T8NZJ/[*OQECC_EK
M:5N_:K?_ )[Q?]]BL2\_Y*'HW_8*O_\ T;:5T% $7VJW_P">\7_?8H^U6_\
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M_P">\7_?8H^U6_\ SWB_[[%2T4 1?:K?_GO%_P!]BC[5;_\ />+_ +[%2T4
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M?^!$G_Q5'V&'^_<?^!$G_P 55FB@"M]AA_OW'_@1)_\ %4?88?[]Q_X$2?\
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MOJECY5S'")8DAE\Q9@6V@ D#!R?3UH Z:BL6VUF\75+>PU.P2V>Z1FA:.;S
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MB;_L%77_ **:N@KG_'?_ "3SQ-_V"KK_ -%-0!T%%%% !1110 4444 %%%%
M!1110 445DZAXH\/:3=&UU+7=,L[@ ,8KF\CC< ]#AB#0!K45#:W=M?6L=U9
MW$5Q;RC='+"X=''J".#4U !1110 4444 %%%% !1110 4444 %%%% !1110
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M^%:%% !1110 4444 5G_ .0G!_UQD_\ 0DJS59_^0G!_UQD_]"2K-,16OO\
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MM=]7*>!+K2KJPNFTKQ-J.O1K* \M\^YHSC[H^1>._0UU= !169KO]N?V>/\
MA'_[.^V[QG^T-_E[.<_<YST_6N/\-^)O&5]X]N=!U*'0IK.QA#WMSIXF_=.P
M.R/+G&[H2,=/>@#T.N?\=_\ )//$W_8*NO\ T4U=!7/^._\ DGGB;_L%77_H
MIJ .@HHHH **** "BBB@ KS;QY>:_::PO]D^.5TU7:!#8?V7',(E:14>5I6^
MZ I9L-C.W ZUZ37D?C:\O(=0N+C3=*U74;74W5)OL%@UP410J,X8' )7)4'.
M<#IDUI3C%OWWH1-R2]W<]!T?4H8=)MX;S7(M4NHTQ+=1Q!/-/KL3(7Z"KO\
M;%CC/GX'NC#^E5]%6SO]&M;I=,GM5EC!$%]#LF3V=><'BK?]EZ<3DV%K_P!^
M5_PJ?='[QF7'C'0K7_6W\"G_ &I5'\S7G_BC4]&\2ZY!+;ZU<6?V6/SEFAU*
M:-?,PR84*X53M9LE1N(;&<9SZNME:+]VUA&?2,5Y_P".O!&L^(]7CN+!;(PQ
MH%7[1=^7@8/ 58"?O%3DR$8!&%SD;4I4E+WE_7H9555Y?<W.J\-ZG;R^']/+
MF2)G@5L3R.Y.1G[[DL?Q)-;@(89!!![BN8\"72W_ (/M;>X0FXL\VMQ'(!E7
M0XP< =L?_7ZUN'3XU.ZWDD@;_8/'Y5E.-I-&D&W%,N451SJ,!Y$=ROM\K?X5
MY]XGM?#]UK\%W+X4L9387'VG4Y9;6+?,K0NNSD9?&]7^;CY!WZ$82D[1&Y*.
MYZ?145N83;1_9]@A"@($& !C@ =JEJ"@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M K/_ ,A.#_KC)_Z$E6:K/_R$X/\ KC)_Z$E6:8BM??\ 'NO_ %VB_P#1BU9J
MM??\>Z_]=HO_ $8M6:.@PHHHI %%%% %34=3LM(M/M>H7*6UN&"M+)PJDG R
M>P]SQ7&67A'Q):SWUQH?C>"#3KVZENXX!I:3)'YC%CM8R<\GZ9SP*[UE5T9'
M4,K#!!&017&2_#+P+J,DLJZ-;D&1A(MM<21IN!Y!5&"Y![8H V]'U:VDE_L>
M36+?4M6M8@UTT*!<<XRRJ2$)_NDYK7?=L;9C?CY=W3/O532](T[1+%;+2[*"
MSMEY$<*!1GU..I]ZNT <FFK>)(_$EEI4Z:5+YJF:?R!)F*('&XY.,D\"NLK$
MT33KF'5=:U&]BVS75R$B.X']PB@)TZ9.XX]ZVZ .?O/^2AZ-_P!@J_\ _1MI
M705SM^I;X@Z, [)_Q*K_ )7'_/6T]16[Y+_\_,OY+_A0!+147DO_ ,_,OY+_
M (4>2_\ S\R_DO\ A0!+147DO_S\R_DO^%'DO_S\R_DO^% $M<;\2-86S\.M
MID0#WNI9AB3&<+U=S[ ?S]JZF<BVMY)YKR1(HD+NY"X50,D]*\VM/M>OW[ZL
MY<7.J[K73T<#,-F#\TA'8M^'?'6MJ,=>=[+\S*J].5=3$\'Z/:V^INBZ6-49
MX2I@E$94].264[?PQ72W'@-KZ3S;;0K+29<YWI=R CZ!#C]*[73]"L]*0K9[
MHR1AFPI9OJ<9J]Y+_P#/S+^2_P"%5+$3<KIBC1C:S.(MO!7B6VC(A\:WD?'"
MR)YX'L"QXKE/&NA>+=/T26XU'5[>\M0Z_.)7609[!3Q^7/ZU[%Y+_P#/S+^2
M_P"%'DO_ ,_,OY+_ (41Q,E*[2?R"5&+5D>*_"BPN[^[U Q:C):K%&-OER#<
M6)[H>J^OOBO4/+\3V6 LUEJ*#KYBF)S[#'%8]PC^'/B%#-Y[K8ZZOE2'CY;A
M?NG&,?,,#ZYKLO)?_GYE_)?\*>(GSSY[:,5&'+'E[&+_ ,)*]M_R$M(O;7G[
MRKYJ?F*K:KXVLK.WAFL/)OB[[73S3&RC&<XVG^E='Y+_ //S+^2_X5SWB/PT
MVIVZ?988'GW$F2640X_%8V+?3BL4XWU-&I6T+GAO7FU^VGF:WC@\M]H19BY(
MQU/RC'ZUM5Q>D>%];TRW+07\-K/QN19#-'*<<GE%V_\ CWUK1_M/5['C4[&X
M9!UFLMLB_P#?.,BAI-^Z";2]XZ.BLJQU:PU$[;;5"S]/+;:K?D5S6AY+_P#/
MS+^2_P"%0U8M.Y+147DO_P _,OY+_A1Y+_\ /S+^2_X4 2T5%Y+_ //S+^2_
MX4>2_P#S\R_DO^% $M%1>2__ #\R_DO^%'DO_P _,OY+_A0!+147DO\ \_,O
MY+_A1Y+_ //S+^2_X4 2T5%Y+_\ /S+^2_X4>2__ #\R_DO^% $M%1>2_P#S
M\R_DO^%'DO\ \_,OY+_A0!+147DO_P _,OY+_A1Y+_\ /S+^2_X4 2T5%Y+_
M //S+^2_X4>2_P#S\R_DO^% $M%1>2__ #\R_DO^%'DO_P _,OY+_A0!+147
MDO\ \_,OY+_A1Y+_ //S+^2_X4 2T5%Y+_\ /S+^2_X4>2__ #\R_DO^% $M
M%1>2_P#S\R_DO^%'DO\ \_,OY+_A0!+147DO_P _,OY+_A1Y+_\ /S+^2_X4
M 2T5%Y+_ //S+^2_X4>2_P#S\R_DO^% $M%1>2__ #\R_DO^%'DO_P _,OY+
M_A0!+147DO\ \_,OY+_A1Y+_ //S+^2_X4 2T5%Y+_\ /S+^2_X4>2__ #\R
M_DO^% $M%1>2_P#S\R_DO^%'DO\ \_,OY+_A0!+147DO_P _,OY+_A1Y+_\
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MC./NR<31^S3?\_UQ_P!\Q_\ Q-<5XA\,:_JFLQ7$-K82VZ2?O?.U1XS=1!6
M5T6W*C#%3R6X4CH>.^HK)2<7=%M)[F9#I 15<SS1RE1N6-EV@^@PHR/P%+);
M:DF/+O"ZCMM4$_B0:TJ*+A8RO/>/BYN;R$^I2,C\PM<]=&^G\96>FVWC'4(X
M+FTN+AXXX[,F-T:$(HW0DX(>0X.2=O7@UVQ (P1D5Y/JUSHMGXQ?3)]=T2U$
MMRU[)<27J)) 4:/]VPXVN=V%R?NAC_#S<(QEN[$R<ELKGIJ6DZHJG4;ER!@L
MRQY/N<)BG?9IO^?ZX_[YC_\ B:ACBN/+66UO5FC<!EW_ #!AV.X4[[7<1?\
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M_B:/LTW_ #_7'_?,?_Q-6:* *WV:;_G^N/\ OF/_ .)H^S3?\_UQ_P!\Q_\
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M]\Q__$U9HH K?9IO^?ZX_P"^8_\ XFC[--_S_7'_ 'S'_P#$U9HH K?9IO\
MG^N/^^8__B:/LTW_ #_7'_?,?_Q-6:* *WV:;_G^N/\ OF/_ .)H^S3?\_UQ
M_P!\Q_\ Q-6:* *WV:;_ )_KC_OF/_XFC[--_P _UQ_WS'_\35FB@"M]FF_Y
M_KC_ +YC_P#B:/LTW_/]<?\ ?,?_ ,35FB@"!+>57#&\G<#^%@F#^2U/110
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M#/%$\-NJRLSRAU!$(9D4+%@J?XOO'-'*[7L%T=O1112&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!6?_D)P?\ 7&3_ -"2K-5G_P"0G!_U
MQD_]"2K-,16OO^/=?^NT7_HQ:LU6OO\ CW7_ *[1?^C%JS1T&%%%%( HHHH
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M17?<P4XZYQS7:UR/@2VTJW35TL7U1[Y;SR[]M5D+W!=54*23U4IM*D=C774
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M&]_+23Y!Y*@K^\ )R,$$8XHLQW.FHHHI %%%% !1110 4444 %%%% !1110
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MJR6BHMUQ_P \HO\ OX?_ (FC=<?\\HO^_A_^)K(T):*BW7'_ #RB_P"_A_\
MB:-UQ_SRB_[^'_XF@"6BHMUQ_P \HO\ OX?_ (FC=<?\\HO^_A_^)H EHJ+=
M<?\ /*+_ +^'_P")HW7'_/*+_OX?_B: .7\=6TUO:V?B*S4M=:/+YQ5>"\)X
MD7/IM_K73VEU#>V<-U;N'AF0.C#N",TV199HGBD@A>-U*LK2$@@]1]VN2\%2
MW.E3ZAX6F"L^GR>9;%WP6MW.5QQS@YR?<5M\=/S7Y?\ #_F9_#/U.UHJ+=<?
M\\HO^_A_^)HW7'_/*+_OX?\ XFL30EHJ+=<?\\HO^_A_^)HW7'_/*+_OX?\
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M\).R?YG/B)3A%2A&[/7XXK](U5KN%RH +M <M[G# ?D*=LO?^?BW_P"_#?\
MQ=4O#6MVWB#0K>_MV/(V2HQRR.!RI]_\16M6,DXNS-TTU=%;9>_\_%O_ -^&
M_P#BZ-E[_P _%O\ ]^&_^+JS12&5ME[_ ,_%O_WX;_XNC9>_\_%O_P!^&_\
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M8"39>_\ /Q;_ /?AO_BZ-E[_ ,_%O_WX;_XNH_M%Y'_K+,,/6-_Z4?VG"O\
MK4EB_P!]#19A<DV7O_/Q;_\ ?AO_ (NC9>_\_%O_ -^&_P#BZ<EY;2?<G0^V
M:GI#*VR]_P"?BW_[\-_\71LO?^?BW_[\-_\ %U9HH K;+W_GXM_^_#?_ !=&
MR]_Y^+?_ +\-_P#%U9HH K;+W_GXM_\ OPW_ ,71LO?^?BW_ ._#?_%U9HH
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MS10! B78<%YX67N%A(/Y[C4]%% !1110!6?_ )"<'_7&3_T)*LU6?_D)P?\
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MHH **** "BBB@ HHHH **** "BBB@#)\3Z]!X7\-7VM7$;2QVD>\QJ0"Q)
MS[DBM.)S)"CLA1F4$HW5?8UP_P 34.I1^'/#ZL?^)GJ\0E7UAC!D?^2UW= ^
M@5A+XC$GCF3PW';[_*T\7LMP).(R7VJA7'4CGKT'O6[7">!U74?%_C37NN_4
M%TZ,YX"P( <?5F/XB@$=W1110(**** "BBB@"M;?\?%[_P!=A_Z+2K-5K;_C
MXO?^NP_]%I5FFP16MO\ CXO?^NP_]%I5FJUM_P ?%[_UV'_HM*LT,$%%%%(
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M<\+Z1)I>FM)=X.H7;>==,.S'H@]E&%'TSWK;HHJ)2<G=E))*R"BBBD,****
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M<$ 8QT^@K5OVB\U^7_ ,TN1^1ZS11161H%%%% !1110 4444 %%%% !1110
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MX8DN0A#29)RVXD$DY^\*]/J)1<79E)W5PHHHI#"BBB@ HHHH **** "BBB@
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ML('%U#_$A]2.H_\ U4RV\>K?3VL5AX=U>[^U0O/ \3VH5T0HKGYI@1@R(,$
M\\"M*D4USQV?X,F#:?*SKZ*;&Q>-69&0L 2C8ROL<$C\C3JR+"BBB@ HHHH
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M $8M6:.@PHHHI %%%% !7CZ:IK7AVYUS3K#Q+X!2VFOKF:)+[46$\+2.Q(D
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MM5O_ ,]XO^^Q1]JM_P#GO%_WV* ):*B^U6__ #WB_P"^Q1]JM_\ GO%_WV*
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MP0:K\0/!>C[LQPW$VIS+Z>2N(S_WTW\Z[NN!TIDO_C'XBU"650FEV%OIT.2
M"9/WK_B#M'XUW/VJW_Y[Q?\ ?8I ^Q+147VJW_Y[Q?\ ?8H^U6__ #WB_P"^
MQ3$2T4U'61=R,&'J#FG4 %%%% %:V_X^+W_KL/\ T6E6:K6W_'Q>_P#78?\
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M_%4?:9O^?&X_[ZC_ /BJLT4#*WVF;_GQN/\ OJ/_ .*H^TS?\^-Q_P!]1_\
MQ56:* *WVF;_ )\;C_OJ/_XJC[3-_P ^-Q_WU'_\55FB@"M]IF_Y\;C_ +ZC
M_P#BJ/M,W_/C<?\ ?4?_ ,55FB@"M]IF_P"?&X_[ZC_^*H^TS?\ /C<?]]1_
M_%59HH K?:9O^?&X_P"^H_\ XJC[3-_SXW'_ 'U'_P#%59HH K?:9O\ GQN/
M^^H__BJ/M,W_ #XW'_?4?_Q56:* *WVF;_GQN/\ OJ/_ .*H^TS?\^-Q_P!]
M1_\ Q56:* *WVF;_ )\;C_OJ/_XJO'[A=<\/?$.2XL=,NEAWRSI;PQE]\)*>
M;M R.<1YQWV^U>TUS-_HGB&X\1Q:M:ZSID(MX)K>&*73)),)(T;-N83KDYB7
M! '4\5K2J\E]+W,*]'VMM;6&:7X^T;5IFMX?.AN5.#!<[(GSZ89AD_3-=!]I
MF_Y\;C_OJ/\ ^*JM?Z%IVL6ZQZK96UVX7!=HL'/<J>J_G6"_@V^TM"WAG7;N
MRQ]VUN6\Z#Z -DCZT6IRV=O7_/\ X!=YK?4Z?[3-_P ^-Q_WU'_\51]IF_Y\
M;C_OJ/\ ^*KEX_$GB+2 5\0Z!)-&/^7O2_WJ_BA.X?6L&'Q1'>>+K&TM?&FL
M&RG1S('M;9<2ED\N,9@R%QY@.>?N\]30Z,]TK^FHG6@OB=O4]&^TS?\ /C<?
M]]1__%4?:9O^?&X_[ZC_ /BJLT5D:E;[3-_SXW'_ 'U'_P#%4?:9O^?&X_[Z
MC_\ BJLT4 5OM,W_ #XW'_?4?_Q5'VF;_GQN/^^H_P#XJK-% %;[3-_SXW'_
M 'U'_P#%4?:9O^?&X_[ZC_\ BJLT4 5OM,W_ #XW'_?4?_Q5'VF;_GQN/^^H
M_P#XJK-% %;[3-_SXW'_ 'U'_P#%4?:9O^?&X_[ZC_\ BJLT4 5OM,W_ #XW
M'_?4?_Q5'VF;_GQN/^^H_P#XJK-% %;[3-_SXW'_ 'U'_P#%4?:9O^?&X_[Z
MC_\ BJLT4 5OM,W_ #XW'_?4?_Q5'VF;_GQN/^^H_P#XJK-% %;[3-_SXW'_
M 'U'_P#%4?:9O^?&X_[ZC_\ BJLT4 5OM,W_ #XW'_?4?_Q5'VF;_GQN/^^H
M_P#XJK-% %;[3-_SXW'_ 'U'_P#%4?:9O^?&X_[ZC_\ BJLT4 5OM,W_ #XW
M'_?4?_Q5'VF;_GQN/^^H_P#XJK-% %;[3-_SXW'_ 'U'_P#%4?:9O^?&X_[Z
MC_\ BJLT4 5OM,W_ #XW'_?4?_Q5'VF;_GQN/^^H_P#XJK-% %;[3-_SXW'_
M 'U'_P#%4?:9O^?&X_[ZC_\ BJLT4 5OM,W_ #XW'_?4?_Q5'VF;_GQN/^^H
M_P#XJK-% %;[3-_SXW'_ 'U'_P#%4?:9O^?&X_[ZC_\ BJLT4 5OM,W_ #XW
M'_?4?_Q5'VF;_GQN/^^H_P#XJK-% %;[3-_SXW'_ 'U'_P#%5QOP])O=>\;:
MNP=7FU@VFU^H$"*@]NY''I7<R2)#$\LC;412S'T ZUQ'PCC<_#RSO92?-OYY
M[M\^KRMC] *!K9G<UP?Q</G^#K?2=K-_:VI6MEA3@G=(&P/^^*[RN%\9DWGC
MWP-I8<;3=SWKIP?]3%\I_-L#ZGTI,([G8_:9O^?&X_[ZC_\ BJ/M,O\ SXW'
M_?4?_P 55FBF(SY$27[^E2GW_=@_^A5#]G9?]3;7T7LLJ8_]"K6HIW8K(\U\
M5/J8O6%V]^ LD!TY%0>6\VX%-VW*EO,VC#''3WKTA-WEKO #X&['3-9^HZ%8
M:K=6MQ>"Y=K61)8T2[ECCW*P92R*P5L, ?F!Z5I54I\R2ML3&-FW<****@LK
M/_R$X/\ KC)_Z$E6:K/_ ,A.#_KC)_Z$E6:8BM??\>Z_]=HO_1BU9JM??\>Z
M_P#7:+_T8M6:.@PHHHI %%%% '$_%=HU\ W G#&U:ZM1<!5)S%YZ;^!R1C/2
MN0TWQMX'T?XC7%_IDJV>DW&E+%+]GTZ:-&G64XR@3KL/7%>RUD7OBOPYIMTU
MK?:_I5K<)]Z*>\C1U^H)S0!=T[4+75M.@O[*0R6TZ!XW*%<CZ, 1^(JRP#*5
M.<$8X.*BM;JWOK6.ZM)XKBWE7='+$X=''J"."*FH YBW\+WIN;$:CK3WMG83
M>=!&T6)&<9VF1]QW;<^@SWKIZ** /*5AUI_&,2RK*]\)O,!8'&T,,D?[ R/;
MD"O5JY^\_P"2AZ-_V"K_ /\ 1MI7054I<Q,8\H4445)04444 %%%% !1110
M4444 %%%% !1110 4444 %13VT%U'Y=Q#',F<[9$##/K@U+10!E:SX;TG7H!
M'J%FDA7[DB_*Z?1AR*Y\6GBOPL,V<YU_35_Y83G;<H/]ENC?C^ KM:*TC5DE
M9ZHAP3=UHS"T3Q;I6NN;>&5H+Y>)+.X79*A[C:>OX5NUCZYX7TGQ#&!?VH,R
MCY+B/Y94^C#G\#Q7C7C6\\2^&_$+V'_"0:J\"HI@E-PR%U([X/)!R,]\5M3H
MQK2M!V?F9SJ.FKR5SWVBN&\(^.M+GTRST[4[I[34TB"R+>EAYA_O;VZYZ\GO
MQ7< AE#*001D$=ZPG3E!VDC6,U)70M%%%04%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ["BBBI**UM_Q\7O_78?^BTJS5:V_P"/B]_Z[#_T6E6:;!%:V_X^+W_KL/\
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MS?!>B66%#0V,*-MZ%M@R?Q.37/\ Q:+3^"1I:8\S5;ZULD'J6E4X'X*:[D
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M?PJ8W^AZKK[+@ZQJMQ=(?^F8.Q1]!L-;GCG5AH?@;6M1)(:*T<1D?WV&U/\
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MNKH ***KQ7]G/>7%G#=0R75L%,\*2 O%N&5W#J,@'&>M %BN?\=_\D\\3?\
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M ?IGW_*I]A/HK^FII[2/4Z^BN<MO'WA6[_U>MVR_]=<Q_P#H0%;%MJFGWO\
MQZ7UK/\ ]<IE;^1J94YQW12E%[,MT445!04444 %%%% !1110 4444 %%%%
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M2U]3&=",W<Y#_BX-L,?\2"]4=_WD;G^GO^='_"1>+;8'[5X-:0#^.VOD;/\
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M7^HL 5M+:2<@],(I;^E<7\-M3TC1_A[I,=]J]A#=3(US,);A$;?(Q<Y&>HW
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M(7 P+B0 =L+_ (4&%R,&XD(/LO\ A4U% $7DO_S\2_DO^%(('&<7$G/7A?\
M"IJ* (1"XZ7$@_!?\*! X&!<2 ?1?\*FKD]7\6:E9Z[?:9IV@B^%C91WLTK7
M@B^5BXVJ-IRW[LXY /.2.X!T_DO_ ,_,OY+_ (4>2_\ S\R_DO\ A7&7?Q$B
MFO+'3]'LU>ZO[:.YMYM1F%M;E'4,N&.6D;!Y5 ?J*R]=UK7HX_%&JQZJ]N?#
MI@"6D*)Y,Y\I)9=^X%B&WE1@C& >M 'H_DO_ ,_,OY+_ (4>2_\ S\R_DO\
MA7/>*;R\.H:#H]G>2V7]IW3I-<1!3(L:0O(0NX$ DJ!G' S7,Z?JVM:MJMIX
M9DUBYA\JZU".>^A2,331P-&(QDJ5!_?#<0.=G;)H ]'\E_\ GYE_)?\ "CR7
M_P"?F7\E_P *\VT75]>\526>EMK4]C+!87$DUS;1QAIYDN7@1CN4@+^[+$#&
M2WI4LWB/Q'J'ACP;K$%Q;6UM>W%@+[:I,LS22JK(O94.2<\GMQUH ]$\E_\
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MH_R%=;7)>!^$U5?2Z-=;5S^(F'PA1114%!1110 4444 %%%% !1110 4444
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M<[.RM(["PMK.'_56\2Q)]%  _E4]%(S*BEF(50,DDX % CA-!D_M;XN^*+_
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M . 4?_Q-'_"(^&O^A>TG_P  H_\ XFD,V:*QO^$1\-?]"]I/_@%'_P#$T?\
M"(^&O^A>TG_P"C_^)H V:*QO^$1\-?\ 0O:3_P" 4?\ \31_PB/AK_H7M)_\
M H__ (F@#9HK&_X1'PU_T+VD_P#@%'_\31_PB/AK_H7M)_\  */_ .)H V:*
MQO\ A$?#7_0O:3_X!1__ !-'_"(^&O\ H7M)_P# */\ ^)H V:*QO^$1\-?]
M"]I/_@%'_P#$T?\ "(^&O^A>TG_P"C_^)H V:*QO^$1\-?\ 0O:3_P" 4?\
M\31_PB/AK_H7M)_\ H__ (F@#9HK&_X1'PU_T+VD_P#@%'_\31_PB/AK_H7M
M)_\  */_ .)H V:*QO\ A$?#7_0O:3_X!1__ !-'_"(^&O\ H7M)_P# */\
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M\D5T%%(9S_\ PD.J?]"9KG_?ZR_^2*/^$AU3_H3-<_[_ %E_\D5T%% '/_\
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M5/\ H3-<_P"_UE_\D5T%% '/_P#"0ZI_T)FN?]_K+_Y(H_X2'5/^A,US_O\
M67_R17044 <__P )#JG_ $)FN?\ ?ZR_^2*/^$AU3_H3-<_[_67_ ,D5T%%
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M[UK5RGBZUMTN]#N5@C$\FKVRO*%&Y@ V 3UP* .KHHHH HZMJMMH]B;JY$C
MG8D<2%GD<]%4#N<4:+J7]L:+9ZB(O*^TQ"3R]V[;GMGO5N89A< 9.TX_*L'P
MW)+IGA/0[>XM+H3/&D+(L)S$<'EQ_"!CJ?44 %IXAO[_ %&6*UT</:1736[7
M!NE!PK;68)C) Y_*NAKSB73(7NK>'3O#MU8:U'J/F-=!79%3?EG,QX967/R^
M^,5Z/0 5SC^--,2\DB,-X;:.X^RO>B#]PLN=NTMG/WCC.,9[UT=>:W?BC1->
MUXZ;/J5I8Z/970+Q$X>]F5LCCM&&Y]6(H ]*HHHH **** "BBB@!"0!DG '4
MUSUAXSTW4;VV@BAO$BNV9;6ZEAVQ7!7)(4]>@)&0,XKH6.%)"EL#H.IKSAM4
MLM7\6:#?Z;=74UW]H,<VD7"C%DFPJ[E0/D88ZDG.[B@#TBBBB@ HHHH ****
M "LJW\0V%WXBNM#@=GN[6(2S$ ;5R?NY]>A_&K.JF_&E71TQ8VOO+(@$IPN[
ML37!>%;74M+\=1V<^EQ1,=+!N)?MGFLY,KL92=@W,S\8[#OVH ])HHHH ***
M* "BBB@"MJ-]#I>FW5_<DB&VB:5]HR<*,G'O5+2-=&KR,JZ9J5HH3>'N[?RU
M;Z')R:C\6Q6\WA348[M+M[9HL2BS ,NW(R5!XX'7VS6#X7N(#XLF@T34[K4-
M'^PAYVFG:9$GWC:%9LX)7<2H]* .XHHHH **** "BBB@"EJVJVNC6#7=V7V;
ME14C4L\CL<*J@=234&CZ[;:R;F..&YM[BU8+/;W,>R1,C*DC)&".A!K$^(<+
MOIFEW'GS06UMJ44MS/"/FBBPREQZ8W#GMU[4[P;=&;4-9BM-0N-0T>)XOLMS
M/(9<N5/F*KGE@/E[\9H ZVBBB@ HHHH 9+*D$+S2L%CC4LS'H .2:XKX21O_
M ,*\L[R7/G7\T]V^?5Y6(_3%:_CN_P#[,\ Z]=AMK)8RA#Z,RE5_4BK'A&Q_
MLSP;HMCM"M!8PHP']X(,G\\T#Z&S7">)2M]\5_!MB&/^B1W=]*N.HV!$_4G\
MJ[NN&L,W_P :]7G'*:9H\%H1_=:5S)Z]2%'^>J8([FBBBF(***X!_%OBBPOM
M'N-5TNPM].U7418QVFY_M<6XL$=C]T\+D@#@'K0!W]%<7J_CE[7QYI'ARPMD
MGCFG\J_N&SB%C&SHBX/WR%R>N!CUKM* "BBB@ HHHH K/_R$X/\ KC)_Z$E6
M:K/_ ,A.#_KC)_Z$E6:8BM??\>Z_]=HO_1BU9JM??\>Z_P#7:+_T8M6:.@PH
MHHI %%%% !1110 4444 %5=0U"UTNS:[O9?*@4@%MI.,G X'-6J* .)\;.=:
M\$7&H:?J<B6"PNS)''@SD,  2>0 0<C'-=MVJEJVFPZQI5QIUPTBPW";':,@
M,![9!J[0 4444 %%%% !61XIO)M/\+:I=6[%9HK9RC#JIQU_#K6O45U;0WEI
M-:W"!X9D,;J>ZD8(H Y.STV#0/$^BPZ?O6.^M9EN07+"0H$8.<G[V2>?>NQK
M%TOPW!IETERUY=WDL4/D0FY=6\J/CA< >@Y.3Q6U0 4444 %%%% !5/4[6YO
M;)K>UO7LW<@-,B!F"]PN>A/KVJY10!SO@3/_  A6FY))V-R3R?G:NBJEI.F0
MZ/ID.GV[2-%""%,A!8Y)/. /6KM #)ED>"189!'*5(1RNX*<<''?Z5S'A&VE
MM-2\003W<MW*MVFZ:7&YB8D)X' '/ [#%=56?%I,,$NI2Q33I)J#;Y&##*'8
M$!7CC@ \YYH YSQ-I&H:CXA29=(BU"R@L\(DMWY(,A?)QC))P .<#GK6_P"'
M+NTOO#MC<V,+0VSQ#9$QR4QP1GV((JK=^%XKF6*>/4]0MKA;<6TL\,BAYT']
M_*GYNO(P>36K86-OIEA!96D?EV\"!$7.<"@"S7)^+;32@WVS53-=L\7D6>GH
MQR\N2<J!R6.1SV KK*P-1\*Q:CK0U;^U-1MKE8O*3R'0!%[XW(<9[T 7?#]M
M>V?A^PM]1D,EY'"JRL3DY],]\=,UI5!9V[6MI' UQ-<%!@RS$%V^N !^E3T
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M.<^_S?I6[K>CVGB#1KG2KX.;6Y4+($;:2,@XS^%7888[>".")=L<:A$7T &
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M:!+2/3-3GL"S2Y#B/;\Y) VYW=.?K6Q:WUG?0&>SNH+B$'!DAD#KGZB@"Q2
M =!BJ]KJ-C?-(MG>6]P8SAQ#*K[3[X/%":A927C6:7ENUT@RT*RJ7'U7.: +
M-%<SH7C*SU635([MK>Q>SU2?3HEDN!F?R]OS ''7=T&<>M;]U>VEA%YMY<PV
M\><;YI @S]30!/138Y$EC62-U=&&593D$?6L*Y\1E?%8T2T@68P6C7=[(7QY
M*](UZ<LQ!..P7/<4 ;]%8'A/Q(?$_@VRU\VHMC<Q-)Y DW[<,1C=@9Z>E-\*
M^*H?$/@RQ\1W4<6GQW*,[)),"L>&*_>('IZ4 =#2  # & .PJ 7]DUG]L%W
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M:)G1]TI)&7))"\YP#[#'JM%% !1110 4444 5G_Y"<'_ %QD_P#0DJS59_\
MD)P?]<9/_0DJS3$5K[_CW7_KM%_Z,6K-5K[_ (]U_P"NT7_HQ:LT=!A1112
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ&LKJ
MS:9(-$DLX[_(\MKQ&:(#(SD*0>F:\]TW7/B1J7B;7-#CN/#"3:1]G\V1K:?:
M_FH7&/G[ <YH ]1HKE+'QG86FC_;/$&M:3'ONYX8Y;=F6,A"?E^;^, <]L]*
M/^%F>"_L4=V?$=B(9)#$I+G.X8SE<9'4<D8YH ZNBL?5/%>@Z+IMOJ.H:M:P
M6ER 8)2^X2@C(V8R6X(/%6])UC3M=L$OM+O(;NU<D"2)LC(Z@^A]C0!=HKSZ
M[U[QEJ/CS6="T"31(;?38;>0M?0RLS>8I/56'<'M5OPQXQOY=2\0:1XI73[6
M\T01RS75K(1;M$ZE@WSG*D <Y/>@#MJ*P=%\:^&O$,TL.E:S:W,L2[W0,58+
M_>P<9'N.*BTWQ]X4UB_:QT_7;2>Y 9A&K'Y@O)VDC#8 )XSTH Z.BN2\#^.K
M/QHNJ?9VA#V=V\2I&Q):$'"2'('WL$TSQK>>,-*M+W5-$FT4:?9V;W$D=Y#*
MTK,@9FP58#! &* .PHK@?#WB3Q!%H]AXA\7:EH%KHU[;12)Y$4J.CRA2@9F8
MC')!K9;X@^$UT:/5VUVU%C)*88Y23\[CJH7&21D=!WH Z6BL5?%WAYM .NC6
M+/\ LL'!N?,&T'^[]?;K6?\ \+$\,W&A:GJFGZK;7::?$9)4#%6!Z*"",@$X
M&<4 =517&:/\2_#UWX6TS5]3U2SLGNXB71F(59%53(@SU*[A^=63\2_!8MK>
MX/B2P$5PQ6,F3G(ZY'5>HZXH ZJBL/6O&7AWP\+<ZKJ]K;?:%WP@MN+K_> &
M3CWZ4^[\6^'K'3K74+G6+..RNP3!.9!LDP"3@].@- &S17#:Y\4= M/!FHZ]
MI%_:Z@UJ1$D0<KF5ONJ1C(R 3TYVGFNHM-<T^\T!=:CND:P\EIFG4':%7.X^
MO&#^5 &C166WB/1T33&;48 NJ8%B=W^OR 1M_ C\ZS=;\406EY;VEEJ>FQ3Q
M:C;V]\EUOR$D5FV)M_Y:$#(SQUS0!TU%>5O\78KOP]?:CI[62R6NL1VC+(6*
M_9FD"B4GC&1N/M7<:'XQ\.^)9YH-&U:VO)H1F1(VY ]<'J/<<4 ;E%<?X]\0
M:SHBZ';Z&++[5J>HI9[KQ&9%#*QSA2#U K-;Q+XO\.>(M%LO$T>BW5EJUQ]E
MCETY94DBD(R"5<G*_3I0!Z%17G5EXC\9>,A<ZAX671[+18Y7BM9]0221[LH2
M"X"D!4R".YXJ2'XC7%MX3\17>K:6(M;\/_)>6<3$QNS?ZMT;D[&'//(&: /0
M:*\Y@USX@6EOIVKW%MHNL:9=/&)X-*CE,T*/_$AR0X7O_3J+OC#Q=J6CZCJ$
M&FI;LNFZ)-J4_FH6!?.V)>",#Y9"?I0!W-%>777B/XB:5X37Q1=#PS=6"6R7
M4MM&DT4IC(!(5BQ&[!KH-'\9MJ7B;4;>;R(-*M]+MM0263Y642!F;>2<   =
MACF@#L:*YS2/'OA;7M2_L[2];M;F[(++$I(+@==N0-W0],]*D7QOX8;7/[%7
M6[,ZCYGE>1YG._.-F>F[/&W.: -^BN>U+QUX6TC51IFH:Y9V]YQNB=_N9Z;C
MT7\2*R=9\?VGA_QZ-)U:[M+72FTD7B3."9&E,Q3:,'D;1G &>] ';T5C2>+?
M#T6@+KKZQ:#2W.%N?,&UCZ#U/!XZ\5+H?B/1_$EL]QH^H0WD<;;9/+/*'T8'
MD?B* -2BN<\4Z[<Z;/I&E::(SJFK77DPF1=RQQJ-TLA'?:HZ>K"H_"?B&\US
M4?$EO=)"J:9J;VD)C4@E JD%LDY//;% '3T5R>C>*Y;K7_%MMJ3VMO8Z+-$J
M3'Y,(T>]BY)QQZ\5?T3QGX<\27,EMI&KVUU/&NYHU)#;?4 X)'N.* -VBLG_
M (2;1?\ A'QKW]HP_P!E'&+KG9R^S_T+BJTOC;PU!K0T>76;5=1,IA^SECN#
M@ X/IP1UH WZ*YW2O'?A;7-3_L[3=;M+F[.=L2,<OCKM)X;\,]*3P]KMS=ZW
MK>AZD(Q?:;,'1XUVB6WD&Z-L>HY4^Z^] '1T444 %%%% !1110 4444 %%%%
M !1110 4444 5K;_ (^+W_KL/_1:59JM;?\ 'Q>_]=A_Z+2K--@BM;?\?%[_
M -=A_P"BTJS5:V_X^+W_ *[#_P!%I5FA@@HHHI %%%% !1110 4444 %%%%
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M9H=WEM#:HI3<,-@@9&0!GUQ3K/PYH>G21/8Z-I]L\3O)&T-JB%&<!6(('!(
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MV=1\$_$GQ"W(O1/;0$=##;QF,$>Q?S#^->KA5#%@H#'J<<FA55%VJH4>@&*
M/-=#^&6EZIX9TEM4U?Q!?VTMK#(UE<:DYMS\JG&P8X'85D^*)_[-\1^/)(-*
MCU!8M$LU6R*DHR[F'(7G:!R0,<"O8:* / #JKZAXO\%F'Q/:ZJ8IVB3['IX@
MM[-GB(1-W))..%)Z+T%:WAG7O#EEX#TCPI?Z6UYX@BNUBDT@H5F%P)<F4G'
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M^/B]_P"NP_\ 1:59JM;?\?%[_P!=A_Z+2K--@BM;?\?%[_UV'_HM*LU6MO\
MCXO?^NP_]%I5FA@@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M6?\ Y"<'_7&3_P!"2K-5G_Y"<'_7&3_T)*LTQ%:^_P"/=?\ KM%_Z,6K-0W,
M+3P[%<(P96!*Y&58'ID>E,V7W_/Q;_\ ?AO_ (N@"S15;9??\_%O_P!^&_\
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MR^_Y^+?_ +\-_P#%T;+[_GXM_P#OPW_Q= %FBJVR^_Y^+?\ [\-_\71LOO\
MGXM_^_#?_%T 6:*K;+[_ )^+?_OPW_Q=&R^_Y^+?_OPW_P 70!9HJMLOO^?B
MW_[\-_\ %T;+[_GXM_\ OPW_ ,70!9HJMLOO^?BW_P"_#?\ Q=&R^_Y^+?\
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M )^+?_OPW_Q=&R^_Y^+?_OPW_P 70!9HJMLOO^?BW_[\-_\ %T;+[_GXM_\
MOPW_ ,70!9HJMLOO^?BW_P"_#?\ Q=&R^_Y^+?\ [\-_\70!9HJMLOO^?BW_
M ._#?_%T;+[_ )^+?_OPW_Q= %FBJVR^_P"?BW_[\-_\71LOO^?BW_[\-_\
M%T 6:*K;+[_GXM_^_#?_ !=&R^_Y^+?_ +\-_P#%T 6:*K;+[_GXM_\ OPW_
M ,71LOO^?BW_ ._#?_%T 6:*K;+[_GXM_P#OPW_Q=&R^_P"?BW_[\-_\70!9
MHJMLOO\ GXM_^_#?_%T;+[_GXM_^_#?_ != %FBJVR^_Y^+?_OPW_P 71LOO
M^?BW_P"_#?\ Q= %FBJVR^_Y^+?_ +\-_P#%T;+[_GXM_P#OPW_Q= %FBJVR
M^_Y^+?\ [\-_\71LOO\ GXM_^_#?_%T %M_Q\7O_ %V'_HM*LU!;0O$96DD5
MWD?>2J[0/E Z9/I4])@5K;_CXO?^NP_]%I5FJOD7*33/#/$JRL&(>(L0=H'7
M</2EV7W_ #\6_P#WX;_XNF(LT56V7W_/Q;_]^&_^+HV7W_/Q;_\ ?AO_ (N@
M99HJMLOO^?BW_P"_#?\ Q=&R^_Y^+?\ [\-_\70!9HJMLOO^?BW_ ._#?_%T
M;+[_ )^+?_OPW_Q= %FBJVR^_P"?BW_[\-_\71LOO^?BW_[\-_\ %T 6:*K;
M+[_GXM_^_#?_ !=&R^_Y^+?_ +\-_P#%T 6:*K;+[_GXM_\ OPW_ ,71LOO^
M?BW_ ._#?_%T 6:*K;+[_GXM_P#OPW_Q=&R^_P"?BW_[\-_\70!9HJMLOO\
MGXM_^_#?_%T;+[_GXM_^_#?_ != %FBJVR^_Y^+?_OPW_P 71LOO^?BW_P"_
M#?\ Q= %FBJVR^_Y^+?_ +\-_P#%T;+[_GXM_P#OPW_Q= %FBJVR^_Y^+?\
M[\-_\71LOO\ GXM_^_#?_%T 6:*K;+[_ )^+?_OPW_Q=&R^_Y^+?_OPW_P 7
M0!9HJMLOO^?BW_[\-_\ %T;+[_GXM_\ OPW_ ,70!9HJMLOO^?BW_P"_#?\
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M_%T 6:*K;+[_ )^+?_OPW_Q=&R^_Y^+?_OPW_P 70!9HJMLOO^?BW_[\-_\
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M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image6.jpg
<TEXT>
begin 644 image6.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (&!+P# 2(  A$! Q$!_\0
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M "BBB@ HHHH *.U%(?NGZ4 )FEJ,&GB@!U%)2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]=7,MQ<-@D*.% ]
M*Z&N9N1)%(^Y3PV,4 6;*ZDBE5&R5)XK=KG[>(RRP^6#G=EO:N@H **** $K
M@_&WQ!?PMJ%O96UFEQ+*I9BS[=H_*NTO+VVL+=IKF5(T4=6.*^</&FM-J_B^
M>\1&,"C9'QP1ZUE5GRQN95I\L=-SUCP#\16\7W]U8W%DEM-#&)%*N6##.#V^
ME=^*^8/ ^M'P]XSM[^1"+<@Q3<=%-?2UA?VNHVPN+2>.:-OXD;(%*C-RCJ%*
M?-'7<M4445L:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<]\4W=Z^=_R_R0=?P_-_J<U_:OC;7+"_TS4/ G]FPW%E-&MQ_:\,WSE"%7:
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*CG_ ./>3_</\JDJ*X_X]I?]P_RH S835V,UG0'I5^,T 65IU,6GT +1110
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MM1635Q&+^ZC+R,QB%N<$#C;N)P!W[?CUI#167Q+;O((1K=TQ:'S@_P!@  7
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MK7I]RT%HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5!>_\>%Q_P!<F_D:GJ"]_P"/
M"X_ZY-_(T <W:=!6Q!T%8]IT%;$'04 74Z5**B3I4HH 6BBB@ HHHH ****
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MZ8T*ZAJ5G:&=ML(N)UC\P^BY/)^E-UO5HM"T2\U6>&>>&TB,LB0*"Y4<G )
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M?G'ZTMMK&F7AMQ:ZC:3FY1I(!%.K>:B\%EP?F R,D>M+NO3\+?Y!V?K^-_\
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M_P"N3?R-3U!>_P#'A<?]<F_D: .;M.@K8@Z"L>TZ"MB#H* +J=*E%1)TJ44
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MN"KC^%L@\'GBCP>VER6'@C^P7W:M'"PU38Q,BP>4V1-Z+OV[ ?;;7K.H>)]
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M]P!%<V\MPT%R2.3&L_S)@]1TSZ]:]*HIWU?G_P  FVB"BBBD,**** "BBB@
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M/HI]++^N@=;_ -?UN%%%%( HHHH **** "BBB@ HHHH **** "H+W_CPN/\
MKDW\C4]07O\ QX7'_7)OY&@#F[3H*V(.@K'M.@K8@Z"@"ZG2I142=*E% "T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% '@GC.^O=.U?XEW.G7D]I
M=*VEA)H)"C+G /(YKLO"']IZ-\2]4\/W6N:CJML^FQ7P:^E#E)"VU@N  J^P
MKN;C0='NVN6N=)L9FNMAN#);(QFV?=WY'S8[9Z586PLDOVOUM(%O&C$37 C
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M,(3R&D]%XY%>VKH.C)JAU1=)L%U$];L6R>:>WW\9_6DE\/:)</=O-H^GR/>
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M05#JNE>'-6OK>WUBPTJ]O-C-!'>0QR2;!C<5# G'(SCVI+=>7^5O^"-]?/\
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M3UCR_P!=?\PZW_KI_D>1^"[N6\\-V\^HQLFG^$898V#]);J+<N?<(@&/=_\
M9K,U&+3+/1M*AU;RC?V6EFY73]3A!MM1DFR[B$YW"</QD#(W#CG->WT4-MZO
M^M[_ )_@"LOZ_K^F>)ZE;Z?JM_;_ &^TCCLI=7L--"WS>9Y20Q&5D9WSDEW*
M')YY'>O2O%^K:'X;\+/-J]M;RV*E(HK5T39(^?D0!OE'(!R< 8SVKHJ*;>EO
MZZ?Y M[_ -=3D/!@M]3N[_Q$^JZ??ZC=*D,J:=<++#:QKDK$&!Y/S$ECC)/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4/6?^P58?^C;NN@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2:@UR+EK<VD ."0Z_,2Q&-OMFK_@!-+T7Q!=:/#I#6MY=V4.H)>/<-.]U$0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M >"5) K1T_4+75+)+RRE\VWD)"/M(#8)!(R.1D<'H>HXH LUS_A[_D.>+/\
ML*I_Z16M=!7/^'O^0YXL_P"PJG_I%:T =!1110 4444 %%%% !1110 4444
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M@<UTNHZ1IFL1)%J>G6E[&C;D2Y@60*?4!@<&KBJJ(J(H55&  , "A-V=^O\
MP?\ /\ :U5NG^2_RN+1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M3K"WLK2/R[>WC6*)-Q.U5& ,GD\#O4]%"T5@>KN%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !4%[_P >%Q_UR;^1J>H+W_CPN/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %07O_'A<?\ 7)OY&IZ@O?\ CPN/^N3?R- '-VG05L0=!6/:=!6Q
M!T% %U.E9GB+PMHWBW3X['7+/[7;1R"54\UX\, 1G*D'H36FG2H-3U6QT73I
MM0U*ZCM;2$9>60X _P 3[4G:VHU?H>'W7P_B@FF$7P4,T*,P60>*2"Z@\';N
MSR.U>G_#-[*3P)8MI^D#2+?=)BR%T;@Q'>V07/.<YR#R.E<9XBU2ZT2*UO+W
MXKW5O;ZDOGVL4>C1NWE'D' &X  CDXKT'P3I>FZ3X3LX-*OFO[60-.+MFR9V
M<EF<_4D\54;\KN3*UU8Z"BBBD,**** "N?\ #W_(<\6?]A5/_2*UKH*Y_P /
M?\ASQ9_V%4_](K6@#H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /F:BBBO6/SX**** "BBB@ HHHH *^F:^9J^F:Y,5T/H<B_P"7
MGR_4****Y#Z **9*Q2)W'55)&:\\TCQEXB;2_#FK:JNEO::W,+<0VD$@D@9E
M8JV2YWCY>5P",]31_7WATN>C45Q>EZ_J]SJEO#/?^9$[X9?^$3O[;(_ZZR.5
M3ZD8KDK*".'0?#OB9%']OWFO".YN@,22J\SH\3'J4"C 7H-H-"W2[_J#V9[#
M17%>(;*WUKX@Z+I.J0QW.FBPN;D6TR;HY)0T:@L#P<*QQGIFL+0+"UUWPO!:
M7,5GJUW8W-Y'86&I79$4L*S% [+M?=M& "5./49S1TO_ %H[#_K\+GJ5%<E\
M-)2_@:SB>25YK:26WE$G.QTD8% <G*KT!ST KK:;5F2@HHHI#"BBB@ HHHH
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M/_9EB5>UMF@4+YMWP5:1R3G/.>XXXYZRD 4444 %%%% !1110 4444 %%%%
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M"X_ZY-_(T <W:=!6Q!T%8]IT%;$'04 74Z55U?1=,UZP:QU:RAO+4D,8Y5R
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M74&LFOF$BW'V5I3;R>2)NGE^=M\O=GC&[.:E3Q;H<FN'1EOA]N$AB"F)PAD
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M,.G<<]>E=17/^'O^0YXL_P"PJG_I%:T@.@HHHH **** "BBB@ HHHH ****
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M**** "BBB@ J[;_ZA?Q_G5*KMO\ ZA?Q_G6M'XB)[$M%%%=!D%%%% !1110
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M+\SHPO\ %7]=#UFBBBOGCUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKKG_ ((;W_XS0!T%%<__ ,)EI?\ SZZY_P""&]_^,T?\)EI?_/KKG_@AO?\
MXS0!T%%<_P#\)EI?_/KKG_@AO?\ XS1_PF6E_P#/KKG_ ((;W_XS0!T%%<__
M ,)EI?\ SZZY_P""&]_^,T?\)EI?_/KKG_@AO?\ XS0!T%%<_P#\)EI?_/KK
MG_@AO?\ XS1_PF6E_P#/KKG_ ((;W_XS0!T%>?5T/_"9:7_SZZY_X(;W_P",
MUPW_  DMA_SPU7_P4W7_ ,;K2!G,V**Q_P#A);#_ )X:K_X*;K_XW1_PDMA_
MSPU7_P %-U_\;K2Z(LS8HK'_ .$EL/\ GAJO_@INO_C='_"2V'_/#5?_  4W
M7_QNBZ"S-BBL?_A);#_GAJO_ (*;K_XW1_PDMA_SPU7_ ,%-U_\ &Z+H+,V*
M*Q_^$EL/^>&J_P#@INO_ (W1_P )+8?\\-5_\%-U_P#&Z+H+,V**Q_\ A);#
M_GAJO_@INO\ XW1_PDMA_P \-5_\%-U_\;HN@LS8HK'_ .$EL/\ GAJO_@IN
MO_C='_"2V'_/#5?_  4W7_QNBZ"S.X\,?\O7_ /_ &:NAK@_#OBS3H?M.ZVU
MDYVXV:+>-Z^D5;G_  F6E_\ /KKG_@AO?_C-8RW-8['045S_ /PF6E_\^NN?
M^"&]_P#C-'_"9:7_ ,^NN?\ @AO?_C-24?-U%5?M\/\ <N?_  &D_P#B:/M\
M/]RY_P# :3_XFOJ?:0[GA<DNQ:HJK]OA_N7/_@-)_P#$T?;X?[ES_P" TG_Q
M-'M(=PY)=BU157[?#_<N?_ :3_XFC[?#_<N?_ :3_P")H]I#N')+L6J*J_;X
M?[ES_P" TG_Q-'V^'^Y<_P#@-)_\31[2'<.278M455^WP_W+G_P&D_\ B:/M
M\/\ <N?_  &D_P#B:/:0[AR2[%JBJOV^'^Y<_P#@-)_\31]OA_N7/_@-)_\
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M$'_ O_036?6AH?\ R&(/^!?^@FD]AK<[&BBBL#<^9J***]8_/@HHHH ****
M"BBB@ KZ9KYFKZ9KDQ70^AR+_EY\OU"O /B3_P C_J?_ &R_]%)7O]> ?$G_
M )'_ %/_ +9?^BDK?*_XS]/U1Z>._AKU.4HHHKWSR@HHHH **** "BBB@#Z5
M\,?\BGHW_7C!_P"BUK5K*\,?\BGHW_7C!_Z+6M6OD:GQOU/H(?"BI=?ZT?[M
M05/=?ZT?[M05PS^)G3'8****D84444 %%%% !5VW_P!0OX_SJE5VW_U"_C_.
MM:/Q$3V):***Z#(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH X5_A[.]K+I']M*/#TE]]L:R%I^]YD\PQB7?C9OY^YG'&:Z?4=(_M+4M.G
MFG_T6RD,WV;9Q)+C",3GHN2<8ZX/:M.BCR!ZG%Z+\/UTC6K6[.IF:SL);F:R
MMO(VM&TYR^]]QW@<X^5>O.:[2BBCI8.MPHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **1F"J68X &37.V7CKP_?FT\FXNUCNV"6\\^GW$,4K'H%D= A)
M[<\]J/(/,Z.BJFG:G9ZM;-<6,WFQ+*\);:5PZ,58<@=""*MT %%%5--U*TU>
MQ2]L9O-MW9E5]I7)5BIX(!Z@T 6Z**K27]M%J$-@\O\ I4Z-(D84G*KC<3C@
M#YAU]: +-%%5-1U*#2[<3W$=TZ%MN+:TEN&S_NQJQQQUQB@"W163I/B72M:M
MKNXLIY?*LW,=P;BVE@\M@,D$2*IX'7TIUGXBTK4+?3KBUNP\.HAOLC[& EP"
M2!D<' )P<9P<=* -2BBB@ HHHH **** "BBB@ HHIDTJ00R32-MCC4LQQG '
M)H;L ^BL:'Q5HEQH5KK4-^LFG74B1PS*C'<SL$48QD'<<<@8[XK9HLP"BBJE
M[J=GISVB7<WEM=SBW@&TG?(02!P..%/)XH MT56NK^VLYK6*>7;)=2^5"H4D
MNV"V./8$YZ#%6: "BH+V\BL+22YF6=HTQD00/,YYQPB L?P%82>//#S"\W75
MU"UD$\]+BPN(64N<( KH"S-V4 D]A0!TE%8]KXIT>\M1<Q7;"/[2+1A+"\;1
MS'&$=64,A.1]X#J/45L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5!>?\>-Q_P!<F_E4]0WG_'E<?]<V_E0!SEJ.E:T'05EVHZ5K0=!0!;3I
M4HJ-.E2"@!:*** *>K7AT[1[Z] R;>W>4 ]]JD_TKS:SEU'3-$\%>(%U;4;B
MZU6Z@COTGNGDBE6=2>(V)5-IQC:!TKT^[MH[VRGM9?\ 5S1M&V/0C!KA+#P?
MX@:W\-Z5J<VG#3="G299K>1VEN?+4K$"A0!.H)PS9Q1'?[ONUN$OA^_[[:'/
MZ3JOBC1KU+N]35I;@P3QWT-YYGD2W;2XMU@W?+@@_P#+/C;UYKT;PQ=6<FE+
M:0ZW!JUW;?+=RQW(E82DDL#@G;SG"]@ .U1ZMH5QK.L1R7$R)8V]NXMU0G>+
MAP5,A&,?*I(7GJQZ8%8?@KP7J6@:C!<ZA+9!;33$TR%;1F/G*KEO-?*C:W^R
M-W4\TX[6?];_ ->C78);W7];?U]_<Z_4M6TW1K=;C5-0M+&!GV+)=3+$I;!.
M 6(&< \>QK#\(7]GJ>H>*;RPNX+NUDU5-DT$@D1L6=L#AAP<$$?A745CWWA/
MPWJ=Y)>7_A_2KNZDQOFGLHY';  &6(R<  ?A2 V**Y__ (03P?\ ]"IH?_@N
MA_\ B:/^$$\'_P#0J:'_ ."Z'_XF@#H**Y__ (03P?\ ]"IH?_@NA_\ B:/^
M$$\'_P#0J:'_ ."Z'_XF@#H**Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0
MJ:'_ ."Z'_XF@#H**Y__ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0J:'_ ."Z
M'_XF@#8O_P#D'77_ %R?^1KAJZ'_ (03P?\ ]"IH?_@NA_\ B:/^$$\'_P#0
MJ:'_ ."Z'_XFJC*Q,HW.>HKH?^$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_
M^"Z'_P")JO:$^S.>HKH?^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXFCV@>S.>HKH?^$$\'_]"IH?_@NA_P#B:/\ A!/!_P#T*FA_^"Z'_P")H]H'
MLSGJT-#_ .0Q!_P+_P!!-:/_  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#
M_P#!=#_\30YW0U"S.@HKG_\ A!/!_P#T*FA_^"Z'_P")H_X03P?_ -"IH?\
MX+H?_B:S+/!J*]Y_X03P?_T*FA_^"Z'_ .)H_P"$$\'_ /0J:'_X+H?_ (FN
MOZUY'S_]A?\ 3S\/^">#45[S_P ()X/_ .A4T/\ \%T/_P 31_P@G@__ *%3
M0_\ P70__$T?6O(/["_Z>?A_P3P:BO>?^$$\'_\ 0J:'_P""Z'_XFC_A!/!_
M_0J:'_X+H?\ XFCZUY!_87_3S\/^">#45[S_ ,()X/\ ^A4T/_P70_\ Q-'_
M  @G@_\ Z%30_P#P70__ !-'UKR#^PO^GGX?\$\&KZ9KG_\ A!/!_P#T*FA_
M^"Z'_P")H_X03P?_ -"IH?\ X+H?_B:RJU?:6T/0P& ^J<WO7O;I;:_F=!7@
M'Q)_Y'_4_P#ME_Z*2O7_ /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_
M .)J\+B/J\W.U]#JKT?:QY;V/G6BOHK_ (03P?\ ]"IH?_@NA_\ B:/^$$\'
M_P#0J:'_ ."Z'_XFN_\ M;^Y^/\ P#D^H?WOP_X)\ZT5]%?\()X/_P"A4T/_
M ,%T/_Q-'_"">#_^A4T/_P %T/\ \31_:W]S\?\ @!]0_O?A_P $^=:*^BO^
M$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H_M;^Y^/\ P ^H?WOP
M_P""?.M%?17_  @G@_\ Z%30_P#P70__ !-'_"">#_\ H5-#_P#!=#_\31_:
MW]S\?^ 'U#^]^'_!+?AC_D4]&_Z\8/\ T6M:M<__ ,()X/\ ^A4T/_P70_\
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MJYU2+SC"D<LDF]D"J!S@<]3T&:O]W%^9FO:R76Q++86TTK2/&=S##8<@,/<
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M@.X#)'/X5,   !T%+12LD[CYG:W0I2Z1837!GDME,A.2<G!_#I5P      <
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MXU'-3_EM]W]=37DJO[5^F[^XMV^EQ)9V\4PW21)MWHQ4^_(P<5.UC;-"D/E
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M%%%D%V'E1_W!1Y4?]P4446078>5'_<%/ P,"BBG8+L****!"8I:** "BBB@
MHHHH **** &>5'_<%'E1_P!P444K(=V'E1_W!1Y4?]P4446078>5'_<%'E1_
MW!1119!=AY4?]P4>5'_<%%%%D%V'E1_W!1Y4?]P4446078>5'_<%'E1_W!11
M19!=AY4?]P4>5'_<%%%%D%V'E1_W!1Y4?]P4446078>5'_<%'E1_W!1119!=
MAY4?]P4>5'_<%%%%D%V'E1_W!1Y4?]P4446078>5'_<%'E1_W!1119!=AY4?
M]P4>5'_<%%%%D%V'E1_W!1Y4?]P4446078>5'_<%'E1_W!1119!=AY4?]P4>
M5'_<%%%%D%V'E1_W!1Y4?]P4446078>5'_<%'E1_W!1119!=AY4?]P4>5'_<
M%%%%D%V'E1_W!1Y4?]P4446078>5'_<%'E1_W!1119!=AY4?]P4>5'_<%%%%
MD%V'E1_W!1Y4?]P4446078>5'_<%'E1_W!1119!=AY4?]P4>5'_<%%%%D%V'
ME1_W!1Y4?]P4446078>5'_<%'E1_W!1119!=AY4?]P4>5'_<%%%%D%V'E1_W
M!1Y4?]P4446078>5'_<%'E1_W!1119!=AY4?]P4>5'_<%%%%D%V'E1_W!1Y4
E?]P4446078>5'_<%'E1_W!1119!=BJBK]U0*=113$%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image7.jpg
<TEXT>
begin 644 image7.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (< ]$# 2(  A$! Q$!_\0
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M_P"/'_&C^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4
M5O[/M?\ GE_X\?\ &C^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_YY?\
MCQ_QJS10!6_L^U_YY?\ CQ_QH_L^U_YY?^/'_&K-% %;^S[7_GE_X\?\:/[/
MM?\ GE_X\?\ &K-% %;^S[7_ )Y?^/'_ !H_L^U_YY?^/'_&K-% %;^S[7_G
ME_X\?\:/[/M?^>7_ (\?\:LT4 5O[/M?^>7_ (\?\:/[/M?^>7_CQ_QJS10!
M6_L^U_YY?^/'_&C^S[7_ )Y?^/'_ !JS10!6_L^U_P">7_CQ_P :/[/M?^>7
M_CQ_QJS10!6_L^U_YY?^/'_&C^S[7_GE_P"/'_&K-% %;^S[7_GE_P"/'_&C
M^S[7_GE_X\?\:LT4 5O[/M?^>7_CQ_QH_L^U_P">7_CQ_P :LT4 5O[/M?\
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MH K?V?:_\\O_ !X_XT?V?:_\\O\ QX_XU9HH K?V?:_\\O\ QX_XT?V?:_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)Y8U=6.]5(!Q@')RPPO4YX!H VJ*R= \3:/XGM)+G1[U;F.)S'(-C(R-Z,K
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M%% !45S_ ,>LW^X?Y5+45S_QZS?[A_E0!SU%%% &[I__ !XQ_C_,U9JMI_\
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M:L[#3N%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5E90K#;Q#"(OYDDGDDG))/)))- %FJ,%]+<PK-#:DQMG:3( >#CI5ZL_1/\
MD#P?\"_]"- $_GW7_/G_ .111Y]U_P ^?_D459HH K>?=?\ /G_Y%%'GW7_/
MG_Y%%6:* *WGW7_/G_Y%%'GW7_/G_P"115FB@"MY]U_SY_\ D44>?=?\^?\
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M@C(H VK/_CT3\?YU/4%G_P >B?C_ #J>N>6YHM@HHHI#"BBB@ HHHH ****
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M<=F7[/\ X]$_'^=3U%;(T=NJL,,,Y'XU+6+W+6P4444AA1110 4444 %%%%
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M8M['Y6SN&2<\Y/>M66%K:4%EW+G(]_:J&D>*+76+R*"'0=5A23</M$]F%B7
M)Y8$^F/K5N21*1+##';P1P1+MCC4(BYS@ 8%:VG_ /'NW^]_05/Y$7_/)/\
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M,C)!(/# 'J"*N?)8B//<E.MV8[N?^ TTZ[:YP$E/_ 1_C6@(HQTC4?\  :<
M , 8J+Q[%VEW,S^VD/W;:8_A1_:TA^[8S'TZ_P"%:E%%X]@L^YE_VE>'[NFR
M#ZY_PH^VZB?NV.,],FM2BCF78+/N9?VC5C]VTC'U/_UZ-^L'_EG"OX]/UK4H
MHYO(.7S,O;K!_CA6C[/JYZW<0'L/_K5J44<_D'*9?V/4CUO@/H*/[-O#][49
M!],_XUJ44<[#E1E_V3,?O7\Q]>O^-']BJ?O74Q_&M2BCGD'(C+_L*VZM),3W
MY'^%/&B6@_YZ'_@5:-%+GEW#ECV* T>R'_+,GZL:>-*LA_RP'XL?\:N44<TN
MX^5=BJ-.LQ_R[I^(IXLK4?\ +M%^*"IZ*7,PLB,6\ Z0QC_@(IPC0=$4?04Z
MBE<84444 %%%% !1110 5SDGA"*75AJ$FLZR^V?SQ;M= PCYL[=NW[O;'I71
MT4 '08%%%% !1110 5%<_P#'K-_N'^52U%<_\>LW^X?Y4 <]1110!NZ?_P >
M,?X_S-97C2;58/!^I2Z*76^6,%&C3>ZKN&]E7NP7<0/4"M73_P#CQC_'^9KG
MOB1!+=?#[5H8;6ZNY'C4"WM49Y)AO7* +S@C@D= 2>U '$1Z3X/=58?&?7>0
M" ?$\0/Y$9%>P+]T8.>.OK7C\6K^$1&@;X+ZXK #/_%,Q'!^I.3]:]@7[HP,
M<=/2@!:*** ,_5M5CTNV:1E+L%+;1Z"OG+[%(UA-?*,0)*(AN/.3D_IC]:]S
M\5ZE8V-[91W$^R:=6"K@G@=SZ#G%9%G>Z+<:K:Z=/]FE%U(< QAE+@9Y/3)Q
MBN>&,J4:[ARWO:WIU'.E3G"[E:WY]#,71+'6_!EJIFN([PZ;Y$;1W<T*<KQN
M", PSUR#706R7]AI,5IIT-M.(;4+')<W<F6E'&&)1CMZG.<]L=ZZB/3[6!%2
M*UA55& %C' K,U+2'9Q=Z>WDW2<[5X5_PZ9_GWJ_:U7-WLOD_P#,.2"CI=F3
MH,&M6T4POK:SB<_O/,M[AYWFE/5F+1H%'  &#Q@<  5HLNJR_>\['INQ3-.\
M6Z?<ZM'HES)Y.L,A?[/L;D#J<XP.AX)S]:O:MKVGZ*$^VO/N=68);VLL[;5Q
MN8K&K$*,C)(QR*B<JU[7MZ+_ #N5%0M>URB-.O&;+0 _[[_X&K$>E7G&%MD_
MWAN_F#6G:W,%[:0W5M*LMO,@DCD0Y#*1D$?A5M?NCZ4HQG+XIO[QMQ6T492Z
M;?8Q]M"#_87'^%._LB1O];?3/_GZUJ457U:F][OYL/:RZ&8-"M<Y9Y6/NP_P
MJ1='L5ZQ%OJQJ_136&I+[*!U9OJ5ETZS7I;Q_B,U*MO"GW88U^B@5)16BA%;
M(AR;W844450CS^[;Q5/>12Q>$5BB^;SH_P"T8B7)'&#_  X/7@Y]JZO19W\I
MK2=#'+%SM)&0#VX]#6K63JD;6UQ%J$0Y4XD'J/\ /%<E2G&D_:P6V_H;1DYK
MDE\C0;[Q^M<5K.OZDWB338]-N!%ID>HI973>6K?:)&#%D!(. @ R1CYCC/RD
M5V:NLBAU.589!KG=2\!^&-4NXKN?1;!;A+D7+RI:Q!IFYR')4E@2<GU(%4FK
MW)+WB!Y8],\R.^O;-5<&22QL_M,Q'3"IL?OC)VG@'IU$/A'4+K4_"UC=WLB2
M7+JPD92N20Q'S!> ^ -P'1LCC&*?)H,A@D2#7-5MY'NFN1*DJ.R;ACRP'1E\
ML=E(..N:LZ/I-OHFFI96[RR*&>1Y)6R\CLQ9F8@ 9+$G@ >@ I= -./[OXT^
MF1_=_&GUT0^$A[A1115""BBB@ HHHH *RM9\.:3X@\C^U+3[1Y&[R_WCKMW8
MS]TCT%:M% &!IO@KP]I%_%?6.G^5<Q9V/YTC8R"#P6(Z$UOT44 %%%% !111
M0 4444 %%%% !1110 4444 %<7?Z/XLEU&:2U&@K;&1C&KF;<5SQNQWQUQQ7
M:44TVMA-)[E/2H[V+3(4U%;5;I00XM=WE]3C&[GIC.>^:N444AA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M",0LB'*\D9)&2#C(!J'P+IFJ:/X1LK'5S#]JB##9$FW8,D@$[V#'OD$=>G%
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M_P#IYN/^_E,19HJM]C_Z>;C_ +^4?8_^GFX_[^4 6:*K?8_^GFX_[^4?8_\
MIYN/^_E %FBJWV/_ *>;C_OY1]C_ .GFX_[^4 6:*K?8_P#IYN/^_E'V/_IY
MN/\ OY0!9HJM]C_Z>;C_ +^4?8_^GFX_[^4 6:*K?8_^GFX_[^4?8_\ IYN/
M^_E %FBJWV/_ *>;C_OY1]C_ .GFX_[^4 6:*K?8_P#IYN/^_E'V/_IYN/\
MOY0!9HJM]C_Z>;C_ +^4?8_^GFX_[^4 6:*K?8_^GFX_[^4?8_\ IYN/^_E
M%FBJWV/_ *>;C_OY7*>,[;9]B_?S-GS/O/G^[5TX<\N4F4N57.THKQ]U2,H'
MN&4NVU07QN/7 ]^#0519%C-PP=@2JE^2!UP/Q'YUT?5?,R]OY'L%%>/[4,IB
M%PWF!0Q3?R >AQZ<&KNF09U:S'FRC,Z=&_VA2>&LKW!5M=CU.BJWV/\ Z>;C
M_OY1]C_Z>;C_ +^5RFY9HJM]C_Z>;C_OY1]C_P"GFX_[^4 6:*K?8_\ IYN/
M^_E'V/\ Z>;C_OY0!9HJM]C_ .GFX_[^4?8_^GFX_P"_E %FBJWV/_IYN/\
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M_IYN/^_E'V/_ *>;C_OY0!9HJM]C_P"GFX_[^4?8_P#IYN/^_E %FBJWV/\
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M%NW%=!I__'C'^/\ ,U6U_6K?P[HESJUW'-);VP#.L*@M@D#/) P,Y))X )H
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M1110 4444 %%%% !1110 4444 %9/B;_ )%ZZ_X!_P"ABM:LGQ-_R+UU_P
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MO3[IYS_M9[[UZ#:TR.\BL42^D$EP"=S!@>_'11V[<_4]3;HH4; W<]#\,_\
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MF]Q-*<[^0,D$CYL< \<@=#D<5Z52OR[(XHT[[G<Z79APMR_*]4'K[UTVD_\
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M\B]:_P# _P#T,UK5D^&?^1>M?^!_^AFM:O.J?&SLA\*"BBBH*"BBB@ HHHH
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M_K-09?\ <!_^M1[:3V@_P0>S762-6HVGA3[\J+]6 K._L1'_ -;=3/\ C_\
MKJ1=%LEZJ[?5O\*.>L]HI?,.6FNOX$[:E9IUN$_ Y_E4#:U9+T=V^B_XU.NF
MV:=+=/QY_G4RP0I]R)%^B@46KOJE]X7I^9G?VVC_ .JM9G_#_P#71_:%^_\
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M'H/RI:*YK(] 3:/0?E4=P +6; _@/\JEJ*Y_X]9O]P_RIV0'/4444 ;NG_\
M'C'^/\S6-XYO;K3_  =?W%G<&VF_=Q_:%QF%7D56<9[JK$_A6SI__'C'^/\
M,UCZW;^);N#5K>RAT&:WEAC2SCOUD97)/[T3 <%=O3'XT >4ZYIZ^&-1UJ*Y
M\>^)&N+&.WN;"SO-9<?;D;[R87:S$E67Y"",BO=E^Z."..AKS.?1OB5=W%I<
M76F_#N::T.;:22"Y9H>GW"1\O0=/05Z8,X&<9[XH 6BLKQ#;-<Z9@0ZG<;'#
M&#3;H6\LG;&\NF ,Y.&&<=^AI^"+F>Z\(V;75RUQ<QF2&5G+,R,CLI1F8 LR
MXVEOXB,\YS0!T-9^B?\ ('@_X%_Z$:T*R-(N?+TN%?(F;&[E4R/O&@#7HJM]
ML_Z=KC_OW1]L_P"G:X_[]T 6:*K?;/\ IVN/^_='VS_IVN/^_= %FBJWVS_I
MVN/^_='VS_IVN/\ OW0!9HJM]L_Z=KC_ +]T?;/^G:X_[]T <AXR_P"0O%_U
MP'_H35Q=UHRWEV))KV[: 2K+]EW+Y>Y<8_AW8R <;L9[5ZK>6EAJ$PENM/N)
M'"[0<,./P/O5;^QM(_Z!=Q^;_P#Q5:*2M8Y)T)N3DF>7WV@)?VKV\FHWRH]Q
MYYPZM_P##*1L']TBM"T@DMH?+ENYKILY\R8(&^GR*H_2O0/[&TC_ *!=Q^;_
M /Q5']C:1_T"[C\W_P#BJ?.B'AJC5KHM>&?^1>M?^!_^AFF>*-&TW6M#N(M3
MBW1Q(TBR+]^,@9RI_P YJU;/#9VZV]O9W"1)G:NTG&3GN?>I'N5DC9'M;AE8
M$$&/J*A2<9<R.M0]SE9\P&ZE+QLQ5C'P"R*<_P"]Q\WXYKHO#>OZYX<\_5["
MSDDL7.RYW1'R-^>/NX"D9'Y^]5M3TO0_[81=-UC.GRLQ+RP/N@'8$8^;T&/Q
MQ7LOA>UT9/!T-C8PSWNGS*X>1X<><22&)!Z<@C\*]7$8G#N*<5=GG4\)4YK[
M6ZF!93_$7Q+917EM>Z986LR[E:/#9'Y.0?Q!JQ_PK?4]0YUOQ9?W*GK%'D*/
MIDD?I6797ES\-=>-K<+<2>&[U\Q.Z\PM_CZ^HYZ@BO3(]026-9(X9W1P&5E3
M((/0BN*6(G'X$DO)'114:B:G?F6ZO_6AR]E\+O"UI@O:S73#O/,?Y+@?I716
M6@Z1IV/L>F6D!'1HX5#?GC-6/MG_ $[7'_?NC[9_T[7'_?NL95JD_BDV=,:<
M([(LUSVMV]U!(TMC>&R>?"F<1"38<@D[3P<@?SK8^V?].UQ_W[JK?W,4EE(L
ML$ZJ1P2G0]JY<1&\+K=:F]-VE;N<5#:O::C>7L?Q)TU+J[*"X8V\'S;!A>"^
M!@>F*]&<X'UKA-+T;2H]5O+FYTVVN_M6PE98481E002N1WSD^IKLC.3SY4IS
MZ+40Q$:L;Q'*FX/4KZK>2V&F374%O]HDC *Q8<[N0/X$=OR4_AUKDX_&FJOX
M*DUDZ0HN4Z1E9L$;-V_A"N,_[>S'613D#M/-_P"F<G_?-'F_],Y/^^:0CD=0
M\8:I:>'[+4$T8F:>78\16;*#>%'6-5R0>[ 9^Z9.,]3I]S)>:=;W,L/DR2QA
MVCPXVDCI\ZJWYJ#["I?-_P"F<G_?-'F_],Y/^^: +!C21 '16'7##-</X]\*
M:'J=K;F2^L=)O%+>3)*RQK*.,@CC...>V?>NQ^UXX^SW!QW"55O(+#4=GV[2
M!=>7G9Y]LK[<]<9Z=!^5=E.I*FU*+,9PC-6D>7_#7PQI4MY::I>ZI9RW66,&
MGB1=X89&64G/09 QZ&O8P   !@#H!6/;:?I%G<+<6N@Q03)G;)%9HK#(P<$#
M/0UH?;/^G:X_[]U=6M.K+FFQ4Z<::M$LT56^V?\ 3M<?]^Z/MG_3M<?]^ZR+
M+-%5OMG_ $[7'_?NC[9_T[7'_?N@"S15;[9_T[7'_?NC[9_T[7'_ '[H LT5
M6^V?].UQ_P!^Z/MG_3M<?]^Z +-%5OMG_3M<?]^Z/MG_ $[7'_?N@"S15;[9
M_P!.UQ_W[H^V?].UQ_W[H LT56^V?].UQ_W[H^V?].UQ_P!^Z +-%5OMG_3M
M<?\ ?NC[7_T[S?\ ?(_QI-I;@6:*K?:_^F$WY#_&C[7_ -,)OR'^-',NX[,L
MT56^U_\ 3";\A_C1]L_Z=KC_ +]T)I["+-%5OMG_ $[7'_?NC[9_T[7'_?NF
M!9HJM]L_Z=KC_OW2&] &3;W '^Y0!:HK.;6K5#@B3/I@?XU&=<C?B"WFD;TQ
M_P#KK*5>E'>1:IS>R-6BL5[[5)/]7:&,>I0DU%Y5[-_Q\2W7NJ1\?TJ/;M_!
M%O\ #\Q^S2^)HO:GJ7V-52,!I6]>@%9'AZ2+1]+CL$ 6UBW>62<MR2Q^O)-,
MU1+'3[59I97M@6V[[I@BL>N 3WX-4=!U;2M0NH6BNXYF;)2!2/,8C/\  >>Q
M/2N2;Q3K:*R_ WBJ*@=(FJ0RN5C5V(&<XXJ7[3*WW8&_&I?M(8;1;S+]4P*K
MWM^;.T>=;*[N67 6&! 7<DX &2!WZD@#J2!6SIS3LY?@9<T7LAV^[;I&J_6C
M9=-UD5?I531]=BUBWFD2TNK>6"9H)X)U7?$XQP=K,IX(.03P:CM?$EM=Z]<:
M0EG?)-!%YIDE@V(XW%?ER<GD=<8/8FE[/NV'-Y%\VDL@*M<,,\<4P:' 3F26
M9S[D59\['/E2''8+3OMG_3M<?]^ZTA0IR^)7$ZDELR)='LE_Y9%OJQJ9;&U3
M[MO%^*@TGVS_ *=KC_OW1]L_Z=KC_OW6RHTX[11#G)[LL*BJ,*H'T%+5;[9_
MT[7'_?NC[9_T[7'_ '[K0DLT56^V?].UQ_W[H^V?].UQ_P!^Z *7B;_D7KK_
M (!_Z&*\\KNO$EWNT"Z'V><?<Y*?[0KR_69=--DIU2U,T(<;(73<)'Z!0G\1
M]!SZ]JUAL<.)5ZB))= TR:5Y9+;+NQ9CYC<D]>]7;:VBM+=8($V1KG"Y)QDY
M[UD:&HTW2K:PNE\N:0R-';D@[5+%MB\\A00./3TJA8Z=IC>*7GL=+MX(M.0Q
MEH+=4)F<<@D#^%"/^^O:JN<_*M3U[P__ ,L_^N _I6/XF>XO/$%A#;1ZM/-;
M7T#"SDLS]B9006F,RH.55F(!DQN4?(3C-_PY?0R2K&@D9U@Y41GCI71^?_TQ
MF_[]FN*2:EL>K1:<$8>IZP9-.G_=Z[IX2[-L9[6P\Z4;>=ZILDS&W0-M/7MU
MH\$03VWA.UAN+5[8JTFQ9%99&3S&*NX8DAV&&8'N3P.@W//_ .F,W_?LT>?_
M -,9O^_9J+.VQK=%F/O3ZJ+<[/\ EA.<^D=.^V?].UQ_W[K>'PD/<LT56^V?
M].UQ_P!^Z/MG_3M<?]^ZH19HJM]L_P"G:X_[]T?;/^G:X_[]T 6:*K?;/^G:
MX_[]T?;/^G:X_P"_= %FBJWVS_IVN/\ OW1]L_Z=KC_OW0!9HJM]L_Z=KC_O
MW1]L_P"G:X_[]T 6:*K?;/\ IVN/^_='VS_IVN/^_= %FBJWVS_IVN/^_='V
MS_IVN/\ OW0!9HJM]L_Z=KC_ +]T?;/^G:X_[]T 6:*K?;/^G:X_[]T?;/\
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M-+J5XKN-3\T<BNQ!!!;!X(.#7J"G<H;U&:X$?!/X> Y'A[_R=N/_ (Y7?
M =!P* *6IZ3::O#'%=B<>4_F(]O<20.K8(X>-E8<$CKWJ33=-M-(L(K&QA$-
MO'G:N2QR3DDDY))))))))))JU10 5GZ)_P @>#_@7_H1K0K/T3_D#P?\"_\
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M+:W@L[A;BUAC@F3.V2)0K#(P<$<]#6-+)?VWB&RA74'N!<-(TUL8T"11 '#
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M  L^=QB#PKJDC#J-IZ?@IH]G+L+ZY0_F_,]#HKSW_A8>O2']QX$U-E;[K,7
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ML(5P">6#GTQ]:T;2.2-.<FUU1SMM;0V=K%;6Z!(8D"(H/0#@5ZGI?_((LO\
MK@G_ *"*J?\ ",Z1_P ^G_D5_P#&M.*)((4BC&U$4*HST Z5$I)G31I2@VV/
MHI"0 22 !R2:S;KQ%HMEG[3JUC$1_"TZ@_EG-19LW<E'=FG17)77Q*\*6V1_
M:?FL.T43M^N,?K66_P 6M,F8IIVDZE>..PC !_(D_I5J$NQC+%45]I'H-%>>
M?\)IXPOO^0?X,FB!^ZURS '\PM&?BA?]M+TW/^ZV/_0Z.1]63]:B_ABW\O\
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M 'I4X_)*L)\)_"Z;=T5T^.NZ<\_EBNXHH]I+N-82@OLHY!/AAX23.[3&?/\
M>N)./R8593X>^%(]NW1H3CIN=V_F:Z:BESR[E+#T5M%?<C!3P5X9C&!HED?]
MZ,'^=64\,Z!&04T/35([BT3/\JU:*7,^Y:I06T44DT?3(QA-.M%'7"P*/Z59
M2"*-MR1(IZ950*DHI7*44M@HHHH&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !45S_QZS?[A_E4M17/_ !ZS?[A_E0!SU%%% &[I
M_P#QXQ_C_,UE^,I],MO"6H2:S?/9:<4"3SI"LI568+C8R.#G..5/7\:U-/\
M^/&/\?YFH=:N]0L=(GN=*TS^T[U,>7:>>L/F9(!^=N!@9//I0!X3+=_#.[@2
MUE^*?C.:$,NV)YYV4%2"N 8,9! (],"O9/#'A;_A&_M)&OZ[JOV@+_R%;SS_
M "\9^YP,9SS]!7(ZU=>/?%FER:+/X#BTM+EDQ?RZQ#,+4A@PD"*-Q(QD8[XK
MTX A0"<D#K0 M%%% !6?HG_('@_X%_Z$:T*S]$_Y \'_  +_ -"- &A1110
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M%="XQQ$EK)+Y:_F>?_\ ";>+;[_D'>#)XP>C7+, ?S"_SH_XNAJ'_0+TS/\
MNMC_ -#KT.BCG71%?5Y/XIO\OR///^$)\6WW_(1\:3Q@]5ME8 _D5_E3X_A+
MI#OYE_J.HWDG<M( #^A/ZUZ!11[20?5*/57]6V<O:_#KPK:8*Z3'(P[S.SY_
M G'Z5MVNCZ98X^R:=:08Z>5"J_R%7:*ER;W9K&E3C\,4@HHHI&@4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT&20*9HNL6^NZ8E];QRQ*7>-XIE >-T8JRL 2,A@1P2/0F@#0K/T3_D#P?\
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M]_*/L?\ T\W'_?RK-% %;['_ -/-Q_W\H^Q_]/-Q_P!_*LT4 5OL?_3S<?\
M?RC['_T\W'_?RK-% %;['_T\W'_?RC['_P!/-Q_W\JS10!6^Q_\ 3S<?]_*/
ML?\ T\W'_?RK-% %;['_ -/-Q_W\H^Q_]/-Q_P!_*LT4 5OL?_3S<?\ ?RC[
M'_T\W'_?RK-% %;['_T\W'_?RC['_P!/-Q_W\JS10!6^Q_\ 3S<?]_*/L?\
MT\W'_?RK-% %;['_ -/-Q_W\H^Q_]/-Q_P!_*LT4 5OL?_3S<?\ ?RC['_T\
MW'_?RK-% %;['_T\W'_?RC['_P!/-Q_W\JS10!6^Q_\ 3S<?]_*P_$OA:XU^
MUCMH]6:"$$F1)K=9PYXP1DC:1ST]:Z6B@32:LSAO#7P^G\.7ZSQZWOB((E1;
M14=Q@X&_<2 #@X]J[#['_P!/-Q_W\JS11>X1BHJT58K?8_\ IYN/^_E'V/\
MZ>;C_OY5FB@96^Q_]/-Q_P!_*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W
M'_?RK-% %;['_P!/-Q_W\H^Q_P#3S<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_
M '\JS10!6^Q_]/-Q_P!_*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?R
MK-% %;['_P!/-Q_W\H^Q_P#3S<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\J
MS10!6^Q_]/-Q_P!_*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-%
M%;['_P!/-Q_W\H^Q_P#3S<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!
M6^Q_]/-Q_P!_*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['
M_P!/-Q_W\H^Q_P#3S<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_
M]/-Q_P!_*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['_P!/
M-Q_W\H^Q_P#3S<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_]/-Q
M_P!_*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['_P!/-Q_W
M\H^Q_P#3S<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_]/-Q_P!_
M*/L?_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['_P!/-Q_W\H^Q
M_P#3S<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_]/-Q_P!_*/L?
M_3S<?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['_P!/-Q_W\H^Q_P#3
MS<?]_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_]/-Q_P!_*/L?_3S<
M?]_*LT4 5OL?_3S<?]_*/L?_ $\W'_?RK-% %;['_P!/-Q_W\H^Q_P#3S<?]
M_*LT4 5OL?\ T\W'_?RC['_T\W'_ '\JS10!6^Q_]/-Q_P!_*=';>7(&\^9L
M=F?(J>B@ HHHH **** "HKG_ (]9O]P_RJ6HKG_CUF_W#_*@#GJ*** -W3_^
M/&/\?YFN"\?^#O%.M:S;ZIH7B&_@M8H=DVF6VH/9F4C<0RR ,NXD@?,N..OI
MWNG_ /'C'^/\S7 ?$+QAXLT?6;?2]!T&_EM)8"\^IVNG/>M$3D (@*IN& ?F
M8CGIZ@',P6&EV]S'9^(O&?Q#\.WC':JZGJH6"1@H9MDZJ8V SC[P/M7MJ_=&
M#GCKZUX=;W6E7-W%>^)/!OQ$\1WR'<K:EI>8(V*@-L@5A&JG&<$'H.>*]Q7[
MHP,<=/2@!:*** "L_1/^0/!_P+_T(UH5GZ)_R!X/^!?^A&@#0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKG_ (]9O]P_
MRJ6HKG_CUF_W#_*@#GJ*** -W3_^/&/\?YFK-5M/_P"/&/\ '^9JS0 4444
M%%%% !6?HG_('@_X%_Z$:T*S]$_Y \'_  +_ -"- &A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?X_S-6:K:?\ \>,?X_S-6: "BBB@ HHHH *S]$_Y \'_  +_ -"-:%9^B?\
M('@_X%_Z$: -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3[HGN))F ]-SL3CVS@4 7*QK"ZDL;)+:6QO"\9()2+(ZGH<ULT4 9_\ :O\
MTX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^
M?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?
MG_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O
M6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1
M_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\
M:O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]
M_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX
M7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G
M_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_
M .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44
M9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_
M].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_V
MK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7
MW_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W
M_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KU
MH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]
M']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10
M!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_
M $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\
MTX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^
M?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?
MG_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O
M6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1
M_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\
M:O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]
M_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX
M7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G
M_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_
M .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44
M9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_
M].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_V
MK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W_?G_ .O1_:O_ $X7
MW_?G_P"O6A10!G_VK_TX7W_?G_Z]']J_].%]_P!^?_KUH44 9_\ :O\ TX7W
M_?G_ .O1_:O_ $X7W_?G_P"O6A10!G_VK_TX7W_?G_Z]20:AY\RQ_9+N//\
M%)%A1^.:N44 %%%% !1110 5%<_\>LW^X?Y5+45S_P >LW^X?Y4 <]1110!N
MZ?\ \>,?X_S-6:K:?_QXQ_C_ #-6: "BBB@ HHHH ***PO%FH3Z;H\<T%U]E
M+7,,;S84[$9P&/S @<=R* -VBN:T357GU?4+>+4_[4L((4D^T@(S*YSE 8P
MW SP,UHV^MI+J$5E/975G+,C/#YX3$H7&<;6)! (.#@T :E%9FGZTFI.C0V=
MV+67=Y5TRKY<F/HQ89P<;@/U%01^);62:+%M="TFF\B*]*KY3OTP/FW8)& 2
MN">_(H VJ*XZVO\ FY^V7=]@:]Y,/DR?3"-G_EGZ@5J3^*+>%K[;8WTR6#E;
MJ2.-=L8 !W<L-PP>BY(QR!QD W:*S+K6H89H(+>WN+V>:/SEBMPN1'_>)9E
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M]%/AB.XTUD6P\M$%\RN#OQ"6BR@S_%OP_0#D@'I%%%% !1110 4444 %%%%
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M>S0S7('SR0Q&)&/LI9B/^^C4]%% !1110 4444 %%%% !1110 4444 %%%%
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MFJVG_P#'C'^/\S5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** *>HZE!I=N)[B.Z="VT"VM);A
ML_[L:L<<=<8K)L/&^B:G<&"S&IRNLWD.?[(NPL<G&5=C%A2,C.XC'>NBKC?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%<_\
M'K-_N'^52U%<_P#'K-_N'^5 '/4444 ;NG_\>,?X_P S5FJVG_\ 'C'^/\S5
MF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ>@"@*!7=44 5[&SBT[3[:R@&(;>)8HQZ*H '\JL444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45
MS_QZS?[A_E4M17/_ !ZS?[A_E0!SU%%% &[I_P#QXQ_C_,U9JMI__'C'^/\
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M=6BHK>7/ 7V!L%LY5@0W/]T]ZZ:W\66-S%9-%!=&6[O);)8-B[XY(R^_=S@
M;#SD]1ZU)H;U%<JGQ TB2&1TBO&>%/\ 2(EC!>"7S/+6%@#_ *QGR !D<$Y
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MOH **** "BJ.K:QI^AV1O-2N5MX-P7<03DGH  "36#_PLSPA_P!!?_R6E_\
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M)J6L:E9I9Q1V=H88QC<J94NY.#(2S%L #H,&NVHH @L[=;.QM[93E88UC'T
MQ4]%% !1110!FS^'M$NIWGN-'T^:9SEY)+9&9C[DCFH_^$6\/?\ 0!TO_P
MX_\ "M:BG=D>SAV.#UCX8VMYJ#76E7W]EK(!YD$=NKQY'&5&1MK9TKP/H&FZ
M?':OIMK>2+DO/=0([N3U))'Z5T=%%];D*A33O8R?^$6\/?\ 0!TO_P  X_\
M"KEEIMAIJNMA96UJKG+"")4#'WP.:M4479HH13ND<5JGP]CU+PO8Z4NHM!=6
M3L8[Q8024<G>A7/W6!QUZA3VI^EZ).OQ&US4_P!\EFD2"V66/$?GR*OFNG]X
M;8XAD'KN'7-=E12*.)/P_<QS,-:E^U7*I-<RM"&$EXD@DCG"DX7:1MV<Y0*N
M1M!JS>^#[O5K+4QJ>JPR7U]#';B:WM#'%%&CEP!&78DDDY);TX&.>MHH I+I
MD*ZU)JH:3SWMUMRN1MVJQ8'IG.6/>L'_ (1?5U@U6Q36+$:;J+W#M&=/<S)Y
MN[H_G8."?[G./QKJZ* .8T_PQ?B?2WUC58+R+2P#:0VMF8%W["F^3=(Y8A2<
M8V@9)P>,6?#?A+2_#=NOV>SL_MQ#":]CMECDE!8M\Q')[=2>E;U% '*:SHL]
MWXGG*AUM]4T>6PDF6/<(75B4)^HD?T^[C/(J^_AQ);^UN)+J39#I[V++$6B9
M@Q0[@ZL&4_)VYYZ\5N44 <Y+X'T:;9YLFL2&-Q(A?6KQBC $ @F7@X)Y'K5;
M3/"%YX?M;M-%UEDFN+U[EFOEENTV-GY"K2@Y&<[PP)(&<UUE% '%WOA^?3?!
M]KH%MYEY+>:@AGF2+:BAYO.E? R$4 , ,]U&23SVE%% !1110!!=V5K?P&"\
MMH;B$G)CFC#KGZ&J'_"+>'O^@#I?_@''_A6M15*<ELQ.*>Z.=U3P/X>U/3IK
M0:7:6K./EFMH$1T/8@@?I7.Z%\)=.TO4EN[Z\_M%$R4@> *A/^T"3N_2O1**
MTCB*L8N*EHR'1IMW:,G_ (1;P]_T =+_ / ./_"E7PQH",&70],5E.01:1@@
M_E6K14>TGW*Y(]C*N-#AN]:FOKAEE@FL3926SID,I8DDG/0@XQBN&U/P%=:?
MX:M=(M=0O+N>?5QMN5A^>*VD3RY%<\\"$$;SC+;>AKTZBH*.:USPF^LW,<PU
M)[4V<:_V<L4?%M,&R93S\_ "[>/E+C^+B!/!]VN^Q.JQ?V(][]M-J+3$NXR>
M:4\W?C89,G&S.#C=WKK** ,O1M'_ +).I'S_ #?MM[)=_<V[-P4;>ISC'7CZ
M5A>%?#\]K:Z0+@O"^B_:K-8VCXF1G 1P<]-JJ>_7VKL:* .=MO"%JFGQVMS>
M7[&.:>56M;V>T!\R1GP1%(-V-V,G/3MFH-9\*WNHZ9+HUMK BTBX@\B>*ZA>
MZGP2=Q29Y,@D'&7#XP,>E=310!R=SX-DEO+J.+4ECTF]N8KN[M&M]\C2($X6
M3=A5;RTR"I/WL$9XNVD-Q/XYU*]D@DCMK>SAM89'4@2L2TCE?4 %!GUR.QK?
MHH **** "FO&DJ[9$5U]&&13J*&K@0?8K7_GVA_[]BHYM.M9HF3R43/1D4 B
MK=%0Z<&K-%*<EU,JVT.*&8/))YH'12N!^-7OL5K_ ,^T/_?L5/14PH4X*T4.
M524G=L@%G:@Y%M""/]@5EZWX8L/$%_ITVI06UU;V9D)MKFW65)"R@ _-P,8]
M#6W16BBELB6V]SF_$'A&/6H[**WO&TZ.T@G@C%M'@J)(O+&W!&W;UZ>W%8UG
M\-UM8M0,=W8VEQ<BV>+^S=-%M%#+ [.C[-YW9)&X$\@'D9&.]HIB./U?P7/K
MHM+K4[K2KW4+8R!?M>E"6UV/MR!"9-P/R AMY.2W8X"0>#M2T^>.YTC4]+TZ
M86GV5X;?2-ML1O=]RQB4%6RP_B(ZY!R,=C10!R</@ZYT=[=O#NIQ66VQCL9A
M=6GVCS%C)*.,.FUQN?U!W=.*Z#2M-@T?2;73;<NT-M$L2LYRS #J3ZGK5RB@
M"EI.FPZ/I5MIUNTC0VZ;$:0@L1[X K!_X1?5U@U6Q36+$:;J+W#M&=/<S)YN
M[H_G8."?[G./QKJZ* .8T_PQ?B?2WUC58+R+2P#:0VMF8%W["F^3=(Y8A2<8
MV@9)P>,6?#?A+2_#=NOV>SL_MQ#":]CMECDE!8M\Q')[=2>E;U% '*-HL\NM
M^*;,AX[;6;2-TN/+W*K^687'U 5#CC.?K5]_#B2W]K<274FR'3WL66(M$S!B
MAW!U8,I^3MSSUXK<HH PE\-_8897T?4;Z"\8 +)?7EQ>Q@!@2#')+CD#&00>
M>#6>?">I#1-8M8]7M!?:Q,\EW.;!C$ T8CQ'&)05.%7DLW.?7CK:* .0U73-
M4C\(V&AR.E_/+<V]NTUM;-$B0JZLS,"SXPB'G/)('&:Z^BB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "HKG_ (]9O]P_RJ6HKG_CUF_W#_*@
M#GJ*** -W3_^/&/\?YFK-8*7D\*^6DF%7H,"E_M"Z_YZ_P#CH_PH W:*PO[0
MNO\ GK_XZ/\ "C^T+K_GK_XZ/\* -VBL+^T+K_GK_P".C_"C^T+K_GK_ ..C
M_"@#=HK"_M"Z_P">O_CH_P */[0NO^>O_CH_PH W:*PO[0NO^>O_ (Z/\*/[
M0NO^>O\ XZ/\* -VBL+^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#=HK"_M"Z_Y
MZ_\ CH_PH_M"Z_YZ_P#CH_PH W:*PO[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\*
M-VBL+^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#=HK"_M"Z_P">O_CH_P */[0N
MO^>O_CH_PH W:*PO[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -VBL+^T+K_ )Z_
M^.C_  H_M"Z_YZ_^.C_"@#=HK"_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W:*
MPO[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -VBL+^T+K_GK_P".C_"C^T+K_GK_
M ..C_"@#=HK"_M"Z_P">O_CH_P */[0NO^>O_CH_PH W:*PO[0NO^>O_ (Z/
M\*/[0NO^>O\ XZ/\* -VBL+^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#=HK"_M
M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W:*PO[0NO\ GK_XZ/\ "C^T+K_GK_XZ
M/\* -VBL+^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#=HK"_M"Z_P">O_CH_P *
M/[0NO^>O_CH_PH W:*PO[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -VBL+^T+K_
M )Z_^.C_  H_M"Z_YZ_^.C_"@#=HK"_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH
M W:*PO[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -VBL+^T+K_GK_P".C_"C^T+K
M_GK_ ..C_"@#=HK"_M"Z_P">O_CH_P */[0NO^>O_CH_PH W:*PO[0NO^>O_
M (Z/\*/[0NO^>O\ XZ/\* -VBL+^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#=H
MK"_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W:*PO[0NO\ GK_XZ/\ "C^T+K_G
MK_XZ/\* -VBL+^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#=HK"_M"Z_P">O_CH
M_P */[0NO^>O_CH_PH W:*PO[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -VBL+^
MT+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#=HK"_M"Z_YZ_\ CH_PH_M"Z_YZ_P#C
MH_PH W:*PO[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -VBL+^T+K_GK_P".C_"C
M^T+K_GK_ ..C_"@#=HK"_M"Z_P">O_CH_P */[0NO^>O_CH_PH W:*PO[0NO
M^>O_ (Z/\*/[0NO^>O\ XZ/\* -VBL+^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"
M@#=HK"_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W:*PO[0NO\ GK_XZ/\ "C^T
M+K_GK_XZ/\* -VBL+^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#=HK"_M"Z_P">
MO_CH_P */[0NO^>O_CH_PH W:*PO[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -V
MBL+^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#=HK"_M"Z_YZ_\ CH_PH_M"Z_YZ
M_P#CH_PH W:*PO[0NO\ GK_XZ/\ "C^T+K_GK_XZ/\* -VBL+^T+K_GK_P".
MC_"C^T+K_GK_ ..C_"@#=HK"_M"Z_P">O_CH_P */[0NO^>O_CH_PH W:*PO
M[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\* -VBL+^T+K_ )Z_^.C_  H_M"Z_YZ_^
M.C_"@#=HK"_M"Z_YZ_\ CH_PH_M"Z_YZ_P#CH_PH W:*PO[0NO\ GK_XZ/\
M"C^T+K_GK_XZ/\* -VBL+^T+K_GK_P".C_"C^T+K_GK_ ..C_"@#=HK"_M"Z
M_P">O_CH_P */[0NO^>O_CH_PH W:*PO[0NO^>O_ (Z/\*/[0NO^>O\ XZ/\
M* -VBL+^T+K_ )Z_^.C_  H_M"Z_YZ_^.C_"@#=J*Y_X]9O]P_RK'_M"Z_YZ
;_P#CH_PI&OKEU*M)D$8(VB@"O13]@]Z* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image8.jpg
<TEXT>
begin 644 image8.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '& A0# 2(  A$! Q$!_\0
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M_#O4C>%=1\RZCFGLTL9M4_M!Y!(P=%4YVXQC)P.<\>]"M?\ KR_X(=/Z\_\
M@&Q9>)+?["9KVZA=S<RPHMI#*Q.TGC;@L2!U(&/PJT?$6D_N,78<3QB5#&C,
M A.-S$#Y1GC+8KC-%\/SZE90:G;$-Y=]=.B&YD@$L;G&1)'R.GH016]IWAZ\
MTC45N=.ALX8Y;=8)87GDD$)#$[E8KE\Y/!V\]Z%TO_6@/K;^M2:P\8V-TMZU
MQ%/;+;71MUS#(QD.0!@;/O'/W.36K+J]C!9P74L^V&>18D8HWWF. ",9'/'.
M,=ZP6\-7?E:I;-!97-O=7IO(_,G>-@2!QE5^0@C(8$^F!5R70KVY\&?V3<W@
MGOQ'\MPY)_> [E)/7@@<]>*%M]W_  0ZEP^(=*'F_P"E@F*Y%HX",2)3T7&/
MUZ5C:=XR$UQIEK/&MQ)>"4M/:0S>6NUL  %,GW/;KT(J&Q\(7L&KV5W/-;M$
M&^T7:HS9>X_>89>.GS^W04ND>%=1THZ++OM99+)IUE7S& *R-G*G;R1Z$#ZT
M+?7^OZ8/;0N>'O%D6IJ(;UTBO'N)8HE2)PC!#TW'(W8YQG/M5^\\0VNG7[6]
M_#<6T/&R\>/]PQ/;>/NG/][%8UCX4OK:/35>6V)M=2ENWVLW*-G ''7G_P"O
M5Z_T6:;73J TZTOBH7RC=WS@18'.V/RV4'WR3]*%T_KH#W?]=2?_ (2$GQ1'
MHPL9E1XFD%RYVJVW'W1W'/7C\:=HNKWNK[YOL-O#:++)%O\ M+-(2C%<[=@'
M./[U5KO3M6F\5V>IQP67V>VB>+#7+AV#8R<>7@$8Z9Y]14<'AV=?$MMJ0@T^
MRC@$GF-9@AKHM_?&T 8Z]6Y[T+I<'U-*VUG[1XAO]*\C;]DBCD\W?G=NSQC'
M&,>M5Y_%>F)9W4UO(\[P0M,J")P)0O!*G;AAG@E<@=ZKOH^I1^)=2OX4M9;6
M^ACA;=<-&Z!002 $(/7U%4=,\'RVMF;2XBA9DM9;:*[%[,Y 88XA8;5SQG![
M4M;?U_78>E_Z\O\ @EJV\:07-WI,'V&Z7[?"9"WDR_NS@<#Y/G'/WAP.M:9\
M2:0)I8C=X,0<EO*?:=@RX5L88CN 2:R[70=3@ET"=EM#)IT+6TJ"=L,A51N4
M[.O&=I'XU1A\%SP6TUH8H)@!/]FN7OY@4,@8#]S@IGYL$@^_6G+R\_\ @"CY
MG31ZU:W.D3ZE9EIH8HV=249 ^!G@L.1[C-9UMXSTI["WGNY&MYI;9;EX51Y/
M+1NY*KTXZ]N]78-,FB\*)I1:/SUL_LY8$[=VS;GIG&?:N=@\':A'93PM-:[I
M-'6P!#-CS 3S]W[O/U]J'HW;^M_^ "U2O_6W_!-YO%>B)%-*]\%CA"%V:-P,
M.<*PX^92?XAD>]*WBG1HX6EDO"BI,L#!X7#!V&0"I7/(Z'&#7&^*]!O+'2'N
MW>%E6RM+/"DD[UE&3C'3]:UYO"NI7FI-J,\EHDTE_;3M$CL5$<0(X)498Y]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS-L\IO+&TIG:20Y.<$^]5%O=8TN=+"_:^9IY(6D"3B21B"0=AW817;: "5P
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M;?X5+10!%YZ?W9/^_;?X4>>G]V3_ +]M_A4M% $7GI_=D_[]M_A1YZ?W9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)HR\K7+S>8A!V9+<@CG(]ZZ2J9(4444AA7/V?_)0]9_[!5A_Z-NZZ"N?L_\
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M?\*[_P"HI_Y+_P#V5=GNG_YYQ_\ ?P_X4;I_^><?_?P_X4>RAV#ZM2['&?\
M"N_^HI_Y+_\ V5'_  KO_J*?^2__ -E79[I_^><?_?P_X4;I_P#GG'_W\/\
MA1[*'8/JU+L<9_PKO_J*?^2__P!E1_PKO_J*?^2__P!E79[I_P#GG'_W\/\
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M-95M/\,#3+T:H+N365GCE\R+?N<!BWFC>,@IMVC)YKT.I7PK^NB&_B84444
M%%%% !1110!P_P 1/^8;_P!M?_9*[BN'^(G_ ##?^VO_ +)7<5G'XY&%/^+/
MY!1116AN%%%% !1110 4444 %%%% &/K'BG2-"N[>TO[B5;FY1GAAAMI9G=5
MQN($:D\9'X<]C23>*M%BL[:Y6^2<7:![:*W!EEG'^PBY8_EQWQ7.^)3JB_$O
M0FTB&SFN!IEWE+N5HT*[XOXE5B#G';GD<=:M:3X!MM,TVT:*[EMM9AB*/J%I
M\I?<Y<J4;*LFYC@,#@="*%\*?];M ][?UT*>K^,-;CDUN?38+.&VT2TBN+JW
MO(F::0LI<H&23:A"CKAN:VO$.O7-G:Z1'IGV<7>JW26\+W"%T0%6<L5!4G"J
M>,CDBL35_".OW$NMQ6<^FR1:[:107EQ*7B>)U4HSH@5@V5/ +#!'4UJZWH>I
MWT6G-9162SZ1>1SV8FG;;.@0HP<A,H<,<8W= ?:C3\O^"'^3_+0S9_&>KV?A
M77;IK""ZU329YH)&A!C@^2,2"1@6+ %2/E!)R<9[CM+*9KBQMYW #21*Y Z9
M(S7)KX4U*7PCXFL[B2T74]<:>5@CL88F= BKN*@D *,G:._%=990M;V-O Y!
M:.)4)'3(&*:VU\ORU_$'Y>?_  ">BBBD 445GZMH]MK,4,-X\IMXY!(\*L D
MV/X7&.5[X]J -"BN)\.VTTEYK[:#)'9Z5))''9L$W1"1>)7C3@8SQQP2*S]-
MTZ^O_"/BK3[*>22Z;5)D5Y),-( 4R"WN 1^-'^5_R_S#_.QZ-17F:)_9C7FG
MW\?]FZ5<7 NI;/(?R(!A0F$R,R2#[JYX#5Z#I^HVFJ6OVBRE\R,,4.5*E6'!
M4J0""/0BCI<"W1110 4444 %%%% !1110 4444 %%%% !7-WI\,2^(E>\>-=
M2AD1,.S*"VTLI(^Z<#.">E=)7,>*K2QDN=.W:38W>H7$_E0R72_(N%8_-CEA
MC.%]:.H=&:VDV>G6OVAK&02O,^^:0S>8S'MDDG\!6C7.^&BEO>:AIS:;I]I=
M6_EM(]A&%CD# E<C&01@\'UJ7Q&]]:6LU[;ZHUOLC"P6Z0(WG2D\*2P).>!A
M<'J<T,$;M%<<^K:M_I&H&ZV);ZA%:-9A$*$'8K?-C=G+DCD#CI5*'Q+JUL5M
MM2FGAEFDC)DDM<-%S^\5%"_.,[54X.2QY.* .^KG[/\ Y*'K/_8*L/\ T;=U
MMVMS#>6L5S;R"2&50R..X-85M($^(>L9#'.E6'W5)_Y:W?I0!T5%1>>G]V3_
M +]M_A1YZ?W9/^_;?X4 2UP_AK_D>]7_ .VW_HT5V?GI_=D_[]M_A7%>') O
MCC5F(;!\[HI)_P!8.U9SW1A6^.'J=U147GI_=D_[]M_A1YZ?W9/^_;?X5H;D
MM%1>>G]V3_OVW^%'GI_=D_[]M_A0!+147GI_=D_[]M_A1YZ?W9/^_;?X4 %M
M:V]G (+6"*"%22(XD"J"3D\#U))_&I:B\]/[LG_?MO\ "CST_NR?]^V_PH E
MHJ+ST_NR?]^V_P *//3^[)_W[;_"@"6BHO/3^[)_W[;_  H\]/[LG_?MO\*
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M+>:[IZ6=KJ?V&,N#/^Z+^<O]PD,I /?!YKC/^%S:;_T";O\ [[6C_A<VF_\
M0)N_^^UJOJ5?^47UFE_,=YI5G?640@N)[%X$0+%':VC0A /K(W'Y5'H>B_V,
M-0_TCSOME[)=_<V[-^/EZG.,=:X?_A<VF_\ 0)N_^^UH_P"%S:;_ - F[_[[
M6G]3KWORB^L4K6N=5?>$UO[6[\R](O9KM+I+CR\A"A_=KMSRH';(SDGC-7]"
MT?\ L:VN%>?SY[JX>YFD";%+MUVKDX' XR?K7#?\+FTW_H$W?_?:T?\ "YM-
M_P"@3=_]]K26#KK[/]?T@>)I/J>FT5YE_P +FTW_ *!-W_WVM'_"YM-_Z!-W
M_P!]K1]3K_RA]8I=STVBL+PUXHM_$NE&_AMYH5$ACVLI8\8[@>];'GI_=D_[
M]M_A6$HN+Y7N;)J2NB6BHO/3^[)_W[;_  H\]/[LG_?MO\*D9+134<.,@-^*
MD?SIU !1110 4444 %8'B#5O#D31Z9K<MN?.(/ER_P /!(8^G3K6_7,>,253
M36)G2+[3B6:VM_-FC78W*_*V.>"<=#28T6O#ESH#?:;301#Y<15I&A&58MG^
M+N>/Y5-?:"+W5(M0&HWD$L2;(UC$3(GJ0'1L$^M5_#+V[)<"WOM4N@"N?M\)
M3;U^[\BY]^O:M^J>Y*,5O#5N]Z9VO+LQM.EQ);Y3RWE4 !C\N>P. 0,CI4E[
MX?M;Z>:XDFN%N':-DE1AF+8<KMR",9))R#G-:U%(96L+*'3;"&S@W>5"NU2Q
MR3[GWK(L_P#DH>L_]@JP_P#1MW705S]G_P E#UG_ +!5A_Z-NZ .@HHHH *X
M?PU_R/>K_P#;;_T:*[BN'\-?\CWJ_P#VV_\ 1HK.>Z,*WQP]3N****T-PHHH
MH **** "BBB@ HHHH **** .4\2ZUJUAJ>F0VL(@M)=0@MY)WPQE#9)51V
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MS7$,]O R0HD,[Y;S$3:[8R=H) X]JZBL#P_97,5[J5_<006GVMT86L,OF!2
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M4+WM;\C7#3]I*4O0****DZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M68DD1 F0[*&4'(5@" RY&<-D5J=*Y;_A)+S_ )Y0?]\G_&C_ (22\_YY0?\
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M_@YF_P#D6N@HH Y>^;QA>V<EO_8NAIOQ\W]L3'&"#_S[>U8_]B>,/^@=H?\
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MKV6+6/M&I3VD%A=2+!*(I;@&,1JVT-W<,>".BUIU7U[$?S?@B?JM+M^9X/\
M\*@\8?\ /30__ R;_P",T?\ "H/&'_/30_\ P,F_^,U[Q11]>Q'\WX(/JM+M
M^9X/_P *@\8?\]-#_P# R;_XS1_PJ#QA_P ]-#_\#)O_ (S7O%%'U[$?S?@@
M^JTNWYG@_P#PJ#QA_P ]-#_\#)O_ (S1_P *@\8?\]-#_P# R;_XS7O%%'U[
M$?S?@@^JTNWYG ^$='\8>%=%.G?V;H=UF5I/,_M69.H'&/LQ]*WOMGC#_H!:
M'_X.9O\ Y%KH**YI2<Y.4MV;QBHJR.?^V>,/^@%H?_@YF_\ D6C[9XP_Z 6A
M_P#@YF_^1:Z"BI&4]-DU*6W9M4M+2VGWX5+6Y:=2N!R6:-"#G/&.PYYXN444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7#^&O^1[U?_MM_P"C17<5
MP_AK_D>]7_[;?^C16<]T85OCAZG<4445H;A1110 4444 %8$XOK/Q+<WL.F7
M%W#-:11JT,D0PRLY(.]P?XAT!K?HH \^N]!UY--N;.&SC=KJWD+R0>5G>[NY
MC9G.=HW#&T'OTZB]96K2^*XK-"IMK=$O+E%(/EW&SRPAQQG&&_#/>NSHH6@/
M4Y+Q!H]]>:C=RQVLTYF@2.V>*98TB8$D^:I8;UR0<8;OQZ]8NX(H8@MCDCUI
M:*.E@ZW"BBB@ HHHH **** .'^(G_,-_[:_^R5W%</\ $3_F&_\ ;7_V2NXK
M./QR,*?\6?R"BBBM#<**** "BBB@ HHHH **** "BBB@ HHHH P)Q?6?B6YO
M8=,N+N&:TBC5H9(AAE9R0=[@_P 0Z USMWH.O)IMS9PV<;M=6\A>2#RL[W=W
M,;,YSM&X8V@]^G4>@T4K#OK<XRRM6E\5Q6:%3;6Z)>7**0?+N-GEA#CC.,-^
M&>];FNV,]XVFFWB#F&^BED.0,(N<GGKUZ5KT55R;=#EIM&9M8$MMHPM;C[:L
M[ZB)$?>@^\,D[QD<;<;?>NIHHI=+#ZW"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA_#7_(]ZO_ -MO_1HK
MN*X?PU_R/>K_ /;;_P!&BLY[HPK?'#U.XHHHK0W"BBB@"CJ^L6&@Z:^H:G<"
MWM8V56D*LV"S!1PH)ZD5GQ^-/#;6KW,VKV]G&DWD/]O)M65\!MI64*<X(/3I
MS3O%FC7&O:%]AMGB63[3;RYE)"[4E5R. ><*<553PW?_ -KZU=1ZQ/IZ7US'
M-&UDL3.0L*H0XEC8#E2>/;GM0NO]=O\ @C(-<\8RV>COK.B1:3J^FH GFIJ9
M#/*6VB- D3AB25 ^8<GMUJ2]\3ZMIDUFVH:#'#9SS06SR+?!Y/-EP,(@3YU5
MC@DE3P2%Q4MWX=O;FYT-9M3DOK>QO&NYWNPBR.0C", 1HJG#,#T'3O53Q)X?
MU;7;^-!#I20Q31R6VI;G6[M "I<(-I#%MN,AU&#@@XY:W7K^']7$]OD=?111
M2 **** ,C6/$^DZ%<V]MJ$\JSW*N\,45M),[A,;L!%)XR/\ (-0OXU\+11P/
M-XBTJ 3Q+-$)[M(V9&Z-AB#@T7^BW%WXOTK5T>+[/:6MQ"ZL3N+2;,8&,8^4
MYYK/T;PGJEAH&FV+>)+^S>UMUB>.R2W:(D=P986;]?PH6W]>?_ &+>^*-6L]
M>T^P&E:;/;WSLT4T.I.76W49:9E\G:  1P'.2P />DT'QC<ZO>Z<ESI26MKJ
MEN]S83)=>8SJI'#KL&QBK!@ 6[\\5>M]!G_X2?4-3NYEFBEL8K.W.?G !8R%
M@  "Q*]/3M61X<\,:U8WFBKJ36(L]$M)+:V:WF=WGW;5#.&0!,*O0%N3UIKS
M_K?_ ( G_7]?>=M1112 X?XB?\PW_MK_ .R5W%</\1/^8;_VU_\ 9*[BLX_'
M(PI_Q9_(****T-PHHHH **** "BBB@ HHHH **** .:\3ZQJMAJ6A:?I/V-9
M-2N7A>2ZC9Q&JQ,^0%9<GY>F>?;K6)#\0+E-+M9+R7PS;W3--'*M]K!LMS1R
MO&61#&Y*G9GKQG'.,UVMUIEG>WEE=W$.^>R=I+=MQ&QF4J3@'!X)'.:73].M
M=+M3;6<7E0F1Y2NXM\SL78\D]68F@'_7X_\  .'U&V77/$.A16=_>PSWJ?VA
M>2V&LW#VX@0*-L>&5"'8J,[!D;CC-69ENM$\?Z4GVO53:7[3+-/>77F0S2%2
MR11Q@XC*[2<[5! QEB:Z\:;:#56U,1?Z8T MS)N/^K#%L8SCJ>N,U0M?"NC6
M6HB_@M7697>2-6GD:*)FSN9(RQ1"<G)4#J?6FM+?/^ONM\P?7^OZU_ V:***
M0!1110!P7B/Q9KVG:KKZV*:<;+1K*&\=9XG:2;<7W("' 7A.#@X]#GBS=>.3
M;ZK)9"Y\+9638(WU_;<_3R?)^_\ [.[KQFN@N_#FE7SZB]S:[VU*!;>[/F,/
M,C7=@<'C[S<C!YK3  4*!P!BET#K_7]=SQZTU[5;7PZNKW]U<V5YJFD3W%O<
M'4'N(6D 5@6@*XB(W#;Y9/'WN:Z[P3/=)JNJV%T-1MQ'%;RQV>I7/VB5-P8,
MX?>XVL5X&[C:>!FMB+P=H,+3%; ,LT;1&.65Y(T1CEEC1F*Q@G!(0#.!5K2]
M!T_1FF>SCF,LV!)+<7,D\C =!OD9FP,G S@9-5="?]?@:5%%%(84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=>^!/ME_<7/]I;
M/.E:3;Y&<9.<9W5V-%3**EN1.G&>DD</_P *[_ZBG_DO_P#94?\ "N_^HI_Y
M+_\ V5=Q14^RAV,_JU+L</\ \*[_ .HI_P"2_P#]E1_PKO\ ZBG_ )+_ /V5
M=Q11[*'8/JU+L</_ ,*[_P"HI_Y+_P#V5'_"N_\ J*?^2_\ ]E7<44>RAV#Z
MM2['#_\ "N_^HI_Y+_\ V5'_  KO_J*?^2__ -E7<44>RAV#ZM2['#_\*[_Z
MBG_DO_\ 94?\*[_ZBG_DO_\ 95U.L6J7.G2EI+A&B1G4P7#Q'.#U*$9^AKG=
M,F6R\,:+?3->W,]Z]NLC27\I^9OXL%B,>J\ ]Z/9P[=OQ!X:EV_I$'_"N_\
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M+7]?+]3H9[NVM?+^T7$4/FN(X_,<+O<]%&>I/I3YIHK>%YIY$BBC4L[NP55
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MZTET8)6E8Z&BBBM3I"BBB@ HHHH **** "L_5_\ CU7_ 'JT*S]7_P"/5?\
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M_%MLRQZ=K"!F.E70N) HR3$04D_)6)_"MB]U.STZ6TCNIO+>[F$$ VD[W()
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MV27R[)T\R5MSMA",L>Y/<UB1?#K1H- NM&@GOXK:>Y6Z5EG_ 'D,@Q@HV/\
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M#)/!CS8E<%H\C(W#J,CIF@":BBB@ HJ-+B&2:6&.:-Y8L>8BL"4STR.V:DH
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MD2\E<CJK 473O_75%W5V_P"MRIX6\>O/XGL]-?Q1!K\=]O!"Z<UJULP4L,9
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MT[6A\+9Y#KV8?[6QY7V-.HG*DYSW<A_PQTKTW1_#FLVFHI=:MXJO-3CA!$,
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M0?&_AWQ-=R6NCZC]IFC3S&7R9$PN0,Y90.I%;-Y>6^GVDEU=2".&,99B"?R
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MS5C4?AQHNI:Q=ZB]QJ,/VT 75M!<E(9R!P74#)_/'MUKN/L%U_SQ:C[!=?\
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M%U_SQ:C[!=?\\6H5UL%I6L<_/X>M;N'5(+VXN[JWU+'F032Y2(8QB,?PCO\
M6J&A^"+'1-2&H'4-4U"Y2,Q0MJ%SYODH>H3@8Z5U_P!@NO\ GBU'V"Z_YXM0
MKH+2M8XF3X>:3)?R3?:]42SED,LFF)=D6CL3DDQ^YYQG'M5[4+*74_$VEH8F
M6RTW-T[%<*\I!2-5/? +$^GR^M=1]@NO^>+4?8+K_GBU"N#YF5J*L_8+K_GB
MU'V"Z_YXM19BY65J*L_8+K_GBU'V"Z_YXM19ARLK459^P77_ #Q:C[!=?\\6
MHLPY65JLV'_']%]:/L%U_P \6JY86$D<HEE&W;T%"3N5&+N:M%%%:G0%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image9.jpg
<TEXT>
begin 644 image9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &,!!,# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M77YHXQ873[(V#@L3\W4?\!-7F\ :\MQI,!AAWZJK-:_O1R H8Y].#2O2\O\
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MF;5K&T)46MS*9%52,?*&X&."/]T5Z6GQ*\'V%W)JEG#K,UWY1CBMYI"8X^G
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M^K_Z ]>05&&H4YPO)%UZTXSM%GIG_"W/^H'_ .3?_P!A1_PMS_J!_P#DW_\
M85YG16_U6EV_,Q^L5>YZ9_PMS_J!_P#DW_\ 84?\+<_Z@?\ Y-__ &%>9T4?
M5:7;\P^L5>YZ9_PMS_J!_P#DW_\ 84?\+<_Z@?\ Y-__ &%>9T4?5:7;\P^L
M5>YZ9_PMS_J!_P#DW_\ 84?\+<_Z@?\ Y-__ &%>9T4?5:7;\P^L5>YZ9_PM
MS_J!_P#DW_\ 84?\+<_Z@?\ Y-__ &%>9T4?5:7;\P^L5>YZ9_PMS_J!_P#D
MW_\ 84?\+<_Z@?\ Y-__ &%>9T4?5:7;\P^L5>YZ9_PMS_J!_P#DW_\ 84?\
M+<_Z@?\ Y-__ &%>9T4?5:7;\P^L5>YZ9_PMS_J!_P#DW_\ 84?\+<_Z@?\
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MF=:&F:'J>L%O[/LI9PAPS*,*#[D\4/#44KM?B"KU7HF=Y_PMS_J!_P#DW_\
M84?\+<_Z@?\ Y-__ &%<%J>B:GH[*NH6<L&_[I89!^A'%4*%AJ+5TOQ!UZJT
M;/3/^%N?]0/_ ,F__L*/^%N?]0/_ ,F__L*X#3=)O]8G,&GVKSR*,L%Z >Y/
M J._T^ZTN[:UO83#.H!*$@XSTZ4OJ]"]K:^H_;U;7N>A_P#"W/\ J!_^3?\
M]A1_PMS_ *@?_DW_ /85YH 6( !))P .]/GMYK69H;B)XI5QN1U((R,\@T_J
MM'M^8OK%7N>D?\+<_P"H'_Y-_P#V%'_"W/\ J!_^3?\ ]A7F=2V]O+=W,=O
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M#_\ )O\ ^PKS.BCZK2[?F'UBKW/3/^%N?]0/_P F_P#["C_A;G_4#_\ )O\
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MI3^!]/U&ZT2[TDQ+ F/M* EBV < ]<\]3QQ6?#HNF:Q\/;BYT^U']H64A#2
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M..8_99K*4+!:8Y"L"<@=N/KR:Z_QE=ZG?:'\,Y]9C=-1-\%G#C#$JZ+N/N0
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M^)_Q#MEN)C%!HC^6&<G:1%'S]:[CQ%\,-(\20Z0+B^U&WGTN$00W-O*JR,H
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M!P*](H **** "BBB@ HHHH **** "BBB@ HHHH *E@^^?I452P??/TH ?/\
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M\.>$FD?1=,CMY9%VO*79W(]-S$D#V'%93_"/P+)<7,SZ!$6N,[P)9 %R<G:
MWR_AB@#RO6M/L-5\;_#FPU28PV-QH%M'*PDV;@5?Y<]MQPOXTV.*#1+_ .)7
MAW1;EY=!ATMI47S-ZI+A,@'U&YQ_P'G.*]DU'X=>$]6:T-_I"3_9+06<&^:3
MY(@" OWNHR>3S[US7B?P/+H?@JZT/P%X?MV?4V\J\>2?YA'@_-N=LDC/ Z#)
MXH \NOIKO4+7X>Z#):M>Z;)8>=]B-V+9+B4O(,&0\ @*N/K@8S6A:W>O>&O
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M/1I=7N]0L[JQ:?\ TM@S)(K8X( X]J[:@ HHHH **** "BBB@ HHHH ****
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MLN[.SQ#(N/3][$<?K^M 'TCKNK1:#H-_JTZ,\=G TQ1>K8&<#Z]*\H@^)OQ
MET:'Q*GA?3KG0Y9-OEVTC/.!G'.&./3[OX5Z=XLO%T_PGJ=V^FG4HH[=C+:
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MPN=1$EPLUXQ2."W#$)GYOF=L'N!TX])#\0+R/0->D#:==7^E&(K-;,6@G1V
MR.<@C)!&>M 'HM13W$%K'YEQ-'"F0NZ1@HR>@R:X?5?$GB;0].M'U/\ LJWD
MO;@(MP$D:*U3;G#]RV>!CC@U%?Z]J,GAB:?4(-'U"..]@2"X@;S(9@S#)VAL
MJR^YZT =['<0322QQ31N\1VR*K E#Z$=J5[B"*>*"2:-)9L^7&S ,^!DX'?
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MC4+5[>.-[34%)2&11@LA"Y(/OS78T4 <3I'@N\TI_"_^E0RKI1N6GY89,JD
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M3_<'UJO0 4444 %%%% 'E?BKQGK\'B:71[JX3PKI&[;%J\MLUP;C_=;&Q/\
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MJ:?IR%KF:#*1IU<APQ ]S@C\:?H7Q!T7_A$O#WA9?"1UG6+:40O87$("HPW
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME_'<V41822JK#:5&3D$9Z<]* -:BL_1=<TWQ#IJ:CI5T+FT=BJR!67)!P>"
M>M:% !16+XA\6:'X5C@DUN_6T6X)6(LC-N(QG[H/J*QK?XK^![NYBMH->C>:
M5Q&B^1*,L3@#[OK0!V=%%% !115:[U&RL7MTN[J&%[B010J[@&1ST51W/TH
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M.HQC[/MMP1;3!E#/@_>!.TX/3%=G/\'KW[1KL%CXLGM-)UB1I;BU%HKN6))
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M0 4444 %6(/N'ZU7JQ!]P_6@"6BBB@ JH_WV^M6ZJ/\ ?;ZT -HHHH ****
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MIGC+3]2U1-->VO["\D4M%#?6QB,@'7;ZUQ\]])-J/@.YT"S61A9W"007$NW
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M>2H[]<UG6/QKMO\ A#=6U#5+2.UUO3Y3!_9^XCS'.0N,\X!!W>FT^HK9\#^
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M)&[^6K+N7RPS=@<NV?Q[5TWAC3;K2/B!?+:V^F:5;3Z9*MSIUMJ0N"1Y9*N
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MZ2"VM@ODR(^V1&7HX8?Q=3G'<U#8>$+6TO)KVYO[[4+N2$VZS7<@8Q(>H7
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MJM$T33O#NDPZ7I5O]GLX2Q2/>SXW$L>6)/4GO6A5.'5],N;62Z@U&TEMXO\
M62QSJR)]2#@5)]OLOL7VW[7!]DQGS_,&S&<?>Z=>* +%%,AFBN(5FAD22)QE
M71@0P]013Z "BBB@ HHHH *E@^^?I452P??/TH ?/]P?6J]6)_N#ZU7H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JQ!]P_6J]6(/N'ZT 2T444 %5'^^WUJW51_OM]: &T444 %>*_&J*\G\
M;>!8=/N%M[U[EEMYF7(CD,D6UB,'.#@]*]JK'U7POHVN:GIVHZC9^==Z;)YM
MI)YKKY;9!SA2 >5'4'I0!PNE_#'7[SQ=I_B#QAXE74Y-/8/;PPPA!N!R.P
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MJ<>6>H.3S[G^[QW?C73M1UJ+P2[:CI.H:M'8KG2[NX&RZ)'^L4Y"MNV_WAG
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MCYL'.<$8S0![#X=UBXUGP_!J5]ILNE32;]]K<-\T8#$<D@=0,].]99\:Q_\
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M?[[?6@!M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "K$'W#]:KU8@^X?K0!+1110 54?[[?6K=5'^^WUH ;1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %2P??/TJ*I8/OGZ4 /G^X/K5>K$_P!P?6J] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6(/
1N'ZU7JQ!]P_6@"6BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image10.jpg
<TEXT>
begin 644 image10.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (+ @T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_?B3_XY7G]%/ZI0_E%]8J]ST#_A<7B7_GUTG_OQ)_\ '*/^%Q>)?^?72?\
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MY]=)_P"_$G_QRN)O-.OM.=4OK*XM68959XF0D>V156A82@U=1!XBJMV>@?\
M"XO$O_/KI/\ WXD_^.4?\+B\2_\ /KI/_?B3_P".5Q5IIFH7\<DEG8W-PD7^
ML:&%G"?4@<54H^J4+VY0^L5=[GH'_"XO$O\ SZZ3_P!^)/\ XY1_PN+Q+_SZ
MZ3_WXD_^.5P8MYC;M<"&0P*P1I0IVACR!GIG@\5'3^J4/Y1?6*O<] _X7%XE
M_P"?72?^_$G_ ,<H_P"%Q>)?^?72?^_$G_QRN$N+:>TE\JYADAD !*2(5.",
M@X/J*BH6$H/[(?6*O<] _P"%Q>)?^?72?^_$G_QRC_A<7B7_ )]=)_[\2?\
MQRN#GMYK6=H+B&2&5.&CD4JP^H-216-Y/&DD-K/(DDGDHR1DAG_N@CJWMUI?
M5:%K\H_K%7N=Q_PN+Q+_ ,^ND_\ ?B3_ ..4?\+B\2_\^ND_]^)/_CE<"Z/'
M(T<BLCJ2K*PP01U!I_V6X^SI<>1+Y+N4238=K,.P/0GVH^J4/Y0^L5>YW?\
MPN+Q+_SZZ3_WXD_^.4?\+B\2_P#/KI/_ 'XD_P#CE<,+*[+3J+68M;@F8",_
MNP#@EO3GCFH*/JE#^4/K%7N>@?\ "XO$O_/KI/\ WXD_^.4?\+B\2_\ /KI/
M_?B3_P".5Y_13^J4/Y1?6*O<] _X7%XE_P"?72?^_$G_ ,<H_P"%Q>)?^?72
M?^_$G_QRO/Z*/JE#^4/K%7N>@?\ "XO$O_/KI/\ WXD_^.4?\+B\2_\ /KI/
M_?B3_P".5Y_11]4H?RA]8J]ST#_A<7B7_GUTG_OQ)_\ '*/^%Q>)?^?72?\
MOQ)_\<KS^BCZI0_E#ZQ5[G?M\8_$JHS?9-)X&?\ 42?_ !RO<J^3)?\ 5/\
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M>/0Y_"L+3BVO7;Y6[]/QN:WBTOU]7?M_PQ%J/V?3OA]!:M;W<=Q'J,T;%;H
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M?VG'^4/J+[GS/17TQ_PB7AK_ *%[2?\ P"C_ ,*/^$2\-?\ 0O:3_P" 4?\
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M&O\ H7M)_P# */\ PH_X1+PU_P!"]I/_ (!1_P"%']IQ_E#ZB^Y\ST5],?\
M")>&O^A>TG_P"C_PH_X1+PU_T+VD_P#@%'_A1_:<?Y0^HON?,]%?3'_")>&O
M^A>TG_P"C_PH_P"$2\-?]"]I/_@%'_A1_:<?Y0^HON?,]%?3'_")>&O^A>TG
M_P  H_\ "C_A$O#7_0O:3_X!1_X4?VG'^4/J+[GS/17TQ_PB7AK_ *%[2?\
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M^+.<Y]O:JC7IR=HLF>&JPCS26A>HHHK4P"BBB@ HHHH **** "BBB@ HHHH
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M /UJ/[9_Z=__ !__ .M1S(.>)JT5E?VS_P!._P#X_P#_ %J/[9_Z=_\ Q_\
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M(CV;L9Y)SCZUI1PTX34F95\7"I3<4F3T445W'G!1110 4444 %%%% !1110
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MEQIUB)+F06=OYET MPWE+F8 8 <X^;CCFI;>W@M+>.WMH8X88QM2.-0JJ/0
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MYBUT/Q3%>027'C'SX$D5I(?[,B7S%!Y7(.1D<9KI)IH[>"2:9PD<:EW9C@*
M,DFM%*ZNU8X:U*,&E":EZ7_5(QKCQAH%IXH@\-SZBB:O<)OCMRC?,,$CYL;0
M>#P3FF>)O&OA[P>MLVO:A]D%R6$/[F23=MQG[BG'4=:^8-6\<:9J&IZIX@V7
MB^(FU:.ZL)E13''!'P$+;LC(/.%_A%>E?%'4I?$DGP]U'1=.M-3FO3+)!9W8
M5HI&*I\C@D XY')'2J5W%/S_ #U_X'R,M.9KR?X'I_A_Q_X7\5-.FBZLEU)
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M5?V/8?\ /#_Q]O\ &C^Q[#_GA_X^W^->?]3J=T>G]?I]G_7S.5HKJO['L/\
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MBR6V1(%7).2<#N3S72_V;:?\\O\ QX_XT?V;:?\ /+_QX_XTN1B]FS HK?\
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M_P"M1S(.>)JT5E?VS_T[_P#C_P#]:M6FFF4I)[!1113&%%%% !1110 4444
M%%%% !1110 4444 %%%% !7/WG_)0]&_[!5__P"C;2N@KG[S_DH>C?\ 8*O_
M /T;:4 =!1110 4444 %%%% !1110 4444 %%%% !1110 4444 9\/W6'<,0
M:?BDF'D7)8_ZN3OZ&DD)9A$IY/+'T%9FJ$0!F,G7'"_U-+BI-H   P!P*3%
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M-M*Z"N?O/^2AZ-_V"K__ -&VE '04444 %%%% !1110 4444 %%%% !1110
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M']*&[";2W+M%97]L_P#3O_X__P#6H_MG_IW_ /'_ /ZU3S(GGB:M%97]L_\
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M31"LRRMY!+AB ,*LI.?FSR!T-;NM?\@'4?\ KVD_]!-<!J@S\!;,'I]CM/\
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M;)6V*2SR.<O*YY9W;^)F/)-1:!H-MX?T\V\#R332N9;FZE.9+B4_>=SZGTZ
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MH&23TS6M7544<HO9>9RM%=511R![+S.5KJJ**:5BHQY0HHHJBPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YS5O^1Y\-_\ 7*\_]!CKHZYS5O\ D>?#
M?_7*\_\ 08Z .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***H:SK%E
MH.ERZA?2%88\ *BEGD8G"HJCEF)P !0!'KNN6^@Z=]IF22:5V$=O;1#,EQ(?
MNH@[D_H,D\"L_P .Z'=17,NN:VRRZU=KM*J<QV<740Q^P_B;^(\^@$>A:/>7
M>H?\)'X@C0:DRE;2U'*V$1_A![R'^)OP' YZ>@ HHHH **** "BBB@ HHHH
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M2-8N-1U'3--T/4;_ $[1X]+EF$<L<4DVZ.4QX)8.,?CT%3CQ#KL?@ZW\8OJ
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MKG**/K=0/J5(Z/\ M^U_YYS?]\C_ !JU9:A%?;_*5QLQG<!W_'VKDJW/#O\
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M)/4DDFK=-RUNO/\ .XG*]_/_ ":_4\4T^99=879<-.I\5Q.)&C";P83\P4
M XXXY'K5WPE%'+J'@CS(U?;_ &FR[AG!$AP?K7KU0B[MC=FT%Q$;E4\PP[QO
M"YQNV]<9XS0I6_KRL-RO_7F_\SRBS$=GXA:ZN@B:-:>([LSEA^[A=HE\MV[
M!B>3P"172>![BPN_%/BZXTPH;62Y@960?*Y\OYF'J"<G/?K73ZQ8K=0I,VJ7
M>G?9B9//MY50 8YWA@488_O XI-&TBUTR.>:">6ZEO'$TUU,X9IC@ 'Y0%Q@
M#   I)Z6\K?E_D$G?7^NO^9IT444B HHHH *ZJN5KJJN!M2ZA1115FH4444
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MB_X+_KJ;E%%%>L>(%%%% !1110 4444 %%%% !1110 4444 %%%% !6+J_\
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M0()$649W.J84D '' ZC([54UG4-1\)^+=8O7O&U&X72(5MY)HE##?/M&X1@
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M*'/E1(F>NU0,UI2PKA-2;,JV,C4IN*0^BBBNPX HHHH **** "BBB@ HHHH
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M?BTO3_RZ7R-;3?@D@!/X9KH*K7VGV6IVS6U_:074#=8IXPZG\#Q0!9HKEO\
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M:%K?6E]'YEI<PSIZQ.&'Z4)ICC5A)V3U)Z***9H%%%% !1110 4444 %%%%
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M+_&NMHJ)04G=W^]K\CIHXNI1AR14;><8M_>TV<E_PC_B_P#Z'C_RDQ?XT?\
M"/\ B_\ Z'C_ ,I,7^-=;14^QCY_>_\ ,U_M&MVA_P""X?\ R)R7_"/^+_\
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M;+34?MEDFX'_ %3$;E)[@LV<=L5ZY5/3M)T[2(#!IFGVME"3N,=M"L:D^N%
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M:Z<8>XF;=(WMGL/88%7Z**:5C2,8Q5HHSI-+\R5W\[&YB<;?_KTW^R/^F_\
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M1110 4444 %%%% !1110 4452O-4M[0[,F28](TY/X^E %WI5&XU2" G :3
MR=E8TEU=W\CJTPB9#Q"O;T)]14EO8333>F#RQZ"J274SE)[1)K75;_59RMI
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M!8V]NYD2,&5NLC<L?Q[#V%6:**1T!1110 4444 %%%% !1110 4444 %%%%
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M'G OE)B0 E_E/ !XI.7NI^?ZV%+$2C3G.VL3=M=5TZ^D,=I?VMQ(!N*Q3*Y
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M0 4444 %%%% !1110 4444 %-==ZE2<9IU% &9/!>7<S1EPD2GJ.]6+?3K>
M?=W'U:K)_P!8/<&G4 )M'&.,4M%% !1110 4444 %%%% !1110 5D:OH]QJ%
M]8WEK>K:S6A<J6A\P'<,=-PK7HI-)D3A&<>66Q0L+;4H9&-]J,5TA&%5+;R\
M'USN.:2'3/*URZU+SL^?$D7E[?N[2><Y]_2M"BBPE2C9+MKNS#N]$O7UQ]4L
M=2CMG>!861[;S. <_P!X4R]T+4;^"T\[5HOM-K<>?'*+3 Z8 *[_ -<UOT4N
M5?UZW(>&IN]^N^K_ ,S'&GZRT4\<^LPN)(F12EGL*DCAOO\ ;TJ>VT2PM].C
MLOLT3HD8C+,@RW&,GWK1HHY45&C!.^_JV_S*6DV+Z9ID-D\YG\D;5<K@[<\#
MJ>@X_"KM%%47"*A%1CL@HHHH*"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH 0C*D>HQ6;/!>7<S1EPD2GJ.]:=-/^L'N#0!6M].MX!]W<?5JM;1Q
MCC%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image12.jpg
<TEXT>
begin 644 image12.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'U!  # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@#&U
M/Q9H6C7_ -AU#48X+DQ+-Y;*Q.PE@#P/56_*JG_"?^%O^@Q#_P!\/_A1:_\
M)2]6_P"P/9?^CKJNDH YO_A/_"W_ $&(?^^'_P */^$_\+?]!B'_ +X?_"ND
MHH YO_A/_"W_ $&(?^^'_P */^$_\+?]!B'_ +X?_"NDHH YO_A/_"W_ $&(
M?^^'_P */^$_\+?]!B'_ +X?_"NDHH YO_A/_"W_ $&(?^^'_P */^$_\+?]
M!B'_ +X?_"NDHH YO_A/_"W_ $&(?^^'_P */^$_\+?]!B'_ +X?_"NDHH Y
MO_A/_"W_ $&(?^^'_P */^$_\+?]!B'_ +X?_"NDHH YO_A/_"W_ $&(?^^'
M_P */^$_\+?]!B'_ +X?_"NDHH YO_A/_"W_ $&(?^^'_P */^$_\+?]!B'_
M +X?_"NDHH YO_A/_"W_ $&(?^^'_P */^$_\+?]!B'_ +X?_"NDHH YO_A/
M_"W_ $&(?^^'_P */^$_\+?]!B'_ +X?_"NDHH YO_A/_"W_ $&(?^^'_P *
M/^$_\+?]!B'_ +X?_"NDHH YO_A/_"W_ $&(?^^'_P */^$_\+?]!B'_ +X?
M_"NDHH YO_A/_"W_ $&(?^^'_P */^$_\+?]!B'_ +X?_"NDHH YO_A/_"W_
M $&(?^^'_P *B'Q'\($D#7;;()!X;@C\*ZFO(;;_ )"FN_\ 85N?_0ZY,9B?
MJU/GM?4Z<)A_;U.2]CMO^%B^$?\ H.VWY-_A1_PL7PC_ -!VV_)O\*Y2HKFY
MAL[66YN'$<,*%Y'/\*@9)KRUG4GHH?C_ , ])Y0E]O\ #_@G8?\ "Q?"/_0=
MMOR;_"C_ (6+X1_Z#MM^3?X5PEOK>G76BMK$%R'L%C>0RA6X5<[CC&>,'C%9
MMAX[\-:G?16=IJBO/*=J*T3IN/IEE S_ #K19K6=[4GIOOI^!F\MI*UZF^W]
M7/3?^%B^$?\ H.VWY-_A1_PL7PC_ -!VV_)O\*\\/BC1ELKV\:]5(;*7R;@O
M&RM&_3&TC)Z]AS3=0\6Z%I4EM'?:@L#W*!XT:-\[3T+#'R_\"QT/H:%FM9NR
MI/\ '_('EM)*[J?U]YZ+_P +%\(_]!VV_)O\*/\ A8OA'_H.VWY-_A7GFJ^*
M=$T1X$U#4(X6G7=& &?*^OR@X'N>.OI1JOBG1-$2!]0U".(3KNBVAGW+ZC:#
MQ[]*%FM5VM2>NV^OX \MI*]ZFW]=ST/_ (6+X1_Z#MM^3?X4?\+%\(_]!VV_
M)O\ "O/=4\4:+HUM;W%]J$4<5P,PLH,GF#&<C:#D=.>G(K3M[B*ZMX[B"19(
M9%#(ZG(8'H14O.*B7,Z>GK_P"EE<&[*IK_7F=?\ \+%\(_\ 0=MOR;_"@?$;
MP@7V#7;8MC.,-G'Y5RE5-._Y'@_]@T_^C!6^$S-XBJJ?+:_F8XK+U0INIS7^
M1W'_  L/PG_T&X/^^6_PH_X6'X3_ .@W!_WRW^%4:*]>QY=R]_PL/PG_ -!N
M#_OEO\*/^%A^$_\ H-P?]\M_A6=+*D$+S2';'&I9CC. .36';^-=!N5M72ZG
M2*Z8)!--9S11R,>@#L@4D_6BP7.M_P"%A^$_^@W!_P!\M_A1_P +#\)_]!N#
M_OEO\*Q-)U:RUS3(=1TZ?S[2;=Y<FQES@E3PP!Z@]JNT6"Y>_P"%A^$_^@W!
M_P!\M_A1_P +#\)_]!N#_OEO\*HU4@U.SN=2N]/AFW75H$:=-I&P."5YQ@Y
M/0T6"YL_\+#\)_\ 0;@_[Y;_  H_X6'X3_Z#<'_?+?X51HHL%R]_PL/PG_T&
MX/\ OEO\*/\ A8?A/_H-P?\ ?+?X51HHL%RZOQ$\)-(8UUN N &("MT/X>U/
M_P"$_P#"W_08A_[X?_"LKPY_R4'4?^P5!_Z-EKN:0SF_^$_\+?\ 08A_[X?_
M  H_X3_PM_T&(?\ OA_\*Z2B@#F_^$_\+?\ 08A_[X?_  H_X3_PM_T&(?\
MOA_\*WKJYCL[62XE65DC&YA#$TKGZ*H+$^P!K M/'F@WVI2Z=;-J;WD+(LT7
M]D78,)?E=^8OD!'.6P,<T +_ ,)_X6_Z#$/_ 'P_^%'_  G_ (6_Z#$/_?#_
M .%;.IZG9:-IL^HZC<);VD"[I97SA1T[591UDC61#E6 (/J#0!SO_"?^%O\
MH,0_]\/_ (4?\)_X6_Z#$/\ WP_^%:EEK>GZCJ.H:?:7'F76G.B74>QAY98;
ME&2,'(],UH4 <W_PG_A;_H,0_P#?#_X4?\)_X6_Z#$/_ 'P_^%=)10!ST'CG
MPS<W,-M%J\+33R+%&NUAN9C@ 9'4FNAKF_&?_'II'_88L_\ T:M=)0 4444
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M<%&U0<#G X'H*MT %%%% '-^,_\ CTTC_L,6?_HU:Z2N;\9_\>FD?]ABS_\
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M4]+*_P"/\BW1117S!]$<WX\NY[3PC=BV;;-.4MU;/W=[!3^A-4+W5=;LM?\
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M0!NT5A?\(K:?]!'6O_!I/_\ %4?\(K:?]!'6O_!I/_\ %4 ;'AS_ )*#J/\
MV"H/_1LM=S7E6@^%K67QO?0'4-955TV%PR:I.K$F208+!LD<=.G6NQ_X0JR_
MZ"OB#_P<W/\ \74E'245S?\ PA5E_P!!7Q!_X.;G_P"+H_X0JR_Z"OB#_P '
M-S_\70!TE%<W_P (59?]!7Q!_P"#FY_^+H_X0JR_Z"OB#_P<W/\ \70!TE%<
MW_PA5E_T%?$'_@YN?_BZ/^$*LO\ H*^(/_!S<_\ Q= '245S?_"%67_05\0?
M^#FY_P#BZ/\ A"K+_H*^(/\ P<W/_P 70!TE%<W_ ,(59?\ 05\0?^#FY_\
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MS%0]&*YR![T 6:*9#-%<1++#(DD;='1@0?Q%/H **** "BBB@ HHHH ****
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MYRM[&P1U^TVB&0KT^4J%;(/)SCC;VS4%A8R6_AN\0Q2+).9Y1&Q+/\Q.W/\
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MK+Q1#IDC/"9(N0Y$L88Y1QC@DG&?>NF_L#4_^%S_ -O_ &;_ (E?]D?9O/\
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M5O\ P('^%'+#^;\ YI=C8HK'_P"$?/\ T&-6_P# @?X4?\(^?^@QJW_@0/\
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M_P!@J#_T;+7<UY5H/ALR^-[Z'^W-93;IL+^8ER QS)(,$[>G'ZFNQ_X1!O\
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MW'(/#+NZA@1UK1O1 /L]WIW]N0![)H$>?3IKH3J';]W,DBF4'/.6*[@W4\8
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M2Q1D:?.7,D9?*>6VX###!(Z'G'H>E/TF(V_B37;N22$07AAEMV$RG>BQ!6;
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M ,(OJ'_0Y^(/RM/_ (Q1_P (OJ'_ $.?B#\K3_XQ0!TE>0VW_(4UW_L*W/\
MZ'7=?\(OJ'_0Y^(/RM/_ (Q7EUOHMT=1UE?^$AU0%-2G4L!!ER&^\?W74^V!
M[5YF;)/#ZNVIZ.6-JMHKZ'145C_V)=_]#'JWY6__ ,:H_L2[_P"ACU;\K?\
M^-5\UR1_F7X_Y'O\\OY?R_S-BBL?^Q+O_H8]6_*W_P#C5']B7?\ T,>K?E;_
M /QJCDC_ #+\?\@YY?R_E_F:C01O-',R_O(P0K9Y /4?3@?D/2I*Q_[$N_\
MH8]6_*W_ /C5']B7?_0QZM^5O_\ &J.2/\WY_P"0<TOY?R_S-BBL?^Q+O_H8
M]6_*W_\ C5']B7?_ $,>K?E;_P#QJCDC_,OQ_P @YY?R_E_F:DD$<KQNZ[FB
M;<F>QP1G\B?SJ2L?^Q+O_H8]6_*W_P#C5']B7?\ T,>K?E;_ /QJCDC_ #?G
M_D'-+^7\O\S8JIIW_(\'_L&G_P!&"J7]B7?_ $,>K?E;_P#QJJMAHUTWC Q#
MQ!JBM]@+>8!!NQY@X_U6,?AFO0RN,5B59WW[]CAS&3>'=UV/0:*PO^$?O?\
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M^.X@FEFBBFC>2!@LJ*P)C) 8!AV."#SV(I7GBCDCCDE17E)6-68 N0"2 ._
M)_"N(L6UZ3QEXN@T@6,*+>0.UQ>(T@8FUA&Q45E/09))[C@]I[C4+KQ'X#OK
MP11V^KZ9--M",2BW-LY^Z>NUMN/HQ%.PKG:455TR^CU/2K._B_U=U DR\YX9
M01_.K5(H**** "BBB@ HHHH **** "BBB@"MI^GVNE:=;Z?91>5:VT8BBCW%
MMJ@8 R22?QJS110 4444 %%%% !1110 57O;*WU"U:VNH_,B8@D9(((((((Y
M!! ((Y!%6** "BBB@ HHHH *K36%M/?6U[)%NN+8.L+[B-H? ;CH<X'6K-%
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MEG<S%F\LL?,$L7W4&.<@#KGO577_  ]%;7#66DFYNAIEF\TD4I#+&A8ND0
M)W,,G))VKCO6JPU)R<7IV]//\#-XBHHW6O?^OO.[F\0VUMI%GJ=S;W,-O<LB
MGS%4&$.<*7YX'(Z9QFM>O-Y]6N-2\+^)(;B\%_9Q6$3QW!C50)63+)E0 <-C
MW&<&N\TKS?['L?/SYWV>/?NZ[MHSG\:YJ]'V<;];_HG^IT4:W.[>7^:+E5-.
M_P"1X/\ V#3_ .C!5NJFG?\ (\'_ +!I_P#1@KHRK_>H_/\ (PS+_=G\OS.J
MHHHKZT^8,?Q%XFTSPOIK7NHRD#^"),&20^B@D9_I5FYU-[>-94T^ZGA,?F&1
M'B55'OO<'@?A6/\ $*-#X$UF0HI<6K -CD#([U2\<S2-X5TW2HG9&U>[M[!F
M7J$?EC],*0?K2&=#H.M1>(-*CU&WMKF""0D1BX507 _B&">#VK.;QKI_E)+!
M;7=PLNH?V="8E3]])@Y*Y8?*,$9..E;-S%Y&D30VB;/+@9850?=PN% _2O.=
M(BT5O _@N34IKVWMXW9DGMI/+B24[L^:XY7)+#((Y)YH [>_\1KIEK!-=Z;>
MQO<74=K##F(O([],8? ''<BFWWB5-.6V%UIE\D]U.(+> &(O*Q!)QB3   Y)
M(KA_-L[VZF_M2^U63P_;:M&=-OTF. WED-OE/S>6&) <'OUJ]8VT.KWVL3S:
MG>?V+I-S'<Z=J)EWM&PC/FA7<-O0>^?:@#IM/\8:;JATM;-;B234!(40(-T2
MQDAS)S\H!X[Y)&*OVNLVUUK%]I062.ZLPC,L@ #HPX9<$Y'4=L$5Y#8"\\,J
MM]#=2Z9!>V$\]G+,B2.0IW10DL"-SEBY"X)+ #&*[*TN+F[^(7AZZFB\F\FT
M$O>1@8VY*G!'H')H [VBBBF(B\.?\E!U'_L%0?\ HV6NYKAO#G_)0=1_[!4'
M_HV6NYJ2@KD8_B'I;FSF:RU&/3[V\^Q6^H21((9)<X'\6\ D$!BH''7I76DX
M!.,^PKR'Q1KUEXBN?#]_IUS=S:E!K$:CP[=HH:-E)5G>-?F4J/F#,Q49'K0!
MWX\9Z,_C*/PM#,T^I&)Y9/*PR0[<?*YSPW/3!]\9&;OB#7;+PUHMQJM^7,,(
M&$C +R,3A44$C+$D "N9U6*.+XO>&1&BH&L+YB%&,DF,D_4U%\3>;GP8)/\
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M'_H<KS_P!M__ (BC^P?$/_0Y7G_@#;__ !% '245S?\ 8/B'_H<KS_P!M_\
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ML?6O^AGN?_ 2#_XF@#=HK"_L?6O^AGN?_ 2#_P")H_L?6O\ H9[G_P !(/\
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M / +&H=.TV2VU/0M/W+)_9%BQGD1<+O<*BJ!Z8#G'8!?6@#JJ*** .;\9_\
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M<^H7-K%*%!$T;1E(V; )52G7&=IZ9KN9YX;:WDN+B5(H8D+R22,%5% R22>
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M8-X"TS6\2R-;WY2W!9&8LHE\SY\KG;D!L@ ^U>BK<0/<R6Z31M/$JM)$&!9
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M_H:;7_P5#_XY1_9/BO\ Z&FU_P#!4/\ XY0!TE%<W_9/BO\ Z&FU_P#!4/\
MXY1_9/BO_H:;7_P5#_XY0!TE%<W_ &3XK_Z&FU_\%0_^.4?V3XK_ .AIM?\
MP5#_ ..4 =)17-_V3XK_ .AIM?\ P5#_ ..4?V3XK_Z&FU_\%0_^.4 =)17-
M_P!D^*_^AIM?_!4/_CE']D^*_P#H:;7_ ,%0_P#CE '245S?]D^*_P#H:;7_
M ,%0_P#CE']D^*_^AIM?_!4/_CE '245S?\ 9/BO_H:;7_P5#_XY1_9/BO\
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MQ7_T--K_ ."H?_'* .DHKF_[)\5_]#3:_P#@J'_QRC^R?%?_ $--K_X*A_\
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M, 0R#Y@#RI'<X .J_P"$HMV"Q)8WK7[3- ; *GFJRJ';)W;  K*<[L?,,9)
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M,C/UH$24444#"BBFR2)%&TDCJB("S,QP !U)- #J*C>X@CGC@>:-9I03'&S
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M_P"0N9_RO\/\S8J&:V2>6&23<?)8NJYXW8QD_3)_SBLWR/$G_02TK_P D_\
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M_P!C-J6IZ1/;?VQ9[DM]/DB<_O5Z,TS#]*[^@ HHHH SZ\__ .%IVG_"S?\
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MX)DPI02KL8Y #?,#Q\OS8R<&O3*';H-7.8\9$WZ:=X=3EM6N LX]+:/YY?S
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M5Q'_ *2\8 !;)QTXR!@''&0:\YMO^0IKO_85N?\ T.O*SC_=_FOU/2RO^/\
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MWH&E:Y\2M1&IV4=R(=(L_+WY^7,USG^0K2_X0#PI_P! 2V_7_&@#I**YO_A
M/"G_ $!+;]?\:/\ A /"G_0$MOU_QH Z2BN;_P"$ \*?] 2V_7_&C_A /"G_
M $!+;]?\: .DHKF_^$ \*?\ 0$MOU_QH_P"$ \*?] 2V_7_&@#I**YO_ (0#
MPI_T!+;]?\:/^$ \*?\ 0$MOU_QH Z2BN;_X0#PI_P! 2V_7_&C_ (0#PI_T
M!+;]?\: .DHKF_\ A /"G_0$MOU_QH_X0#PI_P! 2V_7_&@#I**YO_A /"G_
M $!+;]?\:/\ A /"G_0$MOU_QH Z2BN;_P"$ \*?] 2V_7_&C_A /"G_ $!+
M;]?\: .DHKF_^$ \*?\ 0$MOU_QH_P"$ \*?] 2V_7_&@#I**YO_ (0#PI_T
M!+;]?\:/^$ \*?\ 0$MOU_QH Z2BN;_X0#PI_P! 2V_7_&C_ (0#PI_T!+;]
M?\: .DHKF_\ A /"G_0$MOU_QH_X0#PI_P! 2V_7_&@#I**YO_A /"G_ $!+
M;]?\:/\ A /"G_0$MOU_QH Z2O(;;_D*:[_V%;G_ -#KNO\ A /"G_0$MOU_
MQKGO"W@7PO=Q:LUQHMM(8]5N8T+ \*'X'6N3&8;ZS3Y+VU.G"8CV%3GM<HT5
MUG_"NO"'_0 M/^^3_C1_PKKPA_T +3_OD_XUY?\ 8C_G_#_@GI?VNOY/Q_X!
MR=%=9_PKKPA_T +3_OD_XT?\*Z\(?] "T_[Y/^-']B/^?\/^"']KK^3\?^ <
M>T$;S1S,O[R,$*V>0#U'TX'Y#TJ2NL_X5UX0_P"@!:?]\G_&C_A77A#_ * %
MI_WR?\:/[$?\_P"'_!%_:Z_D_'_@')U&\$<DL<KKEXB2A)^Z2,$_7&1^)]:[
M#_A77A#_ * %I_WR?\:/^%=>$/\ H 6G_?)_QH_L1_S_ (?\$/[77\GX_P#
M.3HKK/\ A77A#_H 6G_?)_QH_P"%=>$/^@!:?]\G_&C^Q'_/^'_!'_:Z_D_'
M_@')U4T[_D>#_P!@T_\ HP5V_P#PKKPA_P! "T_[Y/\ C6#_ ,(+X7'Q 6T&
MBVPMSI9D\O!QN\T#/7TKIPF6/#U54YKV\CGQ68*O3=/EM\S1HJ]_PKSPE_T
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M9:[FO.X? _AG_A8-W:_V/;^0NE0R!.<!C+*">OH!^5=!_P (!X4_Z EM^O\
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MRRRJA*H6$.T,>@S@XSUP:Z:BBX6"BBBD4%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!)!_KEJY5.#_7+5RMZ7PF%3<****U,SF[7_DI>K?]@>R_]'75=)7-VO\
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M 4444 %%%% !1110!S</_)3+W_L#V_\ Z.FKI*YN'_DIE[_V![?_ -'35TE
M!1110 4444 %%%% !1110 4444 <WXS_ ./32/\ L,6?_HU:Z2N;\9_\>FD?
M]ABS_P#1JUTE !1110!GT45Y_P#\+3M/^%F_\(;_ &7/GS/*^U^8/O[=WW,?
M=]\_A7&DWL=3:1Z!1110,*@MKRUO4=[2YAG1':-FB<,%93@J<="#U%3UY3X1
MD?PTTVM;C_96HZK=6^H GB"7[0ZQ3>RGA&_X >QII7$W8]22X@DGD@2:-IH@
M#)&K LF>F1VS@X^E25Q5QK$6@:[XNU.:-I1#!9;8D(!D=@ZJHSZL0/QJ:[U?
MQ/H-O%J6LII4VG^9&ES':)(LEL'(7?N9B) I(S\J\9/M185SKZ*HZSJMOH>B
MWNJ76?(M(6F<+U( S@>YZ"N=NM:\3:/I:ZWJT&FBP3:]U9PJ_G6T9(RWF%MK
ME0<D;5Z'!I)7'<Z2XU?3+2^@L;G4;2&[G_U,$DZK))_NJ3D_A18ZOIFIR3QZ
M?J-I=O;D+,MO.LAC)S@, >.AZ^AKSXVVM/XI\<2QW^FB2&"##O8.S*OE,5"G
MSAM(&<GG).<#I4_A?4-1TWPGX5TFR33YM2U*QCEB?R&BC@MTB0EI &)D8%@,
MC;N+=%P:KE%<]&HKD+CQ5=^')KR#Q(+9Q#8R7T%Q9HR+,L9 =-C,VUP63'S$
M'=VQ4HO/&<$<%]/9:9/"[)YNGVX<3Q*Q .)&;:Y7.2-J@X.#2L.YU D0R-&'
M4NH!90>0#G!Q^!_*G5QNC1:J/B+XA9[VR:U"VY>-;1@Y4K)L ;S" 1W.T[NP
M6MGQ'K4ND6UK':0)/J%]<+:VL;MM3>06+,1SM558G'ICO1;4+FS17+IJVNZ1
MK&GVFNC3[BUU&5H(KFRC>+RI=I95=69LA@K88$<C&.<UD67B3Q?>>$V\2"VT
MB.WABDF-HRR>9.J9R0^[$><' (;MSSP6%<[^BH+&[CO["VO(L^7<1+*F>N&
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M?=N[CA<X-=5I$NI2V;#58;=+A)"H>W8F.5>S@'E<YZ$G!!Y(P:35AW+]%%%
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M(^E6\MQ9W5EJ,&JPW$5L-->-#/*\@)39M<H00"<[L#')% %S^P?$/_0XW?\
MX V__P 11_8/B'_H<;O_ , ;?_XBN7\5_$FYM/(LM,L+VUU*+5+6WO(+E(BR
MQRG(VG>5.\ @$$@8.2O%:.G?$/3FN[FQC76;_49-7N;&*S>* 2*T04R!"I5?
M*4,,,[;CSR: -?\ L'Q#_P!#C=_^ -O_ /$4?V#XA_Z'&[_\ ;?_ .(J[8ZV
MNJZ1=W45M=VDT#2120W46QXW49]P1R"""0?6O);+QWK$O@#3M6LO&!U/Q3,Z
M#^PQ%:OYI,FTKLCC$B_)\V=W;WH ]-_L'Q#_ -#C=_\ @#;_ /Q%']@^(?\
MH<;O_P  ;?\ ^(JG<_$?2K:"[O39:B^DVES]EFU)(T\A9-VT]7#E0Q +!<>]
M<UI'Q$NYKF\_MDZE;A?%$NFVJVL5N5V*H(BER2>,$LR\Y(PV.@!V/]@^(?\
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M=&(/S#CFK,'Q"L+W3H+[3=*U>^@ELFOBT,"*(XP2""SNJE\@_*I)X^E %O\
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M88S%33:GM^GR,Y87#1:3A_7WG3?VEXK_ .AHE_\  *#_ .)H_M+Q7_T-$O\
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MO+R2GF!CO!&<':&SC/>NUHI7"QR,NBZNVHB:X87<G]A2VDEPNU!).S*<!<\
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MUMW(^YSCUKS,VBY8>R[GHY9)*M=]CHJ*Q_MVO?\ 0$MO_ __ .PH^W:]_P!
M2V_\#_\ ["OFO92\OO7^9[_M(^?W/_(M:NFHR:5<1Z3)#'?,N(GF)VJ>YX!Y
M SCCK6=X?TV]TH>5)86:B0EI[H7KS32O_>;,2Y_/CM4_V[7O^@);?^!__P!A
M1]NU[_H"6W_@?_\ 85HE)0<-/O7^9#<7+FU^Y_Y&5J%JD/CV.2[4FSU6P:RS
MDC]XK;MI(Z97./H:ED\))'XBTB\M&:.RLHY$:(W,NX9 "A1DX''(R!]:T/MV
MO?\ 0$MO_ __ .PH^W:]_P! 2V_\#_\ ["KYZJ2LUM;=>G?L1R4W>ZZWV?\
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M=/-;LQ>YD4$+\NT!!SD@$YZ5H_VAXC_Z%^U_\&/_ -KH_M#Q'_T+]K_X,?\
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M6_\ 0KV7_@V_^U4 =)17-_VKXM_Z%>R_\&W_ -JH_M7Q;_T*]E_X-O\ [50
M>,_^/32/^PQ9_P#HU:Z2N!\1W_B"?^QH[_0K:UMSK%GF5-0\TC]ZO\/EC^==
M]0 4444 9]%%>:?\+%UO_A;Q\)?V(G]GYV^=M?S-NW/F9Z;<^WXUR)-G4W8]
M+HHHI#"LC1O$^C:_<WUOI=\MQ-82^3<Q[&4QMDCHP&1D'D<<5KU\]^&H[O0-
M5\0>-K+S)(['7+BVU.W4_?M&8$L!ZH?F_P#U545<ENQ[I'KFG3:]-HB7&=1@
MA$\D.QOE0G .[&.O;.:T*\<UCQ3!H'Q!\3>)+<)=11^'[>2#!^60O(BIR.Q+
M#\*U=4O/&N@>"(O%3Z]'>SQ1QW-UISVD:PF-L95&4!P0#U).<'BCE%S'IU%4
MX+TWVBQW]FJ;I[<30B8E5^9<KN(Z#D9KR/7_ !QJOA_0?[23QM9:GJT,R_:-
M.M+>.2UP6P5#A-ZX'=FS246QMV/:*S=-U_3-7O=0L[&Y\VXTZ7R;I/+9?+?G
MC) !Z'IFN-T_7-=\9^+=9M-,U4Z/IFD;(28H(Y99Y6!)SO! 48(P!SZ^G!Z1
MJ/B/PQ?>+-6>[0O9:[;G5ECA4K/ Q8,R@@E>H/!XR?2FHB<CZ HKSOQMXSOM
M(\1VUOIT_P#HEAI\VJ:BJHK>:@^6*/)!V[GZD<X.:YU_'.J1>#%\1CQSH\NK
M&,7+:)FW\O8<'R@/];O _P!KKQCO0HL?,CV:BO*].U_Q+XO\>W%GINN2:9HP
MTRWOE5+:&213+&K!074]V).<],#&:JP^*=<EO=5M=4\7PZ!JEO<M%965[:1I
M!-&N-KL[+EMW/W6&/3M1RL.9'KU%>8ZGXVN;CQNWAV3Q'IV@6UC:1RWEX6CW
M3RNH8)%YV5VX8'.":TO GBZXU;7M<T&ZU*UU7^SS');:C:[-L\3C^+9\NY3P
M<>_'%+E=KAS*YWE5=1U&TTG3Y[^_G6"U@7?)*_117!>(O&<O_"P!X937K/0+
M*UMA<75].8Q)(S8VQQ^;E1P02<'OZ5P_C3Q1=ZKX5\6:#-KT.J16"VUS;WMF
M(BMU&TT8*R[00&5B/N%<D<\<4U!L3E8]5_X6-X7VVY^VW.ZYSY$?]GW'F2@#
M.53R]Q7'\0&/>NGBE6:%)4SL=0R[E*G!]CR/QKQ6:SN+3XG^%6EUW43C0WF\
M_P N#?&@1R44"+:1@=P3SUJUIOCK4->\.W>NOXWTG1[QC(UEI#M;X"J2 LN_
MY\MCJ".,''.*;AV!2[GL=5K^_M-+L9KV^N([>UA7=)+(V%45Y?X<\>ZS\0]4
ML-.TJZ72(X]/^U:A<)"LDADW[-D8<%0,\Y(/!IWC^R\40?#[Q+!J^J)<V4*Q
MO:W,4:)+.I904E7;@ $Y!3:3CT.*7+K9CYM+H]4AFCN((YHFW1R*'5L=01D4
M^O*]4UC6?#Z>&K*77+RST6XMO,N=7>TBE:-MHVQ<1[$7_:92>>O%=EX/O+N\
ML+AY]>L-;A$Q%O=VNT,4QTD"_*&'MBDXV5P3.BHK@KO6]9U[XC7GAC2=1_LN
MTTNV2:[N$A2261W *JN\%0,$'.#WKF?$?C?Q/X=TWQ;I$]_')J>F1V]S9:BE
MN@,D4DJ*0Z$%<@-C@>M-1;!R1['5+5M6L=#TN?4]2G\BSMP&EDV,VT$@=%!)
MY(Z"O/-9UCQ7X0M/#NK:AKBZ@E_?0VMY9FUC1$$@)_=LH#<8(Y)SQ]*W?BS_
M ,DNUW_KBG_HQ:7+J@OH=A#-'<01SQ-NCD4.AQC((R*?7E&IZOXI\'^&/#^N
MW.LQW4<\T$-SIWV6-8DC=>D; ;\J!C)8YZ^U%GXXF\1:KK3R>,]/\-V=G<O:
MV=NY@\R8KUD<2\[3V"X[C/'+Y6',>KT5Y5I?CC5M?\*6EY+KNCZ,MO?RV>I7
M[.O[S8 5-N&!0[@P.3^%5K7Q[J:ZAXLTNVUHZI%9:'-J-E?R6J1NDB*.,!0K
M#+ YVXX[T<C#F1ZK?W]II=C->WUQ';VL*[I)9&PJBIH9H[B".:)MT<BAU;'4
M$9%>+:W'XEU7X(W&NZSXEGF-S:),UG':P)&5+KMRP3=G')P1R<=!SZMX9MI;
M7P[8I->W%VS0HP>=8P5!4?*-BJ,#W&?<TG&R!.[+NH:A:Z5IUQJ%[+Y5K;1F
M663:6VJ!DG !)_"C3]0M=5TZWU"RE\VUN8Q+%)M*[E(R#@@$?C6'\0O^2=>(
M?^O"7_T$UQO@37+[7;?0=!T74%L[/2M.MYM0F\M6DN&9!B*,," H.0SXZ\#%
M"C=7!O6QZ-I>N:;K4E\FGW/G-8W+6MR-C+LE7[R\@9QZC(I-2U_3-(O=/L[Z
MY\JXU&7R;5/+9O,?CC(! ZCKBO+6^(/B(W.I:1;W43:A=^)IM*L9I85VVL*D
M<X &XC(ZYS[T_P 8:;K=CX[\"_VAK#:I:'40$DE@CCD23*Y'R  J1TXR,'DU
M7+J+FT/8:*\F\.:AXT\1:'K^K-XG-LMC<W$5K$EE"0_E\_.2N<=!Q@]3DU3L
MOBE>Z^?#EDVJV.@_:[-[K4+^;8,;9&CV1B3Y<L4)YS@'VI<C'S(]EHKQ35O'
M?B&VGUC3-&\1VFKM96JZG;WUO'"Y>)6 EADV KG!+9 !^7WKK-0\7W>L:[X0
MTWP]=>2NII_:-XX17*VH7.T[@<;CE<CD$4<K#F1W]8]YXIT:PU&[T^YO/+NK
M.Q;4)X_*<[+=3@OD#!^@Y]JV*\F\17MQIOQ4\27UI)Y=S;>#9IHGV@[75P0<
M'@\@=:45<&['J&GZA:ZKIUOJ%E+YMK<QB6*3:5W*1D'! (_&K->:>"?$^NW&
MO:7;:W??:;76=%CO;0F)$VS* )5&T#.<[N<X[8K%OOB/K<8NKJ"_M8+75-8.
MGZ7+=(@AM88^))RV!NR2.&.!@_2GR.X<RL>RT5Y7)XVFT;Q+I5E!XNLO$EEJ
M(>&0H8#-;2A?E8>4 -I/8CCUJ]\+[KQ1XC\/V/B'6?$,DL4SR!;1+6%5=5+)
MEF"[@=P)X(X H<6E<.;6QZ-1114E!1110!)!_KEJY5.#_7+5RMZ7PF%3<Y;X
MA1F;PFR);0W;FZMBEG-G9=$3(1$>WS8P,\9QGBN5\/K8:SX\TS4-/\":EH%Q
M8)*MW<7-DMO&RLA 1=IPYW$$''3/K73?$JWMKKP1=0W/]H$M+"($TY@L[S>8
MOEA200/FQD^F:Y+X?ZCXS@\5QZ1XDO[^*$P/+#:ZC;1LTR@8^2X0X9E)!(/.
M#6IF=M:_\E+U;_L#V7_HZZKI*YNU_P"2EZM_V![+_P!'75=)0 4444 %%%%
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MN<USVB?$33]=,C6\NFP1Q:A+9N+G4%1V5!D2(H4[LX.!D< G/:N%T/P_=_\
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M?)<M<64B+!(>5R64#G/!'\Q6+?:=KOA33Y?$FG64UOJ1UJ_TY(94,9EAN/\
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M,3CCD<]:U[[7)M,L-.N[ZR$27$B1W.)<_9B_0GCYANP#TZ]ZY+7?"SM=W/\
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MKM,L2\#]R5V;@!CEB/;O73CQ3X>-X;,:]I9N@=IA^V1[\^FW.<U=O-1L=/\
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MANH,?,A(4GKR#CO]*]%HH3:&TF>6M\,-3<:G>)?6D&J#7Y-8TV5=SHH8@[)
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MEE_;:=BE_P )1I7]^Z_\ IO_ (BC_A*-*_OW7_@%-_\ $5L45\U>GV?W_P#
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M9BK39V J1G SCZX[>Q]*/=B_A:^?_ #WI+=/Y?\ !,S_ (2C2O[]U_X!3?\
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M.>PS6?HGB2RO9[.WEL7T_4;^W:Y\EE!#%&VNN\<,RG&?8@UJ9B6O_)2]6_[
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M'[P 8 ;U&..: /.M3GOKG1O$^KMJ=_'<6.D1W5LL-R\<<<H@,A;:I ;+ 9#
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M +\BNDHH YO_ (5_X1_Z%W3O^_(H_P"%?^$?^A=T[_OR*Z2B@#F_^%?^$?\
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MSPU_T!++_OT*/^$,\-?] 2R_[]"MVB@#GM!\&^&Y_&]];2Z)9/"FFPR*AB&
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MK6O_ ,(]KO\ T.FI_P#@):?_ !J@#I**YO\ X1[7?^ATU/\ \!+3_P"-4?\
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MXR22S_A'M=_Z'34__ 2T_P#C5'_"/:[_ -#IJ?\ X"6G_P :H +WP;;WT%_
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MP%0)(?[AR#@=1Q@\GFJ_]BZO_P!#5?\ _@-;_P#QNC^Q=7_Z&J__ / :W_\
MC= %VUM)/[6O;^9=K2*D$2YS^[3<<_4L[?@!6A6%_8NK_P#0U7__ (#6_P#\
M;H_L75_^AJO_ /P&M_\ XW0!NT5A?V+J_P#T-5__ . UO_\ &Z/[%U?_ *&J
M_P#_  &M_P#XW0!L>'/^2@ZC_P!@J#_T;+7<UY5H.C:N_C>^C3Q3?1R#386,
MJVUN2P\R3Y<&/&!@GIGFNQ_X1[7?^ATU/_P$M/\ XU4E'245S?\ PCVN_P#0
MZ:G_ . EI_\ &J/^$>UW_H=-3_\  2T_^-4 ;-UIT-W>V-W(SB2RD:2,*1@E
MD9#GCT8^E5M9L9;AK"\MEWW%A<B9$R!O4JR.N3_LNQ'N!6?_ ,(]KO\ T.FI
M_P#@):?_ !JC_A'M=_Z'34__  $M/_C5 &SJ&G0ZE%#',SJ(;B.X780,LC!@
M#D=,CFG2V4<][;74C.6MPWEID;0S#&[_ '@-P!]&;UK$_P"$>UW_ *'34_\
MP$M/_C5'_"/:[_T.FI_^ EI_\:H E30#I*27.G//<7$4#P65O,ZB. .P) P
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M^SV4&WS)=C/MW,%'"@GJ0.E1:?XBTK5=2N].LKKS;NTCBDGC\MEV+(NY#D@
MY!SP>.]&HM#4HHHH&%%4[S5;'3[BTM[NZCBFO)/*MXV/S2-Z 5%9:YINHZKJ
M.F6ESYEYIQ074>QAY9<$KR1@Y /0F@1HT444#"BBB@ HJG-JMC;ZE;:;+=1K
M>W09H8,_,X49)QZ#UJY0 4444 %%%% $D'^N6KE4X/\ 7+5RMZ7PF%3<****
MU,SF[7_DI>K?]@>R_P#1UU725S=K_P E+U;_ + ]E_Z.NJZ2@ HHHH ****
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MWMO:1+;I%Y#LBM<7! +D _-A3\N!W)]*W'BU8Z#-;VT%C8WFWR[<1S,\<:X
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MS.=L-:\;O\*F\:3^)0;B.,S)9_8H?*=%?:=Y"[LG!/RD8X]ZW?"/C#4_$'Q
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MBZA X.X$ #[PZ$T75@L[G Z9\5-3UJT\-Z=<:K8:-<7D4L]_J<P10L:2.BA
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M;/@WPE=Z%J^N:Q?R6J76K2H[6MD#Y,(0'&"0"Q.3DX'ZT2MT!7.?\36%S/\
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M6_\ C5;%%?-<\?Y5^/\ F>_R2_F?X?Y&/]L\0_\ 0&L?_!BW_P :H^V>(?\
MH#6/_@Q;_P"-5H7URUG8S7"V\MPT:EEBB7+.>P%9=IKUPVMPZ5?V"VT\]M]H
MC,<_FC (!5OE&",^X]ZN*YDVH+\?\R)/E=G)_A_D2?;/$/\ T!K'_P &+?\
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MB6]:UFNI0C,D$2GYL=2S $*H[D_KTH ;]N\3_P#0!T__ ,&C?_&:/MWB?_H
MZ?\ ^#1O_C-:]K/]ILH;C;L\V-7QG.,C/6N;M/%\^I0PRZ=I$MQ%=7DEO;2E
MR(VC3.Z5V"G8,@@#DG% %W[=XG_Z .G_ /@T;_XS1]N\3_\ 0!T__P &C?\
MQFL@^/9/[3715TI?[9^UFV:!KG$7";]XDV$D$=MH-6=!\;1>(I-+2PLF)N[=
M[FYW28^S*K%!GCYB7! '' )H&7OMWB?_ * .G_\ @T;_ .,T?;O$_P#T =/_
M /!HW_QFIK'7!=:_J.CS6_D7%H$DC._<)HF'#C@8P<@CGIUK7H$87V[Q/_T
M=/\ _!HW_P 9H^W>)_\ H Z?_P"#1O\ XS6[10!SV@WWB9?&]\T6A:>\YTV$
M-&VILJA?,DP=WDG)SGC';K78_P!I>,/^A:TO_P '#?\ QBLKPY_R4'4?^P5!
M_P"C9:[FI*.;_M+QA_T+6E_^#AO_ (Q1_:7C#_H6M+_\'#?_ !BNDHH YO\
MM+QA_P!"UI?_ (.&_P#C%']I>,/^A:TO_P '#?\ QBJ6L_$&TTOQQI/A:&U:
MZN;R0)<2J^U;7<"4SP<L0"=O''-:WBKQ'%X7T*34'@:YF9TAMK96VM/,YPB
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M?3M9_LG3=+NFLH$CMHY6FD7[SN7!^7IP,'!Z@BCET'S'0IX\\-22*B:EEFU
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M !J@#I**YO\ X3K1/[NK?^"6\_\ C5'_  G6B?W=6_\ !+>?_&J .DHKF_\
MA.M$_NZM_P""6\_^-4?\)UHG]W5O_!+>?_&J .DHKF_^$ZT3^[JW_@EO/_C5
M'_"=:)_=U;_P2WG_ ,:H Z2BN;_X3K1/[NK?^"6\_P#C5'_"=:)_=U;_ ,$M
MY_\ &J .DHKF_P#A.M$_NZM_X);S_P"-4?\ "=:)_=U;_P $MY_\:H Z2BN;
M_P"$ZT3^[JW_ ();S_XU1_PG6B?W=6_\$MY_\:H Z2BN;_X3K1/[NK?^"6\_
M^-4?\)UHG]W5O_!+>?\ QJ@#I**YO_A.M$_NZM_X);S_ .-4?\)UHG]W5O\
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MAU7[:WA3Q%#*M^UG,;6.Q6^W^8TIV[P-_P V-V/UQ7:_\)/IOI?_ /@NN/\
MXBJMUK&AWLMM)<P7\C6TGFQ9T^YPKX(!QLP2,G&>E5"O5TYX-V];]'^GRNR9
M4:6O+)*__#?UZ(WXE9845CE@H!/O3ZQ_^$GTWTO_ /P77'_Q%'_"3Z;Z7_\
MX+KC_P"(KA]C4_E?W'9[6G_,OO-BJFG?\CP?^P:?_1@JE_PD^F^E_P#^"ZX_
M^(JK8>)=.3Q@9R+[9]@*<:?<$Y\P'ILSCWQBO0RNG..)3:?7\CAS&I"6':3[
M'H-%87_"7:3_ '=2_P#!7<__ !NC_A+M)_NZE_X*[G_XW7U1\V;M8GC&":Z\
M&:S!;Q/--):2*D<:EF8E3@ #DFF_\)=I/]W4O_!7<_\ QNC_ (2[2?[NI?\
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MHG]W5O\ P2WG_P :JGJGB;PMK6F7&FZC:ZI<6=PFR6)M&O1N'U$60>X(Y!H
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M"MH__@%'_A0!TE%<W_PKWP;_ -"MH_\ X!1_X4?\*]\&_P#0K:/_ . 4?^%
M'245S?\ PKWP;_T*VC_^ 4?^%'_"O?!O_0K:/_X!1_X4 =)17-_\*]\&_P#0
MK:/_ . 4?^%'_"O?!O\ T*VC_P#@%'_A0!TE%<W_ ,*]\&_]"MH__@%'_A1_
MPKWP;_T*VC_^ 4?^% '245S?_"O?!O\ T*VC_P#@%'_A1_PKWP;_ -"MH_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]C5R@ HJ&XNH+41^?($\V01)G^)CT%.AF6>/S$#A<D8>-D/!(Z, >W7OU'%
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M76K?VAI-ZD=O?V]C:VL<(-R9)(0^UQOVD[L@$'&".W- '8Z;%LCGWV"VLSR
MS,H7%P^Q09!@DD<;<MAODZ8P3QD7A761I>LV:;83:V,NG:*XE _=.2V<C.WC
MR8^F?W1.,$5IM\0M.AU^UT6YT_4;:\N5'EK*L8RYCW[,!RV<<9QMW<;JJQ?%
M7P_.46*.]>5[:VN$B$:[F,SJBQCYOOJ77<.@SU- %&V\&O.+>&?1Y5T\ZA%+
M-:7AMMNQ8I 6,<("8)91W+8Y&!3;CPM>V5MJ$>GV,=AM;472[C*1K^]C;RF&
MP[OE) Z9&..*T]0^(UC;ZAJ>DQ6UQ%J5M:W,T!N%3RY3"N3PK[P.XW!<C.#5
MZ_\ %$FG?#I?$<D2/=/8QRQPJ#M>:15V(!G."[ =<T <=IMC::OJ^H7.BZ#"
M-+1-/^TV,$L#)<%/M.Y,JYC)'F1,5+#.!GK7:>&O-TP1Z3/92VWG_:+JWA#*
MR6T0D4"(D$X/S@@+E1R < 9YF\^(>IV_P]CU9TT^UU>'4ETW4%G5F@MY!)L<
MX# X PP^;H:CB^(VK1>&KC7YXM.NM-T[4?L]W<VJ.JW-N0H\V#>W568 @E@<
M'!H T=4\/^(;O4M1UV VZW4-U%)8VKQYD>*#.%$GF!4\S?-U' DYQCBAJ_A'
M4;Z[UX1Z0LBWD%Q^\N3"YD8[6C5'!#?>4?+("$QPV ,W;WQ/XIM_ -MXB\C2
MXI)4:YDC\F:?RXF&8D"QG+,01N?( Y.,4:QXRUS3[;0=2CM],%CJ"VH>,L\A
M+RL X$RXCC50PPS9W=!0!)'X7E_M"ZU*'1TMK@ZQ9SVQS&'BME@MXY%&TD #
M;*I4'G'&1BL:Q\%:LFC36L]E<F[:Q$%U*\UN$NY/,0EAL 9\A6;=*0PW8&2S
M5L7GC+5](\7SZ=J,%B]D+6YNHUA619%2)=R_O'PLC,.JJ,KW)%-T+QQJ[O)%
MK6F+/*]A::C!'I,3._ESN4VLK-R4(R6! P"<#'( Z;PSJ%IJUPVE:?#%9K=R
MSV\0=4B&ZR,>=H(*@R<'&#R3[T>%K&Y\+W-Z]QIMQ!:WCVD,,:K;KB0EE8[(
MC@ ?)D_,VWDDX.-'Q=XCGT34](M(]4TG3(;WSO,NM3C+(I0*0H_>1\G<>],T
MOQL9[:'[=IURL@MGN[B>)5$,<*O(HE^9MV&$>X !CAAUY- #/%.CZK<:RFKZ
M9:+/<V-NDEJK2*OF2K)\T>2>-T;.N3P-U9VG^&M6T:2.X%F]XUOK:WSB.2,/
M<*VG""20;F"@^:S$@D< X[9U(OB+HTUI+.%E!C,0">; =WF,54[A(47D<AF4
MCCCD9OCQ;9;#YEM>12^7 ZPNB[G\YS&H7#$$AA@\X'!S@YH X[_A$M4GMDEO
M]$2<QO#,;5GBDW$7LTCJ"S!<^7)U. <X]13'T.8:S-:W?A\:C.\.H2PJ9(LQ
M>;?2O')EF 7Y64Y!W+Z9R*ZQ/'%ALDFGLK^WMPMPR321J5E\ABKA0K%L\'&0
M,]JM/XE\H1QRZ-J:7<TWE0VI2/?(=A<D-O\ +P K9RPP1CJ1D Y34/"NLS7)
M>ZAFOK<7,3SK"8&:XQ:I'O"390X<'AL'G(K=N=%O3X'L=.^SO<20O T]J\ZD
MRQK(K/%NPJGY01@X4XP>.:D;QQ9G<8=-U*=8K<W%P8T3_1U5WC<,"X)96C<$
M*&/'&:?'XXT>;7!I44A=S*(1*)(]N\KN V[O,QR/FV[<]Z ,?3_";RZ[:7-Y
MH\46EQ3W,]M92^6PL\K $&T$KDO'+(-N0I;L:YVPMQ=:DMMIFFV\NL0:7>PW
MMPLJ,+F4M& 7*ON!8AO]9L/4= <>A>+=5O-&\/27EAY'VHW%M AGC+HOFSI&
M25#*3@.3C(Z523Q'=Z3J4^G:Z8;AT2"1+JR@:--LLAB^9&=BNU@,G<>&S@8-
M '/:1X,N/[1A2]T@'2UU)KD07"VX4*;4QY,<7R#Y^P![$DG)K<;1=0_X5Y!I
M36QDGB:(/:F4?O84F5FBW9Q\T:E<$XYP2!FK4OC73TO(;5+>ZEDEEDC3:(QN
M$<@C9E#."P#9^Z"<#.,$9>GBZU:Z>-["^B@6YEM%NG5/+>6/=E1ARW.TX) '
M;.>* .2N--N]'M[V\L+"/2-0GUH'2K1WC_>+);0P-\L;$8!#2$ \>6"<#FM
M>$IK/Q/9&VTWSK*%(H3-<&*1?)6(HV"2)%8]U^9&SD\DXTAX_P!-73OMMU9W
MUG&]O#<0K<"-3,DK;4P0Y"\D [BN,Y/'-+-\0-*AT<ZF()W@222.3;+  A0
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M,P 4MF-) >,&M;3/$<]_K26;V<$5M+:)<07*S2,+C*J3Y?[H(RC<1]\-QG8
M0: .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X7
M59T\+>)Y[F^1O[$U8KYDH'$$PZ$^F>N?\*ZV[M++6].$<I$UO)AT>-_3D,&%
M3W5M#>6LEO<11RQ2+M9)%W*P]Q7#/X5M=(D8V47B"TC9L^5IUV3$?PY(KJ=>
MDXJ4VXR75*Z=OR?YA&#D]#M+6UM-)L%@@41P1*3R<^Y))ZFL.*S>^&GLJD*+
M]KMCCHH#?S)%%II=Y=H(7BDM+/(9_-E,DTO^\QYKI8XUBC6-%"JHP .PKAC.
M4Z_M%LK[[MOJ:SBHT^2^K_"QS%];ZGHGB.XU?3[%K^TO8U6YMXV"R*Z\!ESP
M1CM4<-GJ7B+6HM0U"R?3K.UBD2"&1@TCNXVECC(  [9KK:*[5B6ELKVM?K;;
MTVT,.4Y#1KK7='L[;1I=!EG> B);M)4$+)G[QR<@X[8JO$FN:5_;&EP:*]T+
MNXEF@NA*JQA7'1L\@CZ<UV]%5]:U;Y%KOOOWW#E/.EEOM%U/PM =/DN+J/3Y
M1);QNH;C&<9.#CZU8U#2=8UG3]>U%[!K>YN[=+>ULV<%]JMDECT!)[9KL9M+
MM)]3M]2DBS=V\;1Q2;C\JMUXZ=J<MH5MEB$KY#;BV>?PJYXYIQE".O5_]O7M
MOL.--/=F5K5C=W/]A>1%O^SWL<DW(^50IR:PY]$U5M,U&);4F276EN(QN',6
M5^;]#79-;N1;@2D>5C/^UV_QIRP,MV\^_(88V^G2L*>,J022CM_PY3IQ?4Y[
MQ7H\UW>6&I1:?%J2VN]9;.3 +JV.5SQN!'>K/AI(U-TT7ATZ.AV ;@@:4\]0
MI/ _J:U8+1X$D F9BR@ MSM//^-2V\1A@6,N7V\!CUQ4K$SE25.4?Q\[][?@
M#A%.Z9+11160BO?6HOM/N;0S2PB>)HS+$0'3<,97((R,\9!KE[+X9^&M,N--
MN=,M#8W%C&T?FVX56N%9-A$IQ\V1SG@YYHHH ?I/@*+2-(;28O$.N2:?]F:V
MC@>6)?*!_B5DC5MP[9)'/(-:7AKPO8^%K6YALWEE:ZG-Q-)*$4LY 7[J*JCA
M1T4444 :US;0WEK+;7";X95*.A/#*>H/L:H>(-!L_$F@76C7ID2VN4"LT)"L
MN"""I((!! (X[444 9MIX%T:QU_3-9@69;G3=/&GP+N&SRQP"1C)8 D9SW/%
M5H?AUI=O%:QPWNH(L%C<V! =/WL4Q+,&^3J&(((QT&<C.2B@"2?X?:1<6MS;
MR37A2>QMK$D2 %%MV+1NI"\.&.<].!Q3;;X?V$,[7$VI:G=W#ZA!J+S7$D99
MI8DV*#A -N.H ^F*** %?X?:6_B,:U]KOA*+\:@( R>7YVS83]S=@KCC=QVQ
MDYKVGPN\/66IVU_$+HS6VH3:A&&=2-\@4;/N_<78A4=05')HHH 3_A6.C_;W
MN_MNH_,;O;%OCVI]I!$N/DR>N1DG&!VXK4U'P;I>JZ-I6D7IFFL-.:-E@8J5
MG\M=JB3CYAWP,<@?2BB@#/'PTT"(W"68N+*VGN[:\-K;%%B26$\%1MXW8&[U
MQQBMK6_#EEX@GT]M0>9[>RG^T"U!'E3.!\ID!&6"GD#(&>N:** ,?_A7MBFC
M0Z7;:MK%K;V[S>3Y-PH,<<O#1#*D%!VR"R]B*6Z^'6CW,5K:BYU"+3X(H(6L
M8Y_W,RPG='O!!/!YRI&>^:** )1X#TM]:.HW-S?W:@SF*UN)]\,)F&V3:,;N
M02,%B #QBH].^']AIEM<16VJ:N)94@A6Y^T@2PPPMN2%&"C"=0<@D@D$T44
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M9$8#^\BG/%5(?!$=E):2:;KNJV#6VG0:;F$6[^9%#NV%O,B;YOG.2,#VHHH
MO>)(O+L[&^W$S:?>12QD_P 6[,39^J2O^)JJG@BP,,EM=7E]=V;&X*6LSILC
M,^\2%2JANDC@9)P&.*** )3X2A=GFGU/4)[PM"5NY#%YD8B)*JH"!<99LY4D
M[CD\#%JT\/6EF]DT<DY-G)/)'N8<F5BS9X[%CC^M%% #7\.0G5IK^.^OH5GF
MCN)[:*11'+(BJJL?EW#A$! 8 [1D'G/.^&=+L?$NC:QJ$D<ELVIZ@7 BD^:
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*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image13.jpg
<TEXT>
begin 644 image13.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (.!/\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[!0$_#\?3M7+0M=6]S'XADMU,$D[94#H#W_GSZBNNO-7LK>*W\UG\NZX1U'
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MT]"4(D@MF<[ACK@_AWK3ZU)SY;:7L8?4X>RY^;6S9L:7<RI92RW^HVLX5_\
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M8I\%A:6UL;:&W186^\F,[OKGK5FBG[.%W*VK)]K/EY;NQG0:#I=M<">*T02
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MM5NE,!8JH<\X&>3UJZ^HRS^'K&6;43:R2DJY1"7DP2.,=#4K%IJ[C;2_0N>
M<792OK9Z/U.IK-TC5O[56X/D>5Y+[/O[L_H*Q=%OKA->^Q_:+J:W>,L/M0(;
MIG(SVJQX1^Y?_P#7>B&(=2<;:)WO\K#GA%2IS<M6K-?-G245S?B&:[75=-@M
M;EX#*2I()QR0,D=Z8SWFBZW9Q/?374-T=K+*<X.<9'IU%4\2E)JVB=KF<<(Y
M04E+5IM+T.GHKC[6+4=4U;4H$U2>"**4]&)[G '/ J>(WNLZK=6RW\UM!:80
M>6<,QZ9)_ U,<4Y)6B]=MM;;E2P2BW>:T5WOI>UOS.FEE2&)I9&"H@RS'H!3
M+2ZBO;9+B$DQOG:2,9P<5R4DUW<6&J:?<W<C-9982*<&0#(VMZCI3[.>;2/"
MGVV.>1WFPL:.<K$<GD"I6,]Z]O=M?]/^ 6\!:&_O-I+MJKG845Q"7&JPB*XM
MSJ\TI(+I- 3&P[XY-:,L]YK&NR6,=U-9PP1AB(^&)XZ_G^E5'%IZ*+OV)E@7
M%_$K;M^GD='--';PO-,X2-!EF/:J<^ID:4+ZTMI+G=@K&H()&<9Z&L;4]/OX
MM N5NM0:58CN0J3EEZ8;U[&JVV>Q\&_:(KR?=)L*_.1Y8ST'H*FIB9IR5K65
M^ERJ>$IN*?-=N276QUL$C2P1R,AC9U#%#U4D=*DKE[J]O+B72],@N6A,\"O)
M,/O'CU_ T^*2\TC7K>QDO)+JWN5_Y:G+*>>]:_65S6MI>U_,S>#=KW5[-V\D
M=+17(:?'?ZG<:DG]J7,20RG:%<YZG'/8<=*U/"][/>Z26N'+O'(4#'J1@'G\
MZ*.)51I6M=7%6PCIQ;YKVM?Y[&W11172<84444 %%%% !1110 4444 %%%%
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M%)3Y3-E^2O3<,8.>1BO--&\6176IZRGB?XB>)-*,5TRVT=K+*X9<MGH#C'%
M'U'16=HEQ;OH.FM#>O=1O:Q-'<3G]Y,I48=L\Y/4^YKD-3^+.EZ;J-_&=,U&
M?3=.G^RWFI1(###-TV'G/7 )[$T >@45E^'-;C\1^';'6(K>6WCO(_-2.7&X
M ],X]>OXUJ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+'58+2"YM85@"6CEH]J@*O) YP.E;=%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% %>>X,5S:Q!01,Y4GTPI/]*L5!/)$EQ;+(FYW<B,
MX^Z=I)_0$5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4UP6C91U((IU-DSY;;<YP<8H BLH6M[
M"V@?&^.)4;'3( %3U7L/,&G6PFW>;Y2[]W7=@9S[U8H **** "BBB@ HHHH
M**** "BBB@ HHHH **X@ZGJTWA/0=3BU24:C<&)%MEBB*7;LPW!AMR %#'*%
M< $G.*SKKQ5K4=T=EV NH7,]K$AB3_0?+O8K8..,L2LA8[LC(7&!G(!Z15/5
MO^0-??\ 7O)_Z":X1O$&MQ#5/^)HS_V%(H.88O\ B8!I2N'PO!"C;\FWYCGI
M\M=KK]W!::+=&=]@DC>-."<L5.!Q0!-I/_(&L?\ KWC_ /015RJ>D_\ (&L?
M^O>/_P!!%7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>(K-'=?M06=Q'S')IXD3([& D?SJY\9M+U&R\1^&O&=I9R7MKI4H^U11KDJ
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M4U0VD<<5G!'$^^-(U5&SG< .#4U !1110 4444 %%%% !1110 4444 %%%%
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M% !15+^UK$:V-'\__3S;FZ$6QO\ 5;MN[.,=3C&<U=H **** "BBB@ HHHH
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M ) UC_U[Q_\ H(JY5/2?^0-8_P#7O'_Z"*N4 %%%% !1110 4444 ?)WQ?\
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M8&.$2,/XB<BB;Z(*CZ):E8W*PAHA'@ <<U'#<VD<F)H"Y/0Y/!J*ZD+S-(P
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M_P"BY*^<:^COV@O^1(T__L(I_P"BY*^<:^JRG_=EZLY:WQ!7UK\*?^2;Z/\
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MLK@NQ66W688SCWK'VRH<,2&'45KZ5.L8EC<XW(>?>L:B]TYZJM$AGN))9#N
M11T5>U5\XD*X_&FF7]_Y>.2>M7)+>2%E$J%3@$$^AYHVT"RC9!'"JKYAZM6S
M9HAU*&)7#*%Y/;I6/,=H"D@#K^-7O($-G#<V]RK,?OC."IK">J]3GJ+F6KW+
MFN7"1W7DPA!L'7/.:Q[N^FN9O-D &%VC'I5V.ZL))/.NK1YI<=5? -9UU/'-
M(S11^6H/"YZ44HVTML%&'+96VZA]JMH8<DL93Z#@5#N,F'R"O7:*KL@=B2IV
MU8MY%5,;,J>/I6_*DM#IY4E=#Y%61$,D10+SQWK4TX6OV&3S\+D_*V.3]*IW
MEU'<01Q*""B@$CO5(W+!0O.U>BU#BY1L9.#G&VQ)=!-[;&W+G@MUJGC=B,GC
MUIRR&>[2/:0IZGTJ6YA$,\D1!PIQDC!K5>[H;KW;1(5B.X8.<4DHQ(,CK1:%
MF^4N<J?6IKB1%EW;0W&,4]5*Q6O-8@$0;)(PO>FR- TK+ &Q_M=:G;<UMYF0
M 3C;FJUM%B3S&P .M->8T]+L6/<,@J3@=J]"^*REO OPXSU&FOG_ +XAKA7:
M(D+&V,+R:[[XJC'@?X=#)_Y!S\_\ AK6D]S:B]V>81)G@G%."DD\TP;E&#4T
M$S+(!C*GJ*3N#ON21[%4;B35I+NWB4JELKL1C+\XIKJC9( SCCBJNW!YK/21
MCI+<"5+^F3TJPJ!!GS /8"JS$$]*D5@%VMG_  IL;5T/,C@,%E(7VHLWN%=B
MC@@_>R:B9D12 <D]Z9&Q#Y'%%M MH79D:0^:5(!]JCCDPQ!'&,<UIV>L1Q0F
M&YM%E4CJ ,BLJ5U,IV@@$\5$>;9HRBY-M-&C:0Z;*?GEEC;IT!J[)'!;H8S.
M)(2#P>N:P$R?:GEW; 8DXZ>U2Z;;W)E2;>Y,C;8V4'AN.O457*A?E-/R2!44
MV2^235I&D5J(%P>>12=:7OZ4TU18C+QGL*;MQ\W:G\=Q4T4_EQNFT,K#H13N
M.]AMLB-(6<951GBJ[YD;.,<U<@^2WE8\9X6J<AQTHB]0B[R9])_ &,1^ [T!
M@<ZDY..W[J*O5*\H_9])/@*^)_Z"<G_HJ*O5ZZX?"CNI_"@I'7<C+ZC%+39
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M +4KWBO!OV=O^/GQ!_NV_P#[4KWFODLS_P![G\OR1UTO@04445P&A\G?%_\
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MBB@ HHHH \J^+NL:Q8:YX5L=+U6ZT^.]^U^>;=@"VQ8RO4'ID_G7(?;?$_\
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MISS72T4 %<IX\M=3NM.LAIT!G$=QYKQ+ LV]E5C&&1F4%=^TDYX(![9'5T4
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MHVVH:A''%=6J7*0(6*M+$R,X0*HX!Y '2NWHHH **** "BBB@ HHHH ****
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M 4AFA1110 4444 %%%% !1110 4444 %%%0W8N393BS:);HQMY)F4E ^/EW
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M29&<Y_"DW').<YIF:0GFBP6/I;]GXY\!7Q_ZB<G_ **BKU>O)OV>CGP#??\
M84D_]%15ZS71'X3KA\*"D8;D8$X!&*6FN"T;*.I!%44,M8E@LX84;>L<:J&]
M0!C-2U!90M;6%O Y!:.)4)'3(&*GH **** "BBB@ HHHH **** "L[7[J:RT
M"^NK=]DT4+,C8!P0/0\5HU'-!%<P/!/$DL,BE7CD4,K ]00>HIK<3V,'7Y=:
M;5K*UTB8QEH9)'R8PF0R %]REBO)X4@\]:?I%]=B^OH;^Y>9PIGBV>683%N(
M!0J V>,$,3ST)K4LM+T[3ABQL+6U'/$$*IUQGH.^T?D/2G6VGV5G)-):V=O
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M^;I].N[J6"6XU_79I+=]\+R:C*QC;&,J2>#@D9%3^7JO_0T>(_\ P:S?_%4
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M[83;O-$2A]QR=V!G/O5BJ]C*]QI]M,^-\D2NV/4@&K% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X/HG_
M "#_ (V?]=;O^4]>\5030])B6^6/2[)%OR3>!;= +C.<^9Q\^<GKGJ: //OA
M1XJ\.Z?\,=$M;W7M+MKB..0/%->1HZ_O'/()R.*V8_%7BJ;7-0L_^$0>/3H4
MG:VU'[4'6;:"8R$ S\V!W[UK_P#"">#_ /H5-#_\%T/_ ,36^JJB*B*%51@
M#  H ^7_  9J-_X:/AC4](\1B]O==U(IJ>C@*S#+[=S#J#CG) Z\<9S]0UEV
MOAO0['4Y-2M-'L(+Z7)>YBMT61L]?F SSW]:U* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"">W$MQ;2[]O
MDN6QC[V5(_KFIZK7,#RW=G(N-L4C,W/8HP_F15F@!#]TYX&*\B\$6ZVWB.QA
MM]1BN-'><W=K)'9,DDDK0.%$SEL;S'N<_+SP3C.*]>/3BO,O#DFN1>*;"WN]
M'M;6">22[EAMM)V);L8W5F,V[&_< O3+*X/0TNH^AZ;16+XCU>\T:TAN+:SC
MGC:>*.5Y)=NP/*B<  EC\WL..O8Y^M^)=1L;C56L+*VFM=(MEN+LRRLKOE68
MI& ",A5SDGJ0,=Z8CJJ*Y";Q;>%[B^M;6VDT:UNX;65VD83/O\O+J,8POFC@
MGG:>G%=?0)-/8\O^/W_)+YO^ON'^9KT#0?\ D7M,_P"O2+_T 5X_\<[OQ2_A
M>]M[K2[&/0Q=Q^5=)<$RMZ93M7L&@_\ (O:9_P!>D7_H H&:%%%<%JOB[Q(?
M'-[X=T+3M+E%I:QW#RWL\B9W]AM4T =[17"_VG\1?^@7X9_\#)__ (W1_:?Q
M%_Z!?AG_ ,#)_P#XW0!W5%<+_:?Q%_Z!?AG_ ,#)_P#XW0=4^(H&?[+\,_\
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M 8]%%% !2'I2TAZ4 <1XM_X\KC_<KZXKY'\6_P#'E<?[E?7% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2.VU&;T&:6D? 1BW3'- $5I.;FS@G*[3+&KXSTR,U-4-HT
M3V<#0+MA:-2BXZ+CC]*FH **** "BBB@ HHHH **** "JJ:A;R:A<V08B:VC
M263(P K[L<_\ :K58EUX<@U"^U=KXF2SU&VAMWBCD>-L(9"?F4@X.\=#Z^M
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MC/XXJU5:XG>*ZLXUQMFD96R.P1C_ #%6: $/W3UZ=J\N\!6=NUU9O;ZYILL
MN&NEAP%O99!$T1\U=QPV"68\DD=J]2/3BO/- U/4W\366DW-OIT=Q:/+]LNX
M[BV/VKY6P(XU_>*<D'D# !!SUI=1]#KM>TJ;6;%;1+J."/S8Y6+0ER2CJZX^
M88&5YZ\>E9^H^%9M0DU$_P!IF&/4[5+:]C2 88+N!9"3E258KSGC'>NEHIB.
M:E\)!I;F*.],>G7-Y#>26HA'WH]GRAL\*3&I(QZ\C-=+110%CR_X_?\ )+YO
M^ON'^9KT#0?^1>TS_KTB_P#0!7G_ ,?O^27S?]?</\S7H&@_\B]IG_7I%_Z
M* -"O.K#_DN'B'_L%6W\S7HM>=:?_P EP\0_]@JV_F: .YHHHH *:_W#3J:_
MW#0!X9\8/^0!??[R?^C%KZ!KY^^,'_( OO\ >3_T8M?0- !7/^._^2>>)O\
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MP>,=2.HJ3PW\1#XGDLVM/"^N16=V"4O9HD$('/)(<G&1CI0!VU%%% !1110
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MA_Z :A\)P7%KX;2.2"2)1-.UM#*"K) 96,2D'E<(5&#R!@'I1HLDTNN:PUQ
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MC?X(_P"W_P#]%QUS] !1110 5SVNUT-<]KM 'N/PK_Y)?X>_Z]!_,UV%<?\
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M45K^@XSC+8UZ***YB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M596 R,A@0<$CBJFG?\C'K7_;#_T T :]%%% !1110 4444 %%%% 'S5\??\
MD?[7_L'1_P#HR2O+*]3^/O\ R/\ :_\ 8.C_ /1DE>65]C@/]VAZ''4^)A7U
MQ\+/^2:Z)_UQ_P#9C7R/7UQ\+/\ DFNB?]<?_9C7#G7\*/J70W9V%%%%?.'2
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 5;E93=V13=L61C)@\8V-C/XXJU5:YEDCNK-$^[)(
MROQV",?Y@59H **** "BBB@ HHHH \O^/W_)+YO^ON'^9KT#0?\ D7M,_P"O
M2+_T 5QWQFT74M?^'TMCI5G)=W1N8F$48YP"<FJ^G>-_$=EIEI:M\.];9H(4
MC+!X\$J ,]?:@#TFO.M/_P"2X>(?^P5;?S-2_P#"P/$7_1.=<_[^1_XURT6K
M^*XO'VI>(QX#UCRKNTBMQ%E-RE#G).: /7:*\_\ ^$V\4_\ 1/M9_P"^D_QH
M_P"$V\4_]$^UG_OI/\: /0*:_P!PUP/_  FWBG_HGVL_]])_C2'QKXI(Q_PK
M[6?^^D_QH XOXP?\@"^_WD_]&+7T#7SMXTM/%_BG3+BUB\%ZK"TI4AGVD##
M]C[5Z3_PL#Q%_P!$YUS_ +^1_P"- 'H%<_X[_P"2>>)O^P5=?^BFK"C\?ZZ6
M_>_#S7U7'53&Q_F*S_$_B[6=5\)ZSIT?@/Q&DEW8SP*QCC8 LA4' 8D]>@!-
M '"6'_(.M?\ KDG\A5BL.WN/$<-K%$?!/B0E$"DC3I.P^E2_;/$?_0D^)?\
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M5^O)OAEH6L-#:7%S;V=OI]IJ-Y<*VQUNG=C)&%8$8V8<MGV7CC->LT %%%%
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MXKK?!=S<7O@;0;FZ=GN);"!Y'8Y+$H,D^YZTQ&[1110 4444 %%%% !1110
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M_P##2UE_T+,__@6/_B:^=Z* /HC_ (:6L_\ H69__ L?_$T?\-+6?_0LS_\
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MG%>=>*/B'X1O-)@BMM=M9'74;&4JI/")=1.QZ=E4G\*VO^%G>"O^ABL_S/\
MA5^PJ_RO[A<R.LHJ&UNH+ZSAN[:19;>>-9(I%Z,K#((^H-35D,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @F2%KB
MV:1L2(Y,8SU.T@_IFIZ@GMS-<6TN['DN6QCKE2O]:GH **** "BBB@ HHHH
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MKYV_:"_Y&C3/^O4_^A5W9=",\3&,E=:_D14;4=#G;KXQ^,KR)8IKVW*K(DH
MMD'S(P=>WJHJ?_A=OC?_ )_[;_P%3_"O.Z*^F^IX?^1?<<O/+N?8W@76+O7O
M!>F:E?,KW4\6Z1E4*"<GL*Z*N-^%7_)-M&_ZX_U-=E7Q]9)5))=V=BV"BBBL
MQGS5\??^1_M?^P='_P"C)*\LKU/X^_\ (_VO_8.C_P#1DE>65]C@/]VAZ''4
M^)A7UQ\+/^2:Z)_UQ_\ 9C7R/7UQ\+/^2:Z)_P!<?_9C7#G7\*/J70W9V%%%
M%?.'2%?+?QM_Y*5=?]<(O_0:^I*^6_C;_P E*NO^N$7_ *#7J91_O/R9E6^$
M\[HHHKZ@Y3['\!_\B!X?_P"P=!_Z+6NAKGO ?_(@>'_^P=!_Z+6NAKX>K_$E
MZL[EL%%%%9C"N6\9:)I.I_V7+J&EV5W(+Z&(/<6Z2$(6Y7)'0]Q7DWQ6\>>)
MM$\=7%CI>K36MJD,9$:*N,D<GD5P<_Q)\8W0C$VNW#B.19$RJ\,.AZ5Z=+*J
MU6"FFK/U_P C)U4G8^OJ*^1_^%I^-_\ H8;G_OE/\*^G_"5Y/J/@[1;RZD,E
MQ/8PR2N>K,4!)_$UCBL#4PR3FUKV*A44MC9HHHKB+"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH K7%P\5U:1*%*S2,K9Z@!2>/RJS4$\R1W%LC)
MN:1RJG^Z0I.?R!'XU/0 4444 %%%% !1110 4444 %%%% !103@9-<YX8\;Z
M-XONM3M])DED.G2B.5V4!6SG!4YY'RGF@/,Z.BN.U+XCZ?I^NWNCPZ/KNI7-
MEL^T'3K SJA9=P!(/'%.A^(VBW&@ZGJL<&H_\2L@7MH]L4N( >[(Q'&.?H#Z
M47TN%M;'7T5E7GB/2;'PZ=?N+V-=-\D3"?/#*1D8]2>,"L>;X@Z9!9:?*VGZ
MJUW?QF6WT^.UWW+1C^,HI.U?J11UL&ZN=;17.0^.O#\WAB7Q#]L:.QA<Q2B2
M-EDCD!QY93&=^2!CWHT+QKINNZE)IJV]_8WZ1><+;4+9H'>/.-Z@]1FCK8.E
MSHZ*XV3XG>'HKPQD7YLEG^S-J:VC&T67.-IDZ=>,]/>M/7?%^G:#=PV3PWM[
M?3(9%M+"W,TOECJY Z+[G\*.EPZV-^BJ&C:Q8Z]I4.I:=-YMM,#M)4J00<$$
M'D$$$$&K]#5@"BBHKJYBL[2:ZF;;%#&TCGT4#)I-I*[!*^A+15#1-7M]>T2T
MU6T25+>[C$L8E4!MIZ9&35^J::=F"=U=!1112 **** "BBB@ HKCM3^(VGZ=
MKUYH\.CZ[J5U9A//.G6)G6/<-P!(/''K6AX=\9:9XEN;FTMXKVTOK55::TOK
M9H)55NAVGM0M=@>FYT-%%<W<^-+*#Q8OAR&PU*\NP$,\MK;[XK8/]TR-D;<]
M>AXHZV#I<Z2BD)"J68@ #))[5DZ)XFTOQ%+?KI<_VB.RF\B29.8V?&2%;OC(
MR: ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C_
M (@ZA=66EVOV"6^2[>X"JMHD+A@5;/F"4A=GOGKBKO@ZXUF?2?\ B<MI1F0@
M(-/;@+_MC) ;V!(KG/BC9BYET7_B3Z3J2FX(G74+D0A4VMC![#/?GITYXM_#
M?3?L$6J,FGZ-802RIY=OIESY^W"\EWXY)Z4 =W1110!B^+?^17OO]U?_ $(5
MM5B^+?\ D5[[_=7_ -"%;5 !7R9\>?\ DJEY_P!>\/\ Z *^LZ^3/CS_ ,E4
MO/\ KWA_] % 'F=%%% !1110 4444 >N?LZ?\E$O/^P9)_Z,BKZCKY<_9T_Y
M*)>?]@R3_P!&15]1T %%%% !1110 45GZYJJZ)HUWJ3V\]RMO'O\FW3=(_LH
M[FO)KSXV6:^+[*:VO)SHOV!GN+#[)^_-QD@(,C.>1WQP>: /::*HZ/J0U?1[
M345@F@6YB6413+M=,CHP[$5>H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "FN-R,OJ,4ZFODQL%ZX.* (K.%K:QMX&(+11JA(Z$@8J>J]BLB:?;)-GS
M5B4/DY.<#-6* "BBB@ HHHH **** "BBB@ HHHH *;)(D4;22.J1J,LS'  ]
M2:=6#XMM)KO2[<QVK7D4%W#-<6J@$S1JV2,'@XX;'?;B@#>!!&1R#61IW_(Q
MZU_VP_\ 0#3?#%E=Z?X6LK6X01W$<9Q$S9$0))6/(_N@A>/3BJ-I%XA36-2D
M$=BK2>5N9UD"-A?X3W]Z .GKYV_:"_Y&C3/^O4_^A5[E_P 5'_U"O_(E<+XW
M^&&I^.-1M[R[O[2W>",QA80Q!&<]Q79@*T*-=3GMK^1%1-QLCYHHKV__ (9Z
MN/\ H-1?]\G_  H_X9ZN/^@U%_WR?\*^@_M7"_S?@SG]E(]'^%7_ "3;1O\
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M7TF%S'#TZ,82>J79G-*G)R;1XA7V/X$_Y$#P_P#]@Z#_ -%K7D__  SU<?\
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M/_Q4?_4*_P#(E<A1KT56T^6YFLU:[B6.<,ZLJ@X.UB 1GG! R/K5F@ HHHH
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MS3W-XR[A%V1 H 49YX'7FF:7\/;:SU"QNK_6=4U<:=_QXPWTJE(#C ;"J-S
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MQD;?C(*8S@$'T?[+;F+RC!%Y9.XIL&,^N*=Y<?FB78OF ;0V.<>F: 'T444
M4M7U&/1]%OM3E1GCM+=YV5>K!5+8'Y5FZ;KTX35(];B@MI]-19IFMW:1/*9"
MP(XSD88$8_AR.N!M7-M#>6DUK<QK)!,C1R(W1E(P0?J*SK+PYI]E87=G^_N$
MO%*W#W,S222+MVX+$YP%X'Y]230 R^\5Z-IN_P"T7,FY'5"D5M+*V2H8?*BD
MD8().,#/-5E\8Z9$_EWDKQRNS&%(K>67='O=4;*J1E_+; ZG( R2,XNM^ [I
MUM?['N@SI,9I)-0F,C"0((T<;D<,%4'Y/ER<$,I&:Z<>'=/66&18W4Q1P1(
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MDZK(WT4G->=ZUX<T[1]9\ >'=,LH8Y8KIKMY40!W$,>26;J=S$9KG(KG0/\
MA2FN:QK!M)M<U-[CSC*%:87!<JB#/(VX4@=@,TY;-KI^/;^O+S%%7:OUM^O^
M1Z9X8\:0ZCX,A\1ZY/9:;;SRR")I)/+38'*IDL>I S6]#KFDW&E-JD.J6<FG
MJ"6NEG4Q*!URV<#%>8:#I=G;>.M'T76_)-OI'AZ%[*&XP$:9CB20 \%AC'M7
M/:RT6H?\)7;:-B/2=>UFQTVV,(Q')(/]>Z8XQQ@D=:;6ME\OOY1)W5W_ %I?
M3T1[;;>(=%O-2?3;75K&>^1=S6\=PK2 >NT'-68M1L9UN6AO+>1;5REP4E4B
M)@,D-S\I Z@UYW?Z3IMC\3_">F:990VT6EV-S>R^4@#%=HC7)')Y)Z]:YFW\
M16FF? [5+TW<7]J>(+BY>.%7!D:2:0ITZ\+S4O:Z_IWLOOU*2U2?]:7_ ,OO
M/8+KQ%HEEIL6HW6KV$-C-CRKA[A!')GIM;.#^%9'BKQ<-+\.V6H:,UK?27]Y
M!:VC!]\<AD;&05/.!GH>U<=H%EIEIX]U&UU\VP@\/Z1:6]BET5V*A3,DBAN,
MY&"?PJO;1:-?Z_X,L_#MK<1:9-=7>N&*8%>5&$(4_=4L>!TJG9/R_2_^2?Y$
MW=OE^-O\VCT^_P#$FAZ7>1V>H:Q86MU+C9#/<(CMGI@$YJ?4M7TW1K47.IZA
M:V4!.T27$JQJ3Z9)KP/3)+^3P1J^K:C>>%3_ &E/,MZ+^VEEO1(6*B, -U'&
MU0..*Z*-+F36['2-FBO?^'-*A6:_UQI60[U!)CAW 9 &"Y.>U+IK_6E_Z]1O
M?^N]CUNTU;3K_3_[0L[^VN+/!)N(I5:, =?F!QQ4&E^(M%UQI%TG5K&^:+[X
MMKA9"OUP:\9T!M.O_ ?B$:K?QV=OXCUIK.WN;&#9 K #:^TG"HQ4YR>13M4O
M+[3!KL,]E8'Q'I6BN]KJFCL41X'8(?,0<!P/F'88R*&[:^7Z7_K[QI7T\_UL
M>QQ>)="GU5M*BUFPDU!20;5;E#(".HVYSFM2O!?[(N_[+\+Z'%J/A-/.N(9K
M*33K29KHE<.9"VXXR =S$8YKU7Q_K,6@^"=2O9K9[A"@A\M93%G>0G+CE1\W
M)%.2LO/847=E^V\4:!>:D=-MM;TZ:^!(-O'<HTF1U&T'/%/U/Q%HFBR1QZKJ
M]C8O+_JUN;A8RWT!->-WNGW,&O\ @KPXS>&(O]/CG2'287\Z*.,;B6E9B2#Z
MX&[K6QHEWX=^P^-=>\6BWEN3J4]K*DRJ\J0KA8XT4\\CH!U-+I]_X6_S_ .O
MW?C?_([36/'>F:7XKT;P^+BT>XU!F\QFN57R%"Y7([ER0%'&:N:3K_VK4KRW
MN[W20K7;P6"6]TK22A%!<,,_?!ZJ.@ZUY[H]MH=G\0;Z=+9([3P_H$(ABN@#
M*K$&7)SSN5 ![5FVZ#P_\/O OB:\;8R:M]LNY3V2XW[B?P*T]%O_ %=V7X('
M=[?UI=_FCU[6=;M=,M;I?MUA%?1VSSQPW5PL8(' 9LG(3=@$UST'Q!M(_$FF
M>'K^YTQ;Z2R-S?2QW:B.%P!^[7)R2<YY/W1FN%URSN=5\,MJ^H1O'J7C#4K6
MS@B/WK>SW[D3VRJEF]S72^&[#3=6^)OC*Y>"U)MUAL(5VKN&$_>,._5@,TM5
M^/X+_@H';^O7_@/Y'H#:KIR:9_:;7]JNGE!)]J,RB+:>AWYQCWS2WUXEII=Q
M>B6!4CA:022R!8^!D$L> />O&?!(F\6V6B^$)48Z=X?D>3520=LLB2L(8?<<
M;C]!7<?%F=QX$FTZ$XGU2Y@L(\=S(X!_\=!HDM/=Z[?D@COKTW-NS\16MOH]
MK-K^IZ3:WK6HN9ECNE$84G&Y2QR4R0-W2M2PU"RU2S2[T^[@NK:3[DL$@=6^
MA'%>=:/H^G:S\4]>OKNVBGM=!M+?3[595#(K;2['!XR,X_&M'X11 ^#)M15!
M''J6H7-W'&!@*C.0H [#"T]'K\_QT^]:BU2_#\-?N>AUU_K>DZ5+#%J.J65G
M),<1)<7"1F0_[(8C/X5DZ'XG^WPZY?:A+:6NFV-_);03LVP%(P S.S''W]PS
MQTKD/#]_X<_L;Q)KGBB33SJ#7MS'="[VM)'&C%8X@IYQMQ@#KN]ZQ?"FGV5O
M<^"M,UQ8TTX:5+J4*79PDMV\@.3NX+*C9 /3.:4=?N_/7\D_O'+3Y/\ +3\V
MCV*SU?3=1LFO;'4;2ZM5SNG@F5T&.N6!QQ4$7B/0YV=8M:TZ1HX1.X2Z0[8S
MC#GGA>1STYKRW7KVW@O?&VI^'Q FG?V7%ISO  (IKUW*C;C@LJN 2/4"MK7?
M"GAW2?#6B^'XYK+2[^62,P7$UKOCN9(@'99FXW*Q7H6&>,9QBCI?^OZV?HPZ
MV_KI_P %?([[3M8TO6(7FTS4K.^B0[6>VG655/H2I.*CLO$&BZG=R6EAJ]A=
MW,6?,A@N4=TQP<J#D5Y6WB'3[6/Q!;W^C:?+?3R6^DM=Z1<M!;71D#%5+\^4
M5!.X_,>0.:DL9$;XD:!:,GAZ!='LKF[F32'+^2NP(JLY SD$'&WMFC3Y?\"_
MY!K;^O3\ST#P[KMSK6K^((F6$66GWHM(&12&9E12^XDX/S-@8 Z=ZZ&N.^&,
M;GP/;W\IS-J4TU^YQC_62%A^F*[&FU;1[_KU"][M?UV"BBBD 4444 %%%% !
M1110 4444 %%%% !1110!Y/\8+26\DA$>C:M?SI92&QFL(V86USO0AV*D8X'
MOWKN/"?B!]?T\M+I6J6$D 5'&H6_E&1L<E>3D4GB3Q1;^'%?[5'Y>^!C;3S-
ML@DFYQ$S_P !/')X_*JW@S6M>UF&Z?6M.-HJA#"Q@,.\D$L /,?('&&R,YZ4
M =512$@=3BFQ313+NBD21<XRC C- &1XM_Y%>^_W5_\ 0A6U6#XJGB?PYJ$:
M2HTB*NY0P)'S#J*WJ "ODSX\_P#)5+S_ *]X?_0!7UG7R9\>?^2J7G_7O#_Z
M * /,Z*** "BBB@ HHHH ]<_9T_Y*)>?]@R3_P!&15]1U\N?LZ?\E%O/^P9)
M_P"C(J^HZ "LS7_^1>U'_KVD_P#036G69KY_XIW41_T[2?\ H)I,J'QKU/F?
M_/2C_/2BBO /VJP8_P XI/\ /2EHH"P?YZ48_P XHI#TH%86O</A/_R)F<?\
MO,G]*\.KW+X3_P#(E_\ ;S)_2NO!_P 0^:XJ_P!R7JCNJ***]4_.0HHHH **
M** "BBB@ HHHH **** "D8@(Q;H!S2TC %&#< CF@".U>*2SA>%=L31J47&,
M+C@5+45JD4=G"D+;HEC4(V<Y7'!J6@ HHHH **** "BBB@ HHHH SKC6K>WL
MM3NFCE*:<6$H4#+80/\ +SZ,.N*HV_BRVNKB.VALKMKAF97B!B)C VY)(?##
M# _(6/M27F@7UR-5MUU"V2RU'>71K1FD0M&$X?S ,?*#]WU'O4VJZ$U_%!;P
M306UI&RMY8M@64ALAHV!&QO?!^E:+E(]XT9+V*.Z:WPS2+$9GVC[JYP,_7G'
M^Z:=!=Q3VMO<!MBSJK('(!.1D#ZXJG]BD&MWDN/W5W:I'NQ]QD+]?J)./]TU
M#>:;="QTFVM'4O:RIND=,@*(V7.W(]1QGO4V15V7GU.PC:-7O;96D3>BF5<N
MO7(&>1]*9'K%@T:M)=0PN45VBED573..&&>#R!]:Y!-#U"#7[>S^SS26T=M'
M;_:%RL9 B*&4C=C=ABFW\:W[CPTD\L\AN%#2R3/GRLX\R,1^O;&??I5.,5U)
MO+L7'UF!=/NKW8XAM9FCE+<;0K;6;OP!D_A6E7,7NBZFNF:K9Q7EO);7YF58
M_LK"1#,<9+[R"%W$_=Z"NEC01Q+&O10%&?:IDET*3?4=13)HDN()(95W1R*4
M89QD$8-1V=G!86J6UM'Y<*9VKDG&3GJ?K4C)Z*** "BBB@ JCJVKV6BV3W5[
M,J*JE@I8!GQV4$C)J]4%[:17]E-:3Y\J9"C[3@X--6OJ#\AUO<P7<(FMIHYH
MFZ/&X93^(J6BBD 4444 %%%% !T&36;IVO:;JEQ<06EW%)) Y0JLBDL, [A@
MG*_,!GUS6E4%M:16LEP\><W$OFOD_P 6T+Q^"BFK"U)Z***0PHHHH **** ,
MVUU_3+S4YM/M[N&2>-5;"R*=V=W P<DC:<^F16E4$=I%'>SW:Y\V9$1^>,+N
MQ_Z$:GINW02OU"BBBD,*9)+'#$TLKK'&@+,[' 4#N33Z* ,_3-:L-8$QLKB.
M3R9&C8*ZD\$C/!/!QP>]:%06MG%9I(L6<22O*V3GYF.3^M3TW:^@+S"BBBD
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MF;9YF.VW.,\9KI=8U;2[?P5)H7@2UG8ZQ>/9VRP'"$; 9GBW$?*!D=AN)^M
M%3X<_"?Q%X#\0RZNMWI-^);5K<1^=)'C+*V<[#_=_6O4?/\ $O\ T#M)_P#
M^3_XS7EVE:UK'A30-1\/O'=:0EK>026DMS&DLEO8S2[6/!93L.X9).,C-=EX
M*UR]U'7M9LEU,ZQI%JL1MM1,:@L[9WQ[D 5]N!R!WH WO/\ $O\ T#M)_P#
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MJ$\FG1^;<V(A47"IGE@I;:0.<X;M6EI_Q!T#4?!$OBV*=TTZ%&:59 !(C+_
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MT[8KH+;Q)XZ^(/B'6HO"NJV>B:7I4QMU>6W65YWR1D[E.!P3QC''6A:Q7S_
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M@5OV#:=X-\<>'++6[QK6UTO0&^S/=CYGFDDPRC;D%@O&!FO8S%&91*8T,@&
M^T9 ^M#11NRLZ*S(<J2,X/M1'2W]=&OU"6K?]=4_T/![BZ?7_#/B>_5)89/$
M_B"#2X Z[7$2%5Y'4<!LCZUV'BP:?H'C;P9+J"I:^';&*=(Y&&(89]H$>[L#
M@'!/>O2=B_W1P<CCO0Z)(A215=3U5AD&A:6MT_RM_F_4'K>_]:W_ ,EZ'A_C
M#6!J]WXF\3:/N?35TA=&@NE!"W4TLH!V'^(*#C-=)XATJ"RE^'O@^U14C2]6
MX=5'5;="Q)^K'\Z],$:! @10HZ+C@4NT$@D#(Z'%-:6\G^6OYM_D#UO?S_%6
M_)'ANN>(+2VO]<UK2-6.F:V\QM[[PY?QB5=0*_(NU?O LN,%<U[-I$,=OHUE
M%%9)9(L"8M4  AX'R\>G2K1AB:42M$AD7@.5&1^-/I+2-OZ_K^D#U=PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!"H)R0#CIFC ]!2T4 -V+G.T9]<4;%).5'/7BG44 ( !T
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M#S[?[3"R3;\ID#YOE&#R.F?K704 %%%% !1110 4444 %%%% !1110 4444
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MR_$PMC^\?Q*G_"T;/_H&7'_?:T?\+1L_^@9<?]]K5O\ X5IHG_/:^_[^K_\
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image14.jpg
<TEXT>
begin 644 image14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +^!54# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+:$H&W9 Y_&@=CV>BN%\#6_B",O)J5_]JA)RIW UV=Y>V]A;M/=2K%$O5F/
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M 4444 %%%% !1110 4444 %%%% !1110 445POQ-\4R>'- =[68)<L#MQUH
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MV4++YUH%#_-Z8_PJ;Q?X)U'6['08;<C=9%?-RW88H&CE/G\9_$>WL=0.+=(
M=OKQ5/5]%M?!OQ.TY[:9O(*[RI_&M'QK$;#QA:MIK^3?10@$YVY_&N0-GK.O
M>*)4N)&FN=F$(;('6@-#T#PTBZIJ'B+5VZ%&"\=N:\U\'W+ZMKT.E7TC0V#S
MDL%Z'TKV[PGX7NM+\'W-I* +FXB(Y/<YKF;/X7WD7A"X@D"+J8D+Q.#R.G>@
M#/URR35?'EGX;:4C3H%!4#OTK,\4^';7P]\1=.6S=A&5'RU+K^GWEE_9BO+Y
M6JQ##2$]>G>LJS.I:U\2;,ZA)YA5>H.1Q0(^CX<>1'C^Z*?38QMC4>@%.H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGQW:+?^%[BV
M>8Q!\#</K735A>+-#?Q!H<MG'(4<\J0<4 >37OP]G\+>&1K=IJDAD@ DVXX-
M95[XBE\17FA3W*!&1P"P_BY%:Y\.>-[Q5T"Y+FRS@N9."HKJO$'PZ:?PM96V
MGHB7MI@AEXW$#UH&9/QA8"WTLC^^F*]+&?\ A&??[-_2O*M/\(^*/$FKVS:\
MI2VM>,,^<D=*]AGMMVFO;1\9C*#\J!'@OA#PK9ZS'K%W>2.SH6VCTJ'PSX8M
MM0\$ZU?74CM);,PB]L=*] \)>"=2T:SU..X*[KC=L^;UJ/PYX(U/3O!FKZ9,
M5\ZZ9BGS>M ]#C+K5;RW^&&FP)*0)9O+8Y_AR:G\;>"K#3O MIJ%J[)<%URP
M[UL:GX;70?AU%8ZJ1YX<^61SAN<5P>O7&LS:#:03W)DMPXVQA\_I0!VEN1KN
MI:#9JY86\2LY]>!7%>,-2N;#QY?16_RQN55G'88%>C_#7PI?VEVVHWJE4:("
M,$U-;_#JXN?&&IW]^B-:SIA,G/.!0!DZ\8?#WPY1=,<N;T#S9>X)QFJ.I^ M
M/?X9P:HDS+="/S6?^]QFM!_#=YH'A;5K/5G,EJQ)@).[:.WTKA=6NM:;PM!9
M"\S9@X10YR1]* /9_A.S-X%M2SEB"1D_6NXKD_AQ9M9>"[)&7:2"<?C764""
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0D
M 9-?-_Q=UF35_%4.EP'*[MG'UKW[Q!J,6EZ-/<RMM517R6NN!?&#ZI*&D59R
MZCKWH DO](N?".J6$\BE2S!LX^AKZF\+ZJFK^'8+E2"2G-?-_CKQM;^+(+98
MX&C> ==N*])^"&NI<:/)I\CL95+$ F@#S'QML'C]RP&WSCGCWKUFYO/#)\!1
MQLL(F\H?P]Z\B^(4;2^-)HT)#F5@/SK0M?AKXDO[&*5'8Q2 $#?0!G^ G(^(
M]HUJ/E\[G [5[#\7O!YUK2$U" 8EA!9^/:I/AW\,CX;E%[>A&N,Y!ZXK0^*?
MBN#0M!>WSF6<% /PH ^;WUW47T\:3O(B#8QGO7O_ ,(?!R:1I'V^89FEP5)'
MM7SGY4\4WVTQGRR^0:^I?AEXEMM<\/1Q(W[V$!6!^E SN:Y#QAX#M/%H0W$S
M(5&!@9KKZH7VM6&FN$NKA8V/0&@1X[XYN]"\)^&5\.11(]R!MWE>3Q_]>JWP
M/T&?[3)J9?$+!EVBNA^('@"#Q3!)K%M,API?.?05PWPD\0W&F>)_['ED?ROF
M)YXH&>CWOPXT;3=;E\174I=(R961EX]:\>\<ZG:>*O%:QZ9$J(",;:^B]1OM
M*UVVGT@72F29=NVOGOX@>#V\$:E'<6TO#$$$&@1[6G@I-8\&6NG7<K*1$.1]
M!7-ZK:Z%\-O#4UFRK//<*5!<=*Z#P/XUL[SPU'+>3>6\:A26[\5%XR\+6/CV
MP\ZTG1F0;LY]J!GE/PDT>74?%IU"*0I&@8G%,\?RIJOQ*MH'.Y5<)C_@55/"
M>H7GA/QJ=.5SLY4A3P:7Q"OE_$VSD?(WS!C_ -]4".V^+.@VMGX.M3!&%92N
M2!6I\$-6ENM&EM'^[$1@_A3_ (QSJO@N$]58J!5#X$JPL+AB",D4 >R3OY5O
M(^,[5)KY2\:7S^(O'C03-A P''-?55X,V<P']PU\G:RC6'Q =I05 D!R: /H
M_1=%TC0?#EOYD4>SREW,PZ\5YEXQ\,^']7U=+FTN%16QD*!7>^*].N]>\"01
M:8^9&B4C#8_AKYQUS2=?\--LOI71O9\T#/IRVN8?#7@KS[=O.6"$$>_%>(ZG
M\1?$?B&]F6VBV11L<;<]*[[P!JT47P\NKG5',L*)R&Y[5PS>)X[^[N(M"T\8
M.<D(!Q0!I^ OB;J2>((=)U)5,;$@L2<BK'B;XF:IHWC'R55?LI?"DYY'%>96
M?GIXSMVF!CF,@S7I?Q9T#=X>TO48$^8*"[CKTH ]6OO%"6G@XZU\I^3(';->
M9^#OB3K.K7EY)+$K0Q$D 9Z<UQ>K^-VNO ]OH\;OY@;#8->D?"_1[7P_X-N-
M5OT 210QW#.1B@1Q>O\ Q-U_6M1EM+6 1+&Q *YJSX0^)FL66OVVEWRJZ2OM
MR<YYJ#4_%EC>ZQ-'HFG+O+G+>6!FN.N#=#QG9/<(8Y-ZT ?0?C_QXGAC1HY(
MMIN)A\H)Z<5XY9?$3Q-)<M?+'NCSR.<5#\3;B>>_L8Y&)0!>I]A7LO@+1M-/
M@=2]M"VX$DE10,\ZTKXO:M>>(;6%HD$;, W6NR\>?$\Z'86Z62J]Q*.<GH<5
MXQ B1>.IA$H"B9@N.W)J/Q1<2-KR;B7VL, TK@=%:?$OQ'I]\E[<)F%V&<YK
MW[PGXEM_$VCQ7<1&\J-ZCL:^?]7U.\U+PXEO_9H10,;PH%=Q\#;6_LX+A;A6
M\IA\N3[TQ'LDLBQ1,['  S7RIXTG?Q#\0EM]VY&EV@?C7U->PM/9R1J<%EZU
M\J7BG0_B2C7(8JMQNS[9H ^B/"7A'3](T.",P([L@+$K7D?QG\)0:0\.HV8V
MALD@#&.:]YTB\BOM*M[B%LHZ BO(_CUJD']G6UDK9D()./PH B\'>,9(/AS)
M#]^1(2!D_6N%^'FCQ^*?'3"\)/5C6UX7T.[;P#-=(A(,9Z?C5;X,7$5KXW<3
M/M)5@,T >]:CX4TV^TAK+[.B_)M5@O(K@?#'PE71_$LE^\S-'NR%QQUKU6ZN
MXK.U>XE;$:+N)]JY'1OB1I&KZS+IL3-YJM@9'!H F\8Z%IO_  CUY,+:-9%C
M)!"UX9\-;2WN_&TD4R*Z[^ 1[U]">,N?"U]U_P!6>E> _"_/_">2^GF?UH ^
MCK;1["TDWP6T:-C&0M7J.U% !1110 4444 %%%% !1110 4444 %%%% !111
M0!4U/3;;5K&2SNTWPN.15/0/#FG^&[)K73XMD;-N()SS6O10!QNO_#?1==O6
MO762.X<C<R-C=6A!X*T6WT1]*2W_ -'?[V3R:Z*B@#&D\,:;+HD>DO$3:Q_=
M7/2JTO@K1IEMT:W.VW.8QGI7144 <KXB\ Z-XB9'N8F611C<C8XI8O &A0Z5
M_9\=N1%G).>:ZFB@#FM3\#Z/J>F164T)"PKMC8'!%0>'OA_H_AZ7SX$=Y_[[
MMFNLHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH6-1@ 5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!CX_WZ\;&UN-N/PHV@\ #\J0SV7_ (7M 3C^S'_[[I&^.\(_YAC_ /?=>-;
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M'2 C/]F/@?[=+_PO2#'_ "#'Y_VZ\=51OVX&WZ5(UN,#:!S[4 >NI\=8&/\
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MF#9[4 ?4!^(/A\?\OB?]]"F_\+#\/Y(^UK_WT*^8EB=VS\V#5L6B[02&S]:
M/I-?B#H#?\O:_P#?0IW_  G^@=[M1^(KYQ:T!B!C##'7%1-;@A1ALYYYH ^E
M8O'FA3/L2[4GZBGS^-]$MQE[E<>Q%?.EE;BVN0P#$?6M2ZM#?8 !P!VH ]Q7
MX@: W_+VOYBG_P#">:%_S]+^8KP:/P\./E8'ZUI_V+!;VV7Y;ZT ?0EE>PW]
MJEQ P:-QD&K%<_X,C6/PQ:!1_#704 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %5IM0M8)5BEF5';H":LU\W_$W7
MM1MO'L,,-S(J!N@/'6@#Z/!##(.0:6LCPS.]SH5O)(26*\D]ZUZ "BJE[J=E
MI\>^[N(XE_VFQ4&G:]INJ<6EW%(?16YH TJ*9+-'!$TDKA$49+$\"L0>,=#-
MY]F&H0;_ />H W'=8T+L<*!DFJ<.L6$\YACNHVD'\(:H=6/V[0;H6DJL6C(5
ME->+^#=#U>W\<R//>-)&&Y!;/>@#WRBF22QPQ[I75%'=CBLE/%.C279MA?P^
M8#C&Z@#9HIBR(R;U8%?4&JJZM8/(4%W%N!P1N% %VBLD>)=(-Y]E%]#YP."N
MZM565QE2"/44 +3))4B0NYPH[T^JNHVYNK&6$<%EXH AAUO3KBY^SQ7<3R_W
M0W-:%?)WV_4_#/CYO,N)0!.?O'C&:^H--OQ=:%#?,W#1;R?PH ==:UI]G,(I
M[F-'/8M5R*5)HQ)&P96&017S%X@U"^\1_$M+*TN)"K2 !5/%?1FDQKI6B6L-
MS*%*1@,SG% &I2,P52S' '4FL:/Q7HLMY]E6_A,GINJWJD@;1[AXV!_=D@B@
M!8]8T^6<PI=1F0<;=W-7J^7O#VH7S_$>56NY&4SXV]NM?2[W]K;>7'/<1H[
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MRBK=/UI3"?O8_6M+[.C/R>/I4DML@48/'KB@##:-NF#^=.\KY<XZ=JTOLN9
M/3VHFM74\+0(R2O0_I0!@D]C6C]A.1DXS[4PVGS$=A2 I8'I2;3D'I5TV^QL
M=:<+?=GB@"C@GK_.I$CST[^]6UM@S8Z8]JOV]DF,\?E3 HI:DC@$YJTNF,L>
M>3GWK3CMU!X/0>E7HXTV>OX4 <O-I[XS@G%49X&2(+M/WN:[>6)",!1^54;B
MQB>/'\6[K0![MX%&WPE8CTC7^5=)6'X1C\KPW9K_ -,Q_*MR@ HHHH ****
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MBN."*6&&263;C\: &!1N&!D5/Y0F*@*<CWJ]!IS[ERN,^U=+I6@I)EB,^^*
M,W1?#YOIEW;@@-;%[H-M;W**&) Z\UI6<8LI64' !ZXJ/40'990_7VI@9']D
MAV:.//'-0QZ+^\/^SUK:TYU>\VAASQTJ.Z=HKN54(Y- %.#3X^2_ 7CI3S'Y
M)_=GK4T+DH0W7.*DFB'E@KVYH CCDD!567K4TZ@0-O/2H8F,J;NFWK39'\V,
MH3UZ4 >Q^#R#X;M<?W?6MZL#P<FSPW:KZ+UK?H **** "BBB@ HHHH ****
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M)IHBVGIWJY&H'R]12,@R",#!H @"#S.1S5P +@ 'D4TQ!CT!/K3@A#C)&.]
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MC9M.:-VQQ][BOJBH#9V[2^:8EW^N* /%_"/PKO[+3;B6\11<.,KSWQ53P?\
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M#2@GJ3P/>@ 8X7Z4U"Q/?-+C?DYP/K0A'"]_7- $B'/!-/1PKE<?+4!&"/\
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MQBF*K!6+8*J.*09:!F[#M0 Y2 V[\:?*YNFV#A:@@<O\OI4[+MM]ZG# ]!0
MFP+M13R.I]:=LV28&2QZ\5#G:ZN0?7K4C2%Y=Z<8]Z 'N/(FPISD=JGC;Y@2
M?K5%IE9\<AN]/CG"N1UQ0!9GN68;2"!GO59B?,&T5)(3,=W3':H]YS\JY]Z
M ,Z29)&!1 H\QI7. #TIK+Q\S=:D,:F'.Z@!ZF+SFDQE:)E%S;M+NPB]1ZU2
M2Y'S1!*B>1Q;/$'*J?>@#W'P85/AJUVCC;705S7@7CPI9C.?EKI: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD=>>]1Q2D94BE21@V6 Q0 UY2SD%>/I3E*HI(_/%.@"N&9ACTYI-HV[0>.]
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M7^5=!0(**** "BBB@ HHHH **** "O%?BP2-<AP >?Z"O:J\9^*D;MK4;*.
M?Z4 <!YAS@TT2C<?>I8T#M@FF-'Y<A]30!(DB+]X#/IBE5U#;B *0JIYYS4,
MC''?CI0!964?,W&.U(D@E1LG+=JKJ3LYS3=Q0\9P:&,MQNRH0!R:8C;&;>3S
M2"0D #\*'(*Y)^;VI"'1N5W%?7M5MG!C4]&K.C;Y^:O;D:/&><<4P(Y7^92,
M9S5O>0F3C.*SEW(Q'.:F$_!#]Z 'I<EI>P%23WAQ@8JFQ&20"&[4I/R9QEJ
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M-R3TS[@57=G#@^M.5PK^N>HH M"X^3 &*4,SID' [U7\P,^WG!H-QY;;3D4
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M((ZU+<_O@#CIBG!>=N?TI9V C '0&@#Z&\'KM\,V8_Z9K_*MVL/P@<^&K/\
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M!EOC_MB@1ZY1110 4444 %%%% !1110 C?=/TKYS\2 ?\))? '^-OYU]&/\
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MKFK30A!\I^M-C1)&*D\"@"B5)Y!)_&FH[8;=T]ZT3"L8)X.?:J<L!(XX .:
M'CB'\:KE-K$YYIOFG?@]!4L<32'G.#0,4!3'G/-6DM]T8[U$T&P+STJVLNPJ
M"!B@"-8VBF7G;^-6[BZ"H&(R#WS5&ZN1OR".*JS7+, ,#;0(+F8,W7Z<U6CD
M;=P3D>]$[?,I&.?:A!EQC'/6@9,TI<<Y/XU);X529/3BFG:D@'!'TI2X=CQ@
M4 (YW#*CFIF=/)&1S55"4) .:DW \&@!R8(R3^.:6=P(2,Y/>HY>F%XJ)O\
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MH JS# S@YJD^/X><^M7I%#<;@<].:IE,$XYH @V\]Z0_>'M4C9QP:1@< D4
M1GMUI,@'K4A8;:B=0><T#$+%CDYIRG!YHVC?C(Z4I7CDBD(4L#TIKX)SDT*H
MYQ2!>>WYT#$.1^-)*3L&/6G=3BF2G"],\T"/IGP7_P BM9?]<U_E705S_@K_
M )%:R_ZYK_*N@I@%%%% !1110 4444 %%%% !7AWQ=9AKT(5<Y/]!7N->*_%
M=E77821W_H* /-C$4;><BC(//-6YI4<]*A!B5\$#GWH&1;LCG.:8N=_>KRI
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MG\:;*3D8/3K2,_RJ>GIS0 XD;AUS5S3PK3L'[CBJ#'Y<\=?6KU@N+I3ZD9H
MU)4BA&<#(J(Q^>K% ?05;NQ$;@!C\I%2D0*GR'E1VH$8%P)0PBP21UXJ%PO1
MLUI228E+<<U";7SFWG@4#,]5^;=S@TXC!R,X]:M/;1Q+@L,]JAWKC;@?G0!5
ME)Z &GPJ=O0[J9,^.F./>DBD(Y_K0!:"9&">:=&$C5L]:J>8V_(Z5:@MGE0Y
M/7I0(89 H)VT,YE3 S[5<BT]F)#8%6?L:0 #''>@#*BAG9U&"!]*N'3G(Y5C
MN]*UD$051CM237 AMV3(./>@#V?P+!]G\*VB9/W:Z2N:\"N9/#%JQ[KQ72T
M%%%% !1110 A.%)]*\.^(/BS7[K4FTS3CB'D$HN>]>D_$/5I-%\&WEY$<.H
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M.*;Y#*2"#S0(CPK-C;UI'@7H>_M4^W:1A?FJ&>3)Q_6@8^*P60_*?TJXMI'
M0<\_2LZ*25 2K$$]!5@>>Z98$_C0(U$N+=(^0#^%>A?">X29;T(. P[5Y;%9
MRLI9D.WZUZ7\'X##%>\'E_6@#U:BBB@ HHHH **** "BBB@!&^XWTKYA\4''
MBC4 .\I[>]?3S?<;Z5\Q^)XI/^$IOSM)_>'O[T 9>U0 3R:?M#CZ=JC,,V.$
M/M2?O$4X!W&@9(4!. :0Q%?XOQIB!RK,<C%#"0QG.?:@"98U>3''3TH,)0<-
MD5759@P89Y%78(3-P2?IF@"(1#:S']::5!P3^6*M/"2I4=O>HDB.=HY/UH (
MXT92&&<>U6()$3Y@.:BVE 01^M1JQZ;>,\4 :-S()$4KD^M1&=^0 170:38P
M2VI+H"?6EN=/MTB;8@R!0(YF68$#'6HVFFSA6/T%69H%C9MPZ]*;Y6W&WDT
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MHHH **** "BBB@ HHHH **** *&KR7,.G2R6IQ(JDCBOG.\\=ZZGC/S6FDW
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MHN%W9^M8 F&=ISUJS;2[.,T :S1QL 0*AN((RHQ@?A3HY@L?'ZU5GD8GC\*
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MOE2;2.,]<5T2 H,]/I55Y=LX)Y&: (8]+& 6;  ]*G@L[4J^<9'M3Y;P$]2
M!TJ@+@"9B,XH >VEQ2/@-C\*DALXDR>.N.E0K<L7P"=QIWG$*%- %LIM&U6&
M#VQ36MF8%/Z55>Z*E2N35Q;AF !'- %>33XBO^U]*;_9*L,,?TK34!N6_"I'
M<(#ZT 8PT=%!'7WQ65=Z1LE)'0>U=7$X/K[T2"-U/]Z@#DH[10O*#\JLQ6>6
M7GC/I6X(HE4[AR.U,=H49<YZ\4 4VB:.(I@?E7>_#*,1PW73E_2N.EN-[C"]
MNU=K\."S1W188^:@#OZ*** "BBB@ HHHH **** $;[I^E?//B"W#>([[YQ_K
M#GCWKZ&?[A^E?./B$S_\)3>XS@2'H?>@"H^U3@=:JRQA1GCFE+M&Y9@<^E0B
M1L9()H EC5=I!QTJ6".,@[N:ABC8@N>E/C!;*G@&@9.OE!]I P!3?.AC<[<#
MCTJN\91QUH\O:-Q!R*!$HE7:<8Y/I2KB+YP ?PIJ1D=,\UJ65FD@ <GF@#-=
M#,-P  'M420.\F O0]JZ632GW@1@@"K\%E' %D*CG@YH JZ:TD=N(]N#5S[$
M2"6;[PZ5+)+;A3M.,=*BDN@8MX/S"@#(FTG==8.2,UK+X;BC@$A?YJH_:W>8
MGFK"W,C@9=MH[9H KS:(2QQ@]QQ5=]+*(0XS^%;:7&U@P)+'J#4\_P"^CS@Y
M]Z .%EML2E0,8]J;;0GS3G'!]*Z*XLP23W-58K$K(QZ4 0! QR #^%2M%N"U
M>2T1=IR?<5H?9D:,,, B@#(>)@0@Z^PJPT+$+&.5[FK\;1!#O4;OI3&D'E\
MY)ZT $-BTD6#VI&MXXH#ZGVIWF2[?E)Y':JLD%S<;ERP_&@#UWPKM'A^V"G^
M&MJL3PI$\/A^V1^H6MN@ HHHH **** "BBB@#Y\^-$MQ=>(H;) %4L,-^ K$
M3X9ZU)"K"]?YAQQZUT7QDM;J37H9+<#AO7GH*Y)OB'KFEQ+;R2.2!P=U(#W3
MX;^'[S0-"6"\F,C8[UVM>=?"SQG_ ,)+IABN'/VA!DY^M>BTP"BBB@ HHHH
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MW0@'O69<HC2<?G41N]R8SS[5$9">IH LQPA@Q R*22V4)N--AN"@X[5))*7
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M@4TK'Y6"* *>"DF\D<U,]]\NW R!3YA'LX].*S';9+N8DYH L23 '<Q%,AN
M[LJ@5"X#KDYSZ5+;H(UW YXH EWE0-N,BK,*O*,E\"J#2-G(4Y^E2P/+L(''
MI0!<FA6,9#9%5X)E*D8Z&G"-V4[VXIT=J N\?C0!8CD'&:D-TL<9^49]:KEE
M0\53N92ZMS@"@#V'PQ)YFA6[>HK8K"\('/ANU_W:W: "BBB@ HHHH *1SA"1
MV%+37^XWTH ^7_BKK=^GBJ:+S %5^.*\^N+N:Z;,Y!/:NR^*_/C&Z ZAJXC<
M,\\"D!Z5\%9IQXL\M&Q%M&1Z\U]/5\6:!XCNO#E_]JLGPP/<9KZ6^&WCB7Q=
MIY:X \Y<YXQ3 [VL[6=;LM#LS<WLFQ,X'N:T"<#->#_$37Y-6\5IHLLNVVC?
M)[4 >D:/\1]$U>[%M'*5D)P,BNP5@RAE.0>E>#VWA&R;5[-]*NP)%92PWYS7
MH?BOQ!>>%M(LS$AE/ <XS0!VU%>=3?$ZS7P\MTCI]J/&S/?Z5>TGQ;=W?A>>
M_EC/GA<H-O6@#=U[Q+8Z#$C74H5G;"CK6E9WD5[:)<1-E&&<U\R>*-6US6-3
M6XU#<D*R_*-N*]VTV\.G^ EN0>4@!!_"@!=>^(&CZ%.(9Y29-V" ,XK8T77[
M'7+?S;.4-ZBO!O#FC_\ "=>(]1DO7<A"6&#CO6AX'O[G0/B VCAS]G)/#?2@
M#TOQ]XL_X1RP"Q,!-*.,BN1\%^+]9OM:BBDVR6\N2>.E1?&6TFN;W3Y "( ,
M,?QK!\-WSZ5XCT^&R(D1U^<#G% 'T&.E<]XV_P"17N_]P_RK4_M:P4 /=PJV
M.07&:P?&.J:>_ANZ1;N$L4. ''I0!!\,O^11B_WS795QWPS_ .11B_WS78T
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MGYFIK3P;H=C<+/;V:I(IR#FM^B@ HHHH **** "BBB@ HHHH **** "BBB@
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M/>!86YJ@;ABASUJK-(6B+%OTH ^A/ <OF^%K5O\ 9KIJY3X=D'P?9^NVNKH
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M&031+(O1AFGU7L8C#8PQL/F5 #5BN-[FX4444@"BBB@ HHHH **** "BBB@
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MJWW3]*^<O$EPP\27ZEN!(V/SH N+?J%8"J5S>Y7);@5C&Y*\YQ3?/\W..<T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\S?%'_D>+CGJ?Z5QW3'7FNQ^*0!\<3_7G/TKBRQW C&*
M '\_>YXI!SZ\TF?E[<T8[C'TI +VQS1R.>:,<=L4# '44 .W=C4B/@9&>:AX
MI0P% %D2G'6GB7Y>O6JJ<@G-.5L'VH&78Y> .:"QSD9Q557^;C&>U/W'9R13
M0%D28QUQ4Z2\8YS6;NYZBGK*1W% %UI!VS4+R +UJ+>.O%,W!ES^5("4/@5(
M'XYS5-7QP:>)!F@199@5J%C@$CK2!@5IKMC\:!CDDR><XI=V3WJOGT%.!QCI
M0!*TF#AL\]*A,B#)^;/3-#G@L".!7K_PU\$Z+KOA@7=["7F\P@D&@#R$.",\
M_C3)F+(/KFNE\?Z1;:)XA:UM%VQ\\9]ZY5LE!GKF@1]3^!3_ ,4E8_\ 7)?Y
M5TE<WX%_Y%&P_P"N2_RKI*8!1110 4444 %%%% !1110 5X3\7V \10@XZC^
M0KW:O!/C&X7Q'#USW_(4 <.WM2$_)GG-5S/D9I#(-O)% QRG+=ZDSSGFJH?L
M"*DWC&.*0$Y<@=Z:&&,'--X(SQ321C@B@"0-\QZX[4Y2<?6H=P( IX8=0<^U
M BY'Z"IE'&>]4X7P>:M(<]2*8QYR>QI\#,-PR<>],:0*.,<4V)MQ8\4 !)W8
M.:1\B@D$\XS4;'=W'O0 C'*]Z:2"G!Y-,8@#M@U$<G@4 +*Y\O%5PW&33W^Z
M<FH"3FD!85ZF!(&15,&K"G<N* )#G@\BHGQ_%FI#A1G Z9ZUT/AKP-<^*X)+
MB*3:$/K0!R+94MALBO6O@6.-1/\ MBN \5>&)_"]VMO*P.X<5W_P,^Y?]/OB
MF(]IHHHH **** "BBB@ HHHH 1ON-]*^:_$\3?\ "3WW7_6'^=?2C_<;'I7S
M/XGN"/%%\H(SYA_G0!CW$;8Q4EK S$<<U&9F/7'-7K61<+ZT 3I;!1N(YILP
M^3UJT75DQZ"JTDBE@>,4 ,3 SD4Z0#R\C) -0RR#>-O:HVG&< C;0,),$;@#
MD57:0'CG-+)-ANV.U5)' );(YH G5^>]62VY1DG@5GQM\N>,U(;C(X[<4 6O
M-YS3C(O49]ZHHY)P:<)  >>* +QE!7*D\BH%<8.>IJ$.=O%-9^=V0: %DWJ<
M@G&?6C)SD9]Z0G+8R/:F9&=N1F@"3G!Y/-*F6X%1AN#G&*9'+\Q.0!2$6BVS
M &<T22 X!S54RG[PQ4;W0Q[F@99=P1FH6DPI ZFH/,+CVI=K3.L<0RYX '>@
M0%RPQS44S%83R>E7Y- UF"+SI;.18L9R4-9LP.Q@1TIC/I?X7_\ (DV1_P!F
MNTKC?A@N/!%CT^Y794""BBB@ HHHH *JZD&.FW 3[QC.*M4C ,I!Z'K0!\J0
MSVEEXOU;^V!D,6";AGG-/MM3TF/PEJ$#_P"L<G9@5ZAX_P#A;8ZM*U_;2>5<
M$DD;L"N%TSX5127L:75UB+?\PW\4#.[^!T4J^'7=MPC;[N?J:]8K'\-Z-8Z'
MI,5I8X,:#&0<YK8H$%%%% !1110 4444 %%%% !1110 4444 %<]XV_Y%B[_
M -P_RKH:YWQM_P BQ=_[A_E0!0^&?_(HQ?[YKL:XWX9_\BC%_OFNRH ****
M.,\9^,X- C\D%O//3%<[X7^)4=Q?"WO&<!N!FL;XMZ=='5H[I8V>/..![5Q6
M@Z?=:AJT*0Q,"#R<'%=M.E%PNS%R?,?4,;K)&KJ<JPR*=5;3XVBL($?[RH :
MLUQO<V"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S
M+\4S_P 5U/CU_H*XT 5V7Q3.?'4^,8SZ^PKC >?QI *<]#^%*"??\J.._P#.
ME(]Q^= ";O\ .*;@D]:4CC((Z>M(.G7]:!BDT!<C@TAY-"G'(Z=Z '+P<4#K
MGTI!ZGI2\[J!#U)W$BG;\@]:B'7V^M-R5/6@"4'ZT[OWJ-3\N._UI0??I[T
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M3$<Y\:S_ ,3:W]=HQ^M7/@9PM^/]L9JA\;6(U>#G^$?UJ_\  M@R7^/[P[T
M>TT444 %%%% !1110 4444 (_P!QOI7RQXI8KXOO^2/WA[>YKZF?[C?2OE+Q
M8V?%NH#TE;'/N: *1G'/M5RV;<@(K+W#:<CYCUJW;S;%&#Q0AFNTH9 HX.,&
MH'D6+CKBH?M"XR?PYJO+/SEN<T 2/,=V,'FFEB4[]?2H)9N%/K2J^1DL/SH$
M#MP3GBJS-N/>B0@O@-P>O--X4G/\Z0#Q(<[>?RIZ-R15?S!OQC]:4.4_'WH
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M"ZVU>U\/[-6W>:>FX>YKO*Y/P#XG;Q1HBW;Q^6WI764""BBB@ HHHH ****
M"BBB@ HHHH **** "N>\;?\ (L7?^X?Y5T-<]XV_Y%B[_P!P_P J ,[X9_\
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MQCBD Q1TZT D\4" GTZ4J_>&:!QS2T *V,\<"DQG_P#528)H_/\ .@ X'?\
M2G!>O^%,(YJ3G'?\Z &CI_\ 6I5QBD(.W/\ 6@&@88R#@4W;SBG G!I.=U !
M@D9S2<BG$$#%)R.M A3V_P *4?7MZ4W.XX&?SIV".* (ST;-?17P;Q_PA@P?
M^6IKYU8$ ^]?17P<&/!8X_Y:F@#RWXJ''BU^>[=O>N&E(V#'K7;_ !1RWBV3
M/8MC\ZX>;.P8ZYI@?5?@/_D4;'_KFO\ *NEKF? 7_(GV'_7)?Y5TU !1110
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M3 GP?-_UQ/\ *OE:X# S#G[WI7U5XF)'A";'>$_RKY9N20TIYX;CFF!]+_#
M8\#V'^Y795QOPOS_ ,(-8$_W?ZUV5 !1110 4444 %5M04OI]PJG!*'!JS4=
MPADMY$'5E(H ^9-/TW2F\>WR:]*HC,AP7^M>@'0/ALN<S6WYFN5\5_#'6;S7
MYKJ OAW)&*QV^%OB,Y.^7/3K0!]!^%;31[32U31BAM^Q6MZN)^&N@7N@Z L%
MX[LWHQZ5VU !1110 4444 %%%% !1110 4444 %%%% !7/>-O^18N_\ </\
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M%% !1110 4444 %%%% !1110 5SWC;_D6+O_ '#_ "KH:Y[QM_R+%W_N'^5
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M-7T^,B0B8<, U=IX<\*67AZ+; I+$8+$THP>YGAZ,W-3.A[4445T'K!1110
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M ,(8,_\ /4T >6_%/_D;Y.G5OYUPTV-HQZUW/Q3_ .1N?KU;'YUPTO08]13
M^JO ?_(H6'_7)?Y5TM<UX#_Y%&Q_ZY+_ "KI:!!1110 4444 %%%% !1110
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M0#N.*&X.:!@3@<=?K1_GK2#D\\4IQUX_*@ )_P YH'O_ #II(S]:7OB@ '-
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M@5>=TAZ5YE<+M,B/@,IPV*8'TU\+\_\ ""V'^[_6NSKC?A@0? ]AC&-E=E0
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M5)_PIC1,?ZP_]\T ?/WF*.<GFM#0=331];M[[G$3;J]P/P6T0_\ +0_]\_\
MUZ4_!C16',A_[YH SH_C99;%4Q_,!R<4I^-EGNQY7Z5>_P"%*Z)G_6'_ +YH
M_P"%+:+_ ,]3_P!\TP*'_"[;+_GE^E+_ ,+LLL?ZK]*O'X+:*1_K3_WS2?\
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MP0UMB3]LA_6D7X(:UT-Y#^M '8?#3Q%I=CX;$5S/&C@C[Q [5VG_  E^A?\
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MC7!>![PV/@ W07>8RQQZUPK_ !WECN)8_P"SV^5B/OT >[T5X,WQYE+<:?\
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M+M\1?W_T% 'T]17S#_PNWQ%_?_04?\+M\1?W_P!!0!]/45\P_P#"[?$7]_\
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M% 'T]17S%_PNSQ#_ ,]#^0I/^%V>(?\ GI^@H ^GJ*^8?^%V>(?[_P"@I?\
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M!]:LQ/K[X<C'@G3_ /KDO\A6UKN!HMUGIL-8OPYQ_P (5I^/^>2_R%;>N?\
M(&NO]PT ?%M]C^T[O_KJW\ZAP/:I[[_D)W8_Z:M_.H:0"8'H*,#T%+13 *.*
M** #BBBB@!,#THP/04M% "<4M%%( P">:,#KQ12X.1[T )1QCI4ACP,GBHR,
M&F-H.*.***! 5 I,#T%+DGKFBD F!Z"EXHHI@'%'%%% !1Q110 <4F!Z4M%
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M\!R_]=%KYD&-OTZ4,I$1..:,]O6E- Z4A,,?2D%.S_\ 6H 'O0 #'I4B+DY
MI8TR>]7!&H3OFI;-H0N5&4XP/2HRF.M6BAW \TWR]S$#UJ5(J5,=:MCBII7
M6FQ0E3WITT1*YYJ&TV=45)0*3?,2>*:!SVI_1B#FC//>MCC:U&Y'MB@8]O:E
M(.3UYI.G'-!(N<#-(TF>,TI/'>HAUYHL-RZ#N_TI>#]:"1C'K3<G-!+8=LTJ
M@DT=J<.!UH 0* *7C%!?GO2 F@>@]6"GMFI&F+#@C ZU"3CUI"_;FE8I3L/W
M9SWICDG@_C2;N.])ZTTK$N5Q.U-IW;O3:9FPHH_R*7\\]Z8CUCX"?\C)<?\
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M1113 **** "BBB@ HHHI (>AKTGX'_\ (YR9Q_J_ZBO-^U>D_ XG_A,Y.O\
MJ_ZBF!]/4444 %17*EK:11U*G%2TAP!D]* /EWQ1H'B.'Q7=W5C&R[I"0PJ$
MS^.0@P\F /2O8O''CW1_#CM&(HY;DGGH:Y#0/B]I]Q>I;WMDJH[  [,4 =[\
M,9-6D\/JVJDF3'>NYJGI=S:W=A'/9[?*<9&VKE !1110 4444 %%%% !1110
M 4444 %%%% !7.^-O^17N_\ </\ *NBKG?&W_(KW?^X?Y4 <UX7S_P *RFQU
M^:O ] _Y'FU_Z^A_.O?/# _XMC-_P+^=>!^'Q_Q7-KGK]J'\Z!GV!%_J4_W1
M3Z9%_JD_W13Z!'G7C_QS-H$JVMOCS&..E<KX=^)U\FI+%?$&-SV6KWQ2\/7U
MW?I>6\;.J]@,UQ?AWPSJ6I:I$K0L$!R6VUW4HP=.[,).7-H?2%O,MQ DJ]&
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M6]I8@#FLIL[Z,&]B.5P!C'-0QR?O,X^M7#""<&F-;X^Z*E2-G3E<LH 1FED
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M!R,4V@GCG^5)0 M%%%,!RX&<\YHW<\4VBD N?:DHHQ0 4444 %%%% !1113
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M^\X)&?>O1-<\2ZAH_A+3KN*(NS*-_P"5<CX/\.S^,];.NZG,2B/N5#R,=:]
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MHHIDA112$A02QP!U)H 6D8;D9?48JF=7TX.5-[ ".HWBC^U]._Y_8/\ OL4
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M)C_K7T)3 **** "BBB@ HHHH **** "BBB@ HHHH \T^-_\ R(4G_71:^8E
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MT(N:*/;M1WJSG"@?6CL<48XI .V[N_Z4VE&>@I* "BBBF 4U^@^M.IK]!]:
M/K[X<Y_X0K3^/^62_P A6UKO_(%NO]PUB_#K_D2M/_ZY+_(5M:[_ ,@6ZQ_<
M- 'Q?? _VE=^GFMV]ZAJ:^!_M*Z//^M;'/O4-( HHHH ****8!11[4N#BD-%
MFQE\N3YCQ6C=20R0;1C)]JQ!Q^%7+=&<@'.3[UE.*;N=M&K*W(0F!E.0>/I7
M16$L2Q(@QN[\53O+%EAW(3TK-MYW@F4<G!J)>^M#JH1]C4O8ZYQ&C E0/PIC
MWMJ&VEER3566?=;[L?-C@9KF9Y)&F8\Y)KGITK[L].MB%2^%'5S"VF?<H&<=
M:Y[4FV2%16E81/\ 9_,<GBLB^8O*6.>*VI+WK''C7S4EIJRKSQ3D<H<CBF]:
M*ZO(\1WC+0EDG>3J?PQ40'O^E'/O28]S1:VPG*^X\*2,^E-/^>*>C8&WUII!
M/KQ[T$B $#FBC\Z*8@HHHH **** "BBBD 5Z3\#\_P#":2?]<_3W%>:GI7I7
MP/S_ ,)G)Z>7Z^XI@?3U%%% !2$ @@]#2TA91U('U- 'G?C;X86/B)_M%O&D
M5P3EF ZUYQJWPRB\*VPU*^^>&,Y8'I7T5O7^\/SKSWXQX;P-=88<+T!Z\T :
MGPZU/3=1\.QG345$08(48KL*\H^!:@>%<COZ_4UZO0 4444 %%%% !1110 4
M444 %%%% !1110 5SOC;_D5[O_</\JZ*N=\;?\BO=_[A_E0!S7A?_DF,W_ J
M\#T#_D>;7_KZ'\Z]\\,?\DQFST^:O ] _P"1YM?^OH?SH&?8$7^J3_=%/ID7
M^J3_ '13Z!!1110 4444 >#?'L?Z3:?[A[>]7/@)_J+K_=_K5/X]Y^TVG^X?
MYU<^ O\ J+K/]T?SH ]MHHHH *^9_B?837GC9RJD+SSCWKZ8KPKXEH$\0AD&
M&P<\^]9U9<L;G7@Z2JU.5G$Z/X$N-8F\M)MIQT-;<OP3UK),<_';@57T?4+F
MSU&%XF88<;N:]!UWXA3Z?Y<-O&&9@,DFN>G5NM3TL1ELE+]V>>R_"76--3[5
M.2Z)R>E4_E4D%0-OM7KGA_Q7_P )-9S6LZ['"X;FN*UKPE);ZB5@?,;GTJ*M
MGJF=&#AR2<:BU.?M_!-_XNR]GP$.,BK2?!/7=X#2$C//2O6/"=C;^&]+=WDY
M;#-FKT7C;3Y+LPB09)QUK>G:,=6<.*C4JU'R+1'BNK?">_TBR>XFF QVXKD+
MC198 &ZX/3%>V?$Z^F>*/RI#Y3$#@UYGAF=%;)R1GFH=5J=C2G@$\.ZDGJ>^
M_#P,O@^T5A@@&NJK!\((L?AZW5.@%;U=2=SQ9*SL%9VO?\@*]_ZY-_*M&L[7
M?^0%>_\ 7)J8CY(3_D<3V'VG^M?7ECDZ7%CKY8Q^5?(2@GQ@3@_\?/\ 6OK[
M3C_Q+H#_ + HN+F3/-+[2O'3ZA,T%W,(2QV ,.E5I] \<W41AFNI&!X.2*]>
M_&BAZ@>*Z?X+\7Z2SM:W#J7/.,5>.D>/^0+R;I_>%>NY HI))!8X_P %V?B&
MU60ZW.\F?NACFN/^.O\ R";<9['''N*]>9MHW'@5XS\7;^VU>&.SA;+IGD&A
MM(3FH[F#\!Q_Q.[K_KGZ>]?0U>"?!"QDM];N\DX\OC\Z][H3NAIIJZ"BBBF,
M**** "BBB@ HHHH **** "BBB@#S3XW_ /(A2?\ 71:^8A]T5]/?&_\ Y$*3
M_KHM?,(Z4 +1GZ<4JC)[T,-I[T@LQ,C.2 :?&Y4@KBF9]C3AGMFEI;4TIMIZ
M&[9W!9/FJ?S_ )JH6YV1BI-Q/K7'.&I]!AZ[<47UER*1YAG&.*@4G'7%0R.Q
M/!K/E.J59V$NI4YQUJBDQ1OQJ69#C-53UQVKJA'0\BO6ES7-6&ZW#@U<CE(/
M.*QX"5QC-:D6YAWXK"I%)G?A:TI;ET2!EQQS5:8=<8_*E0NK=\5.R_+DYK#9
MGIM.6AG1+\W/K6A&,+CCBH3& W&:F7CJ:;8Z:Y= )!&#Q3XU .*4*I&3UH?Y
M2,9J&=$8VU)&B!%59(\'-6@W/-12\BB+*KTXRCH9;X!/ J(N O;WJ2Y8J>,^
M_%9TLK=.:ZZ<;GS6*J\CL).P))XJOGG'%2YR*8>O>NI*QX\VVR)CSS24]NWM
M3*LQ:84=Z#3EQFD"#%)V[59"*1Q4,@QQS2*:T/5?@)_R,EQT^X?Z5]'5\Y?
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MT'UH ^OOAR<^"M/X_P"62_R%;6O?\@2Z_P!PUB_#K_D2M/\ ^N2_R%;6N_\
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M.K)(X^7BJB^5W-J524)W9]!:C>BSLI9\C"#-?/OB7Q#/X@O6:<@Q(2%%6?\
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MV1!/.<D'K]:J%CT_K5J\4 YX_*JGXUT1V."M)WU"BBBK, IK]!]:=37Z#ZT
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MDJ:YHK4]'T3QAIOB8-8S[2S_ "[3WJ4_#W1ENC<^0O!W>U>1>#A)_P )';&
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ML_ZBO-J])^!Y_P"*TD''^K_J* /IZBBBF 4444 %%%% !1110 4444 %%%%
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MZU87'!':L)*QZE%W>A<1S]:E XR?Y551QP<_K5@2?+Q_.L6CU*=1=1^!C/\
M2F%<#../I31)S_\ 7H:3:,?UI6*<X]"E/G<>/TJ '#U8G89)_K54D;B>U;16
MAYE9^^7H#W)JV#QUK.MYUZ'K5Y#D=>W-9R6IU4JBL.D?8.M4KBXSQBI)W[9R
M*IRD8]ZJ$3'$UR!VW$_X5$V,$@8/TH9_3\>:83SS_.NR*T/"K3YF1'(/0_E2
M;C[_ )4\MV'7ZU'GVZ^]:)'')NXXG-(& %-/2HB33L0Y-$Y>HVQVJ/>33<FF
MD9N;%-';_P"M24N>/_KTR3UGX"?\C+<<_P#+(_TKZ-KYR^ O_(RS_P#7,_TK
MZ-IB/./C9_R(C?\ 74?R-?+J_=%?47QK_P"1$;_KJ._L:^75Z?\ UZ '5(LK
M!-@SUJ.B@:=@[TH('44E%(0&C&>U.0;G"^M/FC$6 #D_6@:1%[?THQ[49&>?
MYT=^M K#@0.,?I0HWN!GK3:<BL>5'- T65A .#CVI7A,?.,5&A=6&[L:LW$O
MF1@=347.J,5*-V0 X'6H9"":<3@'GZU$3Q32,),,T[S",4RBFT0I,E27:W/\
MJ?+=,R;0"/PJO10HHM5))6'*=S?-_*IHX<MD]!VQ5?G_ ":LQRG8?6A^14-=
M63JWD-TZTYKP;>!SZU1:5F/7I3,D_A4<B>YJ\0XJR-*WNMR,&JA.,RMCIFD5
MBH]*:S;NO\ZJ,$F14JN<1 "S>E.=0#Q3:,]LU1SAWQ1110 4444P"FMT'UIU
M-?H/K0!]??#G'_"%:?C_ )Y+_(5M:]_R!+K_ '#6+\.<?\(5I^/^>2_R%;6N
M_P#(%NO]PT ?%U]_R$[OU\UNWO4-3WQ_XF5WQ_RU;//O4-( I*6B@ _I1113
M **** #OS_*IH8BXX./PJ('G_P"O5R)D7V]LU,C:DEU+MFCQ?-T ]JO(RNK,
M>?PJL"PBY'';FD@?AQT]LUQ2NV>W"481Y3/O)V#';D?A5(99O>KEZI#9QQ]:
M9;[ =Q'2NNG\)Y-5.4V5\;>"*09SD5)<N'ERHQ40Z=:OH<][.QK6Q5[?YN3B
MH3<)%N7%45D=.C'BD9BYR:A1U-W7O&P,<L32=?\ ]5%&?:KLCE>H4449/2@
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MM')_?4-6!XUUJXT/07NK9"T@( Q0!TE%<?X \076OZ7)/=!@P; S77D@=30
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MP!FI9,E@1CGVJK"@7'7-7-W;G%0_(Z*<FT5)3\O;CVJL.6/OVJ](NY<$&JN
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MZ44=^:HD****+ &:.U% QGG-( &":DVC8#D>G2H^^>:<.1WZ4 -( /%%%%,
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M>(](2U>>+%OD*O7D5V'C+Q2+SP +U(U8L1D=JJ_%6"*+P=8%(U!XY ]JYS4
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MG_\ ?NC_ (6=XX];C_OW_P#6H ^H:*^7_P#A9WCC^]/]?+H_X6;XY]9_^_=
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MY&BG(;:['% 'T<?#.D'K9Q?]\TG_  C>C#C['!^0KF]9\</;> EUJ",&60
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MU=B?6O98-6LKB=H8IU:1>H!H NT50NM8L+)]EQ<*C'L334UW3I&"I<H2>G-
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M?Y"MK7O^0)=?[AH$?%]]_P A*['/^M;^=0U+??\ (2NQQCS6S^=0BD M%%%
M!1113 **** "BBBD 4444 %%%% !1113 **** "C\Z*2D!;MRA!!!J2+!N=H
M&15(,5Y!%/CG:)PXQ4M,UC..A:U"$12<<&J-233R3R;GQ4=.*LA56G-M!111
M5&84444 %%%%( KTGX'X/C23KGR_ZBO-3TKTGX'?\CG)G'^K_J* /I^BBBF
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M@ I<\TF'_P">;_E1A_\ GFWY4P"E.328?_GFU*-_>-J0[ADC^M!/OQ2G<?\
MEFWY4F&S_JVQ]*!"448?M&WY4 2#_EDWY4 . .,49_.GY;8?W3>W%1_/U\MO
MRH*T)4/'7ZTYF.VH1OQ_JV_*I,N1D1M^5*Q?-=#"S9R:;GFE;?G_ %;4W#_\
M\V_*F9M@2:*,/_SS;\J,/_SS:@0448?_ )YM^5&)/^>;_E3 .0:.U* ^?]6V
M?I3R'Q_JV]^*0$=+S28?_GF_Y4N'_P">;4QGK/P$S_PDEQU^X>WTKZ-KYS^
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MG-;VE:1:Z1IRV=N@$8'IUK0HH X<?#73$UU]30A79]^,=\UVR+L0*.PQ3J*
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MB@#F?^%?^%_^@3!^5'_"O_"__0)@_*NFHH YG_A7_A?_ *!,'Y4?\*_\+_\
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M/^%?>%_^@3!^5=-10!S/_"O_  O_ - B#_OFC_A7_A?_ *!,'Y5TU% ',_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image00015.jpg
<TEXT>
begin 644 image00015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $( F@# 2(  A$! Q$!_\0
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M2JJ>3++*S9)^4,93GG@#J:3V [.R\5:%=A1'JUBLQMQ<M ]P@DCCVA]S+G(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"6JUO5A-_R/47_ &#7_P#1JTF3(W:***904444 %%%% !1110!#]EM_/\
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M_P#O&@#9_MM/^>+?]]4?VVG_ #Q;_OJL2B@#H+755N+A(A$REN^:TJYC2?\
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M8Y(Y$6TD):9-VX_Q\<C).2ISGKO]:Z=AD8R1]*** &>7_MO^='E_[;_G3Z*
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MUK!-())8E=PC1Y89^5L9'T.!4-OIEG!%Y<4(";UD.26)9<;22?3 QZ8%7**
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M!51&$E$OR!@.2R>AXX(Q5+7](FO7TET\1:7.EE?070AEED896127W/,QR%#
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M4444Q!1110 4444 %%%% !7SWJG_ "$[S_KN_P#Z$:^A*^>]4_Y"=Y_UW?\
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MDDFDTFK,:;3NCN/[#TK_ *!UG_WY7_"C^P]*_P"@;9_]^5_PJ_&&6-1(P9P
M&8# )]<4ZL_84_Y5]QI[>K_,_O,[^P]*_P"@;9_]^5_PJY';0Q1JD<2(BC"J
MHP *EHJHTX1^%6)E4G/23;&>3'_<%8FT+XYCV@#_ (EK_P#HU:WJPF_Y'J+_
M +!K_P#HU:IF4C=HHHIE!1110 4444 %%%% %36'GCTF]>T!-PL+F, 9.[:<
M8_&N3?[7+YLFEWLTEK$\8BWRN=\C!<X/\73!!X&YO2NWHH Q?"]_)>6LB3(X
MDB;#.S;MS')(/'!!_A[<5LL6'W5S^.*6B@!FZ3_GF/\ OJC=)_SS'_?5/HH
M9ND_YYC_ +ZHW2?\\Q_WU3ZY?Q%XM71=<MM.-IYYFC23(F"N=TFS")CYR.I&
M1Q0!I:S83W_E>7L39G.YNN<5F_V!=?WX?S/^%+!XVTG[/;O?2-:/-&T@5E9A
MA=W&X#!.%)Q4\_B_2()((II98KB<92*:%XV')4;@1\N2,#- RO\ V!=?WX?S
M/^%']@77]^'\S_A3;'QSI5SI\%Q+]IAFDC20V_V>1I,,I;( 7+* &^8<<&KU
M]XFL+.6'<S/!) MQYL:EOE=U2/  ))8M^E%@N4_^$?NO[\/YG_"NAMQ)%!'&
M4!*J%)#>@K"7QMH9N8(#<R*\R[@7B90O)!W$CY<%3G/3%5%\:"33DOX=-E:T
M^V&U=FD"E!N"JV/?.<'&!U.>*!,ZS=)_SS'_ 'U1ND_YYC_OJJVDWZZC:M*J
M&-HY9(70G.UD8J?Y?K5R@!FZ3_GF/^^J-TG_ #S'_?5/HH 9ND_YYC_OJC=)
M_P \Q_WU3Z* &;I/^>8_[ZHW2?\ /,?]]4^J&O:G'H^D7-]*AD\I?EC!P9&)
MPJCW)('XT 7-TG_/,?\ ?5>97?P\U*>[GF6ZM ))&< [N,G/I6U-X_@6?34A
ML_-%Y#'+M\X"0%I/+**N/F*D'/(X!JU;>+9KJ'5#:Z4[RZ:?+N$,PXD!.5!
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M/^>8_P"^J?10 U2Q/S* /KFBG44 %%%% !1110 4444 %%%% !1110 4444
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M;DK/(BJ#GN$4<<Y.:]$B8O$C,I1F4$J>WM1T#J8H\)Z("2MBH'E>2%$C!57
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M8?#UR-/F,TD,FH/),Z;V9H8S*3N(7')VL>#_ %KSW_A6_C?_ **IK'_@,/\
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M4444 %%%% !117A'C!O$_B/XW:AX<TCQ9?:'96VF1W2B! P)R >,CKNZY[4
M>[T5XI)\._&D:,\GQ6U9$499FMP !ZD[ZKP^"/%,]N]Q!\8+Z6WC^_*D:,B_
M4B3 J>>)7)(]SHKQ"#P#XOG4-!\6]2E#+O!2%6!7UX?I[TL?P_\ &$K 1?%K
M4W)02 + IRIZ-]_I[T<T0Y)'MU%>*-\._&BE0WQ6U92QPH-N!N/7 ^?VI?\
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MFCC<%2#)G;\N2H&<9S23=F&ES3;P3J][:RHUM<6%H([M[.Q&J.[6TICB$69
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M.C*6KM.2T<@_C01;5&#UR>M:?@72?% \?+J7B6&_;R["YMY9YY86A,C3HRB
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M1L2IP!L )'/(^A;OK\A*VAA:EIWQ/MM%\-C3;V^NKR2W\R_::>(-#='9@,,
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M\3^2'MU9PW(ZJ"^T_P"]@]:;>7_A6/Q"\=S%IK:C<03I<7)BC.(X@OF)+)V
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M_;7_ +_+_C1_:-C_ ,_MK_W^7_&GJ+09-I6GSZA'?3V%I)>QJ42X>%3(JGJ
MQ&0*K0>&M"MT5+?1=,B1)%F54M8U"R+G:XP/O#)P>HR:N?VC8_\ /[:_]_E_
MQH_M&Q_Y_;7_ +_+_C2U#0J?\(YHGV6XMO[&TW[-<.)9HOLJ;)''1F&,$^YJ
M2;0])GTQ-.GTNQDT]#E+5[=&B4YSPA&!R3VJ?^T;'_G]M?\ O\O^-']HV/\
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M8[0 W3)SSZYKL?[1L?\ G]M?^_R_XTWY O,KQZ#I$5Q;3QZ5IZ36R&*"1;9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915763584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ocuphire Pharma, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001228627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3516358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">37000 Grand River Avenue, Suite 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Farmington Hills<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">681-9815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OCUP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,236,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,947,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Detroit, Michigan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915971584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 42,634<span></span>
</td>
<td class="nump">$ 24,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable (Note 10)</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContractAssetCurrent', window );">Contract asset (Note 10)</a></td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">1,453<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">48,986<span></span>
</td>
<td class="nump">26,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">48,992<span></span>
</td>
<td class="nump">26,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,684<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,753<span></span>
</td>
<td class="nump">3,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,753<span></span>
</td>
<td class="nump">3,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4 and Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001; 10,000,000 shares authorized as of December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001; 75,000,000 shares authorized as of December 31, 2022 and 2021; 20,861,315 and 18,845,828 shares issued and outstanding at December 31, 2022 and 2021, respectively.</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="nump">117,717<span></span>
</td>
<td class="nump">111,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(71,480)<span></span>
</td>
<td class="num">(89,368)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">46,239<span></span>
</td>
<td class="nump">22,222<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 48,992<span></span>
</td>
<td class="nump">$ 26,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContractAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContractAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915738896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">20,861,315<span></span>
</td>
<td class="nump">18,845,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">20,861,315<span></span>
</td>
<td class="nump">18,845,828<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910959552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaborations revenue</a></td>
<td class="nump">$ 39,850<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,269<span></span>
</td>
<td class="nump">8,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">14,355<span></span>
</td>
<td class="nump">15,173<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,624<span></span>
</td>
<td class="nump">23,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">18,226<span></span>
</td>
<td class="num">(22,705)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Fair value change in warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">18,203<span></span>
</td>
<td class="num">(56,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(315)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">17,888<span></span>
</td>
<td class="num">(56,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 17,888<span></span>
</td>
<td class="num">$ (56,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share (Note 11):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="num">$ (3.82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">19,931,080<span></span>
</td>
<td class="nump">14,852,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">20,597,212<span></span>
</td>
<td class="nump">14,852,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527909699968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 19,207<span></span>
</td>
<td class="num">$ (32,675)<span></span>
</td>
<td class="num">$ (13,467)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">10,882,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity', window );">Reclassification of Series A warrant liability to equity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">61,793<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">61,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering', window );">Issuance of common stock and warrants in connection with registered direct offering</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering', window );">Issuance of common stock and warrants in connection with registered direct offering (in shares)</a></td>
<td class="nump">3,076,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodValueAtTheMarketProgram', window );">Issuance of common stock in connection with the at-the-market program</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">13,491<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram', window );">Issuance of common stock in connection with the at-the-market program (in shares)</a></td>
<td class="nump">2,778,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors', window );">Issuance of common stock in connection with settlement with investors</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors', window );">Issuance of common stock in connection with settlement with investors (in shares)</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing', window );">Issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants', window );">Exercise of Series B warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of Series B warrants (in shares)</a></td>
<td class="nump">1,629,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">54,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">73,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net and comprehensive income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(56,693)<span></span>
</td>
<td class="num">(56,693)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">111,588<span></span>
</td>
<td class="num">(89,368)<span></span>
</td>
<td class="nump">22,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">18,845,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodValueAtTheMarketProgram', window );">Issuance of common stock in connection with the at-the-market program</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram', window );">Issuance of common stock in connection with the at-the-market program (in shares)</a></td>
<td class="nump">1,848,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing', window );">Issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants', window );">Exercise of Series B warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of Series B warrants (in shares)</a></td>
<td class="nump">60,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">81,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">24,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net and comprehensive income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,888<span></span>
</td>
<td class="nump">17,888<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 117,717<span></span>
</td>
<td class="num">$ (71,480)<span></span>
</td>
<td class="nump">$ 46,239<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">20,861,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock and . Includes, but is not limited to, legal and accounting fees and direct costs associated with common stock; ATM and Registered Direct Financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the warrants converting to equity issued originally in Pre-Merger financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued in connection with the at-the-market program during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued after exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued equity impact of the value of new stock issued in connection with registered direct offering during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued in settlement with investors during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockIssuedDuringPeriodValueAtTheMarketProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued in connection with the at-the-market program during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockIssuedDuringPeriodValueAtTheMarketProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued in connection with registered direct offering during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued in settlement with investors during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910620960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 17,888<span></span>
</td>
<td class="num">$ (56,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Fair value change in warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ShareSettlementWithInvestors', window );">Non-cash share settlement with investors</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement', window );">Receipt of investments related to license agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss from short-term investments</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,298)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_IncreaseDecreaseInContractAssetCurrent', window );">Contract asset</a></td>
<td class="num">(3,552)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(515)<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">14,314<span></span>
</td>
<td class="num">(19,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Transaction costs in connection with asset acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">28,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs attributed to common stock</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(1,511)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments made on short-term loan principal</a></td>
<td class="num">(538)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options and Series B warrants</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,786<span></span>
</td>
<td class="nump">27,605<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">18,100<span></span>
</td>
<td class="nump">8,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">24,534<span></span>
</td>
<td class="nump">16,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">42,634<span></span>
</td>
<td class="nump">24,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount', window );">Non-cash reclassification of Series A warrant liability to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Unpaid issuance costs</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The is the portion of collaborations revenue from the license agreement paid in the form of non-cash equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_IncreaseDecreaseInContractAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_IncreaseDecreaseInContractAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the Series A Warrants in connection with the Pre-Merger Financing which was composed of just common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ShareSettlementWithInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash share settlement with investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ShareSettlementWithInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915753232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Company Description and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Company Description and Summary of Significant Accounting Policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">1.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Company Description and Summary of Significant Accounting Policies</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Nature of Business</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Ocuphire Pharma, Inc. (the &#8220;Company&#8221; or &#8220;Ocuphire&#8221;) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and
            retinal eye disorders. Ocuphire&#8217;s pipeline currently includes two small molecule product candidates targeting several of such
            indications.</span><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2022, the Company entered into a license and collaboration agreement (the &#8220;Nyxol License Agreement&#8221;) with FamyGen Life Sciences, Inc. (acquired by Viatris, Inc. (&#8220;Viatris&#8221;) in January
            2023) pursuant to which it granted Viatris an exclusive license to develop, manufacture, import, export and commercialize its product candidate phentolamine ophthalmic solution 0.75% (Nyxol&#174; Eye Drops or &#8220;Nyxol&#8221;). Nyxol is a once-daily eye drop
            formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically-induced mydriasis (&#8220;RM&#8221;) (dilation of the pupil),
            presbyopia (age-related blurry near vision) and dim light or night vision disturbances (&#8220;DLD&#8221;) (halos, glares and starbursts).</span><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company&#8217;s second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as
            diabetic retinopathy (&#8220;DR&#8221;) and diabetic macular edema (&#8220;DME&#8221;) which, if left untreated, can result in permanent visual acuity loss and eventual blindness. The Company has also in-licensed APX2009 and APX2014, which are second-generation
            product candidates and analogs of APX3330.</span><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">License and collaborations revenue to date was derived from a one-time non-refundable payment and reimbursement of expenses earned under the Nyxol License Agreement, and to a much lesser degree, from
            license agreements with BioSense Global LLC (&#8220;BioSense&#8221;) and Processa Pharmaceuticals, Inc. (&#8220;Processa&#8221;) in connection with the Rexahn RX-3117 drug compound. The Company anticipates that it will recognize revenue as it earns reimbursement for
            research and development services in connection with the Nyxol License Agreement and it may earn additional revenues from future potential milestone and royalty payments from the agreements with Viatris, BioSense, Processa, or from other
            license agreements entered into the future; however, the attainment of milestones or level of sales required to earn royalty payments is highly uncertain. Outside of the license and collaborations revenue, the Company does not expect to
            generate significant revenue unless or until regulatory approval is obtained and commercialization begins for Nyxol or APX3330. Management plans to continue financing the Company&#8217;s operations primarily through additional issuances of the
            Company&#8217;s equity and debt securities or through collaborations or partnerships with other companies. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and
            development programs.</span><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: italic; font-weight: bold;">Reverse Merger with Rexahn</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-style: normal;"><br class="Apple-interchange-newline"/>
                </span></span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-style: normal;"> </span> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;">&#160;On June 17, 2020, Ocuphire, Rexahn
                Pharmaceuticals, Inc. (&#8220;Rexahn&#8221;), Razor Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rexahn (&#8220;Merger Sub&#8221;), entered into an Agreement and Plan of Merger and Reorganization, as amended on June 29, 2020 (as amended,
                the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub would merge with and into Ocuphire, with Ocuphire continuing as a
                wholly-owned subsidiary of Rexahn and the surviving corporation of the merger (the &#8220;Merger&#8221;). The Merger closed on November 5, 2020. Upon completion of the Merger, Rexahn changed its name to Ocuphire Pharma, Inc. and changed its ticker
                symbol on the Nasdaq Capital Market to &#8220;OCUP&#8221;.</span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">The Company&#8217;s headquarters is located in Farmington Hills, Michigan.</div>

<div>&#160;
          </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Global Economic Conditions</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Generally, worldwide economic conditions remain uncertain, particularly due to the effects of th<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">e COVID&#8209;</span></span><span style="background-color: rgb(255, 255, 255); font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">19</span><span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> pande</span>mic and increased
              inflation. The general economic and capital market conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company&#8217;s access to capital and increased the cost of capital. The capital
              and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, the Company&#8217;s future cost of equity or debt capital and access to the capital markets could be adversely
              affected.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The COVID-19 pandemic that began in late 2019 introduced significant volatility to the global
                economy, disrupted supply chains and had a widespread adverse effect on the financial markets.&#160;As a result of the COVID-19 pandemic, the Company has experienced, and may continue to experience, delays and disruptions in our clinical trials,
                as well as interruptions in our manufacturing, supply chain, shipping and research and development operations.&#160; Testing and clinical trials, manufacturing, component supply, shipping and research and development operations may be further
                impacted by the continuing effects of COVID-19.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Additionally, the Company&#8217;s operating results could be materially impacted by changes in the
                overall macroeconomic environment and other economic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflict in Ukraine, and steps taken by governments and central banks,
                particularly in response to the COVID-</span>19<span style="font-size: 10pt; font-family: 'Times New Roman';"> pandemic as well as other stimulus and spending programs, have led to higher inflation, which has led to an increase in costs and
                has caused changes in fiscal and monetary policy, including increased interest rates.</span></div>

<div><br/></div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Basis of Presentation</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America (&#8220;GAAP&#8221;). <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';">On December 31, 2021, the Company merged its wholly owned subsidiary, OcuSub Inc, with and into the Company, with
            the Company remaining as the surviving entity. The merger of the Company&#8217;s wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of this merger, the Company did not have any remaining entities that
            required consolidation for financial statement reporting purposes.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Liquidity</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;">The accompanying consolidated financial statements have
            been prepared on the basis that the Company will continue as a going concern. From its inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting clinical trials.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"><span style="font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company entered into the Nyxol License Agreement, and the</span> Company received a $35 million <span style="font-size: 10pt; font-weight: normal; font-style: normal;">one-time </span> non-refundable payment in November 2022, and commitment from
                Viatris to reimburse budgeted development costs for Nyxol. See Note 10 &#8211; License and Collaboration Agreements for additional information related to the Nyxol License Agreement. Management believes that the Company, as a result of this cash
                payment receipt, has adequate liquidity to meet obligations as they come due without raising additional funds for at least twelve months from the date of issuance of these financial statements. As of December 31, 2022, the Company had $42.6 million in cash and cash equivalents.</span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"> <br/>
              </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"> <span style="font-weight: normal; font-size: 10pt; font-style: normal;">In the future, the Company may need to raise additional funds until it is able to generate sufficient revenues to fund its development activities. The Company&#8217;s future
                  operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to
                  predict the ultimate outcome of these actions to generate the liquidity ultimately required.</span></span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span>
          </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Use of Estimates</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported
          in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div>

<div>&#160;
          </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Segment Information</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating
          decision maker in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its
          business in one operating segment, which is the business of development and commercialization of products related to vision
          performance and health. Accordingly, the Company has a single reporting segment.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Cash and Cash Equivalents</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of deposit to be cash equivalents.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Concentration of Credit Risk</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Financial instruments that potentially subject the
                Company to a concentration of credit risk consist of cash and cash equivalents. As of December 31, 2022, the Company&#8217;s cash was held by two large financial institutions in the United States. Amounts on deposit may at times exceed federally
                insured limits. As of December 31, 2022, the Company had deposits that exceeded federally insured amounts by approximately $42.1
                million.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Short-term Investments<br/>
              </div>

<div style="font-family: 'Times New Roman';"><br/>
              </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and are recorded on a settlement
                date basis. The Company&#8217;s investments are comprised of equity securities, which in accordance with the fair value hierarchy described below are recorded at fair value using Level l inputs on the balance sheets.&#160; Subsequent changes in fair
                values are recorded in other expense, net on the&#160; consolidated statements of comprehensive income (loss). The Company classifies investments available to fund current operations as current assets on its balance sheets. The Company did not recognize any impairments on its investments to date through December 31, 2022.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman';"><br/>
              </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue Recognition</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company follows the provisions of&#160;Accounting Standards Codification (&#8220;ASC&#8221;) 606,&#160;</span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Revenue from Contracts with Customers</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">. The guidance provides a five-step model to determine
                  how revenue is recognized. The Company has entered into license agreements which have revenue recognition implications (See Note 10 &#8211; License and Collaboration Agreements).</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the contracts with a
                customer; (ii) determination of the performance obligations in the contract; (iii) measurement of the transaction price, including potential constraints on variable consideration; (iv) allocation of the transaction price to the performance
                obligations based on estimated stand-alone selling prices; and (v) recognition of revenue when (or as) the Company satisfies a performance obligation.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to
                  the customer and is the unit of account in ASC 606. Performance obligations may include license rights, development and other services. Significant management judgment is required to determine the level of effort required under an
                  arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become
                  inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></div>

<div style="font-family: 'Times New Roman';"><br/>
              </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each
                performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount
                rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the relative standalone selling prices of the promised goods or service underlying each
                performance obligation.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Licenses of intellectual property and research and development services:</span> If the license to the Company&#8217;s intellectual
                property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the
                customer, and the customer can use and benefit from the license. For licenses that are bundled with other obligations, such as research and development services, the Company utilizes judgment to assess the nature of the combined performance
                obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable,
                up-front fees. For research and development services that are distinct from a license transfer obligation, the Company determines whether the services are satisfied over time or at a point in time and, if over time, the appropriate method
                of measuring progress for purposes of recognizing revenue from such services. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Milestone payments: </span>At the inception of each arrangement that includes milestone payments, the Company evaluates
                whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur,
                the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable
                of being achieved until such contingency occurs (such as receipt of those approvals).</div>

<div style="font-family: 'Times New Roman';"><br/>
              </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Royalties:</span> For arrangements that include sales-based royalties, including milestone payments based on the level of
                sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the
                royalty has been allocated has been satisfied (or partially satisfied).</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
              </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Contract Asset</span><br/>
              </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> The Company recognizes a contract asset when goods or services are transferred to the customer before the customer pays or before payment is due, excluding any amounts presented as an
                  accounts receivable. The Company recorded a contract asset in connection with a license and collaboration agreement in the amount of $3.6
                  million as of December 31, 2022.&#160; See Note 10 - License and Collaboration Agreements.</span><br/>
              </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
                </span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;">Accounts Receivable and Allowances for Doubtful Accounts</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"> <br/>
                      </span></span></span></span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;">The Company records a provision for doubtful accounts, when appropriate, based on historical experience
                        and a detailed assessment of the collectability of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of the accounts receivable, its historical
                        write-offs, the credit worthiness of each customer, and general economic conditions. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered.
                        Actual write-offs may be in excess of the Company&#8217;s estimated allowance.&#160; The Company has not incurred any bad debt
                        expense during the years ended December 31, 2022 or 2021 and no allowance for doubtful accounts has been recorded
                        during the periods presented.</span></span></span></span></div>

<div><br/></div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">General and Administrative Expenses</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">General and administrative expenses (&#8220;G&amp;A&#8221;) consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in
          functions not directly associated with research and development activities. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and tax services, settlement costs
          with third parties and other services provided by business consultants.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Research and Development</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Research and development expenses (&#8220;R&amp;D&#8221;) consist of costs incurred in performing research and development activities, including compensation for research and
            development employees and consultants, costs associated with preclinical studies and clinical trials, regulatory activities, manufacturing activities to support clinical activities, license fees, fees paid to external service providers that
            conduct certain research and development, and an allocation of R&amp;D related overhead expenses. R&amp;D costs include costs that are reimbursed under the Nyxol License Agreement.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Other Expense, net</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Other expense, net reflected in this line item includes payments made by the Company in connection with the Contingent Value Rights Agreement discussed further below
          with former Rexahn shareholders. In addition, other expense, net includes interest earned from cash and cash equivalent investments, realized and unrealized gains (losses) from equity investments and reimbursements in connection with grants and
          other sources when they occur.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based Compensation</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The Company accounts for stock-based compensation in accordance with the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718, <span style="font-style: italic;">Compensation &#8212; Stock Compensation</span>. Accordingly, compensation costs related to equity instruments granted are recognized at the grant date fair value. The Company records forfeitures when they occur.
            Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Warrant Liabilities</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company issued Series A Warrants in connection with the Pre-Merger Financing (see Note 3 &#8211; Pre-Merger Financing) and assumed Rexahn warrants issued prior to
            the Merger. The Company accounts for these warrants as a liability while outstanding at fair value during periods when certain provisions preclude equity accounting treatment for these instruments. Additionally, issuance costs associated with
            the warrants classified as liabilities were expensed as incurred and reflected as interest expense in the accompanying consolidated statements of comprehensive income (loss). The change in fair value of the warrant liabilities while outstanding
            were recognized as a component of the fair value change in warrant liabilities line item in the consolidated statements of comprehensive income (loss).</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Measurements</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as
          &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three-level hierarchy:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 1 inputs: Unadjusted quoted prices for identical assets or liabilities in active markets;</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 2 inputs: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the
                  asset or liability; and</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 3 inputs: Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or
                  liability at the measurement date.</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">As of December </span>31,<span style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</span>2022<span style="font-size: 10pt; font-family: 'Times New Roman';"> and </span>2021,<span style="font-size: 10pt; font-family: 'Times New Roman';"> the fair values of cash and cash equivalents, accounts receivable, contract asset, prepaid and other
              assets, accounts payable, accrued expenses and short-term loan, while outstanding,&#160; approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the short-term investments was based on
              observable Level </span>1<span style="font-size: 10pt; font-family: 'Times New Roman';"> inputs in the form of quoted market prices from a major stock exchange. The fair value of the warrant liabilities, while outstanding, was based on cash
              flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and were based on Level </span>3<span style="font-size: 10pt; font-family: 'Times New Roman';"> inputs.</span> </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">There were no transfers between fair value
            hierarchy levels during the years ended December 31, 2022 and 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of financial instruments measured on a recurring basis is as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">As of December 31, 2022</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom">
                <div>Description</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Total</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 1</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 2</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 3</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%;" valign="bottom">
                <div>Assets:<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> Short-term investments<br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom">
                <div>Total assets at fair value</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">As of December 31, 2021</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom">
                <div>Description</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Total</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 1</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 2</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 3</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%;" valign="bottom">
                <div>Assets:</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Short-term investments</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom">
                <div>Total assets at fair value</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides a roll-forward of investments measured at fair value on a recurring basis using observable level 1 inputs for the year ended December
            31, 2022 and 2021 (in thousands):</div>

<div><br/>
          </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Short-term investments</div>
                </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of beginning of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">219</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Receipt of investments related to license agreement</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">289</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Unrealized loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(170</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(70</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of end of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">49</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">219</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides a roll-forward of the warrant liabilities measured at fair value on a recurring basis using unobservable level 3 inputs for the year
          ended December 31,&#160; 2021 (in thousands):</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2021<br/>
                  </span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrant liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of beginning of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">27,964</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">33,829</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Reclassification of warrants from liability to equity</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(61,793</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of end of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The fair value of the warrant liabilities associated with the Rexahn warrants was de minimis during the years ended December 31, 2022 and 2021. See Note 2 - Merger.<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">There were no financial instruments measured on a
          non-recurring basis for any of the periods presented.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Income Taxes</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company utilizes the liability method of accounting for income taxes as required by ASC 740, <span style="font-style: italic;">Income Taxes</span>. Under this
          method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences
          are expected to reverse. The Company currently has a provision for income taxes, but the Company has historically incurred operating losses for all prior year periods.&#160; As such, a full valuation allowance has been provided on the net deferred tax
          assets given the uncertainty of future taxable income and other related factors impacting the realizability or the Company&#8217;s remaining net deferred tax assets.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Property and Equipment, net<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment, net is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the
          assets using the straight-line method. Equipment and furniture are depreciated over a five-year estimated useful life. Tangible
          assets acquired for research and development activities which have alternative use are capitalized and depreciated over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are
          made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged
          directly to expense as incurred.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Recent Accounting Pronouncements</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, &#8220;<span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Financial












































            Instruments &#8211; Credit Losses&#8221;</span>. The ASU sets forth a current expected credit loss (&#8220;CECL&#8221;) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical
          experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some
          off-balance sheet credit exposures. The Company does not expect that the adoption of this ASU on January 1, 2023 will have a significant impact on its consolidated financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br/>
        </div>

<div style="text-align: justify;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In August 2020, FASB issued ASU 2020-06,</span>
          <span style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
            and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span>, <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">which, among other things, provides guidance on how to account for contracts on an entity&#8217;s own equity. This &#8203;ASU eliminates the beneficial conversion and cash
            conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this
            ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for public business entities that meet the definition
            of a Securities and Exchange Commission (&#8220;SEC&#8221;) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
            For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. </span><span style="font-size: 10pt; font-family: 'Times New Roman';">The Company
            does not expect that the adoption of this ASU on January 1,&#160;2023 on its consolidated financial statements will be material</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span> </div>

<div><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In November 2021, <span style="font-size: 10pt; font-family: 'Times New Roman';">the FASB issued ASU 2021-10,&#160;Government Assistance (Topic
              832) - Disclosures by Business Entities about Government Assistance,&#160;to increase the transparency of government assistance including the disclosure of the types of assistance, an entity&#8217;s accounting for the assistance, and the effect of the
              assistance on an entity&#8217;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15,&#160;2021. The Company adopted this
              guidance on January 1,&#160;2022 and it did not have a material impact to the consolidated financial statements.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527914806096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Merger</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Merger</div>
              </td>

  </tr>


</table>

<div>&#160;&#160;
          </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On November 5, 2020, the Company completed the Merger transaction with Rexahn. In connection with the Merger, the Company, Shareholder Representatives Services
            LLC, as representative of the Rexahn stockholders prior to the Merger, and Olde Monmouth Stock Transfer Co., Inc., as the rights agent, entered into a Contingent Value Rights Agreement (the &#8220;CVR Agreement&#8221;).</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the terms of the Merger and the CVR Agreement, Rexahn stockholders of record as of immediately prior to the effective time of the Merger received one contingent value right (&#8220;CVR&#8221;) for each share of Rexahn common stock held.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Each CVR entitles such holders to receive, for each calendar quarter (each, a &#8220;CVR Payment Period&#8221;) during the 15-year period after the Closing (the &#8220;CVR Term&#8221;), an amount equal to the following:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="color: rgb(0, 0, 0); text-align: justify;">90% of all payments received by Rexahn or its affiliates during such
                      CVR Payment Period from or on behalf of BioSense Global LLC (&#8220;BioSense&#8221;) pursuant to that certain License and Assignment Agreement, dated as of February 25, 2019, by and between BioSense and Rexahn, as amended by Amendment No. 1,
                      dated August 24, 2019, and as further amended by Amendment No. 2, dated March 10, 2020, minus certain permitted deductions;</div>
                  </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="color: rgb(0, 0, 0); text-align: justify;">90% of all payments received by Rexahn or its affiliates during such
                      CVR Payment Period from or on behalf of Zhejiang HaiChang Biotechnology Co., Ltd. (&#8220;HaiChang&#8221;) pursuant to that certain Exclusive License Agreement, dated as of February 8, 2020, by and between HaiChang and Rexahn, minus certain
                      permitted deductions; and</div>
                  </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="color: rgb(0, 0, 0); text-align: justify;">75% of the sum of (i) all cash consideration paid by a third party to
                      Rexahn or its affiliates during the applicable CVR Payment Period in connection with the grant, sale or transfer of rights to Rexahn&#8217;s pre-closing intellectual property (other than a grant, sale or transfer of rights involving a sale
                      or disposition of the post-Merger combined company) that is entered into during the 10-year period after the Closing
                      (&#8220;Parent IP Deal&#8221;), plus (ii) with respect to any non-cash consideration received by Rexahn or its affiliates from a third party during the applicable CVR Payment Period in connection with any Parent IP Deal, all amounts received by
                      Rexahn and its affiliates for such non-cash consideration at the time such non-cash consideration is monetized by Rexahn or its affiliates, minus (iii) certain permitted deductions.</div>
                  </td>

  </tr>


</table>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span></span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument, will not accrue interest and will not be registered with the SEC or listed for trading on any exchange.
                The CVR Agreement will continue in effect until the later of the end of the CVR Term and the payment of all amounts payable thereunder. </span>As of December 31, 2022, no milestones had been accrued as there were no
              additional potential milestones yet considered probable beyond those previously reported in the second and third quarters of calendar year 2021.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Former Rexahn Warrants</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Following the closing of the Merger, 231,433
            outstanding, unexercised Rexahn warrants to purchase common stock remained outstanding, the majority of which were subsequently repurchased according to the terms of the original warrant agreements.&#160; As of December 31 2022, 60,713 of the Rexahn warrants remained outstanding with exercise prices ranging from $38.40 to $136.80 per share with an average remaining contractual life of 1.0 years.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912934144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pre-Merger Financing<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingTextBlock', window );">Pre-Merger Financing</a></td>
<td class="text">
<div>
        <div> <br/>
        </div>

        <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">3.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Pre-Merger Financing</div>
              </td>

  </tr>


</table>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On June 17, 2020, Ocuphire, Rexahn and certain investors entered into a Securities Purchase Agreement, which was amended and restated in
        its entirety on June 29, 2020 (as amended and restated, the &#8220;Securities Purchase Agreement&#8221;).&#160; Pursuant to the Securities Purchase Agreement, the investors invested a total of $21.15 million in cash, including $300,000 invested by five directors of Ocuphire Pharma, Inc., prior to the Merger and one director of Rexahn upon closing of the Merger (the &#8220;Pre-Merger Financing&#8221;).&#160; The Pre-Merger Financing also included the issuance of Series A Warrants and Series B Warrants discussed
        further below.</div>

<div><br/></div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Waiver Agreements</div>

<div><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective February 3, 2021, each investor that invested in the Pre-Merger Financing entered into a Waiver Agreement with the Company
        (collectively, the &#8220;Waiver Agreements&#8221;). Pursuant to the Waiver Agreements, the investors and the Company agreed to waive certain rights, finalize the exercise price and number of Series A Warrants and Series B Warrants, eliminate certain financing
        restrictions, extend the term of certain leak-out agreements, and, in the case of certain investors, grant certain registration rights for the shares underlying the warrants.</div>

<div><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Waiver Agreements provide for the elimination of the full ratchet anti-dilution provisions contained in the Series A Warrants (as
        certain of the anti-dilution provisions had previously caused liability accounting treatment for the Series A Warrants). Upon the effective date of the Waiver Agreements, the Series A Warrants were reclassified to equity.</div>

<div><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the Waiver Agreements, the number of shares underlying all of the Series B Warrants was fixed in the aggregate with respect
        to all investors, eliminating any future resets.</div>

<div><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Series A Warrants</div>

<div><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Series A Warrants were issued on November 19, 2020 at an initial exercise price of $4.4795 per share, were immediately exercisable upon issuance and have a term of five years from the date of issuance. The Series A Warrants are exercisable for 5,665,838 shares of common stock in the
        aggregate (without giving effect to any limitation on exercise contained therein) and were outstanding as of December 31, 2022. Prior to the execution of the Waiver Agreements, the Series A Warrants were accounted for and classified as liabilities
        on the accompanying balance sheets given certain price reset provisions not used for a fair valuation under a fixed for fixed settlement scenario as required for equity balance sheet classification. Upon the February 3, 2021 effective date of the
        Waiver Agreements, the Series A Warrants were reclassified to equity. A final fair valuation of the Series A Warrants was performed utilizing a Black Scholes model to estimate the aggregate fair value of the Series A Warrants prior to being
        re-classified as equity. Input assumptions used were as follows: risk-free interest rate 0.4%; expected volatility of 86.6%; expected life of 4.8 years; and
        expected dividend yield zero percent. The underlying stock price used was the market price as quoted on Nasdaq as of&#160; February 3, 2021,
        the effective date of the Waiver Agreement.&#160; The fair value change of the Series A Warrants was $33.8 million and was recorded to the
        fair value change in warrant liabilities line item on the accompanying&#160; consolidated statements of comprehensive income (loss) for year ended December 31, 2021. As a result of the reclassification to equity, the Series A Warrants are no longer
        subject to remeasurement.</div>

<div><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Series B Warrants</div>

<div><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Series B Warrants have an exercise price of $0.0001, were exercisable upon issuance and will expire on the day following the later to occur of (i) the Reservation Date (as defined therein), and (ii) the date on which the investor&#8217;s
        Series B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein) and no shares
        remain issuable thereunder. The Series B Warrants outstanding as of December 31, 2022 were exercisable for 17,869 shares of common
        stock. The Series B Warrants were accounted for and classified as equity on the accompanying balance sheets.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PreMergerFinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PreMergerFinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PreMergerFinancingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about pre-merger financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PreMergerFinancingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912867904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">4.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Commitments and Contingencies</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Apexian Sublicense Agreement</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On January 21, 2020, the Company entered into a sublicense agreement with Apexian Pharmaceuticals, Inc., pursuant to which it obtained exclusive worldwide patent and
          other intellectual property rights. In exchange for the patent and other intellectual rights, the Company agreed to certain milestone payments and royalty payments on future sales (See Note 8 &#8212; Apexian Sublicense Agreement). As of December 31,
          2022, there was sufficient uncertainty with regard to any future cash milestone payments under the sublicense agreement, and as such, no liabilities were recorded related to the sublicense agreement.</div>

<div>&#160;
          </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Facility Leases</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company has a short-term non-cancellable facility lease (the &#8220;HQ Lease&#8221;) for its operations and headquarters. Additionally, Ocuphire leased office space in
          Rockville, Maryland through June 30, 2021 previously occupied by Rexahn (the &#8220;Rexahn Lease&#8221;). The HQ Lease and the Rexahn Lease qualified for the short-term lease exception under ASC 842, Leases. The monthly base rent, as amended, for the HQ
          Lease is approximately $3,000. The monthly base rent for the Rexahn Lease was $13,000. The rent expense associated with the HQ Lease and Rexahn Lease amounted to $39,000
          and $116,000 during the years ended December 31, 2022 and 2021, respectively. The total remaining expected rental payments under
          the HQ Lease amount to $36,000 through its current expiration date of December 31, 2023.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Issuance of Settlement Shares</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> On May 6, 2021, the Company issued 350,000 shares of common stock of the Company to three accredited investors pursuant to a settlement agreement, dated May 6, 2021, in exchange for a release of potential claims. The fair value of
            the share settlement of $1,614,000 was based on the closing Ocuphire stock price for that day. The fair value of the share settlement
            was recorded in general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss).</span><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Other</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In the ordinary course of business, from time to time, the Company may be subject to a broad range of claims and legal proceedings that relate to contractual
          allegations, patent infringement and other claims. In addition, the Company from time to time may be potentially committed to reimburse third parties for costs incurred associated with business development related transactions upon the
          achievement of certain milestones. The Company establishes accruals when applicable for matters and commitments which it believes losses are probable and can be reasonably estimated. To date, no loss contingency for such matters and potential
          commitments have been recorded. Although it is not possible to predict with certainty the outcome of these matters or potential commitments, the Company is of the opinion that the ultimate resolution of these matters and potential commitments
          will not have a material adverse effect on its results of operations or financial position.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912934144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">
<div> <br/>
        </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">5.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Supplemental Balance Sheet Information</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Prepaid and Other Assets</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Prepaid and other assets consist of the following (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Prepaids</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,373</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,243</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>80</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>71</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Total prepaids and other assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>1,453</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>1,314</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Property and Equipment, net</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment held for use by category are presented in the following table (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Equipment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>20</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>20</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Furniture</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>5</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>5</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Total property and equipment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>25</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>25</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Less accumulated depreciation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(19</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(15</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Property and equipment, net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>6</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>10</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Depreciation expense was $4,000 during each of the
          years ended December 31, 2022 and 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Accrued Expenses</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>Accrued expenses consist of the following (in thousands):</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>
                  <div>
                    <div>Income taxes</div>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">315</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#8212;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div>Payroll</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>782</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>488</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>Professional services</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>208</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>84</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div>R&amp;D services and supplies</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>212</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>1,081</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>Other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>167</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>80</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div>Total</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>1,684</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>1,733</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Short-Term Loan</div>

<div><br/>
          </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company entered into an unsecured short-term loan (the &#8220;Loan&#8221;) agreement in the amount of $0.6 million in November 2021 related to financing an insurance policy.&#160; The Loan was payable in six monthly installments of $108,000 beginning in December 2021.&#160; The Loan
            had an annual interest rate of 5.5% per annum.&#160; Interest expense in the amount of $9,000 and $2,000 was recognized in connection with the Loan
            during the years ended December 31, 2022 and 2021, respectively. The final payment on the Loan was made in May 2022.<br/>
          </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912715792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">6.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Related Party Transactions</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Pre-Merger Financing and Waiver Agreements</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Five directors of Ocuphire Pharma, Inc., prior to the
          Merger, and one director of Rexahn participated in the Pre-Merger Financing, investing an aggregate of $300,000.&#160; Following the closing of the Merger, these directors received 17,729 converted initial shares of common stock, 53,189
          converted shares of additional common stock, 80,366 Series A Warrants and 9,444 Series B Warrants. In connection with the Pre-Merger Financing, six
          directors of the Company signed Waiver Agreements, waiving certain reset provisions and financing restrictions. These directors did not receive any of the additional Series B Warrants that were issued in connection with the Waiver Agreements. See
          Note 3 &#8211; Pre-Merger Financing.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Other</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On April 8, 2022, Ocuphire entered into a consulting agreement with a director of the Company. The consulting agreement provided for $10,000 a month in cash payments, effective as of April 1, 2022. Additionally, on April 8, 2022, in connection with the consulting arrangement, the
          director received a stock option grant for 50,000 options, 25% of which will vest on March 31, 2023, with the remainder vesting in equal monthly installments over 36 months. The consulting agreement was amended on September 19, 2022 to provide for vesting acceleration for stock-based awards in the event of a change in control. The
          consulting agreement was also amended effective December 1, 2022 to increase the cash payment to $25,000 per month. The Company
          incurred related consulting expenses of $105,000 during the year ended December 31, 2022. There were no related consulting expenses incurred during the year ended December 31, 2021. As of December 31, 2022, $25,000 of the related consulting expenses were unpaid.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912645024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">7.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Stock-based Compensation</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of
          comprehensive income (loss) for the periods indicated below (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>General and administrative</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,060</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,116</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Research and development</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>747</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>798</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Total stock-based compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>1,807</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>1,914</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Ocuphire Stock Options</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); font-variant: normal; text-transform: none;">Inducement Plan</div>

<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On February 22,
              2021, the Company adopted the Ocuphire Pharma, Inc. 2021 Inducement Plan (the &#8220;Inducement Plan&#8221;), pursuant to which the Company reserved 325,258
              shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&#8217;s entry into employment with the Company within
              the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.</div>

<div><br/>
            </div>

<div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2020 Equity Incentive Plan</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In November 2020, the stockholders of the Company approved the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) for stock-based awards. Under the 2020 Plan, (i) 1,000,000 new shares of common stock were reserved for issuance and (ii) up to 70,325 additional shares of common stock may be issued, consisting of (A) shares that remain available for the issuance of awards under prior equity plans and (B) shares of
          common stock subject to outstanding stock options or other awards covered by prior equity plans that have been cancelled or expire on or after the date that the 2020 Plan became effective. Under the 2020 Plan, the shares reserved automatically
          increase on January 1 of each year, for a period of not more than ten years from the date the 2020 Plan is approved by the
          stockholders of the Company, commencing on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to 5% of
          the shares of common stock outstanding as of December 31st of the preceding calendar year. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The 2020 Plan permits the grant of incentive and nonstatutory stock options, appreciation rights, restricted stock, restricted stock units, performance stock and cash awards, and other
            stock-based awards</span>.</div>

<div><br/></div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2018 Equity Incentive Plan</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Prior to the 2020 Plan, the Company had adopted a 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) in April 2018 under which 1,175,000 shares of the Company&#8217;s common stock were reserved for issuance to employees, directors and consultants. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Upon the effective date of the 2020 Plan,&#160;no additional shares were available for issuance under the 2018 Plan</span>.</div>

<div style="font-style: italic;"><br/>
        </div>

<div style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">General</div>

<div><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">During the years ended December 31, 2022 and 2021, 893,305
            and 420,300 stock options were granted to officers, directors, employees and consultants, respectively, generally vesting over a
            five (5) to forty-eight (48)
            month period. The Company recognized $1.7 million and $1.8 million in stock-based compensation expense related to stock options during the years ended December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021, 24,309 and 73,442 stock options were
            exercised, respectively, with an intrinsic value of $59,000 and $345,000, respectively. <span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table summarizes the Company&#8217;s stock option plan activity:</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Options</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Term (years)</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Aggregate</div>
                <div style="text-align: center; font-weight: bold;">Intrinsic</div>
                <div style="text-align: center; font-weight: bold;">Value<sup>(1)</sup></div>
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Outstanding at December 31, 2020</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>1,784,198</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2.17</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>8.87</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>7,744</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>420,300</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5.72</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                <div>Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(73,442</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                <div>Forfeited/Cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>(34,220</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Outstanding at December 31, 2021</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2,096,836</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2.97</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>8.20</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2,795</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>893,305</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2.64</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                <div>Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(24,309</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>1.09</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                <div>Forfeited/Cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>(29,788</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>6.21</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Outstanding at December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2,936,044</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2.87</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>7.82</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>3,314</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">Vested and expected to vest at December 31, 2022</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">2,936,044</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">2.87</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">7.82</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">3,314</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Vested and exercisable at December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,723,792</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.56</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>7.07</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,680</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></td>

    <td style="width: auto; vertical-align: top;">
                <div>The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and
                  the fair value of our common stock as of December 31, 2022 and 2021 of $3.53 and $3.73 per share, respectively.</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The weighted average
          fair value per share of options granted during the years ended December 31, 2022 and 2021 was $2.06 and $4.36, respectively. The Company measures the fair value of stock options with service-based vesting criteria to employees, directors, consultants and
          directors on the date of grant using the Black-Scholes option pricing model. The Company does not have adequate history to support an internal calculation of volatility and expected term. As such, the Company has used a weighted average
          volatility considering the volatilities of several guideline companies.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">For purposes of
            identifying similar entities (guideline companies), the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The average expected life of the options was based on the contractual term for
            agreements that allow for exercise of vested options through the end of the contractual term upon termination of continuous service, and for all other agreements, was based on the mid&#8209;point between the vesting date and the end of the
            contractual term according to the &#8220;simplified method&#8221; as described in Staff Accounting Bulletin 110. The risk&#8209;free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to
            the expected life assumed at the date of grant. The Company records forfeitures when they occur. The assumed dividend yield was based on the Company&#8217;s expectation of not paying dividends in the foreseeable future.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The weighted average assumptions used in the Black-Scholes option pricing model are as follows during the years ended December 31, 2022 and 2021:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Expected stock price volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>97.4</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>98.1</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                <div>Expected life of options (years)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5.8</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>5.8</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Expected dividend yield</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                <div>Risk free interest rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>2.3</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>0.9</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">During the years ended December 31, 2022 and 2021, 488,621
          and 468,301 stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended
          December 31, 2022 and 2021 was $3.29 and $3.49,
          respectively. During the years ended December 31, 2022 and 2021, 29,788 and 34,220 stock options were forfeited, respectively. As of December 31, 2022, 894,920
          shares in the aggregate were available for future issuance under the 2020 Plan and Inducement Plan.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Unrecognized stock-based compensation cost was $2.6
          million as of December 31, 2022. The unrecognized stock-based expense is expected to be recognized over a weighted average period of 1.2
          years.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Restricted Stock Awards</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On November 11, 2020, the Company granted 40,000
          restricted stock awards (&#8220;RSAs&#8221;) that vested on January 8, 2021. There were no RSAs granted during the years ended December 31,
          2022 or 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160; <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The stock-based compensation expense attributed to the RSAs during each of the years ended December 31, 2022 and 2021 was $0 and $22,000, respectively.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A summary of RSA activity is as follows for the year ended December 31, 2021:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>Non-vested at December 31, 2020</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>Vested</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">(40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div>Non-vested at December 31, 2021</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Common Stock Issued
            for Services <br/>
          </div>

<div><br/>
          </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The Company granted
            common stock for services in the amount of 74,396 and 21,414 shares of common stock during the years ended December 31, 2022 and 2021, respectively, to four and two board members during those periods, respectively, who elected
            to receive their board retainers in the form of stock for services. The stock-based compensation related to these services amounted to $154,000
            and $108,000 during the years ended December 31, 2022 and 2021, respectively.</div>

<div><br/>
          </div>

<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Former Rexahn Options</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Following the closing of the Merger, 123
              unexercised and vested options to purchase common stock granted under the Rexahn Pharmaceuticals Stock Option Plan, as amended (the&#160;&#8220;Rexahn 2003 Plan&#8221;, and together with the Rexahn 2013 Plan, the&#160;&#8220;Prior Plans&#8221;) were outstanding. As of
              December 31, 2022, none of the former Rexahn options remained outstanding under the Prior Plans. During the year ended December
              31, 2022, 82 of the former Rexahn options expired.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912814864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Apexian Sublicense Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ApexianSublicenseAgreementAbstract', window );"><strong>Apexian Sublicense Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ApexianSublicenseAgreementTextBlock', window );">Apexian Sublicense Agreement</a></td>
<td class="text">
<div>  <span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Apexian Sublicense Agreement</div>
              </td>

  </tr>


</table>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On January 21, 2020, as amended on June 4,
          2020, the Company entered into a sublicense agreement (the &#8220;Sublicense Agreement&#8221;) with Apexian, pursuant to which it obtained exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to
          therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions. The lead compound in the Ref-1 Inhibitor program is APX3330, which the Company intends to develop as an oral pill therapeutic to treat diabetic
          retinopathy and diabetic macular edema initially, and potentially later to treat wet age-related macular degeneration.</div>

<div><span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company agreed to
          make one-time milestone payments under the Sublicense Agreement for each of the first ophthalmic indication and the first diabetes mellitus indication for the Development and Regulatory milestones, and once for each of the Sales milestones. These
          milestone payments include (i) payments for specified developmental and regulatory milestones (including completion of the first Phase 2 trial that meets a primary endpoint and the first Phase 3 pivotal trial in the United States, and filing and
          achieving regulatory approval from the FDA for the first New Drug Application for a compound) totaling up to $11 million in the
          aggregate and (ii) payments for specified sales milestones of up to $20 million in the aggregate, which net sales milestone payments
          are payable once, upon the first achievement of such milestone. Lastly, the Company also agreed to make a royalty payment equal to a single-digit percentage of its net sales of products associated with the covered patents under the Sublicense
          Agreement. If it is not terminated pursuant to its terms, the Sublicense Agreement shall remain in effect until expiration of the last to expire of the covered patents.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">None of the milestone
          or royalty payments, were triggered or deemed probable as of December 31, 2022.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ApexianSublicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ApexianSublicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ApexianSublicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Apexian Sublicense Agreement related to exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ApexianSublicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912626144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholder Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder Equity</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">9.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Stockholder Equity<br/>
                </div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: italic; font-variant: normal; text-transform: none;">At-The-Market
              Program</div>

<div><br/>
            </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On February 4, 2021, Ocuphire filed a Form S-3 shelf registration under the Securities Act of 1933 which was declared effective by the SEC on February 12,&#160;2021 (the &#8220;2021 Shelf&#8221;) under which the
                Company may offer and sell, from time to time in its sole discretion, securities having an aggregate offering price of up to $125
                million. In connection with the 2021 Shelf, on March 11,&#160;2021, Ocuphire entered into a sales agreement with JonesTrading Institutional Services LLC (&#8220;JonesTrading&#8221;) under which the Company may offer and sell, from time to time at its sole
                discretion, to or through JonesTrading, acting as agent and/or principal, shares of its common stock having an aggregate offering price of up to $40
                million (the &#8220;ATM&#8221;). During the years ended December 31,&#160;2022 and 2021, 1,848,980 and </span>2,778,890<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> shares of common stock were sold under the ATM for aggregate gross proceeds in the amount of $4.4 million and $13.5 million, respectively, before
                deducting issuance expenses, including the placement agent&#8217;s fees, legal and accounting expenses, in the amount of $133,000 and $0.4 million, respectively.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;">Registered Direct Offering</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On June 4,&#160;2021, the Company entered into a placement agency agreement for a registered direct offering (&#8220;RDO&#8221;) with A.G.P./Alliance Global Partners (&#8220;AGP&#8221;). Pursuant to the terms of the
                placement agency agreement, AGP on June 8,&#160;2021 sold an aggregate of </span>3,076,923<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> shares of the Company&#8217;s common stock and warrants to purchase </span>1,538,461<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> shares of the Company&#8217;s common stock (the &#8220;RDO Warrants&#8221;) at an offering price of $4.875 per one share and </span>0.50<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> RDO Warrants, for gross proceeds of approximately $15.0 million, before AGP&#8217;s fees and related offering expenses in the amount of approximately $1.1 million. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The proceeds were allocated between the relative fair values of common stock and warrants at the sale date. The purchase agreement contains customary representations, warranties and agreements by the
                Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions. The RDO&#160; was made pursuant to the Company&#8217;s 2021 shelf registration.</span></div>

<div><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">The RDO Warrants have an exercise price of $6.09 per share, are exercisable from the
                initial issuance date of June 8,&#160;2021, and will expire </span>five years<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> following the initial issuance date. As of December 31,&#160;2022, </span>1,538,461<span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> RDO Warrants were outstanding.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman';">Subject to limited
                exceptions, a holder of a RDO Warrant will not have the right to exercise any portion of its RDO Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of a holder prior to the date of issuance, 9.99%)
                of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise; provided, however, that upon prior notice to the Company, the holder may increase or decrease the beneficial ownership
                limitation, provided further that in no event shall the beneficial ownership limitation exceed 9.99%.</span><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915688640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License and Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;">10. License and Collaboration Agreements</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Nyxol&#160; License Agreement</div>

<div><br/>
      </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">On November 6, 2022, the Company entered into the Nyxol License Agreement, pursuant to which it granted Famy an exclusive, perpetual, sub-licensable
          license to develop, manufacture, import, export and commercialize (i) Nyxol for treating (a) reversal of mydriasis, (b) night vision disturbances or dim light vision, and (c) presbyopia, and (ii) Nyxol and low dose pilocarpine for treating
          presbyopia (together, the &#8220;Nyxol Products&#8221;) worldwide except for certain countries and jurisdictions in Asia (the &#8220;Viatris Territory&#8221;). The Company retains the exclusive right to develop, manufacture, have manufactured, import, export and
          commercialize the Product outside of the Viatris Territory.&#160; In 2023, Famy was acquired by Viatris Inc., and Viatris has assumed all of Famy&#8217;s obligations under the Nyxol License Agreement.</div>

<div><br/>
        </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the Nyxol License Agreement, the Company will develop the Nyxol Products in the United States in partnership with Viatris, and
              Viatris will be responsible for developing the Nyxol Products in countries and jurisdictions in the Viatris Territory outside of the United States.&#160;Viatris will reimburse the Company for budgeted costs related to the development of the Nyxol
              Products through FDA approval. The parties established a joint steering committee, which oversees and makes decisions regarding the development of the Nyxol Products. The committee is composed of an equal number of representatives of Viatris
              and Ocuphire. Viatris will commercialize the Nyxol Products in the Viatris Territory for each indication that receives regulatory approval.</div>

<div><br/>
        </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the Nyxol License Agreement, the Company received a one-time non-refundable cash payment of $35 million in November 2022 for the exclusive, perpetual, sub-licensable license to develop, manufacture, import, export and commercialize the Nyxol Products in the Viatris
          Territory. In addition, with respect to each Nyxol Product, the Company will be eligible to receive potential additional payments of up to $130
          million in the aggregate upon achieving certain specified regulatory or net sales milestones, with the first potential payment of $10
          million to be made following approval by the FDA of Nyxol for reversal of mydriasis. The Company will also receive tiered royalties, starting at low double-digit royalties up to low twenty percent royalties, based on the aggregate annual net sales of all Nyxol Products in the United States, and will receive low double-digit royalties based on all annual net sales in
          the Viatris Territory outside of the United States. The royalty payments will continue on a country-by-country basis from the date of the first commercial sale of the first Nyxol Product in a country of the Viatris Territory until December 31,
          2040.</div>

<div><br/>
        </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Either party may terminate the Nyxol License Agreement upon written notice in the case of the other party&#8217;s material breach (subject to applicable
          cure periods) or if the other party becomes subject to an insolvency event. In addition, the Company may terminate the agreement in its entirety if Famy, Viatris or their affiliates commence an action challenging the validity, enforceability or
          scope of any of Ocuphire&#8217;s patents that are exclusively licensed under the Nyxol License Agreement. Additionally, if Viatris determines not to pursue development or commercialization of a Product in a country or jurisdiction in the Viatris
          Territory, Viatris may terminate the license with respect to such Product in such country or jurisdiction.</div>

<div><br/>
        </div>

<div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Both Ocuphire and Viatris have agreed to indemnify the other party against certain losses and expenses relating to any breach of the indemnifying
          party&#8217;s obligations, representations, warranties or covenants under the Nyxol License Agreement.</div>

<div><br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Nyxol License Agreement was accounted for under the provisions of ASC 606. In accordance with the p<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">rovisions under ASC 606, the Company identified two distinct performance obligations: <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(1) the license to its intellectual property (&#8220;license transfer&#8221;) and (2) research and development services.</span></span><br/>
      </div>

<div><br/>
      </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The aggregate transaction price associated with the Nyxol License Agreement was $40.2 million which comprised the Initial License Transfer fee of $35.0 million and the estimated $5.2 million payment anticipated under the research and development services that were not subject to cancellation. The transaction price was allocated
        between performance obligations based on their relative standalone selling price (&#8220;SSP&#8221;).</div>

<div>&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The SSP for the license transfer and for the research and development services was determined to be $ 287.8 million and $5.2 million, respectively. The SSP for the
        license tran<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">sfer was determined based on
          a <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">discounted royalty cash flow approach, taking into consideration assumptions, including</span></span> projected worldwide net profit for each of the respective programs based on probability
        assessments, projections based on internal forecasts, industry data, and information from other guideline companies within the same industry and other relevant factors. The SSP for the research and development services was determined using a cost
        plus margin approach, based on anticipated expenditure outlays within the first 120-day non-cancellation window. On a relative SSP
        basis, $39.5 million and $0.7
        million of the transaction price was allocated to the license transfer and to the research and development services obligations, respectively. <br/>
      </div>

<div>&#160;</div>

<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Recognition of Revenue</div>

<div>&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> determined that the licenses transferred represented functional intellectual property. As such, the revenue related to the licenses
            was recognized at the point in time in which the license/know-how was delivered to Famy which occurred during the fourth quarter of 2022. The Company determined that revenue related to the research and development services was to be recognized
            over time as the services are rendered based on an estimated percentage of completion input model.</span> </span>Revenue recognized under the Nyxol License Agreement during the year ended December 31, 2022 was $39.8 million.</div>

<div>&#160;</div>

<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Regulatory Milestones under the Nyxol License Agreement</div>

<div>&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company has evaluated the regulatory milestones that may be received in connection with the Nyxol License Agreement. There is uncertainty that
        the events to obtain the regulatory milestones will be achieved given the nature of clinical development and the stage of the development of the Products. The remaining regulatory milestones will be constrained until it is probable that a
        significant revenue reversal will not occur.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Sales Milestone and Royalty Payments</div>

<div style="text-align: justify;">&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Sales milestones and royalties relate predominantly to a license of intellectual property granted to Famy and are determined by sales or
        usage-based thresholds. The sales milestones and royalties are accounted for under the royalty recognition constraint and will be accounted for as constrained variable consideration. The Company applies the royalty recognition constraint for each
        commercial milestone and will not recognize revenue for each until the subsequent sale of a licensed product (achievement of each) occurs.</div>

<div>&#160;</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">With the exception of the license transfer and the research and development services obligations, each of the remaining regulatory and sales
        milestone performance obligations and royalty payments were fully constrained as of December 31, 2022.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of the closing balance of the contract asset associated with the Nyxol License Agreement is as follows as of December 31, 2022 (in thousands):&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contract Asset</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of&#160;&#160;December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom">Revenue recognized &#8211; license transfer <br/>
            </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">39,519</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Execution of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Nyxol License Agreement and&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">one-time non-refundable&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">payment</span></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(35,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Revenue recognized &#8211; research and development services</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">331</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reclassification to accounts receivable related to&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">costs billed under the Nyxol License Agreement</span></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(1,298</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of December 31, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">3,552</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The remaining amounts in the contract asset as of December 31, 2022 attributed to the research and development services are expected to be settled during the first
        half of 2023.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
      </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;">BioSense License and Assignment Agreement</div>

<div style="font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">On March 10, 2020, pre-Merger, Rexahn entered into an amendment to its collaboration and license agreement, (as amended, the &#8220;BioSense License
          and Assignment Agreement&#8221;) with BioSense to advance the development and commercialization of RX-3117 for all human uses in the Republic of Singapore, China, Hong Kong, Macau, and Taiwan (the &#8220;BioSense Territory&#8221;). Under the terms of the BioSense
          License and Assignment Agreement, the Company (i) granted BioSense an exclusive license to develop and commercialize pharmaceutical products containing RX-3117 as a single agent for all human uses in the BioSense Territory and (ii) assigned and
          transferred all of the former Rexahn patents and patent applications related to RX-3117 in the BioSense Territory. The upfront payment consisted of an aggregate of $1,650,000, of which $1,550,000 was paid to Rexahn prior to the Merger.During
          the year ended December 31, 2021, the Company satisfied a performance obligation for the $100,000 payment that was remaining and
          recorded this amount as license and collaborations revenue.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> <br/>
      </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Under the BioSense
          License and Assignment Agreement, the Company is eligible to receive additional milestone payments in an aggregate of up to $84,500,000
          upon the achievement of development, regulatory and commercial goals and will also be eligible to receive tiered royalties at low double-digit rates on annual net sales in the BioSense Territory. The Company determined that none of the milestone
          payments under the BioSense License and Assignment Agreement were probable of payment as of December 31, 2022, and as a result, no
          revenue related to the milestones was recognized as the achievement of events entitling the Company to any milestone payments were highly susceptible to factors outside of the Company&#8217;s control. Future sales-based royalties related to the
          exclusive license to develop RX-3117 will be recognized in the period the underlying sales transaction occurs.</div>

<div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Payments received
          under the BioSense License and Assignment Agreement are subject to the CVR Agreement described in Note 2 &#8211; Merger.</div>

<div style="font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-size: 10pt; text-align: justify; font-family: 'Times New Roman';">Processa License Agreement</div>

<div style="font-size: 10pt;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On June 16, 2021, the
          Company entered into a license agreement (the &#8220;Processa License Agreement&#8221;) with Processa Pharmaceuticals, Inc. (&#8220;Processa&#8221;), pursuant to which the Company has agreed to grant Processa an exclusive license to develop, manufacture and
          commercialize RX-3117 globally, excluding the BioSense Territory.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">As consideration for the Processa License Agreement, the Company received an upfront payment in July 2021 consisting of 44,689 shares of Processa common stock with a fair value of $289,000 (at the contract date) and a $200,000 cash payment.The Company was
          restricted from selling the Processa common stock for a period of one year ending June 16, 2022. As additional consideration, Processa
          will make payments to the Company upon the achievement of certain development and regulatory milestones, which primarily consist of dosing a patient in pivotal trials or having a drug indication approved by a regulatory authority in the United
          States or another country. In addition, Processa will pay the Company mid-single-digit royalties based on annual sales under the license and will make one-time
















          sales milestone payments based on the achievement during a calendar year of certain thresholds for annual sales. Processa is also required to give the Company 32% of any milestone payments received based on any sub-license agreement Processa may enter into with respect to the Processa License Agreement.The Company determined that none of the
          milestone payments under the Processa License Agreement were probable of payment as of December 31, 2022, and as a result, no revenue
          related to the milestones was recognized, as the achievement of events entitling the Company to any milestone payments were highly susceptible to factors outside of the Company&#8217;s control.</div>

<div style="font-size: 10pt;"><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';">Processa is required to use commercially reasonable efforts, at its sole cost and expense, to conduct development activities in one or more countries, including meeting specific diligence milestones that consist of: (i) first patient administered drug in a clinical trial of a
          licensed product prior to the three (3) year anniversary of the effective date; and (ii) first patient administered drug in a pivotal
          clinical trial of a licensed product or first patient administered drug in a clinical trial for a second indication of a licensed product prior to the five (5) year anniversary of the effective date. Either party may terminate the agreement in the event of a material breach of the agreement that has not been cured following written notice and
          a 120-day opportunity to cure such breach, and Processa may terminate the agreement for any reason upon 120 days prior written notice to Ocuphire.</div>

<div><span style="font-family: 'Times New Roman';"><br/>
          </span> </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As of December 31,
          2021, the Company had fulfilled its performance obligations with respect to the upfront payment under the Processa License Agreement and had recognized the associated licensing revenue in connection with the payment.</div>

<div><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Payments received
          under the Processa License Agreement will be subject to the CVR Agreement described in Note 2 &#8211; Merger.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912659472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net income (loss) per share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">11.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Net income (loss) per share</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Basic income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during
            the period.&#160; Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any
            common stock equivalents, if dilutive. The Company&#8217;s warrants, stock options and restricted stock awards, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method
            for the warrants, stock options and restricted stock. Incremental common stock equivalents that were antidilutive were excluded in calculating diluted income per share.&#160; For the year ended December 31, 2021, no common stock equivalents were
            included in the diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the prior year period.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';">The following table presents the computation of weighted average common shares considered in the computation of
            diluted net income (loss) per share:</div>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" valign="bottom">&#160;2022 </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" valign="bottom">2021 <br/>
                  </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Denominator (weighted average shares)</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;" valign="bottom">&#160;<br/>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;" valign="bottom">&#160;<br/>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Basic common shares outstanding</div>
                    </div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">19,931,080</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">14,852,745</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Dilutive stock options</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">589,165</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">&#8212;</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Dilutive warrants</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">76,967</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">&#8212;</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Diluted common shares outstanding</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">20,597,212</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">14,852,745</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The following potential common shares were not
            considered in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive for the year end periods presented below:</span> <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Series A, Series B and RDO warrants</div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>7,145,201</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">7,282,999</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Stock options</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2,346,879</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2,096,836</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Restricted stock awards including pending issuances of stock for services <br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>6,970</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Former Rexahn warrants</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>60,713</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">66,538</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Former Rexahn options</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">82</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912718224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">12.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Income Taxes<br/>
                </div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The effective tax rate for the years ended December 31, 2022 and 2021 was 1.7 percent and zero percent, respectively.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements
          of comprehensive income (loss) is as follows for the years ended December 31, 2022 and 2021:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">Income tax (benefit) provision at federal statutory rate</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">21.0<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(21.0<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)%<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(21.4<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">11.9<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>State income tax, net of federal benefit</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">4.9<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(4.8<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Warrants</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#8212;<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">15.3<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Stock options</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.4<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(0.1<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Research and development</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(3.1<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(1.1<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(0.1<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(0.2<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Effective tax rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">1.7<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">%<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#8212;<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">%</td>

  </tr>


</table>

<div> <span style="font-family: 'Times New Roman';"><br/>
          </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></div>

<div> <br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The components of income tax provision (benefit) consisted of the following for the years ended December 31, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2022 and 2021 (in thousands):</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
        </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold; font-family: 'Times New Roman';"> 2022 </span><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold; font-family: 'Times New Roman';">2021 </span><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Income (loss) before income taxes:</div>
                </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">18,203</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">(56,693</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Current:</div>
                </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Federal</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">279</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">State</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">36</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Total current tax provision (benefit)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">315</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Deferred:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Federal</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">State</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Total tax provision (benefit</span><span style="font-family: 'Times New Roman';">)</span></div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">315</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities are summarized in the tables below as of December 31, 2022 and 2021 (in thousands):<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                <div style="font-weight: bold;">Deferred tax assets:</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">Federal and state operating loss carryforwards</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">13,087</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">19,244</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Acquired intangibles</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">547</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>547</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">Deferral of research and development costs <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,820</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#8212;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Organizational costs</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">7</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>7</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">Other</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">62</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Stock-based compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,152</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>811</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Research and development credit carryforward<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">731</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>1,035</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Subtotal</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">18,406</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>21,662</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(17,770</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>(21,662</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Total deferred tax assets, net of valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>636</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-weight: bold;">Deferred tax liabilities:</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">Deferred revenue <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(636</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">&#8212;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Total deferred tax liabilities</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(636</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="font-weight: bold;">Net deferred tax assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2022 and 2021, the Company had gross deferred tax assets of approximately $18.4 million and $21.7 million, respectively. Realization of the deferred tax
          assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has cumulative pre&#8209;tax losses <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">and faces significant challenges
            to becoming profitable in the future. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance</span> of $17.8
          million and $21.7 million as of December 31, 2022 and 2021, respectively. U.S. net deferred tax assets will continue to require a
          valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of December 31, 2022 and 2021, the tax effect of the Company&#8217;s federal net operating loss carryforwards was approximately $10.9 million and $15.7 million,
          respectively. The Company had federal research credit carryforwards as of December 31, 2022 and 2021 of approximately $0.7 million and
          $1.0 million, respectively. The federal net operating loss carryforwards will not expire and the tax credit carryforwards will begin to
          expire in 2041 if not utilized.&#160; As of December 31, 2022 and 2021, the Company had state net operating loss carryforwards with a tax effect of approximately $2.2 million and $3.6 million, respectively. The Company did not have any state research credit carryforwards as of December 31, 2022 and 2021. The state net operating loss carryforwards will begin to expire in 2028.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company
            utilized federal and state net operating tax carryforwards with a tax effect in the amount of $4.8 million and $1.4 million, respectively, to offset taxable income for the year ended December 31, 2022. In addition, the Company also utilized its federal
            research credit carryforwards in the amount of $0.9 million to partially offset its tax liability for the year ended December 31,
            2022.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by
          Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#8220;5-percent shareholders&#8221; increase their
          ownership, in the aggregate, by more than 50 percentage points over a 3 year testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and
          credits before utilization. As a result of the Merger, the Company recorded deferred tax assets of $10.3 million relating to net
          operating loss carryforwards which were fully offset by a valuation allowance. The $10.3 million net deferred tax assets recorded in
          relation to the Merger did not include federal and state net operating loss carryforwards that were estimated to expire under Internal Revenue Code Sections 382 as a result of the Merger. The Company has not yet evaluated the impact of Section
          382 and Section 383 on its remaining tax attributes that were generated by Ocuphire since the formation of the Company in 2018.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December 31, 2022 and 2021, and as such, no interest or penalties were recorded to income tax expense.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company&#8217;s corporate returns are subject to examination beginning with the 2019 tax year for federal income tax purposes and 2018 for state income tax purposes.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912757904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Compensation Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Deferred Compensation Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Deferred Compensation Plan</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman';">13.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold; font-family: 'Times New Roman';">Deferred Compensation Plan </div>
              </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
        </span> </div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Effective October 1, 2021, the Company began offering a 401(k) plan (&#8220;401K Plan&#8221;) to its
          employees. All employees are eligible to participate in the 401K Plan. The Company makes matching contributions equal to 100% on the
          first 3% of compensation that is deferred as an elective deferral and an additional 50% on the next 2% of compensation. The Company&#8217;s matching
          contributions are made on a monthly basis. During the years ended December 31, 2022 and 2021, the Company contributed $76,000 and $15,000 to the 401K Plan, respectively.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912799504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 27pt; vertical-align: top; font-weight: bold;">14.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Subsequent Events</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160; <br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">2020 Plan Evergreen Provision</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);"> </span><br/>
        </div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Under the 2020 Plan, the shares reserved automatically increase on January 1 of each year, for a period of not more than ten years from the date the 2020 Plan is approved by the stockholders of the Company, commencing on January 1, 2021 and ending on (and including)
          January 1, 2030, by an amount equal to 5% of the shares of common stock outstanding as of December 31 of the preceding calendar year.
          Notwithstanding the foregoing, the Board of&#160; Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase in the share reserve for such year or that the increase in the share reserve for such year will
          be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, 1,043,066
          shares were added to the 2020 Plan as a result of the evergreen provision.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910756512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Company Description and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NatureOfBusinessPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Nature of Business</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Ocuphire Pharma, Inc. (the &#8220;Company&#8221; or &#8220;Ocuphire&#8221;) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and
            retinal eye disorders. Ocuphire&#8217;s pipeline currently includes two small molecule product candidates targeting several of such
            indications.</span><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In November 2022, the Company entered into a license and collaboration agreement (the &#8220;Nyxol License Agreement&#8221;) with FamyGen Life Sciences, Inc. (acquired by Viatris, Inc. (&#8220;Viatris&#8221;) in January
            2023) pursuant to which it granted Viatris an exclusive license to develop, manufacture, import, export and commercialize its product candidate phentolamine ophthalmic solution 0.75% (Nyxol&#174; Eye Drops or &#8220;Nyxol&#8221;). Nyxol is a once-daily eye drop
            formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically-induced mydriasis (&#8220;RM&#8221;) (dilation of the pupil),
            presbyopia (age-related blurry near vision) and dim light or night vision disturbances (&#8220;DLD&#8221;) (halos, glares and starbursts).</span><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company&#8217;s second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as
            diabetic retinopathy (&#8220;DR&#8221;) and diabetic macular edema (&#8220;DME&#8221;) which, if left untreated, can result in permanent visual acuity loss and eventual blindness. The Company has also in-licensed APX2009 and APX2014, which are second-generation
            product candidates and analogs of APX3330.</span><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">License and collaborations revenue to date was derived from a one-time non-refundable payment and reimbursement of expenses earned under the Nyxol License Agreement, and to a much lesser degree, from
            license agreements with BioSense Global LLC (&#8220;BioSense&#8221;) and Processa Pharmaceuticals, Inc. (&#8220;Processa&#8221;) in connection with the Rexahn RX-3117 drug compound. The Company anticipates that it will recognize revenue as it earns reimbursement for
            research and development services in connection with the Nyxol License Agreement and it may earn additional revenues from future potential milestone and royalty payments from the agreements with Viatris, BioSense, Processa, or from other
            license agreements entered into the future; however, the attainment of milestones or level of sales required to earn royalty payments is highly uncertain. Outside of the license and collaborations revenue, the Company does not expect to
            generate significant revenue unless or until regulatory approval is obtained and commercialization begins for Nyxol or APX3330. Management plans to continue financing the Company&#8217;s operations primarily through additional issuances of the
            Company&#8217;s equity and debt securities or through collaborations or partnerships with other companies. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and
            development programs.</span><br/>
        </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Reverse Merger with Rexahn</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: italic; font-weight: bold;">Reverse Merger with Rexahn</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-style: normal;"><br class="Apple-interchange-newline"/>
                </span></span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-style: normal;"> </span> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;">&#160;On June 17, 2020, Ocuphire, Rexahn
                Pharmaceuticals, Inc. (&#8220;Rexahn&#8221;), Razor Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rexahn (&#8220;Merger Sub&#8221;), entered into an Agreement and Plan of Merger and Reorganization, as amended on June 29, 2020 (as amended,
                the &#8220;Merger Agreement&#8221;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub would merge with and into Ocuphire, with Ocuphire continuing as a
                wholly-owned subsidiary of Rexahn and the surviving corporation of the merger (the &#8220;Merger&#8221;). The Merger closed on November 5, 2020. Upon completion of the Merger, Rexahn changed its name to Ocuphire Pharma, Inc. and changed its ticker
                symbol on the Nasdaq Capital Market to &#8220;OCUP&#8221;.</span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">The Company&#8217;s headquarters is located in Farmington Hills, Michigan.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Basis of Presentation</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America (&#8220;GAAP&#8221;). <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';">On December 31, 2021, the Company merged its wholly owned subsidiary, OcuSub Inc, with and into the Company, with
            the Company remaining as the surviving entity. The merger of the Company&#8217;s wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of this merger, the Company did not have any remaining entities that
            required consolidation for financial statement reporting purposes.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_LiquidityPolicyTextBlock', window );">Liquidity</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Liquidity</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;">The accompanying consolidated financial statements have
            been prepared on the basis that the Company will continue as a going concern. From its inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting clinical trials.</div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"><span style="font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company entered into the Nyxol License Agreement, and the</span> Company received a $35 million <span style="font-size: 10pt; font-weight: normal; font-style: normal;">one-time </span> non-refundable payment in November 2022, and commitment from
                Viatris to reimburse budgeted development costs for Nyxol. See Note 10 &#8211; License and Collaboration Agreements for additional information related to the Nyxol License Agreement. Management believes that the Company, as a result of this cash
                payment receipt, has adequate liquidity to meet obligations as they come due without raising additional funds for at least twelve months from the date of issuance of these financial statements. As of December 31, 2022, the Company had $42.6 million in cash and cash equivalents.</span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"> <br/>
              </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-size: 10pt; font-weight: normal; font-style: normal;"> <span style="font-weight: normal; font-size: 10pt; font-style: normal;">In the future, the Company may need to raise additional funds until it is able to generate sufficient revenues to fund its development activities. The Company&#8217;s future
                  operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to
                  predict the ultimate outcome of these actions to generate the liquidity ultimately required.</span></span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Use of Estimates</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported
          in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Segment Information</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#8217;s chief operating
          decision maker in deciding how to allocate resources and assessing performance. The Company&#8217;s chief operating decision maker is its Chief Executive Officer. The Company&#8217;s Chief Executive Officer views the Company&#8217;s operations and manages its
          business in one operating segment, which is the business of development and commercialization of products related to vision
          performance and health. Accordingly, the Company has a single reporting segment.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Cash and Cash Equivalents</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of deposit to be cash equivalents.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Concentration of Credit Risk</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">&#160;</div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Financial instruments that potentially subject the
                Company to a concentration of credit risk consist of cash and cash equivalents. As of December 31, 2022, the Company&#8217;s cash was held by two large financial institutions in the United States. Amounts on deposit may at times exceed federally
                insured limits. As of December 31, 2022, the Company had deposits that exceeded federally insured amounts by approximately $42.1
                million.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-term Investments</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Short-term Investments<br/>
              </div>

<div style="font-family: 'Times New Roman';"><br/>
              </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and are recorded on a settlement
                date basis. The Company&#8217;s investments are comprised of equity securities, which in accordance with the fair value hierarchy described below are recorded at fair value using Level l inputs on the balance sheets.&#160; Subsequent changes in fair
                values are recorded in other expense, net on the&#160; consolidated statements of comprehensive income (loss). The Company classifies investments available to fund current operations as current assets on its balance sheets. The Company did not recognize any impairments on its investments to date through December 31, 2022.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue Recognition</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The Company follows the provisions of&#160;Accounting Standards Codification (&#8220;ASC&#8221;) 606,&#160;</span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Revenue from Contracts with Customers</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">. The guidance provides a five-step model to determine
                  how revenue is recognized. The Company has entered into license agreements which have revenue recognition implications (See Note 10 &#8211; License and Collaboration Agreements).</span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the contracts with a
                customer; (ii) determination of the performance obligations in the contract; (iii) measurement of the transaction price, including potential constraints on variable consideration; (iv) allocation of the transaction price to the performance
                obligations based on estimated stand-alone selling prices; and (v) recognition of revenue when (or as) the Company satisfies a performance obligation.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to
                  the customer and is the unit of account in ASC 606. Performance obligations may include license rights, development and other services. Significant management judgment is required to determine the level of effort required under an
                  arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become
                  inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.</span></div>

<div style="font-family: 'Times New Roman';"><br/>
              </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each
                performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount
                rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the relative standalone selling prices of the promised goods or service underlying each
                performance obligation.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Licenses of intellectual property and research and development services:</span> If the license to the Company&#8217;s intellectual
                property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the
                customer, and the customer can use and benefit from the license. For licenses that are bundled with other obligations, such as research and development services, the Company utilizes judgment to assess the nature of the combined performance
                obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable,
                up-front fees. For research and development services that are distinct from a license transfer obligation, the Company determines whether the services are satisfied over time or at a point in time and, if over time, the appropriate method
                of measuring progress for purposes of recognizing revenue from such services. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Milestone payments: </span>At the inception of each arrangement that includes milestone payments, the Company evaluates
                whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur,
                the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable
                of being achieved until such contingency occurs (such as receipt of those approvals).</div>

<div style="font-family: 'Times New Roman';"><br/>
              </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold;">Royalties:</span> For arrangements that include sales-based royalties, including milestone payments based on the level of
                sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the
                royalty has been allocated has been satisfied (or partially satisfied).</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContractAssetPolicyTextBlock', window );">Contract Asset</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;">Contract Asset</span><br/>
              </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> The Company recognizes a contract asset when goods or services are transferred to the customer before the customer pays or before payment is due, excluding any amounts presented as an
                  accounts receivable. The Company recorded a contract asset in connection with a license and collaboration agreement in the amount of $3.6
                  million as of December 31, 2022.&#160; See Note 10 - License and Collaboration Agreements.</span><br/>
              </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowances for Doubtful Accounts</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;">Accounts Receivable and Allowances for Doubtful Accounts</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"> <br/>
                      </span></span></span></span></div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;"><span style="font-weight: normal; font-style: normal;">The Company records a provision for doubtful accounts, when appropriate, based on historical experience
                        and a detailed assessment of the collectability of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of the accounts receivable, its historical
                        write-offs, the credit worthiness of each customer, and general economic conditions. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered.
                        Actual write-offs may be in excess of the Company&#8217;s estimated allowance.&#160; The Company has not incurred any bad debt
                        expense during the years ended December 31, 2022 or 2021 and no allowance for doubtful accounts has been recorded
                        during the periods presented.</span></span></span></span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">General and Administrative Expenses</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">General and administrative expenses (&#8220;G&amp;A&#8221;) consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in
          functions not directly associated with research and development activities. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and tax services, settlement costs
          with third parties and other services provided by business consultants.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Research and Development</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">Research and development expenses (&#8220;R&amp;D&#8221;) consist of costs incurred in performing research and development activities, including compensation for research and
            development employees and consultants, costs associated with preclinical studies and clinical trials, regulatory activities, manufacturing activities to support clinical activities, license fees, fees paid to external service providers that
            conduct certain research and development, and an allocation of R&amp;D related overhead expenses. R&amp;D costs include costs that are reimbursed under the Nyxol License Agreement.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_OtherIncomeExpenseNetPolicyTextBlock', window );">Other Expense, net</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Other Expense, net</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Other expense, net reflected in this line item includes payments made by the Company in connection with the Contingent Value Rights Agreement discussed further below
          with former Rexahn shareholders. In addition, other expense, net includes interest earned from cash and cash equivalent investments, realized and unrealized gains (losses) from equity investments and reimbursements in connection with grants and
          other sources when they occur.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based Compensation</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The Company accounts for stock-based compensation in accordance with the provisions of the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 718, <span style="font-style: italic;">Compensation &#8212; Stock Compensation</span>. Accordingly, compensation costs related to equity instruments granted are recognized at the grant date fair value. The Company records forfeitures when they occur.
            Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_WarrantLiabilitiesPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Warrant Liabilities</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company issued Series A Warrants in connection with the Pre-Merger Financing (see Note 3 &#8211; Pre-Merger Financing) and assumed Rexahn warrants issued prior to
            the Merger. The Company accounts for these warrants as a liability while outstanding at fair value during periods when certain provisions preclude equity accounting treatment for these instruments. Additionally, issuance costs associated with
            the warrants classified as liabilities were expensed as incurred and reflected as interest expense in the accompanying consolidated statements of comprehensive income (loss). The change in fair value of the warrant liabilities while outstanding
            were recognized as a component of the fair value change in warrant liabilities line item in the consolidated statements of comprehensive income (loss).</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Fair Value Measurements</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as
          &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three-level hierarchy:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 1 inputs: Unadjusted quoted prices for identical assets or liabilities in active markets;</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 2 inputs: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the
                  asset or liability; and</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Level 3 inputs: Unobservable inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or
                  liability at the measurement date.</div>
              </td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">As of December </span>31,<span style="font-size: 10pt; font-family: 'Times New Roman';">&#160;</span>2022<span style="font-size: 10pt; font-family: 'Times New Roman';"> and </span>2021,<span style="font-size: 10pt; font-family: 'Times New Roman';"> the fair values of cash and cash equivalents, accounts receivable, contract asset, prepaid and other
              assets, accounts payable, accrued expenses and short-term loan, while outstanding,&#160; approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the short-term investments was based on
              observable Level </span>1<span style="font-size: 10pt; font-family: 'Times New Roman';"> inputs in the form of quoted market prices from a major stock exchange. The fair value of the warrant liabilities, while outstanding, was based on cash
              flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and were based on Level </span>3<span style="font-size: 10pt; font-family: 'Times New Roman';"> inputs.</span> </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">There were no transfers between fair value
            hierarchy levels during the years ended December 31, 2022 and 2021.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of financial instruments measured on a recurring basis is as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">As of December 31, 2022</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom">
                <div>Description</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Total</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 1</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 2</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 3</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%;" valign="bottom">
                <div>Assets:<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> Short-term investments<br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom">
                <div>Total assets at fair value</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">As of December 31, 2021</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom">
                <div>Description</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Total</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 1</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 2</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 3</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%;" valign="bottom">
                <div>Assets:</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Short-term investments</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom">
                <div>Total assets at fair value</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides a roll-forward of investments measured at fair value on a recurring basis using observable level 1 inputs for the year ended December
            31, 2022 and 2021 (in thousands):</div>

<div><br/>
          </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Short-term investments</div>
                </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of beginning of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">219</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Receipt of investments related to license agreement</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">289</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Unrealized loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(170</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(70</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of end of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">49</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">219</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides a roll-forward of the warrant liabilities measured at fair value on a recurring basis using unobservable level 3 inputs for the year
          ended December 31,&#160; 2021 (in thousands):</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2021<br/>
                  </span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrant liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of beginning of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">27,964</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">33,829</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Reclassification of warrants from liability to equity</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(61,793</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of end of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">The fair value of the warrant liabilities associated with the Rexahn warrants was de minimis during the years ended December 31, 2022 and 2021. See Note 2 - Merger.<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">There were no financial instruments measured on a
          non-recurring basis for any of the periods presented.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Income Taxes</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company utilizes the liability method of accounting for income taxes as required by ASC 740, <span style="font-style: italic;">Income Taxes</span>. Under this
          method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences
          are expected to reverse. The Company currently has a provision for income taxes, but the Company has historically incurred operating losses for all prior year periods.&#160; As such, a full valuation allowance has been provided on the net deferred tax
          assets given the uncertainty of future taxable income and other related factors impacting the realizability or the Company&#8217;s remaining net deferred tax assets.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Property and Equipment, net<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment, net is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the
          assets using the straight-line method. Equipment and furniture are depreciated over a five-year estimated useful life. Tangible
          assets acquired for research and development activities which have alternative use are capitalized and depreciated over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are
          made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged
          directly to expense as incurred.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Recent Accounting Pronouncements</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, &#8220;<span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Financial












































            Instruments &#8211; Credit Losses&#8221;</span>. The ASU sets forth a current expected credit loss (&#8220;CECL&#8221;) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical
          experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some
          off-balance sheet credit exposures. The Company does not expect that the adoption of this ASU on January 1, 2023 will have a significant impact on its consolidated financial statements.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;<br/>
        </div>

<div style="text-align: justify;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In August 2020, FASB issued ASU 2020-06,</span>
          <span style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
            and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span>, <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">which, among other things, provides guidance on how to account for contracts on an entity&#8217;s own equity. This &#8203;ASU eliminates the beneficial conversion and cash
            conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this
            ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for public business entities that meet the definition
            of a Securities and Exchange Commission (&#8220;SEC&#8221;) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
            For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. </span><span style="font-size: 10pt; font-family: 'Times New Roman';">The Company
            does not expect that the adoption of this ASU on January 1,&#160;2023 on its consolidated financial statements will be material</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">.</span> </div>

<div><br/></div>

<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In November 2021, <span style="font-size: 10pt; font-family: 'Times New Roman';">the FASB issued ASU 2021-10,&#160;Government Assistance (Topic
              832) - Disclosures by Business Entities about Government Assistance,&#160;to increase the transparency of government assistance including the disclosure of the types of assistance, an entity&#8217;s accounting for the assistance, and the effect of the
              assistance on an entity&#8217;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15,&#160;2021. The Company adopted this
              guidance on January 1,&#160;2022 and it did not have a material impact to the consolidated financial statements.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContractAssetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContractAssetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NatureOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NatureOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_OtherIncomeExpenseNetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other income (expense), net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_OtherIncomeExpenseNetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_WarrantLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_WarrantLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915722176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Company Description and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value of Financial Instruments Measured on a Recurring Basis</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The fair value of financial instruments measured on a recurring basis is as follows (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">As of December 31, 2022</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom">
                <div>Description</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Total</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 1</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 2</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 3</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%;" valign="bottom">
                <div>Assets:<br/>
                </div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> Short-term investments<br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom">
                <div>Total assets at fair value</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>49</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center; font-weight: bold;">As of December 31, 2021</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom">
                <div>Description</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Total</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 1</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 2</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <div style="text-align: center;">Level 3</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%;" valign="bottom">
                <div>Assets:</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="3" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Short-term investments</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom">
                <div>Total assets at fair value</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>219</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Investments Measured on a Recurring Basis</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides a roll-forward of investments measured at fair value on a recurring basis using observable level 1 inputs for the year ended December
            31, 2022 and 2021 (in thousands):</div>

<div><br/>
          </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Short-term investments</div>
                </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of beginning of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">219</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Receipt of investments related to license agreement</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">289</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Unrealized loss</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(170</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(70</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of end of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">49</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">219</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Warrant Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides a roll-forward of the warrant liabilities measured at fair value on a recurring basis using unobservable level 3 inputs for the year
          ended December 31,&#160; 2021 (in thousands):</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2021<br/>
                  </span></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Warrant liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of beginning of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">27,964</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Change in fair value of warrant liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">33,829</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Reclassification of warrants from liability to equity</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">(61,793</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of end of period</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
        </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investments, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527913672272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid and Other Assets</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Prepaid and other assets consist of the following (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Prepaids</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,373</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,243</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>80</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>71</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Total prepaids and other assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>1,453</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>1,314</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment held for use by category are presented in the following table (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Equipment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>20</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>20</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Furniture</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>5</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>5</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Total property and equipment</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>25</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>25</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Less accumulated depreciation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(19</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>(15</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Property and equipment, net</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>6</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>10</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>Accrued expenses consist of the following (in thousands):</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>
                  <div>
                    <div>Income taxes</div>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">315</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#8212;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div>Payroll</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>782</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>488</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>Professional services</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>208</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>84</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                <div>R&amp;D services and supplies</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>212</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>1,081</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>Other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>167</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>80</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div>Total</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>1,684</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>1,733</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910473664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of
          comprehensive income (loss) for the periods indicated below (in thousands):</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31,</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>General and administrative</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,060</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>1,116</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Research and development</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>747</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>798</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Total stock-based compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>1,807</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">
                <div>1,914</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Plan Activity</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table summarizes the Company&#8217;s stock option plan activity:</span>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Options</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted</div>
                <div style="text-align: center; font-weight: bold;">Average</div>
                <div style="text-align: center; font-weight: bold;">Exercise</div>
                <div style="text-align: center; font-weight: bold;">Price</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Weighted Average</div>
                <div style="text-align: center; font-weight: bold;">Remaining</div>
                <div style="text-align: center; font-weight: bold;">Contractual</div>
                <div style="text-align: center; font-weight: bold;">Term (years)</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Aggregate</div>
                <div style="text-align: center; font-weight: bold;">Intrinsic</div>
                <div style="text-align: center; font-weight: bold;">Value<sup>(1)</sup></div>
                <div style="text-align: center; font-weight: bold;">(in thousands)</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Outstanding at December 31, 2020</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>1,784,198</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2.17</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>8.87</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>7,744</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>420,300</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5.72</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                <div>Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(73,442</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                <div>Forfeited/Cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>(34,220</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Outstanding at December 31, 2021</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2,096,836</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2.97</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>8.20</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2,795</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>893,305</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2.64</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                <div>Exercised</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(24,309</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>1.09</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom">
                <div>Forfeited/Cancelled</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>(29,788</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <div>6.21</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"/>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Outstanding at December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2,936,044</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>2.87</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>7.82</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>3,314</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom">Vested and expected to vest at December 31, 2022</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">2,936,044</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">2.87</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">7.82</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">3,314</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <div>Vested and exercisable at December 31, 2022</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,723,792</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>2.56</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>7.07</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>1,680</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></td>

    <td style="width: auto; vertical-align: top;">
                <div>The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and
                  the fair value of our common stock as of December 31, 2022 and 2021 of $3.53 and $3.73 per share, respectively.</div>
              </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used in Black-Scholes Option-pricing Model</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The weighted average assumptions used in the Black-Scholes option pricing model are as follows during the years ended December 31, 2022 and 2021:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;"> 2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Expected stock price volatility</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>97.4</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>98.1</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                <div>Expected life of options (years)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>5.8</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>5.8</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Expected dividend yield</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>0</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: middle; width: 76%;" valign="bottom">
                <div>Risk free interest rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>2.3</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>0.9</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <div>%</div>
              </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Restricted Stock Awards Activity</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A summary of RSA activity is as follows for the year ended December 31, 2021:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Number of</div>
                <div style="text-align: center; font-weight: bold;">Shares</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>Non-vested at December 31, 2020</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                <div>Granted</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div>Vested</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">(40,000</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <div>Non-vested at December 31, 2021</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912626144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_LicenseAndCollaborationAgreementsAbstract', window );"><strong>License and Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock', window );">Reconciliation of Contract Asset Associated</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of the closing balance of the contract asset associated with the Nyxol License Agreement is as follows as of December 31, 2022 (in thousands):&#160;</div>

<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contract Asset</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of&#160;&#160;December 31, 2021</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#8212;</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom">Revenue recognized &#8211; license transfer <br/>
            </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">39,519</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Execution of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Nyxol License Agreement and&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">one-time non-refundable&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">payment</span></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(35,000</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Revenue recognized &#8211; research and development services</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">331</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reclassification to accounts receivable related to&#160;</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">costs billed under the Nyxol License Agreement</span></div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(1,298</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Balance as of December 31, 2022</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">3,552</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_LicenseAndCollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_LicenseAndCollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using contract asset associated with agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527906949952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Computation of Weighted Average Common Shares</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';">The following table presents the computation of weighted average common shares considered in the computation of
            diluted net income (loss) per share:</div>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" valign="bottom">&#160;2022 </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" valign="bottom">2021 <br/>
                  </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Denominator (weighted average shares)</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;" valign="bottom">&#160;<br/>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;" valign="bottom">&#160;<br/>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Basic common shares outstanding</div>
                    </div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">19,931,080</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;"><br/>
                    </div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">14,852,745</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Dilutive stock options</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">589,165</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">&#8212;</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Dilutive warrants</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">76,967</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">&#8212;</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px;" valign="bottom">
                    <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Diluted common shares outstanding</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">20,597,212</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-size: 10pt;">14,852,745</div>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share</a></td>
<td class="text">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The following potential common shares were not
            considered in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive for the year end periods presented below:</span> <br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
        </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>
                  <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Series A, Series B and RDO warrants</div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>7,145,201</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">7,282,999</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Stock options</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2,346,879</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>2,096,836</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Restricted stock awards including pending issuances of stock for services <br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>6,970</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Former Rexahn warrants</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>60,713</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">66,538</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>Former Rexahn options</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">82</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910752480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Statutory to Effective Income Tax Rate</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements
          of comprehensive income (loss) is as follows for the years ended December 31, 2022 and 2021:</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">Income tax (benefit) provision at federal statutory rate</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">21.0<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(21.0<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)%<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(21.4<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">11.9<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div>State income tax, net of federal benefit</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">4.9<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(4.8<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Warrants</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#8212;<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">15.3<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Stock options</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.4<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(0.1<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Research and development</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(3.1<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(1.1<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Other</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(0.1<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(0.2<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)<br/>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="color: rgb(0, 0, 0);">Effective tax rate</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">1.7<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">%<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#8212;<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">%</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Provision (Benefit)</a></td>
<td class="text">
<div> <br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The components of income tax provision (benefit) consisted of the following for the years ended December 31, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">2022 and 2021 (in thousands):</span></div>

<div><span style="font-family: 'Times New Roman';"><br/>
        </span></div>

<div><span style="font-family: 'Times New Roman';"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold; font-family: 'Times New Roman';"> 2022 </span><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold; font-family: 'Times New Roman';">2021 </span><span style="font-family: 'Times New Roman';"><br/>
                  </span></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Income (loss) before income taxes:</div>
                </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">18,203</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">(56,693</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Current:</div>
                </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Federal</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">279</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">State</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">36</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Total current tax provision (benefit)</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">315</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Deferred:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">Federal</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">
                  <div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;">State</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom">
                  <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Total tax provision (benefit</span><span style="font-family: 'Times New Roman';">)</span></div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">315</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">&#8212;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities are summarized in the tables below as of December 31, 2022 and 2021 (in thousands):<br/>
        </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2022<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">2021<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom;" valign="bottom">
                <div style="font-weight: bold;">Deferred tax assets:</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">Federal and state operating loss carryforwards</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">13,087</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">19,244</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Acquired intangibles</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">547</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>547</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">Deferral of research and development costs <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,820</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#8212;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Organizational costs</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">7</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>7</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">Other</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">62</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Stock-based compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">1,152</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>811</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Research and development credit carryforward<br/>
                </div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">731</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>1,035</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%;" valign="bottom">
                <div>Subtotal</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">18,406</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <div>21,662</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(17,770</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>(21,662</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">
                <div>Total deferred tax assets, net of valuation allowance</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>636</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <div style="font-weight: bold;">Deferred tax liabilities:</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom">Deferred revenue <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(636</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">&#8212;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Total deferred tax liabilities</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>(636</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>)</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom">
                <div style="font-weight: bold;">Net deferred tax assets</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">
                <div>&#8212;</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912799504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Nature of Business (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>Product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NatureOfBusinessAbstract', window );"><strong>Nature of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfSmallMoleculeProductCandidates', window );">Number of small molecule product candidates</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NatureOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NatureOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfSmallMoleculeProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of small molecule product candidates targeting front and back of the eye indications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfSmallMoleculeProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527907018688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,634<span></span>
</td>
<td class="nump">$ 24,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_NyxolLicenseAgreementMember', window );">Nyxol License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NonRefundableUpfrontPaymentReceived', window );">Non-refundable upfront payment received</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable upfront payment received under the license and collaboration agreement with FamyGen Life Sciences, Inc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocup_NyxolLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocup_NyxolLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912715792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912814864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Concentration of Credit Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ConcentrationOfCreditRiskAbstract', window );"><strong>Concentration of Credit Risk [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Deposits that exceeded federally insured amounts</a></td>
<td class="nump">$ 42.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ConcentrationOfCreditRiskAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ConcentrationOfCreditRiskAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527912617840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Short-term Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract', window );"><strong>Other than Temporary Impairment Losses, Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairments on investments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527909628256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerAssetAbstract', window );"><strong>Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContractAssetCurrent', window );">Contract asset (Note 10)</a></td>
<td class="nump">$ 3,552<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContractAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContractAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527906989920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Fair Value of Financial Instruments Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Company Description and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Transfers in into Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Transfers out of Level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Short- term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Level 1 [Member] | Short- term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Level 2 [Member] | Short- term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Level 3 [Member] | Short- term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910458832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Equity Investments Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Equity Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss</a></td>
<td class="num">$ (170)<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis [Member] | Level 1 [Member] | Short- term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosureAbstract', window );"><strong>Equity Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Balance as of beginning of period</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement', window );">Receipt of investments related to license agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Balance as of end of period</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The is the portion of collaborations revenue from the license agreement stemming from the receipt of non-cash equity investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527906893632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Warrant Liabilities and Premium Conversion Derivatives Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity', window );">Reclassification of warrants from liability to equity</a></td>
<td class="nump">$ 61,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Warrant Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">27,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">33,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity', window );">Reclassification of warrants from liability to equity</a></td>
<td class="num">(61,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring Basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial instruments liabilities at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the warrants converting to equity issued originally in Pre-Merger financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ocup_WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ocup_WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915736176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Description and Summary of Significant Accounting Policies, Property and Equipment, net (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and Equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915950112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger, Contingent Value Rights Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Nov. 05, 2020 </div>
<div>Milestone </div>
<div>Right</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightsAgreementAbstract', window );"><strong>Contingent Value Rights Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightsPaymentPeriod', window );">Contingent value rights payment period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PercentageOfCashConsiderationPayment', window );">Sum of cash consideration paid by a third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightsIPTerm', window );">Parent IP deal period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfMilestonesAccrued', window );">Number of milestones accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfPotentialMilestones', window );">Number of potential milestones</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember', window );">Rexahn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightsAgreementAbstract', window );"><strong>Contingent Value Rights Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld', window );">Number of contingent value right received per common stock | Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember', window );">Rexahn [Member] | BioSense Global LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightsAgreementAbstract', window );"><strong>Contingent Value Rights Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightsPercentage', window );">Percentage of payments received by Rexahn or its affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember', window );">Rexahn [Member] | Zhejiang HaiChang Biotechnology Co., Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightsAgreementAbstract', window );"><strong>Contingent Value Rights Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContingentValueRightsPercentage', window );">Percentage of payments received by Rexahn or its affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent value right per each share of the Company's common stock held of record as of immediately prior to the closing of the merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContingentValueRightsAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContingentValueRightsAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContingentValueRightsIPTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for parent IP deal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContingentValueRightsIPTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContingentValueRightsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment period for contingent value rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContingentValueRightsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContingentValueRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of payments received by Rexahn or its affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContingentValueRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfMilestonesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestones had been accrued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfMilestonesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfPotentialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential milestones had been accrued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfPotentialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PercentageOfCashConsiderationPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash consideration paid by a third party to Rexahn or its affiliates during the applicable CVR payment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PercentageOfCashConsiderationPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ocup_BioSenseGlobalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ocup_BioSenseGlobalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ocup_ZhejiangHaiChangBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ocup_ZhejiangHaiChangBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915673584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger, Former Rexahn Warrants (Details) - Rexahn [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_WarrantsAndStockOptionsAbstract', window );"><strong>Former Rexahn Warrants and Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding (in shares)</a></td>
<td class="nump">60,713<span></span>
</td>
<td class="nump">231,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_WeightedAverageRemainingContractualTermsWarrants', window );">Average remaining contractual life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_WarrantsAndStockOptionsAbstract', window );"><strong>Former Rexahn Warrants and Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 38.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_WarrantsAndStockOptionsAbstract', window );"><strong>Former Rexahn Warrants and Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 136.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_WarrantsAndStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_WarrantsAndStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_WeightedAverageRemainingContractualTermsWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for warrants excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_WeightedAverageRemainingContractualTermsWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527911419728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pre-Merger Financing (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 29, 2020 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 05, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Fair value change of warrant liability and premium conversion derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (33,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember', window );">Rexahn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfDirectors', window );">Number of directors | Director</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Rexahn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfDirectors', window );">Number of directors | Director</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ProceedsFromPreMergerFinancing', window );">Total investment | $</a></td>
<td class="nump">$ 21,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ProceedsFromPreMergerFinancing', window );">Total investment | $</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,665,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Risk-Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetMeasurementInput', window );">Percentage of measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Expected Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetMeasurementInput', window );">Percentage of measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_FairValueAssumptionsExpectedLife', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Expected Dividend Yield Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetMeasurementInput', window );">Percentage of measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Waiver Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Fair value change of warrant liability and premium conversion derivatives | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingOfWarrantsAbstract', window );"><strong>Pre-Merger Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RemainingIssuableShares', window );">Remaining issuable shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_FairValueAssumptionsExpectedLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_FairValueAssumptionsExpectedLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of directors of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PreMergerFinancingOfWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PreMergerFinancingOfWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ProceedsFromPreMergerFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is a cash inflow, proceeds received from Pre-merger Financing,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ProceedsFromPreMergerFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_RemainingIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of remaining issuable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_RemainingIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocup_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocup_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocup_WaiverAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocup_WaiverAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527907327792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 06, 2021 </div>
<div>USD ($) </div>
<div>Investor </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Facility Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_OperatingLeasesMonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">Expected rent payment for the year end 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_IssuanceOfSettlementSharesAbstract', window );"><strong>Issuance of Settlement Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfAccreditedInvestors', window );">Number of accredited investors | Investor</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ocup_AccreditedInvestorMember', window );">Accredited Investor [Member] | General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_IssuanceOfSettlementSharesAbstract', window );"><strong>Issuance of Settlement Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_FairValueShareSettlementAmount', window );">Fair value share settlement amount</a></td>
<td class="nump">$ 1,614,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Accredited Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_IssuanceOfSettlementSharesAbstract', window );"><strong>Issuance of Settlement Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued (in shares) | shares</a></td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember', window );">Rexahn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Facility Lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_OperatingLeasesMonthlyBaseRent', window );">Monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 116,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_FairValueShareSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value shares settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_FairValueShareSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_IssuanceOfSettlementSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_IssuanceOfSettlementSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfAccreditedInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of accredited investors to whom shares are issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfAccreditedInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_OperatingLeasesMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rental expense payable per month for operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_OperatingLeasesMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ocup_AccreditedInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ocup_AccreditedInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915679424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information, Prepaid and Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaids</a></td>
<td class="nump">$ 1,373<span></span>
</td>
<td class="nump">$ 1,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaids and other assets</a></td>
<td class="nump">$ 1,453<span></span>
</td>
<td class="nump">$ 1,314<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527907279856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information, Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527906928816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information, Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent', window );">R&amp;D services and supplies</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,684<span></span>
</td>
<td class="nump">$ 1,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development service and supplies. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527906973712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information, Short-Term Loan (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Intallment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term loan</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 538,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_DebtInstrumentNumberOfInstallments', window );">Number of installments | Intallment</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Annual interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ocup_ShortTermLoanMember', window );">Short-term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short-Term Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Payment on short term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_DebtInstrumentNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of installments to paid monthly for the loan repayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_DebtInstrumentNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ocup_ShortTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ocup_ShortTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910936160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 08, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingAndWaiverAgreementsAbstract', window );"><strong>Pre-Merger Financing and Waiver Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfDirectorsSignedWaiverAgreements', window );">Number of directors signed waiver agreements | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ConsultingFeePayable', window );">Consulting fee payable in cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingAndWaiverAgreementsAbstract', window );"><strong>Pre-Merger Financing and Waiver Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ConsultingFeePayable', window );">Consulting fee payable in cash | $</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock option granted (in shares) | shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Consulting expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Consulting expenses unpaid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member] | Vesting on March 31, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingAndWaiverAgreementsAbstract', window );"><strong>Pre-Merger Financing and Waiver Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ocup_PreMergerFinancingMember', window );">Pre-Merger Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingAndWaiverAgreementsAbstract', window );"><strong>Pre-Merger Financing and Waiver Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfDirectors', window );">Number of directors | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AmountInvestedInPreMergerFinancing', window );">Amount invested in pre-merger financing | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfConvertedInitialSharesReceivedByDirectors', window );">Number of converted initial shares received by directors (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors', window );">Number of converted additional shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ocup_PreMergerFinancingMember', window );">Pre-Merger Financing [Member] | Rexahn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingAndWaiverAgreementsAbstract', window );"><strong>Pre-Merger Financing and Waiver Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfDirectors', window );">Number of directors | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ocup_PreMergerFinancingMember', window );">Pre-Merger Financing [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingAndWaiverAgreementsAbstract', window );"><strong>Pre-Merger Financing and Waiver Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors', window );">Number of converted additional shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ocup_PreMergerFinancingMember', window );">Pre-Merger Financing [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PreMergerFinancingAndWaiverAgreementsAbstract', window );"><strong>Pre-Merger Financing and Waiver Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors', window );">Number of converted additional shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_AmountInvestedInPreMergerFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount invested by directors in Pre-Merger Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_AmountInvestedInPreMergerFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ConsultingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consultation fee payable in cash per month to the director.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ConsultingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of converted additional shares received by directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfConvertedInitialSharesReceivedByDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of converted initial shares received by directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfConvertedInitialSharesReceivedByDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of directors of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfDirectorsSignedWaiverAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents number of directors signed waiver agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfDirectorsSignedWaiverAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PreMergerFinancingAndWaiverAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PreMergerFinancingAndWaiverAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ocup_PreMergerFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ocup_PreMergerFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ocup_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910731504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation, Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">$ 1,807<span></span>
</td>
<td class="nump">$ 1,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">1,060<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">$ 798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527911712800">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation, Stock Option Plan Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 22, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockOptionsAbstract', window );"><strong>Ocuphire Stock Options [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,807,000<span></span>
</td>
<td class="nump">$ 1,914,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockOptionsAbstract', window );"><strong>Ocuphire Stock Options [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockOptionsAbstract', window );"><strong>Ocuphire Stock Options [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of common stock shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockOptionsAbstract', window );"><strong>Ocuphire Stock Options [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MaximumPeriodOfSharesReservedUnderPlan', window );">Period of shares reserved under plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2018Member', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockOptionsAbstract', window );"><strong>Ocuphire Stock Options [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,175,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options granted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2018Member', window );">2018 Equity Incentive Plan [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockOptionsAbstract', window );"><strong>Ocuphire Stock Options [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2018Member', window );">2018 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockOptionsAbstract', window );"><strong>Ocuphire Stock Options [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Vesting period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Ocuphire Stock Options [Member] | 2018 Equity Incentive Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockOptionsAbstract', window );"><strong>Ocuphire Stock Options [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,096,836<span></span>
</td>
<td class="nump">1,784,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">893,305<span></span>
</td>
<td class="nump">420,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,309)<span></span>
</td>
<td class="num">(73,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,788)<span></span>
</td>
<td class="num">(34,220)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,936,044<span></span>
</td>
<td class="nump">2,096,836<span></span>
</td>
<td class="nump">1,784,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,936,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,723,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.64<span></span>
</td>
<td class="nump">5.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.09<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.21<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.87<span></span>
</td>
<td class="nump">$ 2.97<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 10 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual term, vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3,314,000<span></span>
</td>
<td class="nump">$ 2,795,000<span></span>
</td>
<td class="nump">$ 7,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Aggregate intrinsic value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options granted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.06<span></span>
</td>
<td class="nump">$ 4.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and
                  the fair value of our common stock as of December 31, 2022 and 2021 of $3.53 and $3.73 per share, respectively.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MaximumPeriodOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of shares reserved under plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MaximumPeriodOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocup_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocup_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915949504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation, Weighted Average Assumptions Used in Black-Scholes Option-pricing Model (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2020Member', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CommonStockCapitalSharesAvailableForFutureIssuance', window );">Common stock available for future issuance (in shares)</a></td>
<td class="nump">894,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2018Member', window );">2018 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average Assumptions Used in Black-Scholes Option-pricing Model [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">97.40%<span></span>
</td>
<td class="nump">98.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock options vested (in shares)</a></td>
<td class="nump">488,621<span></span>
</td>
<td class="nump">468,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options vesting (in dollars per share)</a></td>
<td class="nump">$ 3.29<span></span>
</td>
<td class="nump">$ 3.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Stock options forfeited (in shares)</a></td>
<td class="nump">29,788<span></span>
</td>
<td class="nump">34,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average period to recognized stock-based compensation</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CommonStockCapitalSharesAvailableForFutureIssuance', window );">Common stock available for future issuance (in shares)</a></td>
<td class="nump">894,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_CommonStockCapitalSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_CommonStockCapitalSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocup_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocup_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocup_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915827984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation, Restricted Stock Awards Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 11, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RestrictedStockAwardsAbstract', window );"><strong>Ocuphire Restricted Stock Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,807,000<span></span>
</td>
<td class="nump">$ 1,914,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Ocuphire Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RestrictedStockAwardsAbstract', window );"><strong>Ocuphire Restricted Stock Awards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Summary of RSA Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested at beginning (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested at ending (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_RestrictedStockAwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_RestrictedStockAwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910956912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation, Common Stock Issued for Services (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Member </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Member </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CommonStockIssuedForServicesAbstract', window );"><strong>Common Stock Issued for Services [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Granted stock for services performed (in shares) | shares</a></td>
<td class="nump">74,396<span></span>
</td>
<td class="nump">21,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfBoardMembersGrantedStockForServices', window );">Number of board members, stock granted for services | Member</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share based compensation for services | $</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_CommonStockIssuedForServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_CommonStockIssuedForServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfBoardMembersGrantedStockForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of board members for whom stock granted for services performed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfBoardMembersGrantedStockForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915935296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation, Former Rexahn Options (Details) - Rexahn [Member] - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_FormerOptionsAbstract', window );"><strong>Former Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of options expired (in shares)</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_FormerOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_FormerOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140528019033216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Apexian Sublicense Agreement (Details) - Apexian Sublicense Agreement [Member] - Maximum [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ocup_ApexianSublicenseAgreementMember', window );">Development and Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_SublicenseAgreementAbstract', window );"><strong>Sublicense Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_FutureMilestoneMethodRevenueNotRecognized', window );">Milestone payments</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ocup_ApexianSublicenseAgreementMember', window );">Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_SublicenseAgreementAbstract', window );"><strong>Sublicense Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_FutureMilestoneMethodRevenueNotRecognized', window );">Milestone payments</a></td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_FutureMilestoneMethodRevenueNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration not recognized during the period for the future milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_FutureMilestoneMethodRevenueNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_SublicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_SublicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ocup_ApexianSublicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ocup_ApexianSublicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=ocup_DevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=ocup_DevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=ocup_SalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=ocup_SalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527915699776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, At-The-Market Program (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 11, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AtTheMarketProgramAbstract', window );"><strong>At-The-Market Program [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,428,000<span></span>
</td>
<td class="nump">$ 28,491,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="nump">$ 1,511,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_ShelfRegistrationMember', window );">2021 Shelf [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AtTheMarketProgramAbstract', window );"><strong>At-The-Market Program [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_AtTheMarketProgramMember', window );">ATM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AtTheMarketProgramAbstract', window );"><strong>At-The-Market Program [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,848,980<span></span>
</td>
<td class="nump">2,778,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_AtTheMarketProgramMember', window );">ATM [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AtTheMarketProgramAbstract', window );"><strong>At-The-Market Program [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_AtTheMarketProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_AtTheMarketProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_ShelfRegistrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocup_ShelfRegistrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_AtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocup_AtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527911721344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Registered Direct Offering (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RegisteredDirectOfferingsAbstract', window );"><strong>Registered Direct Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,428<span></span>
</td>
<td class="nump">$ 28,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 1,511<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RegisteredDirectOfferingsAbstract', window );"><strong>Registered Direct Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RegisteredDirectOfferingsAbstract', window );"><strong>Registered Direct Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold (in shares)</a></td>
<td class="nump">3,076,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in shares)</a></td>
<td class="nump">1,538,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockSoldPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 4.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RegisteredDirectOfferingsAbstract', window );"><strong>Registered Direct Offerings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StockSoldPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,538,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MinimumPercentageOfBeneficialOwnership', window );">Minimum percentage of beneficial ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MaximumPercentageOfBeneficialOwnershipLimitation', window );">Maximum percentage of beneficial ownership limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MaximumPercentageOfBeneficialOwnershipLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MaximumPercentageOfBeneficialOwnershipLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MinimumPercentageOfBeneficialOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MinimumPercentageOfBeneficialOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_RegisteredDirectOfferingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_RegisteredDirectOfferingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StockSoldPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StockSoldPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ocup_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ocup_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527911666496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements, Nyxol License Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Performanceobligation</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract', window );"><strong>Reconciliation of Closing Balance of Contract Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContractAssetCurrent', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,850<span></span>
</td>
<td class="nump">$ 589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContractAssetCurrent', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_NyxolLicenseAgreementMember', window );">Nyxol License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CollaborationAndLicenseAgreementAbstract', window );"><strong>Collaboration and License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NonRefundableCashPaymentReceived', window );">Non-refundable cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum amount of payments receivable for development, regulatory and commercial milestones</a></td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_FirstPotentialMilestonePaymentToBeReceived', window );">First potential payments to be received</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MaximumPercentageOfTieredRoyaltiesReceivable', window );">Maximum percentage of tiered royalties receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfPerformanceObligations', window );">Number of distinct performance obligations | Performanceobligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RevenueFromContractWithCustomerToBeRecognized', window );">Aggregate transaction price to be recognized</a></td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PeriodOfNonCancellationWindowAgreement', window );">Period of non-cancellation window agreement</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract', window );"><strong>Reconciliation of Closing Balance of Contract Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContractAssetCurrent', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NonRefundableCashPaymentReceived', window );">Execution of Nyxol License Agreement and one-time non-refundable payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,000)<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContractAssetCurrent', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_NyxolLicenseAgreementMember', window );">Nyxol License Agreement [Member] | License Transfer Fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CollaborationAndLicenseAgreementAbstract', window );"><strong>Collaboration and License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RevenueFromContractWithCustomerToBeRecognized', window );">Aggregate transaction price to be recognized</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_EstimatedStandaloneSellingPriceForLicenseAgreement', window );">Estimated standalone selling price for license agreement</a></td>
<td class="nump">287,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations', window );">Transaction price allocation of ESSP obligations</a></td>
<td class="nump">39,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract', window );"><strong>Reconciliation of Closing Balance of Contract Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement', window );">Reclassification to accounts receivable related to costs billed under the Nyxol License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_NyxolLicenseAgreementMember', window );">Nyxol License Agreement [Member] | Research and Development Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CollaborationAndLicenseAgreementAbstract', window );"><strong>Collaboration and License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_RevenueFromContractWithCustomerToBeRecognized', window );">Aggregate transaction price to be recognized</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_EstimatedStandaloneSellingPriceForLicenseAgreement', window );">Estimated standalone selling price for license agreement</a></td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations', window );">Transaction price allocation of ESSP obligations</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract', window );"><strong>Reconciliation of Closing Balance of Contract Asset [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_CollaborationAndLicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_CollaborationAndLicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContractAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContractAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This line item represents amounts invoiced that were previously reflected in the Contract Asset account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_EstimatedStandaloneSellingPriceForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated standalone selling price for license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_EstimatedStandaloneSellingPriceForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_FirstPotentialMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payment received upon achieving performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_FirstPotentialMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable upon the achievement of development, regulatory and commercial goals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MaximumPercentageOfTieredRoyaltiesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of tiered royalties receivable based on the aggregate annual net sales of all Nyxol Products in the United States.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MaximumPercentageOfTieredRoyaltiesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NonRefundableCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable cash payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NonRefundableCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of performance obligations in accordance with the provisions under ASC 606, the Company identified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PeriodOfNonCancellationWindowAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of non-cancellation window agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PeriodOfNonCancellationWindowAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_RevenueFromContractWithCustomerToBeRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be recognized, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_RevenueFromContractWithCustomerToBeRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price of license agreement allocated on estimated standalone selling price obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocup_NyxolLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocup_NyxolLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ocup_LicenseTransferFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ocup_LicenseTransferFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ocup_ResearchDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ocup_ResearchDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527911720960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 10, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Milestone </div>
<div>Country</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_BioSenseLicenseAndAssignmentsAgreementMember', window );">BioSense License and Assignments Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CollaborationAndLicenseAgreementAbstract', window );"><strong>Collaboration and License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NonRefundableCashPaymentReceived', window );">Non-refundable cash payment received</a></td>
<td class="nump">$ 1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MilestonePaymentAchievedForPerformanceObligation', window );">Milestone payment achieved for performance obligation, recorded as collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MilestonePaymentsAmountReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum amount of payments receivable for development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_BioSenseLicenseAndAssignmentsAgreementMember', window );">BioSense License and Assignments Agreement [Member] | Rexahn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CollaborationAndLicenseAgreementAbstract', window );"><strong>Collaboration and License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NonRefundableCashPaymentReceived', window );">Non-refundable cash payment received</a></td>
<td class="nump">$ 1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ocup_ProcessaLicenseAgreementMember', window );">Processa License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_CollaborationAndLicenseAgreementAbstract', window );"><strong>Collaboration and License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NonRefundableCashPaymentReceived', window );">Non-refundable cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MilestonePaymentsAmountReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_UpfrontPaymentReceivedInCommonStockShares', window );">Upfront payment received in common shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_UpfrontPaymentReceivedInCommonStockFairValue', window );">Upfront payment received in common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PeriodOfRestrictionFromSellingStock', window );">Period of restriction from selling common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_NumberOfTimesPaymentsForSalesMilestone', window );">Number of times sales milestone payments | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement', window );">Percentage of milestone payments eligible to receive on sub-license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted', window );">Number of countries | Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient', window );">Milestone period to administer drug clinical trial of licensed product on first patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication', window );">Milestone period to administer drug clinical trial of licensed product on first patient for second indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PeriodOfOpportunityToCureBreachOfAgreement', window );">Period of opportunity to cure breach of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements', window );">Period of prior written notice to be served for termination of agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_CollaborationAndLicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_CollaborationAndLicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable upon the achievement of development, regulatory and commercial goals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MilestonePaymentAchievedForPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments achieved under the collaboration agreement during the period and recorded as collaboration revenue for the performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MilestonePaymentAchievedForPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MilestonePaymentsAmountReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment received upon achieving performance obligation..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MilestonePaymentsAmountReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone period to administer drug clinical trail of licensed product on first patient in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone period to administer drug clinical trail of licensed product on first patient after second indication in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum number of countries to conduct development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NonRefundableCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable cash payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NonRefundableCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_NumberOfTimesPaymentsForSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of time sales milestone payments eligible to receive based on the achievement of annual sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_NumberOfTimesPaymentsForSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of milestone payments eligible to receive on sub-license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PeriodOfOpportunityToCureBreachOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of opportunity to cure breach of agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PeriodOfOpportunityToCureBreachOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of prior written notice to be served for termination of agreements in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_PeriodOfRestrictionFromSellingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period, that entity is restricted from selling the common stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_PeriodOfRestrictionFromSellingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_UpfrontPaymentReceivedInCommonStockFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of common shares of an entity that have been received as an upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_UpfrontPaymentReceivedInCommonStockFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_UpfrontPaymentReceivedInCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been received as an upfront payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_UpfrontPaymentReceivedInCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocup_BioSenseLicenseAndAssignmentsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocup_BioSenseLicenseAndAssignmentsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ocup_ProcessaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ocup_ProcessaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527911806928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per share, Computation of Diluted Net Income (Loss) Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Computation of weighted average common shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic common shares outstanding (in shares)</a></td>
<td class="nump">19,931,080<span></span>
</td>
<td class="nump">14,852,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_IncrementalCommonSharesAttributableToOptions', window );">Dilutive stock options (in shares)</a></td>
<td class="nump">589,165<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_IncrementalCommonSharesAttributableToWarrants', window );">Dilutive warrants (in shares)</a></td>
<td class="nump">76,967<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted common shares outstanding (in shares)</a></td>
<td class="nump">20,597,212<span></span>
</td>
<td class="nump">14,852,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_IncrementalCommonSharesAttributableToOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of options using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_IncrementalCommonSharesAttributableToOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_IncrementalCommonSharesAttributableToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_IncrementalCommonSharesAttributableToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527911505184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net income (loss) per share, Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_SeriesASeriesBAndRDOWarrantsMember', window );">Series A, Series B and RDO Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">7,145,201<span></span>
</td>
<td class="nump">7,282,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">2,346,879<span></span>
</td>
<td class="nump">2,096,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards Including Pending Issuances of Stock for Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_FormerRexahnWarrantsMember', window );">Former Rexahn Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">60,713<span></span>
</td>
<td class="nump">66,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_FormerRexahnOptionsMember', window );">Former Rexahn Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_SeriesASeriesBAndRDOWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_SeriesASeriesBAndRDOWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_FormerRexahnWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_FormerRexahnWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_FormerRexahnOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ocup_FormerRexahnOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527910873072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Reconciliation of Statutory to Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Federal Income Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent', window );">Income tax (benefit) provision at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(21.40%)<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="num">(4.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent', window );">Warrants</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate pf income tax (benefit) provision applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527909648832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Components of Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Components of Income Tax Provision (Benefit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="nump">$ 18,203<span></span>
</td>
<td class="num">$ (56,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax provision (benefit)</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision (benefit)</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527907328672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes, Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state operating loss carryforwards</a></td>
<td class="nump">$ 13,087<span></span>
</td>
<td class="nump">$ 19,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferral of research and development costs</a></td>
<td class="nump">2,820<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Organizational costs</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_DeferredTaxAssetsResearchAndDevelopment', window );">Research and development credit carryforward</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">18,406<span></span>
</td>
<td class="nump">21,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(17,770)<span></span>
</td>
<td class="num">(21,662)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of valuation allowance</a></td>
<td class="nump">636<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(636)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(636)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_DeferredTaxAssetsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_DeferredTaxAssetsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527907332256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Operating Loss Carryforwards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carryforward</a></td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal research credit carryforwards</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal', window );">State research credit carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_FederalOperatingLossCarryforwardsTaxEffect', window );">Federal operating loss carryforwards, tax effect</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect', window );">State operating loss carryforwards, tax effect</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_UtilizedFederalResearchCreditCarryforwards', window );">Utilized federal research credit carryforwards</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income Tax Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalty on income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets relating to net operating loss carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets relating to net operating loss carryforwards</a></td>
<td class="nump">13,087<span></span>
</td>
<td class="nump">$ 19,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember', window );">Rexahn stockholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets relating to net operating loss carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Deferred tax assets relating to net operating loss carryforwards</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_FederalOperatingLossCarryforwardsTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the related federal income tax effect on operating loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_FederalOperatingLossCarryforwardsTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the related state and local income tax effect on operating loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_UtilizedFederalResearchCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the federal research credit carryforwards Utilized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_UtilizedFederalResearchCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ocup_RexahnStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527913295824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Compensation Plan (Details) - 401K Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsAbstract', window );"><strong>Deferred Compensation Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, first match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Deferred compensation matched by employer, first match</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution', window );">Additional employer matching contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred', window );">Additional deferred compensation matched by employer</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional percentage employer matches of the employee's deferred percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=ocup_RetirementPlan401KMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=ocup_RetirementPlan401KMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140527911217040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - 2020 Plan Evergreen Provision [Member] - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_SubsequentEventsAdditionalInformationAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ocup_EvergreenProvisionPlan2020Member', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_SubsequentEventsAdditionalInformationAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_MaximumPeriodOfSharesReservedUnderPlan', window );">Period of shares reserved under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_SubsequentEventsAdditionalInformationAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ocup_AggregateNumberOfCommonStockReservedForFutureIssuance', window );">Number of shares added (in shares)</a></td>
<td class="nump">1,043,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_AggregateNumberOfCommonStockReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance" given the addition added to reserve due to Evergreen provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_AggregateNumberOfCommonStockReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_MaximumPeriodOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of shares reserved under plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_MaximumPeriodOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ocup_SubsequentEventsAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ocup_SubsequentEventsAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ocup_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ocup_EvergreenProvisionPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ocup_EvergreenProvisionPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>brhc10050364_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:ocup="http://ocuphire.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ocup-20221231.xsd" xlink:type="simple"/>
    <context id="c20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c20230327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221101to20221130_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20201231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ocup:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ocup:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ocup:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_ZhejiangHaiChangBiotechnologyCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:ZhejiangHaiChangBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_BioSenseGlobalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:BioSenseGlobalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="c20201105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="c20200629to20200629_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="c20200629to20200629_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="c20201119_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-19</instant>
        </period>
    </context>
    <context id="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_TypeOfArrangementAxis_WaiverAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:WaiverAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_BusinessAcquisitionAxis_RexahnStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210506to20210506_RelatedPartyTransactionsByRelatedPartyAxis_AccreditedInvestorMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ocup:AccreditedInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="c20210506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2021-05-06</instant>
        </period>
    </context>
    <context id="c20210506to20210506_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RelatedPartyTransactionsByRelatedPartyAxis_AccreditedInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ocup:AccreditedInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-06</startDate>
            <endDate>2021-05-06</endDate>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c20210101to20211231_DebtInstrumentAxis_ShortTermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ocup:ShortTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_PreMergerFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RelatedPartyTransactionAxis_PreMergerFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_RelatedPartyTransactionAxis_PreMergerFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ocup:SeriesAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:PreMergerFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-08</instant>
        </period>
    </context>
    <context id="c20221201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
        </entity>
        <period>
            <instant>2022-12-01</instant>
        </period>
    </context>
    <context id="c20220408to20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="c20220408to20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20221231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20201130_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c20210222_PlanNameAxis_InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-22</instant>
        </period>
    </context>
    <context id="c20201130_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_PlanNameAxis_InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20201231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c20201111to20201111_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-11</startDate>
            <endDate>2020-11-11</endDate>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_BusinessAcquisitionAxis_RexahnStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentAndRegulatoryMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ocup:DevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:ApexianSublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">ocup:SalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ocup:ApexianSublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210311to20210311_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-11</startDate>
            <endDate>2021-03-11</endDate>
        </period>
    </context>
    <context id="c20210212to20210212_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ShelfRegistrationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:ShelfRegistrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210608to20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="c20210608_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="c20210608to20210608_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ocup:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-06</instant>
        </period>
    </context>
    <context id="c20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221106to20221106_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ocup:LicenseTransferFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-06</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="c20221106to20221106_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ocup:ResearchDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-06</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="c20221106to20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-06</startDate>
            <endDate>2022-11-06</endDate>
        </period>
    </context>
    <context id="c20211231_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ocup:ResearchDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ocup:LicenseTransferFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:NyxolLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20200310to20200310_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ocup:RexahnStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-10</startDate>
            <endDate>2020-03-10</endDate>
        </period>
    </context>
    <context id="c20210701to20210731_TypeOfArrangementAxis_ProcessaLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:ProcessaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c20200310to20200310_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-10</startDate>
            <endDate>2020-03-10</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:ProcessaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:BioSenseLicenseAndAssignmentsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ocup:ProcessaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:FormerRexahnOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:SeriesASeriesBAndRDOWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:FormerRexahnWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:FormerRexahnOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:FormerRexahnWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ocup:SeriesASeriesBAndRDOWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ocup:RetirementPlan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_RetirementPlanNameAxis_RetirementPlan401KMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ocup:RetirementPlan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231_RetirementPlanNameAxis_RetirementPlan401KMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ocup:RetirementPlan401KMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EvergreenProvisionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EvergreenProvisionPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230101_PlanNameAxis_EvergreenProvisionPlan2020Member_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001228627</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ocup:EvergreenProvisionPlan2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U002">
        <measure>shares</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>ocup:Product</measure>
    </unit>
    <unit id="U005">
        <measure>ocup:Segment</measure>
    </unit>
    <unit id="U006">
        <measure>ocup:Right</measure>
    </unit>
    <unit id="U007">
        <measure>pure</measure>
    </unit>
    <unit id="U008">
        <measure>ocup:Milestone</measure>
    </unit>
    <unit id="U009">
        <measure>ocup:Director</measure>
    </unit>
    <unit id="U010">
        <measure>ocup:Investor</measure>
    </unit>
    <unit id="U011">
        <measure>ocup:Intallment</measure>
    </unit>
    <unit id="U012">
        <measure>ocup:Member</measure>
    </unit>
    <unit id="U013">
        <measure>ocup:Performanceobligation</measure>
    </unit>
    <unit id="U014">
        <measure>ocup:Country</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20220101to20221231"
      id="Fact_f0958ed82ea846c79f495e7ace8652ef">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20220101to20221231"
      id="Fact_b2a27dc4162d4322a9f788f303820c61">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20220101to20221231"
      id="Fact_0f0156860f914e65a8107b058f82f9ec">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20220101to20221231"
      id="Fact_a929f8da061b4636a4ff53642fcbc402">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20220101to20221231"
      id="Fact_8c4f7a4db80a46fe936861567f87584a">0001228627</dei:EntityCentralIndexKey>
    <dei:AuditorFirmId
      contextRef="c20220101to20221231"
      id="Fact_3ee0ed147ce34c3f88fb4e30185e37c7">42</dei:AuditorFirmId>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20221231"
      id="Fact_43d8906c354b4cf393d97ed8bb0df71f"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20211231"
      id="Fact_d61305f9bf5e4fdabd17d17016b342ca"
      unitRef="U001"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="c20220101to20221231"
      id="Fact_9083dfc048294d64a80b99f3ac928412">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="c20220101to20221231"
      id="Fact_bc08c28ba02f4d30bb6f9f5695ce23c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20220101to20221231"
      id="Fact_7f559871c8c947b8aec0f102e4a164b9">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20220101to20221231"
      id="Fact_df2d3fc9cc7342c580367a2dde018fe1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20220101to20221231"
      id="Fact_646e7277083c4cc1a4ddbbb96b1c3e9a">001-34079</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20220101to20221231"
      id="Fact_ac4ff62998744f1282a45dcedb0974ed">Ocuphire Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20220101to20221231"
      id="Fact_8e6a949680794fcab0b7adaadb4a46cc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20220101to20221231"
      id="Fact_8312ded7be3d4f148b5759399c97de62">11-3516358</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20220101to20221231"
      id="Fact_59a8140eeb0e426f9563fa01d57644df">37000 Grand River Avenue, Suite 120</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20220101to20221231"
      id="Fact_1e0d9b8ea5554cfd92579607d0cbdf9d">Farmington Hills</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20220101to20221231"
      id="Fact_ccbc074ab6204a15b539e4912cc5a19b">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20220101to20221231"
      id="Fact_5170267e5bd14734a51d8e58411cef75">48335</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20220101to20221231"
      id="Fact_3acbe4f27bdd4794b674737509972021">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20220101to20221231"
      id="Fact_906861cd1d5e430ab914dadd5ce34fdd">681-9815</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20220101to20221231"
      id="Fact_47841d80476043309a66cf5418c8ed15">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20220101to20221231"
      id="Fact_72e3372373d5414c9cefdce3bca22b8e">OCUP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20220101to20221231"
      id="Fact_5d36d6c2fe3144d89e19fec8e413a561">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="c20220101to20221231"
      id="Fact_dc6b26e62aa74cefb88f00b9ae884f91">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="c20220101to20221231"
      id="Fact_9ce0290664694702806fd18bff446716">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="c20220101to20221231"
      id="Fact_14193fb1f41f42eb9aa044a2b62dce51">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20220101to20221231"
      id="Fact_01751b8c995045c89faf0e5528dcd597">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20220101to20221231"
      id="Fact_f03396a4da524442ba6383cf90b5a5d4">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20220101to20221231"
      id="Fact_fc7960c237b4416a939f2321969bf792">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20220101to20221231"
      id="Fact_3213949ebded4c09ba40ceed502a7fc6">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="c20220101to20221231"
      id="Fact_3fc683e5535242ff87c9c88148b681b9">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="c20220101to20221231"
      id="Fact_e881d4858fbf4d3a9f40fe057318618c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="c20220630"
      decimals="0"
      id="Fact_ed3dd85ab16a49c88f4c1000b59003cd"
      unitRef="U001">37236094</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20230327"
      decimals="INF"
      id="Fact_a2ce4c74d2ce4555b22b2fc27b002f1a"
      unitRef="U002">20947830</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="c20220101to20221231"
      id="Fact_696a130351a94d0c8fc587e007153641">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="c20220101to20221231"
      id="Fact_e9edf4bd46904db6a113e4c80b4cc25f">Detroit, Michigan</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20221231"
      decimals="-3"
      id="Fact_4c3cf5caf77f4e5da037fafa8bae1953"
      unitRef="U001">42634000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_40541f5983434d01a3b2f52cdc14f86f"
      unitRef="U001">24534000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_57a15117328a4c2dacdc53aab37087d0"
      unitRef="U001">1298000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_0716a84377b3474981c11557857a13fb"
      unitRef="U001">0</us-gaap:AccountsReceivableNetCurrent>
    <ocup:ContractAssetCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_b0ef46df5a694ee582135a7fbdad491b"
      unitRef="U001">3552000</ocup:ContractAssetCurrent>
    <ocup:ContractAssetCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_694b873b10be4f5f82e10b6e4424c338"
      unitRef="U001">0</ocup:ContractAssetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_5e7905a52b3b4832ae31148a683a964a"
      unitRef="U001">1453000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d2af3956605443cab2678029fdf4bbf3"
      unitRef="U001">1314000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="c20221231"
      decimals="-3"
      id="Fact_4cf2da1d4c7e4d7da5171911bbd8bc1d"
      unitRef="U001">49000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="c20211231"
      decimals="-3"
      id="Fact_225258f3f0d74d729666ccec140c7a71"
      unitRef="U001">219000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_ee81b576bc25413cb7a62fbc8196321b"
      unitRef="U001">48986000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_184843c3bd824037aa3cec844a19d775"
      unitRef="U001">26067000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20221231"
      decimals="-3"
      id="Fact_cc7a924d5667424f8c959babee79b86e"
      unitRef="U001">6000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20211231"
      decimals="-3"
      id="Fact_a35d03b264ec4ae9a60ae4f61e0ce03f"
      unitRef="U001">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="c20221231"
      decimals="-3"
      id="Fact_597af46d25eb4b8b81eaa8fd6ecd9e53"
      unitRef="U001">48992000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20211231"
      decimals="-3"
      id="Fact_70294fb5f79346cdb77d26980a6796e7"
      unitRef="U001">26077000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_d2274ba9bdab4d918c0e31c84c37c9f3"
      unitRef="U001">1069000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_1e3929fc952f4919983d6a68e4de32c2"
      unitRef="U001">1584000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_94b6a818ac9d4d15bdbf9a8f7b119fa9"
      unitRef="U001">1684000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_22d5050fa5e14d6b928622028c26edc4"
      unitRef="U001">1733000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="c20221231"
      decimals="-3"
      id="Fact_5f805b7af1ae4f3b8fa793fd0bbdaded"
      unitRef="U001">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="c20211231"
      decimals="-3"
      id="Fact_8ccb6c3046ca468f99884ee0d62f86ec"
      unitRef="U001">538000</us-gaap:ShortTermBorrowings>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_e0b02fb09bd445b28b22c745614224ac"
      unitRef="U001">2753000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_52cf5ce5c64a44358cce16c3e67adcaf"
      unitRef="U001">3855000</us-gaap:LiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c20221231"
      decimals="-3"
      id="Fact_7468ad245b9749ffbc584a4b9950df1c"
      unitRef="U001">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c20211231"
      decimals="-3"
      id="Fact_eb12305b81514f35b6eadb5a5f914bc0"
      unitRef="U001">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:Liabilities
      contextRef="c20221231"
      decimals="-3"
      id="Fact_de1f3d838d69414180d715025f04a384"
      unitRef="U001">2753000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20211231"
      decimals="-3"
      id="Fact_57db8be508bc42668c45494a0b9e1284"
      unitRef="U001">3855000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20211231"
      decimals="4"
      id="Fact_1d2ec47d13ea44a7a91d3308f3e68ac9"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20221231"
      decimals="4"
      id="Fact_a100338abbcc49ac9808b1194f17d508"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20211231"
      decimals="0"
      id="Fact_d12c026eccc34727b9f0a437d54276e4"
      unitRef="U002">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_1c2637b74e574bfd8ef7edf8c42dfaa0"
      unitRef="U002">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20211231"
      decimals="INF"
      id="Fact_5d43c7f01ac540afb459ef7b0ad68cdb"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20221231"
      decimals="INF"
      id="Fact_8ced08c698294d6fad90561f1a139828"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20211231"
      decimals="INF"
      id="Fact_4bc14a08c386400daa81551883f893ed"
      unitRef="U002">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20221231"
      decimals="INF"
      id="Fact_de589a2ecd3c4af58e633ab46624fe88"
      unitRef="U002">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="c20221231"
      decimals="-3"
      id="Fact_3cfbaa8b6f164362b585c55da7df6050"
      unitRef="U001">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_968a6b746aeb454c95126e21c8fd8515"
      unitRef="U001">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20211231"
      decimals="4"
      id="Fact_c797ebe90f1e45a891ead8b192975f2c"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20221231"
      decimals="4"
      id="Fact_15c53a0e26bc4275be133d4f38030590"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20211231"
      decimals="0"
      id="Fact_228f30a44e464efab17634dfad95a427"
      unitRef="U002">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_f6c07a433dde43c1ae0d8d0e0510c2bd"
      unitRef="U002">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_1dfc57c6a4fb4846b8c8a70f5769a4f7"
      unitRef="U002">20861315</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20221231"
      decimals="0"
      id="Fact_c49b62bd1ca443c7bc4e72696b36eefd"
      unitRef="U002">20861315</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20211231"
      decimals="0"
      id="Fact_4688bdf4210049f5856926ea9fcf0659"
      unitRef="U002">18845828</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20211231"
      decimals="0"
      id="Fact_8f001feee6364c33be001a9ee96c18dd"
      unitRef="U002">18845828</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20221231"
      decimals="-3"
      id="Fact_3c46c99f58b5447b98d4e12a86cd3bb9"
      unitRef="U001">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d956aa6ee79548e5850f4387da0a4eba"
      unitRef="U001">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20221231"
      decimals="-3"
      id="Fact_a573c28abd63414ca51efe97c97c61d5"
      unitRef="U001">117717000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20211231"
      decimals="-3"
      id="Fact_a8c93ba164a64090803a6d8bc9227a8d"
      unitRef="U001">111588000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20221231"
      decimals="-3"
      id="Fact_e4072fa9f7d54735b863fae870d041e6"
      unitRef="U001">-71480000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20211231"
      decimals="-3"
      id="Fact_8544106db22c4914916307b23dff6050"
      unitRef="U001">-89368000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_580765c1d14e4dd392c24cca20c380d8"
      unitRef="U001">46239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_a868d43f52c74a139afc0bb697b2f287"
      unitRef="U001">22222000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_972c4be22c8a4d06808d773f2ccd3e80"
      unitRef="U001">48992000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_4cfc4847382a4598bc498bd01c8a0e34"
      unitRef="U001">26077000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_aa762ff8a9b94b4cb4f4d9f8b3e6a3d1"
      unitRef="U001">39850000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_6f1f052f8b514084b7e854648ad3edec"
      unitRef="U001">589000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_88875b60153745a5893dda65eac02f2e"
      unitRef="U001">7269000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_2d49c03a9ff440ceac62af29ab2f5fe7"
      unitRef="U001">8121000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_6f8f72ee9c4647d882108f6dccba6192"
      unitRef="U001">14355000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_0b8dd95974684155bc00f9b932cbb901"
      unitRef="U001">15173000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OperatingExpenses
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_ad16dfae06a249479c28bb296d71280d"
      unitRef="U001">21624000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_0cd2f16d9e0d4f828159bab89a683278"
      unitRef="U001">23294000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_a37ee4b0c17f448a9004f7860da879bd"
      unitRef="U001">18226000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_477c33f635ab4a779d30f9655f62787f"
      unitRef="U001">-22705000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_ba1eb086ff7b45c98fb86b0903f9b6c0"
      unitRef="U001">9000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_448dd48e63c84a0c9eb589aa5cf678cc"
      unitRef="U001">2000</us-gaap:InterestExpense>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e5c4220debd34d6db0813184c57261bb"
      unitRef="U001">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_c2c391e5f8404371992593b5799d043b"
      unitRef="U001">-33829000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_3c0bc2209b35484d972256497df8d235"
      unitRef="U001">-14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_09cda20bf42c4c6ea9e98918270eb3de"
      unitRef="U001">-157000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_d5b8c87f95d94024b35aeb100b4a7054"
      unitRef="U001">18203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_eaacc63d939e479b83e6833c660f85df"
      unitRef="U001">-56693000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_dd84e31c91dd4905810b121100d48b61"
      unitRef="U001">315000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_905d3b66a0b34365b578d84e34d33161"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_ee9ef358b0fe49caa8404ce4fad109a1"
      unitRef="U001">17888000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_a3f5f1fa75a140f29cafca5feba95350"
      unitRef="U001">-56693000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_0703789e551d4fa9940696d89287b672"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_770020a0fabb4a1180a78c1e4d4fe6b4"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_6625dc0ab4b74dd9aeec15f79a9b66d7"
      unitRef="U001">17888000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_d0578a3fc98c49b8bcc2c049b14b08fe"
      unitRef="U001">-56693000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220101to20221231"
      decimals="2"
      id="Fact_efe3520d9153418e90a4c01c101ad29b"
      unitRef="U003">0.9</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_30e06911d217456b9c43e0ce6fd9a0c5"
      unitRef="U003">-3.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220101to20221231"
      decimals="2"
      id="Fact_becb3dd27c8b466385a7a728e96360a3"
      unitRef="U003">0.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20210101to20211231"
      decimals="2"
      id="Fact_156ec40b25fe421f833677213b2c60a5"
      unitRef="U003">-3.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_ee1f2f9338da4da7946981e980d92baa"
      unitRef="U002">19931080</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_d1751ebb777a4ff1b269979ea50d6eff"
      unitRef="U002">14852745</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_428950934e0d4f8b886974bf22e627c8"
      unitRef="U002">20597212</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_56156f5badc240a18d0ae32ca2ccf080"
      unitRef="U002">14852745</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a957f37183ae4fb2937b44963997d1db"
      unitRef="U002">10882495</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_659d8efc7709442e90b10de0faffbb85"
      unitRef="U001">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_dd2fafd698fc4ad899e23710386697ff"
      unitRef="U001">19207000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0c523b2030024fceb1cf82a1bf7147b8"
      unitRef="U001">-32675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20201231"
      decimals="-3"
      id="Fact_8781ed68629042f58942debfd4af43bc"
      unitRef="U001">-13467000</us-gaap:StockholdersEquity>
    <ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_0c2eb6bb5af54cce8dc19945c3983ef2"
      unitRef="U001">0</ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity>
    <ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9712668b20964321872219e8ca3b0ada"
      unitRef="U001">61793000</ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity>
    <ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c2ab2761c8084e6ba4a40ca92140bd5f"
      unitRef="U001">0</ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity>
    <ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_b8673f7d797f41f69b95c789b4699a6d"
      unitRef="U001">61793000</ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity>
    <ocup:StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_1f533885deec4acb9eb6add4ebfda68c"
      unitRef="U002">3076923</ocup:StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering>
    <ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b904ac6c76d541dcb07173c2066718fa"
      unitRef="U001">1000</ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering>
    <ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7c4f035f382840d0a210b09b5e95c8be"
      unitRef="U001">14999000</ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering>
    <ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d85cdaebe012448d9b9412373d9629f6"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering>
    <ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_8c6a3bcc031d4878bb47795d4f3b0009"
      unitRef="U001">15000000</ocup:StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering>
    <ocup:StockIssuedDuringPeriodSharesAtTheMarketProgram
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_69e0d3ab2fba489b95e8c25cd615ee7c"
      unitRef="U002">2778890</ocup:StockIssuedDuringPeriodSharesAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodValueAtTheMarketProgram
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_56df9cb157a340b0886968b5e1442a42"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodValueAtTheMarketProgram
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9a857e87370e4b8b8d2c996c1c2b6b8d"
      unitRef="U001">13491000</ocup:StockIssuedDuringPeriodValueAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodValueAtTheMarketProgram
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_613b7797b3e9420797f5bcbff3331138"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodValueAtTheMarketProgram
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_d553dca2d7fa45e7bb2be821e46ea6db"
      unitRef="U001">13491000</ocup:StockIssuedDuringPeriodValueAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodSharesInSettlementWithInvestors
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_5ae3f8aa7b49432f95a1ec7ef61eef01"
      unitRef="U002">350000</ocup:StockIssuedDuringPeriodSharesInSettlementWithInvestors>
    <ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_d2bb7d75171c46619a335c5db0c94c0d"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors>
    <ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_c0676eef05a243738e1de3c57e756f18"
      unitRef="U001">1614000</ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors>
    <ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_4a09e49eb3394b11baac1e76fdbb5143"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors>
    <ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_677c7236f1cf4fa89211090766ed838f"
      unitRef="U001">1614000</ocup:StockIssuedDuringPeriodValueInSettlementWithInvestors>
    <ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_fef84335ab9b4120b4977a996076d04f"
      unitRef="U001">0</ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_35d3548289734c339420ccaee2963311"
      unitRef="U001">1517000</ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e3df0db3ab0549929a073f5c5e1f120b"
      unitRef="U001">0</ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_598dd949c65643eca823e2a4b3c04377"
      unitRef="U001">1517000</ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ocup:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4133f520a760474183cf9cf92291217c"
      unitRef="U002">1629634</ocup:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_d9a94f7cf164428c99a895d45ff56dfa"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_1ecae6997aae4f4dbdbbfa5df55609fc"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_5182726086e543dcbeb5efe666cd7da3"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_1df0253c1a2a4020b66051c22768a646"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fae42f7588d1410b92e659fdc54065f1"
      unitRef="U002">54444</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_fee17e26df0c48288eff3130e43cb09e"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_066ba84bc0ad4fab99974c4f801dc7fc"
      unitRef="U001">1914000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_291d02c779464b0ebccf6defe3d78db1"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_cb12aac59b4c40538113ddc97231b885"
      unitRef="U001">1914000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e0b7b8e60aad4fb29007dea33274dbef"
      unitRef="U002">73442</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a59f043a3b314be69e2ab19c47e95251"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_80179f40af8c42f696b3a4de99e19e16"
      unitRef="U001">87000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b67ce146dfc24c55a9f1f76b7658fc63"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_828c6e17576f47ee9e664cbbb2001903"
      unitRef="U001">87000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a0d133d2e6374c82b891a9e089e0de66"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_382c78240c474e79a10419f590ae6f5a"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_479fd01b11e4404fbd59186ed9716c53"
      unitRef="U001">-56693000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_471baea161fa40ffb6c951469f25f9e6"
      unitRef="U001">-56693000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_3368e74a578e4737a1a8f61ca862e789"
      unitRef="U002">18845828</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_74896f5a7790468fbf4023ec55176e73"
      unitRef="U001">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_c766083c36c34ceb852f08fe1779522c"
      unitRef="U001">111588000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_705d2c3bc292482f9b6839003bf818ea"
      unitRef="U001">-89368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_c04b49edbcb241dab212d41b15bbbd1e"
      unitRef="U001">22222000</us-gaap:StockholdersEquity>
    <ocup:StockIssuedDuringPeriodSharesAtTheMarketProgram
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_8ab18d98ae4341fa8b0d85c87f470761"
      unitRef="U002">1848980</ocup:StockIssuedDuringPeriodSharesAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodValueAtTheMarketProgram
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8535c33354e74ec3baaaa5e828612697"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodValueAtTheMarketProgram
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6811a09f89ed4db486d0af5d83497640"
      unitRef="U001">4428000</ocup:StockIssuedDuringPeriodValueAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodValueAtTheMarketProgram
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_51df469e64bb4a67b4e79a78cd53077f"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueAtTheMarketProgram>
    <ocup:StockIssuedDuringPeriodValueAtTheMarketProgram
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_481666e696ca40a9b1f1ae49db30c2ac"
      unitRef="U001">4428000</ocup:StockIssuedDuringPeriodValueAtTheMarketProgram>
    <ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c9cbb17d7b0d4d3990d67fdc3650ede9"
      unitRef="U001">0</ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_e49ea9cd80c4498d97f2d57a3a26b1f5"
      unitRef="U001">133000</ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_566b38c47f0f434abb5b3172ebc07f48"
      unitRef="U001">0</ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bc1df6eb5ff243579028deecc37115fe"
      unitRef="U001">133000</ocup:AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing>
    <ocup:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_120e2a58b45b4334b4bf61b3247f857c"
      unitRef="U002">60832</ocup:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8df28b1279ee451a9fdc5473f208eccb"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7679066f8cea4c3aad281ec09b31b4de"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d34b45ccda3d458293ea3d817957f80b"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_d91ad72c7ca845288eb1a7a9d692a353"
      unitRef="U001">0</ocup:StockIssuedDuringPeriodValueStockExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2d2215d9ba224da9949403c1c3931c09"
      unitRef="U002">81366</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_52e6a89e42c24a97ba829fa9c62bedf8"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_727bba064a304576a5d1f33822e600de"
      unitRef="U001">1807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_5bb97720b27c4067afeac13ddae19ec5"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e96e7b715500478f88ff5d9670dbe07c"
      unitRef="U001">1807000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_43a7e156e7f146f79fa12bae756ec681"
      unitRef="U002">24309</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_d083c10acb2f49c1b4b9bca338589782"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_43089e12c9b2444c9e519cc1953879ce"
      unitRef="U001">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_548f552b407745d08260e91044da32f1"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_0adcd247b9d74f23a744adfb553e1739"
      unitRef="U001">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f1944e245d934e6b91b1041030b92f60"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_e14d8f45b324488fa33f2188bfb10a39"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_aef221e09dbb436e9f04c226a24ee3bd"
      unitRef="U001">17888000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_af7fde185b14426aa6b25bc7e96787a0"
      unitRef="U001">17888000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_45d847830db24a21a10fe9cd1491cc17"
      unitRef="U002">20861315</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c5105cef0fab421c98500c1a5bd07eff"
      unitRef="U001">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b35edda9be8a440a81908b78cb0b13ff"
      unitRef="U001">117717000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_cf8ffff7302d4a8885f8edfbd75ddcdd"
      unitRef="U001">-71480000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_ac8e7843f1e64ed3a3c8f6bc2050bb5a"
      unitRef="U001">46239000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_3b79b566744c43fe82297a3134031f10"
      unitRef="U001">17888000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_742bf4f5096f480ea1311fe7783d9968"
      unitRef="U001">-56693000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_5d9368a01ffb48fe9d177a7ea3974f49"
      unitRef="U001">1807000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_9730e9f4fd8047bdb07ada47ccc2e60e"
      unitRef="U001">1914000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_f1824d084b814e80ada01bc0890fa34b"
      unitRef="U001">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_f8f93eaa7385408aacd4d93d8e1344a6"
      unitRef="U001">4000</us-gaap:Depreciation>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_0aa17d4f0ae74292ac51273f267fc3d2"
      unitRef="U001">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_05c54a465d404d13b73bf16af55b95b2"
      unitRef="U001">-33829000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <ocup:ShareSettlementWithInvestors
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_b9967463e6274ea2a3571d02902d1764"
      unitRef="U001">0</ocup:ShareSettlementWithInvestors>
    <ocup:ShareSettlementWithInvestors
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_eab57389ba0e49ba8636793407f762e3"
      unitRef="U001">1614000</ocup:ShareSettlementWithInvestors>
    <ocup:IncomeLossFromInvestmentsRelatedToLicenseAgreement
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_f4ad1cd66c6b40fb89b9c862eb83c59d"
      unitRef="U001">0</ocup:IncomeLossFromInvestmentsRelatedToLicenseAgreement>
    <ocup:IncomeLossFromInvestmentsRelatedToLicenseAgreement
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_ed85664d9e8a42e4ba112e38b81943f0"
      unitRef="U001">289000</ocup:IncomeLossFromInvestmentsRelatedToLicenseAgreement>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_f3aa0250ee324b9c96e4bfe4c8953ca7"
      unitRef="U001">-170000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_d08ce584a7574152a2b7e6423db9d793"
      unitRef="U001">-70000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e2ae4a783e004109b41e913f574aa12f"
      unitRef="U001">1298000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_e5bce0d9edf9465fb05db5c6ea5f1d87"
      unitRef="U001">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <ocup:IncreaseDecreaseInContractAssetCurrent
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_ff299707451942c98bb865bf1e9a1348"
      unitRef="U001">3552000</ocup:IncreaseDecreaseInContractAssetCurrent>
    <ocup:IncreaseDecreaseInContractAssetCurrent
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_81cbaf51cb3340aa949c15f7806db84c"
      unitRef="U001">0</ocup:IncreaseDecreaseInContractAssetCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_3c01a1ee899148c8be138f9996f61e82"
      unitRef="U001">139000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_08d54f2a6b9d462a85a877dd26f6acd3"
      unitRef="U001">45000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_53463c5f5b8b4f40bddc90b32f13cbcc"
      unitRef="U001">-515000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_594e47798b61457e8bd32880954838e6"
      unitRef="U001">381000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_11076cee8b2f4ff68fad244babb9cd9f"
      unitRef="U001">-51000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_676802fb30a14660bfea1fbd54e4dd73"
      unitRef="U001">-155000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_2f8601085ccb4b28942f37ac60a053c9"
      unitRef="U001">14314000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_6a55622e63c940f2aec8b68b7e2d7310"
      unitRef="U001">-19370000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_9abfa638e1bc4abf859e4f7747947f5b"
      unitRef="U001">0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_82fcfa3dd255434f821ec24a42dd4e77"
      unitRef="U001">100000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e4db1d225f824fba944b6f450c52d03b"
      unitRef="U001">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_7356182db3504d18b927caf603625e03"
      unitRef="U001">-100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_fe490e89baef4154ba477e2f54e71324"
      unitRef="U001">4428000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_f50fa4afdad844faaaa438b592a17d32"
      unitRef="U001">28491000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_4ebb6cbaf999487fbd288f878eb69b74"
      unitRef="U001">131000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_eef91258db4843f9955c85ffada390a7"
      unitRef="U001">1511000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_b41441e399ff4813a9c8269dc3335d7b"
      unitRef="U001">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_aefead4f7c8e48d9ad9dfc96590a8f23"
      unitRef="U001">646000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_5e7ae98f346b4b09bd2afc35238fc0df"
      unitRef="U001">538000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_d21492fe5be34fea831466056a114700"
      unitRef="U001">108000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_086d8f3875a14160a7c1c0a1a5a83cb3"
      unitRef="U001">27000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_94cafed9cace4acd9fb55e48ff4511ce"
      unitRef="U001">87000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e8775b72d8624bea83f1eae4e5a17c1c"
      unitRef="U001">3786000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_bf013c471c9f4f6d9559b77f1a1e5a29"
      unitRef="U001">27605000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_a356e64535234f8eb1c79a3ea727a6a2"
      unitRef="U001">18100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_a18fcae02d064c4dab4975bb7fbd8cdd"
      unitRef="U001">8135000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20211231"
      decimals="-3"
      id="Fact_adde8b87fee74852b253ac4699402925"
      unitRef="U001">24534000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20201231"
      decimals="-3"
      id="Fact_9948fb31d65740d899c6bf9928176183"
      unitRef="U001">16399000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="-3"
      id="Fact_a292aad77a4e4979b5cd5efea22c70f8"
      unitRef="U001">42634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20211231"
      decimals="-3"
      id="Fact_c46937c7dc164b3a8c8a77ead0b9a133"
      unitRef="U001">24534000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_f7fd891789a14091ae226c54ee8d8a6b"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_8c4f8f25ea234a8b87625f23aeeae385"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bc380c3dcaa44a17bbe00eba8cbbed4c"
      unitRef="U001">9000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_ff7c209c80a74190bc4d70356da77db5"
      unitRef="U001">2000</us-gaap:InterestPaidNet>
    <ocup:NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_0f125608860f469a9d3745310fc16f9d"
      unitRef="U001">0</ocup:NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount>
    <ocup:NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_febc298c265a48fe94f4af95ff90380c"
      unitRef="U001">61793000</ocup:NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_feab414b85614da59a32ce49b5c0fc38"
      unitRef="U001">2000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_88581b1e5084408da256da35f8adfb9e"
      unitRef="U001">6000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="c20220101to20221231"
      id="Text_f1dbbe8dce714ee3a93360c4ebafcce6">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;1.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Company Description and Summary of Significant Accounting Policies&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Nature of Business&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Ocuphire Pharma, Inc. (the &#x201c;Company&#x201d; or &#x201c;Ocuphire&#x201d;) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and
            retinal eye disorders. Ocuphire&#x2019;s pipeline currently includes two small molecule product candidates targeting several of such
            indications.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In November 2022, the Company entered into a license and collaboration agreement (the &#x201c;Nyxol License Agreement&#x201d;) with FamyGen Life Sciences, Inc. (acquired by Viatris, Inc. (&#x201c;Viatris&#x201d;) in January
            2023) pursuant to which it granted Viatris an exclusive license to develop, manufacture, import, export and commercialize its product candidate phentolamine ophthalmic solution 0.75% (Nyxol&#xae; Eye Drops or &#x201c;Nyxol&#x201d;). Nyxol is a once-daily eye drop
            formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically-induced mydriasis (&#x201c;RM&#x201d;) (dilation of the pupil),
            presbyopia (age-related blurry near vision) and dim light or night vision disturbances (&#x201c;DLD&#x201d;) (halos, glares and starbursts).&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company&#x2019;s second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as
            diabetic retinopathy (&#x201c;DR&#x201d;) and diabetic macular edema (&#x201c;DME&#x201d;) which, if left untreated, can result in permanent visual acuity loss and eventual blindness. The Company has also in-licensed APX2009 and APX2014, which are second-generation
            product candidates and analogs of APX3330.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;License and collaborations revenue to date was derived from a one-time non-refundable payment and reimbursement of expenses earned under the Nyxol License Agreement, and to a much lesser degree, from
            license agreements with BioSense Global LLC (&#x201c;BioSense&#x201d;) and Processa Pharmaceuticals, Inc. (&#x201c;Processa&#x201d;) in connection with the Rexahn RX-3117 drug compound. The Company anticipates that it will recognize revenue as it earns reimbursement for
            research and development services in connection with the Nyxol License Agreement and it may earn additional revenues from future potential milestone and royalty payments from the agreements with Viatris, BioSense, Processa, or from other
            license agreements entered into the future; however, the attainment of milestones or level of sales required to earn royalty payments is highly uncertain. Outside of the license and collaborations revenue, the Company does not expect to
            generate significant revenue unless or until regulatory approval is obtained and commercialization begins for Nyxol or APX3330. Management plans to continue financing the Company&#x2019;s operations primarily through additional issuances of the
            Company&#x2019;s equity and debt securities or through collaborations or partnerships with other companies. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and
            development programs.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: italic; font-weight: bold;"&gt;Reverse Merger with Rexahn&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;br class="Apple-interchange-newline"/&gt;
                &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-style: normal;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&#160;On June 17, 2020, Ocuphire, Rexahn
                Pharmaceuticals, Inc. (&#x201c;Rexahn&#x201d;), Razor Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rexahn (&#x201c;Merger Sub&#x201d;), entered into an Agreement and Plan of Merger and Reorganization, as amended on June 29, 2020 (as amended,
                the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub would merge with and into Ocuphire, with Ocuphire continuing as a
                wholly-owned subsidiary of Rexahn and the surviving corporation of the merger (the &#x201c;Merger&#x201d;). The Merger closed on November 5, 2020. Upon completion of the Merger, Rexahn changed its name to Ocuphire Pharma, Inc. and changed its ticker
                symbol on the Nasdaq Capital Market to &#x201c;OCUP&#x201d;.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;The Company&#x2019;s headquarters is located in Farmington Hills, Michigan.&lt;/div&gt;

&lt;div&gt;&#160;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Global Economic Conditions&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;Generally, worldwide economic conditions remain uncertain, particularly due to the effects of th&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;e COVID&#x2011;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;19&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; pande&lt;/span&gt;mic and increased
              inflation. The general economic and capital market conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company&#x2019;s access to capital and increased the cost of capital. The capital
              and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, the Company&#x2019;s future cost of equity or debt capital and access to the capital markets could be adversely
              affected.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;The COVID-19 pandemic that began in late 2019 introduced significant volatility to the global
                economy, disrupted supply chains and had a widespread adverse effect on the financial markets.&#160;As a result of the COVID-19 pandemic, the Company has experienced, and may continue to experience, delays and disruptions in our clinical trials,
                as well as interruptions in our manufacturing, supply chain, shipping and research and development operations.&#160; Testing and clinical trials, manufacturing, component supply, shipping and research and development operations may be further
                impacted by the continuing effects of COVID-19.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;Additionally, the Company&#x2019;s operating results could be materially impacted by changes in the
                overall macroeconomic environment and other economic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflict in Ukraine, and steps taken by governments and central banks,
                particularly in response to the COVID-&lt;/span&gt;19&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; pandemic as well as other stimulus and spending programs, have led to higher inflation, which has led to an increase in costs and
                has caused changes in fiscal and monetary policy, including increased interest rates.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basis of Presentation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The accompanying financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"&gt;On December 31, 2021, the Company merged its wholly owned subsidiary, OcuSub Inc, with and into the Company, with
            the Company remaining as the surviving entity. The merger of the Company&#x2019;s wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of this merger, the Company did not have any remaining entities that
            required consolidation for financial statement reporting purposes.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;Liquidity&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"&gt;The accompanying consolidated financial statements have
            been prepared on the basis that the Company will continue as a going concern. From its inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting clinical trials.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt;&lt;span style="font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company entered into the Nyxol License Agreement, and the&lt;/span&gt; Company received a $35 million &lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt;one-time &lt;/span&gt; non-refundable payment in November 2022, and commitment from
                Viatris to reimburse budgeted development costs for Nyxol. See Note 10 &#x2013; License and Collaboration Agreements for additional information related to the Nyxol License Agreement. Management believes that the Company, as a result of this cash
                payment receipt, has adequate liquidity to meet obligations as they come due without raising additional funds for at least twelve months from the date of issuance of these financial statements. As of December 31, 2022, the Company had $42.6 million in cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt; &lt;span style="font-weight: normal; font-size: 10pt; font-style: normal;"&gt;In the future, the Company may need to raise additional funds until it is able to generate sufficient revenues to fund its development activities. The Company&#x2019;s future
                  operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to
                  predict the ultimate outcome of these actions to generate the liquidity ultimately required.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Use of Estimates&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported
          in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;

&lt;div&gt;&#160;
          &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Segment Information&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating
          decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its
          business in one operating segment, which is the business of development and commercialization of products related to vision
          performance and health. Accordingly, the Company has a single reporting segment.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash and Cash Equivalents&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of deposit to be cash equivalents.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;Concentration of Credit Risk&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Financial instruments that potentially subject the
                Company to a concentration of credit risk consist of cash and cash equivalents. As of December 31, 2022, the Company&#x2019;s cash was held by two large financial institutions in the United States. Amounts on deposit may at times exceed federally
                insured limits. As of December 31, 2022, the Company had deposits that exceeded federally insured amounts by approximately $42.1
                million.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Short-term Investments&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and are recorded on a settlement
                date basis. The Company&#x2019;s investments are comprised of equity securities, which in accordance with the fair value hierarchy described below are recorded at fair value using Level l inputs on the balance sheets.&#160; Subsequent changes in fair
                values are recorded in other expense, net on the&#160; consolidated statements of comprehensive income (loss). The Company classifies investments available to fund current operations as current assets on its balance sheets. The Company did not recognize any impairments on its investments to date through December 31, 2022.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Revenue Recognition&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows the provisions of&#160;Accounting Standards Codification (&#x201c;ASC&#x201d;) 606,&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;. The guidance provides a five-step model to determine
                  how revenue is recognized. The Company has entered into license agreements which have revenue recognition implications (See Note 10 &#x2013; License and Collaboration Agreements).&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the contracts with a
                customer; (ii) determination of the performance obligations in the contract; (iii) measurement of the transaction price, including potential constraints on variable consideration; (iv) allocation of the transaction price to the performance
                obligations based on estimated stand-alone selling prices; and (v) recognition of revenue when (or as) the Company satisfies a performance obligation.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to
                  the customer and is the unit of account in ASC 606. Performance obligations may include license rights, development and other services. Significant management judgment is required to determine the level of effort required under an
                  arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become
                  inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each
                performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount
                rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the relative standalone selling prices of the promised goods or service underlying each
                performance obligation.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Licenses of intellectual property and research and development services:&lt;/span&gt; If the license to the Company&#x2019;s intellectual
                property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the
                customer, and the customer can use and benefit from the license. For licenses that are bundled with other obligations, such as research and development services, the Company utilizes judgment to assess the nature of the combined performance
                obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable,
                up-front fees. For research and development services that are distinct from a license transfer obligation, the Company determines whether the services are satisfied over time or at a point in time and, if over time, the appropriate method
                of measuring progress for purposes of recognizing revenue from such services. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestone payments: &lt;/span&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates
                whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur,
                the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable
                of being achieved until such contingency occurs (such as receipt of those approvals).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Royalties:&lt;/span&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of
                sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the
                royalty has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;Contract Asset&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; The Company recognizes a contract asset when goods or services are transferred to the customer before the customer pays or before payment is due, excluding any amounts presented as an
                  accounts receivable. The Company recorded a contract asset in connection with a license and collaboration agreement in the amount of $3.6
                  million as of December 31, 2022.&#160; See Note 10 - License and Collaboration Agreements.&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;"&gt;Accounts Receivable and Allowances for Doubtful Accounts&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt; &lt;br/&gt;
                      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;The Company records a provision for doubtful accounts, when appropriate, based on historical experience
                        and a detailed assessment of the collectability of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of the accounts receivable, its historical
                        write-offs, the credit worthiness of each customer, and general economic conditions. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered.
                        Actual write-offs may be in excess of the Company&#x2019;s estimated allowance.&#160; The Company has not incurred any bad debt
                        expense during the years ended December 31, 2022 or 2021 and no allowance for doubtful accounts has been recorded
                        during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;General and Administrative Expenses&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;General and administrative expenses (&#x201c;G&amp;amp;A&#x201d;) consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in
          functions not directly associated with research and development activities. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and tax services, settlement costs
          with third parties and other services provided by business consultants.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Research and Development&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Research and development expenses (&#x201c;R&amp;amp;D&#x201d;) consist of costs incurred in performing research and development activities, including compensation for research and
            development employees and consultants, costs associated with preclinical studies and clinical trials, regulatory activities, manufacturing activities to support clinical activities, license fees, fees paid to external service providers that
            conduct certain research and development, and an allocation of R&amp;amp;D related overhead expenses. R&amp;amp;D costs include costs that are reimbursed under the Nyxol License Agreement.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Other Expense, net&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other expense, net reflected in this line item includes payments made by the Company in connection with the Contingent Value Rights Agreement discussed further below
          with former Rexahn shareholders. In addition, other expense, net includes interest earned from cash and cash equivalent investments, realized and unrealized gains (losses) from equity investments and reimbursements in connection with grants and
          other sources when they occur.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-based Compensation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The Company accounts for stock-based compensation in accordance with the provisions of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 718, &lt;span style="font-style: italic;"&gt;Compensation &#x2014; Stock Compensation&lt;/span&gt;. Accordingly, compensation costs related to equity instruments granted are recognized at the grant date fair value. The Company records forfeitures when they occur.
            Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Warrant Liabilities&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company issued Series A Warrants in connection with the Pre-Merger Financing (see Note 3 &#x2013; Pre-Merger Financing) and assumed Rexahn warrants issued prior to
            the Merger. The Company accounts for these warrants as a liability while outstanding at fair value during periods when certain provisions preclude equity accounting treatment for these instruments. Additionally, issuance costs associated with
            the warrants classified as liabilities were expensed as incurred and reflected as interest expense in the accompanying consolidated statements of comprehensive income (loss). The change in fair value of the warrant liabilities while outstanding
            were recognized as a component of the fair value change in warrant liabilities line item in the consolidated statements of comprehensive income (loss).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Measurements&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as
          &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201d; Fair value measurements are defined on a three-level hierarchy:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 1 inputs: Unadjusted quoted prices for identical assets or liabilities in active markets;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 2 inputs: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the
                  asset or liability; and&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 3 inputs: Unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or
                  liability at the measurement date.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;As of December &lt;/span&gt;31,&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;2022&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; and &lt;/span&gt;2021,&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; the fair values of cash and cash equivalents, accounts receivable, contract asset, prepaid and other
              assets, accounts payable, accrued expenses and short-term loan, while outstanding,&#160; approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the short-term investments was based on
              observable Level &lt;/span&gt;1&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; inputs in the form of quoted market prices from a major stock exchange. The fair value of the warrant liabilities, while outstanding, was based on cash
              flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and were based on Level &lt;/span&gt;3&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; inputs.&lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no transfers between fair value
            hierarchy levels during the years ended December 31, 2022 and 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The fair value of financial instruments measured on a recurring basis is as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Assets:&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt; Short-term investments&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Short-term investments&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table provides a roll-forward of investments measured at fair value on a recurring basis using observable level 1 inputs for the year ended December
            31, 2022 and 2021 (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2022&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2021&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;219&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Receipt of investments related to license agreement&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;289&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Unrealized loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(70&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;49&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;219&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table provides a roll-forward of the warrant liabilities measured at fair value on a recurring basis using unobservable level 3 inputs for the year
          ended December 31,&#160; 2021 (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2021&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;27,964&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Change in fair value of warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;33,829&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Reclassification of warrants from liability to equity&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(61,793&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The fair value of the warrant liabilities associated with the Rexahn warrants was de minimis during the years ended December 31, 2022 and 2021. See Note 2 - Merger.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no financial instruments measured on a
          non-recurring basis for any of the periods presented.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Income Taxes&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company utilizes the liability method of accounting for income taxes as required by ASC 740, &lt;span style="font-style: italic;"&gt;Income Taxes&lt;/span&gt;. Under this
          method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences
          are expected to reverse. The Company currently has a provision for income taxes, but the Company has historically incurred operating losses for all prior year periods.&#160; As such, a full valuation allowance has been provided on the net deferred tax
          assets given the uncertainty of future taxable income and other related factors impacting the realizability or the Company&#x2019;s remaining net deferred tax assets.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and Equipment, net&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment, net is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the
          assets using the straight-line method. Equipment and furniture are depreciated over a five-year estimated useful life. Tangible
          assets acquired for research and development activities which have alternative use are capitalized and depreciated over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are
          made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged
          directly to expense as incurred.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Recent Accounting Pronouncements&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &#x201c;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Financial












































            Instruments &#x2013; Credit Losses&#x201d;&lt;/span&gt;. The ASU sets forth a current expected credit loss (&#x201c;CECL&#x201d;) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical
          experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some
          off-balance sheet credit exposures. The Company does not expect that the adoption of this ASU on January 1, 2023 will have a significant impact on its consolidated financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In August 2020, FASB issued ASU 2020-06,&lt;/span&gt;
          &lt;span style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
            and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;, &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;which, among other things, provides guidance on how to account for contracts on an entity&#x2019;s own equity. This &#x200b;ASU eliminates the beneficial conversion and cash
            conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this
            ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for public business entities that meet the definition
            of a Securities and Exchange Commission (&#x201c;SEC&#x201d;) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
            For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;The Company
            does not expect that the adoption of this ASU on January 1,&#160;2023 on its consolidated financial statements will be material&lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In November 2021, &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;the FASB issued ASU 2021-10,&#160;Government Assistance (Topic
              832) - Disclosures by Business Entities about Government Assistance,&#160;to increase the transparency of government assistance including the disclosure of the types of assistance, an entity&#x2019;s accounting for the assistance, and the effect of the
              assistance on an entity&#x2019;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15,&#160;2021. The Company adopted this
              guidance on January 1,&#160;2022 and it did not have a material impact to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <ocup:NatureOfBusinessPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_6d1ba289d8b34393abc8b1d726be1ad8">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Nature of Business&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Ocuphire Pharma, Inc. (the &#x201c;Company&#x201d; or &#x201c;Ocuphire&#x201d;) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and
            retinal eye disorders. Ocuphire&#x2019;s pipeline currently includes two small molecule product candidates targeting several of such
            indications.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In November 2022, the Company entered into a license and collaboration agreement (the &#x201c;Nyxol License Agreement&#x201d;) with FamyGen Life Sciences, Inc. (acquired by Viatris, Inc. (&#x201c;Viatris&#x201d;) in January
            2023) pursuant to which it granted Viatris an exclusive license to develop, manufacture, import, export and commercialize its product candidate phentolamine ophthalmic solution 0.75% (Nyxol&#xae; Eye Drops or &#x201c;Nyxol&#x201d;). Nyxol is a once-daily eye drop
            formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically-induced mydriasis (&#x201c;RM&#x201d;) (dilation of the pupil),
            presbyopia (age-related blurry near vision) and dim light or night vision disturbances (&#x201c;DLD&#x201d;) (halos, glares and starbursts).&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company&#x2019;s second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as
            diabetic retinopathy (&#x201c;DR&#x201d;) and diabetic macular edema (&#x201c;DME&#x201d;) which, if left untreated, can result in permanent visual acuity loss and eventual blindness. The Company has also in-licensed APX2009 and APX2014, which are second-generation
            product candidates and analogs of APX3330.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;License and collaborations revenue to date was derived from a one-time non-refundable payment and reimbursement of expenses earned under the Nyxol License Agreement, and to a much lesser degree, from
            license agreements with BioSense Global LLC (&#x201c;BioSense&#x201d;) and Processa Pharmaceuticals, Inc. (&#x201c;Processa&#x201d;) in connection with the Rexahn RX-3117 drug compound. The Company anticipates that it will recognize revenue as it earns reimbursement for
            research and development services in connection with the Nyxol License Agreement and it may earn additional revenues from future potential milestone and royalty payments from the agreements with Viatris, BioSense, Processa, or from other
            license agreements entered into the future; however, the attainment of milestones or level of sales required to earn royalty payments is highly uncertain. Outside of the license and collaborations revenue, the Company does not expect to
            generate significant revenue unless or until regulatory approval is obtained and commercialization begins for Nyxol or APX3330. Management plans to continue financing the Company&#x2019;s operations primarily through additional issuances of the
            Company&#x2019;s equity and debt securities or through collaborations or partnerships with other companies. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and
            development programs.&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;
</ocup:NatureOfBusinessPolicyTextBlock>
    <ocup:NumberOfSmallMoleculeProductCandidates
      contextRef="c20220101to20221231"
      decimals="INF"
      id="Fact_862459d95c0d48e8965af036cdd7e08f"
      unitRef="U004">2</ocup:NumberOfSmallMoleculeProductCandidates>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="c20220101to20221231"
      id="Text_c197bba8ef4e40fa84dd0c66435a6e6e">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-variant: normal; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman'; font-style: italic; font-weight: bold;"&gt;Reverse Merger with Rexahn&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;br class="Apple-interchange-newline"/&gt;
                &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-style: normal;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&#160;On June 17, 2020, Ocuphire, Rexahn
                Pharmaceuticals, Inc. (&#x201c;Rexahn&#x201d;), Razor Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rexahn (&#x201c;Merger Sub&#x201d;), entered into an Agreement and Plan of Merger and Reorganization, as amended on June 29, 2020 (as amended,
                the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub would merge with and into Ocuphire, with Ocuphire continuing as a
                wholly-owned subsidiary of Rexahn and the surviving corporation of the merger (the &#x201c;Merger&#x201d;). The Merger closed on November 5, 2020. Upon completion of the Merger, Rexahn changed its name to Ocuphire Pharma, Inc. and changed its ticker
                symbol on the Nasdaq Capital Market to &#x201c;OCUP&#x201d;.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;The Company&#x2019;s headquarters is located in Farmington Hills, Michigan.&lt;/div&gt;
</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_c7feab1b45df4f7c99239758858b20cb">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basis of Presentation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The accompanying financial statements have been prepared in accordance with accounting standards generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"&gt;On December 31, 2021, the Company merged its wholly owned subsidiary, OcuSub Inc, with and into the Company, with
            the Company remaining as the surviving entity. The merger of the Company&#x2019;s wholly owned subsidiary did not have a financial impact to the periods presented. Upon close of this merger, the Company did not have any remaining entities that
            required consolidation for financial statement reporting purposes.&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <ocup:LiquidityPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_0863595062114c5a8383dcd4cd55e0bf">
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;Liquidity&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"&gt;The accompanying consolidated financial statements have
            been prepared on the basis that the Company will continue as a going concern. From its inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting clinical trials.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none; font-weight: normal; font-size: 10pt; font-style: normal;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt;&lt;span style="font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company entered into the Nyxol License Agreement, and the&lt;/span&gt; Company received a $35 million &lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt;one-time &lt;/span&gt; non-refundable payment in November 2022, and commitment from
                Viatris to reimburse budgeted development costs for Nyxol. See Note 10 &#x2013; License and Collaboration Agreements for additional information related to the Nyxol License Agreement. Management believes that the Company, as a result of this cash
                payment receipt, has adequate liquidity to meet obligations as they come due without raising additional funds for at least twelve months from the date of issuance of these financial statements. As of December 31, 2022, the Company had $42.6 million in cash and cash equivalents.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; font-style: normal;"&gt; &lt;span style="font-weight: normal; font-size: 10pt; font-style: normal;"&gt;In the future, the Company may need to raise additional funds until it is able to generate sufficient revenues to fund its development activities. The Company&#x2019;s future
                  operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the Company and the Company is unable to
                  predict the ultimate outcome of these actions to generate the liquidity ultimately required.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</ocup:LiquidityPolicyTextBlock>
    <ocup:NonRefundableUpfrontPaymentReceived
      contextRef="c20221101to20221130_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-6"
      id="Fact_c2b4b20e75494bb0a9977fd77aaa76c5"
      unitRef="U001">35000000</ocup:NonRefundableUpfrontPaymentReceived>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20221231"
      decimals="-5"
      id="Fact_f990d52bc044431b92b62a8844c5244c"
      unitRef="U001">42600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:UseOfEstimates
      contextRef="c20220101to20221231"
      id="Text_d631c76888554c638da934f5c3017694">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Use of Estimates&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported
          in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_fc20d4026e33408c9d950b2383011b29">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Segment Information&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating
          decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its
          business in one operating segment, which is the business of development and commercialization of products related to vision
          performance and health. Accordingly, the Company has a single reporting segment.&lt;/div&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20220101to20221231"
      decimals="INF"
      id="Fact_9cc1957144d84e2cbb5feb374cf4c7b8"
      unitRef="U005">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_fffa5701510144218e097a4d10b4df8b">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cash and Cash Equivalents&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of deposit to be cash equivalents.&lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="c20220101to20221231"
      id="Text_5caaf684a68345f99084758bbe2b7437">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;Concentration of Credit Risk&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Financial instruments that potentially subject the
                Company to a concentration of credit risk consist of cash and cash equivalents. As of December 31, 2022, the Company&#x2019;s cash was held by two large financial institutions in the United States. Amounts on deposit may at times exceed federally
                insured limits. As of December 31, 2022, the Company had deposits that exceeded federally insured amounts by approximately $42.1
                million.&lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount
      contextRef="c20221231"
      decimals="-5"
      id="Fact_00e55f2329be47c29c2f6675985657cc"
      unitRef="U001">42100000</us-gaap:CashUninsuredAmount>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_617e973009fd4c2ebcc2315c407db08d">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Short-term Investments&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and are recorded on a settlement
                date basis. The Company&#x2019;s investments are comprised of equity securities, which in accordance with the fair value hierarchy described below are recorded at fair value using Level l inputs on the balance sheets.&#160; Subsequent changes in fair
                values are recorded in other expense, net on the&#160; consolidated statements of comprehensive income (loss). The Company classifies investments available to fund current operations as current assets on its balance sheets. The Company did not recognize any impairments on its investments to date through December 31, 2022.&lt;/div&gt;
</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ImpairmentOfInvestments
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_6126547c55914aae8de3ed7102a999e6"
      unitRef="U001">0</us-gaap:ImpairmentOfInvestments>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_38ef849f5ae24df4afc422e341c81547">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Revenue Recognition&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows the provisions of&#160;Accounting Standards Codification (&#x201c;ASC&#x201d;) 606,&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;. The guidance provides a five-step model to determine
                  how revenue is recognized. The Company has entered into license agreements which have revenue recognition implications (See Note 10 &#x2013; License and Collaboration Agreements).&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the contracts with a
                customer; (ii) determination of the performance obligations in the contract; (iii) measurement of the transaction price, including potential constraints on variable consideration; (iv) allocation of the transaction price to the performance
                obligations based on estimated stand-alone selling prices; and (v) recognition of revenue when (or as) the Company satisfies a performance obligation.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to
                  the customer and is the unit of account in ASC 606. Performance obligations may include license rights, development and other services. Significant management judgment is required to determine the level of effort required under an
                  arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations are either completed or become
                  inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each
                performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount
                rates and probabilities of technical and regulatory success. The Company allocates the total transaction price to each performance obligation based on the relative standalone selling prices of the promised goods or service underlying each
                performance obligation.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Licenses of intellectual property and research and development services:&lt;/span&gt; If the license to the Company&#x2019;s intellectual
                property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the
                customer, and the customer can use and benefit from the license. For licenses that are bundled with other obligations, such as research and development services, the Company utilizes judgment to assess the nature of the combined performance
                obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable,
                up-front fees. For research and development services that are distinct from a license transfer obligation, the Company determines whether the services are satisfied over time or at a point in time and, if over time, the appropriate method
                of measuring progress for purposes of recognizing revenue from such services. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Milestone payments: &lt;/span&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates
                whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur,
                the value of the associated milestone (such as a regulatory submission) is included in the transaction price. Milestone payments that are not within the control of the Company, such as approvals from regulators, are not considered probable
                of being achieved until such contingency occurs (such as receipt of those approvals).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Royalties:&lt;/span&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of
                sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the
                royalty has been allocated has been satisfied (or partially satisfied).&lt;/div&gt;
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ocup:ContractAssetPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_e1d6039b61954b0a8c6a2d6203cd9301">
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;Contract Asset&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; The Company recognizes a contract asset when goods or services are transferred to the customer before the customer pays or before payment is due, excluding any amounts presented as an
                  accounts receivable. The Company recorded a contract asset in connection with a license and collaboration agreement in the amount of $3.6
                  million as of December 31, 2022.&#160; See Note 10 - License and Collaboration Agreements.&lt;/span&gt;&lt;br/&gt;
              &lt;/div&gt;
</ocup:ContractAssetPolicyTextBlock>
    <ocup:ContractAssetCurrent
      contextRef="c20221231"
      decimals="-5"
      id="Fact_c10f695b87174ebe94821ca01b5bca68"
      unitRef="U001">3600000</ocup:ContractAssetCurrent>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="c20220101to20221231"
      id="Text_7f0ca4a3de0b41c98cfcb6f58fbae1b2">
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;"&gt;Accounts Receivable and Allowances for Doubtful Accounts&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt; &lt;br/&gt;
                      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;&lt;span style="font-weight: normal; font-style: normal;"&gt;The Company records a provision for doubtful accounts, when appropriate, based on historical experience
                        and a detailed assessment of the collectability of its accounts receivable. In estimating the allowance for doubtful accounts, the Company considers, among other factors, the aging of the accounts receivable, its historical
                        write-offs, the credit worthiness of each customer, and general economic conditions. Account balances are charged off against the allowance when the Company believes that it is probable that the receivable will not be recovered.
                        Actual write-offs may be in excess of the Company&#x2019;s estimated allowance.&#160; The Company has not incurred any bad debt
                        expense during the years ended December 31, 2022 or 2021 and no allowance for doubtful accounts has been recorded
                        during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_683b23f476dd41969ecba877b38fcbda"
      unitRef="U001">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_610d969f35854a448447b8f591590e69"
      unitRef="U001">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_51b1e411006349f69f2546adb695ec5f"
      unitRef="U001">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_0d33cde2828b4e1eb80bf8e82e7df320"
      unitRef="U001">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_7227cbf2796646bd9e90ef1c4ec58b0d">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;General and Administrative Expenses&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;General and administrative expenses (&#x201c;G&amp;amp;A&#x201d;) consist primarily of personnel-related costs, including salaries and stock-based compensation costs, for personnel in
          functions not directly associated with research and development activities. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and tax services, settlement costs
          with third parties and other services provided by business consultants.&lt;/div&gt;
</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20220101to20221231"
      id="Text_7fae9398664d405ea0bf0b685ba5fa79">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Research and Development&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Research and development expenses (&#x201c;R&amp;amp;D&#x201d;) consist of costs incurred in performing research and development activities, including compensation for research and
            development employees and consultants, costs associated with preclinical studies and clinical trials, regulatory activities, manufacturing activities to support clinical activities, license fees, fees paid to external service providers that
            conduct certain research and development, and an allocation of R&amp;amp;D related overhead expenses. R&amp;amp;D costs include costs that are reimbursed under the Nyxol License Agreement.&lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ocup:OtherIncomeExpenseNetPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_e1df800b48924c1e8bb1915674ef31b4">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Other Expense, net&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other expense, net reflected in this line item includes payments made by the Company in connection with the Contingent Value Rights Agreement discussed further below
          with former Rexahn shareholders. In addition, other expense, net includes interest earned from cash and cash equivalent investments, realized and unrealized gains (losses) from equity investments and reimbursements in connection with grants and
          other sources when they occur.&lt;/div&gt;
</ocup:OtherIncomeExpenseNetPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20220101to20221231"
      id="Text_33c799f4f8954cea87024db2d024952c">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-based Compensation&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The Company accounts for stock-based compensation in accordance with the provisions of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 718, &lt;span style="font-style: italic;"&gt;Compensation &#x2014; Stock Compensation&lt;/span&gt;. Accordingly, compensation costs related to equity instruments granted are recognized at the grant date fair value. The Company records forfeitures when they occur.
            Stock-based compensation arrangements to non-employees are accounted for in accordance with the applicable provisions of ASC 718.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <ocup:WarrantLiabilitiesPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_e00369ee1c82481782513fc41fb90a65">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Warrant Liabilities&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company issued Series A Warrants in connection with the Pre-Merger Financing (see Note 3 &#x2013; Pre-Merger Financing) and assumed Rexahn warrants issued prior to
            the Merger. The Company accounts for these warrants as a liability while outstanding at fair value during periods when certain provisions preclude equity accounting treatment for these instruments. Additionally, issuance costs associated with
            the warrants classified as liabilities were expensed as incurred and reflected as interest expense in the accompanying consolidated statements of comprehensive income (loss). The change in fair value of the warrant liabilities while outstanding
            were recognized as a component of the fair value change in warrant liabilities line item in the consolidated statements of comprehensive income (loss).&lt;/div&gt;
</ocup:WarrantLiabilitiesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_989964be4b2e41b297a0769123677eb5">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Fair Value Measurements&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as
          &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201d; Fair value measurements are defined on a three-level hierarchy:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 1 inputs: Unadjusted quoted prices for identical assets or liabilities in active markets;&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 2 inputs: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, whether directly or indirectly, for substantially the full term of the
                  asset or liability; and&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top;"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;
                &lt;div&gt;Level 3 inputs: Unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or
                  liability at the measurement date.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;As of December &lt;/span&gt;31,&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;2022&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; and &lt;/span&gt;2021,&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; the fair values of cash and cash equivalents, accounts receivable, contract asset, prepaid and other
              assets, accounts payable, accrued expenses and short-term loan, while outstanding,&#160; approximated their carrying values because of the short-term nature of these assets or liabilities. The fair value of the short-term investments was based on
              observable Level &lt;/span&gt;1&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; inputs in the form of quoted market prices from a major stock exchange. The fair value of the warrant liabilities, while outstanding, was based on cash
              flow models discounted at current implied market rates evidenced in recent arms-length transactions representing expected returns by market participants for similar instruments and were based on Level &lt;/span&gt;3&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; inputs.&lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no transfers between fair value
            hierarchy levels during the years ended December 31, 2022 and 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The fair value of financial instruments measured on a recurring basis is as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Assets:&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt; Short-term investments&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Short-term investments&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table provides a roll-forward of investments measured at fair value on a recurring basis using observable level 1 inputs for the year ended December
            31, 2022 and 2021 (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2022&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2021&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;219&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Receipt of investments related to license agreement&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;289&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Unrealized loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(70&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;49&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;219&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="margin-left: 5pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table provides a roll-forward of the warrant liabilities measured at fair value on a recurring basis using unobservable level 3 inputs for the year
          ended December 31,&#160; 2021 (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2021&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;27,964&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Change in fair value of warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;33,829&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Reclassification of warrants from liability to equity&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(61,793&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;The fair value of the warrant liabilities associated with the Rexahn warrants was de minimis during the years ended December 31, 2022 and 2021. See Note 2 - Merger.&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;There were no financial instruments measured on a
          non-recurring basis for any of the periods presented.&lt;/div&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_4be0e52b2b0f4a92be25224efa3ce87e"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_1426a5f9696f425d807a111479cf2938"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_df0f3cdb7a154efa943876ac9ef3349b"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_8c9417764310400db99d3897ed7998c7"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="c20220101to20221231"
      id="Text_7650f1381721419d9c52d6c18d2a805e">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The fair value of financial instruments measured on a recurring basis is as follows (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Assets:&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt; Short-term investments&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;49&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 52.02%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="14" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;As of December 31, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Description&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 2&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;Level 3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%;" valign="bottom"&gt;
                &lt;div&gt;Assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="3" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Short-term investments&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52.02%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Total assets at fair value&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;219&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9.01%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.01%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9f6ebe5145a046828ee51077058f0d94"
      unitRef="U001">49000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_28a1aae7be4648b28bc2ca5e119f7635"
      unitRef="U001">49000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_182efa6ab2184ae9bd0cca877e3bf0f7"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_3e5a523338924e3fb0d9fc529fa1f572"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_f903bd52f9504bad90481cd9ca85cf51"
      unitRef="U001">49000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_7e317467126b4fb6b66791fa3ff1d4bd"
      unitRef="U001">49000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_138a70b1b1cd40ba8f2161f97c3c9218"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20221231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_ae97dadd3e4e421ba5c9e8c0b819518f"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_154f208cf8a741ae83e44a9772a54084"
      unitRef="U001">219000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_ef64c83f9c5747a1ac6fa1e305f94946"
      unitRef="U001">219000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_904b8fd04d2d4b1eac51515466296060"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_36448ddc3d954bd48d477e34b20f6307"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20211231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_8811a118ff6b478380404d950661e0bb"
      unitRef="U001">219000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_16e8814191014792afe83371cc638547"
      unitRef="U001">219000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9abc59797b2e4bc0bbe7258043469473"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_a1231afc250b4cf199342e126f3107a4"
      unitRef="U001">0</us-gaap:AssetsFairValueDisclosure>
    <ocup:ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_27ac5e463e434d38a3fcdba4a75099c2">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table provides a roll-forward of investments measured at fair value on a recurring basis using observable level 1 inputs for the year ended December
            31, 2022 and 2021 (in thousands):&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2022&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;2021&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Short-term investments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;219&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Receipt of investments related to license agreement&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;289&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Unrealized loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(70&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;49&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;219&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</ocup:ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_bcae4e4996e64d6791f38a43cd52bb4f"
      unitRef="U001">219000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20201231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_45da091e1065482190698f0ec8e890f3"
      unitRef="U001">0</us-gaap:InvestmentsFairValueDisclosure>
    <ocup:ReceiptOfInvestmentsRelatedToLicenseAgreement
      contextRef="c20220101to20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_7ff5b784bfab4dfca7e18f3c397916a0"
      unitRef="U001">0</ocup:ReceiptOfInvestmentsRelatedToLicenseAgreement>
    <ocup:ReceiptOfInvestmentsRelatedToLicenseAgreement
      contextRef="c20210101to20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_fa88759b101d4433baa6689466bd392e"
      unitRef="U001">289000</ocup:ReceiptOfInvestmentsRelatedToLicenseAgreement>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20220101to20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_6fb1ac02b63b4d429560e5438f270981"
      unitRef="U001">-170000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c20210101to20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_5b5a507ee19848b9b7ec8084debde3ca"
      unitRef="U001">-70000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20221231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_418221681d64424caed85815d6e6aa84"
      unitRef="U001">49000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="c20211231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1d74a3c08942429597d67ff0c3cd35f9"
      unitRef="U001">219000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="c20220101to20221231"
      id="Text_90c51b56b1114195b18eff2231cd1758">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The following table provides a roll-forward of the warrant liabilities measured at fair value on a recurring basis using unobservable level 3 inputs for the year
          ended December 31,&#160; 2021 (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;
          &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2021&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of beginning of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;27,964&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Change in fair value of warrant liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;33,829&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Reclassification of warrants from liability to equity&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(61,793&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of end of period&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember"
      decimals="-3"
      id="Fact_2b637e2a2be84981bc649e49d3916e43"
      unitRef="U001">27964000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20210101to20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember"
      decimals="-3"
      id="Fact_8f8d443c08dc4913a337403f4d96cd57"
      unitRef="U001">33829000</us-gaap:FairValueAdjustmentOfWarrants>
    <ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
      contextRef="c20210101to20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember"
      decimals="-3"
      id="Fact_58ca351961a745b0b6193bcba82efa3f"
      unitRef="U001">-61793000</ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="c20211231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember"
      decimals="-3"
      id="Fact_53519d353f5148389e4f15b2dc54f86f"
      unitRef="U001">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20211231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_5c98959abc134018b463ec9ace830591"
      unitRef="U001">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c20221231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_e3c4cd300cf64f70a8c56607c05a9d5c"
      unitRef="U001">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_4e7a10ea0fa44b2f9329cd52a6b4f1a0">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Income Taxes&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company utilizes the liability method of accounting for income taxes as required by ASC 740, &lt;span style="font-style: italic;"&gt;Income Taxes&lt;/span&gt;. Under this
          method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences
          are expected to reverse. The Company currently has a provision for income taxes, but the Company has historically incurred operating losses for all prior year periods.&#160; As such, a full valuation allowance has been provided on the net deferred tax
          assets given the uncertainty of future taxable income and other related factors impacting the realizability or the Company&#x2019;s remaining net deferred tax assets.&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_f841712e64e646a1be6b8756a78ca59b">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and Equipment, net&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment, net is recorded at cost and reduced by accumulated depreciation. Depreciation expense is recognized over the estimated useful lives of the
          assets using the straight-line method. Equipment and furniture are depreciated over a five-year estimated useful life. Tangible
          assets acquired for research and development activities which have alternative use are capitalized and depreciated over the useful life of the acquired asset. Estimated useful lives are periodically reviewed, and when appropriate, changes are
          made prospectively. When certain events or changes in operating conditions occur, asset lives may be adjusted and an impairment assessment may be performed on the recoverability of the carrying amounts. Maintenance and repairs are charged
          directly to expense as incurred.&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      id="Fact_c5616a9cc6aa4fb5976f6dfc698d3a83">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"
      id="Fact_f725755bb90948cba0fdf7a0fa10c3d0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20220101to20221231"
      id="Text_9287d18005894536848f6118ff6bf899">
&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Recent Accounting Pronouncements&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &#x201c;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Financial












































            Instruments &#x2013; Credit Losses&#x201d;&lt;/span&gt;. The ASU sets forth a current expected credit loss (&#x201c;CECL&#x201d;) model which requires the Company to measure all expected credit losses for financial instruments held at the reporting date based on historical
          experience, current conditions, and reasonable supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost and applies to some
          off-balance sheet credit exposures. The Company does not expect that the adoption of this ASU on January 1, 2023 will have a significant impact on its consolidated financial statements.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In August 2020, FASB issued ASU 2020-06,&lt;/span&gt;
          &lt;span style="font-style: italic; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
            and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;, &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;which, among other things, provides guidance on how to account for contracts on an entity&#x2019;s own equity. This &#x200b;ASU eliminates the beneficial conversion and cash
            conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this
            ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for public business entities that meet the definition
            of a Securities and Exchange Commission (&#x201c;SEC&#x201d;) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years.
            For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;The Company
            does not expect that the adoption of this ASU on January 1,&#160;2023 on its consolidated financial statements will be material&lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;.&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;In November 2021, &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;the FASB issued ASU 2021-10,&#160;Government Assistance (Topic
              832) - Disclosures by Business Entities about Government Assistance,&#160;to increase the transparency of government assistance including the disclosure of the types of assistance, an entity&#x2019;s accounting for the assistance, and the effect of the
              assistance on an entity&#x2019;s financial statements. The amendments in this ASU are effective for all entities within their scope for financial statements issued for annual periods beginning after December 15,&#160;2021. The Company adopted this
              guidance on January 1,&#160;2022 and it did not have a material impact to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="c20220101to20221231"
      id="Text_0f80218aa1404bf1bcf82c50f1661e71">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;2.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Merger&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&#160;&#160;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On November 5, 2020, the Company completed the Merger transaction with Rexahn. In connection with the Merger, the Company, Shareholder Representatives Services
            LLC, as representative of the Rexahn stockholders prior to the Merger, and Olde Monmouth Stock Transfer Co., Inc., as the rights agent, entered into a Contingent Value Rights Agreement (the &#x201c;CVR Agreement&#x201d;).&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Pursuant to the terms of the Merger and the CVR Agreement, Rexahn stockholders of record as of immediately prior to the effective time of the Merger received one contingent value right (&#x201c;CVR&#x201d;) for each share of Rexahn common stock held.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Each CVR entitles such holders to receive, for each calendar quarter (each, a &#x201c;CVR Payment Period&#x201d;) during the 15-year period after the Closing (the &#x201c;CVR Term&#x201d;), an amount equal to the following:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); text-align: justify;"&gt;90% of all payments received by Rexahn or its affiliates during such
                      CVR Payment Period from or on behalf of BioSense Global LLC (&#x201c;BioSense&#x201d;) pursuant to that certain License and Assignment Agreement, dated as of February 25, 2019, by and between BioSense and Rexahn, as amended by Amendment No. 1,
                      dated August 24, 2019, and as further amended by Amendment No. 2, dated March 10, 2020, minus certain permitted deductions;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); text-align: justify;"&gt;90% of all payments received by Rexahn or its affiliates during such
                      CVR Payment Period from or on behalf of Zhejiang HaiChang Biotechnology Co., Ltd. (&#x201c;HaiChang&#x201d;) pursuant to that certain Exclusive License Agreement, dated as of February 8, 2020, by and between HaiChang and Rexahn, minus certain
                      permitted deductions; and&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt;"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);"&gt;&#x2022;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                    &lt;div style="color: rgb(0, 0, 0); text-align: justify;"&gt;75% of the sum of (i) all cash consideration paid by a third party to
                      Rexahn or its affiliates during the applicable CVR Payment Period in connection with the grant, sale or transfer of rights to Rexahn&#x2019;s pre-closing intellectual property (other than a grant, sale or transfer of rights involving a sale
                      or disposition of the post-Merger combined company) that is entered into during the 10-year period after the Closing
                      (&#x201c;Parent IP Deal&#x201d;), plus (ii) with respect to any non-cash consideration received by Rexahn or its affiliates from a third party during the applicable CVR Payment Period in connection with any Parent IP Deal, all amounts received by
                      Rexahn and its affiliates for such non-cash consideration at the time such non-cash consideration is monetized by Rexahn or its affiliates, minus (iii) certain permitted deductions.&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;The CVRs are not transferable, except in certain limited circumstances, will not be certificated or evidenced by any instrument, will not accrue interest and will not be registered with the SEC or listed for trading on any exchange.
                The CVR Agreement will continue in effect until the later of the end of the CVR Term and the payment of all amounts payable thereunder. &lt;/span&gt;As of December 31, 2022, no milestones had been accrued as there were no
              additional potential milestones yet considered probable beyond those previously reported in the second and third quarters of calendar year 2021.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Former Rexahn Warrants&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Following the closing of the Merger, 231,433
            outstanding, unexercised Rexahn warrants to purchase common stock remained outstanding, the majority of which were subsequently repurchased according to the terms of the original warrant agreements.&#160; As of December 31 2022, 60,713 of the Rexahn warrants remained outstanding with exercise prices ranging from $38.40 to $136.80 per share with an average remaining contractual life of 1.0 years.&lt;/div&gt;
</us-gaap:BusinessCombinationDisclosureTextBlock>
    <ocup:ContingentValueRightEntitledPerEachShareOfCommonStockHeld
      contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="INF"
      id="Fact_b9db115b4690424da01874434e075d2f"
      unitRef="U006">1</ocup:ContingentValueRightEntitledPerEachShareOfCommonStockHeld>
    <ocup:ContingentValueRightsPaymentPeriod
      contextRef="c20220101to20221231"
      id="Fact_605183b9dc3b4888b9ed4b01ca774c81">P15Y</ocup:ContingentValueRightsPaymentPeriod>
    <ocup:ContingentValueRightsPercentage
      contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_BioSenseGlobalLLCMember"
      decimals="2"
      id="Fact_4b84d85f39c447f5a272b39ce2240d11"
      unitRef="U007">0.90</ocup:ContingentValueRightsPercentage>
    <ocup:ContingentValueRightsPercentage
      contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_ZhejiangHaiChangBiotechnologyCoLtdMember"
      decimals="2"
      id="Fact_bc61ce2073f14429a0f48586b7e12025"
      unitRef="U007">0.90</ocup:ContingentValueRightsPercentage>
    <ocup:PercentageOfCashConsiderationPayment
      contextRef="c20201105"
      decimals="2"
      id="Fact_a33ff8bd138e4dfaa124ed8b4ca76b22"
      unitRef="U007">0.75</ocup:PercentageOfCashConsiderationPayment>
    <ocup:ContingentValueRightsIPTerm
      contextRef="c20220101to20221231"
      id="Fact_76720dc150cb41768e858f6d96f140a9">P10Y</ocup:ContingentValueRightsIPTerm>
    <ocup:NumberOfMilestonesAccrued
      contextRef="c20201105"
      decimals="INF"
      id="Fact_daead475874a458084fd8b9081cfc933"
      unitRef="U008">0</ocup:NumberOfMilestonesAccrued>
    <ocup:NumberOfMilestonesAccrued
      contextRef="c20221231"
      decimals="INF"
      id="Fact_0e6673e5a00e4deb9b9fa88221812ba1"
      unitRef="U008">0</ocup:NumberOfMilestonesAccrued>
    <ocup:NumberOfPotentialMilestones
      contextRef="c20221231"
      decimals="INF"
      id="Fact_81a95aab41eb49379671b583faf93c12"
      unitRef="U008">0</ocup:NumberOfPotentialMilestones>
    <ocup:NumberOfPotentialMilestones
      contextRef="c20201105"
      decimals="INF"
      id="Fact_02fe62fe32b24971932e215068be8c3f"
      unitRef="U008">0</ocup:NumberOfPotentialMilestones>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20201105_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="0"
      id="Fact_d5c437b30f4c4747bd1e517c885a9658"
      unitRef="U002">231433</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="0"
      id="Fact_cf1f001dcc7c4dff969a87cca0b30feb"
      unitRef="U002">60713</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_0cc45dfb61144090b5ec56aa77af36b7"
      unitRef="U003">38.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_968b2bad1d984b7dae0875827184516b"
      unitRef="U003">136.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ocup:WeightedAverageRemainingContractualTermsWarrants
      contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      id="Fact_6cc1d79995f141dc9d044a4605d3fd54">P1Y</ocup:WeightedAverageRemainingContractualTermsWarrants>
    <ocup:PreMergerFinancingTextBlock
      contextRef="c20220101to20221231"
      id="Text_72d6e04543794ec0b779c576fffd483a">
&lt;div&gt;
        &lt;div&gt; &lt;br/&gt;
        &lt;/div&gt;

        &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;3.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Pre-Merger Financing&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;On June 17, 2020, Ocuphire, Rexahn and certain investors entered into a Securities Purchase Agreement, which was amended and restated in
        its entirety on June 29, 2020 (as amended and restated, the &#x201c;Securities Purchase Agreement&#x201d;).&#160; Pursuant to the Securities Purchase Agreement, the investors invested a total of $21.15 million in cash, including $300,000 invested by five directors of Ocuphire Pharma, Inc., prior to the Merger and one director of Rexahn upon closing of the Merger (the &#x201c;Pre-Merger Financing&#x201d;).&#160; The Pre-Merger Financing also included the issuance of Series A Warrants and Series B Warrants discussed
        further below.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Waiver Agreements&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effective February 3, 2021, each investor that invested in the Pre-Merger Financing entered into a Waiver Agreement with the Company
        (collectively, the &#x201c;Waiver Agreements&#x201d;). Pursuant to the Waiver Agreements, the investors and the Company agreed to waive certain rights, finalize the exercise price and number of Series A Warrants and Series B Warrants, eliminate certain financing
        restrictions, extend the term of certain leak-out agreements, and, in the case of certain investors, grant certain registration rights for the shares underlying the warrants.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The Waiver Agreements provide for the elimination of the full ratchet anti-dilution provisions contained in the Series A Warrants (as
        certain of the anti-dilution provisions had previously caused liability accounting treatment for the Series A Warrants). Upon the effective date of the Waiver Agreements, the Series A Warrants were reclassified to equity.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Pursuant to the Waiver Agreements, the number of shares underlying all of the Series B Warrants was fixed in the aggregate with respect
        to all investors, eliminating any future resets.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Series A Warrants&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The Series A Warrants were issued on November 19, 2020 at an initial exercise price of $4.4795 per share, were immediately exercisable upon issuance and have a term of five years from the date of issuance. The Series A Warrants are exercisable for 5,665,838 shares of common stock in the
        aggregate (without giving effect to any limitation on exercise contained therein) and were outstanding as of December 31, 2022. Prior to the execution of the Waiver Agreements, the Series A Warrants were accounted for and classified as liabilities
        on the accompanying balance sheets given certain price reset provisions not used for a fair valuation under a fixed for fixed settlement scenario as required for equity balance sheet classification. Upon the February 3, 2021 effective date of the
        Waiver Agreements, the Series A Warrants were reclassified to equity. A final fair valuation of the Series A Warrants was performed utilizing a Black Scholes model to estimate the aggregate fair value of the Series A Warrants prior to being
        re-classified as equity. Input assumptions used were as follows: risk-free interest rate 0.4%; expected volatility of 86.6%; expected life of 4.8 years; and
        expected dividend yield zero percent. The underlying stock price used was the market price as quoted on Nasdaq as of&#160; February 3, 2021,
        the effective date of the Waiver Agreement.&#160; The fair value change of the Series A Warrants was $33.8 million and was recorded to the
        fair value change in warrant liabilities line item on the accompanying&#160; consolidated statements of comprehensive income (loss) for year ended December 31, 2021. As a result of the reclassification to equity, the Series A Warrants are no longer
        subject to remeasurement.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Series B Warrants&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The Series B Warrants have an exercise price of $0.0001, were exercisable upon issuance and will expire on the day following the later to occur of (i) the Reservation Date (as defined therein), and (ii) the date on which the investor&#x2019;s
        Series B Warrants have been exercised in full (without giving effect to any limitation on exercise contained therein) and no shares
        remain issuable thereunder. The Series B Warrants outstanding as of December 31, 2022 were exercisable for 17,869 shares of common
        stock. The Series B Warrants were accounted for and classified as equity on the accompanying balance sheets.&lt;/div&gt;
</ocup:PreMergerFinancingTextBlock>
    <ocup:ProceedsFromPreMergerFinancing
      contextRef="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"
      decimals="-4"
      id="Fact_d396c6dd022d42ea8d5a736008f312fd"
      unitRef="U001">21150000</ocup:ProceedsFromPreMergerFinancing>
    <ocup:ProceedsFromPreMergerFinancing
      contextRef="c20200629to20200629_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"
      decimals="-3"
      id="Fact_e84c8255687049789976ee4e945c842f"
      unitRef="U001">300000</ocup:ProceedsFromPreMergerFinancing>
    <ocup:NumberOfDirectors
      contextRef="c20200629to20200629_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact_bc80ebcff77940c0be7bc02ebb25589e"
      unitRef="U009">5</ocup:NumberOfDirectors>
    <ocup:NumberOfDirectors
      contextRef="c20200629to20200629_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact_827d4cf19e604093a31c93ae35e97042"
      unitRef="U009">1</ocup:NumberOfDirectors>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20201119_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember"
      decimals="4"
      id="Fact_49611750bce142348129a093a1f8fc6f"
      unitRef="U003">4.4795</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember"
      id="Fact_a401a326856446ca847c25f307ed9f1a">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20201119_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember"
      decimals="0"
      id="Fact_ea496e52b36048f8a0d971b1cae3ac4c"
      unitRef="U002">5665838</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputRiskFreeInterestRateMember"
      decimals="3"
      id="Fact_584c1d12d5914102a994857512fa800c"
      unitRef="U007">0.004</us-gaap:DerivativeAssetMeasurementInput>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputPriceVolatilityMember"
      decimals="3"
      id="Fact_2f19a5f82eb64ffebf42caeb360a58ae"
      unitRef="U007">0.866</us-gaap:DerivativeAssetMeasurementInput>
    <ocup:FairValueAssumptionsExpectedLife
      contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedTermMember"
      id="Fact_d8fefc8e5148412f90e120e06d26cd0d">P4Y9M18D</ocup:FairValueAssumptionsExpectedLife>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_MeasurementInputTypeAxis_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact_122c4bb2f6264cf6a732a1caf3b9ddf1"
      unitRef="U007">0</us-gaap:DerivativeAssetMeasurementInput>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_TypeOfArrangementAxis_WaiverAgreementsMember"
      decimals="-5"
      id="Fact_27521bed342943b58f5df6c5d0c5e289"
      unitRef="U001">33800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember"
      decimals="4"
      id="Fact_009a84abecde461cbbc384763f8618ab"
      unitRef="U003">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ocup:RemainingIssuableShares
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember"
      decimals="INF"
      id="Fact_154d3faab63947d0affebc4c2fc05d8e"
      unitRef="U002">0</ocup:RemainingIssuableShares>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember"
      decimals="0"
      id="Fact_e054d6e0cc1f4efb9750775778e051cb"
      unitRef="U002">17869</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20220101to20221231"
      id="Text_f4324b533615435389f491f72b1e967e">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;4.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Commitments and Contingencies&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Apexian Sublicense Agreement&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On January 21, 2020, the Company entered into a sublicense agreement with Apexian Pharmaceuticals, Inc., pursuant to which it obtained exclusive worldwide patent and
          other intellectual property rights. In exchange for the patent and other intellectual rights, the Company agreed to certain milestone payments and royalty payments on future sales (See Note 8 &#x2014; Apexian Sublicense Agreement). As of December 31,
          2022, there was sufficient uncertainty with regard to any future cash milestone payments under the sublicense agreement, and as such, no liabilities were recorded related to the sublicense agreement.&lt;/div&gt;

&lt;div&gt;&#160;
          &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Facility Leases&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has a short-term non-cancellable facility lease (the &#x201c;HQ Lease&#x201d;) for its operations and headquarters. Additionally, Ocuphire leased office space in
          Rockville, Maryland through June 30, 2021 previously occupied by Rexahn (the &#x201c;Rexahn Lease&#x201d;). The HQ Lease and the Rexahn Lease qualified for the short-term lease exception under ASC 842, Leases. The monthly base rent, as amended, for the HQ
          Lease is approximately $3,000. The monthly base rent for the Rexahn Lease was $13,000. The rent expense associated with the HQ Lease and Rexahn Lease amounted to $39,000
          and $116,000 during the years ended December 31, 2022 and 2021, respectively. The total remaining expected rental payments under
          the HQ Lease amount to $36,000 through its current expiration date of December 31, 2023.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; text-transform: none;"&gt;Issuance of Settlement Shares&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; On May 6, 2021, the Company issued 350,000 shares of common stock of the Company to three accredited investors pursuant to a settlement agreement, dated May 6, 2021, in exchange for a release of potential claims. The fair value of
            the share settlement of $1,614,000 was based on the closing Ocuphire stock price for that day. The fair value of the share settlement
            was recorded in general and administrative expenses in the accompanying consolidated statements of comprehensive income (loss).&lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In the ordinary course of business, from time to time, the Company may be subject to a broad range of claims and legal proceedings that relate to contractual
          allegations, patent infringement and other claims. In addition, the Company from time to time may be potentially committed to reimburse third parties for costs incurred associated with business development related transactions upon the
          achievement of certain milestones. The Company establishes accruals when applicable for matters and commitments which it believes losses are probable and can be reasonably estimated. To date, no loss contingency for such matters and potential
          commitments have been recorded. Although it is not possible to predict with certainty the outcome of these matters or potential commitments, the Company is of the opinion that the ultimate resolution of these matters and potential commitments
          will not have a material adverse effect on its results of operations or financial position.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ocup:OperatingLeasesMonthlyBaseRent
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_46a73dbc50aa4370a05a0fe51a291e35"
      unitRef="U001">3000</ocup:OperatingLeasesMonthlyBaseRent>
    <ocup:OperatingLeasesMonthlyBaseRent
      contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="0"
      id="Fact_2909c23e759e41cc944cd38069c5eb2a"
      unitRef="U001">13000</ocup:OperatingLeasesMonthlyBaseRent>
    <us-gaap:OperatingLeaseCost
      contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="0"
      id="Fact_acd4391f619947c89b1754ba44563897"
      unitRef="U001">39000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_5844fb5f0d184c40a5ce1dac3d8b052b"
      unitRef="U001">39000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20210101to20211231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="0"
      id="Fact_feb1801141004d87b3efcd1a9b8d3d98"
      unitRef="U001">116000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_a82916da2d47498d9980e1194b8e9a8d"
      unitRef="U001">116000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="c20221231"
      decimals="0"
      id="Fact_1316947663e44f7391a28e1586ac24e6"
      unitRef="U001">36000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210506to20210506_RelatedPartyTransactionsByRelatedPartyAxis_AccreditedInvestorMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_15bdc3ecc4fa488f853767be39ceb1ab"
      unitRef="U002">350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ocup:NumberOfAccreditedInvestors
      contextRef="c20210506"
      decimals="INF"
      id="Fact_dc3a73151a2f432990b2b32d3c61b006"
      unitRef="U010">3</ocup:NumberOfAccreditedInvestors>
    <ocup:FairValueShareSettlementAmount
      contextRef="c20210506to20210506_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RelatedPartyTransactionsByRelatedPartyAxis_AccreditedInvestorMember"
      decimals="0"
      id="Fact_313f9bf0c0854b8a9b69b069716d0f88"
      unitRef="U001">1614000</ocup:FairValueShareSettlementAmount>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="c20220101to20221231"
      id="Text_c445b60d482d4dc0b9318692297addbf">
&lt;div&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;5.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Supplemental Balance Sheet Information&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Prepaid and Other Assets&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Prepaid and other assets consist of the following (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Prepaids&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,373&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,243&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;80&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;71&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total prepaids and other assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,453&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,314&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and Equipment, net&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment held for use by category are presented in the following table (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Equipment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;20&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;20&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Furniture&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;5&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;5&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total property and equipment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;25&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;25&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Less accumulated depreciation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(19&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(15&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Property and equipment, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;6&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Depreciation expense was $4,000 during each of the
          years ended December 31, 2022 and 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accrued Expenses&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Accrued expenses consist of the following (in thousands):&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;div&gt;Income taxes&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;315&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Payroll&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;782&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;488&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Professional services&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;208&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;84&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;R&amp;amp;D services and supplies&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;212&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,081&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;167&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;80&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,684&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,733&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -27pt; margin-left: 27pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Short-Term Loan&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company entered into an unsecured short-term loan (the &#x201c;Loan&#x201d;) agreement in the amount of $0.6 million in November 2021 related to financing an insurance policy.&#160; The Loan was payable in six monthly installments of $108,000 beginning in December 2021.&#160; The Loan
            had an annual interest rate of 5.5% per annum.&#160; Interest expense in the amount of $9,000 and $2,000 was recognized in connection with the Loan
            during the years ended December 31, 2022 and 2021, respectively. The final payment on the Loan was made in May 2022.&lt;br/&gt;
          &lt;/div&gt;
</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="c20220101to20221231"
      id="Text_6da40a05a283487d9fa0af81d68d5025">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Prepaid and other assets consist of the following (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Prepaids&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,373&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,243&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;80&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;71&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total prepaids and other assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,453&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,314&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_e7dc0a3d4fdb4d6398f06fab011c03eb"
      unitRef="U001">1373000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_f6ec9f0dd0fe44dcb70ff469295e57da"
      unitRef="U001">1243000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_5ff281c9fa0348848d82df85b7ae8dfd"
      unitRef="U001">80000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_fde24924796045d89bbfa5ab3f5970b3"
      unitRef="U001">71000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_3343b59c4f2740d7977c95e320d895b9"
      unitRef="U001">1453000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_c51e28e90b2f4be0a7ae8af26f2021a9"
      unitRef="U001">1314000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20220101to20221231"
      id="Text_40d20a7209fe4f6c97e60e04992cba96">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment held for use by category are presented in the following table (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Equipment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;20&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;20&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Furniture&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;5&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;5&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total property and equipment&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;25&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;25&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Less accumulated depreciation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(19&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;(15&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Property and equipment, net&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;6&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;10&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"
      decimals="-3"
      id="Fact_cf9a385737ac4fc4a898f5834f69b236"
      unitRef="U001">20000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember"
      decimals="-3"
      id="Fact_127bf8cb31454abbb5d9a5ca187f7452"
      unitRef="U001">20000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_d622f9340ab04b418a207467af0ec1f6"
      unitRef="U001">5000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20211231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_c7f26d35f6f140e19a1e34cfe9bcf46f"
      unitRef="U001">5000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231"
      decimals="-3"
      id="Fact_06da0c0eac7a40b2aae3e0925cca4430"
      unitRef="U001">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20211231"
      decimals="-3"
      id="Fact_74d1ab19ad6545ceacc349506c654908"
      unitRef="U001">25000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20221231"
      decimals="-3"
      id="Fact_28200a2975b54ac98bee880e049dfa65"
      unitRef="U001">19000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ac57ff1e94604dc6bb865dfe574c5e4e"
      unitRef="U001">15000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20221231"
      decimals="-3"
      id="Fact_8731bb59e67749fdbcb3a533d808e250"
      unitRef="U001">6000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20211231"
      decimals="-3"
      id="Fact_b79d4619d45c4991befb7f1187e7382e"
      unitRef="U001">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_8087a9de95334730858fa497827ed648"
      unitRef="U001">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_d301e02165304b92815539f7145c56e8"
      unitRef="U001">4000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_94cbc1daf51a44dc9149b8fdf8dc4c21">
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Accrued expenses consist of the following (in thousands):&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div&gt;
                    &lt;div&gt;Income taxes&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;315&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Payroll&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;782&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;488&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Professional services&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;208&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;84&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;R&amp;amp;D services and supplies&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;212&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,081&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;167&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;80&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Total&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,684&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,733&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:TaxesPayableCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_3fd79259409241c497ce2fc0417cc137"
      unitRef="U001">315000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_52cc192e8e314eb3818a37705a83addb"
      unitRef="U001">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_5890481403094ff1a7c480ec0ea32810"
      unitRef="U001">782000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_ceb39b8bb1f8405f8a796a2e046added"
      unitRef="U001">488000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_705faaa93edc42e4bc37781f185123ce"
      unitRef="U001">208000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_e454e388033a4429a3e9146ac31cc93f"
      unitRef="U001">84000</us-gaap:AccruedProfessionalFeesCurrent>
    <ocup:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_8af833c7ea8a46ef9c91c3033ca8dc8f"
      unitRef="U001">212000</ocup:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent>
    <ocup:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_017ff32a08d747808ba3443021a878e8"
      unitRef="U001">1081000</ocup:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_cc11575681d9456cb5f70b1baad7925b"
      unitRef="U001">167000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_4316811ea0b545deb9f2c054f15ea794"
      unitRef="U001">80000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="-3"
      id="Fact_3adfaff6ad2444b8963b9016a710947d"
      unitRef="U001">1684000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20211231"
      decimals="-3"
      id="Fact_02dda446576d474d94d2815c4d6a8dc0"
      unitRef="U001">1733000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="c20211130"
      decimals="-5"
      id="Fact_233ec4e5a2964773b697f3557c2c2a9c"
      unitRef="U001">600000</us-gaap:ShortTermBorrowings>
    <ocup:DebtInstrumentNumberOfInstallments
      contextRef="c20220101to20221231"
      decimals="INF"
      id="Fact_17542d96b95c480895d198fa4c23d644"
      unitRef="U011">6</ocup:DebtInstrumentNumberOfInstallments>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="c20210101to20211231_DebtInstrumentAxis_ShortTermLoanMember"
      decimals="0"
      id="Fact_e0bc5faa70834530b5bd2d2cc7d994b3"
      unitRef="U001">108000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate
      contextRef="c20221231"
      decimals="3"
      id="Fact_9326f12e65ec4f6290ac9ede48df269e"
      unitRef="U007">0.055</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:InterestExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_809f1e6702ec4a8fa9491c2282f51333"
      unitRef="U001">9000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_d03d1edff1be45059769ae38dc793d48"
      unitRef="U001">2000</us-gaap:InterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="c20220101to20221231"
      id="Text_44f1238d532f43e0b9bdbb44d3eb273c">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;6.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Related Party Transactions&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Pre-Merger Financing and Waiver Agreements&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Five directors of Ocuphire Pharma, Inc., prior to the
          Merger, and one director of Rexahn participated in the Pre-Merger Financing, investing an aggregate of $300,000.&#160; Following the closing of the Merger, these directors received 17,729 converted initial shares of common stock, 53,189
          converted shares of additional common stock, 80,366 Series A Warrants and 9,444 Series B Warrants. In connection with the Pre-Merger Financing, six
          directors of the Company signed Waiver Agreements, waiving certain reset provisions and financing restrictions. These directors did not receive any of the additional Series B Warrants that were issued in connection with the Waiver Agreements. See
          Note 3 &#x2013; Pre-Merger Financing.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Other&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On April 8, 2022, Ocuphire entered into a consulting agreement with a director of the Company. The consulting agreement provided for $10,000 a month in cash payments, effective as of April 1, 2022. Additionally, on April 8, 2022, in connection with the consulting arrangement, the
          director received a stock option grant for 50,000 options, 25% of which will vest on March 31, 2023, with the remainder vesting in equal monthly installments over 36 months. The consulting agreement was amended on September 19, 2022 to provide for vesting acceleration for stock-based awards in the event of a change in control. The
          consulting agreement was also amended effective December 1, 2022 to increase the cash payment to $25,000 per month. The Company
          incurred related consulting expenses of $105,000 during the year ended December 31, 2022. There were no related consulting expenses incurred during the year ended December 31, 2021. As of December 31, 2022, $25,000 of the related consulting expenses were unpaid.&lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <ocup:NumberOfDirectors
      contextRef="c20220101to20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember"
      decimals="INF"
      id="Fact_a706f4c55dfb473f9d7f9f526287ca39"
      unitRef="U009">5</ocup:NumberOfDirectors>
    <ocup:NumberOfDirectors
      contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember_RelatedPartyTransactionAxis_PreMergerFinancingMember"
      decimals="INF"
      id="Fact_45fc4f3d616f45acae1282676cbc827b"
      unitRef="U009">1</ocup:NumberOfDirectors>
    <ocup:AmountInvestedInPreMergerFinancing
      contextRef="c20220101to20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember"
      decimals="0"
      id="Fact_f899f8a7462049709790fc6ae64fdf60"
      unitRef="U001">300000</ocup:AmountInvestedInPreMergerFinancing>
    <ocup:NumberOfConvertedInitialSharesReceivedByDirectors
      contextRef="c20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember"
      decimals="0"
      id="Fact_99018ed311e0466fa9e326b1e553a9bf"
      unitRef="U002">17729</ocup:NumberOfConvertedInitialSharesReceivedByDirectors>
    <ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors
      contextRef="c20221231_RelatedPartyTransactionAxis_PreMergerFinancingMember"
      decimals="0"
      id="Fact_766c92a3ddae4a5e94a89ab2ea5d9e5d"
      unitRef="U002">53189</ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors>
    <ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesAWarrantsMember_RelatedPartyTransactionAxis_PreMergerFinancingMember"
      decimals="0"
      id="Fact_0a8367f74dca456fb01448716b5c3531"
      unitRef="U002">80366</ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors>
    <ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors
      contextRef="c20221231_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember_RelatedPartyTransactionAxis_PreMergerFinancingMember"
      decimals="0"
      id="Fact_1cac354f7de64a9387c733a6723b3a28"
      unitRef="U002">9444</ocup:NumberOfConvertedAdditionalSharesReceivedByDirectors>
    <ocup:NumberOfDirectorsSignedWaiverAgreements
      contextRef="c20220101to20221231"
      decimals="INF"
      id="Fact_881e475e5f574135b03e2d116c42c09b"
      unitRef="U009">6</ocup:NumberOfDirectorsSignedWaiverAgreements>
    <ocup:ConsultingFeePayable
      contextRef="c20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="0"
      id="Fact_b0beb34095d9464db10c9dd6b51d2922"
      unitRef="U001">10000</ocup:ConsultingFeePayable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220408to20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="0"
      id="Fact_ce7869d0541d425da4740cf3c05ec67a"
      unitRef="U002">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c20220408to20220408_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="Fact_3fb60a4c5a524b3aa43667a57d06e696"
      unitRef="U007">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20220101to20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      id="Fact_019ea7690f904aa8b4080c76ad1e45b2">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ocup:ConsultingFeePayable
      contextRef="c20221201"
      decimals="0"
      id="Fact_3b26b3e88fa8471199a2ba48901e2768"
      unitRef="U001">25000</ocup:ConsultingFeePayable>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="c20220101to20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="0"
      id="Fact_eb3c7497c1714179bcdbe77dc8aa9f7d"
      unitRef="U001">105000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="c20210101to20211231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="0"
      id="Fact_62f4bf6f16da42dc9d120bcad5660aba"
      unitRef="U001">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="c20221231_RelatedPartyTransactionsByRelatedPartyAxis_DirectorMember"
      decimals="0"
      id="Fact_e762d2abeb2149b0ad6369bea7ddc4e1"
      unitRef="U001">25000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20220101to20221231"
      id="Text_e19d84f56a1547d1939fe9ec7bb5720d">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;7.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Stock-based Compensation&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of
          comprehensive income (loss) for the periods indicated below (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;General and administrative&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,060&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,116&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;747&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;798&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total stock-based compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,807&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,914&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Ocuphire Stock Options&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); font-variant: normal; text-transform: none;"&gt;Inducement Plan&lt;/div&gt;

&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;On February 22,
              2021, the Company adopted the Ocuphire Pharma, Inc. 2021 Inducement Plan (the &#x201c;Inducement Plan&#x201d;), pursuant to which the Company reserved 325,258
              shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&#x2019;s entry into employment with the Company within
              the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2020 Equity Incentive Plan&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;In November 2020, the stockholders of the Company approved the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) for stock-based awards. Under the 2020 Plan, (i) 1,000,000 new shares of common stock were reserved for issuance and (ii) up to 70,325 additional shares of common stock may be issued, consisting of (A) shares that remain available for the issuance of awards under prior equity plans and (B) shares of
          common stock subject to outstanding stock options or other awards covered by prior equity plans that have been cancelled or expire on or after the date that the 2020 Plan became effective. Under the 2020 Plan, the shares reserved automatically
          increase on January 1 of each year, for a period of not more than ten years from the date the 2020 Plan is approved by the
          stockholders of the Company, commencing on January 1, 2021 and ending on (and including) January 1, 2030, by an amount equal to 5% of
          the shares of common stock outstanding as of December 31st of the preceding calendar year. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The 2020 Plan permits the grant of incentive and nonstatutory stock options, appreciation rights, restricted stock, restricted stock units, performance stock and cash awards, and other
            stock-based awards&lt;/span&gt;.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2018 Equity Incentive Plan&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Prior to the 2020 Plan, the Company had adopted a 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) in April 2018 under which 1,175,000 shares of the Company&#x2019;s common stock were reserved for issuance to employees, directors and consultants. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Upon the effective date of the 2020 Plan,&#160;no additional shares were available for issuance under the 2018 Plan&lt;/span&gt;.&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;General&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the years ended December 31, 2022 and 2021, 893,305
            and 420,300 stock options were granted to officers, directors, employees and consultants, respectively, generally vesting over a
            five (5) to forty-eight (48)
            month period. The Company recognized $1.7 million and $1.8 million in stock-based compensation expense related to stock options during the years ended December 31, 2022 and 2021, respectively. During the years ended December 31, 2022 and 2021, 24,309 and 73,442 stock options were
            exercised, respectively, with an intrinsic value of $59,000 and $345,000, respectively. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The following table summarizes the Company&#x2019;s stock option plan activity:&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Term (years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Aggregate&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Intrinsic&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Outstanding at December 31, 2020&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,784,198&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.17&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8.87&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,744&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;420,300&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.72&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(73,442&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(34,220&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Outstanding at December 31, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,096,836&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.97&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8.20&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,795&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;893,305&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.64&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(24,309&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.09&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(29,788&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6.21&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Outstanding at December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,936,044&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.87&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7.82&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,314&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;Vested and expected to vest at December 31, 2022&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;2,936,044&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;2.87&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;7.82&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;3,314&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Vested and exercisable at December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,723,792&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.56&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7.07&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,680&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top;"&gt;&lt;sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"&gt;(1)&lt;/sup&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and
                  the fair value of our common stock as of December 31, 2022 and 2021 of $3.53 and $3.73 per share, respectively.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The weighted average
          fair value per share of options granted during the years ended December 31, 2022 and 2021 was $2.06 and $4.36, respectively. The Company measures the fair value of stock options with service-based vesting criteria to employees, directors, consultants and
          directors on the date of grant using the Black-Scholes option pricing model. The Company does not have adequate history to support an internal calculation of volatility and expected term. As such, the Company has used a weighted average
          volatility considering the volatilities of several guideline companies.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;For purposes of
            identifying similar entities (guideline companies), the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The average expected life of the options was based on the contractual term for
            agreements that allow for exercise of vested options through the end of the contractual term upon termination of continuous service, and for all other agreements, was based on the mid&#x2011;point between the vesting date and the end of the
            contractual term according to the &#x201c;simplified method&#x201d; as described in Staff Accounting Bulletin 110. The risk&#x2011;free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to
            the expected life assumed at the date of grant. The Company records forfeitures when they occur. The assumed dividend yield was based on the Company&#x2019;s expectation of not paying dividends in the foreseeable future.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The weighted average assumptions used in the Black-Scholes option pricing model are as follows during the years ended December 31, 2022 and 2021:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Expected stock price volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;97.4&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;98.1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Expected life of options (years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.8&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;5.8&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Expected dividend yield&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Risk free interest rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;2.3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;0.9&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the years ended December 31, 2022 and 2021, 488,621
          and 468,301 stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended
          December 31, 2022 and 2021 was $3.29 and $3.49,
          respectively. During the years ended December 31, 2022 and 2021, 29,788 and 34,220 stock options were forfeited, respectively. As of December 31, 2022, 894,920
          shares in the aggregate were available for future issuance under the 2020 Plan and Inducement Plan.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Unrecognized stock-based compensation cost was $2.6
          million as of December 31, 2022. The unrecognized stock-based expense is expected to be recognized over a weighted average period of 1.2
          years.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Restricted Stock Awards&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On November 11, 2020, the Company granted 40,000
          restricted stock awards (&#x201c;RSAs&#x201d;) that vested on January 8, 2021. There were no RSAs granted during the years ended December 31,
          2022 or 2021.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The stock-based compensation expense attributed to the RSAs during each of the years ended December 31, 2022 and 2021 was $0 and $22,000, respectively.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;A summary of RSA activity is as follows for the year ended December 31, 2021:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Non-vested at December 31, 2020&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Vested&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;(40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Non-vested at December 31, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"&gt;Common Stock Issued
            for Services &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company granted
            common stock for services in the amount of 74,396 and 21,414 shares of common stock during the years ended December 31, 2022 and 2021, respectively, to four and two board members during those periods, respectively, who elected
            to receive their board retainers in the form of stock for services. The stock-based compensation related to these services amounted to $154,000
            and $108,000 during the years ended December 31, 2022 and 2021, respectively.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Former Rexahn Options&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Following the closing of the Merger, 123
              unexercised and vested options to purchase common stock granted under the Rexahn Pharmaceuticals Stock Option Plan, as amended (the&#160;&#x201c;Rexahn 2003 Plan&#x201d;, and together with the Rexahn 2013 Plan, the&#160;&#x201c;Prior Plans&#x201d;) were outstanding. As of
              December 31, 2022, none of the former Rexahn options remained outstanding under the Prior Plans. During the year ended December
              31, 2022, 82 of the former Rexahn options expired.&lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20220101to20221231"
      id="Text_ce369da47f764472a9af8d3eda0756be">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of
          comprehensive income (loss) for the periods indicated below (in thousands):&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31,&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;General and administrative&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,060&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,116&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;747&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;798&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total stock-based compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,807&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,914&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_8b943d13dfa940868cb908f32877b9e6"
      unitRef="U001">1060000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20211231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_137d8bf287744ab48ab5bd0b1ff6f7a8"
      unitRef="U001">1116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_1e6c431043334c8eb5820a884c4aaf06"
      unitRef="U001">747000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20211231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_f3d8e5be876d471c9df99ca1b4a4afd7"
      unitRef="U001">798000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_c3922fd56ae64e09a033fc113173345a"
      unitRef="U001">1807000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_371536f81dea451b8e09885eec615e28"
      unitRef="U001">1914000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20210222_PlanNameAxis_InducementPlanMember"
      decimals="0"
      id="Fact_e2caa4dd44204418a61e1dd8ef9b081c"
      unitRef="U002">325258</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201130_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_0177a438720640cc996bb5dd8e48b2de"
      unitRef="U002">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20201130_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_e2d0eb0082dc494dab58645dc35f50d5"
      unitRef="U002">70325</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ocup:MaximumPeriodOfSharesReservedUnderPlan
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2020Member_RangeAxis_MaximumMember"
      id="Fact_e78c4edaf47748c2aead983c3cf3a479">P10Y</ocup:MaximumPeriodOfSharesReservedUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="2"
      id="Fact_61cf147c1ab24b0b8af40b0e50430abc"
      unitRef="U007">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_6511eebb48854fbaa5d7c0a2615dc988"
      unitRef="U002">1175000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="INF"
      id="Fact_3b126692b99347929e7e73aa2cb486f6"
      unitRef="U002">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_f235835d35c34424abe11fdcc9219914"
      unitRef="U002">893305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_0d0112bb2a5f4436b55d15ab592b9f90"
      unitRef="U002">420300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MinimumMember"
      id="Fact_79effd737e7d4eef9a7e7c2b2264c471">P5M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member_RangeAxis_MaximumMember"
      id="Fact_ca3379e32e974777a3752763d24b401b">P48M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-5"
      id="Fact_f09d06155d484070b4e5c10553f73bcb"
      unitRef="U001">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-5"
      id="Fact_9e487174aa5d4959af17a1be7fd64e65"
      unitRef="U001">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_c83979174d334614b845657778200395"
      unitRef="U002">24309</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_addc35c7d4ba4cb986325820398fa7a9"
      unitRef="U002">73442</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_85f244f3c97d4a05a6289e5cf5df707a"
      unitRef="U001">59000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20211231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_4a58fc8f7dcc490aa2be4d0626bfe6c7"
      unitRef="U001">345000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_28c984ccdc3e482885c0eb9898e76a28">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The following table summarizes the Company&#x2019;s stock option plan activity:&lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Price&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted Average&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Remaining&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Contractual&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Term (years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Aggregate&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Intrinsic&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Outstanding at December 31, 2020&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,784,198&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.17&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8.87&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,744&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;420,300&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.72&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(73,442&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(34,220&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Outstanding at December 31, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,096,836&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.97&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;8.20&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,795&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;893,305&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.64&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Exercised&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(24,309&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1.09&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Forfeited/Cancelled&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(29,788&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6.21&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"/&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Outstanding at December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,936,044&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.87&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7.82&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,314&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;" valign="bottom"&gt;Vested and expected to vest at December 31, 2022&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;2,936,044&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;2.87&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;7.82&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;3,314&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div&gt;Vested and exercisable at December 31, 2022&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,723,792&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2.56&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7.07&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;1,680&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 36pt; vertical-align: top;"&gt;&lt;sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"&gt;(1)&lt;/sup&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and
                  the fair value of our common stock as of December 31, 2022 and 2021 of $3.53 and $3.73 per share, respectively.&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_c30c6dd73c134f9994b04485ef6537ca"
      unitRef="U002">1784198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_0aa796396746408984faac57074c5b53"
      unitRef="U003">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20200101to20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_4756c611fd67476e95db364b85cf9118">P8Y10M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20201231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_46b97527dae540aca27bf64658108ec9"
      unitRef="U001">7744000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_8bd0c8e2fe6f4b1597b5dbe0afa12abc"
      unitRef="U002">420300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_26c8c403726b4957b667e2d61db5ac43"
      unitRef="U003">5.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_f17a79f80ac44063b1b7bc8525d3cff3"
      unitRef="U002">73442</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_51e765073d0a4bc68b2d3b82c48b94ea"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_4b543b09362349e092a6f1064a38188f"
      unitRef="U002">34220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_5c4d73b060ee47b38856658a3ff51580"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_fd4990cf3ffd4772962701b198f88822"
      unitRef="U002">2096836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_3428813e05454c1bae3d055ef6421683"
      unitRef="U003">2.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_213a3daea95546e0923248e62dc502ab">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_3cfe8fa586b34f52a55e354dc7fa3bb7"
      unitRef="U001">2795000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_1ae669ee470d4b7197d985e7828f539d"
      unitRef="U002">893305</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_a7bc92342f62424486235cb4a1598ddc"
      unitRef="U003">2.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_a8d96e33bf0b48b49c07e07f47501d17"
      unitRef="U002">24309</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_cbc5203c9cd54ca6ad629659db5ecfe1"
      unitRef="U003">1.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_a4dfb84f1a014332a4f191b2392ac384"
      unitRef="U002">29788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_bfb9b8dcf9f840d883264db0dbb9f1d0"
      unitRef="U003">6.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_d7acd6cdacfd46f29f47044cb4ed156d"
      unitRef="U002">2936044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_1bfe52cfc35e4e34a5e74c3b4bcb01eb"
      unitRef="U003">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_288bae3959fa4e9ab975217b37b74fd9">P7Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_37c7f8e7261c4c0ea247d23587c35f7a"
      unitRef="U001">3314000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_5e8c37a9a5894c428a8c698f7b0bcfa8"
      unitRef="U002">2936044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_9f8a65c280ed4874b376de2e6036e583"
      unitRef="U003">2.87</ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice>
    <ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_8df741c91b5c4665b228503aaaffb3c7">P7Y9M25D</ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm>
    <ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_4ced063294be4461a959db5d39a759cf"
      unitRef="U001">3314000</ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue>
    <ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_f952b6aa6fe94d10a38cb0363e59b400"
      unitRef="U002">1723792</ocup:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_c4e2e8004813494cad4a03b664c0d31d"
      unitRef="U003">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_33c9f80574b9448eb3947ece1b0b9514">P7Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-3"
      id="Fact_2e21a6a36c364fdba0d8dc06ccade1de"
      unitRef="U001">1680000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_155f4d69648a48edb7d4b1e426b649e3"
      unitRef="U003">3.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_b8e48a7bee99487b9af8787da75af04d"
      unitRef="U003">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_7fee624f3917421783cc39ac611086d9"
      unitRef="U003">2.06</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c20210101to20211231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_bda0a7e2611746a8a1a3b2766ae87dc2"
      unitRef="U003">4.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_416d0ff8b902480f84750f2d3ed8b433">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The weighted average assumptions used in the Black-Scholes option pricing model are as follows during the years ended December 31, 2022 and 2021:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: middle; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt; 2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Expected stock price volatility&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;97.4&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;98.1&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Expected life of options (years)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;5.8&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;5.8&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Expected dividend yield&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;0&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: middle; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Risk free interest rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;2.3&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;0.9&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;%&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="3"
      id="Fact_7019c0240be447d085c3f6fd0d8efd10"
      unitRef="U007">0.974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="3"
      id="Fact_ba110d49eecd4072936192ab9f681898"
      unitRef="U007">0.981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_3507cf65de6142f5b3780a940797b9a9">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_a2e7e64447da4fc1b4ad08a953fd1fac">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_10652bd0686446048a83e644a49bfcd9"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_59d78bbed1614928b52ff313154a1567"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="3"
      id="Fact_d476bce210a841e08e0ea7774a3aeb9e"
      unitRef="U007">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="3"
      id="Fact_098be008da944828879e2fc262c4372a"
      unitRef="U007">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_5d7a4bb747fb4e42aebe1813998c363e"
      unitRef="U002">488621</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_967e39bffe874c37a8e3e5e3449c59af"
      unitRef="U002">468301</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_1239b7e2414449a49ae3d4754413a2de"
      unitRef="U003">3.29</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="2"
      id="Fact_8060c494397a4f929e159c789afc6acf"
      unitRef="U003">3.49</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_1e89e3f0312144c399a0ff4de2897486"
      unitRef="U002">29788</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="c20210101to20211231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="0"
      id="Fact_dcaec75bd422438388d811e183f2288b"
      unitRef="U002">34220</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <ocup:CommonStockCapitalSharesAvailableForFutureIssuance
      contextRef="c20221231_PlanNameAxis_InducementPlanMember"
      decimals="0"
      id="Fact_5b1cc856134c4f8cbc904172a6ad20b7"
      unitRef="U002">894920</ocup:CommonStockCapitalSharesAvailableForFutureIssuance>
    <ocup:CommonStockCapitalSharesAvailableForFutureIssuance
      contextRef="c20221231_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_0fd6d528b1054bc58606c0af0c66c2dc"
      unitRef="U002">894920</ocup:CommonStockCapitalSharesAvailableForFutureIssuance>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      decimals="-5"
      id="Fact_6e2d4625b8874670bcda4fb37d53bfe2"
      unitRef="U001">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20220101to20221231_PlanNameAxis_EquityIncentivePlan2018Member"
      id="Fact_8b487cba5cfa48a2accfc0a5f786607b">P1Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20201111to20201111_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_150dd139817f49cc8b7bcbd0666fbdd9"
      unitRef="U002">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember"
      decimals="INF"
      id="Fact_e29efb79e92446dc93016fd12288eb40"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockMember"
      decimals="INF"
      id="Fact_a1c565d0dd9643c58cb6f2ccd68a6ed3"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_4a14ec592bb94e838795f7973d6349bf"
      unitRef="U001">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_7ea84af383b14814964e99aeec87742b"
      unitRef="U001">22000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_ace1c54d93bf432388e0694dd9356ffd">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;A summary of RSA activity is as follows for the year ended December 31, 2021:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Number of&lt;/div&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Non-vested at December 31, 2020&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Granted&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Vested&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;(40,000&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;Non-vested at December 31, 2021&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20201231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_522c8cf81a4e48478638d9112d022ec0"
      unitRef="U002">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember"
      decimals="INF"
      id="Fact_2b7ff9a033fc4182a65424fcbcb035e9"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20210101to20211231_AwardTypeAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_794af1b256ce40b98309235a1dd9fe78"
      unitRef="U002">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20211231_AwardTypeAxis_RestrictedStockMember"
      decimals="INF"
      id="Fact_b21fbb1eaf56464594bfb76fe64a9d51"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_0dc0850aa5624d119613a7fadb7ade81"
      unitRef="U002">74396</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_095696f1357e4a438e4a7d736586c2f5"
      unitRef="U002">21414</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <ocup:NumberOfBoardMembersGrantedStockForServices
      contextRef="c20220101to20221231"
      decimals="INF"
      id="Fact_7fc25f2f627c4bffa598e8c97318dbb4"
      unitRef="U012">4</ocup:NumberOfBoardMembersGrantedStockForServices>
    <ocup:NumberOfBoardMembersGrantedStockForServices
      contextRef="c20210101to20211231"
      decimals="INF"
      id="Fact_a202e25fa9584acb8bce03347b8bc297"
      unitRef="U012">2</ocup:NumberOfBoardMembersGrantedStockForServices>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_7429844d5d9448c5be772fab97526d73"
      unitRef="U001">154000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_6c2c307dc6d3416ea8ac39ad630cdc9c"
      unitRef="U001">108000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20211231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="0"
      id="Fact_9cf644ff0ce848aa8f5aad98380a1332"
      unitRef="U002">123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="INF"
      id="Fact_a3cd9498ad7e4d0596bbe2438844954b"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="0"
      id="Fact_d6a6ea9d3cf8465580021657d821a242"
      unitRef="U002">82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <ocup:ApexianSublicenseAgreementTextBlock
      contextRef="c20220101to20221231"
      id="Text_2074a37595f94f3fb91cf9d3e70aaa8f">
&lt;div&gt;  &lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Apexian Sublicense Agreement&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On January 21, 2020, as amended on June 4,
          2020, the Company entered into a sublicense agreement (the &#x201c;Sublicense Agreement&#x201d;) with Apexian, pursuant to which it obtained exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to
          therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions. The lead compound in the Ref-1 Inhibitor program is APX3330, which the Company intends to develop as an oral pill therapeutic to treat diabetic
          retinopathy and diabetic macular edema initially, and potentially later to treat wet age-related macular degeneration.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company agreed to
          make one-time milestone payments under the Sublicense Agreement for each of the first ophthalmic indication and the first diabetes mellitus indication for the Development and Regulatory milestones, and once for each of the Sales milestones. These
          milestone payments include (i) payments for specified developmental and regulatory milestones (including completion of the first Phase 2 trial that meets a primary endpoint and the first Phase 3 pivotal trial in the United States, and filing and
          achieving regulatory approval from the FDA for the first New Drug Application for a compound) totaling up to $11 million in the
          aggregate and (ii) payments for specified sales milestones of up to $20 million in the aggregate, which net sales milestone payments
          are payable once, upon the first achievement of such milestone. Lastly, the Company also agreed to make a royalty payment equal to a single-digit percentage of its net sales of products associated with the covered patents under the Sublicense
          Agreement. If it is not terminated pursuant to its terms, the Sublicense Agreement shall remain in effect until expiration of the last to expire of the covered patents.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;None of the milestone
          or royalty payments, were triggered or deemed probable as of December 31, 2022.&lt;/div&gt;
</ocup:ApexianSublicenseAgreementTextBlock>
    <ocup:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentAndRegulatoryMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember"
      decimals="-6"
      id="Fact_7a4ebca61ea84e7baa3c62d6362728f4"
      unitRef="U001">11000000</ocup:FutureMilestoneMethodRevenueNotRecognized>
    <ocup:FutureMilestoneMethodRevenueNotRecognized
      contextRef="c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_SalesMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember"
      decimals="-6"
      id="Fact_4c62d27f43cf4789ba2e8e05f9962bac"
      unitRef="U001">20000000</ocup:FutureMilestoneMethodRevenueNotRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20220101to20221231"
      id="Text_60b313f530e24d9eb46ede39723c428e">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;9.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Stockholder Equity&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; background-color: rgb(255, 255, 255); font-style: italic; font-variant: normal; text-transform: none;"&gt;At-The-Market
              Program&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;On February 4, 2021, Ocuphire filed a Form S-3 shelf registration under the Securities Act of 1933 which was declared effective by the SEC on February 12,&#160;2021 (the &#x201c;2021 Shelf&#x201d;) under which the
                Company may offer and sell, from time to time in its sole discretion, securities having an aggregate offering price of up to $125
                million. In connection with the 2021 Shelf, on March 11,&#160;2021, Ocuphire entered into a sales agreement with JonesTrading Institutional Services LLC (&#x201c;JonesTrading&#x201d;) under which the Company may offer and sell, from time to time at its sole
                discretion, to or through JonesTrading, acting as agent and/or principal, shares of its common stock having an aggregate offering price of up to $40
                million (the &#x201c;ATM&#x201d;). During the years ended December 31,&#160;2022 and 2021, 1,848,980 and &lt;/span&gt;2,778,890&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; shares of common stock were sold under the ATM for aggregate gross proceeds in the amount of $4.4 million and $13.5 million, respectively, before
                deducting issuance expenses, including the placement agent&#x2019;s fees, legal and accounting expenses, in the amount of $133,000 and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;"&gt;Registered Direct Offering&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 4,&#160;2021, the Company entered into a placement agency agreement for a registered direct offering (&#x201c;RDO&#x201d;) with A.G.P./Alliance Global Partners (&#x201c;AGP&#x201d;). Pursuant to the terms of the
                placement agency agreement, AGP on June 8,&#160;2021 sold an aggregate of &lt;/span&gt;3,076,923&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; shares of the Company&#x2019;s common stock and warrants to purchase &lt;/span&gt;1,538,461&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; shares of the Company&#x2019;s common stock (the &#x201c;RDO Warrants&#x201d;) at an offering price of $4.875 per one share and &lt;/span&gt;0.50&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; RDO Warrants, for gross proceeds of approximately $15.0 million, before AGP&#x2019;s fees and related offering expenses in the amount of approximately $1.1 million. &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The proceeds were allocated between the relative fair values of common stock and warrants at the sale date. The purchase agreement contains customary representations, warranties and agreements by the
                Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions. The RDO&#160; was made pursuant to the Company&#x2019;s 2021 shelf registration.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;The RDO Warrants have an exercise price of $6.09 per share, are exercisable from the
                initial issuance date of June 8,&#160;2021, and will expire &lt;/span&gt;five years&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; following the initial issuance date. As of December 31,&#160;2022, &lt;/span&gt;1,538,461&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; RDO Warrants were outstanding.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-family: 'Times New Roman';"&gt;Subject to limited
                exceptions, a holder of a RDO Warrant will not have the right to exercise any portion of its RDO Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of a holder prior to the date of issuance, 9.99%)
                of the number of shares of the Company&#x2019;s common stock outstanding immediately after giving effect to such exercise; provided, however, that upon prior notice to the Company, the holder may increase or decrease the beneficial ownership
                limitation, provided further that in no event shall the beneficial ownership limitation exceed 9.99%.&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210212to20210212_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ShelfRegistrationMember"
      decimals="-6"
      id="Fact_87dc7453a26242e89235234264c82100"
      unitRef="U001">125000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210311to20210311_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-6"
      id="Fact_355a0d916e4c4fc78f6f1d315ab8a8ae"
      unitRef="U001">40000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20220101to20221231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="0"
      id="Fact_959a628e896b4c5799b2b75a806e3be8"
      unitRef="U002">1848980</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210101to20211231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="0"
      id="Fact_d604b8ea295c487dbd6d373ef5c9cb59"
      unitRef="U002">2778890</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20220101to20221231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_f4be0caa3cba4114b7ebb87fc0fd126e"
      unitRef="U001">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210101to20211231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_7f2cae5c954f426a8ba218356cc553e8"
      unitRef="U001">13500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20220101to20221231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="0"
      id="Fact_1a6c6ec10bfa43c4a6c03d39fbfeee8d"
      unitRef="U001">133000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20210101to20211231_SubsidiarySaleOfStockAxis_AtTheMarketProgramMember"
      decimals="-5"
      id="Fact_8f4ef4defb394fae9d92cb398d80d2fc"
      unitRef="U001">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20210608to20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_aa2856fbac4a4a4da7e9cc59b02ef4da"
      unitRef="U002">3076923</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_120f2bcc68e24f65b7f757e4043924e3"
      unitRef="U002">1538461</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ocup:StockSoldPricePerShare
      contextRef="c20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="3"
      id="Fact_879be5e604aa45079fddc709ba342521"
      unitRef="U003">4.875</ocup:StockSoldPricePerShare>
    <ocup:StockSoldPricePerShare
      contextRef="c20210608_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="2"
      id="Fact_a0aefcbdc9664962b957bc66c762cb84"
      unitRef="U003">0.5</ocup:StockSoldPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20210608to20210608_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="-5"
      id="Fact_0ddcd0ec321e4b9a9d7114943e95df71"
      unitRef="U001">15000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20210608to20210608_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="-5"
      id="Fact_e5b811d7ecf2475b8048055af73e3e47"
      unitRef="U001">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20210608_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="2"
      id="Fact_0b81eb6ab0c244dabba28e6ca7c78323"
      unitRef="U003">6.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="c20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      id="Fact_f7547903f1cb43ba8caecc1b0341b740">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="0"
      id="Fact_ffa20a9e3b0e4879b04d8fa734966760"
      unitRef="U002">1538461</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ocup:MinimumPercentageOfBeneficialOwnership
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="4"
      id="Fact_f16bb2dd0c17425e842ed74782a70913"
      unitRef="U007">0.0499</ocup:MinimumPercentageOfBeneficialOwnership>
    <ocup:MaximumPercentageOfBeneficialOwnershipLimitation
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="4"
      id="Fact_a3be6244d18a473884b0bd7246fbc110"
      unitRef="U007">0.0999</ocup:MaximumPercentageOfBeneficialOwnershipLimitation>
    <ocup:MaximumPercentageOfBeneficialOwnershipLimitation
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_WarrantMember_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember"
      decimals="4"
      id="Fact_2927aab3dd724f2d86dcab1a67297d05"
      unitRef="U007">0.0999</ocup:MaximumPercentageOfBeneficialOwnershipLimitation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="c20220101to20221231"
      id="Text_b2bdb8e0cda94547911aa84e669ba94b">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-weight: bold;"&gt;10. License and Collaboration Agreements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Nyxol&#160; License Agreement&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;On November 6, 2022, the Company entered into the Nyxol License Agreement, pursuant to which it granted Famy an exclusive, perpetual, sub-licensable
          license to develop, manufacture, import, export and commercialize (i) Nyxol for treating (a) reversal of mydriasis, (b) night vision disturbances or dim light vision, and (c) presbyopia, and (ii) Nyxol and low dose pilocarpine for treating
          presbyopia (together, the &#x201c;Nyxol Products&#x201d;) worldwide except for certain countries and jurisdictions in Asia (the &#x201c;Viatris Territory&#x201d;). The Company retains the exclusive right to develop, manufacture, have manufactured, import, export and
          commercialize the Product outside of the Viatris Territory.&#160; In 2023, Famy was acquired by Viatris Inc., and Viatris has assumed all of Famy&#x2019;s obligations under the Nyxol License Agreement.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the terms of the Nyxol License Agreement, the Company will develop the Nyxol Products in the United States in partnership with Viatris, and
              Viatris will be responsible for developing the Nyxol Products in countries and jurisdictions in the Viatris Territory outside of the United States.&#160;Viatris will reimburse the Company for budgeted costs related to the development of the Nyxol
              Products through FDA approval. The parties established a joint steering committee, which oversees and makes decisions regarding the development of the Nyxol Products. The committee is composed of an equal number of representatives of Viatris
              and Ocuphire. Viatris will commercialize the Nyxol Products in the Viatris Territory for each indication that receives regulatory approval.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Pursuant to the Nyxol License Agreement, the Company received a one-time non-refundable cash payment of $35 million in November 2022 for the exclusive, perpetual, sub-licensable license to develop, manufacture, import, export and commercialize the Nyxol Products in the Viatris
          Territory. In addition, with respect to each Nyxol Product, the Company will be eligible to receive potential additional payments of up to $130
          million in the aggregate upon achieving certain specified regulatory or net sales milestones, with the first potential payment of $10
          million to be made following approval by the FDA of Nyxol for reversal of mydriasis. The Company will also receive tiered royalties, starting at low double-digit royalties up to low twenty percent royalties, based on the aggregate annual net sales of all Nyxol Products in the United States, and will receive low double-digit royalties based on all annual net sales in
          the Viatris Territory outside of the United States. The royalty payments will continue on a country-by-country basis from the date of the first commercial sale of the first Nyxol Product in a country of the Viatris Territory until December 31,
          2040.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Either party may terminate the Nyxol License Agreement upon written notice in the case of the other party&#x2019;s material breach (subject to applicable
          cure periods) or if the other party becomes subject to an insolvency event. In addition, the Company may terminate the agreement in its entirety if Famy, Viatris or their affiliates commence an action challenging the validity, enforceability or
          scope of any of Ocuphire&#x2019;s patents that are exclusively licensed under the Nyxol License Agreement. Additionally, if Viatris determines not to pursue development or commercialization of a Product in a country or jurisdiction in the Viatris
          Territory, Viatris may terminate the license with respect to such Product in such country or jurisdiction.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Both Ocuphire and Viatris have agreed to indemnify the other party against certain losses and expenses relating to any breach of the indemnifying
          party&#x2019;s obligations, representations, warranties or covenants under the Nyxol License Agreement.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Nyxol License Agreement was accounted for under the provisions of ASC 606. In accordance with the p&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;rovisions under ASC 606, the Company identified two distinct performance obligations: &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(1) the license to its intellectual property (&#x201c;license transfer&#x201d;) and (2) research and development services.&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The aggregate transaction price associated with the Nyxol License Agreement was $40.2 million which comprised the Initial License Transfer fee of $35.0 million and the estimated $5.2 million payment anticipated under the research and development services that were not subject to cancellation. The transaction price was allocated
        between performance obligations based on their relative standalone selling price (&#x201c;SSP&#x201d;).&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The SSP for the license transfer and for the research and development services was determined to be $ 287.8 million and $5.2 million, respectively. The SSP for the
        license tran&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;sfer was determined based on
          a &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;discounted royalty cash flow approach, taking into consideration assumptions, including&lt;/span&gt;&lt;/span&gt; projected worldwide net profit for each of the respective programs based on probability
        assessments, projections based on internal forecasts, industry data, and information from other guideline companies within the same industry and other relevant factors. The SSP for the research and development services was determined using a cost
        plus margin approach, based on anticipated expenditure outlays within the first 120-day non-cancellation window. On a relative SSP
        basis, $39.5 million and $0.7
        million of the transaction price was allocated to the license transfer and to the research and development services obligations, respectively. &lt;br/&gt;
      &lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Recognition of Revenue&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 0px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; determined that the licenses transferred represented functional intellectual property. As such, the revenue related to the licenses
            was recognized at the point in time in which the license/know-how was delivered to Famy which occurred during the fourth quarter of 2022. The Company determined that revenue related to the research and development services was to be recognized
            over time as the services are rendered based on an estimated percentage of completion input model.&lt;/span&gt; &lt;/span&gt;Revenue recognized under the Nyxol License Agreement during the year ended December 31, 2022 was $39.8 million.&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Regulatory Milestones under the Nyxol License Agreement&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company has evaluated the regulatory milestones that may be received in connection with the Nyxol License Agreement. There is uncertainty that
        the events to obtain the regulatory milestones will be achieved given the nature of clinical development and the stage of the development of the Products. The remaining regulatory milestones will be constrained until it is probable that a
        significant revenue reversal will not occur.&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"&gt;Sales Milestone and Royalty Payments&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Sales milestones and royalties relate predominantly to a license of intellectual property granted to Famy and are determined by sales or
        usage-based thresholds. The sales milestones and royalties are accounted for under the royalty recognition constraint and will be accounted for as constrained variable consideration. The Company applies the royalty recognition constraint for each
        commercial milestone and will not recognize revenue for each until the subsequent sale of a licensed product (achievement of each) occurs.&lt;/div&gt;

&lt;div&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;With the exception of the license transfer and the research and development services obligations, each of the remaining regulatory and sales
        milestone performance obligations and royalty payments were fully constrained as of December 31, 2022.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;A reconciliation of the closing balance of the contract asset associated with the Nyxol License Agreement is as follows as of December 31, 2022 (in thousands):&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Contract Asset&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of&#160;&#160;December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;Revenue recognized &#x2013; license transfer &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;39,519&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Execution of &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Nyxol License Agreement and&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;one-time non-refundable&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;payment&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(35,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Revenue recognized &#x2013; research and development services&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;331&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Reclassification to accounts receivable related to&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;costs billed under the Nyxol License Agreement&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(1,298&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of December 31, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;3,552&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The remaining amounts in the contract asset as of December 31, 2022 attributed to the research and development services are expected to be settled during the first
        half of 2023.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; font-style: italic; font-weight: bold;"&gt;BioSense License and Assignment Agreement&lt;/div&gt;

&lt;div style="font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"&gt;On March 10, 2020, pre-Merger, Rexahn entered into an amendment to its collaboration and license agreement, (as amended, the &#x201c;BioSense License
          and Assignment Agreement&#x201d;) with BioSense to advance the development and commercialization of RX-3117 for all human uses in the Republic of Singapore, China, Hong Kong, Macau, and Taiwan (the &#x201c;BioSense Territory&#x201d;). Under the terms of the BioSense
          License and Assignment Agreement, the Company (i) granted BioSense an exclusive license to develop and commercialize pharmaceutical products containing RX-3117 as a single agent for all human uses in the BioSense Territory and (ii) assigned and
          transferred all of the former Rexahn patents and patent applications related to RX-3117 in the BioSense Territory. The upfront payment consisted of an aggregate of $1,650,000, of which $1,550,000 was paid to Rexahn prior to the Merger.During
          the year ended December 31, 2021, the Company satisfied a performance obligation for the $100,000 payment that was remaining and
          recorded this amount as license and collaborations revenue.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Under the BioSense
          License and Assignment Agreement, the Company is eligible to receive additional milestone payments in an aggregate of up to $84,500,000
          upon the achievement of development, regulatory and commercial goals and will also be eligible to receive tiered royalties at low double-digit rates on annual net sales in the BioSense Territory. The Company determined that none of the milestone
          payments under the BioSense License and Assignment Agreement were probable of payment as of December 31, 2022, and as a result, no
          revenue related to the milestones was recognized as the achievement of events entitling the Company to any milestone payments were highly susceptible to factors outside of the Company&#x2019;s control. Future sales-based royalties related to the
          exclusive license to develop RX-3117 will be recognized in the period the underlying sales transaction occurs.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Payments received
          under the BioSense License and Assignment Agreement are subject to the CVR Agreement described in Note 2 &#x2013; Merger.&lt;/div&gt;

&lt;div style="font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold; font-size: 10pt; text-align: justify; font-family: 'Times New Roman';"&gt;Processa License Agreement&lt;/div&gt;

&lt;div style="font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 16, 2021, the
          Company entered into a license agreement (the &#x201c;Processa License Agreement&#x201d;) with Processa Pharmaceuticals, Inc. (&#x201c;Processa&#x201d;), pursuant to which the Company has agreed to grant Processa an exclusive license to develop, manufacture and
          commercialize RX-3117 globally, excluding the BioSense Territory.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"&gt;As consideration for the Processa License Agreement, the Company received an upfront payment in July 2021 consisting of 44,689 shares of Processa common stock with a fair value of $289,000 (at the contract date) and a $200,000 cash payment.The Company was
          restricted from selling the Processa common stock for a period of one year ending June 16, 2022. As additional consideration, Processa
          will make payments to the Company upon the achievement of certain development and regulatory milestones, which primarily consist of dosing a patient in pivotal trials or having a drug indication approved by a regulatory authority in the United
          States or another country. In addition, Processa will pay the Company mid-single-digit royalties based on annual sales under the license and will make one-time
















          sales milestone payments based on the achievement during a calendar year of certain thresholds for annual sales. Processa is also required to give the Company 32% of any milestone payments received based on any sub-license agreement Processa may enter into with respect to the Processa License Agreement.The Company determined that none of the
          milestone payments under the Processa License Agreement were probable of payment as of December 31, 2022, and as a result, no revenue
          related to the milestones was recognized, as the achievement of events entitling the Company to any milestone payments were highly susceptible to factors outside of the Company&#x2019;s control.&lt;/div&gt;

&lt;div style="font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-size: 10pt; font-family: 'Times New Roman';"&gt;Processa is required to use commercially reasonable efforts, at its sole cost and expense, to conduct development activities in one or more countries, including meeting specific diligence milestones that consist of: (i) first patient administered drug in a clinical trial of a
          licensed product prior to the three (3) year anniversary of the effective date; and (ii) first patient administered drug in a pivotal
          clinical trial of a licensed product or first patient administered drug in a clinical trial for a second indication of a licensed product prior to the five (5) year anniversary of the effective date. Either party may terminate the agreement in the event of a material breach of the agreement that has not been cured following written notice and
          a 120-day opportunity to cure such breach, and Processa may terminate the agreement for any reason upon 120 days prior written notice to Ocuphire.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December 31,
          2021, the Company had fulfilled its performance obligations with respect to the upfront payment under the Processa License Agreement and had recognized the associated licensing revenue in connection with the payment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Payments received
          under the Processa License Agreement will be subject to the CVR Agreement described in Note 2 &#x2013; Merger.&lt;/div&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ocup:NonRefundableCashPaymentReceived
      contextRef="c20221101to20221130_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-6"
      id="Fact_f2fe4157faa54671a004bb09a9301149"
      unitRef="U001">35000000</ocup:NonRefundableCashPaymentReceived>
    <ocup:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones
      contextRef="c20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-6"
      id="Fact_c2d489545a0c484bb36bd28ee8fd182b"
      unitRef="U001">130000000</ocup:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones>
    <ocup:FirstPotentialMilestonePaymentToBeReceived
      contextRef="c20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-6"
      id="Fact_e101ef46208d43c4b599b5214d76728a"
      unitRef="U001">10000000</ocup:FirstPotentialMilestonePaymentToBeReceived>
    <ocup:MaximumPercentageOfTieredRoyaltiesReceivable
      contextRef="c20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="2"
      id="Fact_ce8b2bae2de04f4bb96cba7cccdc3d8f"
      unitRef="U007">0.20</ocup:MaximumPercentageOfTieredRoyaltiesReceivable>
    <ocup:NumberOfPerformanceObligations
      contextRef="c20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="INF"
      id="Fact_f3423a0dd685426ab3e59658a228f028"
      unitRef="U013">2</ocup:NumberOfPerformanceObligations>
    <ocup:RevenueFromContractWithCustomerToBeRecognized
      contextRef="c20221106to20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-5"
      id="Fact_4f63833d1f504fcd83d6d902d73e5757"
      unitRef="U001">40200000</ocup:RevenueFromContractWithCustomerToBeRecognized>
    <ocup:RevenueFromContractWithCustomerToBeRecognized
      contextRef="c20221106to20221106_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-5"
      id="Fact_9593d4f1e028421bb36aa8566684a8a0"
      unitRef="U001">35000000</ocup:RevenueFromContractWithCustomerToBeRecognized>
    <ocup:RevenueFromContractWithCustomerToBeRecognized
      contextRef="c20221106to20221106_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-5"
      id="Fact_99c6f8ceba8b48cfab8bc166f07da126"
      unitRef="U001">5200000</ocup:RevenueFromContractWithCustomerToBeRecognized>
    <ocup:EstimatedStandaloneSellingPriceForLicenseAgreement
      contextRef="c20221106to20221106_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-5"
      id="Fact_56ca38346ba34327be746215c43937e7"
      unitRef="U001">287800000</ocup:EstimatedStandaloneSellingPriceForLicenseAgreement>
    <ocup:EstimatedStandaloneSellingPriceForLicenseAgreement
      contextRef="c20221106to20221106_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-5"
      id="Fact_42eb03da25874b98ac14bfbb541a14b8"
      unitRef="U001">5200000</ocup:EstimatedStandaloneSellingPriceForLicenseAgreement>
    <ocup:PeriodOfNonCancellationWindowAgreement
      contextRef="c20221106to20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      id="Fact_50806cbd423f42aa97cf34c5de4c109f">P120D</ocup:PeriodOfNonCancellationWindowAgreement>
    <ocup:TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations
      contextRef="c20221106to20221106_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-5"
      id="Fact_74a78f933ebe4d3d887078ee72212f62"
      unitRef="U001">39500000</ocup:TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations>
    <ocup:TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations
      contextRef="c20221106to20221106_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-5"
      id="Fact_f42aebd72a204d6c8aec2d29422623e1"
      unitRef="U001">700000</ocup:TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-5"
      id="Fact_72aa2e3183ad4c2f8e0d598c2ec185b9"
      unitRef="U001">39800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ocup:ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_b9374f1b7035421a99606737d320be5d">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;A reconciliation of the closing balance of the contract asset associated with the Nyxol License Agreement is as follows as of December 31, 2022 (in thousands):&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Contract Asset&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of&#160;&#160;December 31, 2021&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;Revenue recognized &#x2013; license transfer &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;39,519&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Execution of &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Nyxol License Agreement and&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;one-time non-refundable&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;payment&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(35,000&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Revenue recognized &#x2013; research and development services&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;331&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Reclassification to accounts receivable related to&#160;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;costs billed under the Nyxol License Agreement&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(1,298&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
              &lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Balance as of December 31, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;3,552&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</ocup:ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock>
    <ocup:ContractAssetCurrent
      contextRef="c20211231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-3"
      id="Fact_7a288b845321488a86dd3e54c2babd75"
      unitRef="U001">0</ocup:ContractAssetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-3"
      id="Fact_a33b0cac03c0432487c129207073ca99"
      unitRef="U001">39519000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ocup:NonRefundableCashPaymentReceived
      contextRef="c20220101to20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-3"
      id="Fact_d3e940e90b204c01b5bb67e622d7cc03"
      unitRef="U001">35000000</ocup:NonRefundableCashPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ProductOrServiceAxis_ResearchDevelopmentServicesMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-3"
      id="Fact_7b41045a7dd54c9ba70c38b4afb81c7d"
      unitRef="U001">331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ocup:ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement
      contextRef="c20220101to20221231_ProductOrServiceAxis_LicenseTransferFeeMember_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-3"
      id="Fact_72506667dd5c4b21ba39356fac637d7b"
      unitRef="U001">1298000</ocup:ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement>
    <ocup:ContractAssetCurrent
      contextRef="c20221231_TypeOfArrangementAxis_NyxolLicenseAgreementMember"
      decimals="-3"
      id="Fact_6102c46148c546adb9e37f113dec7c70"
      unitRef="U001">3552000</ocup:ContractAssetCurrent>
    <ocup:NonRefundableCashPaymentReceived
      contextRef="c20200310to20200310_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"
      decimals="0"
      id="Fact_40b278db80aa40fc8825ddfdc9ae4466"
      unitRef="U001">1650000</ocup:NonRefundableCashPaymentReceived>
    <ocup:NonRefundableCashPaymentReceived
      contextRef="c20200310to20200310_BusinessAcquisitionAxis_RexahnStockholdersMember_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"
      decimals="0"
      id="Fact_12efd9b0b1504d2194e77fc2c8071ea1"
      unitRef="U001">1550000</ocup:NonRefundableCashPaymentReceived>
    <ocup:MilestonePaymentAchievedForPerformanceObligation
      contextRef="c20210101to20211231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"
      decimals="0"
      id="Fact_5b95e7947e634f488a9678a5beddd88d"
      unitRef="U001">100000</ocup:MilestonePaymentAchievedForPerformanceObligation>
    <ocup:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones
      contextRef="c20221231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"
      decimals="0"
      id="Fact_0679eb3753f140dc9969657a25205319"
      unitRef="U001">84500000</ocup:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones>
    <ocup:MilestonePaymentsAmountReceived
      contextRef="c20220101to20221231_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember"
      decimals="-3"
      id="Fact_535f8cdc98d14622857eca6215206063"
      unitRef="U001">0</ocup:MilestonePaymentsAmountReceived>
    <ocup:UpfrontPaymentReceivedInCommonStockShares
      contextRef="c20210701to20210731_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      decimals="0"
      id="Fact_6f21a529b6734f5f98396f87ca903d5c"
      unitRef="U002">44689</ocup:UpfrontPaymentReceivedInCommonStockShares>
    <ocup:UpfrontPaymentReceivedInCommonStockFairValue
      contextRef="c20210701to20210731_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      decimals="0"
      id="Fact_e4c0bb9f47df45b5900c4c30491c5deb"
      unitRef="U001">289000</ocup:UpfrontPaymentReceivedInCommonStockFairValue>
    <ocup:NonRefundableCashPaymentReceived
      contextRef="c20210701to20210731_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      decimals="0"
      id="Fact_6e115dfc17e14cb194b658c755cb0227"
      unitRef="U001">200000</ocup:NonRefundableCashPaymentReceived>
    <ocup:PeriodOfRestrictionFromSellingStock
      contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      id="Fact_7f284c287be1484998101d34534bc057">P1Y</ocup:PeriodOfRestrictionFromSellingStock>
    <ocup:NumberOfTimesPaymentsForSalesMilestone
      contextRef="c20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      decimals="INF"
      id="Fact_6fa6fb88aa924f7885fbe4329ee40295"
      unitRef="U008">1</ocup:NumberOfTimesPaymentsForSalesMilestone>
    <ocup:PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement
      contextRef="c20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      decimals="2"
      id="Fact_89496d34f3804659a6023119c2957c42"
      unitRef="U007">0.32</ocup:PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement>
    <ocup:MilestonePaymentsAmountReceived
      contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      decimals="-3"
      id="Fact_dc195ed47fdc494ebfe9739b2c404f33"
      unitRef="U001">0</ocup:MilestonePaymentsAmountReceived>
    <ocup:MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted
      contextRef="c20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      decimals="INF"
      id="Fact_794b2fa53ddc44bf821fd7641fe3976c"
      unitRef="U014">1</ocup:MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted>
    <ocup:MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient
      contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      id="Fact_7996e550867c4a988a3aa951ef2b2a63">P3Y</ocup:MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient>
    <ocup:MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication
      contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      id="Fact_a6e1981d043d433fb2462fa288a3388e">P5Y</ocup:MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication>
    <ocup:PeriodOfOpportunityToCureBreachOfAgreement
      contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      id="Fact_d62c01492b8940b2b14732a134aad90a">P120D</ocup:PeriodOfOpportunityToCureBreachOfAgreement>
    <ocup:PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements
      contextRef="c20220101to20221231_TypeOfArrangementAxis_ProcessaLicenseAgreementMember"
      id="Fact_27437d2b26eb42d69a92a98b2e4c5bdc">P120D</ocup:PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="c20220101to20221231"
      id="Text_b389e89bb99a44f2b22914b55ad571ce">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;11.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Net income (loss) per share&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt;Basic income (loss) per share of common stock is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during
            the period.&#160; Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any
            common stock equivalents, if dilutive. The Company&#x2019;s warrants, stock options and restricted stock awards, while outstanding, are considered common stock equivalents for this purpose. Diluted earnings is computed utilizing the treasury method
            for the warrants, stock options and restricted stock. Incremental common stock equivalents that were antidilutive were excluded in calculating diluted income per share.&#160; For the year ended December 31, 2021, no common stock equivalents were
            included in the diluted loss per share because such inclusion would be anti-dilutive given the net loss reported for the prior year period.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"&gt;The following table presents the computation of weighted average common shares considered in the computation of
            diluted net income (loss) per share:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;2022 &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" valign="bottom"&gt;2021 &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Denominator (weighted average shares)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Basic common shares outstanding&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;19,931,080&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;14,852,745&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Dilutive stock options&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;589,165&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Dilutive warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;76,967&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Diluted common shares outstanding&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;20,597,212&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;14,852,745&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The following potential common shares were not
            considered in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive for the year end periods presented below:&lt;/span&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Series A, Series B and RDO warrants&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,145,201&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;7,282,999&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,346,879&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,096,836&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Restricted stock awards including pending issuances of stock for services &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,970&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Former Rexahn warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;60,713&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;66,538&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Former Rexahn options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;82&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_41a540260c584531a085cecea1cd0c27">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: justify; font-family: 'Times New Roman';"&gt;The following table presents the computation of weighted average common shares considered in the computation of
            diluted net income (loss) per share:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;2022 &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; padding-bottom: 2px; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; white-space: nowrap;" valign="bottom"&gt;2021 &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman';" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Denominator (weighted average shares)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Basic common shares outstanding&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;19,931,080&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;14,852,745&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Dilutive stock options&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;589,165&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Dilutive warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;76,967&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                    &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Diluted common shares outstanding&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;20,597,212&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;14,852,745&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_8fb0e766be404c1f87447d0d4880c691"
      unitRef="U002">19931080</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_03f0373541424e8b94365e50f7479703"
      unitRef="U002">14852745</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <ocup:IncrementalCommonSharesAttributableToOptions
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_fbbb129270c0422db3292d8ae6e102d5"
      unitRef="U002">589165</ocup:IncrementalCommonSharesAttributableToOptions>
    <ocup:IncrementalCommonSharesAttributableToOptions
      contextRef="c20210101to20211231"
      decimals="INF"
      id="Fact_a1bc913e75b24c3a9eec83fe9a5fd7f5"
      unitRef="U002">0</ocup:IncrementalCommonSharesAttributableToOptions>
    <ocup:IncrementalCommonSharesAttributableToWarrants
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_be00286fdb7f4ef4811765daa12d114e"
      unitRef="U002">76967</ocup:IncrementalCommonSharesAttributableToWarrants>
    <ocup:IncrementalCommonSharesAttributableToWarrants
      contextRef="c20210101to20211231"
      decimals="INF"
      id="Fact_368d137a301a4011a08d203800e7615e"
      unitRef="U002">0</ocup:IncrementalCommonSharesAttributableToWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_f5e2200b590449a5b7eb457579632d60"
      unitRef="U002">20597212</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_e2af5fd2efa048729f71b43915fb94bb"
      unitRef="U002">14852745</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20220101to20221231"
      id="Text_1e7d9862e0914a08aa475a8026f53290">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The following potential common shares were not
            considered in the computation of diluted net income (loss) per share as their effect would have been anti-dilutive for the year end periods presented below:&lt;/span&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Series A, Series B and RDO warrants&lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;7,145,201&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;7,282,999&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,346,879&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;2,096,836&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Restricted stock awards including pending issuances of stock for services &lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;6,970&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Former Rexahn warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;60,713&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;66,538&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Former Rexahn options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;82&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember"
      decimals="0"
      id="Fact_a52d93040d754faa9eac39bbcabe42a5"
      unitRef="U002">7145201</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember"
      decimals="0"
      id="Fact_db61516ca985443780773ed3c60fb077"
      unitRef="U002">7282999</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_2029e214b9054ee09ce7011c42bd4c92"
      unitRef="U002">2346879</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_9f682611a2c942b4a117d23f95eba74d"
      unitRef="U002">2096836</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_b2d6bd2824e64df6aad870fd1d5e8eb0"
      unitRef="U002">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockMember"
      decimals="0"
      id="Fact_cb5203c15eb549d39c2d41d145b00281"
      unitRef="U002">6970</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnWarrantsMember"
      decimals="0"
      id="Fact_0ad51c329f8b409eb304759a256cede3"
      unitRef="U002">60713</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnWarrantsMember"
      decimals="0"
      id="Fact_5e3977beac1c4c61885c3886462269de"
      unitRef="U002">66538</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnOptionsMember"
      decimals="0"
      id="Fact_f53eaeb20ccb489dbcd4b25c78d8c2e4"
      unitRef="U002">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20210101to20211231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_FormerRexahnOptionsMember"
      decimals="0"
      id="Fact_ab0a6853353e453fb0946bd6ec3f3187"
      unitRef="U002">82</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20220101to20221231"
      id="Text_50148989e6f34ac8a68fb7d33b1f8246">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;12.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Income Taxes&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The effective tax rate for the years ended December 31, 2022 and 2021 was 1.7 percent and zero percent, respectively.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements
          of comprehensive income (loss) is as follows for the years ended December 31, 2022 and 2021:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Income tax (benefit) provision at federal statutory rate&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;21.0&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(21.0&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)%&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(21.4&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;11.9&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;State income tax, net of federal benefit&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;4.9&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(4.8&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;15.3&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.4&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(0.1&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(3.1&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(1.1&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(0.1&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(0.2&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Effective tax rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;1.7&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;%&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The components of income tax provision (benefit) consisted of the following for the years ended December 31, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"&gt;2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt; 2022 &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2021 &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Income (loss) before income taxes:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;18,203&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;(56,693&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Current:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;279&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;36&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Total current tax provision (benefit)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;315&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Deferred:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"&gt;Total tax provision (benefit&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;315&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are summarized in the tables below as of December 31, 2022 and 2021 (in thousands):&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Deferred tax assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Federal and state operating loss carryforwards&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;13,087&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;19,244&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Acquired intangibles&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;547&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;547&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Deferral of research and development costs &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,820&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Organizational costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;7&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;7&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Other&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;62&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Stock-based compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,152&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;811&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Research and development credit carryforward&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;731&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,035&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Subtotal&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;18,406&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;21,662&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(17,770&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;(21,662&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Total deferred tax assets, net of valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;636&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Deferred tax liabilities:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;Deferred revenue &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(636&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total deferred tax liabilities&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(636&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Net deferred tax assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of December 31, 2022 and 2021, the Company had gross deferred tax assets of approximately $18.4 million and $21.7 million, respectively. Realization of the deferred tax
          assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has cumulative pre&#x2011;tax losses &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;and faces significant challenges
            to becoming profitable in the future. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance&lt;/span&gt; of $17.8
          million and $21.7 million as of December 31, 2022 and 2021, respectively. U.S. net deferred tax assets will continue to require a
          valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;As of December 31, 2022 and 2021, the tax effect of the Company&#x2019;s federal net operating loss carryforwards was approximately $10.9 million and $15.7 million,
          respectively. The Company had federal research credit carryforwards as of December 31, 2022 and 2021 of approximately $0.7 million and
          $1.0 million, respectively. The federal net operating loss carryforwards will not expire and the tax credit carryforwards will begin to
          expire in 2041 if not utilized.&#160; As of December 31, 2022 and 2021, the Company had state net operating loss carryforwards with a tax effect of approximately $2.2 million and $3.6 million, respectively. The Company did not have any state research credit carryforwards as of December 31, 2022 and 2021. The state net operating loss carryforwards will begin to expire in 2028.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company
            utilized federal and state net operating tax carryforwards with a tax effect in the amount of $4.8 million and $1.4 million, respectively, to offset taxable income for the year ended December 31, 2022. In addition, the Company also utilized its federal
            research credit carryforwards in the amount of $0.9 million to partially offset its tax liability for the year ended December 31,
            2022.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by
          Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#x201c;5-percent shareholders&#x201d; increase their
          ownership, in the aggregate, by more than 50 percentage points over a 3 year testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and
          credits before utilization. As a result of the Merger, the Company recorded deferred tax assets of $10.3 million relating to net
          operating loss carryforwards which were fully offset by a valuation allowance. The $10.3 million net deferred tax assets recorded in
          relation to the Merger did not include federal and state net operating loss carryforwards that were estimated to expire under Internal Revenue Code Sections 382 as a result of the Merger. The Company has not yet evaluated the impact of Section
          382 and Section 383 on its remaining tax attributes that were generated by Ocuphire since the formation of the Company in 2018.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December 31, 2022 and 2021, and as such, no interest or penalties were recorded to income tax expense.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;The Company&#x2019;s corporate returns are subject to examination beginning with the 2019 tax year for federal income tax purposes and 2018 for state income tax purposes.&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_4719cc6b5cb44740985b6b7d978abceb"
      unitRef="U007">0.017</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_05c46e94de9c477fa89a2f9a4d1443f7"
      unitRef="U007">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_2df74980b6b743c0aede47789fbe3fd4">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements
          of comprehensive income (loss) is as follows for the years ended December 31, 2022 and 2021:&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: middle; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Income tax (benefit) provision at federal statutory rate&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;21.0&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(21.0&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)%&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(21.4&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;11.9&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;State income tax, net of federal benefit&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;4.9&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(4.8&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;15.3&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.4&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(0.1&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Research and development&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(3.1&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(1.1&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Other&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(0.1&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(0.2&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0);"&gt;Effective tax rate&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;1.7&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;%&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#x2014;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <ocup:EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_1bf4612edbaa487db4f1f090d24d0ab6"
      unitRef="U007">0.21</ocup:EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent>
    <ocup:EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent
      contextRef="c20210101to20211231"
      decimals="3"
      id="Fact_dc76014ab7264f95a9718b7cee8f8e1c"
      unitRef="U007">-0.21</ocup:EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_3e2860fae86f4ab9bdb34a11cd295fff"
      unitRef="U007">-0.214</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20210101to20211231"
      decimals="3"
      id="Fact_5ffdcfbf84c941a8a6db5c4dea845493"
      unitRef="U007">0.119</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_91bab5305d644891a2332e56ae8444e8"
      unitRef="U007">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20210101to20211231"
      decimals="3"
      id="Fact_19154e229e644f73a7ee2628034dfe7e"
      unitRef="U007">-0.048</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ocup:EffectiveIncomeTaxRateReconciliationWarrantsPercent
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_da67d441ccfc483fb35b80d3f315556d"
      unitRef="U007">0</ocup:EffectiveIncomeTaxRateReconciliationWarrantsPercent>
    <ocup:EffectiveIncomeTaxRateReconciliationWarrantsPercent
      contextRef="c20210101to20211231"
      decimals="3"
      id="Fact_d0af7e51399f46899cf1e02599d38605"
      unitRef="U007">0.153</ocup:EffectiveIncomeTaxRateReconciliationWarrantsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_a6b6e8196aa941338a51d9f22d605a4c"
      unitRef="U007">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20210101to20211231"
      decimals="3"
      id="Fact_c61f0406ec094f6989fdecceda087ca9"
      unitRef="U007">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_1d53e59a08fb49a0a5fdc59dc837e49b"
      unitRef="U007">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="c20210101to20211231"
      decimals="3"
      id="Fact_86f57de1d8524390ba7b847ad52cc20a"
      unitRef="U007">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_3abaacf0a8d241e88b07cd147f4a1872"
      unitRef="U007">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20210101to20211231"
      decimals="3"
      id="Fact_6121ad0752374aa298edf6aa5a845060"
      unitRef="U007">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20220101to20221231"
      decimals="3"
      id="Fact_5714fbd188b34893aa42fb13bce6af48"
      unitRef="U007">0.017</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20210101to20211231"
      decimals="0"
      id="Fact_d12189c5b3fa4bb797aaadc01ec42a59"
      unitRef="U007">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_65ef6dfbb2374b06bdb00faf4c7c3175">
&lt;div&gt; &lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The components of income tax provision (benefit) consisted of the following for the years ended December 31, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;"&gt;2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt; 2022 &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: middle; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold; font-family: 'Times New Roman';"&gt;2021 &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Income (loss) before income taxes:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;18,203&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;(56,693&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Current:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;279&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;36&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Total current tax provision (benefit)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;315&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"&gt;Deferred:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: rgb(0, 0, 0); font-size: 10pt;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: middle; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"&gt;Total tax provision (benefit&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;315&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_f79df070aa504b639261ad99e216116d"
      unitRef="U001">18203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_543142ee2e0d429d96a433f95808a4a8"
      unitRef="U001">-56693000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_51cc5f04d77b4137b1e016d4e392ccfa"
      unitRef="U001">279000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_5bd0e1f7144741e0aaee20de73dfdbdf"
      unitRef="U001">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_2888c737d1f44ba4a867cdbf79d0591d"
      unitRef="U001">36000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_fb074044e70646e98a15fb4b1643a30f"
      unitRef="U001">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e06e02e0a3cb4349ac64529363f09cd2"
      unitRef="U001">315000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_f78e1e361d0047279dab46090cf36909"
      unitRef="U001">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_8a518f5a5dcc44f2bc70f5965a644804"
      unitRef="U001">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_b1d29ce2cfcc457b9d5066e773ae67f8"
      unitRef="U001">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_0751244d2edf41e29a92b09182ef163e"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_53030fd15823411daa498fbb9bf9ba5d"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_a0f7c6e7246944d9af70ea11d1377122"
      unitRef="U001">315000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20210101to20211231"
      decimals="-3"
      id="Fact_d74097b046f44b6b8b3699bdb1393b54"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="c20220101to20221231"
      id="Text_7c7b46a6693c4bb28d230a8db5fa8696">
&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are summarized in the tables below as of December 31, 2022 and 2021 (in thousands):&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-align: left; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2022&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;2021&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Deferred tax assets:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Federal and state operating loss carryforwards&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;13,087&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;19,244&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Acquired intangibles&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;547&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;547&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Deferral of research and development costs &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,820&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Organizational costs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;7&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;7&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Other&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;62&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Stock-based compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;1,152&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;811&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Research and development credit carryforward&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;731&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;1,035&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%;" valign="bottom"&gt;
                &lt;div&gt;Subtotal&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;18,406&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;div&gt;21,662&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(17,770&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;(21,662&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Total deferred tax assets, net of valuation allowance&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;636&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Deferred tax liabilities:&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;Deferred revenue &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(636&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#x2014;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total deferred tax liabilities&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;(636&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="font-weight: bold;"&gt;Net deferred tax assets&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;
                &lt;div&gt;&#x2014;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20221231"
      decimals="-3"
      id="Fact_f0a36a13d4c04d4fa6f9692ad85dfb91"
      unitRef="U001">13087000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20211231"
      decimals="-3"
      id="Fact_76d90d17394144ea8f90607da5ee0c70"
      unitRef="U001">19244000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="c20221231"
      decimals="-3"
      id="Fact_fe795f59bd984e8a8535f3de1381703b"
      unitRef="U001">547000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="c20211231"
      decimals="-3"
      id="Fact_4568cadaa3bb433cbd9a38767481b391"
      unitRef="U001">547000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="c20221231"
      decimals="-3"
      id="Fact_ce6125cf7cb3459c8aea7b86f9a2f9fc"
      unitRef="U001">2820000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="c20211231"
      decimals="-3"
      id="Fact_932b9ea99c1243b3aa2057c852ca30a1"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="c20221231"
      decimals="-3"
      id="Fact_961bdd56e7df4f04bf9c4b48cee9d464"
      unitRef="U001">7000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="c20211231"
      decimals="-3"
      id="Fact_909521014bc14f729a03a46f47688483"
      unitRef="U001">7000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c20221231"
      decimals="-3"
      id="Fact_b3ad390323eb4d7389ba2f9566bd21cf"
      unitRef="U001">62000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c20211231"
      decimals="-3"
      id="Fact_8d22e90740f44908909ee885b43bc586"
      unitRef="U001">18000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20221231"
      decimals="-3"
      id="Fact_94fd58cd138e4633b6b3aff7fdb9c2fb"
      unitRef="U001">1152000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20211231"
      decimals="-3"
      id="Fact_3465b989e8ac4df69e3ad1494274f8b5"
      unitRef="U001">811000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ocup:DeferredTaxAssetsResearchAndDevelopment
      contextRef="c20221231"
      decimals="-3"
      id="Fact_b5a33cef17434ebe977d8fbba6867938"
      unitRef="U001">731000</ocup:DeferredTaxAssetsResearchAndDevelopment>
    <ocup:DeferredTaxAssetsResearchAndDevelopment
      contextRef="c20211231"
      decimals="-3"
      id="Fact_470abd24691543398bc3de6c7f75be92"
      unitRef="U001">1035000</ocup:DeferredTaxAssetsResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20221231"
      decimals="-3"
      id="Fact_8196e3008ccd4323baa67a1cfa5bf8ae"
      unitRef="U001">18406000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20211231"
      decimals="-3"
      id="Fact_d878e6a75389414aaf35fef7ba7f61f7"
      unitRef="U001">21662000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20221231"
      decimals="-3"
      id="Fact_35449218ccd04cfd9e9ac9cf82e907f2"
      unitRef="U001">17770000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20211231"
      decimals="-3"
      id="Fact_8ff6e79ac99347a3a2f05f38a9b141ce"
      unitRef="U001">21662000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20221231"
      decimals="-3"
      id="Fact_322313bec1724c2caa59a3bbc8dc4e4c"
      unitRef="U001">636000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20211231"
      decimals="-3"
      id="Fact_80d74139865e4bea953365ad19e8292e"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredRevenue
      contextRef="c20221231"
      decimals="-3"
      id="Fact_a6f01c808eab411c8b4b5adb82f76eca"
      unitRef="U001">636000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="c20211231"
      decimals="-3"
      id="Fact_a878704f4da0490bb2cc61e7612b56fe"
      unitRef="U001">0</us-gaap:DeferredRevenue>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c20221231"
      decimals="-3"
      id="Fact_e5a4d027826b40b5a26f08c6081a3f96"
      unitRef="U001">636000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c20211231"
      decimals="-3"
      id="Fact_b7494cb692164ce290c9f2f0bff61886"
      unitRef="U001">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20221231"
      decimals="-3"
      id="Fact_99b5a44b05b540a6b55b87789004940f"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20211231"
      decimals="-3"
      id="Fact_921cfad713244ccb9558d248f1eb348c"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20221231"
      decimals="-5"
      id="Fact_a3ad7526232245a49def00138527d47f"
      unitRef="U001">18400000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20211231"
      decimals="-5"
      id="Fact_c0636b763bea440b80911e26021fe19a"
      unitRef="U001">21700000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20221231"
      decimals="-5"
      id="Fact_e554b7f243d14fc9a9189721efcec161"
      unitRef="U001">17800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20211231"
      decimals="-5"
      id="Fact_5fc6641b754b4c34b9d8853717257910"
      unitRef="U001">21700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20221231"
      decimals="-5"
      id="Fact_7a21961b7aa94811aef8952f1956472b"
      unitRef="U001">10900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20211231"
      decimals="-5"
      id="Fact_ced72ccc59244c7eb82cbab4bdbe9c6a"
      unitRef="U001">15700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c20221231"
      decimals="-5"
      id="Fact_951880c5fa2c4928b2f00b9a4afb75eb"
      unitRef="U001">700000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c20211231"
      decimals="-5"
      id="Fact_523837b4cb9a4f1383429f78305eaa09"
      unitRef="U001">1000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="c20221231"
      decimals="-5"
      id="Fact_13b07bf6cff14ff2b1c30a16089f850e"
      unitRef="U001">2200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="c20211231"
      decimals="-5"
      id="Fact_60f37ec6ce7b4466a59ec7da82eb4b8f"
      unitRef="U001">3600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <ocup:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
      contextRef="c20211231"
      decimals="-6"
      id="Fact_73d3dd5280874765bf035e4ee71be654"
      unitRef="U001">0</ocup:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal>
    <ocup:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
      contextRef="c20221231"
      decimals="-6"
      id="Fact_180626b903a54b7a9ddc720c4985f9b0"
      unitRef="U001">0</ocup:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal>
    <ocup:FederalOperatingLossCarryforwardsTaxEffect
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_79041aa4b9fe4f668d483572f9993b02"
      unitRef="U001">4800000</ocup:FederalOperatingLossCarryforwardsTaxEffect>
    <ocup:StateAndLocalOperatingLossCarryforwardsTaxEffect
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_561759a5a89344629d7e81adb0fa3b95"
      unitRef="U001">1400000</ocup:StateAndLocalOperatingLossCarryforwardsTaxEffect>
    <ocup:UtilizedFederalResearchCreditCarryforwards
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_99896d65a98648a4bf168014b8644fae"
      unitRef="U001">900000</ocup:UtilizedFederalResearchCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="-5"
      id="Fact_97855a0ea19b4fd9bd08d88e4232f666"
      unitRef="U001">10300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember"
      decimals="-5"
      id="Fact_805f6156266a47489ab32b1b84b3c0e0"
      unitRef="U001">10300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20211231"
      decimals="-6"
      id="Fact_a8f50486263042799e8426b47287c126"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20221231"
      decimals="-6"
      id="Fact_0b3905ab6a7c48b78303a94b533c5b32"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="c20220101to20221231"
      decimals="-6"
      id="Fact_dfa602b2a530471c91ffda4e330d41c9"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="c20210101to20211231"
      decimals="-6"
      id="Fact_a11f0d76f3314601853715526fa7ec68"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="c20220101to20221231"
      id="Text_36390a6c84034e2598bd59693969b64d">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman';"&gt;13.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold; font-family: 'Times New Roman';"&gt;Deferred Compensation Plan &lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Effective October 1, 2021, the Company began offering a 401(k) plan (&#x201c;401K Plan&#x201d;) to its
          employees. All employees are eligible to participate in the 401K Plan. The Company makes matching contributions equal to 100% on the
          first 3% of compensation that is deferred as an elective deferral and an additional 50% on the next 2% of compensation. The Company&#x2019;s matching
          contributions are made on a monthly basis. During the years ended December 31, 2022 and 2021, the Company contributed $76,000 and $15,000 to the 401K Plan, respectively.&lt;/span&gt;&lt;/div&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="2"
      id="Fact_2ddacee8eabc47d5a388b9cce2902596"
      unitRef="U007">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="2"
      id="Fact_d5a6517693a34059bf91fed1995f2c26"
      unitRef="U007">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <ocup:DefinedContributionPlanAdditionalEmployerMatchingContribution
      contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="2"
      id="Fact_2354f68b3b2f4577857d7ab950eaf771"
      unitRef="U007">0.50</ocup:DefinedContributionPlanAdditionalEmployerMatchingContribution>
    <ocup:DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred
      contextRef="c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="2"
      id="Fact_eaa9068dadd940d7b706943beb9c98a4"
      unitRef="U007">0.02</ocup:DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20220101to20221231_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="0"
      id="Fact_f28bfeb2dbed48aa85be00840285119f"
      unitRef="U001">76000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20210101to20211231_RetirementPlanNameAxis_RetirementPlan401KMember"
      decimals="0"
      id="Fact_a1271597ed034037a89678a5090b3bda"
      unitRef="U001">15000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20220101to20221231"
      id="Text_6c4226b9648741c3a703c84d6d351ba9">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 27pt; vertical-align: top; font-weight: bold;"&gt;14.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                &lt;div style="font-weight: bold;"&gt;Subsequent Events&lt;/div&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;2020 Plan Evergreen Provision&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);"&gt; &lt;/span&gt;&lt;br/&gt;
        &lt;/div&gt;

&lt;div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Under the 2020 Plan, the shares reserved automatically increase on January 1 of each year, for a period of not more than ten years from the date the 2020 Plan is approved by the stockholders of the Company, commencing on January 1, 2021 and ending on (and including)
          January 1, 2030, by an amount equal to 5% of the shares of common stock outstanding as of December 31 of the preceding calendar year.
          Notwithstanding the foregoing, the Board of&#160; Directors may act prior to January 1 of a given year to provide that there will be no January 1 increase in the share reserve for such year or that the increase in the share reserve for such year will
          be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, 1,043,066
          shares were added to the 2020 Plan as a result of the evergreen provision.&lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <ocup:MaximumPeriodOfSharesReservedUnderPlan
      contextRef="c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member_RangeAxis_MaximumMember"
      id="Fact_aeefe2d1f86a455b88f424bd9a9c68ce">P10Y</ocup:MaximumPeriodOfSharesReservedUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member"
      decimals="2"
      id="Fact_3bca7085f1ab4a6aad5b32ab8726eb6a"
      unitRef="U007">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <ocup:AggregateNumberOfCommonStockReservedForFutureIssuance
      contextRef="c20230101to20230101_PlanNameAxis_EvergreenProvisionPlan2020Member_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_7bdcf4199547494891c37a33665c69bb"
      unitRef="U002">1043066</ocup:AggregateNumberOfCommonStockReservedForFutureIssuance>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_37c7f8e7261c4c0ea247d23587c35f7a"
          xlink:label="Fact_37c7f8e7261c4c0ea247d23587c35f7a"
          xlink:type="locator"/>
        <link:footnote id="Foot_b060c1ad19c34ed89e1bcfe2db363855" xlink:label="Foot_b060c1ad19c34ed89e1bcfe2db363855" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and
                  the fair value of our common stock as of December 31, 2022 and 2021 of $3.53 and $3.73 per share, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_37c7f8e7261c4c0ea247d23587c35f7a"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_3cfe8fa586b34f52a55e354dc7fa3bb7"
          xlink:label="Fact_3cfe8fa586b34f52a55e354dc7fa3bb7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_3cfe8fa586b34f52a55e354dc7fa3bb7"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_46b97527dae540aca27bf64658108ec9"
          xlink:label="Fact_46b97527dae540aca27bf64658108ec9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_46b97527dae540aca27bf64658108ec9"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_2e21a6a36c364fdba0d8dc06ccade1de"
          xlink:label="Fact_2e21a6a36c364fdba0d8dc06ccade1de"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_2e21a6a36c364fdba0d8dc06ccade1de"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_4ced063294be4461a959db5d39a759cf"
          xlink:label="Fact_4ced063294be4461a959db5d39a759cf"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_4ced063294be4461a959db5d39a759cf"
          xlink:to="Foot_b060c1ad19c34ed89e1bcfe2db363855"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>101
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M1@&T$8#O6P&,V3R8&[;#C>KJ/U!+ P04    " #FB'Y6BK3%%MP"   Y"@
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M+(B 3"6@:$38)?J WB(;R42/RJFM]((&9D<U^4U%[AX@_PS1  V=*^1BU^V
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MMI!0RK4=-0#W-0": ( (?*"%2#CXO8A)W'=@RVC:D- II'MD]/A HAO@PC<
M.0AI@-8_WAP:<-PVPV[ES[ULAO^YVW#!9)7_J\MIW>5,WZ6:^K=\CR.RM*1_
M3MB!6*M??X%SYS==/B[DK)>=69N=F<G[ZGT:R? )D,4#9"UG>$,95A.<RT7B
M0(J2Z,*O?7J53[50'59N&'C.PCZ<QS6V\H*PM>GA>BVN9QS,3WNB\(H=("][
M!<YO=7S>)8?G0LYZ\<[;>.?&X?F#%#+@K!H>',OU)U5%J59>7=BUK_E9PGTT
M#P>C,C8*H)IHNF'Q6TS?B/DD \<L2BK.6-9-1O=JEND@_5'_<.9ZWH!28^5!
MW]5C!BUF8,3\3(7,)1W5D XS& $@.$>S :;&RD7A3(\9MIBA$?.T$&750K1E
M-#\QRVFI8PW'R0H0F@]8QU;7"/F.IX>%3J=@SG=P!9&5+T[IU&J0,^Y\6)@Z
M&S0!=R:OT CW%J<,''!6$A EN-@1)9='S!@N!,A2O$FS5*3Z$FA<GP,-ESB-
MR;7K!FABF8.HXT9&[D\B(>R4T3>@(-JYU#CI=0^'-:HU\OP)PDY6H5&7!E6Z
M(7)+JY);O13X92*EKJY4'7>(/#:[]N;S<&+^PT[MH%GN'AD]I-466.)^GW:F
M&5TX7*HT5LX$9R=ST*@JJX_R R(]3[ 6SQLGTP^"8,@W-C,FL],F:!:GND:C
MWB:J!UW5K=IHR0QK QAKT6B"F4SZW)U80;-:K:>)M93^:!^C3?/8S)CF3K1@
M8-SSC&H!2#$ /,%ROEU]I(( "%]KMT'0*(<_NP^ZE+=^&CI1A&95O,<\C<"5
M7+YCM4]EO$N#?MAJ=\%YY=R,-*<V"GLS_":8D!W4:2(R:^)#FI7J>^/'<1N'
M80\W\ >\&BL3;R>3")IKK,PW$D].U8J0@Y)+>@G?E5J$LZC,ZDV(MMJ048E_
MMMHNY:V?D$Y_D5E_NVJK$Z(?L[&RPC!TH1,,ES&=Y2SPD#^;V'ZA3H>168?/
M2\W$.I94Y'BACR :LFHT6L]JGYU[Y(3MJN,@+A6A+$1]7M"^;8^<[JJ#EL'[
M>WB[K@^..C?U.=8'S':I_!C-R%:Z=&Y\N;ZR^FBH?A!T7YVN;*@0-*]N$X)C
MPI2!_']+Y0K9/*@.V@.ZU?]02P,$%     @ YHA^5K4=$@DB!P  L"T  !@
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MY9E&EUF#Z<6+G-^AAL>N^7$,@T3J]M3X^';B?D_768ZO!GQFIKAYPH/)K[^
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M*!5L*=+.Y! Y8(8MN*X$I1&9^2'/:LBS\%*6>;^(?;UFBB/-C4D+/@!2,FO
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M;H,CFV5#L5&S(0$S_0SR7]JLRT+I-@O+A@V'D7T],D$WD#A:R+Y)ES[JIEV
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M>^E;F(]/'V=^4XY"+BE:5+DST)<\*$C67 BP@!EGJMB(U7"F=Z<G5,5 2E]
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MO%681[O31M'*-S+(BS-GU\*Q--#X(;H:M6&<,AR4N^#P54$O7'P@MR)W-@G
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MG_8_,UM!VR)KIY'7.%TEEW7W%E*+7H*&O]$[=3;I_3C4,XN=X+MZ-A<*,>\
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MPB>J7/)AB0(OP/NU1T3Z&S8P_)?AZF]02P,$%     @ YHA^5JTSWKN#!
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MDOLWASJ^G52A_^+ZYQ[AI>')*&-H=RN!Z:)YC7DPI=F@ZT@Y/CU0HYDQC<'
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MLVA4ZDDRG;Z:E%*9X>(B?KMQBPM;!ZT,W3CAZ[*4;G=%VFXOA[/A_L.MRHO
M'R:+BTKF=$?A2W7C\#;I4#)5DO'*&N%H?3E<SEY?G?'^N.$/15O?>Q8<R<K:
MK_SR(;L<3ID0:4H#(TC\;.@M:<U H/&MQ1QV+MFP_[Q'?Q=C1RPKZ>FMU7^J
M+!27P_.AR&@M:QUN[?8]M?&\9+S4:A__BFVS]VPZ%&GM@RU;8S HE6E^Y7VK
M0\_@_#&#I#5((N_&461Y+8-<7#B[%8YW XT?8JC1&N24X:3<!8=5!;NP6%9T
MKZ01=_5*JQ1BDUCFC@BZAXM)@ ?>-TE;M*L&+7D$;9:(3]:$PHM?3$;9]P 3
M4.OX)7M^5\F3B->4CL5\-A+)-$F>P)MW\<XCWOQ_Q"O^7JY\<"B4?XZ%W@"?
M'0?FYGGM*YG2Y1#=X<EM:+AX_FSV:OKF"=IG'>VSI]#_<YJ>1CL?#Y[4X3<C
M/DI3HTE%TD@_'0GIA<0JTBK031]K0^)L-&C60D'BK2TK:78" .2P29E@A42W
M=PYDY^ %&SQ_=IXDTS?'&,2EV9L3-$,H1,MU)*K:^5K"'LC;0J6%4$'85<#L
M@4.Z3W7MT>,\"'2&/B)1R<#^I %I^'3,"A, (Z&66E0.P\V%G7#<NQYAR"!2
M:WQ0H0X@+&YI?3H3'TRA5BI8QQ:YDR7&D99!F1Q,!HPK*ZJ#2H6L*@0C>>!X
M9ADP*(/(E+<N(^<;.W#%DJT*^-,E6X%>IN2* GE1@A_<>R:2J8@T%K]#+XV9
MBX]E96O#\D;5'R.HO%C>_#6?SY&=1JI^CE@%DT6&&6TPF:N87B.L8UF4UJ(?
M52\0)JG2@<-?8Z%NL>NQQ]92IK663E"&PP-^$(#4>C>*NRK+V8@?!.O@#LA;
MG#\X!$[W NUQ,LK)@ GKT,BPCR%6$RLY*.570DW2:<!Q@2&I"6/3</)W7$Q>
M0"_V!>.CY8ZC39"$1'8=-ZV5\Z&?'X5$-$F-81SV_)BTWE:&Y:W7C<+EOA!O
M*4=H2-;NP-4W EF3T@]T[J1F#]W6*(.GP9% E4$+H.Q?J)/#1\;S%:5JK:!7
M=F"#5+-3=XP/("(6USC7G*88TW<*W10X#D6"#"*E3?.4.(=02"A#Q6<\AD%6
M6=4&_M!RCDK;6*;1(+0E_05% Z)W 870ZK)6FHG@<0!A%&WXK<<;;>?L!A!K
M9\L(\NYZV26@\?D9-X1K5^<8)UV/QBVR:ZH35!/H,'A=<6W^-)NQ)IJW-NP&
M,D?=Y)*G XB]4(\K[1_DC<5K89/I UC1P>[;U: A'B!TC@;2Q1>YTA1K9@1@
M:WK!-BHUY0VWO@9BAS,6OTH?N"G[,T%J;P]-)6)32>'L3FI,R-:UH&\\.)O)
M#ITTG68JQQ3&'$VYI')B?PIB' + !Z0GJU,N#>]MJF*+Q]G.#%*[B2=&,ZR/
MM^N@:]>Q^, .>,(9BZ. '*Y%$;!_/# #7O*CQ_O>H[TURHCOKIP'6J]Q,,!]
M4!JG2:6:L;,O>@W1&#JNT/[K _)C\9DSU2YVD@]0&0^D!+,M++GV\SQ"6!YW
MH):Q7*N87!G5PR6(RA4TV5^$QL>N%)/>+; DE\>[+A\C"*BY$'9?N^OTLKE%
M'K8W=_%/TN4*)YBF-4RGXY]?#ILS<O\2;!7OE"L;<$.-CP6.)W*\ >MKBU'?
MOK"#[I^,Q;]02P,$%     @ YHA^5J&D=A7N!@  X!   !D   !X;"]W;W)K
M<VAE971S+W-H965T,34N>&ULE5A=<]PV$GS7KYC:^%).%<W]E"U9'U5KR?$Y
M%9=5EI,\7-T#E@1W<28!!@"UTK^_'H#D<N65*GZQEB30Z.GI&0 ^WQK[S6VD
M]'1?E=I=C#;>UV_'8Y=M9"5<:FJI\:4PMA(>CW8]=K65(@^3JG(\FTQ>CRNA
M].CR/+R[L9?GIO&ETO+&DFNJ2MB'=[(TVXO1=-2]^*+6&\\OQI?GM5C+6^G_
MJ&\LGL8]2JXJJ9TRFJPL+D;+Z=MW"QX?!ORIY-8-?A-'LC+F&S]\S"]&$R8D
M2YEY1A#X<R>O9%DR$&C\W6*.^B5YXO!WA_YKB!VQK(235Z;\2^5^<S$Z&5$N
M"]&4_HO9_ENV\1PS7F9*%_ZE;1P[GXPH:YPW53L9#"JEXU]QW^HPF'#RU(19
M.V$6>,>% LMKX<7EN35;LCP::/PCA!IF@YS2G)1;;_%589Z_O/4F^[8Q92XM
MO?^[4?[A?.R!RU_'68OQ+F+,GL"8SNB3T7[CZ+W.9;X/, :AGM6L8_5N]BSB
MM<Q2FD\3FDUFLV?PYGV4\X W_\=1TG^6*^<M3/'?0P%'N,5A."Z4MZX6F;P8
MH1*<M'=R=/GS3]/7D[-GR"YZLHOGT/]A2I[%.,SP-#TZ(,32O_JZD:\^"?M-
M^J,;:]965/19TZ]R91L4*BU"'I"-SUE3;Y255*A2YB2("X-N7\T)!BP+%.E:
ML:BAWAK-B_B-I%N9-59Y)1TM,T^FH.GI?$[;C<HVM!4.5925P@)1%H4,94JK
MASCU_169 97I+'*AE_SUYY].9K/)67AQRPS"B^G9+^WB<06,/+HR52WT RKG
M >L7^"9T3F@.94*%-15Y=!KR)OY5FI1WY$PI*5<NLY(C2C"^#V0C[I1> X7$
M>HVXA9<1F-_65F7\2$W-F"^FL^.C2I4E0%+ZJ"DS6K==::M\8$B[(!*.&.D
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MKW0$@Y1WBL_U+H;+%N"#0"7R$/M>R3RV8RR%[PX<.Z3.3+PGL,60<VDSY>3
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MWQR/HC.[!V_J<(==&8^V%7YN))J%Y0'X7ACCNP=>H/]/C<O_ U!+ P04
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M?SA :2*ZWMA>@B86WJ]TN1+:B:7!$[S^DUQOP*%07\NZMPAKK%>F4ZZ7]00
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M3!,OQ>GT;.0$9"#.#$[5-!4C0 >G>!\&.@V-6UH,G=F%,JD]Y%YT1AVO5=+
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MI'X*P#P7_]IX6?^-C5:MGEA!)I.IUX#1#SDQ8)]MU'&B&$3X)$^3<8,\PBL
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MM"HYBE %+U<Z-]BLA19O&Q*\>W85'IL_&M@R#SPH3\&MF4VIKPXJ7JVB!RP
M7ZPW@ A!O2=I%>T2V:*/Y%65@,9GY+%0/)_S"/ &L(3WC_ =6V*!;X.5W.!@
MHN>NRFE!9\-U7^#6:CDOP>B6-4N7PM;5#O8Y+HL5V6,D36K^^Y[.7ULEKX;H
M^E2XVZ=<+#!S?G>'0G &?$78!L@:#,@\=9^B+DC>?<V8ZS^-E9'>57C0.HB
MD_']Y4D!< YW?GSS:SW:5S6L,F6\ZI&D!NL.3J>G89=5QR ]FTRQHU#:#Q,8
MIO/ZZ[NI^^*)8_KV;MU6$]>IR<7PZ[G3XBH0-:<#IW1%"27UO$^1< O-WHE4
MLZQ_Z*1TT#J\SHB&=$1/^-%*_3EV\[3Y*\"M/_S>+O=_0OC$->PP+!4+;,4@
M>]9AVA_+^QNK"G<4/E?6JLQ=K@2'6;0 [Q=*V?J&%#1_&[GY+U!+ P04
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M&A] ^Z76;F/X ]I_W/@_4$L#!!0    ( .:(?E9VJ2!<DP,  !L(   9
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ME&!2M=)@ MXD]MV 6=*[ A@M812[HMTZ +#/=%VWF!U(   SG;((J:RI(=:
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MR$%W7-%5)!@$/KGK1)L%F=@:YD2MR48J-LCUC* C&[CC(8B=FNE%48G?*/R
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M9%P($35$$H1?;(NK@0>BEW4IIT'?A7,?HZ'JA8>[X%RQ:=WQ'LY='RI$QO4
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M2&*@/0QQ<6[=[NXY.D&PUT+GQTZ?/$T^A\P'N=7)R>3Q>7*:G/"_?7!TE?<
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M#3%=J:J>K#I&%JZ&6TF#%:%K9EB"@[(3<#R5TNP[-D!=U,__ U!+ P04
M" #FB'Y6@& !T'H#  "_"   &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6RE5MMNXS80?>=7$-I%D !!=/-%36P#]B:+!NBV1K)M'XH^T-+8(I8BM22U
M3OZ^0TI67511"RQL4"+%.7/F#$>CQ5'I+Z8$L/2E$M(L@]+:^C8,35Y"Q<R-
MJD'BD[W2%;,XU8?0U!I8X8TJ$291- LKQF6P6OBUK5XM5&,%E[#5U#15Q?3K
M!H0Z+H,X."T\\4-IW4*X6M3L ,]@?ZVW&F=ACU+P"J3A2E(-^V6PCF\W,[??
M;_B-P]&<W5,7R4ZI+V[R6"R#R!$" ;EU" POW^ #".& D,;7#C/H73K#\_L3
M^D<?.\:R8P8^*/$[+VRY#+* %K!GC;!/ZO@C=/%,'5ZNA/$C/;9[IU% \\98
M577&R*#BLKVRETZ',X/L+8.D,T@\[]:19WG/+%LMM#I2[78CFKOQH7IK),>E
M2\JSU?B4HYU=/3=U+0!5MDS0#1-,YD"?_7%XE&W.G7B7G]E.@+E:A!:=.M,P
M[QQL6@?)&P[BA'Y2TI:&/L@"BG\"A,BVIYR<*&^24<1[R&]H&E_3)$J2$;RT
MER#U>.GW2?#'>F>LQE/TYY (K8O)L M76;>F9CDL RP= _H;!*N+=_$LNAL)
M8-(',!E#7VTUU(P7E,F"_F)+T'1M#%@SQ',4:9CG.;SR\,S#TUQA;1I+U9[B
M,MTK@27.Y8%><HDKJC%H8JYN"68,JAT:8M:(RYH;8M(!&_*>Q-?I//779)(2
M'P3)(C*/R6?ETE)W6_]%PMM,IJUM&D_HB)[37L_I?^B)[SQM7[VSAZ\-K]WA
MN*8_@QV2=!3L+4G//,#) RU!%"BCIHT!NGNE.;-P4!JW::#>6EHHJ%?W7&_K
MBO/_JMX'A)(E43M\;+3DMM% IO@[23[$D213]_\)#.8BSYNJ$<QQ*@#YY=R7
M"KF,?R!7.$YQ' [UFDIP!&8N;]%8TF9]TF:C25OGN6Z0R,,+]BL#@X=_%&$X
M4R=8Z&"_^] _REQ5@"E[0;#W^'"*X\6[+(F3.[)EKQH!R3Q+R"3+G'A[5!HU
MQ80X1CP'@S@9R2;DZ8)5]=U]O^X5-NYEQMVF.,&*B+*XJZ9X-G<5Y7/KBV6&
M$.XZ3]-!_<.SIE*!/OC6Z>)OI&W[2[_:=^=UVY3^WMZV]D],'[@T5, >3:.;
M.9:,;MME.[&J]BUJIRPV/'];XA<&:+<!G^^5LJ>)<]!_LZS^ E!+ P04
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MH(TX83AN&8Y[&;:5LH5*#X4B3:&ZB#K J).#8]D7<<(R:EE&O2SG)-5=<Z,
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M=G2)#J-]72(,?E^OP3^4 )J;]6#R:[1VJ^H_3'Z'3;M"*J)^:R3(4:[=I*3
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M/J(?F4YD@>XG<R&YRN>')A4+)]UF)[K(ST2&0QA;JHH%\!58P:</;M_YTJ3
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MX'J#6E\P)K<#[:#ZP@C^ %!+ P04    " #FB'Y6+VU$ 58(  !=5   &0
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MN^=35<76E=5:IBB!/V.V)#E'*2RDI'>C:L:LJ"H7-X*N=9UU3H6@F;Y< 4Z
MJ0;R_8)2<;A1'52U_?&_4$L#!!0    ( .:(?E97G>P@;0(  %\&   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*U576_:,!3]*U963:W4D4^@8B$2
M'YK6AVFHM-O#M >37(A5Q\YL0]I_/]L)&=" ^K"7Q';N.3[G^OHFKKAXECF
M0B\%97+LY$J5(]>5:0X%ECU> M-?UEP46.FIV+BR%( S"RJH&WC>P"TP84X2
MV[6%2&*^590P6 @DMT6!Q>L4**_&CN_L%Q[()E=FP4WB$F]@">JI7 @]<UN6
MC!3 ).$,"5B/G8D_FO5-O WX0:"2!V-DG*PX?S:3^VSL>$804$B58<#ZM8,9
M4&J(M(P_#:?3;FF A^,]^Q?K77M980DS3G^23.5CY\Y!&:SQEJH'7GV%QH\5
MF'(J[1-53:SGH'0K%2\:L%90$%:_\4N3AP. 'YT!! T@>"\@; "A-5HKL[;F
M6.$D%KQ"PD1K-C.PN;%H[88P<XI+)?17HG$J66[+DH(^%H4IFF**60IH:>OG
MGM5%HK-]BQ8"2DPRA%F&OJL<!)I("4JBZSDH3*B\09_0TW*.KJ]NT!4B##WF
M?"MUN(Q=I86:[=RT$36M105G1,TA[:'0OT6!%P0=\-G[X?XQW-7I:7,4M#D*
M+%]XAN^L]U^3E51"5^+O+H\U:=1-:F[G2)8XA;&CKY\$L0,G^?C!'WB?NQS_
M)[(C_V'K/[S$OO??>9 ULF^1IF/L$C\<AK&[.Q3?$11$_X*.1$6MJ.BB*'L0
M78IJV.!@LSOO1,_;D*'?K:;?JNE?5//(S?TIFT392N&V4K"ME"Z=_;=)B?JG
MF>L("OWH1*M[</U-Z_V&Q88PB2BL-<SK#35>U.VLGBA>VHZPXDKW%SO,]1\
MA G0W]><J_W$-)GVGY+\!5!+ P04    " #FB'Y6/]Z39DD#  #^#   &0
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M.Y/X!Y.W*I&000D43<]Y8WT=HUL[G5JJ5!]JB"K>]Y3[VX-U=XWS3W.@WEJ
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MN'B[931@/#] _;Y.4WGXD >H__-A\2]02P,$%     @ YHA^5I$<N9?Z @
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MRU&,((50* @L_[8P@S152)+'[Q+4,L]4B=7Q ?VS%B_%+#&'&4U_)I&(Q];
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M;ZD':'FX1$4G"D--9SVW'S4\67F>P)5@I/X8SJ1 #7^F7T_FBH<\F<*=C%#
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M\8'K9Y@HI(*:&*1@-:"8P5H;O;KP</WVKIWU<F[0J_[;8[J_-=W_J<TTW_Y
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MP+\,(WO5E?LZRG,#-VBCMG0,6AV#@SJ^+LW]X',RXU2DA)G[(D\;88M&YI;
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M4<_FNX3O'#9Z;TRLD[F43W;R.1MXOA4$!:3&,C!\K6$$16&)4,;/AM-KM[3
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M#78C-\SQ?P'*)N#Z0DJSF]@-VC]0\AM02P,$%     @ YHA^5E6YEZB* @
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M3"I-0R)*O5YH(Q;3E&@V]*^FIHZ%A!2")V6L3(PLF9!FV5=L7VR@*G54M/"
MET9V6>E+62*L=G3Y:U5YX/XZ?R+^[-:_A)CG)G%+M+5)(WI9117UJ&CA =]-
M'*R>0L 'K8 /W *^3>)X47"ARIRI5T-M7 H@"P$T7INW[K4(5<VCHH4'^N\'
M'DGH:S\UIQ#X02OP [? ;ZDI](4@SX(I!3G)N=)!93A: +'55I^6=13J:*PV
MS;89Z]4_[KJ/I@QU.^" 7YR4H6X3#+>.RV4@5O:<HJS2A>IP6/.T.0MY9T\
M[CP/_>NH.M'8PE0'+.^I6+%<DA26&M([O] =$-69Q>I&\<(>REMPI7AF+]=
M$Q"F@'Z_Y%QM;DP%S<G1V7]02P,$%     @ YHA^5DB9%O3D @  (0@  !D
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M,HD*R#1DU!WIATW4E5?=4;RRQ<N"*UT*V6:NJU409H+^GG&NMAVS0%O_SOX
M4$L#!!0    ( .:(?E:;6(F.+P,  %<+   9    >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;*V66V^;,!3'OXK%JJF5VG))()<E2$VR:GVH%#7M]C#MP8%#
M0 6;V4[2??O9AI ;06V5EP3;Y_S].\?'< 9KREYY#"#06Y82/C1B(?*^:?(@
MA@SS6YH#D2L191D6<L@6)L\9X% [9:GI6)9G9C@AAC_0<U/F#^A2I F!*4-\
MF668_1M!2M=#PS8V$T_)(A9JPO0'.5[ #,1+/F5R9%8J89(!X0DEB$$T-.[L
M_MAVE(.V^)G FN\\(Q7*G-)7-7@(AX:EB""%0"@)+/]6,(8T54J2XV\I:E1[
M*L?=YXWZO0Y>!C/'',8T_96$(AX:70.%$.%E*I[H^@>4 ;E*+Z IU[]H7=I:
M!@J67-"L=)8$64**?_Q6)F+'P?9..#BE@W/HT#[AT"H=6CK0@DR'-<$"^P-&
MUX@I:ZFF'G1NM+>,)B'J&&>"R=5$^@G_@00T _2,WX!?HS'-<DJ "(YHA+9K
M:,KH*M%'=SD" E$BKM#E! 1.4GZ%;M#+;((N+Z[0!4H(>H[IDF,2\H$I)*+:
MR Q*G%&!XYS L1WT2(F(.?I.0@CW!4P96Q6@LPEPY#0J3B"X12W[&CF6X]0
MC=_O;C?@M*I\M[1>ZX3>AS+\^V[.!9.5_J<ND\5&[?J-U/7O\QP',#3D_>;
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MP)2!7(\H%9N!VJ#JI?W_4$L#!!0    ( .:(?E9_NC/;W0,   <.   9
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M7 .:QX6YJ8&T!N;[3 C]VK!W@>[N5_P'4$L#!!0    ( .:(?E:08B<,&00
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MOXK%I*F5MO"4D+9+D-JTTS8I4]1JVXNJ+QRX!*M@4]LD[;??&0A-*LH6B3>
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MA!KZ_<;DV=O7=.B'\4??LW3C(J5#__'B_:]%H6[>>?9^]N'LK/-X>;-KOS#
MI1\X2:\/(+WJZ ME-BA&'Q]$OX<;(^X=IGN?:HRZOTUMAI]K(NMXCKDE#K<K
MF[@V48ASK^-V/M]TQB+WP@/7<.\2&O*@KL31("M$6Y"1;PTZ.LFI]T3XT!\3
MSB:2@5=&<L97UMP%P[3@A?24W@E:3@B6ZH^%0]N#35+SY$P4TL2V$>S?23U\
M!UCW0"#CO!'8]:UA-"B)4E2*6]TQ@XWQ&>35[8=5J17.)%F%W6N_=3 W'612
MR)3*)DSHKTVC :<9R)%L-H>[*LH 0*6*7#=21F:%($;#VJ-N:-HIY?P>GB _
MLRWN9;:QKJ8D1-/4@NJFI;$=X-]DL]R;M->OXO5*]E2H+PL]'6'Z4"WT3M*,
M+4U_F34",/809R=ER5>?.9N)G-K)'QQP-"!K/V]>2/9'1X-2F6H#E;[W1*5B
MTTW+;TG*![I4ZW):9KCF[@EJ_K=YGE%!)>&;HG7M'W.67ZVX?N6^A6;S6-E5
M[!09]8Y?8WW,.':1\2F(/(GE[I^"R.0$1/;>[*GY@B?0220R/$J107U<VS@3
M;IT(&ZL')^^A_P/.^;P-ZDT6C"LFZMZ<I2D5SPZ&FEZ1B?Z'=8M?CT]I1A9<
M/33@T&_;WVG*%GG2C+J#1-2CVO8WF%X8-\=^'8N)E"YI.JZ[<C8Q34\W=-3Z
M H==Y-9<;@3SL9@; 0R+@RG ?*P7%N=_FD\?G8_%,&U])])'??JHC_5R(6/S
MP>*X?1)]N6>:)%$4QUA&QV.G@C&6MSB&KYL-TP8>6!R(]+)<XZN-5\C^.L#6
M=%^%8#/%*Q&;*9YK0-QY X\D<:\V%@<\L%7 :@?BN^- 3;E]H@A6%=.&[6 <
M21(,@5ITUV@<(]F)X>->'VR71%&2N!' W JB"$-@-^((I@ T8$@4F??@SOLH
M6+^G@O97W-%?4$L#!!0    ( .:(?E:7BKL<P    !,"   +    7W)E;',O
M+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +
M&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P
M6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,
M-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4
M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ YHA^5@/=>A4Q!0  7RL   \
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MX!.41E!$Y2BD<A13.0JJ'$55CL(J1W&5H\#*4605*+(*%%D%BJP"15:!(JM
MD56@R"I09!4HL@H4626*K!)%5HDBJT215:+(*E%DE2BR2A19)8JL$D56A2*K
M0I%5H<BJ4&15*+(J%%D5BJP*15:%(JM"D56CR*I19-4HLFH4636*K!I%5HTB
MJT:15:/(JE%D+5!D+5!D+5!D+5!D+5!D+?Y3UF=KEW\</SSSUM3=(9\-__^:
MO0%02P$"% ,4    " #FB'Y6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .:(?E8N/',([@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( .:(?E:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ YHA^5DFK_!:&!P  S#   !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( .:(?E8(/]]9+ 4  %T5   8              " @<D/  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #FB'Y6BK3%%MP"   Y"@
M&               @($K%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ YHA^5I$8Y"[Y!   K!,  !@              ("!/1@  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( .:(?E:U'1()(@<
M + M   8              " @6P=  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #FB'Y6&*1^T/0&  "S'@  &               @('$
M)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ YHA^5G-5
MJ98%(   M%T  !@              ("![BL  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( .:(?E:Y.NI5$@<  '41   8
M  " @2E,  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #F
MB'Y6?='W[[P'  #E%   &               @(%Q4P  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ YHA^5K<L'W :!P  <1   !D
M         ("!8UL  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #FB'Y6K3/>NX,$  !A"@  &0              @(&T8@  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( .:(?E:]:PF=Q00  + +
M   9              " @6YG  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ YHA^5AW9P$]S#0  .B4  !D              ("!:FP
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #FB'Y62GB_
M0%L%  !P#   &0              @($4>@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( .:(?E:AI'85[@8  . 0   9
M  " @:9_  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MYHA^5FT9C>YL$0  9#8  !D              ("!RX8  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #FB'Y6].S#<-D$   U#   &0
M            @(%NF   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( .:(?E9>)A'C% D  "<9   9              " @7Z=  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ YHA^5J30W?P* P
M[P8  !D              ("!R:8  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #FB'Y6=JD@7),#   ;"   &0              @($*
MJ@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( .:(?E9>
MUXPAB!\  !!C   9              " @=2M  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ YHA^5ED"GP40!   X L  !D
M     ("!D\T  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .:(?E9J=UZ$%@4  -0,   9              "
M@<7B  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ YHA^
M5N@Y"JA/ @  [P0  !D              ("!$N@  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #FB'Y6.&TT! 4#  !^"@  &0
M        @(&8Z@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( .:(?E87CD\90 (  .($   9              " @=3M  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ YHA^5IM.9<P^ @  C 0
M !D              ("!2_   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #FB'Y6J+>@%6@"   2!0  &0              @(' \@
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( .:(?E:/*":*
MT0(  )8'   9              " @5_U  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ YHA^5J?[HP6)!   +AP  !D
M ("!9_@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #F
MB'Y6\0CX2&$#  #'"@  &0              @($G_0  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .:(?E:W"*C-Y@,  #</   9
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M970T,"YX;6Q02P$"% ,4    " #FB'Y6?9;8)6H$  #G%P  &0
M    @('8%P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M .:(?E97G>P@;0(  %\&   9              " @7D< 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ YHA^5C_>DV9) P  _@P  !D
M             ("!'1\! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #FB'Y6Z,56Q\@"   0"   &0              @(&=(@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( .:(?E9X/N<Q5 ,
M 'H-   9              " @9PE 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ YHA^5DR"%!4?!@  !3$  !D              ("!
M)RD! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #FB'Y6
MD1RYE_H"   W"P  &0              @(%]+P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( .:(?E;B*Y:5<0L  ,AU   9
M      " @:XR 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ YHA^5AY0IZ?C!   0A4  !D              ("!5CX! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #FB'Y6Y&^@HW$#  #!#P
M&0              @(%P0P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( .:(?E80>=I1T0(  (\'   9              " @1A' 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ YHA^5D 7U.^!
M @  C08  !D              ("!($H! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " #FB'Y65;F7J(H"  !V!P  &0
M@('83 $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .:(
M?E:6DRK3*@0  #H9   9              " @9E/ 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ YHA^5D;2'Y3G!   G1P  !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( .:(?E:,SEMQ8 ,   L+   9
M  " @9MN 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
MYHA^5IM8B8XO P  5PL  !D              ("!,G(! 'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    " #FB'Y6?[HSV]T#   '#@  &0
M            @(&8=0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( .:(?E:08B<,&00  #,2   9              " @:QY 0!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ YHA^5DJ23G8+ P
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M96QS+RYR96QS4$L! A0#%     @ YHA^5@/=>A4Q!0  7RL   \
M     ( !\(@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( .:(?E:U<6!\
M%@(  *HF   :              "  4Z. 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( .:(?E;2-&04[ $   <F   3
M  "  9R0 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !) $D ]A,  +F2
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>166</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>58</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Company Description and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/Merger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Pre-Merger Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/PremergerFinancing</Role>
      <ShortName>Pre-Merger Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Apexian Sublicense Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/ApexianSublicenseAgreement</Role>
      <ShortName>Apexian Sublicense Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Stockholder Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockholderEquity</Role>
      <ShortName>Stockholder Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/LicenseAndCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - Net income (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/NetIncomeLossPerShare</Role>
      <ShortName>Net income (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061300 - Disclosure - Deferred Compensation Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/DeferredCompensationPlan</Role>
      <ShortName>Deferred Compensation Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061400 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>070100 - Disclosure - Company Description and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080100 - Disclosure - Company Description and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ocuphire.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ocuphire.com/role/StockbasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>081000 - Disclosure - License and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/LicenseAndCollaborationAgreementsTables</Role>
      <ShortName>License and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ocuphire.com/role/LicenseAndCollaborationAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>081100 - Disclosure - Net income (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/NetIncomeLossPerShareTables</Role>
      <ShortName>Net income (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ocuphire.com/role/NetIncomeLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>081200 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ocuphire.com/role/IncomeTaxes</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Company Description and Summary of Significant Accounting Policies, Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090106 - Disclosure - Company Description and Summary of Significant Accounting Policies, Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090108 - Disclosure - Company Description and Summary of Significant Accounting Policies, Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090110 - Disclosure - Company Description and Summary of Significant Accounting Policies, Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090112 - Disclosure - Company Description and Summary of Significant Accounting Policies, Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090114 - Disclosure - Company Description and Summary of Significant Accounting Policies, Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090116 - Disclosure - Company Description and Summary of Significant Accounting Policies, Fair Value of Financial Instruments Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Fair Value of Financial Instruments Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090118 - Disclosure - Company Description and Summary of Significant Accounting Policies, Equity Investments Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Equity Investments Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090120 - Disclosure - Company Description and Summary of Significant Accounting Policies, Warrant Liabilities and Premium Conversion Derivatives Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Warrant Liabilities and Premium Conversion Derivatives Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090122 - Disclosure - Company Description and Summary of Significant Accounting Policies, Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails</Role>
      <ShortName>Company Description and Summary of Significant Accounting Policies, Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090206 - Disclosure - Merger, Contingent Value Rights Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails</Role>
      <ShortName>Merger, Contingent Value Rights Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090208 - Disclosure - Merger, Former Rexahn Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails</Role>
      <ShortName>Merger, Former Rexahn Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Pre-Merger Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/PremergerFinancingDetails</Role>
      <ShortName>Pre-Merger Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/PremergerFinancing</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Supplemental Balance Sheet Information, Prepaid and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information, Prepaid and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090502 - Disclosure - Supplemental Balance Sheet Information, Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails</Role>
      <ShortName>Supplemental Balance Sheet Information, Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090504 - Disclosure - Supplemental Balance Sheet Information, Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information, Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090506 - Disclosure - Supplemental Balance Sheet Information, Short-Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails</Role>
      <ShortName>Supplemental Balance Sheet Information, Short-Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Stock-based Compensation, Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation, Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090702 - Disclosure - Stock-based Compensation, Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails</Role>
      <ShortName>Stock-based Compensation, Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090704 - Disclosure - Stock-based Compensation, Weighted Average Assumptions Used in Black-Scholes Option-pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails</Role>
      <ShortName>Stock-based Compensation, Weighted Average Assumptions Used in Black-Scholes Option-pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090706 - Disclosure - Stock-based Compensation, Restricted Stock Awards Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails</Role>
      <ShortName>Stock-based Compensation, Restricted Stock Awards Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>090708 - Disclosure - Stock-based Compensation, Common Stock Issued for Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails</Role>
      <ShortName>Stock-based Compensation, Common Stock Issued for Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>090710 - Disclosure - Stock-based Compensation, Former Rexahn Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails</Role>
      <ShortName>Stock-based Compensation, Former Rexahn Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Apexian Sublicense Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/ApexianSublicenseAgreementDetails</Role>
      <ShortName>Apexian Sublicense Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/ApexianSublicenseAgreement</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Stockholders' Equity, At-The-Market Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails</Role>
      <ShortName>Stockholders' Equity, At-The-Market Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>090902 - Disclosure - Stockholders' Equity, Registered Direct Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails</Role>
      <ShortName>Stockholders' Equity, Registered Direct Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>091000 - Disclosure - License and Collaboration Agreements, Nyxol License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails</Role>
      <ShortName>License and Collaboration Agreements, Nyxol License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>091002 - Disclosure - License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails</Role>
      <ShortName>License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Net income (loss) per share, Computation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net income (loss) per share, Computation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>091102 - Disclosure - Net income (loss) per share, Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails</Role>
      <ShortName>Net income (loss) per share, Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/NetIncomeLossPerShareTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Income Taxes, Reconciliation of Statutory to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes, Reconciliation of Statutory to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>091204 - Disclosure - Income Taxes, Components of Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes, Components of Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>091206 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes, Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>091208 - Disclosure - Income Taxes, Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes, Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>091300 - Disclosure - Deferred Compensation Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/DeferredCompensationPlanDetails</Role>
      <ShortName>Deferred Compensation Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/DeferredCompensationPlan</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="brhc10050364_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>091400 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ocuphire.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://ocuphire.com/role/SubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. brhc10050364_10k.htm 26438</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. brhc10050364_10k.htm 26438</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate -  brhc10050364_10k.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="brhc10050364_10k.htm">brhc10050364_10k.htm</File>
    <File>brhc10050364_ex10-1-1.htm</File>
    <File>brhc10050364_ex10-10-1.htm</File>
    <File>brhc10050364_ex10-15-1.htm</File>
    <File>brhc10050364_ex10-15-2.htm</File>
    <File>brhc10050364_ex10-2-1.htm</File>
    <File>brhc10050364_ex10-7-1.htm</File>
    <File>brhc10050364_ex10-7-2.htm</File>
    <File>brhc10050364_ex10-9-1.htm</File>
    <File>brhc10050364_ex21-1.htm</File>
    <File>brhc10050364_ex23-1.htm</File>
    <File>brhc10050364_ex31-1.htm</File>
    <File>brhc10050364_ex31-2.htm</File>
    <File>brhc10050364_ex32-1.htm</File>
    <File>ocup-20221231.xsd</File>
    <File>ocup-20221231_cal.xml</File>
    <File>ocup-20221231_def.xml</File>
    <File>ocup-20221231_lab.xml</File>
    <File>ocup-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image0.jpg</File>
    <File>image00015.jpg</File>
    <File>image1.jpg</File>
    <File>image10.jpg</File>
    <File>image12.jpg</File>
    <File>image13.jpg</File>
    <File>image14.jpg</File>
    <File>image2.jpg</File>
    <File>image3.jpg</File>
    <File>image4.jpg</File>
    <File>image5.jpg</File>
    <File>image6.jpg</File>
    <File>image7.jpg</File>
    <File>image8.jpg</File>
    <File>image9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="513">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>107
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10050364_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 513,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 166,
   "dts": {
    "calculationLink": {
     "local": [
      "ocup-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ocup-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "brhc10050364_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ocup-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ocup-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ocup-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 568,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 8
   },
   "keyCustom": 94,
   "keyStandard": 250,
   "memberCustom": 30,
   "memberStandard": 26,
   "nsprefix": "ocup",
   "nsuri": "http://ocuphire.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://ocuphire.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060400 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://ocuphire.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060500 - Disclosure - Supplemental Balance Sheet Information",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://ocuphire.com/role/SupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060600 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://ocuphire.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060700 - Disclosure - Stock-based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://ocuphire.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:ApexianSublicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060800 - Disclosure - Apexian Sublicense Agreement",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://ocuphire.com/role/ApexianSublicenseAgreement",
     "shortName": "Apexian Sublicense Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:ApexianSublicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060900 - Disclosure - Stockholder Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://ocuphire.com/role/StockholderEquity",
     "shortName": "Stockholder Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061000 - Disclosure - License and Collaboration Agreements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://ocuphire.com/role/LicenseAndCollaborationAgreements",
     "shortName": "License and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061100 - Disclosure - Net income (loss) per share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://ocuphire.com/role/NetIncomeLossPerShare",
     "shortName": "Net income (loss) per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061200 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://ocuphire.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061300 - Disclosure - Deferred Compensation Plan",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://ocuphire.com/role/DeferredCompensationPlan",
     "shortName": "Deferred Compensation Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010000 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://ocuphire.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061400 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://ocuphire.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070100 - Disclosure - Company Description and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Company Description and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:NatureOfBusinessPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080100 - Disclosure - Company Description and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Company Description and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080500 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://ocuphire.com/role/SupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080700 - Disclosure - Stock-based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://ocuphire.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081000 - Disclosure - License and Collaboration Agreements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://ocuphire.com/role/LicenseAndCollaborationAgreementsTables",
     "shortName": "License and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081100 - Disclosure - Net income (loss) per share (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://ocuphire.com/role/NetIncomeLossPerShareTables",
     "shortName": "Net income (loss) per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081200 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://ocuphire.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ocup:NumberOfSmallMoleculeProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090100 - Disclosure - Company Description and Summary of Significant Accounting Policies, Nature of Business (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Nature of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ocup:NumberOfSmallMoleculeProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090106 - Disclosure - Company Description and Summary of Significant Accounting Policies, Liquidity (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221101to20221130_TypeOfArrangementAxis_NyxolLicenseAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "ocup:NonRefundableUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010100 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://ocuphire.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090108 - Disclosure - Company Description and Summary of Significant Accounting Policies, Segment Information (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090110 - Disclosure - Company Description and Summary of Significant Accounting Policies, Concentration of Credit Risk (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashUninsuredAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090112 - Disclosure - Company Description and Summary of Significant Accounting Policies, Short-term Investments (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Short-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ocup:ContractAssetCurrent",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090114 - Disclosure - Company Description and Summary of Significant Accounting Policies, Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090116 - Disclosure - Company Description and Summary of Significant Accounting Policies, Fair Value of Financial Instruments Measured on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Fair Value of Financial Instruments Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrealizedGainLossOnInvestments",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090118 - Disclosure - Company Description and Summary of Significant Accounting Policies, Equity Investments Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Equity Investments Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20201231_FairValueByAssetClassAxis_ShortTermInvestmentsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20210101to20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ocup:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090120 - Disclosure - Company Description and Summary of Significant Accounting Policies, Warrant Liabilities and Premium Conversion Derivatives Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Warrant Liabilities and Premium Conversion Derivatives Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20201231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByLiabilityClassAxis_WarrantLiabilitiesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentUsefulLife",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090122 - Disclosure - Company Description and Summary of Significant Accounting Policies, Property and Equipment, net (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails",
     "shortName": "Company Description and Summary of Significant Accounting Policies, Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentUsefulLife",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:ContingentValueRightsPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090206 - Disclosure - Merger, Contingent Value Rights Agreement (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails",
     "shortName": "Merger, Contingent Value Rights Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:ContingentValueRightsPaymentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090208 - Disclosure - Merger, Former Rexahn Warrants (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
     "shortName": "Merger, Former Rexahn Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_BusinessAcquisitionAxis_RexahnStockholdersMember",
      "decimals": null,
      "lang": "en-US",
      "name": "ocup:WeightedAverageRemainingContractualTermsWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020000 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090300 - Disclosure - Pre-Merger Financing (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://ocuphire.com/role/PremergerFinancingDetails",
     "shortName": "Pre-Merger Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20200629to20200629_TypeOfArrangementAxis_SecuritiesPurchaseAgreementMember",
      "decimals": "INF",
      "lang": null,
      "name": "ocup:NumberOfDirectors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U009",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ocup:OperatingLeasesMonthlyBaseRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090400 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ocup:OperatingLeasesMonthlyBaseRent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090500 - Disclosure - Supplemental Balance Sheet Information, Prepaid and Other Assets (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails",
     "shortName": "Supplemental Balance Sheet Information, Prepaid and Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090502 - Disclosure - Supplemental Balance Sheet Information, Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails",
     "shortName": "Supplemental Balance Sheet Information, Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090504 - Disclosure - Supplemental Balance Sheet Information, Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails",
     "shortName": "Supplemental Balance Sheet Information, Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxesPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090506 - Disclosure - Supplemental Balance Sheet Information, Short-Term Loan (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails",
     "shortName": "Supplemental Balance Sheet Information, Short-Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20211130",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ocup:NumberOfDirectorsSignedWaiverAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U009",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090600 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://ocuphire.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ocup:NumberOfDirectorsSignedWaiverAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U009",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090700 - Disclosure - Stock-based Compensation, Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation, Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090702 - Disclosure - Stock-based Compensation, Stock Option Plan Activity (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
     "shortName": "Stock-based Compensation, Stock Option Plan Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20210222_PlanNameAxis_InducementPlanMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ocup:CommonStockCapitalSharesAvailableForFutureIssuance",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231_PlanNameAxis_EquityIncentivePlan2020Member",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ocup:CommonStockCapitalSharesAvailableForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090704 - Disclosure - Stock-based Compensation, Weighted Average Assumptions Used in Black-Scholes Option-pricing Model (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails",
     "shortName": "Stock-based Compensation, Weighted Average Assumptions Used in Black-Scholes Option-pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ocup:CommonStockCapitalSharesAvailableForFutureIssuance",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231_PlanNameAxis_EquityIncentivePlan2020Member",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ocup:CommonStockCapitalSharesAvailableForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20201231_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030000 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20201231_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090706 - Disclosure - Stock-based Compensation, Restricted Stock Awards Activity (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails",
     "shortName": "Stock-based Compensation, Restricted Stock Awards Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_AwardTypeAxis_RestrictedStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090708 - Disclosure - Stock-based Compensation, Common Stock Issued for Services (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails",
     "shortName": "Stock-based Compensation, Common Stock Issued for Services (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090710 - Disclosure - Stock-based Compensation, Former Rexahn Options (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails",
     "shortName": "Stock-based Compensation, Former Rexahn Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231_BusinessAcquisitionAxis_RexahnStockholdersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentAndRegulatoryMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ocup:FutureMilestoneMethodRevenueNotRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090800 - Disclosure - Apexian Sublicense Agreement (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://ocuphire.com/role/ApexianSublicenseAgreementDetails",
     "shortName": "Apexian Sublicense Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_HealthCareOrganizationRevenueSourcesAxis_DevelopmentAndRegulatoryMilestonesMember_RangeAxis_MaximumMember_RelatedPartyTransactionAxis_ApexianSublicenseAgreementMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ocup:FutureMilestoneMethodRevenueNotRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090900 - Disclosure - Stockholders' Equity, At-The-Market Program (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
     "shortName": "Stockholders' Equity, At-The-Market Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20210212to20210212_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ShelfRegistrationMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090902 - Disclosure - Stockholders' Equity, Registered Direct Offering (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails",
     "shortName": "Stockholders' Equity, Registered Direct Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20210608to20210608_SubsidiarySaleOfStockAxis_RegisteredDirectOfferingMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ocup:ContractAssetCurrent",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091000 - Disclosure - License and Collaboration Agreements, Nyxol License Agreement (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails",
     "shortName": "License and Collaboration Agreements, Nyxol License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221106_TypeOfArrangementAxis_NyxolLicenseAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "ocup:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20200310to20200310_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ocup:NonRefundableCashPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091002 - Disclosure - License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
     "shortName": "License and Collaboration Agreements, BioSense License and Assignment Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20200310to20200310_TypeOfArrangementAxis_BioSenseLicenseAndAssignmentsAgreementMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ocup:NonRefundableCashPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091100 - Disclosure - Net income (loss) per share, Computation of Diluted Net Income (Loss) Per Share (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net income (loss) per share, Computation of Diluted Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "0",
      "lang": null,
      "name": "ocup:IncrementalCommonSharesAttributableToOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091102 - Disclosure - Net income (loss) per share, Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails",
     "shortName": "Net income (loss) per share, Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesASeriesBAndRDOWarrantsMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040000 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ocup:EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091200 - Disclosure - Income Taxes, Reconciliation of Statutory to Effective Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes, Reconciliation of Statutory to Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "ocup:EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091204 - Disclosure - Income Taxes, Components of Income Tax Provision (Benefit) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails",
     "shortName": "Income Taxes, Components of Income Tax Provision (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091206 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes, Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091208 - Disclosure - Income Taxes, Operating Loss Carryforwards (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes, Operating Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20221231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091300 - Disclosure - Deferred Compensation Plan (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://ocuphire.com/role/DeferredCompensationPlanDetails",
     "shortName": "Deferred Compensation Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20211001to20211001_RetirementPlanNameAxis_RetirementPlan401KMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091400 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://ocuphire.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231_PlanNameAxis_EvergreenProvisionPlan2020Member",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060100 - Disclosure - Company Description and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Company Description and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060200 - Disclosure - Merger",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://ocuphire.com/role/Merger",
     "shortName": "Merger",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:PreMergerFinancingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060300 - Disclosure - Pre-Merger Financing",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://ocuphire.com/role/PremergerFinancing",
     "shortName": "Pre-Merger Financing",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10050364_10k.htm",
      "contextRef": "c20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ocup:PreMergerFinancingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 58,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://ocuphire.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ocup_AccreditedInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An accredited investor is an individual or a business entity that is allowed to trade securities that may not be registered with financial authorities.",
        "label": "Accredited Investor [Member]"
       }
      }
     },
     "localname": "AccreditedInvestorMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_AccruedResearchAndDevelopmentServicesAndSuppliesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development service and supplies. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Services and Supplies Current",
        "terseLabel": "R&amp;D services and supplies"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentServicesAndSuppliesCurrent",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock and . Includes, but is not limited to, legal and accounting fees and direct costs associated with common stock; ATM and Registered Direct Financing.",
        "label": "Adjustments to Additional Paid in Capital, Issuance Costs related to Common Stock, ATM and Registered Direct Financing",
        "negatedLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceCostsRelatedToCommonStockATMAndRegisteredDirectFinancing",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the warrants converting to equity issued originally in Pre-Merger financing.",
        "label": "Adjustments to Additional Paid in Capital, Reclassification of Warrants to Equity",
        "terseLabel": "Reclassification of Series A warrant liability to equity",
        "verboseLabel": "Reclassification of warrants from liability to equity"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_AggregateNumberOfCommonStockReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance\" given the addition added to reserve due to Evergreen provision.",
        "label": "Aggregate Number of Common Stock reserved for future issuance",
        "terseLabel": "Number of shares added (in shares)"
       }
      }
     },
     "localname": "AggregateNumberOfCommonStockReservedForFutureIssuance",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_AmountInvestedInPreMergerFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount invested by directors in Pre-Merger Financing",
        "label": "Amount Invested in Pre-Merger Financing",
        "terseLabel": "Amount invested in pre-merger financing"
       }
      }
     },
     "localname": "AmountInvestedInPreMergerFinancing",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_ApexianSublicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Apexian Sublicense Agreement [Abstract]"
       }
      }
     },
     "localname": "ApexianSublicenseAgreementAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ocup_ApexianSublicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense agreement with Apexian Pharmaceuticals, Inc.",
        "label": "Apexian Sublicense Agreement [Member]",
        "terseLabel": "Apexian Sublicense Agreement [Member]"
       }
      }
     },
     "localname": "ApexianSublicenseAgreementMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_ApexianSublicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Apexian Sublicense Agreement related to exclusive worldwide patent and other intellectual property rights that constitute a Ref-1 Inhibitor program relating to therapeutic applications to treat disorders related to ophthalmic and diabetes mellitus conditions.",
        "label": "Apexian Sublicense Agreement [Text Block]",
        "terseLabel": "Apexian Sublicense Agreement"
       }
      }
     },
     "localname": "ApexianSublicenseAgreementTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_AtTheMarketProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "At-The-Market Program [Abstract]",
        "terseLabel": "At-The-Market Program [Abstract]"
       }
      }
     },
     "localname": "AtTheMarketProgramAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_AtTheMarketProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market is an instruction given to a broker to place a market order to buy or sell securities at the prevailing market bid or ask price during the period.",
        "label": "At-The-Market Program [Member]",
        "terseLabel": "ATM [Member]"
       }
      }
     },
     "localname": "AtTheMarketProgramMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_BioSenseGlobalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity entered into License and Assignment Agreement.",
        "label": "BioSense Global LLC [Member]"
       }
      }
     },
     "localname": "BioSenseGlobalLLCMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_BioSenseLicenseAndAssignmentsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BioSense license and assignments agreement entered by the entity.",
        "label": "BioSense License and Assignments Agreement [Member]",
        "terseLabel": "BioSense License and Assignments Agreement [Member]"
       }
      }
     },
     "localname": "BioSenseLicenseAndAssignmentsAgreementMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_CollaborationAndLicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration and License Agreement [Abstract]",
        "verboseLabel": "Collaboration and License Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_CommonStockCapitalSharesAvailableForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares available for future issuance.",
        "label": "Common Stock, Capital Shares Available for Future Issuance",
        "terseLabel": "Common stock available for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesAvailableForFutureIssuance",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_CommonStockIssuedForServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Issued for Services [Abstract]",
        "terseLabel": "Common Stock Issued for Services [Abstract]"
       }
      }
     },
     "localname": "CommonStockIssuedForServicesAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_ConcentrationOfCreditRiskAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk [Abstract]",
        "terseLabel": "Concentration of Credit Risk [Abstract]"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_ConsultingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consultation fee payable in cash per month to the director.",
        "label": "Consulting Fee Payable",
        "terseLabel": "Consulting fee payable in cash"
       }
      }
     },
     "localname": "ConsultingFeePayable",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_ContingentValueRightEntitledPerEachShareOfCommonStockHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value right per each share of the Company's common stock held of record as of immediately prior to the closing of the merger.",
        "label": "Contingent Value Right Entitled Per Each Share Of Common Stock Held",
        "terseLabel": "Number of contingent value right received per common stock"
       }
      }
     },
     "localname": "ContingentValueRightEntitledPerEachShareOfCommonStockHeld",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_ContingentValueRightsAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Value Rights Agreement [Abstract]"
       }
      }
     },
     "localname": "ContingentValueRightsAgreementAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_ContingentValueRightsIPTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for parent IP deal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Contingent Value Rights IP Term",
        "terseLabel": "Parent IP deal period"
       }
      }
     },
     "localname": "ContingentValueRightsIPTerm",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_ContingentValueRightsPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment period for contingent value rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Contingent Value Rights Payment Period",
        "terseLabel": "Contingent value rights payment period"
       }
      }
     },
     "localname": "ContingentValueRightsPaymentPeriod",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_ContingentValueRightsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of payments received by Rexahn or its affiliates.",
        "label": "Contingent Value Rights Percentage",
        "terseLabel": "Percentage of payments received by Rexahn or its affiliates"
       }
      }
     },
     "localname": "ContingentValueRightsPercentage",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_ContractAssetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract Asset, Current",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Contract asset (Note 10)"
       }
      }
     },
     "localname": "ContractAssetCurrent",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_ContractAssetPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract assets.",
        "label": "Contract Asset [Policy Text Block]",
        "terseLabel": "Contract Asset"
       }
      }
     },
     "localname": "ContractAssetPolicyTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This line item represents amounts invoiced that were previously reflected in the Contract Asset account.",
        "label": "Contract Asset, Reclassification to Accounts Receivable Related to Costs Billed under License Agreement",
        "negatedLabel": "Reclassification to accounts receivable related to costs billed under the Nyxol License Agreement"
       }
      }
     },
     "localname": "ContractAssetReclassificationToAccountsReceivableRelatedToCostsBilledUnderLicenseAgreement",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_DebtInstrumentNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of installments to paid monthly for the loan repayment.",
        "label": "Debt Instrument, Number of Installments",
        "terseLabel": "Number of installments"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfInstallments",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_DeferredTaxAssetsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.",
        "label": "Deferred Tax Assets, Research and Development",
        "terseLabel": "Research and development credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchAndDevelopment",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research, State,and,Local",
        "terseLabel": "State research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_DefinedContributionPlanAdditionalEmployerMatchingContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Additional Employer Matching Contribution",
        "terseLabel": "Additional employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanAdditionalEmployerMatchingContribution",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional percentage employer matches of the employee's deferred percentage contribution matched.",
        "label": "Defined Contribution Plan, Additional Employer Matching Contribution Deferred",
        "terseLabel": "Additional deferred compensation matched by employer"
       }
      }
     },
     "localname": "DefinedContributionPlanAdditionalEmployerMatchingContributionDeferred",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_DevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents development and regulatory milestones.",
        "label": "Development and Regulatory Milestones [Member]"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate pf income tax (benefit) provision applicable to pretax income (loss).",
        "label": "Effective Income Tax (Benefit) Provision Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax (benefit) provision at federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxBenefitProvisionRateReconciliationAtFederalStatutoryIncomeTaxRatePercent",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_EffectiveIncomeTaxRateReconciliationWarrantsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to warrants.",
        "label": "Effective Income Tax Rate Reconciliation, Warrants, Percent",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationWarrantsPercent",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_EquityIncentivePlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to 2018 equity incentive plan.",
        "label": "Equity Incentive Plan 2018 [Member]",
        "terseLabel": "2018 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2018Member",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to 2020 equity incentive plan.",
        "label": "Equity Incentive Plan 2020 [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_EquityInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity investment means purchasing stake in a business and receiving partial ownership in it.",
        "label": "Equity Investment [Member]"
       }
      }
     },
     "localname": "EquityInvestmentMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_EstimatedStandaloneSellingPriceForLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated standalone selling price for license agreement.",
        "label": "Estimated Standalone Selling Price for License Agreement",
        "terseLabel": "Estimated standalone selling price for license agreement"
       }
      }
     },
     "localname": "EstimatedStandaloneSellingPriceForLicenseAgreement",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_EvergreenProvisionPlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to 2020 Plan Evergreen Provision.",
        "label": "Evergreen Provision Plan 2020 [Member]",
        "terseLabel": "2020 Plan Evergreen Provision [Member]"
       }
      }
     },
     "localname": "EvergreenProvisionPlan2020Member",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_FairValueAssumptionsExpectedLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Fair Value Assumptions, Expected Life",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "FairValueAssumptionsExpectedLife",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_FairValueShareSettlementAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of fair value shares settlement.",
        "label": "Fair value share settlement amount",
        "terseLabel": "Fair value share settlement amount"
       }
      }
     },
     "localname": "FairValueShareSettlementAmount",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_FederalOperatingLossCarryforwardsTaxEffect": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the related federal income tax effect on operating loss carry forward.",
        "label": "Federal Operating Loss Carryforwards, Tax effect",
        "terseLabel": "Federal operating loss carryforwards, tax effect"
       }
      }
     },
     "localname": "FederalOperatingLossCarryforwardsTaxEffect",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_FirstPotentialMilestonePaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payment received upon achieving performance obligation.",
        "label": "First Potential Milestone Payment to be Received",
        "terseLabel": "First potential payments to be received"
       }
      }
     },
     "localname": "FirstPotentialMilestonePaymentToBeReceived",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_FormerOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Options [Abstract]",
        "terseLabel": "Former Options [Abstract]"
       }
      }
     },
     "localname": "FormerOptionsAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_FormerRexahnOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time that are formerly Rexahn options.",
        "label": "Former Rexahn Options [Member]"
       }
      }
     },
     "localname": "FormerRexahnOptionsMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_FormerRexahnWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount that are formerly Rexahn Warrants.",
        "label": "Former Rexahn Warrants [Member]"
       }
      }
     },
     "localname": "FormerRexahnWarrantsMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_FutureMilestoneMethodRevenueNotRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consideration not recognized during the period for the future milestone or milestones.",
        "label": "Future Milestone Method, Revenue not Recognized",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "FutureMilestoneMethodRevenueNotRecognized",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_IncomeLossFromInvestmentsRelatedToLicenseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The is the portion of collaborations revenue from the license agreement paid in the form of non-cash equity investments.",
        "label": "Income (Loss) from Investments Related to License Agreement",
        "negatedLabel": "Receipt of investments related to license agreement"
       }
      }
     },
     "localname": "IncomeLossFromInvestmentsRelatedToLicenseAgreement",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_IncreaseDecreaseInContractAssetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration upon the completion of services to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Increase (Decrease) in Contract Asset Current",
        "negatedLabel": "Contract asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractAssetCurrent",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_IncrementalCommonSharesAttributableToOptions": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of options using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Options",
        "terseLabel": "Dilutive stock options (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToOptions",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_IncrementalCommonSharesAttributableToWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Warrants",
        "terseLabel": "Dilutive warrants (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToWarrants",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to inducement plan",
        "label": "Inducement Plan [Member]",
        "terseLabel": "Inducement Plan [Member]"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_IssuanceOfSettlementSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Settlement Shares [Abstract]"
       }
      }
     },
     "localname": "IssuanceOfSettlementSharesAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_LicenseAndCollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementsAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ocup_LicenseTransferFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License transfer fee related to terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Transfer Fee [Member]",
        "terseLabel": "License Transfer Fee [Member]"
       }
      }
     },
     "localname": "LicenseTransferFeeMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_LiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity [Abstract]",
        "terseLabel": "Liquidity [Abstract]"
       }
      }
     },
     "localname": "LiquidityAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the liquidity.",
        "label": "Liquidity [Policy Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments receivable upon the achievement of development, regulatory and commercial goals.",
        "label": "Maximum Amount Of Payments Receivable for Development, Regulatory and Commercial Milestones",
        "terseLabel": "Maximum amount of payments receivable for development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_MaximumPercentageOfBeneficialOwnershipLimitation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants.",
        "label": "Maximum Percentage of Beneficial Ownership Limitation",
        "terseLabel": "Maximum percentage of beneficial ownership limitation"
       }
      }
     },
     "localname": "MaximumPercentageOfBeneficialOwnershipLimitation",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_MaximumPercentageOfTieredRoyaltiesReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of tiered royalties receivable based on the aggregate annual net sales of all Nyxol Products in the United States.",
        "label": "Maximum Percentage of Tiered Royalties Receivable",
        "terseLabel": "Maximum percentage of tiered royalties receivable"
       }
      }
     },
     "localname": "MaximumPercentageOfTieredRoyaltiesReceivable",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_MaximumPeriodOfSharesReservedUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of shares reserved under plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Period of Shares Reserved Under Plan",
        "terseLabel": "Period of shares reserved under plan"
       }
      }
     },
     "localname": "MaximumPeriodOfSharesReservedUnderPlan",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_MilestonePaymentAchievedForPerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments achieved under the collaboration agreement during the period and recorded as collaboration revenue for the performance obligation.",
        "label": "Milestone Payment Achieved for Performance Obligation",
        "terseLabel": "Milestone payment achieved for performance obligation, recorded as collaboration revenue"
       }
      }
     },
     "localname": "MilestonePaymentAchievedForPerformanceObligation",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_MilestonePaymentsAmountReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment received upon achieving performance obligation..",
        "label": "Milestone Payments Amount Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsAmountReceived",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone period to administer drug clinical trail of licensed product on first patient in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Milestone Period to Administer Drug Clinical Trial of Licensed Product on First Patient",
        "terseLabel": "Milestone period to administer drug clinical trial of licensed product on first patient"
       }
      }
     },
     "localname": "MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatient",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone period to administer drug clinical trail of licensed product on first patient after second indication in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Milestone Period to Administer Drug Clinical Trial of Licensed Product on First Patient for Second Indication",
        "terseLabel": "Milestone period to administer drug clinical trial of licensed product on first patient for second indication"
       }
      }
     },
     "localname": "MilestonePeriodToAdministerDrugClinicalTrialOfLicensedProductOnFirstPatientForSecondIndication",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum number of countries to conduct development activities.",
        "label": "Minimum Number of Countries Development Activities to be Conducted",
        "terseLabel": "Number of countries"
       }
      }
     },
     "localname": "MinimumNumberOfCountriesDevelopmentActivitiesToBeConducted",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_MinimumPercentageOfBeneficialOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of beneficial ownership allowed for warrant holder and affiliates in exercise of warrants.",
        "label": "Minimum Percentage of Beneficial Ownership",
        "terseLabel": "Minimum percentage of beneficial ownership"
       }
      }
     },
     "localname": "MinimumPercentageOfBeneficialOwnership",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_NatureOfBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business [Abstract]",
        "terseLabel": "Nature of Business [Abstract]"
       }
      }
     },
     "localname": "NatureOfBusinessAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_NatureOfBusinessPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for nature of business.",
        "label": "Nature of Business [Policy Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfBusinessPolicyTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_NonRefundableCashPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-refundable cash payments received during the period under the collaboration agreement.",
        "label": "Non-refundable Cash Payment Received",
        "negatedLabel": "Execution of Nyxol License Agreement and one-time non-refundable payment",
        "terseLabel": "Non-refundable cash payment received"
       }
      }
     },
     "localname": "NonRefundableCashPaymentReceived",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_NonRefundableUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-refundable upfront payment received under the license and collaboration agreement with FamyGen Life Sciences, Inc.",
        "label": "Non-Refundable Upfront Payment Received",
        "terseLabel": "Non-refundable upfront payment received"
       }
      }
     },
     "localname": "NonRefundableUpfrontPaymentReceived",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the Series A Warrants in connection with the Pre-Merger Financing which was composed of just common stock and warrants.",
        "label": "Noncash or Part Noncash Reclassification of Warrants to Equity, Amount",
        "terseLabel": "Non-cash reclassification of Series A warrant liability to equity"
       }
      }
     },
     "localname": "NoncashOrPartNoncashReclassificationOfWarrantsToEquityAmount",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_NumberOfAccreditedInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of accredited investors to whom shares are issued by the entity.",
        "label": "Number of Accredited Investors",
        "terseLabel": "Number of accredited investors"
       }
      }
     },
     "localname": "NumberOfAccreditedInvestors",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NumberOfBoardMembersGrantedStockForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of board members for whom stock granted for services performed.",
        "label": "Number of Board Members Granted Stock for Services",
        "terseLabel": "Number of board members, stock granted for services"
       }
      }
     },
     "localname": "NumberOfBoardMembersGrantedStockForServices",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NumberOfConvertedAdditionalSharesReceivedByDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of converted additional shares received by directors.",
        "label": "Number of Converted Additional Shares Received by Directors",
        "terseLabel": "Number of converted additional shares (in shares)"
       }
      }
     },
     "localname": "NumberOfConvertedAdditionalSharesReceivedByDirectors",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_NumberOfConvertedInitialSharesReceivedByDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of converted initial shares received by directors.",
        "label": "Number of Converted Initial Shares Received by Directors",
        "terseLabel": "Number of converted initial shares received by directors (in shares)"
       }
      }
     },
     "localname": "NumberOfConvertedInitialSharesReceivedByDirectors",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_NumberOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of directors of the company.",
        "label": "Number of Directors",
        "terseLabel": "Number of directors"
       }
      }
     },
     "localname": "NumberOfDirectors",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NumberOfDirectorsSignedWaiverAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents number of directors signed waiver agreements.",
        "label": "Number of Directors Signed Waiver Agreements",
        "terseLabel": "Number of directors signed waiver agreements"
       }
      }
     },
     "localname": "NumberOfDirectorsSignedWaiverAgreements",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NumberOfMilestonesAccrued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones had been accrued during the period.",
        "label": "Number of Milestones Accrued",
        "terseLabel": "Number of milestones accrued"
       }
      }
     },
     "localname": "NumberOfMilestonesAccrued",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of performance obligations in accordance with the provisions under ASC 606, the Company identified.",
        "label": "Number of Performance Obligations",
        "terseLabel": "Number of distinct performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NumberOfPotentialMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential milestones had been accrued during the period.",
        "label": "Number of Potential Milestones",
        "terseLabel": "Number of potential milestones"
       }
      }
     },
     "localname": "NumberOfPotentialMilestones",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NumberOfSmallMoleculeProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of small molecule product candidates targeting front and back of the eye indications.",
        "label": "Number of Small Molecule Product Candidates",
        "terseLabel": "Number of small molecule product candidates"
       }
      }
     },
     "localname": "NumberOfSmallMoleculeProductCandidates",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesNatureOfBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NumberOfTimesPaymentsForSalesMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of time sales milestone payments eligible to receive based on the achievement of annual sales.",
        "label": "Number of Times Payments for Sales Milestone",
        "terseLabel": "Number of times sales milestone payments"
       }
      }
     },
     "localname": "NumberOfTimesPaymentsForSalesMilestone",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ocup_NyxolLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nyxol license and agreement entered by the entity.",
        "label": "Nyxol License Agreement [Member]",
        "terseLabel": "Nyxol License Agreement [Member]"
       }
      }
     },
     "localname": "NyxolLicenseAgreementMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_OperatingLeasesMonthlyBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rental expense payable per month for operating leases.",
        "label": "Operating Leases Monthly Base Rent",
        "terseLabel": "Monthly base rent"
       }
      }
     },
     "localname": "OperatingLeasesMonthlyBaseRent",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_OtherIncomeExpenseNetPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for other income (expense), net.",
        "label": "Other Income (Expense), Net [Policy Text Block]",
        "terseLabel": "Other Expense, net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetPolicyTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_PercentageOfCashConsiderationPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash consideration paid by a third party to Rexahn or its affiliates during the applicable CVR payment period.",
        "label": "Percentage of Cash Consideration Payment",
        "terseLabel": "Sum of cash consideration paid by a third party"
       }
      }
     },
     "localname": "PercentageOfCashConsiderationPayment",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of milestone payments eligible to receive on sub-license agreement.",
        "label": "Percentage of Milestone Payments Eligible to Receive on Sub-license Agreement",
        "terseLabel": "Percentage of milestone payments eligible to receive on sub-license agreement"
       }
      }
     },
     "localname": "PercentageOfMilestonePaymentsEligibleToReceiveOnSubLicenseAgreement",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ocup_PeriodOfNonCancellationWindowAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of non-cancellation window agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period of Non-Cancellation window Agreement",
        "terseLabel": "Period of non-cancellation window agreement"
       }
      }
     },
     "localname": "PeriodOfNonCancellationWindowAgreement",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_PeriodOfOpportunityToCureBreachOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of opportunity to cure breach of agreement in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period of Opportunity to Cure Breach Of Agreement",
        "terseLabel": "Period of opportunity to cure breach of agreement"
       }
      }
     },
     "localname": "PeriodOfOpportunityToCureBreachOfAgreement",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of prior written notice to be served for termination of agreements in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period of Prior Written Notice to be Served For Termination Of Agreements",
        "terseLabel": "Period of prior written notice to be served for termination of agreements"
       }
      }
     },
     "localname": "PeriodOfPriorWrittenNoticeToBeServedForTerminationOfAgreements",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_PeriodOfRestrictionFromSellingStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period, that entity is restricted from selling the common stock, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period of Restriction from Selling Stock",
        "terseLabel": "Period of restriction from selling common stock"
       }
      }
     },
     "localname": "PeriodOfRestrictionFromSellingStock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_PreMergerFinancingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Merger Financing [Abstract]"
       }
      }
     },
     "localname": "PreMergerFinancingAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ocup_PreMergerFinancingAndWaiverAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Merger Financing and Waiver Agreements [Abstract]"
       }
      }
     },
     "localname": "PreMergerFinancingAndWaiverAgreementsAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_PreMergerFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Merger Financing with directors of Ocuphire and Rexahn.",
        "label": "Pre-Merger Financing [Member]"
       }
      }
     },
     "localname": "PreMergerFinancingMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_PreMergerFinancingOfWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Merger Financing of Warrants [Abstract]",
        "terseLabel": "Pre-Merger Financing [Abstract]"
       }
      }
     },
     "localname": "PreMergerFinancingOfWarrantsAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_PreMergerFinancingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about pre-merger financing.",
        "label": "Pre-Merger Financing [Text Block]",
        "terseLabel": "Pre-Merger Financing"
       }
      }
     },
     "localname": "PreMergerFinancingTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_PremiumConversionDerivativesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents premium conversion derivatives obligations meeting the definition of a liability which are reported as of the balance sheet date.",
        "label": "Premium Conversion Derivatives [Member]",
        "terseLabel": "Premium Conversion Derivatives [Member]"
       }
      }
     },
     "localname": "PremiumConversionDerivativesMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_ProceedsFromPreMergerFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is a cash inflow, proceeds received from Pre-merger Financing,",
        "label": "Proceeds from Pre-Merger Financing",
        "terseLabel": "Total investment"
       }
      }
     },
     "localname": "ProceedsFromPreMergerFinancing",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_ProcessaLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"On June 16, 2021, the Company entered into a license agreement (the \"Processa License Agreement\") with Processa Pharmaceuticals, Inc. (\"Processa\"), pursuant to which the Company has agreed to grant Processa an exclusive license to develop, manufacture and commercialize RX-3117 globally, excluding China.\"",
        "label": "Processa License Agreement [Member]",
        "terseLabel": "Processa License Agreement [Member]"
       }
      }
     },
     "localname": "ProcessaLicenseAgreementMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_ReceiptOfInvestmentsRelatedToLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The is the portion of collaborations revenue from the license agreement stemming from the receipt of non-cash equity investments.",
        "label": "Receipt of Investments Related to License Agreement",
        "terseLabel": "Receipt of investments related to license agreement"
       }
      }
     },
     "localname": "ReceiptOfInvestmentsRelatedToLicenseAgreement",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Registered Direct Offering is an offering of securities that has been registered with the Securities and Exchange Commission (SEC) to pre-identified investors.",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_RegisteredDirectOfferingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registered Direct Offerings [Abstract]",
        "terseLabel": "Registered Direct Offerings [Abstract]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingsAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_RemainingIssuableShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of remaining issuable shares.",
        "label": "Remaining Issuable Shares",
        "terseLabel": "Remaining issuable shares (in shares)"
       }
      }
     },
     "localname": "RemainingIssuableShares",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_ResearchDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to research and development services.",
        "label": "Research Development Services [Member]",
        "terseLabel": "Research and Development Services [Member]"
       }
      }
     },
     "localname": "ResearchDevelopmentServicesMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_RestrictedStockAwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Awards [Abstract]",
        "terseLabel": "Ocuphire Restricted Stock Awards [Abstract]"
       }
      }
     },
     "localname": "RestrictedStockAwardsAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_RetirementPlan401KMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A defined-contribution retirement account which allows employees to save a portion of their salary in a tax-advantaged manner. The money earned in a 401(k) Plan is not taxed until after the employee retires, at which time their income will typically be lower than during their working years.",
        "label": "Retirement Plan, 401K [Member]",
        "terseLabel": "401K Plan [Member]"
       }
      }
     },
     "localname": "RetirementPlan401KMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_RevenueFromContractWithCustomerToBeRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be recognized, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract With Customer, to be Recognized",
        "terseLabel": "Aggregate transaction price to be recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerToBeRecognized",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_RexahnStockholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity owned or controlled by another entity.",
        "label": "Rexahn stockholders [Member]",
        "terseLabel": "Rexahn [Member]"
       }
      }
     },
     "localname": "RexahnStockholdersMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails",
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_SalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents sales milestones.",
        "label": "Sales Milestones [Member]"
       }
      }
     },
     "localname": "SalesMilestonesMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investments, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis.",
        "label": "Schedule of Fair Value, Investments Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Investments Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueInvestmentsMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using contract asset associated with agreement.",
        "label": "Schedule of Reconciliation of Contract Asset Associated [Table Text Block]",
        "terseLabel": "Reconciliation of Contract Asset Associated"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfContractAssetAssociatedTableTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by securities purchase agreement.",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_SeriesASeriesBAndRDOWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A classification of Information by type of warrant or right issued, for example Series A Warrants, Series B Warrants and RDO warrants.",
        "label": "Series A, Series B and RDO Warrants [Member]",
        "verboseLabel": "Series A, Series B and RDO Warrants [Member]"
       }
      }
     },
     "localname": "SeriesASeriesBAndRDOWarrantsMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_SeriesAWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A classification of Information by type of warrant or right issued, for example Series A Warrants.",
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "localname": "SeriesAWarrantsMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A classification of Information by type of warrant or right issued, for example Series B Warrants.",
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Service Time Condition, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableServiceTimeConditionNumber",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionAggregateIntrinsicValue",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageExercisePrice",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ocup_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of a service time condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Service Time Condition, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingServiceTimeConditionWeightedAverageRemainingContractualTerm",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_ShareSettlementWithInvestors": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash share settlement with investors.",
        "label": "Share Settlement with Investors",
        "terseLabel": "Non-cash share settlement with investors"
       }
      }
     },
     "localname": "ShareSettlementWithInvestors",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_ShelfRegistrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf registration, shelf offering, or shelf prospectus is a type of public offering where certain issuers are allowed to offer and sell securities to the public without a separate prospectus for each act of offering and without the issue of further prospectus.",
        "label": "Shelf Registration [Member]",
        "terseLabel": "2021 Shelf [Member]"
       }
      }
     },
     "localname": "ShelfRegistrationMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_ShortTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term borrowing supported by a written promise to pay an obligation.",
        "label": "Short-term Loan [Member]",
        "terseLabel": "Short-term Loan [Member]"
       }
      }
     },
     "localname": "ShortTermLoanMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_StateAndLocalOperatingLossCarryforwardsTaxEffect": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the related state and local income tax effect on operating loss carry forward.",
        "label": "State And Local Operating Loss Carryforwards Tax Effect",
        "terseLabel": "State operating loss carryforwards, tax effect"
       }
      }
     },
     "localname": "StateAndLocalOperatingLossCarryforwardsTaxEffect",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_StockIssuedDuringPeriodSharesAtTheMarketProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued in connection with the at-the-market program during the period.",
        "label": "Stock Issued During Period shares At-the-Market Program",
        "terseLabel": "Issuance of common stock in connection with the at-the-market program (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAtTheMarketProgram",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued after exercise of warrants.",
        "label": "Stock Issued During Period Shares, Exercise of Warrants",
        "terseLabel": "Exercise of Series B warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued equity impact of the value of new stock issued in connection with registered direct offering during the period.",
        "label": "Stock Issued During Period, Shares, in Connection with Registered Direct Offering",
        "terseLabel": "Issuance of common stock and warrants in connection with registered direct offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesInConnectionWithRegisteredDirectOffering",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_StockIssuedDuringPeriodSharesInSettlementWithInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued in settlement with investors during the period.",
        "label": "Stock Issued During Period, Shares, In Settlement with Investors",
        "terseLabel": "Issuance of common stock in connection with settlement with investors (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesInSettlementWithInvestors",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_StockIssuedDuringPeriodValueAtTheMarketProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued in connection with the at-the-market program during the period.",
        "label": "Stock Issued During Period Value At-the-Market Program",
        "terseLabel": "Issuance of common stock in connection with the at-the-market program"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAtTheMarketProgram",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued in connection with registered direct offering during the period.",
        "label": "Stock Issued During Period, Value, in Connection with Registered Direct Offering",
        "terseLabel": "Issuance of common stock and warrants in connection with registered direct offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueInConnectionWithRegisteredDirectOffering",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_StockIssuedDuringPeriodValueInSettlementWithInvestors": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued in settlement with investors during the period.",
        "label": "Stock Issued During Period Value, In Settlement with Investors",
        "terseLabel": "Issuance of common stock in connection with settlement with investors"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueInSettlementWithInvestors",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_StockIssuedDuringPeriodValueStockExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock warrants.",
        "label": "Stock Issued During Period, Value, Stock, Exercise of Warrants",
        "terseLabel": "Exercise of Series B warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockExerciseOfWarrants",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_StockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Abstract]",
        "terseLabel": "Ocuphire Stock Options [Abstract]"
       }
      }
     },
     "localname": "StockOptionsAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_StockSoldPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received for each share of common stock issued or sold in the stock transaction.",
        "label": "Stock Sold, Price Per Share",
        "terseLabel": "Offering price (in dollars per share)"
       }
      }
     },
     "localname": "StockSoldPricePerShare",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ocup_SublicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublicense Agreement [Abstract]",
        "terseLabel": "Sublicense Agreement [Abstract]"
       }
      }
     },
     "localname": "SublicenseAgreementAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_SubsequentEventsAdditionalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events, Additional Information [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAdditionalInformationAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_SupplementalBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ocup_TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price of license agreement allocated on estimated standalone selling price obligations.",
        "label": "Transaction Price Allocated on Estimated Standalone Selling Price Obligations",
        "terseLabel": "Transaction price allocation of ESSP obligations"
       }
      }
     },
     "localname": "TransactionPriceAllocatedOnEstimatedStandaloneSellingPriceObligations",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_UpfrontPaymentReceivedInCommonStockFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of common shares of an entity that have been received as an upfront payment.",
        "label": "Upfront Payment Received in Common Stock, Fair Value",
        "terseLabel": "Upfront payment received in common shares"
       }
      }
     },
     "localname": "UpfrontPaymentReceivedInCommonStockFairValue",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_UpfrontPaymentReceivedInCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been received as an upfront payment.",
        "label": "Upfront Payment Received in Common Stock Shares",
        "terseLabel": "Upfront payment received in common shares (in shares)"
       }
      }
     },
     "localname": "UpfrontPaymentReceivedInCommonStockShares",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ocup_UtilizedFederalResearchCreditCarryforwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the federal research credit carryforwards Utilized during the period.",
        "label": "Utilized Federal Research Credit Carryforwards",
        "terseLabel": "Utilized federal research credit carryforwards"
       }
      }
     },
     "localname": "UtilizedFederalResearchCreditCarryforwards",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ocup_WaiverAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to waiver agreements.",
        "label": "Waiver Agreements [Member]",
        "terseLabel": "Waiver Agreements [Member]"
       }
      }
     },
     "localname": "WaiverAgreementsMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_WarrantLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents warrants meeting the definition of a liability which are reported as of the balance sheet date.",
        "label": "Warrant Liabilities [Member]",
        "terseLabel": "Warrant Liabilities [Member]"
       }
      }
     },
     "localname": "WarrantLiabilitiesMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ocup_WarrantLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrant liabilities.",
        "label": "Warrant Liabilities [Policy Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantLiabilitiesPolicyTextBlock",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ocup_WarrantsAndStockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Stock Options [Abstract]",
        "terseLabel": "Former Rexahn Warrants and Stock Options [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndStockOptionsAbstract",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ocup_WeightedAverageRemainingContractualTermsWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for warrants excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Contractual Terms, Warrants",
        "terseLabel": "Average remaining contractual life"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermsWarrants",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ocup_ZhejiangHaiChangBiotechnologyCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity entered into Exclusive License Agreement.",
        "label": "Zhejiang HaiChang Biotechnology Co., Ltd [Member]"
       }
      }
     },
     "localname": "ZhejiangHaiChangBiotechnologyCoLtdMember",
     "nsuri": "http://ocuphire.com/20221231",
     "presentation": [
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors [Member]",
        "verboseLabel": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r318",
      "r445",
      "r468",
      "r480",
      "r481",
      "r493",
      "r500",
      "r505",
      "r539",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails",
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r318",
      "r445",
      "r468",
      "r480",
      "r481",
      "r493",
      "r500",
      "r505",
      "r539",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r221",
      "r446",
      "r494",
      "r504",
      "r534",
      "r535",
      "r540",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r221",
      "r446",
      "r494",
      "r504",
      "r534",
      "r535",
      "r540",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r297",
      "r318",
      "r354",
      "r355",
      "r356",
      "r444",
      "r445",
      "r468",
      "r480",
      "r481",
      "r493",
      "r500",
      "r505",
      "r533",
      "r539",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails",
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r297",
      "r318",
      "r354",
      "r355",
      "r356",
      "r444",
      "r445",
      "r468",
      "r480",
      "r481",
      "r493",
      "r500",
      "r505",
      "r533",
      "r539",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails",
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r503"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable (Note 10)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r59",
      "r142"
     ],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r503"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r527",
      "r528",
      "r529",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r82",
      "r83",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r144",
      "r226",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities excluded from computation of net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r109",
      "r126",
      "r143",
      "r167",
      "r206",
      "r215",
      "r219",
      "r230",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r400",
      "r402",
      "r418",
      "r503",
      "r537",
      "r538",
      "r644"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r138",
      "r147",
      "r167",
      "r230",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r400",
      "r402",
      "r418",
      "r503",
      "r537",
      "r538",
      "r644"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r395",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails",
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r93",
      "r94",
      "r395",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails",
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails",
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Merger"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/Merger"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Reverse Merger with Rexahn"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r140",
      "r482"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r103"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Deposits that exceeded federally insured amounts"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInContractWithCustomerAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Asset and Accounts Receivable and Allowances for Doubtful Accounts [Abstract]"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r65",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price (in dollars per share)",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrant issued (in shares)",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding (in shares)",
        "verboseLabel": "Number of warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r65",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "License and Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r117",
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (Note 4 and Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r238",
      "r239",
      "r477",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r527",
      "r528",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r503"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $0.0001; 75,000,000 shares authorized as of December 31, 2022 and 2021; 20,861,315 and 18,845,828 shares issued and outstanding at December 31, 2022 and 2021, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Plan [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Provision (Benefit) [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r150",
      "r152",
      "r159",
      "r460",
      "r465"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r122",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Closing Balance of Contract Asset [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAfterAllowanceForCreditLossClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r525",
      "r631",
      "r633"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r383",
      "r389",
      "r525"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax provision (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r525",
      "r631",
      "r633"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r110",
      "r112",
      "r124",
      "r170",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r428",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r170",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r428",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r20",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Payment on short term loan"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangements [Abstract]",
        "terseLabel": "Deferred Compensation Plan [Abstract]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Prepaid and Other Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r525",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r5",
      "r6",
      "r111",
      "r123",
      "r378"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r516"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "negatedLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r525",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r89",
      "r630"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Deferral of research and development costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r629"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets relating to net operating loss carryforwards [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r89",
      "r630"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Federal and state operating loss carryforwards",
        "terseLabel": "Deferred tax assets relating to net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r89",
      "r630"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "State net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r89",
      "r630"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r88",
      "r89",
      "r630"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Federal research credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r89",
      "r630"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r89",
      "r630"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Organizational costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Deferred compensation matched by employer, first match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, first match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r39",
      "r57"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetMeasurementInput": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative asset.",
        "label": "Percentage of measurement input"
       }
      }
     },
     "localname": "DerivativeAssetMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r328",
      "r359",
      "r360",
      "r362",
      "r367",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r116",
      "r132",
      "r246",
      "r247",
      "r248",
      "r252",
      "r253",
      "r254",
      "r435",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Consulting expenses unpaid"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Abstract]"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) per share [Abstract]",
        "terseLabel": "Net income (loss) per share (Note 11):"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r160",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r184",
      "r186",
      "r188",
      "r189",
      "r190",
      "r194",
      "r406",
      "r407",
      "r461",
      "r466",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Net Loss Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r160",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r186",
      "r188",
      "r189",
      "r190",
      "r194",
      "r406",
      "r407",
      "r461",
      "r466",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Net income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Federal Income Tax Rate Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r628",
      "r634"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r628",
      "r634"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r628",
      "r634"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "negatedLabel": "Research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r628",
      "r634"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r628",
      "r634"
     ],
     "calculation": {
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Share based compensation for services"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payroll"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]",
        "terseLabel": "Ocuphire Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholder Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r63",
      "r136",
      "r154",
      "r155",
      "r156",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r183",
      "r196",
      "r231",
      "r285",
      "r363",
      "r364",
      "r365",
      "r385",
      "r386",
      "r405",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r431",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r39",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r408",
      "r409",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value of Financial Instruments Measured on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r98",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r263",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r409",
      "r441",
      "r442",
      "r443",
      "r489",
      "r490",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r408",
      "r409",
      "r411",
      "r412",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r263",
      "r299",
      "r304",
      "r409",
      "r441",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r263",
      "r299",
      "r304",
      "r409",
      "r442",
      "r489",
      "r490",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r263",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r409",
      "r443",
      "r489",
      "r490",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Warrant Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Transfers in into Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Transfers out of Level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r263",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r441",
      "r442",
      "r443",
      "r489",
      "r490",
      "r495",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r408",
      "r409",
      "r411",
      "r412",
      "r414",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring Basis [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring Basis [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Assets [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial instruments liabilities at fair value"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesWarrantLiabilitiesAndPremiumConversionDerivativesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture [Member]",
        "terseLabel": "Furniture [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedLabel": "Fair value change in warrant liabilities",
        "terseLabel": "Fair value change in warrant liabilities",
        "verboseLabel": "Fair value change of warrant liability and premium conversion derivatives"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows",
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Domain]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments",
        "terseLabel": "Impairments on investments"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r108",
      "r118",
      "r134",
      "r206",
      "r214",
      "r218",
      "r220",
      "r462",
      "r487"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income (loss) before income taxes",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r373",
      "r376",
      "r382",
      "r387",
      "r390",
      "r392",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r169",
      "r182",
      "r183",
      "r205",
      "r371",
      "r388",
      "r391",
      "r467"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Total tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://ocuphire.com/role/IncomeTaxesComponentsOfIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r153",
      "r369",
      "r370",
      "r376",
      "r377",
      "r381",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Uncertainties [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r104",
      "r120",
      "r157",
      "r204",
      "r427"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r162",
      "r164",
      "r165"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r229",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investors [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Facility Lease [Abstract]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r640"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months",
        "terseLabel": "Expected rent payment for the year end 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r167",
      "r230",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r401",
      "r402",
      "r403",
      "r418",
      "r486",
      "r537",
      "r644",
      "r645"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r113",
      "r129",
      "r503",
      "r524",
      "r532",
      "r639"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r139",
      "r167",
      "r230",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r401",
      "r402",
      "r403",
      "r418",
      "r503",
      "r537",
      "r644",
      "r645"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Expected Dividend Yield Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Expected Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk-Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r40",
      "r119",
      "r133",
      "r137",
      "r148",
      "r151",
      "r156",
      "r167",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r182",
      "r183",
      "r187",
      "r206",
      "r214",
      "r218",
      "r220",
      "r230",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r407",
      "r418",
      "r487",
      "r537"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net income (loss)",
        "terseLabel": "Net and comprehensive income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows",
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental non-cash financing transactions:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.",
        "label": "Noncash or Part Noncash Acquisition, Other Liabilities Assumed",
        "terseLabel": "Unpaid issuance costs"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r206",
      "r214",
      "r218",
      "r220",
      "r487"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r430",
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Federal net operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Description and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r48",
      "r54",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Company Description and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r146",
      "r503"
     ],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r63",
      "r149",
      "r152",
      "r158",
      "r419",
      "r424",
      "r425",
      "r459",
      "r464",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "negatedLabel": "Transaction costs in connection with asset acquisition"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other than Temporary Impairment Losses, Investments [Abstract]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Issuance costs attributed to common stock",
        "verboseLabel": "Issuance expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows",
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r297",
      "r298",
      "r304",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r324",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Deferred Compensation Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails",
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails",
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r503"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, par value $0.0001; 10,000,000 shares authorized as of December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaids and other current assets",
        "totalLabel": "Total prepaids and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid and Other Assets [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r145",
      "r234",
      "r235",
      "r483"
     ],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaids"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPrepaidAndOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows",
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from short-term loan"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r80"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Exercise of stock options and Series B warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r58",
      "r141"
     ],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r60",
      "r130",
      "r463",
      "r503"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property and Equipment, net [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]",
        "terseLabel": "Property and Equipment, net [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r161",
      "r233"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Bad debt expense"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesContractAssetAndAccountsReceivableAndAllowancesForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowances for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r306",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r135",
      "r434",
      "r435",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails",
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails",
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Consulting expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r306",
      "r434",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r432",
      "r433",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Payments made on short-term loan principal"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock Awards Including Pending Issuances of Stock for Services [Member]",
        "terseLabel": "Ocuphire Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails",
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r64",
      "r128",
      "r472",
      "r473",
      "r503"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r136",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r183",
      "r231",
      "r363",
      "r364",
      "r365",
      "r385",
      "r386",
      "r405",
      "r469",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r500",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r500",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r202",
      "r203",
      "r213",
      "r216",
      "r217",
      "r221",
      "r222",
      "r223",
      "r294",
      "r295",
      "r446"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "License and collaborations revenue",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r296",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Anti-dilutive Securities Excluded from Computation of Net Income (Loss) per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails",
      "http://ocuphire.com/role/MergerContingentValueRightsAgreementDetails",
      "http://ocuphire.com/role/MergerFormerRexahnWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Components of Income Tax Provision (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/DeferredCompensationPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Reconciliation of Statutory to Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r78",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentNetDetails",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r106",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ApexianSublicenseAgreementDetails",
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r325",
      "r327",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Restricted Stock Awards Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Stock Option Plan Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Weighted-Average Assumptions Used in Black-Scholes Option-pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Computation of Weighted Average Common Shares"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]",
        "terseLabel": "Segment Information [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Aggregate intrinsic value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested at ending (in shares)",
        "periodStartLabel": "Non-vested at beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Summary of RSA Activity [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average Assumptions Used in Black-Scholes Option-pricing Model [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Number of options expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited/Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Forfeited/Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of stock option granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "verboseLabel": "Number of shares outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationFormerRexahnOptionsDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of Options [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of common stock shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationRestrictedStockAwardsActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Vesting on March 31, 2023 [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r332",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Stock options forfeited (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average period to recognized stock-based compensation"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted average remaining contractual term, vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Stock options vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Weighted average fair value per share of options granted (in dollars per share)",
        "terseLabel": "Weighted average fair value per share of options vesting (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails",
      "http://ocuphire.com/role/StockbasedCompensationWeightedAverageAssumptionsUsedInBlackscholesOptionpricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r1",
      "r110",
      "r127",
      "r503"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term loan",
        "terseLabel": "Short-term loan"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Loan [Abstract]"
       }
      }
     },
     "localname": "ShortTermBorrowingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.",
        "label": "Annual interest rate"
       }
      }
     },
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationShorttermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r114",
      "r115",
      "r125",
      "r517"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short- term investments [Member]",
        "terseLabel": "Short- term investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesFairValueOfFinancialInstrumentsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r63",
      "r136",
      "r154",
      "r155",
      "r156",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r183",
      "r196",
      "r231",
      "r285",
      "r363",
      "r364",
      "r365",
      "r385",
      "r386",
      "r405",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r431",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Stockholders' Equity (Deficit) [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r196",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Granted stock for services performed (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockbasedCompensationCommonStockIssuedForServicesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Shares sold (in shares)",
        "terseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CommitmentsAndContingenciesDetails",
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r63",
      "r64",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit",
      "http://ocuphire.com/role/StockbasedCompensationStockOptionPlanActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r23",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r56",
      "r503",
      "r524",
      "r532",
      "r639"
     ],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets",
      "http://ocuphire.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r166",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholder Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockholderEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r426",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r426",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r426",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r426",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityAtthemarketProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Income taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/SupplementalBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesLiquidityDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsBiosenseLicenseAndAssignmentAgreementDetails",
      "http://ocuphire.com/role/LicenseAndCollaborationAgreementsNyxolLicenseAgreementDetails",
      "http://ocuphire.com/role/PremergerFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Unrealized loss from short-term investments",
        "terseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesEquityInvestmentsMeasuredAtFairValueDetails",
      "http://ocuphire.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r368",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Interest and penalty on income tax expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/IncomeTaxesOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r197",
      "r198",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/CompanyDescriptionAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://ocuphire.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liabilities"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable term",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/PremergerFinancingDetails",
      "http://ocuphire.com/role/StockholdersEquityRegisteredDirectOfferingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "verboseLabel": "Computation of weighted average common shares [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r185",
      "r190"
     ],
     "calculation": {
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted (in shares)",
        "totalLabel": "Diluted common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Number of shares used in per share calculations:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r184",
      "r190"
     ],
     "calculation": {
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic (in shares)",
        "verboseLabel": "Basic common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://ocuphire.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://ocuphire.com/role/NetIncomeLossPerShareComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r508": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r509": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r511": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r512": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r513": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r514": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r515": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>108
<FILENAME>0001140361-23-014868-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-014868-xbrl.zip
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M-)/E/ Z2S75"LKDE\+O1_3T DCT'I%FX=I#XF>N<^ =LXL;,>Q>0N71O;P9
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M\D7.]"W#O'*_YWP\3:?><EIV;<#K5J-!:0+= 0>8;UAUUFP])>8!J9.R:MZ
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M).M&&@R=XN.)%\RX(.<B8GF"ICH_)IE*^)2X/P0M#'%D[$8H(R%L)U$3[AC
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M"CQ<ZK8T@>-RJ>U8$.H4/1F>@HU"52WKGU/X*77GQ&->6K0[F8B"G$+NCOL
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M@R"<!)1-\RL@"6QA6^+\UAZ)=\S[H12/K(X&1+HVG@H)H8LJ248@%UH40UA
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M9<"IOO-<&"O990ZOA!*,91B3+MY]0>WD@'JYM@!%.6;\?O3MF!PU+-'MD^J
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M<DPJD+/U9W"(KJC6(+UF;DAQ/AX&I\M&)ZE-3BK+U&O%D+U5L(GN_G!?E%R
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M?3QWH"'OV4J#4X5IQ;%WS<Z2RNV4&JAOE-MWI7)@%T'&!'(?<@R<P.)@?>&
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MKS9&6X2?>6>,/K__FU8Q75<C4V>/;WV\ZN)!@L<P]J<I?$;]M#+ENJ,O7?G
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M#IYO3]B2*;3B)U^"S&[2G-(,/R4^.R+X;.P)"49KL'907SEI0.+U1DD<8;7
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MNIWQ.A8%BX/9>+$J9F-!\G'U1?SY/ULZZXJ9=,&^8KDQDG'GB'9E2TWE21$
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MYMKY_<KO(&I]W7IU ?KRI7<.'_3_FN93]9T;!-:!W:CF07,"9?[*PYNCKK1
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M* 1_4GCJP,Y J%P"XF,P>?#T-ZG,;WL4>6]ZDR'U?!AZ1_2_K3;_YX3^TS[
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M'=AI2<005'79 J/=4%=K7($-4L^RY]\ZMAY["DI];C+FV>3=D(9B_X>TJ7@
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MK]FVC3].8THVUUDF)3-/";+$RA./8H[.J.BSP6KF4SR^!TUF1?0J!\\QW96
MN>?_E,:##!1H'+.A"'_",U;=RC6@HVA:*(-)'-&!6AJ.U!J 4O!Z54#=Q28,
M9=0J;(U)X%* RF1_,2.8YJ!#$;80P)4-ZB#N8GH GW=*\#R,5:I+ =\LR PG
MS$BY$\YM)M+G1H7(*/V5LN$.N@D% X$5BW(%E8O7G8.C*F<J)%)9_%#-0BOX
MWE_&V:O.<]*5L/^82N@&V2W.Q$Y<J&?!NW&$DGLHEP(4@9^F22X>P"GL"KI[
MW-^D[!;$+QEOPIE+^[A:XYB>O1Y>W"-[F42Y!5)G:S.^HQQS$IZ_^%,RM7W$
M[G$C=@?[B-T^8K>/V,T-XKX1*W3U6^#J?PXBY]YI<^@J]>H2'K(B5\U6'>E3
MMQ*^^HU\;4KV(R@%[+-1.$6)* 2M:K""!:_=9+' :F1#YB8>DQ)7UPO\&YR<
M "-!"T%VRGLV5XZVTRIA(X W?YY- ^]-S?L%[IYQ+Q[%8YP%.AF8AK-W4\)J
M)I"6B;,MUAO?L9_94 6[U.N.X]X7^BU&TN!VY! 5@=HXSA$FQ6G7[HQB81(2
M(55D@5@.B5@Z^*<O47P;"<)G/N"UYIT'<63CAQ.0K::>2<A8Q0&J2M>G"+X*
MJFB:8*:7$11S;:P88**3F2FMMU[_PL?!8LU\B6JPL1#%45VOKA1-$)C(%Y")
M3LJ2KP6FP9="J,9V ,"OS +M*B+*A3U@-IF-L]BP-BKE37*,5=X5UTIO>!_C
M)(@)](8NV6VLQENRAF"'CL4(C6+$=_H(<XD4C 6/"YK\?0QG!J0ACE^E<XO;
M4(%_FP-0V[C.(FB0DX6/LLUD\F:<OY: )SW$QN'Z4\:Z8/%J:*<R,[5MJ8#&
M%/"P+4$T90]=,X].@$I/-SR7!Y%<-E$J>:KA3NCXP(XHR+ &'=D+$$::L4KM
M"C98FS=B58@W9F_%RDWC%]Q.E?0A5@5I/AS2X)PCPIBQ21@AU"M.X4TW04VM
M=10,??X%>S$V<&H\*Y5K$> HR!..\",0+NF'L7)":S(E^$.<V/.?YF.07X2&
MF4 )[Z*"*2H0KF.W:_%/ @1E"4I<9E?0>J\4I*!+<H5HLYA<ZEX\&2"B"Q;F
M2(=CX#G2E.B(/#G\;@V71>$1]#H)*ALE*9#-5SX;/J7HJ-"1YEQ)2<3V(8IS
MV2U^$4=Z.:Z7UG9]8];KV<^7X (57C$/6+L Y>Z]H_ZI)*%H,UQ/4) _JJC)
M-HP&5-!1.#$ZV_;ZZ1 %?0J+HJ 3FG:*P),X"@@0B+6$%L06?E/1$2SX@^0R
M9D&5A00>W6XV7YB?6P?6:[JSXAL,9%=0L!3)46<H_!<M74%[3&**3()P*M0D
MC,>?AADECKP!N.P46*!@;A8B^''^F5Z%0(2HC 2=>'OZ\:R*:-:Q))\^U-]<
M_,[O00@/EA8,1R3G.;ALZ0+HL<*!CN 2R'**0M+T9Q[X.)FR5#Q*3('"J,>#
M.BB.@!.'%&M3.4-BE+7G'D1XFW#$53U4'H>8))59\DF'H0T#(ZM)Q,\-F<(8
MZ2ZID]65DNKK^3E>P*JLTFB+FF"2X;9 !9B$*2G :8P&1$@RP5F>>C:B>(D
M^N!EHLG":""X;%A(>D:0YN/,PF*[X[,G75DH,6G5A'$%5XTA2ZZ.^3H%9R/@
MP+"*_J@0%86?,=9L<*0EJU\4M895Y^$<]DJ+5.F78176P><4P]"_\;FH F8D
MRB%#T[@E@'?)"8EM#.*0Q%^<8&\%;?60P>PDY&",3&*Z<HJR7"6C(J4+Q%A8
M_:"74+*B\K^'A\^K.I2+G_$IA5F!M0$MA *!QO\DJ'J5.Q%>]P=XM8H +Y0!
M=?I08,'D3F%^?A10MF?M0T =ZOY_GO-_)JO%_ZFA^%CP95HVO/W'\6U@!Q$U
M6!P3>:F#()94L?R%4H^\QUJAN&L@\&U:!*.A*03M!F=14)T8O))J4*ZD0@E$
MJ6L&J*?W-)[&XUGJ]Q 6&/9=.?MP>5VMP^#"B23>P:Y-8C!PARH!G(W"1(9F
M#R:UXO4L:GWO[.+4 ZNF3^84FBI^F$A\'@PE5,7D-K&F["(8'<Q<&G(0]>,H
MQX@/B*S*RNPCBX\;63S<1Q;WD<5]9''I(+3UO0P@V'JIE>657>WU@4NW4$.^
MMY7Z&ZW *?&E4J@72HM>&BT*!E(=K=!X73'(<K!A^[!MP(:MC@,V[-P+;'@_
M2HV5'9V_$TXN C,FP=*(:4[H*K*MV$-S@5)@JXH];UGQ:"PJD[1H=Q9,:(H8
MH=T5H84-&YIB<6.)HT&7,EO=%.A)8GR-^&1L6KK(-E.SE=J^)=F5A4%@H=<\
MG*72/F2#E(3G4*Q3+'+V"/;!UK="1%%=5!)WL3H>K"BI!E..A6,?*F-%>4;:
M. 9SAN:3ZHRI8R&#+R&P.]=$U4OC&"1LKLJKY,4R&FMYU<@J"=>Q$OBJK [K
MX14*[356*-Q;<[1?@I*@F5Z#VJ<=?8.[A"D RD._'>>P@RG5KU_C.I#1QUOT
MD9WDSR6;LEED<NO00B8?.<KB8-O*HC2$(R(<]H)RD06'*P@)\*(/$](GJ+/D
M'B'E:O4M<2T+.;C.UMZX?5SC]FAOW.Z-V[UQ^P E>EG(@OWT,<A\&%*83K81
MVBZ\WJM<_JUJ;*9BOILC<7A_]N,AD2F8"@&.FW;3.)ER)A.+PY.PF_._\!,!
MXELC;7:I)(:)@:B<.3ZEJV/JBD:F&\;^C1^.56H0'B%ESO96'36?<TK50,M#
MON6YD%=FH7/!;']B>%!@C(H* ?F Q&::2V+B4+N< (U-V<:O/@& !X%0-+!=
M'$1H2\];G39.\L0;Q1@:UH,[;IS@HT\:Q^8ON.:\D.W#QJ'Y_22.O@2SM&&O
MPOG7'@;N\4TJ13D!NX8R#K @2#HA<-XH'H[S'OI$X!Y1&2LC@./HCQQK.#A!
MK3>^&_C#,7%\$'!7K9!3)6#M9T#C8.$1C![']O.(L[-]"OGA4F[&)"R>M\^8
M,"1L_(8*TG62D4\12/U7R0_PXE.6M=TTG@PQ,SCI)3YA*^))I99<@7!MJ4+@
MQ1#$CY*DC',DI 9G3555%5)%60Z%BH6Z2!,+#FR-$]RA0<SX[!C1#@%7EWNM
M0\G#UJ73$M8#U!4X76V 0104%0LC&#HHG=DH]?JY[3 JE EK)3WO<1ISNXE3
M+(8WA)T:9^"\TA_'B@2$-N30G:'C3>HE#+&C!6]7%A+^F?BEY)'VX(02C6._
M6,6C6(<2Q)FG&8%*%=B^9$4*S"%2Z6/YE.V#.O%82<FDF[Q>=UI8W\2Z^._,
M0H=?COUH\U?5-U _Z6$CQLH HBYF7V,IB4FR*& $&$G"[[#&"8*&P1;@C]5D
M^55W,8XI1,C5@-G"RON+LZKG3Z=CX8:0$L?N),PR4Z<& F#+TYE=T25L KS]
M6"F9PWEL8UD8Y;:8*X*)8_!MWG'SX,6+*NGD"V11ZY(V:;=KAI'/O!_LP@L0
MOH&:#OUT]5'29M[;H)ODB*) IAM370-R2LI R1O*K]_K!5/F>H%):2"[[UV>
M_?;VU!O&F*45\/@U?%(&=E)C%AU[^CR2D9]:U(&MML+853H:-ZA 6X<:["*?
M(;"_)@+B7U9KH"U23JE[,[A/.'(# APDI?@\7@+,475G(!A@7YY].*-?#\=^
M#D/S-0B#5ONC3^O4K)51'\)"+V07<G0)8X<TNLBG'''.:3):T&$2".5P(@ K
MS%0S?1OJM%X\I44>Y)BA+V5!,MOM,PPN)'6N^$MX.O^=1P%Q(Y;/1T"(Y71)
M\*HW']^8]] #;6&RI-&>_*K/+RQ288F&.9A@*(CS*\2)QM.":,@=9"W4%!P_
MS"T3GY26 'OAQDBV0A 4^C<-[\/9)1E-_3\(,75#,(+$G\Z<!5UU[K^ K9T$
M=3B?U?)5@'/&V$'Z5]H+N;2XIZ;#]44H[].<>-QP81C:@(>>M "O&I_ZAMEH
M)-A*YS?!R27;+%C66-2EI7=!X_ST,E)3F@]G;J6UO?I8^>=/4FM >*%2"1@H
M=2H;E>$HV($1 17)I4' Q +<=VLU_#P;Q5C[P78%S8>.RKK,2W;/[WL;E3I?
M>,UH$AT<*2IX^S89Q!8Q%S@:8/#G@4;D]&"B,>S"V#-56PI*O.@>6GKY.)<4
MW 9RN;1.%MQ%K8-VZ[!=;;BY=M3LH _Q W<6,G/I6K&0>NI3,AS]4:D4JYCJ
MZ*H+9RV]0XX<[/E1X?XP5X5A>7+0A0Y>FT&2LK"UPA_MBEDV7TNH&.</7N&V
M6$P_9QV\XH$K.U)6:97 L!VCL8Q/;^$I17RF!2XBSBS<K;.KK<3NWRA& LS=
M"1\@ZV(N)'BY!1H.?I^Y(%[JBX7'L(T #3H0>*?5VU[EXI__N*QWFJTJ%?K>
MGUFY2*P,JB8!WV/"?,$=I/MRI-O2Z2[? #+-&?W0;DOIZKPQ DK#*34LP37;
MKAHRGC&O*K.)4I4[UHP(JI>E4*YH^-K"&QF?)*8)DOH:OD95NZN9"R5=1Z!)
M4* W-IDB+&4^I9)U?Q)0[3U'0$R6CZT3?I(B8!3Z20&N.X2O12)AQ2],T2)S
M]9*?C*_2'^;\)"X/ ;@9TQVE 9\/[1_#F57+NH"I&7= L68H4DK>!C5N4A0.
M#Z%3ICM$7=0J98,\>W/Q^^D<@?2AO0 EW_KES1ER(2_B7M[^AJUUEYS)W[%A
MIQZ(?H*$-$QV0\7R8:H'2$4"^/3Q.+[E ^*<BTH)_2;7XL(?NBKPZGP*O8*;
ML)]3K?UD"D8OS+1J+3_7AAC^<@[%HMX T:)NVPOHC_>9N<?-S!WO,W/[S-P^
M,[=T$#M(54^F7D>;>NVJMJ,T*[;PO*S;_$.*#<?\<S?2V(*-!Q(U%[8<YXV-
M,MCY*3$AZ?I;:C;R):^"!=A*@\)!?,6)\2SU%QA1TE$%91WAW[[8]D<1W6ZU
M@J#H/U_,#>\]^U5.S$F[8JD%:K.";,'7*>57=!C52]T8;2:<&;;Y#;L%=O:!
MXMH:Q&0"H/.:J.RH^Y#_0MNXL5 3?,/E?+\#<>_XR/U\LK,/9R^]#_^\^ ?L
M;/NO:3[].>K#9.&_KHMV;_;N;9WU7PCJI&)G4DPID"A--<QVIA/,K/&L[:@M
M2;;P*$5H\TH:HX;%2ZPUN Y<B7W)47,%GL^=$29D J2,7!MTA*: +@W=P,:L
M73_(*<.);^"48=0_C(HG'D_;XN-SUW%98_3AC= %2&WTY\+6^*FI>64O@.KP
MF-9->\6H+,A= ><H[OG)%.D0*T+4"(I""!JK>*:N,)]XQR%ZG,8PWQ9Y7=6X
M6^_Y?DOXY()25M0/5BZ&D@"%P'EUI<.-!UNJI B;8G@953 %]ZXHU[*_QHTS
M]W_[4)]M5>-. (XIN\WD+7( R'*%,;";!$C3JY3649VR]IH$L&ZR_BI;KH(3
M8M 49(ZUC]6YIC O&%%,19Q8):K)W#JV^8)+?E2<.H,):G)Y<BDM> 4Z.*J^
MC'93&.7XT 'OH@4G/U*8! :MNE;8O.4EEDC#^Q!'PSH2D5*1%KQO3/QVB';J
M@9L#SOOYFS=5BW</J2/(\J&8.K4S@0<2XF&QI;WL6EL#5?.E*E<U0(!+"FA;
M>8J'Q&5W0ELX-[-F62#1J[G4% 1I4^:H=75;%'S%OFW4F-1F'_AO/](9^/+K
MRR!&*&G@;OH]N]G8/*V.I>T$? :874*@O)M9->M1WGS'3E8A/P@:+_6Q$.]2
M4-;T9@W-H6*.WH$0OR)7[H+C7J+/V!HW2!J!494 :J( ;01<:3#ZXT1Z:[AY
M4BM/,_%GJO[9BPF'DT><4R1&327]W2""D6<+8M ##:93&3M;\:O )O<N//UX
MQL'*=Z?K;<U6ZE S=N!]5/^@>;>);:#W9QZFO"N?[%EOA5#1H!!(_Q(P3;E]
MZ3P$,Z5N5'12K=SX!(N-*$M'Q)6ZQ*MFYX@Q*X<QKIH*CL*W>JC6S%9C3I\N
MDEY.;:DXQU8< 9\T)\;KI%3!?'Q8)+1L]ZY]Q8:,Y.1T_A]#YYH-PS0LA19(
MI>')\@R?NP&TD(YZD&OP[&>Q?L0PURZ(PU+K;*FJ&\%L)ERFRI\QQU"4Y6^-
MZP8K]*]U^GE":POV6?!54JJNZND%":5EZ?9.!&UPFH9^51B_,<H.J@E1MUQ1
M-(=A\#%LPRD6JZD, <OXV_A4$%ODQ$%ZXU4FJ>$$=B:X;GVUB,OFG0IJE)K!
MUDB2R/:-+B#&B4(TR(+^8GO#^;$HO].ZU$;<FBSA GE<7G=.7+!.P',; &0
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M&1*&)Z+]$&08E\-"0JOUBGCJE-["'JQ8L2K-KXD8K3X 0P@NM#3.,%I8 QN
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M1BT(.R9*)X%J-!4G6LT2UL%8I"659G(F0WNVM<T--4":Y]-XIF1R$0_:&7@
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M^\W+'8YYN3$O-^;E;J;.!VG3;' 3NW]K'N*CP<-^%W[]+I]V<-ME+Q&.#W]
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M]I%;O_OV[=)W\$BZV#9W<7[,<*0%LFS+4-OPO.7SX[".'S1P@[^GL2\HP[M
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M45>#5+*<TO,5,[A!E+&9=PMI%R)A3+G'48L1CI#SB&T4=%TL]K)7G%I'X%C
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M2S/DOIP?L6\=#>@5QAK>8[-N1TXPU4>Y2VXDG$P,K\\8CDCZV&*4!!LS-.I
M,N$]\GC1TK.I;14\H(35(LVW07<@3'8O^X!65+)Q^$SZM"19=&'T4=0U1)J-
M[L[@<Q=;-R8!8^;GM6.-K4?(TNJ?5Z;+L,S$=W><DR;E)^,':73A^*#:]2#T
MJ,$B3DE.U<%^1O0,3= &,_&IK0#@DREVN/]\A89)T>I!I=_"@?$4XV:D-*CP
MKB?Z*O_P7IO89(H"U*/6UJ8J1X,E#ZV,R+.Y9*0I\%[B5O=!X F&#Z[N7,4E
M+?<)?051J<]F-2>M,G  :"&IBZO6_JPUXE^D([/=<F&MSLDD#1(U8G3N%Z/S
M_8C1&3$Z(T9GZR"VNF4_\%W*5C'[6G@5A2LQQ*0H1*6!*?+/A\EQF?$Y"GE0
M_(R+-V,F,;HU&G+; O^;9>7=.3EZTSP01B6T4-$F#2^+KM\D%"<&4%#6-A;*
ML0YEZTTB*CO>QKZ&U:QY0(U_"_#FD[XS2>,/0['KO5I/Q69+R'B5J*9 ZH=2
M?XJ+UXO([O+6:!,"%H-!(NU6:JB,Z\%RFU[DB?T$0PSL@X^^#8EMFQSGJL1J
M\!Z^9KRU1$YB<B$LAEZ42Z,^9XFL1IN?B.TMQU/OH2Z-J 0\.JB:V[QAXA@4
MM143-GE\)/3FI(S9#C(R/M@C8D9TW!M.^&"V=JG5+TWX.*8OX]K6V!>@]&63
MR@(88*3Y^)<8\2.X'Z$HY-53,L"9L'#I/ [IO,/"G(E$:XN< ZE=Z4U 3S+!
M^8FI,&_/'1U_9IM F/="1#IL.>;V<,:49GCYZ>CTYSW^'ZVQPN<)BX@/Q?.I
M")*VFK \QZ7\L$Q<MRH>=;!4J>!">H[(!RB+#><(547XF:N!&.[N"T.*>MHM
MI2N0?['!F@<OK^/2'LVHU[!IB :SRB82(%Y[+5(N./(0TC1UPM+)U4!G#O8
MU<@5K$M4,F0S>21&O51)D^:TU2$,!0@4ZPE"@94Y-</U<F;YB(7(M OG3NJ&
MQ#+O9;U_S[,<K_#<]4)6/+,2-/S"$]O@1WHM%#)BM0#91BC#Q9KC/_1(C)5=
M,<,"%4#!\JG"FVQX%C%P@-GD*.\6E6%S@9VY(Z, #^G*0GDL)>],\0RJ/O+?
MENI>=/W@7PJ/\/%/*JTCBATN=IV)2J*SN"E\TEQ4W6*&IH,/WG'*G.I \(5>
M3QK9UL0?FM?JT\6O;30D.-"V DYZE+9NO2O:Z [$CT)E(QEAY ]8YI_9PYQ2
M'<\W%5S>-,K_"K$,GVIP*B89N3'M14UPED]$)RI)EA-U^C^R@_XBQ +OA 3*
M[(_656K:10HE0_A$ Q%S/@-P%:#VD,@"YV/7O0)[X^QW)5(]\!4"5I4+0($6
MUJ=5RNV@J(BY:.YV8>7@[XX4>$#KIB'/PD>QR(2EX#!;5'P^M=\#V%N@.5O<
M&1MZ!2FSN]3R+L6?X',3A6GL!^Y$EYVJM4:*Q1H?8<OR*,D0)-%L5A&UTYKX
MXYXOQ"IC,_1,ZP\Y8&T,-L_#0T(Q\>BFC7MI]VO+MH:]Y/4N6IL";)([QDA8
M7[RT7!7=A\$W,$N169\P'8G*<JCL(K_$(F <;<T49P(!BIK]^;M>-T0;Q,JR
M)Q=R8WJ=Y .#\*%OJWU-M#4)SVH8.TZSA&2\Z/M)/$KZLZ<9@$L$?*=.\AW]
MA!-K[67$ 1+,V#9][PJC^:&7*":?DFP-W!"OJRLPCFLORG[:9/0(!U@2A67\
MC%DRNQ8^ TSQ8Q"+ME@([@[CMB[RB7J) 45@]&G<S.MLQD9"J2@(LSJ_*FW$
M4D J',Q>%.Y27,(X>>^BY]%-J8R^0B3#<5#"B( E5I]OYKT0S_)N-)'#@S0Q
MVD;6PA39D^,T=/T-Z2!7?)L*(CX+E[??=H6(E@^),[_$#@\0.J*2JK4.OET"
M"UGP&0LTTI=TT%@Y8OC$?2D\, ,6A: VY:!;#):,A?[!@C%Q0<A VA<%':P(
M^>J,^@;-?#U)WY[$-&T@)HC=$NKVKH9 I/M ]:XD(32PS86+,&](FT78$$>\
M1T9]!BHR^KH"@RQ3@HCV<]%DM&R@(M#[ )-QZC0YKSL1\FKG>2T9!O^T.%H1
M*)&>2Q4YC1(WH &9P4ND!1=G.%_T''TIW!M22M.Z:II=$+%I 9J%Y <^1SFS
MA<MG7K'*,UJ7+QFEV;*-JB!2MVJ"&39PTANATW2:R11^GS$'<K\YD&=C#F3,
M@8PYD-]N57R"&<YNYMBDSK,W*<+'^'[&Z[ Q5D%TUT^D 2;%,L 1HO"&+^2(
MKEU[@2,F1ZI*ZK@:<\^ND]ZB(2DP8>+(*9@@NV#6[>(/3 \ZB8(N'J"F<PGP
MZBW#HG@'<[QI:(^OE(!E\L8&HL6'GR*&7+%8=&S'D 'J[1^*5G'!P"RI1.4K
M,HZ]1@ZA<>_$Q%((@;5@8/ A>9&'9^Q2H%=R*+(J;(]@<>ZTP\_@F,H+C,GZ
MQM,2=36Y!!(,G";=REAEF.RM&I!=2S%5"5:;%3 T(KTEB.A$$2T!<PM%5,3)
MJ[*;V/XV=C(K:DJ32!U2WI+7*Q8JB$+5U=/ ,!1W$&*ST&!3)EJCU%R@1U'V
M_"WO8XDEHL4=S!UHJ"I#U!21+0'H L]6),I=!-@^)>-_(=$]&O&=D1!]X(5D
M>M]JWEO5?E^G]Q(I0'@Y NS7/:9OR_S9P]2&?.S6)JED>4?!"*2>#IA+1)4Z
M$*B::SEB3T@ <6C;(X.0?#+;.?[X]@$1_"7/"+'#QN8-@]0,9" M(W1(OZ3U
M<OY#$3KV:/,80WDBG-R%)&$38F$QXTUL _;#KH#-Q%BM9%!1FC>NXC[UGA96
M[7SA^,8 M8"GDK##7O9FSL!39KH%E1^/EH)/7-["D:X(A^P%S??A5"HGQ?)%
MT9LH+3LH%E&8CM8T@MCYL/PL8  %2'X1O9&6^1#7Q\/3.+_!N32.%:Y7<IG8
M%:3TWFPO>PGZ5$0EF0>5K0Z!&,/<D$X5$U388HE,B"GS8XF[/A@P$DKI-#IC
M*( ].Y0M';V;='0()8FM8LR<"=H]=)GA[:@3Y.2,Y<303@PJG/[K*NRMY&\H
M7SH+5\=57I?DL'.V=)IW_, SY_?+%/W1&0^P>GEXO*QY.]QGT&H_K@-\U"\7
M2&M$E![7M(?#+)XY&WQ5,TNWS]S[69O*AJ:K+QW8/60D^"P"PO@YJ1O-D1\8
M-)ZDY4FE<@L",;Y"2FP#Q;/E!L%C!/_0Z'"MU1:4_<]+<)_81G-3,'**9ADW
M?:0VCHR!_]8D;2\9K$H#F=G)M*I%XG0#(HT?K'#/_]BFJ-30&0.%009C2F@'
MMP,N@&0GEU1T"=J$.PW#NIP'P\@?!2_N'E%$G <"9S7B'M^H^CC&W'BUX\NX
MP;<MEJ%4Q#?]DS41Z8KGG4!YF&F\1]!]%V;4"2[\D9["CV9D=Z'67E U1-3.
MDA$8?!H<=3?#W@BTI+;M;I.N-](T@A5VZ3R^2ZB7 SNQB<V;,S-<^!/MD2T^
MPJN\GGUV;H7?C>J0*%D!Q@I7I<?@-2YCT7IU'.)_=SD8XAB.38K953W/B[II
MLX=4P(+@-A_9Q*X:JK!B5B&JS89;3/\*7UE6QF?0<>'Q5!(51 L43'7MX[&A
M?UQZTA#\'@Y8>E=^[5D+ZNVZXT0.T\:#0O%FQYDN(:C4[?<U3]&.*B< JYPP
MX)BX'4>;%/$T:7M0S-$PA@DM1%L-$)?54@W4G2/7",UB>PY:S(@+U:Y$G>HO
M<?.%GI %()+ +#7)+G!".B+GQ"B"SRKJ0*NQC FX-&?*_:+@7F.#-S'&^\><
M#UE7PIFJNI(YP@)(U>3?)"O9N/05<^$9W@JRW,N.XXMDN-*7QD?W-35>.9=^
MNK3*5#>M9D:0X-" @=.Y7 ]?+$6.P/BU"V#:4#! $X5<'QJW.F'-QRU5M+P4
MC=_+0BU =-EIIJ%-DE$+M-<21K'%?')HNI48[K[EC=!+M!BTV\5ZR'4B;-[B
MMEP*:HU7W$_WB JMX?V+]21VP^R3I%.J-')%N.,7XC3 )!#JI=()IL;-Y\A%
M+*(,VY-SZRV/AQ7E2V:.QP%7GM^;UR>(QYA2N=>4RN/],:4RIE3&E,IO-P@^
M, ]=N':HOT)>$A6##08IB,68<HPM3N_*35V1Y#:7]CR%HF%9K[)M7Y JAKT&
MMYH[&82"7QO3O^#(77P?H*VVE[TE'!;FV#$TOI;&BMHKK"NY[81_"]>?F%A)
MX.!1$_B2:67F9%0()3J1QL#?M::&BG[+Z7K"Y3.]9HV^J&/")3C%@L#X%2_>
M>NO"323DB.YP1K49S#B_U<3V%C.#X#C/P)Z$"8D]3WK?;7"T!WC8))IB'DME
M <]]=,,_,S8/?<#"AC&D+1>CQ\61U^82(1I!A/6TS&24WH0G_R\C[W#RJ3[3
MX.,GM\:!^/T?DP,Q#IFI$^.#42D%4!S<FH1T@FI IL*R.LF7<<O9J6JCKA"A
MU7AANW9]:?]&7L]1IK?*])S1 A)[EV0,*6O$T9&8QR'T1(>/\CC*X^WJV'G7
M!,4HF4VMC-74'I$05;4)BS7F8\3TPQ92W$8*+)XJ,)S[)%(!UG43;-%1ID>9
MOE69]B%U5_R*YCHF'YS ;"8LERST@1R(0!A+;G=%A5#2^$H#R&@?CU(Z2NDM
M2FE1_J,K0SY8)3 X8-/BLJ"JX&E-D+H%JN-\T=HFKM>NRZW+XK<4)/8BZDVP
MYR>6LV]CPLL<28Y"4P$Z=ON>Q1["7J99R+6T1X4GT(?@]9J+&\13,$=:2A2:
M.NR$)6VTU*OOPN]E1]Q1G@=.27E.VF_@M<;UX62")":T/IS3+9PVQ,AZS!%G
M$C\AUT*P1>1.QXB!<'0M\JM&\H4AZP#CNRC."L\C&BUT-9_OTER(J&#22^$(
ME^R:-Z+ !$S':$1"-Q'V<D6IT+#ZT2-U<TPBR")@%X7 %NX^P49@DR0]%I$5
M)GPE7B9CHD9\S(G]&LID]LZ[L$?HIB+F^<6[(\5WA*,Q- C*_%&J6'L8.R5U
MM'NSP*(8#MPY)%)'>HENF<5-M@4&%1HJQM*1O"X,!0LH)1]'&;AF+_NADNP?
MSL2D_TCH G[I-RQIF*Q-;9GHI*?(B&03#F]7>M@+'&?[ZCOA@Y5LW>/]QSMG
M#W8.'Y"-?!>"3+8Z$21C5A\#?98V1^C'%;MS& AG"*YX32,'%E&?M",.2P.E
MM$AJ$H\(39UV9V$@?,E%5QZ/U,0;:5/O,6TK!Q^3=3YX$#R9XR-+53 !!UN*
M4N.B>,L"M  5C;#MRP!C1&3OX*L.>Z^"PZ_?LOB"'!GN&HM0+(5K$8N]"^Y]
M/AE 4EDDJ,;"0WN"'EJ=UY=9+QIFC _!,&U!2SQ*"P0\YBV1]<>EY_TYTI"%
MO"?P7>8L5-RH&66"4<PF;=T(+/TJJG_0!B7$!A.A[$7[P+NB6X:RTSW"08O4
M'*KZ%?;%*R=,,@%8>,9Q_ZI.GJB\C6$VX6\7P@!2G4G&(\]J/.Q,J3R'EY#,
M"PQ30XK8-(7'+B^\NI"_).M$H_0CW!..R+LABNB:P3T/R.^!H("( >L0$5^4
MWHVU$]SK!8T$OR%2M3E )KDW,!Z&)TKQ3CBFL:90=G-I-D>%GL)H00=GE;<7
M5_DZA9S1UJ 2X@0(FW"8:/%&DOR=+)8X*Y4"HQK"?>-T-IPC$B=$<-JF-$3G
M(HFXJE_"X4^^S?0%8IBT_8<A;I\D<HS+J.4Y;!26RJ;*TF=H0?H<WP/Y)#EY
MJ0KWJ<<(U!(Z#[#;C6MLH9?F/4N7XXWN+WBIF.>*68+O^&/6F[K9CJ3<&:'X
M*L,Z[(20G_3*@IPN0PS-%GT/=!U4A5<"H:XKM*_P16@&@J9 M1@X!^_L4*W(
MD=@B0R-ZY7[1*P<C>F5$KXSHE=X@;NH='9V=U81?Q-P!,F2A&CZRMCYJR!^Q
M[*N8<B3GCF( !\^^?S1A6,<*A!G;/LHE\!I;N>S^DG_!9K5'R$OF[R=U B8H
M*>=,C65\C+X)=2XS8Z2M#V2QSP3W#EP1_*<A8\-@8=DQD1HPNW']\!2U:R,F
MH4H,V:1!E!W3)":[)(>//2_Z@]D]?XD:\YN\C2.N2I-J#0Q-K8E_1^_R#>6L
M?A@6)RI &JS_TWJD8)\D8:E>:Q.SA,$-,#Z,WMA#2RT %V$^90A2WL1W_J[T
M1^-U@^=^?/OB'DC#HB)%E%!I0&,X_0(N+!14TM:B3QE O;H#"*/2 F;B;I]R
MR@0_ W/L4<701K,O9_A[I8=,U1%/?F2N29/*VE3Y2:=5M UMIT'N:62[*!G;
MSK2FTH:MO;FHWRF.X5E1H54*L@]#5%)^F4)1EG H6NGJH5U;S!&:)(<%GQL]
M4'QE7*-BKJ^D5= X"W'TM^EZ^!;34;NH6<5UC.A*QQ0!LV*NSJ?W.ONO&'BN
MD=B[=#=_1E\^4CJEJ@D-TW@.)ALTT,76DQKVL276 PD98L![TZ;27I34"X7"
M(&)P'^E!IPOH1$-D)-F?PK.SE_K<:>1P!,I?5%WL[$2LA/CJ#S4Y+#]4U>>]
M[#AF^928)VQ'Z,<F%<7H,8<!&.&*1(\/.+-B4B0.._?YYC8R\X3W#",2*U?[
M(*_O1A-"MCBVLENZFKKK<2O" J.L>;("6KW79WJS% @L=OW)4*20JRFX9E#C
MB=I_4.0UFC)NCE))H49>N-FY,@ V(O)".B97A2]$-QRK& ]C HD[T=5!B6PP
M(V+,;L).?L1!2.2\0Z_1T.\)E1Y,N:S*702X$M'L=-$UV+9U;<6 ?%+W954H
M*SS9+)8S-CQMCEJ<2M02)65>P]1UR;MRXU9SA)@IM/"WU,*+.->H61T3-=(>
M=34&@QM?".[-E\GP5^F>?7_\<L+$,'P4M,PYQP8S9:5WT;(J,"Q%?\85,/=\
MY*!'''_<;K37E.\]MJT]*I-'%WS0E]7"39%G$2-)7/&+Y3&%/8U$K U6^3E-
M!H60-8#_53[M70 289=F05-J4<X= ,B @F6(=L%''CP:7"7(M%J=4RNVJ&@K
M<"J2C.C)M=,W4B$D^70MIMU_)-!#*YIG)WF=4S_I[,W?8YYN[ATM5<U-1( I
MT2JQ.5%MQ\S.72WCV- _QA=SWV4YOS]2EIM3@CWF;"%M83A<T=X5@4U$@-*-
M+R#%C*PA$:13H;9N'%&>>"PU[#Q8)L(2Y#M)6&-EZGR1?ISBUFCMS4+GZ+T@
M3MX3N$;%!OT(O:9+<"EVJ9>;7099*Y-ZH,B?UMOO-)1Z4=*#$(?;O";$XNVG
M,C&%?##$%MD4(Q\BE CF@WZ!=1Q,-2SK/FO"JMW;,W8M!R;1C<S,R@PNRI6G
MZ(X:V"5>3*P%AT<?::^)[^N40AS8W$VJ&HR2W[#2A=*6%'C-_%PNBL^.- =/
M*5%7[&E>8=,M/1K]J0?VUT4U_>PU%AF]W&V,LNF4^6R<^QQU:\0!)RY-VG4V
MZS<1U[Y>J0Q[#6-7_2X2RI'=<,(W\''4]4#=I8?[N^^0FR4[;?/U?=GU[[GA
M=FX@HV0#.FSF0$UCE(LYK3-&YR2^F;!P*!.C0\JOL9I<9?W2)1K)I$ZD(8;V
M!F#YYRZZK$+DYDAL6LX>O,3W:KZ:7M^HZR2V@ID(RGW(L$J=:F3[_T()"+F+
M32ZS0'A#>L79!4CS.$43+1C?J6O;QQ04 /R632^P8Y+!!_"'N(\#LQ^8P42Z
M87)[#7DD+3_3OW)KXD'%G$Q9:LC2HTJQ*39 6I87\>*W9=-H,19K(2#2)%(2
MZ<&<8>WR63]E-QE((MWR,J>O'%A:?2@%_^SL^^)"U\ ]D=(G$4%=D3009,\K
MSN(O&>(R6.)D/>6OEB-*L^QDNY)].LEPJTW 0KYE_!CXR,--'X&'V8WUW\ 6
M,]2\B'_#9'B8Q"[ >H>;1UMSQPE73LUQ6:/WL]1.IO*YG4=#(R'Z/WA( 6_N
M2D'D<6*A#JVHB'-IC@<I*!>;5AWS??>:[SL<\WUCOF_,]_WVN^0HZ=#EKW:C
MY((V5%7(E\Z&F]M;>9&^%2Q]WK)7IK_D#C:DA@FH%2EB;+21$]YQ6[0"L3VI
MBQ0N1.^B@.\(C]+!]\>6M!DH-EI#PK9&WTR,5D'V'(F1W3.+Q((,=XM):%$0
M<;$8&AV9U8&A= #3<ND&;M1LQX0;HF'Z)P?^_<T@FFO-PP=WR<F86%T<.)3^
MQ]NDQ)B'@S83-]Q&BIN2&H"K?W']$Y5B5BT<.,Y4.:I-N&G$2;]L#G#V^W&;
M6"='@C<\W..F?->;W)AN=$;)L\.D05<(RX%PM\JP;SI-'H<,SXC^\(NDW>6C
MQ]SFWK--V,F;[O);=PP+>M &Y122T" &Y"-'&7SW5K_4)EZ:UXL"W@\O>NB)
MDP,!1M+E/AH)K\XD#KD:AY.)?'V3,W4=HC61V"G58$31VORRJID<O!J0Z;L)
MB=Z/0W=[7ERTH+^C0Y<=-<+NNX IQ'? 8"T!P4C/*$I'5]<W:_;@(/E,TX;$
M3Q2^T^!GF@ABC$G_0AO,YLAP!]:Q%ZN((99^S,SY+TU5<NY[N?W4$R_L&3.3
MM$/*QLX>E<[DFB,_P6*;=N$)ZFD?1%]]W2GN']W?"0MZT^"C>2TL&X9P7V#R
M[Z5-7939SWNGFP:3UG'>'F +5^?GDKH6GE(UTF0@S4KP'I_F?,@1YL'<:2^I
M*3=-[S6Z,UR8%Q5VG$?@*FV>E _;:9&4B<5C"(7,X9E(DT8JB-+$:+"G)I)Y
MX#I\ YE!N+GVI%+HS.;<"P7T&JZ3C+(N/K27=IF])O/"](-B'6O!H2K?2+W&
M%ZUJRKD@<1J;4(Y"\9+/0)!9&_ Z<1KY_?I+M?!<V;BAV'U"\&'-V;I:%>!Z
M+=>SNN"N'?#)%V]?:(FB V'TB=R'(7G7$Y=N0Z)_<PSG#W0TPHEXO.NG>#\9
M_S@==V_)_WO)^,<7SWTF_^\KXV]7X/=+_G_=R;LQ][:;@7+$;..IV*ZH <U5
M>;=XHS"<CZZ!58.E1S0;R H>?=CBP_W]AQ.3LNLG[.*"SU#-A4$57SX:N.78
M[MU0"V83KYZ%2XX*6:FQR6W#!0654J)SX"Y17%9^9E$C'M,41Z#&<"\JDT"<
MAN<+E;(5P\]*0A0&@-@O8-S+?L$3Y4HXT-8$?%553!S,(/=X *=AG=XP[C0Q
M"8XX?0EG]/0-\9O#?AT<VE:V(:K 8)DP%>D>NLBITM]0"_!&+56EHT& ==7\
MR6BS02RDY4JO<#=]#UD=+/#QL>;'ABJSJ!<.?Y4JYHO+/D\THP@GPG@L'=EQ
M3_+BDM@(P7IO6MERUM@VI^0]OS//.>%##7Z 'GH7M='UX45J#5P2S3M1E(=6
M[[12%![1QH]LU/O7^V+E"8$3D0>2M"Z)'(V67PG:$AY'I:XY@K'C8GY<OP!W
M[L%OM*^-:QB<KY!"WSIS@;]MF=(9SM>82[K?7-+#,9<TYI+&7-+60=R(30@4
M'[$FH(&(A3D2HT:+%=V2UB,.4#/&$$14^F0A^TM%V\K;GE1< LP5P>&V(_M'
M0F11'XT>N6AP-O,9PMN90[A;1-J=L#0UP2;Y4FLLA4#TTKB/P5$HG>[1-1-M
M\:RK7=SEQ-^@>F\*Z8+\@\,+K?+WS<WB:/L-YC^ &;%!0O@^,NOP,KLJ&K?A
MRIW$\TF0=O'4M.(%]VK-74)L7495KS#19.H+[B22'>SH"+"+2RCI+Z'^,/YR
M(*MU<:2L'TW2GJ7>;XO@PR2Z;0MF@^^Y6=K:^2>F72-^%NN@M%&$C"7N;V(B
M3%$T-UAFLLSFKQ(W>K)+[XJF)%$2&3SU7BTC<!Q;0DTJT>1&S/.B)DXP_#!7
MSF17-=I-I3^^_DB\DH@0>;]JO#I^FLB-DAI0Q90YD%'RENIF OF(]CGSPS,^
M %NUL^=86T4FFZ"T8S8$%(69 PGFYF6].:5FI<Q,TA5A*P6/++ZUK"CQ2A@@
MN'PYLL+5^(Y9<J@4;19R@&>]3GBXHB;(&5"_1$!&Y$T2."):JM9\@J@4O2"%
MZ)$5#8\5#%#!Q)4BE3-CC>%[C;*L22;8YP))KKV*8B@7N#Q^'[$$C)ZF-9K)
MX"*]PZS1P;M[Q4F5N/9&J-4,<OT.PNT?^.R1P_C"U%'=<B!A8\S OO]HVL:U
M2;9Q<^3&4T,LK<Q3+2T=^[ 4SW=RMNUP*0R+F2\4VQE<()2[,<WULAU3K.IR
MB?XR<H*;WX&*=%>*/SC<WY^ O4*! ]"?'5Y>_?;%2514:RH*C;#Y*!5%0%@,
ML8%! T<4[3KDE9FV"91E6K&=(=PV&G)82N?=9+$\B'_P.B"E;WLL4]!D:'D(
MYG%&668\7Y@@15W9Y LWA&N7]S_0?JO4+@O]6&\H\<;I.&T9GS0V$N4B,7H*
MD IH0I\QU(J"QHGM'1:5!/ZXJ#AT)6Q-B2#%\IGS#6\-WTN 6@M]V#S$ ,.I
MRDNW3I.8^0PC1UB>47!W:M,V&?1!E("/NCKTFI-I9XB[PJ2$OHO6"")5W##"
MX%("+YR0ZE$<;12@$.(J.$;.5ZLMWZR55<PM'*6[/6.-F+CF_D@.<A3''WXG
MEN9XI2(2HY,-9Y_D1R::&>T26R@?AO] FL/TK1JNL]28?T0ZIVM'F?PT8DF_
M-,N!OW_*P6E%R\?13%]L2_<J,NP5];1;<H@?FY/!D02+D3@6.;##$[8^AI9]
MM\$PUO$D0PEW6W*J+Y*$/>NI=8\88G#R>.E*Y9$?B:U?(FFE'8BW/])_8</E
MWDA&:%K]>NF.&I:' >:EG?=97>4SO0VNJ(PMDB\M T_>%]%72.-=29>0EEKP
M=66%[2[Z>++9\PG-GH^@6:O:&@)B!MV%!CKR1IPB2?(>M>1@KC3WDCYHPFW)
MERHA*C-T-\$(K,U"8$IZA1OSV*>$ZNA-<-NT U9?$$.ZJY=ZVZARZ"E_=C/L
MJ\7<]3X/D3\*B*PJW>Y%OI![#>WH,]=>.;EI@MOAJ\S*[,W[%X'P(H0AS">(
M*6$%XC?\U(U?BBY >8,>KW"2\#M[6EA&2V<G*W8Q[&[7Z$EHG3P,_'9-RZO?
MJ7NPRC$J#9]O67<=/-)]\C&.!,V;#.A#R<NI#S2U[\RR,5B326Z%%</$"C(N
MA*Y(G&*L VR-5K1/V1PE5#;!]U#9D$E$BM$?HE"XAND6V KBUR6,0U#; ]4G
M"/DB8,:9"UY30:01I?B,;!V$=(UOLA!UGT191K2.[C<NPJ<:]":JV.P#<HDZ
M$?S&F#UQ:L<OE8DR)*>[JB,IXJ%B'J1?Y 9;K<%+$;; ^+C&C!633RB*;M,;
MTUHD_"3.-+*!M920+>= ZRDQ&/W%I&<7DFEDA&=@[<F,F+/9*L+H^06_R5H<
M<R_?GGMY-.9>QMS+F'OI#6+H!1^#TWMDO(^8*4F<OI<=4OW#MOY<WI%!^D;I
MSJC'+S5OHTM!*[Z[%FF4]!9,XCUY'/H@](1MZ.BICW#REWF]3D"94;8">3G(
M;23*^5H!/_\ 0[.9:?<Z^').W9"U1W'$MC'$XXW_.$<3H=S8S3ZAXYU8!TGH
M!P/;!,QHBA$4#@P-]?\.),:_"/D6,A]7%&GC*['IAQ5,"TY_ )BI0L/PXE,R
M2A1#)K">2<$U6RB*P:.]J97@ H2RC "Q/#/J<"X!J8(M(YHDF@@]FN+:M@V,
MDW0T,HQ(A=V#CT>;Y^$B4>#'>J@@(CP<ML:W"0(U\\[+."I ?=J3) "S>0B'
M(4.7_)\MBNE2#35Q2&2XY![8PH?4M<< V+5BNR2:<W;S!9];$@?) J11G6QA
ML.Z]RLK*'KBONH5#FT_#*747UND>A+@>]WH81$@37$E0-1BCR'V_5D00NT5.
MJ;=0E[#A&=N&05$!=YY+KJ$ 09UJGCFD&D1 =(6_R>J[<:0@9'Q_5*WQ1]3;
M)UW=='E )_D1'.NA_<2']D51LY.,ZKI9-ZU;)@4X/*_TL _.+.!BBZ6 &XF8
ME9'Y'.:$1RRP&\HB\N.6#JU4;702YQ \SIR'-T2:V@NHJ=L[I4 ?NB'^[:K9
MUNQ!)S.P XGR$P-Y2,YNAI8"V:NN1DG$),<0*3SYE/#D&@]-\CC!.,1Q7!T[
M7!/%M#&0.%SG GPUJI(,52R8#2$7^#AYN/$DU<5.X<1E7$^ G90<G,<(Z3NK
MF@;+<>CV%M@G5YL&,)X2 0:P]_6RUR.7K6I)Z>+3@]P@9^*0P'!;"5Y\I"?-
M"7E=E#:,<=X5W&9J5DT[QG;<466>".= 6+6R"0<.T27B:/0=2W^SC3-XDV72
M8PU^=W0T4?9&[2Z-5G$-4_J5>HW'Z%#[-P]ZX1MP\$]]6 7#@&C"B!)>N(UC
M[4D-2CT'W+1NBPO,M8O EA/<;!MC02=JU8%96G.-12-4+ .9O,:"-JCM#Y\.
MI_$'EG?-.YP5""^X*'WYP2IT./?IA#@X+Y'RWJEK)IQ/FS+'=9VOUN$1@D(R
MN!T.&$L=A2]K\/7P@2\GRGO*N*-=Y^12P]4DM_$2-H3TN?'8/=+] NY;O/,%
MILTH,Q.NZV]FTW"V6U(SH$<%B2;,HP*K&!8"":97*]8Q=\Q2.C@F'NZQ5_8X
M^7=>*DYL,NIUAU'\GQNN1J.OO7YW,@E]3U"TVO@\O?.">T1TX?35E]@9C6IX
MX](:N=P43L+8OPA89T#N5IWQP</1$'B+27OC9S?8)@KEG!HQQ_J*$F4$8"#!
M(DDC9R14PK8QPAY>OJQFO@2FR2S*3OLJ^0*]#<K'TE!O4!H]D$.L?GCSEOD7
MZ@2'[L&\QJR>CW5[+F/)'( JQA4Z/-BG&OL)Y[YFS*.+-'Q-6ZVPE371F@7G
MQ-ZY>#H$R84EP;BH[@L"TCU5()LJGEJAU^DI81308+J_;G$C][*CZ=0MD-(X
MKAXQ<V)/QF#4Y$TL"*4D:WD&OLH*X?A]8Z.@ER_S?Q";AYSJD,^H"MYT\LGP
ML!/?M+(H2W=)0S?EOXE?\-^V8(C"5X90$1B9G#9OS%L+)R6:.SE*)N<M-IA=
M. )J8&6.)O /'O-FWQE=ZH8;G(ZF1\APXP06"-R7"H:+G9-"Y,>Z\^B,8^QF
MV^UK2^AL3AP]3$DWSX;L(BD-U$<GD*+>6S@^(0C%#3.-#!+_HK-U1/8J7BWK
M/20KP.1$_"[!A,9*+S*PM.F24+F6;C?R*<REGY["3:T/[/SML](B7+T^(@-1
M(:')('UKPM!S0*Q[12LO:(R^G:JU?Q!W  X+/'L)N[<V42WDY:E!6\-W0"2G
M4C'$G];&L\* ,OV, *&%R^<+U_H6%J'1FYUIFEOUVS-D[0T_ AT34 >N\:,W
MF\B8SS!6K_=ZRZ!'6/6U.&X1"0J;IQ$-[R_\K6?R)<*6HOSWR"*B,6NV=L-]
M:T8]L%U4_32\4.PU($_"S(46 *%O2G*U;GO/W0&SH@DD -*O&+#V-N$,#[>:
M\[BWQK%2 ^DE;I'H4O']:E<=9:;Q#O$X8.U%F^L'\#ZM%EU::+ATR'I<-$L/
M!B(>G([P#&<NZFRPP0U"6P!#J8'G AMCL*_,?3"34S%F0^\U&_IXS(:.V= Q
M&_K;U?\O"GM%RA[TIJZJ^O,D:EW%,$XD=HFB:Q?KL[J8#<14).IUA.X!;-O!
M/O+;8OC>AR0/]_</OOO^X7<OC_>RU_R8"+#:;RML/3*R)+!8AK,Y<4V07O4>
M%%E*@Z_PA=!=%.V6W:C;EF2WXH#\7G::MOFBJ\GG MG1DIR<E);[L*YD?9;.
MM5*=4A<$VYN3QR_.:F@:EJ[G1/H=1"T0I%(F"NSV\&TSMX2AMM1/*6Z8H"$-
M9#^HG6\6('&>-/:TTSR8)-Z<IS28>)Z>2=K^G+JC(GQJN(% VAG'6[F4.PVW
MM#7?DJ6)DAG4F$U8.=3(YY8\^"*_MY)CT5 ]-2MJ B][JY584U8U66@X[_.#
MLDQ'9>F^Z"B'A)OZI5(Q.SLDT6<>?O>$#L!=V'BO-QS56*2)0<TS"5*]51,Z
M5PQZ?E[N^P</(<NF@^ \RF!?%E(X9P+>OY X#C[,;G/R7'[21M\4,V\7/0VC
MD<F(5E+;5O$GNNMB54DQ+I7JF5!%?ZWQ^=05BMPDVP3-'*V):8N<9 HHYBWD
M5!I,\:%)"@EYVDE,9G4EH>*CT)\&R@8#0EN"O)DO#]+G+A!T?!=)X3BO%=+!
M]Y;]_6B!,Y[V19I/WSB9&_S]'Y%;Q<_R!!W\0A3TC\<G$_:!')4K4 <SCGQM
MS/:1]CG<!\WB8<'PF/ !*U'PV<??'7Y/U[!-:F]\6O0'^:I5<O>;YWZY]_->
M&K/H9[@'H1MZ&W@<[8V3W!0)Z+TY9+?SD-+&H'')]UJ<VB:&481[E[2"QY\H
M:FV85_A1 <!-R>&OSRU/$HWRYMW)BTF4W[U1WOFKQ,.PVFQ/&,<)_EX.W^?X
MF2^4IB]Y_9LF\^W4>WE]#5VDT %S:12EHMX)67,WT1EL\%@7"Z1,>C0)8HZ-
M?3EG2=9MJ@\^>M:";.?ESP^R]U7V^.&3[_ A',?;_B65."E8 \$5@N8M"!>X
M-SA7V\B.+%P<6T1(ST7>>8X)GR\*% M#2L+D@ZV/H;H#%B..GA)G7U4A4C%O
MHRN;HM/1?3CP.DV#@X9'6W5J:E>7'8:2J$KU7"SW^.'>OHET3/K&P20TI52F
M6)Z+D>.SA?9!(_Y@Y<G2H%ESD8JI6+J\MXYP7[ ?522^FC39+"I>\Q+23#LL
M;KYKQ(H2 0ET?';ZUT@GEA&BOCS</SR\B61FW#6I OL)) Q9D(D$%U/ARP6W
MS?T-=PZ_&9.B:8P]J:0-5S>8+;EY;V1>)A 'D1"T5#U @_>(PISV5(/NQ5B7
M_QA>_%@NJ5K2YQH=NTC" "SU/$E?.UZO)KMR<(JQ*):7#$%)',25*C(%W7'#
M/#SRS8JL#I4[KL8.)=-4GX@X I_>,)=%! K&83*^% :N6:VSRE,*ANK+Z-[&
M%4!?LBH3J]O/,,X1I<6N/52Q%.HV&574DPN'?LU511&&)MLY0>#8&\K9T:/A
M(__ S<$+9]T/^]H<%LZ#O_XF82_WCS+K $\CDR&.N.O3'CR7\,!BS0$"+ IS
ML-B$*1B>_>8;"]=1;$ !Z-I2_/2N#.Y_>'R4FT=46\W7=B#--?BQ@5+]X5E*
M^R)?;UT15F%!&7V>J<Y=,]P;]<&=X%(9E(S3.^HA*3XZ4%@PIKLP!MYM0'5%
MJ"U#=XH!M!K4%=7FJ21L@H9Y90[S\;:5[:'+>W6&U,+L9=9N-T9<D*(LFL^[
M9_"0>0'&:KX@<5'869S>Q[#6.C&R(]N:A%$&R?W9;'XVLIJWS8P[0;#YK 5Y
M,IS,^V_] 0@8"]WV:D&U;S/?3UX&ARRT"N]P[/YI;<10043D>QB;!40?=:/G
M"&T5] :W@!A>F^:&T9# D]MBRA<QB\4795.2^H)MSY@R9(RO%A(DK%F=>EG8
MOKHQ9! #)[Y:FL[-Q+#N#D)[# 9QRVYP0K6A8# ?$KS'--%H&<*4G/BR."\6
M@BVI6).IC8*X! /W"9T]:S[-2)><QD[\%8)!5F;M-3"#*9F&: >9 @TF$+@&
MU*0 D!UA;F'$X$#(Z0'ACTJS&=>=D:!C0[=>\9FN$8!LAR+5U:XT%6JZ$DV1
MZ2+O&O=-36S&I.>W)SV?C$G/,>DY)CU[@[BI04>-/_!B9H,J[0%R/W'E-T,O
MG@RT($#?B:R,.0/K:6[;VCFLJG+C[4U5>1'V%9TB_S"Y9_H,BNE;D'3 ;IWA
M@)1>5!OJ'X=CP.1Q:AHH *0I[5'5GFB#"1@]:WM(HN[D9V=84HA&6]Q2+EFQ
MB5R(?+O['.PF2TGZ%87(;/"ODK%%:'\<IK>OM0D05_@9I)4X\+K^')3POI$K
MHY8OROS@.30('Z78: Q,8XJF5$]@/E':&+9;D5\K$1RN(6WU.S>RJ;6F-B_[
MF:;(U#= T))9QH>2R;P-T5!-.LPX&Y:YI*C34F$J=7 +CK37'!:T^3;O,:N?
M0AP8F'4N&N7 \-%)'FJ!R827N*"%)-A6>(-QG0OG#7UD_[KF'X$C)[3=5I#P
MN=89FY![(*7LGSIE=]1B\!)Q__ ;LKBG5,1,]0&^OIP_GO@Q/@LH]"#Z-"E)
MIE N%L-U('.(J?>ND?P)QW7&MFL4^XKQ "UQA<+$KD=<<-9@6VV7(2?Y%Z*S
MO%D"TH<B#QYA^F5_/R"PN=2'/8\&VWBB0&XB*J-/%;R6*HNXY;["Y2\AGQTE
MBD7E!$Z^_+RLJ.60J'MUYFR%4I1_@=O+[:)?@CPVS-4+QZ2N2F&?FCD"NK!3
M%TCWF"V3"A<14L.>;5YRG )/#L$1JJXA&#0(N33=Z*$].8OMX0M1F@?Q3C.%
MR-S-]">*CDVG3J4\'#:E8\)+9%9D\^18R^0<::N09;9$RXQHZ)C$%%WUSQ2<
M]:B%E&. 163S I*&88;#%B]&C'04#!-NNYH:?XHP1U"&"PN>XOPEKA.7PTGM
M)(^@L>V[!MN16I233J26]!*1GC:PE V"V=#V",U=;[9MFMWWJZWE.YEOR,1=
MF (D)5DN._&P<A63,).ZE3'QB"=AW3V[TSRZOO36HNL/[VP^%1J-X"Y2/. [
MR5$:A?3]HZ>LD!J'N"L0.KC#"!R><KI[7I"8IG-N==/&;,VIU)*BJK E&=["
ML\\<Y&842PX/>DJP2K03$36:Z>C:?U5HDN=O6:,P]K)-05L)EUE5#-[OC*OI
M>N;>-EM</D*]!"ZJ*[0 )FQJ<A21LF5?C"4HAQVY[_HA^WDQA\L=/SP1-6$+
M'GL*$<Z7$&D@P)%Q=W[/J8FFF:#9EJ@3((QVBI&E5-4&?4)=;2N0>C*44/D'
MS3*X,N]ZO],]A[->?:;Z'"J%15LHVG]FB$5>T[RQ-9%HYZ%2\-"0[;8Q9J45
MK2F-G)"A(&C(_T:X#3M!L1DV,2I-#H4P4JN51(RBTD(*'HS[CT%29:FF#F9-
ML2RP-F\03SKQV DA7N$X9JJJ0HVLV#_]4MF)(7*G]Z8P&#Y *E,^ES[85D D
M>4? =?84!SU2H[@L"G?)HAT$D)HM/-@S@]Q>#<XJ9A6 3W;Z0U:6-Z@B7D9S
MK;(Z\45_0]7VX6Z6O\9Y1=/RJ]9>9YBK#)YF2O<9P8*QPZ:=W5V8QH$5)XNP
M<2QA0?U%N;,[(7SU]T?"G87QQ6M.;R,E1!8%/XC=2&N4T">JW0661E]&E#I$
ME<D5O#X;YC>UG_%@M9 :38$2/GOY,P@ZB8[PK=.L)-U#@D'K[[DA^-3I? *S
M^^ J2/!!O7RZ^."%F]:,6;3ZN#.TSY*6KY:C#)[82]9$P+Z$NJ1H&U]S%@ 9
MO%6(*)/D,<=R''9Z0=Q8F9"=):7W ^FB?IJ=E@HL;]A)8QQ+BF]0+A128A=<
M&16N@31%QDXT?RGV%QH'60*!@7A1DW*-BPYQ?U=E,@;X"55%8<JJUZI/M?N(
MW2.SSGBIVD?)JC84=XH$*PG'^,SSQ@]%.5KS>CM[A8]$FTD F<ZW+S<00Q N
MY+2QX#!Z<!$ #/"1Z8_O3@S$GQS">)Q#1YZZD1 $*@EQP!? ZBJ^E0%G3))]
M>Y+LZ9@D&Y-D8Y)LZR!^2T**U.P,H\R%;TD+FG%9^5(VS69L,I%2RT52)DQ!
M%N("T4.'0+-4J9(+S2,I=/:/0,,CD2A8$2#<*1J7" Z(G)/)T9*9="6VO;)D
MHRNIR&B(N$0391/!M$?6RJR2_E1;[32\G7U?N&M7<X-ET3A>+KD,,RVFXB\2
M7EYK\A,CRKZ-H$LR>@Q?]*\Z:PH8%]5GX$X#2X5XA-EQRE(!UL[I\D0*19)F
MY8.&[QX^RPC4@&5)\S6=<N)1XNMZJ9F8!$]KL> %\UUBSPC+9_"B\+N+XJQH
M^V$]B45]JX.5'/77Q(8PQ1/S$4WYY::^WSW-VM.]H@2_JD'X5Q'?7(2QPE_A
MT_5P8\"H63)AJ=FQW66>E,2$:AP&:HDP:]#.-8ID3J$'YF%!&XYH)J26E2%<
M-FSJYG/J/:?QFRCHY69.VC)SX(+5D,=<\T,QNA;-N@FL3]06D]("!M@:-\3B
M=!Q76?KSJ02L(.IZJ_C#==8UZ-!@3YVNKBD*-AEX[@E7Z>&AT;9[Q'B-\YW1
M_7B,H_6]T@_V;<V6708YE"R$_"U*<,&18R7QT2&(%QP(_B<^DI!B$I\Z.CZ2
M&-0#(L9"'PGK*))Z+1\YO\@EA8[%MD79<0 $5TBRSU43;VY8K'98 /=BFV/(
M5&'AA:$F?=SB>]M]6?' ,/]^SI&>#NXE9*2:1:W9=/QY@F;67FIFE(VK+_DJ
M.:V6PIO$%&KB4>*H2$#6KI5L,B9=U[86CK33PGDZ1+Z(S+/H 924,&>E)FV2
M:1V=V8Y)//&77]RTH[OQ0SUSM1_:"1Q; OS[WO3_Z% K\Y%;+!R?NE_$:01W
M*A1P7W_>^>*+_Q)N>C,YK;W&[2-A0*TBNJYW@ +Y#(6?0Q.+&PB)K_/8:$U>
MISA1"5^O?3FB/76+!;P&L2[_]T_[?Z)_K]#8D']_O;_$KF+D@MS,E/<^PHO3
MDU=OX1(G&SMV$6*1P7_]M:T3)T(_]==VEKHBW],=DBZ.+E$[^[HG9630@,3H
MW,!5AL>3)GKR_*N>A]7OP\_+AG<X?;!<ST=,=YHO)MA+=^8HV$0!8^>(1PCN
M)@&#D#(T@48B5P31IKM*2%/17JISTE.""R&>/XE@4S"Y8#94[CJ(L"8NY*RH
M-(F(]SF9ZB%D7,TAF&F&T4@>I;G(I9&D:)AP&1IEUI\Y%3N=USGQZ"XPYWQ^
MP1!]G+4PZMNFR+[!H[XH> QJ)FIV +/4)IMD,$/>R+I6C$A,OTOD-/S\[_\&
M?T11_]MXQ+/QB%]WQ%^B@: @*DX(<0XFRGY2+BHO9OYH@(TUW DCQXH"/(XA
M$U11SP+_"&^+H$$J)\8:(N3^P*V%ID7>4GF-@V=F!P\?_ME7K(BAN\)G*8\#
MD[NXLW6X,"DU2O6HB0.M_^51<L3?N'ZP\#BTH\%2Y&7YW8_I9I=K/'[7KOD_
MZ?&;N21'IZ&D5/H,G8N74,+R?>0/GO#IY-"-BCV[($5)B%IY(IYI3K3)?4RY
M)X$-A^L8L^K^$3'3D[A*N9QE.WQ$G4S=1-/X\*HC))RFA%6^F'9<XS1X&DM;
MT^NG2%8OCYP*^*JN%4J7OAW!+^?A,ZB8<SS)0E(I5?AJ(RGPH(5<65<+:1'
M T'?TS<M1A(,K$N=S6JNC>6*?89 H0U#);(<?_$CYTJKH8G'&=H;[C)17LF"
M"HZ/M\X3I1<EN#3H:A7E'-FT\ <0R 7_;HF3:-GI+\I_$%IDU&^C?OM=]!M*
M<[M>L:'LK?>T,VCV\-'^#P*R*AIB*%&38Y3,43)O53(C.* +2IY($%X$,_4\
M7_6$$94[YRRX4X#5WERER_U2L\?[?V9ZC-UJOHN.XJY_%)C%@B ^K]I"2%ZP
MVVN@@B#T5<V4TZ38JW!B&#X+SCDU# NE)I3V"4,?]&\9GY8SQ8WM!!_C&XPE
M8JY</Q1B?[JDM 3?6,D2CB=V/+&W&XU"$TO2!+O'E'D&V?O0M>@K(IV&( W?
M^*P8>I\(6'/([$0T+_,U@Z*U;,\'[@UI)^=4?2V/;Q*.20P?!D97%]U?<E<Q
M9Z)=?PAHJY\BZI+[.P>W$O<9$3VWBNCY?D3TC(B>$='#OQDOZOA+_Q(7=6I:
M\U5M LF2D/?1C3>>"5AA!\?O3BFA@PR^IL_;*E][(+-DH9'EK\#B%^SMY19D
MF2*IS:9W-2N."4W2*+% ._H1)?W&WA_V'M^$;0G-ZPPS@L^97WK&= MM"<GF
MVJT<,K%Q4 ZY$9-6@,.9?Z3 QL0^>?S%4N%@X/6LV+<I38 >+"=T-&)<126O
MMJMG1D%9<YM+]Q";K@P)!87,$Z55HT5@!#Q?(8\L5:ICH*S!1(,!+I@GT]^Y
M+!2%A,CRD3;)LZZJSW0C;("I8V>Z28?!.6M&XNO5>;.3=SY)$P:W ;+UU6+R
ME1;@-6BOMXCF8T(Y#[C?@/WZRA=_I=SGVJO+Y'IWM>IBH:.TY1>TV=(.D!*U
MG"\FM%2RH=H6%\0*2X\]Y(DY&T#.Z[2>P?8G],4?@>5+'FSW?! GF8X93[=B
M)Y-6Y)Z;&-[B83=[V2MIQ"TU/C!-%DN/L1$T(QX>U*3NG%7 =PANB=\@F%7/
MZYRK&G41V&E.U2SR"%"EL!L%<F-6C,O!!#I<,7;J957N:I%#:Q;N.28E&8>%
M_*;G^)NKG&&V"]?"'0._4&AE[;#"L.'2\^)7A"0\9T98813TK0.XY_US3=(K
M;PLW!BQ6GN'5X =J5RS/.O KE5Z2DZ)<DM,B;K2QE*5$)1>8<$W9CF+CLKBQ
MJHG_1&W@[^G0W[Q6+8Q;4[1,;(LGP"#(!H4Y()7N;(ZC^1E_Z5_"_/QD  )'
MH(-V?RJFG]%O):1IUSK56(J*;H:A#$J\0:E$S5B0:L >C,ALS!6PR&_ \$9D
MV)P6+5F7A'J@GT(;OTH CI*37':E].F89#.BHUZL,\E#\K^H>] T;R[XU]GG
M@EA"*P**3@?!2]BIQETA;E$(*-@^P99QTD[<PBW0@O&5@JL.3)B<.P53P20U
M+<0:@G*F-=P3LM_.L=L#DWI<4IN'T'U9370Q/)F#A/H(5 LGT^!^2-I57/?*
MZ <-LVO1^J I/\:71[WQ>^F-*9P/OKN\R3$'(P&CPD3=GM9DDME$WWE%'SOF
MCQU-!6?,?P,EXUJL,_%FD#PHUD<1$ &KCJWR&=9502.A_^I*T4&(N.@:04>>
M;0 [TN?=S/=7U34(]LY$IXW'7 ^X1QGPPF#E0)UWLVY!3B+",#\S9QG_G6P
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MQSPPT-'="K<%N1IR+19+(ODQG)?QJ12N,J1W;D-'K""6\?W.!I2])>>@H,E
M\1W$"@^73X+"!M<CH>%ABXVX^QB'3#=9((M 2!-30I,%S"+@_5&/(V7\4H#N
M6=M";Y=A%R#8%(..8GS-3[E]1$&)3RV<I</.[<4]H#(F7D)2*-CXB2%Z)_M3
MTIR=&+R1U>/OQUS,?PI^2^^,I<-,1=$LN02WA'&0"<3\5D(>CW:C=C&#8=8J
MH6?=XK-"JVP5P1]4B<C]A))/=]11=XYLY@=/2'D<;KV;WY3SA3(L$L*ULE?S
M842R^.:C(5F4*YO9YN$O0>WKC96B\M%9BPHXA%(1W$;%U&[H4YT^"0_^E+P
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MDL,[2B= X=8]%EX@J("[='*"X]T3W03<I_;"Q-QB"G=4P?:R!EN1;KZB'<*
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M<8]8BV^@^R8%O6*\')R+!1OJC9&R<3>*O-;V./S 4=8]BO'A3<T+6'DB<X#
MUV5G)AB1 /FS&%@K\RS#M8(=M=*0?X!?57YO)-S"0FH^SL7(CMT)IF=:AC&Z
MT;.;*Z6W35CQ=_#472&=RI>9Y)U^6(";13.O3U\X/#5VM'(-7]Y4I&ZTFA*M
MR?A;_Y;M2KSC;_.;AEER] S,X/E82G,1720466J2<B8L9X&%UB*7<::+D$Z]
M>&<U<U)O:5H6YY5R1)1UCWZ]"CGFYA0!&77S+7!9Z4%/:-^G9%A>_382)55N
M/P@/J &DAA606OJ3J9]9H:##:2V[G42-$E//I8"[ =;#<09IPDR;L$AVY4'$
MTD80+$G$4I(>>=B4]9MP [1V\CU:.%T<_H)!RBH.:)'<L92B$3X)1/7S^Q$]
MGW.]X7F9OCMFC?9*GKE46+CUD,FHSI_$V'XK-?XO4XT_U?A3C9\_2=M[_*/?
MV/;.J:(8%!H!KA%/J7!V'Z;ZS/%2#\ULY.KK^GP1S+XQP[)2*PN=\@25"O%"
M#1:?8MRT",Y+#=AR[N^H<,P ,^8UT;O-KM:>/+-*;&29SE[)+C]%]HV:/"#.
MXC8S.1G!H:K<KX>VHS(:IY/A>LT>";$M5Y P0. U:G_^H>/7!;I3JBEKN\/=
M!YU?6,XFF?F=8_ZO9^8G,5H+:(U?Q1'[@QL<#=SB5 G+E($$ 4.LGMR#/@6V
M"M:38918S9=RO0?$S0QL %S9>PNX-:;JOXVU.4)%C8!>[8A41@ENNJZ!:V+,
M1Z'<N.MW"83S4RA,SY>UNP8K6815,A6]234/!IM[W;76N;:=1J&F&Y!8^)C-
MT/N_%=I,_!!=D PX#7HT.\Q>R</!Z^W L6!6&5]DG[]S.,-%B:H0V!.SI7K]
MC>NH;0W#=(NOE$G5M>2QC:+_PMM!@Q-&WQH\%!2S>@^'9A 42& 0N2 ,2(PZ
M&X'G]!6"NH]"I)&WH+W.:VDQQS-*G\-X*=>+7C2TU6 EBA8/H@CD[,,X H,8
M.&VY=IGXXOR18L0]/&[/-?H1:"'JZ5T&V%CPCD4MY7VT@#=4  ^:VK.G.@.-
MB>O1IM[FW_ 7P7\%."N#"P647S<S:P+<@7)AZ1*@O@)= Q- KTR@=%&!K\.?
MJ<INCH;2]A?#08W$"]7![SI\"FWCQW4:Z)CWA+U [&[$N?&62I%!;=JOVI+.
MQECI=!XDQL=E!4H;R*-:)SY&KJUPS?8_LT?YXPB&RJC;K[)'Z\?@[C:P-6/"
MOB10)OX(K\&E6^MN_*J!$"G#[M.&@%32$M&,D'0RKGY,V;"O"6DU(?:Q:F:P
M')VD_^&8?^W:R6R6].R;QUSN+6FKHN_+BJ!5'W/\@'GBMP3H4H]P['BYXC&^
M*U^,6%MLY8%V7_$X$X!<#@9XY,Q#E:^;EI?D;=.^6UFLWLHLV-5H $;X#I_X
M"&L0GM ]#J02Y+-U;"G:SAYM'U/!0O]JS$5" [XF6ID".V#.NDU;KAWR+\-1
MP0"19U<1=8C.K:,U8K#R6N?=""'"-;:8785Q_8K7*!8CHP&0R,0L$XQG>#6
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M.Q6XNO(]YM[Z7:<4V]*-2XV9'!&]H@S:YUF7;Y'&#\*>IAO"Y8@]%IQ"#:[
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M^JL/.6?OK^:\!<98^&UR6BUAG$5Y:^WTCXZ]CAVDD'%:Z5!M#>:2 A>J.-)
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MW@R8,*JY4XO/:03#F>GCDN)<YU?12!ATJ_"8PN&A$'$R);J <B.$%\K105(
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MEW=-[<ALX]Q+]NV/;S7K,K+8*PQAKI''OMHD@TT&>TZ#_;8:;DI79X^VU=#
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M21FY9_RGVA[_A2#14V<Y-CQZZ-&31;'NTDA2-P(\%$LU%XUC.':SV<1AO:X
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M+.^C"L6AQ;@^F6,RQW.;(^ZL,'W$Y:GDJ]@AT&OX K[S@/!=.4/T<,3 UJ3
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MS2+V-1CJ$A3';7"_4[GD_U[T7>],(C FY_P$_X7P5:GWC\(8P'<2'.H0^)]
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M8[36+'JSZ-VEZ!E3QO!X+F/RB[%@L]C-8G>78H>XST4=PF]$>WM-L*G+8LM
M4#7T9\F;)>\K2]ZV*0)I<:.HLY#Z+G=,\>O:UJV^]]^8!7(6R+LT_BC!"9PZ
MV7=>_PFA''O0Z/'(D3)I'R#=1 0IWX<D#<6Y?A\5)C."X\L1'$]G!,>,X)@1
M' <'<5.CA98K2VKIRSG*W5$4D<+9_N)DQ&=S,*AH\P=3 6KI! N@,_/_FO G
M<KM:PZ9IJ(:@PKM:TUL<1[^?C-)E4;I1YFPBQR!=&6X&J N1.'I=F]F$K$#K
MS+>S0#W.'6(9+MV'-& H^[)<R8;BO3VV,I20UFJO"OEV*UMA0RL&#TTE=F@
M@][!C:3)V\5%79L$0>@4%WHM__#BO?9:S@3SJEE$*ER1U@J9%II0;YR0K YX
MR:$0=4*#+L!QI#?B ]PJ_):;X;@5RN(&W.SY<MG'#N@*<VCH1*(,H',736Q_
M6E=K0)>I[I'%_@"MD[17 O/L/;5+>=_4?HZ;-K:=)DK[LM#S^O<^C^?5 :ZL
M*/,7']YQBQA_1X@0:&=>Y<P/)R#87H+U59 Z/0-(DY9ITDOIHD.!8<9:A((_
MZ@3\B3>Y:!7$,^#G/G="O\_,Q&6^FU(F86M"_$][/X0TR(8 ,9PZU5?%VC["
MTF^V=8NJ264&WOA5)D$JF2R;EP?B0:.-*?#)\4QI/!H&(N1=S0S1+16<.47E
M7,.#2B6S8I,VO!F][KEZ(4?'1=.SXZ-LM8Q1<25  O%FHB&8W9$D1\Q0JIQ[
M8O%2!Y3-!,WZ/B09K65GGI7PNALL3P2ZUUAERM"Y(<]X27< G>H4;+_2;B^F
M:$1WR&8 %5A$:@S_K+E_A()^PIV2]KMR9>N T[)UMU%:PDJJ=(SR[5)3E5<'
M;T#DZQ:A/1MRM95+6R=70!RF7Z,#P:3?89=0##+HYU0Z.:W#]TK17-)$@W[0
MU)M"JL7-HUJW9*A.;%FD/=GW PH%T..8<7S<;&JZ<-S.W(H4T'*VXR(J(9$6
MU0-H'L_=YOS<"=#7*L;H/DK_%'2BJV_P)VH<) :RL:L?/7T:(@1A3#!JT4$-
M*=Y! X7%>5]^8M!9+%OC.ZRFK=G0?DF;#.]<H,5,XX(P)/E\>0H*N =M:_;N
M<$QX&TLOK_)R)RWG8J."J4$&R)XHF92'7OJRF%YL6C@^L:BQ5EWN</]F(V5A
M8CH;K1O!Z8H=A0Y*X?$>*_O.84NBVV2,)5\9&?E&]">OCPAZ",-G"7.-[;>B
M6C>YO_)Z%@TRK_*MQ;!R-SMN9!=%*%$/40AVMB6%V7,NNG/Q7A#EMAXV/[&"
M=A. Q&O03S(''J-!\81V6LED[ PFJ42  \GCVQB7&\1AB<8-'[E+@=:QIO*7
M]AXJ6JW0S]!#$]8O]*$4I=FYF\K-UJ%5"Q"Q[?'8ZO;O4W,=O0+.=]$1H#KJ
MM"QT-//5#<<.F(\EET"G$&S_!3*&Z1 \T$Y+X7Q^@T=3-+=,UL&V K-K38;2
MP&8KJE:\.-,++^+NC/VB2')[OU#OAX"=\5<B0WY#*P\_4']1M:%P?_$3&NV1
M;G!7.3>/&C[3_$:0R8;$8/CN'<H7%=&<3:BGD4Y+=&9<I8)*BENZN0M!<@9N
M"R)A$IA34MB9+<@-8V=16F]D9)TVA.OA7DQE1/@&L ]H!_2'L,+\M;>B;^B7
M2/B:AIICQ6:"XYD9D0S$$%/:OY'F>5J\F5@M@[ !B\%H6OYF1P7RHKTD*#+Z
M7BKF:56T7IVAZ\L6Y1;Q-X&/02(5T@C4.Q-V'L'I4?O--.RTHPK\!V80A""'
M*D4/6>XR&1A.%&JEZ#"GVYBTA^'^:,DXL\5%69_K=:2/":]=W!<N5B\8B3:,
M14"OT/0>UKMS6C?Q51J4D-]7<<JXQ5VPA[@_.NQEW"&;$8A#[F:$$Y)QI??+
M,+RP_.%MB"]P?^J!JL0#_;BF0A,_QI_Z:5*@5?7FE.6RIG;KEU+T8:I9WGSN
M"DTVGQF.&\9,++\6MH8*.1"&<B>7#S&BK$,+YT"$PXT0C:*SH2&]*[AAJ=6,
M![1SA+8.^_VRPR"L5Z$N^A8.1#O0N]>"+JTB -ZT\^15MI.?Y R86/>)&I\P
MS%#UK'$2>7,6/@A]]UC \?&:NNEY+=O2=57ZFS[T3%):*8ED3:^_PI=-Z;$]
MA-B>>E2%GW3E9)UF5V/P0F01%#2[7TYOL6SFB@B=O2']5H9N<\?O8KM:K;/I
M- :M;]"EF3H6LC;[HA )Z4#!O<"(C+U%B^T@A ,\\G5*HC:*F>S7E7'46GQX
M/2@^-)VBC>Q)>#A3+JL])T7HOJ@9V2336M+W&@W'DP7X3-64HYK^PN_3RB97
M(^0^\4O_9:QPZ:.![K*=9&E?A=5"GJB+!BXHUTZPC,'_BVM#-S+Y":C@1!G/
M^!P-?%GEB)HX1=XA8,/0WYI<E8!K@IL,8\>XCHO#68@ ^U.-GM$H]ZPK%RC0
M3 -6Y*"]T-FWT@*ES=11(DC=X:L+BNG!^X&A4\'=C4]&G=JY<Y4.H2 /!'W\
MBBITZI1VMHEN)!SN-CR\Y4; ,^O ;YNS_G;.6<\YZSEG?7 0-_DS,!&1$%UQ
M-3&G5;71]GX*-GMWX\[;RYQ5XP+/;V6-H((-'YZ^_X_'CQ\_E+#)=.0U,=C4
MY^H;O@'3T*>M$O0^7%NGEDLLG\OTS9D,AC-TJ[_U%3LU97U]M")[<EL0$T.S
M]7YR%J*A?-%/D@2$4KYU&E'3$0<?Z/"B1ULCR?6HV1'+7C48*99$ZHRID9&$
MJ#CN%T=VGK=%I&P<>BK6[[(!Y+U6UH HP;_=\E<A5, 5<*N:EJFM.>BG]S(&
M8AO4ETFVJTZM"'K.&Z]S=D'L!@M@=ISY&!/!Y-]7U-^*OJC2F#Y#[7;N*IZ'
MG!*;:I1(CGGD)'"L!8E#!QF&MWEBS%'Q:D)ZK .=NO42:!3ZJO'S.625 "HJ
MD! PX6VPEP_D+?!]); RHE+F_GP$F*#N9=)A>!S8TN"35FUK?H*]GZ+EP)P.
M8^"=/V ;KMLEH2,"SE87W67P.+,XYN7N&_88-@A1D9]*?J2?L0OED"[$4&YQ
M7B08>HMO2C-;)-Z*NF]-GFNU/[$D.DUSZNGQ-M-( ^CD!<1IV2RLN,VK).<4
MJ2<&XTAIMV]JG,TI <V<Q;+;27U)>2^C4L=LYC@VK'\I"MR1=)!BB*(;RF>3
MP&'I#;C5+JFH]0?8FYN!=$^K/U,'B0D036@QVP]"BB6BV="CBOQE1)[(<1C#
M1[P>IC ( J+5Q3?F&F1XS"\C=^J]A#U?\K4IH*J0AXAZ0)0=7Q7P?7_9EG43
M:HZA8 +0+?#[(@00Q<\4G_-4,Q8#L+4D]V 6=/I-B]8._'A$)T=&QO'BE1V3
M3'0T,GN'<^!J)U\O!K(TR,#&HZI+,M8[173O,SVO#-Y!7;L[8F860]!I$!7,
M5=,'@E.F$1&\CYW_+9!U>Q$\=@NRA ?P$$[O=KB= -9)KN#/1^UP.7D$[*3*
MX;.Q.\.K<A++,Z$+[P<NP>0!I-APN<AMQ-+]HU\@X@<_]2?!A?&#V8I<#8H?
M$3C-"GF@E,Y+AFC"'L'S^>DEGHE32ZWD+R3^.@@!ZGL8:<DPE7-7N76A;$YT
M1:4;8]XW_9+[2N]\UI)FOV9-,T)2TA7W-V_D=@NTI6^<L%^50BK,#%G)XING
M[MD'4I9I"'M$1&.X@F%PL0TB"*Q%WE_P/XDN]4;)%WI/UM$-V.0[FZ.UI@'!
MK8+1F]:>H%N -#2P:#=BU&@H&1(BQ1)#9<KX+&W047D]=#3$$I1U=7%$V$N&
MR_GU"SE05)ERLL4TJ%@592^P+P3XX(5T]?+3I3]SN'=B,8R02:@=H30A--!
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MX/&[,&$EZF)BK*6C;9=:F G.$K%MA*PH7!P'Z(IV([*B4&E4$,:'>'PS/5V
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MU'-MY9@I!U!ZFI8\3)=W[X$!IJ,A&,O$'242&<G)^YB*SBQ V\8%)JHH-!;
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MCX%BD4-K1H*MB#F1:5@GSS*QXF?>\#FAX_/TF^\':8"#;ZQ".!?_<;>.+R2
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M:':U'U7@%+Q*]OC,-5=$,$3/>N]O&.<GY&^<'_G+-;?NHF=*_XJ2PY#-5B.
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MM8H-*-&UD4MHXIJEW;@8TE I0X&&7^#52V@A3,Q_]P(&D DI''O/T2)(>46
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MBREZ@8^YB$2?3L7_QJB4QW"O 8;W#]6HX9)\6V[12YG9W/[F&/HW CX$2=_
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MND22T*"4%<@#UMU*3(USN2;] $4>#7.5N:79.8K)O\B@'SU95:.5*"/1W'_
MHTT*'Y7(?K0G0P*$(9!QVU,@&\NN=*/3SNL&^L<WT/?K!OJZ@;YNH,\+ETV;
M;Y_55'J2P]D1X/ / M%? =G\^?7]*D)ND1VX;K=ZD3A\U(#[4F"L.T'(-N43
M[K.H-!:8>IW$!FFJDU>3N3D"Z7GV*% 3TE7L 6P2@F7CF=(A:?D-[Y/LV/+)
MX^FAXRD[ =W[,=K*H7"GHWD8J3!H=OLZF@#2%D&ZDM&])2/*&TGL=(JSO60
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M7-C=NM/.%@G5E5RN9T%@89G6(' NQ/B6$2!ON3@$N027"H?K6/#76\(1MIR
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MK<:-B9]'5@M3$-J2 6<D>+0(B9=O; P!"S^!VI=UZ^C:.ECF12A9L&=9+X#
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M@>/*+*[F2Y(EYN7*TER:?,8YF"3M(LMN-3AS_DHV,S^UK@':0 W0?ET#5-<
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M3:HJK(OCWPXNCK#P CCV^.2W4^NO7R].+H].#I%Y+ZVKWP^NK/.+XS^.3Z^
MK2_/C_D/KX>M'UN\64=F-Q>9[;3JR&P=F:TCL^LL8OF-GA]<@.P^.=F&/%4
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MMM/;;Q=(JPVJ\6ZCW^\\K\!:VU.HD(:O.>\E<Q[PVV@XZ([:K9'H3?J384?
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M<X]=3H@*%!G&@ D&P5@L!64^&5#<Q!$ZGFMAL_8'X9 T+$ZBAVC'8@/(*X\
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MACJ<=N;>$8I;W:51O8?15(^J_&0GPI G9P&WI64.[VR+PEV;-02@(5"N+ K
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M:BG4A5'9KF4)/L".7'W-O"V-A&V>-:^&[NFY:PLSS35";+@%N18L996;ZVB
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MW]R+?.0XH98@&O5L%AQ8[((B!ML@,9.V)M-C$^1_@I'I]L%/B^X\$/*;'4)
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M'GGS!^2N6Y2!&^7V3#88ILFLSHGZ#'D7BNQE]MWDN8ER>4J;-VT ^.;-;G@
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M%O>%5(V3N<U ,>I=XA!H("+<C/Y$ [_<3[YHE)F1Z<* ]MID,1.-]2A+G8D
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M_+:?Z -VZAPQ%_8@O!N,J?^QC>6X3T7#=ZN]!V=2H1U;%=87I:?=R;JHM49
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M4G%&$Q8RGX*ZF$9^'!/I9Z[&0&=8K'?^%N@E+_]RD8_K5H\EW&5*4N)C9[.
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MY"2)V $*Q8FD40(B(&*YHD!I'L/_A;F2>4Y(HH(S*13'8F[X><;'<V_4T'I
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MQE$6")$1$8L@]+,P])]Q(X>35C?3IZQN;ATP?5\[1^S$/7;7ZH_])VW \3P
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MCPLX_/H.\=%+4U'S$0MJFF*1TE4M(BB-LMC/*0MRF@L_2T/"XC0(T@3X2N9
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M2=IF!7W^O35VY5]FD[*-ZR14RD,6)6'"!56"<I8R%;$0[,LT"\)UV);_6#O
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M;N9\F\!_#>RDK3C^S7B$!@[2V.+>?H)M98J/Y1->/W;MB"3Q VXT#0*LE8W
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MBIK\ZJ^CP]UW8PEX^?AKA6SP:E=4A*.,HHFUT ]@9%]8]%W&2 Z%H>ZJ\L%
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M!*M6+FL*3Z.0[@R(!:EF2>*K%(QBS>*8)!&)_4 &"4\YYU4;LV5X]@OUY,G
M3Z(!I]'E6\B7LZ>O<ND[/;+__N37EJX_983S@!H_9"%3@12&:C]$&!9&@HAW
M)1Y=<CXYN4FNB 57@?84IO T!-4E(A:0@ JJA1%)&+((3U<H8=Q$1*O0)Z*C
MK=TIPI5K$ OF)R97Q(*K2+HB%OS8B 54I8:G(N21I"P-B0!SBX9,JS@55,J5
M?;XN%;& #.)DN5'SCR3ASA#BNR(6_.A%8^=$+ B$B:($#XM]S60<)+%.>&AB
M3G@:TD0OB[ GT@IU5=OYLTNS2[2_GN0.OUR+Z%)K0WHA%HA8*O#+&$DCP@AC
M/"(T5)*)($RXUAV8)J>6$+TC3-$%PC-=Q<,%#.E8V_Z[(="5CZY\=(G.U!5)
MX,E7O3RI J1C(@D(KI/(4"I37S(N6:+\V/AQRN+0#W30$5UZ(JX98>"9)9=G
M>EV1!)ZZ4+E<E_ ",Q".A22@I J)3U6B=,B4B(2.2!*%B9:A4:D)SB^W>CJ,
MP<UW)[6N-=87.MHS2)D?@:Q7GKWR[$61]1P^\K7&_UKC?ZWQ;SC:3*>2LS00
M?L H)0(^)H$D-"%"4<[.;[#V=;230<R?0"/#:XW_DR3\!;C5/V*-OTQE(KE6
M:9)RYFO.*8F8EKZ6,DD#W5'C_T3\Z^@&ZQ"_$V%U_B3:[TP(G3]#?\N!?M^D
MO/+FE3>OU?>'K;XGEV?!7BLP+F"37VYEQ9$J\W4LE(Z4%BK5+$I)DK+89TQ)
M9G001EW9R!?M?P\2&@W\'[P+Y%5FG7(*3\=7?_KR:TN'/9"I"8E*%0T-,Y2)
MT,1,4<FDDGY@.JI<+]I-)XV^W5>!=A5H%SR%IR&H+K(RGW-$$$G")!7,),*V
MY@YB26,9LU1W-.,^19!Q965^?,/)M3+_*I*NE?E/PW\\>F5^K.*4FYA$@6+*
M-X*P6!,:\AB,L#3NZ&9T&I.K;V4^'=#@Q_8B+R7\]\S+QU_KX?[=%*!7/7 '
M//-M8A3^,1T#Z8KIBD#?F47WQA5H3>_<LAJ&7$FK'=-.#C:-@TC> \WCN(ZM
MXV5W-&TY^?,8OUH7KPL-5S06B0AYPA0C7' 5)3R-I2]5*OAW%*\[KTP]S[;]
MOF7- <;\;V=W2P\A0,9J=@KI\<GD7S)E/F</!AQ/G>%M6T;0DI2+*%2$^T8S
M'C-P0R-MB(E\&IFP"]OR*4;0GA+G7T7,$QCSN>5,.[!U.6)F50"L(7&X3F,6
MJ"20H6)1%$I">.A3(42:2JK.5'R[8_SK1^'S'T>@',>O.*D9<TK7Z(PBY_;N
M+C=W8KH0I&JV%E1&^Q$E"9.&L2@0B:V1U301<9BHCM:"3S-&]5U(H4L)/W5$
MUW#;$)\-/$(Y_!.&+U8GHK7B574<]6GGI'7,_PD<0ZR4>Y<PP>-*]D/-<*?C
MAV.J@L:11)<J6&Y DX1$1D)$J4F8#GQ!N9+@RE(3)I+Y714<EQPV"P8QH8,X
M(4_V@.*\(N1'E8A'G<WEGLJ>8]IG.3E8G8&R$CJ&&6*X[S,>4)8P)303/I51
MQ)2O:7"V_-_><;[PZ3;ENLK$[TXF7D@L\32R[CA9=3N+NFV2[2A52<K],&8R
M88P;21,6@S\62%\F87 F ((UP48_?JK)=E>I]B/XOI=K_%T()<YM#VZ.CA)#
M A$)&BD:L51+X6NNE1\I, I-H,U3BXX&@XC[5V-P/I>E:.K\\__]?\&/R":O
M\!.0#)<Z&\U$2;/%;^9W_GGA)\M/GX$P_^1,AD% "4^I9-2/DDB;-(U$1&*I
M@S0N<PC@1N#<Z98W,7?PT/U&X4=^HE)AM*(LEB2A04K#6"8F24DB" F[7KGQ
MK@@W-6[B:MU3>,;+5#QDP\<_>?\+(T^%]\Y\]3Z.'\3H?_WLV=^+[+]AE0)_
M,OT9QBQS[Z<FU4HN/!6M]R-;U(MLL26;Y2H/8<R0;X'QK1.'?Y<;P?T]% 7L
M[E\^?7C[>U9,/^--S_J2N]YMOO_O;>W@-FECA]7B_]F*C5'OG;5'#N5 R_?2
M:-(A"J;C"3)",9NLTF=VI'B9-\Q&YN6]-6MA&JT9%B#;AB:'1ST/7OSY)WC<
MI@.?]N#$;#I>-;@UJBL=CZ>C\=0X=0%__%/"^JM Z""!]3>:)V \J]00+6E$
M>1BB=';W?!SC^^^GT\F??OKIZ]>O-]]D/KP9YW<_$7#T?\KAYY^J:Y]YWQZ&
M?P)M 'QA1B__]NG9J\_WQA.5]O*R2GVA4)[!WX4'\U"SH;#'+(4WA<MUEJ8F
M-Z!=/&FF7XT9V:_+ QCC33 *XHU3^RT(79,/'Q$I8.RT*9[6+-/"LU>G(LO+
M5\/]XUD.[/3P -NI0(6' X"OEXYV[/D/=J/#7__M2+9 I5.+:3ZS<,/O8<#Y
MYWLQ*JV$=^/1%VLHK+0!@C!,F0;QP;@ MTC+6#,9&$8B&;'$/+6T+WH3TB4+
MP*[%!:^!Y :H'TMCDH1Q$*@BY3&/M8A#D?JL(R1WT6VEZ4W<L083V!P%4G#@
MY:9 FQ7>/GR\L5=6PF![8^UHYLTVRG<+3=A'?_)3FAV-:_"-I3Y^_?'#VP_B
MSKS.C?CC%OZI=;(:&I%;^_;^9^]!Y'?9"%57I8'+;RH;MQQ.<W&:$VOJZV>+
M[T9E ZQ8\\*JAS3U/'(SZLC%9[ES03L1T,1@-/<@+<?YV;^_E@IZA.P_K"["
M!];?@1>"N>WXJM43Z")V3>@)?/-2XE<O10J3 @T^_"H>BR5U_>?[O+JG='E+
MLOKH8'2LE_.%[:\M@ZFR.RQ\4%5/Y K9.DN-RI^> :=M6J.U"_T?!OS,?&E:
M>VT ;WF5%U>Q7+!L"KRC<,\([SY'D?<_/]^^_OW7]V_?O'_W^==WG]$2L;8L
M:'",+*)P__-/XM6:U=UW]$N";SV[M[E2CH>Z_&H/DG79RCL]E-Y0^!^R4L?V
M<-]]$7DFX+\P&6'!&E?\KL1D\:=JLC'RYM!,@0PO2S]C?F47J>QW&5A^HVFY
M0YSU#0J^0'6&=X_,DLOM'O@5]M?\-?X:!SX,K>]>.?#V': 9QPZ'LN8]T+)9
M/=+&[^6CZM]U5DR&XA&_01?!^Q]>]C 9YU.@#A!D.!;3<MS/7KU7L\E]EAOO
M VC9!S'P0,??K.75$_'7.Q#G!9;LP2:R^,;6<'^;C<1(P22]3U/XXL'MKLXM
MU25CEK[K^*:__N:]]'>RJ+^;)/VO63'-TL?=";@EIW4JJ-6;><VV7-A'BSO$
M^6=?RR,83[@SF.;B-#RFVNJSOE/I;-VYKLN>MOV:K).%IQZ%9V![ZG6^U%?P
MMK8QY/<^?5HX8;)=/7\!-GT+4ULTW^/4F(BPE"9!S$@0<ZH4382*@L#GT;EP
M' YRMNXOGZUO[4R== VD%KZ(#0&:QRP27 2"2A)'D3#@2"G2X4+5:W#1SA2[
MH<MKL.!">;@AD=)B].@]&%&@2NV(7;B 1;4+OV;3>Z]PN70O[4K8FFK<D2H'
M'0BR (6V*2E1#$ 9Y?#.<0X?@9K%;(AJ:"EV4E_EC5T0!N4]OMYN>V]65'O^
M]1 $V\M/ZGX\A.&Z8=E #5[P,-9FV)Z9'L-EX"5Z]R!S/# =_S7#)]]G,*_\
M$<=:S":H'&%$&#4R^0BT2Q4KPH?#(+Z,\?,05FVAHMSD#S?>;0'/4/<#.[[J
MO?<@=&9('K%6ZC6>C-3)P+2M9EK_E!D;+2H,WC[T[F9PE=7KRKX+?K[9RF/K
MK]F2/IJ-^OM[IM5!Q7;^:-MS[#U=ZO>:;K#O=+U.S7]QBOSM./<FLWPR+BQ?
MMLVN#$UE&#<R<9'!U$7NX3>6B9]WL.Z+]K:I-@'L%@7"'D07; B@A')[# .G
M8(X#;?+' 5CRHSL01QB@S87%<"VW]<!NTV(*FPU_'68IO/$1G%LG&\I].-_'
M]H(RSEM+.GB5$W"E1%+S/!&[\5$$MR<O[G+C;%*X08!$&0['7_&R>4@9A8E+
M]:_>,[V'Q;V[=Y%G&'4YC*6WS28X#O@$)G EETHN'<^*2B:[F>,KX>7>&*.*
MC6$-EF?UD.G_YW]RXB<_3\8@_EJ!\$JR6UF,SVV/L3WYI0$+!0Z*7140LG@G
MOH?X/P-;3(#@&8SAP4SOQ_;])/@9UU:; M2(A)^R$9KX:>K=PF-F(SN.U[,A
M.&_P"]A(;B6!-_XHAY_"))T 1XR/W!X"X ,=R>")\A$48!7OAR'98<#WCYD9
M:E!(7P1P*WKN:3Y^\/YV\PE>D5N]^ C456!V6B:V&E# H\KT(3=95"LP[W&;
M)NXTH<EDHBAF#Z@*ILM:KJVX<O3O8%SIO#L!N)EN91Z]L8(!E=Q</A(D#^Z^
M<D++*UT^&,D5Q#\7Y<!J7D(=.1%VXU9/PKWF+((QO-T81YT9CF4KC;.7$ YZ
M"6&RO\[Q%L.A6P9$EUS)0ZA>2GJ1@:XH]:UM;75O]&QHWJ?=YQ/-%KAH-3M3
M'!G-?6=#7#B4UT.X\-E\/BR(M)^F7"8^8=Q/.3;%38FF1G/):-?)4-NM>>:!
M"! 3](/SF>F<O(B9#$3D\X0P&6LIHI@%/ 3;W0A&TR4]?!"'NMN!=9NOE.36
MW"MWS&8SU4/_5N#^1BU1[.[7_JG%E:V4OV,8@;0S$6/C7>M3"C8N98_U/X (
MV&1V'HG"K!>%PWTH3';(OG#G!<U$#)5.IZT<C+WCP$MVL,O%:)T([)6#L672
M()A%>FA6M>3KE:?9+&W=D*JX?8N&/8="-@YE!52A:SFW9ES=22*[A8U!%]N"
MUR5]W-:XB]_NNRK;Y^N=;)WZL<P%<,>A& $5WO?-!YVY"8>7:,?GQ//(J>/N
MNAU2>,^Q^X]'7I?Q=_%D/-'FJ>R0.%K;=WAEBF25=E\&U5U^X3P$? I!=KSF
MVN?@D@L8[6F::Y^X7J0^+6OX_!7S_KWFUX]BVCK2](-$@=OO(VQ.K'T>*II&
MJ?8U-ZD.MNA_V?>8+&X>D\U+/UZ2#>=D27QS)/#FL['U"C[Y]Z<B6RY6C%RN
MQ'@2PD&*(/ U2XQ1FODQ26@4)$3()(UXP),.1.+%L_:3"P=^<Z2NMT]7.)S!
MSMIL3%6G=]6)VG,;/SU,]_&#2;P+-)DNT2[J8_P<&%!@G7A; @@(_5BE4:A-
M%#"2AI+&W!<)"+@$*S*VR.(Z2.%_>,./4O?_-#BMUX8\[]X[\S:[X!TEB(E-
MQ-"!$"Q5@60"/ F1A!1<B%2HP]H)/\J.>FKQD78NPV5I\JOO\IWZ+K^43+?@
MN01^%!*I_8B#6(I\Q@6G**$$2V2JMLG4/HCG0K;W7(X$9_%TW9:K7+C*A8/+
MA3#1,9?2Z !L_X1P&9(TI0$-0B:",.KH1'"4B,95+O27"Y<4SOB8%7]XRTFL
M%R7CKDY3U\J=4"0AD[P%'OFM9)$%D:19'$EE0- (S@+C<^,;$<<Q$U08F71A
M<YWY!(;<+*,^7)10>L(6R76W7O9N]1,NC>]S+1!<E' >)X:DBD1$,1J3CEZX
MYSX2\6^2'W*W=MH)\\_GQ8VAO>#JZ$GAZ@XRSU[X<C0^4CG +[OFZP^\4]0_
M.^R:LJZC:+HK.A9,RIC%J62&$3 (3, #FB1<88>+X]D&/;M7,,X'$5D^@FWN
M0:3M6:F:1+&AB4Q3PV.&+7>YH28TE+%$A8GHZ!5U*!G>EZH1'U!_F:H+==ZN
M2+&K9'RI!&83<$-=1=BY89JK^=0P'&#]$AD;P@(&ZRW@_PT%$SQD+*""=$+A
M'FA+]099(\L*_#*Q&3CB1K*$T03$5IJ0Q 1AHF(.>TI%HJL)VZ$V5F_:LF7:
M#IKLW=Y+%Z<_:LC!\N^WKO!TC? +#$\,37T:$-@!"E2)\-.4:4-X$C,>79Q*
M(<D@YKQ[!UP:<;421L6AU(P01CGE7/,@ )5-4P*^@KPXS4+9 -9WDV+Y"IY0
M5=.\K&!NNW%15[&^[1WVQ@*KVHK5-V*" &V.EK=503?0^JTM6OX-7#,Q:C6V
M"66@% ^C@#+%4JZD2GP6@/,5"4U\V=5.=IFVOXWT3%DNP*\/2-)CS=I/=:1#
MPF7@ATRJD$=^I'R1^BJ*%-$=A^S;;E?B'W#Z/&&#I(.EUIJ$UOZH*]?GB,"6
M\1I%_N.\+&7WLI) #N+7WH83\7!&5C3,U]=^=V2T%=H+!Y0>  =T![25_K/K
MA9)&CX.2]NS5WT:(LW W@N_*JHP2U4@UQ#S\44RW,4%K "@'QM$=3*I5@=4/
MQ><Q[-WF[V_@9>_&T_]C8/M40VOLW<@0S2(22@X>1Q3[4F&BC*2Q#JE,30=H
MU7ZJMMU7(:PW;[0QLKL,0=7<I[!(0Z3@"BALYVS,5BT/@E>,"@OQ,4=C&GO2
M>(T;QE\0_6398P$W)1M;%).CMB1J-"+>LO<0:1K DO%821'"MF!<$*%4"C(Z
M3&,>17[<H?^/DEH8W"SU+V^NHC5=CRT0>\%/L9/#3[7Q8UMXL9TUK4TZ]J<.
MZX56Q;K1JC:.NH>(_0C"#M@&-Z U5SPG]_IAJNQ!IUZ ,NP$:!('F5TOG!A&
MCZ16WX^\=R!]K40/G$3WVT!?%9SGN0#V;?"A^&WTP>J"5F\#7^N )CR(4Y:
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M&EUZ[7SG,G4^D!-\S>1$0A17*0\$,XRSF$>4:S";B 9+V*B.0RW_ ,<Q>Q]
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M7.#GLA#QKR:_,_E66'%]8E7+T"9+,2F@2<18FOK*<,:%X&DHA$XXY;X(*.T
MJ'$QJ=<SF(<IBEOUKUE69'9 +CJ%C&H-B7M@>5"9!SQ!@#=OT!P>O,9\,[G*
M4/.BH*Q*Y$M$,U"NDUFN[H%4;3NS*D&>PTJ5>\Z5/R@SLX&JHG2F'6DMPM0
MD\5AP:RT?@YW.B:NBO;=4XCO4WMU6< _L(.;CN\,A@^]K]GTOOE2T+VT?/CB
M S^ 19/;W^9@ +;,?SQ?YA*;;9$V6T.UG8+S!%5@BB1<:/!&M!\FD90&P?/
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M8IF56 %MAZ:[N+%:)\0UL0O5@%7_#'*PF1X7ARQ.?)H&2C(J!5?"*!5(G[)
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M2(9X7G=9>D\79U==)3K6&=XU[&$8(_^>+$T=0\44!Z$0'!$JN9"(@UA@(HD
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M 1$4(5-2&<(D5',%M6QW1NQ02 4IR:4 PMR', -$F7>%*DFDB+@ FX54>L+
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M@%67V4-O9J*+\:2F$ACN,.^X3Z>&_6W+8_/=>&X>Z 2&4_0?S#6# 5_N@LQ
MD@%M,YB25?+OT[F91VKKF@99NIR;]YBYYF+A9B-JY[CJ&0@[J6?1X6IHJ;8?
M=791I]F!LRJ?EG"5UH:V2]VCH#UGN.&?LD 7C;==EM"6EMO!-\-&>ZFHNS5R
M92"R[20P8Q21*&)*$QH#'=$X01AT*9RY!UJ&-_0@-76G*0HE,1 YC2"!%2=
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M&P(2-,.^/RX4)E"_0(*D=@QE">0QR JGH>-"@: 3+8@_]S@<&(TMA"D(C\B
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M>E41;;-3PO64LX7[*L],($%ZY=&R)6@[>@994^0N;/634DT"I0MD1^HG4)%
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MI4WQ]CX:+JNR.,Z/S@_P>VU[D'V3_A]02P,$%     @ YHA^5L!0!]%\"@
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M;4@6*A4!.#Y)A<'P4S+G2A35F,8Q&$LQB$@FVT5DFL1+#32'A@@^X\:RN2O
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MD^D"^0;X2CX")P5\#YR"HU37#4'!<16.HW$L!)F8G2?+AZK,V&#SB70G#.5
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M)]?4-E='C8.EH#&$\(P'9:=.7SNX:-7&7&7\9P#6L8,('',_Q5(U#^9\D:S
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M\#(5IP1EI\F7X*+!]0D[;)VFDR."S1P .)%@IR 2@$"?6YH#)H3G]4/F-EM
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M3RNSB^_RP-BX=*%;'K(0?",_([\)K"_0U=,I%7.'HL'B+KY*CA;J4WU-!9D
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M_;A,';/::^-V>]XM?KCHN2[._GZXJ(1+\=E\.G^-/QQ%'_2/8_T/4$L#!!0
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M!,P\$9!RQQL1G$CPI?%7](1C\!G5/#O\=LCPU\6.PR^IFB<B&I,]FI7(>+_
MR))F&0P/NZ>%#>& ;Q\LF$@ 45JE,F0\#,4LYRG&/#2&9"=("J%A8XRC8(!@
M2C\H36$*>-[:3QA@ZU $JT@!&J 3V!_Z'Z,%<!=O.C4/$A^(!\'NJ,^[4;@W
M' ;Q'A\%>[N]@U%_,.@-PV@7'DMXEKW;^'CQ^?N?9)9?XM@/%#5XU-" #97>
M47;1TZVBRP;@]MZL-8Z)R[>*P'::;5,41Y<5Q\B,C16,ESKJ@0NUZ!+)(QMZ
MJR)U,ZVN9$81/FNS4WCJ(0-Y4QZ!5 ')KG,S!T 6V721"]']DB8B Q!@4#U'
M*41P1?4 7&?9?:#!_)7=!/EFKL8"9S'BYOZ!UFKL9F!XRA<4: P !2J2L101
M8 ?NQ&6!'- ", \?Q5>4#D8.S+4D@8@BQ6PD<CZQ.P-!O/!DQ#(R5!P#!K3G
M?*'PV%G+1+B-^KRO;.F'O6Y_/Q9\EX?#8! =#/AHOSO<'P;1_FA_U'^1+<]!
MMIS&OD*6F!!@[49,!UB#;<Z2PC(P4T5.>@HIN?V19GIFBX4\M<P22]!R+9S9
M9$-A1 [2AM/(H$:!US2IQ93]!^QX![846>N*)P6XIE/!,U#4Q%GV>;',2#-T
MA+:((],%0)8 SW+-%H)K)[".TP4Q+@HMP+0W%R"*K33HGA\S#@;A'C\8]@=B
M-QZ.PF@_@K]V]X$IH]U^%/$79GP.S/@;:($0B$J8I*H6H9"4:&JHO\ZU6:4J
M44>?M,IF8*,6)M>'I&[8%V_9UB*AY)K3U%G#IHU$ A  >9/"5:3>92AG&&WW
M$UW.],><5[J=R)1L8&^@;)'E8LK U@?"DMFD3;/A'%,NTYS+=,DZ)ILZ-: #
M0G1$L&!6SQCF2P]\(R9$-\3RSOOSS]]_YF/Q7@O^Y1C^*ODG3$"HH+613\K2
M#2 .QRWVBO.&Z:)/(BLG*2>8P97M "]M\SC'(A">S/DB:U!:>P&+'<- 014K
MK(M5*VTY/GL-9*,K<.G?LL#%QP7P;1V;]6]_V]ZV]42X8A-^/A>9R%_!YU?]
M5Z]>V7HAPY3KB\/=_F 8#*->'(*?$\1A,#R(#\(NYWN]8!!'+[;)LQ&'E&D'
MNK;>,"A]PKL$13V7^>0:[^9F(;GLUY1^124UG2EP:J2=N$+A#(^0S:#2&*P4
MM&?RN1!I$QJ2D*VRNQ6@98G8YGG9FH*&7*\J.I90L'39%C$ ]""<D^=GK.P.
MPE%_T.T/1R,Q'(81!]MEV!^!%S$2W5&\_\*=SX$[+UO(&,M@,EL'0]Q"-3I>
M3 M]!<<LSN?UE;P68Z[I+KS*P]\+8"6: ^BW5E&%3V;%#,858 )0/ (,>F .
MI7E"OZ*7G<,\W$&7=9 YI\!%Q#.OR3N?:8'V%C?^"M9W37A>EDPY&;/,FL:?
MMY 9LT28VC<LP8LRF H\?U5DX,XWBM2<'>8 %--9HA8FY%()!/#S8<Q$P"VZ
M XB%_:+8HG>+&Z#Z<6:KCF8*Y-*"A(6!;0D9-9GET(^0(80@N"B(&YHB-YXO
MKQ^%#T8[,D_&&-1-5)%$-DQEY-]S]8JZP6@P' WXOM@=#6/.]^/AP5X0]KO]
M:"\<#O=>!,US$#0?P(P$^D)S/Z-P6R"<7P(\=24YF 1A)F$;0#MZ+@>X$@G;
ME&F8%"119E%LG(B:AU.%]4-@@F2!=Y:6Q2\[%SLL!@&#,N7DXO2',W8<DOKO
MPPYUV"^II)C^237>)3!BQD,C3NAFQX)>1B3A\ZWJAQP? ;&$1L,RHTU%/E%1
M*33""ALL4QXB*)E"J '^)EE#ME. /&Z"BC#"%: \HEI(]QA>A:?H!_HB0.Z$
M%,K!. O)U4+/% C-;^=1W9"[NP_C&S^FD@&C@=@?]'='![WN_K ?10?[>]'N
M(.X?B'@H]D3X9RV1;.5>IM4<D).^V^AMX"SF<W^-!+5=6-^(E>6HG;?N=8O[
M;3COVL$VCG;<;7=.@:](0M]9.NYV5X[XZ&BD8PP_?OKIX\GY>N@[O WZ;E<+
M<3L*NZLJ^H:[]UC5(@]0+'+T?G'W(I!A_XE*0%9MWMWK/VZUHP^YO,=DC>ND
M1LM9I(VC"V>S_.F%X@,L[X%*@NYF/01Q;W# >[NC(.H.XYX(@N'![A LB8.
M#[J]O3^K]?" DNL2CY_^WQ=>K6N_7_'>:L'6#H*SBI\3@W3Y'H_Z Q[S_8/A
MH#\,NC'8V/%@!/\,PU'TPB#W))(_"7]4"J^WDE"?/P]\LV3?->JQ"8!)BQ$$
M*YV!_26'(E5ZRI-ZZ9.]MG'47^$T_'_-0SZ?T^RK3YP_XLG\VA'ZXQ_.3TY^
MAHD?\X3[<<:TB#&H5I;'Z=5UCO<_3>V/UBSP>Q:G[6MGW4T.P9U'I^3*4QS
MKYV$YS><@Z^XWZ9O<I,@<HE7*L9B0 98,&T*0FG3'W:?KSTUO_8!<I?6K=)>
M+6?):X"[G&V9?*W0L<91\N90]A1^[?"X7<.EG^]=>&T \&"_S=BT@V@R<<UR
MXFJ)6)>4R[S(16W<\H:UCZ_?11[@LL8BI3!\>]^"*K9NDFS5PK')P(.?+FB%
M\L8#!ST7S#13KOJ;M7Q9C^RON)9X'H5EH,B3[1 L8)CV!TK%86*#"- U\=E9
M&4%L'\8!8I["'A-__4M%QRO;3:RNT%C1KB(N-*5%&N-(2GMH85.UMLC:YG5U
MD9BD+F:0B\3=8LK3,6<4:S5E.7@5=*@%_PT(K&F1C$G@4'XE ID*G_W.)DU@
M6^I *B2T%H2LK*N_KFYE1<7^=94;WYB8^^L1\TKROHFBVT!H)TQ7&V/A:<\8
M/!!V1JM"]\W>0'SKUNA!1B!BM:(NJ:J7B0+PI!12)^@&6W?@"SK,ULTG"B3@
M-7UH>$Y)1&* J- H$]!R0)F*=E99[JGBBJAGW-0FV/$:*IOXII*^F#K%$U54
MPL&_6J8T>4Z-!1+:JS;EKJ%.2=_'T52F,LO!FH+E8&EV"-951+4-95;6@T"%
M I8!LWB%I:X.='E 7R"8O##"7\L&%X%-Q%I^K]#P&?R%3-!Y#C'WN+4:$N#(
MM30I7P#-],VB+>*!3- J@Z66P/M[9[<B!#^7PZ)G0DL5-?.MWYJ"@]M3L+-"
ME-VG'.D&5C/%XA/:F..*5'[B<W/D#7$'1%;#2)/*'EF#][K[:V)%WA4K_M\A
MSR8=%DY$^*4#/FKZA44:_&5&!QM2@<7.8-2W)<:_Z5)O7"NK_^-I;*^B".NL
M4 @A#8BROMTZ "2)0+*(LK[15[Z<6<,=$49GQ]Q]UH9'/@.W:$H$8NV&2&2A
MED']5%G%QS)>-?>RN 1K9%: 6 E!%(,(B43T]'MR!P)\F(VIZP>_ODW-T?&Y
M3NV4NU/M0^LVO0'*?VH,7ST5@N726:S51XQH.TKV2$7>Y(P*T5R#GS>VIN<-
M;'(KE?-R[.$Y''MX%.-^<"M/M>ZPWL-3O0138:57V@#1.625/UJ>Q:W96$LN
M:B!B<WB02OZJ#E3 BZ4MC)5O2%#5%8$M.436#+245KB-QKD1;2FQ8+7&9*;
MSHS$BIF]!0@CD=@%P8I.8^F 0?@XML[#N3"MVR\! 9&$58-B*)>(J)(IK_DM
M+1TDT(?YP(M,/(Z:_0:F[P -N'R26?*YY=I-"3S/\$Y[T@W\$\)(AWW$4[#&
MCU HOCE(DJ=%4WAG-/7Z=\935%0QO@HE3XR)Z.Z8V*]C@M9%FXOV +I'D2Q]
M]14X>>+%B_46WW 6EN0$AY79;J]^%;4SB]XKKB/*@T3"D K&Z2?6FO([RCA"
MHB.J8'6E(K0_ E)7S-)Y6A3&=T&A_8++;S2,NB&1\FA6]MKK'=^)9'"E$1T
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M  "M_   &0   &)R:&,Q,# U,#,V-%]E>#$P+3DM,2YH=&WM7>MOVSBV_[[
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M7QK\>P:O\PZ&\Q1&6%93,599L=CCJ8I/4VU</_";J<?_IQ(B(C"*:QAV\,S
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M[UN2J-!0/9D4M*:LF"N;W!T7G6&/P:S.SL,$MU\4/"@S5+;AD%;B;8&9O#C
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M.3,PDQTS*L4L&N&IOII;K]CB[60=7[%2@NEJ259ZDI$B!%KWQ&YMT)L0[H#
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MB@%LHNA>9YW^=8GQGWG+@TAE@>XOAWYK+Y1%4=A.W4 =Y8(OL&HC[YNK3JQ
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MBBS=0./4H#.<2DHIO\ E@08O\_,(A[;026L#9F2L96K 7R[;RR"5OU4*=KB
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M6MH]U6-#R0?DJK_=7U <C%B(]"(4,1DM:?&T!D]LMP6W3BM\LTQ0E8Y_O\W
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M*Z+@-9PJ!3L;LH+CE%-/-W#JD5S@P:S-9K,9B@%*=(K]N:R,DL_H\\PHC:(
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M(FK%:A$51'ZM.[I2E; QGXF:B*Z-O4VD($9[PM@@[07C:JU]=BU27M!AX9X
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MBC&::0@F.V?B.\)GN)/T_.;T9R[C#OEP#Y_J4D@]%SL=\*H!-N[HMF8VPDI
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M9UM8M"/=L1L"K"VHA:&5=5D&.TG>Y;:LJ8E\G/SF?1)D2/$^M-1V]@.H5%B
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MJ)@HIHN?<)A12R"I=8^IN&F-*!.#6ZMQ',-\7_IVQ,!JMHA>;8)M_T9AIH#
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M0$[C _L!]RZDIM*AN"F&.C!;K@8OM4HX-K1WF*?.Z_UD7WC %^E#^L&'*CC
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MFI@.C-W.MOH[Y=.GYZ1O%],=.5=S443&!:#(GX^X8_47A:(*) KJ2,1T0,V
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MT8TQ%H.Q#UH8[BS:HG3T 8RH? Q#\;NY41UDA_6<DE$2--\<''M+A)Z*;;]
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M;5ZT3<6X3L[.[7?G]0&N2AX^ .Y\K)I.E<>+=S%)B>Z[2YIQO>Y#DN 9H:8
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M;CC2USR)\YHXQ>8\Y'',!^;VJ/8H&0:&B<^"3YCB_H9,5EI-RMX!+F0H#OP
M\$&'W#.&_RY^%D#_4_6F4SC0L,QI]DH$LP:0;GS7B,7W '#+(+D(9'\ T,#M
MC#+S #A2O4;/'1W6&3R_" 1NOJMY +3X-3T \*7^(DN;_IJ'.3,/+T=^<&P\
M ) )'@"W:I1_W?''Q,^[AF6%ZV>LD,/W-@^ #J7?1464_[>!QI$V;MV@-WWP
MW4^:_^(3] ;G]@]S7H>.W<1ZGQ90<AX YO&S"D9P0Q?O+> \ (:2X*;U.H0<
MJ4*L+\/O?7=2;K%]X+&<BS,RK#-Y?O#E ; I#S=2\R7P,@\(]9""1[ CW+(M
M?Q"4E0#KSS32PA4+P/D@+O[AT[DCRCNT2> E)0K<K*+D+/C]OT.GWSBW0TX9
M?ITV'I2_^%=H<-_5+0.OGQ5!#D6P?_G\=V8(_RTJ:OG8OP-KW,\>$=ZA75#^
M)Y.PJ*#U!P!42 +>S[/K/_HIW=4LLUT_VP?^H3B"G!Z__P%@[1)\[WL3_K_8
M@MOU3QEF(?])]JL&[V]]PO<&<2!#*7;_X*JDLW"^\:5I4Z'Z'U1_4ZF((B,!
MALPDT\"M)K+R#ZO]SO7OB=CPS@.UWV[(URR3=]V_) UK.KG[U5,&3H[R&L\:
M>"@ )Q?)(R# E C'QKY[PDMY28[R1^!O?(%L*OUBMPEG]ZA+2@*<,I-,#:<C
M^8M.ZG_2^5,74<W-S2(P7#_P] 5<OP/EKS#\2P]T\L>E!:45-A>:!J/?U/ 8
M/^,Y/*I9V!M\"O=D^B_K#/T18RX!]WZDX;=8OXXHT\0];'_B;QD:E@Y/.#X
MKL\> ,[7\?V_MU6U<2QT^<GKHNQXY>9917G/&#T5QX*NG1QGDS==V="Z2EG;
MEI>BI*>;OT5((KSD;_?M5^G$U'@_-0G95$^!DW__ZRQ)SN3)_]6^RX^!ZKB
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M5 *;5C.4G%A9XQO_C^5X\_5KNTQHZY DJ,K9FQ%IX\LUDU\] ")YM1X Q?S
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MVOT14@8ZF!WW!SKI(W''C<]NIIG: :V\^:8>4'4-=+=@RXFEYU\D&RWV*#Z
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M1P6S'YUC;,50_&V8'=Q=AL=@#P!3YHBU,.>\?&IU%.%NP3#51)PZ"8#MR:W
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M" 26<J?U/E/B+) +0P>MZ!BS>BL842$[P;C)_4/=#)Y7HM!P%9T$\4RU-PH
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M#Q;(02\<3N&\ O(U/+]QPV]8;^LN-OL!,.A7?'>E#X\Z-H4'0 JZ_LWQ+U_
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M!UBVGE>#1,79EZRDU%D==@7F;GY%WPEW8Z!ZTF$\$K 0C^JA4J51.]HF153
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MN/\*0'1%>$3TSR&J_S5$S#AP_QT\!8^ HV1ST=.Q1P"L5YSHG74=!"P6;O.
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M),I(R9;XU3I<9 Q>SQ\!RG%*%65:"-.\''K7+MG!I6'KIOQ2C#5FYN]#3=C
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MU4Q8ERS9B3CU=1"3I=:_UO,F3$.7&._DV'EX\7.:%C28-67*"W<N+*O3^D0
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M0.?#@8M8 TOH+GW3R4DW=K"YA?+UF$0X!F[WGS[E5^VA>N+#,BGG*9EO/F*
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MAT2,.&6<O4-OF0"FZ X]_$N%L6('KR<SYE,CR" K^Q^K<1@.K[V]R%S7*X'
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M5/BG%<I4>K387I>+D?'='"&ZQKGC0==XDF.AQUUB]I(%J7[RA;8+[4P=$;2
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MZ$GFXT(<<N9 :G#NVPT@=W1V ->E+Y>_4GD4?GAIY(7=!V>DEJ3.T/QM0Y6
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M1DMM@X^P]>++@_R(FIX6!=M2UB7AH^77.$M<^ DSO.:E"Z_90OW%N09L=#P
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MUE@&(J?5>>F PE_3 @H7J=OB!_1=]? 63LPOHL^4RN #7NJV0EW^$4G"_$"
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MRHO&50"LI+9.IN-SYU?@>1(DGZDO#.<7:3Z2"HCG6:1K31G,'MXZ0+UE!A[
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MA15E_P2N0P( 9_@!G(*0KHN\$=XP>)8 [E?Y"=<Y)FG/5CMI:^16J3WXZ/L
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M[;5HTA%:6CMI!*C"=.?@_=.L9K&(2Y\,G;O^>@< *QSZ?[U1^)^Y??DOJO\
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M_"_6JE_[_VJ\246V7-]?2D\]H"=[RMC1^1@K#7N;%"U3KY@C="5 DFJD!J*
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M!8'$Z20I!ELF_K#;5GL_9DN:%! 1>VUSE(:OS#-+VWK1]AYB'$X[Z_.<KD:
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M,E3/0;<[<,0S0YQ5WFS?H+.]DX5ZE3O._#5J53&U.JZV_>/H@D\XV1B%'!M
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MZRV)HY+RO.6*7)N)$M(Y(?.@;VD'YJ:%U^]K7?S(_N@7D(>;3-_]^:^:W?]
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MX2H'L;@(L; OD'V;@XR-T8\6$=7<M%T+>+<2KX%]1"!Y;\:8>NQU"61T4Q8
MM&*1O19Q=,C+BR-GM%ZL7?OUVY.\-_WMZO0=Q=NA!F"QT3 (NBC2VO44+PW)
M^9/G[,?JQ*^U9T-VCQ1INF  J4*'-,16PT55#K&C\*F7P/+ND2SO<[!LO9H1
M\S+NW9O\YSY:T_%57P,=4-=GD;8OX"E*D/.ZX\W3/_QNE$<(?3/UM+1'Y1U+
M- 5H_)<@2.&"&#\^ZK64D808:[%GD:@Y</-,TOE20@XIP3^]+8C7VH\K1.WA
MXM'X)1X3N'C&X9JTWKM\]HHO^@[U-R__V]!7Q&ML*WBD;%_GZWO*7RH/ZIIR
MLE^H3?FW"Q9+K!IXS$/#"GXYHJ[?'-'C ?:^6G7N4M]-M @7D5^B:8#4WQ,K
M_1)-"%PT+\/A$%& ;7)55=)/',:EZ.34523X/G?B=Q9FU!11G^8G9??1Q@U$
M8XO6=+E=R_*MT_SK1J><KY!Z"8=8G7WTII;D/A+2=N1E_S_%?&50VU^W;EJ\
M6"GNM 1:)%AQ;:$$M[9H< \0W*&X%+<2*%J*MTB!$-P=BKM#L.($:RAV>^Z9
M.?,_YYWWS/UV/^POO]E[S=K/DN>9W\Q>4@(B:,Q_9D3F8W?MX\79<B8#QY&>
M$>$=QA:N[K1V:5X?_P),7:E@ ZMIN(JE!2O]M:7-'J<)1I=)^)]]XB]5*5Z&
MTO%UR+/2=#"6N.M3VW^K_D.69,S[/^ 1O)%")Z:_">"V:X4:=4B/B#R6V A4
M_H]N?^"GIXG/\B XN,_.*96I,\< 9I$L?&+?^R]PW5'VQ;7]%Q&+;2R)L<U=
MXDP>AE\;XT?FC)?Y' 8I,?AN)0C9->O^][W_BKQ45[)1@MW7__>-2@%,F(%"
M[S14[S>K5X0L=3B?F#[38X:Y94C]K03-%?_>JQKL*P")P$.3*DC*_3WC\+49
M3 KP[MP(3/J;K6E#Y@G5.+ R\=#(M>OWN?^23']#D6:Q4%))^3^2->%? $]P
M_L^=M!@VGTKYC5%Z6_'+-I]R]K1+]VA(O/2)N:*QRV*;'6>45,9?341*CVFZ
M![#%K-O<^AO^)46.M_LK-#,5-VX>'C"8Z\R[9?TE8*Y#'"PRM<[K,QG.7%PQ
M39]H22O//6# '*-_#S"AEOGS2&>D!06S5T<79, *:\-[RJH,@ 3<P_0$;,G:
MW-T<5R[,3J_W]8=0.H*1G4<NR1C>GC.U"L3X,K=7$'\\H[SGT+/A>DJB@*.N
MV)</71+2L$32.J6%4XPFCW)N7KT=$6V>*^:&;[[13HPP'X9WV>#)K-!0VJVB
MC!:,=CV=K!CV7>_>_&8R(Z:(G\#>,'W7B16[@U<(&9.$E>[-<A2H8'O.OMS]
M#JK=RQX6O)-M,O.\LCAF_H0$OXREBX/]@A;V8=YUB??$IZ*\)Y9V=75GQGOL
M##!+/U(MK'A,D@7Z9.)]T?HJ:Q_,3VF?J$!B")]2=D'FB;4W;6WX611XZ+/Z
M"ZN2\=X-]/CBS'SGB5EK$)("BSUOJ*XB7WI3OS)2M17)>):Q/HM*1<TO:KA\
MY5;F,> J9=QZ'\]'5A?.?Y7>=:H<CNWJ0W$!FS, QN2228JA8-:,^+M>/.5.
M!/K3[/AO7<G);9SQ'.FGSMK%OBV,AE[8WRIO^V5:^-@ZP8Y@Y</K)D % <'B
M$MK$AQO7]7VT7[MZ%TY:,@@.#QP=F78/RS?THQ6&-V0+,ZW77C%LB#%MYP0
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M]WL E48!](]4]D^M98/YJ*(FVX%D[^6I0_P K9J4K+/VO&69=*X 7.G*M=N
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MVH>9(RZVMS%AO];#PMS/-*8##0K\/K?"?!$3!P+3R0:?+OL [F>6[$$ATH^
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M'9M?86NJQ(R,'$5)NY;\&X^ J#]^]7T:WNX5ZF@JIQFUH2WRA\9)'@'^!H^
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MNY(*W_J04Z6^'8>GH#D#YEG \?LJ9'AZU&+K&:8?)"M1_PAX?ITD>Z"9^0@
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M\ -=O?F;^H\1H?K6*O0VI6^WUUI/7IHV0>#<&?G;-/@AQR7T9JLG*_'X)JJ
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M7O<$DR%\RJO4*R=N<B-FS-R*PU+EZ0$='IAZV@>MC?F/ "PER%;<-YXUG]O
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MRS_=[>7\LD9&[(]F'$W<(AJJZGA?7?+6C<,OH6'G> (2I/$V/!3!3;4M^D$
M7,HDJ2'GF(8-&"EX0ZG*FWOF)T6)1]P)H>16,0PGRUL$105IEFN)[ [_)9#1
MD7!Y0BL%U"ADB(O?3!K -F-V7FCE@X>$%F(B.X06OB;9HR,'C5[&'W\>(,P]
MZ2'TOR@H"RJJ7?]Z!XB0E/VB> >0\L_<N=&#895X&\[R>TC\\5A;;/:A,*
M7H7W.-=?O6,!;-"'VLS<TL](L.A+Y^\)T1%7U]5$"",RCQ'QS7+^.*LU(H,
M2XH*L2:,Q09>*]7)E!]>OV,I-53@W,/UU=<,YZZ7B0$'B3&/1%&*]1.<GA+-
M*#TP#XG!;JI@2%/BPONJD7'/WS7^A39RN19C% Z\JGG.*Z*HBO!%8V3@PF[*
MG,,X[QAGW@\YF%,)SU%:[/?71Q"QSGY2\BC@<SBMT=FP9!!"X/FK=$?]<5M(
MW>GBP#.BE:V(P:#^?$ GJ6#>&I1\;X$\@)NAEJHN)TN5.>69QYK#6&DQ99,_
MN;V?'=L,O[C'W/X=X+WY$IK<G6S3SD!,OYE'?3Z)%=7KD$)5$=M":7>Z7ZD#
M"5(*(X:]5> JT#PW\=4XH[R$6?HX^P)?.[O$#=H7^03G/G\?^#7&\!L"+UV$
MH(-RN\5N 4\_+;@9)1]Z[0S'RQ-YN#V2RW%[:-IP:4DW,\\TY\VT0<O7EVJ>
MLF"50?8:V&CV4["JCF^1X?91RS&<_)O@8#D&VK/"_),KX25_B9?'4P\GDT,#
MNMPX4==!EM87751)=5EY W69]*V3#(&J7+9'9>^I&W#9<^J%QVL]0J/OB^NH
M7__J FNW^KZ>>%2:31EK2_@7!\GH% @K:SK=/&X^F]?#I;FI:U#Q+CWNF<?Q
MMQ0CQADLZ0(9UE'FGLKGU81KKS6.3RYG)+%PSIPA5;1R7U-/.+84E^H.&U8H
M=@Y2IQN1!'> F$35.:#2J[F@4KV<=[]!IXR?#7M"\/%,XKRHBI#=ZT=EZU#B
M ]&0 H%-1\H,KJ3RYW-[3R1;''*OET77KON2ZQ\6]-YH<9'W2SR9X::3MK7G
M&V:+3?C,;XY:J6R1WUCFZ#-^=DUP$W,A;5L+8"'NKQ;+C:7]>Y7?#*7!6&K/
M 3W6EC]T38]53Y<K+2MNO_P+;B1T4&#U]\22C_46*#DP$D :914L>,PUV:XG
M'ZF^)1\V1*6OQ:D^7>:;"OEAI35SRVX4;?:YYEZ@WI.(2%O&L+9&W1Y3A;&U
M'-#88TD#NK>C.O81<XFRZR*'G%00UZL<Z\6M^;D12M*J-^XF]?6JGAUTM*C^
M(%?CYXL8=X6Z6?X;:ZUDRDQ7&;O1YN-'3,++L=Y$!IH<XR&^+R>N7Z\+3?V*
MN -H3!ZGHN'+YD\I?\;_QGOVF!H@T2I+;IJU9.PM+>C[9JZ&Z+!CX^/4JMKI
M];5'FJ;^U^46GZ-&R0\]$Q*<^Z*SI4TY&!4O'^*%%9"=O?=-!^]KVT+!Z#\=
MM$U76K85(4"+(LQPCR>Z)%OVJP 7,5CG9<R^T"*CYN=WSC.(0>%^<7 1TCBT
M-H-ZG5F4LR[Y]_X!0=</.T=FV51Y=GH00V"N9>9]-,1EWH4&^[+N^S+-<,Y@
MM&1_MWPAVY]#V>$#:+YJ8KT>$]V(-=#.TPZP,B;TELODGJQXB81;$5@Z,+>U
MA*H1D>P_9F;V>.7T@&*0!EWA4T!]_N(I6_8/'!)UJ?\Q_JNA^:GD7D;NDZ.*
M,KMC-N_ED[F.NBS) X+QRXJ^ZG([VT/$"GP?\BO@D9&B 7O%3":.U=(__S.#
M S 5=P#F=L,[0#G''2"K#$0;YI6!4Q]6H_0GF=K04C532_@)Z10??0=502&&
MK[NIK9ZPNA#D:+#:55PYR/$6@!5_LF./?:F=N.0-1!ZNXC# UJNO!,O(TNO]
MK&.T<-+QTZ,VH'F*MBBP9F3W+>44XM5TRN>F:AYGO^*A3Q1=U=D)TH-FU9)A
M:]L95\'-=%NR'MPIJ/#8;ZY7B \+4\I*"BY1>")\!(-N[%&Y"8YQB@?]6WJ9
M-"CR'LIS+J[:C$==AAR?HI1V=,D(K'/-[9=6-F(K\E^?,NJ<67/T77.AR/M6
MF/FL'W5_B)2=_FJ/P/,OI>C+<<;&N46J7T:,WG^C/^4>DHM&6D$W*3M__?ZL
M6DG:_FD^-A.^$4?%@)P9YR^L.4:]+3:B/;O &CFTQ,.JF1,&>4=E3B7;"7R5
MS_7='.2%^XTRP _MHQ9R(+@?9^&552&7^W]+\U/5ME=H?]'.TPLQ!O2IRL#R
M),PYZ :=7>TM;"[(G7OM'_K\M7 H;FUD#=!%IW)'W]2RAG,QA%=4,.@L()@Y
MF2.WF&@0_4,ML1].\8XIK%/'N^F)EZS1360Y!(5A\J_2#R=5?Y)X[U*(NC&)
M.>\=,&>*H$B#^X. DNL(H8]?9\X46!2VB7'"(^A"W=S8C$)9L<HXLN;13SF&
M:HS#%_+:$N&K&$5.A/(=(#2BZ.HU>R+9EU].*A(F(F?B'.2?,4DHHO?(T= P
M'I=6$IU]F_REX@&]-QU5(=3MX7+RDL8?O >TQ,M!\+J G<S/$10SU8-,.)I8
M1<QGI'*P'M%79P<X^94%2Q]7W83+X^=O =O5;0Q^@T 4T4W0]AU@@L![^0Y
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M)_ *2^\8KDJ"L=>8DH](5$Q4G=F^$OII7EX&?DNI*1:.7X +/3'LZO>1]8B
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M"=KB1J5(')?QLX-.Z?H#]FIT)%"8B('P%3&C>B,EZ>3>]Z+K4&B\);WSML*
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M*SLG:F^>!ADIVM+Y^&CX"+HXQKQ!..<F" Z.V-P#N@LF)XUX#!R<C.I3E!]
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M#EJ/@ A!D;7VL:7EXGC&1P +U.,$=@4,(MB^;>T>N FAB<GKLFG.3CZQ[37
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M&8V5&@->(6&M CSMI-+K-[14B^U!PIBI,RH3$">3<6,-R*6[YU6EQ#;9VB/
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M-4P2%^,")$(Y/DFV,<B_CNK!U\!@!3(\&1"MIWC6KUHK<TEZ>&<M(*T!%X\
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M5(E9SY$@YG*D_AHRZ()Z=_);Z(#<'%M>Q<O%>;.QEEI]JK5CD1CH?^GF+9P
MD55?BZM'#7T[=:')*9/OU1GGPR7@Q=R?_VHCC,A<T-@(D4F<3689\SD5K*/
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MW)X 4+JY>M\X<_NP!8?I$#[,(XSQW0$^4JV56;2LFY/\JI=I\^B37G%/.H%
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MP[TW[UE=UHT6_ [M-C6W=$S,>,$]D=KZR=[+?O<_LX+^1F'8_Y;'^(Z=ZQ&
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MPB\VQ4^7E!"",G .SMM(H+\@' F\I4<"RY'KQ\HG\C1=-%IY,\<$9WH&#Y!
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M!>5ZN=)+!-7@R2)$)H_B:XH#;WWL=$V784)N2U R>N 712]6?HW1>PW[:]%
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MX^7323<M$ED^*-]J-^=I4$Q:2?%?\@_XLB-]U8[UY1N^0 :(\\H1"?"(:7J
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MT4&A55T7QIX/*LSWJ>\A0\"()=$G?&A4]7D9\F5_Y!!-=3V(D[HM7\8(4VI
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M!5FL\'WC:1NZP_??%87'>CW;$"8[PI,\ZKPHWX[1_W">HA4T895N5.LP\%6
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MECN O]0PIO_IP^P U_2(*$5/N>(Y.7R-QH:O"\3+W&/HZ-?.FJ[+[)UD/P$
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MDM+=76M]ZWGVWM_9CV^?;YQSWG'&>S/F#V9>/:^8"SH'_05@O9:6DP;@X."
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M,<?@Z#NAZ$L6Y1Y[%$DT*S+93!5L<76$#, %?Y+%/&VO"KQIB^&QZGJ=.OM
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M)U%SM;95BJI+NB!W[Z>@3-Z7U^HS!S H;V1<4/6%!VHG)TSY=7O',!9]\M(
MP/&RI S?"K/4P^ZL%^?)0>8JS?JV*C&8B_-FLJ3ZX\:T=(/0,/[%E;P]R].I
M0K0CZNA?I]]B]5T*U:+8/0W!$RL%/U1Q$Q1X%B[;=ARO#;'LI2.R#64<L[5;
M%EDF:!<U,1,UF%[?&OTRI< $Z00I3_%2$M_HS$RS\7B'Y4YU6PQX/O_X/<,V
M6R[4)(Z[3L1EJ^D05Z9NC,>#9U S837(;>9S8!^+UC: D3?QM11F9!ZS'?2:
M3T54B\M'[>YIPOI<0=OG'24F'S.)[V-KTF+.)L'=H2^K,X]?7^OZ><'B44%T
MQ(EK"':4O.S$Q*Q,4VVKQS'MA^9"38OE"$\:''@,)03Z('_&A5"EP"O-\M0Z
M/M:K+[KWQ564.UI^O$N[)/AI47ER9N_-C)FY!WG*&N7T&ZLHMBHN06@\!FA!
M73H6*3283#(TE8U'T:SW/V/>W!EA0($HU>Y.M3I%4XC."H0H*?0S+!"VJ[G5
MA9#M/8\?"104[[U$CWD3[ONB\#L30V=^.T)Y3AEOZ@[37^_?DFD%88@,S%0;
M34*!K*=>@IKW4W[@V*ZOX"90TI;K6Q4I7ZMS.#UPI-[R/H3HY!X*])4\#L7K
M88R4,SB$SGWS4Y_3%%SSI3O:NI>>OKAIWA_FVJA+J&>,8T3\ =#X8W!X7F1@
M./7USI_OW+E5N1(DS]1Y?:G@D,(M"F;3]%O;L*#.!9'L@E;I'H]&JRU!WI1G
M!-MG9W>3U"?2*12A%MEA1Y!1*R]VE8C2M=4(H]3ZA3AOB^5&'4F1:>/T+HV[
MD;JR&^N1M64%A6W/Y;=Q+F%?F+":9.<1!18Q#1B7Z2?>J]-/NN3&W?<07K_8
M(PUL'[1L"E@V1=B($J?"N&U'2M[9.)%.95&=;YG>MYI8?,PY0 LW9D^=NV^J
MW;"P.U Q^W6>I^#.FM96V'GM3)QK6SNB'=/T4A').(T!/NW#<*X'%- 93ZC3
M7=3MR\_OA9=5_,$!FJ?BW]:/<D[FB_<042O:=S^]M67*R2DD4/7YO-'01\E-
MMEZ./SZ)!;/W<(2_794.RV0P'0_*AVDC$^8C*:L[+^U3AQ5\MFTE#*N[-SC5
MA@O).:T)-/D.JH)R*S&%!911[KR#-]?BC;/-HI17#AI3%_OU-:BT3H#5.T$4
MN=U/LJ,M@.,LA> I05+V3>[=R(*T G.7YO<!9J47XF>].9JD0:O/T#C<OMVA
M[&^?>H2;2SBN3@&/"U$V@Y_ S:TJ'5<_\I7\70:/,?<3"3'!\!Z!X)IE^J_$
M'J;"<NK/9=N9D$[=MQKGLK Z8QEI55Y&7J[YBZSWN<4KE-PP:_A*RX1=-FFM
M5X=];F^*G6MU0$W_;)3&^0U#P5S?ZJKU1>M-@F?A2_JT#K%1T]$?-6^#/#BA
M@$OB;:7P;+:-SM/2QCL3?3DN<J%;]LRS+^@35$8(II1)6Z(<OOOL:B=TZ076
M)*GSRWL$)NK!QE//:V+QV=2E$0\'9(6=&E2YT %'?A+-J_0NO%/:WB3GTKWK
M1IK7%-IJMIE:?<>X-%P5]M\2!G&:3<+3Q9L@PZ>A@1:U;38[#S)9O"U3-\S;
M<O9$KE^"1@YPFL^C6YB+4]I)+!-WJ_>7)%]'G\T(RW]\GRT>)QU1XW=7H4JX
M.?#)P=>S,#$-VZ/9/GN8_$OMN(AP7C6)^PC1#Y8,YK0&X$7 N9,<G;^P%\,?
M438Q3(%R8V'&-0+T2%(SH<F_#KJYF  =<%K U$_C[T9\M QT$X3T0$O2&_,K
MP4VK]'IYA2M-@ZB74*SW)>@X^0+EG)R_D]^ ^92M84U!\5AO@OA(K,^,O'K8
M>FN9 S#IE36_#;&)$QWYZL8KPE@T6NC#UQ1X P6Z!V'F0.S4>?0K3L+H&@>8
M9,V'\OL#<TJ'E^G=T#S3'JL=R?K0%)\LZ;=-R4#,5=W:9?*V$W"$J[PP9^&>
MD$%#;O^H(]_N3[9/?/SU9'9J 6EY"#5V'DB=\RYBB.,A61GS.6<+9<EL+%.O
M24$]]18@G:;LL,7VD](//B8G6Y#>M;V-A:Z"H7G\B^RO[\*>G9D^.7-PQ\RC
M2,#/+2M^D(@#(1E*S]CFI;:^2.1#&)F?TUJGKO[R0S04?^&F2W7:Y9".&82Y
M>S9:8%#W\W#I!1VSO3:-$4=A5JY7NH'-YRD1=,=?"ZS"AB>="IY%NP-2=TZ&
M:E$++E^/#&G*][R= ^2$@Z3[PGPX,VG:YM.>>[+QR N[!,[*R^IG!5=%=5#_
M</) B 8>I)4"J9I/*?UY(_2%M=-&1M:NM"Y^UMU.SB]L&)-N#:0W _146+[,
M7ML]R3DA^?%*JX_2ZZ\::^58-ZJKW.M#%-UIQK<=#B,QA.]-+*_\:*LB>M)@
M!NA#X/G;-,;W%T55U9\CC;_Z@YCK:7ZEU0^3S'GI#7):DO!W*R#)G63$#=RR
M$;LBQ2Y1UX>]/5+56],<X="D<1ZV]JA[=;+\>3ZZ:>W6[E*FWOGJ5;0@MPV1
M 0Y'*(H,O>?"[+E=B[/G>MUX]3X(T[J6U1Z,O]2SG/G>6->8^,<SI163,=O^
MZY*OS=I%NSJ)61:%-_8J#1*,?+B[;B5<"M@(EL[Q-1TCS@'2W\<VL](UIGS0
M?]D20 $5+KFBQ8.6^D"?ZD]4[C^W&/?>,L5AFNBL_$PT>'83O'IO2\!ME6?#
M*-HR_+V)Z+HW8$(\3\"N4*G%3,=#36_<ASEKSW%W\_C U9.7?F+5Z(W#8#V/
MK!<!BD1?J93=RUD_]M.9F$)T9N7RB0NM+=^[X(;@[63U9_!9SL'$@I</C.72
MV]$AE3ZXA3&8QY I#LCVX/V2]&';H>U2C(_F-^W=%;0:!K_A/&M-$LJ/M:ML
M=EO)S/E;4,#&&]@6%1<0113V<@^/U[.%-S_9R$_^]KY2NA0O3-Q(FZL+@9H:
M-%CB.'_]$3.L6C>*:7WUJ$$LD\661,;5_#O18C3I*#V \""9K#+GM+C+JX2U
M;%FYZ\7:$K\OM#1$&SU#</K)'REV;MN(Y@31:ZWB6,2F:#C'([KK'O= Z"C%
M:MO3T%9#DA2Q.XS*X/6O;UC"F+EB!3G[R58G6RG%Y$[7DK633S21I-A,;2KZ
MCOE\MD2;,;V*LG:<Y_<-V+Q!&'LZO@E;'Z4*%Y%BM]YS"+ZO&U$ZB6\B$LBD
M8:X$/[6.]=!LO]/O/SFQ-='AS&EVNR;=F"*U.^:2-N*#2Z07[+4IJ3FURWG,
MGI<NR(@@U[&QHB^/. R4M1O 4);%LZ6F%C2 &^7M7?%0O5KO6'[2EOZZI8E$
MM'5P28C0PPY%CJ0(OT-C,4=B(38M(6NU!6=@O?=**#II->KUP$ OL;R!]=EB
MF$^??N8[.1H1HV]Q>0M$B"E54_A73!Z:O4*M8;_"7/757N/\9,O?Y1UO6]PK
M$V:N>"KTG$GH3)13_ZI@#;/<9IXO]FG9O!TO_:<*'%NL[HC$3R?./Y21B.E+
MG"!8DR37G5ZSP;RV0G<_(V?E:>)U*WMW6:+5L_RB_"5^G:I#"#OR]S3Y=4;*
M0P\)L.C"X%A3.W'O9Y$>\_I !Q-6UKTI<RVGD=(K&&S=]6?#/?7OOZ%Y%B5O
MB4CF^#!,/H!\77,,=LOW5%X.6][Y9>L8LV$,9^K%CS"7WQ08NQ9XX*S-C$S8
M%.BL+=XJ]^I_Q"D0P9@KC<;$W*FM8IFYD_K 5;;D<1BKY4>EG/J)U\VQ-HUW
MEB4F](*81Y 7W?I<5KZ!N/0)E4"[T:U:G;^BYS8"V8:5W#JYZKIJ_)L)$0%[
M^\-W49? =02>QLA^_2N:>?>Z,9/E%&<SMQ5B%OO@XJUA%^T7-@'$9UU?)5!T
M<QU'F+[A&MQP]WA=))&(98%S]ZI*%@F%?!M28Z^>6BYIQDY276Q%(:@1]K5R
M-T]!"&RXK:[4M/5UAVJ](IT4"70E6^ 0@%#T)N(G#C\/PR<F67F6*/4J)F6"
M#R]:)"Z*"ISM/298F%LD#/P%[1/J**0YM0R>C_'"G/Y0/]XI0[G&Z&O=YD!=
M7U&\'US=<=)X"7H/W?"RY,P5TP>E&S?Q%J[DQ:-VC:Q#"ER]KY'8ONA=_.A8
M2TLLKVD9PGQZ\]4%,QB"5QLXH/NHI(PC966!^Y0+WXU%G@)??,]WOV1"1,W9
ML13\SD9';N*2\,,H?$E[&N,8&=\LX,3%]8S<V<#6?I7T^$:R&3O?P'(^>,(J
M=E'*-Z]S%+U?CFCU,WS))W%AY_X7C4JHEHEQ-Q/D\@HG,YDFQE9V>^R\5G:O
MAJD=:P4V/JTZ?HMK>ZU I9"Z%>\*=K<\LQ:RO_+IU%2/&-5VIP(QFWEL.$=/
M>^7O"J5?E62-7I$NB%8V&^AO&.BFYI'Z_[A54O8.;U$>A 5> <'_A9PJC@2D
MP7I3+>C1:7I@.:G36,WA>SBS&O>_#-T4EB,P*DZ957#UK;$\=:32Q/H\:5N=
M>4?U/UCD^7V;27IXKF%X@7^*!,&P ]\T KL,I?80K"+V.Y0;F*N(Q ]ZT*<\
M"=8&CVEV4]X(-D"!M1V$[.\-;3<OB]MVF-<P'\@6H<"I"[@3WPP*2!AB@7]M
MP:*[B R,N'"8B5Q%J80"&64?02?.SE"@9QP*/%-/>GSJ(P$%@E+2(6S^0J^9
M4Z# !Z9!2& K%13H&!Z% H0R_P/3_W,P_19U-Y7]%4+7S1D(19U0=&6;[30G
M18X0/"]RI;A=]M'&?9K-T'"<AZ]W6K0VV#;/Y/OW"AC<I+#-T@]UH0 B-_CT
M+;B3WQ8*@.;K(&CFL-.*MAJLKA] O](>MQ=.H8#_>Q4M*' 2M0 >O2J!(4;<
M=E,(^FT'I\GC&W 'ZFC=.A0 YO[C(_(W\U9.H$ @8;I]'P2N0LH$"OPV 48U
MNP4(N,;^@6@81EJ50:6V52CPA%UL)>8!X5UXW^_C,-(OU3U  >N5&TX8R<.S
M$M/!79!G!KYME#>(/6\GVS8\0%?HH#L.=?8;F).P?:\!8T?DRH.Z>OG)9=--
M>Z>]JWB;$7N]-2XB%-!"Y&X2N"J39%:^&Z@ZGNQ?'=)K+3UJH@B2,@9W,L/"
M8@ER&QAB\3#"O_V]0_U29CBE6H/PX45M^@7V3-N)%0@*X,O\]5]QTO\N,RA^
M#R@W=3"#2\Q.6RZ0E&?4-16"N^@*A"KHY!!1$7^0N>S.-%'^)GBTY+3X, [\
MIB!9OPDTX/)9D_]W]8CY3<O@)E3T5OZJ'*#?5&P,24[*&?R;=OP+#1/_S\%$
M\5O*%:G;C[AF$EQ1:M(VO64VP]([F/K:\Q/DTJN($[%I[V^!5RDF!#_F44F,
M%W96'4P9]3?Q>U-DU#0%0#<:H$N1FUF8&*P\!E.>%(/W/$_+(.AM]RC'#'E#
M/0/1OZV4>6"FO$OS@<E-D#VDLVF@Q")_;H_"?:Z,]<@G#$WUEJOHUDZHR.A$
M)C/K:RB3P.B_O?\A!62$>:?8M"F ;4MU7'P"CCI@JO"2REL]7/"+4Q8,W6"8
M?JF-1H%/8"HV!U,5E#Y(7CH)%/BU  7*2\\*.HJLZC0&G>WS=881Y#99*H:*
M<\ZC&I!(JWJ%MJ+-R?)A6KT*LP%3Y^N&#Z3@*SQP)TS#"[9[VV[XH, !<_/W
M/R;]^O<G535,O7^?5Q>R=[:,;&=HBLQ26,+LQ4"_)1+]5/M/!/\= AZHJ4]F
M3VU,XD"FR]85CJVK&!,THU];4#D)]CDJ6XL]'W?QC"-7TIH\R'%=+'!VBDTD
MYT+ CE4\8(G6_/=HWAB!B6LI5-)?.UG3PG?V*["3V;M^XSU&'HI<R6N](9;?
M&:8\[T-;4UZGZPTB\FA=?DI3K+QGC(?CY !O$B?W8#.6_Q]A<<SP?S[CB, C
MS2+83)+%B#O#N$%B!)F\*NB6).Y?H3\^6/J$_8JOY"D4>*#U8V@]JP-GK5B+
MO6=/H-[2SQ(8D:G'GYGV;KH7%7UGLU#/FFCUA),X&[EE5(IXKP\)<.XA&V*)
MP%/WMKD7_F$1/7.$O%$'9C,+%^^E@^S#C=V3R)=(]_;*>QRSLQXNKTG@H?(4
MAFB*XCOYF1PPHE5)27C[6N7.BRY=3A'4CJ_[3/9C$](CL'B0?0*1?-7B"E%%
MB?TDXX7(^A?G2-ULBB7Y3AZ_J8X_-B/VL#MHZ*TH4:D34@N@_?TKVKC>J\JN
M%W*D+BY&$@]28OXPQ^M?;31_NE9Y2'>;10DM[!\Z<U>E\#1R+?A_?T?6T&1X
MR^A5]QAPT';A.OWW\LI_U&;9J$U(B@20+$W\E=Y_(_-3']*U6::)-TB73WDU
M07W/P[&HQ+0WP8'=/\$PCU[_@T*-C SCVV6?FIY!6ZZAP5XK-9;.#R:%'*T7
MI1QUI/0-5B_0/'ZHPFU'K8M:(NBJG/I%F*T>RFL%*5<UA_0B)<R@?K;M9GS.
MA?FT(N"R:-)F7K2R?7)O!ALU> G9^[,ACU>I$G7LY$P]%,#MX?_XOH:1)U7L
MTFV'?Z:8MCH.,6%#_6Q=W0'5J,CEET70CP+>W:-C\ZF>FIH+SJ4Y)O&9.Q.>
M.AG,,^'&A$AXQYK.QS7G48#<MC5G>]]]WCZ^[J!"DOYKDW#S\(,)F8E%F5=F
M\<U7GB@3I0H;$Q;W)[[?C6X(!D8J>F7[A+,=A!V(KGK43WI:AG1RAJHD>*SO
M;,-#8E$V/\O5.R^:FKH2%U^-N=IC46(MBG83*.^]^MF;1* XD<UI)V7DT].K
MU51&V8T.V%J3]!8GGUMY:7PU<QJ?S^F.TS<4 >S,E0&M=)##G6N1;;%$WOQ"
MJMN^XF1I;C]V2KORMPL-A^#&F%5RFU VMDMOFQ7LGS<AR-%?R7#(^80W$5T2
M5>@4ZC<HB-U=T9[MZ_!_A[OR;A&^=P*N%.!%[EQF7[IBK#1]I5%C$-QFT72P
MRXL$W/6EI?[ZZ&$OV;A>2.%K4UWT_$9[VGMLLF+[:C.9<D'XYM(%R,ODX\=@
M._"%T%E5S#4X^5%)GAD"ZJ^3PM,<HGSU1U%/I;$U6;C_X)!UPFJ>F_&<9BX\
M(^ '\"W.8[TBWW1F/>:U]VC5P%F!"P?5C^4/(<0[B&\?^A#PEK15[%FWF;U)
MG[C>*WPG1KFX?1W\/NC'B,#" N_3X,A$"&FS)%X$S9;GJ_?RH"%%&)S5TMQ'
M"G99&&]_!GUN2)9>5-IZ%1-II^RHF'_8H6L9\ 3+'\LO@=;HFD_W#U7K++1:
M.1.AO$=,?R1B6OHGUT@S*P'<(K-]2T:<=%]UZV>A#L-D)IWC#TPT6YITF<$\
M?33%BE/1M(LC?1F4:Q[D<O %I44B=P;ISC;OS)(O\:>)![*-<@^J?OURV_U!
M':/P>@LCTS7K1E<ZF-7.;YRVV9$;5<[\7HR:F.TCJNLZF?.BLS@AJ"X'KB0J
M#@I8H<9:4^&:<_6(#"]<;=L-?3L<D>:<Y'?9OV5;WD+]2(":8@4O&T%W295O
M-.# ]4RT?8.D(XSJ5<44R^H4'<%L">WZJ!6+\VL#NI?WQ!+OS014_!&!=?RB
M;.9A<('AEYQPYE"IC_+$TD:%<+9YG[AD-S"^'HN37/S]!<U_LDBM=Y6U1KHD
MQOKRMCKS,2GOR&H[SBFNDNG(7?8*:P#1,9&XH^_]!6^WM<Z43G2!LUG!_#ZV
M5>+D>RR)K*7!J\KZS51JYLWM[P6W%3\Z%L3)\;?J$^>7TW-RJB=:IG(%:8$/
MH==*5#]$.(4Y R8%!=9I(;6)7CD)@;H*/$DX']Q17KY\]@[9I(.FE"_:^X31
M52L[7F7L)[6;UK%V-E/V!TJ++Z9W:)_$LE7WL>58&K6C^1R2"H=KG*O?^REE
M;"@CIO[=TI*M1$*!]4E9F"WL28=$Z>PR_ZOOF"QFTV$>U&0US'N ^=//[*_T
M;L]%RFIN@XX/EZXYKWW/;S0SU)4.6D#W\O?R!WPK=@M5AV*O;YM\^4T$KH:=
MF%V%4N\(=KZ'2Z*<&WX G<.<OSF_]3O-',VO'D*3W:VXZ=W8PZLV@]6MT^9-
M(;)L)?X,?9$AG[ \+G)K35O&*TKWZ4;7%,.,&GT_1/%&#7W?TW(6\7Z;FG^[
MJN2XW"!O_W&9RSY4IG>6P(NA(EQ=HU9K$^=-JU%D9>T9X99 !U(F;XMWSG[R
M; R/@F.U=O%AR4%IQE?S- )3<U7"HX81WZKC/T,([F[*DU'P2<1C$(3>\/QP
M6P86@OA9+"_5'9W/7A9IC"4Y&WDT=3?:9:W&%^ONVEN4]K_ GB\JKAT:0 D<
MZ@89.""]7F7G93ZTESIQ76HFD4X.[4'&<]#YR?5]@(9*5OR3J5?9$RC@H9GI
M$=K56'+1BF1CH[_^ICE<=W29X6R*X<F9Y_8D[\#"#75W;1KFF+*5G]G1US7V
M0V+6I]W&:50;#R5-=EX."BCM1ZZ.-^G=)'7A93["66!S^XG,R#V2X&X,$RL]
M4QI'Y@T74:UUI,EO87Z,*^WQ.Y56;ML]5OFYJ>2-_3ZA[ .#Z<VXY(T7#R00
MK(;:T^C,,CT/H07=RAGJ:#E6._0F)3.N2"R1KO*@-+>ZO#R.90]2[8;:FIEB
M'U#&+DEN:G[.=&FZ>7B:B_P#3G\;H_-<0,!H&5(C2<+#.Q_I5M$3&IWYW;.>
MQ\Q&X0@:%]+*!FD-\RNJ[30/HC+=IL:0WA'OIE#LCB>V+-%>3/D_0)_*^&>+
MF_77[ EN= YN7 ]XEO@NS=.'FX(7XR-K\6, A+&-[1P72NR+0QN=DY2=.YJG
MFZU?G]<G#:EC=7UK\NFVR.40[.!)JY74T3L;M+2OWK?!C% +>S(K5/3#G<#O
M,#*]227FO2/D[$Y3?:WEY<#HND7(,5O7#YO'),;'*4Q!P95 ?#CZL]+D_=70
M#^;C6Q41DA7A,O[=2?#XYWB'[3[KQQ@-I90OQT1L<_<AQ%.7F!C#3BX1R.]-
MS^P.S]99J*E=@J**L](E%7?WF'G<DRC8)XS&+T4EWY0W)GN3:M:?K2@EKW@@
M9%B(@UB^N14:$)\2AEWFNY2(D\.B2J5FN%*32C>Y]QW$&U6?-ERH@:T:2LU3
MVL/F$YT;:U^QS>_V=&MWEC3!AF2(V/VZ3T[;C_7,MH-=4RU4QDI9'UCM5Q]5
M9W;IVJ:-DO&UU65&"JG?#1'!I OCRY$5,_KB9?+J@\E:JO?K4_O0"W*,^5YM
M7A6VK49-,8-VC..$4, T=H6\2$W\]$WC:%BS5)9\GN_GG;/N0!6!^!$<1*I?
M<'7^&%Q>YY'JY-Z24V5^=#=*6G6U*\;&Y',-25XQ+,UFFH%.3KYP!:]'55HT
M0A33U]*)K2DXIWV8PC)S9I*+6.IZB=_8E1:JO/(^(]W:..K#5^U;BRXHU+'2
M,4M+A47(R.27&U>1I<-7'A]$FM.7J<D1O2E\W7E$$=2J;BK6HNR\;9-=+PAV
M[?F_Y'EJC?$/8$@_$Q4O!<F=$(:Y>!=18BW,2=\EIA<N];_/3D6:9]T"S+1P
M"N>6.BZW\_B/X@NF]#TF=4Y6/FK*GJ*GYLPU5"5O#:PK:BKQKJD.8TNS!HK_
MVJZ_7$TC/M4,]Y',VYTO*1]C9[4SI;2LK'73/C2A+W!S(@XE)I6B'8E:,\3U
M&.C3JR^/D0V2J4TYX-1_7<53A\.V-$+]#AX- \$BQH_3-0;%!D)55RYU4E(:
M4];G$"/68,LCZX]PSO5!S,1B/)@5074[8&U:ID>)S+ZYBJERWC>;-0N!X6S%
M;G29_,MQZL^KDF-*CSRMDXU&,A+>G)SAWCPO5C>]HS[JP&?49)<BI\J6R8I5
M63[RI[3[N_9\*<4U33*>9.,!A(F1S\Q82 OZ@.ETDAVOZ)*2&\6UWI7A\"XU
M[2-=K]+N/@/9T3'3\9R^DL@ &(O*HL&K6*9CRX<EP7,M6F;8V3Z!:-YG?6[
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M-HEW".UWGZITGFCG:@?@5IP(T!AISG%M0Q_INI;SV>NKK-(=* 3CN#UJ85P
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MU"6..I 4W_Q!=_M\CY>36BS#5\QSRPP/V7V#S0T8Q1B>;^XB74JSI*KK)T5
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ML4E%<UUJ%UQUO_$\Y^RGJ,E<L<^-H9)<Z.X]A'>8#S1N;LD.Y1Y10R0^X5#
M,I',3.E_L?>647%UZ[I@$0B08($$=PJ"NWN 8"% D. 0W-T= L&AL  )3G K
MW"% </<""G>7PK5H\NU]QMCY^O0^Y_:]HT=WC_NC_JR:ZUW/G&O*^ZYGOL_\
M1FQ9Q8*JF^.(P"6[VC2DHAX\(-DTOK\6UT\\LSZI]!VLIMN).J7K#D!/3==
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M]NG# R!KI),\(?\!0)#]__\B^2:Y4(M3W2';.(\ZQ^LJH;CFH)29"CZE62G
M_M/?/"UK@=_HUBI6_\0#(/(W0_PSZP$@D1$JRJ@(9_^/U*'_CY7Y<]?Z@M\?
MY=63M+?KI)4@ZG <T@^O)O.5V\22*'_"[J=5#CX?Z)E:QW?L'A1N;T0501FW
MG5751"]HEN[1/>LV[!X W07PSJ;'QHY6NRM] %Q->4]3^WWW%5WWNCN!?QJX
M&PIG)+_%.8('"VN?U#T UE3]#'4? *,]Q;YJ#X [2Y#, X#CSJ^7?^.N->DZ
M.0K)CLN) W[")E[K 3@G5T!9%V9XU_/G \AGDOS.V'>7$EH? $39<:)#UP^
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M?"8G!.>]4[U"^^P+ITCK8''?8G5G8>4UM135V#CNZH#S@U)-L?E5-MP!D@?
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M^3OO^:]_Z^G:&96F26LB:GWAV%4)$34DY[1=OS_DW/E/$J=FN)=N,"4> /[
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MC?D^)NEQLGD/:\'?N-,EU95S^JU).V\E:5!*CLG@5NO=I0&01.E>\@Q]6/I
M"SS2V9>HG;>QB&401ZBI);(E6\;>2X/WHV_$6+@JL,N8LYZ1*HJJ6-C-RPC:
MXGWR?XA C"NM-&G.GFC-T)]4UB[NS;@]XVHOZ!VM"F+3589U-GQ!;R>'ZR$S
M 'NDH?,.N-N@1WXG2UG=C%\+)$>-Y]RV?2())XY)&6Z1R?O<\I3R% 8;K]D/
MHXOQ[L33>.53B>!\J!^[-<7ALS!$+A+09F1D*7/91WDO"9AZU%9>.$%E<]I
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MMP*B(X]#>6)24' Q"+YYN$.U*GDKZQU]V6G,(4=<TN;$EI0.-D,,[6GH,:'
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M+_4^21&IZG&ZLZ+6]4RQ2@U/6ZE-^#0%K.=R1@6)Q0RS--85)NSZ=ROG0;+
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M_90=JW+=H2H'K8VT!E&$X#RE/RK0);LK *[O"N/]E=-PM^<,8!3E]5,,AW=
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M9$YMG(EYA#BK, *IVHIQ#8>&K*:F7("#AET[/GO=X;9!Z%/'B'3=Y#!!G4;
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M]!_#?-;5L$^ .V3A/Z@FUY)?@W(L7!MW5S+Q_*J;[N7+\8_U9K46E)&*Q$$
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M.C1=3P-L03Y.D"13^1!;U>Z6(;=0*-E ^1XW$ .*(M'XGMK:XY!9;1-1MEB
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M40+;MJ*Y%W7 ,?,3FI49]9^IWO]9UOU?IR,?QYG('26)&H5<G?&5-"==$N
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MFDC&)@X=8Z3X%1S ZZJHBUX?7EL#@];ZIC:PRV"JWMO\MY8OFR5=JOL0A;V
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M]PAY0NVXK)/)3YDYF^74(C5OPJ YI7;X/>P"6!+5HG7F;UFB0%KHL66SH>_
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M()$DEEE%%S>> B^^D7QT *KP,V?.=WX73O].,GBL8@MW@0,4[99PUNW5=!X
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M6L T&J"R&KG'YA&#^0N0V(9] :C-CA8CMH%':W*N+$D>AP_\G0G'DNEH=;7
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M=*4M--H@6=;6\N66=412P3XW0\HN/">H)-*J?/#6S98W%^>G!:T%ESF*NMR
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M=A"B58V"HB$YTM$S 0^ C$)#[T0@L(6R9KC4Q==1$;5.[-77%4!WL4XG(O.
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M7UFM<7\SQ7*7#/<B=^(KX9?M5^*44%0TWO<:AM<'>.$?NGGL<U/>B"+<6#P
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M2GA[UXMEJO:&RYG1&-[9XP:KO)NRXWP81[E(689)TI$Z_T+H&N:80)P9;2M
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M*9NHSAZ-E=OP?5IVL7F._?^@]E^8_=\C%O3_BMG_(/8_>4T!'A#=^C=Y1)0
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M9N)"CRPA\HW\"X?A"(.DMBBGD4^;W/B+8PXLJ_=37/]<"']IZ1.7P]\'\!L
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M>O ;099?]I(T!K),7P9D=/%M\=T4DQ_&;/T%\ W97[ROCF\ N.+7ROJX]\W
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M]33\K;FYJ:"R ,RQ=$3_\WUQB=%G%6C,X9#O=U!,;+EHY/Y4WA?EC%4M#*A
M0,#<IAU*_)YFE8W=<^G^FGU>^8^="]GU#5#GZ#)(0Z LKXM+H+19,-JC#4+>
M_B[[U=/>3SY$F:MFY$D/$J?TJT5*)ZE>E(BF,:*5S63N4ZU@G&%JQ6$):@>3
M'/[KTVU8CXMBN+=.7:) >?\U$DV4 1?5]YCA/*$@WZ"M;*F!@!S--MR_RZ[2
M8+5URLO5Q_W%3Q..NS>SUV\ <5MNNO;U$1"9#P$OX[>6(VLZ7TI^G&1>95%,
M!UGGSG25=GF<4(+Q8C;J;_YN_8V&:]669H=;Z.;W]WM?02;R8PH6%FV0%\?G
M:8VH1'2NLGSZ#TH-L@K[%<%;;_?_<"+&Q/K5-_ :#Y3[]H'U=G?TR#/5U];R
MRBN6ES$UF5]JFS *G@KZ 2=SH$ #$=2VH(;ZE"A1T2#9KL8,!<I.RZ8$J@ON
M"G2F036\90FOM5K%$X]K*$O/+_*X2QS/>'@]SQ#T6,B.P]J-653\^3,>MBB+
MKHQB3[ B[EQE"J;[!/?3QV@(7H,QVRHG8M&^V?:+W\!2BRQ^7DA$.0ITVFA4
MX;*)RG1=<L5+;?'VVSW@.FPJP^J:_.RG"EJ+AWM<D;L-@AHB6MTGY:1JX7A=
MEU6%\P[]5)71A]&)#VO382V'L+>?W=PWL0C/:GT0*4D<9ICCE-2ZB$?2IKAY
M%CF]#//P_S'&F;$PP <UADW>"VNA7++.U.W2WM2W3+D>5*VMC-K*1=T_JS7^
M_/<80)1V33-E #[S!OHVX"HUVE>#WRL^=376(AFYPN^>73;WCN+HE[DNQO+2
MA=#%UQAZKWJY^IAOR ?@-\-_!CYW/1 =NM9W&]=J2CG@3 5BM^9?)ST7LW7.
MDS%\$UJ1G<VMI_WIU_M;FDCKKT&0.?1 IWN7IJ'!,-J9+ZTI)\]"R]-U9=WK
MU/(&,/:V\MXD7-(/UQEA(Y&)Z(#)?5XRC?_R>]#2Y+$^MJTS;1JW2[@NM=&E
MD?DQ)HD^OH*\SP[G<_\9Y/^9IJ,:+.D[8"A]4:L3B-!ZISD4$6'Y?$5IM4<A
M!#*XGI+Q/TH+/ Y3@2=Y&2=-S@FU7S!..R'RHIIP!9YJ5'GF:J3*H]B6OYY7
MO#,TY#^88,A3,7W;[.R,L+F5]ZKSW2%)C^N1;5.= 4:?IES7T\;DK?#;3P0J
M/G_P"0M9]I K9*HP,Z.)+"^'<.057G6]$48]KD.41GF CR<ZJO?.HM=WRIS9
M,3^S7O9);!-;CUY<>YI]%.:=[/X@#E0NIC(0IO][D;&(#U\KR-NK3D$UTUV)
M*-29G#;_K8?!Q,[IX^Q)U*I')5_"0U>?*S;_.5W,;S2. !X<3Z(4%16L' ].
M//YZ#Z(1$&V# EW-D\-+?E#[F$/_J84_YO+->P;UC*_OQQ4RZ.-D?9'4N@DP
M=O9S)>&T__H^^VP$O=Y9K%CQ*") Q;)['LL1%56!(=J*PG@GG=8-OMTW*//(
MK'%(]&X*&*Q*VYI,GR:LAH]D)Y7GX]'S%18FQ?YSS4Z8GVYGOK@3XRT4*8S6
M.IG24%IA>M] #$8/(9,I6='F(V$PI8SI2AG-#IU?;S4=-HDV*JH,8?/[6,^
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M,$JK]]#EF=I>;$;K9T+%B+TY;/)]BW9DF=Z+AACI=XI#.#8KR01)1:7J<!3
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M.1E(?9XNZ1U/EI-DJ<('M5,&GG.N=ZL1%5Q/S!J9GH#]4_T\934G6]?P?5
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M[\>8//K\;<'B^<^Q!]EO[&*/1N7D6]>L'TJ8Y<ARK]D*U-<,*82&? UZT,_
M($K0]X5PY1T[QN=?*0K'_.?Y,XCU>8?%;7E?%&#1Z>1V#AVI=UKN.KR2BG1E
M#65^^*CAX*WK#\T _H6JX(C3SVOF<^7?;E@&\)$1B-LFY;OAC"C?9E&HL2'R
MY?3BV0$;,L 2, 99PS=#0XHC%&#K:9FV)!ORY13P[( !&<"Y_I=@W5VX QBV
MP'9X$%7#S:::,FO+/>"KYXY%;Z8C<:=8)F,?D<Z=?@S?5WP&][)=T/3)H''#
MH^?_W W5N6Q% 5C4#*[;48!LC;JPZP$A0D+.Y_$!C<K'HBRB3I)J[PX+NAC(
MK5N>C57?].X9P%?6F6*XZ^X5B8@(GLIZ@Y?4KAB<>:_OT)Y1IKPB6-I$"B27
MQEGQ5F<$'F]KS4VJ;J)?J"YK=IFCTS32A Z&]&>E/<Y%TE<L\^N?(_>(DVMC
MHA.7  ^PTK/]A-B+SWD]6%)M(?>(C&D/HAY&%#:EO@\KDC"[E"^0_-]K5#HF
MR2OX0-VFQIJJ&_V4P7-5ULH4HD@_</T(ID.?P\.ESR-A$YF88>S_+N%.4Q"2
M3>8JD9:.O:CU]"--!W)6O55[(0^VB?B>(L]9<)/+(7KKSQ"I]C?I(E8#WR\U
ML>T8;:=?-QY[KI[(B!$_%P>X$,3O*BJ FQC.SBT:M+LX@N^]>%-\G'&NE0I;
M-KJ(_O##AW5!.9IY7M;-;L3^?0*F>W_EYZW,M7.JO92BE?S1,Z\;'P&6N.'G
M02O&2L9A3('F<YBBZZE[C/=OZN? 72_%>@55I.CDN,4,;[1:DI6[;<;9$R9<
MGCC%B4CB6,-,;(M>V5P83&B\C"R3@EE/19D-?.?'T-'I<N4,ZJ7%$_*<SAVI
M)<B2=8=T ^]=NO:W7;2PP,;/K4_FNS>,/,;H$%&$?8;V]DKG^#A(V3U^9/-3
M%&#D/L#ROU5)TFJM*96K%8  [R00W[/(NU  [4:[WZMTJGRID_!_FC7AJ'Q<
M44'WLD 3[6TT4  EP)6!?02]E/+V"&BQ4?>)_,S2*LY=G_11='==[S0:=I4K
M "_#5NRJSA'1UUN+0REA^HHBJQ/3 KDWJ8ZIC6G=MSR$# ?#YRA __:Y"'JH
M]F7W:E7W^>%PP2PC"K#"%8*G1O^9C/3YUSG#9AX+V\YA+NMA:;5PI+@=$":&
M HSG,MS*&M1<0E>++"(-C2B?80SF,J']0AGF8ZT@K#Q+ACG9V%L]44E9,\ZX
MK0$V'2]65S<4@$S"!>2,5E5;6T J8>4K%*!#6^#RUVI"PNN4!=W6:V;TG$[3
ML _Z$V+!<R\(N#@=WEQ&@%]SJD#UBK0+)W.'CB'A]"+W'DA(MS*!GPX12+:L
MH^=XY-:-WF_,!5+Q%WI"7:JAYRJ&H8Q" ZX;;YR0 F)QRN"&\;#Y-(7+QM52
MIS+(VI^56QO<:A\YU-[(#C5@<MV?/==S[$9>E0/C[K]6^YXH(-<A,O2\J5"2
M7Y.C%TKS5)N-)3<9L>BM>Y1-PMU2^UJ^HCJ8"P6(TO&\-3E:_@"!(4VO3SZC
M "&E(,3,QMA*T$OZ-;Z%R^[^&1VFKJ<T#=S:8O$@'6W.*G"5S1YPV<']-UZ:
M>X9]I31ZN>KH]4.Z9171$"+XGC.#V>>,6\<Z*Q+OPIY%7D\=_%M.+E6W.42Z
M\="ZU'/WHY\(:!PZZ,W^<Z=6Q:W!T0FY>BF%C8-4+R$*0&S$K+*>&JN3T^+\
MU<;V,]W+C;PAGP<)2FE4<]U'_"NO8S%=A-"0;\HA @5833#97(%%V\8[N0<Z
MBOO$X:'-)UE/2Y;S:.7W9-SX6Y64@9;DM.<$/MLRVC238:D[?0;-! @D!46T
MC!WZ[9M>.__9;]EF=RM1DW:.N_PO-[AKT=K<C@XW-^(NG?6$P49>Y".CX^ X
M'>@GHV@,CGU2"VC6]^G+,6^)PT><F_WCCM*GLV3.M2MILQ-K2VFSP81=A'24
MRLHK3VEH(5E_WJ.6%5J4\]\(A_R197:T@"XSXUUQQ?"/)3+R#^-,Y20?.(KF
M@>8.S"_;5R>]>9H3Z)#=.&@F*$@]O[P,D$-#DC@'R!%9S_Q39K!=K(F,*$+[
M)V61-EV(-O/DOFO&8=VM3P3$WA=H]F<C19JK%%&-NU<H .R/VBR'J'=QC'8$
M4K6&.).*MJRZL-@.7=X:'?WZ9>S^[OR&F1:RFG O@\+;FP6>@@(PG&W^>;"1
M<.H.;@!FAG4<'M77'M6?'DQE'$Z*($>/_)IZ.&$$O20*D'D!_/M8^5L>!OJH
MALU_$5DZH6'1V]+?P_WI=85'\A*-P=5)3K4,E-[NNLA732C ="I:8MG^**P%
M$BWO5VQ_>YP^Y5NK@M2W!3Q+Q<KU\(P(J;\]X.\S:D#:5HXN;-&BPKST-V66
M]-A6N6<1YCVVKX%6_N%;'B ]9.1_?LT!7 9?7K3\85D,FF4='U\.B>9B>?P\
M*QCD6=U,<JICH&SRRK@BI(7\;24XJPS1\K?=K<>JA,BG=3Z!GN.TZ@,W :D9
MFO5 *F^O=,&#V_@_3,UGB&@!KD5"&,[_SA^1GX."0=*818H7W(H74B67HBNV
MIITF1 TM4V7(22>ZD[;R]>SWK\$QSS,)2B%BIYS'IK.;T0!3R(R&VAT9F>>D
M/5U4R&_2:9K8I(D/:2H.;VQP- @XOLI:/#+40_SL( \3E)&7>=FIIOW[L<+I
MKOE7XJ<=6<>.3OXI%?\ @G1\*WSAMF%&'!%8X'MOS+?(UK78CLU4N!JQ7 78
MR^35CVP'R&'V'^FJC^5=#V4C?S_0:_?_TONLF]&9UM=.+#_?A7+A 71@^@4T
M+E3YP60<6^R,&=N!=^LA=9F<V@NQ/JZ UB/\L_-(NXNWOVR2"$$2MGBE2OY.
MU'4?7I[=5AD/:':*D0=IQ4K_8O\9@21--9BS5DSM#K]EX0UEB<R)&X'D*-JH
M=+S9(S@N& P)>+YJ?[QFEN+D3KZCF!HIQY@XU@LN^/1429&ES0B6/#R U07H
MDM+P6FGD*&.L?6"1(O*Y+O+1#^,!=US^B?2V3%M#%=UZN0EN+(/(:=Q/1FV2
MIAE)1T54?1GW=WC/R_G?UJ  H25!DWR/G GK'M2OKK.\<+H[L-X6O(%4;\%>
M#:5PQS9NL"(:<=VE<N"YU M?%RVZ"LQ]QQ0^4SRZ&2,@6/"U<U])0P?LU#?(
MYC6T6U0!4*O=^I="=A> =_>T^PIR48 >ZFYD\RKZ.UFCOP +PO@67A2@5W.J
MY0?:]GPM>]H("4<!CK7.RDN!URQ<(>4U;2@ )GWXL4C!$7_6(=MM= /%G2\Z
M4,O2G6G/+(_R?H@",.T'HFU1!?I^[?/G6USM0ZV1#&H3"]%M?U 57\6Z*8,=
M*^Q0Q3](-R)-]H5Z"'!G[;0\C>9MLS/GM%/ECU_8,M(,:3[X-]*0GM@"%&!&
M%GAJE' 2Z:.JD3295")J?2M;OL=U<'57CP*T0I&"9VYMV[D9RT-1QXWB'B)S
MW<S'H#7/Z^EEM=MX'P9D/413ST*14_V,,^KW[ZWLL*OQ3*Y'2!)[7,C(<#8*
ML.1M>JMMJP1^%+L%6BX^=:!D7ZFO3X/:3PSESJF5G/)2N'_B-NLX8 NI_JI8
M(^">7&Z&,?T[L3_VQ/%%Z0OQ '%=]0(07*B<J3O?>HJB[+,3M*9/0<LS)G>E
MA;W\W5W&0WK621QH\1]6C(?U+<N%%^9YD>"6J7:/HO&@>_ZO?R?[?X_DBL&R
M]D3M0#B#J]RX )AO[1G@3JX<;O5HCT_T'; Y@8FA#(*;[H>[?-I*M3.==/P+
M.P(^&/$Z>**4]&?PK(99\'5.C4M#!CPJ[<4L]LTK0'%/'ZZYGY[=/7-,U0>B
M75R#39@NH0?."/'PWOW?IV,_8WUL?E$RL2^$I%L<.7_:?[@M,T??7?PO^ AC
M'6U56]>2!M%OUP$%X#?QST0+4G,^9#K7]!I0#KR\0UNN%OOKF^"KE--_A&5&
MU2;\FJLWT7@J[SY$$GN7+ IS,><)7WF!?R'JHE1=4T;&F^2MW#X*#HZWFS,U
MU=6H/_MI=YQKWL-&Y[I)5[7@)V19"-V'[J^<V!:$N9]$CHJ\SW@3MIEW%&%Z
MF&IP:;<P/:RK2S)?6J=G_L!(/L)[L-K\F"_A+),@Y3^ IO]".74TT#SC2-:W
MD6$(9? (_22+HPG/H>U!Z#XTO^9(IR+G&;MZSH_D6//>(=4'&T$X,<)!$EK>
MRG3Y\_*_@U5 @:-!1>%95AO^:U<(2?"Q10%-E:G,;*$RC0NQQ),/ZNN-=N:K
M6:*B3-."*[[XAP15*SZ4UB>7:.<08_RPH):%9^ZVB(E78_;73Y%R<*227/'0
MD!; N"+Q0@3@*Q.52 "C^U=B0C;H'JW?/.X")8?/3GYH^&Z>62A*I7[I(I :
M!TM.LZ[(PQ&U:5V.2DSFO4ZZIFYOGD9OPS8JZD?7A[IH+]&AY8L&7^UZWNN"
MZ[<IUEM,&OQV7%E'=/# NH1P_"ZY'@:#\@U;@\03H%T=?:7P27&EPMLOB!@?
M4,JTA6!9_X,7+SC7:YJ2\-<Y3#QZ18IK2Z,YN\0(FW7($LH $IA>N$.Z?&GG
M;,<#H"HZ0G4=<^X7I9^>8T9\]#J:BK-,N=_7P_S&Z7.JMN7^*X:O/@LU4=??
M0-SJGBP?; <46V3[_'>URH2+; @<09\>E]M]K(U^3(\C25AC;BP1,_=MW1B:
MD:RPK8GC*BLT5_J"4<]1M 3N4Y2^GO66+BRM3O+GH$7<D%"A:,EYA1I)B6Q"
M/%U#M('33/%W.XWD 0@79K<(F6^_4MRV<.+,@P-#G6NZU%!:6!+]6U]YZ4Z6
MR8TT$(GA#!.YB;#H[K4.0:MPX_VBP6=JPHTJUD[3SWW29MWM/6V2'CJ95U >
MZEX&/HN+,QS44)3D#_O2=;E ^J7L2_7$3MBHT5.8W,NL5H_&S-,"SE_G(U$W
M3#B)W=8I"Z)/0@8H0C&TI;[VE&:=P.:5UQGWYL8WYKSAC97-$]8?(>R),NZ#
MG"]IT+84BZU^T.13:&JXL[B\KE2"C'[EI0YN,X%59VVI2&_-AX=K@92Y'\-2
MS6-')IY(WUS!Q2:G@S >5PEMFOTDTQW"'<+]G"ZZITLQ ^>YH3HNQ@NDQ&YV
M6\'OEUTB#+;*2#1^%H0"M#PIYXB3Z).3,CA=#,.Q\/.E-4/Z1Z*!RRMC!E(#
M,>>OU"*$++9E ZI+)[]P1 >5;%>_+HE%O](7[1D&*U#+@>,[S9<NZL/S%V"\
M I9-(N)5,Q-/PH6QZ+_R.["_C_"ZR'KH$66B]N;.^N#<JSEG("X[@8HC':PU
MO7LUD6QO--%XRJK;$O@NEV-^*E^NSXPROW9%!#NUONM!?I_=UEO"<NQT22LR
M+ZV1E^8QF4"A%YR&_#8AFW96X8/*+SP<*S_7$9QVBFIVL6\)_N@"7!0V5>UJ
MBK!8^8.UDA6W6+'OJ^%7]3F2+EUTDU%>>9YL<6HW)A-EVB?=-!>)GY(T5],X
M9K0P.FD?G9B/G)!_4)6^'A.2HRYB#5?,92)P4CDOX ]H<LV/DE/1X&!01 YG
M'#,N0F94_P9].CV$?U^@ $_Q+^X"F5& 477=TNG7KF++AYGY/0J1(3L8G6*Q
M"&M^3[Q)4NGW3(,%ALH< ]&/JVC-F-'HYRW\C9U-9JI?OMYD#UTEO^9?E5J[
MW"9S@KN#XE$#D(\9L:/^&>_&'+=*%O >9$)9._F%A8H;_BSZ[,&.' #'BG(.
M<&58V'L&539DM^7FWANA(&)_<.PXV_6(Y&XU/GZ1M714=7^*+&'_Y;EKI>RZ
M9#4WO=!ORU^40^#H0M)=+T,OA3Y#:5)V5:4N?VFI)JUJ#:HN]W'%*7L72:D+
M1>6D%/C#Q/G,1&:B(810+V/\ 2L6%HP[X"4.:Z6=-Q>T%WP\6T3M,W"AWIKB
M9^J15&'TA79=0:\O;8:**T!.X32%'6N(IOUZKA6><<1ECIR/51P811N[IF=Y
ME9=VBIJ-:_,G>,Y7);"ICFZYQF/SR >!_?8RL\8%C.\B&'Q]$[*TSNROL$PA
MTTT9UP\SL=#Q6(Q@])T7&F]DAM5KG69<8>FA@7@3Y/I!R=?_/93'.';K1$-R
M3L_I*8:[QPD=NO9'$*12>LU9, KP.@],=EYGNO1JU%>>%,GJ+'4/!8B]D$''
M,S,HP"GG#:4SV=&P/W#-9Z1U]QQXA]O217??W6/Z*&?[^OOHI6QV&%>7D$32
M>0#Z+B8U%.!'&&2KGFN3^EK\7U\J+;B;]:Q*A'60G96W95RQ7@/O')'Y+4KE
M4%]2-,H21K-B-^E,,,CEEOTZ*NCO^*0]UWQQQ_1NW!1?=ZX*4@2Y4/$6-#E'
M[YQ7RK1HV#13]X<O6@KYK3/.=EJOR=SOO'!^HP,D)J$B%,"DY \.RTJ&- RO
M7^6(F5)+A:!7NZ;Z\U_]]^!?";.FL['?Q8HSX1%>Q&!Z+AE3]%#I)"B6K[&*
M;_^X(W+CW5%D9 12I$0  W^BLAW#G7M@GTH^D9+C%R-)?#<6VV$9EG2-\@'I
M-OP\+]]$S871_?>98KFMZWWV;FOF9\*860U!3/'I9XL+!NT^%H)Y;?9!YNR[
M=1$!S^7DGS:-_UJ@BE:8<!99/9SOK,VR-C?<39:V5%<2P1;F<734PB-L4 4K
M%U[31Q?NZ!BH1"0U!$[H3(U&-%76CG# &FHS"N0?+9B\PAS:I34Q\S/_Q C(
MJ5_3$8X.  ;4Z"%[)2<[:JMD;6(,F@XVFFQR,$@3=N3V <-L*7U'DGMITT$V
M;-%O)O(:K1B)R<9XJ+5>I[/&$*_O2W\9(A"VI1Q\83R4OMMAH)*8GV+;N9*W
M&OB4L525,J; OTM!TH=+M4[255HHYRXG.]*7[M,*)3F+(4?B@K8.R^O&>&O_
MYF/*$KSKE<8^; ](]\$5RPED>@XX,)UI"3SFM<HXVZ9 ^G%U(D4NL61^C-C?
M:M]SBM18V0?R1>06#/ZZ@N">1_X%/SFZ+5 T3[IDD#;85:?(5]6-VS_HT<^.
M6 XNQ D0#Y#5'?7F*]JE)_(73!.6"[A=-)[KQRXJ>#3YBGE@D?&$@LYS;>U#
M\^.P^V9,+T>'0O,$4[KS.CIG?XZ72O43]=!>>2'2144WP]:>'!:$.@]ZM6](
MRJO6A]&$)^_SR'W;Z<S5K,^]N^H7<N#S$UGR#SNU9M_]CW?\^$/O=GT%#A>#
M>36&]::X2_?I^3B[.1@3F/T\/3]?Z9RY0SIN: P/POB@D]7\Q5L_$AYGVC"(
MV1L 3@DO#=+OHT4ZI1MY#5R6O^56PT1S8] ,!?!A."RG1_Y$Z\\6Q4<4P&\7
M20IY9XE6WT>5*,!/%Q0 %[#;0NTM?9@?FV4M!+N>S*M" :SG%8D^ 25L9G5H
MG47ON-!7 HN63*^I2B$'.4BRU<49:N =YN_60SI(6\P6M11P[<_4OA2W[%@S
MK<O6[A3((!##S1;Z+E>RHX/0TUTN+\4!H1@YF4.-YWS7NC-:?\DEZC*LJO!K
M-[6,[5<WFDKNZ:>N?P4XYEHP>^J^-UH,;Y(&YR 0B!DY^NN]<]G8M&;1;J>>
MTATX/'6F$T=&*:?R^$P4%*Y&;;2K<UV=8@ZQ@AD7!:G4;1;.[X.R1P\D]+FW
MC4VZ*&TE:EF2[)RBQ/A*40 24U!M8@-9@_$WWC*@&Y_&<]-UVB7/](D#0NN4
MYMI&CZQ=S:NQ;["NJV'I= *<>Q#.$'WE!.'ID9/WO:H-1N.3)0M3C09L5PP\
MII2#$WWA)QZ1)[ZL)7*%PR<1*^4+E ;[[TB#%F:OUR:$SH]Z20,S\,3P7$J-
MXL3J2[6#"+EG?RVEM#[RT/_41?AF7(>NP-Z .3+TWNG@JR2^QTG\$W5EH39.
M 0.>FA_T1NAZT]IA!E$BM?D;]U:@*H62 ^".7DKBLKG 7TP+E;YR!'?X#UC]
MMI\R/'N(=0M-AU /?[LKEAG#V#"C:;RSILP7'P#U70Q:&AC("H0P.X;)*7:Y
M%U9^MNGK^^YH9FQKFXY=^[4Z2*)E>;1^B&-'WVZBMU?"7X?G:7#_";&[:8*T
M1(9GGA/>Z ML%$ ?!M[,4[**28FE&UR[H,AHTH&K3JK_Q,QTGT\.P?=?*$6H
MB#''D\MIQE!@/2UA'GMNEHHQ+9BM,TK3:2@[4F:T+UX5:Z"#8/-[><)9>+]^
MRZ=**TMO_NA)EQK]638+K.:=V1>%]LO0GFS[;-SH;(.$R+XVZB?T %HG]78G
M*]IO*9AKIZ(2U&$[,B<"$0#FM1NM1'"[PUI3[V-V-B<WJ:]C.HT,G.J-C[EB
M&L-$9*3[TH.*6[J\A5ZH65M\?51E3R.]FEY#.E#1QQ<'DJ5S%HH@.V75!WHV
M8LS3F&M^0PQ*X?[6D5B;<%"MJ*+%BQV4^4UUXI]28JT17@?3?*J<ULHF?4JV
MU4KZ8P'KTKF]X!R$5B:BZ90$*V8-+3(ZT)@45^TBIK=H-]5X!@KP,@B67UTQ
MKLBE=T(<\0Y\5B ?'^__*[^<ZU(S5FT H\OJA?X[=B:!1E^CHS<1PIQ>FN%F
MZUBL53OF%S^61+>5KM3/\KF(?(]PX*G*"CY@!1TBO!@<T:(WMM.TXV8GPF6_
MQN'0:L>T>9&]%)5XMD_2C_"71.$M=46Y(62$M,G#=F<X7+\P\R,*7TV[62?-
M/[[)VK;@D%FC-8/* 9UQ*S^G9X:-U+28V9Q?^<,<A-/E5[7V,Q.9@DVS:#]?
M3N0??'IM?F!%U*3DZSXD+2G)B?G<O:2V6.K#3S(L-GC)FS!HO1Z9H.*NF4*S
MC70/\\V'[VH" U-!(9_F#N4-: KIBM2H!AE[!65#M#S']<'#@JPX3$ E.1S
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M@7&XB-]R3'HJC9)^@>MP_\=L!.,Z&!<*=,=VW\5>_$VB[5[P>,OPV$XT%"@
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M5QTO5.QQNT*\*M5J5%T--4#65'$H =V4 F:DU^D8K_(25[$3*"P4C;WW7_W
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M[OKL$<"H?O;0LOJ7B,C;W/"5E_L3["YZ^C$X?O(5R+ZB(_^X::7^?1IH(]L
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MBK;BXZW(!Q@\(MZ!VSP"JO4'&JA5<[7&?\VQDGD5YL;X/Q-J'^77]3+.EWF
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MAI+ -.:H@6AV7IUO$;F\P;ZR.-#@[S:#:R:\]GA!H'HM7I]C&VU[QL</P[>
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MM3.N/6;6S!+7R%[.\%.#P..,4F9IQ@I OQ8B9LHV@OWQ^B@<Z". R,NR:%\
M;M!B;&U=8$AD6<X19P_IQIQ$I?-%$F80$\ZM<7EHPE!*/Y)UH_TJSFFX>%VA
M/O'92]-\M8E:7!I+F2, HNBT$MV'1,;<?XF8J;WZTOH*:L!X_*J!C]>207=\
M@6F>4[\#2L^])EV/0X72T6>3QL+D=D9G-3)TL<?6SG?T-?WE>+-YUJS^==.[
M$X[6')XN>^*RJLRZA0Y)O&+>@:O=,;.\$]+NJ.<5D<YIKV!$>M=:;"P"NO+B
M*=ME,Z*DWJ6J!",KW $(E;JT1P#@Z-[&HRZ\&9I_3?N^MG5RI2F![6M/([:)
MEE'WB[B&8"IM.;Q-5%?R"MJ3F8@[Y1POP3%G/8BV\L-88[-.?N.$U#!J4=!M
MZZ>3,?-(/,NEER>"$:^NFUN)Q_B5H!:O?NABP#FFIAFJ8]<CND_:F:C.<P:'
M*SI7Y_[XU(KYA)[B8UW?=HL8_%Q#4/9H<ULY6&B5N=2][JXDQ4*:#P0XD!E'
M"N_KNAC07^<4N[&>]0G<M*91)R:RQUBVF7ZHY0>2X(8?D@&1W]L?A2J7&.:5
M\]74Z<U>B0R=D+28KT8@G^E."MXG3PG6AR,/CP  T3R**&5&7NPSSER$7F(3
M-<K@;03I3[ZLS=FB5(5VNTP\7Y=RIO6$2MS-1T#P'=5,]+RTI\//I4'V+!(A
MOW9V%8#W^NB5K'!^WN!4$Q8'_]"E?.XUJ.?&-J+Z98GE)Z?@(8MDX4FV'+QN
M9'DI?(.+82B([%R9LCNQ\87%#6)S,PG9L'(>&-:/P;"-0169W8 ?E%R>LKH<
MYG$5Q#>_#TUC4 =95,8NF<:C^#59T,6,_7@$^(:.A'5KTU!<WZ^5-%GCJTU3
MKQ%\9Z?G$0F7<WV.\9[[^G=.;.VPX+U7ET;:E;(/4^XNB,1+K-Q")+*@0+)0
MY54:;8KCIY=J=D7I.BS6N7B.00@P&-9-C:)V+-/*$>JJ+$)D%F\"4 AO:Y>S
MKS_Q2W<0@X9<6V?M-P9W*[OVPFO#7D58>^/'$Z=VX77'#[!*B+V(E1C@WZ1Y
M"7DUNL;Q" @J<U;,.@Z_*55V(X"Y4H8?JAT\^YAA<RM+8EUX +]-ZY))V6DC
M\L:'GC!()W: CA,6\Y8R\GF)HQ#VA;$?4G&+2^<&1L2_G&\5NYFOS01[J93V
MY?;AY7STY+'U?W.-ZF/7ZZ-.%NE[T>NIK6*_BGBA.FY]OI_&,[+5BV9(ST*O
MK0$P(AY]_R;T!"$',> *7Z)L.MEL%C@FM:C..#C[?G78^2>)L:G<OE<!D6PU
M4L E?^^]YKK1IGGOW>>\9AMF0'7<6\&9" 0'9;DCV]9'=B(Q18O<;?Q J6A]
M,]U3%]G\QG45_>2M%1;?-W4#;76L:/OJ"LC<.O4I]_3/.]W<_?^GN2L/:BKK
M\@\!41'3S2:*!$1H$ 1$ 1&!X (*$1#"(@$36G9""&L$8@B("@*21AMIL2&
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M?]PMGA6$]IC CAG#4F4&ZLB1T09TL< LJ<1F)54"Z*MCTD&C;IVY*9*>E^;
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MO8 ]@JD>?J\NIAR=>#F%'L1H?VDI"S.Y\2\*2_]/&DCXZ1]02P,$%     @
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M,H-RM<W$QK>;>^"TN$$<'X:$?/ECNS%#\U3"[W$1K-3-50K9G^)L;<7 M<@
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M5#.-T-3+H)E^VD+*;I5A*=Q@V@98]MZ9R=_E\FVNDHGP%*]V-YSA.Q!N%HG
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M;B'1@YWFU(4W*6-6&Y8>3C:CU5YM ED0$N1YT*H*XB"QF/QMBHKM*_==O;G
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M7N^U6IB< U,':*8H?J)Q=Z2MXB=_1XZ^,$#< Q/L_UALY7-0]*[\(U,!V@3
MD^F&XXO#_)M_]#%\Y#OQ;WC&&3D?&*R*B0TUG$JFZ7N8'@:YPA"_/9>]!VBR
MI(:F:1$>R%%_:>SHX=P8T)LUYP?>5'ZBUG NIUFY5<E*0+41@]66IB'H4+M?
MTE'=[?HF?(K_#_NU5H;;$NR3 <%,[&C9BLE D4"EY*&AJ-<'*;&G856_?)]
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M_08XBQ/[T.E_D[F&O!'G[']'H^AP[,;3YY+JL<\PQHAW<+*OXI;GG0:3%!U
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MD,8O*U0.6GX))=^5@T7.W') #J?,D>NCH]"4/G?M\R'56O$#EQR!A>9/3*G
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M9CN$ R?__-\4!'^]5("U4^4-8T.),C+=Q_G0YEQYJMT-B84#LYYJ&CN.NY@
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MOX3CZ+IJQWX5_;@/1E!N2<7/%W_G'2YA#7$>S*;!?PV5]+C=OO#80WDR2B:
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MZZ;6\[H-[OBX-ANZK9VY]+7XF7XN.<-G1I4>7_4,'HRR';QF5GM>GFJ9,,%
M"<P%)1S%HM*D8 #R3!$'V7'H.DS@#K5(HCBLFU;6[@%*][87HP+A_#%*29(G
M\<"^Y1;\V-/S6H2.;;$>S3O6Q_D/_1MT<@!#7]V+8+(LQ[)PT$X^S<_Y0:-
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M4=S#B80?]EQ;5D=Y]%13B5_$*DQD$^1WA6[X].&U)%K[L;!>AZ))Y;[GM/1
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M/#("97Q-10DD_]]D3O%M>!96/LOV&*VP/K"K@K+OU,_-])0*=Z@VIPHW02(
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M7W=#+&>HROU :F_5!-%J>U_D&]^D-7[FN7LXZ*Z[@Z60.QRLW<L?(E2M[>2
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M36=KJ4@8&QYYX&8Y<UOP/R%[%XN]1U*%IS#879H]SGH_?*_KU&-BSBX-L!&
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MT^;R9K).$C\X17I237LNA9Y[>950/B7FHVA4EGD?%VYTM]/?F,G9O0.]KR2
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MED681!"4\;;%=FPU=C+^E!=. 0Y6*<!\@.7:L!;.F:#IL?!!&^/=1B71-M]
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M,/4W-:OL9G!# +T]O/P\KU(C>'%%_1,F2C]@W8UTS%[^?2<OV=K\WS*0*('
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M(5U* XGR/@2&6+TXM5>UO[Y+X[;),"\<1/$(QMDT DS@O<Z><G#_LE6E!4)
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M3F:>UI_Q3*HWX'QDHR^VX3ZUTB1IJRPH>"X_.]B1N,BQUH,+RJ*^-F#X[*3
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M*W>1$%D/^BDBFN!:BF#")^]B?#R>7T!/:WLUU%?]\.$[;R,%/(0W$D9?7"J
M#EC];@#E#/4-,4)#E[('PUL$7(^=[\F1^SW?5,\;$')VP0^R+B"FP)4N,T!8
M9&QA0#:O[Q_X1O>/U>'FP/DZ# 2D(LY1#^W2YHBV&U A,K2/^&X =R?/@D9-
M!6;VZ'PW3*#+UP+(N81NQKP"1K'4[)%D,>-.M QZ;+]3XVY2%5BYF?HBH_K]
M6E9#P#X9^-ON]G7#A=?XP.A"VIUGIG5CNX<*0BT@@=-&@L8GED7IF1#&T/\U
MS59$QH!#*AED('C48@Q\JSD\3XK,W\1BKAM9O-L%E% 'T_(("SF\!KY:[DD_
M^];5+XV>1AI'6<J8^)-K,74R)Z>&*W?*D[36[6[,6@'RM87FZZ9$06(<16I@
M?%8^Z!2?'25.$JBCUD@Z^?()DUTZQ&DJA)[ 8[?BS%^SYB@XCN5G=Y >%)B)
MAXZJCI,7%>(/'#*/)7#W:=G5X>+HA:O@\16[8^J9<!<\6B,_*V:2H'-;M);5
M37CIGT#FK)Y+[AC1$W>_R*U#H?=P9:U\,C5)08=DD*T/7F(A^;Q^&?*^$\T1
MFNB^95DK8)T@2HL?T"'"#5B*98J*&0L^E^ZT(ADDGE:1_("O;AJ!P6W!*S2B
M<L@0PM3,UR- 8N^GB)K)BOKSM(!5JV!9!*'QMK).P;HTV<Y[C*F,ICRFG#:5
MJ<4#1L3JQ!A<YKDE"XO@F:8V@7/%_MS9>57$;AE(OL&UVFF)BJWBNJ,AQDBF
MQH'MV$<-'3@Q]$L[Y-![>QE\H3DX>I30IGH#(/J3!ZOV8AU("EIY:9?VN]Z>
M%OLGE^O/"OPZ(6 KFK4^?\N"ABU-5GXBOT2R'".7222HQ'8]3S8LDF N@;O7
MX3/I([2?V;%VMNTY]PB74QF_>3UAU:P:*$KU4HLJ]1!N+G1G>3F.(NFQK?OX
M$3-1!E8>I:>:0DXU;UY@\O)W<XEG+T3;X$,9<5_X]7RLT!JT_6F?1#AVK0PK
MM^2JIE1;#-8U2RMHJ2?:/=I Y!%]\!"6UZI-,$V')@ZWY(Y4/#PSZ!R??.^P
M>MY5W(#[E&]3Y_'C5)L74J_4N4.\'H*Q^E.63@2*>CB&:$W6UB.L8GIL4-E5
M[K5MIC+U-083KR7G&3,J-<C34?HY0NJ?J@13FF_*<)<.-[S(5TN96,NI[O]4
MH.I=+",-?P'CUB_E?=ZA;U&706S'S!@7+=MH*XS-+G3@^;";$<:MWK"IRJM@
MR?/N.;,UK<?PYX& &B*&CQ=(%!GJY[PG,9A&TX"QP%"D^!#;92UI):R!I.\Q
MGMF@ 41U')G2_R_Y._&^1AH<46FXPFQM< .(?#K^S]2VQDO@E)L/YUHM2" H
MKP5TP/EY.^TO"G"$)Z/:F_;A.Z5/616L++.PT'%>R.".&>'B6$S(YHK6 ^/,
MS5&+M;NZGZ/1BXPF_S17H+#C:!C6+Y>3I$3K<-Z7[.-_EG5GK*D*6 7D+"^,
MCV96X..&/QIJV.E73@EA395]*$U#9$#Z-JJWG&+D2F4%;35"%M+OT$;G^3:G
M]REII@E?CVM%Z8;(=QJ#JR+6G[VGA@RD1<K*W1IDPW81L6AQ/:?%6?2/G2M+
MB$<#)[L;.7B(4>1++I.\/")E^>BA[3&H8ABRN^_/HXZTH$+1Y7,(%8ID%+FS
MH8-Y[HSOO(=];#:.'6P4QY\E^V8&J*J5.X4W_FX4_$?F/O$'%P\9U<IXX 8U
MFR"T#[\V-1PB-^5B#!\C0RY&CCO&MQ3G#B7WR)P(:#G*X0]CP?'64>84NIZ=
M.GG4AA-J/Q%]Y%X1G;-N>N!YR8(MSX@0;FL3^[=T[G!B8WD?U2O_7# \&QP'
MG'ABCKB0.E?"P-PW;M^"?:6R,YE05/P^GCNBI-MA2RP=21W>GO//WL'_:,3"
M7W9_^4])VW]&_QN /UC@7YNOJ[$O4=ENR^YYP]0W +6T78C/OXH$0J3+\PCO
M*>2<<#X*]TO;8FV=O563W6YS^;VM]78;L-_OMW]1B^-94A&IX>/ZA#@2V+JA
ME.9W(-'.2L-!4F'!EI?7B)I,B4+RLQR2.<&4/#\A'FA.B)4-87; *D:-D7N=
M0I+"Z"3PKG3/>#J"*U+;G8>!).C$(.5R_/ZRO'Q938(>&1LY,Z3).'I5)("M
M2*=$\[O<PD9NM5?(C._>FS=;(I3-\=?B:U%'WEGTD.E]^<%&3JU&1(9[H4Y=
M4$Z("C5G9&?%Z%?51B:*P5P]><^UTZ_.63&1]7W(Z4.:C!.5E+_/4\!28THS
MV$P[7([5<SRM8Y7\)0:P$9?].&/VL?SPZ!>*F/RI$OC737M6$7.(<%M:B?OW
MQB7BGWESL_X=7IWUQB <^U!#Y^Z=$Z(C);0^8OH]36]+NACS?O5O??SB&2=I
M7]<]A)Y:[8T$Z,L[M>)ABN!5PS-*"VNE8NA=B5)*>R(W$NSI9P^[2I[T')"W
M3KUESK\!3- %5Q"T,E<<F4:U-8[4,1/SQ3@LSS5C>\NS;X98$U-+$/<SP]=#
M<22UB/QMSSID/'(4C=*_9YN:FFIRQKS:7]>I9H4K[T=\H_)XR\(*?^: 6?;B
M>K3RF2;\E7^R68M%7;R<^5&FC<!1E"J.V96Y9>#7U7INY?PA[KQ/.CQ1FP8L
M9T%C4PF3-DF"&-P-"W!2B1*VR57:5UG)XQ_U$E,->=2==).C]&%?69@\:L1=
M@M64DY?#JR5MNQK5MQ3RHK9U$-&L8?PA>[9++38I*]%;JLP/)X6MMQB-M8T9
M$ 7$W$LW@(?5I#CW6&;KJ3X]E/0:[:>7I(O-JW!>?(QXSZJ ,7-=\T-]$7BW
M!I/59;I<BE3 9*YYKA"K:^/KE_9'KR4(U9/^-\DBA?5!D_D?Q7C1MK+\%J[2
M/519T&;F>!\F1N^16JV>T53#'>NYW.=[*TNI2@Q=Z?+A_#FN5EG&H*KG.RKB
M ,/F4#0-]5,Z9V5^,R'SPP*;0;'>3\[U!FF!3/ MCT)XFBJ\1FID*8&E1YV\
M#U@=ZCB4K:&A F:":] $J':>\:U#/XI-D[_=:K"087.P2O+#(V=^F;NH1JLQ
M>S:(7BSAWCQHU2W^'(-LK%S=@*\X2>W-ESO7ZCXY@EX'.UJC;N8Y =7&B4Y"
M!--$M"&'RY "[&"2M>)=%AA89]V\##V16*_.RD,9"E@7VO=AA/$A++94=!Y4
M)Y&2%%#%\JT5=O'GB(H6U@8]3U)A354D;,\C+\@_(RZ0Z1DA/7(F2<AXX%I<
MH.GV0O?Q/;VC9!^FHC;I9;X+375&6G?W1EP5#H?)'=5GHJF.$*AT(AY-7@V6
MS _WTG#K$CRJ(4=7"X@TH1-3[52+TSQ;R<N#J*@I:%3RYK2:VC14Y?E=!0*:
M' KEX\(UCA4:2>8.[DX%]P(LHBWWW&CIO7,E'(JB?7*>L^CEO(NJX?VRS.UU
ML#\_<HZ,7KYN2-LT?*E.0^<!ZX2?XY/F70S>TO6R0L?_8HO?%NPU!278<8FR
MLOW,IV !VK<KWKPYU.);R[3:F'L?:YIMT.J?GD#I7:-]SV0:.E,.91$CDSEM
MWDSP%$%QER8N)I(@)]FZ4IWR/11^E>G'BP9QEESQ&>#4_/'LJ8=_C!_SFQ(:
MT\G->:+D ZQG6UGQ/=EV3HY=MF8S-56/2J.E:OQHCPO>#*$=\_WL$,&AYKO^
MR1"GU35HM#6D41O,[2VNQXY&4EB_5./R28._/%AHS)![5'Z.'K[4PA-P/A3>
M0!B;!2K1AC_J'7@@J2B;(KW%5 RHW&<:HE+0<BFF-QG(GENDL15N**"RP5YY
MF_^&-O0(5B,9.KG,+50GV3046JIO';3A^-(*KR\*6BP>%0YF^FR.UB6IB#95
M"94A/W/;>6IF,=4>+=7/5/(3^H['E&PL6]G#VC^M)]KFWCZ,&_XD3$Y\O"0P
M),_,,?R]M"235KK@H0>1YQ+Y<'26GZ7QAXHVXM)YJP;%)'<YZ0@+-4IU]_;/
MD5X:[VN_T3A/59),D82CY&%\E_?4"^,QO*2NGYU0MXZ8Q<96KS>G)D@^4LO%
MX?JTH\#;DJO^<'78*>H+_U(R0?BHY4YM #3T]8MKE\:*#@;M+4TA,F79><_H
MQ,A;YL-P0=F CP7:]EXPO0C67VV&/V@.8VR_M$W_DF_>DB**P?\2,9&9]-E<
MN]PKV*NZRG';8?Z#FD\(4(U3D&1O3-*PS6)UNM?&E?TCY-WG"LPY)]+TW&4,
MZ/0E4Q/E 337EIU.AC@_[&5_XB)4D_-@3V4JL@J=KTAE.O=[P5K!0Z45<Y!L
M3L$[A22NOH$&"CF3U+B\-[;85,ZA:9[K-+/UST$Y%D7UHM,?ERJ*[A?1#+>/
MG]9(S!KWT*O2NB.VZ085CG1Y!GO=4+#=+]1=JM_4,X $>CADA8KWXNA6\@@-
MRF/+NA2LY(8OTSYAJSZ<:5O\N)3B0F>K_:&KPZ@F/M@K6@UJ)KPRZ(%5-+ZM
MS3*6QFRFT29LR2.(O0PYIHR6ZEEZ"J<;^*X<SM_!)GPD>M)GX?3V :LB,(QU
MC.PANZ+?CG?R@9S#91I-SI,XVWO!&9T6.135L0^0TR(2[ C6<85 Q<L_G1*:
MA*ZHS6FHNFX%^5FU.P<DW\JS;@!1_:^6KPQ/B-9F+L9SO''A"#HGEQN YN8N
MXX<+S__C4@;_%9*L(R$)$F%9_;WX4.:]#P-AFP'W-']K0F\ XP/7;__OF.1@
MSR4">02=O(,]D&7UKX:%0,,^P97$;8_^-RRYL\Z]"'IH%.8M#;28A8/"O)J]
MCP[8--0.+/V_;$F"G_14VO%(F:$KAZFMJ RZZ!8)RQ(O)V#2^$G5N!K0[NO.
M$>_:/DAPP"PTP-P'_ZSZ6B 8\#!2%-;L)>10[)@/>[&I=[S)4PQ7) H/X\^3
M/FP&?E5Q!RO$GT2][^#O<W";ZI@YK90VITD=/=:?A>I/RV!>4TIX\&3LMQ_L
MZ75P>-CX,*IE_A1O-\EB!%F\F:BYKEB<'(FA4O;WU_LN\&9XIJ0U^C+$:.5M
MF?/^>"!Z1)Z'8LVGDPXK'-1!NJ/W5F2G'0R+*[I]KTD[: +&M+G@@-[7#FTR
M3+:=/ML=V0-+^/;B1[O+T)]X'W^JVD D[N33T&(=:?1PL&_6FQ7T=6H06HKE
M8"BG7NU?\(2T:^0OKP'&5;5$'D29[E]]9GNE<>+*$I&6]HTHK11=X.G:?/,J
MF4:@Z5G\PK3%8P5TWU=*/ZD5>M9[Q4CA9W(D_6(?#]U/2_=@O!\='>T*3E^:
MY#AK$M1-K\52R$4S9PYZ"[HM?>+-,@H(C=([=#,/ULFKM<.7XK4K'+HW$9;7
MS/!19$33;7=DW+#(F[]IZ&V#W92:<0 MUN*AG"U@MY]=N7=F]>W,L^RPD!U)
M?GPJ-94'+F4OSNR77D9>^<>I^8^/-1TJXFXIBY.]>V3J^XG(&%A[YDP@4"F]
MO+I4R!8W,Q4G(^9F/J 3ME%5&>\=2MGG?;ED^ "^='_,LHN=BDH"&5'>]ZI_
M%K_[+3O+P9I&:7BU$E4&!5^FBR^/O\'&9:1TB_G;CB^>CA1%A0L3@"-MK+FP
M27/Q[I)(F3-6\B*HQ$O=%B<<(7S.C1RCQ3/_P!OHBT"3^U7/L.%X<]>'ZB#[
M!M"!R7;;DDCP)523T9MZ6%G!R8N!L*(EL<&_&"A)K:&3]/)5JY702W$-O %L
M#P\3;\+'BH+0B[-#-D!,?1MOA^;U/Y@JN).?(U/%F'Z^HI=!0BBR]PB=)T95
M%'2(L(P>2@VEH#L?%R41?<G_>=>.R6/7HGSW6:(\8YTV/QK47,%*W=NMV-ZD
ME(G%"D4H8_@DCZAK^7P8T09+]E4[5O(!,86D..1"!R \3*[7WJ-QL6P&:3K6
MWP1"S8IBTFX ZLQZXUJ/$ =1$>NJC#TN\!+S<!SM(/%3>6:MJ12YC<Z>!E\!
M%?_#A? X1L"PEI%9M,]=ANWTOC8R7Q>1%SI%\X3[ZWE6S_ADIP@>A/)W^E8G
M$>X#EN<^Z3N.^*H5+M<R3-#WVDJ;U>#$1,"X);+P4Z6V=3@4!!P[E!,#R))]
MU8MI?PHA7E(99Z64'$:4L.'RY2W@RV-6'PPULF6LU%O1S38M)=&FXS+9MAVH
MKX>Z ,/XMKH+"./?8R\DKT/,?H O-M\OA0;H:BTXC9RT^F/C?61UO $(P<$Y
M/@2&_-[HZ]\2,*X3D>A$<O0!_"\QV_S$>&^A^^;%?^*3/!LEJI$&ONS,L*"4
MCR6[%+-US ^8LX=/+')$HY_#FYU:Q^*T"NZ0X6NI99&DQA,0;H+>[@7-%?*=
M$#8Y7G-'9%E1>'JP>I!OFP0, ^,\J@)"*G[R"1PD$XBA@H$EIEOCJKJ'V?X1
M.N-=<.5S=7*5\9WG#_%>;"K$1Y]^[&RQLH.K1L6[)?;RTP]#S<'7S<\JSNV4
M?O[,?2?@>*Y97#)PYME]9,7FR3^[(W6<%=6=:V*\FNPGBZ;Q?:L$-79[KJ':
MN$27Y[%@_Y@0;@U<@\UYL%T-<OIF).C5#R'GDVQ_)Q^\L5*9)UWK=]2P4[7;
M5JZ8"'>+W\K&-'?KVJ&#A$:O>-30,$@NQ@@/*WF)\Z9G1"1Q^7/X]$D'OCT5
MQJW(QOI<=3$FT;$8+5\TE.?_/>KU=+(Z"<TTW=9:Z$-AG?J/"CP2G]1==QV8
M&,W"^%Z9949-L#+=T8=WEZ@I"%2MZA58R=J1M!QT%7)(K/7"0&%:#9&2KGY,
M]9^H<%)KF@BD#[=&% :CS+L8@<)7&Z98Z?X7(\YS) [HZ'>YZ>$]EMJYXBF"
MDP\4^;LQRL8*'PF#2G2:E'#=$85YR_KX$PLE]#YB$(:B_U1MW.JH$7]J!K^#
MC?_0#(:Z_T7+K+_N:(3+!_F)L#7? "+CQJM+YN<R"LI:5YXB Z>^[OD?_10F
M"S/V A@1#EI:#HX^T6-S9X7[RW48959ECH+F[ZS*C5MB'SUSA ;>26PJZN[\
M#D7M5Z0_RNT/Y*<!ACUM:E%='TMS>1[[$Y$_&>72ZRH9CIIF6&)G6;O-A9*4
M*PC](GK?3][B?MI3(A,;X]Q,6PL7HW7B_D-ND8']5S3J;1>C=:\/*\.]QM[R
M5G3U%*/8ZZEOFH43N[F4RKSXX16[W?&M=M4 I^0+=T3^=ZI:]J!ND1.Q;=6X
MY!]"6)F'38DSDWV6"@$ZR?7%3HZK'\ZH\:+!3QKL-,1>WQ\J?+EN-L!/;K53
M;5-,JS-EF^T1^YB34>_;8->\H4[9S$%$9^W>:_V J)B=5T'M_(]9$/EA\E@%
M00F<$ YWYK1M^1N L)7UAWA&V0#84,9R+EAV4C"9,R2@"G=$^5SYE5]6^+$R
MS!/ T'V[^&Z>EO^KM72^?D:<W,B,_AESB"PRK"-_P'JHY9<*Y<KYY)1H[59-
M67$#P$Q. 8U>>$&,15+_KY:MI6Z=\X?,LS> >G#<6_6_6BKIN-9?B6\ @2:\
M"*S_1"V_W806/#$0$3RM)\>@E/].?+@! 'G2=BFN3YP7Z"]"BF\ ;\$"2- "
M_ NT/+X%+5GG QBU@[=^P[W@Q]T4S[T=QUN;?60,61"&H ,M:6'X448<B=9/
MT'O:N@"C63APK!G%3]@:WH)W ^A*Q!B^@!XS/2S//GD P"!\P+<4#[E#&!PE
M)P%P\@5)#[<_/HK%'DQG3IT9_\ZYK?J*Q\0>'H[C(W& =_W25O&Z(6*->>5K
MW7=!C_,;0(DBK;VK/=819%51?!L8G"B"5TT;+<U?6MA@&&PN@EMU\62K,%3W
M,U;_^$-^+KD*RKO>E0K6DE4NB\BDGG3O8FF^YYU.HXAI?=,[>3LY-1H6UL&(
M$L_KI (M=WJ)<!)M[]/SBGGHOCJIMXZ#KWTU6.<83(XIL5H0<^V!.QH:'9Z7
MIA&=VY!9(PQ\>1"4M&0TQKGS[ ; .CR7 \)[^Z:15T1LW\U+,\J=3P;YO,DK
M_%*^G"^U? S3_M'>.L<<H"!RR)2LKNY1HDAU  H-#,^VL:72@%!UWG5N#,IS
M7(I5PW^==5P@]"9C=M)Z&!2O;1CIJ(_W-0*[EV5:?Z:4!O#@7O&.FTGB0'*A
MTS'?%>?7QKC=##+JJ1<!W=PC"(,:><'VG\\+[T:I8DM1Q&T?:.E\H3M;5+=7
M8NYI$8@XB].]PCLB*K8\3!FQ8&"F23Y[<%E35*F@F#!S.3X0=S3>9@.VF3V&
M)6SN&8J-I>#&%M^.DM?_BS4!1A+"AF^?\)=)AXBV%-GX,)@4_*L!4N+]O="!
MCS#1D2S?$0J.5Q1:2JF_ SLJ,(IR?(<"KQ$W.UYJC S/@B3UTN+BK2M.'JVC
MIN*Z$Q?/1(UBV?C+,>ZI=KKQ2.=Y\'=3JKY\Z2 PTB.3Y3Y4\-CI9QO-=0V!
M5*?EP-NO:GG^4PV[>QF;^4<O\Q?"[W*9Y3&Y.8^%I>PSSL G)S\2=Y,[:S[
M#Z\AL^!K(S+Q$]2P3:E.'\N"+#IO*WN(DL- *;)Y(I^R7Q]&=<CW!]^E%5.W
M_/P.&T(KAD=>X"]B8#78R]P13W2*?1V;!WTGE%]0]XZOP&*(H\6/IH_7$KVX
M(P@9L-/ALIH"1$^M$Q/NQI["QK*.POO!N-;:BY(1D:UQRJEP=D2&U3)MO\Y
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M*8&1EV1K@21"R)G/(UMUPKZ9L%G*2A83ZSC-_P9P*" #0U1=9S9--=,O>-P
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MU4QUS6V;3'V)\$WF07&D9R*M.H%)+#LGV5%92;H<[:V]XSE:87YHX2VC$J3
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MUN!JXPRO4;1OS8BWRBC+VGY+PAV<AG 4M$U1BL#]PRW=5DQ=H;QG')SZ^DY
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MG-^9F7/NS'PS]Z_[K76*]3;=[]YOK=I[5SW[V;NJ^W'Z<1EX(2,A+0' P,
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MMJ.A/6P$T?L9& %$"8:^"@R8C^(C']GQ PH;9#/>F_<V>&7-(I,M(QEH(93
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M8U?HN0%OCZ!R@C-IIQEE\J=SCE[KE83UT#(7Y^7Q;ZII@6%F@M>+R4N*]YU
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M72B+;(A!JL5U()YS[S*,U!(,*'\=_904*YQUOZ&;_=5O_/"_Z"XC*2YCAKI
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M_Q^U]:.SOQ]D_-TP;[+):DS11MKT4AW9#[E@$UYB@^>1C*KO?>-UF4(,%1$
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MV2(;/O$'-+Y[0_!K:IA%]&R(R,+>QB>75( DW&Q@\ IMZ0:&GGG)>@^N*T$
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M"N]H(([-+PJ^YGV]=D7E4FG)Y@(>9D4VB]M7/BT<P+OC":IE3=,E%<0^+:C
MCY0]OCV/IJK6-BVGC,J1G_RQH2W=9^I?RE=2%M.W4#R@ZT&K&3^8/-B2P*/D
M5 TSW=NJLI(LO+9X6C 5M.9RJ6G8)/Y=&@I%XJ*A;S03>EKPAWH4E]M:Z WO
M3.;Z_2TJALO6NHKTIA/_#I!3X6@B$%1%QGE'7.&5,95/R@U.5<?A),?]T">H
M:\.<&[I0PJLU77HVK4K>1QVF\",1^QV/9*KB%'E-D/]R@@M1KO$;55@% >L(
M>)V^I*)N4'[T]3ET[ J%)]/6A7^[R:P? 5@C.?U;V;NLH"22<#"#9ED$K 9A
M>/A$;#>"(\JNQV )]_$!RDNN"E%O0%])I]9K)EIZE(YEZ=51?^+UXV\4\=%8
M#UPD4"([XH]\HHCZAO;!N]?6,Z-V&@'0,VD%JAS_$82Z>+:S$O)+9AJF78D\
MSY\3H([,[$>V$%>MA%E"E[;F.#63[QM'&(V,JTOAKLV>OHTX]4ZM#N7SEYOL
M,]\W\VW/L5:$EA[L24IXE&?*'4I@[.<BAC^Q.=>_%V%'A(3P[][K)J/'B)8.
MY]ET4+?-9,N9Z:E(<)S@'=5RZ3E$V,51OYI5-S,BC@Z,?"U>1BFX1+OQZIQ>
M66)FL^*I.ZU<0$6&0XU$T92FS4TO)U%65D"U'@\KRADW!SUFZ;&GHB!/?":W
M:(>JL6S]BD=#,7Z"Z<O5.R$)<[7A']]W!CW_P<6WRIJ_;WT6U:VJN1[XYH#[
M2:<K^VX( '<W?&0U@Y[]0O)\])*"^QSEKZ^2\Y"UW_[$HF5?'CZ^>ZFU&'Y!
M %VN'F<9B_"91I=%1O%F1K"M!Q_1HUFYWK9P1!C&L9\3[A?6T7T'<CG-C^8.
M;_^:8ZNR3#:4I<# RG(!L,LR-@&4GG/ 9L4^WUZ;A?/F3C!@=/?^&_ST&JX-
MU: :[PGN%,QI&L^(BNWC_KM>HJ%2L@FU35!;_/Q2GHL O07EJBP&IBBA2-(>
MLBPM93=0$E@DL1_V$,H<F,^WGRS88E9"3WS0RU6Z".4\!]?YJPJ-$$_X&6P.
M:\C)#WP0M>["65)6I"8HR2$0Z=EGP4DJ6$_$U4]=P4  HOZT7;4C +M2FBTV
M6IC ,_9$> /PZ:U9;>E6H\W_<PU^(^2CH32_"!^3IHA=*V582URF9+(Y6^-%
M0MG+9?&"RM)-8R?W37!;T&]Z"/5,A7N4# I5PV%XZ,&7MN\<BIFF 12PQ,D*
M7!$+KPX"6#Y=-WAT,Q!?V^[GQ ?\&Q;)[B(L[TD^4U!U]3<6<=5(<E[/>-88
M-.5N8]Z^O^^Y'NF,@[T256Z&IC*&;C,0 ,D%GO<C:#P2R4JYB4-A]L^+AG"Y
M+IP:-=1V.,>WNF!/8XD[AT @ <?=?K6_+&7T6B+:>K#H:4H#M;<LY"A%]$O,
MG>W"0-4*<_<5Q7:ZBX6-%8H-Z?JR^'99;]GA6^13SA*.+^2B>'S+W!L%.QHQ
M)JFB&J6;7W5IS6%D89FN@Z>:<]6WL5DC42S.E1?PU0$$H!J\#34=$YQ8JIB/
MR+UZI/=I:CK_FM-4^PXGJB$:WP$=0Z!LB5;),._#!,3X ;NIS!_B6Z="Z9>Q
M2H_T?/)L -;<[!00WWSCS*C3S<-VR X-0G<'V$R:T_&^?_-\>?O98:H6)-B^
M/2D+ B ^8W$E,*E0Y7.8J4R#K?T8$J/,H_GN&3)8>;.ZE;=0AD]=,P./>Q<-
M@CP99H'Q=E/M_]H-(0Y][*7"'B O]]\:GVMF=KJ10\[$!,,8A>V2(^MZ#&';
MKVWBC[2KZP(F#^XSZLF C#,OK CXT!H'^L:?UQ4ISHO)1ZT$QS/#F(2)@5<S
M=;U**<Q*<=58'<!C12;G54WNS]4M32;JG_*6A/NHD'65 0A 1JWW!I_+5_AG
MTQCZZBZT4'L"^-^./JN6!CB;V-'/(;RW!M<G6I[DF:G2$8,V&O7<^'\$BG[,
M:3K]U'!XLX8 ]&8X:.J=,-87 O,VD^ .PRC;AB-_O)!69Z"Y'T.\ZJE7LM^6
MUZ@[+1.)J<X.W+&%#KL2_=,66(+MY'WQX^Q-UU->8^RC&;[6DGH:-V9?GE:@
MBG7CMS/XB/E2H@(7!3^(0#L7_J.IY;R1@*@,B'P%?7UF<=SSI7CI[R7(!')6
M6J0W<:6*)Y&CLJVUJ7>U)\M-3!L8KA>'D4Q0M).,)F3N'+(M/#!],A7==R\4
M>:!Z EW- =YF[J.W9IH]WY9Y<X5F+L%%KGV!6QED@_LWKFZ*M+@+IYRZH<RA
ME>;L&EJDAJ;N-FEAB4//P" $ G8OR^YI[ 0H.YP_F:&N<SEM-5PCA^S] 5JJ
M'4E<E4RWB&3SK7:5A K?@R/^"TX6+S"X62CL@1W^4PBJ-M</U;L149N";'YP
M00 T@,_$A@W<=QQ27PCIISN!-X#@/B:_>3=PGLDW"^6BN1[U;*W&]N^R@3"-
M]*@EI1(WZN0 ,=)X0Y@,Q;%G;<%#PX>7C=3R"JO"5OB%]V$^HYP?HSAS&_Z(
MQ_WU0E90)<QHP:UD*KJ@@*]G9*IM,5[QI(OJ$8J_]/59[2P8PUQG\RNFS.8Q
M_K6O=),1M#3E_IT71@=,7LSBXV\HI;5Z[%UM:*1^T3\JFQVQ<UDLUTV9.!CK
MVBVC;G.WU2??]U!+]_DN%TPT[YCKA^7_#,H<\1\//M(?N]94G.7EXN4L_?&/
MJQ#TM;.+#W*-?92]1S4H.-[$ER]^(\__%[AN92?[J7?@E<V6XI80YE7YTP:\
M/U>8EB7_J)MCM.\VM>WND4?>C6A2+9%4Y=IGN'C8^L4G_0=EDO5&QK)R_[+U
M+YT!*-Q,Q[)0>[51WZ=RB[<2P@HBGV*X^%"*CAF@FS\I_"1\>YW)=TVH+01S
M7=;7;?#4%$21S#<?P)U"6Y]>0R1GV6?&*Q>J:$F^]:9O!5MS_+U>RLY;CJHX
MIA?Z:(SL7WPAWE%WQ,DV7H/1]C7VPTX#9WY+&BTPF97!=[;P<:_'5/CO!.^D
MIMZ7W6!F7+$15?].H4H779L^B.GTF7!T1^%@)?')IY?TKRC,&Z(GG7XM@S 1
M $VGSH]BH6#W*H_^9 .]AA(?S-/,O1[6;^']48QK"R)TD*R2ER0ACO7::YA/
M[T3%PR68EX3=#&P++MCJ^MC7_/1?*!LU$6^7SFDM[][8K,XMU7!@ :,W.NO'
M(@20Q\*4]$E_+9%R]-W89/9/JMM9BWIT1N[]^+%/.#/4<Y<I&<Y0^\=0DX,S
MY.^-F:WG'M\&Z!0HN9VL29)CK^] J:KRRX?;A\\D**P49;""ZY6UB,.X]OQM
M!FN@1K1%K=(+W6GQ=9UY2\#!T:>=63X3=K8/*1$,5R4V/4?@$]:2%KHKZ%<=
MIA^_V=_V&_ 1B*_%79/[2A$[Q!J>A;#^X7/!R"S$_?.ZYB&7_<:4^\[B46A9
M!M\MQ#(K3SIWWVX.5IN!U^[P4%80;W#]R8>_%MTZ@1=U?V*DMAQ3N-OP0DJ.
M@&]E+C,1?JL7F8,IF3XXG]9MC6W]VL+DGGY8B/E,;0'L_R? 8;VI69WS\\]O
MG)=9(A5V4GI4?2+M $JKA=V<L) HS3Z4N_>>5,E4)53?*.A \^M0$0(NB12Y
MO4KA1MMBOA'02$4@7(T>TL2BL51_D%;]TD,"=E%<91H=4>598XQG?H!19)II
M2P720 VOK4 >(-;;ERACNPKJ$THINX?]?C)NN,,8N!J*O=&BN*>"0(47>@8.
M[!& 4UPY#3W38U<;.1)YH4?%,GZ%6NZTP-(+8&D27(F@#:9L=Q7=UMNP>D0+
M:A.[]LM<S1$XKZY\T+V!/5VO;DA<Y]X@ &WA<+8^!, 8= /;$;OV10#<X?8U
M),ES'L6@Z[:3#4@XIR;U31Y00MJFS2KVX1E>T4SI _M$TWU@C0MH60@ 7P'P
M]!,DJ2 T#0$8<D( O#^Q]83+RSTJ?9K>)-FMPG1KG L6.* PVO>3/P(?$=QS
MW,Z2-4TZ%26JD^R==VM,</M:AL]0/7+!E= 3Y$AO[\/ #*[K$.>0%HS&Z$@.
M\K'Q0?_AGE3IC4]@^QD*:W#=Y,\ V1;")\7U7*H5N?-&;4.")Q%B[U%KUX@H
M8CRECC)39T)JNB[<@P]S>*^* X&':;,LQ<8E-+J^Z-QA=O+K\BF<U)+C8X>_
M+JBGRS<P=0K6%MCW6 N>-+2#"4"'O@K/*'D)YD!2@_4Q11DEA"=V(N\,K0];
M('O^FQD]MI0X:&O=[F;SWAK7 \=MK&8J_R1K>'5)P_1C]8HF5\RZ$[/X3B.;
MR :4.J+DCSU&KQT5G05(\L_T"7BB]TV*+MI[E!>*#H;4_G)+&?1Z,F.D]\BM
M3<GF-0VIYHFVZ#ZK2R+[)X?<3F3A4NIA\^SQ.=]GU%2Y8FV&9X7M350<K@7.
M(^U&Y"]8/*(NW'36E&AS)$B.:\/X"^J9%EU#K5WKGUC)GY8<RLS<I.A9A\^K
M8T95&Y^GT:BI?,W,=\Q7T[3OURQ$$R@LP!H8WL^. 10O?%"?8-R! )@$@_)4
M?Z+\94W:;ZZ@91X4%PM@YXOFJ-^V4[(U%R-R<?YUQ]?^0^^9GUET?2,&R9TH
M=?F!6IRLS/WA ?$JZ55=>-/O;@;:^;NFI@8YIG$)%D6="-5D^=,_T%WB4]5]
MKDDK)))@;?U@0C4116&*Y7G1)EO08BZ!9]">#*O1>]E !Y6UPY0>?)OS];"J
M_+7-5>&Q^4=+U41^WY2]U[E,6RE?#M]XZC6#TI69&2+*WVN&L;0?J*KL*I;G
M<"Z&XZY\U_6?R_"UL$J=/H4G&Y%T\H:)!X.98F059BO*O%\X_)S_Y$KLZ?!Z
M.J^EJS 9=QC"[.98TF8=SH9V?LPYS(Y-]"K,5[5T+P9#[^?\1BF#*Q9\H"3"
MO_=OPRM[G<?])%';P6\&8=9$N4%NP*VKG1:4"1.U32,;QTC#^;ACXXYVJ^LH
M!.!M"=Z]W_5?YM9OCB?D2/P1(+^'RVS.=>=LKJ5^%,V#"TPE_HV\=P_Q<\V$
M7-]1#UDNP7Q]6?O<"HVQ(6;]>S5''C]\"#I"-(R0LTA_WY0EH-7$BXISG6B9
MH)-)@44Q.M3]J-\17"+?*95\T77C4*D/?&6 'T$!'"\1GS*S@T&]Y&<R G_#
MC(@/HE7J\:Q>_-577#"L?[? .-,%7*.JPTRT3ENOD[GOOJ!^*W ^0MS+(A4R
M_F<RB&?25_4AI&Z62/UN5HG[9D(][:+ 0M?*61C2/:-]_Q=R25DVVG"""ND'
M__NOWIJ$S?]G8<3@3,ZJ\3-*GRZN'S_Q#JS%_,5O=>;GJ?20YE3&.V@W!<?=
M [UG0!T]B;C:E@]XUZ>V::*QL#75H/1=G.NFZ/5&?SO5QY6J#1]YV_F^F1HR
M;U$.:]!GU5H<>65JK.,XYL>C9:\2V:V^]V*6'BQ2.X=^016-^$O.Q:?M8:OL
M=T1%[>M^BVJ^$N:J]2&T^AJ8_<I*AI4"^&2\[[FH8Q& F5(42Y$DHB_QLC=+
M8_=I 18!HM&1IS3MN.%20[J)R5.AT^91X@*SR 1YW -T>EC%A<=FD<LN#DQO
MS&G@)P*W,R'BY (5";^X8-3/UE"ER7')%":LWE(7^3/V9H*]DR5LAF\[$$O4
M6!FK<+^SKA1756GGL\M>6JS\,F[S%_3OUMRNBG0QH56N'P>;TA,[TT4G-4\]
M3OQ.O&(/=\]PJ),_Q7(]!I.?EZ>[*ZP]9*([QSR(-2%[U/@K5=Y,%E?<AQ%>
MAI,='W2T4M1/KU%DI]=C76*+>I["<Y90CSV_.#-BDCB;+G;?OU4/'7+F*$]@
MN0[BXKQ:PA GW52N%BQ.L^<R[>C)>/=LM_-N];I3;/:CN@K%CL<E*B(?UETP
M']\T+NRZX^VV,E;6)_MTN6IU"KJ^3B?$EIWTA*!V..<&B(8HT9)AEQ84DA="
MPP+D9')[ "_3Q5__QQY#DF^,7\@1S-'YJ*0!D"EFI^$DDY-KB9W^%TH*/XT?
MYP5ZI;LB/JY:(>WFSB:[O[_U7*@KSJ">TB7K')2]5'18-PD\@S05//L19TQ!
M^NS;V'7#6;;N2?-5STS].49H=\P-_U];Y(T#57 FA:69:&I:!.D*3*\B61W#
M5G]?XJ9HL]I XS.#WZE=]/,WADHY/_;7-3W8R17SE>Z8O=$:7"[Q88Z+N!.K
M%%VFJ@.11\,^!PA <5)VA@;".)H([99$OBWTZ_'=%F&_10T00T>^NY]L;<:R
M8*.'SB:A&)^[^8[025@"?<;JZR7C<\(SF=,+9A(LON1%VDJTR+::B5!6C0V*
MVY^)<7M)IITUBKZC<&16#^NAI^'[_JGH\:YTCG_1BC4:/WG:5=^QQ,R3"[P4
M.!X@(EO,8I!%,?-0#R. F6-%]L^PK2Z4\?8%;+^5-4 7 $)5&EO#R FP.4B+
MQ1&  S#)4L(YXVU7#D8@%\YA\X?*#P3U1ZDGRFY_0W]-?NYSO>C?-C%X$>%2
MKG%*68 R!_U4BURYG^)J[BWVWZ2UE9;-NG)'2O]5.J8:_4][]-K"*-;4*E<4
M(.AFH+@.9*^TV'/!>N 'ZOF .3;6?M&P'K.Y)J (=RBQ,"!I>BGR X_'^/Z%
MZL?[?G2]P&V;CDO</EJ/(I;B="[I<P%"94(_\'B"(>IK6]?$H,V&.XL;!HOT
M7(\]_HR5*\%MU1/&)(VTXHN*#)0K_A7?%H4+N)-QD)%-S-'H]-6]*\:3&8%T
M]7263QC)5@F0C$6 G#=#E7R;?AQYMC%[K(^8U$2S690LLA7SGVWX,J[08QDJ
M&23?!J,P8*H27VKOFW9;%_^@;(BS"'8"\%3N0Q) J,.71&_\J^ VG;BKO.FI
MX\CU=R<R2AFJ @9,X8V@PXBNIXU[A3]%6LXK6N3 ;S]VD"O@!5,;$Z7DK..5
MP7$[7B.3Y52QV,?*"G4F&>0!"[A2]J1>;A@%4Q-":#F].4GQ$H:\F>>VTO0]
M9#)!.9_J-!OV$(#9HE)?BDKUV%9!-!Y7H\RI%-2JB)[V5^;JKRKQ'^EJ)UWD
MT(DKZ+MLK<4)BI9X,Q3>OHCD"4#6EO0N(U<OJEC,0WGQXY)X/:K6#7=Q<)FN
MT6+W!2BX/5^]V*6L5R"JX2X2;269"%+J$G2A_VL3PY<$>4Q>V#ILC&J;&9?X
M%]ZQQ"5IZ]SO\965LUR8 9F+S\%@L R2- '@"6440F<ZMS+XNY1GC/0'!B7
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MV>*Y5NM"8PB T#$]V89*N//7-,?2V_*\F1K5(S1@K>J;!E\2K:]WQFV!*PA
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M--B'3R+"ML&T6)[2^L-\R>B$J\ -^NJ2VM\KTE1_T-5_!ZB@D,#^E[?/^Q&
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M\#_O,X7;2/F/BF?K(.AR,?EMNTIR\#V2XJ'G;I%#(_973%-Y\36L+P:&AIR
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M ^T8>9E45G\S]32W'E +(6^1HY,XV>1[.69'"[701EV4%45DI42N]-8!GKI
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MV04%;T\?D/2NHVG\'#O0 \ &V&,B;]\KS-^\+2_'8REEC]^&?)00M1K,3ZS
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MU[<]K'Z-J[EZ;I9Q82 <#^$L6:[R+N],:>9S.OWGGKD*=&L@X0F[8/X-0SQ
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MG!@#,YAL&$@A Q6D]Q"C$[(1TS@!7<P$Z0J#@D]E)!G$1 PY)T40O'LO/1\
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MMEY+:*NF3#-9E;\A;%5IO4%3B$@"O_L9X1@])0%RF]M<%QG+P5Q^1@V[N2Q
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MI:JSYSS#*5>K*,H)-'4JTT]EZDP0&DS1QB]96]9E^86!XP@\HV#GH04P1W/
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ME4=5T@?&SV]PAO?ZM%,*?ZTL+%^(4"\>)#H7BGQ8;M)FGMWV!1+]&,JU(?$
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M=.KL[Z-.)K*]AG&&L%.I1GDTWXU[];-=)G]1,[MIPEZX<8!0D' :U6ZSO/?
M_<0\[BKD^+G646[$7E%1/.H89470I0(ZF;;X-)D2EGV/RMT6TI1)*>=5Q>J^
M7'M\-98)RN)AK@;+)]/G+I)8=K8'ZA]NB6(ZR7@G+0RNO)F_!; TV5LE?(P!
M,0706><N<2%L ]7PCE$[;R!!FT=CIAL4W*2:3%)WG8NWU4*K([=3<I^%U*"R
M,E!!%]8.9U4BP_@+OPWSAIF!RH#E_7 W$A3"&]YW=@C;#FJD>2X1#X V,D"R
MVK%A=4W"Q37!=\503OQ.,\Z1J+ 4VV%4$NA,S[&Q:G6HHOO]4YG35P[C:]7.
M]+D5-?(S>YCK,TAC6R4L(%PSYN,@O6?QH;?\#M[5"!6;IT*M39YL;DI>C%=I
MBD<0/\-)ATRL>HW5,$(ENQ6(D#RJI9AM*GG%53!&.>Z5O\HH"]<(\6#$U'.-
M)VWS?N("T :!?^OA,D5\L.ZXGJCLJ_L\\DCA&5J*LD($H\*KI_\^AOZ_-"']
MN[C%AQR>B4CTCP]WY?[<]^9#\^LNK7]-I<)702V8W.:)9Y#G>J+FWD 1#YP$
M=BF<<FK&J[9UN7[[<;YMW4!E1_3GTI-@4IEW%8WL]\.5K=\M;ZQ0@0C0)?*)
M<R:X"2 3]C/?#9>0J,#MR/ZIO3F81)%;M^;#$Y6:_'G?MVEY.&A*H"=(B#W?
MW*VY.'^^RQQYD,BQLV.OO+K-MPSCU3"A,!\_X7 ^L:!JQ2VQUFM+)U<O*=$*
M:]D&-X.YK"""XA7)#^%48&ZTSV#$/%( 4GHZ)O&Q<]#9(9Z'5\4X-W=<<43P
MACX#&DD(.0DXUWI%F+7M 5!)'F11&??E8WR[J;HL0^3!+-N.IT^I!8]JT)5N
MLKKLC-Q+N74(&^NELV-/%?7,;)\[Z>Y<Z[1MR<373.0)^U:K=#MO <"Q)RKL
MM1Y1RX+U/2*T0-.4EP?TK)%X=9&6QU/B=4#RY^FBB\#Y0=W@])>>O@;3> =,
M.>K4VM_5YQD:'@ 0/RJ%3<?;.X]%.3TE13%32VLSYH\U8$%'G0R:5UB8[S#8
M7Y$+S6_5S WO_<R5RFXW3I";6+KL0Y,18.I]#'!&J#A#:=*2OJI:;E)L7UJ]
MM5J:TW *JDZ)BX);E2<$FZAA$4REE155935:[H(FEBN*DA' QYG"+B0J$D<'
M(2\NY],DQN=.G0XKN;\3<NXV$ X!7!\ ^P@/ )IVN9N[X)NIS2[O:YJ;RWMW
M5EA0U?3BK*89ENOSZK*%]O<>=9D8=>=MT*^VELB+#?,+;20CM1T25"BJ9,M'
M)DB=,-*VHYTI.0R=-U#^>5VV]I9/YC4,F_7(#!4$.YWZA;,N(!@\:/O\$[MX
M6GVB<MO )<#HA]WG];C6T^=7$P:YI'+%[B]%B$>*-Z2^C3IL98?[4V<7,#&0
M/J:P,=OCX8F_Q-46-7^D]$,TZ6T8DU1$\N>U\\-7)*QMEJK"<BO98>:6Z(W5
M',)9Q^W)*.?\?>1+E+%IBE(ESIU)KUT*5U$_<^DC<+B\:Z\3>B*T;@CRQP,%
MNJU7A6<G)%]HJ7\XU>ZCBR/0V7,K[U$Z?#VK^6)WJ;B(R6&W?!/;9Z\YL#ZJ
M%>HCXC@JM@EN1("V8)NQ(PM8!9.%6J:VU,N?1 M+S=D?B#F(,&*:']VN!']>
MXB<;D(SN-J\@.F @ZQ1LX>Z9 %_$?#*;.IFOJJ1]8K\A;D"L)VPG0#(>/;<D
MJ& 6^;9Z1:@<ZQ46"WN80[>@/&KDU7BGIEZ$D-IR,7F'L^V.DEA^]GU'JUU9
M9R)-^9YMJG#Y@K$:%.V.>^J<_^6=1$''QV)U*BB4_YE2YV,, %^'8R_)*AT!
M;1.JW.C9$(TDUZ+ V*"DW0/ R-=@\7P.Q31A#C^JX%V,&9%*^,)GME);JVB\
M&QP,>J3V\-R01NLCE+7!:8& *8&0^'XIK.L:I^,PXY1X$.=-3 U):G-"EH?.
MD5%N]AMGE@KK3YSTI\Q63S2HO7;#[/T7;'7Z"S("Y?%>M0)LD(UE5A9QW ^K
MAS)-3W0VG5,O\@R'2Z"<28!3636]L4;^6U%9]R(],6.+.4"X80S?RT^/,(1]
M[PI 82(48QY21Q$[IQ+-X)-%5FA(%H3O&3]UFCY(X)QI"%-R@N[TT*&!Z4MY
MS6#J(FGY=K2 (OI322W:[SJ,G9J<AR;(]1;,.VH$PTAI9H#3%J3Y._Z*X[<2
M'<W4M4T3V>&K$4]8EEYU$"?["2+3-BE6%#N@$W6O6#%SA3YU'1<T!,]B!XEC
M/";<UN0"_/6VZU=2,EQ'%XAJW@>PFTF;Y/Z/T_K_$?T#3$-_.XTBB;W$>4#
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M>5W>LA8_U7,OI(  9%#<5#?\_/Y>(\S!3C*!0%MM3O8J_5I+G QY*1TN/X
M=(XA -C,'<!S0@2@SQU\G02U9*V\$TYPO?<*%Z\3[_WKVY_!AW,6$0 #VMN-
M.X8E\*KQM1'<#WS#R8D $,K V-)QP*-*" #3)@*P9M66G_4WV_[[L0=1[@A
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MCW0 7X>J#8KSTUS;M,B[4$=;*E^8GBUT5N^&-MT:9SH,1C^=H!W99Q98LL1
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MXO*:2XJT+4[JLQ;ZRS$,6QG7^798H9;7;\?D2[08HK]_8R7Q<EX/]X'TN G
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M/6*SJSB\0;Z-E8YA@O9\1>V)[&G_>._!J0B)F5&,W)[<15DF K#Z_AH$]T4
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MD\Q<U@"\<OEP;S0V6[$=K3XU%E$'W%OQ+TT<SGFWXU]$Y[->JW\Y$CTD,#[
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MCT(L*(*W#E:#2TMVUZH4K-D_<,4G.HMGN-UI'-IHME!FA;G]W%5G:-]AU.P
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MA&,_95YFM=KR98D\6:^^*^OZHXB>\.DI)RTF<85ZA:S,[$SZ&EH3P$,C;-T
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MWK]DA)PS$FS0CHD>K5PS$M)JC0^.*YL4.5A)%,*?LV]YVY?9RO"T<SHM%0G
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MERXECT613_W.N]/*D]*]<H-83;PF4(T<LWG;TJ]B/Q.MV$/:<;8EOA3DH&]
MKU+V*G[0DIN0J-P^ ,-V$DB>2+5",0>AORQPIVHXDY6U)Y;*]#VLG2!2%[F4
M)T($#ZXS'I[BT=\_UK7?1SVOM4A>%UI.,#(1R4]OHA&1+?>[D1EJD>K ,@BB
M%];DK'(^\\A+DO:6Q(^)\B@D<T:)RC5$J >Q? I4\ONUNE(V9+[1@F;L\4'*
M)D!\;V6C>6'CNIS#G(DQ,!+>=)N[!]RUP1G_"5J5A.(QKQR JYV/4F7=[:HS
M&GNVU'W,44V,FJZ\N*_C&%0Z?P!4K+5E3HE(0]XBW(@(R8D?!8'RS TI4;I_
MSK(O>'M#A:7KG.E^6=Q+WL0[262#'E3J;B74IKPN =T3X>'T3 L7L!V,SZ)U
MRZ,_;O^>V,YJ\AF(X1O6U<#K;ZNC-58[*</1>@R?3[*T@AED$I0KFZ<3%TCX
M?CA<*N_XN)_=%5\<U,7\V8X7J2](H+N]X>B2<N+O<.^C5LM7D(X8&1CCSF>R
M,Z;B4ALQH^Z6O6<^UD'E@ADJ0\(_B94E1RL4E6.:"'R(&J-2C6LVVZ0K\W)]
MG*J,35!6T(:M7"K6?VU IAFZ SJ[V-22; @E)N>7EJZZE:ECY;(8T/!%Z+GR
M:/ /Q._.<)#(*5I1,?SYRC:G8L[^0[O[*-U2T@[22)@YJP"E[S7S4?YBL-R(
M8O&V,8AP5RG]5 ET&??EMS#B>TTGPB;=KAWMT8LE+I2,SM;KP?N3!A1)1(@
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MWZ42[IC@I@.3"7*R%P-JB:0[T3>E(^Z*,@TV_K+*>IC KN&M7';T#D"_83!
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MB@K=>0LF.1KBS3*/C@>3U17TXA'V\?;;?5LUN"->5"NL2;Y<(.]%%GTJK\0
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M)W83>W:Q$QUPPJ_V13@/@ )K_?4G?I]<QBAYPD("Y;AU"VRC.9&:TBEG#@Z
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M%4Z'Q",;V*&8+7C\ P>]3_C4ABUZ0R%2*, Q5F5IAQW4M5YIP;RG>2E.GM7
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M=$GB5A$<_![7:JQZ4.!/LL S;IVE]Y"QR8)LG<)G6U;RDX5I6YN$A6J9;!N
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M-SQ=J),@GD*KJK(%R_ [ *XM#!4+J$/\H7OV#I]4O,O&-4[HM[Z.HR>%])Z
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M#6,M(".2X8BGV']DNBJV5C5S7HX/%?_A.M(<>?\O<Q%O8]W+Q[>0-BQE':*
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M0X[X3C*/H7OUZZ;@MV@26'V=E3?>W *:A$RZ3,MJ!A68&"U.%-2:JYA?T2@
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M77"/?;HL46Y-4NL=_QA#?CCPY(DIG[8I+7#OCR'R$' F@U)NX21B/Q4TPJ]
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M?L.O@<WXW9?<_V+B\A?R7Q?,2, @[.O-$-M6X;U>HJC<-1*0@.\'2$"A!Q+
MZ'.K!_R+EY :+T8"V%<#]KB;,G+O>Q;VV]'700*>U"%RC^#W&<>!H\_?2)7+
MX&UAN"6CA^Z)T2),]S*[V?R5^=\HO63;3A%,HE7@AEU]L?/L>XDWVO[*^A_4
M_Z#^!_4_J/]!_0_J_P/J%]^I6 :0@+\&TL3_?<2>).)0Z%8;+?.I/O=@E1@\
M14S8D"_J[Q_,?UT3.4EIT!W2FDG-]X(@9_X'4$L#!!0    ( .:(?E8<3[D)
M;/T  *!L 0 *    :6UA9V4T+FIP9^R\!70<2Y,N6+*8F=%"RP);S.P66BR+
MR18SM!@LM)AEH<7,S"R+;3&KQ<S,_'3GP=Q_YOXSL^_M[MES]E:?Z-/5&145
M49T9WQ>5E?T\^[P"8$B+2XD#4%!0@/[+"WB>!\0 !#@X>#A8!'AX>$1$!"04
M'%049&040BQL=!Q2(G(R4B(2$@IJ9CH*2D8J$I(W7/2,[UG8V=G)Z7@$N%GY
MF=G86?\P H6(B(B"C$* BDK ^IKD->O_Y>VY \!$>(4/ZP8-10F\PH2"QH1Z
M[@;( 0 *%NI?-N!_;%"OH&%@X> 1$)&07Q1J,8!74-#0KV"@86%A8%Y:/5_:
M 1A,6*S7+")PV(J?X2GM<%A]HC,1J$0K.W&5QDZHV;[8^R(BX>$3$!+1T-*]
MH7_+SL')Q<W#*_8!)"XA*26MK/))54U=0]/ T,C8Q-3,'.S@Z.3LXNKFY_\M
M(# H."0F]GM<?$)B4G)6=DYN7GY!85%5=4UM77U#8]//KNZ>WK[^@5_C$Y-3
MTS.S<Y#5M?6-S:WMG=V]T[/SB\NKZYO;NS_B@@*@H?[G]I=Q8;[$]0H&!AH&
M_H^XH%XY_Z& "0/[F@4.2T01_K,=-B6K#P*.:'1F92<B%9O2">X7^S$D/&KV
M59K3/T+[E\C^:X'Y_F]%]K\"^]>X(  *--3+CP>-"0@!UW=OLKR1_DH8AEID
MUG2L?W?77]4UA7;!?/3! !'V&JCRQ]$5<L0] XC.0>T[[^@>;P*?@:!27-JI
MP465U$C=K); )ZQC3*]17?G[4_1G %/B@6:)\AG(:$F_7B-_HDROC&JMD?]/
MU2(-**[&!-Q"SLAO9%I SX"(J]!QM] #B/PDP27TR??,:SG(ZR9$(,QO_L/E
M'D._URKS*?XC[,8ST([Q#)SB>/W467MWASSP#'Q]_0RLO;EB1;?"GBDH?]GQ
M;^[6N\"/?7H0>P:Z%?]-'-FS_0)_>_>W=W][]_\;[UCU"%PBN WMBJ7BE,3U
M_]7@YZP0!BJ%K) WP']=SLIQ]WC]=1DFOX0JMH:PF_[,46,.:6\2ZX GE2H*
M<TT-_M[X:>135HO,O;+RBV=UV<^ 3\Q+["I>YN9>%WB37B>L>D]O:Z[>-:;7
MZ41:_6>*D5_N __6^UOO;[V_]?Z_H2?HJ?5)DMIHJA9#- 9]GOKB&7!K_9EE
MN\F,O?5"*C,J_EW*C$Y2E&&#_41(G0*\;;\*CWQXTGH&EJ>> 2*@&J3Z-%;Y
M#*3_]KJ_:U^7^(=6I\\.&EG%7J:SS\#(9OOCH]YI]KUXWY,7TS-PO/<,A./]
M/]_NJA;:OF$[);0<^0R : Q4VT-RI#RT"ENLR[ZM=]'W"S5)]Y<U/+Q93^C^
M&?(FC^*?H4;9NO0)*"\[J]/%VD0C-]()CM/O5@U=MSAK"5D(=2>W[6"XDOP&
M[^!K0\D>9WS ]W$;Y8"3)6^.4CD+,XAD]C=$^X9^G@Z2)Z$XL\4;Z?'E[FFB
M+PMR7QK#DQ+7;3OH(@2*"V383^[VB;P[N+#A(D][A4ZW..!RGP&JI_!G0-OP
M&1C5S$^MS_0(9I*SGO\97^U2=2YIMH71B1"M;6 G1%=_+UY>[G=!6*8Y3OHY
M?#PFCW5'DJJ@QU3=:T!F\AG8G_+Z[F@A-W&!6+M?7*S*JM?%1@C-AAHF!0_=
ML+\O-> ;PK^M/IX[5DO/N*E_;_NIHW?%C6CGP@:FKV#'S)7]K(^_:(@HS*KO
M9#OB\6M<:A%'7Y"'W@8[$W2-+VE@C+<CW27'3@S('2XSO\>$*!0A.M[F!P'!
MSQ7W+T7V9LP;/^GK9T_[Q"/$)91*<@+@*W%V7L=LK7%3ZHQ+=N*XQ=@R%)_2
M!2[IX4N@T!B\])Q4]0AH+_R;)PYE]9.XZ6##^G!'DO06)!A]OUC5O"0T5*+]
M%1D8%LA(L55;M/-;H.5N59[:ZYO=75HZ<US!D!$+[!KW B^&N,A#N&,:9DN%
MS&RL@HQ?,1MNB$8]!DX$,+#>;GT9N#;+K'^*VP?)T2#[R&U$0&SGTV=I@,MB
MDSQ82//;0>]D.\"RUI/2?;\YZ3.FY"_I*$ A8V/#?6J@!=L(_)FF-[K0,S,*
M"R=.OV^"*K,X#5G2Z"0@F[3KNT]NM*'MU[W$&;JSW-HI#[[55-Y5]OOZIGCY
M1/K;8.[U% !6YGO9@5*891D8$AB847-2FU84\VM"3@6'&\**N'Y6YN*;#X/A
MB>HF8SZ2[4(LWQSR9B/!_*T-R2N1[;,AL36]=XIC-3J@DNZ)W^P:P7+( 4K2
M)J/1<FR>H#?,@6D'5LUUJ6T-:\E0=(#A3"5DP.LJT2 9F4%&]2,"='PL]V$8
MRE?'I!RQ_#F72/6ZP(&0@Z9$/ZB?W^$WR9+X?0XE:L_0C;9<_1CHN^CA1T->
M5;_Z)-6GC1:WT\;LI_!#XD-C36UB<<&]BJ6(J!:Y0P34,&_R_#UN;X*)E46.
MA'%E_MU(#1YL:R]?FBO[8Y[OE5N:@ YZ(#_;8S7.C!H^N4F-_VHZ26Q86@L
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M;.U*A?1)K=E@:.ZKQK-H];%R-+Q^Z !XH/,0+\JL0^AS8JJPK9HKLD+H@UX
M#OAG$O(GV/]UPI=^<_GCL>NA>)F!:!&UX/(% BNX_A<6EA8\ _VLQT\-[4^^
MYD/_ ,CLTRN_V15!% S_",N?:LEOX72>@1G\E\$OJY$_^NHOQCL\6Y$+E?R4
M(\_Q9G-KA-2O>/4DSI-,EU^QHVB7RD^XO4DO]E$EGNY"GX&@LMZ0,E=GNAB!
M"+Y_TY+][S4]SHY(H@_LED_*V$?N$,R%KB?U_IC%^_.>$[OB"//J %D?Z3.
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M C/>H;1:RW.-YJ^'@_9]E#@NLXZJROWLR?&->690H,L-.\EE^]?GDL_ 4<&
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ML#6LLFR]K_J(XHUO X5Y. (+7;Z@HVN;M5&,UOPTKG>4*38U8#8,;OA2/+#
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M=)(:<2)*"DI:GC=/.7(GF+FP=!];<\@,+9/]ZT<VYAE(<+V=[MS%5<$?_^*
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M%J=8Q!1GC_IB?Y2('?.C*\6/44W](413O;J9FG=&U<;%"+Z4G+PE#0^)NO/
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M/Q=OC )^DF#OOM8307)7E5!&BVG?"1;S12*YX*L$G)0*\-?OK(0]"'?VU8$
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M\:_XJ0KS7SYENFOI2['+,0:!@^!SV5(["#2_"4J@IWOOP:7&7Z( ><7@&Z^
M>]0W64L!@B068YV#)1RD.],5"*Y$^#L4\#K;6$4@'K<H1KENR!ZPH*VL5%-Z
M')A5B/^0B?*!SD5I&QRZ*A(FVV&2G52_LL<JFF^]B>=MF.APL(P..SB:S);I
M1(GO.'-D8CM037S4W/.JSP/)];X6^M,8):TGTC9PJO#=E^9>0[JJZ0X1Z.Y?
MVC.GMT="S&F;VEY=C;_OTU3->Z6-.?LJE6*\I";F2+([9ZZ=H+",IU->DA4K
M;_BDBJ.U/Z#E8X96OQ0X;#$R0DK*R\(2+(%Q,]<ZD69#B0@]05=!7H2<\3^
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M[*SV?F?9!9EY6/5?JOMG HC/-Q/NSG YX@T;TGW_-2CB0TR6D#!24/8]$6*
MM)>:@X3B!PI^08IO:E#]F]X"@7<?;@$*B,P S3E.BI Q94)_;F(N&-:DIBB?
MI\-7/!N/4/]U0JO;.[%(_&HE*#-EW9EP?%J-3X0=,+>D.2=4:VH[S,>D$>"
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M'^@+[.KXG#M%?,$Y^9[+.B#PQUS6FKF_-N!T<68E=PL2ML)E[GZ/O4(CSY5
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MB;,BX\U&^4FT 5N<C;3]NB$6?K7%5KI,@4S>KRT2P#5@:!<:.YJ_B *^MDC
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M:U^P4^6AC3)-%4VN(<9/YM8.)7_'FF^&'_&'588(36ENG+KPP>N4/,U*O9/
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MQ</V+7@O5<]\AP&YY_V\OWGF3.ZKR$=67] ,1K^5SE<_J>'%<.. ='[F>>3
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MC?!]A70::^@]2#=E.?D36/[A/SGV5=8ZTG[XMJ,%<3UE>Y[EYL'L\ #O00(
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MR-XO-YP,!0Q%8SAJBSS''W72?^^21( [ SY<%0_]\AB*DK?3(54=&>>'H-N
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M(?E('$+YH%Z[$#')+GHN:"M;S=GP=437=A:C%ZKREJ].9U-HR<QF@LIE0Y6
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MMSA=?8126>1^Q(XBFS_K_IQX'Y%-F[]PM/*K3'>H\B O<!UA7,G0]23[+^?
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M/?M=OPOIHLAWN)P3J:,#)K"5:U9S@PT.^\IB:3+N8;NPYRCP$O#^@T@W>?*
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MQ7B6:&O4>GPS*TGJCXM ><"DI*TU#=N A8[S/"G*VQ=[!#CEHT$)BY'7F7
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M:)O,Y-@"!V=4V2=6[5R2,#MU"!;JG.Z4LS_]:K7FR]W%VFHF;43CL<]+(3M
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M.9:O">$:I7<J;4(18!!@*'DU$2],=_^)3<,C3U<3FMEJTJJH/D3!+F%%<[9
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MENJ?.[_(GW,"_JV5E8G WXL*D,#DIX5+E!+J$MU#DH:"I7"MQ.DI7,%@M;R
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M@[Q+]J10^;>\T6/_G609R]>6-*'"1#^4G:PFSXHV1S$2S/I3;=NX,@*23KO
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M['*J,".$Z^R-MJ/.2JA@@VH25^_K(J:U7-C([S7GK(O3[/X+:/;WMR'XL/X
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M'D7JYQ"C]%@8W/-14)T44?#T.K#@>V[+%L-D@@X2R23(C.;<\2G0%O%9LN2
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MDQMV9.+#XI'7PB__#]Q!7]XP@[96EV"W7/< 7(G^I2OH3\@QU'M YT]-;M!
MM7K5(7L<9ZNJV3<%(>B=T3;.I4?,0 JIA3$R[P^P%AGCQ_J:=6-[DLL> X_/
M6C$-HD6=:7-E-VPEB1Z[4AU:7?/7M5<^?A'?G?/S0["%U> !<"W8F9?&F_<
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M[MDWV. 8XX]>HM?D\>Z7RSZJ\4I\=2;CDK8(T3*MY&&R]<2^<%$6YT-NL'O
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ML$G>P)//?:&?+/C'P"0U6D=,O).@O],8_L.CJC(GXDP29X_B2.58)8;R>B]
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M>H638I9\(+4>LABNZ&Q.T:!GCSD"EUKM7;LT9HH><'3Q<-/#^^2[W)?55*K
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M$B>)DL1R]=9)T =@@^D#*9]+OMJE:W5@74>3W9*SY6X:$T?"\.4PYP\,(^-
M5:.I(*4Q"W2Q]-5[H,8_.'1;XU)J[5+ F-FEWB:Y48;P9!G6X(W(U<E?]6\5
M%YZ\(,$Q"RH9E(V#..ZUQ )-J3RA<J8HI!G.R"2]5RS<'DYHF[P,%CD;<+Y#
M7G;V2A'<V EYCKTL0Z/7MGUM7A+\N5<J+M^3EJ/AL9YT'A"R/4W0 F_JC129
MI?]U'-D%-LUO+31 5L;W (Q2^FZB_-J.2<[BS.?X"8GH[#JK]G:"=K*+A9$3
M"$E%19K2Z]%TE) T,JY=^#?O!D#F; -49W,/>!Z!#EG_,+7=&2E'==/8KBZ1
MPXJRRJBDE1'H]> [%\JY6H#8U@LG* K9,=5\L.2BW-YLHM);$CIF20'FJ$$W
MEW61]1)=KO.3("_+I-IE1:C\>_,_N$5/Z2V4)7;-&1F+BG>_0J$0;UU)9WVD
MPJ=]Z"29-FA8**ORIHU<X%%&R\P7^$[LCLB,-? VA=[JX_<J7LV)@!^/X*]7
M0RC"?V<!_=ZE73Y>/:O%GQ-J5OIB)H2RE]:+B+Z&F[5>6"B6,G(:)__D*"M&
M;<%485SD\</-RLK5MJA\@L1FC#+#[BQ9<^C%'*UGL4X WK,9DV\:GJXA!8@:
M__3%B7/ BG9+!6_VVJ0T6@0+'*MW0@Y /HP(SXP%[>!T)GKWP-"'DHJ@VK$D
M1T?J#D9[&[(#7^.#>Z"+_[J-")0[;? 3X3(_ZZYU8M?_"B6$32YLTM4E52!0
M?8^VX.QX:W\[GW^ #^M5_W*BX'5A/_,%]N6^'N]GT'YDD, B[:%%#3[ILVO9
MN].BOJ;,=V8U&>&F*8<ZDVFVCN;+DYVV'YLVX2\F=V_5+-S;R0)83RYB%K^]
M6#K34!.HXZL*$KOC%G&HZJ8(,YBA-][>Z(T48^. @L@NK*NN!'ZU>G<T$D/N
M 87"F;H3PL'5H#&I3S!%;+*D+5>\[UUW2I^V6U+(H-VI(F6.?!I=LJ#W+&JV
M[AP'W5^'U*6,UR^*]_1U1CGO@5,Y4YE"09<S,;&_=V!HFO'?8Y]@XVV7N=)7
M!BJ2I>,V3=VQ_F88@7#5YQ"&+8N$[@Q<,J?;=ZDO_%DA;9O??A<_X7_8F5+^
M0_L[.N_6T1)PU@5(K@K)(/;UCS<['5P(A'=*DK^(_(IS+DQI3T!(,[V6J*)U
M-0D\>N^&/55QXJR4]T_[5<97>_L2:@I8KOKX<BM-YH=.]O_NKILEW ,^<>V4
MT0N!Y?-$/F)7<O? $[& 3H:%0JB;5H>43'E<'+RI;Q0F=O7Y[U%;8G;WK-_>
M%HXQ9K/+_%SLAOJJ=A5*7*@WE2XP$*XGL)E^_:!F)9(99]+O5COO$+O_#8[I
M=PZR]8-:C/*PFQ9NS;'/]!1N?T,!@&UXW .H%Y[89Q;?[ZK<".\!*92J0.&6
MSPG^;8-$6V9-^J(3/7P]BJ'E43=D9^&7_4[@9G>:B'EC[HXRX>\%9APJGU[:
M%M;2/MC;3N#(K!I.4' TLSO'F,4R8<+A(CC$-2Y2[*C?P5I30T.C$TEN%G7I
M0Q#_( V @;U80KF4?&(]>R$ZO%P7_:V29(8:8N4DKEB.X':D<E1L=:&JC+B_
M2;3D:EEF"5*O'?T!#GJM$"(O]0\?KVW$?[Y\?'34(=A.[(;>XJG'A0/5R9S^
MS5V,=DON4?3NE]E_P-L7,OYB\U&'V)GJ$G>XH);>@U_7YTY/-B$CVJ!#&)^O
MSNJ7W_Y_9(_&.MT(Z1YP14$\IL@MY9BX>[4Y"M\LS=JN*0=EM='X:+SR73K&
M[YM?$]7AX=#[@K>QX =XH?)ZO:5^(KRDC*KH,R/G5%8E)R)A\#_N>(9AA0O;
MCFLDK:TY6+UAYTZ,P='\7*=$2%Q/:I,ROG8&PG+7P>N9VY)83+8\==4T'9G3
MQ#E1.&)<R&CP"P+R<ZA77 T@.L4%<P4(;V&/*%!NDX[#BZ7LGFNJ2Z%].H &
M=%70P(5$F?G:)44 &V72YV,G34\W&;"RZ:M?Q!Z1Z^%*5KU0J 3T]YJI(8>3
M"59A-VIYSGHJ!^?3/J(M+EG<?J>]J(II]+G5<ZOA927PLM_:AS0O$5]SE1BV
M/9V9G>G&ZKLL9'[,NQZ"L.$ZA,*0[QQF<ZA?($8YM>DJ DLE%Y:@:JJ-%=$\
M^*9#0[HR,;X>9I_XL>8+WVDGC($"XB/XC,F&SB<0N+N.LN9V+XYB4E/7\0_W
MXQ5+T^AV>I=N@QR?/RLC$.-?9\=0+3V;\DT7&-1]V^3/^^C(V70W>8]UNPZ,
M5S_:=^CG)IX>D>@\S>(%S,4,BE%RI3TI;GS52S*0-SGA6O8D7S@7ID8-U3%^
MQHO0]24YEXH=E;.9I*Y8W%V)(OB,R70RFOIH1LP(,TN2ZN.OJ!A#AAJ B?IG
M7G<G)U*GR8+;<-X]8+S%/>;$8570GB^N5W4TNN+90BD'7=#U3DI)OAIE _GW
MYVMJ23/N3LGD/XPE-NL59JO_MD@^36&E=3%=^S+D^8CG*U*>J*M[X*,4-^QB
M1H=MS E9?&D>L;49R;(3)3IDQ;Y?RF3YIT"E.3%1=3;+YM"\EJ2)$<&17H3U
M7CSG ,&N_(KNZ;;4Z#=2F>SV7'0/;9*SN#B6FBM41>/UZPT\S<>=7SE)?U1_
M0QAC_4D>+'Z(4S6?,[-Y'N41;2=.+E](!1+8FT<*<\)*^8'0M$3R&"J<Z>&_
M>R1$Y/P:2T_Y'E!Y*Q%B,VG)?9AR^R9.FU"C_YO4)[-I#%N3?=V#'<T80PSI
M_5&"&S,'T7'T*&NF*%L38\0!UD%?89GJJ%E3Q_*"Z5X3*[Z4.%Q\@'L7FRJ3
M?@>%D-@N2DK,ZB ^TU\V]%224V3MYY6+!@F3KEPL!I4 %_WLRY7C3LJ7)_R(
ML1+V;JGLHHX:L81ZT>?*D );94=<K?$!9BO$.6UUTUZG8I3:L?6J%#5*,%K!
MT*5+RQXO1]QVA]ORS]-!?YMMJ_S>=QD8<2IEVBVOP1)ZH4LA8O[";4$?N,@8
M=<PGK43(DZ1C'O3N-;<']_+N1#=;\3&<6VWS<*9M)MW8JZ#T X<1O6J*AW,L
M&9(F;,O1:0(V,/UJK*24@*^,/,HN5O 8XST)<>JYFXJ>"/#7,+N*5;)(?QN&
M5O*_,5Q^S%[50:1:(W^= K;&\_,LAHS[9:EE3+8(($1N_?X=%>#8\C *&9\2
M>4D(N^+A5NH_)I5\F$L>]:41_C.[2=][ "TA"/ 16LYN\S[0.4C[L*"K*8XR
M#&K)*9%1.33,-BJ9-TEP]&+T#?WA5/EITHLQ)CBT@#VI9F^ "SB.XO&TO_N;
M#V 3!\*A2#CJE!G>&=\KW<VLJTF4^ZFA\<,!HU8O-K+,11%EBXY1:P*\L7PH
M6DA:<+;>F@/$1F2XL*2^H8[[MJ#J!U?4#=$EK4+8^-OSV\'?0*'<?MZ9TW!)
M@]M<^TVV-L'/P41"1T_KOP-1:48O,299<K=@$\4%,&=#J:]K9&^W9</<-N29
M6(=_#0=T?(I!.6^U04Q.KC!&'+Z)NP=2XT'4#ZS@_?WVV )?91*J1)T2"QL[
M8V[^8D,UR3[<0>02M;H@RO/#LZF>_D.'I*MBI7-XFZN_'R]QD:"-A86%FXTN
M8W4^<]_(IX*NAA@LB4&:&I*')7C_YA*Q04!P-^CR,NY(YR#S/V_RC=-0H?_J
MX3D2QM1:%9\&&D/RQ.Z\E1\41SZ4*WL65%I1'5<S:/$<Q%;P[ *[U0Z#/\Z<
ML[,;C>;H$>33VW&)XOAW3&Z985:^=R_T8BICV4\EID#J**T>S"R)'@KJ-?=
MB4H6Z-..<<'9*2@^>B=]:@7;RXKR'I!;NO7PX)UN2^U[,'-0UX,IR&H/JWZ>
MQ$F'/BBX21T14IB'Q?FK,YN[1,[1G(NK=Y23)W6WJ^#I>R MR$0 A_RZ.T,S
M_$I_Q^<>F!>J_T1[UK#4N'#VS?R@B=BYM$-9'>HX:2>1L_-ADZ3*V^P>J%+5
M$Q#>')T$CSJ 2.$FCI6AI-CPC\5K4M8!.N%014;"DY(M,S,WO] <KS=$+'7H
M:=0R>8.?8L&Q%%AH;]&%*#]]DCIF"499HD]Z:VQ]W;4W=>/+.'5'WL188&SC
M)H9><XPW/:SFIK-76MMDM#; :7S'%7UK%%1,\?#\CFCS RGN;$OYG(D=QSCW
MP.>3C>A+HNV\S!G)BNNX2Y1*;9 ;%_:%L,.#CZ.US*![#TPRYPL>/*N]/0_B
ME:29>#!9>RT<3C5DH>'2HY:E.0_2U *][V;9%REU5:PF%=3%]T-&X,(H*XN4
M^C V(UJ*U^P;Q%Y>D\M%P+:)7\:]\EO,)EN'^]NJA)E%>"+?Y(V'3CQCCM4^
MH6:MP'FW^LXV74TAF^E U^(=_6Q/"E*B]&\V<K+Z$@D_65$82R?H!YN9Q@5Q
M:_5P@5BV^M,"7*OJT &4<3/B=DM87%LJBG%A;!!*HF(M:>+3(J.[*SVM.<[N
MXI\2KV/Z F[8LMKO2CK&N09[S9[> ].FLZ[F[Y=[VIPWJUD)[H%.TU5<+H[Z
MU]TXOT/[=C.X;R2\,7 *[2!4D_7B0YU1ILUB810_.(M)O_27K@A"CKC9*^ @
M,[]R4\[&5;"H<:2*&OZM7L+@SY S!7^*CDIY_8-J#()7OX%V3&(,5Q1:?$7%
M#%FXF@R;=W9;(OU)S5U=G[=U97P9 K&I4<,3<_13;+YY.5DN_K*CA1DQPC%Z
M:C*LIC6<9'Z6\/161F12>K<7[Z:&_U.J<28L]2<KPM0-U[BY@Q;%FB3CTWFS
M1UQ"$F=3RC0UNOQKC_+N0 ^,1VFI)JI.S.6KSK?(F/&UFFW/^GC8@4_2ZC28
M;?7OV=>J< :PV3ZR6750L[H'_]*KSC0&8HP[<*4B6],E8*ISNLUXYV52W'9&
MDK7UIM D8I[*@JBW'JV3ZDO 78QCF?N#K4Z1''=;]6 NPFKRHBJ-*?:B?X=0
M8B0XS-]@V'2XE8? 5J!F;5<LKEH@.17L@/@;&@T17,6_&Z7_X^5"M%ES!;VC
M':6O>C5HL_0XPK11_XONU->OTM*W/0@S54^='-<@VXR/JWU+I?(WG'J?P676
MM)N=@)]=3RZK)=N";(:>]?#1%8;1+LVO=@0VU%2/(]JYIBK(I&%SCK"2V#)>
MB%5IA#)D@(=*LR%F^]S,<6@OE )>8=8^7_.:\>P8[>Y7'R,_?+95N<U^1QIK
MXL!';KX"QG^_!XXG$JJ?*GN,&K%2(M,[M%8/HT7L)6M)N O--$W #$L^NSBU
MH( U6T[H*];8>W?9+@98U%NW&O-U/%:=<&<K+OI&-;13M597-?D1@1&Z,6[Q
M*Y BN@]CIA9GCUC8B'.IX5T0\&O<?J8^%=_9]8J@1D,=/97O'*'2%8 ^CX[B
M4;[]+7/>&J+21EQ8K_7N'I =(AV4'N?(+BK7O#S"5S2"#?L2S.)4+T0Y=Q'F
MX2]AKN6F;1/!XXU,'D@SXNW@"?:<%/THI,@JD4JO;U=7&=;BR8<<M'3RY%1+
MH-T1HG16:I,OYI:5.&$RCA"F;Z\\4RZ* VUN'F _+2K649]0=/;6\E9,(+#7
MDJ83+\)[WA/+*[QFU;-'#]?3]6+Z'G8)G"30]9>R%>N3B+4]*?A<IKI=OMF;
M6T#SX\"EO&7ZTLF*NA<QY3TRDT@LN*ANA%?H*FL0*[U8,K<Q18[WAW]?+&L'
MON.!G&K2<12W+$K6L*9?L$M):H!Z0UBAG>7$MAYF.[@!DEQ.)\E\)$/?]HKJ
M@ <KGL_C;QX?I3'6"S8>80OK<SK"5]%6=E28G==R%=5\E4HG%FB='RI?)(!@
MRK./E<+,ZHQ0@5_H:RP6@",!7O;O,^ ):S3>]0ZQD0AS7C,45:Z3L.=;;:IL
MAUX4VY^E8H K<6Y7AAD@6#OZ#I^QFT,1U2NL_-C%9"Z,%B^DF<^"!<A.1IE!
M.^,32F[H(F6C%N:CQ R+XG$D[].P-Y5I40HYM60X[@&B*F)S+XAEC(U;B#WS
M^V"N&X'DW^H5/*36VYOPM6,>F^_NTF?:[.6(D7VGJ"] \/V/5K)8C&WSV!F'
M^ '%#C+58H_(!>UP/"L_([Q$QJJ7AK-X;^]J)>0IH64"& B2(@I)65%67RFE
M<2SEU!L>WL]\^J)[X.BY]UWM@Q.;3JU6,'@/D',*;(>D7CU32OA*]Z=JS__2
M\L=XX_W? ")"Z-7YO+PD&I5)\$)!E'-GW>Y;6>[VMI:4[8/:.9(_*;TZM5IE
M< #+:SS'KY43P:/^2QY/G&=M>9..9.:-KP.XVYG,9UQE9&-20T4@X*<[^3\3
M$WCM6]I8]>-0O?SYQER/+T9VN<TFB5Q/"3^82!8B*W=BU'[Q8K8VJ\KPI.4/
MS)',[,R2^F+%GOK2[)E&W_>AMR$(WBE>Y590E!SX7,_2UAE\9$7HW<X7AZ>S
M 67/'17+%A[SJ.H#F ZLLLC(Z8O&IWCT5SD9<4QPCXJ)12UT6'5_HEY/9)G7
MM#(*3WCUVWN@!=V )#L!9LH=6KQ;5/D9XF/IYT*D%R^Y)Y1KTTGL#&,*45$0
M 6S#%XB1P!7^,F-L)-R2&D[@:Y&JP#5)XN2!EY RJFH-:\!+ DDY"4XXNCI\
M,O<&*4+=9&2FU[+\_7*W@3Y2A"V_7,KZ1/6_%\!A7-\ZB8]DJX))E#L&1($"
M34TJ_96(]P1A661=8Q"_PMQ-=BF7/.T9V Q61?\KI9M!]46'8^8;V5IC=Y[;
M*HT/JB%?EN03<Z)+?WZ V7B'I"01Q?8NMK;F;JAXR[V_\)8J"YH<=(Y=>EZ%
M$1K&N1[:HU0.]V0]9213FV8=T=@\KZEVK![6@L\)X3) Y1\I1K2QD*25 _K8
M/=5L#8XD1 -P*PJ-NI)U23?55S,0$X)G /T'1"!*8@%1TQ*<<1'-3PGVEY*<
M.,3SD64;8\ZRT9!<)<BB+YFIUMTC=B*%GQ:6J)F.A+)+2KV6 )6!4;,#W2_.
MM456JBP5J!Y_62,E"-D]3WL2URG;:X$FG*W=7=#K1!UW9FW<FE5>LC[;7FV!
M[EW/NZ?ID*5#TNQ@H7>;G*VCK3-'WV>NV!$EO%(KX12KFXDA=" M0;"<T%HS
M=#K#($^&2T(A8>0AO;6FQ<Z5<1Q%^$4\+JH9'?N-!'%3P)&-1/:&ZSW@#T:7
M<C?>]["QK9DW*Z])>7_ >OY(OY7GL2X3N,QMQ="3P^H;^<9$@FCD-Z\EJUWE
M $$T4:<\)T7ZVQ]T[U%H2A'9)B91X?AC"Q=?<C>"GTGFB?!EC61PHJ%")/2;
M.9%HYTX[26/FAOY<)X77([:\R[>_\KWJ5IK'N'0@F?JXI5%HL$E7<V_.:PJA
M>CDR"A-PL%=ALUHF]E!09.<F"1W(*IMUX7 21[+6B+">=NPX(PW"'E-FCUEJ
M,%WRP%:$N+%D;3M%P40L7E))(".%/L>?=7I&P;7@L1B6Y.DTID)>NDVT;%;C
MJNW/EH3Y)2?X4GL)D3&A;^ 9/X$%6;UYB@PE7C!'Z&F#F.086S'ECK7:IJM!
M8SH#])"EH3F*D2O:^DL9TB\4E.C-=L!5"F^]II%I LTT82X:]BXT6[O5C+HJ
M(II^JX62<G_.E[)_0?=V- 5JWEA?5-HFR4>J09LVD@NNC>+Z_#TK.?.HT1P;
MDMG7R9OB:A.!E?.;=5';%#1YI.;.,Y;NG1A\&\N$L?Q:&4WL]DB]_M.BN_%V
MWL5\L^M3+C(+CT]RX9!70K*IA>S\54R==I4556$M+; !LE/E0WJ)$UG@3HD/
M-Z0G2"U "9$JVO/Q(TXI9)E=J^!&VJ9?3)NQL5?ZTCQ[?178S678BUJKUDUH
M!/ +Y7U-?5K81+:=1U6*(CXL<^,1VEX^>:_U@U ,H"T:_/OYL_*FD+6X]%_1
MIA#?AB1+Q_2$#_7A[JZ'_8!.1D7IC53ZYL,; "J<UNBTY_@P\CE-'.K>.N[R
M\F1%H10JEK$9YW@6!RO.;FCOP)#KI576E4;H3.=%W&X'3(:5<INJJNO!50E+
MG'OOIF-1XQM-T/(-?^U[,IOV __H:_T4Q3^$5DSW^LV<^U/FI>R#O[""D ^:
M+&JZ>E)X&K=$7.CF@77Z.H43IN'RXOT.@EW5 9\46VU*NPXRJ"O7X!ZP$#AA
M+]Y:Y\5SL+Q[":Y66S89XG)NQ>SAJ)$;<\ ;'HUK:R?S??R?Q?4JU,LI%",S
M(QLJ&IJ@<,/@'4=3*F$*3:_>6GT,TG'KBX#4%D=<!8H4.I]YC'R*=>+([V39
M_&EE_S]0)1%]#ZP\5T98Y_# &M?3ZZ,Q*70<,42HU+K-\=;IX1B_++\B+X>H
MR( 6=RD5XM>AH\6K*>+:<SFTB#_G'"OV7BYXCU1MI&%];6V6G6)H!9EO5<YV
M&YT16&9'";##<+IP(CR-.'E^/K-F&4FT6= @3KRD<;O]H#%(SS(W'?B\NR[V
M5;K6G=;T)3ZY.(IQ5TE.$+!F>" 2 JN'$\^L5D?M,F:/CD]V12W:@+MFZ@OR
M?YD_0Z (!B&ISI@.P]%GUJK]MB2G6,\<KGD5&G<'D.?FU (>!SP.? 0QI7WD
M9?+B\,++PYBWR21A@D=97O17P,"O[R'KS*1W,=_^B@\#D[4'#Z;%S97D@^M+
M! P7U"3$Q";C1FEKM3[J?/YY9O81CJA:^>0C:&ES@KZ3GM!=:_G82=05;^36
M9#%B>P.<=:HYR2*FU2#&;P%E$L]Q_U="0YP?>)>?QPSST]I1AXB4;&5P=V)>
MF-1J97V.,,)=5QK6NL@A>W*I%"^[WQ)7^L?(C+H:9\V.2]@")U)^\SHL/;&#
MFY5H\DRCGR.!1D/YAT:=[VM=M []CJ$VG ZW[V,3F#EYY]IOZP^938@@JC.;
MD>H$\(Z/"1+J\FWT^LBZWH248=)/V@VTU77PQGG966>6G=R6"$HSZC0<WZ/R
M;F0S$]I4X:&JF'!UO7PYA&*$'6)O<IJ>W<D*-_M\MOFFQ@:]SS,V5)_21!=A
MF2_<VGC472_3%)(PI=[/%"5([B568Q^T_*7UTE*4S&3;>X^9+KB\LLFX"H1)
MPGW%4X_I:M:]ES#G0RH3SQI,T1M:I,H=@I@4'<$D?=!0?-R[4/SFI'?&Y8:_
M$GW3H,8^  ?]XR,N8AT;W5837BR;#R3PF"4^.HV&,0;[F:HZ-Q35/2)^)=60
M!0XA,7=[7N5BVT;BD8[XI:9G]"\$#,JM*H*M(W9"? .\*Q%?DM:6%'BB+?*_
M_N[8B#]2[7]M66].)>3:EI@\N(*RKC5GG4)^#TA?U"P2O\\JCFF8VTE)R@L%
M4<BLO7F0B?49087YVCF)V7 =B7.&-)?$C0*).\4VFWF,L]GV)0M5(_RKU5Y1
MT&;"T^";4,?C66$SQ$$;>NL6;P:J$#Q%M^B11ON#V'A#R.OTQVLQ>5O</V"*
MSTV.-6:@?F]6C_61F ^)#7[L<R[*\#?&.RTT?-G?/0T.9&#;C*4]WX1EO@][
M\\BSXQESD$3W943JF2^J[>RF%:]>INK6NE2*"70\EM,@QF(NPT^"J5S[ WN^
M>8C^.6&'B.8$6R\#%BW13M^1IL2JX&,H WU4-?K3@K1HSR<T:>W61.W9!SK/
MG5WL9S8MP1[JQ(D: ;O3Z4<!GBRLGA9:*1KZS[ 1@;7JTYE-@47R88?RG"TI
MHQPM+?59WTI'&\C[%THBCY.9F>H$K\=0Q^(ZKBA,SE0B)>UL:PIVD90G*B3H
MD#BC:9%53!96,$BY1[2=UP4KJ\&UUQ\G<30U/,JEBJ'1%C7+S-5#CGF#"F%W
M?K5SSXCWL;;.4LB;1L#/39PA<7NZ8!>#:A8M^F&_4,$O=6*Y*,!2X>8+UW!?
M!F7)6XH[.[<T!JB-A@;K&I=/I4#4#,),)'-($O:/XP==RG >Q&K!O_RY)N6*
M44 Q4GZ$E2=!:]8/ &$W?9HJ>03"DC)*<WY-^95ZS-RHS&O+.&-V*S(=A1[9
M$9GJRFY?Z_9?E:S^EZNH7@9G$__\'O@*;@R3#$]$0T"H/H6)M^I-)8RE87VZ
M!^X^:<?< ]K%-]DEU=!]V4,\R,42[+)X3\F"TI@J)&^^?OTEQO*%O^L)U=?#
M0CQ]>H2W<V+EA0FF;8*Y-F-_:6".IWVU6K1C6">NKO=L;RH7Z?OD21J66;.[
MYK;DIL.M.@1VO(]B]AC<VT4)-KPVS]'<ZXS-I$G5!F^P.>!EB7 X/[A-LJK_
MI]@#@V\%./M7<Q-4OGAD.L)K!W-9K_ZS]<3?N*#;GP[\RMVO?A#Y7GB+1VO'
M7DPGZL#%7X"8F%[O('TM:+,8U'8I%<GP9"KA9<B<-1TV;9G<N?*Q++&T2&H[
MTETWBZ%T3?%A%]$S@:/65D#+Q,9CM>@^UR:LM8QI6-@[82&?SSHA/6,'Y,;T
MDU0,1 ";<SC.Q#L#C5IW05QUGRO0F<?)KEZ=H52?<(8_\4LK=_VR]5P\[>/%
M[4L.=F[MXC,&YJL>8N(ITOD^IS"V*33^Q?(@]ZR(UD:ZV@Q/SM[Y1[TV3BX8
M1!G-&?-SPDY.!F<6 X,$@C[13CW%JSF"\LZ<E&P-#ID>N6T0P_+UW6O,AC9^
MY;[]X\]&7(,$1[=8=C-XA?_AEK5L;K#)A!*USV"4A.8(&C9^7WLM_ZW^ ]FG
MO4+O"\U4L]'3P:?/4W=#M9><PV^9E8^&W)9-UKX7Q\-56 Z?*Q$QMO8[7JS@
M&!^2DZ3(1,K<GK1 3!?Y*2OF-2\T6F\UY,:7HCYV8F)P1=X#9^H$8G:Y!Q/Q
MMZ&+'G2?.S"+L^0XZA\#J8-L^2*XJ(=S5AKOM[7I<2Z"9<.UP(V^]J%<EC^I
M?-IQ8.7V$2S/"'1W7QXFI42K#I^>'SZ?W0JT*]HPE-6M+(>\6$.X!Z0H+]UW
M2%V^S=O6HY.\G92!--5Z<L1[V)P%!K^\N<;C/"$0*1Q#6#&SL=3F0W]P#:S"
M"8BK:^Z!V$:5%/UCFTFCZ(Z]G\M\A4YRAUBA^*&LR8Y[=X^'$Z6AX* ]A8!8
M&WJW.)K,IR$H)2/(9HV_!FP&BY$>O1<U1FRWEPR6P9XJ=/9_4:9UH2ML&(=(
MW)G(0J!(6@I>NG1-X5Q*V$L0\W,7SMI.?5V<Y_RM!YW6@ Q:&Z'Q\^S55E_%
M^BO[ ;,95)2\ =I?5,^X[=.P\!6'=XNA3@MS$HLH"K$F7Q)LVP/131@1:;ZG
M6'.GF#WH . ?%*B:E(G\HPBH,-+#KK_Z"]0.KU2&Q!(#EA8#VY.=9XYR]&4>
M9Q]LN[ M6D.NB([#$4.Y1Y>*QU."<[4W7B!^;HO%7UPVJT-*^A30MH+0;+Z>
MDBSE2A-DWR^C-$Q*0JQ@P2,;]C&6L [V*6G'FCM_ U3ZJ674G6>)3ZQ#F9_B
MD&4S(ID;+FYA477FA#%BO=?WR^;[K^8T+'@9KY&5%:,OX]X[K/%*W[V:Y;T=
M^<X3).5;9M7,!)H@135*A[<;R^3?MU#WWN0:V; YZ*4<:$?8SY$-QK#/:BY.
MX73I+))-'I9$E3<MXAQ,WJ+#9.X0Q'[[XG\/H(;[-6UHCX .T 3N7OOM[3U1
M4YW.^&?C(OH3Z(CO<,@P04,-6??  B[H1HKL(.#"[,YWE^8> '[K%&B,:%A;
M^G)#QGY(!]:A+M]"B.O4W9+:MWR(5_=?9@N_^.C.=@\(G47? YYR]\ AZ_([
M%9M/O#WM<W0R4HR?:RK#R>HUF<C:Y@;75?[INB88_YQ^3W;C(JN_6A740KE8
M>H5?E7KS*/P>"$S#_&\]9%#'/> CUJISPF@B</&8[!YX+G9#P4]T#Z2[2=P#
MOVCO@8O?NM#\+TG_2]*_B*0<*0RGIQ(8!:1<N)GY>ZC->-'_](5"R+>PPDPN
M8I\X#%CT1;))VRA !FX*U/_OXT"M%,>MP+)AG=W@C:1]L!L_]-MI7].0BLA_
M6;(.Y!?KV%W@/' V0K#P_30.',:9B9K^11:*T,$L15X<O\'6[2[3X(;MEW R
MG)J\&X(8LMY'P8L-2H# %OG?T$)'H0)9S"[!>=NQ99^2[0BHIY:''N>T\"2S
M^V>H;TS(9K$?=G)6>SW1$@CXF*CH ?2;3G#\%6<$_LR5(<I_Y8FJ!V$:L\<]
ML;'(,"GK)^R1(,F@>W.*A!$T]N^H:W\*<?\Y_)U#\:<V]@5_['P8YOVG( A;
M3Y&YJL$'JA"C\&SN(&!!O[;2PJV5 ^8P#KW2ZQF"J;:2Q0[%"A'>BA-P(6$8
MUF]E(T?FJ,/Y5AM3S?#ZXN>8A0K6^5P0V1P]N3"=Q*(8G\%,SZZD)C*2#?S&
MT^5)OFV3,0WI;<C,G1?> P<16ZDGK\U2SZ]Z[X$HNK2,1(M JC#0W3,2A3N?
M?KN[>T -="1"]E?#(@;^^1A/K@?.BCO(7#UG&[R^-;@'NG%!+<+Y#_Y ? EH
M?IOQ3KS$*PA8M)=SR]31T11;F#._W+\NHZZX?%XBL+P\>?*HNFF1?%Q@X_.D
MP/YIW#U I2(HPCXS*T%=_L#G%N$"T%_FR?POM-CCRA/^\S&R* +WP!.L!X*$
M#!^4'ZBHZ9(B_,\$XPW)?7AY#]Q0<>?>/DE8O[VKN =6@@3^BBS [K^R\N%4
M^?@K/FP]B^8]T#2A<Q.I]1@7X7^)^E^B_I\@JLTYMX,[-FY12OGD0D>MBDF]
ML3>0NHJ..-*7QGRUO#;,,]5TZH _"D;VO4J+:](\ D;SLS%,=.T>Z PL8@P*
MF71ECUX\00@#%\S NFJ[C[RM'*\PO?D[ZGM0AN@&V-PV+?F98;>IG^O'\45&
MIOL<^Y\:&R:7I\(AV+4-@;SAKB>NB_QD,6/@00)GSR^-DP4>L30D1+1/*2)W
MH\8>;?4W_;58^@,#'Z02TK^.]X^U^+?,>N58KSSZO:/$HFV'XTCO@7I'G8GB
M_ZSJ_Y=&S]E6Q#--J!P^RJK%AP&(=:Q;737^JG5U$&^58,GHSY&$<A18 []2
M$/TNQ6>2AA"K!)YNWE'X;5FP"].S3V):ZG?V[ !4I7F7_FR%FIT^.'KUAQ2B
MZ3@.AF@%[X&CKPLJ,K^OI&<*IZX:>1<[7KRW5^*>R2-B\N),O+GC;$77Z)!S
MJ=HL%#I.?\.S7'_=KVYC9>60*[+R:7E5CYA_!:7>_=<RW).[GJ[70Z@#O5<-
M*?8X+8J#9"PD*.7A>"*JRQ@L%+]%#X"]^<@38OY>D8D>X>07!03M+_$@.AJ%
MP]?Q65OLW!YME]"&F*]!N,V6H("PWGWU\1YGR,3<NQ.>&"\FWH2&"FBZZ!K
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M<:C?,QA"K,E).K*A_\3>#>]>?6$*>^?V(">X65I_<E?8CNAPZ/U=?WG)<8:
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M;FU3ROUD,I%5$B.&[%DG&=IX/<:5!5(["98-MS.JRG/=_(+<].TN*WGB8N<
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M^?XOPFK]1?_)\&/7,_\&4$L#!!0    ( .:(?E9M^^S+#PD!  0O 0 *
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M9$O1=RADO Q(2<&R<9OV4QY&4901I>C\ *]9JTH,;>U673U]W<7>,&XQ&Z>
MB!M RN2TL71YEXB(4?R8%4H]=KP&1OA3T<C@7V.</5A4KE-:@-O)_4T>A[H!
MYE*;/T;Y"JN%]_H;P!  ]T?@8E_T0(/9!2YYI\Y 8! &@Y(,)AJHG^YP0\F)
M$CB^B+-K<5.:;"0RNE.?E"CIT0]<)4-6M;>R/\)8131I7JK]B\)!K0H-0$J[
MFLB<KH<11! =FBR7P]3,&I-$ :D;!'=N(X"F7S0/INH_QV'O@+'.7 C? )_<
MK7I:A'Z[R(44O,XTU7XJXY]B#X1+]?LP;B![(UO&\40]HZ.(X[KYD'N9LOVU
MP^C;GNVQ.?Z)E.H3V."WL]7C:YG[QR,2\@F.3%(+95#-_MP=!K'VU (SSO<P
M;ON:$^>M'^-X_6CY?-TCW3A"PN=L[AI*3S)Q^-NM$BT@$:</#[\Q77GWR$RR
M-ML/Y=F!*2]V^=4-<1>4K$P]8@42XK/B)CR\ NI<^>LKO-=#%!,G'"NDBH21
M[==\S@J0XWGDX2^\E/Z.GZT[*SE?Q=<NGFW>  AG FX]<XF+=L&^N/JKX\3M
M>=J!^W$>.I8T6GY# FC]I4=WB2ECR5M'J83YB8L^CKU2 DPQ'OVJ+U+P[85B
MYPKQ>>Y\(SUNBJ+%BTO0P,5U#=2=<)Q%1P0J2.SY:9!)"GLN:)<WG42-JSC8
M["D_B)>R6I!^27?TX;7X]6=K_0O8ZWF<IGF:L"N#_X(X*0AEYKL!LHS73G*&
M\AW4.=5#*'5G?^D]M^P]V,4L%^]F))GS1']8^NS$J-4#9:N&E-5<W]6$%N'S
M4;S^PBV2\ G:"5J-Z.T:R] 3,%%@-'EL9<5U+\VYY#8%)[9P5<[#+%]S24_^
MM<'"9I+XM0P>N*4R-?ZX]OP&@,YT>;'H'+D0\CQ?*8BV6[=#D#$V?IU,ZKW=
M?%$W_HNO+Y*:1&LW,OTCHPUR%KK9-ODL47&/VL^+PX*MU^5@,<P3J?L&R /O
M"PJB>%'<VXG)((?G' SO.CAJ:F?1**7)I/ELQ%^Y[):/%"X O>".(:Z7>DO^
MY.F;*E2&-Q_G!\>]5=I7UGQ\=PI7.S:$&AY\SI['4[S5K-C=&WLQ="T]F9-?
M8BYZ"M/%#@]Y3S8^0A.:A@=MP3Z7><U-\7UNL4$"<D^5-7Y?9.<(041^DI1&
MAMI^]/,I9KZ6IWF])!P991[>/42[49&WC;IX [3TFOIB^_X\(10^>B62]YJ3
MR@2] 2[U73*?H,7? +D,XRY 5,U#/O/>=N.="OG5U&(9IF2Y8(D@"<#91U0D
MUR&$'_T,JY#N49;5%QLRG2%TR3OH+U2F1(%,,]&6/_<7M8)./Q4L_*[4K)_R
M0&IP]$S">XB>X^2:&JE]UAL&ZCQ4=FD^'/4[KEGY4M4&J\]PA)3G3#*=VHS5
MNS@@FPU#7TKM8+3(+ZSO\>Q;Z8^(D7R^P/UQ_09 7P6#Q&DB^>48V>3QFD4&
MOLO!>IN >&%XSO3G/++V%R/01;WRYG7[[*)I>$]B(8SV7/X\S_1=TV61VQI!
M8\LK8D$\A:S,U__L#S*OCZ6ESTOODSY^3C.V1OT(CKUBZ25L18I4,6BKL<AN
MGSJ-6_Q0Z2*%*U,5V%>'"/APNK"OX&A5,GO2QE3BK3Y#<1%Y[P^1QUEYC^,,
MHS3^",1(2A\B[%LMG H(YNCICCLYY1Y< >TS=*>&K".F:.\T8^,$(XW W9W3
M9A>!M_7NB4FN;NH.VBA\5A(66_.B"'%2MJF2].I#PD>207<MK_52ORQ:TL>#
MG(61[D_WE\=!2,L'\<.'<B.66A%43_!XSZ6S0O@'*IKW,G9G&@1!E>R'W%K'
M4T0_[IDGE=U;N]CN2QB(^9\T%RR4L)_4T[%+,.RQ_+.$56&(X5Q*2D**_.B+
M_L!4E71$/TZ_(LW(6W:6>_J,B%K\9T5<_QW_(TCQ8;.[P02W@!, 3ELO1H^S
M^X<A;P"]]RU7.J3JQZ'?2'J&=J1='Y_S!A@9>.IYA-1+_Y==.9!P>@.0Q(.;
MUH;SBVS?'?H8^'%W;=B/M7Q<=C+D0DM](-]2S#T+24Y9%:3\$:#]+W(F:WL#
M1,L(H^UI.OA<W)2/C-_?@'L>($3"1W <<-.OQ6^ %0X+\.'.&\#O#:!-^"+W
MOA<M)MX LR/W8&T\@ED-I??V^._MU4LJ<M\[RN9+.A:#YZ) K-Z_>;B[RN!G
MUO#>#I$,31?SB[TH G[7^NQP-_CC@AS30IQ7+LKJ!B-Y=V29'%N0(A[T@*#3
M'V(V.M3 <&&, X+ ;E$K]YHA,CCH7.\_%:>H7]SWEB@%)2SG&#.@IHR;JIN"
MY'[OUB)BBJRW!O+VL,*E"J"VP0%,4@XM8.P4WCO%\9BYIWZ8D?[>*:L;X;&*
M?SUO^I^%;ZDOWS)/4WS46^2"Q:IJ(AXGX'&3&[:+2?L@E67514,NI)'<3VP>
M>,EBIG?P:1RB*W^>V>6_X'X]<'@]%QZK+V%PQUQE"A$JA.3G_9?U47$5//#K
M#7 SVID@KZ@/'H@<>'&TVQ'!PRG,M^R9JCX!RLX%9&4A%4_E86.JYOCA_-MY
M\W\<B+8/]0[7KR[C/2QG_E4PJPVG6RVQ#DAT)#=?0<K-?\/\,L5%8.3P0B^/
M[H">\5_? &IDUP,W>7H8XM"Z:-;?ZS9#R2,HD &?&V .VP^3:I*EE'^JA8FQ
M?0%!]2]H+XV8['!8*@V,(3@RB#%8;/T:+EE:$NX%7FU6<V:B6=XVUNB"<./[
M:XC[R4ENQJ<1L$/)+[;-$<>VYHX1GNE@LMO.(<E.3IR]L6-4R0'2)DVQW.A?
M>!"FBEF"KU?X-BK*L\V:/N^<@;1"2=(R/0<-[H%4/,:':. JTO-R>>Z>QY>3
M8:Y"+YX(TA16W,3"ZRQSAQQHCG#PG958,B;BEJJ27RY 91_]/W3EX?^G4,7M
MO-AP> /HICX09&2UOV\^I.C'[;7!"01NT(1Z+S&<R:(S=C6"J BN2KXL/=6!
M<MB_;*?^OT/9*%@GH&>18S']+_LHT;?PG3]8K3B&62B]J&5\L2($SNIPE6$X
M\L9K<IU3G"C,NP?$Y1T0([-4PQ& <>RYR!X"R:SODO[D&75SV)QZ58:<HGRW
MA&.$T8#>.FE2]I$( 9:ZV'UI3[DYT^;1HU9]H+_,E[9H8]9])'- QD+Q:?T)
M2?\PX=*H=O?JE+>'RJAC2)RIJ8VQO?MU%LI'!K:[7D^<%%6#(VV78F=,NHR#
M3XX9/TVO>02>U$PVVVE?,9L$^)ASN&NU4W]!JVZ;&HF,R5 R36?1^''3E6A'
MU>8?(!%:>B:DQR0T]-N::]YEBC9%I RW7Q0DF&^FDJ(R$$:*G0C\J99#QZC$
M8VKNXAT34>SU4Z#3;H6:5-),20HUKI[5D&N8/G-A$NG9:\/Q_V(2S8,\2IES
M*0HP%YIE3MJ49U&O;TQ!RH^LH')7_C H\RTT_:#N4LO>$=[3/!])T9-@1IWX
M+KS."^F(08LY]G66HPH_-Q;97D!:KS?8;<1/6*BIU$2W.K;N#5 +1/FK<3P"
M.S&.+]F=.#@"O8*VC.SC/I2%0D ?F5&?;\G-OJ1YZ*JA@;/W20+V\ 1_3,@0
M54JH7O*IGP N*K-X%6RYH, Q/[+<A_+7^B J3/(4+P/ ,[09[ZI!(-]*^$N=
MBH1Y@JIV^I0*XKPOM$;0WB+CAL=F'L$BS(H0Q0^INU._[2<7N)#8XXD29NT^
M<YJ4],Q @RXNJ*/F/Y234.&KR*!(!#9J_PJSHQ#?8\;1]4-/.U\@,[P:K'!Z
MQ1$*W!M'^(T\ 2I4=H]S-S7V^U3MROLN>=]]FN@X)_=K)V;9&Z"RZ6B_K)RP
M-T6R$[,AO4@'R/*K9@CZ6R25:)"(B[)K2G[I?8T@@NJEBR#7(Q-GS)=9RNC1
M'V@.-,LU)E'2 X(27&7'O?4:4A(2HM@G9;=R'BA_V;1K/,+9>.@TYMR^>4'@
M [=&T7K="-H\36M&<!*Q"YH686WQ/OWB'2+]O ?P_!Z<__S#TGE&@W9#F$3G
MOL.FH06UW=S6Z"JWM:,6HX=N$,8JB"P^[06J7/T")<>]1A@5;^_)9"'USY-4
M4A77LCGOF$\G@:M;E>Y<3O$A04-JGEBMI6=@^2^%);73[YHSF2*:45;<2A>)
M ?E6+;Z1'D5=Q#OW3)C)6 #6+F,@833,S'4>_ WV.(B$YWRWV:9(=^&PH7\-
M^&O @6&XI 3A8CNSR:.'""8@;,(&+*DG1"Q:;P5EQ@X;MKU<F$1)\D.'AS;@
MSS]K(>5PT3E%Q3)V36>HL,R&O#E*9/)$=_N4R-#P56U VUMGPK;RQ,@+Q1(R
M=BF*79'O9&Q2GQXM4J'@<0<=U8":Q+_(('2D-WELMUG5.FMM<T8SD&3'U$T5
MG0&/E9;9G45"-:TL_U5/MPN$_;,8:QKHA/BM"M8<5?8&!A4KX\\$?#NVPH#Z
MM M7LC4GDD[#CX9O9,FFK(VYAN<^D=_? -T&^32=)2!<5,AXP=* @X,#K^I/
MRNN'<%\/:#_NHA(N;4A",9 1AR ]?6828!KU878!:E\:(0*BMA?IG(I&L'"O
MO#<6]7J)QH?_,?IS,Z6M4_H Z"3:DV^>3W=_OTR0OR]%/Q>G\G-L.?E4Q>K4
MKDY.=989(!&!9VEP>[,2Q4J63^,V:^9X+#URS>IJ;KC?(?UAP,"33U<@?$;=
M\((DR/G^!JKLH']82Z#HU'<F0Z?S3MP<]DFM5>=(;HFZK:XE:'.VRRP%'R87
M:L:?1Y!N'@E+@V'C#4 *$J+L\%^$$#8%SBC+@QB'?]AB<BWNN%8;!2QTIQP6
M 7**YJWX;(L=7. "CW'9M+_(]+(T20[PP$:Q#RC,CJT\B]4U7J@NPA+@M/MP
M8 Y@W7&I&TM3,$,1IKH!8.)CCR1/NW9=L=2!(=[BH(UR(8:EP;TX7F;*1FAL
MV%/7130JAXSZ0L;)+J11CE B:23^5D )@B-05$HN..:1 4;EHC+8N1-5IE*F
M9'&TD-(:<TFV)AA\6H&*Y*5J[W[6X\;W4A!N5[(DY^%B=QOB+UN6[_YGD(?1
M*09> 8K#I<HCG1A;;$EGRHZJ.6I.M2;]!+RU8=PD^>4-T 'UX$E2#^O[^?RZ
M85IWH!)D!_NQG+'4 U^SQV=J@ >P%7&3A6))WY[PDI%OV:B.:Z^GT[F2^ $F
MUP=QL^Q_H;[TWP #@?](KFU+3_^[5P%FX:-X,*4(T4JAJ ZZ,W;TO[M1@)Y"
M EU1?+XL'93%_YSOJ_ $$^Z[7JUT7QHTSF^S+LO@)#M1*7T!Q$PQFDE"P5[U
MV78):*A?+(M2C""7$!.CBG_&AR65?9_^T'__1,FA=F1%;('N(7<-WHE-+LC,
M/K\JR_2<EP-^I^1S=<L(P6"GBY_1-2?*S4U#JI&#CP=]CXT=?IP684X1/DUP
MP7K]?+6$8B.$T98C^L2 <Z,&T91-3^S<1FDV;! *ID/Z8%1UNDTC]S I%&0G
M,")0HD_=5)^(QBNE@A^KRG.6,$XT">F:VIW%FG.)XHH=PQ8U]@&4+-H6@DH/
M7!\3(CI<\GN-I?,0>QPS@F%A'A7A6N@9K'ZV-$2Y0R1D<.TQ>R>K'DL!HK=D
MJG4 )=7U629F%[EVOL](NHN,-FPG9'3>)WN=*X+T.P L):W'Q%JS/)WE<<^I
M 93ZYN9$49@:6&)?PR_ )][Q>H"%DBH39SC2BMAF]ZK/G/KD ./DL5&U*6SV
M$!YOUS[(Q4>=&/=;DF)3V*:T<?^%'4;L'RKD$Z(8]OBH/Q/7RSBMN$4E? KU
M!4<0!J]\ U$WZQ42VC&T[%.TZMULB(!$G@7-K(O<_LGJH9D_+"\39?4?  "X
M->&6LS@O,"K+D'K!$MW&OH'TF^EFY9NV/!]NI'<HU7! Q'.8PSTD?[>Q4-,"
M6+Z\[.'I*$8+:F#MQHAQ_9'QPIK"I\LW/Y&3C#RY+$HTR;6_K7CH$.'/]IDV
M@\'*@YDVUB2(FOET $H5.0Z8CR;?955-C9U,&L*1K/'MLP_&ZPQ^#=&N4:.K
MR/4 9^%[R*G!OPDD=C?O9L'RW"W'+JN)R/,BD**<LX06N:/$TD4-"\O/MUST
M;2Z4* (E.>AIR[+%]3NB54X\$:2<7C+P3.YHS?.'#,3###MZFI)1H2F[$X_B
M-/@!);#%M2'OCAP-I&+IF3^P<+PQD$S3[VWJQZ,(5.97A'O\C!V09<:KC@]?
M?+A8'Q68KVOI^>M5(KWE-%$^8DG285*4MM)(?-I>^U@OIP8M]-HP12Y\QW1V
MGBF<GOU#J-Z*R%:TKGH[SC^_* !RJF^BL?87D2^ZBE8X'-MLF ?7XY2K*S4,
MPURS3@=@5NN-$WDW9(Q=W%?$*3\/&GK *L+L%\AQ*-*!\J5G?],Q_X&6^4-T
M1U/;)KHI2-N]J#53GUIM94%$'C]B_A M&@C[^DL719:!H>>5<LI;I0!%3K+U
M22W;"2]^Q/DA6"D(\)K E5 .>IQQPP3=D3@NZ0K6%9HP+Z!O).W"\-P0*1DV
M^X8QL#Z+YTF0Y%,>HI=Y@OJV<#8_1:QGZKIFH?!]COF;A"[%(=_"B\679D(6
M$?;/Y1Q5EIMTX6]M575M39=[G;]ZK%OQ'J+@'6*^\!!?B.#N_ZL7,A/O0\U=
MBMSI#Q?'>+?3=QL7R>1/6=DP1;KVH019^UPX%!%H?=8/]L(V3V[:)=\ JG*\
MV=5QQ[VEME.?X?S"./ %')U.PK:<?;#SISGN=Z+[$!2GZQ8V<*XTQ5':D(WI
MAMJ-Q>EH"R#>:9_TVR5H*E+.W@ (S_WI*3Z=Z^#8G=M%O?Z$ F^!SDS9%BMY
MKIGR8_3%MK@>RF[HYE!18W%;!$!LZ]&WCII8;_%\*QP(WVIX+E<F4YOB/,A!
MAJDM2'[ 64BW]6M DZ)[CPE/I4I9.F4O5\I8=JF6S@#?4($NDD=$&. [/2&#
MO^,7K\WB#A#WX>N+L+)RG<WEBP):3P?^$UK(W,BT"Z5I!HE[MH\D]FK9="O>
M6%<5$6D++]*/L/@N+K='U^P-KHZJC@A2M%3)[PV.%+_X&@9X'GA(^W[T,TRP
M<)8S %O](7<JM0W-33Q!^(6J'L(KL-NO6"E!S7D@MAZ<_)+YA2'NQ[SF)NF1
M-T +7L0K%JTY^.@$?"DR^R[U@)>\>EJ$WRYV5DO!^?H&\RL@.2L8'>WZL3GD
MG2WZK 3DCY<B^KR<R>LK:&I3S^(;LQVU*:QV67+(D?Y#G_!G$]E>V' CS.O=
MDEINHPN6>VQ\2C47QX4?BPJ;OH+XO;/>I4J2SNS)-3'JG7J+C/[J%$Z*1 AT
M+]JW&/;[*6""0?T;P."*4'=LY>01'#MR7[(Z9H#>1Y.=?_0%KA')KLQBE'\8
M=5.;5EJU@0^CB2TM(_T"@_,^.HC31WM-N2T .%/AZV2I?W0\3D@%I%**V,NP
M;SZ(X:U8$3!XEP/5XDX.I?,+#U52]B8MS5'<7QT2EI$<TB )*]=<*=9WQ]]B
MQ)&^>;=A#L.['[OG;BB\P&PN53YH7C(PZ#2YR'.K=IS?%D"&-AF>&H#5_&W2
M!Y?2BM">6WCCE%$2GPZT W07D-S-IE-59V\^U-WG YDV->I<U!EF'?\TH"*.
M"\P!\[QU)^OEPK&2I.;JCJSN,);TUQ9@&V.C5Q0W0H9.%ALRMD2;YFSK=2":
MMAP&RZGAX=N7.:C-M(8Q/ZF(S&8UHY4DZFI/[$:>8PQTW@#::\\+_>YNXHF;
M*#28JS3A*M/'U($F335!JXNSBVR!WEV8^%@9DA!?OTSM3/D&+6^ ,\=Y^[7G
M;$,@9^XX==2?Z"K_< 83W]N][64TE;!C3@,B=R?I\S? [?)B>1D$KE=IR(9^
MD,I[RS+&'E@I ) IC;M/%?U1KFYC)Q]9,2-8Y=74E0P42Q;^(C0C>]F9^4QZ
MA?A4+K1V+CQXY:/P06@XJ0&';\KRT\&7I?9R2,@<5V,^&ZSR9[U)]-[M:E%_
M-(I64EPM _U[W-&@Z5>:1#'">9MUPDXO#+1JASD>>M8C'6Y?RHECVCBD42N%
MAA2*'.G=EJ^F3'>.'[8$VRUU7LQEIQ)Q9ESX^3E_GX0L*U0'"X4WO:_C)3NU
MM5?$N/K8G56"<T@]2:,-]D["L)8^W5S%PLR&[:###NGM#U-K<+7:]0N+2OU$
MRJH-@R+F\KW HF3.E/C3#MLG0D/O<O\OA/AC\/*>L[?5^0>1'P\)$M*STQNZ
MF6DUGWOVFP4R\[EU9G,FZN1&U=W-,PBE(VJH/B(E$*5!BQR,:R=KCS<^PW?"
MO@&@<U:>KY^GG[6?%;BEIVRMG^76YZ*!*7AD$_G^KN@)FDMW7RF)[!T) \[4
M!!S<".[31(L/A-AGKR>A8\WR%K^/AM(*F3# .TWOT)+TM[2.XX,2&U*(N\ON
MA)<<!XC3[.D3;49:'88 =,0*[L4;%_I1BV*';FZ0!IQRAJ\DNZ?$^;]B(X>/
MF[<*G ZA2N)MCB8[Q]X Q:R3H 6PP0_F ,[R-T"PC3XQC0\?1'JX/'*V*7!+
M-[8^=U\H(ZC)B@GSQ5O\@MQDZO0K=XPH<9:R#<2>G%Z=]V,,ZS09.HJ;DU6#
MTC(H=H#*J2*G5Y31J:]NP\W4UE[7Y.E'],:H;,I8 DW1HZEG>NHA(C=GR5B!
M&DD^>^R#LN7)PPH*/_6E>>(S^R1-S87YHG,EVA$?3CQ)YO9:7PG[]\T]2N3W
M)04@_0U'TL-9O!DI=M:SAGW"F;WQ8J=:R\>O@S/-&+&C.]**$(, ,]=4L=$F
MD\TTMZ"C/2TQD&9X&3EE=X6@VN_4NE2N-<.)6+>?$Z<4RSB$^+))R]PEM6:&
M4"D:YP7M7NBZ"(8TO@%8J4WG;@J?63<[T=<AWFH^N>Y!2Q)S9-.!=0TG5ES!
MQ-OG0YUGA!Z$@"\PJ*B2@H?;0CA)TC.O)$"O; /+29T>IO;>\D+R1.)>#R'+
M(,-L]CF'I8 H]TKUX%Y/XK[[J@"MZ?PVXS\Z^5,</XO)(K/V_!&%Q96L.LBB
MQ;P0(P-7CN^F?Y,%S8T@:U+R#L7.BG1G7.<6K+P!QI_[;];^.=7T>0/\O#&X
MEW)9X5<XW]G):^@@>](M)TF):E1/M@DG2/O@[W+YZ$CO+D!>/+3N9:'?H]H<
M=-:K/CUD[I";GQWUY6.K!VLMG!AK6B"1\Q[G89*^<-5T^0W"3-V)9/]FGW&<
MCM9/27&BZ&H]6>E!R=-.+DD^]9N,QKQ#G"N@68F6;@\4!8B\24IS\*@IX,?]
M)#'NRKW.<XR@P=K]VO/?\4_N-IRDT);ZI%,Y07_E+2]T!C!#ME1FD%$!M)60
MMCG%66^W4J[(_ ,"KLI\W05&I>4NI_PNZF0S,GR<C:%^!)%2_83B^[6>1W#0
M:?W\#;_<"+\C5GWY7UO\<0D$GO$&RZ?[:/'0$TP]<Z!4F^+M\)PT\I]K.O8K
MF!.Q*8UKA/.EF8O.4'6"CNJ2(]?)>[:-"HSLN&FEZFD3)_K/>G^O8G0;#4/'
M8:IX,_OX4"L]<KQ%PYCH7]7;9A@S  UCVF90W-AX#WY[/ ?Z[0Z;3)A3]YK+
M1P3>W&;=B%0M$C'5@!]U:=O^/'?YKTLUDC,HO9,Z$H9=YBE:6Q^;%1=XC#7\
MA>Y5[@TG":E?W RV@\Z\WMZ#'X8>7R(]F,W^[)?4/$(F&GD2[#7LCD%]Q>=+
M>"232L_>"]_PDN4C,+IIXS0+M5PY 6+Y(@_^SS&^$G0A8T$XS]%_HC&+)%=N
M13T=X964?XO&UN<8["XP(39<Q&K7\OHH-%H_*1Y%H2)EP"S4ZLKKMEO\%I:/
MPL+];X!=NJ>61U^<-P!EVOE>(+C*E^S>UD98THM??0+9+5[*6NE;LTHH'K+=
M>"5'!NNYS7B8$&WG*;-1I+/ XB$2H770P??EW[ZI[;7OFN@'2ZASJ59%;D='
M?0W.94CXLM[7[-3OKT+6T4EI7Q!@> 8XA6]/8U\27DI?2DU>TM\ PF +($.%
MT*O#W&JJ&^BV<PM\!5M6OKH6V#EX'NHMN(4"_,-7EJ2MMXP[T NV;FW0$25/
M^>+'3@4,3'9SQ,WNLP!YZE?F>@LW_W+WO5+WOU*-DBFS<T8TCD.\W=@.F]7[
ME0$@=9O#VVW/?3*7?1UYG7F=KGT=[S^K?SC:,9GS=7B<6K(B,-MHQ&F)S-O=
M(9"&52GU*&K#T27]C1P1>R37<OW,]"JZ\/C*_09@[]H\;\CG#K8MT^EI^>4Z
M[5ZRNJXU\AV>:?BRST3OAT/7TI]]JZ5Z!IU([NZYQ%?"NL:@0P9S'$4*>LG*
M@#JH":=[%:DPCB'.5":N#X$]>CT<D^-(#+VPW["[##W]'::KQ^BE!90VGO*;
MN1Y/D^GJE>_@^9N6AI1F.M"&!4?1-)<>%U@F<.(Z;]K? "I]S^P%5OI8%Q()
MJ^'YA_%]18PPVBEGL@[498%79!$)BL,RO$LQ7U"\<,.\^=\ '[BBK(7K;,M\
M[9_6;4E)NX^>I;TJ)*W$>M2F;^3<,A4Z&MH"\7(%ZT8H@HA%Z8%"LZ,ZSV(-
M23+!FJGBLR?.'O:^:_1_)G/B(_\6,_#HWBT->*MX5A@</1XC2?WMK#PJ]NKF
MXLM(,&).!1>"U*N7JM!E"I@'"Y1Y:=B'N8DN/6\JF>>\N=U8HI@S%<[[FQ%"
M\F<Q-]>TGD3C1@V'3ZF#)IJ5(G^RGL3_J=3LO.#@:HF^=4D//"WVK XU#1J4
M>LKC7=3*<U%*(T+>?E3_]@;X)"!H\Y)H2[*)4:0G THV0;KUB"=,5%10W?[1
M+\5[,/JAPXRY\QP\_OSS9'CKQ>95 APVH3>^@:@]UG_Z*.V"!$HAE/X6AZT!
MNR%550'N)Q@KWGH#P%EZ?H_=J,0$S6%XJ'R9L885<T;EIH">=XIRS6CJ<UT<
MB.1XP7F\A6RNGDK6UD==FH=BE?2>J@A4"1C&#R@D'VAK!]5;%<H7BAU1U1Q^
M"B&3%J%ZS@\GBKWT^T!3,&<@/"#QB.TEG/1,.G,^ H0_U#! ]=8BFZ[_7-"$
M+H#CQH?%A;)+Z7@A0=C(+X/_,>\)<@.),+N(BB\"=6"VUD8]B7I9><!G%%G;
M>LQ/;;THP43<[,&T>TH]4R_:/=,(GT?89)YT %-WK4G4'=)3:].??*U-"CU7
M"VY>VU(PIQ^OP=E7XWX"E.6+EM9S7"GU9;>>/KWLDHM87!??M!"7]DI/?Y]V
MP18+N([:ZKAS#:^M=\0E^1+.0%[TF)D_ :M"3[^%&<!KY@_\_M)K0W9S$'9;
M0F=[=/I,""YB(EU[)&+I[IU1Z;F3\\HI2,9=!"[\F)[JUXJW>-@._/!Q82NJ
MJ>(P['.C [7A__S7'3W2VOUYTQN@0OXY$OA_R1-9P*36[3,8H_I7G_!]G/_W
ML[E\;$SG8@D T_]TA$SBD@-ZW,UVV)QGY-0AY)=Q >4Z4 ?(T_VU^*!^I29%
MS%9X<:#[VIR["/*E() L+CIP]90OB$?F,TWIRU7(JUC?9:..8%SXZ#Y"PAIV
MJ_U9YVN[,)S1FOH;H/S4@SDIAWHM_%3;]75VAO&9W^(V24-]AVBD1;[&VE?M
M$D%?2JB@^"!8Q@!*P5O X/632J[P$BP\4/@OZ9' >IM':J/-VA78+>S6\G.[
MW=X_4>+-->9DX<%[7++AM'B0V_UX_*C0FB^;.<^.%,[$H!"';2S2H]"O :TT
M^%"U1UM!;_#)(A&'=75>4_-KS/*]@DYRCG37U7<IL9HOIUNTNT=G^FL27.\!
M5^?S&P"@K?-X\FH0VGL?VNA-]^O>/@!M(??R#5!;_5KJ>'9Y"ZYMS;=_)0_H
MN<,AH3! ZK-B#NH@C3T-K EJQ"7_$?+HD>V&Z7OW;:Y12>9PZ>P%K&]$ZD*]
M] KU5U\+E/@&0-FNBY=+M.$_)C2MK0I!H-?8G<^%$8CO<^1*\4O2F+*^[D37
MOJ]8^1E"F8*8<00T^.P7,^AG<U 7K*BPR:Z?BOV2=I>$8[_213W;L2:$%8,;
M;C]\JC0X>)!2_;5]=\T^NB7NV#TJNGAAW/S\ZEN8B]<27D5NJY_//I%.$_W6
MO0[9N<=F-$)#$G6POW"5@6LY$2.G?,2W<(1?"Y\\F5]:H6Z7]&N+W#-%IIA]
M1XNM4LP2^B=6U4:7'1K0Q(/(-M.+]3270=+!FE%C_)?DC<UAFEVNMOYLZZ68
M[#\"OJ8FK('OA7<_4)O-7WAAR5@_\Z2LW,:"\MX 1N1U/OJ3A0%CRZO?UU:S
MM!P:$>*CTH^,#"?79XXW+BIRYAZ5+4(8F<]RXDC9@*R-OY3=0AN.^U&?G2O5
MISA:;3Y)U4T=]R!Y:2;2W:6E044!R[6BW,T\,'F5%KF6R-1AL_OM?5 12^ST
M^#OGGGM>$0Y>I6(.(7Q0D#8=HB36 Z"3B0FC&XOU";M$9EK+!24Y^=>?L:^3
MV-/>W$WUYK,GUF77O?Z?*>WJ+2ZK:]*3/2XGXHHDA0SSHB05K-IRXB;4!5A4
MXNZD+N"6E?*ZI[NY*TN,X+_&ZO(1Y^Y'"V\+'LH;2+I,UVO:E2=:#3TS,1WO
M#[6%KCJ1_[E1=K_^4VF?DV\1=_+ZO@]8FDJ/P$?O$B5SU3WO43V@6&Z+H8G)
MNM!_6J0AKF_CHS(FQ:^@:"+HCQ$8@[NM[5*ZJ;+W1C:E'?EPOW+&5C(N=Q&2
M%1LF-',<!S($'R_TON+>NFEPX]S>V<L+5B,)* WBYU"9PL,D4'G.X#R>QGK8
MQV@?-K"/DMO']ME'_%4Y\X,:6EJ;;N<N/YE[17N(2RC?>0- ^0;#G9^IG:N]
M=KHQQU>.E]V';:+<N2DOR:!>*_,Q]TG@4_X8;\Z[K\W79+G%*6$R>?(ZXE+D
M[,(',[*C-Q^S.?5YFK#EX+I^+&&3X0&HJB>YSMU6KV@MBSO9D0W+(05+DF1%
MH? ?9EKYFNS/.?5WT(Y;F6WQAR^X=/XWZMXJ+*ZHRQ8M)"%X@.":X![<(4#0
M"A""0[ 0I(#"W0H)[A @ 8($EZ*PPC4$M^!2N 9W*Z"X_-WW?+=/]SWW]#VG
M_X?S,/?#>MC?^O::<\PQYEI[KN<@GZ)+V]X"Z%>*J-WWOR.N*M;F/O%_X770
M()WQF@;N!&#;\MLF1EP\'9^J> _!^T8=OIU^9%-2W[!^[_XH&):7/J":((F;
M\2?TBC,MI.YYUQHZ2>N_<0OJD_$\QLL<M&_J4M_SB_5*^>AE73.^ ^LIG7#7
MNNIK?$*^"SOL&3)U$.$,4W+E/S@3P7L.'<TE/0]MG6J=%T!HO!B(&ZM17 VT
M%+44/23$]"@!#>HNNZ,@C\2NA&?TKKWOYM>HVK%3]36HY!OU/IBQTYOWJ.HR
M,#<X:_TJ_WS]^,4H-KXEBEUN1B15%WD\2;/$%.WC8!7B/%")8S97G[(SY@WS
MKCN!A#GRC(_/_#9\>\4O/!G&.3LWBWR"GV2GCMML5_@=?/CJ>TY"-UML%\4"
M0+5.G(:H\Z*TO75X#PDQ2<>&>:8A]^[]XOFO)7) @XZE>TM 6I4+ZF9'L?Q/
M9#*O:7-=:UT$,JU*[0SGO<A[4!R3< 5EJ\F5\%O.]\UU24;.\->?+"BXGAXZ
MB5_ 3(H96NH:T]?86.-4N!>4^//0+>PQ0OXZR?:V*KU-4S"_ %]X2LIQF[^\
MUGH$O>-N>-MWS[(;ZWV@*Q@MMO+=(=H9CK6DF750D(&X9APOMH:E_2$7^,X8
M=*F?+D;RV5XGC$Q.'V/R\^T5+(^#.KK,]ZU28Q:;SJ*%%F,HWI!3J<!D<@?M
M;G(M;.=1T+032>FT0J@?PV/%[Z#"IJ[HW<E5I(AZ4VH&+,1J1Z XXNA=0LY*
M$C4EHR3.^0,@!L]TE:YXNXSK4>$O3\+>E!]H_*;BB3HI+"O;N21D8";;W7S%
MA?5!A"@=J%Q\6;^2=D,.\<V8.;LGQ)VYD[$LW<TFAE/#1$<+$?.C=M56;Y*>
MN= #5A)C7+,*FQ\ U!]5/(^I=M>L>+F:/O+L^R8]3S8>,NSY+@5MG12/S4^]
M(F ,UOZAJMK[LP0+\^2/SCQ5RT=_&<(S%I[Q#P</ (R[>,SZJO;C[9@[TAS^
MEJ:W:=F.$X46V5R22D/AQQ:)^U.)JR^A,MULAENG \LF5"$9OQ,=U2;_.(CI
MHKVC%CYMQ<(=]F=6$+P_=-PKNO'K=O18GC$]D_:HFW1K;H],ERXI-!@NM(V'
M"K7E) D-)3V1""16/MB,G5U]$2#IBO"C_2.X63_E?L0<EX^,7:S/'.?#I?]&
M\*=Q7HQR1, D5_#$2);I;"!1GBK-F\FLM%2,*?D/SJM_J78G?HZ=Y!>G"</*
MQ6HHH"6_F%[>0)T,ZD'V8#<HK+ [79+EZXK[[:;Z\<>,:)]@J,3X+5L_=L3R
MBZAY8L]B#DDR0FBG#3#3OOKJ^"MY]B<@?MPQKM"(F;:HCAA&IAE*:%+7H6"-
MED0AD7'*/5:Z1^7IAE'9UXC*"[2(85P%,Y_F3.7C2ZC%&L+W/J#S3H.R@=ZR
M3<4C Z\>:[]WHV-]^V,]93?P!&2OGI;75@(I!2'=1/:X9M+]T.6Q<1! FDTQ
MR=>ZV_6JAP>P\B.NZ=/I7>P# T^N$V7*9Q=XHMVZE3.U8)U--0G=RA8OR#2T
M=4!9:Z\V,T!0"CKK.=6V+7!<??6A[;AVW/3CXN)\=+^>>G/+Z ]G>[XJ! .Q
MAF3BL(LT[G7TJ@9N_QJ^@,%4P+#7_"8B C7*N0E<H2E-G+V"&1B;JOES[8**
MYX6S7E0UD91$H'5*G,4$"'%##Z"[?=-IKQ>X'"Q<7P0%5^X6T3X[+[J$;3H.
MWD7N.$H\(HS?MO-]#6_W8(C004I%XWU9AE*#T80$PH%:!]-VS%O!:\-G(ZJJ
MQ,NUJT^:51\:DSU?25^+Z/WN\O+&R&D;TU%L^T:OO0Y:6)C-?+M+%FU)] H8
MPA_Q)Z0V>*ZC<^5V*M\]D70LA!&@\W7CN6_4UU:$M]$CK^$=*KN=.;N#H:R'
MZ-AN!6BQ[0MK0KK:YR+OT[C_MLVF4<=_LSB5=104#KAFI+BLV.IZ$V]R758@
MOZ9QCHAVQ$<L"'#V4[4,\A+(SO=F.77!-$W&%(POVC,@V3<H3 30F_D&DKAB
M0NW/J'I=1:,+OJ\O_6C25Z-1?3E_.&?$]%WG >#VMX4@)$=4JMDT2AR>&EY^
M+: U673*=7#!ZOUY=KC6^[/;>Y6[)SX*I)QOT\Q;C?Q'7YW 8MPT*+QLY\$<
MJ-VCKFED#*B"6M\R-G4AV'L@C#/3&NPZA@#5F^"?2/H$%/B;K\37(N!?:CI=
M!<%!W[4PKH*)G;#[MEM]+UX8062NZ3<D]KW(TI&*><=Y^C6Q[=5NOG9]?:UP
MX-R!0Z\N-?55<3B%_7,T*8V T96IS4PD_GU;ACD-F? 50,'5D;M+UD5YHZ?F
MKC]DTFT49GA>RKZL]TA1 1DVP5%L^:__9:/I_\V*%<IW)NRT_IX8,^X^?UL#
MQ-GX*N>$+?747WS:'Q;K)^,-H<TD'_J<JAO&3K6D$V: I:.B^L5CY9@BBVT!
M'\F)UF*W>C%)U0_[IEQ/;PE2:\E2SBA*VP:?7EG'.(S8:I\XA+,TN%FVT3L0
M4P1_RWR9@-^-^6WV(T92SO9\:$5G%5Q!IV:2VQW#B=OR3'I40)8=YPU!0Q]F
M#(TUC75F7,Y4Z?^S#=1?^P @,KY6ZD9Q&<5C>V4A)1;?J.$A S(M8[\RT'LE
M9OD+F-0HT#K>NST &'8LNN[4\D>%&]?$>.^(BNVT[!Z3W>=%[@9(%>J(FC;R
MOE]73#2O1YJNJ0K,XCGF[F]D% ^,FMHT?H6O.*(G.];U8RPS.95B93O+;H'M
MY[P!Q.@Q'PSQ5K0_ I&7=8Q@!KR]9E+KE^$7Y,+T<\5CEM@GJ!^M>H>6<7_?
M, 4KBF/TT2!%8KAAL  RV]1??1DW;N.%TW.X:W(M/]'ZMX.B]FPY,[[ ZY+6
M%!*3A+A^L:4K,OAP! _Y![)\A4<;_Q)7D>Z-[ESIF80WW\"-T0W&>7%D21L;
MX,QOUR2?-]+O8>5LZ(%7!R4VKH7L+%W!3FEE^8**V(ROWB">X=93CLI&356?
MU$47FPJE5$XNK8F1B;W8(;?;% "\<;% $V6XFUU/7ZS_P0-=S^)[E1<3Q 6F
M)BRMQ/1_5L3KP^WY  A^ +R/;YHX^!=:%@DZM:-C.'X:N>)UQ_X(+&^GU[:0
MR-&^8.;8+@%.DB2O%3.J/U-WDE?@==@!/KUAUKRQZOS:\K[P(&-_-=\9ATIH
MBNQ*7$#*OK:6PT'; ^!8ID_%<+#^COY,DLJ81&=*FLSN??T7U6>.9JG],E7K
MM4T_Y'F_#:-_=NA15.3'7J?1-A&K;9]YU5Y;<^WOB2[TA;!PV#%?88LC]$FJ
MP3-FRH"_L6+KI/O(]LAS?P++\/=--AN?^4GCR+_^),!MZY8@N2_LN()JNR4)
M)0GCQ:#I:B7('K([PB[@[;)0&9A$%G?QM10<[-I37S__XDK=393LE\$!931P
MXVQSP__X#8T+(:DAF&5WQ)CL ?";#F]24@'$&VY6';<DX<AW4(&UA%?T[>P>
M];.UZ,/D?FVT@"?$*>$-!<_6*)<Z ."B(A4N!-0]48_/7>!NO9]@ZA%@5\Y)
M^I 8A]N@\*\3RT,^"KTA\HMK2.):@/!Q5C,/M$A]7C&7+)LGA;3<XS+=SZ?+
M\/6(!8ONAR_H,EX$_GL(-RF^E>/8L+2 TX_\<_DDE'\X11'!%$_-"$1%67=M
M;TT0/%F.=^?"P;P2PUHI[#&'%+M\PUH9OPUUVD*?PKG[C:6=*>.T2#9;?J'[
M-2SVFR-:I>.DEK<AUZ]VLR\F4&A;RX0M E#YM:T0 WB*X!$>TW23=E+/FTS5
MC? /7J)OR.,-N]*ZDG@#SXLFW>B?JWC;0;S&F"O22)<Z3NDO$M2N@B@8@A#%
M:ZU;4:8SN](/@!D@G4*1OET:_3%LJ^F/0HC1TJ)@U?R<-SN>)06C.,];R^:8
M"Z&00B]K36)0.NO=*Y$$KZ0)W5OCT8ATHDW)3W+=7^8&D_+Q4X[<M-3'&Z %
M[17M6UXL\)7&0S=>^EWZX_B/P++^\O#*M/V8\5KSR</HF)3-:KV0:[UBKX'I
MW3.%<5UJ[\)$(2 [D_Z?*AT#[9KGX@ Q5KA^P\E("%AHPY'[+)J=2N*[^82#
M912+9BK^JQYM,SKOM?J5+,X,K^U@A21*;7'QS+ /_,\N"VB)ZX$!9'?[8K:+
MR.63!P#C@-F?HY_'PQ7#/)L\[:L\MUIKBR$W$)!,BZ2UP^C:3KSMGB2H<&G7
M$!8Z/0)LD(0J9 $S]*?FGYPR4<=M6@*2GBH?[1F[Z]1/@GD.#Z%FWU2$\CC4
M<^@3(Q;0I 2"":1ZH;@*CGN?V]_XUB\] &(?767ESFYERQ1[CT2)):]\-ZW=
M*G+CN\["[V3VV1(JCE#*3TYM^5/T9->0#\TG3ULO:?E!8,-!#0LJ)3@/&?M<
MUFLO77 (Q3F#)TSN ? E!/CXB$81/0#J>"^+YE 3E_Y%TB;.F>NTOM9"0F$E
MEB6M\P;#6QDJP[77'X3[ ,PN2J)]&Y_?-QG-G-]U-4%F3/O.-(@,C/=Z?S=E
M)><M=X-9$DGKYL!TE#R6!B)^5:_Q/&"4O6(=PS+OH]3:7L?YXVJV)IM$"115
M5B6$FS*]RDMJ;^2X$?5O&%'P*7AA!(08=TH\!N2FMUZ \%B%H"]42:>QJA9N
M\+(.I+-QRQ](>?(%K0T\].8H,PHN'%3^IM[1V<+=D[:PIFAAH?3MD,.GN"4A
M#]GX)?,P)X$K?[MQ;HNQ_3LU?]H&1)G)[S01QFV),8@'='1 ZC5?>MAM#Y5P
M=O&"OAKS1AI9'TP< ;HBB0C!"QZF>OTQ4(,E6[AE*3ND?2OX7QKSE)'8",PM
M&AE_- "1[(SU.PTM^</FYE<;AC)$'?P_HCM/%'@+Q<4<K/CZ4MO)D"BLV1S&
M)"@Q>9;9QK%RE7<^ )S('5G/MUH+QP^74"/4S2I)OMY?)5T4YW2Q<I\6Y5G?
MN^&/;8HT,=_WQD^#W 8CP>VK+\-<7P;%^)*-4I_%@ E[?*SC:KO'X;@:SX$E
M&@4FP,)YKW3?HB@)#Q?-%1V#I-?\*V*LFYC;3'KE8RJ@>Q](@A0$9GHFF6K,
M<5\1UY"NL+9#?YQ8\ "8;0D[>R='&V;*2EVSY7?KW-PF8/A!A;8]6M#QN:&7
MZX?:"4S/A+XJT! 3B":76% 9-_!68ZB#YJ+;1S")B4^R^K6V M>0!H"@L"36
MI+M6JYSK]ZSWT_7A9PL]3SW18K+$=A3V6V4&EI.PRBX> !*HHB2;)JM&.\>"
MCY!?4LY<8Z#Y-K!#SDO<%D22R"C]ZX,L)=4BZ)P=58U@U:QM/?V)^J+ABLVH
M'8T+J=RKMXCFJAX56O0KF&7&QPFSL=6I_$;T 7/*J#<QP",&EA=X22ZB/=YE
M3A^9?]6\ZD-O?GGVZK,8%A9:8-\Y8\A\6),/JGU+\&+KK'T3I0#F602[ 96)
MB<@&W8R#G&/8*'I7H\Y\<:._MQ$7A9J-75A-L];X:G" Q;TL8AH9757_D@!H
MCC7J[,:%\$T&5>-4'"V]/L7)\.7SB;WA?X'?85;%9.Z3K9I^B9Q1JTJ_O'2K
MKPOU[.<*1U-J)?9L]N63.ZDVRHNM5&FA79-2!2(D]LJHK\$M965  QZ<%LT;
M^[BJX"Y13!J+Y.'W4URP%M.*:_<+?W2;VNU4I$C46R[=I]'/QM>_6$D]]5IO
M]6A2BG ;=BX$8F_P=]8.OOBC@A=%8:FB0FJ$5=6#;ZOE<\C\\\\9(8Z-X9"T
MR+3@O<^\4<:SVJ]5P3>3*4WAOD0-YTND=8D'61=YJU(".M&:26#;)0NZ((=Y
M_^@4I@6\C8$\FJ1@YO4&<^.+%Q4']]Y[UU4/ -.T&\8^TZX 3E0G'>M3C&)\
M^5O'6XE]?NK<GF56R/<'@&2;<;-4V?1:@AJ>2Z@[06Z@.T>7=,XI(5PZRI^K
MO2)H^A'Y+QK^1S\ _Q?4B/^]T6&O2^PM2NA=I[D6F6B W* %7]*Q<?BW :=B
M%8._Z.=]1'ZW:G5=&6[EE2*D,TB/[7;DOR;43>,&HL,J*[;69<<.YS<KW#(H
MT_?,&_B-&"GK_!=OZ(4EK OTC7"9VNTN:H,<J?A(/C[K2,@1PS&B[/'5I"4V
MG9Z^N\"^'46>2M;H/V*I!8K<_>J.66:.WA+5'3V FCB]=#PC7#P3'1&82.\9
M=W2P=Z-]#2+7>VXSX34D;[&I/%!M2!R@.<IFY(D5=7$OWT7U%.9Z^0,H/\'K
M(!QZY@!F3*P4QZMD);55X]5(I?8JJ()['?SX'$1%^HK%)":/GITVXJ>X$?)6
M[P$02/R/+PZ$=$IZS!AFO[M.@I9XE1YI&K4J=V(:6L'Q*G.L?N6GAGKRB)-]
M<)+=6990:9CP$[)>UVXZD:ZG&;=3'.(B'XO4)N9CYWK]Y91*0V$]T62^B2 F
M/7>*7*72^.U%,UG_5M8RA/(>Q'Q\&>ETY2@<7]1W%8B;ZJO-XB3NV'=3=:1B
MDW1:OXDRC4 T0V8@9W>$V-(,TS.= 2_A52="![_F[70KYTUCWRPHDXXR#J-Y
MQG?1*C$FPXMMEUX>^U[OJ<%GA+C?SAL@C&6=?=8,&/B%F3A[ (\Y\C7?>*LC
MBF@8=]#K 5#E=L0]0&9:74A1]$RY5\+7QZ-,7KV*W'4QFM/95?S95L: \2G;
MW_+9?KJ>[(MKYINR2,=[S_;-W'6]]-MKSU\FKQSQKK?.?FLI@? :&F1L?.4.
M23/5I34[95YN.F<;SES+E.YYIOG\@!X@%D$[5"HD&A5&NUJ*&PFR7HTX/H%*
M%#"5JC$W*/^\D1T^_\ XM@J_PI.F'E@6P1L*(3S=><)0MYV"*'P1I2I,P8J(
MU)-@KR?Q&']<U00S/L''E3(>YZ_9<,P:PR.4P;;8&^&V5:,3ZV/"2L2'#.M=
MU:V]I<[&]DKK;*,+0^J;J;$<'&KW^=5GH$57CA!05/57=.RA<&<JP- 16(ZM
M0"]KAB-18YB5WGOU34JFYP)]&[J_G79F3A&VB=UVS@PQ]UD'.A^_.#33_SGY
M<Z;"R;LWLAQ]%[:X?+&)Y!TZB<?:\R239K*CE>\FGV^]V"#93QTU#+O\4UTF
M[)>3N[+B'!(WM_\,CMA;QKTF[M4]D;I,++(5/E/Q+H6.IG'VA6_("U@[^",?
M:3=9&]V8O4-A4^W8^:UO9"<)D+2:L8_0^#=>YNU$_I]:[]K:\<WQ<E.-=_:U
M=FY\/&(4[\P"M-UNVTW/[C!@R\A'VMME.'-A1T\P*[NF)K]_ZA5F]\Q=^3."
M>;$:AN?519?'1).8?HBB_&B:G\4\=N3..:P@V*J6$[QVJL'_(52V2P2":G7S
M=/$R&3E2GSBB5PK>(L,W!_-%&A.^^:35)]5F^&W!AHHG=T-P'AQZF,?R ."J
M=59QN1>(P\V:VTJ'Q-\1GD*\TE&/LN3,U'EK_F/]_'+TOMM>JZF.D6*V+C\3
M^?COCTKB7ZA3@M!DUS'-G"=>-6N$SUSYQ <=%+8V^$8FJ:SR][D,$>LI</EF
MLFVWV@/M?H(XYK].(_V3.FC3=\88B8[$7#ZN4\=A;R=/IXJ=@UD5R34'S:T+
M@K8B=9)$7V]+U/PZ57==EKZ0L4CK*RK/.)/<[FI2;UTS#46JQU^"^1'JB9IM
M<Y>-=)8ZR1YO3=ZC-?0NK\.$LCV2=Z8#!&:@O$>YS;4GZ,^2)-+T*]^]K%<D
MF.FS]^LX7R?=2\52CY*I O5,,0;I79'=OHDU2KG1RY%,W%-&*F8PB3QO^V$S
M]K%_:R06/27E^N:;Q98,V\99QWEI:P%DSQTEYP/;&[T;Y9^\D.C*ORXR =M>
MXAN]FYQ?&IGCH?RD\^&GZ!## >0U73FVV$J,#@@OW:$$]HP7QK7>=L(-+UA8
MVY7[%+FJ*,K5:\XE=TC!\!R-@N+\ME5 GBI&''H0E\F;DBI:L14JV:&!4[IA
M+;D"\)VL_MND??9QF.>[-5.],F.#9Q#P7<C/QMXAJ5BV'<>]^FVP?\#)'F2O
M?=.?D&OFZ+#V=E%)L?[D:2[!]Z<E10Q-(@ZGB)N"EMF[:>:(#JTP5NI6CJF#
M^\OOI;M4.JEE_MRA=;""<A<5M],FRL_W^RQR0/YU4!?)5=5X,[=%IX]#7M[<
MCJZ3(>C2XVK,^-M+N"GWI?!:LR+6\(1,+M1&4(IE>D""TY]G@%-_@SB?"/'S
M9X,8W@L\=$*QO71GC^7V&TCR"_AM^]"Z).WK23^HG?8)_H;XU_38J:IJN^'*
MMAE+_;?<B0FEU)MHS4D*0%AO\>")J:(Q_^[T/&0_(\ED:Z[(N.VS'UA//BMS
M^[BB?">=N:ZR*:AJ8FV*AS_:>?/5,"LE@[ ('9:&[/O=)KUP(;L]7_]/7:JM
M+;/#CYRMERGCJ0@I'G8OH^AE?KV)Z:;C-:._WP-@Y%%O$XI/',+*R8Q,);D[
M3GQZ75VM#$4K/"O6T#=6"%Y4:# FJ<FO[K6JCRH=FU0(@=4/S[2:TG&_-C8G
MZ6^H):508\\_8VM@L)Y,/^^)[JK#?IHYMN.QYW#2CU]%E!/Y/2J/XP& S9WP
MC";KB9$:JUH8M7[>Q &QA"*O0S1.$*YK4@@]^\:IE!J]]>$=L>S4 \#8Z%Y#
M<.R"&C[A1P]E@?NZEMI>!7,B0#R4Z^XO8Z)>C<S>56-Q/.4;<56K;$K=[O"D
M8V@XX<DC:W8%!TCW\:KF*><>1Q+=0BG>*PY#>U2$_NJ2M=&(1TX*[OFS+1LK
M;65DN,4/IV#W' P.XEWM:!KSAKIQ V_E3MS TJCCK[?O?K$59&;E.7<Z+&AR
M:QD_  A?%ED']&;9(7]?"5.!FW;Y59.]%$]](WYO?HG=9*$-\Y;QQ;R=PK?0
M2T8]OT7\$-_3 <:RJL&?0@[DP4]:PDC-B 4?%8(R8S@FL=.S;;HJQ]5L0@36
MK7!XX5MF/;W3 T;CW96G6!@)'7C(M50(G@VY -<,%=UWKC+R)!ASOOTO20LS
M)O\%Y[BO_\B:N@\ (QQQHT$4U@U-46AH#W0=ZK%UICE):S\]U.E0[\+%80(P
MX@NIW3@+)I2<SL\^U04_ /:Q65%QJG\/:F\Y11(/P-PKWG*15&S!:3BO&SNV
M,8+^<M05K!Z0&"8R3;GY2R.5>R;MRK2_%I\_">K&O^VOR-XT9SZ<NPG IS,O
M^_9EB?VU!8IH^:",L,[;=+?J]+Y(JNI*!"5V9+Q4BJ)5LU8\(Z+6MBDPED0D
MI\2;+ZA/Q/-2["5F>D)O?3F!0*&:.G@8M8YQ-)YSZ)NV("6*TJ: H#P0+^=.
MDT)HLBK?R[HZY<%[CZ#TU-8ETST[4G\'+P[H:&@ @6"I58;"C#VEL;=CM7%F
MH']B1V\-VIY):.G2@I>29H.O("N*&%=_>LR[HQW- @.%6:!Q7R.T](-1#<Q[
MRUV[)U]T@+B41[_1'W&NH>CQ+P5Q@PM>?^=><\5P_%*-L5GW; !)0\POI:8%
MJK\'(9"GY(Y[QC*#IM^WZ5Y.3"_1XU^_&E5OF +G:GH6RV/'2"8J_:E*G KP
M5F;-S*1:N 9#G'G#,E3:H_1AY]ZQ7ZN&M!LT0R@E5+#8]!*4^R1G].OJ]CRN
M[##E-O\P#CUWM*1D()D,2NYM+.RUML.?G-$TDDLC"24>*,;HKS\\E%)_Y)38
M1P'MV7>OTQ&#R+O^O__9K@!R_/F?8V*<@0H [XJ,0ME\/]49KO/9 <P_KSA3
MN8:V5 BV+ ;Y)).\R[^R21->4ULCCPYP"7EI/6_:1=9CY^[L)I.5*^,-,_25
M^2""N(Y,S8AODTE/!>+RSV*FP;!@/RG+8B7?)]%<B:H3"I0-*3^C%'?[B3Y%
MJ6N\5#(D2VU/6T'<RQDN(Q>9D71.7M=/O"P? /&P VR!^R.)@Y8 L6[[O262
M-.66N$N$)G'M?)F)OC[%ZP< .,7C$"3B2A4[HOC'B5!HAA[SVAO.&&!//2Q"
M;\MW_].4:?@!((5GU-*Z>%8OM@4OF#BPGN2&%42[=U<W_>J.(_$0<<ZTCK&F
MW-NU0;7SGF(UWSP*.R<4_LEG;):TGPI%@A[DA*Y/?JQFNR7WH]VO]V4H+O8Z
M8[E:MW$VM36DCH^HK%9G72KT, 3F>/9C!.^7]9HH[^QU6^M?:\A/N(.$)(!H
MM!-IX"6+%+GK)4WL^=!*?FV\*VBZ9Y/>@OA?BQWQD\D+ZF;L\[(#\=UIML+/
MS:]_]+],8'\J1N,>V;0.M]>3L7X ,!,:/  J=<)1L<T5P0G_09J86WHSF1+<
MZ55T=_= _5TO77P/'5]Q!<A57OCC#*S1DRJ#IW6K@=RXZHM]<6K%(FS[G044
M4DK_Z+JA@*O1=?P "(*TT-^@Q!\ B>MM#)5I"FF_!U?OIYVZP.9VWLX45JYM
MBB KO^=#OX0I[;>QBBN2.\2-OU)![P]3RG;2=,$X<L<[PH1/2IQ4SD0H:8U/
M.AFV"[TKD%&@6:K&3?&L'&Z8G[O5-B3"70DH)3U!+UGY3:YG0"+'*J'&C4(,
M6B+)6?HK0=;1>KL;DTB.Z5'FE*(F/"9QLSD$.5HEZ'PNA)8T56S:CCKH8,A=
MIS;.L?(C=WH<HX7Y\#;?V4!>B8%7RMH#W4!/9KFT#BNL])(U&,G?HS7.=D*$
M+95BFC\3+EE>J0F0QO&%$I-B1@2_-#;CM9Z8F*3>SS&EY%D"SIXQA3P_WFS5
MB7Z=I&>U" <7YY?ZX3,A^FW,?V#V1WZ</[NAN^)?P![,1D81!].O4T_2Z'?7
M=&\[L5AI9HK&Y)MG8!>.O\FB>F.]?/=%U%:]W?9'UVK<+W\XK%B/1J+7IR=G
ME>*:ZQ#F=*P+WDOH5TX>2+(6=#O3U P7#Y?MOI0VQU8[>^$Z%\+O5Y08=<G!
M7H] /BY'7=#>O>/UKM?5I6(L8:#;+50S:V#;).. 9!>*T^+LZ,K?*_:)#WM5
M=0/=9_U1?G80SQ/B+2P@]&4MP)<E4???,_9/2S.]J]A%M<WXT4\FSS)G3!5X
M+O$/7(?\:'_N-?4&9\F6&\[-V;F,NG,4A AU&!C'$W_WV*AX[>'\\:*[,+..
MJB=[\^C$SW-M5#DT4H3L3ZY.:-XH)X5LXS<G[WZ8X\_TL46,*5MO_,DFM>6X
M@/$Q_V:M[ ]1TVK2!W[-"#YZ.C^"V 8YYX;X)EG)4]GI8RX7EA^EMNE/T_)&
M_;W+C/W+@2[@>6;BYQ&J;[=%.^>=KVJ66E]% 17NO?];92G*6<#T.KR7DVXO
MEE4G%A"3^@!0"N.CV16EI/ F5"_E2($/CR3F72O]GKZ,=_8O65I*B8&0&#^U
MZ;P<Z$W^B^^K8Z7QL\L=BMCU)"<9 ,O>2M6 3W^ZO/X,X%F;97)1IA3%$.19
MGIZ_7WD P"8.&S>SN.'Q"FG R@F'"NDY$"[DEVRQ4=#7NA^]WPZRUZP'\5QR
M2,:3M>O^0 M.N$,O2H5SP30>;325G3Q5-\"J@U[CGG>I[AO@C1.3405:[GN_
M]@I8PQ'T\=W9%V,>HJ-/>UV=H7MZ]16?&^J!8*%\5HETMI ^R%&CT6DY!,^K
M1A8^>6=0;+R;V@YNF-Q0WA_7L0M7UE;,M<!R_5QFAK;4RA,%7EP>O(M4'5B>
ML>BQ+]^O+8,*#_9BXU$9[IR9R((\!' _#DHTLRS%OWKYGCRYOZ-TAMY*#4,Q
MY+?:QL<Y0PU/L 7T+=WT 6W&9S%6:1>V-Z)<C7^]'Q<R#0@QA@QY3F^'?^RB
MO<QSMBM?F ,]+\RV3[<,*P,)[??!Z QR[G=K5"M4DS!>SXOKY5T'[YH2^(DG
M%IVYLS/ X[ MK;V V\_&^;0: ?V?9/LZ*TJC''7,# 5OZ9Y 6+)*UBXFJ)7!
M8H+*YLY%776+!:G&;1;$R@D5V&>B5QM6K67JX^=[$ +YPED%AR;O^MEH],"8
M<O$8)]?,[38[]2@-_=-'1@<9$E]&[J"4$J]Y#HU&\1&CQ3W]1=>*E!9F]\Q-
MT2[;"Z_0XCT? %8U0A2U@U+4JN&ZI['WJ:D.>AJ3JT\1FDGVS1'JGMA=)PG\
M(@1BP[[^+X278,BE?QR_P!E$HMH+O;(*'(MVZR\? (ZU<1+L[K[X@MQGWED?
MY(E2$G^<)1D/T&1YT^Z-MYB6V010']<,ER&,!C\5O(J:&A-6OKEY_O1&B8$F
M$RWFLB(J"KSSCV,,Z(\OG]%*.#:KGSP\NGN+K,B&%"]RR'. 9G"YA*LJ5']3
MT&D,J5C$)'>@-R'9<@/_9XWL_E?J6:2DPT-DNM6+'P<2.G'(DY1$==[SJTBG
M#()0TM5M=2>DZX;#3[*B, 23G";8XX<67@3J,>9(GHV(?VA#R=>([W+&U9[
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MKHL&E2)R*0#]_8WCN"5HY(:&*/Y2$0TY];<B74W1SH\W-;&,G58=- H!TZ"
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M?KE.1E77K%3_'(.E8/Q]15:,3R,/A$2/U/LGRX%:]06_P8=G)@8$DPI<O;2
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M?JJ#-D).@7$*DZH_'H&SAM6:8@.+!(E :4Y]R/1!^A0F9^D537GOC%G ,PZ
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MJ%$U[7T=9R.';_^ /(4U^U?."7=QZ<UIX6JQ'#"@U70/N(+DY55,BW"3OB3
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M""HV#19-$L:9/*0]/KS>W6K^$RDBS A;3QND$ BPIY M7$.,&05\RT'*=J*
MCJG:J?Z)DP%'0\.8P@A7QB+E')!(XHRKSY($J3K+_I\MNSLZS^.X1#C/-7Q4
MXS#KA+45D%5B*&">IK)<E?-]Y^A-E3+C-=I+6LOOF0_.8]?'\QGW^PQOL^*:
M,?;S</1.Y:<@EW,*56KKY43?)%O*90]'-%*EOR%[3RQLC!E>J7R@=*58;?N$
MK9TKFOR++T[3((AUT[S0Y+5<O2@B;$GOJ8S@'(0GOBY%N&8_N5<S6T+BA@#K
M-ZK3F:$U+6)+2NNZ968M;BEA]IZA+:UQ)4KND#JK?;0)OOY,/33C^U@U!$%$
M'SMNHMW+!-WMI=--,7;P.:"V>[HPF;S>V;B&/]/9$H_S&UR0O'4E8K+.@U6L
M^, 320N3U<A,S[#M1N)$]HN4RC GQ_N'.435?5[ >&N$&:ZP)A>9YAHE=V0C
M(.8 1'%(/O5]W@-ZO6V>L3W4C$8)K'OL['$K*  8'('R6#_N;.6^9Q"X[3T3
M?5I$R5S\62J6A:J2<8")+O^8I^\1M!59BCQ$;E^.]O'8$K?4;]CXC<U.7+'Q
M582N'L1<N)Z"EMY&)Y;=C<JN3;F^]2V ?4DC@UR5/(\YO4ZYK$QPQGHN0&U<
M! 7LSD#*4$!W=Q12_0HN>&TYP&V14>TKL_XNLBMK+N+=39GTUUO?PC=\+2(R
MK&A(84-^)^D/E,</2/2)'Q,E?CX:O<B!/.'BT8T+0 &EJ<N3F5ZLL059G5D,
MKMD]S!]FW5/I+GR46UW-R*:WXGQH&NJUD_D*M?;/IFU<)?/+^FX)$KK-JHM5
MNLJ-5ES3S.Q"K<,:D[!#R!=#Z1A.F:@5&G5/ZX]1 &>MC_%^T=;%PH')=^;T
M3(/_?[G53=U"VJ "(4[P7><^4.6,%%V,RH ;K.5.4AY.&E]V,BN!@FKIB--6
M)<'K;6%M:4D]34( O8KW9*#0,/VTI7-]HF5?"W]];/SA#"Y-G&!ICF\PE_TA
M^DH/<+M 671++'O.%J9T]=SC)P$C-4^I][[H'"=MT!T)J5,LLROOO J>/#I?
M;IQH;,IL\BY4VARI=Y?Z8G=S$:"/#CZAQ=KRL(E>$A;D+5AOKOS"N[R7^-C%
M03/I6D9$51)1O/I]2NWGGM^7MI];WO]]X21$\;GIP:<10[][ORD>$E^PE;#:
MZ206^ @%Q*5RCJ,)SJK8!^;LUYV/7*E592@@(J,B)LN/1Q'/"BP+LAJSJ[FJ
MB:'B=%$W30R+HC;<+MQU;O",CUQ[+XUN9"CIZ,5!ML^%LAIX%BXBA9?BD'>$
MK]Y'7.[0QRCDD1>__HZ[-.PEO&RL=-WL#L'=M_G0$570OWGX=%N1N47/SYR7
M??3@TF\ZI5W"7N]A6?5D$]UFG7P>OJN0>4EM[;VQQYNKO_%:XF&VMI5V>9B6
M5.#AZ;JVP;1T.LT*='_,SDL9&.3I1I*6%'9BENUYST@"C/*BDHY2LBA 2YCH
M$L'A$4/6Z\7[6_/'PF5W1O>BS-AY)29A:H9WBE1)^2<XHD!Q5:*:\;<_7I'_
M\X&@%QJ48%I=OVYG7,VJ8=+,>G1-^$V&W^E)4?X+S!NX6#3?)E6R,_<K3(?S
MEPM/)2W+ZCXIXXKB9N7(9F4OGXV2DY]BQH "GO=YXES.@/G C7>&MC3YF!'2
MTX)]2\85JO:>-UW*26VEL-ZFFR?N?P_<;(N*\GQ:(V,3.")3"VX "1FD,%Z-
M?KLLR7%BXW[-6MOH)ZQ8$;89+">J=@8^M<.-NQI- ;/J].[ER1/8IM%SI^^;
M H2KX[AFC<+6GWY<];='M*CF5N2>X]2Z)'>?URC!56$ .2:@FN\0UYF6E-\%
M(BSTG1QD>_40XXG/<4J1&G-ZM0RCL>-K>?E==/,-;QN79HZ(*.>ZS;TN2_&G
M24^5>/!QJ>D1C#]PJ9E,6WN+?5FXKR"$^^%HQ4RV9!#F:NUOU;TT;GCA#5-*
ML#5>.%_]CIK"G6FK.\_Q8X4ZE[Z2]RY+7[12D/<4@>]L:B%H6/PZD!17^%/Z
MQE?4 UD[W$]*]V>S-)S>.4X%BPBD61V[9:]T(!_S*\XEBIM96QCW]Y%Z5I/T
M>Y0*;G4*NE\@JV[]W"-T<>[3A<^/+G1?@OW3/N;4U(;-6_@MO8/6^Z8\,\1Y
M$WJ#R&-S'SEV]@S9]4A 3]O]D?(+V^X'G[%61.WU) ACBC=3A&#&]V.UK.9E
MV7?'9K,0X38,YE/]+OWT-CAS2I$?;DKRR'BIX91.@#HH1D=UC:XH% )7FJXH
M&NZ#T3"DN18O4O1UNKX)L9+T-M)+7%/D1:Q<-MG8ZGCFZ$K#\='ZTGW[?D\W
M>5R"FA0A=4*;Q9"E@"G?A@E;XF29O=B.U/DJ&]? F2G3]GI7!8]=+]FE1H;M
MR>$?6E]/DY75V+F_7QE$F-]]<U>8[+L!)D92R7K V.4>"L"Y?'YN-74JE$RD
M+C27%)>'$V=IZE3E<'&<H1+!0[Y(0BATZ+= EJ.GN8@"2*Q(X"E#KWG\B*/V
M'Q0Q/P_F_9'>\F$56.#J?B+]_C!4/6N!<376@=T?)NYD7R:SQ)U^Q!.#GWF8
MNDS3<)(SPDNM9?I/'ESF4^8&YZ+B/%<+1]"929!Z994Y*6>B:ZM:9.^SH6?[
M@BLI9?]TOOX__BCSL-(+4[&&1GG>YL<PA]R)7MX(J_0?YXO @ZM-KK37>866
M#=FM]GQOB.+:08@LLAF)[J2/^W!-:WL)C"&4K-\=S5F2>*?@/9ICI,"_A?FM
M.UM>Z@W,J?FTN'5R83(Q)5["G2/@4*"37^_)V DMC9O/S!MKA1"9O<2UWL4;
M B7/1)RQC(W?SK/"8R!;T+/:FT'96V,62)I@%KY[]:XDLLTX=ZP7W]%<;,'O
M7EY58T-.%XPFF(M!>H>AAQ8>1&=43V7S=LHDV1_5**O2TPG7 ^)MD&9E-@A%
MRY >/,?4/\%P1(+TTU]RM/U;+&?.OX4:\6(,_%WC:9S]S=Y2Q![?TM'OZ*&]
M DF,TPQJ#X#D)Q[5-OHRS'?1D=O,(,1E<,B@3*^')D5>YFQR;_7Z[-'.[$M4
M*'RL>(85UI&"0^JL5W!,&+'N/A^WS/[4N0B\3%-$=78)BKF7F$UA/>/UF5O;
MTDC05)!L',%54C>&P+.,<QFR')/EZW 9Y#((6S55I:_&LM?6LOU<H6O3HPO5
M:V5X)/E<?^UA9'#* YQ<D<E"!X9<&@%UE9'?5E6T.'<N)[:)U*\]?%[FYHK-
M6)T=E'IGTU9>^-A&KA/QF-K7V^J8A4YHZX(EFYJCNL;42FH:0L1,&@28CQX+
MK8GW9-X,(WL]I3[&6;S/_N3T@6Q(HF/0TB=GU\\HH.+;&IBRU-81>U;/NN)P
M@&:Y?L6NG>Z+I)2=.,ZL(E;E?Y\#U&L 3=D+?;Q^-U8G UX#^F^F'K.EG3R[
MCVBX\$E#O_3P!)-1^5"(L# 3?XI^B0CXX>8I.]HT@1NG7!;RH+._[$74G4_F
M(^$33./,3$R3==/KLI[N3-'"]"_V/D9_X-%[".K2IV#/3&&(:.-?:2N==6=G
MB+K#[VJ]4Q_N=N6/V66NH%2QZYEL*+Y$<'M!#3D:W%/4$I.CM"%M*$-ND&S(
M7JIQ_N[;D?MZB9?!(=$53ANE36F6Q:CEW>ULOO+/OCB#&-BEIYC4O86VN%Y2
MAU3SO JWW,9>5H]5LGT.G3QX/ZT,,&'9V+36$HP;D8YZ#3B_JMY?2)N=@ZO+
M-%=5?5H7SB,H+V\7F#&]*ZE]8*AX!7,,M>GB$L)XD]I&27KFXM)LR-5M?'N&
MKV)4G.'Y]2(U.3^1C_N!'K@(H3KUA$_4]*SOS=@J;#_((U;]D[J](_W35I:(
MWP!O<11 .*1_R#=159UF7B=B)^N=)[/^W519[8$JA2O=G:'GHEOLRMXH -*G
M+]Y(TPB"]"^,5<R(/FIC>X#GY M]Z!\F1.C@DQDEPU2D]0^%GE:?NENE,FL]
MMR8Y5"TX>-->IB+FQVA]V>/T&FOA[NKR&?,ICY00[(#B\CM6,CX+Z];@)SU8
MS?4/, !$2W4--:LU6S<(JO6;FN].FX/MW)$&W&_O+M4-'PU$S-S8N/V 0-;!
ML,R"2GEZ T2F:=Q@K.'ALL#X@6G=9"4&V2JGW0&&S,LO!13"*J83K8I$.,^*
M(S0U3U-IM,T=].:U?DAD-ZZP)_>U'$GK/%K[XA= (3C(+>DHD3+?[%L#UO<L
M_3&BI[+4^%+YT'LR.MM2*V;7KC5G5I8-.BO:$$?"V!J@&8\KB.$8NA@]H%(Y
MQ>=MNB#NZSI1^?A>'-B\<HQ#KG!_Y+N13'(['=0E,FPV.KGHY<&U!?@(\T=N
M,;CEO'R;!F]TW\968JU=(LBT=7!1FM4!8_:I7\LJY29+I9D!T\]5\3#,6)W<
M&5\4=^ YU#O1N2H"IJ.:P"*84\?R6M94!?F]% 6D.B,&1)VN)+:L:9=K"WC?
M7@ER^#F;7I:2D=V\\R+B^5-9"3+CWX$\=6[Z!Y%!_:"$73V.Z#<HP)]>S=.I
MDMO=@C(^Y&"FAOKJC1O"47N>YI#I,]\"<4\<S8.Z4:?/>V5Z%\]CUF>Y[N-+
MSM7N3=8VT^AW,D44GH3I=PGX4(]J*_!T3:H;SJTF^N"ZMK9TOX'966FWG-7A
M4Q:U6^B)CB,DG@82V+H6L(]VU=(**MXD$D_U>)BO,'5Z:W.A[T3X^__PD4B6
M:+8&$@9E=P?N+Y#0/<'%E4:B=R)]RS@AD$JKWH9;2[@2\Q!'BO"S%5!]>5B-
M=??5#U!@[7(9P@(&79"#:V9:Q"8T9B6O1W"EL(7TQI*OQX1KV!A]D'E&^UQT
M&T_AH\=9JFC_)(C$^8&,36I_<M%>"@^;@\.,*85(2E/EE!QLV+*9*#  (5ZL
M9QE=F&T\;HPSH-8[<QY?_D&ZR\-#N3)C(^?TB/KZ@+['2Y\IW!9AM%C;H&MM
M9&4W91Y;-1E.\9GDL6Y)_[.>34\GLNUY)KCF=6W1ML"9#UW-&'NE^4K$VRII
MLLZV[*>?F%8%J>W R>)+G/YH_G?:5%GDYGNLUU@A%YMJKIP'=)-C?ST<? :8
M9;GXL)5-.'/B+VALEHMCG_;[* \(<VE,U)B28VU0=#>Q--*;-#5'G.9F'%JM
MP<%:- 8XGY]4U-<W4X0\X]C=T^4E(H328ZRO?'JG #PEG]O\^8&.F_ >>%HE
MFVPCMQRGZMCC.[K3#04<;9)O ZFX!$4+A#O 1!+GOKR-=R5JPT<WI&)9=C-C
M9%XR@!>Z15:CO"W!-^"R*L,0OB(CW;J*1/7)QYI,VGP&^ ;BMPOJH\=/\[4K
M4$!1LX!GT&X"LGDI)GPPF#F/_+_;KE6=.-'ET2NQHM;Z_J!/^27YFLX'J1>B
M1(U:\C',F:>8+15#-[7T9V85EB 86]"4:(*./.K)/ ]EJZ)"\1^D0#[A6[,2
MLLUYVD/:P K;3Z 9M5C0=()U>H]Q^> ;Y<"'&;T'S:%7$R8P]> *L]H*6'>P
M]>Y)_)J[,E[B0[:9^PPEDCT]O0R8HW40?+C/0CLE05.<[9-HW#Z1:-GS+!?&
M^(A:AC%]@H\S"4APX.EERLN,;1A3>*7NFYTJ@81*%!!H$M\TX!+%X&C#^"X"
M)_]1. X3UGE1JS5V]4<?BEGM_&ZA^6EL9ZI4;IYU'W>&J;3FP,*%CCV(\.LI
M3I.S>Z&1:U_/]P>?)FTLD.]I:KE^<+H66Y%G4APO+N+MYM:8UI'^Q.9"]T&2
MF.<=R<WU]RIJ97JI?K9'AK'5%T@6SN%EVG;*Z@"3L9=ZT]U/N&9__!C">QHE
MSA9/8R&N2"KYH0KC?;5]DKK5XM!=\_.S,ZADHIF[>:1FYEF!0[#(E=<>"<>D
M" DHA&#0?L!Z*%U+UQ*2JV,;#QV'%MI(=D@^\\(W8V]A$B5U*CP@A'/*P^:F
MH.S[G!P,LO86&+7.MH^ 3G^K "KCT_<I.+Q,(RA &UF'6/BR-@?6]DG-B8?D
M6=I9J.V(=KC:A%X!E16Q2^6^[AH3GZF<NX0\@MMA :M:G]*6$W.5G<).W[:D
MX 1T/=D+9%[DVIIUG,IR_B-]H?O70<.LPB&?K=E7:VH3! W"7$6BN%25MF46
M;T-R+"]-2_'DLK;YXT98H$-60M^_79)D#F-_9_V44;Q%*?RJ+J7 R'@4!13<
M%[A% <Y>YI%,*[80>G-G*,\R5LWNNSU5G, MRF8?O#L)0+.$<MTD;Q^[J#->
MH^3H?&]I2)"9:NA&3K_\L[S" VL^O+=U:.MX?:Y+6<.8,.R$WN_YW1$E;5WM
M^>=,E2DL2X;/HYCP,_W\>D[H(MJR_A.."^,Q"5N\ =X@*J4\,]=W9,^W942Q
MW?4["X0C2-R>GA:Q=?!7"Q&DW\HI_7PS^-CH^&KU&?G6QUF/J3Q=K59/"[ZB
M?MDG=Q^&2_\PYH[T)5K2>[X K)"(_D;#.6$(0T1=1&1]L -3SSB.1?D?*H^]
MSQP53KT-KW[5"/L4X+X.M;"?[WA469%@HA O/Q"49--*3GX&$7';;Z ^;)9-
M[7"U*!XJE%K5TOV*B"WO(X,2D]2LXI^NINJ<TSR&&Z2YA;2=43["*:&THS5,
M(=2BU6L4W_96>%;8?!OQ*$+B$%_KK'X9;X'84FW%NB+N^4?BO78>$DGY9RU#
MKT>WQM>W('-(4Q?+5,Y3^[J-MA#/.17E.C&ZE*$7XTS:<[+RQ'F:NL]ZOB1]
MVW<#]9%/TC CAVKBNO2G';8IXS[;?$I.TPB\<^=](.:Z#>G3BPB]]$:B+BA_
MSC(M05^F11SQC'?1)%M>IN'M%H6A<F#M\PH.9O2 ";RY54 K+-:/*9"IJKQY
MV%3SR>B2=J\)0!!6_84+A_YRG%T45("DY(RWU=_91SB#Z65;4S@B.B]-.M:_
MRS[H$_Y465\1V?XU2^\;U[8HC"VS6*J%YFX]K"K9YS)F7( R)<OM/$[.!C=(
MMSG <1 G[[2X+B_*]^>U!_G04 6Q>&=\JSJ9A\Y*2<9?GA?P*D?5E8R5UW;
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M3_O)XY4.2O^=/'VI)-ZR^_B]< Z 9B)M$4].5NGPK'$YOD)[CJ9M>Q+/O.C
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MP7"9]Z"-3P5H,1(A2 $I!$,5[7&[*@IHE9M" 0_2-Y\,!+/1(DFTB2Z6\E'
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M7WJC^.G4\##V]_^$U2CQ*IE5Z3G>KZSH/^YTP_9$ 1<XNN I)J1DC>6^+9J
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M:K]W$PI-@'=!D<;#*5MSOF]#B*T6!SVRQ]4"LLX=#YZ=@K'XT:1[(.^CVV.
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M[1*QS8\%<%LK#V?Y#,WN1'MA62_GU;A]<6!PY-AA]"%CRQ-O\6/O=1W\BI;
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MERN5E3L?>^GWX0QY0[\14AGE9W8]56C>VI$>0>*3#S$9+.(:"=W3H!<\A6W
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M@.1W, !1^;-Z-[C/Z>H%'',<QVR[Y-WNO J0$PO/:B*@5W@^7X[PHRO-^3E
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M*"K8Y;Y13!4Z'W&@P9\7CZRD"'SC0;6,,!^G;)G2R'\185.HT\'Y>IYF0S8
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M)?S?B%YK,GHU[>8E%+("N26!6IP7>GP]"&A'H4;^/VLI_FR,.4<)IODW$,N
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MV3KHNM<"M$IW>GD-=X4I,=FZ+X(4!J!NA 3N6I:K/C<U';.#QS3#7AVG/$C
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M)13*LBGQ3^OY;(@C\@H>.^BZ6]:DKZJIB_2C0#X7";!$J8F]8CJ;/X6:B/$
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M'KL '7[7Y=482F-B9V/&;4";P0M/&C$\[7)G\SMT-#IQY.%Y.^R>-U!"*1E
M:4?K3TN9[ -Z<FE'G"P89*=NFJ* I9QXIUW@;0SJU,>?%0=;N>=J: TTQF9U
M&'G)B\)%BX GT$OA]RDV7?'7C&Y=E&+AN=+ '.-9/1TX]W0HM'U!>K5Q>D!^
M?X %(=*2E9H>=-%[B1'''<5GZFA+HJE,Y3L2M!9';0?#E^VC(%"QH,OS,FYH
MO<SHG_5@/:G.?3HWZ-C1= [<J /F.*IIX43F&1ZX&6=C.)JM?EI.Y503F44"
MY*>!UT?A-9#QZI[[NV)CK6S$&Q['[F2:"N9I8>C\HBB-K*'KUU2/-\D?:&?L
ML005,*D@ C-WIO>".I#EAB*( T&<$G.9?*$D1M[[N7H[O";66JVD<>?8QF05
MGE+S_"6]GE-Z.=FB"I_5T"8@3YO?2LLCS%RFT>053\OO8Q=6C,)J9UO;<C6-
M=VKM:AJ*WXU%,4HD/39N$P]"-LXW91QVJI]W2A3;X/U.\ITH+5R2-<B5<WK8
M.D<;\J#<8.CH'0+#&1Z#H+",#N].+((QRAGM/F%5SC8V:2/CM5E]L@XZ/.C1
M)-C &1]$ G+M(<M<X-:+(86[K8@PR4^G_@7FJW<LHEQ?3%)UP_$T*WQ=%:>X
M=2+<RTCN<N4Y)W:O.?3,IZXY.C;ZF WFA/CFI';/"VNWTN^>Q/];:]^8B<<^
MH(UJ.'4\F\9=7WYBYI8"K8^Z[9%N4EKZ&%7171'&\7B=;SUU]KJDY]!U_> :
MDZ)=5;N7F9LBS7KLX71\2JIG1<O"9;>;(S#66;F T4J&N=LV9#(;#.G0?V:N
MM*1E$=^0DURK:?@HE59WU5]"4WI8-()]QW+F%P#P"+#ST'#>_%8\I7U!:X==
ME,/T:Z1F9EEO6QNZ,+;9/X:\KM9X$:MYN7(>J<7HGX*I_^.Q!_^GLW^KHOK[
M?M9AVL6A'1+@M?-@D%#[GP?_L / G]JLO^__TZB^_;]M5/]>$-7%'N&GV7/:
MWG]<6.NM >\&J#N\&@D8QVI]A>!R8%VO_-/Z-!+PD0X> /N7RZ-+;?]/_S;W
M+_YQC&SDD5SS+^#1IX>%3/S512I\U!]O/T-")9QZEW^P;$4VLZ/XMCA'+\8E
MTB)YJ7<RLUSO3B7Z7C<CQ"V&=D)/]6#Y])1ENB'; R(3;KW<1H0$X YX#;(%
M9E[E%7B&JM*@Y=CH?5.3#,@.EAQ;+WM'-,6RI$G/TL?LU13]<1*_1Z%:,R?V
MT-NJ\>@G=?G^-P4O;,41)RNF3PU^F8UA)E]CO*7.B4.0 +3M<F&F*!N"?;/B
M5G370D9,J<1LCGJ-R1GOY/6@^$..VD7O5M+XPU?^HS8<]\H/BI:6DP0E4[Z6
M'&G:$A$_?VDO#R"A<MF30B^@4AM*'J^,7S$>?%E!T7+8(%%TF64\[A2IOJO*
MY>G,\F7)'']L;TF#SHS>QTGWE*\'TY(C]3$_QHF%H#Z^MN[^-*F8YC+MB/A6
MPFO?+WP+ZIM]?1M.W;A?S-U%#@-X(SWF9*D8IY]Q]A"T9?R2-XHS%=E031,D
MOU$B=WXJ_P^3&"-XT[^F_J+@=26U+F4?9#/2IH@TX:N5\M%\%RR?*^W?@]G4
M[U"^0X+WR:D'9?F%;PLQ1Y0F_P^3V1>3_8^&%/\7NFHZ:RS%UST:80V8W08Z
M1*4=/CF[-]'EFGTSR?)Q)(#LE>,"K9>W& 3O@OSV"FI0WA&HGA_X>H2K+P=L
M5-/?2&2XQ4M[>:QN!<VLJM6@DHLLL:VG)^$_UB0E#>65J2EKT&<U?Q9*44]U
MJ-15PR;DAX$C+,SH%Y:2RQNDYT[!NO2X:H,]SF?Q4T*R/18Z[%/XW?Y<X3:(
M<>+R&!<)Z/_;NP=#6,(1FY"H 7:56]6YMOZ[]B%9SBNZ3Z+F(;]]8]6^H$63
MQ7A\7^>%\WL^BRHVHS75X%<D6<]Q](+<LR<A[A/7HBRT*:%$R7@!!?N/Y 0@
MB_L-KK*57TVKR\YSR,!+!14?NQ?1K83=G;+:GBM8K0IJ6+/HS11)EQNI:9((
M=3,>$4=1^)-X'Z'DS<(Y$K ;LGQ],(I2C>,DK<>S^94UW;7B/^_&]S(7#E B
M]D7RK>0_G^<2$ O7_C_Y@8S_KVRB^?\'\/P_:?2O^:[+?S>O0K>?B-'QS:JS
M$IIS]G.P9O=C8<Y#.>N/XW;FE,I0R4(Y(^JQ1(S(&2Q*S2?/4ZXBH/[7-$%6
MWP7\JGAL6:"AU54&<5)CIA'K0-8IQJ9M_MZ2+)51D_&,%]3#7(;'T3B+K05K
MH2^D=(UU;L;:>V?X VB(AQPBC[46K<$+T:VOJ_D&><7>[H/FE#3,KYC+*YC5
M=(Z915D/R^U=?Q$?@;>:T=M:SU[&(^J ]U@6R_!7H,OG2$ OZ#[6;&>) M'7
MY!Y>#6[,>E/;/[] ?BD2RRK379:CG,(3^ILALU+0YU\?'_D7BZ?CN 4QI&,O
M_CU-J@342?KI-"!DON,V=&#]?66Y;%(PGQ'[?8DTQ>3[BI683]]7\/HPJYW_
M60^F04D#<UI5(++ @D!W]2T:I#IED "SV+?I48\(O^W) >SGKKVK( "S>$K:
MDZ@%<Q>UAZ:)7 VQ:XVA"H/D00>B&$1M*[Z^>NEY]OZ7)"48'B]@KCB2 :UG
MSNLHM:CN 0"@C=@R/(C+RYZS..DAG$D&*VS1S"](HQ=]#J/D42/'%[@NX%KD
M&9<J"^KNQL-N L_5,]O+2]-N1$G_>?$593%) %#[;]P]/ K:P,6$/T5I-RZT
MC/^;:H>'+-K255,7?55W.]=M#&V7RC/A8DS>)UM0EY446U=UW6BGD ">EZ'7
MM@J 6]P-SS#+L?V7G0BRJE.1B"MUFJ^^6_Z?^4/OO5*SFG6,:MS)+PMX[K-%
M7L-NR%34T59:\75GEVN_PS\X6_ @ 2Q- ZXI@L^N^7;<P^V&(3**=LY<.:HJ
MX2A^]W]2E#_/O9@D$8"=7.)I,:DZ4=Q:]?5UU9WJ8&E"^+)67X5X&Z;_X3A0
MS)*_2YZ5K:#02C#K9VUMU-:5)5_0S4CL>;3+;5-(Z++B6$UZ:]P(%'H@[CH7
MUHQMV'."6&(*+*$YQ?R!;UZ^U5N;SO63F"QL(1DGH:1"8TSJ=X,_A:VX_7NL
M@]C=?F5SM>TQJ1_/)40QW*;T$M:$V=0;HN:&S#_F^^A6S/<17="CC31\VT];
MTPF3% JJ&NE_I/= PVEV7T<^.O\C@KEN4KRETH5T=PS<:EWQM@\=\UG9.Y[,
M%J^O)SV;^FFY4K]OA3&F#0LG/12RS>*?/KSO[WD5/O@Y0IHJ2&C=PX_@QS2H
M<X:<TI6[^+'QLVS415#L#U^:ULLNVJ_?,2G&WSE(^3-]D%5WU@1$$&?/1^)1
M?DDN?]JW[:O;G88^MUM3<\:S2^V'ES3Q#:W(+.KV?O0B)UN_022F>JR&\PE#
MYL__<3T( G7L0DB[5.*,K )!H68?K1\2,&((,M'+SVJ\-:7)M3#E:].3[U"T
MGSFR>#$QJ<MO;3!N$'8$TY='8[&GQCONH_7(\O;VAJE N<RO4R "O[-'%3]F
MV:UA4TY_(GI)&EOL(@GH' .H1#WPW9$V^ ;F7^>B_\$%YJ;)H\NQF/:N 8N)
MIL#AJ0<\4>KYZ+2J3Q=?RK9,4TUFOPQW 5 +Q[,6MKJD8V[>-?G]^IKR:TQR
M==YN#7-J/6S3AL(YSCV>AL0PY,6UETV=E^(W,=]!P\-7XTHWFJ,J4;+D[SFD
M\D%S?(4B<AWW-^4'59$[<84.KZ+4CNM;VPM?%%P97@?F7QIN3C%G[;YRV/')
M0$S6)2&$BXT,[K=V$1#25L*<)M#>JKA((QB^9]$B,P;+L1%'?-GRF271Y@8C
M+B)_"6/J[[\;;>I(2BHP!NF?#EJ,2DZF(YA:U2BG=+D8Q7-FN\8>&NXM( $"
M587Y;PL!%P_B@N;>AG@1?OFS4(IMRZO6)E_=^C"F^G71VB=1SS%_"ZH[Z8'7
M;&Z(K5M7@+< J$']8*#5^_<<1^9.C[^K5P@/&-1B) 1_<S/%;*4_SV>!KE36
M:0=K&/H8#<U2?RKF>&LK*8QM*/OZOO;'UPQ=T:.''5+CVL0CM(H VU_>=08U
M8=)#"NB5EU,34[(FY7<VL[\<0#.=C^1];6Z7V*?SN',#7C9[#O5_G& SKC>.
M.EOM;K<=*S\2WL^;(#5,3V,<6SM=XE8+6EKOBXU985=?J/O,(3G0+!"TXL@B
ML0C-:)*F=#7^3AAM]FRVK8_\,X)P-P[47%83Z<8ETR&RHLYMUF*9U?B4A?3K
MI@>O5='.E#*UV1E+\U!>@R#X*(M3^]<OFRC)ATW=2R3E]3_]@;S$N"%[ 6OD
M\=!T?99@S6!V>^/:^4@:'CB6BQ55^.IPM1-"\RJK7V0RG+F10OV]^C$N5$[Q
M.Y5OE[26LAR+.!V!HKB9U#_RO*-17?JRY$^7$I=R-9553-!H'%M1U8L+QIJ$
M\&%.8ZB735E79HL7SAWR:8[_7!Z?N5/M5AO9AHH/GM.!K5KB\^8>=U6'5E%S
MR(!M"P_I?20P28Z5NS ^/7K>&1GPY0#O73]E]GK]9>ZLQX?X#A?>.7=SH#G>
M1U&C^A6\-J$W%'YN7@'Y?:A;GCZ;S\86B#L;,V! IP>^7=GX?&=***^VXS">
M0QHL;6&/^.N\DVX7@9K58DK,:A\9:I1*C3#D-@42#X05<H:4=ZE[RK=3?XB?
MZI6D=RQDOQVA&UNH%C<!_;A@^,5AJ65OFKN?#9PJ H4T<5,>SFUZ]^A6%D$8
M/8KCE9XZA_YF2H( 86I"UE.?^1$[AG _-4A@*MZ[Y5-N9DGCVO@TN O!S>N9
M@!_9M5%WHU.C.LIPU9.*Y*=) =<:9+>3ZK#6U6H2#2?,*PWUVVJ0*6MGD^[#
MJ\CE43UW)."I@TST(VQZE4B%]YNE]">&TJA3(B[$ONT-V2$"H7EY*[GAIJSM
MMYNX6_#A]YE-UP@BRN97]SW>W#QJ=\5=J+L>A4Q%(UZPD<@BBMKL2P1N0I97
M&*[L<:%CNQ!48(_<<51/10+:Q4_Q]2]%"*MUEUT&HO.FMX%CT7>2:]^;D( O
MN[;K-9?\*&#P#Y-<Q)S*&N.X2_CS5U:P##:RBSH7AU2<Y6W)*],N+#!B86RU
MA\SYS7#K;98D?2)N<>M&_"(2@'$AP#0,6B6%^;+APRH>8B9G.B !Z4&@U:>G
MWY/[U\TG&PP(R^%=Y$5U[N"+7)18.A?&"3H?AJD+S)^"PIRD7Y;=W"(X2$&K
MZD+)PVN>2A(@UZ,]$+[99KCM577K]O):^/O\U+TEEB6C4[JEQN1GZNA(P!-?
MR>A[K[Q"*4R%)7I@8F*"R'.8.<]1U/WIM&/_\$9F\/LZ=Q1S]+8@ 3!,O=NI
M6$JA0?E!SG''/1!4#4+HZO;6Q;+!AN)=@QB$>>J)!^-)H:E3\7':L?R"EZJQ
M"*FK.$_:04JGBV6@/ 1[)FOAZ9J^^'7K&:OLNO[3;TIR%GVQ_H]QZ_!@ZN%+
M_9;T@6F*(YE25FL-Y^F)<D-&QE^W,5;>@,(>NJVY8K:7AV 3+6S?=86?<V]J
M0:'- 8'&8X[@K$9-UA#V]_ZA&?8S,[*LC[%_44TY)<> '%H3DB?5Q@MJ8X_<
M2GT]/B)HQK?N/DH3'A9]3U ^JI%XCVNX>ZC[VD'DZ<E "T592LF&9'.C[=D-
MQ E K$I9MYWFMEM0-*\[E*BS$/R3(3,(^\'_@N]*!4^MXKXY>9H@D(">%J:Q
MP1C;?A<K0S#U^P<MA$_R0RYI:L#T?*4?_KG^6<Z:E1G,I6/:+7.N>KR=0/)!
MS3+[K$_^XHRQOX+!.TIF[K2 !&)8X[KO,/Q^ 7*:>+W9W=5&:^CC/IVR: G!
M@PM^O:UI-EY-@M(M8SL0)='NVSY/QF]$*$DXA,%^E7[ I )J ;3^5/_^A<NX
M,S1OZ>'>*TB -V1'XAO77U-Y_Z=M$VZ^R@"7_5PQ7Q:@4G,#S</$I$G)OC5M
M-1PNL72EZ:JPQ.O+L2C:L%2#,(^6M47@\*+M[]]<EW37A9/!E-;.I."B&=$X
MU:;GV"DFBO,+Z^?DE)-VYB5J]I/?,]@L%;8:D8"V%]WZ9R^#$76X]UA%J3DV
M+[K6O+&'AAGW&#ZXH##<J<TZM0<)@.I,!Q87EP[/XB_Q5X/7Y]$CXVIU4*>'
M3P#@WC9:M$%SD]@P=8:)- XWSNP"JL_Q>)7DC'6T".[ 8@N)N;[5:O/7]0OE
M_/X\L>D+(G?4#]P>2)(GJP(?5C?,Z&O/T^Z3JT=9G1LX\M&'-SU2*(5H 0T8
M&ATH^S-DXHE83RE^T]+P]? 1>FDK,FS:+F56")&AT#<0LH^RC!&U!M*-%.):
M$[>80I$/ SU1VG@)WF:M38_LU*@2!6.6G_I3W(MK4^'Y<&";Z)AK1 ]70.@4
M9QRYOQ?(D_:HSA<TQ!BWA(Q1/&0Q;BODL@>_'/V9C;CBXTKLKN/R1B,UR?&B
M6_0UQ$RJ)+Y;"#$5\L2VD<\V:1[G%^]Q4$O<\.YR:& +@5[N_\"?EIH<(ZFU
M:HB;>2R!-J3#3B$ATJ1V5R./*>/@+";[:6FIRL9&*ZNPQYTU@<-\#.QBA,MR
M_;V'1BC&;AS4#L')B@Z7._UYHA(W[-:C!K+S^^WSTH1GNY]>L-&&-O5#\(BA
MRT(C30.JE0W:;>[H3,E\[5UVNE*!?N>G-IZKWB3KF25\/<2T+B9WW:?--;XB
M1K\Y8>/*E=<_[1?-@AW5+/>=+:]E6^^*$%S#A^;92("B =-=&A*@RAN8LX1(
M#*A(,U0+^GU^"?8ZK+(+5P/=NXGT%_8C*DZ?0\I M^WQM:T=1 @U>,?LM=ED
M?NK68P1\M'32SQ0),'R)!.B#N=+"85LY<J1] EF@NP%(#OEEZJCL)"JNV8]K
MEQ\7:=+#:Q8@LQB33,/X\UK:0NU8&RK=SMX+ZU-58[^G0(TVQ-?SB<.G#.@=
MM>\ F'WC]Z?R[,5+%;*C+_C%V*UH".'V%6\TBNEU0HS+$=1E2, J=97D348:
MU=F3\-/BQO[<ZD M0=G@/),YFF^LGO:RS]/M%H(Z?'05-,RJG]I4]) K4#_.
M62!^+A-KRX&%X<QWD:?^D#1NZ^N&OT V42!EH$WIG-QC7FRW0C=:BZSPH8:G
M6,5'8C^^1!\]HC01L#O64\ZQ.%O\S<)F];JZ\6P@_2V:D=S,[]5 B@HRS-38
M70',5X_L[KQ[X6\4L.6352-SF.6THJI"5S(D .@[;RS#1Z%S0))!HI1\BY?.
M/%=0RO1K=?N/H?::,GX+,D4/ES3H  M9%&^/R36[[E--_:U$G63C9 5I?97J
MO)\5V^+T+JH<DOT\'943;Z"@UU6>?$IF4ZZA/9>0D]R!W[,UL)ERPEX?N!$]
MD=BJ-;;WT2>( 2K]SX4'SH?_6M/I1F&JNZ/E=' L=+69XU5,$?#5;:V0=:"[
MFI=OEE+4,H,[-X-[PPUZRMFW)1-&_7DI.(W-5G$$X)K'$TP_N^[''2KS-E\Q
M:4#"'(WV3%.!AJ^WK6=$#=%H[<'K'.I@)3Q9'F'8]S%.[V;#<.1>W'S'!4%Q
M^G! <18&4=/(87XX$%GF9XNUZ9OVT=-28HR?1M[>RDE2T,H*.Z58;6H'GSB"
MFD$8L*)>L LY>_QGE06L/_&W  EX/!2)!(BDW1 B =U5:X%4?M0A5A\^%7*.
MX,3B1YG*D2KY6H5G1D2@T7[#I$T<;#@E"C9.J]J;8L>#LPCXWIAR$WU=[)-T
M-A_5B9WN+'VB;00QORD6%']1NQ_B51V'!!!5]?W,3<G>4P\3?/P+\XP6$6N!
M?V#(K$IX%;G#]6>%"_/UI\<WF# .,^\[J/T &KQ]-"WHY7U5,R_HJ 9T(< /
M5%.8RD00UYXA 9PCNR2Q!)5EJA32?(3;K2?^KMUW"#%*SC@JMV!5 WC0>/PJ
M3PHGYD2UI_SI_<=OZ#<^$"U^P\F ZD($*<1=_T2^9+_S%CO5:[18(P/8L5U@
MTTL^Q3W=>8RZ:M;T\[)# E:($N#>?*H56^B-E>]]HHG!DF9*Z\?U"VB1/HY9
MG ;/G'C(!PC^KWKX::(PBJO,/>.74/RP@=L5+.C/E&N6F+*.P_<.%+<79D,(
M6U;VERH6>O6Z]&?.>QW^AP[=7E;5.^D//Q4"T+]A6FCQ9XUBEA<B&-/L9>'#
M*5_.#N+[ZKN:.P$]7/;D;PVF:?9UP_TO<,GZ,B7I$HK%\S1ZCVEYSO(&")*W
MCY+1)YY=7Y<4*<)<\BP2L_9>DN9"MZO\1H+].C7YVXWM 0=,.>-?6RN+J?\(
M_>GXM&5=Z1:)/OJXXVG@.R92QTE^&=E2>S72*R5WYY$UT"K>:57.]Q9.8\PH
MP_=IXP1I)]]@<1])/,#Y;RBR_G"4Q),+1B8;<^J6 @4HXAIA^@<6*QL] N&Z
MA5)Y->O3IX:2<$9W>JKA$HL*7H<MM$B8KYZ?..68;L>>(R3^7.A>!!=FQ]FP
MKNB!!+BIK)_)E*5AP5F37,0=8?L-#L.;04<,67.R=5/X/G<,&R]6 [Y'"U9U
M__G=-7D0':&Q""5,2;C1T4Q>P-K%9LLR-S->J#&F[$)M5-_^K7*;'DG(9[,X
MR?N=-H23L1!GNH2H'*Z<DF#PA^$SJ-8;!Y'-PD_:X@31DN,TQ'("HY(ZS$]
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M?=B6WU;DXG2I&-<HON;*R/ABBDJV9Z1!/\N-;S?%/ _TA1MB6/GI!D#/)?\
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MKH/(C-T3P5'!X [F.J[1Y93QRZY;F2G#ZF%HQ\%RZZJ055EVT@F-&2"^ 7!
MG''^N/D;$W'T](U92ZV'G:V[8/+VWLQR(F4Q^1_J;<2 NDP49!5L"T_A67.^
M=T;G,E[WMX 42/EMNL!?&_^72P/_?DY!X9 DR;^?4U# JW+G?S+IH(\8!?3_
M_++?KQ06K,(^C(M8')OY$LA',<.U6I(?R\@A9,7$K++2?7@3R@5M<#W$4UKB
MMT3=YLX^T;\%2<O:^?DTV#U \XNPW/Z;9:5W"8.#H6K!_[XGNUH"*\4_T8_^
M<]D_E_VG6?;1T+2K/<;1JK63>6?>^N^--/Z>*Z'8'4B\ R58X?1F MDGFQ^P
M8)H8<!S";^JKW(P4AS?/+J//$9?@UL;<;PC3EHZ@UG"QCTX+/OR3!@,)DC?@
M%L^QRA';>J$DB>6=_XX<<]5(:&,3I;?),&MZIL-\D9OB2FI_9XDFOSHYG_0N
M.:O9E'!>F'>_^+[XV$[!J0R>R]:6'HV-8Y;.;)O[HC+&U8L#FD.:;D1<_!<&
MHU3^3I*/ECD439BI:\&G))<9:-3O?_XG>XG\/R=_QVLMX /]UM3%LN]W"O%_
M?G#P3RT:[(O8$H1]BS3"$+;-#=ZS*<5A64:%)A&EP6Y[2:9$)QGB.RA5-&K$
M*,TZ,RX1+8B NJ)YL;'Q*(@5[^#SHU8!\O-[C2S=>$O0W,Z[1[N,QF\ZVISU
MK</GM89Q@RK+K7I>H_?9]X>$K7?G8D5BZ,<ZH\7XVJG76MGPS?L<3[N[9":
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MJ@B_8DL?0=;M8OS6K40TQV"L4(F@,ME<78:IWCL%'+TX:)VA5TE7M=$N'=K
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M$K0W#0FD]82X*EV=SB^J#/ZWL'C2^-SH/BS21_G*D@#Q;Z!-F;W9D,-_QI]
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MJ]!PYNG-_*E9<ITVS@_$OHXKOIBK X+')!9:XW=E$X8X*Q1X9OICS)_>\OO
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M)A=E]??9&:Z%J' =%T.#=HC 0N@EE&/^XP)*B I^F0LQ7A <-QD)1* ,RNV
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M$WDIMI4VS'8T%J%3LC5D,[[!:.Z*^/AB^.X5+LMQ=D4]9AQOV./CC")/KFM
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M+8EQ^'G8IVW?_3AC9$EQ(\4D=R-,R#^./R4R!IN&GJX^K=A9NS,-[P3;>82
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M4IF/J;\LB SC,S,OM) :S%PA4PX*MB[!J1N2C..QX<V*[J2AS?0"K3F/?E9
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MULS&HJ2NA( 5W5.5$I65SEK?-XSINYT2[<HA=VR$"DDIN0@P*WSS-%;%%8Z
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M+".S %1O?Y:1[Y,UP4H%+!(#DL#7#VHX3#=J.5EXWK7O=<8V?-]';]QI9M/
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M,M7N<8X<(8%@/-UCMCMF[$((B^KLL>7J&D"U&& D*;3JSK?OFR3X]7,W,M=
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M*:D^$4,"=Z[4MA3,?I).31MJU-FYW_*_WD2/"56B^\E[G0S2QW^;)ZP9EZ:
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M'TG7/H4SOBN!AO4!Q]$=I:6"TLEU(=/BW^D%\ HL1 L2.+)' M_SP6VS2*"
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MWMW=:]8V:]'7P[$NRWE<U377*]4KTN_(,%@KG89V,39-7YK3[%^M\M,EDV-
M[ WQ#-9@<MOYY7T9W+4J,.EFO517/7<I3W95HYS1NQ;T/#+_N813>VV=DTQB
M@RDXJ_:P9:BSLRLC/W_!% JNF-@@+&.<^-OJ3.4<!74A$V1V9DRPUV@!9?/
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M75>=]FU]Q-[[R<H#H*^I&G[_VI+N&1)<'N@"?@UEB!P6%<8%G*+EO0A3=RQ
MK3F/_/,+D@;BVW6Q1%<Y=BS@+6?A=4K;B%;M?B$BK.'["C@J*LC^'J63;$V$
MHW\F^7/O,7=K&NUJ?<Z"&+[;$#(DGHZ"5O6\@'PNTW!JQ].BN=CRD^ -7[NE
M7I_/)%]N(H&8?)YD(+_WT%]\0=P_X$>Z@O[!Y@[3]>?_EN^U=6LCG)OIC2;.
ME((38>>L7<0YIFB+O\Y ,;!JWLZNOX:H5O4Q/?FF  [A3NA9N%?QW]H@X?U3
MCPM^M+'_K?\[9D@@NUO]SCR]WZX-Z%5GK$B3"#V5@0]G^"YF$92'GQ2B9FE_
M5*3;=>AN)8.9?IQN__"3>L.'<C+,)ZT<Q7-ZW[X>]XZ)X >=3!;V^.=JL.;H
MNPE;%[$K/->:_A;YI]K^9S0IVP*$=&5TY!/GAU*R4P(4+I3H>6J%HU2Q*EL@
M81J?*K1__Y].Q/]1/E=XGYX5_0_NJH'^%UN['@![;ZOF__UG^2?3N!=AFXG3
M3+*OAWK1I/<48)Q2%$=VFPW)G2WX4^?>@G/A_9!(-1H7!DR1\QZG&$7@7)$C
M$Q$2Z=Q*N1-1;#G4!W)W[.0"=:%&"+?;C_4V_1A(L#S4T,>53Y\-G5R6G_#5
MBJ_/DO*'^B6[J&$IL%&0 GNOFL\/6U(+]8T6)0<](2F6]..?33/[M-(L'PT.
M=FX@2-U*N$=.Y5K\,KCG7N/IP'S-62^(F0"GQP(TN0,3F6UYI92/*K^1GFSB
M+K9^IO.*TG"4,VJ .I9TO?S53#62TQE,+YNB_/3J/$HOE!_6^"K6WLW4U(6V
M"-244Q^#"9F9[$GQ'JK4'39W,^<)V)NP:W[F&X)=L4%5N"X52HS2TZB<L#E+
M3=?3:M9 ZDJ[IN>*)P3N>+I*_D2;&]?G#FQAY@X3F(=B:XR7.X.-X5)OYE7F
M [EI";#% R>SA]W$DFT/.^GJLS!SZJT? "J6F"X)C@ZYOD8K\F%[KJ8%C*<T
MZ[8B#X#6_E)-M8&<$BW)OMK?:L^K%Z']-$2UO'&W#'X6Z'=DZ;E6CGNB9#6Y
M[J;7SO&]+4KNH\//)7 8?%^-8;S!()+9();&E14PE7]--AV>]@9;6/(\</4!
M>+Z[Q#(M$,&!F2RJWX%CZN!WG(1MYX7?; '*ROF5(,O$V\O(Q[WTM"WNO,#0
MH/V;F<3F5  'A,F2V76G!$OAM@C=BF.X_/ZU0'(@?ROQ<+9PA$:3(.+=16:J
M^7 (FYUW8<Q,;9/G^F>$8)QUD42@(6Y$?LV3/P?SB29IC_[N=OZ?S5OWQ?D9
M3#O:"]&87FO\+7EI_K5$--X>$^ D2R[?=[!HH6J=^8(YY!K+/T_<MEQE3KE5
MWXWZ7="[NDRXEZSY5Y:K_E6WG>T/R0D]R]<+>'A;?F(>'(DUR#(M>F+N)F:;
M 6HE'E?;H5QKT-^HNO7C\U&K/5"V6OO/4F>1E3%041XS.AK#LXDDOZ<<B8C+
MJ)S96RV8A8(QHB5VE<J$X1L;LSU/KV+CFK?'I4S B!(GR?87RR,,KE@2/$69
MJU'L<& Q)_:-Q!/AL[RE5"5;@]SB470_6EE^T3_8FI@?^KY"LD3YR CR_?J!
MTW# A736.5HP7NYI."X?3QO@)K#I1D_%DGKHIDO_0X#STX<J8Y963?8LM'AI
M..2XG\;109H.*FN"LNZ"^X8W26']+:PG/PFL-VVS^&?_I?G) [ _4^;8^\HN
M^KW+_4F-+" 9;I=*8::QGW23*^'S4SR, G/Q\S,_[?64QP>3 /W"Z"GQS*&T
MM#J$+_S[^(&]ESGO.:M$DWKL"87/"T:Y$^R8ZT:Z.6/TGP+QX2?4W%$I4?>I
MK(7@%65%L"3C^V2BX>9/-&FK8B"#SZU$N8T(@];06[$\@WV.UQVL51&;27PC
M;@ U1=MM^W^1*6HKFKUS:)]"8M&OW+PG0R"F'6FI,B-W8/5<R49P\.]WWXCL
M8<#E\R?-]X[MM-K%G5^WL6)XQ$>Y/8Z9Q)Q&)!RD"7+J;V#/=V=:^/\@*DEJ
MLEUP56,EWTM3%Y^+J:)GKBYZ7.IF?HH^?5\_J3FRTOEL2.$Y;L(I#!0M<3V&
M=4@Z'4=3H:7YRKZ-9N5F5FR5GIP[+'?*.&7V0#<XU?6B5G/I^UT>'04-7F!@
MM!@5L,M>+M5CR#OMQ6T?,-I1VU!=&_L]:0U'L$R;C>&VL&+8!**T%IR_UC@H
MQ=%>6[%;2Z!>32CEY; NPK9!VR,ZAITWKDP0.50RH'@.G&4S*Z#Q-%1@8Q2/
M/JKX%9_X6W7B1(R0V-1@WU>==-R3F3W;'7%ANE><45TQ?L38%)1'*D=3CZ%!
MF9<A5L[@746?ACN_6)YU@_P7]<5H3$ T?-/9CHJU<AULUVG<G0/F_!*YI1_&
M%[/:2^NM[/(9^!(JN7H][5&)O2"E"R2%LV>AET@MVT'U2F(NY_>E\?\G(Z-
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M+]DU"='N3=GT7<^=M98]_M"@J_B(1W]XR"- =NV8<,%::);\PO7M%DYZ;VI
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MS"/OR39=-9/QUVB-O;'5QS!'+TCW66 A:VER^YMI-+&?)5T? *(-@O.P8J&
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MAEU"2+P3\N%^AJHYYL+5]:[T$'<3E&;BZI"&# ?7AIU1#W_<K8$/_YAM,S]
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MI<&A91XN2XD<\AZ@+8$VY@H)OTYSF$IU%-)\33SC^0=^SE?::].PV&=.+Z[
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M$/>)3DXO!H<%TFP//!P_]$,?/017B4,/UZ7V;TTP''.7AN>'.HK@53C*7,9
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M0]'\MJ?0?Z@*ASXQZXV6"8YWU3@['?$/OIIHQZ=79I,]M9\,I (JRLYU^/U
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M_A B<I!4MRX/#$S;_Z:.CA2TB:NH1<,5]:/'N3S4_HU^+XXYX"(NB8]WY,Q
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M(4=Q=]J=7)*:SP#EQH[L+>V::C !4YTS4_UI=*8LJSO=MC4U^GO 31;[+XF
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M_?QB;$?0[Q;Z19B;SE]8J*;JQ;O#H*NGILK_O^F5AJ$YTQ=FYCA89&H,X-Y
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MK\\TQ8TIQ6!V,2M$QE,:\<]))0L^MJ==_,=D@#I+?&&":.T'%&<[06!5.(P
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MBJB>,!MTH(EY$K>$^Q_."F]F/6)0?\+Q[&8V_W-Q2V4F;S[^D93*=*I$Y,;
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M\*NCV:0R7=JRZT*5[IJE]/9>K]&>.<BMY[EQ)+FV$0OWOC=WE&EOL0DNNWO
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MSY1<<%E%G[TJ, 24%<LAJ+\_C1\.X$614/(5R04]X?4!OD:>P\'AT>#X: ^
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MVZB[N:R3&%?F/7*H^?4 JDKX,SHGO_T?4$L#!!0    ( .:(?E;*'*R$@A
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M5042JPM=E))</ OL7##5-U$W@ZE0;\W%"+L\DS3T$>6_KG"W:3S$7(B!#BP
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MKIXPH':=>82\+3!Y\4B@[>;T):4)D*+DI/ $=D'O5$DAP*G)OH[F]"^MYP9
M";2FF Q1TF*3@A/,^+Y8DG(?\X3%+H!4/R-"@RV?IDO QY2V*0(.T!XB)@[F
MH4X=#_@]- $^$NWT%)7VVD#PK!3LFD GG"*931;YISLEJ_9.D[7043E+)S/
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M\]Z]PI#(+PP8_%B%IX0H6 OH#6@L]A5&_C+BT#44)++2D.%HZC !MH'F$",
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MJ<>JV_'#YI#U.61]#EF?0];GD/61'-<Y9-T/IW<.69]#UB<3LOZU>%0@:[B
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MFC6M-6;NG4%(*_N)2<UMO(N;E;,#IE:HT@A:R%%'!-D&#]2]V1M%%=%N"*W
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MJ* C%P$P C"P FX!&7*.;H)*%;Z-),6M_M]Q%&1A%&:O(! )RW#PPRDS*>A
M]!Z.&@YWWX:>^CHDO=H/0@N_  <JK *3PHE4X^$@8;%V?9C'D_$B? [7*%Z#
M)R=Y00EB6 4GB1QI"^@CB%5%?Y-SO$Q[YWB_#[,Z6((^8!'&6Q2O0N3RF;%K
ME*8(79,V1!<H727A4Z4K,^<>D+JRH93:16<NA5J2E7E #="5CI.B3[%4JP$
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M:@Z!X")SM(OU>P<OSJ;Z._W?8Y"B__C_4$L#!!0    ( .:(?E:2!;)7S]T
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M32B!II ,ZH>D\]2+%;"Z#DV,?OT!2L0"/5BH=/H" _9G2L5+/L'M%= 8M+<
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MM\=("5VZE!S1 6NL0DJGL0VX7$86#NH 63(&3E^!"CV7OIS8 >Q^'9"$G01
M4R.GA=3 @C>XNF6S#Q!,]1JJ\%0UM($EKMHZCKI6C#'4"JOPPUOY")U^+^M@
M,^H/ &2XC!8N'<W>0.7#-YINHHQ>I]&&-@^;BG(-01%4API@>ATVL*>SNLP$
M"] +8]B"] 9U*_+(FO$QX#;9[\.T<Z.MC\-!<-3I &\2!  NT*G3T@3,'U=P
ML#M) O7 "A;6/\!@%@*^H,&G.0_AH<" EJKDB'00L$*W]?H3?/BO3EI5@7IQ
MXB^DKW4HU)WRJQ#2 LKUR;Y"IZZ.>9:',5L"#(&.H+D*/[WF-D#4,6 =26-;
MQG :JFA?J"7M$\_?!HA"0 <K23<!L-61U )L9&6!B#.JRIYH>I=,&*<(;,X-
MO:+D*E]O,$+_^EU&H4DU-2,,7=5(K'J^2]*072E_QOR[IP=^BE&\_53\V)+'
MM\5?6;CAYU)*9\DMJ*ZS"*KJN?A'= 8U.^'[I:03;'-!3R/IR)0+USK_OLH?
M"HK*'\*8](4\>FE@ PV)_2@<L!ZBE1Y#HGOO$YGJ3\F=(*FA0AOGY1K86H+(
MIIV<:ZHMN(PV-,[*U;(=X20F9_<I+</43VX!GK [L5MAS* Y:]?8MAM<'PY1
M7O,16\M;%&TTWD0T:_V4+8Z?(MM@VTAV-KH-K.'BV]RP&N&F^H*.2(7SCI _
M2^ GQ5*"T,5#K!NHZ:/=V+YG>(>C&XYEF\A="*?S4"G&X*:'P5>?DIR2_\R?
M\#__['J^ =#U,.A- AH05EZ""%(/3Q$V29N85;&)N<43IUEM;*Q0G3J]A2BX
M-)[:MQ,RIJ1 -O? %=R3^'->./$;93/& D0+GW= .WB.@,N>1FSHB93KT#66
M"<J/"?^<?"F?>%!HBCLK ?Z^X_#O-1U&N$"/XR ^#Q^C/-Q_YJ\V;FA&TR>Z
M_9BD'X]Y ;B++#NR3;/R(#>3'X, *H\'$IA%2R R,@X$F8'.&H09!V%:M>4[
MHJ.JG4=ONB9'F1B]YATO13=,E03])GXX9H?K,+U*/^=A3K?\DH]KFG*WY7R@
MDQ@S@%P"#_,R&Y90KC$'Q+522P_)*_(8IN2)W]OBY5I!@_@08Q?2@5*TRH0E
M^%3;<HS(/T27GDD>C['V!\Y59@.%EE#T!_1N,I&(%!__Z=<__?KKK^O_2OZ?
M?U\5?[#_K](="8_Y0Y)&_V)'-_&E?>_IIBSCWJY7A/4*'_D5?Q3B;WY=_?F_
MK%=OU__./US_>?7G__SOJS^_^7.MK=K,S!YV%Y*$N4+MBN7D1[IA;PGVSW_R
M!K5_2.^B4H2"%(]_C"Z8$FIQC+0R/U_P7I0#3M1JC+M^*SSX=?5:0J' !!",
M(\D!)OLX\;'L%':N./IE/2$%05= @H6Q3B\@<=;0I X6XY8R:'1;8L.CU6T5
M(B,S1C 92(NATDE0_L)%T.DJR(A[1P.;5D@)G:%N+^"C6&,.:"H#$.K:<H5R
MJQ R7%.N$Q>":.7ILEY(WZMP!%M4KI!2(DFWF'PI*#W2...+DOCA[GF4#E;1
MR%>GF$JV0(-+SL<=U!8R# W-:E!II"UX3W<T9:>C=B7)=6' IP4IQN&3S.[7
M$72A2@9(-K/M"MA)S-[]7>WJ<+@-O_&3(S,%I,$R'3 #9!!@K+6"#6"H01UT
M87I:T!;/R]-7O5H^9A 9R8R.&R-4*S[$)M">1ZB\C,*[:,\/@#.#ID)0C4^A
MH!V0"DPM@%2YU0EPE2GK8[;3RG?@JN)&CUY-CX(@+- !P+'4LD=@KK@FWDY&
M-40#*/U*-%A-QD*;RZ5FE?GIB5JN-6@%R]<;XR3.WD2<$#> H@^<XK7A8)+P
MA<K@Z5_ABVO^N(@WR8$6KG[XQL86]!V-Z2[*RT5[QRB^OWJDY=8A")?,T";@
ME4G:$#EF@GU;?#/=%2CW3+4PX*%2#6>AZS1YBC(V ?"J4O:SEQ0T)V@E=#0S
M<N34-$&QC*8F^^B*LE+Z4/@9/='2\T\TO]H5[@OH2-.R0S72E@@T(M%M? "@
M]J)MK2T=!ZBD@UX#=IDUP_>K?9)Y,,VN[>G$N$O&V),(#7&EU&TWG/ .T-/;
MF1%+ZV$P5<GBU24+IA5AEZ47*:1HO2)G>9Y&=\>\/@7U.DRI\^NV4 -.=D@+
M2L0Y.YJE^/'8M4$L;=Q$V3_.BSHXRME?(YK6MFQH6M%R-JZDNO'/:=7:4D-+
M+1WT&C 8E0T(:^$:-OJN3HS[9(@:J5 ?-1K==N,)D:>U=F8$TWH83>S!JAM0
M'M\RBQIL4H[&B#9W')V+[W7;%1S6W*WW,4E+=UERYJ>!1;N(;J63 )A*6^9'
M43H?U ANX,X,('JD(0HL0\$-9;"-]E&;H8I!!%NL\B[<\RTV[*/^+9#^3!>@
MAG=B,[A&5(6@?\!J:!X[X;]CRH82?%,(FYDMC.Q'LR!#>C.1J=D+)C.7G"!6
M\&M9 ZM*?@'K"7@;QRQ@% 7)C$X:8!@BWH,HW-Y2X8=7^II81(D]5@Z7;0EO
M7+Y78\WY-'<ET$YRO_0@E17%UJ+45:%<^O>1;FD*3A&ZUOWD(&^-@TN9?EL)
M06,/ $>EAJ!ZZ@7"M#T]QA:D.X2@D@D*X*2V83^LL(E>9VMF3'7(O6KF,:DC
MAYR:R)%BSBUY2UYRBKE;T[A/W=+&.!"3J,=_>0@Q!\"82D%PR[P@FPIG>8&O
MQW9MP)U/"-.%P!A@@(X2PDLB)T"7TH+U:,/F<XVI>:'68?/.0A0_R1PUU-14
MCA)K7A*YR3JUV8I "<#NZK3)IFU5_)86ILU37I/ 7WT&NO'Z,I2^-^$'\*JR
MF9XY!<5"^0WBACU$ //BBK2*2*O)G]<P'@%J4L9=!E&.,O5[>E=X7+AQ9'M2
MS[Y%PY/'Y0VJWU#48"8YC%5BOHB5:E=!62(4L,])^Z! 7?'(,>(4799 ?^0^
M0,9MNX$OT^0^GJ]I&B7;:',=/K-_*D-;TE88Y:.VJ $_T(Y>!4*LP;$@D@^J
M?Q!V^,=#DA8\2=,#V2=A[!,T9%TN18FB9U2 &8C)L2/4;SNVT(HID*59@;4>
M$>Z*U,U(U>ZE!9BD9L&+,"\JCT_A@0JOS-8U$_)SMQDJ?%K%]BJ2D0TX9 :B
M8["P!I[<CZWM6"E(Q)V@@D<K(4?&4*L;3 QVH?XM2;9?H_W^+-Y>Q'D1!-'=
MGI:/1C@Q%VVP8R(Z&T]P8Q8J'V/C:O 9J@O.-O\\1FS'=]0\=GQWR:2X2>;W
MYQ"N<"U]")M:7SA\$8LK<\.8L;L6GCFT(K487V#5"E;/OZ_8EI9JRP2WLT)N
MX";?T\;.D2X//:L7%TM>\4P5ER4OK3@V V@,VD]B, >,R "BLN4#MC@@+,,W
MI?LPKPZSC-G6T'*RL_B ;3XFFS!-GW=)^C5,M_Y,44\.0157&(2%ABXTFI24
M ?+" 2+LY46@<6PXR/)CM3^Z$2:-]'<?_M!T:3G^':?-W@&AW1OIU>D2*C9(
MDWHQ)#+0&;*6%H&&(?@'J3J%\W.-@T: ;),.%0-:IT$$9)C5!6,6/7%!C6(%
M[%H6L5V![RYR-;G(5N@ZSCW5&G#8@FLSH4'>T0DA(5AM!G?.WL B!+L 17YL
MI3&, P$@X;TD1J-:7H1%B$6W16"69]6]E.RZE.N4/H;1]BS>7N4/U59MP'7F
M6.I&1>-4=6B)>9H#-@ _TQ=8&I]A(JA:\PE9WMZKN=C9H2E,\//#0Y;WIVD6
MUP-SO'3)3@UM=D[$E3"/JNF 5<1-D1A#I!S,!G\IV2"F]^P.TEO==BR 30CJ
MI>+55JQM=[IUW[;Q ]?*CA=@5M=!8CR*I$18DVNW'%_HPT.5H3E1-9RO[#Q>
MD;^E2?;"XDHSP)L;6(X'<O-W6B%HDO'[@GNM9MBV-B%I9[?57.T-^AWOM\*(
M.Q4-8.RXFJ%4R2$+[[F::=]>:L/==35;?9L83WG?E5_ @J9?)\ARG+QOZ!.-
MCT/42IX.DFSS%(D;*GT3ATJ0=-BW  %R5Z+%9EI^Z@?(AITD ([@EQ5CH6HH
MBN^>#OP>1V?X@6[#SNXR\<WI]K:&^F#=[<O:OLZPYQ/5+N43MY:MW!NVQEZ6
MU->/?BH/S)[1NB.!AH M*.I-!84>S>[J>EZU8DC>/9KU07U!Y7(@D0W[869O
ML9O8ULP84RQE>XE1!EV&-BO,'/-W[[Q.L]?])J(#9H>)(N$/8LS&^T #NQ!<
M@M7Y<+CRI!@1H-.T[\1(A6@1P19NW8L2[*I>4L\/:>\NJ.]]$5UM9JA&5K2!
MU6"G6:!A&Y"?Z(-16C9175*!;K^%'U0Q.?Y427U"+&B2/5"CL@HP\LH+:@$,
MZ0#C."N#MT5&;!.':<W83/"B/JR*Y[C<!_+4[ ,)Z[T(GN$26DB;C=%T%;.U
MT9CU(=C4<9=^L"79-W3:\6*PZ0<2,+[,B_$5$SKN[#62'KY0-D+?I\[4VF?0
MKAFS[>>-8/#Y>,<->Q;H_=Y3;A,?_M:Z_>"LO7KG=ZO16F!8/*J@:V):5$B/
M'_!GI=*<0 &?' "/%%^845X%GS<7FT./!IBBRWS@*M*UW.AU;-W1$%;J"-(X
M5J)?C/-&#6%Z2$_1BK2JO%M^,2]VIPUZU2$T>>0[5CMQ^"OSSPN^NHBOTV1#
ML^R&9K3HZ(=BG/Z>/M%]\B@\0W2:N(R5M.+81*0Q:/_T$I@#1IP#45G13#%<
M+T99:=6.[YG9MBW)ANW9\(Q(H!&FX@Z#7M?0A4:3DB% 7C@(>'N5,- X=K3+
MJN<H)I4LN>E"H"/^?08_M!ZW'/W^U_#3*_;I]?F2U;BCVANWTNYM'N< S_@+
M(]7A7)[A'A!'TVIEE,IX8AUL)\&I[1GE-O-J3F\<,:;7\\^@^Y["')K4K,2Y
M-ZF,[;769JUN(VF"*ANAPY>IM3_LZIHQ@V0C&/ _?4-0K^N48!G^T#I8\+,4
ME AH-5J+"GMCDYZ):2$A&V>\D$ !$R@\4GRAQ>*/\^+?4=XC[GIDHN-+F+2,
M2'72V%A2V[-:\8-,&V$/H+&I_)MIK@V7\+H2 H:4"K?P?M;@6:U("72(#[X0
M0/U9M?*U=WY=O*T6PF:?'\*4O@NS_@%W[' ; $M@F5!0R7P3%OAFKE.V20G)
M/U/F0C$;?,Z3S3]>W[$&9--IX1^CH86_AO8PPTW/C7.MZ0@4Y]MXRK*@\:A&
M#,Z&EL:L$D/V1[%JPS/IJ#O23>_#./H7#ZFBD/+QM: N1LPHPW1P+-%@"&V+
M VB%,7M#:HU1K/B4#;O9W\V#2LC/P;BEX(4.V)&CUY=!_?C> UVBD4O(<HQ(
M AN[8QL6SR?16S6"K41+\(?W&T$4L:""H[JS-$ <"RLQ*+.U3 #:RQMR>PBQ
M)\L6_F\U08U(:&Y "4EW&2&*V8 HSM/H[LC<8O>2?#@\[I-GFOX6YIN'*+[O
M/:<%+D3+'&<J:O/'9$7S43W1M(UQS#Q7-#0P1WE+#MVY%')@8L6'=\^$5II6
M9!>EQ?"=/W).%7/C,\&.E!&O3-0YH)M9GCF%$&:^G.F&/?R4V94I(-T6_#ZH
M%:F5D%I+KQ&_S)YW>;*KF]+LW\I-3NQ^^Q\@&\62?R@[N5Q_M>,/T5+^0-_L
MS-_H<\9>E0<>U0%]C^S06==&T##7H6:N38^Y7D I,(Q;%+(2A X6956J<9BK
MYZ</0/.@6AAX8QUE:+7#;S]@" @LWW'H9R'!;BA**7\1ECYW&YT=DJ/IQ %0
M&:R$T"JS2VL:\TL7#S!W9G :Q$!;-G2K!:^9"1J2<%HR" PC2M+H-> CD(?.
MT;-410!TQ2YT@+5 3U._9:GK!]:D8>0OV-QF_FI%%?.YO8[PLGARD=.#8,<G
M7*:?QW4R.(2CMH*\L!)L$$ > #T-1=2GV_);Y]O6Y MK3[B ^_-0#.)D#'AX
M-PIAK187H!=BSPU&'U.ZB?A+F1$4QX\:Q'4?S096JPP7/R.]:I@,F@?=3UQ'
MNZ K$OU/.(S=ME4_1(?2R#V*O4EXK-VD8]?]GB6T7&YU6CTLK3I@7>RL(DBC
MI\*))\I7-_Q&0T:#['B*B_CQ.![L@UHWG*1I/3NHE?IQF0MB2AWS>@U!-444
MWE,VR7=HVY"(-7(-"%CG)Y-Z:(@:I6 ?2  ;3J#55!57N^Z.A1MV>D%U6WB[
MI^$Z?&8^9Z/[T&OHX6BKH3E7VUSHSK.//]6&XH\2_P@6>ANASOW9"(44FHF5
M^!@0RSS%/>+!\-$]CO FW7!\L0RBHM;D+5[S)J1J0\[2M#!:YMHO3(!P"==C
M:B^1):MTO8*6JWH:ZOE=UW/9\<@HRDQ3OD394DPE-(]:RV-X@L)2<@/23._/
M\<<XL3F%F;01,I&7A'HGT9+"0R>D=*2W2>7D=9BR6PO/CVE:.'<6;S\5?5S^
M8\@^9E(US4"EYO()S XJ<1B95#*$@:;@/(FSXYX?;U=-C&7D&#^&D>L+OPSC
M(YG5>0-,PQ3TP&MBTV.4RFJ%:=)FJ,6K!LSL.4"Q2;Z?H#&HVA,F\$QNB]%'
M5CSS*L-/C"ASG -RN)FB";AWGZ4_A&E<D'QV3=-Z;!-M!OA1MJE^,DF;F8@5
M:L7$I<J "GURN8#_25Y%,=DF^WV89N21IB1CK7YVBRUU/R8&/WL?)\+F730H
M]/D0\^^C_;' J2;J!ZTD<=^T0H[\2J_-V.^;,(G^KF10_>,D$##L4P4&!!V@
M1D'].RAPT-/I Q)D[X&T[21HP'MW(]5L$Q$FKUK4L@&[>#+BEX"35^R\\)];
M3/@%">4\+J@7U+ 03KUJ]/H #9ZS),,@4%M5H80VQ%%J1W^!";%F7$7U1RP,
M-_QNMJ(-X8V\&:K >EU75NF'(4HQ;9FE'&*@AQ?:>SV0I5FQM?XIJ-NTP;4B
M9?'Z<F-,\AX-+\@<O0,;^@6D:B!+6R-H&Y--&ALFJ!F3L:2(\18Q)F QYV((
M0JPR\&3R-4[N<\AWP+NJ.'KU*<DI6:]__NO+B",@WYH&DBN6W>WHABU[O.#=
M=QM^NPES>D/9#QGMRX7%YP]L4<M%;'YPI"7M-:=C:Y\+95Q_4#.(%=>4C&'!
MHG^G8=H*\&21J!HP&*ZA'O'9^ Z^TN6G)-[2[;%H=K>GU9F_H$NB[2@W($L3
MY0MP)=P="^?\6G%P+F$:&@QN)!=6^T^:$^+<D#.G19<Y9<+MF#*FZ3?P#K)X
MDTM67%L6K6SZJE9*2JW\W&6FE_05KTA/=7MFO^QV[N;4IQ_ GQRCIXM\CX>6
MHB\BNNH&1=?,2@CG4IQ9UO%?^"!X8X,F_;H]%B?Z$&A*<]W.++48'(1W,<]L
M#YS7%N K?! ,S*\<N+(3+Q/LP0VY",#'F\<I_G->?%04)9>%!_NF'1T>$(6A
MRB#!RU4M0%PRXT[2N\:9N<RE5!_PI_6KHSS\MB(QY4?3[JJ[B._*\Y7\)R1M
M;!KR$21&S-E(IM64C-3>.8;0HJE?YXA-_!@E_A)J;&* J^JTI]D))?XE<38C
M[2\!-(^3OJA8 =\(;L_ S!D B[>!X[ODS5S!K.O +1DM=\:3Y)%]ZOB*7HOA
MCC &FG+[-[XMC,&2X<W??B#8^32&WKWEX8LQX:$YON>$*B)?N0%YTL0E.7A5
M:;&SP*/X&,7W5X_%&)EG,% %I1)45D9B02M\*3)E7,DD>;@WKV04ILTI3JJL
MPUQY05G%(R^7L"EC14L=NEZ$,()(AQ[I<LN+AJOEM*TRBQ>K1FG6XW1I)Y:-
MTAMN,'N?CH1I5[:!!U>K<2+3:%V,-I1^V%\+/M4E'+K16^I0T<?JW8":DOS9
MP(0<X),8"QQ=4]E,:6 :U0%\=D*#U8W+GVGZ%&TD(X=BC/%$LYQNS[Z&Z3:[
M927I<&3Q*<G_)\W9U[N/HW^-SRNQ;:>F2GMVYI*G+<]0Z=2RDTJ"M6H[^#U.
MFT](UCE+=-,]2W13R#MF6.M(218.R@$+VS+9XV6[W\LI4[/0O>)S_;_1P]UX
M=:FNW9 IQ^VPF&ZH&?\MCL82B&Z$LL'5YOCX$*64E"]7R@89^5*V<5V%:?M8
MA'%5=T@P.A018DRLUV80X<U(Z*Q,CJ!U_5KNI4:.;,I@=NBXFA" I RV:W/#
M_[K:M4GAFJ91LN5G75]*KHRTI-VDZC71OD2M"_=G\0K7V+79=:VAQ>K"CO%A
M^"O2:F)+#SOE4:F,<&T>79)I"QFF5>ZT<)Q0V\(-&5>TIM_!6YZ=4IJ77_-C
MDE8?L7;K*32,;MSVW(3$N*\3%D)W[8T-EG3?R?R&W*'@CT(7NR7AD3<Y :+'
MQ]X2LQW:B%YH"D3HQR+S(HI?X.1H"']TN:CK?G&0_G(YOJJM-$BXQ16O48M/
M<_),\TX)NZIKV%V2DHZA'[SF#"+?+[$YGJ9X5^XER\[BK?C+2BI?L-R@: 7(
M(1&]UI*U4A%J&<*P,%TE-Q+!BRA&<5D9S*Z7]!M'CH":C#I53"I:%2(^ -I=
M,G31RPNP5;2X98OIJO:D%N"[\;JIOBOTO42P)B_:"V''V:BZ3.HR"N^B?=2Y
M4$J2A;3M!]E'T1X)NE(+-B:?=<8@0%7K"(I"NW!G[P?P]-TM !RH1\0XDXJ*
M\*6QXP16_SQ&_,0K\1M^\=,:,L.G<P'2UX=?? GU*Q$@D B:#WUYT2KII 3T
MRP["NM^P%\0B'?@]CE>SB'4;=O?ZI?2WK%XPZG!7N;_P)'^6+807/NQ05/<A
M0KRVZE#SM4BS+E8' N4RD(=DORTZLGSNSVIN<2\ED-]V'+%MNV' #C6X"U=6
M-R=Q 9_WR2&,1I,DJC:]X!VU08GA@5;\4!8;T$>T2"ZH@KEY1KZ43[T(:EDG
MCF);\9N+0GS0?!SI0GTN OYC&*7LN'EZMOW?QRQG.>-J]_>03;SGP^5)H+;5
MSZ%I.Q,(2NWHQ2?$F@H=>OF@O J %*&R*QJ3)]::K<SY6K8B^W;<X18WL!A(
M)G15'T=*L2Z> /IM!QM:W0NR-"O2BIJ8M2&\$6E;L5BKV[VT ).4SW@1YJBT
M;OSZC8;9,>6O2:^3?;1Y+O]7=A.NL=R0TO5R6(C36;)']4#+(#""='5QV1'P
M!8W@6!$ATZ0;)2#5J1 "%F9WR6#%3Q50JVB1NI:%ZHJ4K<F7ZK],C' YQ\7^
M<E&LRS76PMAU#GKWW/'R8TK_>:3QYOGL6R0=1.@EAGE')8$%8KD-S'$VW!P(
MMAHM0><I:1Z3+ZR!+\@$1(,(D[#NDH!1+BR$H<Z6V^$[OSB.'9O:CA0K=[=7
M\0W='-,TBN^+!I\2ML>Y_">[^5BZ&\F*[M'T (INM!$>@C=6> +1,=CX$<M>
MIU98D5)K>2)SJ[>N(;8DB4FCFK?J*N?7FONT)\D./H0C6^2PE V$$<R(!\YH
M_CNN<6K_G\_W89:IJQMYVW%=(VJ+5]&,M5NJ9:2&@%6,1#YH/B?\@6^5BZ*G
MQ36+ND.DU<I83%*GR/1[4*$(8,]Q_GN<W+&5K.'=GE[$C\>\?P;2NV<NSK^/
M\*6<;3/BN@71#&X)@^:8Q6H&VT>#P@;7=, _K;G)B]>;UN$@+U.LA)ZR8D&S
MJ"A>D+^5XSJF=4I=PXC;C>N783N\VJ6OV5+=(C0"K%D$LGT^\*M6D?2HN$Z1
M__C2&J4O(JE/1'H]J$TF#5!N&?(MS)ST]"+.FE1Z/9@QX9[X-EO2=<KV3$EK
MJS=+HI@"^<)%?&$3M.A&GO,8!1;^? <W@3W7T?';<7W0_/D_(IH6(?'P?,DN
MV%87"P"A<>6@%,(K(Q1F+-44>HO  D.GJ/LVMFE24L?9'[Z5'Y 8$=<BP!Z4
M%B8*>4F5HK7HRZ*?OT?YPV@<DO4'(LV4T&T:QMF.IME%G"?\"[T%K _",J%8
M2C3?A(6%''.=6F2!$I*3IBM$4,P&S0.V^#4J'A+^E+SUA+-L@$"SN@0SZ/3K
M4.9:TRU9P?DVGF+;ZGHN+ == 'O=']-T5Z!\+=23KGY2&AA=L-/86)&6)2Y^
M4 1V[+X,CG"] JZ[:+<[M!/NSC:44I1-0BD+;"FPLTAQ([=K2FLR38%HE8D7
MVX5-HT1#&IHNU-. 0($.V5*;RX6HU1RML(D4GX-,VI\/_(["U"!=X<6I1TEE
M6HZ\.N97.\O#?($-]'%^SX8W@X&.5QZ/],=>+C,B&-KMC/63(]]R^,+J>!$0
MK!3RDKBS5<AWS-FIY$??QU>$>SC>%WCH!-[61OP_N,)*!+\4LO"H1,MNS ?]
M$A'5B'\D8F,L=>-BK"\V:CR0$JD);DYGB"^+"=W 2=%G@$'3C>&(26AMH5"T
M.Z:7&,2(P[5LK<_W$8XF@WB$>/0H-T!R7?L5JKU/5>KCNI"&[R ;,X?O&AN.
MBGNE5Z;YK;PKYW,>IKF-03S$5QM5OMYN\"XLK&XH"3-6E=_1^RB.&8$5__#A
M B&[N$"HT,%AB%.@*\UA%.B [^,KX(VJB#*X/\1;)WBW-:P'&!X@GL;;'UA'
MC\"7 O;Y-PI:<^V-Z[D[D(=.0/X&8>YN,+[N3.:5:G]0!5+XOA2J>.//X*PY
MS4>]MUPOH1@XC20L\.3 AI6M#5ISI@PFTB([LLJOS=6 >- P@Z+#]# ?".M
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MR7@]M\NY1^$R"U!;]?PCTF(*I7;\-ST :Q.F(KM+)123D5XLC8!UO7Y"4K<
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M5"Z.32U1-DJM3BD?)<I:Q-8-R/^,Z'[K\R@/$#F ZE+=I[ J<ZP#4FW*++N
M\R>:L\-4K].$^;1]]_Q[1K<7\<<H#N--%-^?;?+"6[[40_PZ8+J"ZB>>HF F
MS,U-8L)]LG45["<J#9H&)&Q:N$7[C(!*L+JXCWYS75T6F.J)1VS0["!I?86Q
M@$)0C7ZAH!W4"TRAKZ(P-CT!ZC)E 3M >L,/S*XDR-TS>74LA$@4_TR2YL0
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M,6B'"+&>9OQ%VAI+4%2-90=@REB#UX4_![)/G&^+T/:P!#O2SI!#IB<B@XI
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MA&$SS0-;7J&P&.A)3_6 BP!FO1#/\= ;6:[F&QN=.G4Q/+=#6NMY='2'080
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M%@0!#*Z%1AP2V:K,H;"M_OOXBFWWLQ 0#YT &V=N@/^'U!11VEF1ZQ]4@1W
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MUD.?KE,R]-DF:\-\"*IF=/O+.9L_V.]?$GO#T83(Y48!B\OL6M.8/ _\GJ=
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M*;AA#D7QK+U:=2C):0)]MTTST%Z!;4Y9APJY.!@GTZY*=<;E@=L0IJYA#;I
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MN-Y3[J"PSK-L_^3A@9?$X1QMCUEY!+IQ+N/RKS>LTSR/V(4=SAP).&&,C,1
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ML51[-O=4;@D\X@R/ME$.\U6V:2,^++IA9GL[/1ZX/F=WN6IAO0P7#PXM340
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MRPF-(LB!WZL#.])Y3./BY8Y<'C/\,<,4)5</ID._]HR=@[\VC! GR,QZ@AT
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M5B</&,U,[048V!X5Q\,AX:5B4?)1>/=;YMP;6Y":W/ (SK)_@PNGUX$<>T6
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M:#=WM;/QHQ.'#]2[2%S)T;P^?$!D*#3!>$>3AE$X.M< :1E.$@0J&D?IA97
MSO(BW?X6T:5T5K60UK5P&L6K=:N#O+#6,: JI,E8J'6P(Z,TM7$Q5RSXZEL&
MEM-E9QRD])9H^Z5-YCD@9\!FS=KA._%<$AI?L1-(=9&-V/,K,V0?7SZ5<W1W
M\\U#1*<WCYL(B-X/+AJ#=>L9,0AC.PAGF9W^/9N2'T6]LJMJ.^_^I8[<YMZ-
M\T%AMUG$6%2HFT:X2.MUCW ?RAQF =OB9XQV<(-H-?VIF%&C"%'64-TTK*&2
M\(:-P= /:%)K .H0Y*HV0*N@,4, MXG6,?VA&6(Q55BS6H*AF="DEA"D?V.E
MX39^3'$O:M4$BI9<G=C0R 5AZ 8EP2) .[U&>[810^.\.$<XP;)^X$#?"U_,
MU;%?G8W+N1ST+%9^56764H(]6R1U#=GA,ZM-UR"@9ZU6"B<",&RL9JD0 KJM
MB*SVC(*AGYTX>8@: JT & 4*IRPT!8B@++5"(+45)YF]Z<DCU1 (!4 J[-V%
MO,Y9[$#B[=>TG[+KH-V>H;R1T(+!ZV(EHWSPT,9:I?Z^)#L):T$GBS$Z62E6
M4J%*:,]\89(]/LBH+]BY!<G(6U]X9*DF/!B![KVSUN4)P_,*AR7E&X.>[C(Z
M:.SY7C%GI03R-CEKA9X(7/4]8<QZR.$/>X' AQ-'H.X..&@$ M^!E+(SZ53T
M%XROQ6VU'=P.D51W'*E(_"Z1Z4L$CQ$&E S<$J/AZ1Q)VP@Z<:;L >/J*F!J
M%)LHW['[)D2G9?;YV9&T,FB8.;DQ^+F)Y>?IW@C3IV[< *,3%0(_4'=@Z:4[
M(X??<54^0O09D@]?,0ZTUU6- (+W=51JL:#73^E5.,-AU8*#PG.\8EAH;XP:
M 8L@.PK5ML;7-&;%\:.+4&SY=14H9G[0C463NO"U)Y8CL-]3M!*HK3J)!?>K
M*CFQQIQV8]$%!H9-19,H_8ZBW2 FAW^@&A-;U;# UU272-;75%HR#>AMBTK"
MHAZZG,1&9\A:$EO]L-C75)'8>/P%%Y9,8P>V)25A[0#V6HGC?8[_<:3!RN<G
M7NM<%;1\3=F%D#R$T9PE&,5;7D7AQNO59MY%%=Q<-TJMOBN]N[1US8,$TUFS
M@++!MYBC!.,01;P_=*?_O8N<NC/^".V3PAKR7H4QNN&PO5)@^ZUB6'>'PS08
MAMWI?WS,\&-4X'I:K*['OL'L-DQ^0?:78W',,+LO.TI[IN$EHZP'&"?#:V-L
MC$KXJ@&/4>CWST8+75>LK20%;Z%:Q:E" +^M\8&+0''U11YI]"1Z$Y=%TNQ_
MB.9$DA-MCSS91O&>L1H6?N_34YS/?\F3'Y()%+ ZVWECQ-4[?.,',XMQ 55!
M^*B'-ZOSIETUTR"B-3'OK3UD5F_:*G1U%O.8A6\UQEB]D 4:/F. -XY6=D3.
M,6+*6$SN8V8+T-5YS&,!L.VZRAC@N@P!KBF\*-V?U(V[+,G+%EY&<J]62P;I
M\&V][!3JFS#9\*^;28H,)U$A@C=&AAA](VZ[7DC<9@T+,N+3=7HW&3CK+DY6
M*D+C#ZCIEZ4F+^2Q1F!]9 G(<? MH]]-$*SI&H5!@LTS<K%1 1BDV*KS@AP-
M/0;=VBE#3A-4@$(.-E5UP#_B*+T]WLM6^M4!&,U>B3U#F82R8/ *_HWR 5?
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MV<W>AQ/ ( @P,+LM$,=+;;1%]!W:G!8+U>O3?Q3!;)7W!)6&Q])U0@C_GZH
MM I/S\0^RQFUMC,N[-V>^K!9H$%YAKB^Z@&#7HBA!#.K:O]VP='PHFQ&$S$O
MPF:JJ+KYO;[1_T7_6/Z)_A]6%[S^_P%02P,$%     @ YHA^5A*(K\$9<@
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M\+]0D+ '7 96.P=<,/>&'<B29.3Y6*K!_Q>'![]6VR/U5^27E#/9.5"]Z3Z
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MB'MC"V %.%F[&.J1=C^6]@5%T7_&9+?WB(*4+"2;HF8I.Y8F@>TXRUQ8]Y1
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MF,6C 64KE%;;.J-=K:U?*CA&,"-T4[%;+^_DWR?X-4R);!@\]M03 GI\B4<
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MC3!6,60 8=9NC!#I!_9AH,NB(0=%T)V-6[RCE^>S/ UCE*:K-?&LTI 3LY9
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M[H@X<D?$+YLP\K*)'V9"X=:*I[='1XBHN7'7?5YD8F=!L5=#Y@/<ZV(^IAE
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M;NDF_\#4"I(#]"\^:A1S_;Y\0\DZ3%%AHIN/S:+]">*Y07&(_#4Y#C^4TX2
M3/EF\FXK=?Y7_U;BFAE:T[?@IO5PW1-*#NQPJQ2\&X$5@/NAC8IL:RB>O(=*
MQ_[FGXXQ)U6+/XAM9("+S& 'W \=4V3;E''K]%#IV-\=*-U=O7!.=CMKRN:.
M&-XS%*-MN Z#Z.YK3'1Z'[[T5$>M4?>->&DC/]1(2P0:R@3MIU*IGUP)5E37
MB25TWX2'L!1'7\,TFW<O:2LT]T3KQHE%1_^4>ZPT\6=/LZV ITB"O#;8^Z#B
M?D1I;:?S#BCLP%3I7$_EQ%2&^!3O!X"SHF79_B)$7N;NWU0%)./-.8X(';@L
MJM44E$QOW]]P=#/U^Y52,CC'QLKMJG%6:&?W4<L6>:^H_6 J(?T6QVO.YW:5
M3_&+EZ8[&#R'::X#&R/Q1'#?;5MT,1(ZA3"5/#@P-E@:CD' %CN[7IU>Z[KB
MA6IK<[XYTY Q601 5NP((>U=S]4<(JS">N_*KEJ7="D5=N6YBR>V"'CL+.K*
MGME9<8]7M1-_DQ G7,\PS,#SRJ:;HH<.*(<.=Y*5)-7G[A.\R<F6+GE$R2N9
M^8RU5 1R/']G@,S, QV^JG_VVYE2N"XW+#AS:U]E9@NE(NIQA=C%"F5@7>>9
M 69M_LNEC<'L=6<R%S.=D'R,KE4C?B \$3'N6R]MUNQPKFP"X9M\7"F\V\JA
MRK""E@!0>UZH6&BU,=P8,H7:P5HE%?&P+1X,VX,!+*MS.#!L,OR\I#%>+(-H
M;G/=T#SJYJ:B2=3FEJ=N%"[>]/>%G/"?:K.A%"3-#(8?Z'NLVSS>T+EP'J3[
M*H?M :T1$7;_K38H>!V(D(+;.^Y0'2.LS'WO^ /881&$D';DFB-7'4VN#CB/
ML[MMG0E9$DRYN,))R]$XOJ5>Q+H/!YIM%D3'A[391]#&T7>/J VB]TJO)Y:N
M_CPP3YAK]TBNPB3-[G%&J&]36G'ZA,\0QQ*K-ZR?S51HZ)46:TM$7S]5NK1V
M<P6>%/04T@2'!_P>1/0VUG&:R1."I$WYR4""IE[IWPBIC+:0P$[U+[5,HX/U
M#4!"_A8GA^(:SG,4[@K.^SX #+CV/"7 7FF6$N<CO$Y)-_H76*8*'A9O%]-+
M7.<X+MCX$F;[\YP88;+T5^:7_>BT5MLFJ*C4UBM5&R,7?<U3[-7:U1..(EZF
M67B@#]8^TJSR("(NP".*(GJ/GUZ?(4YJG_F>-NHCJ*M6:2#P2B]'2TA?.76Z
MMG9QA:.A93V)N^TMCL^I72?<4\Z_A/$&?^5II5JC^N 0V,@K[=.2A+[&0;O3
MO[HRC9:UXK'%U%A%16NTN8LEDXCO]1G%66>]F<'IE0I/(4=]#3=$S107;>R,
MH[D3%:Q]_L =SM'$E949H43IQ[8=N"C/<%]7:8JRU9:H'%7SK]2B$Z?AG# 5
M9C<X38OL_7 ;H@WW/,DDTN:TR0Q2DZ=M)44%%>=YD@Q=$A%(CZ\NB,4Y;G3L
M,$@&_9EL@H1R#K.ZUI^O+V69LRQ(,HMS5K+[O'Q;1SF]*TRY)O^W>0K>U*()
M(@RPF (;PPDI]7@)3J7S6I1Y7XO6_ B//#PW-9S@HW65@YJ?R[&+T8XZKL;W
M51VS2PBM&%L7PGG"J_6:GH^V(OT/***$/.&B]-!92*OJ_1H3MB1QJ.D[8BW2
MACLZH3DSVWC,XC 89D#C,&O.>0IW8'__87%A&5*PXL1J'&Z53NQES-:GDP@G
M3+#]G#K88(9DPSG )Y.X/6$N\!P)WV;)][<TA7J= CS#)?VN!H!I+,H&3T#;
M:1;0. O)+I- ' &)?0QW<1&*70IJ+ 4UEH(:2T$-'PMJ$,/VR#-LJ;C"AD[3
MBF&UIC[6X!@AG-%%.=3Z=NUN3%%M/DT#4)47&'"[YK\ V$<]4Q+ :,V2]>;Y
M#>BEXLM);;N7BB_FW:2S/"5;^31=K?^9AVE8Z,C0]Y- U5X #\H5QNB?Q,(Q
M2\. X07,]N!-YOJ_!?OR;98]CHB:\>J#B,&:TW8>F#7# 9<^!K/9-072'LK3
M;AYFSVN?R28P5I\ <O%6ZQ\ \;+BL5<\F-V=8\WC4K+4">D?<2YU0I8Z(4N=
MD*5."/.)D^X=^141.2*47N&$>>VTIU>ZS9MG3U2;>Z5W(Z4SXA:Z<L>NU>'H
M<Y"6-4<XY@T(S=&Z ;372B;FW9Q.#?IQM*#&4@)I*8'D0PDD9XJ _/I"ABW.
M>J[+==QZCK=X_+D_(93;56.AT,XK%=:5A[YN*O3H6NT0 .E709C\%D1Y/Z="
MIRE<]5I-3TW[>%*95 %;G;I6-J2^YO] 3',2%N$)>LNHNNW,?!,>WJ)7CD'8
MPBM%4Y?!^$(,PKY<J_51EW%Z"@\HK?T%XB4\!L0':!R!?L!&J5&OR):LD5?Z
MI26)\46W9-VY5NNC77%NL%6[)!O]D/BF3[BRR7?Q8_XLN7QF$./1^(W'Z)7R
MFI?A*.,YGA;GGM(MGP"N9^TYW94E(4I;6[ 562=>0UIZD=8M.\<QK2W/""&-
M1=1]RED+D5>Z;4QB8V)2^B1,\12OF8AGX>0\X=7F0-BCC]Q>)/GNG& (UT'T
ME-"WA;>55#;U4PEQ6?J6"&UHR"? /(BD&L#LF?)/)5,3$5H#--4' @Z>5(WF
MCKIS:$U,P76\J>X^3S=E!)V9GT7,SC[JQ))+WHFYQB2SGG[.',C56^^[EQ><
M9'D<9N]/^#Q/T%F"@O7^;BNK6@EOV N50!IZI>+:$AD?.(%T6:N>,P=Y-?'W
MY#_)ER3,,A3?XHRP2UTZ^D94<;+]A!(R!0MIM/@9O!QI!%E/1761>:FV1B0W
M7I5UR:C5V^AYVTE4E5B*5)YNWNY2(.)F*1"Q%(APMT#$+<JN"9,'1$O?D#6N
M.*@_QX>7/*L6L8LPRC.T80+J%X88G;E^&21Q&.\:4CBYU3*P^N$$+IB-K/PO
M*-SMB<Q79(T(=JB,,U;C4&92W.592NMBTX*3F__.TTR07FX(6R6IT=B<$>C=
M=D#O69"&:XCX9&U%PN*WM6;?3:D('B>NKD$?210U\XK$6*PXSMF#$I.;%.M-
M$%7)+ 7IJRQ+PF=BHHNCL[N78AGJZ:U.TVH<U)J>@M:.$)9QI56CQ;4,>A#U
M7XJ+_X,@B59;%9T]MOTP2LL1EQVM/1)C+6M_*E^")RV8-R%K+?8G^*U/0<W'
MB6PNGX)/SHA$>TQFD^T D70'Q1LB[2U&=\AX_7/'0J5?LQZ? UOW59R%&RJ
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MSOIJ4*9Q(72J)RP&#.IYL'J.ZPGZJ[.ZJ1+OU,/;DL,=9()3^5Z_#<3=U9=
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M@:AQ\9)V'__RUT__R8F7B,&8%+?!K*U24EEC,'?=I8B'N(R8\!!Z[G1)9N1
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M&GFHCNT]V<7]Y;D6$J/17@&9R";/!JJ^T/]Y)FOK__Y_4$L! A0#%     @
MYHA^5K-J;M3F%P0 ^0$B !0              ( !     &)R:&,Q,# U,#,V
M-%\Q,&LN:'1M4$L! A0#%     @ YHA^5C=1XF7+"@  7S$  !D
M     ( !&!@$ &)R:&,Q,# U,#,V-%]E>#$P+3$M,2YH=&U02P$"% ,4
M" #FB'Y6Y:4KQ),*  "<+@  &@              @ $:(P0 8G)H8S$P,#4P
M,S8T7V5X,3 M,3 M,2YH=&U02P$"% ,4    " #FB'Y6P% 'T7P*  !'.P
M&@              @ 'E+00 8G)H8S$P,#4P,S8T7V5X,3 M,34M,2YH=&U0
M2P$"% ,4    " #FB'Y6+%.FE+H&  !L(   &@              @ &9. 0
M8G)H8S$P,#4P,S8T7V5X,3 M,34M,BYH=&U02P$"% ,4    " #FB'Y65787
M::,*  #H+@  &0              @ &+/P0 8G)H8S$P,#4P,S8T7V5X,3 M
M,BTQ+FAT;5!+ 0(4 Q0    ( .:(?E;$?H'OZQ0  "5K   9
M  "  65*! !B<FAC,3 P-3 S-C1?97@Q,"TW+3$N:'1M4$L! A0#%     @
MYHA^5F_3^9,9&@  ^(T  !D              ( !AU\$ &)R:&,Q,# U,#,V
M-%]E>#$P+3<M,BYH=&U02P$"% ,4    " #FB'Y6^-' IELE  "M_   &0
M            @ '7>00 8G)H8S$P,#4P,S8T7V5X,3 M.2TQ+FAT;5!+ 0(4
M Q0    ( .:(?E:LDMG):P(  -@(   7              "  6F?! !B<FAC
M,3 P-3 S-C1?97@R,2TQ+FAT;5!+ 0(4 Q0    ( .:(?E;!/03)V@(  #8'
M   7              "  0FB! !B<FAC,3 P-3 S-C1?97@R,RTQ+FAT;5!+
M 0(4 Q0    ( .:(?E;GXP[XI@<  "X>   7              "  1BE! !B
M<FAC,3 P-3 S-C1?97@S,2TQ+FAT;5!+ 0(4 Q0    ( .:(?E;TJ=A5T0<
M #$>   7              "  ?.L! !B<FAC,3 P-3 S-C1?97@S,2TR+FAT
M;5!+ 0(4 Q0    ( .:(?E8T%AMG_ 0  )D6   7              "  ?FT
M! !B<FAC,3 P-3 S-C1?97@S,BTQ+FAT;5!+ 0(4 Q0    ( .:(?E;884XY
M;B@! #EC 0 *              "  2JZ! !I;6%G93 N:G!G4$L! A0#%
M  @ YHA^5N2%(EQ:9   !W    X              ( !P.(% &EM86=E,# P
M,34N:G!G4$L! A0#%     @ YHA^5NE*=>7J_0  M1\!  H
M ( !1D<& &EM86=E,2YJ<&=02P$"% ,4    " #FB'Y6QU.+Q91Z  "YE
M"P              @ %810< :6UA9V4Q,"YJ<&=02P$"% ,4    " #FB'Y6
M< Q'^:QP 0!:K@$ "P              @ $5P < :6UA9V4Q,BYJ<&=02P$"
M% ,4    " #FB'Y6;N>V,E46 0!/-0$ "P              @ 'J, D :6UA
M9V4Q,RYJ<&=02P$"% ,4    " #FB'Y6.0&<8.PD 0 (20$ "P
M    @ %H1PH :6UA9V4Q-"YJ<&=02P$"% ,4    " #FB'Y6&7)@,O_   !/
MUP  "@              @ %]; L :6UA9V4R+FIP9U!+ 0(4 Q0    ( .:(
M?E:"0\K'(/0  %42 0 *              "  :0M# !I;6%G93,N:G!G4$L!
M A0#%     @ YHA^5AQ/N0EL_0  H&P!  H              ( !["$- &EM
M86=E-"YJ<&=02P$"% ,4    " #FB'Y68J]J+.?G  #(0 $ "@
M    @ & 'PX :6UA9V4U+FIP9U!+ 0(4 Q0    ( .:(?E9M^^S+#PD!  0O
M 0 *              "  8\'#P!I;6%G938N:G!G4$L! A0#%     @ YHA^
M5A$NI\WML@  Z^,   H              ( !QA 0 &EM86=E-RYJ<&=02P$"
M% ,4    " #FB'Y6=-A)H<R   "TF@  "@              @ ';PQ  :6UA
M9V4X+FIP9U!+ 0(4 Q0    ( .:(?E9>D6LYP L! %@P 0 *
M  "  <]$$0!I;6%G93DN:G!G4$L! A0#%     @ YHA^5J6QUQ>F&0  NB4!
M !$              ( !MU 2 &]C=7 M,C R,C$R,S$N>'-D4$L! A0#%
M  @ YHA^5LH<K(2"$   0^(  !4              ( !C&H2 &]C=7 M,C R
M,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( .:(?E9P;3<!OD@  # /!0 5
M          "  4%[$@!O8W5P+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4
M" #FB'Y6D@6R5\_=  !8APT %0              @ $RQ!( ;V-U<"TR,#(R
M,3(S,5]L86(N>&UL4$L! A0#%     @ YHA^5A*(K\$9<@  #0\( !4
M         ( !-*(3 &]C=7 M,C R,C$R,S%?<')E+GAM;%!+!08     (@ B
+ '$(  " %!0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
